PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kisselev, AF; Garcia-Calvo, M; Overkleeft, HS; Peterson, E; Pennington, MW; Ploegh, HL; Thornberry, NA; Goldberg, AL				Kisselev, AF; Garcia-Calvo, M; Overkleeft, HS; Peterson, E; Pennington, MW; Ploegh, HL; Thornberry, NA; Goldberg, AL			The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; POSITIONAL-SCANNING LIBRARIES; 20S PROTEASOME; BRANCHED-CHAIN; ACTIVE-SITES; COMBINATORIAL APPROACH; PEPTIDE HYDROLYSIS; CRYSTAL-STRUCTURE; CLEAVING BONDS; CELL-PROTEINS	Proteasomes are the primary sites for protein degradation in mammalian cells. Each proteasome particle contains two chymotrypsin-like, two trypsin-like, and two caspase-like proteolytic sites. Previous studies suggest a complex network of allosteric interactions between these catalytic and multiple regulatory sites. We used positional scanning combinatorial substrate libraries to determine the extended substrate specificity of the caspase-like sites. Based on this analysis, several new substrates were synthesized, the use of which confirmed earlier observations that caspase-like sites ( often termed postglutamyl peptide hydrolase) cleave after aspartates better than after glutamates. Highly selective inhibitors of the caspase-like sites were also generated. They stimulated trypsin-like activity of yeast 20 S proteasomes up to 3-fold but not when binding of the inhibitor to the caspase-like sites was prevented in a mutant carrying an uncleaved propeptide. Although substrates of the caspase-like sites allosterically inhibit the chymotrypsin-like activity, inhibitors of the caspase-like sites do not affect the chymotrypsin-like sites. Furthermore, when caspase-like sites were occupied by the uncleaved propeptide or inhibitor, their substrates still inhibited the chymotrypsin-like activity. Thus, occupancy of the caspase-like sites stimulates the trypsin-like activity of proteasomes, but substrates of the caspase-like sites inhibit the chymotrypsin-like activity by binding to a distinct noncatalytic site.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Merck Res Labs, Rahway, NJ 07065 USA; Bachem Biosci Inc, King Of Prussia, PA 19406 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Merck & Company	Kisselev, AF (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alexei_kisselev@hms.harvard.edu		Overkleeft, Herman/0000-0001-6976-7005; pennington, michael/0000-0001-5446-3447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051923] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046147, GM51923-08, GM46147-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Cardozo C, 1999, BIOCHEMISTRY-US, V38, P9768, DOI 10.1021/bi990735k; Cardozo C, 1996, ARCH BIOCHEM BIOPHYS, V334, P113, DOI 10.1006/abbi.1996.0436; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 2000, J AM CHEM SOC, V122, P1237, DOI 10.1021/ja993588m; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Kessler BM, 2001, CHEM BIOL, V8, P913, DOI 10.1016/S1074-5521(01)00069-2; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Li J, 2001, EMBO J, V20, P3359, DOI 10.1093/emboj/20.13.3359; Loidl G, 2000, J PEPT SCI, V6, P36, DOI 10.1002/(SICI)1099-1387(200001)6:1<36::AID-PSC232>3.3.CO;2-U; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; Schmidtke G, 2000, J BIOL CHEM, V275, P22056, DOI 10.1074/jbc.M002513200; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Sheppeck JE, 2000, TETRAHEDRON LETT, V41, P5329, DOI 10.1016/S0040-4039(00)00853-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607	47	138	150	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35869	35877		10.1074/jbc.M303725200	http://dx.doi.org/10.1074/jbc.M303725200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12815064	Green Published, hybrid			2022-12-25	WOS:000185318300003
J	Speer, O; Morkunaite-Haimi, S; Liobikas, J; Franck, M; Hensbo, L; Linder, MD; Kinnunen, PKJ; Wallimann, T; Eriksson, O				Speer, O; Morkunaite-Haimi, S; Liobikas, J; Franck, M; Hensbo, L; Linder, MD; Kinnunen, PKJ; Wallimann, T; Eriksson, O			Rapid suppression of mitochondrial permeability transition by methylglyoxal - Role of reversible arginine modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GD3 GANGLIOSIDE; TRIOSEPHOSPHATE ISOMERASE; FLEXIBLE LOOP; CELL-DEATH; PROTEIN; MODULATION; APOPTOSIS; BOVINE; BIOCHEMISTRY; INHIBITOR	Methylglyoxal (MG) ( pyruvaldehyde) is a reactive carbonyl compound produced in glycolysis. MG can form covalent adducts on proteins resulting in advanced glycation end products that may alter protein function. Here we report that MG covalently modifies the mitochondrial permeability transition pore (PTP), a high conductance channel involved in the signal transduction of cell death processes. Incubation of isolated mitochondria with MG for a short period of time ( 5 min), followed by removal of excess free MG, prevented both ganglioside GD3- and Ca2+-induced PTP opening and the ensuing membrane depolarization, swelling, and cytochrome c release. Under these conditions MG did not significantly interfere with mitochondrial substrate transport, respiration, or oxidative phosphorylation. The suppression of permeability transition was reversible following extended incubation in MG-free medium. Of the 29 physiological carbonyl and dicarbonyl compounds tested only MG and its analogue glyoxal were able to specifically alter the behavior of the PTP. Using a set of arginine-containing peptides, we found that the major MG-derived arginine adduct formed, following a short time exposure to MG, was the 5-hydro-5-methylimidazol-4- one derivative. These findings demonstrate that MG rapidly modifies the PTP covalently and stabilizes the PTP in the closed conformation. This is probably due to the formation of an imidazolone adduct on an arginine residue involved in the control of PTP conformation (Linder, M. D., Morkunaite-Haimi, S., Kinnunen, P. J. K., Bernardi, P., and Eriksson, O. ( 2002) J. Biol. Chem. 277, 937 - 942). We deduce that the permeability transition constitutes a potentially important physiological target of MG.	Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland; ETH Honggerberg, Inst Cell Biol, ETH, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	University of Helsinki; Swiss Federal Institutes of Technology Domain; ETH Zurich	Eriksson, O (corresponding author), Univ Helsinki, Inst Biomed Biochem, Helsinki Biophys & Biomembrane Grp, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	ove.eriksson@helsinki.fi	Franck, Marina/A-9498-2008; Wallimann, Theo/C-6047-2008; Liobikas, Julius/J-4278-2016; Eriksson-Rosenberg, Ove/GVU-6692-2022	Franck, Marina/0000-0002-2174-6392; Wallimann, Theo/0000-0003-4957-5836; Liobikas, Julius/0000-0001-6314-9898; 				Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; EGYUD LG, 1966, P NATL ACAD SCI USA, V56, P203, DOI 10.1073/pnas.56.1.203; Eriksson O, 1999, AM J PHYSIOL-CELL PH, V276, pC1297, DOI 10.1152/ajpcell.1999.276.6.C1297; Eriksson O, 1997, FEBS LETT, V409, P361, DOI 10.1016/S0014-5793(97)00549-8; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Godbout JP, 2002, J BIOL CHEM, V277, P2554, DOI 10.1074/jbc.M100385200; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Niwa T, 1999, J CHROMATOGR B, V731, P23, DOI 10.1016/S0378-4347(99)00113-9; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; RILEY ML, 1995, BBA-MOL BASIS DIS, V1270, P36, DOI 10.1016/0925-4439(94)00069-3; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; SHONK CE, 1964, CANCER RES, V24, P709; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; THORNALLEY PJ, 1995, CRIT REV ONCOL HEMAT, V20, P99, DOI 10.1016/1040-8428(94)00149-N; Van Herreweghe F, 2002, P NATL ACAD SCI USA, V99, P949, DOI 10.1073/pnas.012432399; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	41	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34757	34763		10.1074/jbc.M301990200	http://dx.doi.org/10.1074/jbc.M301990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12815061	hybrid			2022-12-25	WOS:000185164400006
J	Ben-Yehoyada, M; Ben-Dor, I; Shaul, Y				Ben-Yehoyada, M; Ben-Dor, I; Shaul, Y			c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; YES-ASSOCIATED PROTEIN; DNA-DAMAGE; SAM DOMAIN; CELL-CYCLE; TRANSCRIPTIONAL ACTIVITY; SUBNUCLEAR TRAFFICKING; APOPTOTIC RESPONSE; INDUCE INTERACTION; P53 REGULATION	p73 is a structural and functional homologue of the p53 tumor-suppressor protein. Like p53, p73 is activated in response to DNA-damaging insults to induce cell cycle arrest or apoptosis. Under these conditions p73 is tyrosine-phosphorylated by c-Abl, a prerequisite modification for p73 to elicit cell death in fibroblasts. In this study we report that in response to ionizing radiation, p73 undergoes nuclear redistribution and becomes associated with the nuclear matrix. This association is c-Abl-dependent because it was not observed in cells that are defective in c-Abl kinase activation. Moreover, STI-571, a specific c-Abl kinase inhibitor, is sufficient to block significantly p73alpha nuclear matrix association. The observed c-Abl dependence of nuclear matrix association was recapitulated in the heterologous baculovirus system. Under these conditions p73alpha but not p53 is specifically tyrosine-phosphorylated by c-Abl. Moreover, the phosphorylated p73alpha is predominantly found in association with the nuclear matrix. Thus, in response to ionizing radiation p73 is modified in a c-Abl-dependent manner and undergoes nuclear redistribution and translocates to associate with the nuclear matrix. Our data describe a novel mechanism of p73 regulation.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Agami R, 1999, NATURE, V399, P809; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BOYER JC, 1995, CANCER RES, V55, P6063; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GOGA A, 1995, ONCOGENE, V11, P791; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Granetto C, 1996, MUTAT RES-FUND MOL M, V352, P61, DOI 10.1016/0027-5107(95)00235-9; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; Hamer G, 2001, ONCOGENE, V20, P4298, DOI 10.1038/sj.onc.1204568; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Iborra FJ, 1996, J CELL SCI, V109, P1427; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MCCREADY SJ, 1984, J CELL SCI, V70, P189; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nie Y, 2000, MOL CELL BIOL, V20, P741, DOI 10.1128/MCB.20.3.741-748.2000; NILOLAEV AY, 2003, CELL, V112, P29; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; UNGER C, 1994, CANCER RES, V54, P3651; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang WK, 2000, ACTA CRYSTALLOGR D, V56, P769, DOI 10.1107/S0907444900005059; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	62	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34475	34482		10.1074/jbc.M301051200	http://dx.doi.org/10.1074/jbc.M301051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824179	hybrid			2022-12-25	WOS:000185047500107
J	Gavrilova, O; Haluzik, M; Matsusue, K; Cutson, JJ; Johnson, L; Dietz, KR; Nicol, CJ; Vinson, C; Gonzalez, FJ; Reitman, ML				Gavrilova, O; Haluzik, M; Matsusue, K; Cutson, JJ; Johnson, L; Dietz, KR; Nicol, CJ; Vinson, C; Gonzalez, FJ; Reitman, ML			Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PARTIAL LIPODYSTROPHY; LIPOATROPHIC A-ZIP/F-1 MICE; PPAR-GAMMA; ADIPOSE-TISSUE; GENE-EXPRESSION; INSULIN-RESISTANCE; DIABETES-MELLITUS; SKELETAL-MUSCLE; ADIPOCYTE DIFFERENTIATION; TRANSGENIC MICE	Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor that mediates the antidiabetic effects of thiazolidinediones. PPARgamma is present in adipose tissue and becomes elevated in fatty livers, but the roles of specific tissues in thiazolidinedione actions are unclear. We studied the function of liver PPARgamma in both lipoatrophic A-ZIP/F- 1 (AZIP) and wild type mice. In AZIP mice, ablation of liver PPARgamma reduced the hepatic steatosis but worsened the hyperlipidemia, triglyceride clearance, and muscle insulin resistance. Inactivation of AZIP liver PPARgamma also abolished the hypoglycemic and hypolipidemic effects of rosiglitazone, demonstrating that, in the absence of adipose tissue, the liver is a primary and major site of thiazolidinedione action. In contrast, rosiglitazone remained effective in non-lipoatrophic mice lacking liver PPARgamma, suggesting that adipose tissue is the major site of thiazolidinedione action in typical mice with adipose tissue. Interestingly, mice without liver PPARgamma, but with adipose tissue, developed relative fat intolerance, increased adiposity, hyperlipidemia, and insulin resistance. Thus, liver PPARgamma regulates triglyceride homeostasis, contributing to hepatic steatosis, but protecting other tissues from triglyceride accumulation and insulin resistance.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gavrilova, O (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10,Rm 8N-250,10 Ctr Dr, Bethesda, MD 20892 USA.		Haluzik, Martin/I-8190-2017; Reitman, Marc/B-4448-2013; Dietz, Kelly/AAE-3074-2021	Haluzik, Martin/0000-0002-0201-6888; Reitman, Marc/0000-0002-0426-9475; Dietz, Kelly/0000-0003-3670-2912; Johnson, Lisa K./0000-0002-3600-7218	NATIONAL CANCER INSTITUTE [ZIABC005271, Z01BC005271] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Ahuja HS, 2001, MOL PHARMACOL, V59, P765, DOI 10.1124/mol.59.4.765; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger J, 1996, ENDOCRINOLOGY, V137, P1984, DOI 10.1210/en.137.5.1984; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen LH, 2001, DIABETES, V50, pA57; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Colombo C, 2003, J BIOL CHEM, V278, P3992, DOI 10.1074/jbc.M207665200; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Edvardsson U, 1999, J LIPID RES, V40, P1177; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOYT HL, 2000, DIABETES MELLITUS FU, P788; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Gavrilova O, 2000, DIABETES, V49, P1910, DOI 10.2337/diabetes.49.11.1910; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Haluzik M, 2002, DIABETES, V51, P2113, DOI 10.2337/diabetes.51.7.2113; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; HOGAN B, 1986, MANIPULATING MOUSE E, P271; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang GQ, 2002, DIABETES, V51, P2412, DOI 10.2337/diabetes.51.8.2412; Kelly IE, 1999, DIABETES CARE, V22, P288, DOI 10.2337/diacare.22.2.288; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mori Y, 1999, DIABETES CARE, V22, P908, DOI 10.2337/diacare.22.6.908; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Qi NN, 2002, J BIOL CHEM, V277, P48501, DOI 10.1074/jbc.M206655200; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Tietge UJF, 1999, J LIPID RES, V40, P2134; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	72	600	622	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34268	34276		10.1074/jbc.M300043200	http://dx.doi.org/10.1074/jbc.M300043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12805374	hybrid			2022-12-25	WOS:000185047500082
J	Karahalil, B; de Souza-Pinto, NC; Parsons, JL; Elder, RH; Bohr, VA				Karahalil, B; de Souza-Pinto, NC; Parsons, JL; Elder, RH; Bohr, VA			Compromised incision of oxidized pyrimidines in liver mitochondria of mice deficient in NTH1 and OGG1 glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; COLI ENDONUCLEASE III; BASE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; SUBSTRATE SPECIFICITIES; HOMOLOG; IDENTIFICATION; PURIFICATION; 8-OXOGUANINE; PRODUCTS	Mitochondrial DNA is constantly exposed to high levels of endogenously produced reactive oxygen species, resulting in elevated levels of oxidative damaged DNA bases. A large spectrum of DNA base alterations can be detected after oxidative stress, and many of these are highly mutagenic. Thus, an efficient repair of these is necessary for survival. Some of the DNA repair pathways involved have been characterized, but others are not yet determined. A DNA repair activity for thymine glycol and other oxidized pyrimidines has been described in mammalian mitochondria, but the nature of the glycosylases involved in this pathway remains unclear. The generation of mouse strains lacking murine thymine glycol-DNA glycosylase (mNTH1) and/or murine 8-oxoguanine-DNA glycosylase (mOGG1), the two major DNA N-glycosylase/apurinic/apyrimidinic (AP) lyases involved in the repair of oxidative base damage in the nucleus, has provided very useful biological model systems for the study of the function of these and other glycosylases in mitochondrial DNA repair. In this study, mouse liver mitochondrial extracts were generated from mNTH1-, mOGG1-, and [ mNTH1, mOGG1]-deficient mice to ascertain the role of each of these glycosylases in the repair of oxidized pyrimidine base damage. We also characterized for the first time the incision of various modified bases in mitochondrial extracts from a double-knockout [ mNTH1, mOGG1]-deficient mouse. We show that mNTH1 is responsible for the repair of thymine glycols in mitochondrial DNA, whereas other glycosylase/ AP lyases also participate in removing other oxidized pyrimidines, such as 5-hydroxycytosine and 5-hydroxyuracil. We did not detect a backup glycosylase or glycosylase/ AP lyase activity for thymine glycol in the mitochondrial mouse extracts.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey; Christie Hosp NHS Trust, Paterson Inst Canc Res, Carcinogenesis Grp, Canc Res UK, Manchester M20 4BX, Lancs, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Gazi University; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Bohr, VA (corresponding author), NIA IRP, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Souza-Pinto, Nadja C./C-3462-2013; Karahalil, Bensu/AFU-8097-2022; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Parsons, Jason/0000-0002-5052-1125; Elder, Rhoderick/0000-0003-4614-175X	NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Ide H, 2001, PROG NUCLEIC ACID RE, V68, P207; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Kang D, 2002, CURR GENET, V41, P311, DOI 10.1007/s00294-002-0312-0; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Luna L, 2000, MUTAT RES-DNA REPAIR, V460, P95, DOI 10.1016/S0921-8777(00)00015-X; Masaoka A, 1999, Nucleic Acids Symp Ser, P291; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Stevnsner T, 2002, EXP GERONTOL, V37, P1189, DOI 10.1016/S0531-5565(02)00142-0; Stierum RH, 1999, J BIOL CHEM, V274, P7128, DOI 10.1074/jbc.274.11.7128; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Teebor G, 1987, Free Radic Res Commun, V2, P303, DOI 10.3109/10715768709065296; Wang YS, 2002, CHEM RES TOXICOL, V15, P671, DOI 10.1021/tx0155855; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i	28	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33701	33707		10.1074/jbc.M301617200	http://dx.doi.org/10.1074/jbc.M301617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819227	hybrid			2022-12-25	WOS:000185047500013
J	Contin, C; Pitard, V; Itai, T; Nagata, S; Moreau, JF; Dechanet-Merville, J				Contin, C; Pitard, V; Itai, T; Nagata, S; Moreau, JF; Dechanet-Merville, J			Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme - Implications for CD40 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-B; TNF-ALPHA; MATRIX-METALLOPROTEINASE; COSTIMULATORY ACTIVITY; SECRETASE CLEAVAGE; DENDRITIC CELLS; FACTOR-RECEPTOR; HUMAN MONOCYTES; T-LYMPHOCYTES; SOLUBLE FORM	The soluble form of CD40 (sCD40), which co-exists with the membrane-anchored form (mCD40), is a natural antagonist of mCD40/CD154 interaction. However, the mechanism leading to the production of sCD40 has never been investigated. Here, we show that the engagement of mCD40 on the surface of B lymphocytes by anti-CD40 antibody led to enhanced sCD40 release associated with decreased amounts of mCD40. This sCD40 production was not affected by vesicular traffic inhibitors but was completely blocked by a broad-spectrum synthetic metalloproteinase ( MP) inhibitor (GM6001) or a membrane-anchored MP-specific inhibitor (dec-RVKR-cmk). Recombinant MP disintegrin tumor necrosis factor-alpha converting enzyme ( TACE) cleaved the purified CD40 ectodomain/Fc chimeric protein in vitro, giving rise to an sCD40 form similar to that shed from B cell cultures. Moreover, spontaneous production of sCD40 by mCD40-transfected human embryonic kidney cells ( constitutively expressing TACE) was enhanced by the overexpression of TACE and abrogated by co-transfection with a dominant-negative TACE mutant. These results provide strong evidence that sCD40 production is an active process regulated by the engagement of mCD40 and its proteolytic cleavage by TACE or a related MP disintegrin. Given the antagonistic activity of sCD40 on the CD40/CD154 interaction, this shedding mechanism might represent an important negative feedback control of CD40 functions.	Univ Bordeaux 2, CNRS, UMR 5540, IFR 66, F-33076 Bordeaux, France; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Osaka University	Dechanet-Merville, J (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, IFR 66, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	julie.dechanet@umr5540.u-bordeaux2.fr	Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Barlaam B, 1999, J MED CHEM, V42, P4890, DOI 10.1021/jm990377j; BJORCK P, 1994, IMMUNOLOGY, V83, P430; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Erickson LD, 2002, J CLIN INVEST, V109, P613, DOI 10.1172/JCI200214110; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1995, EUR J IMMUNOL, V25, P863, DOI 10.1002/eji.1830250335; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047; HERMANN P, 1993, EUR J IMMUNOL, V23, P961, DOI 10.1002/eji.1830230430; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1999, AM J PATHOL, V154, P229, DOI 10.1016/S0002-9440(10)65269-8; Malik N, 1996, J IMMUNOL, V156, P3952; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; Noguchi M, 2001, CANCER GENE THER, V8, P421, DOI 10.1038/sj.cgt.7700320; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 1999, J CELL SCI, V112, P3603; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; Shinde S, 1996, J IMMUNOL, V157, P2764; Solomon KA, 1999, J IMMUNOL, V163, P4105; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; van Kooten C, 1999, EXP NEPHROL, V7, P429; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Vincent B, 2001, J BIOL CHEM, V276, P37743; Vollmer P, 1999, EUR J BIOCHEM, V263, P438, DOI 10.1046/j.1432-1327.1999.00511.x; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Xiang R, 2001, J IMMUNOL, V167, P4560, DOI 10.4049/jimmunol.167.8.4560; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhang ZL, 2001, FASEB J, V15, P303	73	108	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32801	32809		10.1074/jbc.M209993200	http://dx.doi.org/10.1074/jbc.M209993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810728	hybrid, Green Submitted			2022-12-25	WOS:000184901800040
J	Song, C; Zhang, YT; Parsons, CG; Liu, YF				Song, C; Zhang, YT; Parsons, CG; Liu, YF			Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR; SYNAPTIC TRANSMISSION; POSTSYNAPTIC DENSITY; TRINUCLEOTIDE REPEAT; CAG REPEAT; DISEASE; PROTEIN; BRAIN; GENE; PLASTICITY	In our previous studies, we found that expression of polyglutamine-expanded huntingtin in HN33 cells induced sensitization of N-methyl-D-aspartate (NMDA) receptors (Sun, Y., Savinainen, A., and Liu, Y. F. (2001) J. Biol. Chem. 276, 24713-24718). Following this study, we investigated whether tyrosine phosphorylation of NMDA receptors might contribute to the altered property of the receptors. Expression of polyglutamine-expanded huntingtin induced elevation of phosphorylated or activated Src and increased targeting of PSD-95 (post-synaptic density 95) and activated Src to cell surface membrane. Expression of the mutated huntingtin also induced tyrosine phosphorylation of NR2B (NMDA receptor 2B) subunits, and co-expression of PSD-95 enhanced the phosphorylation. Treatment of SU6656 (a specific Src inhibitor) or co-expression of a mutated NR2B subunit with mutations of all three major tyrosine phosphorylation sites significantly attenuated neuronal toxicity induced by the mutated huntingtin. Addition of AP-5 did not further inhibit the neuronal toxicity. Taken together, our studies show that polyglutamine-expanded huntingtin increases tyrosine phosphorylation of NMDA receptors via PSD-95 and Src, and increased tyrosine phosphorylation may contribute to the sensitization of the receptors mediated by polyglutamine-expanded huntingtin.	Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA; Merz & Co, Dept Pharmacol, D-60318 Frankfurt, Germany	Boston University; Merz Pharmaceuticals GmbH	Liu, YF (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, 715 Albany St, Boston, MA 02118 USA.			Parsons, Christopher/0000-0002-3122-8572				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ALBIN RL, 1990, NEW ENGL J MED, V322, P1293, DOI 10.1056/NEJM199005033221807; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Bibb JA, 2000, P NATL ACAD SCI USA, V97, P6809, DOI 10.1073/pnas.120166397; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Guo W, 2002, J NEUROSCI, V22, P6208; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Hunt CA, 1996, J NEUROSCI, V16, P1380; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Song C, 2002, J BIOL CHEM, V277, P6703, DOI 10.1074/jbc.M110338200; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Takagi N, 1997, J NEUROCHEM, V69, P1060; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	28	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33364	33369		10.1074/jbc.M304240200	http://dx.doi.org/10.1074/jbc.M304240200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810713	hybrid			2022-12-25	WOS:000184901800107
J	Hevi, S; Chuck, SL				Hevi, S; Chuck, SL			Ferritins can regulate the secretion of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; DISEASE TYPE-C; HEPG2 CELLS; APO-B; ENDOPLASMIC-RETICULUM; HEREDITARY HEMOCHROMATOSIS; CONTAINING LIPOPROTEINS; MOLECULAR CHAPERONES; VISCERAL ORGANS	Apolipoprotein B is secreted with atherogenic lipids as lipoprotein particles from hepatocytes. Regulation of the secretion of apolipoprotein B is largely post-translational and reflects the balance between processes that leads to particle assembly or to intracellular degradation. Previously, we conducted a proteomic screen to find proteins that bind apolipoprotein B in rat liver microsomes. We identified ferritin heavy and light chains in this screen among other proteins and showed that the two ferritins bind apolipoprotein B directly in vitro. In hepatocytes and other cells, ferritin heavy and light chains form cytosolic cages that store iron. We now show that ferritin heavy or light chains post-translationally inhibit the secretion of apolipoprotein B without altering the export of other hepatic proteins including albumin, factor XIII, and apolipoprotein A-I. This inhibition of apolipoprotein B secretion is not due to diminished lipid synthesis and can be partially overcome by stimulating triglyceride synthesis. The block in apolipoprotein B secretion by ferritins leads to an increase in endoplasmic reticulum-associated degradation of the apolipoprotein. Thus, despite being cytosolic proteins without known chaperone activity, ferritins can specifically regulate the secretion of apolipoprotein B post-translationally. The metabolic pathways for iron storage and intercellular cholesterol and triglyceride transport could intersect.	Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Chuck, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol Med Unit, RW663,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062545] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62545] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Britton RS, 1996, SEMIN LIVER DIS, V16, P3, DOI 10.1055/s-2007-1007214; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Chan L, 2000, RECENT PROG HORM RES, V55, P93; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHRISTOMANOU H, 1995, BIOCHEM MOL MED, V55, P105, DOI 10.1006/bmme.1995.1040; Christomanou H, 1996, BIOCHEM MOL MED, V58, P176, DOI 10.1006/bmme.1996.0046; Christomanou H, 2000, MOL GENET METAB, V70, P196, DOI 10.1006/mgme.2000.3004; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hussain SP, 2000, P NATL ACAD SCI USA, V97, P12770, DOI 10.1073/pnas.220416097; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Rusinol AE, 1996, J LIPID RES, V37, P2296; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SPARKS JD, 1988, J CLIN INVEST, V82, P37, DOI 10.1172/JCI113597; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; VANLENTEN BJ, 1995, J CLIN INVEST, V95, P2104, DOI 10.1172/JCI117898; WETTERAU JR, 1992, SCIENCE, V258, P999; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Xia H, 2000, BIOCHEM BIOPH RES CO, V273, P377, DOI 10.1006/bbrc.2000.2914; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31924	31929		10.1074/jbc.M303081200	http://dx.doi.org/10.1074/jbc.M303081200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12813058	hybrid			2022-12-25	WOS:000184782100060
J	Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T				Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T			Chronic myelogenous leukemia molecular signature	ONCOGENE			English	Article						BCR/ABL; CML; microarrays; gene profiling	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR/ABL-MEDIATED LEUKEMOGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; PHILADELPHIA-CHROMOSOME; CYCLIN D2; SIGNALING PATHWAYS	To obtain comprehensive information about the genes involved in BCR/ABL-dependent leukemogenesis, samples from 15 chronic myelogenous leukemia (CML) patients and seven normal donors were analysed using a cDNA microarray assay. After subtraction of the artificial, random or cross-hybridization signals, data about 5315 genes have been effectively analysed in all samples. The assay revealed greater than or equal to4-fold difference in the average expression of 263 genes in all CML samples when compared to normal counterparts, with 148 genes being upregulated and 115 being downregulated. Differentially expressed genes include those associated with BCR/ABL-induced abnormalities in signal transduction, gene transactivation, cell cycle, apoptosis, adhesion, DNA repair, differentiation, metabolism and malignant progression. Interestingly, CML-blast crisis cells in peripheral blood differ from those from bone marrow, indicating major changes in gene expression profiles upon entering into the bloodstream. Moreover, BCR/ABL modulates expression of genes, which are involved in regulation of chromosome/chromatin/DNA dynamics during S and M cell cycle phase. Moreover, the ability of CML cells to recognize and respond to a pathogen infection may be compromised. Altogether, this work provides a large body of information regarding gene expression profiles associated with CML and also represents a source of potential targets for CML therapeutics.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; UC Irvine, Coll Med, Dept Pathol, Orange, CA USA; Univ Mainz, Dept Med 3, D-55131 Mainz, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Irvine; Johannes Gutenberg University of Mainz	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.			Nowicki, Michal/0000-0002-5807-0007	NCI NIH HHS [CA87300] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AKIYAMA H, 1991, REV INFECT DIS, V13, P815; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Behrens P, 2001, ANTICANCER RES, V21, P2413; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Deininger MWN, 2001, CANCER RES, V61, P8005; Deininger MWN, 2000, CANCER RES, V60, P2049; Dotti G, 1999, BRIT J HAEMATOL, V105, P163, DOI 10.1111/j.1365-2141.1999.01299.x; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Huang HT, 2000, CANCER RES, V60, P6868; Itoh M, 2001, Rinsho Ketsueki, V42, P209; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Janowska-Wieczorek A, 2002, LEUKEMIA, V16, P1160, DOI 10.1038/sj.leu.2402486; Jena N, 2002, CANCER RES, V62, P535; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Maio M, 1998, INT J ONCOL, V13, P305; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Olesen SH, 2001, CARCINOGENESIS, V22, P813, DOI 10.1093/carcin/22.5.813; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Soto T, 1999, APPL ENVIRON MICROB, V65, P2020; Tauchi T, 2001, EXP HEMATOL, V29, P356, DOI 10.1016/S0301-472X(00)00673-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vieira SAD, 2001, GENE CHROMOSOME CANC, V32, P353, DOI 10.1002/gcc.1200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	73	94	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3952	3963		10.1038/sj.onc.1206620	http://dx.doi.org/10.1038/sj.onc.1206620			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813469				2022-12-25	WOS:000183612000015
J	Heidbreder, M; Frohlich, F; Johren, O; Dendorfer, A; Qadri, F; Dominiak, P				Heidbreder, M; Frohlich, F; Johren, O; Dendorfer, A; Qadri, F; Dominiak, P			Hypoxia rapidly activates HIF-3a mRNA expression	FASEB JOURNAL			English	Article						hypoxia-inducible factors; systemic hypoxia; PAS proteins	INDUCIBLE FACTOR-I; PAS DOMAIN PROTEIN; FACTOR 1-ALPHA; TARGET GENES; NUCLEAR TRANSLOCATION; CEREBRAL-ISCHEMIA; ALPHA-SUBUNITS; RAT; TRANSCRIPTION; CELLS	The role of the hypoxia-inducible factor (HIF) subunits 1alpha and 1beta in cellular response to hypoxia is well established, whereas little is known about HIF-2alpha and HIF-3alpha with respect to organ distribution and transcriptional regulation by hypoxia. We investigated mRNA levels of all HIF subunits and of their target genes erythropoietin (EPO) and glucose-transporter 1 (GLUT1) in rats undergoing systemic hypoxia for 30 or 120 min by quantitative real-time RT-PCR. In normoxia, persistently high mRNA levels of all HIF subunits were detected in cerebral cortex, hippocampus, and lung; the heart contained the lowest amounts. Hypoxia did not affect mRNA levels of HIF-1alpha, -1beta, and -2alpha. HIF-3alpha mRNA levels increased in all organs examined after 2 h of hypoxia. A significant rise of EPO and GLUT1 mRNA levels occurred in cortex, heart, liver, and kidney after 2 h of hypoxia, indicating activation of the HIF system. Protein levels of all HIF subunits, determined in brain and lung by immunoblotting, showed a marked increase corresponding to the duration of hypoxia. Our results suggest that induction at the transcriptional level is a unique feature of HIF-3alpha, which therefore may represent a rapidly reacting component of the HIF system in protection against hypoxic damage.	Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany	University of Lubeck	Heidbreder, M (corresponding author), Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	heidbred@medinf.mu-luebeck.de	Jöhren, Olaf/G-6967-2011; Bader, Michael/K-2124-2013	Joehren, Olaf/0000-0002-0532-5133				Ambrosini G, 2002, J BIOL CHEM, V277, P34601, DOI 10.1074/jbc.M205172200; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Drutel G, 1996, BIOCHEM BIOPH RES CO, V225, P333, DOI 10.1006/bbrc.1996.1176; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Johren O, 2001, ENDOCRINOLOGY, V142, P3324, DOI 10.1210/en.142.8.3324; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Madan A, 2002, MOL GENET METAB, V75, P244, DOI 10.1006/mgme.2001.3293; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; NAGAO M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P99, DOI 10.1016/0167-4781(92)90146-Q; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Wolfrum S, 2002, CARDIOVASC RES, V55, P583, DOI 10.1016/S0008-6363(02)00408-X; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zou AP, 2001, PHYSIOL GENOMICS, V6, P159, DOI 10.1152/physiolgenomics.2001.6.3.159	55	148	168	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1541	+		10.1096/fj.02-0963fje	http://dx.doi.org/10.1096/fj.02-0963fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824304				2022-12-25	WOS:000183818000034
J	Bernichtein, S; Kayser, C; Dillner, K; Moulin, S; Kopchick, JJ; Martial, JA; Norstedt, G; Isaksson, O; Kelly, PA; Goffin, V				Bernichtein, S; Kayser, C; Dillner, K; Moulin, S; Kopchick, JJ; Martial, JA; Norstedt, G; Isaksson, O; Kelly, PA; Goffin, V			Development of pure prolactin receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ADVANCED BREAST-CANCER; GENE-EXPRESSION; PROSTATE HYPERPLASIA; LACTOGENIC HORMONES; TRANSGENIC MICE; BINDING SITE; RAT-LIVER; IN-VIVO; BROMOCRIPTINE	Prolactin (PRL) promotes tumor growth in various experimental models and leads to prostate hyperplasia and mammary neoplasia in PRL transgenic mice. Increasing experimental evidence argues for the involvement of autocrine PRL in this process. PRL receptor antagonists have been developed to counteract these undesired proliferative actions of PRL. However, all forms of PRL receptor antagonists obtained to date exhibit partial agonism, preventing their therapeutic use as full antagonists. In the present study, we describe the development of new human PRL antagonists devoid of agonistic properties and therefore able to act as pure antagonists. This was demonstrated using several in vitro bioassays, including highly sensitive assays able to detect extremely low levels of receptor activation. These new compounds also act as pure antagonists in vivo, as assessed by analyzing their ability to competitively inhibit PRL-triggered signaling cascades in various target tissues ( liver, mammary gland, and prostate). Finally, by using transgenic mice expressing PRL specifically in the prostate, which exhibit constitutively activated signaling cascades paralleling hyperplasia, we show that these new PRL analogs are able to completely revert PRL-activated events. These second generation human PRL antagonists are good candidates to be used as inhibitors of growth-promoting actions of PRL.	Hormone Targets, INSERM, U584, F-75730 Paris 15, France; Karolinska Inst, Karolinska Sjukhuset L801, Dept Mol Med, S-17176 Stockholm, Sweden; Ohio Univ, Edison Biotechnol Inst, Mol & Cellular Biol Program, Athens, OH 45701 USA; Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Univ Liege, Lab Mol Biol & Genet Engn, B-4000 Sart Tilman Par Liege, Belgium; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, SE-41345 Gothenburg, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Karolinska Institutet; University System of Ohio; Ohio University; University System of Ohio; Ohio University; University of Liege; Sahlgrenska University Hospital; University of Gothenburg	Goffin, V (corresponding author), Hormone Targets, INSERM, U584, 156 Rue de Vaugirard, F-75730 Paris 15, France.	goffin@necker.fr	GOFFIN, Vincent/G-3322-2013; Kelly, Paul/A-7951-2008	GOFFIN, Vincent/0000-0002-8021-3086; 				ANDERSON E, 1993, EUR J CANCER, V29A, P209, DOI 10.1016/0959-8049(93)90178-I; Baudhuin A, 2002, ANN NY ACAD SCI, V973, P454, DOI 10.1111/j.1749-6632.2002.tb04682.x; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; Bernichtein S, 2003, ENDOCRINE, V20, P177, DOI 10.1385/ENDO:20:1-2:177; Bernichtein S, 2001, ENDOCRINOLOGY, V142, P3950, DOI 10.1210/en.142.9.3950; BERNICHTEIN S, IN PRESS MOL CELL EN; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; Brisken C, 2002, DEV CELL, V3, P877, DOI 10.1016/S1534-5807(02)00365-9; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Cataldo L, 2000, INT J ONCOL, V17, P1179; Chen NY, 2002, INT J ONCOL, V20, P813; Chen TJ, 1998, ENDOCRINOLOGY, V139, P609, DOI 10.1210/en.139.2.609; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CHEN WY, 1994, J BIOL CHEM, V269, P15892; Clark R, 1996, J BIOL CHEM, V271, P21969, DOI 10.1074/jbc.271.36.21969; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; Dillner K, 2002, PROSTATE, V52, P139, DOI 10.1002/pros.10102; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GINSBURG E, 1995, CANCER RES, V55, P2591; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; GOUT PW, 1980, CANCER RES, V40, P2433; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; Kabuto M, 2000, CANCER EPIDEM BIOMAR, V9, P575; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kindblom J, 2003, ENDOCRINOLOGY, V144, P2269, DOI 10.1210/en.2002-0187; Kinet S, 1999, J BIOL CHEM, V274, P26033, DOI 10.1074/jbc.274.37.26033; Kinet S, 1996, J BIOL CHEM, V271, P14353, DOI 10.1074/jbc.271.24.14353; KINET S, 2001, RRD ENDOCRINOL 1, V2, P1; Kopchick JJ, 2002, ENDOCR REV, V23, P623, DOI 10.1210/er.2001-0022; Kuo CB, 2002, CELL TISSUE RES, V309, P429, DOI 10.1007/s00441-002-0598-8; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; MANNI A, 1989, BREAST CANCER RES TR, V14, P289, DOI 10.1007/BF01806300; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Mertani HC, 1998, INT J CANCER, V79, P202; Mode A, 1996, ENDOCRINOLOGY, V137, P447, DOI 10.1210/en.137.2.447; Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Ormandy CJ, 1998, DNA CELL BIOL, V17, P761, DOI 10.1089/dna.1998.17.761; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; PICCOLETTI R, 1994, BIOCHEM J, V303, P429, DOI 10.1042/bj3030429; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; Tollet-Egnell P, 2001, MOL ENDOCRINOL, V15, P308, DOI 10.1210/me.15.2.308; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; van Neck JW, 2000, J ENDOCRINOL, V167, P295, DOI 10.1677/joe.0.1670295; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; WANG DY, 1992, INT J EPIDEMIOL, V21, P214, DOI 10.1093/ije/21.2.214; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Xu XL, 2001, CANCER RES, V61, P6098; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	68	97	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35988	35999		10.1074/jbc.M305687200	http://dx.doi.org/10.1074/jbc.M305687200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12824168	hybrid, Green Published			2022-12-25	WOS:000185318300016
J	Reszko, AE; Kasumov, T; Pierce, BA; David, F; Hoppel, CL; Stanley, WC; Des Rosiers, C; Brunengraber, H				Reszko, AE; Kasumov, T; Pierce, BA; David, F; Hoppel, CL; Stanley, WC; Des Rosiers, C; Brunengraber, H			Assessing the reversibility of the anaplerotic reactions of the propionyl-CoA pathway in heart and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; ANIMAL TISSUES; COENZYME-A; METHYLMALONYL-COENZYME; PIG-HEART; IN-VIVO; ACID; METABOLISM; PYRUVATE; CYCLE	While a number of studies underline the importance of anaplerotic pathways for hepatic biosynthetic functions and cardiac contractile activity, much remains to be learned about the sites and regulation of anaplerosis in these tissues. As part of a study on the regulation of anaplerosis from propionyl-CoA precursors in rat livers and hearts, we investigated the degree of reversibility of the reactions of the propionyl-CoA pathway. Label was introduced into the pathway via (NaHCO3)-C-13, [U-C-13(3)]propionate, or [U-C-13(3)]lactate + [U-C-13(3)]pyruvate, under various concentrations of propionate. The mass isotopomer distributions of propionyl-CoA, methylmalonyl-CoA, and succinyl-CoA revealed that, in intact livers and hearts, (i) the propionyl-CoA carboxylase reaction is slightly reversible only at low propionyl-CoA flux, (ii) the methylmalonyl-CoA racemase reaction keeps the methylmalonyl-CoA enantiomers in isotopic equilibrium under all conditions tested, and (iii) the methylmalonyl-CoA mutase reaction is reversible, but its reversibility decreases as the flow of propionyl-CoA increases. The thermodynamic disequilibrium of the combined reactions of the propionyl-CoA pathway explains the effectiveness of anaplerosis from propionyl-CoA precursors such as heptanoate.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Universite de Montreal	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxb8@cwru.edu	Rosiers, Christine Des/O-6285-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL58653] Funding Source: Medline; NIA NIH HHS [P01AG15885] Funding Source: Medline; NIDDK NIH HHS [DK07319, R01DK35543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN SHG, 1969, METHOD ENZYMOL, V13, P194; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; BUNGER R, 1986, J MOL CELL CARDIOL, V18, P423, DOI 10.1016/S0022-2828(86)80905-1; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; ELBERS R, 1974, H-S Z PHYSIOL CHEM, V355, P378, DOI 10.1515/bchm2.1974.355.1.378; Fenton WA, 2001, METABOLIC MOL BASES, P2165; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; FLAVIN M, 1955, NATURE, V176, P823, DOI 10.1038/176823a0; FRIEDMAN DL, 1961, BIOCHEM BIOPH RES CO, V4, P266, DOI 10.1016/0006-291X(61)90231-5; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; Kasumov T, 2002, FASEB J, V16, pA33; Kasumov T, 2002, ANAL BIOCHEM, V305, P90, DOI 10.1006/abio.2002.5639; KATZ J, 1993, J BIOL CHEM, V268, P25509; KATZ J, 1955, J AM CHEM SOC, V77, P2659, DOI 10.1021/ja01614a105; KAZIRO Y, 1961, J BIOL CHEM, V236, P1917; KORNBERG HL, 1967, B SOC CHIM BIOL, V49, P1479; LARDY HA, 1956, J BIOL CHEM, V219, P933; LECLERC J, 1995, AM J PHYSIOL-ENDOC M, V268, pE446, DOI 10.1152/ajpendo.1995.268.3.E446; MARSOLAIS C, 1989, J BIOL CHEM, V264, P19761; Martini WZ, 2003, AM J PHYSIOL-ENDOC M, V284, pE351, DOI 10.1152/ajpendo.00354.2002; MAZUMDER R, 1962, J BIOL CHEM, V237, P3065; MAZUMDER R, 1969, METHOD ENZYMOL, V13, P198; MONTGOMERY JA, 1983, J CLIN INVEST, V72, P1937, DOI 10.1172/JCI111158; NUUTINEN EM, 1981, BIOCHEM J, V194, P867, DOI 10.1042/bj1940867; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Panchal AR, 2000, AM J PHYSIOL-HEART C, V279, pH2390, DOI 10.1152/ajpheart.2000.279.5.H2390; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; Puchowicz MA, 1999, AM J PHYSIOL-ENDOC M, V277, pE1022, DOI 10.1152/ajpendo.1999.277.6.E1022; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; Roe CR, 2002, J CLIN INVEST, V110, P259, DOI [10.1172/JCI200215311, 10.1172/JCI0215311]; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; RUSSELL RR, 1991, J CLIN INVEST, V87, P384, DOI 10.1172/JCI115008; RUSSELL RR, 1995, AM J PHYSIOL-HEART C, V268, pH441, DOI 10.1152/ajpheart.1995.268.1.H441; SUMEGI B, 1995, BIOCHEM J, V312, P75, DOI 10.1042/bj3120075; TIETZ A, 1959, J BIOL CHEM, V234, P1394	36	36	39	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34959	34965		10.1074/jbc.M302013200	http://dx.doi.org/10.1074/jbc.M302013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824185	hybrid			2022-12-25	WOS:000185164400028
J	Spencer, JPE; Rice-Evans, C; Williams, RJ				Spencer, JPE; Rice-Evans, C; Williams, RJ			Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GINKGO-BILOBA EXTRACT; PROTEIN-KINASE; HYDROGEN-PEROXIDE; PHOSPHATIDYLINOSITOL 3-KINASE; FLAVONOID CONSTITUENTS; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; INDUCED TOXICITY; CELL-LINE; C-JUN	Much recent interest has focused on the potential of flavonoids to interact with intracellular signaling pathways such as with the mitogen-activated protein kinase cascade. We have investigated whether the observed strong neurotoxic potential of quercetin in primary cortical neurons may occur via specific and sensitive interactions within neuronal mitogen-activated protein kinase and Akt/protein kinase B (PKB) signaling cascades, both implicated in neuronal apoptosis. Quercetin induced potent inhibition of both Akt/PKB and ERK phosphorylation, resulting in reduced phosphorylation of BAD and a strong activation of caspase-3. High quercetin concentrations ( 30 muM) led to sustained loss of Akt phosphorylation and subsequent Akt cleavage by caspase-3, whereas at lower concentrations (< 10 mu M) the inhibition of Akt phosphorylation was transient and eventually returned to basal levels. Lower levels of quercetin also induced strong activation of the pro-survival transcription factor cAMP-responsive element-binding protein, although this did not prevent neuronal damage. O-Methylated quercetin metabolites inhibited Akt/PKB to lesser extent and did not induce such strong activation of caspase-3, which was reflected in the lower amount of damage they inflicted on neurons. In contrast, neither quercetin nor its O-methylated metabolites had any measurable effect on c-Jun N-terminal kinase phosphorylation. The glucuronide of quercetin was not toxic and did not evoke any alterations in neuronal signaling, probably reflecting its inability to enter neurons. Together these data suggest that quercetin and to a lesser extent its O-methylated metabolites may induce neuronal death via a mechanism involving an inhibition of neuronal survival signaling through the inhibition of both Akt/PKB and ERK rather than by an activation of the c-Jun N-terminal kinase-mediated death pathway.	Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Wolfson Ctr Age Related Dis, London SE1 9RT, England	University of London; King's College London	Williams, RJ (corresponding author), Kings Coll London, Guys Kings & St Thomas Sch Biomed Sci, Wolfson Ctr Age Related Dis, Hodgkin Bldg,Guys Campus, London SE1 9RT, England.	robert.williams@kcl.ac.uk	Williams, Robert/A-9180-2008; Spencer, Jeremy P. E./F-4757-2010	Williams, Robert/0000-0002-2369-1989; Spencer, Jeremy P. E./0000-0003-2931-7274				Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boulton DW, 1999, J PHARM PHARMACOL, V51, P353, DOI 10.1211/0022357991772367; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi JA, 2001, INT J ONCOL, V19, P837; Coffer PJ, 1998, BIOCHEM J, V335, P1; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Csokay B, 1997, LIFE SCI, V60, P2157, DOI 10.1016/S0024-3205(97)00230-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEL PL, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Inanami O, 1998, FREE RADICAL RES, V29, P359, DOI 10.1080/10715769800300401; Ishikawa Y, 2000, KIDNEY INT, V58, P1078, DOI 10.1046/j.1523-1755.2000.00265.x; Joseph JA, 1999, J NEUROSCI, V19, P8114; Joseph JA, 1998, J NEUROSCI, V18, P8047; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kobuchi H, 1999, AM J PHYSIOL-CELL PH, V277, pC403, DOI 10.1152/ajpcell.1999.277.3.C403; Kong ANT, 2000, ARCH PHARM RES, V23, P1, DOI 10.1007/BF02976458; Kuo SM, 1996, CANCER LETT, V110, P41, DOI 10.1016/S0304-3835(96)04458-8; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Metodiewa D, 1999, FREE RADICAL BIO MED, V26, P107, DOI 10.1016/S0891-5849(98)00167-1; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; OYAMA Y, 1994, BRAIN RES, V635, P125, DOI 10.1016/0006-8993(94)91431-1; Oyama Y, 1999, EUR J PHARMACOL, V384, P47, DOI 10.1016/S0014-2999(99)00649-4; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rong Y, 2000, ANTICANCER RES, V20, P4339; Russo M, 1999, FEBS LETT, V462, P322, DOI 10.1016/S0014-5793(99)01544-6; Rzymowska J, 1999, FOLIA HISTOCHEM CYTO, V37, P125; Samanta S, 1998, J NEUROCHEM, V70, P2082; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; Schroeter H, 2002, NEUROBIOL AGING, V23, P861, DOI 10.1016/S0197-4580(02)00075-1; Spencer JPE, 2003, BIOCHEM J, V372, P173, DOI 10.1042/BJ20021972; Spencer JPE, 2001, FREE RADICAL BIO MED, V31, P1139, DOI 10.1016/S0891-5849(01)00704-3; Spencer JPE, 1999, FEBS LETT, V458, P224, DOI 10.1016/S0014-5793(99)01160-6; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Wang LM, 2002, NEPHRON, V91, P142, DOI 10.1159/000057616; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEI YQ, 1994, CANCER RES, V54, P4952; Weinreb O, 2003, FASEB J, V17, P935, DOI 10.1096/fj.02-0712fje; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Yang K, 2000, CARCINOGENESIS, V21, P1655, DOI 10.1093/carcin/21.9.1655; Youdim KA, 2003, J NEUROCHEM, V85, P180, DOI 10.1046/j.1471-4159.2003.01652.x; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zimmermann M, 2002, CELL MOL BIOL, V48, P613	63	263	281	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34783	34793		10.1074/jbc.M305063200	http://dx.doi.org/10.1074/jbc.M305063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826665	hybrid			2022-12-25	WOS:000185164400009
J	Tornaletti, S; Patrick, SM; Turchi, JJ; Hanawalt, PC				Tornaletti, S; Patrick, SM; Turchi, JJ; Hanawalt, PC			Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; CYCLOBUTANE PYRIMIDINE DIMER; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); HAMSTER OVARY CELLS; ELONGATION COMPLEX; EXCISION-REPAIR; STRUCTURAL BASIS; CROSS-LINKS; IN-VITRO; STRAND	Transcription-coupled DNA repair is dedicated to the removal of DNA lesions from transcribed strands of expressed genes. RNA polymerase arrest at a lesion has been proposed as a sensitive signal for recruitment of repair enzymes to the lesion site. To understand how initiation of transcription-coupled repair may occur, we have characterized the properties of the transcription complex when it encounters a lesion in its path. Here we have compared the effect of cisplatin-induced intrastrand cross-links on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II. We found that a single cisplatin 1,2-d(GG) intrastrand cross-link or a single cisplatin 1,3-d(GTG) intrastrand cross-link is a strong block to both polymerases. Furthermore, the efficiency of the block at a cisplatin 1,2-d(GG) intrastrand cross-link was similar in several different nucleotide sequence contexts. Interestingly, some blockage was also observed when the single cisplatin 1,3-d(GTG) intrastrand cross-link was located in the non-transcribed strand. Transcription complexes arrested at the cisplatin adducts were substrates for the transcript cleavage reaction mediated by the elongation factor TFIIS, indicating that the RNA polymerase II complexes arrested at these lesions are not released from template DNA. Addition of TFIIS yielded a population of transcripts up to 30 nucleotides shorter than those arrested at the lesion. In the presence of nucleoside triphosphates, these shortened transcripts could be re-elongated up to the site of the lesion, indicating that the arrested complexes are stable and competent to resume elongation. These results show that cisplatin-induced lesions in the transcribed DNA strand constitute a strong physical barrier to RNA polymerase progression, and they support current models of transcription arrest and initiation of transcription-coupled repair.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	Stanford University; University System of Ohio; Wright State University Dayton	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	hanawalt@stanford.edu	Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NCI NIH HHS [CA-77712, R01 CA077712, CA82741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077712, R01CA077712, R01CA082741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANIN MF, 1990, NUCLEIC ACIDS RES, V18, P4395, DOI 10.1093/nar/18.15.4395; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; CHEN YH, 1993, J BIOL CHEM, V268, P5849; Choi DJ, 1996, J MOL BIOL, V264, P213, DOI 10.1006/jmbi.1996.0635; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; Conconi A, 2002, P NATL ACAD SCI USA, V99, P649, DOI 10.1073/pnas.022373099; CORDA Y, 1991, BIOCHEMISTRY-US, V30, P222, DOI 10.1021/bi00215a032; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P1377; Furuta T, 2002, CANCER RES, V62, P4899; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1993, P A BENTON S, V35, P231; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JONES JC, 1991, J BIOL CHEM, V266, P7101; Kalogeraki VS, 2003, J BIOL CHEM, V278, P19558, DOI 10.1074/jbc.M301060200; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; MAY A, 1993, J BIOL CHEM, V268, P1650; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Perlow RA, 2002, J MOL BIOL, V321, P29, DOI 10.1016/S0022-2836(02)00593-4; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; REINES D, 1991, J BIOL CHEM, V266, P10510; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHI YB, 1988, J BIOL CHEM, V263, P527; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Teuben JM, 1999, BIOCHEMISTRY-US, V38, P12305, DOI 10.1021/bi9904757; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; Turchi JJ, 1997, BIOCHEMISTRY-US, V36, P7586, DOI 10.1021/bi963124q; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Verhage RA, 1997, MOL GEN GENET, V254, P284, DOI 10.1007/s004380050417; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; ZHEN WP, 1993, CARCINOGENESIS, V14, P919, DOI 10.1093/carcin/14.5.919	60	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35791	35797		10.1074/jbc.M305394200	http://dx.doi.org/10.1074/jbc.M305394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829693	hybrid			2022-12-25	WOS:000185164400127
J	Vispe, S; Ho, ELY; Yung, TMC; Satoh, MS				Vispe, S; Ho, ELY; Yung, TMC; Satoh, MS			Double-strand DNA break formation mediated by flap endonuclease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; BASE EXCISION-REPAIR; MULTIPLY DAMAGED SITES; LIGASE-I; REPLICATION FORK; MAMMALIAN-CELLS; HUMAN FEN1; BINDING; RECOMBINATION; MECHANISMS	Double-strand DNA breaks are the most lethal type of DNA damage induced by ionizing radiations. Previously, we reported that double-strand DNA breaks can be enzymatically produced from two DNA damages located on opposite DNA strands 18 or 30 base pairs apart in a cell-free double-strand DNA break formation assay (Vispe, S., and Satoh, M. S. ( 2000) J. Biol. Chem. 275, 27386 - 27392). In the assay that we developed, these two DNA damages are converted into single-strand interruptions by enzymes involved in base excision repair. We showed that these single-strand interruptions are converted into double-strand DNA breaks; however, it was not due to spontaneous denaturation of DNA. Thus, we proposed a model in which DNA polymerase delta/epsilon, by producing repair patches at single-strand interruptions, collide, resulting in double-strand DNA break formation. We tested the model and investigated whether other enzymes/factors are involved in double-strand DNA break formation. Here we report that, instead of DNA polymerase delta/epsilon, flap endonuclease-1 (FEN-1), an enzyme involved in base excision repair, is responsible for the formation of double-strand DNA break in the assay. Furthermore, by transfecting a flap endonuclease-1 expression construct into cells, thus altering their flap endonuclease-1 content, we found an increased number of double-strand DNA breaks after gamma-ray irradiation of these cells. These results suggest that flap endonuclease-1 acts as a double-strand DNA break formation factor. Because FEN-1 is an essential enzyme that plays its roles in DNA repair and DNA replication, DSBs may be produced in cells as by-products of the activity of FEN-1.	Univ Laval, Fac Med, CHUQ, Med Ctr,Lab DNA Repair,Hlth & Environm Unit, Ste Foy, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), CHU Laval, Res Ctr, Local 9700,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	masahiko.sato@crchul.ulaval.ca						ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Boudaiffa B, 2000, SCIENCE, V287, P1658, DOI 10.1126/science.287.5458.1658; BRENNER DJ, 1992, INT J RADIAT BIOL, V61, P737, DOI 10.1080/09553009214551591; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CIMINO G, 1993, BLOOD, V82, P544; CLEAVER JE, 1985, CANCER RES, V45, P1163; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; HUNGER SP, 1991, BLOOD, V77, P687; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Legault J, 1997, MOL CELL BIOL, V17, P5437, DOI 10.1128/MCB.17.9.5437; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; TAN CK, 1986, J BIOL CHEM, V261, P2310; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vispe S, 2000, J BIOL CHEM, V275, P27386; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALKER IG, 1984, CAN J BIOCHEM CELL B, V62, P329, DOI 10.1139/o84-046; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WLODEK D, 1991, INT J RADIAT BIOL, V60, P779, DOI 10.1080/09553009114552591; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	46	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35279	35285		10.1074/jbc.M303448200	http://dx.doi.org/10.1074/jbc.M303448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832398	hybrid			2022-12-25	WOS:000185164400066
J	Peterson, S; Bogenmann, E				Peterson, S; Bogenmann, E			Osmotic swelling induces p75 neurotrophin receptor (p75NTR) expression via nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; PHOSPHOLIPASE-C; SPINAL-CORD; NEURONAL DIFFERENTIATION; BRAIN EDEMA; CELL-LINE; P75(NTR); INJURY; STRESS	Brain injuries by physical trauma, epileptic seizures, or microbial infection upset the osmotic homeostasis resulting in cell swelling (cerebral edema), inflammation, and apoptosis. Expression of the neurotrophin receptor p75NTR is increased in the injured tissue and axon regeneration is repressed by the Nogo receptor using p75NTR as the signal transducer. Hence, p75NTR seems central to the injury response and we wished to determine the signals that regulate its expression. Here, we demonstrate that tonicity mediated cell swelling rapidly activates transcription of the endogenous p75NTR gene and of a p75NTR promoter-reporter gene in various cell types. Transcription activation is independent of de novo protein synthesis and requires the activities of phospholipase C, protein kinase C, and nitric-oxide synthase. Hence, p75NTR is a nitric oxide effector gene regulated by osmotic swelling, thereby providing a strategy for therapeutic intervention to modulate p75NTR functions following injury.	Childrens Hosp, Div Hematol & Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Bogenmann, E (corresponding author), Univ So Calif, Dept Pediat, MS 57,4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036978] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36978] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BOGENMANN E, 1995, ONCOGENE, V10, P1915; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; Faris M, 1998, J IMMUNOL, V160, P134; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Flugel A, 2001, EUR J IMMUNOL, V31, P11, DOI 10.1002/1521-4141(200101)31:1<11::AID-IMMU11>3.0.CO;2-G; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; Godwin SL, 2002, BONE, V30, P559, DOI 10.1016/S8756-3282(01)00700-1; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; GROB PM, 1985, J BIOL CHEM, V260, P8044; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Handy RLC, 1998, BRIT J PHARMACOL, V123, P1119, DOI 10.1038/sj.bjp.0701735; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Kim RD, 2001, J CELL BIOCHEM, V83, P56, DOI 10.1002/jcb.1205; Kimura C, 2000, BIOCHEM BIOPH RES CO, V274, P736, DOI 10.1006/bbrc.2000.3205; Ko GY, 1999, J NEUROSCI, V19, P6784, DOI 10.1523/JNEUROSCI.19-16-06784.1999; Lam HHD, 1996, NEUROSCI LETT, V210, P201, DOI 10.1016/0304-3940(96)12702-6; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Leong SK, 2002, ANN NY ACAD SCI, V962, P161, DOI 10.1111/j.1749-6632.2002.tb04066.x; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Pasantes-Morales H, 2000, NEUROCHEM RES, V25, P1301, DOI 10.1023/A:1007652330703; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Schwartzkroin PA, 1998, EPILEPSY RES, V32, P275, DOI 10.1016/S0920-1211(98)00058-8; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SEKIGUCHI M, 1979, JPN J EXP MED, V49, P67; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; TOMITA M, 1992, AM J PHYSIOL, V262, pH603, DOI 10.1152/ajpheart.1992.262.2.H603; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urdiales JL, 1998, J NEUROSCI, V18, P6767; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	50	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33943	33950		10.1074/jbc.M302376200	http://dx.doi.org/10.1074/jbc.M302376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821676	hybrid			2022-12-25	WOS:000185047500041
J	Schjott, JM; Hsu, SC; Plummer, MR				Schjott, JM; Hsu, SC; Plummer, MR			The neuronal beta(4) subunit increases the unitary conductance of L-type voltage-gated calcium channels in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; HIPPOCAMPAL-NEURONS; FUNCTIONAL-PROPERTIES; ALPHA(1A) SUBUNIT; HEART-CELLS; RAT-BRAIN; N-TYPE; EXPRESSION; LTP; POTENTIATION	beta subunits of voltage-gated calcium channels influence channel behavior in numerous ways, including enhancing the targeting of alpha(1) subunits to the plasma membrane and shifting the voltage dependence of activation and inactivation. Of the four beta subunits that have been identified, beta(4) is of particular interest because mutation of its alpha(1) subunit interaction domain produces severe neurological defects. Its differential distribution in the hippocampus prompted us to examine whether this subunit was responsible for the heterogeneity of hippocampal L-type calcium channels. To study the functional effects of the beta(4) subunit on native L-type calcium channels, we transfected beta(4) cDNA subcloned out of embryonic hippocampal neurons into PC12 cells, a cell line that contains the beta(1), beta(2), and beta(3) subunits but not the beta(4) subunit. Cell-attached single-channel recordings of L-type channel activity from untransfected and transfected PC12 cells compared with recordings obtained from hippocampal neurons revealed an effect of the beta(4) subunit on single-channel conductance. L-type channels in untransfected PC12 cells had a significantly smaller conductance (19.8 picosiemens (pS)) than L-type channels in hippocampal neurons (22 pS). After transfection of beta(4), however, L-type single-channel conductance was indistinguishable between the two cell types. Our data suggest that calcium channel beta(4) subunits affect the conductance of L-type calcium channels and that native hippocampal L-type channels contain the beta(4) subunit.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Plummer, MR (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.		Tuluc, Petronel/C-2527-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034061] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34061] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Borroni AM, 2000, J NEUROSCI, V20, P9272; Brice NL, 1999, J PHYSIOL-LONDON, V515, P685, DOI 10.1111/j.1469-7793.1999.685ab.x; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1998, J BIOL CHEM, V273, P18308, DOI 10.1074/jbc.273.29.18308; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Cloues RK, 2000, J PHYSIOL-LONDON, V524, P19, DOI 10.1111/j.1469-7793.2000.00019.x; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; Day NC, 1998, MOL BRAIN RES, V60, P259, DOI 10.1016/S0169-328X(98)00186-7; Dirksen RT, 1997, BIOPHYS J, V73, P1402, DOI 10.1016/S0006-3495(97)78172-4; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Fan JS, 2001, AM J PHYSIOL-CELL PH, V280, pC565, DOI 10.1152/ajpcell.2001.280.3.C565; FORTI L, 1993, NEURON, V10, P437, DOI 10.1016/0896-6273(93)90332-L; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gondo N, 1998, FEBS LETT, V423, P86, DOI 10.1016/S0014-5793(98)00070-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Hivert B, 1999, J GEN PHYSIOL, V113, P679, DOI 10.1085/jgp.113.5.679; HUBER KM, 1995, NEUROREPORT, V6, P1281, DOI 10.1097/00001756-199506090-00013; Josephson IR, 2002, BIOPHYS J, V83, P2587, DOI 10.1016/S0006-3495(02)75269-7; Kapur A, 1998, J NEUROPHYSIOL, V79, P2181, DOI 10.1152/jn.1998.79.4.2181; KAVALALI ET, 1994, J PHYSIOL-LONDON, V480, P475, DOI 10.1113/jphysiol.1994.sp020376; Kavalali ET, 1996, J NEUROSCI, V16, P1072; Kavalali ET, 1997, J NEUROSCI, V17, P5334; Liu HY, 1996, J NEUROSCI, V16, P7557; Ludwig A, 1997, J NEUROSCI, V17, P1339; Meir A, 1998, NEURON, V20, P341, DOI 10.1016/S0896-6273(00)80461-4; Morgan SL, 1999, J NEUROPHYSIOL, V82, P736, DOI 10.1152/jn.1999.82.2.736; Pan JQ, 2000, J NEUROSCI, V20, P4769; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Qian J, 2001, J NEUROSCI, V21, P3721, DOI 10.1523/JNEUROSCI.21-11-03721.2001; Schjott JM, 2000, J NEUROSCI, V20, P4786; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; THIBAULT O, 1993, P NATL ACAD SCI USA, V90, P11792, DOI 10.1073/pnas.90.24.11792; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180	54	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33936	33942		10.1074/jbc.M302059200	http://dx.doi.org/10.1074/jbc.M302059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821675	hybrid			2022-12-25	WOS:000185047500040
J	Zhong, Q; Greenberg, ML				Zhong, Q; Greenberg, ML			Regulation of phosphatidylglycerophosphate synthase by inositol in Saccharomyces cerevisiae is not at the level of PGS1 mRNA abundance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; CARDIOLIPIN SYNTHASE; GENE-EXPRESSION; YEAST; GROWTH; MYOINOSITOL; PHOSPHATIDYLINOSITOL; MITOCHONDRIA; SEQUENCE; ENCODES	Phosphatidylglycerophosphate synthase catalyzes the committed step in the synthesis of the mitochondrial phospholipid cardiolipin. We showed previously that phosphatidylglycerophosphate synthase activity in Saccharomyces cerevisiae is increased in conditions favoring mitochondrial development and during growth in the absence of inositol. Interestingly, the regulatory effects of inositol were not altered in ino2, ino4, or opi1 mutants suggesting that regulation in response to inositol is not at the level of gene transcription. We report here that steady state mRNA levels of the PGS1 gene, which encodes phosphatidylglycerophosphate synthase, were not altered by inositol or choline. Growth in the presence of the inositol-depleting drug valproate led to an increase in phosphatidylglycerophosphate synthase activity unaccompanied by increased PGS1 mRNA. PGS1 mRNA abundance was not decreased in ino2 or ino4 mutants and was unaffected in an opi1 mutant. Therefore, regulation of phosphatidylglycerophosphate synthase by inositol is not mediated at the level of mRNA abundance and does not require the INO2-INO4-OPI1 regulatory circuit. PGS1 was increased in glycerol/ethanol compared with glucose media and was maximally expressed as cells entered the stationary phase. Deletion of the mitochondrial genome did not affect PGS1 expression. Thus, whereas inositol controls phosphatidylglycerophosphate synthase activity, regulation of PGS1 expression occurs primarily in response to mitochondrial development cues.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu	zhong, quan/AAE-8893-2021	Zhong, Quan/0000-0003-2910-5597	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ASHBURNER BP, 1995, P NATL ACAD SCI USA, V92, P9722, DOI 10.1073/pnas.92.21.9722; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; EBLE KS, 1990, J BIOL CHEM, V265, P19434; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FRY M, 1981, J BIOL CHEM, V256, P1874; Gallet PF, 1997, BIOCHEM J, V324, P627, DOI 10.1042/bj3240627; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; Griac P, 1999, NUCLEIC ACIDS RES, V27, P2043, DOI 10.1093/nar/27.9.2043; HALLMAN M, 1980, BIOCHEM BIOPH RES CO, V92, P1151, DOI 10.1016/0006-291X(80)90407-6; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; JACKOWSKI S, 1988, J BIOL CHEM, V263, P16830; JAKOVCIC S, 1971, J CELL BIOL, V48, P490, DOI 10.1083/jcb.48.3.490; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; Miller LL, 2001, CURR GENET, V39, P77, DOI 10.1007/s002940100186; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; Xu FY, 1999, BIOCHEM J, V337, P483, DOI 10.1042/0264-6021:3370483	39	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33978	33984		10.1074/jbc.M305242200	http://dx.doi.org/10.1074/jbc.M305242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821656	hybrid			2022-12-25	WOS:000185047500045
J	Debierre-Grockiego, F; Azzouz, N; Schmidt, J; Dubremetz, JF; Geyer, H; Geyer, R; Weingart, R; Schmidt, RR; Schwarz, RT				Debierre-Grockiego, F; Azzouz, N; Schmidt, J; Dubremetz, JF; Geyer, H; Geyer, R; Weingart, R; Schmidt, RR; Schwarz, RT			Roles of glycosylphosphatidylinositols of Toxoplasma gondii - Induction of tumor necrosis factor-alpha production in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRODUCTION; PROTEIN-KINASE-C; TNF-ALPHA; SIGNAL-TRANSDUCTION; TRYPANOSOMA-CRUZI; INTERFERON-GAMMA; MEMBRANE ANCHOR; CUTTING EDGE; IFN-GAMMA; CELLS	Toxoplasma gondii is a ubiquitous parasitic protozoan, which causes congenital infectious diseases as well as severe encephalitis, a major cause of death among immune-deficient persons, such as AIDS patients. T. gondii is normally controlled by the immune system of healthy individuals, leading to an asymptomatic infection. T. gondii triggers early cytokine production, which, to a certain extent, protects the host against replication of tachyzoites, the infective form of the parasite. Glycosylphosphatidylinositols (GPIs) constitute a class of glycolipids that have various functions, the most fundamental being to link proteins to eucaryotic cell membranes. GPIs are involved in the pathogenicity of other protozoan parasites and are known to induce tumor necrosis factor-alpha (TNFalpha) production. We show that GPIs highly purified from T. gondii tachyzoites, as well as their core glycans, induce TNFalpha production in macrophages. A chemically synthesized GPI of T. gondii lacking its lipid moiety, GPIa, has the same effect as the natural GPIs, whereas a chemically synthesized molecule with dialkylglycerol instead of diacylglycerol as lipid moiety, GPIb, does not induce TNFalpha production. Moreover, GPIb inhibits the TNFalpha production induced by T. gondii GPI or by GPIa. The core glycan prepared from the two chemically synthesized molecules activates macrophages, showing that the lipid moiety may regulate signaling. Stimulation of macrophages with GPIs of T. gondii results in activation of the transcription factor NF-kappaB, which is inhibited by the chemically synthesized GPIb, suggesting the involvement of NF-kappaB in TNFalpha gene expression. Our results support the idea that T. gondii GPIs are bioactive factors that participate in the production of TNFalpha during toxoplasmal pathogenesis.	Univ Marburg, Inst Virol, Med Ctr Hyg, D-35037 Marburg, Germany; Univ Montpellier 2, CNRS, UMR 5539, F-34095 Montpellier 05, France; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Konstanz, Dept Chem, D-78457 Constance, Germany	Philipps University Marburg; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Justus Liebig University Giessen; University of Konstanz	Debierre-Grockiego, F (corresponding author), Univ Marburg, Inst Virol, Med Ctr Hyg, Robert Koch Str 17, D-35037 Marburg, Germany.	debierre@mailer.uni-marburg.de	Debierre-Grockiego, Francoise/AAD-4322-2021					Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; Aosai F, 2002, CELL STRESS CHAPERON, V7, P357, DOI 10.1379/1466-1268(2002)007<0357:TGDHSP>2.0.CO;2; Belloni A, 2000, PARASITOL RES, V86, P406, DOI 10.1007/s004360050685; Bliss SK, 1999, J IMMUNOL, V162, P7369; Butcher BA, 2002, INFECT IMMUN, V70, P5216, DOI 10.1128/IAI.70.9.5216-5224.2002; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Daubener W, 2001, INFECT IMMUN, V69, P6527, DOI 10.1128/IAI.69.10.6527-6531.2001; Daubener W, 1996, EUR J IMMUNOL, V26, P487, DOI 10.1002/eji.1830260231; DECKERTSCHLUTER M, 1995, IMMUNOLOGY, V85, P408; Dobbin CA, 2002, J IMMUNOL, V169, P958, DOI 10.4049/jimmunol.169.2.958; Fischer HG, 1997, EUR J IMMUNOL, V27, P1539, DOI 10.1002/eji.1830270633; Fischer HG, 1999, INT IMMUNOL, V11, P341, DOI 10.1093/intimm/11.3.341; GAZZINELLI RT, 1993, INFECT AGENT DIS, V2, P139; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; GRIMWOOD BG, 1979, EXP PARASITOL, V48, P282, DOI 10.1016/0014-4894(79)90110-3; Grunvald E, 1996, INFECT IMMUN, V64, P2010, DOI 10.1128/IAI.64.6.2010-2018.1996; Hoshino K, 1999, J IMMUNOL, V162, P3749; HUNTER CA, 1992, EUR J IMMUNOL, V22, P2317, DOI 10.1002/eji.1830220921; Hunter CA, 1996, CURR TOP MICROBIOL, V219, P113; JOINER KA, 1993, INFECT IMMUN, V61, P1169, DOI 10.1128/IAI.61.4.1169-1172.1993; LI ZY, 1994, INFECT IMMUN, V62, P3434, DOI 10.1128/IAI.62.8.3434-3440.1994; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; Magez S, 1998, J IMMUNOL, V160, P1949; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MENON AK, 1990, J BIOL CHEM, V265, P9033; Mordue DG, 2001, J IMMUNOL, V167, P4574, DOI 10.4049/jimmunol.167.8.4574; Pekari K, 2001, J ORG CHEM, V66, P7432, DOI 10.1021/jo015840q; PELLOUX H, 1994, PARASITOL RES, V80, P271, DOI 10.1007/BF02351866; PELLOUX H, 1992, INFECT IMMUN, V60, P2672, DOI 10.1128/IAI.60.7.2672-2676.1992; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; Ricard J, 1996, CELL SIGNAL, V8, P439, DOI 10.1016/S0898-6568(96)00079-4; Ropert C, 2002, MICROBES INFECT, V4, P1015, DOI 10.1016/S1286-4579(02)01609-X; Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; Shapira S, 2002, J INFECT DIS, V185, pS66, DOI 10.1086/338000; SHER A, 1993, J IMMUNOL, V150, P3982; Striepen B, 1997, J MOL BIOL, V266, P797, DOI 10.1006/jmbi.1996.0806; Striepen B., 1992, Biochemical Society Transactions, V20, P296; TACHADO SD, 1994, BIOCHEM BIOPH RES CO, V205, P984, DOI 10.1006/bbrc.1994.2763; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; TOMAVO S, 1989, MOL CELL BIOL, V9, P4576, DOI 10.1128/MCB.9.10.4576; Zinecker CF, 2001, MOL BIOCHEM PARASIT, V116, P127, DOI 10.1016/S0166-6851(01)00313-9	45	79	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32987	32993		10.1074/jbc.M304791200	http://dx.doi.org/10.1074/jbc.M304791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815041	hybrid			2022-12-25	WOS:000184901800062
J	Murata, K; Kumagai, H; Kawashima, T; Tamitsu, K; Irie, M; Nakajima, H; Suzu, S; Shibuya, M; Kamihira, S; Nosaka, T; Asano, S; Kitamura, T				Murata, K; Kumagai, H; Kawashima, T; Tamitsu, K; Irie, M; Nakajima, H; Suzu, S; Shibuya, M; Kamihira, S; Nosaka, T; Asano, S; Kitamura, T			Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL TANDEM DUPLICATION; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; IN-VITRO; MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELLS; STEM-CELLS; 32D CELLS; GENE	The receptor tyrosine kinase FLT3 is constitutively activated by an internal tandem duplication (ITD) mutation within the juxtamembrane domain in 20 - 30% of patients with acute myeloid leukemia. In this study, we identified GTP-14564 as a specific kinase inhibitor for ITD-FLT3 and investigated the molecular basis of its specificity. GTP-14564 inhibited the growth of interleukin-3-independent Ba/F3 expressing ITD-FLT3 at 1 muM, whereas a 30-fold higher concentration of GTP-14564 was required to inhibit FLT3 ligand-dependent growth of Ba/F3 expressing wild type FLT3 (wt-FLT3). However, this inhibitor suppressed the kinase activities of wt-FLT3 and ITD-FLT3 equally, suggesting that the signaling pathways for proliferation differ between wt-FLT3 and ITD-FLT3. Analysis of downstream targets of FLT3 using GTP-14564 revealed STAT5 activation to be essential for growth signaling of ITD-FLT3. In contrast, wt-FLT3 appeared to mainly use the MAPK pathway rather than the STAT5 pathway to transmit a proliferative signal. Further analysis demonstrated that the first two tyrosines in an ITD were critical for STAT5 activation and growth induction but that all of the tyrosines in the juxtamembrane region were dispensable in terms of the proliferation signals of wt-FLT3. These results indicate that an ITD mutation in FLT3 elicits an aberrant STAT5 activation that results in increased sensitivity to GTP-14564. Thus, FLT3-targeted inhibition is an attractive approach, with the potential for selective cytotoxicity, to the treatment of ITD-FLT3-positive acute myeloid leukemia.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Hematopoiet Factors,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Mol Therapy,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Genet,Minato Ku, Tokyo 1088639, Japan; Chugai Pharmaceut Co Ltd, Toshima Ku, Tokyo 1718545, Japan; Kumamoto Univ, Ctr AIDS Res, Div Hemopoiesis, Kumamoto 8600811, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Lab Med, Nagasaki 8528501, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Kumamoto University; Nagasaki University	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Suzu, Shinya/F-5786-2013; Kitamura, Toshio/AAA-2071-2021	Suzu, Shinya/0000-0003-2531-4770				Abu-Duhier FM, 2000, BRIT J HAEMATOL, V111, P190, DOI 10.1046/j.1365-2141.2000.02317.x; AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Antonsson B, 1999, ANAL BIOCHEM, V267, P294, DOI 10.1006/abio.1998.2986; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BIRG F, 1992, BLOOD, V80, P2584; Buchdunger E, 1996, CANCER RES, V56, P100; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Cheng KR, 1996, J BIOL CHEM, V271, P311, DOI 10.1074/jbc.271.1.311; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FARLEY K, 1992, ANAL BIOCHEM, V203, P151, DOI 10.1016/0003-2697(92)90056-D; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; GATTA F, 1984, J HETEROCYCLIC CHEM, V21, P937, DOI 10.1002/jhet.5570210401; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Levis M, 2001, BLOOD, V98, P885, DOI 10.1182/blood.V98.3.885; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUI ALF, 1996, EMBO J, V15, P2245; NAKOINZ I, 1990, J IMMUNOL, V145, P860; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; ZEIGLER FC, 1994, BLOOD, V84, P2422, DOI 10.1182/blood.V84.8.2422.bloodjournal8482422; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719	47	52	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32892	32898		10.1074/jbc.M210405200	http://dx.doi.org/10.1074/jbc.M210405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815052	hybrid			2022-12-25	WOS:000184901800050
J	Sagi, SA; Weggen, S; Eriksen, J; Golde, TE; Koo, EH				Sagi, SA; Weggen, S; Eriksen, J; Golde, TE; Koo, EH			The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PROINFLAMMATORY RESPONSES; RANDOMIZED CONTROLLED-TRIAL; ALZHEIMERS-DISEASE; INFLAMMATORY MECHANISMS; A-BETA-42 PRODUCTION; PRECURSOR PROTEIN; TRANSGENIC MICE; CACHE COUNTY; GAMMA; IBUPROFEN	Epidemiological evidence suggests that chronic use of non-steroidal anti-inflammatory drugs ( NSAIDs) reduces the risk of Alzheimer's disease. Recently, NSAIDs have been shown to decrease amyloid pathology in a transgenic mouse model of Alzheimer's disease. This benefit may be partially attributable to the ability of NSAIDs to selectively reduce production of the amyloidogenic Abeta42 peptide in both cultured cells and transgenic mice. Although this activity does not appear to require the action of cyclooxygenases in cultured cells, it is not known whether other NSAID-sensitive targets contribute to this Abeta42 effect. In this study, we have used both pharmacological and genetic means to determine if other known cellular targets of NSAIDs could mediate the reduction in Abeta42 secretion from cultured cells. We find that altered arachidonic acid metabolism via NSAID action on cyclooxygenases and lipoxygenases does not alter Abeta42 production. Furthermore, we demonstrate that alterations in activity of peroxisome proliferator-activated receptors, IkappaB kinase beta or nuclear factor kappaB do not affect Abeta42 production. Thus, NSAIDs do not appear to alter Abeta42 production indirectly through previously identified cellular targets and may interact directly with the gamma-secretase complex itself to affect amyloid production.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Mayo Clin, Dept Neurosci & Pharmacol, Jacksonville, FL 32224 USA	University of California System; University of California San Diego; Mayo Clinic	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.		González, Lorenzo/A-5325-2010; Eriksen, Jason/A-8054-2008	González, Lorenzo/0000-0003-4199-4526; Eriksen, Jason/0000-0003-1549-4165	NATIONAL INSTITUTE ON AGING [T32AG000216, P01AG020206] Funding Source: NIH RePORTER; NIA NIH HHS [2T32 AG00216, AG 20206] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2000, NEUROBIOL AGING, V21, P447, DOI 10.1016/S0197-4580(00)00140-8; Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Carlson MC, 2002, ALZ DIS ASSOC DIS, V16, P24, DOI 10.1097/00002093-200201000-00004; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, NEUROCHEM INT, V39, P449, DOI 10.1016/S0197-0186(01)00052-3; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; Golde TE, 2002, NAT MED, V8, P936, DOI 10.1038/nm0902-936; HASSID A, 1977, RES COMMUN CHEM PATH, V18, P507; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Koch HJ, 2000, NEUROLOGY, V55, P1067, DOI 10.1212/WNL.55.7.1067; Kolasa T, 1997, J MED CHEM, V40, P819, DOI 10.1021/jm9606150; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Manev H, 2000, FASEB J, V14, P1464, DOI 10.1096/fj.14.10.1464; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Uljon SN, 2000, METH MOL B, V146, P439, DOI 10.1385/1-59259-045-4:439; VANDERHOEK JY, 1984, J ALLERGY CLIN IMMUN, V74, P412, DOI 10.1016/0091-6749(84)90140-4; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Watson GS, 2003, CNS DRUGS, V17, P27, DOI 10.2165/00023210-200317010-00003; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wyss-Coray T, 2000, NAT MED, V6, P973, DOI 10.1038/79661; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	42	72	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31825	31830		10.1074/jbc.M303588200	http://dx.doi.org/10.1074/jbc.M303588200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805355	hybrid			2022-12-25	WOS:000184782100045
J	Lin, JD; Tarr, PT; Yang, RJ; Rhee, J; Puigserver, P; Newgard, CB; Spiegelman, BM				Lin, JD; Tarr, PT; Yang, RJ; Rhee, J; Puigserver, P; Newgard, CB; Spiegelman, BM			PGC-1 beta in the regulation of hepatic glucose and energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COACTIVATOR PGC-1; RECEPTOR-ALPHA; MITOCHONDRIAL BIOGENESIS; GAMMA COACTIVATOR-1; GLUCONEOGENESIS; LIVER; TRANSCRIPTION; PGC-1-ALPHA; ADENOVIRUS; CELLS	Peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) is a transcriptional coactivator that regulates multiple aspects of cellular energy metabolism, including mitochondrial biogenesis, hepatic gluconeogenesis, and beta-oxidation of fatty acids. PGC-1alpha mRNA levels are increased in both type-1 and type-2 diabetes and may contribute to elevated hepatic glucose production in diabetic states. We have recently described PGC-1beta, a novel transcriptional coactivator that is a homolog of PGC-1alpha. Although PGC-1beta shares significant sequence similarity and tissue distribution with PGC-1alpha, the biological activities of PGC-1beta in the regulation of cellular metabolism is unknown. In this study, we used an adenoviral-mediated expression system to study the function of PGC-1beta both in cultured hepatocytes and in the liver of rats. PGC-1beta, like PGC-1alpha, potently induces the expression of an array of mitochondrial genes involved in oxidative metabolism. However, in contrast to PGC-1alpha, PGC-1beta poorly activates the expression of gluconeogenic genes in hepatocytes or liver in vivo, illustrating that these two coactivators play distinct roles in hepatic glucose metabolism. The reduced ability of PGC-1beta to induce gluconeogenic genes is due, at least in part, to its inability to physically associate with and coactivate hepatic nuclear receptor 4alpha (HNF4alpha) and forkhead transcription factor O1 (FOXO1), two critical transcription factors that mediate the activation of gluconeogenic gene expression by PGC-1alpha. These data illustrate that PGC-1beta and PGC-1alpha have distinct arrays of activities in hepatic energy metabolism.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Duke University; Duke University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, Smith Bldg,Rm 958,1 Jimmy Fund Way, Boston, MA 02115 USA.		Rhee, James/V-9973-2019		NIDDK NIH HHS [R01DK61562, P01DK58398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061562, P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; RHEE J, 2003, P NATL ACAD SCI US; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; ZARET KS, 1990, MOL CELL BIOL, V10, P4582, DOI 10.1128/MCB.10.9.4582	27	187	203	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30843	30848		10.1074/jbc.M303643200	http://dx.doi.org/10.1074/jbc.M303643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12807885	Green Published, hybrid			2022-12-25	WOS:000184658800054
J	Dumaz, N; Marais, R				Dumaz, N; Marais, R			Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; PHOSPHORYLATION; INHIBITION; ACTIVATION; SERINE; RECRUITMENT; MECHANISM; PATHWAY; CAMP	Cyclic AMP ( cAMP) blocks Raf-1 activation by stimulating its phosphorylation on serine 43 ( Ser(43\)), serine 233 (Ser(233)), and serine 259 (Ser(259)). We show here that phosphorylation of all three sites blocks Raf-1 binding to Ras. GTP in vivo and that cAMP stimulates binding of 14-3-3 proteins to Ser(233) and Ser(259). We also show that Raf-1 and protein kinase A ( PKA) form a complex in vivo that is disrupted by cAMP and that ablation of PKA by use of small interfering RNA blocks phosphorylation by cAMP. The ability of PKA to block Raf- 1 activation is ablated by the PKA inhibitor H89. These studies suggest that Raf- 1 and cAMP form a signaling complex in cells. Upon activation of PKA, Raf- 1 is phosphorylated and 14-3-3 binds, blocking Raf- 1 recruitment to the plasma membrane and preventing its activation.	Inst Canc Res, Signal Transduct Team, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marais, R (corresponding author), Inst Canc Res, Signal Transduct Team, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	rmarais@icr.ac.uk	Dumaz, Nicolas/B-5907-2008	Dumaz, Nicolas/0000-0003-3511-2160; Marais, Richard/0000-0001-7484-4183				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Harlow E., 1988, ANTIBODIES LAB MANUA; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; Marais R, 1996, CANCER SURV, V27, P101; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	30	198	203	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29819	29823		10.1074/jbc.C300182200	http://dx.doi.org/10.1074/jbc.C300182200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12801936	hybrid			2022-12-25	WOS:000184507000054
J	Kunapuli, P; Chitta, KS; Cowell, JK				Kunapuli, P; Chitta, KS; Cowell, JK			Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene	ONCOGENE			English	Article						LGI1; tumor suppressor gene; brain tumors; leucine-rich repeat; tumor invasion	MALIGNANT BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; CHROMOSOME-10; HETEROZYGOSITY; PTEN; IDENTIFICATION; PROGRESSION; ASTROCYTOMA; MUTATIONS; REGIONS	The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 2000, PATHOLOGY GENETICS T; Krex D, 2002, ACTA NEUROPATHOL, V103, P255, DOI 10.1007/s004010100463; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MYERS PM, 1997, P NATL ACAD SCI USA, V94, P9502; Papazisis KT, 1997, J IMMUNOL METHODS, V208, P151, DOI 10.1016/S0022-1759(97)00137-3; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sasaki H, 2002, CANCER RES, V62, P1790; Somerville RPT, 2000, MAMM GENOME, V11, P622, DOI 10.1007/s0033500101280; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Wang SI, 1997, CANCER RES, V57, P4183	31	55	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3985	3991		10.1038/sj.onc.1206584	http://dx.doi.org/10.1038/sj.onc.1206584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821932				2022-12-25	WOS:000183707600001
J	Battista, S; Pentimalli, F; Baldassarre, G; Fedele, M; Fidanza, V; Croce, CM; Fusco, A				Battista, S; Pentimalli, F; Baldassarre, G; Fedele, M; Fidanza, V; Croce, CM; Fusco, A			Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation	FASEB JOURNAL			English	Article						HMGA1; homologous recombination; T lymphocytes; interleukin; ES cells	IN-VITRO DIFFERENTIATION; C GENE; EXPRESSION; TRANSCRIPTION; PROTEINS; BINDING; IL-2; PRECURSORS; CYTOKINE; ELEMENTS	By interacting with transcription machinery, high-mobility group A 1 (HMGA1) proteins alter the chromatin structure and thereby regulate the transcriptional activity of several genes. To assess their role in development, we studied the in vitro differentiation of embryonic stem (ES) cells that bear one or both disrupted Hmga1 alleles. Here, we report that Hmga1 null ES cells generate fewer T-cell precursors than do wild-type ES cells. Indeed, they preferentially differentiate to B cells, probably consequent to decreased interleukin 2 expression and increased interleukin 6 expression. Moreover, a lack of HMGA1 expression induces changes in hemopoietic differentiation, i.e., a reduced monocyte/macrophage population and an increase in megakaryocyte precursor numbers, erythropoiesis, and globin gene expression. Re-expression of the Hmga1 gene in Hmga1 null ES cells restores the wild-type phenotype. The effect on megakaryocyte/erythrocyte lineages seems, at least in part, mediated by the GATA-1 transcription factor, a key regulator of red blood cell differentiation. In fact, we found that Hmga1-/- ES cells overexpress GATA-1 and that HMGA1 proteins directly control GATA-1 transcription. Taken together, these data indicate that HMGA1 proteins play a prime role in lymphohematopoietic differentiation.	Univ Naples Federico II, Fac Med & Chirurg, CNR,Dipartimento Biol & Patol Cellulaire & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, CNR,Dipartimento Biol & Patol Cellulaire & Mol, Ctr Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Baldassarre, Gustavo/K-1350-2016; Pentimalli, Francesca/K-4936-2014; Young, Richard A/F-6495-2012; Battista, Sabrina/AAY-2981-2020; Fedele, Monica/C-1417-2015	Baldassarre, Gustavo/0000-0002-9750-8825; Pentimalli, Francesca/0000-0003-4740-6801; Young, Richard A/0000-0001-8855-8647; Battista, Sabrina/0000-0001-5899-9759; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chase MB, 1999, AM J HEMATOL, V60, P27, DOI 10.1002/(SICI)1096-8652(199901)60:1<27::AID-AJH6>3.0.CO;2-0; CHEN U, 1992, P NATL ACAD SCI USA, V89, P2541, DOI 10.1073/pnas.89.7.2541; Chiappetta G, 1996, ONCOGENE, V13, P2439; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; Dani C, 1999, CELLS TISSUES ORGANS, V165, P173, DOI 10.1159/000016697; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LEONARD M, 1993, BLOOD, V82, P1071; Lewis RT, 2001, J BIOL CHEM, V276, P9550, DOI 10.1074/jbc.M008726200; MAGIS W, 1995, BIOCHEM BIOPH RES CO, V214, P927, DOI 10.1006/bbrc.1995.2375; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Meng AM, 1999, BLOOD, V93, P500, DOI 10.1182/blood.V93.2.500.402k09_500_508; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Shannon MF, 1998, IMMUNOL CELL BIOL, V76, P461, DOI 10.1046/j.1440-1711.1998.00770.x; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Takatsu K, 1997, P SOC EXP BIOL MED, V215, P121; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILES MV, 1991, DEVELOPMENT, V111, P259; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	44	60	65	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1496	+		10.1096/fj.02-0977fje	http://dx.doi.org/10.1096/fj.02-0977fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824305				2022-12-25	WOS:000183818000027
J	Geiszt, M; Witta, J; Baffi, J; Lekstrom, K; Leto, TL				Geiszt, M; Witta, J; Baffi, J; Lekstrom, K; Leto, TL			Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense	FASEB JOURNAL			English	Article						ThOx1 protein; ThOx2 protein; duox protein; lactoperoxidase; reactive oxygen species	NADPH OXIDASE; IDENTIFICATION; THIOCYANATE; CEPACIA; CLONING; SYSTEM; SALIVA; THOX2; GENE	Lactoperoxidase (LPO) is an enzyme with antimicrobial properties present in saliva, milk, tears, and airway secretions. Although the formation of microbial oxidants by LPO has been recognized for some time, the source of hydrogen peroxide (H2O2) for LPO-catalyzed reactions remains unknown. Reactive oxygen species produced by the phagocyte NADPH oxidase (phox) play a critical role in host defense against pathogens; however, analogous oxidant-generating systems in other tissues have not been associated with antimicrobial activity. Several homologues of gp91(phox), the catalytic core of this enzyme, were described recently; dual oxidase (Duox)1/thyroid oxidase 1 and Duox2/thyroid oxidase 2 were identified in the thyroid gland and characterized as H2O2 donors for thyroxin biosynthesis. We examined Duox1 and Duox2 expression in secretory glands and on mucosal surfaces and give evidence for their presence and activity in salivary glands, rectum, trachea, and bronchium. Epithelium cells in salivary excretory ducts and rectal glands express Duox2, whereas tracheal and bronchial epithelial cells express Duox1. Furthermore, we detected Duox1-dependent H2O2 release by cultured human bronchial epithelial cells. Our observations suggest that Duox1 and Duox2 are novel H2O2 sources that can support LPO-mediated antimicrobial defense mechanisms on mucosal surfaces.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; NEI, Ocular Gene Therapy Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Semmelweis University; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.	tleto@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Boucher R C, 2001, Trans Am Clin Climatol Assoc, V112, P99; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; FOX CH, 1993, CURRENT PROTOCOLS IM; Ganz T, 2002, J CLIN INVEST, V109, P693, DOI 10.1172/JCI200215218; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; Hoidal JR, 2001, AM J RESP CELL MOL, V25, P661, DOI 10.1165/ajrcmb.25.6.f213; KINNULA VL, 1992, AM J PHYSIOL, V262, pL708, DOI 10.1152/ajplung.1992.262.6.L708; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KLEBANOFF SJ, 1966, BIOCHIM BIOPHYS ACTA, V117, P63, DOI 10.1016/0304-4165(66)90152-8; KLEBANOFF SJ, 1965, P SOC EXP BIOL MED, V118, P483, DOI 10.3181/00379727-118-29882; KONTOGHIORGHES GJ, 1995, BLOOD REV, V9, P33, DOI 10.1016/0268-960X(95)90038-1; LAVIGNE MCH, CIRCULATION, V104, P79; Leto TL., 1999, INFLAMMATION BASIC P, P769; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; LiPuma JJ, 1998, CLIN CHEST MED, V19, P473, DOI 10.1016/S0272-5231(05)70094-0; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; PILEWSKI JM, 1999, PHYSL REV S, V1, pS215; REITER B, 1963, J GEN MICROBIOL, V33, P12; Riedel C, 2001, TRENDS BIOCHEM SCI, V26, P490, DOI 10.1016/S0968-0004(01)01904-1; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SPEERT DP, 1994, J INFECT DIS, V170, P1524, DOI 10.1093/infdis/170.6.1524; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; ZELDOW BJ, 1963, J IMMUNOL, V90, P12	33	404	424	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1502	+		10.1096/fj.02-1104fje	http://dx.doi.org/10.1096/fj.02-1104fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824283				2022-12-25	WOS:000183818000030
J	Jendrossek, V; Handrick, R; Belka, C				Jendrossek, V; Handrick, R; Belka, C			Celecoxib activates a novel mitochondrial apoptosis signaling pathway	FASEB JOURNAL			English	Article						Bcl-2; caspase; Apaf-1; mitochondria; FADD	DRUG-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; TYROSINE KINASE LCK; BCL-2 FAMILY; CYTOCHROME-C; CYCLOOXYGENASE-2 INHIBITOR; IONIZING-RADIATION; DISTINCT PATHWAYS; LYMPHOMA-CELLS; BREAST-CANCER	The cyclooxygenase (COX)-2 inhibitor Celecoxib may inhibit cancer cell growth independently of its capacity to block the COX-2 enzyme. The growth inhibitory effect had been attributed to its pro-apoptotic effects. However, the molecular details of Celecoxib-induced apoptosis have not been analyzed yet. To differentiate between death receptor and mitochondrial signaling pathways, induction of apoptosis upon treatment with Celecoxib was tested in Jurkat T- and BJAB B-lymphoma cell lines with defects in either pathway. Celecoxib-induced dose- and time-dependent apoptosis in Jurkat and BJAB cells involving i) activation of caspases-9, -8, and -3, ii) cleavage of poly(ADP-ribose) polymerase and inhibitor of caspase-activated DNAase, iii) breakdown of the mitochondrial membrane potential, and iv) release of cytochrome c. Lack of Fas-associated death domain protein (FADD), overexpression of a dominant negative FADD, lack of caspase-8, and treatment with caspase-8-specific inhibitors had no influence on Celecoxib-induced apoptosis. In contrast, overexpression of a dominant negative caspase-9 or pharmacological inhibition of caspase-9 strongly interfered with Celecoxib-induced cell death. Furthermore, expression of Apaf-1 was required for Celecoxib-induced apoptosis. Importantly, Bcl-2 overexpression did not abrogate caspase activation, mitochondrial alterations, and apoptosis upon Celecoxib treatment while inhibiting radiation induced apoptosis. In conclusion, Celecoxib induces apoptosis via a novel apoptosome-dependent but Bcl-2-independent mitochondrial pathway.	Univ Tubingen, Dept Radiat Oncol, Expt Radiotherapy Grp, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Expt Radiotherapy Grp, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Komhoff M, 2000, AM J PATHOL, V157, P29, DOI 10.1016/S0002-9440(10)64513-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILAS L, 1991, INT J RADIAT BIOL, V60, P65, DOI 10.1080/09553009114551561; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ochs K, 2000, CANCER RES, V60, P5815; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SANO H, 1995, CANCER RES, V55, P3785; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seno H, 2002, CANCER RES, V62, P506; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song XQ, 2002, J NATL CANCER I, V94, P585; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Waskewich C, 2002, CANCER RES, V62, P2029; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	71	126	129	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1547	+		10.1096/fj.02-0947fje	http://dx.doi.org/10.1096/fj.02-0947fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824303				2022-12-25	WOS:000183818000024
J	Crofts, AR; Shinkarev, VP; Kolling, DRJ; Hong, SJ				Crofts, AR; Shinkarev, VP; Kolling, DRJ; Hong, SJ			The modified Q-cycle explains the apparent mismatch between the kinetics of reduction of cytochromes c(1) and b(H) in the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER CHAIN; UBIHYDROQUINONE OXIDATION; RHODOBACTER-SPHAEROIDES; UBIQUINOL OXIDATION; RHODOPSEUDOMONAS-SPHAEROIDES; DOMAIN MOVEMENT; Q(O) SITE; INHIBITOR BINDING; QUINOL OXIDATION	Crystallographic structures of the bc(1) complex from different sources have provided evidence that a movement of the Rieske iron-sulfur protein (ISP) extrinsic domain is essential for catalysis. This dynamic feature has opened up the question of what limits electron transfer, and several authors have suggested that movement of the ISP head, or gating of such movement, is rate-limiting. Measurements of the kinetics of cytochromes and of the electrochromic shift of carotenoids, following flash activation through the reaction center in chromatophore membranes from Rhodobacter sphaeroides, have allowed us to demonstrate that: (i) ubiquinol oxidation at the Q(o)-site of the bc(1) complex has the same rate in the absence or presence of antimycin bound at the Q(i)-site, and is the reaction limiting turnover. (ii) Activation energies for transient processes to which movement of the ISP must contribute are much lower than that of the rate-limiting step. (iii) Comparison of experimental data with a simple mathematical model demonstrates that the kinetics of reduction of cytochromes c(1) and b(H) are fully explained by the modified Q-cycle. (iv) All rates for processes associated with movement of the ISP are more rapid by at least an order of magnitude than the rate of ubiquinol oxidation. (v) Movement of the ISP head does not introduce a significant delay in reduction of the high potential chain by quinol, and it is not necessary to invoke such a delay to explain the kinetic disparity between the kinetics of reduction of cytochromes c(1) and b(H).	Univ Illinois, Dept Biochem, Roger Adams Lab 419, Urbana, IL 61801 USA; Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Crofts, AR (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 419, 600 S Mathews Ave, Urbana, IL 61801 USA.	a-crofts@life.uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53508, GM 35438] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BOWYER JR, 1980, BIOCHIM BIOPHYS ACTA, V592, P445, DOI 10.1016/0005-2728(80)90091-2; BOWYER JR, 1981, BIOCHIM BIOPHYS ACTA, V636, P218, DOI 10.1016/0005-2728(81)90096-7; BOWYER JR, 1981, BIOCHIM BIOPHYS ACTA, V635, P167, DOI 10.1016/0005-2728(81)90016-5; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Cramer W.A., 1990, ENERGY TRANSDUCTION; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15827, DOI 10.1021/bi990963e; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DEVRIES S, 1986, J BIOENERG BIOMEMBR, V18, P195, DOI 10.1007/BF00743464; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DEVRIES S, 1983, THESIS AMSTERDAM U A; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; Engstrom G, 2002, J BIOL CHEM, V277, P31072, DOI 10.1074/jbc.M202594200; Garland PB, 1975, ELECTRON TRANSFER CH, P351; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; Hansen KC, 2000, BBA-BIOENERGETICS, V1456, P121, DOI 10.1016/S0005-2728(99)00107-3; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JACKSON JB, 1969, FEBS LETT, V4, P185, DOI 10.1016/0014-5793(69)80230-9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KING TE, 1975, ELECTRON TRANSFER CH, P105; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MEINHARDT SW, 1983, BIOCHIM BIOPHYS ACTA, V723, P219, DOI 10.1016/0005-2728(83)90121-4; MEINHARDT SW, 1982, FEBS LETT, V149, P217, DOI 10.1016/0014-5793(82)81104-6; MEINHARDT SW, 1982, FEBS LETT, V149, P223, DOI 10.1016/0014-5793(82)81105-8; MEINHARDT SW, 1984, THESIS U ILLINOIS UR; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Sharp RE, 1999, BIOCHEMISTRY-US, V38, P14973, DOI 10.1021/bi9914863; Shinkarev VP, 2002, BIOCHEMISTRY-US, V41, P14372, DOI 10.1021/bi026198c; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; SNOZZI M, 1984, BIOCHIM BIOPHYS ACTA, V766, P451, DOI 10.1016/0005-2728(84)90261-5; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; TAKAMIYA KI, 1979, BIOCHIM BIOPHYS ACTA, V546, P1, DOI 10.1016/0005-2728(79)90166-X; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X; TSAI AL, 1983, J BIOL CHEM, V258, P2122; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Yu CA, 2002, BBA-BIOENERGETICS, V1555, P65, DOI 10.1016/S0005-2728(02)00256-6; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	66	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36191	36201		10.1074/jbc.M305461200	http://dx.doi.org/10.1074/jbc.M305461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829696	hybrid			2022-12-25	WOS:000185318300041
J	Hernandez-Urzua, E; Mills, CE; White, GP; Contreras-Zentella, ML; Escamilla, E; Vasudevan, SG; Membrillo-Hernandez, J; Poole, RK				Hernandez-Urzua, E; Mills, CE; White, GP; Contreras-Zentella, ML; Escamilla, E; Vasudevan, SG; Membrillo-Hernandez, J; Poole, RK			Flavohemoglobin Hmp, but not its individual domains, confers protection from respiratory inhibition by nitric oxide in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN-LIKE PROTEIN; BACTERIAL HEMOGLOBIN; ALCALIGENES-EUTROPHUS; FLAVOHAEMOGLOBIN HMP; OXIDATIVE STRESS; NITROSATIVE STRESS; OXYGEN-AFFINITY; CYTOCHROME-O; IN-VIVO; VITREOSCILLA	Escherichia coli possesses a two-domain flavohemoglobin, Hmp, implicated in nitric oxide ( NO) detoxification. To determine the contribution of each domain of Hmp toward NO detoxification, we genetically engineered the Hmp protein and separately expressed the heme (HD) and the flavin (FD) domains in a defined hmp mutant. Expression of each domain was confirmed by Western blot analysis. CO-difference spectra showed that the HD of Hmp can bind CO, but the CO adduct showed a slightly blue-shifted peak. Overexpression of the HD resulted in an improvement of growth to a similar extent to that observed with the Vitreoscilla heme-only globin Vgb, whereas the FD alone did not improve growth. Viability of the hmp mutant in the presence of lethal concentrations of sodium nitroprusside was increased (to 30% survival after 2 h in 5 mM sodium nitroprusside) by overexpressing Vgb or the HD. However, maximal protection was provided only by holo-Hmp (75% survival under the same conditions). Cellular respiration of the hmp mutant was instantaneously inhibited in the presence of 13.5 muM NO but remained insensitive to NO inhibition when these cells overexpressed Hmp. When HD or FD was expressed separately, no significant protection was observed. By contrast, overexpression of Vgb provided partial protection from NO respiratory inhibition. Our results suggest that, despite the homology between the HD from Hmp and Vgb (45% identity), their roles seem to be quite distinct.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Biol Mol & Biotecnol, Lab Microbiol & Genet Mol, Mexico City 04510, DF, Mexico; James Cook Univ N Queensland, Dept Biochem & Mol Biol, Townsville, Qld 4811, Australia; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim, Mexico City 04510, DF, Mexico	University of Sheffield; Universidad Nacional Autonoma de Mexico; James Cook University; Universidad Nacional Autonoma de Mexico	Poole, RK (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk	White, Gregory P/C-8932-2012; Membrillo-Hernández, Jorge/AAN-4996-2021	White, Gregory P/0000-0001-9532-0856; Membrillo-Hernández, Jorge/0000-0001-7650-8116; Vasudevan, Subhash/0000-0002-5083-3831	Biotechnology and Biological Sciences Research Council [P18939] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; Bollinger CJT, 2001, BIOTECHNOL PROGR, V17, P798, DOI 10.1021/bp010091j; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; DMELLO R, 1995, J BACTERIOL, V177, P867, DOI 10.1128/jb.177.3.867-870.1995; ELVIN CM, 1990, GENE, V87, P123, DOI 10.1016/0378-1119(90)90503-J; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Frey AD, 2002, APPL ENVIRON MICROB, V68, P4835, DOI 10.1128/AEM.68.10.4835-4840.2002; Frey AD, 2000, APPL ENVIRON MICROB, V66, P98, DOI 10.1128/AEM.66.1.98-104.2000; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; GONZALESPREVATT V, 1980, J BIOL CHEM, V255, P1478; Gore M., 2000, SPECTROPHOTOMETRY SP; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; JAKOB W, 1992, ARCH BIOCHEM BIOPHYS, V292, P29, DOI 10.1016/0003-9861(92)90046-Y; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; MAGNOLO SK, 1991, BIO-TECHNOL, V9, P473, DOI 10.1038/nbt0591-473; Membrillo-Hernandez J, 1997, FEMS MICROBIOL LETT, V155, P179, DOI 10.1111/j.1574-6968.1997.tb13875.x; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; MILLER JH, 1972, MOL CLONING LAB MANU; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; OSHINO R, 1973, EUR J BIOCHEM, V35, P23, DOI 10.1111/j.1432-1033.1973.tb02805.x; Park KW, 2002, J BIOL CHEM, V277, P33334, DOI 10.1074/jbc.M203820200; Pathania R, 2002, MOL MICROBIOL, V45, P1303, DOI 10.1046/j.1365-2958.2002.03095.x; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POOLE RK, 1979, BIOCHEM J, V184, P379, DOI 10.1042/bj1840379; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; Roos V, 2002, BIOTECHNOL PROGR, V18, P652, DOI 10.1021/bp020005v; Sambrook J, 2001, MOL CLONING LAB MANU; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Stevanin TM, 2002, INFECT IMMUN, V70, P4399, DOI 10.1128/IAI.70.8.4399-4405.2002; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; WU G, 2003, IN PRESS ADV MICROB, V47; WU G, 2003, IN PRESS RESP ARCHAE; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131	52	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34975	34982		10.1074/jbc.M303629200	http://dx.doi.org/10.1074/jbc.M303629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826671	hybrid			2022-12-25	WOS:000185164400030
J	Li, BS; Ma, W; Jaffe, H; Zheng, YL; Takahashi, S; Zhang, L; Kulkarni, AB; Pant, HC				Li, BS; Ma, W; Jaffe, H; Zheng, YL; Takahashi, S; Zhang, L; Kulkarni, AB; Pant, HC			Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-SURVIVAL; NEGATIVE REGULATION; SIGNALING PATHWAYS; REGULATORY SUBUNIT; CDC2-LIKE KINASE; MICE LACKING; CDK5; P35; RECEPTOR	The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway plays an important role in mediating survival signals in wide variety of neurons and cells. Recent studies show that Akt also regulates metabolic pathways to regulate cell survival. In this study, we reported that cyclin-dependent kinase-5 (Cdk5) regulates Akt activity and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway. We found that brain extracts of Cdk5 -/- mice display a lower PI 3-kinase activity and phosphorylation of Akt compared with that in wild type mice. Moreover, we demonstrated that Cdk5 phosphorylated Ser-1176 in the neuregulin receptor ErbB2 and phosphorylated Thr-871 and Ser-1120 in the ErbB3 receptor. We identified the Ser-1120 sequence RSRSPR in ErbB3 as a novel phosphorylation consensus sequence of Cdk5. Finally, we found that Cdk5 activity is involved in neuregulin-induced Akt activity and neuregulin-mediated neuronal survival. These findings suggest that Cdk5 may exert a key role in promoting neuronal survival by regulating Akt activity through the neuregulin/PI 3-kinase signaling pathway.	NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA; USN, Res Lab, Ctr Biomol Sci & Engn, Washington, DC 20375 USA; Natl Inst Dent & Craniofacial Res, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; NIMH, Behav & Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Defense; United States Navy; Naval Research Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Pant, HC (corresponding author), NINDS, Neurochem Lab, NIH, Bldg 36,Rm 4D24,9000 Rockville Pike, Bethesda, MD 20892 USA.	panth@ninds.nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000698, Z01DE000664, Z01DE000698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002725, ZIANS002725] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anton ES, 1997, DEVELOPMENT, V124, P3501; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bu BT, 2002, NEUROBIOL DIS, V11, P285, DOI 10.1006/nbdi.2002.0551; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Gao C, 2001, J CELL SCI, V114, P1145; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Humbert S, 2000, J CELL SCI, V113, P975; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Ko J, 2001, J NEUROSCI, V21, P6758; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Kwon YT, 1999, J COMP NEUROL, V415, P218, DOI 10.1002/(SICI)1096-9861(19991213)415:2<218::AID-CNE6>3.0.CO;2-F; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Nakamura S, 1997, ACTA NEUROPATHOL, V94, P153, DOI 10.1007/s004010050687; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Ohshima T, 1999, J NEUROSCI, V19, P6017, DOI 10.1523/JNEUROSCI.19-14-06017.1999; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 2002, MOL NEUROBIOL, V26, P153, DOI 10.1385/MN:26:2-3:153; Ohshima T, 2001, P NATL ACAD SCI USA, V98, P2764, DOI 10.1073/pnas.051628498; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Patrick GN, 2001, NATURE, V411, P764, DOI 10.1038/35081149; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Tanaka T, 2001, J NEUROSCI, V21, P550, DOI 10.1523/JNEUROSCI.21-02-00550.2001; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Veeranna, 1998, J NEUROSCI, V18, P4008; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	72	124	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35702	35709		10.1074/jbc.M302004200	http://dx.doi.org/10.1074/jbc.M302004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824184	hybrid			2022-12-25	WOS:000185164400116
J	Palaniaappan, N; Kim, BS; Sekiyama, Y; Osada, H; Reynolds, KA				Palaniaappan, N; Kim, BS; Sekiyama, Y; Osada, H; Reynolds, KA			Enhancement and selective production of phoslactomycin B, a protein phosphatase IIa inhibitor, through identification and engineering of the corresponding Biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIFUNGAL ANTIBIOTICS PHOSLACTOMYCINS; CYCLOHEXANECARBOXYLIC ACID MOIETY; MODULAR POLYKETIDE SYNTHASES; COLONY-STIMULATING FACTORS; ASYMMETRIC TOTAL-SYNTHESIS; FAMILY INDUCE PRODUCTION; MARROW STROMAL CELLS; TUMOR AGENTS CI-920; STREPTOMYCES-COLLINUS; RABBIT CARDIOMYOCYTES	Phoslactomycins (PLMs), potent and selective inhibitors of serine threonine phosphatases, are of interest for their antitumor and antiviral activity. Multiple analogs and low titers in the fermentation process have hampered the development of this class of natural products. The entire 75-kb PLM biosynthetic gene cluster of Streptomyces sp. HK-803 was cloned, sequenced, and analyzed. The loading domain and seven extension modules of the PLM polyketide synthase generate an unusual linear unsaturated polyketide chain containing both E- and Z-double bonds from a cyclohexanecarboxylic acid (CHC) primer. Hydroxylation of the CHC-derived side chain of the resulting PLM-B by PlmS(2), and a subsequent esterification, produces the remaining PLM analogs. A new PCR targeting technology allowed rapid and facile allelic replacement of plmS(2). The resulting mutant selectively produced the PLM-B, at 6-fold higher titers than the wild type strain. This mutant and the biosynthetic gene cluster will facilitate engineered microbial production of hybrid PLMs with improved properties.	Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan	Virginia Commonwealth University; Virginia Commonwealth University; RIKEN	Reynolds, KA (corresponding author), Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, 800 E Leigh St, Richmond, VA 23219 USA.		Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Sekiyama, Yasuyo/F-2561-2017	Sekiyama, Yasuyo/0000-0002-7057-0864; Reynolds, Kevin/0000-0003-0270-9809				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Armstrong SC, 1998, J MOL CELL CARDIOL, V30, P61, DOI 10.1006/jmcc.1997.0572; Armstrong SC, 1997, J MOL CELL CARDIOL, V29, P3009, DOI 10.1006/jmcc.1997.0507; Baltz RH, 1998, TRENDS MICROBIOL, V6, P76, DOI 10.1016/S0966-842X(97)01161-X; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Boger DL, 2001, J AM CHEM SOC, V123, P4161, DOI 10.1021/ja010195q; CASATI R, 1987, J AM CHEM SOC, V109, P8102, DOI 10.1021/ja00260a035; Chen S, 1999, EUR J BIOCHEM, V261, P98, DOI 10.1046/j.1432-1327.1999.00244.x; Cropp TA, 2000, NAT BIOTECHNOL, V18, P980, DOI 10.1038/79479; de Jong RS, 1999, BRIT J CANCER, V79, P882, DOI 10.1038/sj.bjc.6690141; Esumi T, 2002, CHEM COMMUN, P3042, DOI 10.1039/b209742g; Faulkner NE, 2003, J VIROL, V77, P2276, DOI 10.1128/JVI.77.3.2276-2281.2003; Fujii K, 2003, ORG LETT, V5, P733, DOI 10.1021/ol027528o; FUSHIMI S, 1989, J ANTIBIOT, V42, P1026, DOI 10.7164/antibiotics.42.1026; FUSHIMI S, 1989, J ANTIBIOT, V42, P1019, DOI 10.7164/antibiotics.42.1019; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Hopwood DA, 1999, MICROBIOL-UK, V145, P2183, DOI 10.1099/00221287-145-9-2183; Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1111/j.1574-6968.1999.tb13576.x; JIRICNY J, 1989, J CHEM SOC P1, P1487; Kawada M, 2003, INT IMMUNOPHARMACOL, V3, P179, DOI 10.1016/S1567-5769(02)00231-X; KIESER T, 2000, PRACTICAL STREPTOMYC, P170; Kim BS, 2002, J BIOL CHEM, V277, P48028, DOI 10.1074/jbc.M207770200; KOHAMA T, 1993, J ANTIBIOT, V46, P1512, DOI 10.7164/antibiotics.46.1512; KOHAMA T, 1993, J ANTIBIOT, V46, P1503, DOI 10.7164/antibiotics.46.1503; Lewy DS, 2002, CURR MED CHEM, V9, P2005, DOI 10.2174/0929867023368809; Lomovskaya N, 1997, MICROBIOL-UK, V143, P875, DOI 10.1099/00221287-143-3-875; Lu HX, 2002, BIOCHEMISTRY-US, V41, P12590, DOI 10.1021/bi026006d; Miyashita K, 2002, CHEM COMMUN, P742, DOI 10.1039/b201302a; MOORE BS, 1993, J AM CHEM SOC, V115, P5254, DOI 10.1021/ja00065a042; ORERE DM, 1977, J CHEM SOC CHEM COMM, P280, DOI 10.1039/c39770000280; Patton SM, 2000, BIOCHEMISTRY-US, V39, P7595, DOI 10.1021/bi0005714; Reddy YK, 2002, ORG LETT, V4, P969, DOI 10.1021/ol025537r; Reid R, 2003, BIOCHEMISTRY-US, V42, P72, DOI 10.1021/bi0268706; Sambrook J., 2002, MOL CLONING LAB MANU; Shen B, 2002, J NAT PROD, V65, P422, DOI 10.1021/np010550q; STAMPWALA SS, 1983, J ANTIBIOT, V36, P1601, DOI 10.7164/antibiotics.36.1601; TOMIYA T, 1990, J ANTIBIOT, V43, P118, DOI 10.7164/antibiotics.43.118; Tsai SC, 2002, BIOCHEMISTRY-US, V41, P12598, DOI 10.1021/bi0260177; TUNAC JB, 1983, J ANTIBIOT, V36, P1595, DOI 10.7164/antibiotics.36.1595; URAMOTO M, 1985, J ANTIBIOT, V38, P665, DOI 10.7164/antibiotics.38.665; Usui T, 1999, J BIOCHEM, V125, P960, DOI 10.1093/oxfordjournals.jbchem.a022375; Wang P, 1996, J BACTERIOL, V178, P6873, DOI 10.1128/jb.178.23.6873-6881.1996; Wang YG, 2002, ORG LETT, V4, P4615, DOI 10.1021/ol020193q; Weinbrenner C, 1998, CIRCULATION, V98, P899, DOI 10.1161/01.CIR.98.9.899; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9	45	56	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35552	35557		10.1074/jbc.M305082200	http://dx.doi.org/10.1074/jbc.M305082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819191	hybrid			2022-12-25	WOS:000185164400098
J	Park, KJ; Gaynor, RB; Kwak, YT				Park, KJ; Gaynor, RB; Kwak, YT			Heat shock protein 27 association with the I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; SMALL STRESS-PROTEINS; IKK-BETA SUBUNIT; CELL-DEATH; LIVER DEGENERATION; RNA INTERFERENCE; MICE LACKING; TNF-ALPHA	Heat shock protein 27 (Hsp27) is a ubiquitously expressed member of the heat shock protein family that has been implicated in various biological functions including the response to heat shock, oxidative stress, and cytokine treatment. Previous studies have demonstrated that heat shock proteins are involved in regulating signal transduction pathways including the NF-kappaB pathway. In this study, we demonstrated that Hsp27 associates with the IkappaB kinase (IKK) complex and that this interaction was stimulated by tumor necrosis factor alpha treatment. Phosphorylation of Hsp27 by the kinase mitogen-activated protein kinase-activated protein kinase 2, a downstream substrate of the mitogen-activated protein kinase p38, enhanced the association of Hsp27 with IKKbeta to result in decreased IKK activity. Consistent with these observations, treatment of cells with a p38 inhibitor reduced the association of Hsp27 with IKKbeta and thus resulted in increased IKK activity. These studies indicate that Hsp27 plays a negative role in down-regulating IKK signaling by reducing its activity following tumor necrosis factor alpha stimulation.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Arrigo AP, 1998, BIOL CHEM, V379, P19; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Garrido C, 1997, CANCER RES, V57, P2661; GUESDON F, 1993, J BIOL CHEM, V268, P4236; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; KHALID H, 1995, CELL MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02073332; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; UNGAR DR, 1994, J NATL CANCER I, V86, P780, DOI 10.1093/jnci/86.10.780; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; WILKINSON JM, 1993, ANAT REC, V237, P453, DOI 10.1002/ar.1092370403; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	53	161	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35272	35278		10.1074/jbc.M305095200	http://dx.doi.org/10.1074/jbc.M305095200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829720	hybrid			2022-12-25	WOS:000185164400065
J	Arganaraz, ER; Schindler, M; Kirchhoff, F; Cortes, MJ; Lama, J				Arganaraz, ER; Schindler, M; Kirchhoff, F; Cortes, MJ; Lama, J			Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased env incorporation and viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-SURFACE CD4; LONG-TERM SURVIVOR; TYPE-1 NEF; ENVELOPE GLYCOPROTEIN; SORTING PATHWAYS; T-CELLS; IN-VIVO; INFECTIVITY; EXPRESSION	Three viral proteins participate in the down-modulation of CD4 in human immunodeficiency virus type 1 (HIV-1)-infected cells. The underlying mechanisms have been extensively investigated. However, the physiological relevance of this phenomenon remains poorly understood. To address the role of CD4 down-modulation in HIV-1 pathogenesis in vivo, we have characterized the functional properties of nef alleles isolated from seven HIV-1-infected patients at either the stage of AIDS (late alleles) or during the asymptomatic phase of infection (early alleles). HIV-1 variants carrying these nef alleles showed striking differences in CD4 down-modulation, virus infectivity, and replication properties. Infection of T cells with late strains resulted in production of viral particles with enhanced infectivity, as compared with variants carrying early nef alleles. These differences in infectivity were observed only when viruses were produced in cells with high levels of the viral receptor, suggesting a functional link between CD4 levels and the ability of Nef to down-modulate CD4 and to enhance viral infectivity. Similarly, late nef alleles were substantially more active than early nef genes in stimulating HIV-1 replication in high CD4-positive cells, including primary lymphocytes, but not in cells expressing low levels of the CD4 receptor. Single-round assays showed that differences in infectivity between late and early strains are largely reduced when evaluated in target cells with high levels of CD4, suggesting that the inhibitory effect occurs at the entry step. Supporting this, enhanced CD4 down-modulation by late nef alleles was associated with higher levels of envelope incorporation into viral particles, a phenomenon that likely accounted for the augmented infectivity. Our data suggest a mechanistic link between the Nef-mediated CD4 down-modulation and the enhancement of replication in CD4-positive lymphocytes. As progression to disease occurs, HIV-1 Nef variants with enhanced ability to down-modulate CD4 are selected. These strains efficiently overcome the deleterious effects of CD4 and replicate more aggressively in CD4-positive primary lymphocytes. These results highlight the importance of the virus-induced CD4 down-modulation in HIV-1 pathogenesis.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Rebecca & John Moores Canc Ctr, La Jolla, CA 92093 USA; Univ Ulm, Dept Virol, D-89081 Ulm, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; Ulm University	Lama, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr,Dept Code 0665, La Jolla, CA 92093 USA.	jlama@ucsd.edu	Schindler, Michael/C-1647-2015; Kirchhoff, Frank/O-8367-2018	Schindler, Michael/0000-0001-8989-5813; Kirchhoff, Frank/0000-0002-7052-2360	NIAID NIH HHS [5P30AI36214-10] Funding Source: Medline; NIDA NIH HHS [DA13866] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013866] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Birch MR, 2001, J CLIN VIROL, V22, P263, DOI 10.1016/S1386-6532(01)00198-6; Bour S, 1999, J BIOL CHEM, V274, P33800, DOI 10.1074/jbc.274.47.33800; Bresnahan PA, 1999, J IMMUNOL, V163, P2977; Carl S, 2000, J INFECT DIS, V181, P132, DOI 10.1086/315187; Carl S, 2001, J VIROL, V75, P3657, DOI 10.1128/JVI.75.8.3657-3665.2001; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; Cortes MJ, 2002, J BIOL CHEM, V277, P1770, DOI 10.1074/jbc.M109807200; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; GELEZIUNAS R, 1994, J GEN VIROL, V75, P857, DOI 10.1099/0022-1317-75-4-857; Glushakova S, 2001, J VIROL, V75, P10113, DOI 10.1128/JVI.75.21.10113-10117.2001; GOMATOS PJ, 1990, J IMMUNOL, V144, P4183; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GUATELLI JC, 1990, J VIROL, V64, P4093, DOI 10.1128/JVI.64.9.4093-4098.1990; Hanna Z, 1998, J VIROL, V72, P121, DOI 10.1128/JVI.72.1.121-132.1998; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; Jekle A, 2002, J VIROL, V76, P6966, DOI 10.1128/JVI.76.14.6966-6973.2002; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; Lafrate AJ, 2000, J VIROL, V74, P9836, DOI 10.1128/JVI.74.21.9836-9844.2000; Lama J, 2003, CURR HIV RES, V1, P167, DOI 10.2174/1570162033485276; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203; LeGall S, 1997, RES VIROLOGY, V148, P43, DOI 10.1016/S0923-2516(97)81912-7; Lundquist CA, 2002, J VIROL, V76, P4625, DOI 10.1128/JVI.76.9.4625-4633.2002; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; MILLER MD, 1995, J VIROL, V69, P579, DOI 10.1128/JVI.69.1.579-584.1995; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Platt EJ, 1997, J VIROL, V71, P883, DOI 10.1128/JVI.71.2.883-890.1997; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rhodes DI, 2000, J VIROL, V74, P10581, DOI 10.1128/JVI.74.22.10581-10588.2000; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; SAGGIORO D, 1993, J BIOL CHEM, V268, P1368; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; Stoddart CA, 2003, J VIROL, V77, P2124, DOI 10.1128/JVI.77.3.2124-2133.2003; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Tobium M, 2001, J VIROL METHODS, V97, P151, DOI 10.1016/S0166-0934(01)00349-4; Tobiume M, 2002, J VIROL, V76, P5959, DOI 10.1128/JVI.76.12.5959-5965.2002; Tobiume M, 2001, ARCH VIROL, V146, P1739, DOI 10.1007/s007050170060; TREMBLAY M, 1994, EMBO J, V13, P774, DOI 10.1002/j.1460-2075.1994.tb06320.x; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wei BL, 2003, CURR HIV RES, V1, P41, DOI 10.2174/1570162033352057; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	62	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33912	33919		10.1074/jbc.M303679200	http://dx.doi.org/10.1074/jbc.M303679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12816953	hybrid			2022-12-25	WOS:000185047500037
J	Raymond, WW; Ruggles, SW; Craik, CS; Caughey, GH				Raymond, WW; Ruggles, SW; Craik, CS; Caughey, GH			Albumin is a substrate of human chymase - Prediction by combinatorial peptide screening and development of a selective inhibitor based on the albumin cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL CHYMASE; HUMAN CATHEPSIN-G; ANGIOTENSIN-II; SERUM-ALBUMIN; HUMAN HEART; CHLOROMETHYL KETONE; CRYSTAL-STRUCTURES; ALPHA-CHYMASE; SPECIFICITY; PROTEASE	Human chymase is a chymotryptic serine peptidase stored and secreted by mast cells. Compared with other chymotryptic enzymes, such as cathepsin G and chymotrypsin, it is much more slowly inhibited by serum serpins. Although chymase hydrolyzes several peptides and proteins in vitro, its target repertoire is limited compared with chymotrypsin because of selective interactions in an extended substrate-binding site. The best-known natural substrate, angiotensin I, is cleaved to generate vasoactive angiotensin II. Selectivity of angiotensin cleavage depends in major part on interactions involving substrate residues on the carboxyl-terminal (P1'-P2') side of the cleaved bond. To identify new targets based on interactions with residues on the amino-terminal (P4-P1) side of the site of hydrolysis, we profiled substrate preferences of recombinant human chymase using a combinatorial, fluorogenic peptide substrate library. Data base queries using the peptide (Arg-Glu-Thr-Tyr-X) generated from the most preferred amino acid at each subsite identify albumin as the sole, soluble, human extracellular protein containing this sequence. We validate the prediction that this site is chymase-susceptible by showing that chymase hydrolyzes albumin uniquely at the predicted location, with the resulting fragments remaining disulfide-linked. The site of hydrolysis is highly conserved in vertebrate albumins and is near predicted sites of metal cation binding, but nicking by chymase does not alter binding of Cu2+ or Zn2+. A synthetic peptidic inhibitor, diphenyl N-alpha-benzoxycarbonyl-L-Arg-Glu-Thr-Phe(P)-phosphonate, was designed from the preferred P4-P1 substrate sequence. This inhibitor is highly potent (IC50 3.8 nM) and 2,700- and 1,300-fold selective for chymase over cathepsin G and chymotrypsin, respectively. In summary, these findings reveal albumin to be a substrate for chymase and identify a potentially useful new chymase inhibitor.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NHLBI NIH HHS [HL-24136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balcells E, 1997, AM J PHYSIOL-HEART C, V273, pH1769, DOI 10.1152/ajpheart.1997.273.4.H1769; Bar-Or D, 2001, EUR J BIOCHEM, V268, P42, DOI 10.1046/j.1432-1327.2001.01846.x; BASTOS M, 1995, P NATL ACAD SCI USA, V92, P6738, DOI 10.1073/pnas.92.15.6738; Bertrand JA, 1996, BIOCHEMISTRY-US, V35, P3147, DOI 10.1021/bi9520996; BONE R, 1991, BIOCHEMISTRY-US, V30, P2263, DOI 10.1021/bi00222a032; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CAUGHEY GH, 1998, HDB PROTEOLYTIC ENZY, P66; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GURISH MF, 1993, J BIOL CHEM, V268, P11372; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Hayashi Y, 2000, BIOORG MED CHEM LETT, V10, P199, DOI 10.1016/S0960-894X(99)00659-9; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; HUANG RY, 1994, IMMUNOGENETICS, V40, P397, DOI 10.1007/BF00177823; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; Longley BJ, 1997, P NATL ACAD SCI USA, V94, P9017, DOI 10.1073/pnas.94.17.9017; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; Mellon MB, 2002, J IMMUNOL, V168, P290, DOI 10.4049/jimmunol.168.1.290; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; Muilenburg DJ, 2002, BBA-PROTEIN STRUCT M, V1596, P346, DOI 10.1016/S0167-4838(02)00224-8; Nakano A, 1997, J IMMUNOL, V159, P1987; Ohyoshi E, 1999, J INORG BIOCHEM, V75, P213, DOI 10.1016/S0162-0134(99)00090-2; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pemberton AD, 1997, BIOCHEM J, V321, P665, DOI 10.1042/bj3210665; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208; Polanowska J, 1998, BBA-PROTEIN STRUCT M, V1386, P189, DOI 10.1016/S0167-4838(98)00085-5; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; Reiling KK, 2003, BIOCHEMISTRY-US, V42, P2616, DOI 10.1021/bi020594d; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SCHECHTER NM, 1983, J BIOL CHEM, V258, P2973; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHOENBERGER OL, 1989, FEBS LETT, V259, P165, DOI 10.1016/0014-5793(89)81519-4; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; URATA H, 1990, J BIOL CHEM, V265, P22348; Walter M, 1999, ARCH BIOCHEM BIOPHYS, V368, P276, DOI 10.1006/abbi.1999.1309	47	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34517	34524		10.1074/jbc.M304087200	http://dx.doi.org/10.1074/jbc.M304087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815038	hybrid			2022-12-25	WOS:000185047500112
J	Trueb, B; Zhuang, L; Taeschler, S; Wiedemann, M				Trueb, B; Zhuang, L; Taeschler, S; Wiedemann, M			Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE DIFFERENTIATION; HEPARAN-SULFATE; CARTILAGE; MATRILIN-3	Clones for a novel transmembrane receptor termed FGFRL1 were isolated from a subtracted, cartilage-specific cDNA library prepared from chicken sterna. Homologous sequences were identified in other vertebrates, including man, mouse, rat and fish, but not in invertebrates such as Caenorhabditis elegans and Drosophila. FGFRL1 was expressed preferentially in skeletal tissues as demonstrated by Northern blotting and in situ hybridization. Small amounts of the FGFRL1 mRNA were also detected in other tissues such as skeletal muscle and heart. The novel protein contained three extracellular Ig-like domains that were related to the members of the fibroblast growth factor (FGF) receptor family. However, it lacked the intracellular protein tyrosine kinase domain required for signal transduction by transphosphorylation. When expressed in cultured cells as a fusion protein with green fluorescent protein, FGFRL1 was specifically localized to the plasma membrane where it might interact with FGF ligands. Recombinant FGFRL1 protein was produced in a baculovirus system with intact disulfide bonds. Similar to FGF receptors, the expressed protein interacted specifically with heparin and with FGF2. When overexpressed in MG-63 osteosarcoma cells, the novel receptor had a negative effect on cell proliferation. Taken together our data are consistent with the view that FGFRL1 acts as a decoy receptor for FGF ligands.	Univ Bern, Res Inst, ITI, CH-3010 Bern, Switzerland	University of Bern	Trueb, B (corresponding author), Univ Bern, Res Inst, ITI, POB 54, CH-3010 Bern, Switzerland.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Belluoccio D, 1998, GENOMICS, V53, P391, DOI 10.1006/geno.1998.5519; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; Bianco P, 1998, MATRIX BIOL, V17, P185, DOI 10.1016/S0945-053X(98)90057-9; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; Kim I, 2001, BBA-GENE STRUCT EXPR, V1518, P152, DOI 10.1016/S0167-4781(00)00282-7; Li B, 2001, J BIOL CHEM, V276, P33328, DOI 10.1074/jbc.M100789200; LOBB RR, 1984, BIOCHEMISTRY-US, V23, P6295, DOI 10.1021/bi00321a001; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Szebenyi G, 1999, INT REV CYTOL, V185, P45; UENO H, 1992, J BIOL CHEM, V267, P1470; Vortkamp A, 2001, OSTEOARTHR CARTILAGE, V9, pS109, DOI 10.1053/joca.2001.0452; WALCHLI C, 1994, J CELL SCI, V107, P669; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Wiedemann M, 2001, BBA-GENE STRUCT EXPR, V1520, P247, DOI 10.1016/S0167-4781(01)00267-6	27	64	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33857	33865		10.1074/jbc.M300281200	http://dx.doi.org/10.1074/jbc.M300281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813049	hybrid			2022-12-25	WOS:000185047500031
J	Maccarrone, M; Bari, M; Di Rienzo, M; Finazzi-Agro, A; Rossi, A				Maccarrone, M; Bari, M; Di Rienzo, M; Finazzi-Agro, A; Rossi, A			Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANANDAMIDE HYDROLASE; DOWN-REGULATION; ENDOCANNABINOIDS; EXPRESSION; CELLS; CYTOKINES; BINDING; PREGNANCY; TRANSPORT; SYSTEM	Physiological concentrations of progesterone stimulate the activity of the endocannabinoid-degrading enzyme fatty acid amide hydrolase ( FAAH) in human T lymphocytes, up to a similar to 270% over the untreated controls. Stimulation of FAAH occurred through up-regulation of gene expression at transcriptional and translational level and was specific. Indeed, neither the activity of the anandamide-synthesizing N-acyltransferase and phospholipase D, nor the activity of the anandamide transporter, nor the binding to cannabinoid receptors were affected by progesterone under the same experimental conditions. The activation of FAAH by progesterone was paralleled by a decrease ( down to 60%) of the cellular levels of anandamide and involved increased nuclear levels of the transcription factor Ikaros. Analysis of the FAAH promoter showed an Ikaros binding site, and mutation of this site prevented FAAH activation by progesterone in transient expression assays. Electrophoretic mobility shift and supershift assays further corroborated the promoter activity data. Furthermore, the effect of progesterone on FAAH promoter was additive to that of physiological amounts of leptin, which binds to a cAMP response element-like site in the promoter region. Taken together, these results suggest that progesterone and leptin, by up-regulating the FAAH promoter at different sites, enhance FAAH expression, thus tuning the immunomodulatory effects of anandamide. These findings might also have critical implications for human fertility.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; IRCCS C Mondino, Mondino Tor Vergata Santa Lucia Ctr Expt Neurobio, I-00179 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Teramo; IRCCS Fondazione Casimiro Mondino; IRCCS Santa Lucia; University of Rome Tor Vergata	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.	Maccarrone@vet.unite.it						Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Cadas H, 1997, J NEUROSCI, V17, P1226; Chaouat G, 1995, HUM REPROD, V10, P55, DOI 10.1093/humrep/10.suppl_2.55; Correale J, 1998, J IMMUNOL, V161, P3365; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cunningham MJ, 1999, BIOL REPROD, V60, P216, DOI 10.1095/biolreprod60.2.216; Day TA, 2001, MOL PHARMACOL, V59, P1369, DOI 10.1124/mol.59.6.1369; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Dorsam G, 2002, J BIOL CHEM, V277, P13488, DOI 10.1074/jbc.M107922200; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Gubellini P, 2002, J NEUROSCI, V22, P6900; LEBEAU MC, 1994, HUM REPROD, V9, P11, DOI 10.1093/humrep/9.suppl_2.11; Lee JH, 1996, J BIOL CHEM, V271, P4561; Maccarrone M, 2002, MOL HUM REPROD, V8, P188, DOI 10.1093/molehr/8.2.188; Maccarrone M, 2001, J IMMUNOL, V166, P7183, DOI 10.4049/jimmunol.166.12.7183; Maccarrone M, 2000, EUR J BIOCHEM, V267, P2991; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; Maccarrone M, 2003, J BIOL CHEM, V278, P13318, DOI 10.1074/jbc.M211248200; Maccarrone M, 2002, PROSTAG LEUKOTR ESS, V66, P309, DOI 10.1054/plef.2001.0354; Maccarrone M, 2002, BLOOD, V100, P4040, DOI 10.1182/blood-2002-05-1444; Matarese G, 2002, TRENDS IMMUNOL, V23, P182, DOI 10.1016/S1471-4906(02)02188-9; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; Moesgaard B, 2000, J LIPID RES, V41, P985; Paria BC, 2001, J BIOL CHEM, V276, P20523, DOI 10.1074/jbc.M100679200; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Puffenbarger RA, 2001, NEUROSCI LETT, V314, P21, DOI 10.1016/S0304-3940(01)02274-1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; SzekeresBartho J, 1996, AM J REPROD IMMUNOL, V35, P348; Waleh NS, 2002, GENE, V291, P203, DOI 10.1016/S0378-1119(02)00598-X; Wan MH, 1998, GENOMICS, V54, P408, DOI 10.1006/geno.1998.5597; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Wargnier A, 1998, J BIOL CHEM, V273, P35326, DOI 10.1074/jbc.273.52.35326	40	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32726	32732		10.1074/jbc.M302123200	http://dx.doi.org/10.1074/jbc.M302123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799380	hybrid			2022-12-25	WOS:000184901800031
J	Storey, NM; Gomez-Angelats, M; Bortner, CD; Armstrong, DL; Cidlowski, JA				Storey, NM; Gomez-Angelats, M; Bortner, CD; Armstrong, DL; Cidlowski, JA			Stimulation of Kv1.3 potassium channels by death receptors during apoptosis in Jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; CYTOCHROME-C; KINASE-C; SIGNALING COMPLEX; VOLUME REGULATION; K+ CHANNELS; CASPASE ACTIVATION; MEDIATED APOPTOSIS; FAS; SHRINKAGE	The loss of intracellular potassium is a pivotal step in the induction of apoptosis but the mechanisms underlying this response are poorly understood. Here we report caspase-dependent stimulation of potassium channels by the Fas receptor in a human Jurkat T cell line. Receptor activation with Fas ligand for 30 min increased the amplitude of voltage-activated potassium currents 2-fold on average. This produces a sustained outward current, similar to 10 pA, at physiological membrane potentials during Fas ligand-induced apoptosis. Both basal and Fas ligand-induced currents were blocked completely by toxins that selectively inhibit Kv1.3 potassium channels. Kv1.3 stimulation required the expression of Fas-associated death domain protein and activation of caspase 8, but did not require activation of caspase 3 or protein synthesis. Furthermore, Kv1.3 stimulation by Fas ligand was prevented by chronic stimulation of protein kinase C with 20 nM phorbol 12-myristate 13-acetate during Fas ligand treatment, which also blocks apoptosis. Thus, Fas ligand increases Kv1.3 channel activity through the same canonical apoptotic signaling cascade that is required for potassium efflux, cell shrinkage, and apoptosis.	NIEHS, Membrane Signaling Grp, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Endocrinol Grp, Lab Signal Transduct, US Dept HHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Membrane Signaling Grp, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090079, Z01ES090079, Z01ES080052, Z01ES080043, ZIAES080043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson KL, 1996, J IMMUNOL, V156, P4083; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; Bock J, 2002, BIOCHEM BIOPH RES CO, V295, P526, DOI 10.1016/S0006-291X(02)00695-2; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 2001, METHOD CELL BIOL, V66, P49; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Chang MC, 2001, CELL PHYSIOL BIOCHEM, V11, P123, DOI 10.1159/000047800; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kalman K, 1999, BIOPHYS J, V76, pA410; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; PAYET MD, 1992, J BIOL CHEM, V267, P18270; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Platoshyn O, 2002, AM J PHYSIOL-CELL PH, V283, pC1298, DOI 10.1152/ajpcell.00592.2001; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Sharoy VG, 2002, J AM COLL CARDIOL, V39, p176A; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Singh R, 2002, J BIOL CHEM, V277, P37630, DOI 10.1074/jbc.M203648200; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; Trimarchi JR, 2002, AM J PHYSIOL-CELL PH, V282, pC588, DOI 10.1152/ajpcell.00365.2001; Wang L, 1999, J MEMBRANE BIOL, V172, P113, DOI 10.1007/s002329900589; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	43	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33319	33326		10.1074/jbc.M300443200	http://dx.doi.org/10.1074/jbc.M300443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807917	hybrid			2022-12-25	WOS:000184901800102
J	Wang, Q; Song, CC; Yang, XY; Li, CCH				Wang, Q; Song, CC; Yang, XY; Li, CCH			D1 ring is stable and nucleotide-independent, whereas D2 ring undergoes major conformational changes during the ATPase cycle of p97-VCP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; VALOSIN-CONTAINING PROTEIN; AAA-ATPASE; MEMBRANE-FUSION; BINDING-SITES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CLPAP PROTEASE	The 97-kDa valosin-containing protein (p97-VCP) belongs to the AAA ( ATPases associated with various cellular activities) family and acts as a molecular chaperone in diverse cellular events, including ubiquitin-proteasome-mediated degradation. We previously showed that VCP contains a substrate-binding domain, N, and two conserved ATPase domains, D1 and D2, of which D2 is responsible for the major enzyme activity. VCP has a barrel-like structure containing two stacked homo-hexameric rings made of the D1 and D2 domains, and this structure is essential for its biological functions. During ATPase cycles, VCP undergoes conformational changes that presumably apply tensions to the bound substrate, leading to the disassembly of protein complexes or unfolding of the substrate. How ATPase activity is coupled with the conformational changes in VCP complex and the D1 and D2 rings is not clear. In this report, we took biochemical approaches to study the structure of VCP in different nucleotide conditions to depict the conformational changes in the ATPase cycles. In contrast to many AAA chaperones that require ATP/ADP to form oligomers, both wild type VCP and ATP-binding site mutants can form hexamers without the addition of nucleotide. This nucleotide-independent hexamerization requires an intact D1 and the downstream linker sequence of VCP. Tryptophan fluorescence and trypsin digestion analyses showed that ATP/ ADP binding induces dramatic conformational changes in VCP. These changes do not require the presence of an intact ATP-binding site in D1 and is thus mainly attributed to the D2 domain. We propose a model whereby D1, although undergoing minor conformational changes, remains as a relatively trypsin-resistant hexameric ring throughout the ATPase cycle, whereas D2 only does so when it binds to ATP or ADP. After ADP is released at the end of the ATP hydrolysis, D2 ring is destabilized and adopts a relatively flexible and open structure.	NCI, Basic Res Program, Sci Applicat Int Corp, NIH, Frederick, MD 21702 USA; NCI, Basic Res Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, CCH (corresponding author), NCI, Basic Res Program, Sci Applicat Int Corp, NIH, Frederick, MD 21702 USA.	licc@ncifcrf.gov			NCI NIH HHS [N01-CO-56000] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010029] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; De la Cruz EM, 2000, J MOL BIOL, V295, P517, DOI 10.1006/jmbi.1999.3390; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yen CH, 2000, J IMMUNOL, V165, P6372, DOI 10.4049/jimmunol.165.11.6372; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097	41	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32784	32793		10.1074/jbc.M303869200	http://dx.doi.org/10.1074/jbc.M303869200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807884	hybrid			2022-12-25	WOS:000184901800038
J	Nishimiya, Y; Ohgiya, S; Tsuda, S				Nishimiya, Y; Ohgiya, S; Tsuda, S			Artificial multimers of the type III antifreeze protein - Effects on thermal hysteresis and ice crystal morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CELL-SURVIVAL; BINDING; SURFACE; POUT; CRYOPRESERVATION; IDENTIFICATION; POLYPEPTIDE; INHIBITION; ADSORPTION	A variant of antifreeze protein (AFP) named RD3 from antarctic eel pout (Lycodichthys dearborni) comprises the type III AFP intramolecular dimer, which is known to exhibit a significant enhancement of thermal hysteresis when compared with the type III AFP monomer (Miura, K., Ohgiya, S., Hoshino, T, Nemoto, N., Suetake, T., Miura, A, Spyracopoulos, L., Kondo, H., and Tsuda, S. (2001) J. Biol. Chem. 276, 1304-1310). Here we genetically synthesized intramolecular dimer, trimer, and tetramer of the type III AFP, for which we utilize the genes encoding the primary sequences of the N-domain, the C-domain, and the 9-residue linker of RD3, and we examined the AFP multimerization effects on thermal hysteresis and ice crystal morphology. Significantly, (i) the thermal hysteresis increases in proportion with the size of the multimers, (ii) a larger size of the multimer exerts the maximum activity at lower concentration, (iii) every multimer changes the morphology of a single ice crystal into a unique shape that is similar but not identical to the ordinary hexagonal bipyramid, and (iv) the size of ice crystal becomes dramatically small with increasing the concentration of the multimer. The thermal hysteresis enhancement of the multimer was detected in both molar and domain bases. These results suggest that a molecule comprising the multiple AFP domains connected in tandem acquires an enhanced affinity for the ice binding.	Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Prot Struct Res Grp, Sapporo, Hokkaido 0628517, Japan; Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Mol Adaptat Res Grp, Sapporo, Hokkaido 0628517, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University	Tsuda, S (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Prot Struct Res Grp, 2-17-2-1 Tsukisamu Higashi, Sapporo, Hokkaido 0628517, Japan.		Tsuda, Sakae/M-2756-2018; Ohgiya, Satoru/V-3117-2018; Nishimiya, Yoshiyuki/M-4173-2018	Tsuda, Sakae/0000-0002-1399-0619; Ohgiya, Satoru/0000-0001-8257-8284; Nishimiya, Yoshiyuki/0000-0002-0701-7775				Baardsnes J, 2002, BBA-PROTEINS PROTEOM, V1601, P49, DOI 10.1016/S1570-9639(02)00431-4; CARPENTER JF, 1992, P NATL ACAD SCI USA, V89, P8953, DOI 10.1073/pnas.89.19.8953; CHAO H, 1995, FEBS LETT, V357, P183, DOI 10.1016/0014-5793(94)01357-7; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; Chao HM, 1996, J EXP BIOL, V199, P2071; Chapsky L, 1997, FEBS LETT, V412, P241, DOI 10.1016/S0014-5793(97)00787-4; DeLuca CI, 1998, J MOL BIOL, V275, P515, DOI 10.1006/jmbi.1997.1482; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Hobbs P.V., 1974, ICE PHYSICS, P18; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LI XM, 1985, J BIOL CHEM, V260, P2904; Miura K, 1999, J BIOCHEM-TOKYO, V126, P387, DOI 10.1093/oxfordjournals.jbchem.a022462; Miura K, 2001, J BIOL CHEM, V276, P1304, DOI 10.1074/jbc.M007902200; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WANG X, 1995, BBA-PROTEIN STRUCT M, V1247, P163, DOI 10.1016/0167-4838(94)00205-U; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c	22	24	28	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32307	32312		10.1074/jbc.M304390200	http://dx.doi.org/10.1074/jbc.M304390200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805364	hybrid			2022-12-25	WOS:000184782100107
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein	ONCOGENE			English	Article						VHL; HIF-1 alpha; RCC	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; REGULATE HIF; HYDROXYLATION; DEGRADATION; DISEASE; ALPHA; GENE; CELL; FIBRONECTIN; TRAFFICKING	Mutations in the von Hippel-Lindau (VHL) tumour-suppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/DNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.		Lewis, Martin/A-3881-2010; Lewis, Martin/A-8489-2008	Lewis, Martin/0000-0002-3332-3776				Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	22	25	25	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3992	3997		10.1038/sj.onc.1206683	http://dx.doi.org/10.1038/sj.onc.1206683			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821933				2022-12-25	WOS:000183707600002
J	Farnegardh, M; Bonn, T; Sun, S; Ljunggren, J; Ahola, H; Wilhelmsson, A; Gustafsson, JA; Carlquist, M				Farnegardh, M; Bonn, T; Sun, S; Ljunggren, J; Ahola, H; Wilhelmsson, A; Gustafsson, JA; Carlquist, M			The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; CRYSTAL-STRUCTURE; CHOLESTEROL EFFLUX; MOLECULAR-BASIS; LXR-ALPHA; ACTIVATION; HORMONE; IDENTIFICATION; REQUIREMENTS; ANTAGONISM	The structures of the liver X receptor LXRbeta (NR1H2) have been determined in complexes with two synthetic ligands, T0901317 and GW3965, to 2.1 and 2.4 Angstrom, respectively. Together with its isoform LXRalpha (NR1H3) it regulates target genes involved in metabolism and transport of cholesterol and fatty acids. The two LXRbeta structures reveal a flexible ligand-binding pocket that can adjust to accommodate fundamentally different ligands. The ligand-binding pocket is hydrophobic but with polar or charged residues at the two ends of the cavity. T0901317 takes advantage of this by binding to His-435 close to H12 while GW3965 orients itself with its charged group in the opposite direction. Both ligands induce a fixed "agonist conformation" of helix H12 (also called the AF-2 domain), resulting in a transcriptionally active receptor.	Karo Bio AB, NOVUM, SE-14157 Huddinge, Sweden; Huddinge Univ Hosp, NOVUM, Karolinska Inst, Dept Med Nutr, SE-14157 Huddinge, Sweden; Huddinge Univ Hosp, NOVUM, Karolinska Inst, Dept Biosci, SE-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Farnegardh, M (corresponding author), Karo Bio AB, NOVUM, SE-14157 Huddinge, Sweden.	mathias.farnegardh@karobio.se						APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Costet P, 2000, J BIOL CHEM, V275, P28240; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Evans W, 1997, CHEM BRIT, V33, P22; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LESLIE AGW, 1992, JOINT CCP4 ESF EAMBC, V26; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Urban F, 2000, FEBS LETT, V484, P159, DOI 10.1016/S0014-5793(00)02130-X; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Watkins RE, 2003, BIOCHEMISTRY-US, V42, P1430, DOI 10.1021/bi0268753; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a	46	122	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38821	38828		10.1074/jbc.M304842200	http://dx.doi.org/10.1074/jbc.M304842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12819202	hybrid			2022-12-25	WOS:000185575100090
J	Davila, M; Frost, AR; Grizzle, WE; Chakrabarti, R				Davila, M; Frost, AR; Grizzle, WE; Chakrabarti, R			LIM kinase 1 is essential for the invasive growth of prostate epithelial cells - Implications in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO INVASION; COFILIN PHOSPHORYLATION; PROTEIN-KINASE; METALLOPROTEINASE MT1-MMP; ACTIVATION; RHO; EXPRESSION; GTPASES; MATRIX; OVEREXPRESSION	Mammalian LIM kinase 1 (LIMK1) is involved in reorganization of actin cytoskeleton through inactivating phosphorylation of the ADF family protein cofilin, which depolymerizes actin filaments. Maintenance of the actin dynamics in an ordered fashion is essential for stabilization of cell shape or promotion of cell motility depending on the cell type. These are the two key phenomena that may become altered during acquisition of the metastatic phenotype by cancer cells. Here we show that LIMK1 is overexpressed in prostate tumors and in prostate cancer cell lines, that the concentration of phosphorylated cofilin is higher in metastatic prostate cancer cells, and that a partial reduction of LIMK1 altered cell proliferation by arresting cells at G(2)/ M, changed cell shape, and abolished the invasiveness of metastatic prostate cancer cells. We also show that the ectopic expression of LIMK1 promotes acquisition of invasive phenotype by the benign prostate epithelial cells. Our data provide evidence of a novel role of LIMK1 in regulating cell division and invasive property of prostate cancer cells and indicate that the effect is not mediated by phosphorylation of cofilin. Our study correlates with the recent observations showing a metastasis-associated chromosomal gain on 7q11.2 in prostate cancer, suggesting a possible gain in LIMK1 DNA (7q11.23).	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	State University System of Florida; University of Central Florida; University of Alabama System; University of Alabama Birmingham	Chakrabarti, R (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 12722 Res Pkwy, Orlando, FL 32826 USA.	rchak@mail.ucf.edu	Davila, Monica/I-4170-2018	Davila, Monica/0000-0002-4638-9766	NCI NIH HHS [CA81329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA081329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Alers JC, 1998, J PATHOL, V185, P273, DOI 10.1002/(SICI)1096-9896(199807)185:3<273::AID-PATH92>3.0.CO;2-8; Alers JC, 1997, LAB INVEST, V77, P437; Alers JC, 2001, AM J PATHOL, V158, P399, DOI 10.1016/S0002-9440(10)63983-1; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Chakrabarti R, 2002, CANCER GENET CYTOGEN, V139, P115, DOI 10.1016/S0165-4608(02)00641-6; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dionne CA, 1998, CLIN CANCER RES, V4, P1887; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; Ellis JG, 2003, J BIOL CHEM, V278, P1936, DOI 10.1074/jbc.M209274200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Lian JP, 2000, J BIOL CHEM, V275, P2869, DOI 10.1074/jbc.275.4.2869; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MIZUNO K, 1994, ONCOGENE, V9, P1605; Morote J, 1999, INT J CANCER, V84, P421, DOI 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Strefford JC, 2001, CANCER GENET CYTOGEN, V124, P112, DOI 10.1016/S0165-4608(00)00339-3; Sumi T, 2002, BIOCHEM BIOPH RES CO, V290, P1315, DOI 10.1006/bbrc.2002.6346; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P23092, DOI 10.1074/jbc.C100196200; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Upadhyay J, 1999, CLIN CANCER RES, V5, P4105; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; Wouters CH, 2001, AM J MED GENET, V102, P261, DOI 10.1002/ajmg.1468; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; YU DH, 1994, CANCER RES, V54, P3260	47	125	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36868	36875		10.1074/jbc.M306196200	http://dx.doi.org/10.1074/jbc.M306196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12821664	hybrid			2022-12-25	WOS:000185318300120
J	Pilipuk, GP; Galigniana, MD; Schwartz, J				Pilipuk, GP; Galigniana, MD; Schwartz, J			Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEINS; RNA-POLYMERASE-II; MESSENGER-RNA; CENTROMERIC HETEROCHROMATIN; CONSTITUTIVE HETEROCHROMATIN; ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; ADIPOSE CONVERSION; GENE-EXPRESSION	Localization of transcription regulatory proteins in the nucleus is dynamically regulated, and may alter nucleoplasmic concentrations and/or assembly of multimolecular transcription regulatory complexes, which ultimately regulate gene expression. Since growth hormone (GH) regulates multiple transcription factors including C/EBPbeta, the effect of GH on the subcellular localization of C/EBPbeta was examined in 3T3-F442A preadipocytes. Indirect immunofluorescence shows that C/EBPbeta is diffusely distributed in nuclei of quiescent cells. Within 5 min of GH treatment, the diffuse pattern dramatically becomes punctate. The relocalization of C/EBPbeta coincides with DAPI staining of heterochromatin. Further, C/EBPbeta and heterochromatin protein (HP)-1alpha colocalize in the nucleus, consistent with localization of C/EBPbeta to pericentromeric heterochromatin. In contrast, C/EBPdelta exhibits a diffuse distribution in the nucleus that is not modified by GH treatment. C/EBPbeta is rapidly and transiently phosphorylated on a conserved MAPK consensus site in response to GH (Piwien-Pilipuk, G., MacDougald, O. A., and Schwartz, J. ( 2002) J. Biol. Chem. 277, 44557 44565). Indirect immunofluorescence using antibodies specific for C/EBPbeta phosphorylated on the conserved MAPK site shows that GH also rapidly induces a punctate pattern of staining for the phosphorylated C/EBPbeta. In addition, phosphorylated C/EBPbeta colocalizes to pericentromeric heterochromatin. The satellite DNA present in heterochromatin contains multiple C/EBP binding sites. DNA binding analysis shows that C/EBPbeta, C/EBPdelta, and C/EBPalpha (p42 and p30 forms) can bind to satellite DNA as homo- or heterocomplexes in vitro. Importantly, GH rapidly and transiently increases binding of endogenous C/EBPbeta from 3T3-F442A cells to satellite DNA. Further, the GH-promoted nuclear relocalization of C/EBPbeta to pericentromeric heterochromatin was prevented by the MEK inhibitor U0126. This observation suggests that GH-dependent MAPK activation plays a role in the regulation of nuclear relocalization of C/EBPbeta. Nuclear redistribution introduces a new level of transcriptional regulation in GH action, since GH-mediated phosphorylation and nuclear redistribution of C/EBPbeta may be coordinated to achieve spatial-temporal control of gene expression.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schwartz, J (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.			GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46072] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Grande MA, 1997, J CELL SCI, V110, P1781; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; HERTZ E, 1928, WISS BOTONIK, V69, P762; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Remboutsika E, 1999, J CELL SCI, V112, P1671; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SCOTT LM, 1992, BLOOD, V80, P1725; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; STEPHANOVA E, 1988, EXP CELL RES, V179, P545, DOI 10.1016/0014-4827(88)90292-3; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; vanSteensel B, 1996, J CELL SCI, V109, P787; Vicent GP, 2002, EXP CELL RES, V276, P142, DOI 10.1006/excr.2002.5532; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Zhang WH, 2001, J BIOL CHEM, V276, P40373, DOI 10.1074/jbc.C100505200	56	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35668	35677		10.1074/jbc.M305182200	http://dx.doi.org/10.1074/jbc.M305182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12821655	Green Submitted, hybrid			2022-12-25	WOS:000185164400112
J	Samanta, S; Ayvaz, T; Reyes, M; Shuman, HA; Chen, J; Davidson, AL				Samanta, S; Ayvaz, T; Reyes, M; Shuman, HA; Chen, J; Davidson, AL			Disulfide cross-linking reveals a site of stable interaction between C-terminal regulatory domains of the two MalK subunits in the maltose transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-CASSETTE; ESCHERICHIA-COLI; ABC TRANSPORTER; INDUCER EXCLUSION; CRYSTAL-STRUCTURE; CATALYTIC CYCLE; ACTIVE-SITE; PROTEIN; SYSTEM; MECHANISM	Understanding the structure and function of the ATP-binding cassette (ABC) transporters is very important because defects in ABC transporters lie at the root of several serious diseases including cystic fibrosis. MalK, the ATP-binding cassette of the maltose transporter of Escherichia coli, is distinct from most other ATP-binding cassettes in that it contains an additional C-terminal regulatory domain. The published structure of a MalK dimer is elongated with C-terminal domains at opposite poles (Diederichs, K., Diez, J., Greller, G., Muller, C., Breed, J., Schnell, C., Vonrhein, C., Boos, W., and Welte, W. (2000) EMBO J. 19, 5951 - 5961). Some uncertainty exists as to whether the orientation of MalK in the dimer structure is correct. Superpositioning of the N-terminal domains of MalK onto the ATP-binding domains of an alternate ABC dimer, in which ATP is bound along the dimer interface between Walker A and LSGGQ motifs, places both N- and C-terminal domains of MalK along the dimer interface. Consistent with this model, a cysteine substitution at position 313 in the C-terminal domain of an otherwise cysteine-free MalK triggered disulfide bond formation between two MalK subunits in an intact maltose transporter. Disulfide bond formation did not inhibit the function of the transporter, suggesting that the C-terminal domains of MalK remain in close proximity throughout the transport cycle. Enzyme IIA(glc) still inhibited the ATPase activity of the disulfide-linked transporter indicating that the mechanism of inducer exclusion was unaffected. These data support a model for ATP hydrolysis in which the C-terminal domains of MalK remain in contact whereas the N- terminal domains of MalK open and close to allow nucleotide binding and dissociation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Baylor College of Medicine; Columbia University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Davidson, AL (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza,MS BCM-280, Houston, TX 77030 USA.	davidson@bcm.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049261, R01GM049261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; BUKAU B, 1986, J BACTERIOL, V166, P884, DOI 10.1128/jb.166.3.884-891.1986; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Dean M, 2001, J LIPID RES, V42, P1007; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Mannering DE, 2001, J BIOL CHEM, V276, P12362, DOI 10.1074/jbc.M011686200; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stein A, 2002, EUR J BIOCHEM, V269, P4074, DOI 10.1046/j.1432-1033.2002.03099.x; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	40	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35265	35271		10.1074/jbc.M301171200	http://dx.doi.org/10.1074/jbc.M301171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12813052	hybrid			2022-12-25	WOS:000185164400064
J	Colell, A; Garcia-Ruiz, C; Lluis, JM; Coll, O; Mari, M; Fernandez-Checa, JC				Colell, A; Garcia-Ruiz, C; Lluis, JM; Coll, O; Mari, M; Fernandez-Checa, JC			Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; RAT-LIVER MITOCHONDRIA; INNER MEMBRANE; CASPASE ACTIVATION; CREATINE-KINASE; CELL-DEATH; APOPTOSIS; ETHANOL; PORE; TRANSPORT	Mitochondrial permeability transition (MPT) has been proposed to play a key role in cell death. Downstream MPT events include the release of apoptogenic factors that sets in motion the mitochondrial apoptosome leading to caspase activation. The current work examined the regulation of MPT by membrane fluidity modulated upon cholesterol enrichment. Mitochondria enriched in cholesterol displayed increased microviscosity resulting in impaired MPT induced by atractyloside, a c-conformation stabilizing ligand of the adenine nucleotide translocator (ANT). This effect was dependent on the dose of cholesterol loaded and reversed upon the fluidization of mitochondria by the fatty acid derivative A(2)C. Mitoplasts derived from cholesterol-enriched mitochondria responded to atractyloside in a similar fashion as intact mitochondria, indicating that a significant amount of cholesterol is still found in the inner membrane. The effects of cholesterol on MPT induced by atractyloside were mirrored by the release of intermembrane proteins, cytochrome c, Smac/Diablo, and apoptosis inducing factor. However, cholesterol loading did not affect the uptake rate of adenine nucleotide hence dissociating the function of ANT as a MPT-mediated protein from its adenine nucleotide exchange function. Thus, these findings indicate that the ability of atractyloside to induce MPT via ANT requires an appropriate membrane fluidity range.	Hosp Clin Barcelona, Inst Malaties Digest, Liver Unit, Inst Invest Biomed August Pi Suner, Barcelona 08036, Spain; CSIC, Dept Expt Pathol, Inst Invest Biomed Barcelona, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Inst Malaties Digest, Liver Unit, Inst Invest Biomed August Pi Suner, C Villarroel 170, Barcelona 08036, Spain.		MARI, MONTSERRAT/M-2871-2019; Fernández-Checa, José Carlos/L-8342-2014; Coll, Olga/H-6129-2015; Colell, Anna/N-8710-2014; Garcia-Ruiz, Carmen/L-8211-2014; Mari, Montserrat/A-7376-2013	Fernández-Checa, José Carlos/0000-0003-3422-2990; Coll, Olga/0000-0002-7946-1250; Colell, Anna/0000-0001-5236-1834; Garcia-Ruiz, Carmen/0000-0002-2652-6102; Mari, Montserrat/0000-0002-6116-3247	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014135, P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA11999, 1R21 AA014135-01] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; BARBOUR RL, 1981, J BIOL CHEM, V256, P1940; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Campbell AM, 2002, BBA-BIOMEMBRANES, V1567, P123, DOI 10.1016/S0005-2736(02)00607-7; CASTRO J, 1991, BIOCHEM PHARMACOL, V41, P1987, DOI 10.1016/0006-2952(91)90140-Z; CEDERBAUM AI, 1975, FED PROC, V34, P2045; CHARNYAK BV, 1996, EUR J BIOCHEM, V238, P623; CHERNYAK BV, 1995, FEBS LETT, V365, P75, DOI 10.1016/0014-5793(95)00411-2; Colell A, 1997, HEPATOLOGY, V26, P699, DOI 10.1053/jhep.1997.v26.pm0009303501; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; CUNNINGHAM CC, 1983, ALCOHOL CLIN EXP RES, V7, P424, DOI 10.1111/j.1530-0277.1983.tb05500.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUNCAN IW, 1979, J CHROMATOGR, V162, P281, DOI 10.1016/S0378-4347(00)81515-7; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FEO F, 1975, BIOCHIM BIOPHYS ACTA, V413, P116, DOI 10.1016/0005-2736(75)90063-2; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GORDON ER, 1977, BIOCHEM PHARMACOL, V26, P1229, DOI 10.1016/0006-2952(77)90110-1; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; HILDENBRAND K, 1979, BIOCHIM BIOPHYS ACTA, V553, P365, DOI 10.1016/0005-2736(79)90292-X; Huang XX, 2001, MOL CELL BIOCHEM, V224, P1, DOI 10.1023/A:1011990300114; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOSOWER EM, 1977, BIOCHIM BIOPHYS ACTA, V471, P311, DOI 10.1016/0005-2736(77)90259-0; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAU BWC, 1984, CANCER RES, V44, P4458; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lluis JM, 2003, GASTROENTEROLOGY, V124, P708, DOI 10.1053/gast.2003.50089; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; MARTINEZ F, 1988, J LIPID RES, V29, P1005; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Pastorino JG, 1999, BIOCHEM BIOPH RES CO, V265, P405, DOI 10.1006/bbrc.1999.1696; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Polster BM, 2001, J BIOL CHEM, V276, P37887; Ricchelli F, 1999, BIOCHEMISTRY-US, V38, P9295, DOI 10.1021/bi9900828; ROUSLIN W, 1982, AM J PHYSIOL, V242, pH254, DOI 10.1152/ajpheart.1982.242.2.H254; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Sugrue MM, 2001, BIOL SIGNAL RECEPT, V10, P176; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; Vander Heiden MG, 1999, MOL CELL, V3, P159; VANDERHEIDEN MG, 1997, CELL, V91, P632; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; VIGNAIS PV, 1979, TRENDS BIOCHEM SCI, V4, P90, DOI 10.1016/0968-0004(79)90190-7; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	71	112	114	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33928	33935		10.1074/jbc.M210943200	http://dx.doi.org/10.1074/jbc.M210943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821666	hybrid			2022-12-25	WOS:000185047500039
J	Dawson, PA; Haywood, J; Craddock, AL; Wilson, M; Tietjen, M; Kluckman, K; Maeda, N; Parks, JS				Dawson, PA; Haywood, J; Craddock, AL; Wilson, M; Tietjen, M; Kluckman, K; Maeda, N; Parks, JS			Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYLASE GENE; AFRICAN-GREEN MONKEYS; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7-ALPHA-HYDROXYLASE; INTESTINAL-ABSORPTION; FAMILIAL HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; JEJUNAL-ABSORPTION; DEOXYCHOLIC-ACID; CHOLESTYRAMINE	The ileal apical sodium bile acid cotransporter participates in the enterohepatic circulation of bile acids. In patients with primary bile acid malabsorption, mutations in the ileal bile acid transporter gene (Slc10a2) lead to congenital diarrhea, steatorrhea, and reduced plasma cholesterol levels. To elucidate the quantitative role of Slc10a2 in intestinal bile acid absorption, the Slc10a2 gene was disrupted by homologous recombination in mice. Animals heterozygous (Slc10a2(+/-)) and homozygous (Slc10a2(-/-)) for this mutation were physically indistinguishable from wild type mice. In the Slc10a2(-/-) mice, fecal bile acid excretion was elevated 10- to 20-fold and was not further increased by feeding a bile acid binding resin. Despite increased bile acid synthesis, the bile acid pool size was decreased by 80% and selectively enriched in cholic acid in the Slc10a2(-/-) mice. On a low fat diet, the Slc10a2(-/-) mice did not have steatorrhea. Fecal neutral sterol excretion was increased only 3-fold, and intestinal cholesterol absorption was reduced only 20%, indicating that the smaller cholic acid-enriched bile acid pool was sufficient to facilitate intestinal lipid absorption. Liver cholesteryl ester content was reduced by 50% in Slc10a2(-/-) mice, and unexpectedly plasma high density lipoprotein cholesterol levels were slightly elevated. These data indicate that Slc10a2 is essential for efficient intestinal absorption of bile acids and that alternative absorptive mechanisms are unable to compensate for loss of Slc10a2 function.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Gastroenterol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Dawson, PA (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Gastroenterol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	pdawson@wfubmc.edu			NHLBI NIH HHS [HL54176, R01 HL042630, HL49373, HL42360, R37 HL042630] Funding Source: Medline; NIDDK NIH HHS [DK47987, R01 DK047987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054176, R37HL042630, R01HL042630, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047987, R29DK047987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERLUND JE, 1994, GUT, V35, P1116, DOI 10.1136/gut.35.8.1116; ALDINI R, 1994, EUR J CLIN INVEST, V24, P691, DOI 10.1111/j.1365-2362.1994.tb01062.x; Aldini R, 1996, GASTROENTEROLOGY, V110, P459, DOI 10.1053/gast.1996.v110.pm8566593; Amelsberg A, 1999, AM J PHYSIOL-GASTR L, V276, pG737, DOI 10.1152/ajpgi.1999.276.3.G737; Amelsberg A, 1996, GASTROENTEROLOGY, V110, P1098, DOI 10.1053/gast.1996.v110.pm8612999; ANGELIN B, 1987, P NATL ACAD SCI USA, V84, P5434, DOI 10.1073/pnas.84.15.5434; ANGELIN B, 1978, J LIPID RES, V19, P1017; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; Claudel T, 2002, J CLIN INVEST, V109, P961; Dawson PA, 2002, SLEISENGER FORDTRANS, P1051; DIETSCHY JM, 1968, J LIPID RES, V9, P297; Duane WC, 2000, J LIPID RES, V41, P1384; Elzinga BM, 2002, BBA-GEN SUBJECTS, V1573, P9, DOI 10.1016/S0304-4165(02)00275-1; FLOCH MH, 1971, GASTROENTEROLOGY, V61, P228; Gillotte KL, 1998, J LIPID RES, V39, P2065; GRUNDY SM, 1971, J LAB CLIN MED, V78, P94; Gui XY, 2001, GASTROENTEROLOGY, V120, P151, DOI 10.1053/gast.2001.20876; Gui XY, 2001, AM J PHYSIOL-GASTR L, V281, pG1413, DOI 10.1152/ajpgi.2001.281.6.G1413; Hagey LR, 2002, J LIPID RES, V43, P685; HEPNER GW, 1977, GASTROENTEROLOGY, V72, P499; HEUBI JE, 1982, GASTROENTEROLOGY, V83, P804; HOFMANN AF, 1972, GASTROENTEROLOGY, V62, P918; HOFMANN AF, 1987, GASTROENTEROLOGY, V93, P693, DOI 10.1016/0016-5085(87)90430-6; Hofmann Alan F., 1994, P677; Hofmann Alan F., 1994, P1845; Hylemon PB, 1998, FEMS MICROBIOL REV, V22, P475, DOI 10.1111/j.1574-6976.1998.tb00382.x; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jolley CD, 2000, HEPATOLOGY, V32, P1309, DOI 10.1053/jhep.2000.19811; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lorenzo-Zuniga V, 2003, HEPATOLOGY, V37, P551, DOI 10.1053/jhep.2003.50116; Love MW, 2001, ARTERIOSCL THROM VAS, V21, P2039, DOI 10.1161/hq1201.100262; MARCUS SN, 1991, GASTROENTEROLOGY, V100, P212; MASHIGE F, 1981, CLIN CHEM, V27, P1352; MEKHJIAN HS, 1979, DIGEST DIS SCI, V24, P545, DOI 10.1007/BF01489324; MILLER NE, 1974, LANCET, V2, P929; MOYER MS, 1986, GASTROENTEROLOGY, V90, P1188, DOI 10.1016/0016-5085(86)90384-7; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; ROSSI SS, 1987, J LIPID RES, V28, P589; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; Rudel LL, 1998, ARTERIOSCL THROM VAS, V18, P1818, DOI 10.1161/01.ATV.18.11.1818; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; Schwarz M, 2001, J LIPID RES, V42, P1594; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; Shneider BL, 2001, J PEDIATR GASTR NUTR, V32, P407, DOI 10.1097/00005176-200104000-00002; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Thomas LA, 2000, GASTROENTEROLOGY, V119, P806, DOI 10.1053/gast.2000.16495; TINT GS, 1989, J LIPID RES, V30, P633; Turley SD, 1996, J CARDIOVASC PHARM, V27, P71, DOI 10.1097/00005344-199601000-00012; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Walters HC, 2000, AM J PHYSIOL-GASTR L, V279, pG1188, DOI 10.1152/ajpgi.2000.279.6.G1188; Wang DQH, 2002, J LIPID RES, V43, P1960, DOI 10.1194/jlr.M200297-JLR200; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340	64	234	242	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33920	33927		10.1074/jbc.M306370200	http://dx.doi.org/10.1074/jbc.M306370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819193	Green Published, hybrid			2022-12-25	WOS:000185047500038
J	Recchi, C; Sclavi, B; Rauzier, J; Gicquel, B; Reyrat, JM				Recchi, C; Sclavi, B; Rauzier, J; Gicquel, B; Reyrat, JM			Mycobacterium tuberculosis Rv1395 is a class III transcriptional regulator of the AraC family involved in cytochrome P450 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA PAO1; SIGNAL-TRANSDUCTION SYSTEM; COMPLETE GENOME SEQUENCE; ALTERNATIVE SIGMA-FACTOR; GLOBAL GENE-EXPRESSION; DNA-DAMAGE INDUCTION; 2-COMPONENT SYSTEM; ESCHERICHIA-COLI; VIRULENCE REGULATOR; RESPONSE REGULATOR	Rv1395 is annotated as a potential transcriptional regulator of the AraC family. The Rv1395 insertional mutant was identified in a signature tag mutagenesis study in Mycobacterium tuberculosis and was shown to be attenuated in the lungs of mice. Here, we used comparative genomics and biochemical methods to show that Rv1395 is unique to the M. tuberculosis complex and that it encodes a protein that binds the region between two divergent genes, a member of the cytochrome P450 family (Rv1394c or cyp132) and Rv1395 itself. Rv1395 binds to this DNA region by its helix-turn-helix-containing C-terminal domain, and it recognizes two sites with different affinity. We identified the transcriptional start points (TSP) of Rv1394c and Rv1395: both genes have two TSPs, three of which are located in the intergenic region. We constructed and compared various transcriptional fusions consisting of the promoter regions and a reporter gene in Mycobacterium smegmatis: this showed that Rv1395 induces the expression of the cytochrome P450 gene ( Rv1394c) and represses its own transcription. This was confirmed in M. tuberculosis when the wild type and a Rv1395-overexpressing strain were used as hosts for the fusions. Site-directed mutagenesis showed that Rv1395 binds to the two sites in a co-operative manner and that binding to both sites is required for Rv1395 optimal activity. A model describing the potential mode of action of Rv1395 is discussed.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Ecole Normale Super, CNRS, Unite Enzymol & Cinet Struct, F-94230 Cachan, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Reyrat, JM (corresponding author), Fac Med Necker Enfants Malad, INSERM, U570, 156 Rue Vaugirard, F-75730 Paris 15, France.	jmreyrat@necker.fr	Sclavi, Bianca/AAT-4554-2021	Sclavi, Bianca/0000-0002-3883-8592; Recchi, Chiara/0000-0003-1605-0945				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Audia JP, 2001, INT J MED MICROBIOL, V291, P97, DOI 10.1078/1438-4221-00106; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Bartoleschi C, 2002, CELL MICROBIOL, V4, P613, DOI 10.1046/j.1462-5822.2002.00216.x; Bashyam MD, 1998, J BACTERIOL, V180, P2568, DOI 10.1128/JB.180.9.2568-2573.1998; Bashyam MD, 1996, J BACTERIOL, V178, P4847, DOI 10.1128/jb.178.16.4847-4853.1996; Bentrup KHZ, 2001, TRENDS MICROBIOL, V9, P597, DOI 10.1016/S0966-842X(01)02238-7; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Dasgupta N, 2000, TUBERCLE LUNG DIS, V80, P141, DOI 10.1054/tuld.2000.0240; Davis EO, 2002, MOL MICROBIOL, V46, P791, DOI 10.1046/j.1365-2958.2002.03199.x; Davis EO, 2002, J BACTERIOL, V184, P3287, DOI 10.1128/JB.184.12.3287-3295.2002; DEBARBOUILLE M, 1978, J MOL BIOL, V124, P359, DOI 10.1016/0022-2836(78)90304-2; Dhandayuthapani S, 1997, J BACTERIOL, V179, P2401, DOI 10.1128/jb.179.7.2401-2409.1997; Durbach SI, 1997, MOL MICROBIOL, V26, P643, DOI 10.1046/j.1365-2958.1997.5731934.x; Durbach SI, 2003, INFECT IMMUN, V71, P997, DOI 10.1128/IAI.71.2.997-1000.2003; Dussurget O, 1999, J BACTERIOL, V181, P3402, DOI 10.1128/JB.181.11.3402-3408.1999; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EGAN SM, 1994, J MOL BIOL, V243, P821, DOI 10.1006/jmbi.1994.1684; Egan SM, 2002, J BACTERIOL, V184, P5529, DOI 10.1128/JB.184.20.5529-5532.2002; Ewann F, 2002, INFECT IMMUN, V70, P2256, DOI 10.1128/IAI.70.5.2256-2263.2002; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Gendlina I, 2002, J BIOL CHEM, V277, P37349, DOI 10.1074/jbc.M203462200; Gold B, 2001, MOL MICROBIOL, V42, P851, DOI 10.1046/j.1365-2958.2001.02684.x; GUILHOT C, 1992, FEMS MICROBIOL LETT, V98, P181; Gupta S, 1999, FEMS MICROBIOL LETT, V172, P137, DOI 10.1016/S0378-1097(99)00028-2; GUPTA S, 1993, GENE, V126, P157, DOI 10.1016/0378-1119(93)90607-5; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; Haydel SE, 1999, MICROB PATHOGENESIS, V26, P195, DOI 10.1006/mpat.1998.0265; Haydel SE, 2002, J BACTERIOL, V184, P2192, DOI 10.1128/JB.184.8.2192-2203.2002; Hebert MD, 1997, J BACTERIOL, V179, P7834, DOI 10.1128/jb.179.24.7834-7842.1997; Himpens S, 2000, MICROBIOL-SGM, V146, P3091, DOI 10.1099/00221287-146-12-3091; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Jacobs WR, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P1; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; Long SR, 2001, PLANT PHYSIOL, V125, P69, DOI 10.1104/pp.125.1.69; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x; Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x; Manganelli R, 2001, MOL MICROBIOL, V41, P423, DOI 10.1046/j.1365-2958.2001.02525.x; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Mayuri, 2002, FEMS MICROBIOL LETT, V211, P231, DOI 10.1111/j.1574-6968.2002.tb11230.x; Mederle I, 2002, INFECT IMMUN, V70, P303, DOI 10.1128/IAI.70.1.303-314.2002; Merlin C, 2002, J BACTERIOL, V184, P5513, DOI 10.1128/JB.184.19.5513-5517.2002; Mulder MA, 1997, TUBERCLE LUNG DIS, V78, P211, DOI 10.1016/S0962-8479(97)90001-0; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; Munson GP, 2001, INFECT IMMUN, V69, P186, DOI 10.1128/IAI.69.1.186-193.2001; Munson GP, 2000, MOL MICROBIOL, V36, P1391, DOI 10.1046/j.1365-2958.2000.01957.x; MURRAY A, 1992, MOL MICROBIOL, V6, P3331, DOI 10.1111/j.1365-2958.1992.tb02201.x; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; Parish T, 2003, INFECT IMMUN, V71, P1134, DOI 10.1128/IAI.71.3.1134-1140.2003; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x; Pieters J, 2002, TRENDS MICROBIOL, V10, P142, DOI 10.1016/S0966-842X(02)02305-3; Pym AS, 2001, MOL MICROBIOL, V40, P879, DOI 10.1046/j.1365-2958.2001.02427.x; Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; Steyn AJC, 2003, MOL MICROBIOL, V47, P1074, DOI 10.1046/j.1365-2958.2003.03356.x; Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; TIMM J, 1994, MOL MICROBIOL, V12, P491, DOI 10.1111/j.1365-2958.1994.tb01037.x; Tobes R, 2002, NUCLEIC ACIDS RES, V30, P318, DOI 10.1093/nar/30.1.318; Unniraman S, 2002, J BACTERIOL, V184, P5449, DOI 10.1128/JB.184.19.5449-5456.2002; Via LE, 1996, J BACTERIOL, V178, P3314, DOI 10.1128/jb.178.11.3314-3321.1996; Zahrt TC, 2001, MOL MICROBIOL, V39, P1174, DOI 10.1046/j.1365-2958.2001.02321.x; Zahrt TC, 2000, J BACTERIOL, V182, P3832, DOI 10.1128/JB.182.13.3832-3838.2000; Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198	83	19	20	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33763	33773		10.1074/jbc.M305963200	http://dx.doi.org/10.1074/jbc.M305963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826660	hybrid			2022-12-25	WOS:000185047500021
J	Loidl, A; Sevcsik, E; Riesenhuber, G; Deigner, HP; Hermetter, A				Loidl, A; Sevcsik, E; Riesenhuber, G; Deigner, HP; Hermetter, A			Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; KAPPA-B; LDL; ATHEROSCLEROSIS; CERAMIDE; KINASE; EXPRESSION; OXIDATION; IDENTIFICATION; PROLIFERATION	Oxidized phospholipids, including 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) and 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), typically present in minimally modified low density lipoprotein, have been found in atherosclerotic lesions. These compounds are gaining increasing importance as inducers of different cellular responses (inflammation, proliferation, or cell death). It was the aim of this study to understand their impact on intracellular signal transduction pathways that are responsible for these biological effects. We found that in arterial smooth muscle cells, PGPC and POVPC activated sphingomyelinases, in particular the acid isoform, which is known to participate in the very early phase of apoptotic stress responses. In addition, mitogen-activated protein kinases, which are involved in induction of stress response and apoptosis were phosphorylated (activated). Finally, activation of caspase 3 was observed, showing that stimulation of smooth muscle cells with POVPC and PGPC is associated with apoptosis. Stimulation of all these enzymes by the oxidized phospholipids almost perfectly matched their activation by minimally modified LDL. Consequently, these phospholipids seem to be responsible for the effect of this particle on cell signaling. Survival and proliferation pathways including NF-kappaB or AKT kinase were not induced by POVPC and PGPC. Experiments with a specific inhibitor of acid sphingomyelinase named NB6 showed that this enzyme plays a central role in mediating the apoptotic effects of the oxidized lipids. Thus, we conclude that modified phospholipids induce signaling cascades via activation of acid sphingomyelinase finally leading to apoptosis of smooth muscle cells, which is a detrimental process in the development of atherosclerosis.	Graz Tech Univ, Dept Biochem, A-8010 Graz, Austria; Univ Jena, D-07740 Jena, Germany	Graz University of Technology; Friedrich Schiller University of Jena	Hermetter, A (corresponding author), Graz Tech Univ, Dept Biochem, Petersgasse 12-2, A-8010 Graz, Austria.			Sevcsik, Eva/0000-0002-2155-1675				Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG BH, 1980, J LIPID RES, V21, P284; Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; ELSAADANI M, 1989, J LIPID RES, V30, P627; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; LEITINGER N, 1999, DEV CARDIOVASCULAR D, V224; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu W, 1999, J CELL SCI, V112, P2409; Loidl A, 2002, J LIPID RES, V43, P815; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martinet W, 2001, CURR OPIN LIPIDOL, V12, P535, DOI 10.1097/00041433-200110000-00009; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0; Mertens A, 2001, FASEB J, V15, P2073, DOI 10.1096/fj.01-0273rev; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Takahashi M, 2002, ATHEROSCLEROSIS, V161, P387, DOI 10.1016/S0021-9150(01)00674-8; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Young IS, 2001, BIOCHEM SOC T, V29, P358, DOI 10.1042/0300-5127:0290358	38	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32921	32928		10.1074/jbc.M306088200	http://dx.doi.org/10.1074/jbc.M306088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816958	hybrid			2022-12-25	WOS:000184901800054
J	Tiraby, C; Tavernier, G; Lefort, C; Larrouy, D; Bouillaud, F; Ricquier, D; Langin, D				Tiraby, C; Tavernier, G; Lefort, C; Larrouy, D; Bouillaud, F; Ricquier, D; Langin, D			Acquirement of brown fat cell features by human white adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; PPAR-GAMMA COACTIVATOR-1; ACTIVATED RECEPTOR-GAMMA; DIET-INDUCED THERMOGENESIS; IN-VIVO REGULATION; ADIPOSE-TISSUE; TRANSCRIPTIONAL REGULATION; INSULIN-RESISTANCE; ENERGY-BALANCE; MESSENGER-RNA	Obesity, i.e. an excess of white adipose tissue (WAT), predisposes to the development of type 2 diabetes and cardiovascular disease. Brown adipose tissue is present in rodents but not in adult humans. It expresses uncoupling protein 1 (UCP1) that allows dissipation of energy as heat. Peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgamma coactivator 1alpha (PGC-1alpha) activate mouse UCP1 gene transcription. We show here that human PGC-1alpha induced the activation of the human UCP1 promoter by PPARgamma. Adenovirus-mediated expression of human PGC-1alpha increased the expression of UCP1, respiratory chain proteins, and fatty acid oxidation enzymes in human subcutaneous white adipocytes. Changes in the expression of other genes were also consistent with brown adipocyte mRNA expression profile. PGC-1alpha increased the palmitate oxidation rate by fat cells. Human white adipocytes can therefore acquire typical features of brown fat cells. The PPARgamma agonist rosiglitazone potentiated the effect of PGC-1alpha on UCP1 expression and fatty acid oxidation. Hence, PGC-1alpha is able to direct human WAT PPARgamma toward a transcriptional program linked to energy dissipation. However, the response of typical white adipocyte targets to rosiglitazone treatment was not altered by PGC-1alpha. UCP1 mRNA induction was shown in vivo by injection of the PGC-1alpha adenovirus in mouse white fat. Alteration of energy balance through an increased utilization of fat in WAT may be a conceivable strategy for the treatment of obesity.	Univ Toulouse 3, CHU Toulouse, Inst Louis Bugnard, INSERM,U586,Unite Rech Obes, F-31403 Toulouse, France; Fac Med Necker Enfants Malad, CNRS, Unite 9078, F-75730 Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Langin, D (corresponding author), Univ Toulouse 3, CHU Toulouse, Inst Louis Bugnard, INSERM,U586,Unite Rech Obes, F-31403 Toulouse, France.		Bouillaud, Frédéric R/L-3238-2017	Bouillaud, Frédéric R/0000-0002-7518-9237; Langin, Dominique/0000-0002-2669-7825; Tavernier, Genevieve/0000-0002-0214-0344; Larrouy, Dominique/0000-0002-4120-5593				Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Brown NF, 1997, BIOCHEM J, V327, P225, DOI 10.1042/bj3270225; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; CHAKRABARTY K, 1983, J LIPID RES, V24, P381; Clement K, 2002, GENOME RES, V12, P281, DOI 10.1101/gr.207702; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; COUSIN B, 1992, J CELL SCI, V103, P931; Crowley VEE, 2002, NAT REV DRUG DISCOV, V1, P276, DOI 10.1038/nrd770; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; Del Mar Gonzalez-Barroso M, 2000, Obes Rev, V1, P61, DOI 10.1046/j.1467-789x.2000.00009.x; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; Frayn KN, 1996, CLIN SCI, V90, P243, DOI 10.1042/cs0900243; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; GARRUTI G, 1992, INT J OBESITY, V16, P383; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Gonzalez-Barroso MD, 2000, J BIOL CHEM, V275, P31722, DOI 10.1074/jbc.M001678200; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hertzel AV, 2000, J LIPID RES, V41, P1082; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; KLAUS S, 1995, J CELL SCI, V108, P3171; KLIGENBERG M, 1999, BIOCHIM BIOPHYS ACTA, V1415, P271; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE776, DOI 10.1152/ajpendo.1996.270.5.E776; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lean M. E. J., 1986, BROWN ADIPOSE TISSUE, P339; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; LONCAR D, 1991, CELL TISSUE RES, V266, P149, DOI 10.1007/BF00678721; MERCER SW, 1986, FEBS LETT, V195, P12, DOI 10.1016/0014-5793(86)80120-X; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oberkofler H, 1997, J LIPID RES, V38, P2125; Oberkofler H, 2002, J BIOL CHEM, V277, P16750, DOI 10.1074/jbc.M200475200; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RAFAEL J, 1986, AM J PHYSIOL, V250, pC228, DOI 10.1152/ajpcell.1986.250.2.C228; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; Rosen ED, 2000, GENE DEV, V14, P1293; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Rothwell NJ, 1997, OBES RES, V5, P650, DOI 10.1002/j.1550-8528.1997.tb00591.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; Stefl B, 1998, AM J PHYSIOL-ENDOC M, V274, pE527, DOI 10.1152/ajpendo.1998.274.3.E527; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YOUNG P, 1984, FEBS LETT, V167, P10, DOI 10.1016/0014-5793(84)80822-4; ZANCANARO C, 1994, BIOL CELL, V80, P75, DOI 10.1016/0248-4900(94)90021-3; [No title captured]	67	356	378	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33370	33376		10.1074/jbc.M305235200	http://dx.doi.org/10.1074/jbc.M305235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807871	hybrid			2022-12-25	WOS:000184901800108
J	Watanabe, JJ; Marathe, GK; Neilsen, PO; Weyrich, AS; Harrison, KA; Murphy, RC; Zimmerman, GA; McIntyre, TM				Watanabe, JJ; Marathe, GK; Neilsen, PO; Weyrich, AS; Harrison, KA; Murphy, RC; Zimmerman, GA; McIntyre, TM			Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ACTIVE OXIDIZED PHOSPHOLIPIDS; FACTOR PAF; RABBIT PLATELETS; FACTOR RECEPTOR; LUNG INJURY; IN-VITRO; MEMBRANE; LIPOPOLYSACCHARIDE	Lipopolysaccharides and triacyl-cysteine-modified proteins of Gram-negative and positive organisms are potent endotoxins. Animal models show that the receptor for platelet-activating factor (PAF) is responsible for many of the deleterious effects of endotoxin, where regulated, localized PAF production localizes the inflammatory response. In contrast, biologically active analogs of PAF (PAF-like lipids) are generated by oxidative attack on phospholipids by chemical reactions that are unregulated and unlocalized. The identity and distribution of the PAF receptor ligand in endotoxemia is unknown. We found human polymorphonuclear leukocytes (PMNs) were a significant source of PAF receptor agonists after stimulation by either class of endotoxin. Production of PAF receptor agonists required that the PMN adhere to a surface, and adhesion (and therefore accumulation of PAF-like bioactivity) in response to endotoxic stimulation was delayed for several minutes. PAF-like oxidized phospholipids were found by mass spectroscopy, but biosynthetic PAF accounted for most of the phospholipid agonists arising from endotoxic stimulation. A significant portion of the PAF made by PMNs was secreted, in contrast to its near complete retention by other inflammatory cells. Endotoxic stimulation induced a respiratory burst with the production of superoxide and the formation and shedding of microparticles. Free and microparticle-bound PAF appeared in the media, and blocking microvesiculation with calpeptin blocked PAF release. The released material activated platelets, and platelets co-aggregated with endotoxin-stimulated PMNs. Adherent PMNs therefore behave differently than suspended cells and are a significant source of free PAF after endotoxin exposure. Leukocytes can couple endotoxic challenge to the widespread circulatory and inflammatory effects of endotoxin.	Univ Utah, Eccles Inst Human Genet 4130, Dept Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Jewish Health	McIntyre, TM (corresponding author), Univ Utah, Eccles Inst Human Genet 4130, Dept Human Mol Biol & Genet, 15 N 2030 E, Salt Lake City, UT 84112 USA.			Weyrich, Andrew/0000-0001-9622-4647; Marathe, Gopal/0000-0002-0025-6677	NHLBI NIH HHS [HL44525, HL44513, HL50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R01HL044513, R37HL044525, P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PLATELET ACTIVATING, P191; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; DeKimpe SJ, 1995, BRIT J PHARMACOL, V116, P3191; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FOX JEB, 1991, J BIOL CHEM, V266, P13289; Fujimi S, 2002, J TRAUMA, V52, P443, DOI 10.1097/00005373-200203000-00005; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall LM, 1998, ANAL BIOCHEM, V258, P184, DOI 10.1006/abio.1998.2602; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENSON PM, 1981, AGENTS ACTIONS, V11, P545, DOI 10.1007/BF01978732; HINSHAW DB, 1991, ARCH BIOCHEM BIOPHYS, V288, P311, DOI 10.1016/0003-9861(91)90200-3; Huber J, 2002, ARTERIOSCL THROM VAS, V22, P101, DOI 10.1161/hq0102.101525; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; LYNCH JM, 1986, J IMMUNOL, V137, P2653; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001; Matsumoto T, 1997, FEMS IMMUNOL MED MIC, V17, P171, DOI 10.1016/S0928-8244(97)00005-9; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Mesri C, 1998, J IMMUNOL, V161, P4382; Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846; Miyoshi H, 1996, GASTROENTEROLOGY, V110, P1897, DOI 10.1053/gast.1996.v110.pm8964416; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; MUELLER HW, 1984, J LIPID RES, V25, P383; MUELLER HW, 1982, LIPIDS, V17, P72, DOI 10.1007/BF02535178; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; Neilsen PO, 2001, J IMMUNOL, V167, P5231, DOI 10.4049/jimmunol.167.9.5231; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; PATEL KD, 1992, J BIOL CHEM, V267, P15168; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; SISSON JH, 1987, J IMMUNOL, V138, P3918; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TOOL ATJ, 1992, BLOOD, V79, P2729; Ward BJ, 1997, MICROVASC RES, V53, P179, DOI 10.1006/mvre.1996.1997; Wilson M E, 1981, Prog Clin Biol Res, V62, P157; Wooten RM, 1996, J IMMUNOL, V157, P4584; WORTHEN GS, 1992, J CLIN INVEST, V90, P2526, DOI 10.1172/JCI116146; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; YOSHIKAWA D, 1992, CIRC SHOCK, V38, P29; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; ZIMMERMAN GA, 2003, ACUTE RESP DISTRESS, P245; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, P149	56	76	80	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33161	33168		10.1074/jbc.M305321200	http://dx.doi.org/10.1074/jbc.M305321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810708	hybrid			2022-12-25	WOS:000184901800082
J	Yoon, SW; Goh, SH; Chun, JS; Cho, EW; Lee, MK; Kim, KL; Kim, JJ; Kim, CJ; Poo, H				Yoon, SW; Goh, SH; Chun, JS; Cho, EW; Lee, MK; Kim, KL; Kim, JJ; Kim, CJ; Poo, H			alpha-melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; MAP KINASE; ANTIINFLAMMATORY ACTION; MELANOCORTIN PEPTIDES; DEPENDENT KINASE; ACTIVATION; MSH; RECEPTORS; CELLS; INFLAMMATION	The neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) inhibits inflammation by down-regulating the expression of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) in leukocytes via stimulation of alpha-MSH cell surface receptors. However, the signaling mechanism of alpha-MSH action has not yet been clearly elucidated. Here, we have investigated signaling pathways by which alpha-MSH inhibits lipopolysaccharide (LPS)-induced TNF-alpha production in leukocytes such as THP-1 cells. We focused on the possible roles of protein kinase A (PKA), p38 kinase, and nuclear factor kappaB (NFkappaB) signaling. In THP-1 cells, LPS is known to activate p38 kinase, which in turn activates NFkappaB to induce TNF-alpha production. We found that pretreatment of cells with alpha-MSH blocked LPS-induced p38 kinase and NFkappaB activation as well as TNF-alpha production. This response was proportional to alpha-MSH receptor expression levels, and addition of an alpha-MSH receptor antagonist abolished the inhibitory effects. In addition, alpha-MSH treatment activated PKA, and PKA inhibition abrogated the inhibitory effects of alpha-MSH on p38 kinase activation, NFkappaB activation, and TNF-alpha production. Taken together, our results indicate that stimulation of PKA by alpha-MSH causes inhibition of LPS-induced activation of p38 kinase and NFkappaB to block TNF-alpha production.	Korea Res Inst Biosci & Biotechnol, Proteome Res Lab, Taejon 305600, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; PaiChai Univ, Dept Biol, Taejon 302735, South Korea; Chungnam Natl Univ, Dept Vet Med, Taejon 305764, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Gwangju Institute of Science & Technology (GIST); Sungkyunkwan University (SKKU); Pai Chai University; Chungnam National University	Poo, H (corresponding author), Korea Res Inst Biosci & Biotechnol, Proteome Res Lab, Taejon 305600, South Korea.	haryoung@mail.kribb.re.kr	yoon, sun-woo/V-6285-2019	Kim, Chul-Joong/0000-0001-8827-6332				AIRAGHI L, 1995, AM HEART J, V130, P204, DOI 10.1016/0002-8703(95)90430-1; Andersen GN, 2001, CLIN EXP IMMUNOL, V126, P441, DOI 10.1046/j.1365-2249.2001.01604.x; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Bohm M, 1999, ANN NY ACAD SCI, V885, P277; CANNON JG, 1986, J IMMUNOL, V137, P2232; CATANIA A, 1993, ANN NY ACAD SCI, V680, P412, DOI 10.1111/j.1749-6632.1993.tb19699.x; Catania A, 1996, PEPTIDES, V17, P675, DOI 10.1016/0196-9781(96)00037-X; Catania Anna, 1994, Neuroimmunomodulation, V1, P93, DOI 10.1159/000097096; Catania Anna, 1994, Neuroimmunomodulation, V1, P321, DOI 10.1159/000097183; Chambers DA, 2000, IMMUNOL TODAY, V21, P332, DOI 10.1016/S0167-5699(00)01691-1; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chiao H, 1996, J CLIN INVEST, V97, P2038, DOI 10.1172/JCI118639; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Getting SJ, 2002, TRENDS PHARMACOL SCI, V23, P447, DOI 10.1016/S0165-6147(02)02103-X; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Haddad E, 2001, BRIT J PHARMACOL, V132, P1715, DOI 10.1038/sj.bjp.0704022; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Haycock JW, 2000, J BIOL CHEM, V275, P15629, DOI 10.1074/jbc.275.21.15629; Ichiyama T, 1999, EXP NEUROL, V157, P359, DOI 10.1006/exnr.1999.7064; Ichiyama T, 1999, J NEUROIMMUNOL, V99, P211, DOI 10.1016/S0165-5728(99)00122-8; Kurosaka K, 1998, J IMMUNOL, V161, P6245; Lipton JM, 1998, ANN NY ACAD SCI, V840, P373, DOI 10.1111/j.1749-6632.1998.tb09576.x; Lipton JM, 1999, ANN NY ACAD SCI, V885, P173; Luger TA, 2000, ANN NY ACAD SCI, V917, P232; MacKenzie S, 2002, J LEUKOCYTE BIOL, V71, P1026; Mancuso G, 2002, J IMMUNOL, V169, P1401, DOI 10.4049/jimmunol.169.3.1401; Mandrika I, 2001, BIOCHEM PHARMACOL, V61, P613, DOI 10.1016/S0006-2952(00)00583-9; Manna SK, 1998, J IMMUNOL, V161, P2873; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nagahira A, 2001, BIOCHEM BIOPH RES CO, V281, P1030, DOI 10.1006/bbrc.2001.4476; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Oktar BK, 2000, PEPTIDES, V21, P1271, DOI 10.1016/S0196-9781(00)00269-2; Rajora N, 1997, PEPTIDES, V18, P381, DOI 10.1016/S0196-9781(96)00345-2; Rajora N, 1997, J NEUROSCI, V17, P2181; Rajora N, 1996, J LEUKOCYTE BIOL, V59, P248, DOI 10.1002/jlb.59.2.248; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Salituro FG, 1999, CURR MED CHEM, V6, P807; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Taherzadeh S, 1999, AM J PHYSIOL-REG I, V276, pR1289, DOI 10.1152/ajpregu.1999.276.5.R1289; Uzzo RG, 2001, BIOCHEM BIOPH RES CO, V287, P895, DOI 10.1006/bbrc.2001.5678; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; White JE, 2000, J CELL PHYSIOL, V182, P381; Wikberg JES, 2000, PHARMACOL RES, V42, P393, DOI 10.1006/phrs.2000.0725; Yan XJ, 2002, BIOL REPROD, V66, P1667, DOI 10.1095/biolreprod66.6.1667; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	48	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32914	32920		10.1074/jbc.M302444200	http://dx.doi.org/10.1074/jbc.M302444200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816950	hybrid			2022-12-25	WOS:000184901800053
J	Pakkanen, O; Hamalainen, ER; Kivirikko, KI; Myllyharju, J				Pakkanen, O; Hamalainen, ER; Kivirikko, KI; Myllyharju, J			Assembly of stable human type I and III collagen molecules from hydroxylated recombinant chains in the yeast Pichia pastoris - Effect of an engineered C-terminal oligomerization domain foldon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENTED COILED-COIL; TRIPLE-HELIX; BACTERIOPHAGE-T4 FIBRITIN; PROLYL 4-HYDROXYLASES; REQUIRES COEXPRESSION; PROCOLLAGEN; PROTEIN; EXPRESSION; RECOGNITION; NUCLEATION	The C-propeptides of the proalpha chains of type I and type III procollagens are believed to be essential for correct chain recognition and chain assembly in these molecules. We studied here whether the 30-kDa C-propeptides of the human pCalpha1(I), pCalpha2(I), and pCalpha1(III) chains, i.e. proalpha chains lacking their N-propeptides, can be replaced by foldon, a 29-amino acid sequence normally located at the C terminus of the polypeptide chains in the bacteriophage T4 fibritin. The alphafoldon chains were expressed in Pichia pastoris cells that also expressed the two types of subunit of human prolyl 4-hydroxylase; the foldon domain was subsequently removed by pepsin treatment, which also digests non-triple helical collagen chains, whereas triple helical collagen molecules are resistant to it. The foldon domain was found to be very effective in chain assembly, as expression of the alpha1(I) foldon or alpha1(III) foldon chains gave about 2.5-3-fold the amount of pepsin-resistant type I or type III collagen homotrimers relative to those obtained using the authentic C-propeptides. In contrast, expression of chains with no oligomerization domain led to very low levels of pepsin-resistant molecules. Expression of alpha2(I)foldon chains gave no pepsin-resistant molecules at all, indicating that in addition to control at the level of the C-propeptide other restrictions at the level of the collagen domain exist that prevent the formation of stable [alpha2(I)](3) molecules. Co-expression of alpha1(I) foldon and alpha2(I) foldon chains led to an efficient assembly of heterotrimeric molecules, their amounts being about 2-fold those obtained with the authentic C-propeptides and the alpha1(I) to alpha2(I) ratio being 1.91+/-0.31 (S.D.). As the foldon sequence contains no information for chain recognition, our data indicate that chain assembly is influenced not only by the C-terminal oligomerization domain but also by determinants present in the alpha chain domains.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Medipolis, Fibrogen Europe, FIN-90230 Oulu, Finland	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; Boudko SP, 2002, EUR J BIOCHEM, V269, P833, DOI 10.1046/j.1432-1033.2002.02734.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; Cereghino GPL, 2001, GENE, V263, P159, DOI 10.1016/S0378-1119(00)00576-X; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Keizer-Gunnink I, 2000, MATRIX BIOL, V19, P29, DOI 10.1016/S0945-053X(99)00059-1; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Letarov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P817; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Merle C, 2002, FEBS LETT, V515, P114, DOI 10.1016/S0014-5793(02)02452-3; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Nokelainen M, 2001, YEAST, V18, P797, DOI 10.1002/yea.730; Olsen DR, 2001, J BIOL CHEM, V276, P24038, DOI 10.1074/jbc.M101613200; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; TKOCZ C, 1969, EUR J BIOCHEM, V7, P454; Toman PD, 2000, J BIOL CHEM, V275, P23303, DOI 10.1074/jbc.M002284200; Vuorela A, 1997, EMBO J, V16, P6702, DOI 10.1093/emboj/16.22.6702; 2002, MANUAL METHODS EXPRE	32	44	54	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32478	32483		10.1074/jbc.M304405200	http://dx.doi.org/10.1074/jbc.M304405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805365	hybrid			2022-12-25	WOS:000184782100129
J	Geuens, E; Brouns, I; Flamez, D; Dewilde, S; Timmermans, JP; Moens, L				Geuens, E; Brouns, I; Flamez, D; Dewilde, S; Timmermans, JP; Moens, L			A globin in the nucleus!	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION-ASSOCIATED PROTEIN; LIGAND-BINDING PROPERTIES; HEME-BASED SENSORS; NONVERTEBRATE HEMOGLOBINS; HEXACOORDINATE HEMOGLOBIN; TRANSCRIPTION FACTOR; OXYGEN SENSOR; DNA-BINDING; NEUROGLOBIN; LOCALIZATION	Cytoglobin and neuroglobin are recently discovered members of the globin family. In situ hybridization localized neuroglobin mainly in brain and retina, while cytoglobin was expressed ubiquitously in all analyzed tissues. In the present study, polyclonal antibodies were raised against both proteins and the distribution of them was studied by immunocytochemistry at tissue and subcellular level. Cytoglobin immunoreactivity was uniformly distributed and found in all tissues studied. At the subcellular level, cytoglobin immunoreactivity was exclusively detected in the cell nucleus. In contrast, neuroglobin immunoreactivity was detected in specific brain regions with varying intensities and in the islet of Langerhans in the pancreas. The immunoreactivity was restricted to the cytoplasm of neurons and endocrine beta cells. The nuclear localization of cytoglobin opens new perspectives for possible function(s) of globin-folded proteins as transcriptional regulators.	Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	University of Antwerp	Moens, L (corresponding author), Univ Antwerp, Dept Biomed Sci, Univ Pl 1, B-2610 Antwerp, Belgium.		Brouns, Inge/GZM-7277-2022	Timmermans, Jean-Pierre/0000-0003-2506-6252				Asahina K, 2002, BBA-GENE STRUCT EXPR, V1577, P471, DOI 10.1016/S0167-4781(02)00477-3; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Brouns I, 2002, J HISTOCHEM CYTOCHEM, V50, P575, DOI 10.1177/002215540205000415; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burr AHJ, 2000, J BIOL CHEM, V275, P4810, DOI 10.1074/jbc.275.7.4810; BURSTYN JN, 1995, BIOCHEMISTRY-US, V34, P5896, DOI 10.1021/bi00017a019; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gilles-Gonzalez MA, 2001, IUBMB LIFE, V51, P165, DOI 10.1080/152165401753544232; GONYEA LM, 1977, CLIN CHEM, V23, P234; Hardison R, 1998, J EXP BIOL, V201, P1099; Hou SB, 2001, EXTREMOPHILES, V5, P351, DOI 10.1007/s007920100220; Imai K, 1999, NATURE, V401, P437, DOI 10.1038/46707; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LLEWELLYNSMITH IJ, 1985, J HISTOCHEM CYTOCHEM, V33, P857, DOI 10.1177/33.9.3926868; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Park KW, 2002, J BIOL CHEM, V277, P33334, DOI 10.1074/jbc.M203820200; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Seregelyes C, 2000, FEBS LETT, V482, P125, DOI 10.1016/S0014-5793(00)02049-4; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; Spiro TG, 2001, CURR OPIN CHEM BIOL, V5, P715, DOI 10.1016/S1367-5931(01)00271-X; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Tata J R, 1974, Methods Enzymol, V31, P253; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	47	134	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30417	30420		10.1074/jbc.C300203200	http://dx.doi.org/10.1074/jbc.C300203200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796507	hybrid			2022-12-25	WOS:000184658800002
J	Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I				Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I			TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappa B	ONCOGENE			English	Article						TRAIL; proliferation; survival; apoptosis resistance; NF-kappa B	HUMAN T-CELLS; ACTIVATION; DEATH; FAS; CONTRIBUTES; EXPRESSION; CASPASE-8; PATHWAYS; PROTEIN; KINASE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells. Examining primary cells of children with untreated acute leukemia, TRAIL induced apoptosis in 50% of cells, but to our surprise attenuated spontaneous apoptosis in the remaining samples or, most importantly, even mediated proliferation. W e therefore examined tumor cell lines of leukemic and nonleukemic origin with apoptosis resistance towards TRAIL because of absent Caspase-8 or dysfunctional FADD. In all cell lines tested, TRAIL treatment increased cell numbers in average to 163% within 4 days and accelerated doubling time from 24 to 19 h. TRAIL-mediated proliferation was completely abrogated by blockade of NF-kappaB activation using proteasome inhibitors or in RIP-negative, IKKgamma-negative cells or in cells overexpressing dominant-negative IkappaBalpha. Our data describe the biological significance of TRAIL-mediated activation of NF-kappaB in cancer cells resistant to TRAIL-mediated apoptosis: TRAIL leads to an increase in tumor cell count by a prosurvival and possibly mitogenic function. Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors.	Univ Kinderklin, Dept Hematol Oncol, D-89075 Ulm, Germany; Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Lady Davis Institute; McGill University	Debatin, KM (corresponding author), Univ Kinderklin, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.		Ehrhardt, Harald/L-9007-2018; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Ehrhardt, Harald/0000-0003-4587-1734; Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thilenius ARB, 1997, EUR J IMMUNOL, V27, P1108, DOI 10.1002/eji.1830270510; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x	20	232	253	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3842	3852		10.1038/sj.onc.1206520	http://dx.doi.org/10.1038/sj.onc.1206520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813457				2022-12-25	WOS:000183612000003
J	Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A				Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A			Regulation of Hoxb2 by APL-associated PLZF protein	ONCOGENE			English	Article						leukaemia; transcription; repressor; fusion protein; retinoic acid receptor	ACID RECEPTOR-ALPHA; ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	The PLZF gene is translocated in a subset of all-trans-retinoic acid resistant acute promyelocytic leukaemia (APL) cases, encodes a DNA binding transcription factor and is expressed highly in haematopoietic progenitor cells as well-developing central nervous system (CNS). The spatially restricted and temporally dynamic pattern of PLZF expression in the developing CNS suggested that it might play a role in the circuitry regulating hindbrain segmentation. We have now identified a PLZF binding site (PLZF-RE) in an enhancer region of Hoxb2 that itself is required for directing high-level expression in rhombomers 3 and 5 of the developing hindbrain. The wild-type r3/r5 enhancer linked to a heterologous promoter was responsive to regulation by PLZF, and this activity was lost in variants containing a mutated PLZF-RE. Compared with the wild-type protein, the binding of the APL-associated reciprocal RARalpha-PLZF fusion to PLZF-RE was much stronger, suggesting that the N-terminal PLZF sequences missing from the fusion may play a role in the regulation of DNA binding. Consistent with this, the N-terminal POZ domain was required for cooperative binding of PLZF to a multimerized PLZF-RE. In the context of the r3/r5 enhancer, the PLZF-RE cooperated for PLZF binding with an additional A/T-rich motif positioned downstream of the PLZF-RE. This A/T motif was previously shown to be essential for the regulation of Hoxb2 expression in r3 and r5 in cooperation with another Kruppel-like zinc finger protein Krox 20. The presence of both the PLZF-RE and the A/T-rich motif was required for a maximal effect of PLZF on a heterologous promoter and was essential in vivo to direct the expression of a lacZ reporter in the chick neural tube. Hence, both PLZF and Krox20 cooperate with a common A/T motif in mediating in vivo activity of the Hoxb2 enhancer. Our findings indicate that Hoxb2 is a direct target for regulation by PLZF in the developing CNS and suggest that deregulation of Hox gene expression may contribute to APL pathogenesis.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Stowers Inst Med Res, Kansas City, MO 64110 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Stowers Institute for Medical Research	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.	a.zelent@icr.ac.uk	Guidez, Fabien/B-3750-2009; Zelent, Arthur/B-3532-2009; Guidez, Fabien/P-4220-2019; Krumlauf, Robb/AAH-5012-2019	Guidez, Fabien/0000-0003-1380-4473; Krumlauf, Robb/0000-0001-9102-7927; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Barrow JR, 1996, DEVELOPMENT, V122, P3817; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Davenne M, 1999, NEURON, V22, P677, DOI 10.1016/S0896-6273(00)80728-X; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MATHEWS CHE, 1991, BLOOD, V78, P2248; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Quaranta MT, 1996, J IMMUNOL, V157, P2462; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Vesque C, 1996, EMBO J, V15, P5383, DOI 10.1002/j.1460-2075.1996.tb00922.x; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	66	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3685	3697		10.1038/sj.onc.1206328	http://dx.doi.org/10.1038/sj.onc.1206328			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802276				2022-12-25	WOS:000183551000003
J	Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V				Udtha, M; Lee, SJ; Alam, R; Coombes, K; Huff, V			Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors	ONCOGENE			English	Article						WT1; c-MYC; Wilms' tumor; cDNA microarray; smooth t-test	SUPPRESSOR GENE WT1; GROWTH-FACTOR; BETA-CATENIN; KIDNEY DEVELOPMENT; TRANSGENIC MICE; PRODUCT; REPRESSION; PROMOTER; RECEPTOR; PROTOONCOGENES	The Wilms' tumor suppressor gene, WT1, functions as a transcriptional regulator that represses or activates the expression of a variety of putative target genes. However, it is not clear which genes are the biological targets of WT1, nor which cellular pathway(s) is critically altered in tumors as a result of WT1 mutation. To investigate in Vivo the role of WT1 as a transcription factor in Wilms' tumors, we used cDNA microarrays to compare the expression of putative WT1 target genes in a set of 15 primary Wilmstumors carrying WT1-inactivating mutations versus a set of 16 tumors with no WT1 mutations. We hypothesized that the expression of direct downstream targets of WT1 that are relevant to tumor development would differ between these two genetically distinct sets of tumors. Using the Atlas Human Cancer 1.2 cDNA arrays to quantitate gene expression in the 31 tumors, we found that the expression of one WT1 putative target gene, c-MYC, statistically significantly differed between the two sets of tumors and was upregulated in WT1-mutant tumors. This increase of relative gene expression for c-MYC was confirmed using real-time reverse transcription-polymerase chain reaction. The differential expression of another putative target gene, EGR1, approached significance and was also upregulated in WT1-mutant tumors. These data, in addition to the coexpression of c-MYC and WT1 in embryonic renal mesenchyme, strongly suggest that c-MYC is a biologically relevant target of WT1 in Wilmstumors.	MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huff, V (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet Canc Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.			Coombes, Kevin/0000-0002-7630-2123	NCI NIH HHS [CA16672, CA78257, CA34936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baggerly KA, 2001, J COMPUT BIOL, V8, P639, DOI 10.1089/106652701753307539; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coombes KR, 2002, J COMPUT BIOL, V9, P655, DOI 10.1089/106652702760277372; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Geick A, 2001, TRANSGENIC RES, V10, P501, DOI 10.1023/A:1013085228119; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GOODYER P, 1995, ONCOGENE, V10, P1125; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEWITT SM, 1995, CANCER RES, V55, P5386; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huff V, 1998, AM J MED GENET, V79, P260, DOI 10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maiti S, 2000, CANCER RES, V60, P6288; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NISEN PD, 1986, CANCER RES, V46, P6217; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Zhang XH, 1999, ANTICANCER RES, V19, P1641	36	33	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3821	3826		10.1038/sj.onc.1206597	http://dx.doi.org/10.1038/sj.onc.1206597			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802290				2022-12-25	WOS:000183551000017
J	Prieto-Sanchez, RM; Bustelo, XR				Prieto-Sanchez, RM; Bustelo, XR			Structural basis for the signaling specificity of RhoG and Rac1 GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GDP/GTP EXCHANGE; EFFECTOR DOMAIN; FAMILY GTPASES; CELL-ADHESION; ACTIVATION; CDC42; PROTEINS; BINDING; CYTOSKELETON	RhoG is a new GTPase that has high sequence similarity with members of the Rac subfamily ( Rac1, Rac2, and Rac3), including the regions involved in effector recognition and binding. To characterize its biological properties, we have compared the activity of RhoG and Rac1 in a number of experimental systems, including the study of their subcellular localization, oncogenic potential, activation of effectors, and effect on F-actin dynamics. Our study indicates that RhoG and Rac1 share overlapping, but not identical, signal transduction pathways. In contrast to previous results, we also provide evidence that RhoG works in parallel to Rac1 rather than as a Rac1 upstream activator. Using an extensive collection of Rho/Rac1 chimeras and point mutants, we demonstrate that the different biological properties of RhoG and Rac1 can be traced to specific amino acid variations in their switch I, beta2/beta3 hairpin, alpha5 helix, and C-terminal polybasic regions. Taken collectively, our results highlight the complexity of the signal transduction pathways activated by Rho/Rac GTPases and provide insight into the structural determinants that mediate the differential engagement of biological responses by GTPases of very similar structure.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blangy A, 2000, J CELL SCI, V113, P729; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1994, ONCOGENE, V9, P2405; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; May V, 2002, J NEUROSCI, V22, P6980; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Movilla N, 2001, ONCOGENE, V20, P8057, DOI 10.1038/sj.onc.1205000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; VAN AL, 1997, GENE DEV, V11, P2295; van der Eb A J, 1980, Methods Enzymol, V65, P826; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Vigorito E, 2003, ONCOGENE, V22, P330, DOI 10.1038/sj.onc.1206116; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37916	37925		10.1074/jbc.M301437200	http://dx.doi.org/10.1074/jbc.M301437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12805377	hybrid			2022-12-25	WOS:000185437200114
J	Akimov, SS; Belkin, AM				Akimov, SS; Belkin, AM			Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-INDUCED EXPRESSION; CELL-CYCLE PROGRESSION; SWISS 3T3 FIBROBLASTS; GTP-BINDING PROTEIN; TISSUE TRANSGLUTAMINASE; INTEGRIN ACTIVATION; GENE PROMOTER; MAP KINASE; SUSTAINED ACTIVATION; RESPONSE ELEMENT	Tissue transglutaminase (tTG) serves as a potent and ubiquitous integrin-associated adhesion co-receptor for fibronectin on the cell surface and affects several key integrin functions. Here we report that in fibroblasts, activated H-Ras and Raf-1 oncogenes decrease biosynthesis, association with beta(1) integrins, and surface expression of tTG because of down-regulation of tTG mRNA. In turn, the reduction of surface tTG inhibits adhesion of H-Ras- and Raf-1-transformed cells on fibronectin and, in particular, on its tTG-binding fragment I(6) II(1,2) I(7-9), which does not interact directly with integrins. Analysis of Ras/Raf downstream signaling with specific pharmacological inhibitors reveals that the decrease in tTG expression is mediated by the p38 MAPK, c-Jun NH2-terminal kinase, and phosphatidylinositol 3-kinase pathways. In contrast, increased activation of the ERK pathway by constitutively active MEK1 stimulates tTG mRNA expression, biosynthesis, and surface expression of tTG, whereas MEK inhibitors or dominant negative MEK1 exert an opposite effect. This modulation of surface tTG by ERK signaling alters adhesion of cells on fibronectin and its fragment that binds tTG. Furthermore, transient stimulation of ERK signaling in untransformed fibroblasts by adhesion on fibronectin or growth factors elevates tTG biosynthesis, increases complex formation with beta(1) integrins, and raises surface expression of tTG. Finally, ERK activation is required for growth factor-induced redistribution of tTG on the surface of adherent fibroblasts and co-clustering of beta(1) integrins and tTG at cell-matrix adhesion contacts. Together, our data indicate that down-regulation of surface tTG by Ras and Raf oncogenes contributes to adhesive deficiency of transformed fibroblasts, whereas stimulation of biosynthesis and surface expression of tTG by the MEK1/ERK module promotes and sustains cell-matrix adhesion of untransformed cells. Contrasting effects of Ras/Raf oncogenes and their immediate downstream signaling module, MEK1/ERK, on tTG expression are consistent with adhesive function of surface tTG.	Amer Red Cross, Jerome H Holland Lab, Dept Biochem, Rockville, MD 20855 USA; George Washington Univ, Dept Biochem & Mol Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Belkin, AM (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NIGMS NIH HHS [GM62895] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062895] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2003, J BIOL CHEM, V278, P15859, DOI 10.1074/jbc.M300037200; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Birckbichler PJ, 2000, CANCER-AM CANCER SOC, V89, P412, DOI 10.1002/1097-0142(20000715)89:2<412::AID-CNCR29>3.0.CO;2-O; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen RH, 2000, AM J PHYSIOL-LUNG C, V279, pL161, DOI 10.1152/ajplung.2000.279.1.L161; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; Gentile V, 1997, BBA-MOL CELL RES, V1357, P115, DOI 10.1016/S0167-4889(97)00024-4; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; Hager H, 1997, J PATHOL, V183, P398, DOI 10.1002/(SICI)1096-9896(199712)183:4<398::AID-PATH947>3.0.CO;2-3; Haroon ZA, 1999, LAB INVEST, V79, P1679; Hettasch JM, 1996, LAB INVEST, V75, P637; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Johnson K, 2001, AM J PATHOL, V159, P149, DOI 10.1016/S0002-9440(10)61682-3; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Jones RA, 1997, J CELL SCI, V110, P2461; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MENTER DG, 1991, CELL BIOPHYS, V18, P123, DOI 10.1007/BF02989810; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MIRZA A, 1997, AM J PHYSIOL, V272, P281; Monsonego A, 1998, J MOL BIOL, V282, P713, DOI 10.1006/jmbi.1998.2052; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; Retta SF, 2001, MOL BIOL CELL, V12, P3126, DOI 10.1091/mbc.12.10.3126; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TURNER PM, 1989, BIOCHEMISTRY-US, V28, P628, DOI 10.1021/bi00428a032; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001	62	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35609	35619		10.1074/jbc.M303488200	http://dx.doi.org/10.1074/jbc.M303488200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832399	hybrid			2022-12-25	WOS:000185164400105
J	Balasubramanian, A; Ganju, RK; Groopman, JE				Balasubramanian, A; Ganju, RK; Groopman, JE			Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; CANCER CELL-LINE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; NATURAL-HISTORY; BINDING-SITES; LIVER	Hepatitis C virus (HCV) infects similar to40% of human immunodeficiency virus (HIV) patients, and the resulting hepatic dysfunction that occurs is the primary cause of death in patients with co-infection. We hypothesized that hepatocytes exposed to HCV and HIV proteins might be susceptible to injury via an "innocent bystander" mechanism. To assess this, we studied the effects of envelope proteins, E2 of HCV and gp120 of HIV, in model HepG2 cells. Upon co-stimulation with HCV-E2 and HIV-gp120, we observed a potent proinflammatory response with the induction of IL-8. Furthermore, our studies revealed that HCV-E2 and HIV-gp120 act collaboratively to trigger a specific set of downstream signaling pathways that include activation of p38 mitogen-activated protein (MAP) kinase and the tyrosine phosphatase, SHP2. Both specific inhibitors of p38 MAP kinase and sodium vanadate, a potent protein-tyrosine phosphatase inhibitor, blocked IL-8 production in a dose-dependent manner. The role of p38 MAP kinase and SHP2 was further defined by transiently overexpressing dominant negative mutants of these proteins into HepG2 cells. These studies revealed that overexpression of an inactive p38 MAP kinase or SHP2 mutant partially abrogated HCV-E2- and HIV-gp120-induced IL-8 production. Further studies revealed that IL-8 induction was not mediated through activation of the NF-kappaB pathway. However, HCV-E2 plus HIV-gp120 was shown to increase the DNA binding activity of AP-1. These results emphasize that expression of the proinflammatory chemokine IL-8, induced by HCV-E2 and HIV-gp120, may be mediated through p38 MAP kinase and SHP2 in an NFkappaB- independent manner, albeit through AP-1-driven processes.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ganju, RK (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Rm 343,4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu; jgroopma@bidmc.harvard.edu			NIAID NIH HHS [AI49140] Funding Source: Medline; NIDA NIH HHS [DA15008] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Atta-ur-Rahman, 1999, CURR PHARM DESIGN, V5, P241; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Bonacini M, 2000, ARCH INTERN MED, V160, P3365, DOI 10.1001/archinte.160.22.3365; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Daar ES, 2001, J ACQ IMMUN DEF SYND, V26, P466, DOI 10.1097/00126334-200104150-00011; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; Di Martino V, 2001, HEPATOLOGY, V34, P1193, DOI 10.1053/jhep.2001.29201; Dienes HP, 1999, J HEPATOL, V31, P43, DOI 10.1016/S0168-8278(99)80373-0; Dieterich Douglas T., 1999, American Journal of Medicine, V107, p79S; Dodig M, 2001, J CLIN GASTROENTEROL, V33, P367, DOI 10.1097/00004836-200111000-00005; Fukuda R, 1996, LIVER, V16, P390; GarciaSamaniego J, 1997, AM J GASTROENTEROL, V92, P1130; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Germi R, 2002, J MED VIROL, V68, P206, DOI 10.1002/jmv.10196; GILBERT M, 1991, J CLIN MICROBIOL, V29, P142, DOI 10.1128/JCM.29.1.142-147.1991; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaplanski G, 1997, DIGEST DIS SCI, V42, P2277, DOI 10.1023/A:1018818801824; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Marie C, 1997, AM J RESP CRIT CARE, V156, P1515, DOI 10.1164/ajrccm.156.5.9702108; Marin V, 2001, BLOOD, V98, P667, DOI 10.1182/blood.V98.3.667; Martinez EH, 2001, REV MED VIROL, V11, P253, DOI 10.1002/rmv.323; MARTY C, 1994, CRIT CARE MED, V22, P673, DOI 10.1097/00003246-199404000-00025; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Masumoto T, 1998, HEPATO-GASTROENTEROL, V45, P1630; Misse D, 1999, BLOOD, V93, P2454, DOI 10.1182/blood.V93.8.2454.408k35_2454_2462; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; MOORE JP, 1990, AIDS, V4, P297, DOI 10.1097/00002030-199004000-00003; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Na YJ, 2001, INT IMMUNOPHARMACOL, V1, P1877, DOI 10.1016/S1567-5769(01)00113-8; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Penner CG, 2001, BIOCHEM BIOPH RES CO, V281, P1331, DOI 10.1006/bbrc.2001.4497; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Poles MA, 2000, CLIN INFECT DIS, V31, P154, DOI 10.1086/313892; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Puoti M, 2000, J INFECT DIS, V181, P2033, DOI 10.1086/315529; Puoti M, 2001, J INFECT DIS, V183, P134, DOI 10.1086/317644; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shimoda K, 1998, HEPATOLOGY, V28, P108, DOI 10.1002/hep.510280116; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STRIETER RM, 1994, J LAB CLIN MED, V123, P183; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Villarete LH, 1997, SHOCK, V7, P29, DOI 10.1097/00024382-199701000-00003; Volk T, 1997, FEBS LETT, V415, P169, DOI 10.1016/S0014-5793(97)01117-4; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	82	77	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35755	35766		10.1074/jbc.M302889200	http://dx.doi.org/10.1074/jbc.M302889200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824191	hybrid			2022-12-25	WOS:000185164400123
J	Efimova, T; Broome, AM; Eckert, RL				Efimova, T; Broome, AM; Eckert, RL			A regulatory role for p38 delta MAPK in keratinocyte differentiation - Evidence for p38 delta-ERK1/2 complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INVOLUCRIN PROMOTER ACTIVITY; SIGNAL-TRANSDUCTION PATHWAY; CCAAT/ENHANCER-BINDING-PROTEINS; SELECTIVE ACTIVATION; GENE-EXPRESSION; PHORBOL ESTER; OKADAIC ACID; C/EBP-BETA; EPIDERMAL KERATINOCYTE	p38 MAPK isoforms are important in the regulation of a variety of cellular processes. Among the four described p38 isoforms, p38alpha, beta, and delta are expressed in keratinocytes (Dashti, S. R., Efimova, T., and Eckert, R. L. (2001) J. Biol. Chem. 276, 8059 - 8063). However, very little is known about how individual p38 isoforms regulate keratinocyte function. In the present study, we use okadaic acid (OA) as a tool to study the role of p38 MAPKs as regulators of keratinocyte differentiation. We demonstrate that OA activates p38delta but not other p38 isoforms. p38delta activation is increased as early as 0.5 h after OA addition, and activity is maximal at 8 and 24 h. ERK1 and ERK2 activity are reduced on an identical time course. We show that p38delta forms a complex with ERK1/2, and overexpression of p38delta inhibits ERK1/2 activity without reducing ERK1/2 level. Thus, p38delta may directly suppress ERK1/2 activity. Additional studies show that p38delta is expressed in the epidermis, suggesting a role for p38delta in regulating differentiation. To evaluate its function, we show that increased p38delta activity is associated with increased levels of AP1 and CAATT enhancer binding protein factors, increased binding of these factors to the involucrin (hINV) promoter, and increased expression. Moreover, these responses are maintained in the presence of SB203580, an agent that inhibits p38alpha and beta, further suggesting a central role for the p38delta isoform. Dominant-negative p38 also inhibits these responses. These unique observations suggest that p38delta is the major p38 isoform driving suprabasal hINV gene expression and that p38delta directly regulates ERK1/2 activity via formation of a p38delta-ERK1/2 complex.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu		Broome, Ann-Marie/0000-0002-2384-5212; Efimova, Tatiana/0000-0002-9869-1545	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Balasubramanian S, 2000, BIOCHEM J, V350, P791, DOI 10.1042/0264-6021:3500791; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Hale KK, 1999, J IMMUNOL, V162, P4246; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Kam E, 1997, BRIT J DERMATOL, V137, P874; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LEA MA, 1993, CANCER LETT, V68, P231, DOI 10.1016/0304-3835(93)90151-X; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 1998, J INVEST DERMATOL, V110, P493; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NG DC, 2000, J BIOL CHEM; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; SCHONTHAL AH, 1995, SEMIN CANCER BIOL, V6, P239, DOI 10.1006/scbi.1995.0031; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	53	122	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34277	34285		10.1074/jbc.M302759200	http://dx.doi.org/10.1074/jbc.M302759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810719	hybrid			2022-12-25	WOS:000185047500083
J	Graceffa, P; Dominguez, R				Graceffa, P; Dominguez, R			Crystal structure of monomeric actin in the ATP state - Structural basis of nucleotide-dependent actin dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND DIVALENT-CATION; SHOCK COGNATE PROTEIN; D-BINDING PROTEIN; F-ACTIN; BETA-ACTIN; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; MUSCLE-CONTRACTION; SUBDOMAIN 2; IN-VITRO	A nucleotide-dependent conformational change regulates actin filament dynamics. Yet, the structural basis of this mechanism remains controversial. The x-ray crystal structure of tetramethylrhodamine-5-maleimide-actin with bound AMPPNP, a non-hydrolyzable ATP analog, was determined to 1.85-Angstrom resolution. A comparison of this structure to that of tetramethylrhodamine-5- maleimide-actin with bound ADP, determined previously under similar conditions, reveals how the release of the nucleotide gamma-phosphate sets in motion a sequence of events leading to a conformational change in subdomain 2. The side chain of Ser-14 in the catalytic site rotates upon Pi release, triggering the rearrangement of the loop containing the methylated His-73, referred to as the sensor loop. This in turn causes a transition in the DNase I-binding loop in subdomain 2 from a disordered loop in ATP-actin to an ordered alpha-helix in ADP-actin. Despite this conformational change, the nucleotide cleft remains closed in ADP-actin, similar to ATP-actin. An analysis of the existing structures of members of the actin superfamily suggests that the cleft is open in the nucleotide-free state.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Dominguez, R (corresponding author), Boston Biomed Res Inst, Watertown, MA 02472 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07707] Funding Source: Medline; NHLBI NIH HHS [HL66219] Funding Source: Medline; NIAMS NIH HHS [AR41637, P01 AR041637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Borovikov YS, 2000, BBA-PROTEIN STRUCT M, V1478, P138, DOI 10.1016/S0167-4838(00)00005-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN X, 1995, J BIOL CHEM, V270, P11415, DOI 10.1074/jbc.270.19.11415; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; De la Cruz EM, 2000, J MOL BIOL, V295, P517, DOI 10.1006/jmbi.1999.3390; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Drenth J., 2010, PRINCIPLES PROTEIN C, V3rd; Egelman EH, 2001, NAT STRUCT BIOL, V8, P735, DOI 10.1038/nsb0901-735; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 2000, PHILOS T R SOC B, V355, P419, DOI 10.1098/rstb.2000.0583; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 2000, J MOL BIOL, V299, P421, DOI 10.1006/jmbi.2000.3727; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moraczewska J, 1996, BIOCHEM J, V317, P605, DOI 10.1042/bj3170605; Moraczewska J, 1999, BIOPHYS J, V77, P373, DOI 10.1016/S0006-3495(99)76896-7; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; Nyman T, 2002, J MOL BIOL, V317, P577, DOI 10.1006/jmbi.2002.5436; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Schuler H, 2000, EUR J BIOCHEM, V267, P476, DOI 10.1046/j.1432-1327.2000.01023.x; Schuler H, 1999, EUR J BIOCHEM, V265, P210, DOI 10.1046/j.1432-1327.1999.00716.x; Schuler H, 2001, BBA-PROTEIN STRUCT M, V1549, P137, DOI 10.1016/S0167-4838(01)00255-2; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P1; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; SPRANG SR, 2000, SCI STKE; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Winder SJ, 2003, CURR OPIN CELL BIOL, V15, P14, DOI 10.1016/S0955-0674(02)00002-9; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	55	167	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34172	34180		10.1074/jbc.M303689200	http://dx.doi.org/10.1074/jbc.M303689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813032	hybrid			2022-12-25	WOS:000185047500071
J	Hanson, BJ; Hong, WJ				Hanson, BJ; Hong, WJ			Evidence for a role of SNX16 in regulating traffic between the early and later endosomal compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HOMOLOGY PX DOMAIN; SORTING NEXIN; PROTEIN TRAFFICKING; FYVE-FINGER; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; RAB5 EFFECTOR; LDL RECEPTOR; PHOX DOMAIN; IDENTIFICATION	Sorting nexins (SNXs) are a growing family of proteins characterized by the presence of a PX domain. The PX domain mediates membrane association by interaction with phosphoinositides. The SNXs are generally believed to participate in membrane trafficking, but information regarding the function of individual proteins is limited. In this report, we describe the major characteristics of one member, SNX16. SNX16 is a novel 343-amino acid protein consisting of a central PX domain followed by a potential coiled-coil domain and a C-terminal region. Like other sorting nexins, SNX16 associates with the membrane via the PX domain which interacts with the phospholipid phosphatidylinositol 3-phosphate. We show via biochemical and cellular studies that SNX16 is distributed in both early and late endosome/lysosome structures. The coiled-coil domain is necessary for localization to the later endosomal structures, as mutant SNX16 lacking this domain was found only in early endosomes. Trafficking of internalized epidermal growth factor was also delayed by this SNX16 mutant, as these cells showed a delay in the segregation of epidermal growth factor in the early endosome for its delivery to later compartments. In addition, the coiled-coil domain is shown here to be important for homo-oligomerization of SNX16. Taken together, these results suggest that SNX16 is a sorting nexin that may function in the trafficking of proteins between the early and late endosomal compartments.	Membrane Biol Lab, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Membrane Biol Lab, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbhwj@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kay BK, 1999, PROTEIN SCI, V8, P435; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; RENFREWHAFT C, 2000, MOL BIOL CELL, V11, P4105; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	43	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34617	34630		10.1074/jbc.M300143200	http://dx.doi.org/10.1074/jbc.M300143200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813048	hybrid			2022-12-25	WOS:000185047500123
J	Nes, WD; Song, ZH; Dennis, AL; Zhou, WX; Nam, J; Miller, MB				Nes, WD; Song, ZH; Dennis, AL; Zhou, WX; Nam, J; Miller, MB			Biosynthesis of phytosterols - Kinetic mechanism for the enzymatic C-methylation of sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENERGY INTERMEDIATE; SIDE-CHAIN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; 2ND METHYLATION; DELTA-24-STEROL METHYLTRANSFERASE; ERGOSTEROL BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; HYDROGEN MIGRATION; HIGHER-PLANTS; ACTIVE-SITE	Cloned soybean sterol methyltransferase was purified from Escherichia coli to gel electrophoretic homogeneity. From initial velocity experiments, catalytic constants for substrates best suited for the first and second C-1 transfer activities, cycloartenol and 24(28)-methylenelophenol, were 0.01 and 0.001 s(-1), respectively. Two-substrate kinetic analysis using cycloartenol and S-adenosyl-L-methionine (AdoMet) generated an intersecting line pattern characteristic of a ternary complex kinetic mechanism. The high energy intermediate analog 25-azacycloartanol was a noncompetitive inhibitor versus cycloartenol and an uncompetitive inhibitor versus AdoMet. The dead end inhibitor analog cyclolaudenol was competitive versus cycloartenol and uncompetitive versus AdoMet. 24(28)-Methylenecycloartanol and AdoHcy generated competitive and noncompetitive kinetic patterns, respectively, with respect to AdoMet. Therefore, 24(28)-methylenecycloartanol combines with the same enzyme form as does cycloartenol and must be released from the enzyme before AdoHcy. 25-Azacycloartanol inhibited the first and second C1 transfer activities with about equal efficacy (K-i = 45 nM), suggesting that the successive C-methylation of the Delta(24) bond occurs at the same active center. Comparison of the initial velocity data using AdoMet versus [H-2(3)-methyl] AdoMet as substrates tested against saturating amounts of cycloartenol indicated an isotope effect on V-CH3/V-CD3 close to unity. [25-H-2]24(28)-Methylenecycloartanol, [28E-H-2]24(28)-methylenelanosterol, and [28Z-H-2]24(28)-methylene lanosterol were prepared and paired with AdoMet or [methyl-H-3(3)] AdoMet to examine the kinetic isotope effects attending the C-28 deprotonation in the enzymatic synthesis of 24-ethyl(idene) sterols. The stereochemical features as well as the observation of isotopically sensitive branching during the second C-methylation suggests that the two methylation steps can proceed by a change in chemical mechanism resulting from differences in sterol structure, concerted versus carbocation; the kinetic mechanism remains the same during the consecutive methylation of the Delta(24) bond.	Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA	Texas Tech University System; Texas Tech University	Nes, WD (corresponding author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.		Zhou, Wenxu/T-6917-2019		NIGMS NIH HHS [GM 63477] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063477] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AcunaJohnson AP, 1997, BIOORGAN MED CHEM, V5, P821, DOI 10.1016/S0968-0896(97)00010-2; Arigoni D., 1978, CIBA FDN S, P243; ATOR MA, 1989, BIOCHEMISTRY-US, V28, P9633, DOI 10.1021/bi00451a014; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; Bouvier-Nave P, 1998, EUR J BIOCHEM, V256, P88, DOI 10.1046/j.1432-1327.1998.2560088.x; BouvierNave P, 1997, EUR J BIOCHEM, V246, P518, DOI 10.1111/j.1432-1033.1997.t01-1-00518.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL J, 1995, PLANT PHYSIOL, V109, P1337, DOI 10.1104/pp.109.4.1337; Cook PF, 1991, ENZYME MECH ISOTOPE; COPELAND RA, 2000, ENZYMES PRACTICAL IN; Dennis AL, 2002, TETRAHEDRON LETT, V43, P7017, DOI 10.1016/S0040-4039(02)01550-2; Diener AC, 2000, PLANT CELL, V12, P853, DOI 10.1105/tpc.12.6.853; FENNER GP, 1986, LIPIDS, V21, P48, DOI 10.1007/BF02534302; GOAD LJ, 1974, LIPIDS, V9, P582, DOI 10.1007/BF02532508; Grebenok RJ, 1997, PLANT MOL BIOL, V34, P891, DOI 10.1023/A:1005818210641; GUO DA, 1995, LIPIDS, V30, P203, DOI 10.1007/BF02537823; Guo DA, 1996, TETRAHEDRON LETT, V37, P6823, DOI 10.1016/0040-4039(96)01534-1; Guo DA, 1996, J AM CHEM SOC, V118, P8507, DOI 10.1021/ja9612155; Kaneshiro ES, 2002, MOL MICROBIOL, V44, P989, DOI 10.1046/j.1365-2958.2002.02932.x; Mangla AT, 2000, BIOORGAN MED CHEM, V8, P925, DOI 10.1016/S0968-0896(00)00040-7; Marshall JA, 2001, PHYTOCHEMISTRY, V58, P423, DOI 10.1016/S0031-9422(01)00219-9; MIHAILOVIC MM, 1984, THESIS SWISS I TECHN; MOORE JT, 1970, J BIOL CHEM, V245, P4684; NARULA AS, 1981, J AM CHEM SOC, V103, P2408, DOI 10.1021/ja00399a045; Nes WD, 2002, J BIOL CHEM, V277, P42549, DOI 10.1074/jbc.M204223200; Nes WD, 2002, BIOCHEM J, V367, P587, DOI 10.1042/BJ20020551; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; NES WD, 1991, J BIOL CHEM, V266, P15202; Nes WD, 1998, ARCH BIOCHEM BIOPHYS, V353, P297, DOI 10.1006/abbi.1998.0665; Nes WD, 1999, CRIT REV BIOCHEM MOL, V34, P81, DOI 10.1080/10409239991209219; Nes WD, 1999, J ORG CHEM, V64, P1535, DOI 10.1021/jo9819943; NES WD, 2003, PHYTOCHEMISTRY; NES WR, 1978, J BIOL CHEM, V253, P6218; Okuzumi T, 2000, TETRAHEDRON LETT, V41, P3623, DOI 10.1016/S0040-4039(00)00428-7; RAHIER A, 1984, J BIOL CHEM, V259, P5215; RAHIER A, 1986, LIPIDS, V21, P51; Shi JR, 1996, J BIOL CHEM, V271, P9384, DOI 10.1074/jbc.271.16.9384; Venkatramesh M, 1996, BBA-LIPID LIPID MET, V1299, P313, DOI 10.1016/0005-2760(95)00218-9; WAGSCHAL K, 1991, TETRAHEDRON, V47, P5933, DOI 10.1016/S0040-4020(01)86486-3; Zhou W, 1996, TETRAHEDRON LETT, V37, P1339, DOI 10.1016/0040-4039(96)00017-2; ZIMMERMAN MP, 1991, J AM CHEM SOC, V113, P3530, DOI 10.1021/ja00009a046	41	52	53	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34505	34516		10.1074/jbc.M303359200	http://dx.doi.org/10.1074/jbc.M303359200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807886	hybrid			2022-12-25	WOS:000185047500111
J	Rubin, J; Murphy, TC; Zhu, LP; Roy, E; Nanes, MS; Fan, X				Rubin, J; Murphy, TC; Zhu, LP; Roy, E; Nanes, MS; Fan, X			Mechanical strain differentially regulates endothelial nitric-oxide synthase and receptor activator of nuclear kappa B ligand expression via ERK1/2 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SHEAR-STRESS; BONE-FORMATION; IN-VIVO; SIGNALING PATHWAYS; PROSTAGLANDIN E-2; FUNCTIONAL-ROLE; STROMAL CELLS; KINASE; GENE	Exercise promotes positive bone remodeling through controlling cellular processes in bone. Nitric oxide (NO), generated from endothelial nitric-oxide synthase (eNOS), prevents resorption, whereas receptor activator of nuclear kappaB ligand (RANKL) promotes resorption through regulating osteoclast activity. Here we show that mechanical strain differentially regulates eNOS and RANKL expression from osteoprogenitor stromal cells in a magnitude-dependent fashion. Strain (0.25-2%) induction of eNOS expression was magnitude-dependent, reaching a plateau at 218 +/- 36% of control eNOS. This was accompanied by increases in eNOS protein and a doubling of NO production. Concurrently, 0.25% strain inhibited RANKL expression with increasing response up to 1% strain (44 +/- 3% of control RANKL). These differential responses to mechanical input were blocked when an ERK1/2 inhibitor was present during strain application. Inhibition of NO generation did not prevent strain-activated ERK1/2. To confirm the role of ERK1/2, cells were treated with an adenovirus encoding a constitutively activated MEK; Ad.caMEK significantly increased eNOS expression and NO production by more than 4-fold and decreased RANKL expression by half. In contrast, inhibition of strain-activated c-Jun kinase failed to prevent strain effects on either eNOS or RANKL. Our data suggest that physiologic levels of mechanical strain utilize ERK1/2 kinase to coordinately regulate eNOS and RANKL in a manner leading to positive bone remodeling.	Vet Affairs Med Ctr, Dept Med, Atlanta, GA 30033 USA; Emory Univ, Sch Med, Atlanta, GA 30033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Rubin, J (corresponding author), VAMC, 151,1670 Clairmont Rd, Decatur, GA 30033 USA.							Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002-9440(10)63963-6; Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799; Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760; AWOLESI MA, 1994, SURGERY, V116, P439; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; Bennell KL, 1997, BONE, V20, P477, DOI 10.1016/S8756-3282(97)00026-4; Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039; Collin-Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Fan X, 2003, J BIOL CHEM, V278, P10232, DOI 10.1074/jbc.M209911200; Fan X, 2001, AM J PHYSIOL-ENDOC M, V280, pE103, DOI 10.1152/ajpendo.2001.280.1.E103; Gross TS, 2002, J BONE MINER RES, V17, P493, DOI 10.1359/jbmr.2002.17.3.493; Haapasalo H, 1996, J BONE MINER RES, V11, P864; Haapasalo H, 2000, BONE, V27, P351, DOI 10.1016/S8756-3282(00)00331-8; Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108; Hsieh YF, 2001, J BONE MINER RES, V16, P2291, DOI 10.1359/jbmr.2001.16.12.2291; Hukkanen MVJ, 1999, J BONE MINER RES, V14, P868, DOI 10.1359/jbmr.1999.14.6.868; Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755; Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756-3282(02)00797-4; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Judex S, 1997, J BONE MINER RES, V12, P1737, DOI 10.1359/jbmr.1997.12.10.1737; Kanamaru Yuichi, 2001, Kobe Journal of Medical Sciences, V47, P1; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; Kleinhenz DJ, 2003, FREE RADICAL BIO MED, V34, P856, DOI 10.1016/S0891-5849(02)01438-7; Koyama A, 2000, EUR J PHARMACOL, V391, P225, DOI 10.1016/S0014-2999(00)00100-X; Lane P, 1999, SEMIN NEPHROL, V19, P215; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756-3282(98)00173-2; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Ralston SH, 1997, BRIT J RHEUMATOL, V36, P831; RIANCHO JA, 1995, J BONE MINER RES, V10, P439; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 1999, PRIMER METABOLIC BON, P39; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452; Rubin J, 2000, AM J PHYSIOL-CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126; Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002-020656; Smalt R, 1997, ADV EXP MED BIOL, V433, P311; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Srinivasan S, 2002, J BONE MINER RES, V17, P1613, DOI 10.1359/jbmr.2002.17.9.1613; Standley PR, 2002, AM J PHYSIOL-HEART C, V283, pH1907, DOI 10.1152/ajpheart.01043.2001; Turner CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634; UEBELHART D, 1995, PARAPLEGIA, V33, P669, DOI 10.1038/sc.1995.140; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015; Weyts FAA, 2002, J CELL BIOCHEM, V87, P85, DOI 10.1002/jcb.10278; Whitmarsh AJ, 2001, METHOD ENZYMOL, V332, P319; Wimalawansa S, 2000, J BONE MINER RES, V15, P1119, DOI 10.1359/jbmr.2000.15.6.1119; Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240; WOLFF J, 1892, VERLAG AUGUST HIRSCH; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123	65	93	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34018	34025		10.1074/jbc.M302822200	http://dx.doi.org/10.1074/jbc.M302822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824189	hybrid			2022-12-25	WOS:000185047500050
J	Rishi, AK; Zhang, LY; Boyanapalli, M; Wali, A; Mohammad, RM; Yu, YJ; Fontana, JA; Hatfield, JS; Dawson, MI; Majumdar, APN; Reichert, U				Rishi, AK; Zhang, LY; Boyanapalli, M; Wali, A; Mohammad, RM; Yu, YJ; Fontana, JA; Hatfield, JS; Dawson, MI; Majumdar, APN; Reichert, U			Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; POSTTRANSCRIPTIONAL REGULATION; DEPENDENT TRANSCRIPTION; CANCER CELLS; DNA-DAMAGE; S-PHASE; ACID; EXPRESSION; POLYMERASE; ARREST	CD437, a novel retinoid, causes cell cycle arrest and apoptosis in a number of cancer cells including human breast carcinoma (HBC) by utilizing an undefined retinoic acid receptor/retinoid X receptor-independent mechanism. To delineate mediators of CD437 signaling, we utilized a random antisense-dependent functional knockout genetic approach. We identified a cDNA that encodes similar to130- kDa HBC cell perinuclear protein ( termed CARP-1). Treatments with CD437 or chemotherapeutic agent adriamycin, as well as serum deprivation of HBC cells, stimulate CARP-1 expression. Reduced levels of CARP-1 result in inhibition of apoptosis by CD437 or adriamycin, whereas increased expression of CARP-1 causes elevated levels of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and apoptosis. CARP-1 interacts with 14-3-3 protein as well as causes reduced expression of cell cycle regulatory genes including c-Myc and cyclin B1. Loss of c-Myc sensitizes cells to apoptosis by CARP-1, whereas expression of c-Myc or 14-3-3 inhibits CARP-1-dependent apoptosis. Thus, apoptosis induction by CARP-1 involves sequestration of 14-3-3 and CARP-1-mediated altered expression of multiple cell cycle regulatory genes. Identification of CARP-1 as a key mediator of signaling by CD437 or adriamycin allows for delineation of pathways that, in turn, may prove beneficial for design and targeting of novel antitumor agents.	John D Dingell Vet Affairs Med Ctr, Dept Internal Med, Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Burnham Inst, La Jolla, CA 92037 USA; Galderma Res & Dev, Sophia Antipolis, France	Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; Wayne State University; Sanford Burnham Prebys Medical Discovery Institute; Galderma R&D SNC	Rishi, AK (corresponding author), John D Dingell Vet Affairs Med Ctr, Dept Internal Med, Karmanos Canc Inst, Rm B4334,4646 John Rd, Detroit, MI 48201 USA.			Fontana, Joseph/0000-0003-3829-3358	NCI NIH HHS [CA51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Charpentier B, 1995, J MED CHEM, V38, P4993, DOI 10.1021/jm00026a006; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; DE LUCA LM, 1991, FASEB J, V5, P2924; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Farhana L, 2000, CELL GROWTH DIFFER, V11, P541; Farhana L, 2002, CANCER RES, V62, P3842; Fontana JA, 1998, ONCOL RES, V10, P313; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Gudas Lorraine J., 1994, P443; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHAO ZM, 1995, ONCOGENE, V11, P493; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Yu YJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1083, DOI 10.1152/ajpcell.2001.280.5.C1083; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350	35	79	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33422	33435		10.1074/jbc.M303173200	http://dx.doi.org/10.1074/jbc.M303173200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816952	hybrid			2022-12-25	WOS:000184901800115
J	Schroder, HC; Ushijima, H; Krasko, A; Gamulin, V; Thakur, NL; Diehl-Seifert, B; Muller, IM; Muller, WEG				Schroder, HC; Ushijima, H; Krasko, A; Gamulin, V; Thakur, NL; Diehl-Seifert, B; Muller, IM; Muller, WEG			Emergence and disappearance of an immune molecule, an antimicrobial lectin, in basal Metazoa - A tachylectin-related protein in the sponge Suberites domuncula	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEODIA-CYDONIUM; AGGREGATION FACTOR; STRUCTURAL PROTEINS; GENE-EXPRESSION; MARINE SPONGES; CLONING; PURIFICATION; EVOLUTION; PRIMMORPHS; INDUCTION	Sponges ( phylum Porifera) represent the evolutionarily oldest metazoans that comprise already a complex immune system and are related to the crown taxa of the protostomians and the deuterostomians. Here, we demonstrate the existence of a tachylectin-related protein in the demosponge Suberites domuncula, termed Suberites lectin. The MAPK pathway was activated in response to lipopolysaccharide treatment of the three-dimensional cell aggregates, the primmorphs; this process was abolished by the monosaccharide D-GlcNAc. The cDNA encoding the S. domuncula lectin was identified and cloned; it comprises 238 amino acids ( 26 kDa) in the open reading frame. The deduced protein has one potential transmembrane region, three characteristic Cys residues, and six internal tandem repeats; it shares the highest sequence similarity with lectins from the horseshoe crab Tachypleus trunculus. The steady-state level of expression of the Suberites lectin rises in primmorphs in response to lipopolysaccharide, an effect that was prevented by co-incubation with D-GlcNAc. The natural sponge lectin was purified by affinity chromatography; it has a size of 27 kDa and displays antibacterial activity against the Gram-negative bacteria Escherichia coli and the Gram-positive bacteria Staphylococcus aureus. The putative protein, deduced from the cloned gene, is identical/ similar to the purified natural protein, as demonstrated by immunological cross-reactivity with specific antibodies. We conclude that the S. domuncula lectin acts as an antibacterial molecule involved in immune defense against bacterial invaders.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Univ Tokyo, Grad Sch Med, Inst Int Hlth, Bunkyo Ku, Tokyo 1130033, Japan; Rudjer Boskovic Inst, Dept Mol Genet, HR-10000 Zagreb, Croatia	Johannes Gutenberg University of Mainz; University of Tokyo; Rudjer Boskovic Institute	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	wmueller@mail.uni-mainz.de	Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Krasko, Anatoli/0000-0002-2765-3525; Schroder, Heinz C./0000-0003-0992-6427				BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; Blumbach B, 1998, J CELL SCI, V111, P2635; Bohm M, 2001, MAR BIOL, V139, P1037; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; Chen SC, 2001, J BIOL CHEM, V276, P9631, DOI 10.1074/jbc.M008414200; Custodio MR, 1998, MECH AGEING DEV, V105, P45, DOI 10.1016/S0047-6374(98)00078-5; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; Felsenstein J., 1993, PHYLIP VERSION 3 5; Gonzalez JM, 1997, APPL ENVIRON MICROB, V63, P4237; Grebenjuk VA, 2002, EUR J BIOCHEM, V269, P1382, DOI 10.1046/j.1432-1033.2002.02781.x; Huh CG, 1998, J BIOL CHEM, V273, P6565, DOI 10.1074/jbc.273.11.6565; Kawabata S, 2003, INFEC DIS S, P109; Kawabata S, 2001, ADV EXP MED BIOL, V484, P195, DOI 10.1109/IITC.2001.930058; Krasko A, 1997, MOL MAR BIOL BIOTECH, V6, P296; Kruse M, 1997, MOL BIOL EVOL, V14, P1326, DOI 10.1093/oxfordjournals.molbev.a025742; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Metchnikoff E, 1892, LECONS PATHOLOGIE CO; Moore DD, 1995, GLOB MOB SURV; Muller WEG, 1999, TRANSPLANTATION, V68, P1215; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; MULLER WEG, 2003, IN PRESS INTEGR COMP, V43; Nagai T, 1999, J BIOL CHEM, V274, P37673, DOI 10.1074/jbc.274.53.37673; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Osinga R, 2003, J BIOTECHNOL, V100, P141, DOI 10.1016/S0168-1656(02)00257-2; Pahler S, 1998, J EXP ZOOL, V282, P332, DOI 10.1002/(SICI)1097-010X(19981015)282:3<332::AID-JEZ6>3.3.CO;2-6; PROKSCH P, 1994, TOXICON, V32, P639, DOI 10.1016/0041-0101(94)90334-4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Schutze J, 2001, J MOL EVOL, V53, P402, DOI 10.1007/s002390010230; Schutze J, 2001, J CELL SCI, V114, P3189; SMITH LC, 1986, PROC R SOC SER B-BIO, V226, P465, DOI 10.1098/rspb.1986.0004; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tunkijjanukij S, 1998, DEV COMP IMMUNOL, V22, P139, DOI 10.1016/S0145-305X(98)00017-2; VANDEVYVER G, 1986, DEV COMP IMMUNOL, V10, P429, DOI 10.1016/0145-305X(86)90032-7; VOGEL S, 1977, P NATL ACAD SCI USA, V74, P2069, DOI 10.1073/pnas.74.5.2069; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; Wiens M, 2003, BBA-MOL CELL RES, V1593, P179, DOI 10.1016/S0167-4889(02)00388-9; Wiens M, 2001, CELL DEATH DIFFER, V8, P887, DOI 10.1038/sj.cdd.4400906; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; Wilkinson Clive R., 1992, P111; Wimmer W, 1999, EUR J BIOCHEM, V260, P156, DOI 10.1046/j.1432-1327.1999.00146.x; Xie J, 2001, GENE, V271, P109, DOI 10.1016/S0378-1119(01)00491-7; [No title captured]	47	78	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32810	32817		10.1074/jbc.M304116200	http://dx.doi.org/10.1074/jbc.M304116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805362	hybrid			2022-12-25	WOS:000184901800041
J	Wolcke, J; Reimann, M; Klumpp, M; Gohler, T; Kim, E; Deppert, W				Wolcke, J; Reimann, M; Klumpp, M; Gohler, T; Kim, E; Deppert, W			Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy - Evidence for different modes of high affinity DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; WILD-TYPE; 3'-TO-5' EXONUCLEASE; CRYSTAL-STRUCTURE; CORE DOMAIN; PROTEIN; COMPLEX; TARGET; GENES	The concept that the tumor suppressor p53 is a latent DNA-binding protein that must become activated for sequence-specific DNA binding recently has been challenged, although the "activation" phenomenon has been well established in in vitro DNA binding assays. Using electrophoretic mobility shift assays and fluorescence correlation spectroscopy, we analyzed the binding of "latent" and " activated" p53 to double-stranded DNA oligonucleotides containing or not containing a p53 consensus binding site (DNA(spec) or DNA(unspec), respectively). In the absence of competitor DNA, latent p53 bound DNA(spec) and DNA(unspec) with high affinity in a sequence-independent manner. Activation of p53 by the addition of the C-terminal antibody PAb421 significantly decreased the binding affinity for DNA(unspec) and concomitantly increased the binding affinity for DNA(spec). The net result of this dual effect is a significant difference in the affinity of activated p53 for DNA(spec) and DNA(unspec), which explains the activation of p53. High affinity non-specific DNA binding of latent p53 required both the p53 core domain and the p53 C terminus, whereas high affinity sequence-specific DNA binding of activated p53 was mediated by the p53 core domain alone. The data suggest that high affinity nonspecific DNA binding of latent and high affinity sequence-specific binding of activated p53 to double-stranded DNA differ in their requirement for the C terminus and involve different structural features of the core domain. Because high affinity nonspecific DNA binding of latent p53 is restricted to wild type p53, we propose that it relates to its tumor suppressor functions.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Evotec OAI, D-22525 Hamburg, Germany; Univ Hamburg, Fachbereich Chem, D-20146 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; Evotec; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de		Klumpp, Martin/0000-0003-3373-9605				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bessard ACH, 1998, ONCOGENE, V16, P883, DOI 10.1038/sj.onc.1201598; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; HALL AR, 1995, ONCOGENE, V10, P561; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Janus F, 1999, MOL CELL BIOL, V19, P2155; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEPPARD K, 1983, EMBO J, V2, P1993, DOI 10.1002/j.1460-2075.1983.tb01690.x; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1987, ONCOGENE, V1, P453; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Palecek E, 2001, EUR J BIOCHEM, V268, P573, DOI 10.1046/j.1432-1327.2001.01898.x; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200	45	33	33	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32587	32595		10.1074/jbc.M303615200	http://dx.doi.org/10.1074/jbc.M303615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813031	hybrid			2022-12-25	WOS:000184901800015
J	Yan, AX; Ahmed, E; Yan, Q; Lennarz, WJ				Yan, AX; Ahmed, E; Yan, Q; Lennarz, WJ			New findings on interactions among the yeast oligosaccharyl transferase Subunits using a chemical cross-linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ACTIVITY IN-VIVO; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY; N-GLYCOSYLATION; GENE ENCODES; ER MEMBRANE; COMPLEX; LINKING	At present, there is very limited knowledge about the structural organization of the yeast oligosaccharyl transferase (OT) complex and the function of each of its nine subunits. Because of the failure of the yeast two-hybrid system to reveal interactions between luminal domains of these subunits, we utilized a membrane permeable, thiocleavable cross-linking reagent dithiobis-succinimidyl propionate to biochemically study the interactions of various OT subunits. Four essential gene products, Ost1p, Wbp1p, Swp1p, and Stt3p were shown to be cross-linked to each other in a pairwise fashion. In addition, Ost1p was found to be cross-linked to all other eight OT subunits individually. This led us to propose that Ost1p may reside in the core of the OT complex and could play an important role in its assembly. Ost4p and Ost5p were found to only interact with specific components of the OT complex and may function as an additional anchor for optimal stability of Stt3p and Ost1p in the membrane, respectively. Interestingly, Ost3p and Ost6p subunits exhibited a surprisingly identical pattern of cross-linking to other subunits, which is consistent with their proposed redundant function. Based on these findings, we analyzed the distribution of the lysine residues that are likely to be involved in cross-linking of OT subunits and propose that the OT subunits interact with each other through either their transmembrane domains and/or a region proximal to it, rather than through their luminal or cytoplasmic domains.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu	/A-2734-2010	/0000-0003-0310-5492	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033185, R01GM033185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; Back JW, 2002, PROTEIN SCI, V11, P2471, DOI 10.1110/ps.0212602; BASKIN LS, 1982, BIOCHIM BIOPHYS ACTA, V684, P263, DOI 10.1016/0005-2736(82)90015-3; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; Dempski RE, 2002, CURR OPIN CHEM BIOL, V6, P844, DOI 10.1016/S1367-5931(02)00390-3; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; HAMADA H, 1987, ANAL BIOCHEM, V160, P483, DOI 10.1016/0003-2697(87)90080-7; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HORDERN JS, 1979, VIROLOGY, V97, P131, DOI 10.1016/0042-6822(79)90379-9; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JOSHI S, 1990, J BIOL CHEM, V265, P14518; Kalies KU, 1996, J BIOL CHEM, V271, P3925; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; Kim H, 2000, P NATL ACAD SCI USA, V97, P1516, DOI 10.1073/pnas.040556797; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luz J M, 1996, EXS, V77, P97; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Park H, 2000, GLYCOBIOLOGY, V10, P737, DOI 10.1093/glycob/10.7.737; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PATHAK R, 1995, FEBS LETT, V362, P229, DOI 10.1016/0014-5793(95)00253-6; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; Romisch KB, 2002, MOL BIOL CELL, V13, p233A; Rose MD., 1990, METHODS YEAST GENETI; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Yan Q, 1999, J BIOL CHEM, V274, P5021, DOI 10.1074/jbc.274.8.5021; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	44	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33078	33087		10.1074/jbc.M305337200	http://dx.doi.org/10.1074/jbc.M305337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805367	hybrid			2022-12-25	WOS:000184901800073
J	Zhang, HFM; Yuan, J; Cheung, P; Luo, HL; Yanagawa, B; Chau, D; Stephan-Tozy, N; Wong, BW; Zhang, JC; Wilson, JE; McManus, BM; Yang, DC				Zhang, HFM; Yuan, J; Cheung, P; Luo, HL; Yanagawa, B; Chau, D; Stephan-Tozy, N; Wong, BW; Zhang, JC; Wilson, JE; McManus, BM; Yang, DC			Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; PROTEIN-KINASE-B; CASPASE ACTIVATION; ANTIVIRAL ACTIVITY; SIGNALING PATHWAY; EXPRESSED GTPASE; GENE-EXPRESSION; GROWTH-FACTOR; AKT; CLEAVAGE	Our previous studies using differential mRNA display have shown that interferon-gamma-inducible GTPase (IGTP), was up-regulated in coxsackievirus B3 (CVB3)-infected mouse hearts. In order to explore the effect of IGTP expression on CVB3-induced pathogenesis, we have established a doxycycline-inducible Tet-On HeLa cell line overexpressing IGTP and have analyzed activation of several signaling molecules that are involved in cell survival and death pathways. We found that following IGTP overexpression, protein kinase B/Akt was strongly activated through phosphorylation, which leads to phosphorylation of glycogen synthase kinase-3 (GSK-3). Furthermore, in the presence of CVB3 infection, the intensity of the phosphorylation of Akt was further enhanced and associated with a delayed activation of caspase-9 and caspase-3. These data indicate that IGTP expression appears to confer cell survival in CVB3-infected cells, which was confirmed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt cell viability assay. However, the ability of IGTP to induce phosphorylation of Akt and to promote cell survival was attenuated by the phosphotidylinositol-3 kinase (PI3-K) inhibitor LY294002. Transient transfection of the cells with a dominant negative Akt construct followed by doxycycline induction and CVB3 infection reversed Akt phosphorylation to basal levels and returned caspase-3 activity to levels similar to those when the PI3-K inhibitor LY294002 was added. Moreover, IGTP expression inhibited viral replication and delayed CVB3-induced cleavage of eukaryotic translation initiation factor 4G, indicating that IGTP-mediated cell survival relies on not only the activation of PI3-K/Akt, inactivation of GSK-3 and suppression of caspase-9 and caspase-3 but also the inhibition of viral replication.	Univ British Columbia, St Pauls Hosp, Cardiovasc Res Lab, MRL iCAPTUR4E Ctr,Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Yang, DC (corresponding author), Univ British Columbia, St Pauls Hosp, Cardiovasc Res Lab, MRL iCAPTUR4E Ctr,Dept Pathol & Lab Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Wong, Brian/B-6168-2009	Wong, Brian/0000-0001-8447-3064				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barco A, 2000, VIROLOGY, V266, P352, DOI 10.1006/viro.1999.0043; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlow DA, 1998, J IMMUNOL, V161, P2348; Carthy CM, 1998, J VIROL, V72, P7669, DOI 10.1128/JVI.72.9.7669-7675.1998; CARTHY CM, 2003, IN PRESS VIROLOGY; Collazo CM, 2001, J EXP MED, V194, P181, DOI 10.1084/jem.194.2.181; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Goldstaub D, 2000, MOL CELL BIOL, V20, P1271, DOI 10.1128/MCB.20.4.1271-1277.2000; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Liu P, 2000, NAT MED, V6, P429, DOI 10.1038/74689; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Luo HL, 2002, J VIROL, V76, P3365, DOI 10.1128/JVI.76.7.3365-3373.2002; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Roberts LO, 2000, J GEN VIROL, V81, P1703, DOI 10.1099/0022-1317-81-7-1703; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taylor GA, 1997, J BIOL CHEM, V272, P10639; Taylor GA, 2000, P NATL ACAD SCI USA, V97, P751, DOI 10.1073/pnas.97.2.751; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Taylor LA, 2000, CIRC RES, V87, P328, DOI 10.1161/01.RES.87.4.328; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang DC, 1999, CIRC RES, V84, P704, DOI 10.1161/01.RES.84.6.704; Zhang HM, 2002, CIRC RES, V90, P1251, DOI 10.1161/01.RES.0000024690.69379.5C	49	49	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33011	33019		10.1074/jbc.M305352200	http://dx.doi.org/10.1074/jbc.M305352200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819192	hybrid			2022-12-25	WOS:000184901800065
J	Zhang, L; Li, Z; Yan, JL; Pradhan, P; Corpora, T; Cheney, MD; Bravo, J; Warren, AJ; Bushweller, JH; Speck, NA				Zhang, L; Li, Z; Yan, JL; Pradhan, P; Corpora, T; Cheney, MD; Bravo, J; Warren, AJ; Bushweller, JH; Speck, NA			Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; MYOSIN HEAVY-CHAIN; DNA-BINDING; CBF-BETA; TRANSCRIPTION FACTOR; FACTOR-ALPHA; BIOPHYSICAL CHARACTERIZATION; CLEIDOCRANIAL DYSPLASIA	Core-binding factors (CBFs) are a small family of heterodimeric transcription factors that play critical roles in several developmental pathways and in human disease. Mutations in CBF genes are found in leukemias, bone disorders, and gastric cancers. CBFs consist of a DNA-binding CBFalpha subunit (Runx1, Runx2, or Runx3) and a non-DNA-binding CBFbeta subunit. CBFalpha binds DNA in a sequence-specific manner, whereas CBFbeta enhances DNA binding by CBFalpha. Both DNA binding and heterodimerization with CBFbeta are mediated by a single domain in the CBFalpha subunits known as the "Runt domain." We analyzed the energetic contribution of amino acids in the Runx1 Runt domain to heterodimerization with CBFbeta. We identified two energetic "hot spots" that were also found in a similar analysis of CBFbeta (Tang, Y.-Y., Shi, J., Zhang, L., Davis, A., Bravo, J., Warren, A. J., Speck, N. A., and Bushweller, J. H. (2000) J. Biol. Chem. 275, 39579-39588). The importance of the hot spot residues for Runx1 function was demonstrated in in vivo transient transfection assays. These data refine the structural analyses and further our understanding of the Runx1-CBFbeta interface.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22906 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Dartmouth College; University of Virginia; University of Virginia; MRC Laboratory Molecular Biology	Speck, NA (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	nancy.speck@dartmouth.edu	Bravo, Jeronimo/K-9103-2014	Bravo, Jeronimo/0000-0001-6695-2846; Bushweller, John/0000-0002-5386-1758; Cheney, Matthew/0000-0001-8367-3427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI139536, R01AI039536] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI39536] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADJA N, 1998, MOL CELL BIOL, V18, P7432; Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bartfeld D, 2002, STRUCTURE, V10, P1395, DOI 10.1016/S0969-2126(02)00853-5; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Goger M, 1999, NAT STRUCT BIOL, V6, P620; Golling G, 1996, MOL CELL BIOL, V16, P932; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; Huang XM, 1998, J BIOL CHEM, V273, P2480, DOI 10.1074/jbc.273.4.2480; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Lewis AF, 1999, J VIROL, V73, P5535, DOI 10.1128/JVI.73.7.5535-5547.1999; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lukasik SM, 2002, NAT STRUCT BIOL, V9, P674, DOI 10.1038/nsb831; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Ma BY, 2001, CURR OPIN STRUC BIOL, V11, P364, DOI 10.1016/S0959-440X(00)00216-5; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Panda M, 2000, J PROTEIN CHEM, V19, P399, DOI 10.1023/A:1026491615076; Perez-Alvarado GC, 2000, FEBS LETT, V470, P125, DOI 10.1016/S0014-5793(00)01296-5; Rubnitz J E, 1998, Curr Opin Hematol, V5, P264; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P384, DOI 10.1038/87531; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tang YY, 2000, J BIOL CHEM, V275, P39579, DOI 10.1074/jbc.M007350200; Tang YY, 2000, FEBS LETT, V470, P167, DOI 10.1016/S0014-5793(00)01312-0; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015	68	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33097	33104		10.1074/jbc.M303972200	http://dx.doi.org/10.1074/jbc.M303972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807883	hybrid			2022-12-25	WOS:000184901800075
J	Mahata, SK; Mahapatra, NR; Mahata, M; Wang, TC; Kennedy, BP; Ziegler, MG; O'Connor, DT				Mahata, SK; Mahapatra, NR; Mahata, M; Wang, TC; Kennedy, BP; Ziegler, MG; O'Connor, DT			Catecholamine secretory vesicle stimulus-transcription coupling in vivo - Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; HYDROXYLASE MESSENGER-RNA; PEPTIDE CATESTATIN; TYROSINE-HYDROXYLASE; SECRETOGRANIN-II; GENE-EXPRESSION; LOCUS-CERULEUS; SYNAPTIN SYNAPTOPHYSIN; NORADRENERGIC NEURONS; ADRENAL-MEDULLA	Stimulation of chromaffin cell secretion in vitro triggers not only secretion but also resynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine release-inhibitory, nicotinic cholinergic antagonist peptide catestatin. Does stimulus-transcription coupling occur in vivo? And does catestatin antagonize secretion and transcription in vivo? To answer these questions, we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter transgene. Tissue-specific expression of the reporter was established by both luminescence and reverse transcription-PCR. Secretion and transcription in vivo were triggered by either direct nicotinic stimulation or vesicular transmitter depletion. Nicotinic blockade in vivo was attempted with either the classical antagonist chlorisondamine or the novel antagonist catestatin. Luciferase reporter expression was exquisitely sensitive over a large dynamic range, was specific for the transgenic animals, and paralleled typical neuroendocrine distribution of endogenous chromogranin A. Adrenal ontogeny revealed a rise of embryonic transgene expression until embryonal day 18, with an abrupt postnatal decline. Direct nicotinic stimulation of chromaffin cells caused catecholamine release and transgene transcription, each of which was nearly completely blocked by chlorisondamine. Similar adrenal results were obtained during vesicular catecholamine depletion. Both secretion and transcription were substantially blocked in the adrenal gland by catestatin. In brain and sympathetic nerve, stimulation of transcription was more modest, and reserpine responses were only incompletely blocked by chlorisondamine or catestatin, perhaps because of limited blood-brain barrier penetration by these cationic antagonists. Thus, nicotinic cholinergic stimulus-transcription coupling occurs in vivo and can be provoked either directly or indirectly (by vesicular transmitter depletion). Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin. Catestatin itself blocks stimulation of both secretion and transcription in vivo. Thus, chromogranin A and its catestatin fragment may lie at the nexus of nicotinic cholinergic signaling in vivo.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Ctr Mol Genet, San Diego, CA 92161 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; Univ Massachusetts, Dept Med, Worcester, MA 01655 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Massachusetts System; University of Massachusetts Worcester	O'Connor, DT (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	doconnor@ucsd.edu	Ziegler, Michael/L-4728-2019; Mahata, Sushil/AAF-8781-2021; Mahapatra, Nitish R/D-4123-2014	Mahapatra, Nitish R/0000-0002-0695-3510				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AGUIRRE P, 1989, AM J CLIN PATHOL, V92, P140, DOI 10.1093/ajcp/92.2.140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budinger TF, 1999, ANNU REV BIOMED ENG, V1, P611, DOI 10.1146/annurev.bioeng.1.1.611; CARMICHAEL SW, 1980, J NEUROCHEM, V35, P270, DOI 10.1111/j.1471-4159.1980.tb12516.x; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Curry WJ, 2002, ANN NY ACAD SCI, V971, P311, DOI 10.1111/j.1749-6632.2002.tb04485.x; Dani JA, 2001, PHARMACOL BIOCHEM BE, V70, P439, DOI 10.1016/S0091-3057(01)00652-9; DAVIDOFF MS, 1993, CELL TISSUE RES, V271, P429, DOI 10.1007/BF02913725; ERANKO O, 1962, ANN MED EXP BIOL FEN, V40, P134; GONON F, 1993, NEUROSCIENCE, V56, P535, DOI 10.1016/0306-4522(93)90354-I; Greer LF, 2002, LUMINESCENCE, V17, P43, DOI 10.1002/bio.676; GUNDLACH AL, 1990, EUR J PHARMACOL, V184, P163, DOI 10.1016/0014-2999(90)90677-X; Haass M, 1997, CARDIOVASC DRUG THER, V10, P657, DOI 10.1007/BF00053022; Haley KJ, 1997, MICROSC RES TECHNIQ, V37, P62, DOI 10.1002/(SICI)1097-0029(19970401)37:1<62::AID-JEMT6>3.0.CO;2-Y; Harrison MB, 2001, EXP NEUROL, V167, P321, DOI 10.1006/exnr.2000.7555; HARTMAN RD, 1992, MOL BRAIN RES, V13, P223, DOI 10.1016/0169-328X(92)90030-F; Herrero CJ, 2002, J NEUROSCI, V22, P377, DOI 10.1523/JNEUROSCI.22-02-00377.2002; HILLARP NA, 1960, NATURE, V187, P1032, DOI 10.1038/1871032a0; HIREMAGALUR B, 1995, MOL BRAIN RES, V32, P109, DOI 10.1016/0169-328X(95)00068-4; Hocker M, 2001, GASTROENTEROLOGY, V121, P43, DOI 10.1053/gast.2001.25526; Jacobs I, 2002, NEUROPHARMACOLOGY, V43, P847, DOI 10.1016/S0028-3908(02)00166-1; KAMEDA Y, 1990, HISTOCHEMISTRY, V94, P609; KANNER BI, 1979, FEBS LETT, V100, P175, DOI 10.1016/0014-5793(79)81158-8; KENNEDY B, 1990, LIFE SCI, V47, P2143, DOI 10.1016/0024-3205(90)90314-H; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KIRSHNER N, 1963, J PHARMACOL EXP THER, V141, P285; Kupryjanczyk J, 1997, Verh Dtsch Ges Pathol, V81, P253; LBIZRI H, 1994, BRIT J PHARMACOL, V113, P917; Li JY, 1998, NEUROSCIENCE, V84, P281, DOI 10.1016/S0306-4522(97)00484-3; Li MD, 2000, BRAIN RES, V867, P157, DOI 10.1016/S0006-8993(00)02283-6; Mahata M, 1996, HYPERTENSION, V28, P414, DOI 10.1161/01.HYP.28.3.414; MAHATA M, 1993, DEV BRAIN RES, V76, P43, DOI 10.1016/0165-3806(93)90121-P; Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525; MAHATA SK, 1993, MOL BRAIN RES, V19, P83, DOI 10.1016/0169-328X(93)90152-F; MAHATA SK, 1989, GEN COMP ENDOCR, V73, P165, DOI 10.1016/0016-6480(89)90089-0; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MIDDENDORFF R, 1993, ANDROLOGIA, V25, P257; MITCHELL SN, 1993, NEUROSCIENCE, V56, P989, DOI 10.1016/0306-4522(93)90145-6; MOLENAAR WM, 1990, EXP NEUROL, V108, P1, DOI 10.1016/0014-4886(90)90001-9; NEUMAN B, 1984, NEUROSCIENCE, V13, P921, DOI 10.1016/0306-4522(84)90106-4; O'Connor DT, 2002, J HYPERTENS, V20, P1335, DOI 10.1097/00004872-200207000-00020; O'Leary KT, 2003, J NEUROCHEM, V84, P952, DOI 10.1046/j.1471-4159.2003.01575.x; OCONNOR DT, 1983, LIFE SCI, V33, P1657, DOI 10.1016/0024-3205(83)90721-X; OCONNOR DT, 1983, J CLIN ENDOCR METAB, V57, P1084, DOI 10.1210/jcem-57-5-1084; OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90; Pineda J, 1997, BRIT J PHARMACOL, V122, P833, DOI 10.1038/sj.bjp.0701455; Prendergast MA, 1998, NEUROREPORT, V9, P1385, DOI 10.1097/00001756-199805110-00025; Reuben M, 1998, BRIT J PHARMACOL, V125, P1218, DOI 10.1038/sj.bjp.0702215; SALVI E, 1995, ANAT EMBRYOL, V192, P547; Serova L, 1999, J PHARMACOL EXP THER, V291, P884; SLOTKIN TA, 1973, BIOCHEM PHARMACOL, V22, P549, DOI 10.1016/0006-2952(73)90368-7; Sterling CR, 2001, J PHARMACOL EXP THER, V296, P15; STJARNE L, 1959, NATURE, V184, P2023, DOI 10.1038/1842023a0; Sundler F, 1998, YALE J BIOL MED, V71, P155; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; TAKIYYUDDIN MA, 1994, J AUTON PHARMACOL, V14, P187, DOI 10.1111/j.1474-8673.1994.tb00601.x; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 2000, REGUL PEPTIDES, V95, P9, DOI 10.1016/S0167-0115(00)00135-X; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taylor CV, 2000, J BIOL CHEM, V275, P22905, DOI 10.1074/jbc.M001232200; Westfall DP, 1996, J AUTON PHARMACOL, V16, P393, DOI 10.1111/j.1474-8673.1996.tb00061.x; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Wong T, 2003, PEDIATR RES, V53, P814, DOI 10.1203/01.PDR.0000057985.43569.95; WOOD JG, 1970, Z ZELLFORSCH MIK ANA, V111, P539, DOI 10.1007/BF00330930; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1991, J BIOL CHEM, V266, P13130; Xiao Q, 1998, LIFE SCI, V64, P63, DOI 10.1016/S0024-3205(98)00534-7; Zago WM, 1999, BRAZ J MED BIOL RES, V32, P999, DOI 10.1590/S0100-879X1999000800010	75	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32058	32067		10.1074/jbc.M305545200	http://dx.doi.org/10.1074/jbc.M305545200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799369	hybrid			2022-12-25	WOS:000184782100076
J	Naranjo-Suarez, S; Castellanos, MC; Alvarez-Tejado, M; Vara, A; Landazuri, MO; del Peso, L				Naranjo-Suarez, S; Castellanos, MC; Alvarez-Tejado, M; Vara, A; Landazuri, MO; del Peso, L			Down-regulation of hypoxia-inducible factor-2 in PC12 cells by nerve growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA; TRANSCRIPTIONAL ACTIVITY; FACTOR-ALPHA; HIF-ALPHA; HIF-1-ALPHA; EXPRESSION; GENE; FACTOR-1-ALPHA; HYDROXYLATION; DESTRUCTION	Cellular responses to low oxygen tension are mediated, at least in part, by the activation of the hypoxia-inducible factors (HIFs). In the presence of oxygen, specific HIF residues become hydroxylated by the action of a recently described group of dioxygenases. These post-translational modifications target HIF for proteosomal degradation and prevent its transcriptional activity. Despite these detailed studies, little is known about the regulation of HIF by stimuli other than hypoxia. Here we report that, in rat pheochromocytoma PC12 cells, nerve growth factor (NGF) stimulation results in a decrease of both basal and hypoxia-induced levels of HIF-2alpha protein. NGF treatment did not increase HIF-hydroxylase gene expression or activity, and the reduction of the HIF-2alpha protein level upon stimulation was observed even in the presence of HIF-hydroxylase inhibitors such as deferoxamine or dimethyloxoglutarate. Thus, in contrast to the response to hypoxia, the effect of NGF on HIF-2alpha protein levels is not mediated by the HIF hydroxilases. Quantitative real time (RT)-PCR showed that NGF stimulation results in a decrease of the HIF-2alpha mRNA level similar to that found at the protein level. Interestingly, NGF effect was specific for HIF-2alpha mRNA because it did not affect HIF-1alpha mRNA levels. NGF treatment reduced HIF-2alpha mRNA levels even in the presence of actinomycin D, suggesting an effect on mRNA stability. Finally, the effect of NGF on HIF2alpha correlates with reduction of both basal and hypoxia-induced vascular endothelial growth factor mRNA levels. Reporter assays suggest that the reduced expression of hypoxia-inducible genes upon NGF treatment is related, at least in part, to the reduction of HIF-2alpha protein. Hence, in PC12 cells the level of HIF-2alpha protein and its effect on gene expression can be down-regulated by stimuli other than oxygen.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa	del Peso, L (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego de Leon 62, Madrid 28006, Spain.	lpeso@lpr.insalud.es	del Peso, Luis/K-9391-2014; Suarez, Salvador Naranjo/K-8450-2017	del Peso, Luis/0000-0003-4014-5688; Suarez, Salvador Naranjo/0000-0002-7038-0753				Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Charlier N, 2002, MOL BRAIN RES, V104, P21, DOI 10.1016/S0169-328X(02)00198-5; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gross J, 2000, LIFE SCI, V67, P2595, DOI 10.1016/S0024-3205(00)00843-2; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kanno H, 2000, CANCER RES, V60, P2820; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Richard DE, 2000, J BIOL CHEM, V275, P26765; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Schumacker PT, 2002, AM J PHYSIOL-LUNG C, V283, pL918, DOI 10.1152/ajplung.00205.2002; SETA KA, 2002, SCI STKE, V146, pRE11, DOI DOI 10.1126/STKE.2002.146.RE11; Shimizu S, 1996, CANCER RES, V56, P2161; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; WAX SD, 1994, J BIOL CHEM, V269, P13041; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541	36	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31895	31901		10.1074/jbc.M304079200	http://dx.doi.org/10.1074/jbc.M304079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805361	hybrid			2022-12-25	WOS:000184782100056
J	Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL				Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL			Hepatitis B virus X protein activates a survival signaling by linking Src to phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FAS-MEDIATED APOPTOSIS; HBX PROTEIN; TUMOR PROMOTER; CELL-DEATH; IN-VIVO; KINASE; PATHWAY; GENE; RAS	We have previously shown that transactivation-proficient hepatitis virus B X protein (HBx) protects Hep 3B cells from transforming growth factor-beta (TGF-beta)-induced apoptosis via activation of the phosphatidylinositol 3-kinase ( PI 3-kinase)/Akt signaling pathway. This work further investigated how HBx activates PI 3-kinase. Src activity was elevated in Hep 3B cells following expression of transactivation-proficient HBx or HBx-GFP fusion proteins. The Src family kinase inhibitor PP2 and C-terminal Src kinase (Csk) both alleviated HBx-mediated PI 3-kinase activation and protection from TGF-beta-induced apoptosis. Therefore, HBx activated a survival signal by linking Src to PI 3-kinase. Systemic subcellular fractionation and membrane flotation assays indicated that similar to 1.5% of ectopically expressed HBxGFP was associated with periplasmic membrane where Src was located. However, neither nucleus-targeted nor periplasmic membrane-targeted HBxGFP was able to upregulate Src activity or to augment PI 3-kinase survival signaling pathway.	Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Taipei 10063, Taiwan; Natl Taiwan Univ, Ctr Canc Res, Coll Med, Taipei 10063, Taiwan; Natl Taiwan Univ, Inst Toxicol, Coll Med, Taipei 10063, Taiwan; Natl Hlth Res Inst, Taipei 11564, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10063, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10063, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Doong, SL (corresponding author), Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, 1 Sect 1,Jen Ai Rd, Taipei 10063, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; Cheng, Ann-Lii/0000-0002-9152-6512; DOONG, SHIN-LIAN/0000-0002-0936-3858				ANTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Baron KT, 1997, EUR J PHARMACOL, V340, P295, DOI 10.1016/S0014-2999(97)01433-7; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bouchard M, 2001, J VIROL, V75, P4247, DOI 10.1128/JVI.75.9.4247-4257.2001; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; CALPHAM DE, 1995, CELL, V80, P259; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MAGUIRE HF, 1991, SCIENCE, V92, P3819; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Ohno H, 1999, J MED VIROL, V58, P11, DOI 10.1002/(SICI)1096-9071(199905)58:1<11::AID-JMV2>3.0.CO;2-H; OKADA M, 1989, J BIOL CHEM, V264, P20886; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WANG XW, 1995, CANCER RES, V55, P6012; Weil R, 1999, MOL CELL BIOL, V19, P6345; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	50	49	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31807	31813		10.1074/jbc.M302580200	http://dx.doi.org/10.1074/jbc.M302580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805382	hybrid			2022-12-25	WOS:000184782100043
J	Takano, K; Scholtz, JM; Sacchettini, JC; Pace, CN				Takano, K; Scholtz, JM; Sacchettini, JC; Pace, CN			The contribution of polar group burial to protein stability is strongly context-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; CONFORMATIONAL STABILITY; RIBONUCLEASE SA; HYDROGEN-BONDS; T4 LYSOZYME; THERMODYNAMIC STABILITY; CHYMOTRYPSIN INHIBITOR-2; HYDROPHOBIC INTERACTIONS; PACKING INTERACTIONS; ESCHERICHIA-COLI	We previously suggested that proteins gain more stability from the burial and hydrogen bonding of polar groups than from the burial of nonpolar groups ( Pace, C. N. (2001) Biochemistry 40, 310 - 313). To study this further, we prepared eight Thr-to-Val mutants of RNase Sa, four in which the Thr side chain is hydrogen-bonded and four in which it is not. We measured the stability of these mutants by analyzing their thermal denaturation curves. The four hydrogen-bonded Thr side chains contribute 1.3 +/- 0.9 kcal/mol to the stability; those that are not still contribute 0.4 +/- 0.9 kcal/ mol to the stability. For 40 Thr-to-Val mutants of 11 proteins, the average decrease in stability is 1.0 +/- 1.0 kcal/ mol when the Thr side chain is hydrogen- bonded and 0.0 +/- 0.5 kcal/ mol when it is not. This is clear evidence that hydrogen bonds contribute favorably to protein stability. In addition, we prepared four Val-to-Thr mutants of RNase Sa, measured their stability, and determined their crystal structures. In all cases, the mutants are less stable than the wild-type protein, with the decreases in stability ranging from 0.5 to 4.4 kcal/ mol. For 41 Val-to-Thr mutants of 11 proteins, the average decrease in stability is 1.8 +/- 1.3 kcal/ mol and is unfavorable for 40 of 41 mutants. This shows that placing an - OH group at a site designed for a -CH3 group is very unfavorable. So, - OH groups can contribute favorably to protein stability, even if they are not hydrogen- bonded, if the site was selected for an - OH group, but they will make an unfavorable contribution to stability, even if they are hydrogen- bonded, when they are placed at a site selected for a -CH3 group. The contribution that polar groups make to protein stability depends strongly on their environment.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Osaka Univ, Dept Mat & Life Sci, Osaka 5650871, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Osaka 5650871, Japan; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Adv Biomol Res, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Osaka University; Japan Science & Technology Agency (JST); Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Pace, CN (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.			Takano, Kazufumi/0000-0002-7548-7314	NIGMS NIH HHS [GM-52483, GM-37039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052483, R29GM052483, R01GM037039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BELL JA, 1992, BIOCHEMISTRY-US, V31, P3590, DOI 10.1021/bi00129a006; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLABER M, 1993, BIOCHEMISTRY-US, V32, P11363, DOI 10.1021/bi00093a013; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burnett M.N., 1996, ORNL6895; BYRNE MP, 1995, BIOCHEMISTRY-US, V34, P13949, DOI 10.1021/bi00042a029; Chen JM, 2001, BIOCHEMISTRY-US, V40, P15280, DOI 10.1021/bi011776v; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; De Vos S, 2001, BIOCHEMISTRY-US, V40, P10140, DOI 10.1021/bi010565n; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1995, PROTEIN SCI, V4, P2247, DOI 10.1002/pro.5560041101; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Grimsley GR, 1999, PROTEIN SCI, V8, P1843, DOI 10.1110/ps.8.9.1843; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Habermann SM, 1996, PROTEIN SCI, V5, P1229, DOI 10.1002/pro.5560050702; Hebert EJ, 1997, PROTEIN EXPRES PURIF, V11, P162, DOI 10.1006/prep.1997.0776; Hebert EJ, 1998, BIOCHEMISTRY-US, V37, P16192, DOI 10.1021/bi9815243; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; Horii K, 2001, PROTEINS, V45, P16, DOI 10.1002/prot.1119; Huyghues-Despointes BMP, 2003, J MOL BIOL, V325, P1093, DOI 10.1016/S0022-2836(02)01274-3; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laurents D, 2001, PROTEINS, V44, P200, DOI 10.1002/prot.1085; Laurents DV, 2003, J MOL BIOL, V325, P1077, DOI 10.1016/S0022-2836(02)01273-1; Lazaridis T, 1995, ADV PROTEIN CHEM, V47, P231, DOI 10.1016/S0065-3233(08)60547-1; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; Lomize AL, 2002, PROTEIN SCI, V11, P1984, DOI 10.1110/ps.0307002; Lu WY, 1997, BIOCHEMISTRY-US, V36, P673, DOI 10.1021/bi9625612; Main ERG, 1998, BIOCHEMISTRY-US, V37, P6145, DOI 10.1021/bi973111s; Otwinowski Z., 1990, DENZO DATA PROCESSIN; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; Pace CN, 1998, J MOL BIOL, V279, P271, DOI 10.1006/jmbi.1998.1760; Pace CN, 2001, J MOL BIOL, V312, P393, DOI 10.1006/jmbi.2001.4956; Pace CN, 2001, BIOCHEMISTRY-US, V40, P310, DOI 10.1021/bi001574j; Perl D, 2001, J MOL BIOL, V313, P343, DOI 10.1006/jmbi.2001.5050; PERRY KM, 1987, BIOCHEMISTRY-US, V26, P2674, DOI 10.1021/bi00384a004; Ratnaparkhi GS, 2000, BIOCHEMISTRY-US, V39, P12365, DOI 10.1021/bi000775k; Ross PD, 1996, BIOPHYS J, V71, P2144, DOI 10.1016/S0006-3495(96)79415-8; SANDBERG WS, 1995, BIOCHEMISTRY-US, V34, P11970, DOI 10.1021/bi00037a039; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SEVCIK J, 1996, ACTA CRYSTALLOGR D, V52, P257; Shaw KL, 2001, PROTEIN SCI, V10, P1206, DOI 10.1110/ps.440101; Sippl MJ, 1996, FOLD DES, V1, P289, DOI 10.1016/S1359-0278(96)00042-9; Takano K, 2001, BIOCHEMISTRY-US, V40, P4853, DOI 10.1021/bi002792f; Takano K, 1999, BIOCHEMISTRY-US, V38, P6623, DOI 10.1021/bi9901228; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; THORSON JS, 1995, J AM CHEM SOC, V117, P9361, DOI 10.1021/ja00141a032; Tsai J, 1999, J MOL BIOL, V290, P253, DOI 10.1006/jmbi.1999.2829; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Xu J, 2001, PROTEIN SCI, V10, P1067, DOI 10.1110/ps.02101	61	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31790	31795		10.1074/jbc.M304177200	http://dx.doi.org/10.1074/jbc.M304177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799387	hybrid			2022-12-25	WOS:000184782100041
J	Nilius, B; Prenen, J; Droogmans, G; Voets, T; Vennekens, R; Freichel, M; Wissenbach, U; Flockerzi, V				Nilius, B; Prenen, J; Droogmans, G; Voets, T; Vennekens, R; Freichel, M; Wissenbach, U; Flockerzi, V			Voltage dependence of the Ca2+-activated cation channel TRPM4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; HYPOMAGNESEMIA; KINASE	TRPM4 is a Ca2+-activated but Ca2+-impermeable cation channel. An increase of [Ca2+](i) induces activation and subsequent reduction of currents through TRPM4 channels. This inactivation is strikingly decreased in cell-free patches. In whole cell and cell-free configuration, currents through TRPM4 deactivate rapidly at negative potentials. At positive potentials, currents are much larger and activate slowly. This voltage-dependent behavior induces a striking outward rectification of the steady state currents. The instantaneous current-voltage relationship, derived from the amplitude of tail currents following a prepulse to positive potentials, is linear. Currents show a Boltzmann type of activation; the fraction of open channels increases at positive potentials and is low at negative potentials. Voltage dependence is not due to block by divalent cations or to voltage-dependent binding of intracellular Ca2+ to an activator site, indicating that TRPM4 is a transient receptor potential channel with an intrinsic voltage-sensing mechanism. Voltage dependence of TRPM4 may be functionally important, especially in excitable tissues generating plateau-like or bursting action potentials.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany	KU Leuven; Saarland University	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	bernd.nilius@med.kuleuven.ac.be	Voets, Thomas/E-2466-2012; Vennekens, Rudi/AAQ-1664-2020; Voets, Thomas/AAD-4389-2019	Voets, Thomas/0000-0001-5526-5821; Vennekens, Rudi/0000-0002-2564-5150; Voets, Thomas/0000-0001-5526-5821				Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Connors BW, 2002, NATURE, V420, P133, DOI 10.1038/420133a; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8	21	254	292	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30813	30820		10.1074/jbc.M305127200	http://dx.doi.org/10.1074/jbc.M305127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12799367	hybrid			2022-12-25	WOS:000184658800050
J	Deininger, MH; Wybranietz, WA; Graepler, FTC; Lauer, UM; Meyermann, R; Schluesener, HJ				Deininger, MH; Wybranietz, WA; Graepler, FTC; Lauer, UM; Meyermann, R; Schluesener, HJ			Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway	FASEB JOURNAL			English	Article						anti-angiogenic therapy; glioblastoma pathology; nitric oxide synthase	ANGIOGENESIS INHIBITORS ENDOSTATIN; GROWTH-FACTOR; TUMOR-GROWTH; SYNTHASE EXPRESSION; NUCLEAR ANTIGEN; ZINC-BINDING; APOPTOSIS; COLLAGEN; THERAPY; CANCER	Endostatin is a 20 kDa carboxyl-terminal fragment of collagen XVIII that, when added exogenously, inhibits endothelial proliferation and migration in vitro and angiogenesis and tumor growth in vivo. Previous results showed endostatin/collagen XVIII labeling in few endothelial cells in human glioblastoma multiforme. We have now observed constitutive release of endostatin from one of four endothelial cell lines. Induction of endostatin release was observed after H2O2, an in vitro model of cell stress, CoCl2, a model of hypoxia, and by IFN-gamma challenge. Endostatin expression and release was reduced by the nitric oxide synthase inhibitors aminoguanidine and L-NAME and induced by the NO synthase-independent NO donors sodium nitroprusside ( SNP) and spermine-NONO-ate. SNP-mediated endostatin induction was abrogated by the soluble guanylate cyclase inhibitor 1H-(1.2.4) oxadiazolo (4,3-A) quinoxalin-1-one. Adenoviral endostatin transduction resulted in the release of endostatin from endothelial cells and in down-regulation of iNOS (NOS2) and eNOS (NOS3), and surprisingly in a 10% induction of PCNA. These results describe the modulation of endostatin release by the NO signaling cascade and provide important new pharmacological information for the systemic induction of endogenous endostatin release by common NO donor pharmacotherapy.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany; Med Univ Clin Tubingen, Dept Internal Med 1, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Deininger, MH (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	martin.deininger@uni-tuebingen.de						Bartlett SR, 1999, J PHYSIOL-LONDON, V521, P705, DOI 10.1111/j.1469-7793.1999.00705.x; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boehm T, 1998, BIOCHEM BIOPH RES CO, V252, P190, DOI 10.1006/bbrc.1998.9617; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Boye E, 2001, J CLIN INVEST, V107, P745, DOI 10.1172/JCI11432; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Christov C, 1998, NEUROPATH APPL NEURO, V24, P29; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; Feldman AL, 2000, CANCER RES, V60, P1503; Iwata S, 1999, NEUROSURGERY, V45, P24, DOI 10.1097/00006123-199907000-00006; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; John H, 1999, BIOCHEMISTRY-US, V38, P10217, DOI 10.1021/bi990787+; Kane AJ, 2001, BRIT J PHARMACOL, V132, P1631, DOI 10.1038/sj.bjp.0703944; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miller MJS, 1996, INFLAMM RES, V45, P272, DOI 10.1007/BF02280990; Milligan SA, 1996, AM J PHYSIOL-LUNG C, V271, pL114, DOI 10.1152/ajplung.1996.271.1.L114; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schuppan D, 1998, LANCET, V352, P879, DOI 10.1016/S0140-6736(05)60006-2; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; Strik HM, 2001, CANCER, V91, P1013, DOI 10.1002/1097-0142(20010301)91:5<1013::AID-CNCR1092>3.0.CO;2-Q; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Walter JW, 1999, AM J MED GENET, V82, P77, DOI 10.1002/(SICI)1096-8628(19990101)82:1<77::AID-AJMG15>3.0.CO;2-A; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wen W, 1999, CANCER RES, V59, P6052; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	50	26	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1267	1276		10.1096/fj.02-1118com	http://dx.doi.org/10.1096/fj.02-1118com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832291				2022-12-25	WOS:000184471600038
J	Waki, T; Tamura, G; Sato, M; Motoyama, T				Waki, T; Tamura, G; Sato, M; Motoyama, T			Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples	ONCOGENE			English	Article						age-related methylation; tumor suppressor gene; autopsy	ABERRANT PROMOTER METHYLATION; CPG-ISLAND METHYLATION; E-CADHERIN GENE; DNA METHYLATION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; MULTIPLE GENES; HYPERMETHYLATION; P16	Age-related methylation may have the potential to behave as a mutator process. To clarify the physiological consequence of age-related methylation of tumor suppressor and tumor-related genes, we studied promoter methylation status in non-neoplastic cells of various organs obtained at autopsy by methylation-specific PCR. Promoter methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes, which are frequently silenced in certain human malignancies, was studied in non-neoplastic cells of the esophagus, stomach, small and large intestines, liver, pancreas, kidney and lung obtained from 38 Japanese autopsies. The tumor suppressor and tumor-related genes, except APC and RASSF1A, were generally unmethylated in samples obtained from people who were less than 32 years old (n = 11). Methylated promoters were present at variable frequencies in a tissue-specific manner in samples obtained from people who were greater than 42 years old (n = 27), although GSTP1 and hMLH1 methylation was absent or infrequent and lacked tissue specificity. In the majority of organs, the incidence of age-related methylation paralleled the reported methylation incidence in malignant counterparts. Thus, age-related methylation of a different set of genes is thought to constitute a field defect in different organs.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan	Yamagata University	Tamura, G (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Belinsky SA, 2002, CANCER RES, V62, P2370; Byun DS, 2001, CANCER RES, V61, P7034; Chan AOO, 2003, GUT, V52, P502, DOI 10.1136/gut.52.4.502; Esteller M, 2001, CANCER RES, V61, P3225; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang GH, 2001, CANCER RES, V61, P2847; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nakagawa H, 2001, CANCER RES, V61, P6991; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Paz MF, 2002, CANCER RES, V62, P4519; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783; Tokugawa T, 2002, CANCER RES, V62, P4938; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8; Yanagawa N, 2002, JPN J CANCER RES, V93, P1107, DOI 10.1111/j.1349-7006.2002.tb01212.x; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	25	152	170	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4128	4133		10.1038/sj.onc.1206651	http://dx.doi.org/10.1038/sj.onc.1206651			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821947				2022-12-25	WOS:000183707600016
J	Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR				Llorca, O; Rivera-Calzada, A; Grantham, J; Willison, KR			Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an arm-like domain to clamp around double-stranded DNA	ONCOGENE			English	Article						ATM; electron microscopy reconstruction; DNA repair	DEPENDENT PROTEIN-KINASE; CONFORMATIONAL-CHANGES; ATAXIA-TELANGIECTASIA; BREAST-CANCER; SUSCEPTIBILITY; PURIFICATION; MUTATIONS; BREAKS/; DAMAGE; SITES	The human tumor suppressor gene ataxia telangiectasia mutated (ATM) encodes a 3056 amino-acid protein kinase that regulates cell cycle checkpoints. ATM is defective in the neurodegenerative and cancer predisposition syndrome ataxia-telangiectasia. ATM protein kinase is activated by DNA damage and responds by phosphorylating downstream effectors involved in cell cycle arrest and DNA repair, such as p53, MDM2, CHEK2, BRCA1 and H2AX. ATM is probably a component of, or in close proximity to, the double-stranded DNA break-sensing machinery. We have observed purified human ATM protein, ATM-DNA and ATM-DNA-avidin bound complexes by single-particle electron microscopy and obtained three-dimensional reconstructions which show that ATM is composed of two main domains comprising a head and an arm. DNA binding to ATM induces a large conformational movement of the arm-like domain. Taken together, these three structures suggest that ATM is capable of interacting with DNA, using its arm to clamp around the double helix.	Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, London SW3 6JB, England; CSIC, Ctr Invest Biol, Madrid 28040, Spain	Cancer Research UK; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Willison, KR (corresponding author), Canc Res UK, Canc Res Inst, Ctr Cell & Mol Biol, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.		Llorca, Oscar/K-1144-2014; Rivera-Calzada, Angel/K-3617-2014; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009	Llorca, Oscar/0000-0001-5705-0699; Rivera-Calzada, Angel/0000-0003-2472-5535; Llorca, Oscar/0000-0001-5705-0699; 				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Concannon P, 2002, NAT GENET, V32, P89, DOI 10.1038/ng0902-89; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Rhodes N, 2001, PROTEIN EXPRES PURIF, V22, P462, DOI 10.1006/prep.2001.1459; Rosano C, 1999, BIOMOL ENG, V16, P5, DOI 10.1016/S1050-3862(99)00047-9; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098	30	45	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3867	3874		10.1038/sj.onc.1206649	http://dx.doi.org/10.1038/sj.onc.1206649			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813460				2022-12-25	WOS:000183612000006
J	Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M				Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M			New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells	ONCOGENE			English	Article						antineoplastic drugs; apoptosis; CCRF-CEM; reactive oxygen species; caspase-8	CERVICAL-CARCINOMA CELLS; JURKAT LEUKEMIA-CELLS; CYTOCHROME-C; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; DEATH; MITOCHONDRIA; CANCER; CHEMOTHERAPY; INVOLVEMENT; DIARYLSULFONYLUREAS	In this work, we describe the process of cell death induced by a series of new benzo(b)thiophenesulphonamide 1,1-dioxide derivatives (BTS) that have been selected as candidate antineoplastic drugs. Human leukaemic CCRF-CEM cells incubated with BTS undergo a typical apoptotic process that includes cell shrinkage, phosphatidylserine translocation to the cell surface, mitochondrial dysfunction, caspase activation, chromatin condensation and internucleosomal DNA degradation. Mitochondrial alterations included dissipation of the mitochondrial membrane potential, oxidation of the phospholipid cardiolipin, release of cytochrome c and uncoupling of the mitochondrial respiratory chain, leading to a decrease of the intracellular ATP pool. Activation of caspase-8, -9 and -3 takes place during BTS-induced apoptosis. Either the addition of the specific caspase-8 inhibitor Z-IETD-fmk, or the overexpression of the antiapoptotic protein Bcl-2 significantly prevented BTS-induced apoptosis, suggesting the involvement of both caspase-8-regulated and mitochondria-dependent signalling pathways in this process. BTS induce a significant increase in the production and accumulation of intracellular reactive oxygen species (ROS) that can be observed within minutes after drug addition. Moreover, cytochrome c release, caspase-3 activation and cell death can be completely abrogated by a previous incubation with the antioxidant N-acetyl-cysteine. These results suggest that ROS are essential mediators in BTS-induced apoptosis.	Univ Publ Navarra, Dept Hlth Sci, Pamplona 31008, Spain; Univ Basque Country, Dept Cell Biol, Leioa 31006, Spain; Univ Publ Navarra, Dept Appl Chem, Pamplona 31013, Spain	Universidad Publica de Navarra; University of Basque Country; Universidad Publica de Navarra	Migliaccio, M (corresponding author), Univ Publ Navarra, Dept Hlth Sci, Avd Baranain S-N, Pamplona 31008, Spain.	marco.migliaccio@una.varra.es	Alonso, Marta M/AAI-9457-2020; Martinez-Merino, Victor/K-5177-2014; Asumendi, Aintzane/ABF-7001-2021	Alonso, Marta M/0000-0002-7520-7351; Martinez-Merino, Victor/0000-0002-1873-0699; Encio, Ignacio/0000-0003-1732-1989; Asumendi, Aintzane/0000-0002-2156-2323				Alonso MM, 2001, BRIT J CANCER, V85, P1400, DOI 10.1054/bjoc.2001.2083; Boutonnat J, 2000, CYTOMETRY, V42, P50, DOI 10.1002/(SICI)1097-0320(20000215)42:1<50::AID-CYTO8>3.3.CO;2-3; BOZOLLA JJ, 1992, ELECT MICROSCOPY; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; COTTER TG, 1992, ANTICANCER RES, V12, P773; Ferreira CG, 2000, CANCER RES, V60, P7133; Green D R, 1994, Important Adv Oncol, P37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HOWBERT JJ, 1990, J MED CHEM, V33, P2393, DOI 10.1021/jm00171a013; Huschtscha LI, 1996, BRIT J CANCER, V73, P54, DOI 10.1038/bjc.1996.10; Keller JN, 1998, J NEUROSCI, V18, P687; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Koren R, 2000, J STEROID BIOCHEM, V73, P105, DOI 10.1016/S0960-0760(00)00068-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTINEZMERINO V, 2000, Patent No. 0063202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Oridate N, 1995, J CELL BIOCHEM, P80; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SOSINSKI J, 1993, BIOCHEM PHARMACOL, V45, P2135, DOI 10.1016/0006-2952(93)90027-T; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Umansky V, 2000, J CELL BIOCHEM, V78, P578, DOI 10.1002/1097-4644(20000915)78:4<578::AID-JCB7>3.0.CO;2-A; Umansky V, 2001, EXP CELL RES, V265, P274, DOI 10.1006/excr.2001.5188; Zamai L, 2001, CYTOMETRY, V44, P57, DOI 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.3.CO;2-F; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	40	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3759	3769		10.1038/sj.onc.1206435	http://dx.doi.org/10.1038/sj.onc.1206435			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802283				2022-12-25	WOS:000183551000010
J	Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E				Gabet, AS; Mortreux, F; Charneau, P; Riou, P; Duc-Dodon, M; Wu, YL; Jeang, KT; Wattel, E			Inactivation of hTERT transcription by Tax	ONCOGENE			English	Article						telomere; telomerase HTLV-1 hTERT oncogene; oncogenegic leukemogenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; COMPARATIVE GENOMIC HYBRIDIZATION; INHIBITS TELOMERASE ACTIVITY; HTLV-1 TAX; P53 GENE; IN-VIVO; BINDING ELEMENT; CANCER CELLS; CYCLE ARREST	Telomerase expression is the hallmark of tumor cells in which this ribonucleoprotein complex preserves chromosome integrity by maintaining telomere length and thereby prevents cell death. However, recent data support a role of the combination of p53 and telomerase inactivation in initiating genetic instability that promotes malignant transformation. Through its pleiotropic effects on infected T-cell metabolism, the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax plays a central role in leukemogenesis. Here, we show that Tax inhibits human telomerase reverse transcriptase (hTERT) transcription, which is the rate-limiting factor of telomerase activity. This inhibitory effect, that occurs in competition with c-Myc through a canonical c-Myc binding site within the hTERT promoter, results in a decreased telomerase activity of Tax-expressing cells. This is the first demonstration of hTERT inhibition by an oncogene. Tax, which is only expressed in preleukemic cells, triggers infected T-cell cycle and keeps these cells cycling while inactivating p53. We propose that, in combination with these effects, h TER T repression by Tax at an early phase of carcinogenesis might contribute to the massive ploidy changes associated with the development of HTLV-1-associated malignancies.	Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Viral, F-69373 Lyon 08, France; Inst Pasteur, Grp Virol Mol & Vector, F-75724 Paris, France; Fac Med Lyon Laennec, CNRS UMR 5537, F-69372 Lyon 8, France; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Hop Edouard Herriot, Hematol Serv, F-69437 Lyon 03, France	UNICANCER; Centre Leon Berard; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); CHU Lyon	Wattel, E (corresponding author), Univ Lyon 1, UMR5578 CNRS, Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; CESARMAN E, 1992, BLOOD, V80, P3205; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; FUJII M, 1991, ONCOGENE, V6, P1023; FURUKAWA Y, 1995, BLOOD, V85, P1865, DOI 10.1182/blood.V85.7.1865.bloodjournal8571865; Gauthier LR, 2001, BRIT J CANCER, V84, P631, DOI 10.1054/bjoc.2000.1662; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Horikawa I, 1999, CANCER RES, V59, P826; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; LEE M, J BIOL CHEM, V277, P27748; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NISHIMURA S, 1995, LEUKEMIA, V9, P598; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; REID RL, 1993, ONCOGENE, V8, P3029; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Royer-Leveau C, 2002, J VIROL METHODS, V105, P133, DOI 10.1016/S0166-0934(02)00097-6; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SAKASHITA A, 1992, BLOOD, V79, P477; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Uchida N, 1999, LEUKEMIA RES, V23, P311, DOI 10.1016/S0145-2126(98)00170-2; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	59	71	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3734	3741		10.1038/sj.onc.1206468	http://dx.doi.org/10.1038/sj.onc.1206468			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802280				2022-12-25	WOS:000183551000007
J	Yang, HS; Knies, JL; Stark, C; Colburn, NH				Yang, HS; Knies, JL; Stark, C; Colburn, NH			Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation	ONCOGENE			English	Article						Pdcd4; AP-1; c-Jun; c-Fos; transformation	NF-KAPPA-B; C-JUN; TRANSCRIPTIONAL REGULATION; TRANSFORMATION SUPPRESSOR; CYCLE PROGRESSION; ANTISENSE RNA; EXPRESSION; GENES; PROMOTION; PROTEIN	Transformation suppressor Pdcd4 is downregulated in transformed (Tx) mouse epidermal JB6 RT101 cells relative to transformation-resistant (P-) and susceptible (P+) variants. Whether Pdcd4 downregulation is necessary not only to induce transformation but also to maintain tumor phenotypes has not been determined previously. In the present study, overexpression of Pdcd4 cDNA in stably transfected RT101 cells resulted in 40% fewer anchorage-independent colonies that were smaller in size than the vector control colonies, indicating that elevated Pdcd4 expression is sufficient to suppress tumor phenotype. Transient transfection of Pdcd4 expression plasmid and 4 x AP-1 reporter gene showed that activation of AP-1-dependent transcription was inhibited by Pdcd4 expression in a concentration-dependent manner. In contrast, Pdcd4 did not inhibit serum response element-dependent transcription, indicating specificity. In a Gal4 fusion assay, Pdcd4 specifically inhibited activation of c-Jun and c-Fos activation domains, but did not inhibit activation of JunB, JunD, Fra-1, or Fra-2. Gel mobility shift assay demonstrated that c-Jun is the major component detected in the AP-1 complex in RT101 cells. Previous studies suggested that AP-1 activity is required for maintaining the transformed phenotype in RT101 cells. Thus, Pdcd4 suppresses tumor phenotype by inhibiting AP-1-dependent transcription, possibly through inhibiting c-Jun and c-Fos activation.	Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, HS (corresponding author), Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Gene Regulat Sect,Bldg 567,Rm 180, Frederick, MD 21702 USA.	hyang@ncifcrf.gov	Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NATIONAL CANCER INSTITUTE [Z01BC010026, ZIABC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Colburn N H, 1980, Carcinog Compr Surv, V5, P33; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Hsu TC, 2001, CANCER RES, V61, P4160; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; KAZUMI S, 2002, ONCOGENE, V21, P2181; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; RAPP UR, 1994, ONCOGENE, V9, P3493; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Svitkin YV, 2001, RNA, V7, P1743; TAKAHASHI K, 1986, CANCER RES, V46, P5923; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	42	142	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3712	3720		10.1038/sj.onc.1206433	http://dx.doi.org/10.1038/sj.onc.1206433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802278				2022-12-25	WOS:000183551000005
J	Koo, JW; Park, CH; Choi, SH; Kim, NJ; Kim, HS; Choe, JC; Suh, YH				Koo, JW; Park, CH; Choi, SH; Kim, NJ; Kim, HS; Choe, JC; Suh, YH			Postnatal environment can counteract prenatal effects on cognitive ability, cell proliferation, and synaptic protein expression	FASEB JOURNAL			English	Article						prenatal environment; enrichment; stress	ADULT-RAT HIPPOCAMPUS; SPONTANEOUS-ALTERNATION BEHAVIOR; DENTATE GYRUS; ANTIDEPRESSANT TREATMENT; ENRICHED ENVIRONMENT; NEUROTROPHIC FACTOR; ADHESION MOLECULES; INDUCED IMPAIRMENT; ALCOHOL EXPOSURE; SPATIAL MEMORY	Many environmental factors during the pre- or postnatal period can affect an individual's cognitive function and neural development throughout life. Little is known, however, about the combined effects of the pre- and postnatal environments on cognitive function of adult offspring and structural alterations in the adult brain. In this study, we confirmed that pre- or postnatal stress impaired learning and memory performance of rats. Conversely, pre- or postnatal enriched housing improved behavioral performance. These experience-dependent behavioral alterations were consistent with changes in 5-bromo-2'-deoxyuridine-labeled cell number in the granule cell layer of the hippocampus and in the expression level of synaptic markers such as neuronal cell adhesion molecule and synaptophysin, and expression of a neurotrophic factor, brain-derived neurotrophic factor. Postnatal stress appeared to have no influence on cell proliferation, however. We did find that postnatal environment could attenuate prenatal effects partly via a longitudinal cross-housing study, in which pups born to mothers housed under enriched conditions were reared under stressful conditions and vice versa. These results suggest that postnatal environmental manipulations can counteract the cognitive alterations in early adulthood and the structural changes in the young adult brain induced by prenatal experience.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Natl Creat Res Initiat Ctr Alzheimers Dementia, 28 Youngon Dong, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Berman RF, 1996, ALCOHOL, V13, P209, DOI 10.1016/0741-8329(95)02049-7; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; Duman RS, 1999, BIOL PSYCHIAT, V46, P1181, DOI 10.1016/S0006-3223(99)00177-8; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Graham KS, 1999, CURR OPIN NEUROBIOL, V9, P245, DOI 10.1016/S0959-4388(99)80035-X; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; JORGENSEN OS, 1995, NEUROCHEM RES, V20, P533, DOI 10.1007/BF01694535; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KIYONO S, 1985, PHYSIOL BEHAV, V34, P431, DOI 10.1016/0031-9384(85)90207-0; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Liu JL, 1998, J NEUROSCI, V18, P7768; Lordi B, 1997, PHYSIOL BEHAV, V62, P1087, DOI 10.1016/S0031-9384(97)00261-8; Magarinos AM, 1997, P NATL ACAD SCI USA, V94, P14002, DOI 10.1073/pnas.94.25.14002; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nakamura H, 1999, J NEUROSCI RES, V56, P307; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Parent JM, 1997, J NEUROSCI, V17, P3727; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rampon C, 2000, HIPPOCAMPUS, V10, P605, DOI 10.1002/1098-1063(2000)10:5<605::AID-HIPO11>3.0.CO;2-3; Rema V, 1999, J NEUROSCI, V19, P10993, DOI 10.1523/JNEUROSCI.19-24-10993.1999; Roy NS, 2000, NAT MED, V6, P271; Saffell JL, 1995, MOL CELL NEUROSCI, V6, P521, DOI 10.1006/mcne.1995.0004; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; SHIOTA K, 1989, BIOL NEONATE, V56, P6; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Vallee M, 1997, J NEUROSCI, V17, P2626; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; WALAAS SI, 1988, SYNAPSE, V2, P516, DOI 10.1002/syn.890020507; Weinstock M, 1997, NEUROSCI BIOBEHAV R, V21, P1, DOI 10.1016/S0149-7634(96)00014-0; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460	56	116	124	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1556	+		10.1096/fj.02-1032fje	http://dx.doi.org/10.1096/fj.02-1032fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824278				2022-12-25	WOS:000183818000040
J	Sengupta, S; Xiao, YJ; Xu, Y				Sengupta, S; Xiao, YJ; Xu, Y			A novel laminin-induced lysophosphatidic acid autocrine loop in the migration of ovarian	FASEB JOURNAL			English	Article						LPA; ovarian cancer; cell migration; beta(1) integrin	CELL-ADHESION MOLECULES; LYSOPHOSPHOLIPASE-D; EPITHELIAL TUMORS; PROTEIN-KINASE; CANCER; EXPRESSION; GROWTH; CARCINOMA; INTEGRIN; RECEPTORS	We have reported previously that levels of lysophosphatidic acid (LPA) are elevated in the blood and ascites from patients with ovarian cancer. LPA stimulates proliferation of ovarian cancer cells and has been proposed as an autocrine growth factor. Here, we show that a novel autocrine loop of LPA promotes the imigration of ovarian cancer cells, which is a critical step of tumor metastasis. We report that laminin, but not other extracellular matrix proteins, induces LPA production in ovarian cancer cells. A neutralizing antibody against beta(1) integrin and a calcium-independent phospholipase A(2)-specific inhibitor, HELSS, block both LPA production and the haptotactic activity of laminin. Exogenously added LPA restores the migratory ability of HEY ovarian cancer cells to laminin. These data suggest that laminin-induced cell migration is mediated by LPA. We further show that a specific receptor for LPA, LPA(3), is required for mediating the chemotactic activity of LPA. In addition, we show that cytosolic PLA(2) is required for cell migration and its activation is phosphatidylinositol-3 kinase-dependent. These findings have revealed a new mechanism of crosstalk between a beta(1) integrin receptor and a G protein-coupled receptor.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Obstet & Gynecol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org						Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BARTOLAZZI A, 1993, ANTICANCER RES, V13, P1; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Buczek-Thomas JA, 1998, CELL SIGNAL, V10, P55, DOI 10.1016/S0898-6568(97)00074-0; BYERS LJ, 1995, CANCER LETT, V88, P67, DOI 10.1016/0304-3835(94)03625-S; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Capo-Chichi CD, 2002, CANCER-AM CANCER SOC, V95, P1802, DOI 10.1002/cncr.10870; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Casey RC, 2000, CLIN EXP METASTAS, V18, P67, DOI 10.1023/A:1026519016213; CATTERALL JB, 1994, CANCER LETT, V87, P199, DOI 10.1016/0304-3835(94)90223-2; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Erickson JR, 2001, PROSTAG OTH LIPID M, V64, P63, DOI 10.1016/S0090-6980(01)00100-9; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Ito H, 1997, DIAGN CYTOPATHOL, V16, P500, DOI 10.1002/(SICI)1097-0339(199706)16:6<500::AID-DC6>3.0.CO;2-D; Kuwashima Y., 1995, European Journal of Gynaecological Oncology, V16, P181; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; Lu J, 2002, J LIPID RES, V43, P463; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Maatta M, 2001, J HISTOCHEM CYTOCHEM, V49, P711; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; MIYASAKA M, 1995, CLIN ORTHOP RELAT R, V312, P10; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nelson PR, 1996, J VASC SURG, V24, P25, DOI 10.1016/S0741-5214(96)70141-6; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; Plopper George E., 2000, Molecular Cell Biology Research Communications, V4, P129, DOI 10.1006/mcbr.2001.0267; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2001, J EXP CLIN CANC RES, V20, P585; Sengupta S, 2000, J EXP CLIN CANC RES, V19, P81; Shen ZZ, 2001, GYNECOL ONCOL, V83, P25, DOI 10.1006/gyno.2001.6357; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Silfani TN, 2002, ARCH BIOCHEM BIOPHYS, V402, P84, DOI 10.1016/S0003-9861(02)00066-8; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; XU Y, 1997, OVARIAN CANC, V5, P109; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yoshida Y, 2001, INT J ONCOL, V18, P913	57	74	78	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1570	+		10.1096/fj.02-1145fje	http://dx.doi.org/10.1096/fj.02-1145fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824286				2022-12-25	WOS:000183818000036
J	Suzuki, H; Wu, JH; Hossain, K; Ohhata, T; Du, J; Akhand, AA; Hayakawa, A; Kimura, H; Hagiwara, M; Nakashima, I				Suzuki, H; Wu, JH; Hossain, K; Ohhata, T; Du, J; Akhand, AA; Hayakawa, A; Kimura, H; Hagiwara, M; Nakashima, I			Involvement of MKK6 in TCRa beta(int)CD69(lo): a target population for apoptotic cell death in thymocytes	FASEB JOURNAL			English	Article							KINASE SIGNALING PATHWAYS; NEGATIVE SELECTION; POSITIVE SELECTION; T-LYMPHOCYTES; STEM-CELLS; IN-VIVO; MAP; DIFFERENTIATION; RESPONSES; MICE	By analyzing real-time caspase activity and DNA fragmentation in live thymocytes, we found that apoptosis occurs predominantly in a TCRalphabeta(int/hi)CD69(lo) population. The number of caspase-active cells and DNA-fragmented cells in MKK6-deficient mice, which were originally generated in our laboratory by gene targeting, was decreased in the TCRalphabeta(int)CD69(lo) population but not in the TCRalphabeta(hi)CD69(lo) population. The percentage of caspase-active cells in the H-Y-specific TCRint population was more clearly decreased in male MKK6-deficient H-Y TCR-transgenic mice. Furthermore, the absolute number of TCR(hi)CD4(lo)CD8(lo) cells, which are developmentally next to TCR(int)CD4(hi)CD8(hi) cells, was increased in MKK6-deficient H-Y TCR-transgenic mice. Deletion of TCRalphabeta(int)CD4(hi)CD8(hi) cells by injecting antigenic lymphocytic chorio-meningitis virus (LCMV) peptide into LCMV-specific TCR-transgenic mice was incomplete in MKK6-deficient mice. Cellular death of TCRalphabeta(int) fetal thymocytes induced by adding an antigenic peptide into an in vitro fetal thymic organ culture system was also diminished in MKK6-deficient TCR-transgenic thymi. These results indicate that MKK6 plays a role in the developing thymocytes, especially in the population of TCRalphabeta(int)CD69(lo) cells, which possibly undergo negative selection.	Nagoya Univ, Grad Sch Med, Dept Immunol, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Res & Educ, Dept Equipment, Aichi, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Aichi, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo, Japan	Nagoya University; Nagoya University; Nagoya University; Tokyo Medical & Dental University (TMDU)	Suzuki, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Aichi 4668550, Japan.	k46200a@nucc.cc.nagoya-u.ac.jp		Hossain, Khaled/0000-0003-0878-915X; Ohhata, Tatsuya/0000-0003-1124-6164				Akashi K, 1998, IMMUNOL REV, V165, P13, DOI 10.1111/j.1600-065X.1998.tb01226.x; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Dautigny N, 1999, J IMMUNOL, V162, P1294; Hare KJ, 2002, IMMUNOLOGY, V105, P163, DOI 10.1046/j.1365-2567.2002.01364.x; Jiang D, 1999, CELL DEATH DIFFER, V6, P402, DOI 10.1038/sj.cdd.4400513; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Page DM, 1998, J IMMUNOL, V160, P120; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Sant'Angelo DB, 1998, IMMUNITY, V9, P179, DOI 10.1016/S1074-7613(00)80600-7; Sen J, 1996, J IMMUNOL, V156, P4535; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683	21	5	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1538	+		10.1096/fj.02-0869fje	http://dx.doi.org/10.1096/fj.02-0869fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824301				2022-12-25	WOS:000183818000043
J	DeSousa, D; Mukhopadhyay, M; Pelka, P; Zhao, XL; Dey, BK; Robert, V; Pelisson, A; Bucheton, A; Campos, AR				DeSousa, D; Mukhopadhyay, M; Pelka, P; Zhao, XL; Dey, BK; Robert, V; Pelisson, A; Bucheton, A; Campos, AR			A novel double-stranded RNA-binding protein, disco interacting protein 1 (DIP1), contributes to cell fate decisions during Drosophila development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME ADAR1; ACTIVATED T-CELLS; C-TERMINAL DOMAIN; NUCLEAR-MATRIX; DISTAL-LESS; DISCONNECTED GENE; POLYMERASE-II; EGF RECEPTOR; TRANSCRIPTION; EXPRESSION	We report the identification of the Disco Interacting Protein 1 (DIP1) gene isolated in a yeast interaction trap screen using the zinc finger protein disconnected ( disco) as a bait. DIP1 encodes a protein containing two double-stranded RNA binding domains (dsRBD). Consistent with the presence of dsRBD, DIP1 binds dsRNA or structured RNAs in Northwestern assays. DIP1 is found in nuclear subdomains resembling speckles known to accumulate transcription and splicing factors. In early embryos, nuclear localization of DIP1 protein coincides with the onset of zygotic gene expression. Later in development DIP1 expression is decreased in dividing cells in different tissues. Overexpression of DIP1 in the eye-antennal imaginal disc, early in embryonic and larval development, causes the formation of supernumerary structures in the head capsule. A role for DIP1 in epigenetic mechanisms that lead to the establishment and/or maintenance of cell fate specification is discussed.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; CNRS, Inst Genet Humaine, F-34396 Montpellier 5, France	McMaster University; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Campos, AR (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	camposa@mcmaster.ca	Robert, Valerie/N-9102-2018	Dey, Bijan/0000-0001-9386-2475				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BESSA J, 2002, GENE DEV, V16, P2145; Birchler JA, 2001, DEV BIOL, V234, P275, DOI 10.1006/dbio.2001.0262; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; CAMPOS AR, 1995, J NEUROBIOL, V28, P313, DOI 10.1002/neu.480280305; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; COHEN SM, 1993, DEV DROSOPHILA MELAN, V1, P747; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dirks RW, 1997, J CELL SCI, V110, P515; Dong PDS, 2002, DEVELOPMENT, V129, P1967; Dong PDS, 2000, DEVELOPMENT, V127, P209; Donzeau M, 1997, J VIROL, V71, P2628, DOI 10.1128/JVI.71.4.2628-2635.1997; Doyle M, 2002, J STRUCT BIOL, V140, P147, DOI 10.1016/S1047-8477(02)00544-0; Eckmann CR, 1999, J CELL BIOL, V144, P603, DOI 10.1083/jcb.144.4.603; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831; FOE VE, 1989, DEVELOPMENT, V107, P1; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hazelett DJ, 1998, DEVELOPMENT, V125, P3741; HEILIG JS, 1991, EMBO J, V10, P809, DOI 10.1002/j.1460-2075.1991.tb08013.x; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; Ho CK, 1996, J VIROL, V70, P2611, DOI 10.1128/JVI.70.4.2611-2614.1996; KAO PN, 1994, J BIOL CHEM, V269, P20691; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; Kumar JP, 2001, CELL, V104, P687, DOI 10.1016/S0092-8674(01)00265-3; Lallena MJ, 1997, J CELL SCI, V110, P239; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; Lee KJ, 1999, DEV BIOL, V214, P385, DOI 10.1006/dbio.1999.9420; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; Morata G, 1999, DEVELOPMENT, V126, P2823; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; Panganiban G, 2000, DEV DYNAM, V218, P554, DOI 10.1002/1097-0177(200008)218:4<554::AID-DVDY1023>3.0.CO;2-#; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; PELKA P, 2000, THESIS MCMASTER U HA; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; Robert V, 2001, GENETICS, V158, P701; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; STEHBLOW A, 2002, MOL BIOL CELL, V13, P3822; Stein GS, 1998, J CELL BIOCHEM, V70, P200; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	71	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38040	38050		10.1074/jbc.M303512200	http://dx.doi.org/10.1074/jbc.M303512200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12829713	hybrid			2022-12-25	WOS:000185437200126
J	Christensen, AE; Selheim, F; de Rooij, J; Dremier, S; Schwede, F; Dao, KK; Martinez, A; Maenhaut, C; Bos, JL; Genieser, HG; Doskeland, SO				Christensen, AE; Selheim, F; de Rooij, J; Dremier, S; Schwede, F; Dao, KK; Martinez, A; Maenhaut, C; Bos, JL; Genieser, HG; Doskeland, SO			cAMP analog mapping of Epac1 and cAMP kinase - Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; REGULATORY SUBUNIT; SIGNALING PATHWAYS; BINDING; ACTIVATION; RAP1; LOCALIZATION; INHIBITION; EXPRESSION	Little is known about the relative role of cAMP-dependent protein kinase (cAPK) and guanine exchange factor directly activated by cAMP ( Epac) as mediators of cAMP action. We tested cAMP analogs for ability to selectively activate Epac1 or cAPK and discriminate between the binding sites of Epac and of cAPKI and cAPKII. We found that commonly used cAMP analogs, like 8-Br-cAMP and 8-pCPT-cAMP, activate Epac and cAPK equally as well as cAMP, i.e. were full agonists. In contrast, 6-modified cAMP analogs, like N-6-benzoyl-cAMP, were inefficient Epac activators and full cAPK activators. Analogs modified in the 2'-position of the ribose induced stronger Epac1 activation than cAMP but were only partial agonists for cAPK. 2'-O-Alkyl substitution of cAMP improved Epac/cAPK binding selectivity 10-100-fold. Phenylthio substituents in position 8, particularly with MeO- or Cl- in p-position, enhanced the Epac/cAPK selectivity even more. The combination of 8-pCPT- and 2'-O-methyl substitutions improved the Epac/cAPK binding selectivity about three orders of magnitude. The cAPK selectivity of 6-substituted cAMP analogs, the preferential inhibition of cAPK by moderate concentrations of Rp-cAMPS analogs, and the Epac selectivity of 8-pCPT-2'-O-methyl-cAMP was also demonstrated in intact cells. Using these compounds to selectively modulate Epac and cAPK in PC-12 cells, we observed that analogs selectively activating Epac synergized strongly with cAPK specific analogs to induce neurite outgrowth. We therefore conclude that cAMP-induced neurite outgrowth is mediated by both Epac and cAPK.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; BIOLOG Life Sci Inst, D-28071 Bremen, Germany	University of Bergen; University of Bergen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Doskeland, SO (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Jonas Lies Vei 91, N-5009 Bergen, Norway.	stein.doskeland@iac.uib.no	de rooij, johan/C-1325-2019; Martinez, Aurora/M-3088-2019	Martinez, Aurora/0000-0003-1643-6506; Genieser, Hans-Gottfried/0000-0002-4904-5790; Doskeland, Stein Ove/0000-0002-4009-4756; de rooij, johan/0000-0001-6101-7875				Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHRISTENSEN AE, 2001, FASEB J, V15, P3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; ENGELS J, 1977, J MED CHEM, V20, P907, DOI 10.1021/jm00217a008; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FURUTA T, 1993, J CHEM SOC PERK T 1, P3139, DOI 10.1039/p19930003139; GENIESER HG, 1989, SYNTHESIS-STUTTGART, P53; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kopperud R, 2002, J BIOL CHEM, V277, P13443, DOI 10.1074/jbc.M109869200; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MILLER JP, 1973, BIOCHEMISTRY-US, V12, P5310, DOI 10.1021/bi00750a014; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; Schwede F, 2000, BIOCHEMISTRY-US, V39, P8803, DOI 10.1021/bi000304y; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Ueno H, 2001, GENOMICS, V78, P91, DOI 10.1006/geno.2001.6641; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	42	200	205	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35394	35402		10.1074/jbc.M302179200	http://dx.doi.org/10.1074/jbc.M302179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819211	hybrid			2022-12-25	WOS:000185164400079
J	Li, YT; Maskos, K; Chou, CW; Cole, RB; Li, SC				Li, YT; Maskos, K; Chou, CW; Cole, RB; Li, SC			Presence of an unusual GM2 derivative, taurine-conjugated GM2, in Tay-Sachs brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE AMINO-ACIDS; C-13 ASSIGNMENTS; H-1-NMR SPECTRA; SPECTROSCOPY; GANGLIOSIDES; NMR; CHROMATOGRAPHY; SENSITIVITY; GM2-GANGLIOSIDOSIS; RESOLUTION	Tay-Sachs disease (TSD) is a classical glycosphingolipid (GSL) storage disease. Although the genetic and biochemical bases for a massive cerebral accumulation of ganglioside GM2 in TSD have been well established, the mechanism for the neural dysfunction in TSD remains elusive. Upon analysis of GSLs from a variant B TS brain, we have detected a novel GSL that has not been previously revealed. We have isolated this GSL in pure form. Using NMR spectroscopy, mass spectrometry, and chemical synthesis, the structure of this unusual GSL was established to be a taurine-conjugated GM2 (tauro-GM2) in which the carboxyl group of N-acetylneuraminic acid was amidated by taurine. Using a rabbit anti-tauro-GM2 serum, we also detected the presence of tauro-GM2 in three other small brain samples from one variant B and two variant O TSD patients. On the other hand, tauro-GM2 was not found in three normal human brain samples. The presence of tauro-GM2 in TS brains, but not in normal brains, indicates the possible association of this unusual GM2 derivative with the pathogenesis of TSD. Our findings point to taurine conjugation as a heretofore unelucidated mechanism for TS brain to cope with water-insoluble GM2.	Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Coordinated Instrumentat Facil, New Orleans, LA 70118 USA; Univ New Orleans, Dept Chem, New Orleans, LA 70148 USA	Tulane University; Tulane University; University of Louisiana System; University of New Orleans	Li, YT (corresponding author), Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, New Orleans, LA 70112 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD083284] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-8-3284] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT A, 1950, BIOCHEM J, V47, P531, DOI 10.1042/bj0470531; Anderson K, 2000, ANAL BIOCHEM, V287, P337, DOI 10.1006/abio.2000.4829; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; Haverkamp J., 1982, SIALIC ACIDS CHEM ME, P127; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; HWANG TL, 1992, J AM CHEM SOC, V114, P3157, DOI 10.1021/ja00034a083; KAUFFMAN FC, 1987, FASEB J, V46, P2434; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KING EJ, 1953, J AM CHEM SOC, V75, P2204, DOI 10.1021/ja01105a053; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; LEFAUCONNIER JM, 1976, BRAIN RES, V117, P105, DOI 10.1016/0006-8993(76)90559-X; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANSSON JE, 1985, J CHROMATOGR, V322, P465, DOI 10.1016/S0021-9673(01)97712-X; MINN A, 1991, BRAIN RES REV, V16, P65, DOI 10.1016/0165-0173(91)90020-9; MOMOI T, 1976, BIOCHIM BIOPHYS ACTA, V441, P488; Momose T, 1997, LIPIDS, V32, P775, DOI 10.1007/s11745-997-0099-8; MRAZ W, 1980, H-S Z PHYSIOL CHEM, V361, P177, DOI 10.1515/bchm2.1980.361.1.177; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PERRY TL, 1971, J NEUROCHEM, V18, P521, DOI 10.1111/j.1471-4159.1971.tb11980.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SNYDER PD, 1972, J LIPID RES, V13, P128; STURMAN JA, 1975, J NEUROCHEM, V25, P831, DOI 10.1111/j.1471-4159.1975.tb04414.x; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; SUZUKI K, 1970, NEUROLOGY, V20, P190, DOI 10.1212/WNL.20.2.190; SUZUKI Y, 1971, NEUROLOGY, V21, P313, DOI 10.1212/WNL.21.4.313; SVENNERHOLM L., 1956, ACTA SOC MED UPSALIENSIS, V61, P75; Triggs-Raine B, 2001, ADV GENET, V44, P199; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; YAMADA S, 1975, J AM CHEM SOC, V97, P7714; YU RK, 1983, BRAIN RES, V275, P47, DOI 10.1016/0006-8993(83)90415-8	40	8	8	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35286	35291		10.1074/jbc.M306126200	http://dx.doi.org/10.1074/jbc.M306126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829702	hybrid			2022-12-25	WOS:000185164400067
J	Friedman, J; Lad, L; Deshmukh, R; Li, HY; Wilks, A; Poulos, TL				Friedman, J; Lad, L; Deshmukh, R; Li, HY; Wilks, A; Poulos, TL			Crystal structures of the NO- and CO-bound heme oxygenase from Neisseriae meningitidis - Implications for O-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ALPHA-MESO-HYDROXYHEME; CARBON-MONOXIDE; NITRIC-OXIDE; CORYNEBACTERIUM-DIPHTHERIAE; PATHOGENIC NEISSERIA; PROTEIN MODELS; HMU-O; DEGRADATION; COMPLEX	Heme oxygenases catalyze the oxidation of heme to biliverdin, carbon monoxide, and free iron while playing a critical role in mammalian heme homeostasis. Pathogenic bacteria such as Neisseriae meningitidis also produce heme oxygenase as part of a mechanism to mine host iron. The key step in heme oxidation is the regioselective oxidation of the heme alpha-meso-carbon by an activated Fe(III)-OOH complex. The structures of various diatomic ligands bound to the heme iron can mimic the dioxygen complex and provide important insights on the mechanism of O-2 activation. Here we report the crystal structures of N. meningitidis heme oxygenase (nm-HO) in the Fe(II), Fe(II)-CO, and Fe(II)-NO states and compare these to the NO complex of human heme oxygenase-1 ( Lad, L., Wang, J., Li, H., Friedman, J., Bhaskar, B., Ortiz de Montellano, P. R., and Poulos, T. L. (2003) J. Mol. Biol. 330, 527 - 538). Coordination of NO or CO results in a reorientation of Arg-77 that enables Arg-77 to participate in an active site H-bonded network involving a series of water molecules. One of these water molecules directly H-bonds to the Fe( II)- linked ligand and very likely serves as the proton source required for oxygen activation. Although the active site residues differ between nm-HO and human HO-1, the close similarity in the H-bonded water network suggests a common mechanism shared by all heme oxygenases.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University System of Maryland; University of Maryland Baltimore	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NIAID NIH HHS [AI48551] Funding Source: Medline; NIGMS NIH HHS [GM33688] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Ciotti M, 1998, BIOCHEMISTRY-US, V37, P11018, DOI 10.1021/bi980747q; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P3333, DOI 10.1073/pnas.73.10.3333; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; Ingi T, 1995, J NEUROSCI, V15, P8214; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sigfridsson E, 2002, J INORG BIOCHEM, V91, P101, DOI 10.1016/S0162-0134(02)00426-9; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; Spiro TG, 2001, CURR OPIN CHEM BIOL, V5, P715, DOI 10.1016/S1367-5931(01)00271-X; Stojiljkovic I, 1996, J BACTERIOL, V178, P4670, DOI 10.1128/jb.178.15.4670-4678.1996; Stojiljkovic I, 1997, J BACTERIOL, V179, P805, DOI 10.1128/jb.179.3.805-812.1997; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1994, J BIOL CHEM, V269, P29553; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	37	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34654	34659		10.1074/jbc.M302985200	http://dx.doi.org/10.1074/jbc.M302985200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819228	hybrid			2022-12-25	WOS:000185047500126
J	Gianni, M; Tarrade, A; Nigro, EA; Garattini, E; Rochette-Egly, C				Gianni, M; Tarrade, A; Nigro, EA; Garattini, E; Rochette-Egly, C			The AF-1 and AF-2 domains of RAR gamma 2 and RXR alpha cooperate for triggering the transactivation and the degradation of RAR gamma 2/RXR alpha heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; ACTIVATION FUNCTIONS AF-1; LIGAND-BINDING DOMAINS; BREAST-CANCER CELLS; NUCLEAR RECEPTORS; X-RECEPTORS; RAR-ALPHA; F9 CELLS; TRANSCRIPTIONAL ACTIVITY; 26S PROTEASOME	In eukaryotic cells, liganded RARgamma2/RXRalpha heterodimers activate the transcription of retinoic acid ( RA) target genes and then are degraded through the ubiquitin-proteasome pathway. In this study, we dissected the role of the RARgamma2 and RXRalpha partners as well as of their respective AF-1 and AF-2 domains in the processes of transactivation and degradation. RARgamma2 is the "engine" initiating transcription and its own degradation subsequent to ligand binding. Integrity of its AF-2 domain and phosphorylation of its AF-1 domain are required for both the degradation and the transactivation of the receptor. Deletion of the whole AF-1 domain does not impair these processes but shifts the receptor toward other proteolytic pathways through RXRalpha. In contrast, RXRalpha plays only a modulatory role, cooperating with RARgamma2 through its AF-2 domain and its phosphorylated AF-1 domain in both the transcription activity and the degradation of the RARgamma2/RXRalpha heterodimers. Our results underline that the AF-1 and AF-2 domains of each heterodimer partner cooperate with one other and that this cooperation is relevant for both the transcription and degradation processes.	ULP, INSERM, IGBMC, CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, France; Ist Ric Farmacol Mario Negri, Mol Biol Lab, I-20157 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rochette-Egly, C (corresponding author), ULP, INSERM, IGBMC, CNRS,UMR 7104, BP 10142, F-67404 Illkirch Graffenstaden, France.		Gianni, Maurizio/ABG-6322-2020; Garattini, Enrico/AAI-1998-2019; Nigro, Elisa Agnese/Z-5679-2019	Gianni, Maurizio/0000-0002-6945-708X; Nigro, Elisa Agnese/0000-0002-5806-9495; Garattini, Enrico/0000-0001-8983-886X				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bommer M, 2002, J BIOL CHEM, V277, P37961, DOI 10.1074/jbc.M206001200; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Depoix C, 2001, J BIOL CHEM, V276, P9452, DOI 10.1074/jbc.M008004200; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Laudet V., 2001, NUCL RECEPTOR FACTSB; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Osburn DL, 2001, MOL CELL BIOL, V21, P4909, DOI 10.1128/MCB.21.15.4909-4918.2001; Plassat JL, 2000, J CELL SCI, V113, P2887; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	43	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34458	34466		10.1074/jbc.M304952200	http://dx.doi.org/10.1074/jbc.M304952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824162	hybrid			2022-12-25	WOS:000185047500105
J	Baldwin, MR; Pullinger, GD; Lax, AJ				Baldwin, MR; Pullinger, GD; Lax, AJ			Pasteurella multocida toxin facilitates inositol phosphate formation by bombesin through tyrosine phosphorylation of G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; G-PROTEIN; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; DNA-SYNTHESIS; VASOPRESSIN; RECEPTOR; GROWTH; TRANSFORMATION; INVOLVEMENT	The intracellularly acting Pasteurella multocida toxin (PMT) is a potent mitogen that stimulates G(q)-dependent formation of inositol trisphosphate. We show that PMT, a nontoxic mutant of PMT (PMTC1165S), and bombesin each stimulate time-dependent phosphorylation of Galpha(q) at tyrosine 349. Although PMT and PMTC1165S each cause phosphorylation of Galpha(q), only the wild-type toxin activates G(q). Pretreatment of cells with wild-type or mutant PMT potentiated the formation of inositol phosphates stimulated by bombesin equally. These data show that PMT potentiates bombesin receptor signaling through tyrosine phosphorylation of G(q) and distinguishes between the two proposed models of G(q) activation, showing that tyrosine phosphorylation is not linked to receptor uncoupling.	Guys Hosp, Univ London Kings Coll, Inst Dent, Dept Microbiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lax, AJ (corresponding author), Guys Hosp, Univ London Kings Coll, Inst Dent, Dept Microbiol, Floor 28 Guys Tower, London SE1 9RT, England.			Lax, Alistair/0000-0002-1424-5071; Baldwin, Michael/0000-0002-7155-6271				BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KROOG GS, 1995, J BIOL CHEM, V270, P8217, DOI 10.1074/jbc.270.14.8217; Lax AJ, 2001, INT J MED MICROBIOL, V291, P261, DOI 10.1078/1438-4221-00129; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Panchalingam S, 2000, NEUROCHEM RES, V25, P759, DOI 10.1023/A:1007553004615; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1978, J CELL PHYSIOL, V97, P241, DOI 10.1002/jcp.1040970213; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; Umemori H, 1999, ONCOGENE, V18, P7399, DOI 10.1038/sj.onc.1203152; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Ward PN, 1998, INFECT IMMUN, V66, P5636, DOI 10.1128/IAI.66.12.5636-5642.1998; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	29	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32719	32725		10.1074/jbc.M303524200	http://dx.doi.org/10.1074/jbc.M303524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799383	hybrid			2022-12-25	WOS:000184901800030
J	Barbier, O; Duran-Sandoval, D; Pineda-Torra, I; Kosykh, V; Fruchart, JC; Staels, B				Barbier, O; Duran-Sandoval, D; Pineda-Torra, I; Kosykh, V; Fruchart, JC; Staels, B			Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; FARNESOID-X-RECEPTOR; PPAR-ALPHA; METABOLIZING-ENZYMES; POTENTIAL MECHANISM; NUCLEAR RECEPTORS; RESPONSE ELEMENT; HUMAN LIVER; INDUCTION; IDENTIFICATION	Glucuronidation, a major metabolic pathway for a large variety of endobiotics and xenobiotics, is catalyzed by enzymes belonging to the UDP-glucuronosyl-transferase (UGT) family. Among UGT enzymes, UGT2B4 conjugates a large variety of endogenous and exogenous molecules and is considered to be the major bile acid conjugating UGT enzyme in human liver. In the present study, we identify UGT2B4 as a novel target gene of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha), which mediates the hypolipidemic action of fibrates. Incubation of human hepatocytes or hepatoblastoma HepG2 and Huh7 cells with synthetic PPARalpha agonists, fenofibric acid, or Wy 14643 resulted in an increase of UGT2B4 mRNA levels. Furthermore, treatment of HepG2 cells with Wy 14643 induced the glucuronidation of hyodeoxycholic acid, a specific bile acid UGT2B4 substrate. Analysis of UGT2B mRNA and protein levels in PPARalpha wild type and null mice revealed that PPARalpha regulates both basal and fibrate-induced expression of these enzymes in rodents also. Finally, a PPAR response element was identified in the UGT2B4 promoter by site-directed mutagenesis and electromobility shift assays. These results demonstrate that PPARalpha agonists may control the catabolism of cytotoxic bile acids and reinforce recent data indicating that PPARalpha, which has been largely implicated in the control of lipid and cholesterol metabolism, is also an important modulator of the metabolism of endobiotics and xenobiotics in human hepatocytes.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Russian Cardiol Complex, Inst Expt Cardiol, Moscow 121552, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; National Medical Research Center of Cardiology	Staels, B (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Barbier, Olivier/0000-0002-3067-1134; Pineda Torra, Ines/0000-0002-7349-2208				Albert C, 2000, ENDOCRINOLOGY, V141, P2472, DOI 10.1210/en.141.7.2472; Albert C, 1999, ENDOCRINOLOGY, V140, P3292, DOI 10.1210/en.140.7.3292; ALME B, 1980, J STEROID BIOCHEM, V13, P907, DOI 10.1016/0022-4731(80)90164-8; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; BACK P, 1976, H-S Z PHYSIOL CHEM, V357, P213, DOI 10.1515/bchm2.1976.357.1.213; Barbier O, 2003, GASTROENTEROLOGY, V124, P1926, DOI 10.1016/S0016-5085(03)00388-3; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; BODE BP, 1995, HEPATOLOGY, V21, P511; Claudel T, 2002, J CLIN INVEST, V109, P961; Collett GP, 2000, CLIN CANCER RES, V6, P3241; Congiu M, 2002, DRUG METAB DISPOS, V30, P129, DOI 10.1124/dmd.30.2.129; COWEN AE, 1975, GASTROENTEROLOGY, V69, P67; De Tomassi A, 2002, J VIROL, V76, P7736, DOI 10.1128/JVI.76.15.7736-7746.2002; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DONOVAN JM, 1993, BIOCHIM BIOPHYS ACTA, V1182, P37, DOI 10.1016/0925-4439(93)90150-Y; Drewe J, 2000, BRIT J CLIN PHARMACO, V50, P237, DOI 10.1046/j.1365-2125.2000.00226.x; Dutton G.F., 1980, GLUCURONIDATION DRUG; Goodwin B, 2002, AM J PHYSIOL-GASTR L, V282, pG926, DOI 10.1152/ajpgi.00044.2002; HAUTANEN A, 1992, J STEROID BIOCHEM, V42, P433, DOI 10.1016/0960-0760(92)90149-D; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Huang LY, 2001, DRUG METAB DISPOS, V29, P634; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Jemnitz K, 2000, DRUG METAB DISPOS, V28, P34; Jung D, 2002, J BIOL CHEM, V277, P30559, DOI 10.1074/jbc.M203511200; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; Kockx M, 1999, BLOOD, V93, P2991; Kok T, 2003, BIOCHEM J, V369, P539, DOI 10.1042/BJ20020981; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; KUIPERS F, 1989, J LIPID RES, V30, P1835; Kwon Y, 1996, J PHARM SCI, V85, P935, DOI 10.1021/js9600540; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Levesque B, 1999, PHARMACOGENETICS, V9, P207; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Mano N, 2002, STEROIDS, V67, P257, DOI 10.1016/S0039-128X(01)00162-3; Marrapodi M, 2000, J LIPID RES, V41, P514; MARSCHALL HU, 1992, J CLIN INVEST, V89, P1981, DOI 10.1172/JCI115806; Owsley E, 2003, BIOCHEM BIOPH RES CO, V304, P191, DOI 10.1016/S0006-291X(03)00551-5; PILLOT T, 1993, J BIOL CHEM, V268, P25636; Post SM, 2001, ARTERIOSCL THROM VAS, V21, P1840, DOI 10.1161/hq1101.098228; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Radominska-Pandya A, 1998, BBA-LIPID LIPID MET, V1394, P199, DOI 10.1016/S0005-2760(98)00115-5; Rolo AP, 2002, TOXICOL LETT, V126, P197, DOI 10.1016/S0378-4274(01)00464-7; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Sarbu C, 2001, J CHROMATOGR A, V917, P361, DOI 10.1016/S0021-9673(01)00726-9; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; TAKIKAWA H, 1983, DIGESTION, V27, P189, DOI 10.1159/000198952; Torra IP, 2002, MOL ENDOCRINOL, V16, P1013; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; Turgeon D, 2001, ENDOCRINOLOGY, V142, P778, DOI 10.1210/en.142.2.778; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; ZIMNIAK P, 1989, J LIPID RES, V30, P907	63	118	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32852	32860		10.1074/jbc.M305361200	http://dx.doi.org/10.1074/jbc.M305361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810707	hybrid			2022-12-25	WOS:000184901800046
J	He, XX; Okino, N; Dhami, R; Dagan, A; Gatt, S; Schulze, H; Sandhoff, K; Schuchman, EH				He, XX; Okino, N; Dhami, R; Dagan, A; Gatt, S; Schulze, H; Sandhoff, K; Schuchman, EH			Purification and characterization of recombinant, human acid ceramidase - Catalytic reactions and interactions with acid sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIQUID-CHROMATOGRAPHIC ASSAY; MOLECULAR-CLONING; ALKALINE CERAMIDASE; NEUTRAL CERAMIDASE; ENZYMATIC-HYDROLYSIS; STORAGE-DISEASE; MOUSE; IDENTIFICATION	Human acid ceramidase was overexpressed in Chinese hamster ovary cells by amplification of the transfected, full-length cDNA. The majority of the overexpressed enzyme was secreted into the culture media and purified to apparent homogeneity. The purified protein contained the same 13- (alpha) and 40 (beta)-kDa subunits as human acid ceramidase from natural sources, had an acidic pH optimum (4.5), and followed normal Michaelis-Menten kinetics using C-14- and BODIPY-labeled C-12-ceramide as substrates. Deglycosylation studies showed that the recombinant enzyme contained mostly "high mannose" type oligosaccharides and that two distinct beta-subunits were present. Amino acid sequencing of these subunit polypeptides revealed a single N terminus, suggesting that the similar to2-4-kDa molecular mass difference was likely due to C-terminal processing. The purified enzyme also catalyzed ceramide synthesis in vitro using C-14-labeled C12 fatty acid and sphingosine as substrates. Surprisingly, we found that media from the overexpressing hamster cells had increased acid sphingomyelinase activity and that this activity could be coprecipitated with acid ceramidase using anti-ceramidase antibodies. Overexpression of acid ceramidase in normal human skin fibroblasts also led to enhanced acid sphingomyelinase secretion, but this was not observed in Niemann-Pick disease cells. RNA studies showed that this increased activity was not due to overexpression of the endogenous acid sphingomyelinase gene. Uptake studies using mouse macrophages revealed rapid internalization of the acid ceramidase activity from the hamster cell media but not acid sphingomyelinase. These studies provide new insights into acid ceramidase and the related lipid hydrolase, acid sphingomyelinase.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Carl C Ichan Inst Gene Therapy & Mol Med, New York, NY 10029 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hebrew University of Jerusalem; University of Bonn	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 14-98,1425 Madison Ave,Rm 14-20A, New York, NY 10029 USA.	Edward.Schuchman@mssm.edu	Okino, Nozomu/AAY-2635-2021		FIC NIH HHS [5R03 TW 01372] Funding Source: Medline; NIDDK NIH HHS [R01 DK54830] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar J, 2001, HUM MUTAT, V17, P199, DOI 10.1002/humu.5; Berg T, 2001, MOL GENET METAB, V73, P18, DOI 10.1006/mgme.2001.3173; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Dagan A, 2000, METHOD ENZYMOL, V312, P293; Dhami R, 2001, LAB INVEST, V81, P987, DOI 10.1038/labinvest.3780311; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; He XX, 2003, ANAL BIOCHEM, V314, P116, DOI 10.1016/S0003-2697(02)00629-2; He XX, 1999, ANAL BIOCHEM, V274, P264, DOI 10.1006/abio.1999.4284; He XX, 1999, MOL GENET METAB, V67, P106, DOI 10.1006/mgme.1999.2860; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; KRESS BC, 1978, CLIN CHIM ACTA, V85, P23, DOI 10.1016/0009-8981(78)90096-7; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Linke, 2001, METABOLIC MOL BASES, P3573; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Martiniuk F, 2000, BIOCHEM BIOPH RES CO, V276, P917, DOI 10.1006/bbrc.2000.3555; MCGOVERN MM, 1981, ENZYME, V26, P206, DOI 10.1159/000459176; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; MUNAKATA H, 1986, BIOCHEM MED METAB B, V35, P179, DOI 10.1016/0885-4505(86)90072-1; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; QUINTERN LE, 1989, BIOCHIM BIOPHYS ACTA, V1003, P121, DOI 10.1016/0005-2760(89)90244-0; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Zhao KW, 2000, PROTEIN EXPRES PURIF, V19, P202, DOI 10.1006/prep.2000.1230	42	80	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32978	32986		10.1074/jbc.M301936200	http://dx.doi.org/10.1074/jbc.M301936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815059	hybrid			2022-12-25	WOS:000184901800061
J	Kambhampati, S; Li, YZ; Verma, A; Sassano, A; Majchrzak, B; Deb, DK; Parmar, S; Giafis, N; Kalvakolanu, DV; Rahman, A; Uddin, S; Minucci, S; Tallman, MS; Fish, EN; Platanias, LC				Kambhampati, S; Li, YZ; Verma, A; Sassano, A; Majchrzak, B; Deb, DK; Parmar, S; Giafis, N; Kalvakolanu, DV; Rahman, A; Uddin, S; Minucci, S; Tallman, MS; Fish, EN; Platanias, LC			Activation of protein kinase C delta by all-trans-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER CELLS; INTERFERON-ALPHA; INDUCED APOPTOSIS; GENE-EXPRESSION; PKC-DELTA; GROWTH-INHIBITION; I INTERFERONS; PHORBOL ESTER; UP-REGULATION	All-trans-retinoic acid (RA) is a potent inhibitor of leukemia cell proliferation and induces differentiation of acute promyelocytic leukemia cells in vitro and in vivo. For RA to induce its biological effects in target cells, binding to specific retinoic acid nuclear receptors is required. The resulting complexes bind to RA-responsive elements (RAREs) in the promoters of RA-inducible genes to initiate gene transcription and to generate protein products that mediate the biological effects of RA. In this report, we provide evidence that a member of the protein kinase C (PKC) family of proteins, PKCdelta, is activated during RA treatment of the NB-4 and HL-60 acute myeloid leukemia cell lines as well as the MCF-7 breast cancer cell line. Such RA-dependent phosphorylation was also observed in primary acute promyelocytic leukemia cells and resulted in activation of the kinase domain of PKCdelta. In studies aimed at understanding the functional relevance of PKCdelta in the induction of RA responses, we found that pharmacological inhibition of PKCdelta (but not of other PKC isoforms) diminished RA-dependent gene transcription via RAREs. On the other hand, overexpression of a constitutively active form of the kinase strongly enhanced RA-dependent gene transcription via RAREs. Gel shift assays and chromatin immunoprecipitation studies demonstrated that PKCdelta associated with retinoic acid receptor-alpha and was present in an RA-inducible protein complex that bound to RAREs. Pharmacological inhibition of PKCdelta activity abrogated the induction of cell differentiation and growth inhibition of NB-4 blast cells, demonstrating that its function is required for such effects. Altogether, our data provide strong evidence that PKCdelta is activated in an RA-dependent manner and plays a critical role in the generation of the biological effects of RA in malignant cells.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Affairs Med Ctr, Chicago, IL 60611 USA; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Univ Hlth Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Univ Chicago, Ben May Canc Inst, Chicago, IL 60637 USA; Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Rochester; University of Chicago; University of Chicago; University System of Maryland; University of Maryland Baltimore; IRCCS European Institute of Oncology (IEO)	Platanias, LC (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks Ave,Olson Pavil 8250, Chicago, IL 60611 USA.		Minucci, Saverio/J-9669-2012	Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R01CA094079, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA94079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Brodowicz T, 1999, BRIT J CANCER, V80, P1350, DOI 10.1038/sj.bjc.6690528; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen YH, 1999, BLOOD, V94, P251, DOI 10.1182/blood.V94.1.251.413k42_251_259; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; GRIGNANI F, 1994, BLOOD, V83, P10; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guzhova I, 2001, INT J CANCER, V94, P97, DOI 10.1002/ijc.1443; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Hsu SL, 1999, EXP CELL RES, V248, P87, DOI 10.1006/excr.1999.4397; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; KAMBHAMPATI S, 2003, HAEMA, V6, P149; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lutz PG, 2002, LEUKEMIA, V16, P1933, DOI 10.1038/sj.leu.2402728; Malhotra A, 2001, MOL CELL BIOCHEM, V225, P97, DOI 10.1023/A:1012261903611; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MINNUCCI S, 1994, MOL CELL BIOL, V14, P360; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Reddig PJ, 1999, CANCER RES, V59, P5710; Schnaper HW, 2000, PEDIATR NEPHROL, V14, P254, DOI 10.1007/s004670050050; Slosberg ED, 2000, MOL CARCINOGEN, V27, P166, DOI 10.1002/(SICI)1098-2744(200003)27:3<166::AID-MC3>3.0.CO;2-Z; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Szondy Z, 1998, CELL DEATH DIFFER, V5, P4, DOI 10.1038/sj.cdd.4400313; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; Van Heusden J, 1998, BRIT J CANCER, V77, P1229, DOI 10.1038/bjc.1998.207; vanderLeede BM, 1997, J BIOL CHEM, V272, P17921, DOI 10.1074/jbc.272.29.17921; Ventura C, 2001, CRIT REV EUKAR GENE, V11, P243; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; Xu XC, 1999, CANCER RES, V59, P2477; Yen A, 1998, CANCER RES, V58, P3163; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Yokoyama M, 2001, OBSTET GYNECOL, V98, P332, DOI 10.1016/S0029-7844(01)01449-1	78	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32544	32551		10.1074/jbc.M301523200	http://dx.doi.org/10.1074/jbc.M301523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805378	hybrid			2022-12-25	WOS:000184901800010
J	Zhong, XT; Malhotra, R; Guidotti, G				Zhong, XT; Malhotra, R; Guidotti, G			ATP uptake in the Golgi and extracellular release require Mcd4 protein and the vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL-VOLUME REGULATION; SACCHAROMYCES-CEREVISIAE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; TRANSFERRING PHOSPHOETHANOLAMINE; GUANOSINE DIPHOSPHATASE; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; MEMBRANE-PROTEINS; ENDOTHELIAL-CELLS	Extracellular nucleotides signal via a large group of purinergic receptors. Although much is known about these receptors, the mechanism of nucleotide transport out of the cytoplasm is unknown. We developed a functional screen for ATP release to the extracellular space and identified Mcd4p, a 919-amino acid membrane protein with 14 putative transmembrane domains, as a participant in glucose-dependent ATP release from Saccharomyces cerevisiae. This release occurred through the vesicular trafficking pathway initiated by ATP uptake into the Golgi compartment. Both the compartmental uptake and the extracellular release of ATP were regulated by the activity of the vacuolar H+-ATPase. It is likely that the Mcd4p pathway is generally involved in non-mitochondrial ATP movement across membranes, it is essential for Golgi and endoplasmic reticulum function, and its occurrence led to the appearance of P2 purinergic receptors.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.			Malhotra, Rajeev/0000-0003-0120-4630	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; Bankston LA, 1996, J BIOL CHEM, V271, P17132, DOI 10.1074/jbc.271.29.17132; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Bodas E, 2000, J BIOL CHEM, V275, P20268, DOI 10.1074/jbc.M000894200; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756-3282(01)00430-6; Boyum R, 1997, MICROBIOL-SGM, V143, P1901, DOI 10.1099/00221287-143-6-1901; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Burnstock G, 2001, TRENDS PHARMACOL SCI, V22, P182, DOI 10.1016/S0165-6147(00)01643-6; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Crotti LB, 2001, ANAL BIOCHEM, V292, P8, DOI 10.1006/abio.2001.5051; Devidas S, 1997, CURR OPIN CELL BIOL, V9, P547, DOI 10.1016/S0955-0674(97)80032-4; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; Grygorczyk R, 2001, J PHYSIOL-LONDON, V532, P582, DOI 10.1111/j.1469-7793.2001.0582e.x; Guidotti G, 1996, CHEM BIOL, V3, P703, DOI 10.1016/S1074-5521(96)90244-6; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Kane PM, 2000, J EXP BIOL, V203, P81; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MENON AK, 1992, J BIOL CHEM, V267, P15277; Mimikakis JL, 1998, J MEMBRANE BIOL, V163, P19, DOI 10.1007/s002329900366; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Mondesert G, 1997, GENETICS, V147, P421; MOTTE S, 1995, INT J BIOCHEM CELL B, V27, P1, DOI 10.1016/1357-2725(94)00059-X; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; Roman RM, 2001, J MEMBRANE BIOL, V183, P165, DOI 10.1007/s00232-001-0064-7; SHERMAN F, 1986, METHODS YEAST GENETI, P160; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sugita M, 1998, EMBO J, V17, P898, DOI 10.1093/emboj/17.4.898; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOHE A, 1993, YEAST, V9, P481, DOI 10.1002/yea.320090504; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; VOGEL K, 1990, MOL MICROBIOL, V4, P2013, DOI 10.1111/j.1365-2958.1990.tb00560.x; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Yada T, 2001, J BIOL CHEM, V276, P13579, DOI 10.1074/jbc.M009260200; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998; Zhong XT, 2001, J BIOL CHEM, V276, P41518, DOI 10.1074/jbc.M104415200; Zhong XT, 2000, J BIOL CHEM, V275, P35592, DOI 10.1074/jbc.M006932200; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7; [No title captured]	69	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33436	33444		10.1074/jbc.M305785200	http://dx.doi.org/10.1074/jbc.M305785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807869	hybrid, Green Published			2022-12-25	WOS:000184901800116
J	Lin, L; Kobayashi, M				Lin, L; Kobayashi, M			Stability of the rel homology domain is critical for generation of NF-kappa B p50 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED P105 PROTEOLYSIS; GLYCINE-RICH REGION; DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; PROTEASES DEGRADE; NF-KAPPA-B1 P105; PRECURSOR P105; ACTIVATION; SIGNAL; KINASE	The NF-kappaB transcription factor p50 and the Rel protein-specific transcription inhibitor p105 are both encoded by the nfkb1 gene. The p50 protein is incorporated within the N-terminal portion of p105 and is a unique product of proteasomal processing. Because proteasome-mediated proteolysis generally results in complete degradation of the substrate, how p50 survives the proteasomal processing remains unknown. Survival of proteasomal processing has also been observed recently for the yeast transcription factors SPT23 and MGA2, but the mechanism is also unclear. Here we show evidence that stability of the Rel homology domain (RHD) within the N-terminal portion of the NF-kappaB 1 protein is required for p50 generation. We demonstrated that proteolysis initiated at an internal location of the NF-kappaB 1 protein, which normally generates p50, degrades the N-terminal portion of the NF-kappaB 1 protein when the RHD is destabilized. Our findings highlight the critical role of the unique structure of the RHD for the survival of p50 during proteosomal processing.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Lin, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Ishikawa H, 1996, ONCOGENE, V13, P255; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Snapper CM, 1996, J IMMUNOL, V156, P183; Vancurova I, 2002, J VIROL, V76, P1533, DOI 10.1128/JVI.76.3.1533-1536.2002; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	39	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31479	31485		10.1074/jbc.M304140200	http://dx.doi.org/10.1074/jbc.M304140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12807880	hybrid			2022-12-25	WOS:000184782100006
J	Beebe, SJ; Fox, PM; Rec, LJ; Willis, LK; Schoenbach, KH				Beebe, SJ; Fox, PM; Rec, LJ; Willis, LK; Schoenbach, KH			Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells	FASEB JOURNAL			English	Article						electroporation; caspases; cytochrome c; annexin-V; flow cytometry	MAMMALIAN-CELLS; GENE-TRANSFER; DEATH; ELECTROCHEMOTHERAPY; FUNDAMENTALS; MECHANISM	Electroporation by using pulsed electric fields with long durations compared with the charging time of the plasma membrane can induce cell fusion or introduce xenomolecules into cells Nanosecond pulse power technology generates pulses with high-intensity electric fields, but with such short durations that the charging time of the plasma membrane is not reached, but intracellular membranes are affected. To determine more specifically their effects on cell structure and function, human cells were exposed to high intensity (up to 300 kV/cm) nanosecond (10-300 ns) pulsed electric fields (nsPEF) and were analyzed at the cellular and molecular levels. As the pulse duration decreased, plasma membrane electroporation decreased and appearances of apoptosis markers were delayed. NsPEF induced apoptosis within tens of minutes, depending on the pulses duration. Annexin-V binding, caspase activation, decreased forward light scatter, and cytochrome c release into the cytoplasm were coincident. Apoptosis was caspase- and mitochondria-dependent but independent of plasma membrane electroporation and thermal changes. The results suggest that with decreasing pulse duration, nsPEF modulate cell signaling from the plasma membrane to intracellular structures and functions. NsPEF technology provides a unique, high-power, energy-independent tool to recruit plasma membrane and/or intracellular signaling mechanisms that can delete aberrant cells by apoptosis.	Eastern Virginia Med Sch, Ctr Pediat Res, Norfolk, VA 23510 USA; Old Dominion Univ, Phys Electron Res Inst, Norfolk, VA USA	Eastern Virginia Medical School; Old Dominion University	Beebe, SJ (corresponding author), Eastern Virginia Med Sch, Ctr Pediat Res, 855 W Brambleton Ave, Norfolk, VA 23510 USA.	sbeebe@chkd.com						Amstad PA, 2001, BIOTECHNIQUES, V31, P608, DOI 10.2144/01313pf01; Beebe SJ, 2002, IEEE T PLASMA SCI, V30, P286, DOI 10.1109/TPS.2002.1003872; BELEHRADEK M, 1993, CANCER-AM CANCER SOC, V72, P3694, DOI 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2; Chang D.C., 1992, GUIDE ELECTROPORATIO; Cole KS, 1937, T FARADAY SOC, V33, P0966, DOI 10.1039/tf9373300966; Deng JD, 2000, CONFERENCE RECORD OF THE 2000 TWENTY-FOURTH INTERNATIONAL POWER MODULATOR SYMPOSIUM, 50TH ANNIVERSARY, P47, DOI 10.1109/MODSYM.2000.896161; DEV SB, 1994, CANCER TREAT REV, V20, P105, DOI 10.1016/0305-7372(94)90013-2; Dev SB, 2000, IEEE T PLASMA SCI, V28, P206, DOI 10.1109/27.842905; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Foster KR, 2000, IEEE T PLASMA SCI, V28, P15, DOI 10.1109/27.842819; FOSTER KR, 1996, HDB BIOL EFFECTS ELE; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hofmann F, 1999, J MEMBRANE BIOL, V169, P103, DOI 10.1007/s002329900522; KARSTEN U, 1988, HYBRIDOMA, V7, P627, DOI 10.1089/hyb.1988.7.627; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li LH, 2001, FASEB J, V15, P586, DOI 10.1096/fj.00-0447fje; Li LH, 1999, EXP CELL RES, V253, P541, DOI 10.1006/excr.1999.4666; LO MMS, 1984, NATURE, V310, P792, DOI 10.1038/310792a0; Muller KJ, 2001, J MEMBRANE BIOL, V184, P161, DOI 10.1007/s00232-001-0084-3; Neumann E, 1998, BIOPHYS J, V74, P98, DOI 10.1016/S0006-3495(98)77771-9; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Neumann E, 1999, BIOELECTROCH BIOENER, V48, P3, DOI 10.1016/S0302-4598(99)00008-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Schoenbach KH, 1997, IEEE T PLASMA SCI, V25, P284, DOI 10.1109/27.602501; Schoenbach KH, 2000, IEEE T DIELECT EL IN, V7, P637, DOI 10.1109/94.879359; Schoenbach KH, 2001, BIOELECTROMAGNETICS, V22, P440, DOI 10.1002/bem.71; Schoenbach KH, 1997, 11TH IEEE INTERNATIONAL PULSED POWER CONFERENCE - DIGEST OF TECHNICAL PAPERS, VOLS. 1 & 2, P73, DOI 10.1109/PPC.1997.679279; SCHOENBACH KH, 1998, P ERDEC SCI C CHEM B, P583; Shimokawa T, 2000, BIOCHEM BIOPH RES CO, V270, P94, DOI 10.1006/bbrc.2000.2388; Somiari S, 2000, MOL THER, V2, P178, DOI 10.1006/mthe.2000.0124; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Weaver J.C., 1996, CRC HDB BIOL EFFECTS, P247; Weaver JC, 1999, ADV DRUG DELIVER REV, V35, P21, DOI 10.1016/S0169-409X(98)00061-1; WEAVER JC, 2000, BIOMEDICAL ENG HDB, P1431; WONG TK, 1982, BIOCHEM BIOPH RES CO, V107, P584, DOI 10.1016/0006-291X(82)91531-5; Zimmermann U, 2000, IEEE T PLASMA SCI, V28, P72, DOI 10.1109/27.842868	41	326	362	3	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1493	+		10.1096/fj.02-0859fje	http://dx.doi.org/10.1096/fj.02-0859fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824299				2022-12-25	WOS:000183818000022
J	Warrener, R; Beamish, H; Burgess, A; Waterhouse, NJ; Giles, N; Fairlie, DP; Gabrielli, B				Warrener, R; Beamish, H; Burgess, A; Waterhouse, NJ; Giles, N; Fairlie, DP; Gabrielli, B			Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints	FASEB JOURNAL			English	Article						apoptosis; histone deacetylase inhibitors; mitotic spindle checkpoint	HISTONE-DEACETYLASE INHIBITORS; IN-VITRO; EXPRESSION; CENTROMERE; CANCER; HETEROCHROMATIN; MICROTUBULES; KINETOCHORES; TRANSDUCTION; DISRUPTION	Cell cycle checkpoints act to protect cells from external stresses and internal errors that would compromise the integrity of the cell. Checkpoints are often defective in cancer cells. Drugs that target checkpoint mechanisms should therefore be selective for tumor cells that are defective for the drug-sensitive checkpoint. Histone deacetylase inhibitors typify this class of agents. They trigger a G(2)-phase checkpoint response in normal cells but are cytotoxic in tumor cells in which this checkpoint is defective. In this study, we investigated that molecular basis of the tumor-selective cytotoxicity of these drugs and demonstrated that it is due to the disruption of two cell cycle checkpoints. The first is the histone deacetylase inhibitor-sensitive G(2)-phase checkpoint, which is defective in drug-sensitive cells and permits cells to enter an aberrant mitosis. The second is the drug-dependent bypass of the mitotic spindle checkpoint that normally detects aberrant mitosis and blocks mitotic exit until the defect is rectified. The disruption of both checkpoints results in the premature exit of cells from an abortive mitosis followed by apoptosis. This study of histone deacetylase inhibitors demonstrates that drugs targeting cell cycle checkpoints can provide the selectivity and cytotoxicity desired in effective chemotherapeutic agents.	Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	University of Queensland; University of Queensland; Peter Maccallum Cancer Center	Gabrielli, B (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Fairlie, David P/F-8865-2014; Waterhouse, Nigel/I-9813-2016; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019; Waterhouse, Nigel/B-2498-2012	Fairlie, David P/0000-0002-7856-8566; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226; 				Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Butler LM, 2000, CANCER RES, V60, P5165; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mello JA, 2001, CURR OPIN GENET DEV, V11, P136, DOI 10.1016/S0959-437X(00)00170-2; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Van Hooser AA, 1999, FASEB J, V13, pS216, DOI 10.1096/fasebj.13.9002.S216; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	33	127	138	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1550	+		10.1096/fj.02-1003fje	http://dx.doi.org/10.1096/fj.02-1003fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824307				2022-12-25	WOS:000183818000041
J	Fontaine, C; Dubois, G; Duguay, Y; Helledie, T; Vu-Dac, N; Gervois, P; Soncin, F; Mandrup, S; Fruchart, JC; Fruchart-Najib, J; Staels, B				Fontaine, C; Dubois, G; Duguay, Y; Helledie, T; Vu-Dac, N; Gervois, P; Soncin, F; Mandrup, S; Fruchart, JC; Fruchart-Najib, J; Staels, B			The orphan nuclear receptor Rev-Erb alpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPAR gamma-induced adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE DEVELOPMENT; C/EBP-ALPHA; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; OPPOSITE STRAND; ADIPOGENESIS; CELLS; PROTEIN; BINDING; METABOLISM	Rev-Erbalpha (NR1D1) is an orphan nuclear receptor encoded on the opposite strand of the thyroid receptor alpha gene. Rev-Erbalpha mRNA is induced during adipocyte differentiation of 3T3-L1 cells, and its expression is abundant in rat adipose tissue. Peroxisome proliferator-activated receptor gamma (PPARgamma) (NR1C3) is a nuclear receptor controlling adipocyte differentiation and insulin sensitivity. Here we show that Rev-Erbalpha expression is induced by PPARgamma activation with rosiglitazone in rat epididymal and perirenal adipose tissues in vivo as well as in 3T3-L1 adipocytes in vitro. Furthermore, activated PPARgamma induces Rev-Erbalpha promoter activity by binding to the direct repeat (DR)-2 response element Rev-DR2. Mutations of the 5' or 3' half-sites of the response element totally abrogated PPARgamma binding and transcriptional activation, identifying this site as a novel type of functional PPARgamma response element. Finally, ectopic expression of Rev-Erbalpha in 3T3-L1 preadipocytes potentiated adipocyte differentiation induced by the PPARgamma ligand rosiglitazone. These results identify Rev-Erbalpha as a target gene of PPARgamma in adipose tissue and demonstrate a role for this nuclear receptor as a promoter of adipocyte differentiation.	Inst Pasteur, INSERM, UR545, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Inst Biol Lille, F-59021 Lille, France; Univ So Odense, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; University of Southern Denmark	Staels, B (corresponding author), Inst Pasteur, INSERM, UR545, Dept Atherosclerose, 1 Rue Calmette, F-59019 Lille, France.		SONCIN, Fabrice/A-1475-2009; Staels, Bart/N-9497-2016; Mandrup, Susanne/B-6693-2008; Fontaine, Coralie/N-3814-2017	SONCIN, Fabrice/0000-0001-6312-0673; Staels, Bart/0000-0002-3784-1503; Mandrup, Susanne/0000-0002-0961-5787; Fontaine, Coralie/0000-0002-7253-922X				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Bennett CN, 2003, BIOCHEM BIOPH RES CO, V302, P12, DOI 10.1016/S0006-291X(03)00092-5; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Blagoev B, 2002, J BIOL CHEM, V277, P42011, DOI 10.1074/jbc.M206975200; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; Holst D, 2002, CURR OPIN LIPIDOL, V13, P241, DOI 10.1097/00041433-200206000-00002; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; Raspe E, 1999, J LIPID RES, V40, P2099; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799; Villena JA, 2002, HORM METAB RES, V34, P664, DOI 10.1055/s-2002-38244; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	57	184	198	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37672	37680		10.1074/jbc.M304664200	http://dx.doi.org/10.1074/jbc.M304664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12821652	hybrid			2022-12-25	WOS:000185437200083
J	Marchand, B; Gotte, M				Marchand, B; Gotte, M			Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase - Implications for polymerase translocation and drug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; PRIMER UNBLOCKING; NUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; PEROXONITROUS ACID; KINETIC MECHANISM; AZT RESISTANCE; RNA-POLYMERASE; TERMINATED DNA; ACTIVE-SITE	Resistance to nucleoside analogue inhibitors of the reverse transcriptase of the HIV-1 often involves phosphorolytic excision of the incorporated chain terminator. Previous crystallographic and modeling studies suggested that this reaction could only occur when the enzyme resides in a pre-translocational stage. Here we studied mechanisms of polymerase translocation using novel site-specific footprinting techniques. Classical footprinting approaches, based on the detection of protected nucleic acid residues, are not sensitive enough to visualize subtle structural differences at single nucleotide resolution. Thus, we developed chemical footprinting techniques that give rise to hyperreactive cleavage on the template strand mediated through specific contacts with the enzyme. Two specific cuts served as markers that defined the position of the polymerase and RNase H domain, respectively. We show that the presence of the next correct dNTP, following the incorporated chain terminator, caused a shift in the position of the two cuts a single nucleotide further downstream. The footprints point to monotonic sliding motions and provide compelling evidence for the existence of an equilibrium between pre- and post-translocational stages. Our data show that enzyme translocation is reversible and uncoupled from nucleotide incorporation and the release of pyrophosphate. This translocational equilibrium ensures access to the pre- translocational stage after incorporation of the chain terminator. The efficiency of excision correlates with an increase in the population of complexes that exist in the pre- translocational stage, and we show that the latter configuration is preferred with an enzyme that contains mutations associated with resistance to nucleoside analogue inhibitors.	McGill Univ, Lady Davis Inst, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2T5, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Gotte, M (corresponding author), McGill Univ, Lady Davis Inst, Jewish Gen Hosp, AIDS Ctr 226, 3755 Chemin Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mgoette@ldi.jgh.mcgill.ca						Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gotte M, 2001, J BIOL CHEM, V276, P6711, DOI 10.1074/jbc.M009097200; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Gotte M, 1996, FEBS LETT, V390, P226, DOI 10.1016/0014-5793(96)00662-X; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; GUO Q, 1991, BIOCHEMISTRY-US, V30, P11735, DOI 10.1021/bi00115a001; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; KING PA, 1993, NUCLEIC ACIDS RES, V21, P2473, DOI 10.1093/nar/21.10.2473; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Lavigne M, 2001, J BIOL CHEM, V276, P31439, DOI 10.1074/jbc.M102976200; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Meyer PR, 2003, J VIROL, V77, P3871, DOI 10.1128/JVI.77.6.3871-3877.2003; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; Rigourd M, 2002, J BIOL CHEM, V277, P18611, DOI 10.1074/jbc.M110836200; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Sarafianos SG, 2003, J BIOL CHEM, V278, P16280, DOI 10.1074/jbc.M212911200; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z	41	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35362	35372		10.1074/jbc.M304262200	http://dx.doi.org/10.1074/jbc.M304262200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819205	hybrid			2022-12-25	WOS:000185164400076
J	Hiromasa, Y; Roche, TE				Hiromasa, Y; Roche, TE			Facilitated interaction between the pyruvate dehydrogenase kinase isoform 2 and the dihydrolipoyl acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOYL DOMAIN; PROTEIN-X; TRANSACETYLASE COMPONENT; BOVINE KIDNEY; BOUNDARY ANALYSIS; COMPLEX; BINDING; MECHANISM; PHOSPHATASE; EXPRESSION	The dihydrolipoyl acetyltransferase (E2) has an enormous impact on pyruvate dehydrogenase kinase (PDK) phosphorylation of the pyruvate dehydrogenase (E1) component by acting as a mobile binding framework and in facilitating and mediating regulation of PDK activity. Analytical ultracentrifugation (AUC) studies established that the soluble PDK2 isoform is a stable dimer. The interaction of PDK2 with the lipoyl domains of E2 (L1, L2) and the E3-binding protein (L3) were characterized by AUC. PDK2 interacted very weakly with L2 (K-d similar or equal to 175 muM for 2 L2/PDK2) but much tighter with dimeric glutathione S-transferase (GST)- L2 (K-d similar or equal to 3 muM), supporting the importance of bifunctional binding. Reduction of lipoyl groups resulted in similar to8-fold tighter binding of PDK2 to GST-L2(red), which was similar to300-fold tighter than binding of 2 L2(red) and also much tighter than binding by GST-L1(red) and GST-L3(red). The E2 60-mer bound similar to18 PDK2 dimers with a K-d similar to GST-L2. E2.E1 bound more PDK2 (similar to27.6) than E2 with similar to2-fold tighter affinity. Lipoate reduction fostered somewhat tighter binding at more sites by E2 and severalfold tighter binding at the majority of sites on E2 . E1. ATP and ADP decreased the affinity of PDK2 for E2 by 3-5-fold and adenosine 5'-(beta,gamma-imino) triphosphate or phosphorylation of E1 similarly reduced PDK2 binding to E2 . E1. Reversible bifunctional binding to L2 with the mandatory singly held transition fits the proposed "hand-over-hand" movement of a kinase dimer to access E1 without dissociating from the complex. The gain in binding interactions upon lipoate reduction likely aids reduction-engendered stimulation of PDK2 activity; loosening of binding as a result of adenine nucleotides and phosphorylation may instigate movement of lipoyl domain-held kinase to a new E1 substrate.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	bchter@ksu.edu			NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BOWERKINLEY M, 1999, BIOCHEM J, V344, P47; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; CATE RL, 1978, J BIOL CHEM, V253, P496; Correia JJ, 2000, METHOD ENZYMOL, V321, P81; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0; Hiromasa V, 2001, FASEB J, V15, pA196; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; JILKA JM, 1986, J BIOL CHEM, V261, P1858; Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; Liu SJ, 2001, ARCH BIOCHEM BIOPHYS, V386, P123, DOI 10.1006/abbi.2000.2222; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; ONO K, 1993, J BIOL CHEM, V268, P26135; Peng T, 2000, FASEB J, V14, pA1528; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Popov KM, 1997, FEBS LETT, V419, P197, DOI 10.1016/S0014-5793(97)01453-1; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; PRATT ML, 1979, J BIOL CHEM, V254, P7191; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Roche T. E., 1996, CHANNELING INTERMEDI, P115; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STAFFORD WF, 2003, IN PRESS CURRENT PRO; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; TANFORD C, 1967, PHYSICAL CHEM MACROM, P372; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Yan XH, 2001, FASEB J, V15, pA197; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698	55	24	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33681	33693		10.1074/jbc.M212733200	http://dx.doi.org/10.1074/jbc.M212733200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12816949	hybrid			2022-12-25	WOS:000185047500011
J	Bialkowska, K; Zaffran, Y; Meyer, SC; Fox, JEB				Bialkowska, K; Zaffran, Y; Meyer, SC; Fox, JEB			14-3-3 zeta mediates integrin-induced activation of Cdc42 and Rac - Platelet glycoprotein IB-IX regulates integrin-induced signaling by sequestering 14-3-3 zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BINDING PROTEIN RHO; ACTIN STRESS FIBERS; CELL-ADHESION; CYTOPLASMIC DOMAIN; V COMPLEX; TYROSINE PHOSPHORYLATION; THROMBIN-BINDING; FOCAL COMPLEXES; 14-3-3-PROTEINS	Integrin-induced cytoskeletal reorganizations are initiated by Cdc42 and Rac1 but little is known about mechanisms by which integrins activate these Rho GTPases. 14-3-3 proteins are adaptors implicated in binding and regulating the function and subcellular location of numerous signaling molecules. In platelets, the 14-3-3zeta isoform interacts with the glycoprotein (GP) Ibalpha subunit of the adhesion receptor GP Ib-IX. In this study, we show that integrin-induced activation of Cdc42, activation of Rac, cytoskeletal reorganizations, and cell spreading were inhibited in Chinese hamster ovary cells expressing full-length GP Ibalpha compared with GP Ibalpha lacking the 14-3-3zeta binding site. Activation of Rho GTPases and cytoskeletal reorganizations were restored by expression of 14-3-3zeta. Spreading in cells expressing truncated GP Ibalpha was inhibited by co-expressing a chimeric receptor containing interleukin 2 receptor alpha and GP Ibalpha cytoplasmic domain. These results identify a previously unrecognized function of 14-3-3zeta, that of mediating integrin-induced signaling. They show that 14-3-3zeta mediates Cdc42 and Rac activation. They also reveal a novel function of platelet GP Ib-IX, that of regulating integrin-induced cytoskeletal reorganizations by sequestering 14-3-3zeta. Signaling across integrins initiates changes in cell behavior such as spreading, migration, differentiation, apoptosis, or cell division. Thus, introduction of the 14-3-3zeta binding domain of GP Ibalpha into target cells might provide a method for regulating integrin-induced pathways in a variety of pathological conditions.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R23HL030657, R01HL030657, R01HL056264] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56264, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Bradford HN, 2000, J BIOL CHEM, V275, P22756, DOI 10.1074/jbc.M002591200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Fagerholm S, 2002, J BIOL CHEM, V277, P1728, DOI 10.1074/jbc.M106856200; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; FOX JEB, 1983, CELL MOTIL CYTOSKEL, V3, P579, DOI 10.1002/cm.970030524; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GANGULY P, 1979, BRIT J HAEMATOL, V42, P137, DOI 10.1111/j.1365-2141.1979.tb03706.x; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; LARSEN NE, 1981, BIOCHEMISTRY-US, V20, P4141, DOI 10.1021/bi00517a030; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; Savage B, 2001, CURR OPIN HEMATOL, V8, P270, DOI 10.1097/00062752-200109000-00002; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	58	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33342	33350		10.1074/jbc.M301217200	http://dx.doi.org/10.1074/jbc.M301217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810725	hybrid			2022-12-25	WOS:000184901800105
J	Yingsung, W; Zhuo, LS; Morgelin, M; Yoneda, M; Kida, D; Watanabe, H; Ishiguro, N; Iwata, H; Kimata, K				Yingsung, W; Zhuo, LS; Morgelin, M; Yoneda, M; Kida, D; Watanabe, H; Ishiguro, N; Iwata, H; Kimata, K			Molecular heterogeneity of the SHAP-hyaluronan complex - Isolation and characterization of the complex in synovial fluid from patients with rheumatoid arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; HEAVY-CHAINS; FREE-RADICALS; BINDING; PROTEIN; ACID; SERUM; FAMILY; FIBROBLASTS	We previously found that a covalent complex of SHAPs (serum-derived hyaluronan-associated proteins), the heavy chains of inter-alpha-trypsin inhibitor family molecules, with hyaluronan ( HA) is accumulated in synovial fluid of patients with rheumatoid arthritis, and the complex is circulated in patient plasma at high concentrations. How the SHAP-HA complex participates in this disease is unknown. To address this question, it is essential to clarify the structural features of this macromolecule. The SHAP-HA complex purified from synovial fluid of the patients by three sequential CsCl isopycnic centrifugations was heterogeneous in density, and the fractions with different densities had distinct SHAP-to-HA ratios. Agarose gel electrophoresis and column chromatography revealed that there was no apparent difference in the size distribution of HA to which SHAPs were bound between the fractions with different densities. The SHAP-HA complex in the higher density fraction had fewer SHAP molecules per HA chain. Therefore, the difference between the fractions with different densities was due to a heterogeneous population of the SHAP-HA complex, namely the different number of SHAP molecules bound to an HA chain. Based on the SHAP and HA contents of the purified preparations, we estimated that an HA chain with a molecular weight of 2 x 10(6) has as many as five covalently bound SHAPs, which could give a proteinaceous multivalency to HA. Furthermore, we also found that the SHAP-HA complex tends to form aggregates, judging from the migration and elution profiles in agarose gel electrophoresis and gel filtration, respectively. The multivalent feature of the SHAP-HA complex was also confirmed by the negative staining electron micrographic images of the purified fractions. Taken together, those structural characteristics may underlie the aggregate-forming and extracellular matrix-stabilizing ability of the SHAP-HA complex.	Aichi Med Univ, Res Ctr Infect Dis, Inst Mol Sci Med, Aichi 4801195, Japan; Aichi Med Univ, Res Ctr Infect Dis, Matrix Glycoconjugate Grp, Aichi 4801195, Japan; Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Nagoya Univ, Grad Sch Med, Dept Orthoped, Showa Ku, Aichi 4668550, Japan	Aichi Medical University; Aichi Medical University; Lund University; Nagoya University	Kimata, K (corresponding author), Aichi Med Univ, Res Ctr Infect Dis, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@amugw.aichimed-u.ac.jp	Ishiguro, Naoki/I-1563-2012					BALAZS EA, 1965, AMINO SUGARS       A, V2, P401; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; CHAWLA RK, 1984, CANCER RES, V44, P2718; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; Cowman MK, 1998, WENN GR INT, V72, P17; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; GREENWALD RA, 1980, ARTHRITIS RHEUM-US, V23, P455, DOI 10.1002/art.1780230408; Heinegard D, 1998, WENN GR INT, V72, P113; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; Kida D, 1999, J RHEUMATOL, V26, P1230; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; MASSELISSMITH A, 1996, BLOOD, V5, P1891; Mizon C, 1996, J IMMUNOL METHODS, V190, P61, DOI 10.1016/0022-1759(95)00257-X; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Odum L, 2002, REPRODUCTION, V124, P249, DOI 10.1530/reprod/124.2.249; ODUM L, 1987, CLIN CHIM ACTA, V162, P189, DOI 10.1016/0009-8981(87)90450-5; ROUET P, 1992, BIOL CHEM H-S, V373, P1019, DOI 10.1515/bchm3.1992.373.2.1019; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SUNDBLAD L, 1965, AMINO SUGAR A, V2, P250; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; UNDERHILL C, 1992, J CELL SCI, V103, P293; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; YONEDA M, 1988, J CELL SCI, V90, P265; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoneda M, 2000, INT CONGR SER, V1196, P21; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	35	85	93	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32710	32718		10.1074/jbc.M303658200	http://dx.doi.org/10.1074/jbc.M303658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799384	hybrid			2022-12-25	WOS:000184901800029
J	Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L				Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L			Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation	ONCOGENE			English	Article						beta-catenin; cell identity; transdifferentiation; neoplasia; prostate	HAIR FOLLICLE MORPHOGENESIS; SIGNALING PATHWAYS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; GENE; PREGNANCY; EPIDERMIS; DELETION; GROWTH	The Wnt/beta-catenin signaling pathway is critical for normal mammalian development, the specification of epidermal cells and neoplastic transformation of intestinal epithelium. However, precise molecular information regarding cell-specific responses to beta-catenin signaling has been limited. This question was addressed using a mouse model in which exon 3 of the beta-catenin gene was deleted in several cell types with loxP-mediated recombination utilizing a Cre transgene under control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). The stabilization of beta-catenin in prostate epithelium resulted in hyperplasias and extensive transdifferentiation into epidermal-like structures, which expressed keratins 1 and 6, filaggrin, loricrin and involucrin. The cell-specific loss of NKCC1 protein and reduced nuclear Stat5a is further suggestive of a loss of prostate epithelial characteristics. In addition to the prostate, hyperplasias and squamous metaplasias were detected in epithelia of the epididymis, vas deferens, coagulating gland, preputial gland and salivary gland. However, and in contrast to a recent study, no lesions reminiscent of high-grade prostate intraepithelial neoplasia were detected. Since beta-catenin was activated in several cell types and impinged upon the viability of these mice, it was not possible to evaluate the cumulative effect over more than 3 months. To assess long-term consequences of beta-catenin activation, mutant and control prostate tissues were transplanted into the mammary fat pads of wild-type males. Notably, squamous metaplasias, intra-acinous hyperplasia and possible neoplastic transformation were observed after a total of 18 weeks of beta-catenin stimulation. This suggests that the transdifferentiation into squamous metaplasias is an early response of endoderm-derived cells to beta-catenin, and that the development of intra-acinous hyperplasias or neoplastic foci is a later event.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 7708504, Japan; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr, Omaha, NE USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Kyoto University; University of California System; University of California Davis; Tokushima University; University of Nebraska System; University of Nebraska Medical Center	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.	hennighausen@nih.gov	Wagner, Kay-Uwe/B-6044-2009; Robinson, Gertraud/I-2136-2012	Hennighausen, Lothar/0000-0001-8319-9841; Miyoshi, Keiko/0000-0001-6910-4172; Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTATTER T, 1985, J HISTOCHEM CYTOCHEM, V33, P415, DOI 10.1177/33.5.2580881; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BARRESI G, 1984, VIRCHOWS ARCH A, V403, P59, DOI 10.1007/BF00689338; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Brault V, 2001, DEVELOPMENT, V128, P1253; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; de Lau W, 2001, NAT GENET, V28, P3, DOI 10.1038/88233; DEOME KB, 1959, CANCER RES, V19, P515; Fischer DF, 1998, NUCLEIC ACIDS RES, V26, P5288, DOI 10.1093/nar/26.23.5288; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li XF, 1999, J BIOL CHEM, V274, P27249, DOI 10.1074/jbc.274.38.27249; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105; Niemann C, 2002, DEVELOPMENT, V129, P95; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Polakis P, 2000, GENE DEV, V14, P1837; REESE JH, 1992, PROSTATE, V20, P73, DOI 10.1002/pros.2990200109; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Widelitz RB, 2000, DEV BIOL, V219, P98, DOI 10.1006/dbio.1999.9580	53	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3875	3887		10.1038/sj.onc.1206426	http://dx.doi.org/10.1038/sj.onc.1206426			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813461				2022-12-25	WOS:000183612000007
J	Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G				Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G			Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine	ONCOGENE			English	Article						Bax; Bcl-2; cell death; lysosomes; mitochondria	CELL-DEATH; GLYCOPROTEIN COMPLEX; CYTOCHROME-C; BCL-2; BAX; P53; TRANSLOCATION; CHLOROQUINE; DYSFUNCTION; ACTIVATION	Hydroxychloroquine (HCQ) is a lysosomotropic amine with cytotoxic properties. Here, we show that HCQ induces signs of lysosomal membrane permeabilization (LMP), such as the decrease in the lysosomal pH gradient and the release of cathepsin B from the lysosomal lumen, followed by signs of apoptosis including caspase activation, phosphatidylserine exposure, and chromatin condensation with DNA loss. HCQ also induces mitochondrial membrane permeabilization (MMP), as indicated by the insertion of Bax into mitochondrial membranes, the conformational activation of Bax within mitochondria, the release of cytochrome c from mitochondria, and the loss of the mitochondrial transmembrane potential. To determine the molecular order among these events, we introduced inhibitors of LMP (bafilomycin A(1)), MMP (Bcl-X-L, wild-type Bcl-2, mitochondrion-targeted Bcl-2, or viral mitochondrial inhibitor of apoptosis from cytomegalovirus), and caspases (Z-VAD.fmk) into the system. Our data indicate that caspase-independent MMP is rate-limiting for LMP-mediated caspase activation. Mouse embryonic fibroblasts lacking the expression of both Bax and Bak are resistant against hydroxychloroquine-induced apoptosis. Such Bax(-/-) Bak(-/-) cells manifest normal LMP, yet fail to undergo MMP and subsequent cell death. The data reported herein indicate that LMP does not suffice to trigger caspase activation and that Bax/Bak-dependent MMP is a critical step of LMP-induced cell death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Poncet, Delphine A/A-7190-2016; González-Polo, Rosa A./I-6076-2016; Kroemer, Guido/AAY-9859-2020; PERFETTINI, Jean-Luc/N-4699-2017; Vieira, Helena/AAZ-9562-2021; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Boya, Patricia/K-2911-2014	Poncet, Delphine A/0000-0003-0446-5262; González-Polo, Rosa A./0000-0002-0163-2953; PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X; Andreau, Karine/0000-0002-9773-0733; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; BOYA P, IN PRESS; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai JH, 2001, J IMMUNOL, V166, P6914, DOI 10.4049/jimmunol.166.11.6914; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; Munafo DB, 2001, J CELL SCI, V114, P3619; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	52	310	317	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3927	3936		10.1038/sj.onc.1206622	http://dx.doi.org/10.1038/sj.onc.1206622			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813466				2022-12-25	WOS:000183612000012
J	Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ				Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ			Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells	ONCOGENE			English	Article						DLC-1; methylation; histone deacetylation; gastric cancer	HISTONE DEACETYLASE INHIBITOR; DNA METHYLATION; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; RECEPTOR GENE; SP1 SITES; ACTIVATION; CHROMATIN; PROMOTER	DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma. However, little is known about the genetic status and the expression of this gene in gastric cancer. In this study, Northern and Southern analysis showed that seven of nine human gastric cancer cell lines did not express DLC-1 mRNA, but contained the DLC-1 gene. To identify the mechanism of the loss of DLC-1 mRNA expression in these cell lines, we investigated the methylation status of DLC-1 gene by using methylation-specific PCR (MSP) and Southern blot, and found that five of seven DLC-1 nonexpressing gastric cancer cell lines were methylated in the DLC-1 CpG island. Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) induced DLC-1 mRNA expression in the gastric cancer cell lines that have the methylated alleles. Studies using SNU-601 cell line with methylated DLC-1 alleles revealed that nearly all CpG sites within DLC-1 CpG island were methylated, and that the in vitro methylation of the DLC-1 promoter region is enough to repress DLC-1 mRNA expression, regardless of the presence of transcription factors capable of inducing this gene. In all, 29 of 97 (30%) primary gastric cancers were also shown to be methylated, demonstrating that methylation of the DLC-1 CpG island is not uncommon in gastric cancer. In addition, we demonstrated that DLC-1 mRNA expression was induced, and an increase in the level of acetylated H3 and H4 was detected by the treatment with trichostatin A (TSA) in two DLC-1 nonexpressing cell lines that have the unmethylated alleles. Taken together, the results of our study suggest that the transcriptional silencing of DLC-1, by epigenetic mechanism, may be involved in gastric carcinogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Canc Epigenet, Canc Res Inst, Seoul 110744, South Korea; Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Seoul National University (SNU); Seoul National University (SNU); Georgetown University	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/F-9149-2012; Bang, Yung Jue/J-2759-2012; Kim, Tae-You/J-2750-2012; Lee, Jung Weon/AAC-1146-2020	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; KIM, TAI YOUNG/0000-0001-8086-2476				Baffa R, 2000, CLIN CANCER RES, V6, P1372; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EMI M, 1992, CANCER RES, V52, P5368; Euer N, 2002, ANTICANCER RES, V22, P733; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jong HS, 1999, CANCER, V86, P559, DOI 10.1002/(SICI)1097-0142(19990815)86:4<559::AID-CNCR3>3.0.CO;2-4; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kurimoto F, 2001, INT J MOL MED, V8, P89; MORII N, 1993, J BIOL CHEM, V268, P27160; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng IOL, 2000, CANCER RES, V60, P6581; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Sondak VK, 2001, CANCER GENET CYTOGEN, V131, P97, DOI 10.1016/S0165-4608(01)00539-8; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Stirzaker C, 1997, CANCER RES, V57, P2229; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tsutsumi S, 2002, CANCER RES, V62, P4484; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wistuba II, 1999, CANCER RES, V59, P1973; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	48	97	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3943	3951		10.1038/sj.onc.1206573	http://dx.doi.org/10.1038/sj.onc.1206573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813468				2022-12-25	WOS:000183612000014
J	Alesci, S; De Martino, MU; Mirani, M; Benvenga, S; Trimarchi, F; Kino, T; Chrousos, GP				Alesci, S; De Martino, MU; Mirani, M; Benvenga, S; Trimarchi, F; Kino, T; Chrousos, GP			L-Carnitine: a nutritional modulator of glucocorticoid receptor functions	FASEB JOURNAL			English	Article						GR; immunity; cytokines	PHOSPHATIDYLCHOLINE SPECIES COMPOSITION; RAT; BETAMETHASONE; TRANSPORT; DETERMINANTS; COMBINATIONS; DEFICIENCY; ANTAGONIST; EXCRETION; MUSCLE	L-Carnitine is an essential nutrient with a major role in cellular energy production. There is evidence that, at high doses, L-carnitine might mimic some of the biological activities of glucocorticoids, especially immunomodulation. To explore the molecular basis of this effect, we tested the influence of L-carnitine on glucocorticoid receptor-alpha (GRalpha) functions. Millimolar concentrations of L-carnitine, which were not cytotoxic in vitro, significantly reduced the whole cell binding of [H-3]dexamethasone to GRalpha by decreasing the affinity of this receptor for its steroid ligand. At the same concentrations, L-carnitine was able to trigger nuclear translocation of green fluorescent protein (GFP)-fused human GRalpha and transactivate the glucocorticoid-responsive mouse mammary tumor virus (MMTV) and TAT3 promoters in a dose-dependent fashion. This effect was solely dependent on the presence of glucocorticoid-responsive elements on the promoter and on the expression of functional GRalpha by the cell. Finally, similarly to glucocorticoids, L-carnitine suppressed tumor necrosis factor-alpha (TNFalpha) and interleukin-12 release by human primary monocytes stimulated with lipopolysaccharide ex vivo. Both GRalpha transactivation and cytokine suppression by L-carnitine were abrogated by the GRalpha-antagonist RU 486. Taken together, our results suggest that pharmacological doses of L-carnitine can activate GRalpha and, through this mechanism, regulate glucocorticoid-responsive genes, potentially sharing some of the biological and therapeutic properties of glucocorticoids.	NICHD, PREB, NIH, Bethesda, MD 20892 USA; Univ Messina, Dipartimento Clin Sperimentale Med & Farmacol, Sez Endocrinol, I-98100 Messina, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Messina	Alesci, S (corresponding author), NICHD, PREB, NIH, 10 Ctr Dr,Bldg 10,Room 9D42, Bethesda, MD 20892 USA.	alescis@mail.nih.gov		Mirani, Marco/0000-0002-4187-5378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD008732, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD008732, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002659, Z01MH002659] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGELINI C, 1976, NEUROLOGY, V26, P633, DOI 10.1212/WNL.26.7.633; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; Bamberger CM, 1997, MOL CELL ENDOCRINOL, V131, P233, DOI 10.1016/S0303-7207(97)00115-9; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Benvenga S, 2001, J CLIN ENDOCR METAB, V86, P3579, DOI 10.1210/jc.86.8.3579; BOHLES H, 1984, EUR J PEDIATR, V143, P61, DOI 10.1007/BF00442751; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; BRASS EP, 1997, L CARNITINE ITS ROLE, P21; Bremer J., 1997, CARNITINE TODAY, P1, DOI [10.1007/978-1-4615-6005-0_1, DOI 10.1007/978-1-4615-6005-0_1]; Chiu KM, 1999, CALCIFIED TISSUE INT, V64, P527, DOI 10.1007/s002239900644; CHRISTIANSEN RZ, 1976, BIOCHIM BIOPHYS ACTA, V448, P562, DOI 10.1016/0005-2736(76)90110-3; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; DaoPhan HP, 1997, MOL ENDOCRINOL, V11, P962, DOI 10.1210/me.11.7.962; DELOGU G, 1993, MEDIAT INFLAMM, V2, pS33, DOI 10.1155/S0962935193000730; DESIMONE C, 1993, IMMUNOPHARM IMMUNOT, V15, P1, DOI 10.3109/08923979309066930; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FATTOROSSI A, 1993, MEDIAT INFLAMM, V2, pS37, DOI 10.1155/S0962935193000742; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FOSTER SJ, 1993, AGENTS ACTIONS, V38, pC77, DOI 10.1007/BF01991143; Franchimont D, 2002, NEUROIMMUNOMODULAT, V10, P247, DOI 10.1159/000069969; FRITZ IB, 1965, P NATL ACAD SCI USA, V54, P1226, DOI 10.1073/pnas.54.4.1226; GUDJONSSON H, 1985, GASTROENTEROLOGY, V88, P1880, DOI 10.1016/0016-5085(85)90014-9; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; HUTH PJ, 1981, J NEUROCHEM, V36, P715, DOI 10.1111/j.1471-4159.1981.tb01647.x; KATAKAMI N, 1991, Kobe Journal of Medical Sciences, V37, P179; Kino T, 2001, J CLIN ENDOCR METAB, V86, P5600, DOI 10.1210/jc.86.11.5600; KURZ C, 1993, Z GEBURTSH PERINATOL, V197, P215; LEFEBVRE P, 1988, BIOCHEMISTRY-US, V27, P9186, DOI 10.1021/bi00426a017; LOBEMEIER M, 1999, P 27 GOTT NEUR C, V2, P761; Lohninger A, 1996, J PERINAT MED, V24, P591, DOI 10.1515/jpme.1996.24.6.591; LOHNINGER A, 1986, J CLIN CHEM CLIN BIO, V24, P361; LOHNINGER A, 1984, PEDIATR RES, V18, P1246, DOI 10.1203/00006450-198412000-00004; PANTER RA, 1969, FEBS LETT, V5, P169, DOI 10.1016/0014-5793(69)80322-4; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; Pratt W B, 1996, EXS, V77, P79; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; Rani PJA, 2001, EXP GERONTOL, V36, P1713, DOI 10.1016/S0531-5565(01)00116-4; Ray A, 1995, ANN NY ACAD SCI, V762, P79; RAY A, 1995, ANN NY ACAD SCI, V762, P87; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; REBOUCHE CJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P22, DOI 10.1016/0304-4165(80)90133-6; ROE CR, 1984, J CLIN INVEST, V73, P1785, DOI 10.1172/JCI111387; RUGGIERO V, 1993, MEDIAT INFLAMM, V2, pS43, DOI 10.1155/S0962935193000754; SALZER H, 1983, WIEN KLIN WOCHENSCHR, V95, P724; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Walter P, 2000, ANN NUTR METAB, V44, P77, DOI 10.1159/000012825; WINTER BK, 1995, BRIT J CANCER, V72, P1173, DOI 10.1038/bjc.1995.482	49	36	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1553	+		10.1096/fj.02-1024fje	http://dx.doi.org/10.1096/fj.02-1024fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824292				2022-12-25	WOS:000183818000017
J	Kojima, E; Takeuchi, A; Haneda, M; Yagi, F; Hasegawa, T; Yamaki, K; Takeda, K; Akira, S; Shimokata, K; Isobe, K				Kojima, E; Takeuchi, A; Haneda, M; Yagi, F; Hasegawa, T; Yamaki, K; Takeda, K; Akira, S; Shimokata, K; Isobe, K			The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress - elucidation by GADD34-deficient mice	FASEB JOURNAL			English	Article						unfolded protein response; translational attenuation; eukaryotic initiation factor	HERPES-SIMPLEX VIRUS; PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM; DNA-DAMAGE; GROWTH ARREST; TRANSLATIONAL CONTROL; GAMMA(1)34.5 PROTEIN; ALPHA-SUBUNIT; KINASE; GENES	GADD34 is a protein that is induced by stresses such as DNA damage. The function of mammalian GADD34 has been proposed by in vitro transfection, but its function in vivo has not yet been elucidated. Here we generated and analyzed GADD34 knockout mice. Despite their embryonic stage- and tissue-specific expressions, GADD34 knockout mice showed no abnormalities at fetal development and in early adult life. However, in GADD34(-/-) mouse embryonic fibroblasts (MEFs), recovery from a shutoff of protein synthesis was delayed when MEFs were exposed to endoplasmic reticulum (ER) stress. The phosphorylation of eukaryotic translation initiator factor 2alpha (eIF2alpha) at Ser51 induced by thapsigargin or DTT was prolonged in GADD34(-/-) MEF, although following treatment with tunicamycin, the eIF2alpha phosphorylation level did not change in either GADD34(+/+) or GADD34(-/-) cells. ER stress stimuli induced expressions of Bip (binding Ig protein) and CHOP (C/EBP homologous protein) in MEF of wild-type mice. These expressions were strongly reduced in GADD34(-/-) MEF, which suggests that GADD34 up-regulates Bip and CHOP. These results indicate that GADD34 works as a sensor of ER stress stimuli and recovers cells from shutoff of protein synthesis.	Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Showa Ku, Aichi 4668520, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 565, Japan	Nagoya University; Osaka University	Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo,Morioka Cho, Aichi 4748522, Japan.	kenisobe@nils.go.jp	Takeda, Kiyoshi/C-9331-2009; isobe, ken-ichi/A-6685-2011; Akira, Shizuo/C-3134-2009; Haneda, masataka/I-7266-2014; Takeuchi, Akihide/AAT-4675-2020	isobe, ken-ichi/0000-0002-8150-2496; Takeuchi, Akihide/0000-0002-2781-0180				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Imai H, 2002, EUR J NEUROSCI, V15, P1929, DOI 10.1046/j.1460-9568.2002.02025.x; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Takeuchi A, 2003, NAT GENET, V33, P172, DOI 10.1038/ng1072; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	36	170	190	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1573	+		10.1096/fj.02-1184fje	http://dx.doi.org/10.1096/fj.02-1184fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824288				2022-12-25	WOS:000183818000039
J	Ward, CW; Reiken, S; Marks, AR; Marty, I; Vassort, G; Lacampagne, A				Ward, CW; Reiken, S; Marks, AR; Marty, I; Vassort, G; Lacampagne, A			Defects in ryanodine receptor calcium release in skeletal muscle from postmyocardial infarcted rats	FASEB JOURNAL			English	Article						calcium sparks; heart failure; mammalian skeletal muscle; multiphoton microscopy; ryanodine receptor	CHRONIC HEART-FAILURE; INDIVIDUAL CA2+ SPARKS; PERFUSED MOUSE HEART; MYOCARDIAL-INFARCTION; EXERCISE CAPACITY; 2 MECHANISMS; FROG; FIBERS; EVENTS; RHOD-2	Defective calcium (Ca2+) signaling and impaired contractile function have been observed in skeletal muscle secondary to impaired mycocardial function. However, the molecular basis for these muscle defects have not been identified. In this study, we evaluated the alterations of the ryanodine-sensitive Ca2+ release channels (RyR1) by analyzing global and local <LF>Ca2+ signaling in a rat postmycocardial infarction (PMI) <LF>model of myocardial overload. Ca2+ transients, measured with multiphoton imaging in individual fibers within a whole extensor digitorum longus (EDL) muscle, exhibited significantly reduced amplitude and a prolonged time course in PMI. Spatio-temporal properties of spontaneous Ca2+ sparks in fibers isolated from PMI EDL muscles were also significantly altered. In addition, RyR1 from PMI skeletal muscles were PKA-hyperphosphorylated and depleted of the FK506 binding protein (FKBP12). These data show that PMI skeletal muscles exhibit altered local Ca2+ signaling, assocated with hyperphosphorylation of RyR1. The observed changes in Ca2+ signaling may contribute to defective excitation-contraction coupling in muscle that can attribute to the reduced exercise capacity in PMI, out of proportion to the degree of cardiac dysfunction.	CHU Arnaud de Villeneuve, INSERM, U390, IFR3, F-34295 Montpellier 05, France; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Columbia Univ, Coll Phys & Surg, Ctr Mol Cardiol, New York, NY USA; CEA Grenoble, DBMS, INSERM, E9931, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University System of Maryland; University of Maryland Baltimore; Columbia University; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lacampagne, A (corresponding author), CHU Arnaud de Villeneuve, INSERM, U390, IFR3, F-34295 Montpellier 05, France.	lacamp@montp.inserm.fr	Marty, Isabelle/N-7114-2017; Marty, Isabelle/ABF-5362-2020; Lacampagne, Alain/S-3719-2016	Marty, Isabelle/0000-0003-3625-913X; Lacampagne, Alain/0000-0003-0264-1787	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002177] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01 AR002177] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; ARNOLDA L, 1991, AM J PHYSIOL, V261, pH434, DOI 10.1152/ajpheart.1991.261.2.H434; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Cicoira M, 2001, CYTOKINE, V15, P80, DOI 10.1006/cyto.2001.0918; Clark AL, 1996, J AM COLL CARDIOL, V28, P1092, DOI 10.1016/S0735-1097(96)00323-3; Coats AJS, 1996, J MOL CELL CARDIOL, V28, P2255, DOI 10.1006/jmcc.1996.0218; DREXLER H, 1992, CIRCULATION, V85, P1751, DOI 10.1161/01.CIR.85.5.1751; Du CW, 2001, BIOPHYS J, V80, P549, DOI 10.1016/S0006-3495(01)76037-7; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Duscha BD, 2002, J AM COLL CARDIOL, V39, P1170, DOI 10.1016/S0735-1097(02)01740-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hollingworth S, 2001, J GEN PHYSIOL, V118, P653, DOI 10.1085/jgp.118.6.653; Jiang YH, 1999, BIOPHYS J, V77, P2333, DOI 10.1016/S0006-3495(99)77072-4; Kirsch WG, 2001, J PHYSIOL-LONDON, V537, P379, DOI 10.1111/j.1469-7793.2001.00379.x; Klein MG, 1999, J PHYSIOL-LONDON, V515, P391, DOI 10.1111/j.1469-7793.1999.391ac.x; Klein MG, 1997, P NATL ACAD SCI USA, V94, P11061, DOI 10.1073/pnas.94.20.11061; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Lacampagne A, 2000, P NATL ACAD SCI USA, V97, P7823, DOI 10.1073/pnas.97.14.7823; Lacampagne A, 2003, J GEN PHYSIOL, V121, P179; Lacampagne A, 1998, J GEN PHYSIOL, V111, P207, DOI 10.1085/jgp.111.2.207; Lacampagne A, 1999, J GEN PHYSIOL, V113, P187, DOI 10.1085/jgp.113.2.187; Lannergren J, 2001, J MUSCLE RES CELL M, V22, P265, DOI 10.1023/A:1012227009544; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Lunde PK, 2002, J PHYSIOL-LONDON, V540, P571, DOI 10.1113/jphysiol.2001.013324; Lunde PK, 2001, ACTA PHYSIOL SCAND, V171, P277, DOI 10.1046/j.1365-201x.2001.00830.x; Lunde PK, 2001, CIRC RES, V88, P1299, DOI 10.1161/hh1201.092041; MacGowan GA, 2001, J BIOMED OPT, V6, P23, DOI 10.1117/1.1316091; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MINOTTI JR, 1991, J CLIN INVEST, V88, P2077, DOI 10.1172/JCI115537; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; PERREAULT CL, 1993, CIRC RES, V73, P405, DOI 10.1161/01.RES.73.2.405; Peters DG, 1997, CIRC RES, V81, P703; Schneider MF, 2002, FRONT BIOSCI-LANDMRK, V7, pD1212, DOI 10.2741/schneide; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Simonini A, 1999, HEART, V81, P303, DOI 10.1136/hrt.81.3.303; VOLTERRANI M, 1994, EUR HEART J, V15, P801, DOI 10.1093/oxfordjournals.eurheartj.a060588; Williams JH, 1998, EXP PHYSIOL, V83, P85, DOI 10.1113/expphysiol.1998.sp004094; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	45	73	80	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1517	+		10.1096/fj.02-1083fje	http://dx.doi.org/10.1096/fj.02-1083fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824280				2022-12-25	WOS:000183818000031
J	Bergo, V; Spudich, EN; Spudich, JL; Rothschild, KJ				Bergo, V; Spudich, EN; Spudich, JL; Rothschild, KJ			Conformational changes detected in a sensory rhodopsin II-transducer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON RELEASE GROUP; PHARAONIS PHOBORHODOPSIN; NATRONOBACTERIUM-PHARAONIS; VIBRATIONAL SPECTROSCOPY; BACTERIORHODOPSIN MUTANTS; MOLECULAR-MECHANISM; PROTEIN INTERACTION; STRUCTURAL-CHANGES; PHOTOCYCLE; RECEPTOR	Sensory rhodopsins (SRs) are light receptors that belong to the growing family of microbial rhodopsins. SRs have now been found in all three major domains of life including archaea, bacteria, and eukaryotes. One of the most extensively studied sensory rhodopsins is SRII, which controls a blue light avoidance motility response in the halophilic archaeon Natronobacterium pharaonis. This seven-helix integral membrane protein forms a tight intermolecular complex with its cognate transducer protein, HtrII. In this work, the structural changes occurring in a fusion complex consisting of SRII and the two transmembrane helices (TM1 and TM2) of HtrII were investigated by time-resolved Fourier transform infrared difference spectroscopy. Although most of the structural changes observed in SRII are conserved in the fusion complex, several distinct changes are found. A reduction in the intensity of a prominent amide I band observed for SRII indicates that its structural changes are altered in the fusion complex, possibly because of the close interaction of TM2 with the F helix, which interferes with the F helix outward tilt. Deprotonation of at least one Asp/Glu residue is detected in the transducer-free receptor with a pK(a) near 7 that is abolished or altered in the fusion complex. Changes are also detected in spectral regions characteristic of Asn and Tyr vibrations. At high hydration levels, transducer-fusion interactions lead to a stabilization of an M-like intermediate that most likely corresponds to an active signaling form of the transducer. These findings are discussed in the context of a recently elucidated x-ray structure of the fusion complex.	Boston Univ, Dept Phys, Mol Biophys Lab, Boston, MA 02215 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA	Boston University; University of Texas System	Rothschild, KJ (corresponding author), Boston Univ, Dept Phys, Mol Biophys Lab, 590 Commonwealth Ave, Boston, MA 02215 USA.	kjr@bu.edu	Rothschild, Kenneth J/P-6177-2018	Rothschild, Kenneth J/0000-0002-2847-6671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750, R01GM027750] Funding Source: NIH RePORTER; NEI NIH HHS [EY05499] Funding Source: Medline; NIGMS NIH HHS [GM27750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1999, BIOCHEMISTRY-US, V38, P2026, DOI 10.1021/bi981926a; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Bergo V, 2000, BIOCHEMISTRY-US, V39, P2823, DOI 10.1021/bi991676d; Bergo V, 2003, BIOPHYS J, V84, P960, DOI 10.1016/S0006-3495(03)74912-1; Bergo V, 2002, PHOTOCHEM PHOTOBIOL, V76, P341, DOI 10.1562/0031-8655(2002)076<0341:AFTISO>2.0.CO;2; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BRAIMAN MS, 1987, P NATL ACAD SCI USA, V84, P5221, DOI 10.1073/pnas.84.15.5221; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1988, PROTEINS, V3, P219, DOI 10.1002/prot.340030403; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; Furutani Y, 2002, BIOPHYS J, V83, P3482, DOI 10.1016/S0006-3495(02)75347-2; Gellini C, 2000, FEBS LETT, V472, P263, DOI 10.1016/S0014-5793(00)01472-1; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Hein M, 2003, BIOPHYS J, V84, P1208, DOI 10.1016/S0006-3495(03)74935-2; HIRAYAMA J, 1992, BIOCHEMISTRY-US, V31, P2093, DOI 10.1021/bi00122a029; IMAMOTO Y, 1992, PHOTOCHEM PHOTOBIOL, V56, P1129, DOI 10.1111/j.1751-1097.1992.tb09737.x; Iwamoto M, 2002, BIOPHYS J, V83, P1130, DOI 10.1016/S0006-3495(02)75236-3; Jung KH, 1998, J BACTERIOL, V180, P2033, DOI 10.1128/JB.180.8.2033-2042.1998; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kelemen L, 2001, BIOPHYS J, V81, P3577, DOI 10.1016/S0006-3495(01)75988-7; Krebs MP, 1995, PROTEIN EXPRES PURIF, V6, P780, DOI 10.1006/prep.1995.0009; Kunji ERS, 2001, J MOL BIOL, V308, P279, DOI 10.1006/jmbi.2001.4565; LUDLAM CFC, 1995, BIOCHEMISTRY-US, V34, P2, DOI 10.1021/bi00001a001; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; MAEDA A, 1992, BIOCHEMISTRY-US, V31, P4684, DOI 10.1021/bi00134a022; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; PARKER FS, 1983, APPL INFRARED RAMAN; Ren L, 2001, BIOCHEMISTRY-US, V40, P13906, DOI 10.1021/bi0116487; ROEPE P, 1987, BIOCHEMISTRY-US, V26, P6696, DOI 10.1021/bi00395a020; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1986, P NATL ACAD SCI USA, V83, P347, DOI 10.1073/pnas.83.2.347; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; SCHARF B, 1992, EUR J BIOCHEM, V206, P359, DOI 10.1111/j.1432-1033.1992.tb16935.x; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; SIEBERT F, 1983, EUR J BIOCHEM, V130, P565, DOI 10.1111/j.1432-1033.1983.tb07187.x; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Spudich J, 2002, NAT STRUCT BIOL, V9, P797, DOI 10.1038/nsb1102-797; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; Spudich JL, 2002, CURR OPIN STRUC BIOL, V12, P540, DOI 10.1016/S0959-440X(02)00359-7; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Sudo Y, 2002, BIOPHYS J, V83, P427, DOI 10.1016/S0006-3495(02)75180-1; Sudo Y, 2001, PHOTOCHEM PHOTOBIOL, V74, P489, DOI 10.1562/0031-8655(2001)074<0489:PPBTIC>2.0.CO;2; Sudo Y, 2001, BIOPHYS J, V80, P916, DOI 10.1016/S0006-3495(01)76070-5; Vogel R, 2000, CURR OPIN CHEM BIOL, V4, P518, DOI 10.1016/S1367-5931(00)00125-3; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; YAN B, 1991, BIOCHEMISTRY-US, V30, P10686, DOI 10.1021/bi00108a012; YAO VJ, 1994, J BACTERIOL, V176, P6931, DOI 10.1128/JB.176.22.6931-6935.1994; Zhang XN, 1999, P NATL ACAD SCI USA, V96, P857, DOI 10.1073/pnas.96.3.857	58	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36556	36562		10.1074/jbc.M303719200	http://dx.doi.org/10.1074/jbc.M303719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12821665	hybrid			2022-12-25	WOS:000185318300085
J	Coddou, C; Morales, B; Gonzalez, J; Grauso, M; Gordillo, F; Bull, P; Rassendren, F; Huidobro-Toro, JP				Coddou, C; Morales, B; Gonzalez, J; Grauso, M; Gordillo, F; Bull, P; Rassendren, F; Huidobro-Toro, JP			Histidine 140 plays a key role in the inhibitory modulation of the P2X(4) nucleotide receptor by copper but not zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY-BULB NEURONS; DIFFERENTIAL MODULATION; NICOTINIC RECEPTORS; GLYCINE RECEPTOR; RAT-BRAIN; ZN2+; SUBUNIT; PH; IDENTIFICATION; EXCITABILITY	To elucidate the role of extracellular histidines in the modulation of the rat P2X(4) receptor by trace metals, we generated single, double, and triple histidine mutants for residues 140, 241, and 286, replacing them with alanines. cDNAs for the wild-type and receptor mutants were expressed in Xenopus laevis oocytes and in human embryonic kidney 293 cells and examined by the two electrode and patch clamp techniques, respectively. Whereas copper inhibited concentration-dependently the ATP-gated currents in the wild-type and in the single or double H241A and H286A receptor mutants, all receptors containing H140A were insensitive to copper in both cell systems. The characteristic bell-shaped concentration-response curve of zinc observed in the wildtype receptor became sigmoid in both oocytes and human embryonic kidney cells expressing the H140A mutant; in these mutants, the zinc potentiation was 2.5-4-fold larger than in the wild-type. Results with the H140T and H140R mutants further support the importance of a histidine residue at this position. We conclude that His-140 is critical for the action of copper, indicating that this histidine residue, but not His-241 or His-286, forms part of the inhibitory allosteric metal-binding site of the P2X4 receptor, which is distinct from the putative zinc facilitator binding site.	Pontificia Univ Catolica Chile, Fac Ciencias Biol,Dept Fisiol & Genet Mol, Ctr Regulac Celular & Patol JV Luco, Inst Milenio Biol Fundamental & Aplicada,MIFAB, Santiago 1, Chile; Pontificia Univ Catolica Chile, Fac Ciencias Biol,Dept Microbiol, Ctr Regulac Celular & Patol JV Luco, Inst Milenio Biol Fundamental & Aplicada,MIFAB, Santiago 1, Chile; Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier, France; Univ Santiago Chile, Fac Quim & Biol, Dept Ciencias Biol, Santiago 1, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universidad de Santiago de Chile	Huidobro-Toro, JP (corresponding author), Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Neurohumoral Regulat Unit, Alameda 340,Casilla 114-D, Santiago 1, Chile.	jphuid@genes.bio.puc.cl	Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461; Grauso, Marta/0000-0003-0413-9950				Acuna-Castillo C, 2000, J NEUROCHEM, V74, P1529, DOI 10.1046/j.1471-4159.2000.0741529.x; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Aitken A, 1999, MOL BIOTECHNOL, V12, P241, DOI 10.1385/MB:12:3:241; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BLOOMENTHAL AB, 1994, MOL PHARMACOL, V46, P1156; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; Clarke CE, 2000, J PHYSIOL-LONDON, V523, P697, DOI 10.1111/j.1469-7793.2000.00697.x; Clyne JD, 2002, J PHYSIOL-LONDON, V539, P347, DOI 10.1113/jphysiol.2001.013244; Coddou C, 2002, J NEUROCHEM, V80, P626, DOI 10.1046/j.0022-3042.2001.00732.x; Eyzaguirre Jaime, 1996, Biological Research, V29, P1; Hansen MA, 1997, BIOCHEM BIOPH RES CO, V236, P670, DOI 10.1006/bbrc.1997.6815; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horning MS, 2001, J NEUROPHYSIOL, V86, P1652, DOI 10.1152/jn.2001.86.4.1652; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Hsiao B, 2001, J NEUROSCI, V21, P1848, DOI 10.1523/JNEUROSCI.21-06-01848.2001; KARDOS J, 1989, NEUROSCI LETT, V103, P139, DOI 10.1016/0304-3940(89)90565-X; LORCA R, 2001, BIOL RES, V34, P105; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; MA JY, 1993, BRAIN RES, V607, P222; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Palma E, 1998, P NATL ACAD SCI USA, V95, P10246, DOI 10.1073/pnas.95.17.10246; RICHARDSON JS, 1975, P NATL ACAD SCI USA, V72, P1349, DOI 10.1073/pnas.72.4.1349; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Stoop R, 1997, J NEUROPHYSIOL, V78, P1837, DOI 10.1152/jn.1997.78.4.1837; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; Trombley PQ, 1996, J NEUROPHYSIOL, V76, P2536, DOI 10.1152/jn.1996.76.4.2536; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Wilkins ME, 2002, J NEUROSCI, V22, P5328; Xiong KM, 1999, J NEUROPHYSIOL, V81, P2088, DOI 10.1152/jn.1999.81.5.2088	33	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36777	36785		10.1074/jbc.M305177200	http://dx.doi.org/10.1074/jbc.M305177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12819199	hybrid			2022-12-25	WOS:000185318300110
J	Du, N; Liu, XY; Hew, CL				Du, N; Liu, XY; Hew, CL			Ice nucleation inhibition - Mechanism of antifreeze by antifreeze protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADSORPTION; BINDING; GROWTH	The effect of antifreeze protein type III ( one type of fish antifreeze protein) on ice crystallization was examined quantitatively based on a "micro-sized ice nucleation" technique. It was found for the first time that antifreeze proteins can inhibit the ice nucleation process by adsorbing onto both the surfaces of ice nuclei and dust particles. This leads to an increase of the ice nucleation barrier and the desolvation kink kinetics barrier, respectively. Based on the latest nucleation model, the increases in the ice nucleation barrier and the kink kinetics barrier were measured. This enables us to quantitatively examine the antifreeze mechanism of antifreeze proteins for the first time.	Natl Univ Singapore, Dept Phys, Singapore 119260, Singapore; Natl Univ Singapore, Dept Biol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Liu, XY (corresponding author), Natl Univ Singapore, Dept Phys, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	phyliuxy@nus.edu.sg	Liu, XY/E-5090-2010; Zhou, Weiqian/B-8991-2011; Li, Jingliang/A-6039-2011; Hew, Choy Leong/I-1501-2012	Liu, XY/0000-0002-4747-1251; Li, Jingliang/0000-0003-0709-2246; Hew, Choy Leong/0000-0002-9441-0064				ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Knight CA, 2000, NATURE, V406, P249, DOI 10.1038/35018671; Knight CA, 2001, CRYST GROWTH DES, V1, P429, DOI 10.1021/cg015531t; KNIGHT CA, 1984, NATURE, V308, P295, DOI 10.1038/308295a0; Liu JQ, 2001, BOT BULL ACAD SINICA, V42, P61; Liu XY, 1999, J CHEM PHYS, V111, P1628, DOI 10.1063/1.479391; Liu XY, 2001, J PHYS CHEM B, V105, P11550, DOI 10.1021/jp010671z; Liu XY, 2001, APPL PHYS LETT, V79, P39, DOI 10.1063/1.1384007; Liu XY, 2002, J AM CHEM SOC, V124, P15055, DOI 10.1021/ja0206137; Liu XY, 2000, LANGMUIR, V16, P7337, DOI 10.1021/la991333g; LIU XY, 2000, J PHYS CHEM, V112, P11550; Mutaftschiev B., 1993, HANDB CRYST GROWTH, P187; Ning D, 2002, APPL PHYS LETT, V81, P445, DOI 10.1063/1.1492849; RAYMOND JA, 1989, P NATL ACAD SCI USA, V86, P881, DOI 10.1073/pnas.86.3.881; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zettlemoyer A. C., 1969, NUCLEATION	21	62	69	4	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36000	36004		10.1074/jbc.M305222200	http://dx.doi.org/10.1074/jbc.M305222200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829706	hybrid			2022-12-25	WOS:000185318300017
J	Murphy, PJM; Morishima, Y; Chen, HF; Galigniana, MD; Mansfield, JF; Simons, SS; Pratt, WB				Murphy, PJM; Morishima, Y; Chen, HF; Galigniana, MD; Mansfield, JF; Simons, SS; Pratt, WB			Visualization and mechanism of assembly of a glucocorticoid receptor center dot Hsp70 complex that is primed for subsequent Hsp90-dependent opening of the steroid binding cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; 7-AMINO ACID SEQUENCE; CHAPERONE SYSTEM; PROGESTERONE-RECEPTOR; LIGAND-BINDING; CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; AMINO-TERMINUS; REACTION CYCLE; HSP90	A minimal system of five proteins, hsp90, hsp70, Hop, hsp40, and p23, assembles glucocorticoid receptor (GR).hsp90 heterocomplexes and causes the simultaneous opening of the steroid binding cleft to access by steroid. The first step in assembly is the ATP-dependent and hsp40 (YDJ-1)-dependent formation of a GR.hsp70 complex that primes the receptor for subsequent ATP-dependent activation by hsp90, Hop, and p23. This study focuses on three aspects of the GR priming reaction with hsp70. First, we have visualized the primed GR.hsp70 complexes by atomic force microscopy, and we find the most common stoichiometry to be 1: 1, with some complexes of a size similar to1: 2 and a few complexes of larger size. Second, in a recent study of progesterone receptor priming, it was shown that hsp40 binds first, leading to the notion that it targets hsp70 to the receptor. We show here that hsp40 does not perform such a targeting function in priming the GR. Third, we focus on a short amino-terminal segment of the ligand binding domain that is required for GR.hsp90 heterocomplex assembly. By using two glutathione S-transferase (GST)/ligand binding domain fusions with (GST/520C) and without (GST/ 554C) hsp90 binding and steroid binding activity, we show that the priming step with hsp70 occurs with GST/ 554C, and it is the subsequent assembly step with hsp90 that is defective.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Engn, N Campus Electron Microbeam Anal Lab, Ann Arbor, MI 48109 USA; NIDDK, Steroid Hormones Sect, LMCB, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			GALIGNIANA, MARIO/0000-0002-9130-8574	NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	40	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34764	34773		10.1074/jbc.M304469200	http://dx.doi.org/10.1074/jbc.M304469200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12807878	hybrid			2022-12-25	WOS:000185164400007
J	Shrestha, R; Dixon, RA; Chapman, KD				Shrestha, R; Dixon, RA; Chapman, KD			Molecular identification of a functional homologue of the mammalian fatty acid amide hydrolase in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACYLETHANOLAMINES; RAT-BRAIN; ANANDAMIDE AMIDOHYDROLASE; CANNABINOID RECEPTOR; SIGNAL-TRANSDUCTION; ENZYME; PALMITOYLETHANOLAMIDE; ENDOCANNABINOIDS; CLONING; GENE	N-Acylethanolamines (NAEs) are endogenous constituents of plant and animal tissues, and in vertebrates their hydrolysis terminates their participation as lipid mediators in the endocannabinoid signaling system. The membrane-bound enzyme responsible for NAE hydrolysis in mammals has been identified at the molecular level (designated fatty acid amide hydrolase, FAAH), and although an analogous enzyme activity was identified in microsomes of cotton seedlings, no molecular information is available for this enzyme in plants. Here we report the identification, the heterologous expression ( in Escherichia coli), and the biochemical characterization of an Arabidopsis thaliana FAAH homologue. Candidate Arabidopsis DNA sequences containing a characteristic amidase signature sequence (PS00571) were identified in plant genome data bases, and a cDNA was isolated by reverse transcriptase-PCR using Arabidopsis genome sequences to develop appropriate oligonucleotide primers. The cDNA was sequenced and predicted to encode a protein of 607 amino acids with 37% identity to rat FAAH within the amidase signature domain (18% over the entire length). Residues determined to be important for FAAH catalysis were conserved between the Arabidopsis and rat protein sequences. In addition, a single transmembrane domain near the N terminus was predicted in the Arabidopsis protein sequence, similar to that of the rat FAAH protein. The putative plant FAAH cDNA was expressed as an epitope/His-tagged fusion protein in E. coli and solubilized from cell lysates in the nonionic detergent, dodecyl maltoside. Affinity-purified recombinant protein was indeed active in hydrolyzing a variety of naturally occurring N-acylethanolamine types. Kinetic parameters and inhibition data for the recombinant Arabidopsis protein were consistent with these properties of the enzyme activity characterized previously in plant and animal systems. Collectively these data now provide support at the molecular level for a conserved mechanism between plants and animals for the metabolism of NAEs.	Univ N Texas, Dept Biol Sci, Div Biochem & Mol Biol, Denton, TX 76203 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73401 USA	University of North Texas System; University of North Texas Denton; Noble Research Institute	Chapman, KD (corresponding author), Univ N Texas, Dept Biol Sci, Div Biochem & Mol Biol, Denton, TX 76203 USA.	chapman@unt.edu		Chapman, Kent/0000-0003-0489-3072				Becker HD, 2000, FEBS LETT, V476, P140, DOI 10.1016/S0014-5793(00)01697-5; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; Blancaflor EB, 2003, PLANTA, V217, P206, DOI 10.1007/s00425-003-0985-8; Boger DL, 2000, BIOORG MED CHEM LETT, V10, P2613, DOI 10.1016/S0960-894X(00)00528-X; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; CHANG TH, 1990, NUCLEIC ACIDS RES, V18, P7180, DOI 10.1093/nar/18.23.7180; Chapman KD, 1999, PLANT PHYSIOL, V120, P1157, DOI 10.1104/pp.120.4.1157; Chapman KD, 2000, CHEM PHYS LIPIDS, V108, P221, DOI 10.1016/S0009-3084(00)00198-5; Chapman KD, 1998, PLANT PHYSIOL, V116, P1163, DOI 10.1104/pp.116.3.1163; CHEBROU H, 1996, BIOCHIM BIOPHYS ACTA, V1298, P185; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2002, CHEM PHYS LIPIDS, V121, P135, DOI 10.1016/S0009-3084(02)00147-0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; ELBING K, 2002, CURRENT PROTOCOLS MO, V1; Fowler CJ, 2001, BIOCHEM PHARMACOL, V62, P517, DOI 10.1016/S0006-2952(01)00712-2; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Goparaju SK, 1999, BBA-MOL CELL BIOL L, V1441, P77, DOI 10.1016/S1388-1981(99)00143-2; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; HASHIMOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P225, DOI 10.1016/0167-4781(91)90058-T; HILLARD CJ, 1995, J NEUROCHEM, V64, P677; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Katayama K, 1999, BBA-MOL CELL BIOL L, V1440, P205, DOI 10.1016/S1388-1981(99)00124-9; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; LAMBERT DM, 1999, CURR MED CHEM, V6, P663; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McKinney MK, 2003, J BIOL CHEM, V278, P37393, DOI 10.1074/jbc.M303922200; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Omeir RL, 1999, BIOCHEM BIOPH RES CO, V264, P316, DOI 10.1006/bbrc.1999.1524; Pappan K, 1998, ARCH BIOCHEM BIOPHYS, V353, P131, DOI 10.1006/abbi.1998.0640; Paria BC, 2000, CHEM PHYS LIPIDS, V108, P211, DOI 10.1016/S0009-3084(00)00197-3; Patricelli MP, 2000, J BIOL CHEM, V275, P19177, DOI 10.1074/jbc.M001607200; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; PERTWEE RG, 1995, EUR J PHARMACOL, V272, P73, DOI 10.1016/0014-2999(94)00618-H; Pertwee RG, 2001, PROG NEUROBIOL, V63, P569, DOI 10.1016/S0301-0082(00)00031-9; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, CHEM PHYS LIPIDS, V121, P111, DOI 10.1016/S0009-3084(02)00157-3; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Servant Florence, 2002, Brief Bioinform, V3, P246, DOI 10.1093/bib/3.3.246; Shrestha R, 2002, PLANT PHYSIOL, V130, P391, DOI 10.1104/pp.004689; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tiger G, 2000, BIOCHEM PHARMACOL, V59, P647, DOI 10.1016/S0006-2952(99)00373-1; Tripathy S, 1999, PLANT PHYSIOL, V121, P1299, DOI 10.1104/pp.121.4.1299; Tripathy S, 2003, PLANT PHYSIOL, V131, P1781, DOI 10.1104/pp.102.014936; TSUCHIYA K, 1989, J BACTERIOL, V171, P3187, DOI 10.1128/jb.171.6.3187-3191.1989; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; Ueda N, 2002, PROSTAG OTH LIPID M, V68-9, P521, DOI 10.1016/S0090-6980(02)00053-9; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545	62	53	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34990	34997		10.1074/jbc.M305613200	http://dx.doi.org/10.1074/jbc.M305613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824167	hybrid, Green Submitted			2022-12-25	WOS:000185164400032
J	Gao, ZY; Chen, YF; Randlett, MD; Zhao, XC; Findell, JL; Kieber, JJ; Schaller, GE				Gao, ZY; Chen, YF; Randlett, MD; Zhao, XC; Findell, JL; Kieber, JJ; Schaller, GE			Localization of the Raf-like kinase CTR1 to the endoplasmic reticulum of Arabidopsis through participation in ethylene receptor signaling complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GENE FAMILY; VACUOLAR MEMBRANE; RESPONSE PATHWAY; MULTIGENE FAMILY; H+-ATPASE; ETR1; PROTEIN; TOMATO; EXPRESSION	The plant hormone ethylene is perceived by a five-member family of receptors related to the bacterial histidine kinases. The Raf-like kinase CTR1 functions downstream of the ethylene receptors as a negative regulator of ethylene signal transduction. CTR1 is shown here to be associated with membranes of the endoplasmic reticulum in Arabidopsis as a result of its interactions with ethylene receptors. Membrane association of CTR1 is reduced by mutations that eliminate ethylene receptors and by a mutation in CTR1 that reduces its ability to bind to the ethylene receptor ETR1. Direct evidence that CTR1 is part of an ethylene receptor signaling complex was obtained by co-purification of the ethylene receptor ETR1 with a tagged version of CTR1 from an Arabidopsis membrane extract. The histidine kinase activity of ETR1 is not required for its association with CTR1, based on co-purification of tagged ETR1 mutants and CTR1 after expression in a transgenic yeast system. These data demonstrate that CTR1 is part of an ethylene receptor signaling complex in Arabidopsis and support a model in which localization of CTR1 to the endoplasmic reticulum is necessary for its function. Additional data that demonstrate a post-transcriptional effect of ethylene upon the expression of CTR1 suggest that production of ethylene receptor signaling complexes may be coordinately regulated.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University System Of New Hampshire; University of New Hampshire; University of North Carolina; University of North Carolina Chapel Hill	Schaller, GE (corresponding author), Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.		Kieber, Joseph/GLN-6328-2022	Kieber, Joseph/0000-0002-5766-812X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064425] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064425-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeles F, 1992, ETHYLENE PLANT BIOL; [Anonymous], 2002, ARABIDOPSIS BOOK; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bleecker AB, 1999, TRENDS PLANT SCI, V4, P269, DOI 10.1016/S1360-1385(99)01427-2; Cancel JD, 2002, PLANT PHYSIOL, V129, P1557, DOI 10.1104/pp.003780; Chang C, 1999, CURR OPIN PLANT BIOL, V2, P352, DOI 10.1016/S1369-5266(99)00004-7; Chang C, 2001, BIOESSAYS, V23, P619, DOI 10.1002/bies.1087; Chen YF, 2002, J BIOL CHEM, V277, P19861, DOI 10.1074/jbc.M201286200; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; DENECKE J, 1991, PLANT CELL, V3, P1025, DOI 10.1105/tpc.3.9.1025; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Gamble RL, 2002, PLANT PHYSIOL, V128, P1428, DOI 10.1104/pp.010777; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; Hall AE, 1999, PLANT PHYSIOL, V121, P291, DOI 10.1104/pp.121.1.291; HOFTE H, 1992, PLANT CELL, V4, P995, DOI 10.1105/tpc.4.8.995; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Huang YF, 2003, PLANT J, V33, P221, DOI 10.1046/j.1365-313X.2003.01620.x; Hyodo H., 1991, PLANT HORMONE ETHYLE; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lashbrook CC, 1998, PLANT J, V15, P243, DOI 10.1046/j.1365-313X.1998.00202.x; Leclercq J, 2002, PLANT PHYSIOL, V130, P1132, DOI 10.1104/pp.009415; LORD JM, 1987, METHOD ENZYMOL, V148, P542; LUETHY MH, 1993, PLANT PHYSIOL, V101, P931, DOI 10.1104/pp.101.3.931; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Novikova GV, 2000, FEBS LETT, V474, P29, DOI 10.1016/S0014-5793(00)01565-9; Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; Santoni V, 1999, BIOCHIMIE, V81, P655, DOI 10.1016/S0300-9084(99)80122-9; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schaller GE, 2000, ADV BOT RES, V32, P109, DOI 10.1016/S0065-2296(00)32023-7; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Solano R, 1998, CURR OPIN PLANT BIOL, V1, P393, DOI 10.1016/S1369-5266(98)80262-8; Stepanova AN, 2000, CURR OPIN PLANT BIOL, V3, P353, DOI 10.1016/S1369-5266(00)00096-0; Tieman DM, 1999, PLANT PHYSIOL, V120, P165, DOI 10.1104/pp.120.1.165; Tieman DV, 2000, P NATL ACAD SCI USA, V97, P5663, DOI 10.1073/pnas.090550597; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; Wang WY, 2003, P NATL ACAD SCI USA, V100, P352, DOI 10.1073/pnas.0237085100; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; Zhao XC, 2002, PLANT PHYSIOL, V130, P1983, DOI 10.1104/pp.011635	49	242	276	3	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34725	34732		10.1074/jbc.M305548200	http://dx.doi.org/10.1074/jbc.M305548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821658	hybrid, Green Published			2022-12-25	WOS:000185047500134
J	Meyers, G				Meyers, G			Translation of the minor capsid protein of a calicivirus is initiated by a novel termination-dependent reinitiation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMORRHAGIC-DISEASE VIRUS; OPEN READING FRAMES; MESSENGER-RNA; FELINE CALICIVIRUS; CLEAVAGE SITE; IN-VITRO; EXPRESSION; IDENTIFICATION; POLYPROTEIN; PLANT	Caliciviruses represent a family of positive strand RNA viruses responsible for a variety of syndromes in man and animals. VP10, a minor structural protein of the calicivirus rabbit hemorrhagic disease virus, is encoded in the small 3'-terminal open reading frame (ORF) 2 and is translated with an efficiency of similar to20% of the preceding ORF1. The presence of the ORF1 termination codon is crucial for VP10 expression. Translation of VP10 starts at an AUG codon located at positions -5 to -3 of the ORF1 termination codon. However, VP10 was also expressed in the absence of an AUG initiation codon. The majority of ORF1 could be deleted or replaced by different sequences without significant influence on VP10 expression as long as translation terminated at the given position. The RNA sequence of the 3'-terminal 84 nucleotides of ORF1 but not the encoded peptide was found to be crucial for VP10 expression. In contrast, nearly the entire ORF2 could be replaced by a foreign sequence without abrogation of its translation. Accordingly, VP10 is expressed in a translation termination/ reinitiation process that is particular because it is independent of an AUG translational start codon and requires the presence of a sequence element upstream of the initiation site.	Fed Res Ctr Virus Dis Anim, Dept Immunol, D-72001 Tubingen, Germany		Meyers, G (corresponding author), Fed Res Ctr Virus Dis Anim, Dept Immunol, POB 1149, D-72001 Tubingen, Germany.	gregor.meyers@tue.bfav.de						Ahmadian G, 2000, EMBO J, V19, P2681, DOI 10.1093/emboj/19.11.2681; BONIOTTI B, 1994, J VIROL, V68, P6487, DOI 10.1128/JVI.68.10.6487-6495.1994; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; CARTER MJ, 1994, ARCH VIROL, P429; CURRAN JA, 1986, J VIROL, V57, P684, DOI 10.1128/JVI.57.2.684-687.1986; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GOWDA S, 1989, P NATL ACAD SCI USA, V86, P9203, DOI 10.1073/pnas.86.23.9203; GREEN KY, 2000, VIRUS TAXONOMY, P725; Hemmings-Mieszczak M, 2000, MOL CELL BIOL, V20, P6212, DOI 10.1128/MCB.20.17.6212-6223.2000; Herbert TP, 1997, J GEN VIROL, V78, P1033, DOI 10.1099/0022-1317-78-5-1033; Herbert TP, 1996, J GEN VIROL, V77, P123, DOI 10.1099/0022-1317-77-1-123; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HORVATH CM, 1990, EMBO J, V9, P2639, DOI 10.1002/j.1460-2075.1990.tb07446.x; Kessler S W, 1981, Methods Enzymol, V73, P442; Konig M, 1998, J VIROL, V72, P4492; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2001, NUCLEIC ACIDS RES, V29, P5226, DOI 10.1093/nar/29.24.5226; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LAWSON M, 1995, NATURE, V378, P531, DOI 10.1038/378531b0; Liu S. J., 1984, Animal Husbandry and Veterinary Medicine (Xumu yu Shouyi), V16, P253; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Meyers G, 2000, VIROLOGY, V276, P349, DOI 10.1006/viro.2000.0545; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; MEYERS G, 1991, VIROLOGY, V184, P664, DOI 10.1016/0042-6822(91)90436-F; MEYERS G, 1991, VIROLOGY, V184, P677, DOI 10.1016/0042-6822(91)90437-G; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Moss B., 1996, FIELDS VIROLOGY, P2637; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Pennisi E, 1997, SCIENCE, V275, P1415, DOI 10.1126/science.275.5305.1415a; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; Rijnbrand RCA, 1996, VIROLOGY, V226, P47, DOI 10.1006/viro.1996.0626; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; Ryabova LA, 2000, GENE DEV, V14, P817; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sambrook S, 1989, MOL CLONING LAB MANU; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stacey SN, 2000, J VIROL, V74, P7284, DOI 10.1128/JVI.74.16.7284-7297.2000; STARK R, 1993, J VIROL, V67, P7088, DOI 10.1128/JVI.67.12.7088-7095.1993; Thumfart JO, 2002, VIROLOGY, V304, P352, DOI 10.1006/viro.2002.1660; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; Yueh A, 2000, GENE DEV, V14, P414	62	64	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34051	34060		10.1074/jbc.M304874200	http://dx.doi.org/10.1074/jbc.M304874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824160	hybrid			2022-12-25	WOS:000185047500054
J	Shafer, AM; Bennett, VJ; Kim, P; Voss, JC				Shafer, AM; Bennett, VJ; Kim, P; Voss, JC			Probing the binding pocket and endocytosis of a G protein-coupled receptor in live cells reported by a spin-labeled substance P agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROKININ-1 RECEPTOR; TACHYKININ NK1 RECEPTOR; LOOP-GAP RESONATOR; ANTAGONIST-BINDING; MOLECULAR CHARACTERIZATION; INDUCED INTERNALIZATION; DISULFIDE BONDS; XENOPUS OOCYTES; NK-1 RECEPTOR; PATHWAY	To probe the molecular nature of the binding pocket of a G protein-coupled receptor and the events immediately following the binding and activation, we have modified the substance P peptide, a potent agonist for the neurokinin-1 receptor, with a nitroxide spin probe specifically attached at Lys-3. The agonist properties and binding affinity of the spin-labeled substance P are similar to the native peptide. Using electron paramagnetic resonance (EPR) spectroscopy, the substance P analogue is capable of reporting the microenvironment found in the binding pocket of the receptor. The EPR spectrum of bound peptide indicates that the Lys-3 portion of the agonist is highly flexible. In addition, we detect a slight increase in the mobility of the bound peptide in the presence of a non-hydrolyzable analogue of GTP, indicative of the alternate conformational states described for this class of receptor. The down-regulation of neurokinin-tachykinin receptors is accomplished by a rapid internalization of the activated protein. Thus, it was also of interest to establish whether spin-labeled substance P could serve as a real time reporter for endocytosis. Our findings show the receptor agonist is efficiently endocytosed and the loss of EPR signal upon internalization provides a real time monitor of endocytosis. The rapid loss of signal suggests that endosomal trafficking vesicles maintain a reductive environment. Whereas the reductive capacity of the lysosome has been established, our findings indicate this capacity in early endosomes as well.	Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; NE Ohio Univ, Coll Med, Dept Neurobiol & Pharmacol, Rootstown, OH 44272 USA; Peptidogen Res, Livermore, CA 94550 USA	University of California System; University of California Davis; Northeast Ohio Medical University (NEOMED)	Voss, JC (corresponding author), Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA.			Voss, John/0000-0001-9279-209X				ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; ATHERTON E, 1979, TETRAHEDRON LETT, V32, P3041; Barbosa SR, 1999, FEBS LETT, V446, P45, DOI 10.1016/S0014-5793(99)00172-6; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BODANSKZKY M, 1978, J ORG CHEM, V44, P1622; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; CHEN K, 1989, BIOCHIM BIOPHYS ACTA, V992, P131, DOI 10.1016/0304-4165(89)90060-3; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Columbus L, 2001, BIOPHYS J, V80, p174A; COPELAND ES, 1975, BIOPHYS J, V15, P1125, DOI 10.1016/S0006-3495(75)85889-9; CORKER WR, 1966, P NATL ACAD SCI USA, V56, P1365; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; FEENER EP, 1990, J BIOL CHEM, V265, P18780; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1995, CAN J PHYSIOL PHARM, V73, P860, DOI 10.1139/y95-118; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; Fong Tung Ming, 1992, Society for Neuroscience Abstracts, V18, P454; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Grady EF, 1996, NEUROSCIENCE, V75, P1239, DOI 10.1016/0306-4522(96)00357-0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Huang RRC, 1995, BIOCHEMISTRY-US, V34, P16467, DOI 10.1021/bi00050a030; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; JOCELYN PC, 1967, EUR J BIOCHEM, V2, P327, DOI 10.1111/j.1432-1033.1967.tb00142.x; Khawaja AM, 1996, INT J BIOCHEM CELL B, V28, P721, DOI 10.1016/1357-2725(96)00017-9; Knowles P.F., 1976, MAGNETIC RESONANCE B; Kocherginsky N., 1995, NITROXIDE SPIN LABEL; Kroll C, 1999, BIOELECTROCH BIOENER, V48, P233, DOI 10.1016/S0302-4598(98)00219-0; LARSEN PJ, 1989, MOL CELL ENDOCRINOL, V65, P91, DOI 10.1016/0303-7207(89)90169-X; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)90663-5; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; MARCHETTO R, 1993, J AM CHEM SOC, V115, P11042, DOI 10.1021/ja00076a093; Marullo S, 1999, RECEPTOR CHANNEL, V6, P255; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Nakaie CR, 2002, PEPTIDES, V23, P65, DOI 10.1016/S0196-9781(01)00580-0; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; RADDATZ R, 1995, J NEUROCHEM, V64, P1183; Sachon E, 2002, J PEPT RES, V59, P232, DOI 10.1034/j.1399-3011.2002.01977.x; Sagan S, 1997, MOL PHARMACOL, V52, P120, DOI 10.1124/mol.52.1.120; Sagan S, 2001, EUR J BIOCHEM, V268, P2997, DOI 10.1046/j.1432-1327.2001.02192.x; Sagan S, 1999, J BIOL CHEM, V274, P23770, DOI 10.1074/jbc.274.34.23770; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; WEAVER EC, 1966, SCIENCE, V153, P301, DOI 10.1126/science.153.3733.301; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	61	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34203	34210		10.1074/jbc.M212712200	http://dx.doi.org/10.1074/jbc.M212712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821667	hybrid			2022-12-25	WOS:000185047500074
J	Voegtli, WC; Madrona, AY; Wilson, DK				Voegtli, WC; Madrona, AY; Wilson, DK			The structure of Aip1p, a WD repeat protein that regulates cofilin-mediated actin depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN-1; CRYSTAL-STRUCTURE; FILAMENTS; TURNOVER; HOMOLOG; BINDING; APOPTOSOME; MOLSCRIPT; DYNAMICS; ENCODES	Actin-interacting protein 1 (Aip1p) is a 67-kDa WD repeat protein known to regulate the depolymerization of actin filaments by cofilin and is conserved in organisms ranging from yeast to mammals. The crystal structure of Aip1p from Saccharomyces cerevisiae was determined to a 2.3-Angstrom resolution and a final crystallographic R-factor of 0.204. The structure reveals that the overall fold is formed by two connected seven-bladed beta-propellers and has important implications for the structure of Aip1 from other organisms and WD repeat-containing proteins in general. These results were unexpected because a maximum of 10 WD repeats had been reported in the literature for this protein using sequence data. The surfaces of the beta-propellers formed by the D-A and B-C loops are positioned adjacent to one another, giving Aip1p a shape that resembles an open "clamshell." The mapping of conserved residues to the structure of Aip1p reveals dense patches of conserved residues on the surface of one beta-propeller and at the interface of the two beta-propellers. These two patches of conserved residues suggest a potential binding site for F-actin on Aip1p and that the orientation of the beta-propellers with respect to one another plays a role in binding an actin-cofilin complex. In addition, the conserved interface between the domains is mediated by a number of interactions that appear to impart rigidity between the two domains of Aip1p and may make a large substrate-induced conformational change difficult.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Wilson, DK (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	dave@alanine.ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM66135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Adler HJ, 1999, GENOMICS, V56, P59, DOI 10.1006/geno.1998.5672; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; Hisbergues M, 2001, PROTEIN SCI, V10, P293, DOI 10.1110/ps.22701; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Konzok A, 1999, J CELL BIOL, V146, P453, DOI 10.1083/jcb.146.2.453; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 2002, J BIOL CHEM, V277, P43011, DOI 10.1074/jbc.M203111200; Ono S, 2001, J CELL BIOL, V152, P1313, DOI 10.1083/jcb.152.6.1313; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Shi YG, 2002, STRUCTURE, V10, P285, DOI 10.1016/S0969-2126(02)00732-3; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	36	63	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34373	34379		10.1074/jbc.M302773200	http://dx.doi.org/10.1074/jbc.M302773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807914	hybrid			2022-12-25	WOS:000185047500094
J	Xiao, Z; Brownawell, AM; Macara, IG; Lodish, HF				Xiao, Z; Brownawell, AM; Macara, IG; Lodish, HF			A novel nuclear export signal in Smad1 is essential for its signaling activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASM; BINDING; TRANSLOCATION; LOCALIZATION; INHIBITION; TRANSPORT; PROTEINS	To investigate the subcellular distributions of Smad proteins, the intracellular mediators of transforming growth factor-beta family cytokines, we examined their sequences for nuclear export signals (NES). We found a leucine-rich NES-like motif ( termed NES2) in the central linker region of the receptor-regulated Smads that is absent from the other two classes of Smads (Co-Smads and I-Smads). In microinjection assays, NES2 peptide caused nuclear export of a fused glutathione S-transferase protein. Mutations in NES2 converted Smad1 from an even distribution throughout the cells into an exclusive nuclear localization in both transiently and stably expressing cell lines, and this nuclear enrichment was more pronounced than that induced by mutations in NES1. Furthermore, overexpression of CRM1, the cellular export receptor, transforms Smad1 into a mostly cytoplasmic profile by enhancing its nuclear export. The Smad1 NES2 mutant but not the Smad1 NES1 mutant is mostly resistant to this cytoplasmic targeting, indicating that NES2, not NES1, is the major target for CRM1 in Smad1. We further confirmed the functionality of NES2 by a heterokaryon assay. The Smad1 NES1 mutant displays good ligand responsiveness and moderately lowered transcriptional activity compared with wild type Smad1. In contrast, the Smad1 NES2 mutant shows a severe disruption in reporter gene activation, minimal response to bone morphogenetic protein stimulation, and significantly lowered bone morphogenetic protein-induced phosphorylation, which may be the reason for its deficient transcription activity. Thus, we have defined a major NES in Smad1 that is essential for its ligand-induced coupling with cell surface receptors and hence, transcriptional activity. Our study, along with recent studies of the nucleocytoplasmic shuttling of Smad2 and Smad3 proteins, demonstrate that continued nucleocytoplasmic shuttling is a common requisite for the active signaling of R-Smads. Although conserved in other R-Smads such as Smad3, NES2 is not functional in these R-Smads because CRM1 overexpression fails to target them to cytoplasm. Possible reasons for this discrepancy are discussed.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Virginia	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MICHAEL WM, 1995, CELL, V83, P415; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	23	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34245	34252		10.1074/jbc.M301596200	http://dx.doi.org/10.1074/jbc.M301596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821673	hybrid			2022-12-25	WOS:000185047500079
J	Arikawa, K; Takuwa, N; Yamaguchi, H; Sugimoto, N; Kitayama, J; Nagawa, H; Takehara, K; Takuwa, Y				Arikawa, K; Takuwa, N; Yamaguchi, H; Sugimoto, N; Kitayama, J; Nagawa, H; Takehara, K; Takuwa, Y			Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P(2) G protein-coupled receptor - Requirement of inhibition of cellular Rac activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE; EDG FAMILY; SPHINGOSINE-1-PHOSPHATE; MOTILITY; ACTIVATION; LYSOPHOSPHOLIPIDS; PATHWAYS	We investigated mechanisms for inhibition of B16 melanoma cell migration and invasion by sphingosine-1-phosphate (S1P), which is the ligand for the Edg family G protein-coupled receptors and also implicated as an intracellular second messenger. S1P, dihydro-S1P, and sphingosylphosphorylcholine inhibited B16 cell migration and invasion with the relative potencies expected as S1P(2) receptor agonists. The S1P(2)-selective antagonist JTE013 completely abolished the responses to these agonists. In addition, JTE013 abrogated the inhibition by sphingosine, which is the S1P precursor but not an agonist for S1P receptors, indicating that the sphingosine effects were mediated via S1P(2) stimulation, most likely by S1P that was converted from sphingosine. S1P induced inhibition and activation, respectively, of Rac and RhoA in B16 cells, which were abrogated by JTE013. Adenovirus-mediated expression of N(17)Rac mimicked S1P inhibition of migration, whereas C3 toxin pretreatment, but not Rho kinase inhibitors, reversed the S1P inhibition. Overexpression of S1P(2) sensitized, and that of either S1P(1) or S1P(3) desensitized, B16 cells to S1P inhibition of Rac and migration. In JTE013-pretreated, S1P(3)-overexpressing B16 cells, S1P stimulated cellular RhoA but failed to inhibit either Rac or migration, indicating that RhoA stimulation itself is not sufficient for inhibition of migration. These results provide compelling evidence that endogenously expressed S1P(2) negatively regulates cell motility and invasion through ligand dependent reciprocal regulation of cellular Rac and RhoA activities. In the presence of JTE013, S1P instead stimulated Rac and migration in B16 cells that overexpress either S1P(1) or S1P(3), unveiling counteractions between S1P(2) and S1P(1) or S1P(3) chemotactic receptor.	Kanazawa Univ, Grad Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208640, Japan; Univ Tokyo, Grad Sch Med, Dept Surg Oncol, Tokyo 1138655, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Takuwa, N (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Physiol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ntakuwa@med.kanazawa-u.ac.jp	Sugimoto, Naotoshi/C-4739-2015	Sugimoto, Naotoshi/0000-0003-1995-5002; TAKUWA, Noriko/0000-0002-4278-2704				Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Igarashi Y, 1998, ANN NY ACAD SCI, V845, P19, DOI 10.1111/j.1749-6632.1998.tb09659.x; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; TAKUWA Y, 2001, BIOCHIM BIOPHYS ACTA, V1582, P112; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	32	131	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32841	32851		10.1074/jbc.M305024200	http://dx.doi.org/10.1074/jbc.M305024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810709	hybrid, Green Submitted			2022-12-25	WOS:000184901800045
J	Geisbrecht, BV; Dowd, KA; Barfield, RW; Longo, PA; Leahy, DJ				Geisbrecht, BV; Dowd, KA; Barfield, RW; Longo, PA; Leahy, DJ			Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; COLORECTAL-CANCER; COMMISSURAL AXONS; MOTOR AXONS; DROSOPHILA; GUIDANCE; CNS; IDENTIFICATION; ATTRACTION; ACTIVATION	Netrins are secreted proteins that elicit both attractive and repulsive responses in migrating cells in the central and peripheral nervous systems. Netrins interact with members of two distinct families of transmembrane receptors, represented by DCC ((d) under bar eleted in (c) under bar olorectal (c) under bar ancer) and UNC5. A human netrin fragment (soluble netrin; sNetrin) was purified from an engineered Chinese hamster ovary cell line and used in a pull-down assay to map the interactions between netrin and its receptors. We find that sNetrin binds exclusively to the fifth fibronectin type III repeat of DCC and to each immunoglobulin repeat of UNC5. Both DCC and UNC5 bind to sNetrin with 1:1 stoichiometry in solution, and the minimal receptor fragments behave similarly to larger fragments in cross-linking experiments with purified sNetrin. We find no evidence for formation of a ternary complex between sNetrin and soluble forms of DCC and UNC5. We also find no evidence for an interaction between DCC and heparin and instead demonstrate that a loop on the fifth fibronectin type III repeat of DCC previously implicated in mediating interactions with heparin is important for sNetrin binding. Since netrin binds heparin, our results suggest that interactions between DCC and heparin are probably mediated by netrin.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Leahy, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, 725 N Wolfe St, Baltimore, MD 21205 USA.			Dowd, Kimberly/0000-0003-3641-6852				Bennett KL, 1997, J BIOL CHEM, V272, P26940, DOI 10.1074/jbc.272.43.26940; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Dick JM, 1996, FOREST ECOL MANAG, V87, P175, DOI 10.1016/S0378-1127(96)03827-3; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Galko MJ, 2000, J BIOL CHEM, V275, P7832, DOI 10.1074/jbc.275.11.7832; Geisbrecht BV, 1999, J BIOL CHEM, V274, P21797, DOI 10.1074/jbc.274.31.21797; Gitai Z, 2003, NEURON, V37, P53, DOI 10.1016/S0896-6273(02)01149-2; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Kappler J, 2000, BIOCHEM BIOPH RES CO, V271, P287, DOI 10.1006/bbrc.2000.2583; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Li XD, 2002, J BIOL CHEM, V277, P37788, DOI 10.1074/jbc.M205428200; Lim YS, 2002, J NEUROSCI, V22, P7080; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391	22	82	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32561	32568		10.1074/jbc.M302943200	http://dx.doi.org/10.1074/jbc.M302943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810718	hybrid			2022-12-25	WOS:000184901800012
J	Papish, AL; Ladner, CL; Turner, RJ				Papish, AL; Ladner, CL; Turner, RJ			The twin-arginine leader-binding protein, DmsD, interacts with the TatB and TatC subunits of the Escherichia coli twin-arginine translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; TRANSPORT SYSTEM; EXPORT PATHWAY; DIMETHYLSULFOXIDE REDUCTASE; MEMBRANE; COMPLEX; COMPONENTS; FORM	The twin-arginine translocase (Tat) pathway is involved in the targeting and translocation of fully folded proteins to the inner membrane and periplasm of bacteria. Proteins that use this pathway contain a characteristic twin-arginine signal sequence, which interacts with the receptor complex formed by the TatBC subunits. Recently, the DmsD protein was discovered, which binds to the twin-arginine signal sequences of the anaerobic respiratory enzymes dimethylsulfoxide reductase (DmsABC) and trimethylamine N-oxide (TMAO) reductase. In this work, the targeting of DmsD within Escherichia coli was investigated. Using cell fractionation and Western blot analysis, DmsD is found to be associated with the inner membrane of wild-type E. coli and a dmsABC mutant E. coli under anaerobic conditions. In contrast, DmsD is predominantly found in the cytoplasmic fraction of a DeltatatABCDE strain, which suggests that DmsD interacts with the membrane-associated Tat complex. Under aerobic conditions DmsD was also found primarily in the cytoplasmic fraction of wildtype E. coli, suggesting that physiological conditions have a significant effect upon the targeting of DmsD to the inner membrane. Size exclusion chromatography data and membrane washing studies indicate that DmsD is interacting tightly with an integral membrane protein and not with the lipid component of the E. coli inner membrane. Additional investigation into the nature of this interaction revealed that the TatB and TatC subunits of the translocase are important for the interaction of DmsD with the E. coli inner membrane.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Turner, RJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.		Turner, Raymond J./M-3961-2015	Turner, Raymond J./0000-0002-9263-0776; Ladner-Keay, Carol/0000-0003-0273-713X				BARRETT EL, 1985, ANNU REV MICROBIOL, V39, P131, DOI 10.1146/annurev.mi.39.100185.001023; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Gibson T., 1984, STUDIES EPSTEIN BARR; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P179; Millman JS, 2001, J BIOL CHEM, V276, P25982, DOI 10.1074/jbc.M011331200; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; PUGSLEY AP, 1993, MOL MICROBIOL, V10, P665, DOI 10.1111/j.1365-2958.1993.tb00938.x; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Sambasivarao D, 2000, J BIOL CHEM, V275, P22526, DOI 10.1074/jbc.M909289199; Sambasivarao D, 2001, J BIOL CHEM, V276, P20167, DOI 10.1074/jbc.M010369200; Sargent F, 2002, ARCH MICROBIOL, V178, P77, DOI 10.1007/s00203-002-0434-2; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; Tranier S, 2003, STRUCTURE, V11, P165, DOI 10.1016/S0969-2126(03)00008-X; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200	34	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32501	32506		10.1074/jbc.M301076200	http://dx.doi.org/10.1074/jbc.M301076200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813051	hybrid			2022-12-25	WOS:000184901800005
J	Yegneswaran, S; Mesters, RM; Griffin, JH				Yegneswaran, S; Mesters, RM; Griffin, JH			Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA BINDING; ACTIVATED PROTEIN-C; GAMMA-CARBOXYGLUTAMIC ACID; SERINE PROTEASES; SITE; DOMAIN; FLUORESCENCE; THROMBIN; EXOSITE; MEIZOTHROMBIN	To identify amino acid sequences in factor Xa (fXa) and prothrombin (fII) that may be involved in prothrombinase complex (fXa . factor Va . fII . phospholipids) assembly, synthetic peptides based on fXa and fII sequences were prepared and screened for their ability to inhibit fXa-induced clotting of normal plasma. One fII peptide (PT557-571 homologous to chymotrypsin (CHT) residues 225 - 239) and two fXa peptides (X404-418, CHT231 - 244, and X415 - 429, CHT241 - 252C) potently inhibited plasma clotting and prothrombinase activity with 50% inhibition between 41 and 115 muM peptide. Inhibition of prothrombinase by PT557 - 571 and X415 - 429 was fVa-independent, whereas the inhibition by X404 - 418 was fVa-dependent. X404 - 418 inhibited the binding of fVa to fluorescein-labeled, inhibited fXa(i) in the presence of phosphatidylcholine/ phosphatidylserine vesicles, whereas X415 - 429 inhibited binding of fII to phospholipid-bound fluorescein-labeled, inhibited fXa(i). PT557 - 571 altered the fluorescence emission of fluorescein-labeled fXa(i), showing that PT557 - 571 binds to fXa(i). These data suggest that residues 404 - 418 in fXa provide fVa binding sites, whereas residues 557 - 571 in fII and 415 - 429 in fXa mediate interactions between fXa and fII in the prothrombinase complex.	Scripps Res Inst, Dept Mol & Expt Med, MEM 180, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544, P01HL031950, R37HL052246, R01HL052246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52246, HL-31950, HL21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P6210; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MESTER RM, 1993, PROTEIN SCI, V9, P1482; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; MORITA T, 1986, J BIOL CHEM, V261, P4015; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2453; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1976, J BIOL CHEM, V251, P355; TANS G, 1991, BLOOD, V77, P2641; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1	42	40	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33312	33318		10.1074/jbc.M305906200	http://dx.doi.org/10.1074/jbc.M305906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805370	hybrid			2022-12-25	WOS:000184901800101
J	Sugahara, KN; Murai, T; Nishinakamura, H; Kawashima, H; Saya, H; Miyasaka, M				Sugahara, KN; Murai, T; Nishinakamura, H; Kawashima, H; Saya, H; Miyasaka, M			Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE GENE-EXPRESSION; NITRIC-OXIDE SYNTHASE; SMALL G-PROTEINS; ANGIOGENIC OLIGOSACCHARIDES; MURINE MACROPHAGES; DEPENDENT MECHANISM; MOUSE MACROPHAGES; ENDOTHELIAL-CELLS; DENDRITIC CELLS; BLADDER-CANCER	CD44 is an adhesion molecule that serves as a cell surface receptor for several extracellular matrix components, including hyaluronan ( HA). The proteolytic cleavage of CD44 from the cell surface plays a critical role in the migration of tumor cells. Although this cleavage can be induced by certain stimuli such as phorbol ester and anti-CD44 antibodies in vitro, the physiological inducer of CD44 cleavage in vivo is unknown. Here, we demonstrate that HA oligosaccharides of a specific size range induce CD44 cleavage from tumor cells. Fragmented HA containing 6-mers to 14-mers enhanced CD44 cleavage dose-dependently by interacting with CD44, whereas a large polymer HA failed to enhance CD44 cleavage, although it bound to CD44. Examination using uniformly sized HA oligosaccharides revealed that HAs smaller than 36 kDa significantly enhanced CD44 cleavage. In particular, the 6.9-kDa HA (36-mers) not only enhanced CD44 cleavage but also promoted tumor cell motility, which was completely inhibited by an anti-CD44 monoclonal antibody. These results raise the possibility that small HA oligosaccharides, which are known to occur in various tumor tissues, promote tumor invasion by enhancing the tumor cell motility that may be driven by CD44 cleavage.	Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan	Osaka University; Kumamoto University	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Miyasaka, Masayuki/AAM-6343-2020; Saya, Hideyuki/J-4325-2013					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; DAHL IMS, 1988, CANCER-AM CANCER SOC, V62, P326, DOI 10.1002/1097-0142(19880715)62:2<326::AID-CNCR2820620217>3.0.CO;2-Y; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Fujisaki T, 1999, CANCER RES, V59, P4427; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Ishiwatari-Hayasaka H, 1999, J IMMUNOL, V163, P1258; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KUMAR S, 1989, INT J CANCER, V44, P445, DOI 10.1002/ijc.2910440311; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lesley J, 2000, J BIOL CHEM, V275, P26967; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Montesano R, 1996, LAB INVEST, V75, P249; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Pham HT, 1997, CANCER RES, V57, P778; ROONEY P, 1993, J CELL SCI, V105, P213; Ropponen K, 1998, CANCER RES, V58, P342; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Xu HP, 2002, J BIOL CHEM, V277, P17308, DOI 10.1074/jbc.M112371200; Yang TB, 2002, CANCER RES, V62, P2583; Zeng CX, 1998, INT J CANCER, V77, P396	47	158	168	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32259	32265		10.1074/jbc.M300347200	http://dx.doi.org/10.1074/jbc.M300347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801931	hybrid			2022-12-25	WOS:000184782100101
J	Zhao, L; Buckman, B; Seto, M; Morser, J; Nagashima, M				Zhao, L; Buckman, B; Seto, M; Morser, J; Nagashima, M			Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA CARBOXYPEPTIDASES; PROCARBOXYPEPTIDASE-B; PLASMINOGEN SYSTEM; CRYSTAL-STRUCTURE; INACTIVATOR; BRADYKININ; RESOLUTION; KININS	Thrombin-activable fibrinolysis inhibitor (TAFI) is a zymogen that inhibits the amplification of plasmin production when converted to its active form (TAFIa). TAFI is structurally very similar to pancreatic procarboxypeptidase B. TAFI also shares high homology in zinc binding and catalytic sites with the second basic carboxypeptidase present in plasma, carboxypeptidase N. We investigated the effects of altering residues involved in substrate specificity to understand how they contribute to the enzymatic differences between TAFI and carboxypeptidase N. We expressed wild type TAFI and binding site mutants in 293 cells. Recombinant proteins were purified and characterized for their activation and enzymatic activity as well as functional activity. Although the thrombin/thrombomodulin complex activated all the mutants, carboxypeptidase B activity of the activated mutants against hippuryl-arginine was reduced. Potato carboxypeptidase inhibitor inhibited the residual activity of the mutants. The functional activity of the mutants in a plasma clot lysis assay correlated with their chromogenic activity. The effect of the mutations on other substrates depended on the particular mutation, with some of the mutants possessing more activity against hippuryl-His-leucine than wild type TAFIa. Thus mutations in residues around the substrate binding site of TAFI resulted in altered C-terminal substrate specificity.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94806 USA; Berlex Biosci, Dept Med Chem, Richmond, CA 94806 USA; Berlex Biosci, Dept Biophys, Richmond, CA 94806 USA		Zhao, L (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94806 USA.	lei_zhao@berlex.com						AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; Bajzar L, 2000, ARTERIOSCL THROM VAS, V20, P2511, DOI 10.1161/01.ATV.20.12.2511; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; COLL M, 1991, EMBO J, V10, P1; EATON DL, 1991, J BIOL CHEM, V266, P21833; Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; Nagashima M, 2000, THROMB RES, V98, P333, DOI 10.1016/S0049-3848(00)00184-5; Nesheim M, 2001, ANN NY ACAD SCI, V936, P247; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; Plow EF, 1997, TRENDS CARDIOVAS MED, V7, P71, DOI 10.1016/S1050-1738(97)00012-1; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REGOLI D, 1980, PHARMACOL REV, V32, P1; Samanta U, 1999, ACTA CRYSTALLOGR D, V55, P1421, DOI 10.1107/S090744499900726X; Schatteman K, 2001, CLIN APPL THROMB-HEM, V7, P93, DOI 10.1177/107602960100700203; SCHMID MF, 1976, J MOL BIOL, V103, P175, DOI 10.1016/0022-2836(76)90058-9; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Skidgel R. A., 1996, ZINC METALLOPROTEASE, P241; SKIDGEL RA, 1998, HDB PROTEOLYTIC ENZY; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Zhao L, 1998, THROMB HAEMOSTASIS, V80, P949	28	9	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32359	32366		10.1074/jbc.M300803200	http://dx.doi.org/10.1074/jbc.M300803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799375	hybrid			2022-12-25	WOS:000184782100114
J	Takahashi, S; Mendelsohn, ME				Takahashi, S; Mendelsohn, ME			Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt - Calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-BOUND eNOS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHORYLATION; ESTROGEN-RECEPTOR; NO RELEASE; KINASE; CELLS; HEAT-SHOCK-PROTEIN-90; BINDING; SITES	Endothelial nitric-oxide synthase (eNOS), which generates the endogenous vasodilator, nitric oxide (NO), is highly regulated by post-translational modifications and protein interactions. We recently used purified proteins to characterize the mechanisms by which heat shock protein 90 (HSP90) increases eNOS activity at low and high Ca2+ levels (Takahashi, S. and Mendelsohn, M. E. (2003) J. Biol. Chem. 278, 9339-9344). Here we extend these studies to explore interactions between HSP90, Akt, and eNOS. In studies with purified proteins, HSP90 increased the initial rate and maximal extent of Akt-mediated eNOS phosphorylation and activation at low Ca2+ levels. Akt was not observed in the eNOS complex in the absence of HSP90, but both active and inactive Akt associated with eNOS in the presence of HSP90. Direct binding of Akt to HSP90 was observed even in the absence of eNOS. HSP90 also facilitated CaM binding to eNOS irrespective of Akt presence. Geldanamycin (GA) disrupted HSP90-eNOS binding, reduced HSP90-stimulated CaM binding, and blocked both recruitment of Akt to the eNOS complex and phosphorylation of eNOS at Ser-1179. Akt phosphorylated only CaM-bound eNOS, in an HSP90-independent manner. HSP90 and active Akt together increased eNOS activity synergistically, which was reversed by GA. In bovine aortic endothelial cells (BAECs), the effects of vascular endothelial growth factor (VEGF) and insulin on eNOS-HSP90-Akt complex formation and eNOS activation were compared. BAPTA-AM inhibited VEGF- but not insulin-induced eNOS-HSP90-Akt complex formation and eNOS phosphorylation. Insulin caused rapid, transient increase in eNOS activity correlated temporally with the formation of eNOS-HSP90-Akt complex. GA prevented insulin-induced association of HSP90, Akt and CaM with eNOS and inhibited eNOS activation in BAECs. Both platelet-derived growth factor (PDGF) and insulin induced activation of Akt in BAECs, but only insulin caused HSP90-Akt-eNOS association and eNOS phosphorylation. These results demonstrate that HSP90 and Akt synergistically activate eNOS and suggest that this synergy contributes to Ca2+-independent eNOS activation in response to insulin.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr Hosp, Dept Med, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr Hosp, Div Cardiol, Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	mmendelsohn@tufts-nemc.org						Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Harris MB, 2000, GEN PHARMACOL-VASC S, V35, P165, DOI 10.1016/S0306-3623(01)00104-5; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Smith PJ, 2002, SIGHT SOUND, V12, P32; Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200; TSIEN R, 1989, METHOD ENZYMOL, V172, P230	24	160	167	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30821	30827		10.1074/jbc.M304471200	http://dx.doi.org/10.1074/jbc.M304471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12799359	hybrid			2022-12-25	WOS:000184658800051
J	Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA				Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA			Epigenetic silencing of multiple interferon pathway genes after cellular immortalization	ONCOGENE			English	Article						senescence; immortalization; interferon gene silencing; LI-Fraumeni syndrome	LI-FRAUMENI-SYNDROME; INDUCIBLE NEGATIVE REGULATOR; HUMAN-CELLS; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; DNA METHYLATION; EPITHELIAL-CELLS; CPG ISLAND; CANCER; EXPRESSION	Abrogating cellular senescence is a necessary step in the formation of a cancer cell. Promoter hypermethylation is an epigenetic mechanism of gene regulation known to silence gene expression in carcinogenesis. Treatment of spontaneously immortal Li-Fraumeni fibroblasts with 5-aza-2'-deoxycytidine (5AZA-dC), an inhibitor of DNA methyltransferase (DNMT), induces a senescence-like state. We used microarrays containing 12 558 genes to determine the gene expression pro. le associated with cellular immortalization and also regulated by 5AZA-dC. Remarkably, among 85 genes with methylation-dependent downregulation (silencing) after immortalization, 39 (46%) are known to be regulated during interferon signaling, a known growth-suppressive pathway. This work indicates that gene silencing may be associated with an early event in carcinogenesis, cellular immortalization.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Tainsky, MA (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.		Studitskaia, Olga/D-8551-2014; Draghici, Sorin/B-3074-2013	Studitskaia, Olga/0000-0001-5417-9964; Draghici, Sorin/0000-0002-0786-8377; Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P30CA022453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bechter OE, 2002, EXP HEMATOL, V30, P26, DOI 10.1016/S0301-472X(01)00760-3; Bender CM, 1998, CANCER RES, V58, P95; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Dessain SK, 2000, CANCER RES, V60, P537; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 2000, BIOGERONTOLOGY, V1, P103, DOI 10.1023/A:1010000132671; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Harada M, 2001, J IMMUNOTHER, V24, P323, DOI 10.1097/00002371-200107000-00008; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Liang G, 2002, CANCER RES, V62, P961; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; Mori Y, 2001, CANCER RES, V61, P6046; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wen Y, 2001, CANCER RES, V61, P7142; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	49	112	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4118	4127		10.1038/sj.onc.1206594	http://dx.doi.org/10.1038/sj.onc.1206594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821946				2022-12-25	WOS:000183707600015
J	Hayashida, T; deCaestecker, M; Schnaper, HW				Hayashida, T; deCaestecker, M; Schnaper, HW			Cross-talk between ERK MAP kinase and Smad-signaling pathways enhances TGF-beta dependent responses in human mesangial cells	FASEB JOURNAL			English	Article						signal transduction; kidney cells; collagen; fibrogenesis	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; FIBRONECTIN SYNTHESIS; EXTRACELLULAR-MATRIX; REGULATED KINASE; BINDING-PROTEIN; EXPRESSION; GENE; RAS	Transforming growth factor beta (TGF-beta) stimulates renal cell fibrogenesis by a poorly understood mechanism. Previously, we suggested a synergy between TGF-beta1 activated extracellular signal regulated kinase (ERK) and Smad signaling in collagen production by human glomerular mesangial cells. In a heterologous DNA binding transcription assay, biochemical or dominant-negative ERK blockade reduced TGF-beta1 induced Smad3 activity. Total serine phosphorylation of Smad2/3, but not phosphorylation of the C-terminal (SSXSP)-X-P motif, was de creased by pretreatment with the MEK/ERK inhibitors, PD98059 (10 muM) or U0126 (25 muM). This effect was not seen in the mouse mammary epithelial NMuMG cell line, indicating that ERK-dependent activation of Smad2/3 occurs only in certain cell types. TGF-beta stimulated phosphorylation of an expressed S m ad 3 A construct, wit h a mutated C-terminal (SSXSP)-X-P motif, was reduced by a MEK/ERK inhibitor. In contrast, MEK/ERK inhibition did not affect phosphorylation of a Smad3 construct mutated at consensus phosphorylation sites in the linker region (Smad3EPSM). Constitutively active MEK (caMEK) induced alpha2(I) collagen promoter activity, an effect blocked by co-transfected Smad3EPSM, but not Smad3A. The effects of caMEK and TGF-alpha1 on collagen promoter activity were additive. These results indicate that ERK-dependent R-Smad linker region phosphorylation enhances collagen I synthesis and imply positive cross talk between the ERK and Smad pathways in human mesangial cells.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Vanderbilt Univ, Dept Med Hypertens & Nephrol, Nashville, TN USA	Northwestern University; Feinberg School of Medicine; Vanderbilt University	Hayashida, T (corresponding author), Northwestern Univ W140, Feinberg Sch Med, 303 E Chicago Ave,Ward 12-112, Chicago, IL 60611 USA.	hayashida@northwestern.edu		Hayashida, Tomoko/0000-0002-4160-7859	NIDDK NIH HHS [R01 DK049362] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049362] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BRUIJN JA, 1994, J LAB CLIN MED, V123, P34; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Frey RS, 1997, CANCER RES, V57, P628; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kitamura M, 1997, NEPHROL DIAL TRANSPL, V12, P669, DOI 10.1093/ndt/12.4.669; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, GENE DEV, V14, P627; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MCKAY NG, 1993, EXP MOL PATHOL, V59, P211, DOI 10.1006/exmp.1993.1040; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; SUZUKI S, 1993, EXP NEPHROL, V1, P229; TOMOOKA S, 1992, KIDNEY INT, V42, P1462, DOI 10.1038/ki.1992.442; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakmovych I, 2001, FASEB J, V15, P553; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	69	317	335	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1576	+		10.1096/fj.03-0037fje	http://dx.doi.org/10.1096/fj.03-0037fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824291				2022-12-25	WOS:000183818000018
J	Minchenko, AG; Stevens, MJ; White, L; Abatan, OI; Komjati, K; Pacher, P; Szabo, C; Obrosova, IG				Minchenko, AG; Stevens, MJ; White, L; Abatan, OI; Komjati, K; Pacher, P; Szabo, C; Obrosova, IG			Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(adp-ribose) polymerase activation	FASEB JOURNAL			English	Article						3-aminobenzamide; diabetic nephropathy; 1,5-isoquinolinediol; poly(ADP-ribosyl)ation; streptozotocin-diabetic rat	ALPHA-LIPOIC ACID; NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; GLOMERULAR-LESIONS; PERIPHERAL-NERVE; GENE-EXPRESSION; TRANSGENIC MICE; GROWTH-FACTOR; UP-REGULATION	We hypothesize the poly (ADP-ribosyl)ation, that is, poly (ADP-ribose) polymerase (PARP)-dependent transfer of ADP-ribose moieties from NAD to nuclear proteins, plays a role in diabetic nephropathy. We evaluated whether PARP activation is present and whether two unrelated PARP inhibitors, 3-aminobenzamide (ABA) and 1,5-isoquinolinediol (ISO), counteract overexpression of endothelin-1 (ET-1) and ET receptors in the renal cortex in short-term diabetes. The studies were performed in control rats and streptozotocin-diabetic rats treated with/without ABA or ISO (30 and 3 mg*kg-1*day(-1), intraperitoneally, <LF>for 2 weeks after 2 weeks of diabetes). Poly (ADP-ribose) immunoreactivity was increased in tubuli, but not glomeruli, of diabetic rats and this increase was corrected by ISO, whereas ABA had a weaker effect. ET-1 concentration (ELISA) was increased in diabetic rats, and this elevation was blunted by ISO. ET-1, ET(A), and ET(B) mRNA (ribonuclease protection assay), but not ET-3 mRNA (RT/PCR), abundance was increased in diabetic rats and three variable were at least partially corrected by ISO. ABA produced a trend towards normalization of ET-1 concentration and ET-1, ET(A), and ET(B) mRNA abundance, but the differences with untreated diabetic group were not significant. Poly(ADP-ribosyl)ation is involved in diabetes-induced renal overexpression of ET-1 and ET receptors. PARP inhibitors could provide a novel therapeutic approach for diabetic complications including nephropathy, and other diseases that involve the endothelin system.	Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Inotek Pharmaceut Corp, Beverly, MA USA	University of Michigan System; University of Michigan; Jefferson University; Inotek Pharmaceuticals	Obrosova, IG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB 2,Room 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu	Pacher, Pal/B-6378-2008; Szabo, Csaba/D-1882-2013; Minchenko, Oleksandr/AAV-5742-2020; Szabo, Csaba/ABG-2644-2021	Pacher, Pal/0000-0001-7036-8108; Minchenko, Oleksandr/0000-0002-7093-5173				ANDREONE TL, IN PRESS J IMMUNOL; Arikawa E, 2001, J HYPERTENS, V19, P803, DOI 10.1097/00004872-200104000-00018; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Beisswenger PJ, 2001, CLIN LAB MED, V21, P53; Benigni A, 1998, DIABETES, V47, P450, DOI 10.2337/diabetes.47.3.450; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Boffa JJ, 2001, HYPERTENSION, V37, P490, DOI 10.1161/01.HYP.37.2.490; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Cameron NE, 1996, J PHARMACOL EXP THER, V278, P1262; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen HC, 2000, J LAB CLIN MED, V135, P309, DOI 10.1067/mlc.2000.105616; Chen S, 2002, NEPHRON, V90, P86, DOI 10.1159/000046319; Cooper ME, 2001, DIABETOLOGIA, V44, P1957, DOI 10.1007/s001250100000; DOBASHI K, 1991, VIRCHOWS ARCH B, V60, P67, DOI 10.1007/BF02899529; Du X, 2002, DIABETES, V51, pA175; GomezGarre D, 1996, KIDNEY INT, V50, P962, DOI 10.1038/ki.1996.397; Gupta S, 2002, AM J PHYSIOL-CELL PH, V282, pC560, DOI 10.1152/ajpcell.00343.2001; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Haneda M, 2001, AM J KIDNEY DIS, V38, pS178, DOI 10.1053/ajkd.2001.27438; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hocher B, 1998, J CARDIOVASC PHARM, V31, pS492, DOI 10.1097/00005344-199800001-00141; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Itoh Y, 2001, HORM RES, V56, P165, DOI 10.1159/000048113; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Khan MA, 1999, NEPHRON, V83, P261, DOI 10.1159/000045519; Lal MA, 2000, DIABETES, V49, P1381, DOI 10.2337/diabetes.49.8.1381; Lariviere R, 1998, AM J HYPERTENS, V11, P989, DOI 10.1016/S0895-7061(98)00088-0; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Liaudet L, 2001, BRIT J PHARMACOL, V133, P1424, DOI 10.1038/sj.bjp.0704185; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Melhem MF, 2002, J AM SOC NEPHROL, V13, P108, DOI 10.1681/ASN.V131108; Melhem MF, 2001, J AM SOC NEPHROL, V12, P124, DOI 10.1681/ASN.V121124; MINCHENKO A, 1994, LAB INVEST, V71, P374; Minchenko AG, 1999, ENDOTHELIUM-NEW YORK, V6, P303, DOI 10.3109/10623329909078497; Nakamura T, 1996, NEPHROL DIAL TRANSPL, V11, P1528; Oates, 1999, Expert Opin Investig Drugs, V8, P2095, DOI 10.1517/13543784.8.12.2095; OBROSOVA I, 2002, OPHTHALM RES S1, V34, P128; Obrosova IG, 2003, FREE RADICAL BIO MED, V34, P186, DOI 10.1016/S0891-5849(02)01195-4; Obrosova IG, 2002, DIABETOLOGIA, V45, pA323; Obrosova IG, 2002, INT REV NEUROBIOL, V50, P3; Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631; Oku H, 2001, RETINA-J RET VIT DIS, V21, P647, DOI 10.1097/00006982-200112000-00013; Ortiz A, 1997, J INVEST MED, V45, P50; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Reddi AS, 1997, BIOCHEM BIOPH RES CO, V235, P598, DOI 10.1006/bbrc.1997.6836; Schnackenberg CG, 2001, KIDNEY INT, V59, P1859, DOI 10.1046/j.1523-1755.2001.0590051859.x; Shindo T, 2002, J MOL MED, V80, P105, DOI 10.1007/s00109-001-0284-4; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Song Y, 1999, MOL BIOL CELL, V10, P1609, DOI 10.1091/mbc.10.5.1609; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; STEVENS EJ, 1995, BRIT J PHARMACOL, V115, P373, DOI 10.1111/j.1476-5381.1995.tb15888.x; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 2002, CIRCULATION, V106, P2680, DOI 10.1161/01.CIR.0000038365.78031.9C; Theuring F, 1998, J CARDIOVASC PHARM, V31, pS489, DOI 10.1097/00005344-199800001-00140; TRACHTMAN H, 1995, AM J PHYSIOL-RENAL, V269, pF429, DOI 10.1152/ajprenal.1995.269.3.F429; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; VIOSSAT I, 1990, ARCH MAL COEUR VAISS, V83, P1263; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vogel V, 1999, CLIN SCI, V97, P91, DOI 10.1042/CS19980369; WONG M, 1995, BIOCHEM MOL BIOL INT, V35, P1359; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yorio T, 2002, J GLAUCOMA, V11, P259, DOI 10.1097/00061198-200206000-00016; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang WP, 1997, BIOCHEM MOL MED, V61, P58, DOI 10.1006/bmme.1997.2592	71	88	97	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1514	+		10.1096/fj.03-0013fje	http://dx.doi.org/10.1096/fj.03-0013fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824290	Green Submitted			2022-12-25	WOS:000183818000032
J	Wolff, N; Sapriel, G; Bodenreider, C; Chaffotte, A; Delepelaire, P				Wolff, N; Sapriel, G; Bodenreider, C; Chaffotte, A; Delepelaire, P			Antifolding activity of the SecB chaperone is essential for secretion of HasA, a quickly folding ABC pathway substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; HEME ACQUISITION-SYSTEM; ESCHERICHIA-COLI; SERRATIA-MARCESCENS; MOLECULAR CHAPERONE; PHYSIOLOGICAL LIGAND; SELECTIVE BINDING; CRYSTAL-STRUCTURE; EXPORT; TRANSPORTER	We have previously shown that SecB, the ATP-independent chaperone of the Sec pathway, is required for the secretion of the HasA hemophore from Serratia marcescens via its type I secretion pathway, both in the reconstituted system in Escherichia coli and in the original host. The refolding of apo-HasA after denaturation with guanidine HCl was followed by stopped-flow measurements of fluorescence of its single tryptophan, both in the absence and presence of SecB. In the absence of SecB, HasA folds very quickly with one main phase (45 s(-1)) accounting for 92% of the signal. SecB considerably slows down HasA folding. At stoichiometric amounts of SecB and HasA, a single phase (0.014 s(-1)) of refolding is observed. Two double point mutants of HasA were made, abolishing two hydrogen bonds between N-terminal and C-terminal side chain residues. In both cases, the mutants essentially maintained the same secondary and tertiary structure as wild-type HasA and were fully functional. Refolding of both mutants was much slower than that of wild-type HasA and they were secreted essentially independently of SecB. We conclude that SecB has mainly an antifolding function in the HasA ABC secretion pathway.	Inst Pasteur, CNRS, UMR 2172, Unite Membranes Bacteriennes, F-75724 Paris 15, France; Inst Pasteur, CNRS, UMR 2172, Unite Resonance Magnet Nucl Biomol, F-75724 Paris 15, France; Inst Pasteur, CNRS, UMR 2172, Unite Repliement & Modelisat Prot, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Delepelaire, P (corresponding author), Inst Pasteur, CNRS, UMR 2172, Unite Membranes Bacteriennes, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	pdelep@pasteur.fr		Delepelaire, Philippe/0000-0002-5190-7118				ALTMAN E, 1990, J BIOL CHEM, V265, P18148; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; COLLIER DN, 1993, ADV PROTEIN CHEM, V44, P151, DOI 10.1016/S0065-3233(08)60567-7; COLLIER DN, 1989, J BACTERIOL, V171, P4640, DOI 10.1128/jb.171.9.4640-4647.1989; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; Debarbieux L, 2001, EMBO J, V20, P4657, DOI 10.1093/emboj/20.17.4657; Delepelaire P, 1998, EMBO J, V17, P936, DOI 10.1093/emboj/17.4.936; Diamond DL, 1997, J BIOL CHEM, V272, P28994, DOI 10.1074/jbc.272.46.28994; Driessen AJM, 2001, TRENDS MICROBIOL, V9, P193, DOI 10.1016/S0966-842X(01)01980-1; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Ghigo JM, 1997, J BACTERIOL, V179, P3572, DOI 10.1128/jb.179.11.3572-3579.1997; HARDY SJS, 1993, PHILOS T R SOC B, V339, P343, DOI 10.1098/rstb.1993.0033; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Izadi N, 1997, BIOCHEMISTRY-US, V36, P7050, DOI 10.1021/bi962577s; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; LETOFFE S, 1994, J BACTERIOL, V176, P5372; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; Rossi MS, 2001, INFECT IMMUN, V69, P6707, DOI 10.1128/IAI.69.11.6707-6717.2001; Sapriel G, 2003, J BACTERIOL, V185, P80, DOI 10.1128/JB.185.1.80-88.2003; Sapriel G, 2002, J BIOL CHEM, V277, P6726, DOI 10.1074/jbc.M108632200; Smith VF, 1997, PROTEIN SCI, V6, P1746, DOI 10.1002/pro.5560060815; Stenberg G, 1997, J MOL BIOL, V274, P268, DOI 10.1006/jmbi.1997.1398; TOPPING TB, 1994, PROTEIN SCI, V3, P730; Topping TB, 1997, J BIOL CHEM, V272, P19314, DOI 10.1074/jbc.272.31.19314; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040	35	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38247	38253		10.1074/jbc.M302322200	http://dx.doi.org/10.1074/jbc.M302322200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12829711	hybrid			2022-12-25	WOS:000185575100021
J	Siegel, PM; Shu, WP; Massague, J				Siegel, PM; Shu, WP; Massague, J			Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; MAMMARY-GLAND DEVELOPMENT; MYC ANTAGONIST MAD1; TGF-BETA; C-MYC; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; CYCLE ARREST; GROWTH-FACTOR-BETA-1 TRANSGENE; TUMOR SUPPRESSION	The growth inhibitory cytokine TGF-beta enforces homeostasis of epithelia by activating processes such as cell cycle arrest and apoptosis. Id2 expression is often highest in proliferating epithelial cells and declines during differentiation. Recently, Id2 expression has been found to depend on Myc-Max transcriptional complexes. We observed that TGF-beta signaling inhibits Id2 expression in human and mouse epithelial cell lines from different tissue origins. Furthermore, the observed Id2 down-regulation by TGF-beta in mouse mammary epithelial cells occurs without a concurrent drop in c-Myc levels. However, sustained Id2 repression in these cells and in human keratinocytes coincides with induction of the Myc antagonistic repressors Mad2 and Mad4, decreased formation of Myc-Max heterodimers and the replacement of Myc-Max complexes with Mad-Max complexes on the Id2 promoter. These results argue that induction of Mad expression and Id2 down-regulation are important events during the TGF-beta cytostatic program in epithelial cells.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA94060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Norton JD, 2000, J CELL SCI, V113, P3897; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 2001, MOL CELL BIOL, V21, P703, DOI 10.1128/MCB.21.3.703-712.2001; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; ROBINSON SD, 1993, J CELL BIOL, V120, P245, DOI 10.1083/jcb.120.1.245; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937	55	72	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35444	35450		10.1074/jbc.M301413200	http://dx.doi.org/10.1074/jbc.M301413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824180	hybrid			2022-12-25	WOS:000185164400085
J	LaVoie, MJ; Selkoe, DJ				LaVoie, MJ; Selkoe, DJ			The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DORSAL-VENTRAL BOUNDARY; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; TRANSMEMBRANE ASPARTATES; NUCLEAR-LOCALIZATION; PLANAR POLARITY; BETA-APP; DROSOPHILA; CLEAVAGE	The cleavage of Notch by presenilin (PS)/ gamma-secretase is a salient example of regulated intramembrane proteolysis, an unusual mechanism of signal transduction. This cleavage is preceded by the binding of protein ligands to the Notch ectodomain, activating its shedding. We hypothesized that the Notch ligands, Delta and Jagged, themselves undergo PS-mediated regulated intramembrane proteolysis. Here, we show that the ectodomain of mammalian Jagged is cleaved by an A disintegrin and metalloprotease ( ADAM) 17-like activity in cultured cells and in vivo, similar to the known cleavage of Drosophila Delta by Kuzbanian. The ectodomain shedding of ligand can be stimulated by Notch and yields membrane-tethered C-terminal fragments (CTFs) of Jagged and Delta that accumulate in cells expressing a dominant-negative form of PS or treated with gamma-secretase inhibitors. PS forms stable complexes with Delta and Jagged and with their respective CTFs. PS/gamma-secretase then mediates the cleavage of the latter to release the Delta and Jagged intracellular domains, a portion of which can enter the nucleus. The ligand CTFs compete with an activated form of Notch for cleavage by gamma-secretase and can thus inhibit Notch signaling in vitro. The soluble Jagged intracellular domain can activate gene expression via the transcription factor AP1, and this effect is counteracted by the co-expression of the gamma-secretase-cleaved product of Notch, Notch intracellular domain. We conclude that Delta and Jagged undergo ADAM-mediated ectodomain processing followed by PS-mediated intramembrane proteolysis to release signaling fragments. Thus, Notch and its cognate ligands are processed by the same molecular machinery and may antagonistically regulate each other's signaling.	Brigham & Womens Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02215 USA.	DSelkoe@rics.bwh.harvard.edu		LaVoie, Matthew/0000-0002-2583-1578	NIA NIH HHS [AG00222, AG06173, AG15379] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006173, R01AG006173, P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deCelis JF, 1996, DEVELOPMENT, V122, P2719; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hooper NM, 2000, ADV EXP MED BIOL, V477, P379; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Jonsson F, 1996, DEV GENES EVOL, V206, P91, DOI 10.1007/s004270050035; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Skovronsky DM, 2000, P NATL ACAD SCI USA, V97, P7609, DOI 10.1073/pnas.97.13.7609; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMAS U, 1995, GENETICS, V139, P203; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Weber U, 2000, DEVELOPMENT, V127, P3619; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	78	290	301	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34427	34437		10.1074/jbc.M302659200	http://dx.doi.org/10.1074/jbc.M302659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826675	hybrid			2022-12-25	WOS:000185047500101
J	Fong, CW; Leong, HF; Wong, ESM; Lim, J; Yusoff, P; Guy, GR				Fong, CW; Leong, HF; Wong, ESM; Lim, J; Yusoff, P; Guy, GR			Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RAS/MAPK SIGNALING PATHWAY; TRANSLOCATION DOMAIN; PROTEIN; KINASE; ACTIVATION; BINDING; IDENTIFICATION; INHIBITOR	Mammalian Sprouty ( Spry) proteins are now established as receptor tyrosine kinase-induced modulators of the Ras/mitogen-activated protein kinase pathway. Specifically, hSpry2 inhibits the fibroblast growth factor receptor (FGFR)-induced mitogen-activated protein kinase pathway but conversely prolongs activity of the same pathway following epidermal growth factor (EGF) stimulation, where activated EGF receptors are retained on the cell surface. In this study it is demonstrated that hSpry2 is tyrosine-phosphorylated upon stimulation by either FGFR or EGF and subsequently binds endogenous c-Cbl with high affinity. A conserved motif on hSpry2, together with phosphorylation on tyrosine 55, is required for its enhanced interaction with the SH2-like domain of c-Cbl. A hSpry2 mutant (Y55F) that did not exhibit an enhanced binding with c-Cbl failed to retain EGF receptors on the cell surface. Furthermore, individually mutating hSpry2 residues 52-59 to alanine indicated a tight correlation between their affinity for c-Cbl binding and their inhibition of ERK2 activity in the FGFR pathway. We postulate that tyrosine phosphorylation "activates" hSpry2 by enhancing its interaction with c-Cbl and that this interaction is critical for its physiological function in a signal-specific context.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Jormay/A-7257-2011	Lim, Jormay/0000-0001-7191-545X				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	25	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33456	33464		10.1074/jbc.M301317200	http://dx.doi.org/10.1074/jbc.M301317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815057	hybrid			2022-12-25	WOS:000184901800119
J	Ismail, TM; Hart, CA; McLennan, AG				Ismail, TM; Hart, CA; McLennan, AG			Regulation of dinucleoside polyphosphate pools by the YgdP and ApaH hydrolases is essential for the ability of Salmonella enterica serovar Typhimurium to invade cultured mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; GENE HOMOLOG INVA; DIADENOSINE 5',5'''-P-1,P-4-TETRAPHOSPHATE; BARTONELLA-BACILLIFORMIS; NUDIX HYDROLASE; HEAT-SHOCK; ADENYLYLATED NUCLEOTIDES; APPPPA; ENCODES; PYROPHOSPHOHYDROLASE	The ygdP and apaH genes of Salmonella enterica serovar Typhimurium (S. Typhimurium) encode two unrelated dinucleoside polyphosphate (NpnN) hydrolases. For example, YgdP cleaves diadenosine tetraphosphate (Ap(4)A) producing AMP and ATP, while ApaH cleaves Ap(4)A producing 2ADP. Disruption of ygdP, apaH individually, and disruption of both genes together reduced intracellular invasion of human HEp-2 epithelial cells by S. Typhimurium by 9-, 250-, and 3000-fold, respectively. Adhesion of the mutants was also greatly reduced compared with the wild type. Invasive capacity of both single mutants was restored by transcomplementation with the ygdP gene, suggesting that loss of invasion was due to increased intracellular NpnN. The normal level of 3 muM adenylated NpnN (Ap(n)N) was increased 1.5-, 3.5-, and 10-fold in the ygdP, apaH and double mutants, respectively. Expression of the putative ptsP virulence gene downstream of ygdP was not affected in the ygdP mutant. Analysis of 19 metabolic enzyme activities and the ability to use a range of carbohydrate carbon sources revealed a number of differences between the mutants and wild type. The increase in intracellular NpnN in the mutants appears to cause changes in gene expression that limit the ability of S. Typhimurium to adhere to and invade mammalian cells.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Dept Med Microbiol & Genitourinary Med, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	McLennan, AG (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,POB 147, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk						Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; AbdelRaheim SR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-5; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; FARR SB, 1989, P NATL ACAD SCI USA, V86, P5010, DOI 10.1073/pnas.86.13.5010; FLETCHER JN, 1992, INFECT IMMUN, V60, P2229, DOI 10.1128/IAI.60.6.2229-2236.1992; FUGE EK, 1993, J BACTERIOL, V175, P2321, DOI 10.1128/JB.175.8.2321-2326.1993; Galan JE, 1996, CURR TOP MICROBIOL, V209, P43; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Gaywee J, 2002, MOL CELL PROTEOMICS, V1, P179, DOI 10.1074/mcp.M100030-MCP200; Gaywee J, 2002, INFECT IMMUN, V70, P6346, DOI 10.1128/IAI.70.11.6346-6354.2002; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; GURANOWSKI A, 1989, BIOCHEM J, V262, P241, DOI 10.1042/bj2620241; GURANOWSKI A, 1983, J BIOL CHEM, V258, P4784; HELMANN JD, 1991, MOL MICROBIOL, V5, P2875, DOI 10.1111/j.1365-2958.1991.tb01847.x; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Higa F, 2001, INFECT IMMUN, V69, P4782, DOI 10.1128/IAI.69.8.4782-4789.2001; JOHNSTONE DB, 1991, EMBO J, V10, P3897, DOI 10.1002/j.1460-2075.1991.tb04959.x; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LEE PC, 1983, J BIOL CHEM, V258, P6827; LEVEQUE F, 1990, J MOL BIOL, V212, P319; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; MCLENNAN AG, 1989, BIOCHEMISTRY-US, V28, P3868, DOI 10.1021/bi00435a036; McLennan AG, 2001, DRUG DEVELOP RES, V52, P249, DOI 10.1002/ddr.1122; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; McLennan AG., 1992, AP4A OTHER DINUCLEOS; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; Murphy GA, 2000, CANCER RES, V60, P2342; Nishimura A, 1997, GENES CELLS, V2, P401, DOI 10.1046/j.1365-2443.1997.1300328.x; Nishimura A, 1998, TRENDS BIOCHEM SCI, V23, P157, DOI 10.1016/S0968-0004(98)01197-9; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; PLATEAU P, 1987, J BACTERIOL, V169, P419, DOI 10.1128/jb.169.1.419-422.1987; PLATEAU P, 1985, BIOCHEMISTRY-US, V24, P914, DOI 10.1021/bi00325a016; PRESCOTT M, 1992, INT J BIOCHEM, V24, P565, DOI 10.1016/0020-711X(92)90328-X; Rabus R, 1999, J BIOL CHEM, V274, P26185, DOI 10.1074/jbc.274.37.26185; Saarela M, 1998, ANAEROBE, V4, P139, DOI 10.1006/anae.1998.0158; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarker MR, 1997, MOL MICROBIOL, V23, P410, DOI 10.1046/j.1365-2958.1997.t01-1-00190.x; Sillero A, 2000, PHARMACOL THERAPEUT, V87, P91, DOI 10.1016/S0163-7258(00)00047-4; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	48	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32602	32607		10.1074/jbc.M305994200	http://dx.doi.org/10.1074/jbc.M305994200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12824172	hybrid			2022-12-25	WOS:000184901800017
J	Olayioye, MA; Guthridge, MA; Stomski, FC; Lopez, AF; Visvader, JE; Lindeman, GJ				Olayioye, MA; Guthridge, MA; Stomski, FC; Lopez, AF; Visvader, JE; Lindeman, GJ			Threonine 391 phosphorylation of the human prolactin receptor mediates a novel interaction with 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATASE; ACTIVATION; ASSOCIATION; IDENTIFICATION; SUPPRESSORS	The prolactin receptor (PrlR) is a member of the cytokine receptor superfamily that lacks an intrinsic kinase domain and relies on the cytoplasmic Jak tyrosine kinases to transduce signals. Prolactin-induced Jak2 activation and consequent tyrosine phosphorylation of the receptor and downstream signaling molecules have been studied, but phosphorylation of the PrlR on serine or threonine residues has not been reported. Here we describe a novel interaction between the PrlR and the phosphoserine/phosphothreonine- binding 14-3-3 proteins. This association is mediated by the (KCSTWP)-W-391 motif, which occurs in the major functional isoform of the human receptor and is conserved among a wide variety of species. Mutagenesis of threonine 391 to alanine significantly impaired 14-3-3 binding to the PrlR in both glutathione S-transferase pulldown and coimmunoprecipitation assays. In breast carcinoma and mouse mammary epithelial cell lines, the endogenous receptor was found to associate with glutathione S-transferase-14-3-3 proteins independent of prolactin stimulation. A phospho-specific peptide antibody was generated and used to demonstrate phosphorylation of Thr(391) in vivo. Phosphorylation of this site was found to be sensitive to okadaic acid, a specific inhibitor of serine/threonine protein phosphatases. Interestingly, the T391A PrlR mutant exhibited increased basal and prolactin-induced tyrosine phosphorylation compared with the wild-type receptor. This was accompanied by a ligand-induced increase in protein kinase B and Erk activation but not that of Stat5a. Phosphorylation of the receptor on Thr(391) may therefore provide a new mechanism by which prolactin signaling is attenuated.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Bone Marrow Res Labs, Melbourne, Vic 3050, Australia; Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Walter & Eliza Hall Institute	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	lindeman@wehi.edu.au	Lopez, Angel F/E-2260-2011; guthridge, mark a/I-1889-2014	guthridge, mark a/0000-0002-0536-3471; Lopez, Angel F/0000-0001-7430-0135; Lindeman, Geoffrey/0000-0001-9386-2416				Al-Sakkaf KA, 1997, J MOL ENDOCRINOL, V19, P347, DOI 10.1677/jme.0.0190347; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; Das R, 1996, ONCOGENE, V13, P1139; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Horsch K, 2001, MOL ENDOCRINOL, V15, P2182, DOI 10.1210/me.15.12.2182; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Huang XZ, 1997, GENOMICS, V44, P336, DOI 10.1006/geno.1997.4891; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kline JB, 1999, J BIOL CHEM, V274, P35461, DOI 10.1074/jbc.274.50.35461; Kline JB, 2002, MOL ENDOCRINOL, V16, P2310, DOI 10.1210/me.2001-0033; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Pezet A, 1997, J BIOL CHEM, V272, P25043, DOI 10.1074/jbc.272.40.25043; Stomski FC, 1999, BLOOD, V94, P1933; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Trott JF, 2003, J MOL ENDOCRINOL, V30, P31, DOI 10.1677/jme.0.0300031; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vincent V, 1997, J BIOL CHEM, V272, P7062, DOI 10.1074/jbc.272.11.7062; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	41	22	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32929	32935		10.1074/jbc.M302910200	http://dx.doi.org/10.1074/jbc.M302910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819209	hybrid			2022-12-25	WOS:000184901800055
J	Truniger, V; Lazaro, JM; de Vega, M; Blanco, L; Salas, M				Truniger, V; Lazaro, JM; de Vega, M; Blanco, L; Salas, M			phi 29 DNA polymerase residue Leu(384), highly conserved in motif B of eukaryotic type DNA replicases, is involved in nucleotide insertion fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ACTIVE-SITE; TERMINAL PROTEIN; AMINO-ACID; PHAGE PHI-29; O-HELIX; SECONDARY-STRUCTURE; CRYSTAL-STRUCTURES; TERNARY COMPLEXES; BINDING-PROTEIN	Replicative DNA polymerases achieve insertion fidelity by geometric selection of a complementary nucleotide followed by induced fit: movement of the fingers subdomain toward the active site to enclose the incoming and templating nucleotides generating a binding pocket for the nascent base pair. Several residues of motif B of DNA polymerases from families A and B, localized in the fingers subdomain, have been described to be involved in template/primer binding and dNTP selection. Here we complete the analysis of this motif, which has the consensus "KLX(2)NSXYG" in DNA polymerases from family B, characterized by mutational analysis of conserved leucine, Leu(384) of phi29 DNA polymerase. Mutation of Leu(384) into Arg resulted in a phi29 DNA polymerase with reduced nucleotide insertion fidelity during DNA-primed polymerization and protein-primed initiation reactions. However, the mutation did not alter the intrinsic affinity for the different dNTPs, as shown in the template-independent terminal protein-deoxy-nucleotidylation reaction. We conclude that Leu(384) of phi29 DNA polymerase plays an important role in positioning the templating nucleotide at the polymerization active site and in controlling nucleotide insertion fidelity. This agrees with the localization of the corresponding residue in the closed ternary complexes of family A and family B DNA polymerases, contributing to form the binding pocket for the nascent base pair. As an additional effect, mutant polymerase L384R was strongly reduced in DNA binding, resulting in reduced processivity during polymerization.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, Canto Blanco, E-28049 Madrid, Spain.	msalas@cbm.uam.es	Truniger, Veronica/H-3554-2011; Salas, Margarita/J-9873-2014; de Vega, Miguel/K-2878-2014; Blanco, Luis/I-1848-2015	Truniger, Veronica/0000-0001-8221-2434; Salas, Margarita/0000-0001-5939-3441; de Vega, Miguel/0000-0003-1285-7549; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1988, J VIROL, V62, P4167, DOI 10.1128/JVI.62.11.4167-4172.1988; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1994, J BIOL CHEM, V269, P30030; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Pavlov YI, 2001, GENETICS, V159, P47; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Saturno J, 1995, J BIOL CHEM, V270, P31235, DOI 10.1074/jbc.270.52.31235; Saturno J, 1997, J MOL BIOL, V269, P313, DOI 10.1006/jmbi.1997.1053; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tosaka A, 2001, J BIOL CHEM, V276, P27562, DOI 10.1074/jbc.M010635200; Truniger V, 2002, NUCLEIC ACIDS RES, V30, P1483, DOI 10.1093/nar/30.7.1483; Truniger V, 2002, J MOL BIOL, V318, P83, DOI 10.1016/S0022-2836(02)00022-0; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	57	5	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33482	33491		10.1074/jbc.M303052200	http://dx.doi.org/10.1074/jbc.M303052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805385	hybrid			2022-12-25	WOS:000184901800122
J	Yamazaki, A; Yu, H; Yamazaki, M; Honkawa, H; Matsuura, I; Usukura, J; Yamazaki, RK				Yamazaki, A; Yu, H; Yamazaki, M; Honkawa, H; Matsuura, I; Usukura, J; Yamazaki, RK			A critical role for ATP in the stimulation of retinal guanylyl cyclase by guanylyl cyclase-activating proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; KINASE HOMOLOGY DOMAIN; CYCLIC-GMP SYNTHESIS; GTP-BINDING PROTEIN; FUNCTIONAL-CHARACTERIZATION; CGMP-PHOSPHODIESTERASE; CALCIUM MODULATION; PURIFICATION; LOCALIZATION; TRANSDUCTION	It has been believed that retinal guanylyl cyclase (retGC), a key enzyme in the cGMP recovery to the dark state, is solely activated by guanylyl cyclase-activating proteins (GCAPs) in a Ca2+-sensitive manner. However, a question has arisen as to whether the observed GCAP stimulation of retGC is sufficient to account for the cGMP recovery because the stimulated activity measured in vitro is less than the light/GTP-activated cGMP phosphodiesterase activity. Here we report that the retGC activation by GCAPs is larger than previously reported and that a preincubation with adenine nucleotide is essential for the large activation. Under certain conditions, ATP is two times more effective than adenylyl imidodiphosphate (AMP-PNP), a hydrolysis-resistant ATP analog; however, this study mainly used AMP-PNP to focus on the role of adenine nucleotide binding to retGC. When photoreceptor outer segment homogenates are preincubated with AMP-PNP (EC50 = 0.65 +/- 0.20 mM), GCAP2 enhanced the retGC activity 10 - 13 times over the control rate. Without AMP-PNP, GCAP2 stimulated the control activity only 3-4-fold as in previous reports. The large activation is due to a GCAP2-dependent increase in V-max without an alteration of retGC affinity for GCAP2 (EC50 = 47.9 +/- 2.7 nM). GCAP1 stimulated retGC activity in a similar fashion but with lower affinity (EC50 = 308 nM). In the AMP-PNP preincubation, low Ca2+ concentrations are not required, and retGC exists as a monomeric form. This large activation is accomplished through enhanced action of GCAPs as shown by Ca2+ inhibition of the activity (IC50 = 178 nM). We propose that retGC is activated by a two-step mechanism: a conformational change by ATP binding to its kinase homology domain under high Ca2+ concentrations that allows large enhancement of GCAP activation under low Ca2+ concentrations.	Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Nagoya Univ, Sch Med, Dept Anat & Cell Biol, Nagoya, Aichi 466, Japan	Wayne State University; Wayne State University; Wayne State University; Nagoya University	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA.	ayamazak@med.wayne.edu	Matsuura, Isao/E-3979-2010	Usukura, Jiro/0000-0003-2286-5403	NEI NIH HHS [EY09631] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009631] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; APARICIO JG, 1995, PROTEIN EXPRES PURIF, V6, P501, DOI 10.1006/prep.1995.1067; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIERNBAUM MS, 1979, J GEN PHYSIOL, V74, P649, DOI 10.1085/jgp.74.6.649; Bondarenko VA, 2002, MOL CELL BIOCHEM, V230, P125, DOI 10.1023/A:1014244107675; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Cooper N, 1995, J MOL NEUROSCI, V6, P211, DOI 10.1007/BF02736766; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; Cuenca N, 1998, INVEST OPHTH VIS SCI, V39, P1243; Detwiler P, 2002, NEURON, V36, P3, DOI 10.1016/S0896-6273(02)00940-6; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Duda T, 1996, BIOCHEM J, V319, P279, DOI 10.1042/bj3190279; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Duda T, 2000, BIOCHEMISTRY-US, V39, P12522, DOI 10.1021/bi001514d; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; Goraczniak R, 1997, BIOCHEM BIOPH RES CO, V234, P666, DOI 10.1006/bbrc.1997.6579; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; HAYASHI F, 1993, METH NEUROSCI, V15, P237; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Johnston JP, 1997, GENE, V193, P219, DOI 10.1016/S0378-1119(97)00125-X; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KOUTALOS Y, 1995, J GEN PHYSIOL, V106, P863, DOI 10.1085/jgp.106.5.863; KRISHNAN N, 1978, BIOCHIM BIOPHYS ACTA, V523, P506, DOI 10.1016/0005-2744(78)90053-0; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Lucas KA, 2000, PHARMACOL REV, V52, P375; Margulis A, 1996, BIOCHEM BIOPH RES CO, V218, P243, DOI 10.1006/bbrc.1996.0043; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OLSHEVSKAYA EV, 2002, ASS RES VIS OPHTH AN; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; Seno K, 1998, J BIOL CHEM, V273, P22169, DOI 10.1074/jbc.273.35.22169; Sharma RK, 2001, CAN J PHYSIOL PHARM, V79, P682, DOI 10.1139/cjpp-79-8-682; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tucker CL, 1999, P NATL ACAD SCI USA, V96, P9039, DOI 10.1073/pnas.96.16.9039; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; Yang RB, 1997, J BIOL CHEM, V272, P13738, DOI 10.1074/jbc.272.21.13738; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547	72	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33150	33160		10.1074/jbc.M303678200	http://dx.doi.org/10.1074/jbc.M303678200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799385	hybrid			2022-12-25	WOS:000184901800081
J	Haug, G; Leemhuis, J; Tiemann, D; Meyer, DK; Aktories, K; Barth, H				Haug, G; Leemhuis, J; Tiemann, D; Meyer, DK; Aktories, K; Barth, H			The host cell chaperone Hsp90 is essential for translocation of the binary Clostridium botulinum C2 toxin into the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFRINGENS IOTA-TOXIN; LIPID BILAYER-MEMBRANES; PROTECTIVE ANTIGEN; COMPONENT C2II; ANTHRAX TOXIN; ION CHANNELS; BINDING; EXPRESSION; REQUIRES; SYSTEM	Clostridium botulinum C2 toxin is the prototype of the binary actin-ADP-ribosylating toxins and consists of the binding component C2II and the enzyme component C2I. The activated binding component C2IIa forms heptamers, which bind to carbohydrates on the cell surface and interact with the enzyme component C2I. This toxin complex is taken up by receptor-mediated endocytosis. In acidic endosomes, heptameric C2IIa forms pores and mediates the translocation of C2I into the cytosol. We report that the heat shock protein (Hsp) 90-specific inhibitors, geldanamycin or radicicol, block intoxication of Vero cells, rat astrocytes, and HeLa cells by C2 toxin. ADP-ribosylation of actin in the cytosol of toxin-treated cells revealed that less active C2I was translocated into the cytosol after treatment with Hsp90 inhibitors. Under control conditions, C2I was localized in the cytosol of toxin-treated rat astrocytes, whereas geldanamycin blocked the cytosolic distribution of C2I. At low extracellular pH ( pH 4.5), which allows the direct translocation of C2I via C2IIa heptamers across the cell membrane into the cytosol, Hsp90 inhibitors retarded intoxication by C2I. Geldanamycin did not affect toxin binding, endocytosis, and pore formation by C2IIa. The ADP-ribosyltransferase activity of C2I was not affected by Hsp90 inhibitors in vitro. The cytotoxic actions of the actin-ADP-ribosylating Clostridium perfringens iota toxin and the Rho-ADP-ribosylating C2-C3 fusion toxin was similarly blocked by Hsp90 inhibitors. In contrast, radicicol and geldanamycin had no effect on anthrax lethal toxin-induced cytotoxicity of J774-A1 macrophage-like cells or on cytotoxic effects of the glucosylating Clostridium difficile toxin B in Vero cells. The data indicate that Hsp90 is essential for the membrane translocation of ADP-ribosylating toxins delivered by C2II.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Barth, H (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25 Otto Krayer Haus, D-79104 Freiburg, Germany.	Holger.Barth@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; 				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BARTH H, 2002, N-S ARCH PHARMACOL, V366, P5201; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Blocker D, 2000, INFECT IMMUN, V68, P4566, DOI 10.1128/IAI.68.8.4566-4573.2000; Blocker D, 2001, INFECT IMMUN, V69, P2980, DOI 10.1128/IAI.69.5.2980-2987.2001; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Eckhardt M, 2000, J BIOL CHEM, V275, P2328, DOI 10.1074/jbc.275.4.2328; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Hildebrand B, 1997, BRAIN RES, V759, P285, DOI 10.1016/S0006-8993(97)00268-0; Knapp O, 2002, J BIOL CHEM, V277, P6143, DOI 10.1074/jbc.M103939200; Koriazova LK, 2003, NAT STRUCT BIOL, V10, P13, DOI 10.1038/nsb879; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; Ohishi I, 2000, HANDB EXP PHARM, V145, P253; Olsnes S, 2000, HANDB EXP PHARM, V145, P1; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028; SCHMID A, 1994, J BIOL CHEM, V269, P16706; STILES BG, 1986, INFECT IMMUN, V54, P683, DOI 10.1128/IAI.54.3.683-688.1986; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	34	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32266	32274		10.1074/jbc.M303980200	http://dx.doi.org/10.1074/jbc.M303980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805360	hybrid			2022-12-25	WOS:000184782100102
J	Tanioka, T; Hattori, A; Masuda, S; Nomura, Y; Nakayama, H; Mizutani, S; Tsujimoto, M				Tanioka, T; Hattori, A; Masuda, S; Nomura, Y; Nakayama, H; Mizutani, S; Tsujimoto, M			Human leukocyte-derived arginine aminopeptidase - The third member of the oxytocinase subfamily of aminopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUROMYCIN-SENSITIVE AMINOPEPTIDASE; PLACENTAL LEUCINE AMINOPEPTIDASE/OXYTOCINASE; INSULIN-REGULATED AMINOPEPTIDASE; LEUCYL-SPECIFIC AMINOPEPTIDASE; THYROTROPIN-RELEASING-HORMONE; CLASS-I MOLECULES; EXOPEPTIDASE SPECIFICITY; MEMBRANE AMINOPEPTIDASE; METALLOPEPTIDASE FAMILY; ENDOPLASMIC-RETICULUM	In this study we report the cloning and characterization of a novel human aminopeptidase, which we designate leukocyte-derived arginine aminopeptidase ( LRAP). The sequence encodes a 960-amino acid protein with significant homology to placental leucine aminopeptidase and adipocyte-derived leucine aminopeptidase. The predicted L-RAP contains the HEXXH(X)(18)E zinc-binding motif, which is characteristic of the M1 family of zinc metallopeptidases. Phylogenetic analysis indicates that L-RAP forms a distinct subfamily with placental leucine aminopeptidase and adipocyte-derived leucine aminopeptidase in the M1 family. Immunocytochemical analysis indicates that L-RAP is located in the lumenal side of the endoplasmic reticulum. Among various synthetic substrates tested, L-RAP revealed a preference for arginine, establishing that the enzyme is a novel arginine aminopeptidase with restricted substrate specificity. In addition to natural hormones such as angiotensin III and kallidin, L-RAP cleaved various N-terminal extended precursors to major histocompatibility complex class I-presented antigenic peptides. Like other proteins involved in antigen presentation, L-RAP is induced by interferon-gamma. These results indicate that L-RAP is a novel aminopeptidase that can trim the N-terminal extended precursors to antigenic peptides in the endoplasmic reticulum.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; RIKEN, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Dept Agr, Lab Appl Prot Chem, Tokyo 1830054, Japan; Nagoya Univ, Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan	RIKEN; RIKEN; Tokyo University of Agriculture & Technology; Nagoya University	Hattori, A (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		NOMURA, Yoshihiro/H-6596-2013	NOMURA, Yoshihiro/0000-0002-9788-2809				Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; Fukasawa KM, 1996, J BIOL CHEM, V271, P30731, DOI 10.1074/jbc.271.48.30731; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2001, J BIOCHEM-TOKYO, V130, P235, DOI 10.1093/oxfordjournals.jbchem.a002977; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Iturrioz X, 2001, BIOCHEMISTRY-US, V40, P14440, DOI 10.1021/bi011409j; Keller SR, 2003, FRONT BIOSCI-LANDMRK, V8, pS410, DOI 10.2741/1078; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kessler BM, 2002, MOL IMMUNOL, V39, P171, DOI 10.1016/S0161-5890(02)00100-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; Masuda S, 2003, EUR J BIOCHEM, V270, P1988, DOI 10.1046/j.1432-1033.2003.03570.x; Matsumoto H, 2001, EUR J BIOCHEM, V268, P3259, DOI 10.1046/j.1432-1327.2001.02221.x; Miyashita H, 2002, BLOOD, V99, P3241, DOI 10.1182/blood.V99.9.3241; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Nakamura H, 2000, ENDOCRINOLOGY, V141, P4481, DOI 10.1210/en.141.12.4481; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Osada T, 2001, MOL ENDOCRINOL, V15, P960, DOI 10.1210/me.15.6.960; Osada T, 2001, MOL ENDOCRINOL, V15, P882, DOI 10.1210/me.15.6.882; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Papadopoulos T, 2001, BIOCHEMISTRY-US, V40, P9347, DOI 10.1021/bi010695w; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2002, MOL IMMUNOL, V39, P203, DOI 10.1016/S0161-5890(02)00102-5; SCHAUDER B, 1994, P NATL ACAD SCI USA, V91, P9534, DOI 10.1073/pnas.91.20.9534; Schomburg L, 2000, EUR J BIOCHEM, V267, P3198, DOI 10.1046/j.1432-1327.2000.01348.x; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Thoidis G, 2001, TRAFFIC, V2, P577, DOI 10.1034/j.1600-0854.2001.20807.x; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; Yamamoto N, 2002, HUM MUTAT, V19, P251, DOI 10.1002/humu.10047	49	161	164	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32275	32283		10.1074/jbc.M305076200	http://dx.doi.org/10.1074/jbc.M305076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799365	hybrid			2022-12-25	WOS:000184782100103
J	Wang, HL; Gao, F; Bren, N; Sine, SM				Wang, HL; Gao, F; Bren, N; Sine, SM			Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT INTERFACES; CHOLINERGIC-RECEPTOR; D-TUBOCURARINE; MOLECULAR DISSECTION; STATE TRANSITIONS; IDENTIFICATION; RESIDUES; SELECTIVITY; AFFINITY	Curariform alkaloids competitively inhibit muscle acetylcholine receptors ( AChR) by bridging the alpha and non-alpha subunits that form the ligand-binding site. Here we delineate bound orientations of d-tubocurarine (d-TC) and its methylated derivative metocurine using mutagenesis, ligand binding measurements, and computational methods. When tested against a series of lysine mutations in the epsilon subunit, the two antagonists show marked differences in the consequences of the mutations on binding affinity. The mutations epsilonL117K, epsilonY111K, and epsilonL109K decrease affinity of metocurine by up to 3 orders of magnitude but only slightly alter affinity of d-TC. At the alpha subunit face of the binding site, the mutation alphaY198T decreases affinity of both antagonists, but alphaY198F preferentially enhances affinity of d-TC. Computation of antagonist docking orientations, based on our structural model of the alpha-epsilon site of the human AChR, indicates distinct orientations of each antagonist; the flatter metocurine fits into a pocket formed principally by the epsilon subunit, whereas the more compact d-TC spans the narrower crevasse between alpha and epsilon subunits. The side chains of epsilonTyr-111 and epsilonThr-117 juxtapose one of two quaternary nitrogens in metocurine but are remote from the equivalent quaternary nitrogen in d-TC, which instead closely approaches alphaTyr-198. The different docked orientations arise through tilt of the curariform scaffold by similar to60degrees normal to the nitrogen-nitrogen axis, together with a 20degrees rotation about the axis. The overall mutagenesis and computational results show that despite their similar structures, d-TC and metocurine bind in distinctly different orientations to the adult human AChR.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Grad Program Biomed Engn, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Carlson HA, 2000, MOL PHARMACOL, V57, P213; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; CODDING PW, 1973, ACTA CRYSTALLOGR B, VB 29, P935, DOI 10.1107/S0567740873003663; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; DILGER JP, 2002, BIOPHYS J, V82, P214; EVERETT AJ, 1970, J CHEM SOC CHEM COMM, P1020, DOI 10.1039/c29700001020; Fletcher GH, 1996, MOL PHARMACOL, V49, P938; FU DX, 1994, J BIOL CHEM, V269, P26152; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Grishkovskaya I, 2002, J BIOL CHEM, V277, P32086, DOI 10.1074/jbc.M203999200; Molles BE, 2002, J BIOL CHEM, V277, P5433, DOI 10.1074/jbc.M109232200; Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Osterberg F, 2002, PROTEINS, V46, P34, DOI 10.1002/prot.10028; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; SINE SM, 1980, J BIOL CHEM, V255, P144; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SOBELL HM, 1972, P NATL ACAD SCI USA, V69, P2212, DOI 10.1073/pnas.69.8.2212; STEINBACH JH, 1995, J NEUROSCI, V15, P230; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEILAND G, 1979, MOL PHARMACOL, V15, P197; Willcockson IU, 2002, J BIOL CHEM, V277, P42249, DOI 10.1074/jbc.M205383200; Winget P, 2002, J PHYS CHEM A, V106, P5160, DOI 10.1021/jp020277g	29	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32284	32291		10.1074/jbc.M304366200	http://dx.doi.org/10.1074/jbc.M304366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799358	hybrid			2022-12-25	WOS:000184782100104
J	Pike, BL; Yongkiettrakul, S; Tsai, MD; Heierhorst, J				Pike, BL; Yongkiettrakul, S; Tsai, MD; Heierhorst, J			Diverse but overlapping functions of the two forkhead-associated (FHA) domains in Rad53 checkpoint kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN; PHOSPHORYLATION; MECHANISMS; SITES; ATM	Forkhead-associated (FHA) domains are phosphothreonine-binding modules prevalent in proteins with important cell cycle and DNA damage response functions. The yeast checkpoint kinase Rad53 is unique in containing two FHA domains. We have generated novel recessive rad53 alleles with abolished FHA domain functions resulting from Ala substitution of the critical phosphothreonine-binding residues Arg(70) and Arg(605). In asynchronous cells, inactivation of the N-terminal FHA1 domain did not impair Rad53 activation and downstream functions, whereas inactivation of the C-terminal FHA2 domain led to reduced Rad53 activation and significantly increased DNA damage sensitivity. Simultaneous inactivation of both FHA domains abolished Rad53 activation and all downstream functions and dramatically increased the sensitivity to DNA damage and replication blocks similar to kinase-defective and rad53 null alleles, but did not compromise the essential viability function of Rad53. Interestingly, in G(2)/M synchronized cells, mutation of either FHA domain prevented Rad53 activation and impaired the cell cycle arrest checkpoint. Our data demonstrate that both FHA domains are required for normal Rad53 functions and indicate that the two FHA domains have differential but partially overlapping roles in Rad53 activation and downstream signaling.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.		Pike, Brietta L./H-5317-2019; Tsai, Ming-Daw/G-4689-2019; Yongkiettrakul, Suganya/C-5503-2011	Pike, Brietta L./0000-0002-4763-1729; Tsai, Ming-Daw/0000-0003-1374-0414; 	NATIONAL CANCER INSTITUTE [R01CA087031] Funding Source: NIH RePORTER; NCI NIH HHS [CA87031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Hammet A, 2000, FEBS LETT, V471, P141, DOI 10.1016/S0014-5793(00)01392-2; Hammet A, 2002, J BIOL CHEM, V277, P22469, DOI 10.1074/jbc.M202473200; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sanchez Y, 1997, METHOD ENZYMOL, V283, P398; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	25	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30421	30424		10.1074/jbc.C300227200	http://dx.doi.org/10.1074/jbc.C300227200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12805372	hybrid			2022-12-25	WOS:000184658800003
J	Tan, YV; Couvineau, A; Van Rampelbergh, J; Laburthe, M				Tan, YV; Couvineau, A; Van Rampelbergh, J; Laburthe, M			Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PHARMACOLOGY; EXTRACELLULAR DOMAIN; CRUCIAL ROLE; AMINO-ACIDS; VIP; PROTEINS; IDENTIFICATION; SELECTIVITY; MUTAGENESIS; RESIDUES	Vasoactive intestinal peptide (VIP) is a prominent neuropeptide whose actions are mediated by VPAC receptors belonging to class II G protein-coupled receptors. To identify contact sites between VIP and its VPAC1 receptor, an analog of VIP substituted with a photoreactive para-benzoyl-L-Phe (Bpa) at position 22 has been synthesized and evaluated in Chinese hamster ovary cells stably expressing the recombinant human receptor. Bpa(22)-VIP and native VIP are equipotent in stimulating adenylyl cyclase activity in cell membranes. Cyanogen bromide cleavage of the covalent I-125-[Bpa(22)-VIP]-hVPAC(1)R complex yielded a single labeled fragment of 30 kDa that shifted to 11 after deglycosylation, most consistent with the 67-137 fragment of the receptor N-terminal ectodomain. Further cleavage of this fragment with V8 endoproteinase and creation of receptor mutants with new CNBr cleavage sites (XaMet), demonstrated that I-125-[Bpa(22)-VIP] was covalently attached to the short receptor 109-120 fragment (GWTHLEPG-PYPI). In a three-dimensional model of the receptor N-terminal ectodomain, this fragment is located on one edge of the putative VIP binding groove and encompasses several amino acids previously shown to be crucial for VIP binding (reviewed in Laburthe, M., Couvineau, A., and Marie, J. C. (2002) Receptors Channels 8, 137-153). Our data provide the first direct evidence for a physical contact between VIP and the N-terminal ectodomain of the hVPAC1 receptor.	Univ Paris 07, INSERM, U410, Fac Med Xavier Bichat, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Univ Paris 07, INSERM, U410, Fac Med Xavier Bichat, F-75018 Paris, France.	laburthe@bichat.inserm.fr	couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; 				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Du K, 2002, J BIOL CHEM, V277, P37016, DOI 10.1074/jbc.M203049200; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Gaudin P, 1996, EUR J PHARMACOL, V302, P207, DOI 10.1016/0014-2999(96)00096-9; Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Klimaschewski L, 1997, ANAT EMBRYOL, V196, P269, DOI 10.1007/s004290050096; LABURTHE M, 1978, P NATL ACAD SCI USA, V75, P2772, DOI 10.1073/pnas.75.6.2772; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, REGUL PEPTIDES, V108, P165, DOI 10.1016/S0167-0115(02)00099-X; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Nicole P, 2000, BIOCHEM BIOPH RES CO, V276, P654, DOI 10.1006/bbrc.2000.3375; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; NICOLE P, BIOCH BIOPHYS RES CO, V276, P654; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8	32	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36531	36536		10.1074/jbc.M304770200	http://dx.doi.org/10.1074/jbc.M304770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12807902	hybrid			2022-12-25	WOS:000185318300082
J	Zhang, DH; Li, N; Lok, SM; Zhang, LH; Swaminathan, K				Zhang, DH; Li, N; Lok, SM; Zhang, LH; Swaminathan, K			Isomaltulose synthase (PalI) of Klebsiella sp LX3 - Crystal structure and implication of mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE ISOMERASE; DIFFRACTION DATA; AMYLOSUCRASE; PROGRAM; CONVERSION; CLONING; STRAIN	Isomaltulose synthase from Klebsiella sp. LX3 ( PalI, EC 5.4.99.11) catalyzes the isomerization of sucrose to produce isomaltulose (alpha-D-glucosylpyranosyl-1,6-D-fructofuranose) and trehalulose (alpha-D-glucosylpyranosyl-1,1- D-fructofuranose). The PalI structure, solved at 2.2-Angstrom resolution with an R-factor of 19.4% and R-free of 24.2%, consists of three domains: an N-terminal catalytic (beta/alpha)(8) domain, a subdomain between Nbeta3 and Nalpha3, and a C-terminal domain having seven beta-strands. The active site architecture of PalI is identical to that of other glycoside hydrolase family 13 members, suggesting a similar mechanism in substrate binding and hydrolysis. However, a unique RLDRD motif in the proximity of the active site has been identified and shown biochemically to be responsible for sucrose isomerization. A two-step reaction mechanism for hydrolysis and isomerization, which occurs in the same pocket is proposed based on both the structural and biochemical data. Selected C-terminal truncations have been shown to reduce and even abolish the enzyme activity, consistent with the predicted role of the C-terminal residues in the maintenance of enzyme conformation and active site topology.	Natl Univ Singapore, Inst Mol & Cell Biol, Lab Macromol Crystallog, Singapore 117609, Singapore; Natl Univ Singapore, Dept Pathol, Singapore 119074, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Lab Biosignals & Bioengn, Singapore 117609, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Swaminathan, K (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Lab Macromol Crystallog, 30 Med Dr, Singapore 117609, Singapore.	nathan@imcb.nus.edu.sg	Lok, Shee-mei/I-7050-2012	Lok, Shee-Mei/0000-0003-4631-8041				BAER A, 1989, WISS TECHNOL, V22, P46; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bornke F, 2001, J BACTERIOL, V183, P2425, DOI 10.1128/JB.183.8.2425-2430.2001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Huang JH, 1998, J IND MICROBIOL BIOT, V21, P22, DOI 10.1038/sj.jim.2900552; IMMEL S, 1995, LIEBIGS ANN, P1925, DOI 10.1002/jlac.1995199511272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li N, 2003, ACTA CRYSTALLOGR D, V59, P150, DOI 10.1107/S0907444902017547; Mattes R., 1998, US Patent, Patent No. 5786140; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; MIYATA Y, 1992, BIOSCI BIOTECH BIOCH, V56, P1680, DOI 10.1271/bbb.56.1680; NAGAIMIYATA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P2049, DOI 10.1271/bbb.57.2049; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Veronese T, 1998, FEBS LETT, V441, P348, DOI 10.1016/S0014-5793(98)01582-8; Veronese T, 1999, ENZYME MICROB TECH, V24, P263, DOI 10.1016/S0141-0229(98)00115-X; Watanabe K, 1997, J MOL BIOL, V269, P142, DOI 10.1006/jmbi.1997.1018; Zhang DH, 2003, FEBS LETT, V534, P151, DOI 10.1016/S0014-5793(02)03835-8; Zhang DH, 2002, APPL ENVIRON MICROB, V68, P2676, DOI 10.1128/AEM.68.6.2676-2682.2002	29	54	61	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35428	35434		10.1074/jbc.M302616200	http://dx.doi.org/10.1074/jbc.M302616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819210	hybrid			2022-12-25	WOS:000185164400083
J	Bjornson, KP; Blackwell, LJ; Sage, H; Baitinger, C; Allen, D; Modrich, P				Bjornson, KP; Blackwell, LJ; Sage, H; Baitinger, C; Allen, D; Modrich, P			Assembly and molecular activities of the MutS tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; DNA MISMATCH; ESCHERICHIA-COLI; ATP HYDROLYSIS; PROTEIN MUTS; HELICASE II; BINDING; GENE; HETERODUPLEX; COMPLEX	Analytical equilibrium ultracentrifugation indicates that Escherichia coli MutS exists as an equilibrating mixture of dimers and tetramers. The association constant for the dimer-to-tetramer transition is 2.1 x 10(7) M-1, indicating that the protein would consist of both dimers and tetramers at physiological concentrations. The carboxyl terminus of MutS is required for tetramer assembly because a previously described 53-amino acid carboxyl-terminal truncation ( MutS800) forms a limiting species of a dimer (Obmolova, G., Ban, C., Hsieh, P., and Yang, W. ( 2000) Nature 407, 703 - 710; Lamers, M. H., Perrakis, A., Enzlin, J. H., Winterwerp, H. H., de Wind, N., and Sixma, T. K. ( 2000) Nature 407, 711 - 717). MutS800 binds a 20-base pair heteroduplex an order of magnitude more weakly than full-length MutS, and at saturating protein concentrations, the heteroduplex-bound mass observed with MutS800 is only half that observed with the full length protein, indicating that the subunit copy number of heteroduplex-bound MutS is twice that of MutS800. Analytical equilibrium ultracentrifugation using a fluorescein-tagged 20-base pair heteroduplex demonstrated that native MutS forms a tetramer on this single site-sized heteroduplex DNA. Equilibrium fluorescence experiments indicated that dimer-to-tetramer assembly promotes mismatch binding by MutS and that the tetramer can bind only a single heteroduplex molecule, implying nonequivalence of the two dimers within the tetramer. Compared with native MutS, the ability of MutS800 to promote MutL-dependent activation of MutH is substantially reduced.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Box 3711,Rm 150 MS1A, Durham, NC 27702 USA.			Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023719, R37GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hopfner KP, 2000, STRUCTURE, V8, pR237, DOI 10.1016/S0969-2126(00)00545-1; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Li GM, 1999, ONCOL RES, V11, P393; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; SCHLENSOG V, 1991, J BACTERIOL, V173, P7414, DOI 10.1128/jb.173.23.7414-7415.1991; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; Wong I, 1995, METHOD ENZYMOL, V259, P95; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	38	53	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34667	34673		10.1074/jbc.M305513200	http://dx.doi.org/10.1074/jbc.M305513200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829697	hybrid			2022-12-25	WOS:000185047500128
J	Boja, ES; Hoodbhoy, T; Fales, HM; Dean, J				Boja, ES; Hoodbhoy, T; Fales, HM; Dean, J			Structural characterization of native mouse zona pellucida proteins using mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM RECEPTOR-ACTIVITY; FURIN CLEAVAGE-SITE; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; CHARGE-DISTRIBUTION; TRANSGENIC MICE; O-GLYCOSYLATION; COMBINING-SITE; EGG COAT	The zona pellucida is an extracellular matrix consisting of three glycoproteins that surrounds mammalian eggs and mediates fertilization. The primary structures of mouse ZP1, ZP2, and ZP3 have been deduced from cDNA. Each has a predicted signal peptide and a transmembrane domain from which an ectodomain must be released. All three zona proteins undergo extensive co- and post-translational modifications important for secretion and assembly of the zona matrix. In this report, native zonae pellucidae were isolated and structural features of individual zona proteins within the mixture were determined by high resolution electrospray mass spectrometry. Complete coverage of the primary structure of native ZP3, 96% of ZP2, and 56% of ZP1, the least abundant zona protein, was obtained. Partial disulfide bond assignments were made for each zona protein, and the size of the processed, native protein was determined. The N termini of ZP1 and ZP3, but not ZP2, were blocked by cyclization of glutamine to pyroglutamate. The C termini of ZP1, ZP2, and ZP3 lie upstream of a dibasic motif, which is part of, but distinct from, a proprotein convertase cleavage site. The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied. Potential O-linked carbohydrate sites are more ubiquitous, but less utilized.	NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Boja, ES (corresponding author), NHLBI, Biophys Chem Lab, NIH, 50 South Dr,Rm 3122,Bldg 50, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001003, ZIAHL001003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; EAST IJ, 1985, DEV BIOL, V109, P268, DOI 10.1016/0012-1606(85)90454-3; EAST IJ, 1984, J CELL BIOL, V98, P795, DOI 10.1083/jcb.98.3.795; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; FRENCH LE, 1993, J CELL BIOL, V122, P1119, DOI 10.1083/jcb.122.5.1119; GREVE JM, 1982, CELL, V31, P749, DOI 10.1016/0092-8674(82)90329-4; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Herrler A, 2000, CELLS TISSUES ORGANS, V166, P233, DOI 10.1159/000016736; Jovine L, 2002, NAT CELL BIOL, V4, P457, DOI 10.1038/ncb802; Kiefer SM, 2002, BIOL REPROD, V66, P407, DOI 10.1095/biolreprod66.2.407; Kubo H, 1999, DEV GENET, V25, P123, DOI 10.1002/(SICI)1520-6408(1999)25:2<123::AID-DVG6>3.3.CO;2-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH BS, 1980, BIOCHEMISTRY-US, V19, P5734, DOI 10.1021/bi00566a011; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; Litscher ES, 1999, BIOCHEMISTRY-US, V38, P12280, DOI 10.1021/bi991154y; Liu CY, 1996, P NATL ACAD SCI USA, V93, P5431, DOI 10.1073/pnas.93.11.5431; LIU CY, 1995, MOL BIOL CELL, V6, P577, DOI 10.1091/mbc.6.5.577; Lopaticki S, 1998, J MASS SPECTROM, V33, P950, DOI 10.1002/(SICI)1096-9888(199810)33:10<950::AID-JMS704>3.3.CO;2-1; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; Nehrke K, 1997, GLYCOBIOLOGY, V7, P1053, DOI 10.1093/glycob/7.8.1053-c; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qi HY, 2002, MOL BIOL CELL, V13, P530, DOI 10.1091/mbc.01-09-0440; Rankin T, 1996, DEVELOPMENT, V122, P2903; Rankin T, 1999, DEVELOPMENT, V126, P3847; Rankin T, 2000, REV REPROD, V5, P114, DOI 10.1530/ror.0.0050114; Rankin TL, 2001, DEVELOPMENT, V128, P1119; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Rankin TL, 1998, DEVELOPMENT, V125, P2415; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; ROLLER RJ, 1983, J BIOL CHEM, V258, P3243; SALZMANN GS, 1983, EMBO J, V2, P1451, DOI 10.1002/j.1460-2075.1983.tb01607.x; Sasanami T, 2002, EUR J BIOCHEM, V269, P2223, DOI 10.1046/j.1432-1033.2002.02880.x; Scheiffele P, 2000, ESSAYS BIOCHEM, V36, P27, DOI 10.1042/bse0360027; SCHNIER PD, 1995, J AM CHEM SOC, V117, P6747, DOI 10.1021/ja00130a015; Schwager SLU, 2001, BIOCHEMISTRY-US, V40, P15624, DOI 10.1021/bi011063c; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; SHIMIZU S, 1983, J BIOL CHEM, V258, P5858; SMITH RD, 1991, MASS SPECTROM REV, V10, P359, DOI 10.1002/mas.1280100504; Spargo SC, 2003, BIOL REPROD, V68, P358, DOI 10.1095/biolreprod.102.008086; Talbot P, 2003, BIOL REPROD, V68, P1, DOI 10.1095/biolreprod.102.007856; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; Wassarman PM, 2002, MT SINAI J MED, V69, P148; Williams Z, 2003, BIOCHEM BIOPH RES CO, V301, P813, DOI 10.1016/S0006-291X(03)00044-5; Williams Z, 2001, BIOCHEMISTRY-US, V40, P929, DOI 10.1021/bi002275x; Yanagimachi R., 1994, P189; YUREWICZ EC, 1993, BIOCHIM BIOPHYS ACTA, V1174, P211, DOI 10.1016/0167-4781(93)90119-X; Zapun A, 1999, STRUCT FOLD DES, V7, pR173, DOI 10.1016/S0969-2126(99)80112-9; Zhao M, 2002, MOL CELL BIOL, V22, P3111, DOI 10.1128/MCB.22.9.3111-3120.2002	61	143	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34189	34202		10.1074/jbc.M304026200	http://dx.doi.org/10.1074/jbc.M304026200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12799386	hybrid			2022-12-25	WOS:000185047500073
J	Braunstein, J; Brutsaert, S; Olson, R; Schindler, C				Braunstein, J; Brutsaert, S; Olson, R; Schindler, C			STATs dimerize in the absence of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; IFN-GAMMA; TARGETED DISRUPTION; ACTIVATION; PROTEIN; DNA; GENE; COMPLEXES	Upon activation by tyrosine kinases, members of the STAT family of transcription factors form stable dimers that are able to rapidly translocate to the nucleus and bind DNA. Although crystal structures of activated, near full-length, Stat1 and Stat3 illustrate how STATs bind to DNA, they provide little insight into the dynamic regulation of STAT activity. To explore the unique structural changes Stat1 and Stat3 undergo when they become activated, full-length inactive recombinant proteins were prepared. To our surprise, even though these proteins are unable to bind DNA, our studies demonstrate that they exist as stable homodimers. Similarly, the Stat1 and Stat3 found in the cytoplasm of unstimulated cells also exhibit a dimeric structure. These observations indicate that Stat1 and Stat3 exist as stable homodimers prior to activation.	Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Integrated Grad Program, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Schindler, C (corresponding author), Columbia Univ, Dept Microbiol, HHSC 1208,701 W 168th St, New York, NY 10032 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012848] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR12848] Funding Source: Medline; NHLBI NIH HHS [HL55413] Funding Source: Medline; NIDDK NIH HHS [T32 DK07328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; Biswas I, 2000, BIOCHEM J, V347, P881, DOI 10.1042/0264-6021:3470881; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Collum RG, 2000, P NATL ACAD SCI USA, V97, P10120, DOI 10.1073/pnas.170192197; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; HAYES DT, 2000, SEDNTERP PROGRAM VER; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Krause CD, 2002, MOL CELL PROTEOMICS, V1, P805, DOI 10.1074/mcp.M200065-MCP200; KRETSOVALI A, 1995, NUCLEIC ACIDS RES, V23, P2919, DOI 10.1093/nar/23.15.2919; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; LARY J, 1998, REEDIT PROGRAM; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P., 2002, SEDFIT PROGRAM; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Tanese N, 1997, METHODS, V12, P224, DOI 10.1006/meth.1997.0475; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; YPHANTIS D, 1999, MATCH PROGRAM; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	44	152	156	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34133	34140		10.1074/jbc.M304531200	http://dx.doi.org/10.1074/jbc.M304531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12832402	hybrid			2022-12-25	WOS:000185047500066
J	Choi, HY; Karten, B; Chan, T; Vance, JE; Greer, WL; Heidenreich, RA; Garver, WS; Francis, GA				Choi, HY; Karten, B; Chan, T; Vance, JE; Greer, WL; Heidenreich, RA; Garver, WS; Francis, GA			Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CASSETTE TRANSPORTER A1; ENDOGENOUSLY SYNTHESIZED CHOLESTEROL; CELLULAR CHOLESTEROL; PLASMA-MEMBRANE; INTRACELLULAR TRAFFICKING; DISTAL AXONS; ABCA1; PROTEIN	The cholesterol trafficking defect in Niemann-Pick type C (NPC) disease leads to impaired regulation of cholesterol esterification, cholesterol synthesis, and low density lipoprotein receptor activity. The ATP-binding cassette transporter A1 (ABCA1), which mediates the rate-limiting step in high density lipoprotein (HDL) particle formation, is also regulated by cell cholesterol content. To determine whether the Niemann-Pick C1 protein alters the expression and activity of ABCA1, we determined the ability of apolipoprotein A-I (apoA-I) to deplete pools of cellular cholesterol and phospholipids in human fibroblasts derived from NPC1(+/+), NPC1(+/-), and NPC1(-/-) subjects. Efflux of low density lipoprotein-derived, non-lipoprotein, plasma membrane, and newly synthesized pools of cell cholesterol by apoA-I was diminished in NPC1(-/-) cells, as was efflux of phosphatidylcholine and sphingomyelin. NPC1(+/-) cells showed intermediate levels of lipid efflux compared with NPC1(+/+) and NPC1(-/-) cells. Binding of apoA-I to cholesterol-loaded and non-cholesterol-loaded cells was highest for NPC1(+/-) cells, with NPC1(+/+) and NPC1(-/-) cells showing similar levels of binding. ABCA1 mRNA and protein levels increased in response to cholesterol loading in NPC1(+/+) and NPC1(+/-) cells but showed low levels at base line and in response to cholesterol loading in NPC1(-/-) cells. Consistent with impaired ABCA1-dependent lipid mobilization to apoA-I for HDL particle formation, we demonstrate for the first time decreased plasma HDL-cholesterol levels in 17 of 21 (81%) NPC1(-/-) subjects studied. These results indicate that the cholesterol trafficking defect in NPC disease results in reduced activity of ABCA1, which we suggest is responsible for the low HDL-cholesterol in the majority of NPC subjects and partially responsible for the overaccumulation of cellular lipids in this disorder.	Univ Alberta, Heritage Med Res Ctr 328, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipid, Edmonton, AB T6G 2S2, Canada; Dalhousie Univ, Dept Pathol, Halifax, NS B3H 1V8, Canada; Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA	University of Alberta; University of Alberta; University of Alberta; Dalhousie University; University of Arizona	Choi, HY (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Dept Med, Edmonton, AB T6G 2S2, Canada.	gordon.francis@ualberta.ca		Karten, Barbara/0000-0003-2395-3333				Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; ARGOFF CE, 1991, BIOCHIM BIOPHYS ACTA, V1096, P319, DOI 10.1016/0925-4439(91)90068-K; Assmann G, 2001, METABOLIC MOL BASES, P2937; Attie AD, 2001, J LIPID RES, V42, P1717; BERENSON GS, 1981, AM J EPIDEMIOL, V113, P157, DOI 10.1093/oxfordjournals.aje.a113080; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG BH, 1980, J LIPID RES, V21, P284; Costet P, 2000, J BIOL CHEM, V275, P28240; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Garver WS, 2000, J LIPID RES, V41, P673; Garver WS, 2002, J LIPID RES, V43, P579; Greer WL, 1999, AM J HUM GENET, V65, P1252, DOI 10.1086/302620; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Hovingh GK, 2003, J LIPID RES, V44, P1251, DOI 10.1194/jlr.M300080-JLR200; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lee CY, 2003, HUM GENET, V112, P552, DOI 10.1007/s00439-002-0893-1; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; Mendez AJ, 1997, J LIPID RES, V38, P1807; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Millat G, 1999, AM J HUM GENET, V65, P1321, DOI 10.1086/302626; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; *NIH, 1980, PUBL NIH; *NIH, 2001, PUBL NIH; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Oram JF, 1996, J LIPID RES, V37, P2473; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PATTERSON MC, 1993, NEUROLOGY, V43, P61, DOI 10.1212/WNL.43.1_Part_1.61; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; Reid PC, 2003, J LIPID RES, V44, P1010, DOI 10.1194/jlr.M300009-JLR200; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; Shamburek RD, 1997, J LIPID RES, V38, P2422; SOKAL R, 1995, BIOMETRY PRINCIPLES, V3, P207; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; VANIER MT, 1988, CLIN GENET, V33, P331; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811	70	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32569	32577		10.1074/jbc.M304553200	http://dx.doi.org/10.1074/jbc.M304553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813037	hybrid			2022-12-25	WOS:000184901800013
J	Feng, GJ; Kellett, E; Scorer, CA; Wilde, J; White, JH; Milligan, G				Feng, GJ; Kellett, E; Scorer, CA; Wilde, J; White, JH; Milligan, G			Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH CYTOPLASMIC LOOP; COUPLED RECEPTOR; INTERMEDIATE-FILAMENTS; SPLICE VARIANTS; CARBOXY-TERMINUS; MESSENGER-RNA; PLAKIN FAMILY; RHODOPSIN; GENERATION; BINDING	Analysis of interactions between the C-terminal tail of the MOP-1 and MOP-1A variants of the human mu-opioid receptor with proteins derived from a human brain cDNA library resulted in identification of the actin and intermediate filament-binding protein periplakin. Mapping of this interaction indicated that the predicted fourth intracellular loop/helix VIII of the receptor interacts with the C-terminal rod and linker region of periplakin. Periplakin is widely expressed in the central nervous system of both man and rat and demonstrated an overlapping but not identical distribution with mu-opioid (MOP) receptors. Co-expression of periplakin with MOP-1 or a MOP-1-eYFP fusion construct in HEK293 cells did not interfere with agonist-mediated internalization of the receptor. When co-expressed with a MOP-1-G(i1)alpha fusion protein periplakin significantly reduced the capacity of the agonist to stimulate binding of S-35-labeled guanosine 5'-3-O-(thio)triphosphate ([S-35]GTPgammaS) to the receptor-associated G protein. By contrast, periplakin did not interfere with agonist-stimulation of [S-35]GTPgammaS binding to either an alpha(2A)-adrenoreceptor-G(i1)alpha fusion protein or a beta(2)-adrenoreceptor-G(s)alpha fusion protein, indicating its selectivity of function. This represents the first example of an opioid receptor-interacting protein that functions to disrupt agonist-mediated G protein activation.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; GlaxoSmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline Inc, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Glasgow; GlaxoSmithKline; GlaxoSmithKline	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Abbadie C, 2000, NEUROSCIENCE, V100, P141, DOI 10.1016/S0306-4522(00)00248-7; Abbadie C, 2000, NEUROREPORT, V11, P1953, DOI 10.1097/00001756-200006260-00029; Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BARE LA, 1994, FEBS LETT, V354, P213, DOI 10.1016/0014-5793(94)01129-X; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Connor M, 1999, CLIN EXP PHARMACOL P, V26, P493, DOI 10.1046/j.1440-1681.1999.03049.x; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Gaveriaux-Ruff C, 2002, NEUROPEPTIDES, V36, P62, DOI 10.1054/npep.2002.0900; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Massotte D, 2002, J NEUROCHEM, V81, P1372, DOI 10.1046/j.1471-4159.2002.00946.x; McLean AJ, 2002, MOL PHARMACOL, V62, P747, DOI 10.1124/mol.62.3.747; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Milligan G, 2002, METHOD ENZYMOL, V343, P260; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, BIOCHEM BIOPH RES CO, V297, P659, DOI 10.1016/S0006-291X(02)02258-1; Pasternak GW, 2001, LIFE SCI, V68, P2213, DOI 10.1016/S0024-3205(01)01008-6; Premont RT, 2002, METHOD ENZYMOL, V343, P611; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197	46	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33400	33407		10.1074/jbc.M305866200	http://dx.doi.org/10.1074/jbc.M305866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810704				2022-12-25	WOS:000184901800112
J	Marchesini, S; Poirier, Y				Marchesini, S; Poirier, Y			Futile cycling of intermediates of fatty acid biosynthesis toward peroxisomal beta-oxidation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC PLANTS; BINDING PROTEIN; ARABIDOPSIS; SYNTHASE; POLYHYDROXYALKANOATES; IDENTIFICATION; BACTERIAL; METABOLISM; POLYESTERS; VECTORS	The flux of fatty acids toward beta-oxidation was analyzed in Saccharomyces cerevisiae by monitoring polyhydroxyalkanoate synthesis in the peroxisome from the polymerization, by a bacterial polyhydroxyalkanoate synthase, of the beta-oxidation intermediates 3-hydroxyacyl-CoAs. Synthesis of polyhydroxyalkanoate was dependent on the beta-oxidation enzymes acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase multifunctional protein, which are involved in generating 3-hydroxyacyl-CoAs, and on the peroxin PEX5, which is involved in the import of proteins into the peroxisome. In wild type cells grown in media containing fatty acids, the polyhydroxyalkanoate monomer composition was largely influenced by the nature of the external fatty acid, such that even-chain monomers are generated from oleic acid and odd-chain monomers are generated from heptadecenoic acid. In contrast, polyhydroxyalkanoate containing predominantly 3-hydroxyoctanoate, 3-hydroxydecanoate, and 3-hydroxydodecanoate was synthesized in a mutant deficient in the peroxisomal 3-ketothiolase (fox3Delta0) growing either on oleic acid or heptadecenoic acid as well as in wild type and fox3Delta0 mutants grown on glucose or raffinose, indicating that 3-hydroxyacyl-CoAs used for polyhydroxyalkanoate synthesis were generated from the degradation of intracellular short- and medium-chain fatty acids by the beta-oxidation cycle. Inhibition of fatty acid biosynthesis with cerulenin blocked the synthesis of polyhydroxyalkanoate from intracellular fatty acids but still enabled the use of extracellular fatty acids for polymer production. Mutants affected in the synthesis of lipoic acid showed normal polyhydroxyalkanoate synthesis capacity. Together, these results uncovered the existence of a substantial futile cycle whereby short- and medium-chain intermediates of the cytoplasmic fatty acid biosynthetic pathway are directed toward the peroxisomal beta-oxidation pathway.	Univ Lausanne, Inst Ecol, Lab Biotechnol Vegetale, CH-1015 Lausanne, Switzerland	University of Lausanne	Poirier, Y (corresponding author), Univ Lausanne, Inst Ecol, Lab Biotechnol Vegetale, CH-1015 Lausanne, Switzerland.	yves.poirier@ie-bpv.unil.ch	Marchesini, Stefano/GYR-1409-2022; Marchesini, Stefano/A-6795-2009	Marchesini, Stefano/0000-0002-6798-2913				Allenbach L, 2000, PLANT PHYSIOL, V124, P1159, DOI 10.1104/pp.124.3.1159; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gurvitz A, 1999, J BIOL CHEM, V274, P24514, DOI 10.1074/jbc.274.35.24514; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; HORTNER H, 1982, EUR J BIOCHEM, V128, P179; Kim YB, 2001, ADV BIOCHEM ENG BIOT, V71, P51; LAGEVEEN RG, 1988, APPL ENVIRON MICROB, V54, P2924, DOI 10.1128/AEM.54.12.2924-2932.1988; Leaf TA, 1996, MICROBIOL-SGM, V142, P1169, DOI 10.1099/13500872-142-5-1169; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; Mittendorf V, 1999, PLANT J, V20, P45, DOI 10.1046/j.1365-313X.1999.00572.x; Mittendorf V, 1998, P NATL ACAD SCI USA, V95, P13397, DOI 10.1073/pnas.95.23.13397; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; Omura S, 1981, Methods Enzymol, V72, P520; Poirier Y, 1999, PLANT PHYSIOL, V121, P1359, DOI 10.1104/pp.121.4.1359; POIRIER Y, 1992, SCIENCE, V256, P520, DOI 10.1126/science.256.5056.520; Poirier Y, 2002, PROG LIPID RES, V41, P131, DOI 10.1016/S0163-7827(01)00018-2; Poirier Y, 2002, FEMS MICROBIOL LETT, V207, P97, DOI 10.1111/j.1574-6968.2002.tb11035.x; Poirier Y, 2001, ADV BIOCHEM ENG BIOT, V71, P209; Poirier Y, 2001, APPL ENVIRON MICROB, V67, P5254, DOI 10.1128/AEM.67.11.5254-5260.2001; POIRIER Y, 1995, BIO-TECHNOL, V13, P142, DOI 10.1038/nbt0295-142; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schjerling CK, 1996, J BIOL CHEM, V271, P22514, DOI 10.1074/jbc.271.37.22514; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; Slater S, 1999, NAT BIOTECHNOL, V17, P1011, DOI 10.1038/13711; Steinbuchel A, 1998, TRENDS BIOTECHNOL, V16, P419, DOI 10.1016/S0167-7799(98)01194-9; Tuller G, 1999, YEAST, V15, P1555, DOI 10.1002/(SICI)1097-0061(199910)15:14<1555::AID-YEA479>3.0.CO;2-Z; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; Williams MD, 1996, APPL ENVIRON MICROB, V62, P2540, DOI 10.1128/AEM.62.7.2540-2546.1996	35	35	37	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32596	32601		10.1074/jbc.M305574200	http://dx.doi.org/10.1074/jbc.M305574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819196	hybrid			2022-12-25	WOS:000184901800016
J	Sun, JP; Wu, L; Fedorov, AA; Almo, SC; Zhang, ZY				Sun, JP; Wu, L; Fedorov, AA; Almo, SC; Zhang, ZY			Crystal structure of the Yersinia protein-tyrosine phosphatase YopH complexed with a specific small molecule inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-TRAPPING MUTANTS; OUTER-MEMBRANE PROTEINS; VIRULENCE DETERMINANT; FOCAL ADHESIONS; PSEUDOTUBERCULOSIS; 1B; PHOSPHORYLATION; MECHANISM; PLASMID; ENTEROCOLITICA	The pathogenic bacteria Yersinia are causative agents in human diseases ranging from gastrointestinal syndromes to bubonic plague. There is increasing risk of misuse of infectious agents, such as Yersinia pestis, as weapons of terror as well as instruments of warfare for mass destruction. Because the phosphatase activity of the Yersinia protein tyrosine phosphatase, YopH, is essential for virulence in the Yersinia pathogen, potent and selective YopH inhibitors are expected to serve as novel anti-plague agents. We have identified a specific YopH small molecule inhibitor, p-nitrocatechol sulfate (pNCS), which exhibits a K-i value of 25 muM for YopH and displays a 13-60-fold selectivity in favor of YopH against a panel of mammalian PTPs. To facilitate the understanding of the underlying molecular basis for tight binding and specificity, we have determined the crystal structure of YopH in complex with pNCS at a 2.0-Angstrom resolution. The structural data are corroborated by results from kinetic analyses of the interactions of YopH and its site-directed mutants with pNCS. The results show that while the interactions of the sulfuryl moiety and the phenyl ring with the YopH active site contribute to pNCS binding affinity, additional interactions of the hydroxyl and nitro groups in pNCS with Asp-356, Gln-357, Arg-404, and Gln-446 are responsible for the increased potency and selectivity. In particular, we note that residues Arg-404, Glu-290, Asp-356, and a bound water (WAT185) participate in a unique H-bonding network with the hydroxyl group ortho to the sulfuryl moiety, which may be exploited to design more potent and specific YopH inhibitors.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		sun, Jinpeng/AAR-9196-2020; SUN, JINPENG/F-9551-2013		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48506] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; BUTLER T, 1985, TXB MED, P1600; Chen YT, 2001, BIOORG MED CHEM LETT, V11, P1935, DOI 10.1016/S0960-894X(01)00325-0; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HARTLAND EL, 1994, INFECT IMMUN, V62, P4445, DOI 10.1128/IAI.62.10.4445-4453.1994; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; JAYARAMAN KS, 1994, NATURE, V371, P467, DOI 10.1038/371467b0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1993, PROGRAM O VERSION 5; McGovern TW, 1999, ARCH DERMATOL, V135, P311, DOI 10.1001/archderm.135.3.311; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PORTNOY DA, 1984, INFECT IMMUN, V43, P108, DOI 10.1128/IAI.43.1.108-114.1984; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; TAINER J, 1994, NATURE, V370, P506, DOI 10.1038/370506a0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang Z-Y, 2003, HDB CELLULAR SIGNALI, P677; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	51	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33392	33399		10.1074/jbc.M304693200	http://dx.doi.org/10.1074/jbc.M304693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810712	hybrid			2022-12-25	WOS:000184901800111
J	Watson, WH; Pohl, J; Montfort, WR; Stuchlik, O; Reed, MS; Powis, G; Jones, DP				Watson, WH; Pohl, J; Montfort, WR; Stuchlik, O; Reed, MS; Powis, G; Jones, DP			Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ESCHERICHIA-COLI; SULFHYDRYL-GROUPS; OXIDATIVE STRESS; GLUTATHIONE; REDUCTION; CELLS; PURIFICATION; MUTAGENESIS; PROTECTION	Thioredoxin (Trx1) is a redox-active protein containing two active site cysteines (Cys-32 and Cys-35) that cycle between the dithiol and disulfide forms as Trx1 reduces target proteins. Examination of the redox characteristics of this active site dithiol/disulfide couple is complicated by the presence of three additional non-active site cysteines. Using the redox Western blot technique and matrix assisted laser desorption ionization time-of-flight mass spectrometry mass spectrometry, we determined the midpoint potential (E-0) of the Trx1 active site (-230 mV) and identified a second redox-active dithiol/disulfide (Cys-62 and Cys-69) in an alpha helix proximal to the active site, which formed under oxidizing conditions. This non-active site disulfide was not a substrate for reduction by thioredoxin reductase and delayed the reduction of the active site disulfide by thioredoxin reductase. Within actively growing THP1 cells, most of the active site of Trx1 was in the dithiol form, whereas the non-active site was totally in the dithiol form. The addition of increasing concentrations of diamide to these cells resulted in oxidation of the active site at fairly low concentrations and oxidation of the non-active site at higher concentrations. Taken together these results suggest that the Cys-62-Cys-69 disulfide could provide a means to transiently inhibit Trx1 activity under conditions of redox signaling or oxidative stress, allowing more time for the sensing and transmission of oxidative signals.	Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, Atlanta, GA 30322 USA; Emory Univ, Microchem Facil, Atlanta, GA 30322 USA; Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	Emory University; Emory University; University of Arizona; University of Arizona	Watson, WH (corresponding author), Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, 1510 Clifton Rd, Atlanta, GA 30322 USA.	wwatson@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F32AA013233] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62969] Funding Source: Medline; NIAAA NIH HHS [F32 AA13233] Funding Source: Medline; NIEHS NIH HHS [R01 ES011195] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bersani NA, 2002, METHOD ENZYMOL, V347, P317; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Gasdaska JR, 1996, BIOCHEM PHARMACOL, V52, P1741, DOI 10.1016/S0006-2952(96)00595-3; Gitler C, 2002, BIOCHEM BIOPH RES CO, V290, P624, DOI 10.1006/bbrc.2001.6214; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1982, J BIOL CHEM, V257, P6926; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; JOELSON T, 1990, J BIOL CHEM, V265, P3183; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Li G, 1997, ELECTROPHORESIS, V18, P391, DOI 10.1002/elps.1150180313; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE EC, 1964, J BIOL CHEM, V239, P3453; PORQUE PG, 1970, J BIOL CHEM, V9, P2363; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Ritz D, 2002, METHOD ENZYMOL, V347, P360; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	40	234	242	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33408	33415		10.1074/jbc.M211107200	http://dx.doi.org/10.1074/jbc.M211107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816947	hybrid			2022-12-25	WOS:000184901800113
J	Antignac, A; Boneca, IG; Rousselle, JC; Namane, A; Carlier, JP; Vazquez, JA; Fox, A; Alonso, JM; Taha, MK				Antignac, A; Boneca, IG; Rousselle, JC; Namane, A; Carlier, JP; Vazquez, JA; Fox, A; Alonso, JM; Taha, MK			Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; AMINO-ACID SUBSTITUTIONS; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; ESCHERICHIA-COLI; BACTERIAL PEPTIDOGLYCAN; GENETIC-TRANSFORMATION; ENTEROCOCCUS-FAECIUM; GONORRHOEAE; STRAIN	Reduced susceptibility to penicillin G in Neisseria meningitidis is directly correlated with alterations in the penA gene, which encodes the penicillin-binding protein 2 (PBP2). Using purified PBP2s from different backgrounds, we confirmed that the reduced susceptibility to penicillin G is associated with a decreased affinity of altered PBP2s for penicillin G. Infrared spectroscopy analysis using isogenic penicillin-susceptible strains and strains with reduced susceptibility to penicillin G suggested that the meningococcal cell wall is also modified in a penA-dependent manner. Moreover, reverse-phase high pressure liquid chromatography and mass spectrometry analysis of these meningococcal strains confirmed the modifications of peptidoglycan components and showed an increase in the peaks corresponding to pentapeptide-containing muropeptides. These results suggest that the D, D-transpeptidase and/or D, D-carboxypeptidase activities of PBP2 are modified by the changes in penA gene.	Inst Pasteur, Unite Neisseria, F-75724 Paris 15, France; Inst Pasteur, Ctr Natl Reference Meningocoques, F-75724 Paris 15, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Inst Pasteur, Unite Bacteries Anaerobies & Toxines, F-75724 Paris 15, France; Inst Salud Carlos III, Spanish Reference Lab Meningococci, Natl Ctr Microbiol, Madrid 28220, Spain; Withington Hosp, Meningococcal Reference Unit, Manchester Publ Hlth Lab, Manchester M20 2LR, Lancs, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Taha, MK (corresponding author), Inst Pasteur, Unite Neisseria, 28 Rue Dr Roux, F-75724 Paris 15, France.	mktaha@pasteur.fr	Boneca, Ivo G/H-1677-2014; Namane, Abdelkader/O-1857-2013	Boneca, Ivo G/0000-0001-8122-509X; Namane, Abdelkader/0000-0001-7180-7619; Vazquez, Julio A/0000-0003-3326-8831				ABDILLAHI H, 1987, FEMS MICROBIOL LETT, V48, P367, DOI 10.1016/0378-1097(87)90077-2; Antignac A, 2003, J BIOL CHEM, V278, P31521, DOI 10.1074/jbc.M304749200; Antignac A, 2001, J ANTIMICROB CHEMOTH, V47, P285, DOI 10.1093/jac/47.3.285; BARBOUR AG, 1981, ANTIMICROB AGENTS CH, V19, P316, DOI 10.1128/AAC.19.2.316; Boneca IG, 1997, J BIOL CHEM, V272, P29053, DOI 10.1074/jbc.272.46.29053; BOTHA P, 1988, LANCET, V1, P54; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; BURROUGHS M, 1993, J INFECT DIS, V167, P464, DOI 10.1093/infdis/167.2.464; BURROUGHS MH, 1993, J BIOL CHEM, V268, P11594; Dabernat H, 2002, ANTIMICROB AGENTS CH, V46, P2208, DOI 10.1128/AAC.46.7.2208-2218.2002; Deghmane AE, 2000, EMBO J, V19, P1068, DOI 10.1093/emboj/19.5.1068; Dessen A, 2001, J BIOL CHEM, V276, P45106, DOI 10.1074/jbc.M107608200; DILLON JR, 1983, LANCET, V1, P779; DOUGHERTY TJ, 1985, J BACTERIOL, V163, P69, DOI 10.1128/JB.163.1.69-74.1985; DOUGHERTY TJ, 1985, ANTIMICROB AGENTS CH, V28, P90, DOI 10.1128/AAC.28.1.90; DOUGHERTY TJ, 1981, ANTIMICROB AGENTS CH, V20, P109, DOI 10.1128/AAC.20.1.109; Feil EJ, 1999, MOL BIOL EVOL, V16, P1496, DOI 10.1093/oxfordjournals.molbev.a026061; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; FONTANALS D, 1989, EUR J CLIN MICROBIOL, V8, P90, DOI 10.1007/BF01964130; FRASCH CE, 1985, REV INFECT DIS, V7, P504; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; Ghosh AS, 2003, J BACTERIOL, V185, P2178, DOI 10.1128/JB.185.7.2178-2186.2003; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Guibourdenche M, 1997, J CLIN MICROBIOL, V35, P745, DOI 10.1128/JCM.35.3.745-750.1997; Hakenbeck R, 1998, CELL MOL LIFE SCI, V54, P332, DOI 10.1007/s000180050160; Hakenbeck R, 1998, ELECTROPHORESIS, V19, P597, DOI 10.1002/elps.1150190423; Holmes EC, 1999, MOL BIOL EVOL, V16, P741, DOI 10.1093/oxfordjournals.molbev.a026159; Jennings GT, 2002, EUR J BIOCHEM, V269, P3722, DOI 10.1046/j.1432-1033.2002.03064.x; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Kriz P, 1999, RES MICROBIOL, V150, P273, DOI 10.1016/S0923-2508(99)80052-7; LAONSO JM, 2003, FEMS MICROBIOL LETT, V222, P99; LUJAN R, 1991, ANTIMICROB AGENTS CH, V35, P300, DOI 10.1128/AAC.35.2.300; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mayer LW, 2002, J INFECT DIS, V185, P1596, DOI 10.1086/340414; MENDELMAN PM, 1988, ANTIMICROB AGENTS CH, V32, P706, DOI 10.1128/AAC.32.5.706; Miller JH., 1972, EXPT MOL GENETICS; NAUMANN D, 1982, EUR J BIOCHEM, V125, P505, DOI 10.1111/j.1432-1033.1982.tb06711.x; Oppenheim BA, 1997, CLIN INFECT DIS, V24, pS98, DOI 10.1093/clinids/24.Supplement_1.S98; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PERKINS JB, 1986, P NATL ACAD SCI USA, V83, P140, DOI 10.1073/pnas.83.1.140; ROMEIS T, 1994, EUR J BIOCHEM, V224, P597, DOI 10.1111/j.1432-1033.1994.00597.x; Ropp PA, 2002, ANTIMICROB AGENTS CH, V46, P769, DOI 10.1128/AAC.46.3.769-777.2002; SAEZNIETO JA, 1990, ANTIMICROB AGENTS CH, V34, P2269, DOI 10.1128/AAC.34.11.2269; Severin A, 1996, J BACTERIOL, V178, P1788, DOI 10.1128/jb.178.7.1788-1792.1996; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; SPRATT BG, 1992, J MOL EVOL, V34, P115; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taha MK, 1998, MOL MICROBIOL, V28, P1153, DOI 10.1046/j.1365-2958.1998.00876.x; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Tomasz A, 1997, CLIN INFECT DIS, V24, pS85, DOI 10.1093/clinids/24.Supplement_1.S85; Ubukata K, 2001, ANTIMICROB AGENTS CH, V45, P1693, DOI 10.1128/AAC.45.6.1693-1699.2001; van Heijenoort J, 2000, P NATL ACAD SCI USA, V97, P5028, DOI 10.1073/pnas.97.10.5028; Vazquez JA, 1996, EUR J CLIN MICROBIOL, V15, P181, DOI 10.1007/BF01591498	57	46	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31529	31535		10.1074/jbc.M304607200	http://dx.doi.org/10.1074/jbc.M304607200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799360	hybrid			2022-12-25	WOS:000184782100012
J	Wang, HY; Li, WW; Benedetti, NJ; Lee, DHS				Wang, HY; Li, WW; Benedetti, NJ; Lee, DHS			alpha(7) nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; KINASE CASCADE; IN-VITRO; BETA-AMYLOID(1-42); ACCUMULATION; AFFINITY; NEURONS; BINDING; CORTEX; SITES	The Alzheimer's disease pathogenic peptide, beta-amyloid(42) (Abeta(42)), induces tau protein phosphorylation. Because hyperphosphorylated tau is a consistent component of neurofibrillary tangles, a pathological hallmark of Alzheimer's disease, we investigated the signaling molecules involved in Abeta(42)-induced tau phosphorylation. We show that Abeta(42) elicited rapid and reversible tau protein phosphorylation on three proline-directed sites (Ser-202, Thr-181, and Thr-231) in systems enriched in alpha(7) nicotinic acetylcholine receptors (alpha7nAChR) including serum-deprived human SK-N-MC neuroblastoma cells and hippocampal synaptosomes. Although alpha7nAChR agonists induced similar phosphorylation, pretreatment with antisense-alpha7nAChR oligonucleotides (in cells) or alpha7nAChR antagonists (in cells and synaptosomes) attenuated Abeta-induced tau phosphorylation. Western analyses showed that the mitogen-activated kinase cascade proteins, ERKs and c-Jun N-terminal kinase (JNK-1), were concomitantly activated by Abeta(42), and their respective kinase inhibitors suppressed Abeta-induced tau phosphorylation. More importantly, recombinant-activated ERKs and JNK-1 could differentially phosphorylate tau protein in vitro. Thus, the alpha7nAChR may mediate Abeta-induced tau protein phosphorylation via ERKs and JNK-1.	Biogen Inc, Cambridge, MA 02142 USA; CUNY, Sch Med, Dept Physiol & Pharmacol, New York, NY 10031 USA	Biogen; City University of New York (CUNY) System	Lee, DHS (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	Daniel_Lee@Biogen.com						Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Blum S, 1999, J NEUROSCI, V19, P3535; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200; Fabian-Fine R, 2001, J NEUROSCI, V21, P7993, DOI 10.1523/JNEUROSCI.21-20-07993.2001; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Lee DHS, 2003, J NEUROBIOL, V55, P25, DOI 10.1002/neu.10203; Lee VMY, 2001, SCIENCE, V293, P1446, DOI 10.1126/science.1064684; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; Pettit DL, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-01-j0003.2001; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SMITH C, 1994, NEUROPATH APPL NEURO, V20, P322, DOI 10.1111/j.1365-2990.1994.tb00977.x; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2000, J NEUROCHEM, V75, P1155, DOI 10.1046/j.1471-4159.2000.0751155.x; Wang HY, 1999, NEUROPEPTIDES, V33, P197, DOI 10.1054/npep.1999.0024; Williams R, 2002, MATER WORLD, V10, P20; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	35	193	202	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31547	31553		10.1074/jbc.M212532200	http://dx.doi.org/10.1074/jbc.M212532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801934	hybrid			2022-12-25	WOS:000184782100014
J	Li, ZY; Zhang, GY; Le Breton, GC; Gao, XP; Malik, AB; Du, XP				Li, ZY; Zhang, GY; Le Breton, GC; Gao, XP; Malik, AB; Du, XP			Two waves of platelet secretion induced by thromboxane A(2) receptor and a critical role for phosphoinositide 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; INTEGRIN ALPHA(IIB)BETA(3); PROSTAGLANDIN ENDOPEROXIDES; SIGNALING PATHWAYS; THROMBIN RECEPTOR; ACTIVATION; KINASE; GAMMA; AGGREGATION; IDENTIFICATION	Thromboxane A(2) (TXA(2))-mediated platelet secretion and aggregation are important in thrombosis. Here, we present a novel finding that the stable TXA2 analogue, U46619, induces two waves of platelet secretion, each of which precedes a distinct wave of platelet aggregation. ADP released from platelets during the first wave of secretion played a major role in augmenting the first wave of platelet aggregation. The second wave of platelet secretion and aggregation required the first wave of both ADP secretion and aggregation and were blocked by either the integrin inhibitor RGDS or a P2Y12 receptor antagonist, indicating a requirement for both the integrin outside-in signal and ADP-activated G(i) pathway. U46619 stimulated phosphoinositide 3-kinase (PI3K)-dependent phosphorylation of Akt, which was augmented by ADP but did not require integrin outside-in signaling. Platelets from PI3Kgamma knock-out mice or PI3K inhibitor-treated platelets showed an impaired second wave of platelet secretion and aggregation. However, the second wave of platelet aggregation was restored by addition of exogenous ADP to PI3Kgamma deficient or PI3K inhibitor-treated platelets. Thus, our data indicate that PI3K, together with the integrin outside-in signaling, play a central role in inducing the second wave of platelet secretion, which leads to the second wave of irreversible platelet aggregation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.			Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [R01 HL062350, HL68819, HL62350, R01 HL068819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068819, R29HL052547, R01HL062350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Cairns J A, 1987, Cardiovasc Clin, V18, P231; CHARO IF, 1977, NATURE, V269, P66, DOI 10.1038/269066a0; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; NEEDLEMAN P, 1976, SCIENCE, V193, P163, DOI 10.1126/science.945611; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	40	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30725	30731		10.1074/jbc.M301838200	http://dx.doi.org/10.1074/jbc.M301838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796499	hybrid			2022-12-25	WOS:000184658800039
J	Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG				Coppo, P; Dusanter-Fourt, I; Millot, G; Nogueira, MM; Dugray, A; Bonnet, ML; Mitjavila-Garcia, MT; Le Pesteur, D; Guilhot, F; Vainchenker, W; Sainteny, F; Turhan, AG			Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells	ONCOGENE			English	Article						BCR-ABL; STAT3; embryonic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; CHRONIC MYELOID-LEUKEMIA; SIGNAL TRANSDUCERS; KINASE-ACTIVITY; SELF-RENEWAL; IN-VIVO; GENE; EXPRESSION; BCR/ABL	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia (CML) arises in a primitive hematopoietic stem cell with both differentiation and self-renewal ability. To study the phenotypic effects of BCR-ABL in a clonal in vitro self-renewal and differentiation model, we have introduced BCR-ABL in the ES cell line CCE. The major effect of BCR-ABL expression was the persistence of primitive morphology of ES cells despite LIF deprivation, correlated with a constitutive activation of STAT3, the major self-renewal factor of ES cells, but no evidence of activation of STAT5. The enforced expression of BCR-ABL in an ES cell line, engineered to express a tetracycline-inducible dominant-negative form of a STAT3, triggered ES cell differentiation with an increased generation of hematopoietic cells expressing erythroid and megakaryocytic phenotypes. RT-PCR analysis for Oct4, Brachyury and beta-globin expression confirmed a delay of differentiation in BCR-ABL expressing clones, which could be entirely reversed upon activation of the dominant-negative form of STAT3. To study the possible relevance of STAT3 activation by BCR-ABL in human CML, Western blot analyses performed on the CD34+ cells, purified from CML patients at different stages of their disease, also demonstrated increased levels of STAT3 proteins phosphorylated both on tyrosine and serine residues. These results represent to our knowledge the first functional link between BCR-ABL oncogene and a self-renewal in the context of ES cells through constitutive activation of STAT3. Thus, the BCR-ABL embryonic stem cell model that we developed as well as the results obtained in human CML samples suggests a role for STAT3 in the pathogenesis of human CML.	Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, F-94805 Villejuif, France; Hop Cochin, ICGM, INSERM, U363, F-75674 Paris, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France; CHU Poitiers, Dept Oncol & Cell Therapy, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; UNICANCER; Gustave Roussy; CHU Poitiers	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Translat Res Cell Therapy Lab, PR-1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Dusanter-Fourt, Isabelle/P-4558-2017; Mitjavila-Garcia, Maria Teresa/L-8909-2018	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Nogueira, Maria Manuela/0000-0002-8353-1979; Guilhot, Francois/0000-0001-7222-487X; Vainchenker, William/0000-0003-4705-202X; TURHAN, Ali/0000-0002-4861-0137				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUGRAY A, 2001, LEUKEMIA, V14, P662; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 1999, CANCER RES, V59, P5059; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4102	4110		10.1038/sj.onc.1206607	http://dx.doi.org/10.1038/sj.onc.1206607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821944				2022-12-25	WOS:000183707600013
J	Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC				Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC			Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro	ONCOGENE			English	Article						Dupuytren's contracture; fibromatosis; beta-catenin; extracellular matrix	TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; E-CADHERIN; CONTRACTURE; COMPLEX; CANCER; FIBROMATOSIS; ABNORMALITIES; ASSOCIATION; INHIBITION	Dupuytren's disease (DD) is a superficial fibromatosis of the hand. Although the molecular mechanisms responsible for this disease are unknown, recent studies suggest that beta-catenin may be a key factor involved in fibromatosis. In this study, we analysed the in vivo and in vitro expression levels of beta-catenin in DD, using surgical specimens and primary cell lines. Although no somatic mutations (exon 3) of beta-catenin were detected, Western blot analysis revealed high levels of beta-catenin in diseased palmar fascia, and low to undetectable levels of beta-catenin in patient-matched normal palmar fascia. Immunohistochemistry analysis showed high levels of beta-catenin expression within the disease fascia, as well as cytoplasmic and nuclear accumulations of the protein. Immunoprecipitation of beta-catenin from seven patient lesions showed the protein to be tyrosine phosphorylated. Lastly, Western analysis of three patient-matched (disease and normal fascia) primary cell cultures showed significantly elevated levels of beta-catenin in disease cells cultured in three-dimensional collagen lattices. This is the first extensive in vivo and in vitro characterization of beta-catenin in DD, and the first to suggest that the extracellular matrix may play an important role in modulating beta-catenin stability in DD.	Univ Western Ontario, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, London, ON, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Howard, JC (corresponding author), St Josephs Hlth Care, Hand & Upper Limb Ctr, Cell & Mol Biol Lab, 268 Grosvenor St, London, ON N6A 4V2, Canada.							Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; AN HS, 1988, J HAND SURG-AM, V13A, P872, DOI 10.1016/0363-5023(88)90262-6; ARAFA M, 1992, J HAND SURG-BRIT EUR, V17B, P221, DOI 10.1016/0266-7681(92)90095-J; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BONNICI AV, 1992, J HAND SURG-BRIT EUR, V17B, P349, DOI 10.1016/0266-7681(92)90128-O; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; Burge P, 1999, HAND CLIN, V15, P63; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheon SS, 2002, P NATL ACAD SCI USA, V30, P30; Dal Cin P, 1999, CANCER GENET CYTOGEN, V108, P137, DOI 10.1016/S0165-4608(98)00126-5; De Wever I, 2000, MODERN PATHOL, V13, P1080, DOI 10.1038/modpathol.3880200; Dupuytren B, 1834, LANCET, V2, P222; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Gudmundsson KG, 2002, J CLIN EPIDEMIOL, V55, P5, DOI 10.1016/S0895-4356(01)00413-9; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kloen P, 1999, BRIT J PLAST SURG, V52, P629, DOI 10.1054/bjps.1999.3187; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhn MA, 2002, J SURG RES, V103, P146, DOI 10.1006/jsre.2001.6350; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; MCFARLANE RM, 1991, J HAND SURG-AM, V16A, P775, DOI 10.1016/S0363-5023(10)80134-0; MIKKELSEN OA, 1978, HAND, V10, P1, DOI 10.1016/S0072-968X(78)80019-9; Mikkelsen OA, 1999, J HAND SURG-BRIT EUR, V24B, P515, DOI 10.1054/jhsb.1999.0229; Montgomery E, 2001, MODERN PATHOL, V14, P695, DOI 10.1038/modpathol.3880374; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NOBLE J, 1992, J HAND SURG-BRIT EUR, V17B, P71, DOI 10.1016/0266-7681(92)90015-T; NOBLE J, 1984, J BONE JOINT SURG BR, V66, P322, DOI 10.1302/0301-620X.66B3.6725338; Polakis P, 2000, GENE DEV, V14, P1837; Rayan GM, 1999, HAND CLIN, V15, P87; Ross DC, 1999, HAND CLIN, V15, P53; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SERGOVICH FR, 1983, NEW ENGL J MED, V308, P162; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SKOOG T, 1960, PLAST RECONSTR SURG, V31, P258; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WURSTERHILL DH, 1988, AM J HUM GENET, V43, P285	43	47	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3680	3684		10.1038/sj.onc.1206415	http://dx.doi.org/10.1038/sj.onc.1206415			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802275				2022-12-25	WOS:000183551000002
J	Coyle, CM; Puranik, M; Youn, H; Nielsen, SB; Williams, RD; Kerby, RL; Roberts, GP; Spiro, TG				Coyle, CM; Puranik, M; Youn, H; Nielsen, SB; Williams, RD; Kerby, RL; Roberts, GP; Spiro, TG			Activation mechanism of the CO sensor CooA - Mutational and resonance Raman spectroscopic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTIONAL ACTIVATOR; HEME-LIGAND; RHODOSPIRILLUM-RUBRUM; REGULATOR COOA; AXIAL LIGAND; HISTIDINE 77; DNA-BINDING; PROTEIN; MYOGLOBIN; IDENTIFICATION	CooA is a CO-dependent heme protein transcription factor of the bacterium Rhodospirillum rubrum. CO binding to its heme causes CooA to bind DNA and activate expression of genes for CO metabolism. To understand the nature of CO activation, several CooA mutational variants have been studied by resonance Raman spectroscopy, in vivo activity measurements, and DNA binding assays. Analysis of the Fe-C and C-O stretching Raman spectroscopy bands permits the conclusion that when CO displaces the Pro(2) heme ligand, the protein forms a hydrophobic pocket in which the C-helix residues Gly(117), Leu(116), and Ile(113) are close to the bound CO. The displaced Pro(2) terminus is expelled from this pocket, unless the pH is raised above the pK(a), in which case the terminus remains in H- bond contact. The pK(a) for this transition is 8.6, two units below that of aqueous proline, reflecting the hydrophobic nature of the pocket. The proximal Fe - His bond in Fe[II] CooA is as strong as it is in myoglobin but is weakened by CO binding, an effect attributable to loss of an H- bond from the proximal His(77) ligand to the adjacent Asn(42) side chain. A structural model is proposed for the position of the CO-bound heme in the active form of CooA, which has implications for the mechanism of CO activation.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Princeton University; University of Wisconsin System; University of Wisconsin Madison	Spiro, TG (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.		Nielsen, Steen Brondsted/G-5844-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228, R01GM033576] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33576, GM 53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; CARTLING B, 1981, BIOCHIM BIOPHYS ACTA, V637, P61, DOI 10.1016/0005-2728(81)90210-3; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OTHMAN S, 1994, BIOCHEMISTRY-US, V33, P15437, DOI 10.1021/bi00255a026; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; Rubtsov IV, 2001, J AM CHEM SOC, V123, P10056, DOI 10.1021/ja011023w; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STEIN P, 1980, J AM CHEM SOC, V102, P7795, DOI 10.1021/ja00546a035; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Youn H, 2003, J BIOL CHEM, V278, P2333, DOI 10.1074/jbc.M210825200; Youn H, 2002, J BIOL CHEM, V277, P33616, DOI 10.1074/jbc.M203684200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200	34	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35384	35393		10.1074/jbc.M301000200	http://dx.doi.org/10.1074/jbc.M301000200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12796503	hybrid			2022-12-25	WOS:000185164400078
J	Mandal, D; Rulli, SJ; Rao, R				Mandal, D; Rulli, SJ; Rao, R			Packing interactions between transmembrane helices alter ion selectivity of the yeast Golgi Ca2+/Mn2+-ATPase PMR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY CA2+/MN2+-ATPASE; HAILEY-HAILEY-DISEASE; CALCIUM-PUMP; MUTATIONS; CA2+; RETICULUM; CA2+-ATPASE; RESIDUES; HOMOLOG; ATPASE	PMR1 is the yeast secretory pathway pump responsible for high affinity transport of Mn2+ and Ca2+ into the Golgi, where these ions are sequestered and effectively removed from the cytoplasm. Phenotypic growth assays allow for convenient screening of side chains important for Ca2+ and Mn2+ transport. Earlier we demonstrated that mutant Q783A at the cytoplasmic interface of M6 could transport Ca2+, but not Mn2+. Scanning mutagenesis of side chains proximal to residue Gln-783 in membrane helices M2, M4, M5, and M6 revealed additional residues near the cytoplasmic interface, notably Leu-341 ( M5), Phe-738 ( M5), and Leu-785 ( M6) that are sensitive to substitution. Importantly, we obtained evidence for a packing interaction between Val-335 in M4 and Gln-783 in M6 that is critical for Mn2+ transport. Thus, mutant V335G mimics the Mn2+ transport defect of Q783A and mutant V335I can effectively suppress the Mn2+-defective phenotype of Q783A. These changes in ion selectivity were confirmed by cation-dependent ATP hydrolysis using purified enzyme. Other substitutions at these sites are tolerated individually, but not in combination. Exchange of side chains at 335 and 783 also results in ion selectivity defects, suggesting that the packing interaction may be conformation-sensitive. Homology models of M4, M5, and M6 of PMR1 have been generated, based on the structures of the sarcoplasmic reticulum Ca2+-ATPase. The models are supported by data from mutagenesis and reveal that Gln-783 and Val-335 show conformation-sensitive packing at the cytoplasmic interface. We suggest that this region may constitute a gate for access of Mn2+ ions.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062142] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62142] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; East JM, 2000, MOL MEMBR BIOL, V17, P189, DOI 10.1080/09687680010009646; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LOUKIN S, 1995, J CELL BIOL, V131, P1025, DOI 10.1083/jcb.131.4.1025; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wuytack F, 2003, PFLUG ARCH EUR J PHY, V446, P148, DOI 10.1007/s00424-003-1011-5	23	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35292	35298		10.1074/jbc.M306166200	http://dx.doi.org/10.1074/jbc.M306166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824173	Green Submitted, hybrid			2022-12-25	WOS:000185164400068
J	Sumandea, MP; Pyle, WG; Kobayashi, T; de Tombe, PP; Solaro, RJ				Sumandea, MP; Pyle, WG; Kobayashi, T; de Tombe, PP; Solaro, RJ			Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT REGULATION; ACTOMYOSIN MGATPASE ACTIVITY; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; SKELETAL-MUSCLE; SHORTENING VELOCITY; S1-INDUCED MOVEMENT; TROPOMYOSIN; ACTIVATION; ACTIN	Cardiac Troponin T (cTnT) is one prominent substrate through which protein kinase C (PKC) exerts its effect on cardiomyocyte function. To determine the specific functional effects of the cTnT PKC-dependent phosphorylation sites (Thr(197), Ser(201), Thr(206), and Thr(287)) we first mutated these residues to glutamate (E) or alanine (A). cTnT was selectively mutated to generate single, double, triple, and quadruple mutants. Bacterially expressed mutants were evaluated in detergent-treated mouse left ventricular papillary muscle fiber bundles where the endogenous troponin was replaced with a recombinant troponin complex containing either cTnT phosphorylated by PKC-alpha or a mutant cTnT. We simultaneously determined isometric tension development and actomyosin Mg-ATPase activity of the exchanged fiber bundles as a function of Ca2+ concentration. Our systematic analysis of the functional role of the multiple PKC phosphorylation sites on cTnT identified a localized region that controls maximum tension, ATPase activity, and Ca2+ sensitivity of the myofilaments. An important and novel finding of our study was that Thr(206) is a functionally critical cTnT PKC phosphorylation residue. Its exclusive phosphorylation by PKC-alpha or replacement by Glu (mimicking phosphorylation) significantly decreased maximum tension, actomyosin Mg-ATPase activity, myofilament Ca2+ sensitivity, and cooperativity. On the other hand the charge modification of the other three residues together (T197/S201/T287-E) had no functional effect. Fibers bundles containing phosphorylated cTnT-wt (but not the T197/S201/T206/T287-E) exhibited a significant decrease of tension cost as compared with cTnT-wt.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Solaro, RJ (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, Program Cardiovasc Sci, M-C 901,835 S Wolcott Ave, Chicago, IL 60612 USA.			Pyle, Glen/0000-0003-0980-4729	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010409, P01HL062426] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL2231, P01-HL62426, F32 HL 10409] Funding Source: Medline; PHS HHS [T3207692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Andrew CD, 2002, BIOCHEMISTRY-US, V41, P1897, DOI 10.1021/bi0113216; Bacchiocchi C, 2002, BIOPHYS J, V82, P1524, DOI 10.1016/S0006-3495(02)75505-7; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Brenner B, 1999, BIOPHYS J, V77, P2677, DOI 10.1016/S0006-3495(99)77102-X; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; Chandra M, 1999, BIOCHEM BIOPH RES CO, V263, P219, DOI 10.1006/bbrc.1999.1341; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Eidenmuller J, 2000, BIOCHEMISTRY-US, V39, P13166, DOI 10.1021/bi001290z; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GUO XD, 1994, J BIOL CHEM, V269, P15210; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Janssen PML, 1997, AM J PHYSIOL-HEART C, V273, pH2415, DOI 10.1152/ajpheart.1997.273.5.H2415; Janssen PML, 1997, AM J PHYSIOL-HEART C, V272, pH1892, DOI 10.1152/ajpheart.1997.272.4.H1892; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Kajiwara H, 2000, BIOCHEM BIOPH RES CO, V272, P104, DOI 10.1006/bbrc.2000.2741; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Kimura C, 2002, J BIOCHEM, V132, P345, DOI 10.1093/oxfordjournals.jbchem.a003229; Kimura C, 2002, J BIOCHEM, V132, P93, DOI 10.1093/oxfordjournals.jbchem.a003204; Kobayashi T, 1999, BIOCHEMISTRY-US, V38, P5386, DOI 10.1021/bi981320m; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Maytum R, 2002, J BIOL CHEM, V277, P29774, DOI 10.1074/jbc.M201761200; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Montgomery DE, 2001, AM J PHYSIOL-HEART C, V280, pH1011, DOI 10.1152/ajpheart.2001.280.3.H1011; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; NOLAND TA, 1993, J MOL CELL CARDIOL, V25, P53, DOI 10.1006/jmcc.1993.1007; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Pyle WG, 2002, AM J PHYSIOL-HEART C, V283, pH1215, DOI 10.1152/ajpheart.00128.2002; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; She MD, 2000, J MUSCLE RES CELL M, V21, P737, DOI 10.1023/A:1010300802980; Smart JL, 1999, BIOPOLYMERS, V49, P225, DOI 10.1002/(SICI)1097-0282(199903)49:3<225::AID-BIP4>3.0.CO;2-B; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; SOLARO RJ, 2001, HDB PHYSL 2, V1, P264; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; STRANG KT, 1995, CIRC RES, V77, P114, DOI 10.1161/01.RES.77.1.114; Takeda S, 2002, BIOPHYS J, V82, p170A; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 2002, J BIOL CHEM, V14, P14; van der Velden J, 2000, CARDIOVASC RES, V46, P487, DOI 10.1016/S0008-6363(00)00050-X; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200	58	160	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35135	35144		10.1074/jbc.M306325200	http://dx.doi.org/10.1074/jbc.M306325200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832403	hybrid			2022-12-25	WOS:000185164400049
J	Collaco, RF; Kalman-Maltese, V; Smith, AD; Dignam, JD; Trempe, JP				Collaco, RF; Kalman-Maltese, V; Smith, AD; Dignam, JD; Trempe, JP			A biochemical characterization of the adeno-associated virus Rep40 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; ESCHERICHIA-COLI; ATPASE ACTIVITIES; BINDING PROTEIN; RECQ HELICASE; GENE-PRODUCT; REPLICATION; IDENTIFICATION; RECOMBINATION; PROMOTERS	The human adeno-associated virus (AAV) has generated much enthusiasm as a transfer vector for human gene therapy. Although clinical gene therapy trials have been initiated using AAV vectors, much remains to be learned regarding the basic mechanisms of virus replication, gene expression, and virion assembly. AAV encodes four nonstructural, or replication (Rep), proteins. The Rep78 and Rep68 proteins regulate viral DNA replication, chromosomal integration, and gene expression. The Rep52 and Rep40 proteins mediate virus assembly. To better understand Rep protein function, we have expressed the Rep40 protein in Escherichia coli and purified it to near homogeneity. Like the other Rep proteins, Rep40 possesses helicase and ATPase activity. ATP is the best substrate, and Mg2+ is the most efficient divalent metal ion for helicase activity. A Lys to His mutation in the purine nucleotide-binding site results in a protein that inhibits helicase activity in a dominant negative manner. Rep40 unwinds double-stranded DNA containing a 3' single-stranded end, or blunt end, unlike the Rep68 and Rep52 enzymes, which have a strict requirement for DNA duplexes containing a 3' single-stranded end. Values for K-ATP in the ATPase assay are 1.1 +/- 0.2 mM and 1.2 +/- 0.2 mM in the absence and presence, respectively, of single-stranded DNA. Values for V-max are 220 +/- 10 and 1,500 +/- 90 nmol/min/mg in the absence and presence, respectively, of single-stranded DNA. These studies provide the first enzymatic characterization of the AAV Rep40 protein and elucidate important functional differences between the AAV helicases.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA		Trempe, JP (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, Block Hlth Sci Bldg,Rm 408,3035 Arlington Ave, Toledo, OH 43614 USA.			Smith, Andrew/0000-0002-8124-1038	NIAID NIH HHS [AI51471] Funding Source: Medline; NIGMS NIH HHS [GM64765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEJANOVSKY N, 1990, J VIROL, V64, P1764, DOI 10.1128/JVI.64.4.1764-1770.1990; CHIORINI JA, 1994, J VIROL, V68, P797, DOI 10.1128/JVI.68.2.797-804.1994; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HOLSCHER C, 1994, J VIROL, V68, P7169; HORER M, 1995, J VIROL, V69, P5485; King JA, 2001, EMBO J, V20, P3282, DOI 10.1093/emboj/20.12.3282; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MCCARTY DM, 1991, J VIROL, V65, P2936, DOI 10.1128/JVI.65.6.2936-2945.1991; MENDELSON E, 1986, J VIROL, V60, P823, DOI 10.1128/JVI.60.3.823-832.1986; Meyers C, 2000, VIROLOGY, V272, P338, DOI 10.1006/viro.2000.0385; MUZYCZKA N, 2001, FIELDS VIROLOGY, V2, P2327; OWENS RA, 1993, J VIROL, V67, P997, DOI 10.1128/JVI.67.2.997-1005.1993; Pereira DJ, 1997, J VIROL, V71, P1079, DOI 10.1128/JVI.71.2.1079-1088.1997; Smith RH, 1998, J VIROL, V72, P4874, DOI 10.1128/JVI.72.6.4874-4881.1998; Smith RH, 1997, J VIROL, V71, P4461, DOI 10.1128/JVI.71.6.4461-4471.1997; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WONDERLING RS, 1995, J VIROL, V69, P3542, DOI 10.1128/JVI.69.6.3542-3548.1995; YAKOBSON B, 1987, J VIROL, V61, P972, DOI 10.1128/JVI.61.4.972-981.1987; YANG QC, 1993, J VIROL, V67, P4442, DOI 10.1128/JVI.67.7.4442-4447.1993; Young SM, 2000, J VIROL, V74, P3953, DOI 10.1128/JVI.74.9.3953-3966.2000; Zhou XH, 1999, J VIROL, V73, P1580, DOI 10.1128/JVI.73.2.1580-1590.1999	26	27	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34011	34017		10.1074/jbc.M301537200	http://dx.doi.org/10.1074/jbc.M301537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824181	hybrid			2022-12-25	WOS:000185047500049
J	Peng, CH; Rich, ED; Varnum, MD				Peng, CH; Rich, ED; Varnum, MD			Achromatopsia-associated mutation in the human cone photoreceptor cyclic nucleotide-gated channel CNGB3 subunit alters the ligand sensitivity and pore properties of heteromeric channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CIS-DILTIAZEM; ION CHANNELS; ALPHA-SUBUNIT; RETINAL ROD; K+-CHANNEL; CATION CHANNEL; CHROMOSOMAL LOCALIZATION; FUNCTIONAL EXPRESSION; TOTAL COLOURBLINDNESS; POTASSIUM CHANNELS	Cone photoreceptor cyclic nucleotide-gated (CNG) channels are thought to form by assembly of two different subunit types, CNGA3 and CNGB3. Recently, mutations in the gene encoding the CNGB3 subunit have been linked to achromatopsia in humans. Here we describe the functional consequences of two achromatopsia-associated mutations in human CNGB3 (hCNGB3). Co-expression in Xenopus oocytes of human CNGA3 ( hCNGA3) subunits with hCNGB3 subunits containing an achromatopsia-associated mutation in the S6 transmembrane domain (S435F) generated functional heteromeric channels that exhibited an increase in apparent affinity for both cAMP and cGMP compared with wild type heteromeric channels. In contrast, co-expression of a presumptive null mutation of hCNGB3 (T383f.s.DeltaC) with hCNGA3 produced channels with properties indistinguishable from homomeric hCNGA3 channels. The effect of hCNGB3 S435F subunits on cell-surface expression of green fluorescent protein-tagged hCNGA3 subunits and of non-tagged hCNGA3 subunits on surface expression of green fluorescent protein-hCNGB3 S435F subunits were similar to those observed for wild type hCNGB3 subunits, suggesting that the mutation does not grossly disturb subunit assembly or plasma membrane targeting. The S435F mutation was also found to produce changes in the pore properties of the channel, including decreased single channel conductance and decreased sensitivity to block by L-cis-diltiazem. Overall, these results suggest that the functional properties of cone CNG channels may be altered in patients with the S435F mutation, providing evidence supporting the pathogenicity of this mutation in humans. Thus, achromatopsia may arise from a disturbance of cone CNG channel gating and permeation or from the absence of functional CNGB3 subunits.	Washington State Univ, Dept VCAPP, Pullman, WA 99164 USA; Washington State Univ, Program Neurosci, Pullman, WA 99164 USA	Washington State University; Washington State University	Varnum, MD (corresponding author), Washington State Univ, Dept VCAPP, POB 646520, Pullman, WA 99164 USA.				NEI NIH HHS [EY12836] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012836] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Dzeja C, 1999, EMBO J, V18, P131, DOI 10.1093/emboj/18.1.131; Eksandh Louise, 2002, Ophthalmic Genet, V23, P109, DOI 10.1076/opge.23.2.109.2210; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Fodor AA, 1997, J GEN PHYSIOL, V110, P591, DOI 10.1085/jgp.110.5.591; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; Gerstner A, 2000, J NEUROSCI, V20, P1324; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; Hille B, 2001, ION CHANNELS EXCITAB, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kohl S, 1998, NAT GENET, V19, P257, DOI 10.1038/935; Kohl S, 2000, HUM MOL GENET, V9, P2107, DOI 10.1093/hmg/9.14.2107; KORENBROT JI, 1995, CELL CALCIUM, V18, P285, DOI 10.1016/0143-4160(95)90025-X; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mallouk N, 2002, J MEMBRANE BIOL, V185, P129, DOI 10.1007/s00232-001-0119-9; MCLATCHIE LM, 1992, P ROY SOC B-BIOL SCI, V247, P113, DOI 10.1098/rspb.1992.0016; MILLER JL, 1994, J GEN PHYSIOL, V104, P909, DOI 10.1085/jgp.104.5.909; Ohyama T, 2000, J GEN PHYSIOL, V116, P735, DOI 10.1085/jgp.116.6.735; Peng CH, 2003, J BIOL CHEM, V278, P24617, DOI 10.1074/jbc.M301699200; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; PICONES A, 1995, BIOPHYS J, V69, P120, DOI 10.1016/S0006-3495(95)79881-2; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rho SH, 2000, FEBS LETT, V478, P246, DOI 10.1016/S0014-5793(00)01863-9; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; Rojas CV, 2002, EUR J HUM GENET, V10, P638, DOI 10.1038/sj.ejhg.5200856; Rosenbaum T, 2002, NEURON, V33, P703, DOI 10.1016/S0896-6273(02)00599-8; Sachs Oliver, 1997, ISLAND COLORBLIND; SAKMANN B, 1995, SINGLE CHANNEL RECOR, P643; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; Sundin OH, 2000, NAT GENET, V25, P289, DOI 10.1038/77162; Trudeau MC, 2002, P NATL ACAD SCI USA, V99, P8424, DOI 10.1073/pnas.122015999; Trudeau MC, 2002, NEURON, V34, P197, DOI 10.1016/S0896-6273(02)00647-5; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Wissinger B, 1997, EUR J NEUROSCI, V9, P2512, DOI 10.1111/j.1460-9568.1997.tb01680.x; Wissinger B, 2001, AM J HUM GENET, V69, P722, DOI 10.1086/323613; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; [No title captured]	59	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34533	34540		10.1074/jbc.M305102200	http://dx.doi.org/10.1074/jbc.M305102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815043	hybrid			2022-12-25	WOS:000185047500114
J	Sternfeld, L; Krause, E; Guse, AH; Schulz, I				Sternfeld, L; Krause, E; Guse, AH; Schulz, I			Hormonal control of ADP-ribosyl cyclase activity in pancreatic acinar cells from rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ADENINE-DINUCLEOTIDE PHOSPHATE; CA2+-INDUCED CA2+ RELEASE; PROTEIN-KINASE-C; NAD(+) GLYCOHYDROLASE; CALCIUM-CONCENTRATION; CARDIAC MYOCYTES; ZYMOGEN GRANULES; WAVE-PROPAGATION; T-LYMPHOCYTES	Cyclic ADP-ribose, a metabolite of NAD(+) evokes Ca2+ release from intracellular stores in different cells. We have determined the activity of cADPr-producing enzymes (ADP-ribosyl cyclases) in different cellular fractions prepared from isolated pancreatic acinar cells by measuring the conversion of the beta-NAD(+) analogs 1, N-6-etheno- NAD and nicotinamide guanine dinucleotide to the fluorescent products 1, N-6-etheno-cADPr and cyclic GDP-ribose, respectively. Substrate/product analyses were carried out by reverse-phase high pressure liquid chromatography. In all subcellular fractions examined ( cytosol, mitochondria, plasma, and intracellular membranes), ADP-ribosyl cyclase activity was detected except in zymogen granular membranes. Western blot analysis and immunoprecipitation experiments revealed the presence of the ADP-ribosyl cyclase CD38 in both plasma membranes and mitochondria but not in the cytosol. Hormonal stimulation of intact acinar cells for 1 min with acetylcholine (ACh), cholecystokinin (CCK), or a membrane-permeant analog of cGMP increased ADP-ribosyl cyclase activity in the cytosol by 1.8-,1.6-, and 1.9-fold, respectively, as compared with the control but had no effect in any other fraction. Both ACh and CCK also increased accumulation of cGMP in the cells by about 2-fold. Bombesin had no significant effect on either ADP-ribosyl cyclase activity or cGMP accumulation within this short period of stimulation. We conclude that at least two types of ADP-ribosyl cyclases are present in pancreatic acinar cells: membrane- bound CD38 and a cytosolic enzyme different from CD38. Stimulation of pancreatic acinar cells with CCK or ACh results in exclusive activation of the cytosolic ADP-ribosyl cyclase activity, most likely mediated by cGMP.	Univ Saarland, Inst Physiol, D-66421 Homburg, Germany; Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol Cellular Signal Transduct, D-20246 Hamburg, Germany	Saarland University; University of Hamburg	Schulz, I (corresponding author), Univ Saarland, Inst Physiol, Bldg 58, D-66421 Homburg, Germany.	irene.schulz@uniklinik-saarland.de		Krause, Elmar/0000-0003-0891-2373				Bruzzone S, 2001, FASEB J, V15, P10; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; Fogarty KE, 2000, J PHYSIOL-LONDON, V526, P515, DOI 10.1111/j.1469-7793.2000.t01-1-00515.x; Franco L, 1998, FASEB J, V12, P1507; Fukushi Y, 2001, J BIOL CHEM, V276, P649, DOI 10.1074/jbc.M004469200; Gobel A, 2001, CELL CALCIUM, V29, P29, DOI 10.1054/ceca.2000.0154; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GUSE AH, 1994, BIOCHEM J, V301, P83, DOI 10.1042/bj3010083; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; Hotta T, 2000, J NEUROCHEM, V74, P669, DOI 10.1046/j.1471-4159.2000.740669.x; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Klebl BM, 1996, ANAL BIOCHEM, V239, P145, DOI 10.1006/abio.1996.0309; Krause E, 2002, J BIOL CHEM, V277, P11696, DOI 10.1074/jbc.M107794200; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 2000, J MEMBRANE BIOL, V173, P1, DOI 10.1007/s002320001001; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Looms DK, 2001, BIOCHEM J, V355, P87, DOI 10.1042/bj3550087; LOPEZMEDIAVILLA C, 1992, EXP CELL RES, V203, P134, DOI 10.1016/0014-4827(92)90048-D; Matsumura N, 1998, BIOCHEM BIOPH RES CO, V253, P246, DOI 10.1006/bbrc.1998.9752; MAY RJ, 1978, AM J PHYSIOL, V235, pE112, DOI 10.1152/ajpendo.1978.235.2.E112; Meszaros LG, 1997, BIOCHEM BIOPH RES CO, V234, P252, DOI 10.1006/bbrc.1997.6620; MullerSteffner H, 1997, ADV EXP MED BIOL, V419, P399; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; Schweitzer K, 2001, ANAL BIOCHEM, V299, P218, DOI 10.1006/abio.2001.5419; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Thevenod F, 1996, J BIOL CHEM, V271, P3300, DOI 10.1074/jbc.271.6.3300; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yu JZ, 2000, AM J PHYSIOL-HEART C, V279, pH873, DOI 10.1152/ajpheart.2000.279.3.H873; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	45	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33629	33636		10.1074/jbc.M301043200	http://dx.doi.org/10.1074/jbc.M301043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807891	hybrid			2022-12-25	WOS:000185047500006
J	Tang, LY; Reddy, MN; Rasheva, V; Lee, TL; Lin, MJ; Hung, MS; Shen, CKJ				Tang, LY; Reddy, MN; Rasheva, V; Lee, TL; Lin, MJ; Hung, MS; Shen, CKJ			The eukaryotic DNMT2 genes encode a new class of cytosine-5 DNA methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; FISSION YEAST; METHYLATION; CELLS; HOMOLOG	DNMT2 is a subgroup of the eukaryotic cytosine-5 DNA methyltransferase gene family. Unlike the other family members, proteins encoded by DNMT2 genes were not known before to possess DNA methyltransferase activities. Most recently, we have shown that the genome of Drosophila S2 cells stably expressing an exogenous Drosophila dDNMT2 cDNA became anomalously methylated at the 5'-positions of cytosines (Reddy, M. N., Tang, L. Y., Lee, T. L., and Shen, C.- K. J. ( 2003) Oncogene, in press). We present evidence here that the genomes of transgenic flies overexpressing the dDnmt2 protein also became hypermethylated at specific regions. Furthermore, transient transfection studies in combination with sodium bisulfite sequencing demonstrated that dDnmt2 as well as its mouse ortholog, mDnmt2, are capable of methylating a cotransfected plasmid DNA. These data provide solid evidence that the fly and mouse DNMT2 gene products are genuine cytosine-5 DNA methyltransferases.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.		shen, Che-Kun James/L-1343-2015; Hung, Ming-Shiu/C-1375-2010; Hung, Ming-Shiu/ABY-8059-2022; Rasheva, Vanya/K-2310-2014	Rasheva, Vanya/0000-0003-1018-5566				Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BRAND AH, 1993, DEVELOPMENT, V118, P401; DELPUS R, 2002, NUCLEIC ACIDS RES, V30, P2831; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Lin MJ, 2000, FEBS LETT, V469, P101, DOI 10.1016/S0014-5793(00)01254-0; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Pinarbasi E, 1996, J MOL BIOL, V257, P804, DOI 10.1006/jmbi.1996.0203; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REDDY MN, 2003, IN PRESS ONCOGENE; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; SEDOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; WILKINSON CRM, 1995, NUCLEIC ACIDS RES, V23, P203, DOI 10.1093/nar/23.2.203; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	20	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33613	33616		10.1074/jbc.C300255200	http://dx.doi.org/10.1074/jbc.C300255200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819212	hybrid			2022-12-25	WOS:000185047500002
J	Kaji, N; Ohashi, K; Shuin, M; Niwa, R; Uemura, T; Mizuno, K				Kaji, N; Ohashi, K; Shuin, M; Niwa, R; Uemura, T; Mizuno, K			Cell cycle-associated changes in Slingshot phosphatase activity and roles in cytokinesis in animal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING FACTOR; LIM-KINASE 1; COFILIN PHOSPHORYLATION; PROTEIN-KINASE; ACTIVATION; DEPHOSPHORYLATION; REORGANIZATION; DYNAMICS; BIOLOGY; FAMILY	During cytokinesis the actomyosin-based contractile ring is formed at the equator, constricted, and then disassembled prior to cell abscission. Cofilin stimulates actin filament disassembly and is implicated in the regulation of contractile ring dynamics. However, little is known about the mechanism controlling cofilin activity during cytokinesis. Cofilin is inactivated by phosphorylation on Ser-3 by LIM-kinase-1 (LIMK1) and is reactivated by a protein phosphatase Slingshot-1 (SSH1). Here we show that the phosphatase activity of SSH1 decreases in the early stages of mitosis and is elevated in telophase and cytokinesis in HeLa cells, a time course correlating with that of cofilin dephosphorylation. SSH1 co-localizes with F-actin and accumulates onto the cleavage furrow and the midbody. Expression of a phosphatase-inactive SSH1 induces aberrant accumulation of F-actin and phospho-cofilin near the midbody in the final stage of cytokinesis and frequently leads to the regression of the cleavage furrow and the formation of multinucleate cells. Co-expression of cofilin rescued the inhibitory effect of phosphatase-inactive SSH1 on cytokinesis. These results suggest that SSH1 plays a critical role in cytokinesis by dephosphorylating and reactivating cofilin in later stages of mitosis.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Kyoto Univ, Inst Virus Res, Dept Mol Genet, Kyoto 6068507, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068507, Japan	Tohoku University; Kyoto University; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X; UEMURA, Tadashi/0000-0001-7204-3606				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Endo M, 2003, J NEUROSCI, V23, P2527; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Narumiya S, 2002, NATURE, V419, P27, DOI 10.1038/419027a; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Sumi T, 2002, BIOCHEM BIOPH RES CO, V290, P1315, DOI 10.1006/bbrc.2002.6346; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	25	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33450	33455		10.1074/jbc.M305802200	http://dx.doi.org/10.1074/jbc.M305802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807904	hybrid			2022-12-25	WOS:000184901800118
J	Magid, R; Murphy, TJ; Galis, ZS				Magid, R; Murphy, TJ; Galis, ZS			Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress - role of c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; ATHEROSCLEROTIC PLAQUES; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; TRANSGENIC MICE; PULSATILE FLOW; FOAM CELLS; IN-VITRO; TRANSCRIPTION	Atherosclerotic plaques preferentially localize to areas of the vasculature with complex laminar or oscillatory blood flow. Prior data implicate matrix metalloproteinases (MMPs) in the initiation and progression of atherosclerotic lesions. In cultured endothelial cells, oscillatory but not unidirectional shear significantly increases MMP-9 mRNA as well as secretion of the MMP-9 protein (p<0.05). In contrast, cell-associated protein levels of <(T)under bar>issue (I) under bar nhibitor of (M) under barM (P) under bar 1 (TIMP-1), an inhibitor of MMP-9, are insensitive to the shear regimen. To investigate transcriptional regulation of MMP-9 gene expression, we utilized retroviral-based reporter constructs containing different lengths of the human MMP-9 promoter. The activity of the full MMP-9 promoter is 3-fold higher (p<0.05) in unidirectional shear compared with static conditions, and the activity is further increased &SIM;10-fold by oscillatory shear (p<0.01) over unidirectional flow. Our data identify a shear-sensitive binding site at -152 in the MMP-9 promoter. We show that the c-Myc transcription factor binds specifically to this site and that reporter constructs in which the c-Myc binding site was abolished lacked the shear responsiveness of native MMP-9 reporter constructs. Our results suggest that endothelial MMP-9 expression is flow-sensitive and is up-regulated by oscillatory flow via activation of c-Myc. This effect may contribute to the development and progression of atherosclerotic lesions in areas of vasculature that are subject to disturbed flow.	Emory Univ, Sch Med, Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA	Emory University; University System of Georgia; Georgia Institute of Technology; Emory University; Emory University	Galis, ZS (corresponding author), Emory Univ, Sch Med, Dept Med, 1639 Pierce Dr,WMB 319, Atlanta, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071061, R01HL064689] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL71061, R01 HL64689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GIDDENS DP, 1993, J BIOMECH ENG-T ASME, V115, P588, DOI 10.1115/1.2895545; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HELMLINGER G, 1991, J BIOMECH ENG-T ASME, V113, P123, DOI 10.1115/1.2891226; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Mazzolai L, 2002, THROMB HAEMOSTASIS, V87, P1062; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; MOORE JE, 1994, ATHEROSCLEROSIS, V110, P225, DOI 10.1016/0021-9150(94)90207-0; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; OHTSUKA A, 1993, BIOCHEM BIOPH RES CO, V193, P303, DOI 10.1006/bbrc.1993.1624; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Rao VH, 1999, INT J ONCOL, V14, P291; SAMPATH R, 1995, ANN BIOMED ENG, V23, P247, DOI 10.1007/BF02584426; SATO H, 1993, ONCOGENE, V8, P395; SCHNITTLER HJ, 1993, AM J PHYSIOL, V265, P289; SHAH PK, 1995, CIRCULATION, V92, P1565; Silacci P, 2000, NITRIC OXIDE-BIOL CH, V4, P47, DOI 10.1006/niox.2000.0271; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621	33	101	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32994	32999		10.1074/jbc.M304799200	http://dx.doi.org/10.1074/jbc.M304799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816956	hybrid			2022-12-25	WOS:000184901800063
J	Sun, JJ; Barbieri, JT				Sun, JJ; Barbieri, JT			Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NICOTINAMIDE ADENINE-DINUCLEOTIDE; EXOENZYME-S; EPITHELIAL-CELLS; CLOSTRIDIUM-BOTULINUM; CRYSTAL-STRUCTURE; DIPHTHERIA-TOXIN; III CYTOTOXIN; C3 EXOENZYME; IN-VIVO	Pseudomonas aeruginosa ExoT is a type III cytotoxin that functions as an anti-internalization factor with an N-terminal RhoGAP domain and a C-terminal ADP-ribosyltransferase domain. Although ExoT RhoGAP stimulates actin reorganization through the inactivation of Rho, Rac, and Cdc42, the function of the ADP-ribosylation domain is unknown. The present study characterized the mammalian proteins that are ADP-ribosylated by ExoT, using two-dimensional SDS-PAGE and matrix-assisted laser desorption ionization/time of flight (MALDI-TOF) analysis. ExoT ADP-ribosylated two cytosolic proteins in cell lysates upon type III delivery into cultured HeLa cells. MALDI-TOF mass spectrometry analysis identified the two proteins as Crk-I and Crk-II that are Src homology 2-3 domains containing adaptor proteins, which mediate signal pathways involving focal adhesion and phagocytosis. ExoT ADP-ribosylated recombinant Crk-I at a rate similar to the ADP-ribosylation of soybean trypsin inhibitor by ExoS. ExoS did not ADP-ribosylate Crk-I. ADP-ribosylation of Crk-I may be responsible for the anti-phagocytosis phenotype elicited by ExoT in mammalian cells.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Sun, Jianjun/B-1525-2009		NHLBI NIH HHS [HL68912] Funding Source: Medline; NIAID NIH HHS [AI30165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030165, R29AI030165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banwart B, 2002, J INFECT DIS, V185, P269, DOI 10.1086/338197; Bell CE, 1997, PROTEIN SCI, V6, P2084; Bell CE, 1997, ADV EXP MED BIOL, V419, P35; BJORN MJ, 1979, INFECT IMMUN, V24, P837, DOI 10.1128/IAI.24.3.837-842.1979; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, J BIOL CHEM, V266, P6438; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Cowell BA, 2000, INFECT IMMUN, V68, P403, DOI 10.1128/IAI.68.1.403-406.2000; Deleuil F, 2003, CELL MICROBIOL, V5, P53, DOI 10.1046/j.1462-5822.2003.00236.x; Evans DJ, 2002, MICROB PATHOGENESIS, V33, P135, DOI 10.1006/mpat.2002.0521; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Ganesan AK, 1999, J BIOL CHEM, V274, P9503, DOI 10.1074/jbc.274.14.9503; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Geiser TK, 2001, CELL MICROBIOL, V3, P223, DOI 10.1046/j.1462-5822.2001.00107.x; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; Kazmierczak BI, 2002, INFECT IMMUN, V70, P2198, DOI 10.1128/IAI.70.4.2198-2205.2002; KNIGHT DA, 1995, INFECT IMMUN, V63, P3182, DOI 10.1128/IAI.63.8.3182-3186.1995; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; KULICH SM, 1994, J BIOL CHEM, V269, P10431; Liu SY, 1997, J BACTERIOL, V179, P1609, DOI 10.1128/jb.179.5.1609-1613.1997; Liu SY, 1996, BIOCHEMISTRY-US, V35, P2754, DOI 10.1021/bi952340g; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; Pederson KJ, 2002, MOL MICROBIOL, V46, P1381, DOI 10.1046/j.1365-2958.2002.03256.x; Radke J, 1999, INFECT IMMUN, V67, P1508, DOI 10.1128/IAI.67.3.1508-1510.1999; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Sundin C, 2001, CELL MICROBIOL, V3, P237, DOI 10.1046/j.1462-5822.2001.00108.x; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Yahr TL, 1996, J BACTERIOL, V178, P1412, DOI 10.1128/jb.178.5.1412-1419.1996	42	123	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32794	32800		10.1074/jbc.M304290200	http://dx.doi.org/10.1074/jbc.M304290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807879	hybrid			2022-12-25	WOS:000184901800039
J	Wang, J; Cao, Y; Steiner, DF				Wang, J; Cao, Y; Steiner, DF			Regulation of proglucagon transcription by activated transcription factor (ATF) 3 and a novel isoform, ATF3b, through the cAMP-response element/ATF site of the proglucagon gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; RAT GLUCAGON GENE; PROTEIN-KINASE-A; CYCLIC-AMP; LIVER DYSFUNCTION; REPRESSOR ATF3; MESSENGER-RNA; BETA-CELLS; ALPHA-CELL; EXPRESSION	Glucagon, the second major glucose-regulated hormone in the control of glucose homeostasis, functions as a counter-regulator to insulin and is specifically produced by the pancreatic alpha cells. Its excessive biosynthesis and secretion is associated with diabetes mellitus. The expression of the proglucagon gene has been demonstrated to be regulated by a cAMP-dependent pathway through cAMP-response element-binding protein ( CREB) and possibly other transcription factors bound to its cAMP-response element (CRE)/activated transcription factor (ATF) site. Elsewhere we have shown that ATF3, a member of the ATF/CREB subfamily of the basic leucine zipper domain proteins, is expressed predominantly in the alpha cells of the pancreatic islets. In our attempts to further dissect the role of ATF3 proteins in alpha cells, we have identified and characterized a novel alternatively spliced form, ATF3b, and have compared the specific binding ability of ATF3 and ATF3b on the CRE/ ATF motif of the proglucagon promoter. Our findings indicate the existence of a novel mechanism by which the transcription of the proglucagon gene is regulated in response to cAMP signals, in addition to CREB and in relation to glucose fluctuations in pancreatic alpha cells.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028,Rm 216, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, R37DK013914, P60DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20595, DK13914] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Arava Y, 1998, FEBS LETT, V425, P24, DOI 10.1016/S0014-5793(98)00186-0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN L, 1989, J CLIN INVEST, V84, P711, DOI 10.1172/JCI114219; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Dumonteil E, 2000, ENDOCRINOLOGY, V141, P174, DOI 10.1210/en.141.1.174; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; Nawa T, 2000, BIOCHEM BIOPH RES CO, V275, P406, DOI 10.1006/bbrc.2000.3332; Ni ZY, 2003, J BIOL CHEM, V278, P1380, DOI 10.1074/jbc.M206006200; Nian M, 1999, AM J PHYSIOL-GASTR L, V277, pG829, DOI 10.1152/ajpgi.1999.277.4.G829; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; STEINER D, 2000, ENDOCRINOLOGY, P667; UNGER R, 1996, ELLENBERG RIFKINS DI; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200	38	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32899	32904		10.1074/jbc.M305456200	http://dx.doi.org/10.1074/jbc.M305456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815047	hybrid			2022-12-25	WOS:000184901800051
J	Kurland, JF; Voehringer, DW; Meyn, RE				Kurland, JF; Voehringer, DW; Meyn, RE			The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line - MEK inhibition restores radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PANCREATIC-CANCER CELLS; SIGNAL-REGULATED KINASE; NUCLEAR TRANSLOCATION; IONIZING-RADIATION; LEUKEMIA-CELLS; IN-VIVO; ACTIVATION; IDENTIFICATION; TRANSCRIPTION	In a previously published report (Kurland, J. F., Kodym, R., Story, M. D., Spurgers, K. B., McDonnell, T. J., and Meyn, R. E. (2001) J. Biol. Chem. 276, 45380-45386), we described the NFkappaB status for two murine B-cell lymphoma cell lines, LY-as (apoptosis-sensitive) and LY-ar (apoptosis-refractory) and provided evidence that NFkappaB1 (p50) homodimers contribute to the expression of Bcl-2 in the LY-ar line. In the present study, we investigated the upstream signals leading to p50 homodimer activation and Bcl-2 expression. We found that in LY-ar cells, ERK1 and ERK2 were constitutively phosphorylated, whereas LY-as cells had no detectable ERK1 or ERK2 phosphorylation. Treatment of LY-ar cells with the MEK inhibitors PD 98059, U0126, and PD 184352 led to a loss of phosphorylated ERK1 and ERK2, a reversal of nuclear p50 homodimer DNA binding, and a decrease in Bcl-2 protein expression. Similarly, activation of the MEK/ERK pathway in LY-as cells by phorbol ester led to Bcl-2 expression that could be blocked by PD 98059. Furthermore, treatment of LY-ar cells with tumor necrosis factor-alpha, an IkappaB kinase activator, did not alter the suppressive effect of PD 98059 on p50 homodimer activity, suggesting an IkappaB kinase-independent pathway for p50 homodimer activation. Lastly, all three MEK inhibitors sensitized LY-ar cells to radiation-induced apoptosis. We conclude that the MEK/ERK pathway acts upstream of p50 homodimer activity and Bcl-2 expression in this B-cell lymphoma cell system and suggest that the use of MEK inhibitors could be useful clinically in combination with ionizing radiation to treat lymphoid malignancies.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	rmeyn@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA069003] Funding Source: NIH RePORTER; NCI NIH HHS [CA69003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Belka C, 2000, ANTICANCER RES, V20, P3243; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Herrera R, 2002, TRENDS MOL MED, V8, pS27, DOI 10.1016/S1471-4914(02)02307-9; Hirano T, 2002, ONCOGENE, V21, P5923, DOI 10.1038/sj.onc.1205643; Hu YP, 2001, BREAST CANCER RES TR, V70, P11, DOI 10.1023/A:1012564620853; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHARA R, 1995, J CELL SCI, V108, P97; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schwartz SA, 1999, SURG ONCOL, V8, P143, DOI 10.1016/S0960-7404(00)00012-8; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038/sj.cdd.4401050; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	52	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32465	32470		10.1074/jbc.M212919200	http://dx.doi.org/10.1074/jbc.M212919200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801933	hybrid			2022-12-25	WOS:000184782100127
J	Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y				Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y			Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c	ONCOGENE			English	Article						STI571; ETV6/ARG; cell cycle arrest; p18/INK4c	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; INK4 FAMILY; APOPTOSIS; DIFFERENTIATION; P18(INK4C); EXPRESSION; PROTEIN; FUSION	ARG is a tyrosine kinase closely related to ABL, which is oncogenic when fused to the transcriptional repressor ETV6 (ETS translocation variant 6). In this study, we investigated the growth-inhibitory effect of STI571 (signal transduction inhibitor number 571) on ETV6/ARG-expressing cells and its molecular mechanisms using HT93A, a cell line derived from a patient with AML-M3 carrying t(1;12). STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein, as well as the growth of HT93A cells with an IC50 of 200 nM. The growth inhibition was primarily because of cell cycle arrest at G1 phase when cells were treated with 100 nm STI571 for 48 h, and apoptosis was induced after longer exposure (72 h) or by a higher dose (1000 nM). STI571 increased the amount of p18/INK4c after 2 h of culture, when the cell cycle pattern was not yet affected, but not that of other CDK inhibitors (CKI). p18/INK4c was more abundant in G1-enriched fractions than in S- and G2/M-enriched fractions of STI571-treated HT93A cells, suggesting that the upregulation of p18/INK4c expression correlates with the cell cycle arrest. Treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene abrogated the growth inhibition by STI571. These results suggest that leukemogenesis by an aberrant ARG kinase involves the suppression of p18/INK4c, which is ubiquitously expressed and considered the major CKI in hematopoietic stem cells. STI571 can be an effective drug for the treatment of leukemias with deregulated ARG kinase activity.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minamikachi, Tochigi 3290498, Japan; Tokai Univ, Sch Med, Dept Hematol & Rheumatol, Kanagawa 2591193, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Int Med Ctr Japan, Div Mol Cytogenet, Tokyo 1620052, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Tokai University; Kyoto Prefectural University of Medicine; National Center for Global Health & Medicine - Japan; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minamikachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Iijima Y, 2000, BLOOD, V95, P2126; Iijima Y, 2002, ONCOGENE, V21, P4374, DOI 10.1038/sj.onc.1205544; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; KRUSH GD, 1986, SCIENCE, V234, P1545; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; PEREGO R, 1991, ONCOGENE, V6, P1899; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; Schiffer CA, 2001, SEMIN ONCOL, V28, P34, DOI 10.1016/S0093-7754(01)90101-0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Toba K, 1998, EXP HEMATOL, V26, P135; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	37	26	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4074	4082		10.1038/sj.onc.1206498	http://dx.doi.org/10.1038/sj.onc.1206498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821941				2022-12-25	WOS:000183707600010
J	Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW				Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW			BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest	ONCOGENE			English	Article						BRCA1; p53; senescence; microarray; DNA damage	DNA-DAMAGE RESPONSE; TRANSCRIPTIONAL ACTIVATION; P53; CHECKPOINT; CYCLE; GADD45; PHOSPHORYLATION; REPAIR; CELLS; EXPRESSION	The tumor suppressor protein BRCA1 has been shown to enhance p53 transcription, whereas activated p53 represses BRCA1 transcription. To further understand the functional interaction of these proteins, we investigated the role of BRCA1 in p53-induced phenotypes. We found that BRCA1 when subjected to forced expression acts synergistically with wild-type p53, resulting in irreversible growth arrest, as shown by VhD mouse fibroblast cells expressing a temperature-sensitive mutant of p53. Furthermore, reintroduction of both BRCA1 and p53 into BRCA1(-/-)/p53(-/-) mouse embryonic fibroblasts markedly increased the senescence phenotype compared to that induced by Ill alone. In particular, we found that BRCA1 expression attenuated p53-mediated cell death in response to gamma-irradiation. Moreover, microarray screening of 11 000 murine genes demonstrated that a set of genes upregulated by p53 is enhanced by coexpression of BRCA1 and p53, suggesting that BRCA1 and p53 exert a promoter selectivity leading to a specific phenotype. Taken together, our results provide evidence that BRCA1 is involved in p53-mediated growth suppression rather than apoptosis.	Harvard Univ, Inst Med, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee, SW (corresponding author), Harvard Univ, Inst Med, Sch Med, Room 921,4 Blackfan Circle, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu	deng, chuxia/N-6713-2016		NCI NIH HHS [CA85214, CA80058, CA78356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085214, R01CA078356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee EYHP, 2002, CELL CYCLE, V1, P178, DOI 10.4161/cc.1.3.121; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang SC, 2001, CANCER RES, V61, P2838; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3749	3758		10.1038/sj.onc.1206439	http://dx.doi.org/10.1038/sj.onc.1206439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802282				2022-12-25	WOS:000183551000009
J	Ling, TY; Huang, YH; Lai, MC; Huang, SS; Huang, JS				Ling, TY; Huang, YH; Lai, MC; Huang, SS; Huang, JS			Fatty acids modulate transforming growth factor-beta activity and plasma clearance	FASEB JOURNAL			English	Article						arachidonic acid; myristic acid; TGF-beta; activated alpha(2-)macroglobulin; TGF-beta-alpha M-2 complexes	TGF-BETA; BINDING-PROTEIN; TISSUE-INJURY; RECEPTOR; ALPHA(2)-MACROGLOBULIN; GROWTH-FACTOR-BETA-1; COMPLEX; ALPHA-2-MACROGLOBULIN; INHIBITION; CYTOKINES	The activity and plasma clearance of transforming growth factor (TGF)-beta are known to be regulated by activated alpha(2)-macroglobulin (alpha(2)M*). This has been implicated in pathophysiological processes, but no small molecule compounds have been reported to modulate TGF-beta activity by affecting the interaction of TGF-beta and alpha(2)M*. Here, we demonstrate that fatty acids are capable of inhibiting complex formation of TGF-beta isoforms and alpha(2)M* as demonstrated by nondenaturing and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This is dependent on carbon chain length (C20, C18, C16, C14 > C12 > C10), degree of unsaturation (polyunsaturated > saturated), and TGF-beta isoforms (TGF-beta1 > TGF-beta2 > TGF-beta3). Arachidonic acid, which is one of the most potent inhibitors, is also capable of dissociating TGF-beta-alpha(2)M* complexes, but higher concentrations are required. Arachidonic acid appears to inhibit TGF-beta-alpha(2)M* complex formation by binding specifically to alpha(2)M* on TGF-beta binding, TGF-beta-induced growth inhibition, and TGF-beta-induced transcriptional activation in mink lung epithelial cells and affects plasma clearance of TGF-beta-alpha(2)M* complexes in mice. These results show that fatty acids are effective modulators of TGF-beta activity and plasma clearance and my be useful in treating human diseases through their effects on the interaction of TGF-beta and alpha(2)M*.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Taipei Med Univ, Grad Inst Med Sci, Dept Biochem, Taipei, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Taipei Medical University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X				BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BRUNING PF, 1986, CANCER RES, V46, P2606; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Gaedeke J, 2001, CONTRIB NEPHROL, V135, P153; HALL SW, 1991, J BIOL CHEM, V266, P12329; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; HUANG SS, 1988, J BIOL CHEM, V263, P1535; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KURECKI T, 1909, ANAL BIOCHEM, V99, P415; Liu QJ, 2001, J BIOL CHEM, V276, P46212, DOI 10.1074/jbc.M105177200; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MENDEL CM, 1986, J CLIN ENDOCR METAB, V63, P1394, DOI 10.1210/jcem-63-6-1394; MERWIN JR, 1991, AM J PATHOL, V138, P37; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIPER HM, 1986, BASIC RES CARDIOL, V81, P373, DOI 10.1007/BF01907458; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SHAH M, 1995, J CELL SCI, V108, P985; STARNES HF, 1988, J CLIN INVEST, V82, P1321, DOI 10.1172/JCI113733; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; Wilson DM, 1997, AM J PATHOL, V150, P2181; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	39	11	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1559	+		10.1096/fj.02-1063fje	http://dx.doi.org/10.1096/fj.02-1063fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824279				2022-12-25	WOS:000183818000033
J	Slagter-Jager, JG; Wagner, EGH				Slagter-Jager, JG; Wagner, EGH			Loop swapping in an antisense RNA/target RNA pair changes directionality of helix progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET RNA; PLASMID R1; REPLICATION CONTROL; ESCHERICHIA-COLI; COMPARATIVE GENOMICS; STRUCTURAL-ANALYSIS; RIBOSOME-BINDING; KISSING COMPLEX; 4-WAY JUNCTION; REPA SYNTHESIS	The binding pathway of the natural antisense RNA CopA to its target CopT proceeds through a hierarchical order of steps. It initiates by reversible loop-loop contacts followed by unidirectional helix progression into the upper stems. This involves extensive breakage of intramolecular base pairs and the subsequent formation of two intermolecular helices, B and B'. Based on the known tRNA anticodon loop structure and on results from the Sok/Hok antisense/target RNA system, it had been suggested that a U-turn ( or pi-turn) in the loop of CopT might determine the directionality of helix progression. Data presented here show that the putative U-turn is one of the structural elements of antisense/target RNA pairs required to achieve fast binding kinetics. Swapping of the hypothetical U-turn structure from the target RNA to the antisense RNA retained regulatory performance in vivo and binding rates in vitro but altered the binding pathway by changing the direction in which the initiating helix was extended. In addition, our data indicate that a helical stem immediately adjacent to the target loop sequence is required to provide a scaffold for the U-turn.	Uppsala Univ, Biomed Ctr, Dept Microbiol, Inst Cell & Mol Biol, S-75124 Uppsala, Sweden	Uppsala University	Wagner, EGH (corresponding author), Uppsala Univ, Biomed Ctr, Dept Microbiol, Inst Cell & Mol Biol, Box 596,Husargatan 3, S-75124 Uppsala, Sweden.	Gerhart.Wagner@icm.uu.se						Argaman L, 2001, CURR BIOL, V11, P941, DOI 10.1016/S0960-9822(01)00270-6; Asano K, 1998, J BIOL CHEM, V273, P11826, DOI 10.1074/jbc.273.19.11826; Asano K, 2000, J BIOL CHEM, V275, P1269, DOI 10.1074/jbc.275.2.1269; Ashraf SS, 1999, RNA, V5, P503, DOI 10.1017/S1355838299981931; Auffinger P, 2001, RNA, V7, P334, DOI 10.1017/S1355838201002382; BARCISZEWSKI J, 1982, FEBS LETT, V150, P459, DOI 10.1016/0014-5793(82)80789-8; BLOMBERG P, 1994, MOL MICROBIOL, V12, P49, DOI 10.1111/j.1365-2958.1994.tb00994.x; BLOMBERG P, 1992, EMBO J, V11, P2675, DOI 10.1002/j.1460-2075.1992.tb05333.x; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DIX DB, 1986, J BIOL CHEM, V261, P112; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; Franch T, 2000, CURR OPIN MICROBIOL, V3, P159, DOI 10.1016/S1369-5274(00)00069-2; Franch T, 1999, J MOL BIOL, V294, P1115, DOI 10.1006/jmbi.1999.3306; Gerdes K, 1997, ANNU REV GENET, V31, P1, DOI 10.1146/annurev.genet.31.1.1; GIVSKOV M, 1984, MOL GEN GENET, V194, P286, DOI 10.1007/BF00383529; HJALT T, 1992, NUCLEIC ACIDS RES, V20, P6723, DOI 10.1093/nar/20.24.6723; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P580, DOI 10.1093/nar/23.4.580; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; KITTLE JD, 1989, J MOL BIOL, V210, P561, DOI 10.1016/0022-2836(89)90132-0; Kolb FA, 2000, RNA, V6, P311, DOI 10.1017/S135583820099215X; Kolb FA, 2001, J MOL BIOL, V309, P605, DOI 10.1006/jmbi.2001.4677; Kolb FA, 2001, NUCLEIC ACIDS RES, V29, P3145, DOI 10.1093/nar/29.15.3145; Kolb FA, 2000, EMBO J, V19, P5905, DOI 10.1093/emboj/19.21.5905; Malmgren C, 1997, J BIOL CHEM, V272, P12508, DOI 10.1074/jbc.272.19.12508; Malmgren C, 1996, RNA, V2, P1022; Miller JH., 1972, EXPT MOL GENETICS; Nordgren S, 2001, J MOL BIOL, V310, P1125, DOI 10.1006/jmbi.2001.4802; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; OHMAN M, 1991, MOL GEN GENET, V230, P321, DOI 10.1007/BF00290683; OHMAN M, 1989, NUCLEIC ACIDS RES, V17, P2557, DOI 10.1093/nar/17.7.2557; Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572; PERSSON C, 1988, EMBO J, V7, P3279, DOI 10.1002/j.1460-2075.1988.tb03195.x; PERSSON C, 1990, EMBO J, V9, P3777, DOI 10.1002/j.1460-2075.1990.tb07591.x; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Rivas E, 2001, CURR BIOL, V11, P1369, DOI 10.1016/S0960-9822(01)00401-8; SIEMERING KR, 1994, J BACTERIOL, V176, P2677, DOI 10.1128/JB.176.9.2677-2688.1994; TAKECHI S, 1994, MOL GEN GENET, V244, P49, DOI 10.1007/BF00280186; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; Wagner EGH, 1986, NUCLEIC ACIDS RES, V14, P2523, DOI 10.1093/nar/14.6.2523; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wagner EGH, 1998, TRENDS BIOCHEM SCI, V23, P451, DOI 10.1016/S0968-0004(98)01322-X; Wagner EGH, 2002, ADV GENET, V46, P361; Wassarman KM, 2001, GENE DEV, V15, P1637, DOI 10.1101/gad.901001; Zhang H, 2001, BIOCHEMISTRY-US, V40, P9879, DOI 10.1021/bi011226x	46	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35558	35563		10.1074/jbc.M304867200	http://dx.doi.org/10.1074/jbc.M304867200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819201	hybrid			2022-12-25	WOS:000185164400099
J	Farrell, EF; Antaramian, A; Rueda, A; Gomez, AM; Valdivia, HH				Farrell, EF; Antaramian, A; Rueda, A; Gomez, AM; Valdivia, HH			Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC RYANODINE RECEPTORS; CA2+-INDUCED CA2+ RELEASE; LOCAL-CONTROL; PHOSPHORYLATION; PROTEIN; MUSCLE; MODEL; TRANSLOCATION; ACTIVATION; ADAPTATION	Activation of Ca2+ release channels/ryanodine receptors (RyR) by the inward Ca2+ current (I-Ca) gives rise to Ca2+-induced Ca2+ release (CICR), the amplifying Ca2+ signaling mechanism that triggers contraction of the heart. CICR, in theory, is a high-gain, self-regenerating process, but an unidentified mechanism stabilizes it in vivo. We reported previously (Lokuta, A. J., Meyers, M. B., Sander, P. R., Fishman, G. I., and Valdivia, H. H. ( 1997) J. Biol. Chem. 272, 25333 - 25338) that sorcin, a 22-kDa Ca2+-binding protein, binds to cardiac RyRs with high affinity and completely inhibits channel activity. Here we show that sorcin significantly inhibits both the spontaneous activity of RyRs in quiescent cells (visualized as Ca2+ sparks) and the I-Ca-triggered activity of RyRs that gives rise to [Ca2+](i) transients. Because sorcin decreased the amplitude of the [Ca2+](i) transient without affecting the amplitude or kinetics of ICa, the overall effect of sorcin was to reduce the "gain" of excitation-contraction coupling. Immunocytochemical staining shows that sorcin localizes to the dyadic space of ventricular cardiac myocytes. Ca2+ induces conformational changes and promotes translocation of sorcin between soluble and membranous compartments, but the [Ca2+] required for the latter process (ED50 = similar to200 muM) appears to be reached only within the dyadic space. Rapid injection of 5 muM sorcin onto the cytosolic face of RyRs reconstituted in lipid bilayers resulted in complete inhibition of channel activity in less than or equal to 20 ms. Thus, sorcin is a potent inhibitor of both spontaneous and I-Ca-triggered RyR activity and is kinetically capable of playing a role in terminating the positive feedback loop of CICR.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; INSERM, U390, CHU A de Villeneuve, F-34295 Montpellier, France	University of Wisconsin System; University of Wisconsin Madison; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Valdivia, HH (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	agomez@montp.inserm.fr; valdivia@physiology.wisc.edu	Rueda, Angelica/A-1394-2009; Gomez, Ana M./B-5376-2013; Rueda, Angelica/AAW-4621-2020; Rueda, Angelica/G-4055-2012	Gomez, Ana M./0000-0003-0009-2884; Rueda, Angelica/0000-0001-8749-8494; Rueda, Angelica/0000-0001-8749-8494	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047053, R01HL055438] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL47053, R01 HL55438] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEDLER JL, 1988, MECHANISMS DRUG RESI, P42; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Farrell EF, 2003, BIOPHYS J, V84, p17A; Greenstein JL, 2002, BIOPHYS J, V83, P2918, DOI 10.1016/S0006-3495(02)75301-0; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; MELLA M, 2003, J BIOL CHEM; Meyers MB, 2003, J BIOL CHEM, V278, P28865, DOI 10.1074/jbc.M302009200; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1981, BIOCHEM BIOPH RES CO, V99, P228, DOI 10.1016/0006-291X(81)91736-8; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; Peskoff A, 1998, BIOPHYS J, V74, P153, DOI 10.1016/S0006-3495(98)77776-8; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Terentyev D, 2002, CIRC RES, V91, P414, DOI 10.1161/01.RES.0000032490.04207.BD; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X; Zamparelli C, 2000, BIOCHEMISTRY-US, V39, P658, DOI 10.1021/bi991648v	29	88	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34660	34666		10.1074/jbc.M305931200	http://dx.doi.org/10.1074/jbc.M305931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824171	hybrid			2022-12-25	WOS:000185047500127
J	Lamark, T; Perander, M; Outzen, H; Kristiansen, K; Overvatn, A; Michaelsen, E; Bjorkoy, G; Johansen, T				Lamark, T; Perander, M; Outzen, H; Kristiansen, K; Overvatn, A; Michaelsen, E; Bjorkoy, G; Johansen, T			Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; EPIDERMAL-GROWTH-FACTOR; COILED-COIL DOMAIN; KAPPA-B ACTIVATION; CELL-POLARITY; 1 BMK1; MEDIATED ACTIVATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; BINDING-PROTEIN	The Phox and Bem1p (PB1) domain constitutes a recently recognized protein-protein interaction domain found in the atypical protein kinase C ( aPKC) isoenzymes, lambda/iota and zetaPKC; members of mitogen-activated protein kinase (MAPK) modules like MEK5, MEKK2, and MEKK3; and in several scaffold proteins involved in cellular signaling. Among the last group, p62 and Par6 (partitioning-defective 6) are involved in coupling the aPKCs to signaling pathways involved in cell survival, growth control, and cell polarity. By mutation analyses and molecular modeling, we have identified critical residues at the interaction surfaces of the PB1 domains of aPKCs and p62. A basic charge cluster interacts with an acidic loop and helix both in p62 oligomerization and in the aPKC-p62 interaction. Subsequently, we determined the abilities of mammalian PB1 domain proteins to form heteromeric and homomeric complexes mediated by this domain. We report several novel interactions within this family. An interaction between the cell polarity scaffold protein Par6 and MEK5 was found. Furthermore, p62 interacts both with MEK5 and NBR1 in addition to the aPKCs. Evidence for involvement of p62 in MEK5-ERK5 signaling is presented.	Univ Tromso, Dept Biochem, Inst Med Biol, N-9037 Tromso, Norway; Univ Tromso, Dept Pharmacol, Inst Pharm, N-9037 Tromso, Norway	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Dept Biochem, Inst Med Biol, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/N-2971-2015; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Bjorkoy, Geir/0000-0003-0031-8361; Perander, Maria/0000-0002-1177-2407; Lamark, Trond/0000-0001-6338-3342				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Avila A, 2002, MOL CELL BIOL, V22, P8787, DOI 10.1128/MCB.22.24.8787-8795.2002; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hernandez L, 1999, BLOOD, V94, P3265; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Pawson T, 2000, GENE DEV, V14, P1027; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SETH A, 1992, J BIOL CHEM, V267, P24796; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Smith FD, 2002, CURR BIOL, V12, pR32, DOI 10.1016/S0960-9822(01)00646-7; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Whitehouse C, 2002, EUR J BIOCHEM, V269, P538, DOI 10.1046/j.0014-2956.2001.02681.x; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143	51	286	299	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34568	34581		10.1074/jbc.M303221200	http://dx.doi.org/10.1074/jbc.M303221200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813044	hybrid			2022-12-25	WOS:000185047500118
J	Murakami, T; Sakane, F; Imai, S; Houkin, K; Kanoh, H				Murakami, T; Sakane, F; Imai, S; Houkin, K; Kanoh, H			Identification and characterization of two splice variants of human diacylglycerol kinase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PDZ DOMAINS; TYROSINE KINASES; SAM DOMAIN; RECEPTOR; GENE; FAMILY; PHOSPHORYLATION	Diacylglycerol kinase (DGK) participates in regulating the intracellular concentrations of two bioactive lipids, diacylglycerol and phosphatidic acid. DGKeta (eta1, 128 kDa) is a type II isozyme containing a pleckstrin homology domain at the amino terminus. Here we identified another DGKeta isoform (eta2, 135 kDa) that shared the same sequence with DGKeta1 except for a sterile alpha motif (SAM) domain added at the carboxyl terminus. The DGKeta1 mRNA was ubiquitously distributed in various tissues, whereas the DGKeta2 mRNA was detected only in testis, kidney, and colon. The expression of DGKeta2 was suppressed by glucocorticoid in contrast to the marked induction of DGKeta1. DGKeta2 was shown to form through its SAM domain homo-oligomers as well as hetero-oligomers with other SAM-containing DGKs (delta1 and delta2). Interestingly, DGKeta1 and DGKeta2 were rapidly translocated from the cytoplasm to endosomes in response to stress stimuli. In this case, DGKeta1 was rapidly relocated back to the cytoplasm upon removal of stress stimuli, whereas DGKeta2 exhibited sustained endosomal association. The experiments using DGKeta mutants suggested that the oligomerization of DGKeta2 mediated by its SAM domain was largely responsible for its sustained endosomal localization. Similarly, the oligomerization of DGKeta2 was suggested to result in negative regulation of its catalytic activity. Taken together, alternative splicing of the human DGKeta gene generates at least two isoforms with distinct biochemical and cell biological properties responding to different cellular metabolic requirements.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Neurosurg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Sakane, F (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1,West 17, Sapporo, Hokkaido 0608556, Japan.	sakane@sapmed.ac.jp	Sakane, Fumio/H-2693-2017; Houkin, Kiyohiro/G-5364-2012	Sakane, Fumio/0000-0003-0857-0377; 				Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Harris BZ, 2001, J CELL SCI, V114, P3219; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; Kayali AG, 2000, DIABETES, V49, P1783, DOI 10.2337/diabetes.49.11.1783; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Raddatz D, 1996, HEPATOLOGY, V24, P928; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Schultz J, 1997, PROTEIN SCI, V6, P249; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3	37	77	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34364	34372		10.1074/jbc.M301542200	http://dx.doi.org/10.1074/jbc.M301542200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810723	hybrid			2022-12-25	WOS:000185047500093
J	Vartiainen, MK; Sarkkinen, EM; Matilainen, T; Salminen, M; Lappalainen, P				Vartiainen, MK; Sarkkinen, EM; Matilainen, T; Salminen, M; Lappalainen, P			Mammals have two twinfilin isoforms whose subcellular localizations and tissue distributions are differentially regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING FACTOR; PROFILIN ISOFORMS; ADP-ACTIN; NUCLEOTIDE EXCHANGE; ESCHERICHIA-COLI; PROTEIN; BINDING; EXPRESSION; MONOMERS; FILAMENTS	Twinfilin is a highly conserved actin monomer-binding protein that regulates cytoskeletal dynamics in organisms from yeast to mammals. In addition to the previously characterized mammalian twinfilin-1, a second protein with similar to65% sequence identity to twinfilin-1 exists in mouse and humans. However, previous studies failed to identify any actin binding activity in this protein (Rohwer, A., Kittstein, W., Marks, F., and Gschwendt, M. ( 1999) Eur. J. Biochem. 263, 518 - 525). Here we show that this protein, which we named twinfilin-2, is indeed an actin monomer-binding protein. Similar to twinfilin-1, mouse twinfilin-2 binds ADP-G-actin with a higher affinity (K-D = 0.12 muM) than ATP-G-actin (K-D = 1.96 muM) and efficiently inhibits actin filament assembly in vitro. Both mouse twinfilins inhibit the nucleotide exchange on actin monomers and directly interact with capping protein. Furthermore, the actin interactions of mouse twinfilin-1 and twinfilin-2 are inhibited by phosphatidylinositol ( 4,5)- bisphosphate. Although biochemically very similar, our Northern blots and in situ hybridizations show that these two proteins display distinct expression patterns. Twinfilin-1 is the major isoform in embryos and in most adult mouse non-muscle cell-types, whereas twinfilin-2 is the predominant isoform of adult heart and skeletal muscles. Studies with isoform-specific antibodies demonstrated that although the two proteins show similar localizations in unstimulated cells, they are regulated by different mechanisms. The small GTPases Rac1 and Cdc42 induce the redistribution of twinfilin-1 to membrane ruffles and cell-cell contacts, respectively, but do not affect the localization of twinfilin-2. Taken together, these data show that mammals have two twinfilin isoforms, which are differentially expressed and regulated through distinct cellular signaling pathways.	Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Program Dev Biol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Lappalainen, P (corresponding author), Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Vartiainen, Maria K/F-4767-2013; Vartiainen, Maria/P-7043-2019	Vartiainen, Maria K/0000-0002-2017-0475; Vartiainen, Maria/0000-0002-2017-0475; Lappalainen, Pekka/0000-0001-6227-0354; Salminen, Marjo/0000-0003-0696-6845				Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; DETMERS P, 1981, J BIOL CHEM, V256, P99; Di Nardo A, 2000, J CELL SCI, V113, P3795; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; GIESELMANN R, 1995, EUR J BIOCHEM, V229, P621, DOI 10.1111/j.1432-1033.1995.tb20506.x; Goode BL, 1998, J CELL BIOL, V142, P723, DOI 10.1083/jcb.142.3.723; Hart MC, 1997, CELL MOTIL CYTOSKEL, V38, P120, DOI 10.1002/(SICI)1097-0169(1997)38:2<120::AID-CM2>3.0.CO;2-B; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Lambrechts A, 2000, MOL CELL BIOL, V20, P8209, DOI 10.1128/MCB.20.21.8209-8219.2000; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; Ojala PJ, 2002, MOL BIOL CELL, V13, P3811, DOI 10.1091/mbc.E02-03-0157; ONO S, 1994, J BIOL CHEM, V269, P15280; Paavilainen VO, 2002, J BIOL CHEM, V277, P43089, DOI 10.1074/jbc.M208225200; Palmgren S, 2002, J CELL SCI, V115, P881; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rice DPC, 2000, DEVELOPMENT, V127, P1845; Rohwer A, 1999, EUR J BIOCHEM, V263, P518, DOI 10.1046/j.1432-1327.1999.00537.x; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; Soeno Y, 1998, J MUSCLE RES CELL M, V19, P639, DOI 10.1023/A:1005329114263; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Vartiainen MK, 2002, MOL BIOL CELL, V13, P183, DOI 10.1091/mbc.01-07-0331; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Wahlstrom G, 2001, J CELL BIOL, V155, P787, DOI 10.1083/jcb.200108022; WEEDS AG, 1986, EUR J BIOCHEM, V161, P77, DOI 10.1111/j.1432-1033.1986.tb10126.x; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	39	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34347	34355		10.1074/jbc.M303642200	http://dx.doi.org/10.1074/jbc.M303642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807912	hybrid			2022-12-25	WOS:000185047500091
J	Zhao, CM; Ma, H; Bossy-Wetzel, E; Lipton, SA; Zhang, ZH; Feng, GS				Zhao, CM; Ma, H; Bossy-Wetzel, E; Lipton, SA; Zhang, ZH; Feng, GS			GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; EPIDERMAL-GROWTH-FACTOR; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; SCAFFOLDING PROTEIN; 3-KINASE ACTIVATION; JNK ACTIVATION; CELL-SURVIVAL	Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk. To identify new binding partners for GAB proteins and better understand their functions, we performed a yeast two-hybrid screening with hGab2-(120-587) as bait. This work led to identification of a novel GTPase-activating protein ( GAP) for Rho family GTPases. The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro. The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42. GC-GAP is predominantly expressed in the brain with low levels detected in other tissues. Antibodies directed against GC-GAP recognized a protein of similar to200 kDa. Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA. Suppression of GC-GAP expression by siRNA inhibited proliferation of C6 astroglioma cells. In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro. We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities. Given that GC-GAP is specifically expressed in the nervous system and that it is localized to the dendritic processes of cultured neurons, GC-GAP may play a role in dendritic morphogenesis and also possibly in neural/ glial cell proliferation.	Burnham Inst, La Jolla, CA 92037 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Sanford Burnham Prebys Medical Discovery Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Feng, GS (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org		Lipton, Stuart/0000-0002-3490-1259	NHLBI NIH HHS [R01HL66208] Funding Source: Medline; NIGMS NIH HHS [R01GM53660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azim AC, 2000, METHOD ENZYMOL, V325, P257; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bourgin C, 2002, MOL CELL BIOL, V22, P3744, DOI 10.1128/MCB.22.11.3744-3756.2002; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Crouin C, 2001, FEBS LETT, V495, P148, DOI 10.1016/S0014-5793(01)02373-0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hallam SJ, 2002, NAT NEUROSCI, V5, P1137, DOI 10.1038/nn959; Harada A, 2000, J BIOL CHEM, V275, P36885, DOI 10.1074/jbc.M004069200; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Hong-Geller E, 2001, P NATL ACAD SCI USA, V98, P1154, DOI 10.1073/pnas.98.3.1154; James P, 1996, GENETICS, V144, P1425; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sagnier T, 2000, MECH DEVELOP, V94, P267, DOI 10.1016/S0925-4773(00)00291-4; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schutzman JL, 2001, MOL CELL BIOL, V21, P8104, DOI 10.1128/MCB.21.23.8104-8116.2001; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SETTLEMAN J, 1995, METHOD ENZYMOL, V256, P105; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	72	42	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34641	34653		10.1074/jbc.M304594200	http://dx.doi.org/10.1074/jbc.M304594200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819203	hybrid			2022-12-25	WOS:000185047500125
J	Eaton, EM; Sealy, L				Eaton, EM; Sealy, L			Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MODIFICATION; ACTIVATION; DOMAIN; UBC9; PML	CCAAT/enhancer-binding protein-beta (C/EBPbeta) activator isoforms, C/EBPbeta-1 and C/EBPbeta-2, differ by only 23 amino acids in the human; however, evidence is accumulating that these transcription factors are functionally distinct. Here we demonstrate that C/EBPbeta-1, but not C/EBPbeta-2, is conjugated to the small ubiquitin-like modifier ( SUMO) family members, SUMO-2 and SUMO-3 despite the fact that the SUMO target consensus is present in both isoforms of this transcription factor. This conjugation is dependent on the integrity of the extreme N terminus of C/EBPbeta-1 and requires lysine 173 in the human protein. Furthermore, mutation of this lysine relieves the repression of the cyclin D1 promoter by C/EBPbeta-1 without altering the subnuclear localization of C/EBPbeta-1. The sumoylation of C/EBPbeta-1 is likely to be important in the functional differences observed between C/EBPbeta-1 and C/EBPbeta-2.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.							Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	21	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33416	33421		10.1074/jbc.M305680200	http://dx.doi.org/10.1074/jbc.M305680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810706	hybrid			2022-12-25	WOS:000184901800114
J	Louria-Hayon, I; Grossman, T; Sionov, RV; Alsheich, O; Pandolfi, PP; Haupt, Y				Louria-Hayon, I; Grossman, T; Sionov, RV; Alsheich, O; Pandolfi, PP; Haupt, Y			The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; NUCLEAR EXPORT; C-ABL; PML; MDM2; PHOSPHORYLATION; CHECKPOINT; APOPTOSIS; CHK2; ACTIVATION	The p53 protein is kept labile under normal conditions. This regulation is governed largely by its major negative regulator, Mdm2. In response to stress however, p53 accumulates and becomes activated. For this to occur, the inhibitory effects of Mdm2 have to be neutralized. Here we investigated the role of the promyelocytic leukemia protein (PML) in the activation of p53 in response to stress. We found that PML is critical for the accumulation of p53 in response to DNA damage under physiological conditions. PML protects p53 from Mdm2-mediated ubiquitination and degradation, and from inhibition of apoptosis. PML neutralizes the inhibitory effects of Mdm2 by prolonging the stress-induced phosphorylation of p53 on serine 20, a site of the checkpoint kinase 2 (Chk2). PML recruits Chk2 and p53 into the PML nuclear bodies and enhances p53/Chk2 interaction. Our results provide a novel mechanistic explanation for the cooperation between PML and p53 in response to DNA damage.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Hebrew University of Jerusalem; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chehab NH, 2000, GENE DEV, V14, P278; Chen JD, 1996, MOL CELL BIOL, V16, P2445; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Douer D, 2002, ACTA HAEMATOL-BASEL, V107, P1, DOI 10.1159/000046623; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANOTTE M, 1991, BLOOD, V77, P1080; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LOURIAHAYON I, 2002, CELL CYCLE, V1, P111; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; RENZING J, 1995, ONCOGENE, V10, P1865; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Shieh SY, 2000, GENE DEV, V14, P289; Shtutman Michael, 2002, Cancer Research, V62, P5947; Sionov R. V., 2001, CELL CYCLE CHECKPOIN, P106; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	50	107	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33134	33141		10.1074/jbc.M301264200	http://dx.doi.org/10.1074/jbc.M301264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810724	hybrid			2022-12-25	WOS:000184901800079
J	Tanaka, T; Kawashima, H; Yeh, ETH; Kamitani, T				Tanaka, T; Kawashima, H; Yeh, ETH; Kamitani, T			Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; SENTRIN FAMILY; PATHWAY; IDENTIFICATION; DEGRADATION; EXPRESSION; P27(KIP1); CUL-1; CDC34	NEDD8 is a ubiquitin-like protein that controls vital biological events through its conjugation to target proteins. We previously identified a negative regulator of the NEDD8 conjugation system, NUB1, which works by recruiting NEDD8 and its conjugates to the proteasome for degradation. Recently, we found its splicing variant, NUB1L. It possesses an insertion of 14 amino acids that codes for a UBA domain. Structural study revealed that NUB1 has a NEDD8-binding site at the C terminus, whereas NUB1L has an additional site at the newly generated UBA domain. Interestingly, the sequence A(X-4) L(X-10) L(X-3) L was conserved in these NEDD8-binding sites among human and other mammals. Mutational studies revealed that at least three Leu residues in the conserved sequence are required for binding with NEDD8. Functional study suggested that the NEDD8-binding ability at the C terminus of NUB1 and NUB1L is mainly involved in the down-regulation of NEDD8, but the NEDD8-binding ability at the UBA2 domain of NUB1L is minimally or not involved at all. The NEDD8-binding ability at the UBA2 domain might be required for an unknown function of NUB1L.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Kamitani, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Box 449, Houston, TX 77030 USA.		Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56298] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akey DT, 2002, HUM MOL GENET, V11, P2723, DOI 10.1093/hmg/11.22.2723; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; KITO K, 1999, BIOCHIM BIOPHYS ACTA, V1449, P303; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	29	62	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32905	32913		10.1074/jbc.M212057200	http://dx.doi.org/10.1074/jbc.M212057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816948	hybrid			2022-12-25	WOS:000184901800052
J	Weibezahn, J; Schlieker, C; Bukau, B; Mogk, A				Weibezahn, J; Schlieker, C; Bukau, B; Mogk, A			Characterization of a trap mutant of the AAA plus chaperone ClpB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ATPASE DOMAIN; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; DNAK CHAPERONE; BINDING-SITES; PROTEIN; MECHANISM; MEMBRANE; STRESS; HSP104	The AAA+ protein ClpB mediates the solubilization of protein aggregates in cooperation with the DnaK chaperone system (KJE). The order of action of ClpB and KJE on aggregated proteins is unknown. We describe a ClpB variant with mutational alterations in the Walker B motif of both AAA domains (E279A/E678A), which binds but does not hydrolyze ATP. This variant associates in vitro and in vivo in a stable manner with protein substrates, demonstrating direct interaction of ClpB with protein aggregates for the first time. Substrate interaction is strictly dependent on ATP binding to both AAA domains of ClpB. The unique substrate binding properties of the double Walker B variant allowed to dissect the order of ClpB and DnaK action during disaggregation reactions. ClpB-E279A/E678A outcompetes the DnaK system for binding to the model substrate TrfA and inhibits the dissociation of small protein aggregates by DnaK only, indicating that ClpB acts prior to DnaK on protein substrates.	Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bukau, B (corresponding author), Heidelberg Univ, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	bukau@zmbh.uni-heidelberg.de; a.mogk@zmbh.uni-heidelberg.de		Bukau, Bernd/0000-0003-0521-7199				Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Arsene F, 1999, J BACTERIOL, V181, P3552; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Barthel TK, 1999, J BIOL CHEM, V274, P36670, DOI 10.1074/jbc.274.51.36670; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; GIESE KC, 2002, J BIOL CHEM, V23, P23; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartman JJ, 1999, SCIENCE, V286, P782, DOI 10.1126/science.286.5440.782; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hong SW, 2000, P NATL ACAD SCI USA, V97, P4392, DOI 10.1073/pnas.97.8.4392; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlothauer T, 2003, P NATL ACAD SCI USA, V100, P2306, DOI 10.1073/pnas.0535717100; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	40	113	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32608	32617		10.1074/jbc.M303653200	http://dx.doi.org/10.1074/jbc.M303653200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805357	hybrid			2022-12-25	WOS:000184901800018
J	Antignac, A; Rousselle, JC; Namane, A; Labigne, A; Taha, MK; Boneca, IG				Antignac, A; Rousselle, JC; Namane, A; Labigne, A; Taha, MK; Boneca, IG			Detailed structural analysis of the peptidoglycan of the human pathogen Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE DEACETYLASE; PENICILLIN-BINDING PROTEIN-4; BETA-LACTAM ANTIBIOTICS; STAPHYLOCOCCUS-AUREUS; MASS-SPECTROMETRY; STREPTOCOCCUS-PNEUMONIAE; LIQUID-CHROMATOGRAPHY; BORDETELLA-PERTUSSIS; ENTEROCOCCUS-FAECIUM; ESCHERICHIA-COLI	We used reverse-phase high pressure liquid chromatography (HPLC), matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and post source decay analysis (MALDI-PSD) to determine the muropeptide composition of the human pathogen Neisseria meningitidis. Structural assignment was determined for 28 muropeptide species isolated after HPLC separation and purification. Fourteen of these muropeptides were O-acetylated to different degrees. We identified the entire O-acetylation spectrum of dimers and trimers both in muropeptides and 1,6-anhydromuropeptides. On average, one of three disaccharides was O-acetylated. Furthermore, the degree of cross-linking of the N. meningitidis peptidoglycan was around 39% in all the strains analyzed. MALDI-PSD analysis of several muropeptide species indicated that meningococci only synthesize D-alanyl-meso-diaminopimelate cross-bridges. No muropeptides representative of covalent linkages of lipoproteins to the peptidoglycan could be identified, unlike in Escherichia coli. Finally, comparison of the muropeptide composition of penicillin-susceptible and penicillin-intermediate clinical strains of meningococci showed a positive correlation between the minimum inhibitory concentration ( MIC) of penicillin G and the amount of muropeptides carrying an intact pentapeptide chain in the peptidoglycan. This suggests that reduced susceptibility to penicillin G in N. meningitidis is associated with a decrease in D, D-carboxypeptidase activity and/or D, D-transpeptidase activity.	Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Inst Pasteur, Unite Neisseria, F-75724 Paris, France; Inst Pasteur, Ctr Natl Reference Meningocoques, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Boneca, IG (corresponding author), Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, 28 Rue Dr Roux, F-75724 Paris 15, France.		Namane, Abdelkader/O-1857-2013; Boneca, Ivo G/H-1677-2014	Namane, Abdelkader/0000-0001-7180-7619; Boneca, Ivo G/0000-0001-8122-509X				ABDILLAHI H, 1987, FEMS MICROBIOL LETT, V48, P367, DOI 10.1016/0378-1097(87)90077-2; Antignac A, 2003, J BIOL CHEM, V278, P31529, DOI 10.1074/jbc.M304607200; Antignac A, 2001, J ANTIMICROB CHEMOTH, V47, P285, DOI 10.1093/jac/47.3.285; Boneca IG, 1997, J BIOL CHEM, V272, P29053, DOI 10.1074/jbc.272.46.29053; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BURROUGHS MH, 1993, J BIOL CHEM, V268, P11594; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; CLARKE AJ, 1992, CAN J MICROBIOL, V38, P85, DOI 10.1139/m92-014; Cloud KA, 2002, INFECT IMMUN, V70, P2752, DOI 10.1128/IAI.70.6.2752-2757.2002; Domanski TL, 1997, J BACTERIOL, V179, P2651, DOI 10.1128/jb.179.8.2651-2657.1997; DOUGHERTY TJ, 1985, J BACTERIOL, V163, P69, DOI 10.1128/JB.163.1.69-74.1985; DOUGHERTY TJ, 1985, ANTIMICROB AGENTS CH, V28, P90, DOI 10.1128/AAC.28.1.90; FRASCH CE, 1985, REV INFECT DIS, V7, P504; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Henze UU, 1996, MICROB DRUG RESIST, V2, P193, DOI 10.1089/mdr.1996.2.193; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; JOHANNSEN L, 1990, AM J PHYSIOL, V258, pR182, DOI 10.1152/ajpregu.1990.258.1.R182; JOHANNSEN L, 1989, INFECT IMMUN, V57, P2726, DOI 10.1128/IAI.57.9.2726-2732.1989; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; LUKER KE, 1993, P NATL ACAD SCI USA, V90, P2365, DOI 10.1073/pnas.90.6.2365; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; MELLY MA, 1984, J INFECT DIS, V149, P378, DOI 10.1093/infdis/149.3.378; OPPENHEIM BA, 1997, CLIN INFECT DIS   S1, V24, P98; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; QUINTELA JC, 1995, FEMS MICROBIOL LETT, V125, P95, DOI 10.1016/0378-1097(94)00479-B; STEPHENS DS, 1987, A VAN LEEUW J MICROB, V53, P575, DOI 10.1007/BF00415519; Taha MK, 2002, TRENDS MICROBIOL, V10, P376, DOI 10.1016/S0966-842X(02)02402-2; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Vollmer W, 2002, INFECT IMMUN, V70, P7176, DOI 10.1128/IAI.70.12.7176-7178.2002; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073	40	50	50	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31521	31528		10.1074/jbc.M304749200	http://dx.doi.org/10.1074/jbc.M304749200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799361	hybrid			2022-12-25	WOS:000184782100011
J	Greenberg, CC; Meredith, KN; Yan, LM; Brady, MJ				Greenberg, CC; Meredith, KN; Yan, LM; Brady, MJ			Protein targeting to glycogen overexpression results in the specific enhancement of glycogen storage in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; INSULIN-RESISTANCE; SYNTHASE ACTIVATION; SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; TRANSGENIC MICE; RAT HEPATOCYTES; ADIPOSE-TISSUE; PHOSPHATASE 1; METABOLISM	Protein phosphatase-1 (PP1) plays an important role in the regulation of glycogen synthesis by insulin. Protein targeting to glycogen (PTG) enhances glycogen accumulation by increasing PP1 activity against glycogen-metabolizing enzymes. However, the specificity of PTG's effects on cellular dephosphorylation and glucose metabolism is unclear. Overexpression of PTG in 3T3-L1 adipocytes using a doxycycline-controllable adenoviral construct resulted in a 10-20-fold increase in PTG levels and an 8-fold increase in glycogen levels. Inclusion of 1 mug/ml doxycycline in the media suppressed PTG expression, and fully reversed all PTG-dependent effects. Infection of 3T3-L1 adipocytes with the PTG adenovirus caused a marked dephosphorylation and activation of glycogen synthase. The effects of PTG seemed specific, because basal and insulin-stimulated phosphorylation of a variety of signaling proteins was unaffected. Indeed, glycogen synthase was the predominant protein whose phosphorylation state was decreased in P-32-labeled cells. PTG overexpression did not alter PP1 protein levels but increased PP1 activity 6-fold against phosphorylase in vitro. In contrast, there was no change in PP1 activity measured using myelin basic protein, suggesting that PTG overexpression specifically directed PP1 activity against glycogen-metabolizing enzymes. To investigate the metabolic consequences of altering PTG levels, glucose uptake and storage in 3T3-L1 adipocytes was measured. PTG overexpression did not affect 2-deoxy-glucose transport rates in basal and insulin-stimulated cells but dramatically enhanced glycogen synthesis rates under both conditions. Despite the large increases in cellular glucose flux upon PTG overexpression, basal and insulin-stimulated glucose incorporation into lipid were unchanged. Cumulatively, these data indicate that PTG overexpression in 3T3-L1 adipocytes discretely stimulates PP1 activity against glycogen synthase and phosphorylase, resulting in a marked and specific increase in glucose uptake and storage as glycogen.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Brady, MJ (corresponding author), MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.							Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1999, TRENDS ENDOCRIN MET, V10, P408, DOI 10.1016/S1043-2760(99)00201-5; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cohen PTW, 2002, J CELL SCI, V115, P241; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; Delibegovic M, 2003, DIABETES, V52, P596, DOI 10.2337/diabetes.52.3.596; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Gasa R, 2002, J BIOL CHEM, V277, P1524, DOI 10.1074/jbc.M107744200; Gnudi L, 1996, P NUTR SOC, V55, P191, DOI 10.1079/PNS19960020; Holloszy John O., 1998, Frontiers in Bioscience, V3, pD1011; Jensen TC, 2000, J BIOL CHEM, V275, P40148, DOI 10.1074/jbc.M004902200; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KATO K, 1972, J BIOL CHEM, V247, P7420; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lerin C, 2000, J BIOL CHEM, V275, P39991, DOI 10.1074/jbc.M006251200; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Munro S, 2002, DIABETES, V51, P591, DOI 10.2337/diabetes.51.3.591; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Nielsen JN, 2001, J PHYSIOL-LONDON, V531, P757, DOI 10.1111/j.1469-7793.2001.0757h.x; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Orlicky DJ, 2001, J LIPID RES, V42, P460; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SALTIEL AR, 1996, AM J PHYSIOL, V270, P375; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Yang RJ, 2002, J BIOL CHEM, V277, P1514, DOI 10.1074/jbc.M107001200	45	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30835	30842		10.1074/jbc.M303846200	http://dx.doi.org/10.1074/jbc.M303846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12805359	hybrid			2022-12-25	WOS:000184658800053
J	Matteucci, E; Modora, S; Simone, M; Desiderio, MA				Matteucci, E; Modora, S; Simone, M; Desiderio, MA			Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency	ONCOGENE			English	Article						hepatocyte growth factor; apoptosis; hypoxia-inducible factor-1; ornithine decarboxylase; caspases	ORNITHINE-DECARBOXYLASE; TRANSDUCTION PATHWAYS; FACTOR PROTECTS; HEPG2 HEPATOMA; FACTOR 1-ALPHA; CYTOCHROME-C; RECEPTOR; DEATH; INVOLVEMENT; SURVIVAL	Two hepatocarcinoma cell lines, the Hepa-1 wild-type (c1c7) and the beta-subunit mutated (c4) lacking hypoxia-inducible factor-1 (HIF-1) activity, were differentially susceptible to apoptosis by hepatocyte growth factor (HGF). The c4 cells were 40% apoptotic 48 h after HGF treatment. On the contrary, the wild-type c1c7 cells showed modest signs of apoptosis only at 72 h. The revertant vT{2} cells, consisting of c4 cells stably transfected with HIF-1b expression vector, behaved as the parental cells. To understand the mechanisms of this different sensitivity, we examined a panel of genes involved in apoptosis: ornithine decarboxylase, c-Myc and p53 protein levels progressively decreased while JNK1, caspase 8 and 3 activities persistently increased in c4 cells undergoing apoptosis. Distinct time-related events in c1c7 cells were the transient activations of JNK1 and caspase 8 followed by the accumulation of ODC and c-Myc proteins. The proapoptotic effect of HGF in c4 hepatocarcinoma cells seems to be related to HIF-1 deficiency with loss of cytoprotective and signalling functions. This may contribute to the triggering of the extrinsic pathway consisting in caspase 8 activation, which in turn causes BID cleavage and cytochrome c release. The effector caspase 3 is also activated.	Univ Milan, Sch Med, Inst Gen Pathol, I-20133 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, Flow Cytometry Unit, I-20157 Milan, Italy	University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Desiderio, MA (corresponding author), Univ Milan, Sch Med, Inst Gen Pathol, Via L Mangiagalli 31, I-20133 Milan, Italy.	a.desiderio@unimi.it	Desiderio, Maria Alfonsina/M-8870-2016	Desiderio, Maria Alfonsina/0000-0002-9894-9462				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Akakura N, 2001, CANCER RES, V61, P6548; Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bendinelli P, 1996, FEBS LETT, V398, P193, DOI 10.1016/S0014-5793(96)01228-8; Bowers DC, 2000, CANCER RES, V60, P4277; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Grassilli E, 1998, BIOCHEM BIOPH RES CO, V250, P293, DOI 10.1006/bbrc.1998.9291; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Katoh O, 1998, CANCER RES, V58, P5565; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; Matteucci E, 2001, J CELL PHYSIOL, V186, P387, DOI 10.1002/1097-4652(2000)9999:9999<000::AID-JCP1033>3.0.CO;2-8; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Semenza GL, 2000, GENE DEV, V14, P1983; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tacchini L, 2000, EXP CELL RES, V256, P272, DOI 10.1006/excr.2000.4824; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	46	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4062	4073		10.1038/sj.onc.1206519	http://dx.doi.org/10.1038/sj.onc.1206519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821940				2022-12-25	WOS:000183707600009
J	Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R				Orend, G; Huang, WT; Olayioye, MA; Hynes, NE; Chiquet-Ehrismann, R			Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4	ONCOGENE			English	Article						fibronectin; tenascin-C; syndecan-4; cell cycle; cdk2; FAK	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; HEPARIN-BINDING; MAMMARY-GLAND; RHO GTPASES; INTEGRIN; EXPRESSION; P27(KIP1); GROWTH	Tenascin-C is an adhesion-modulatory extracellular matrix protein that is predominantly expressed during embryonic development, wound healing and in tumor stroma. Here we report that anchorage-dependent human, rat and mouse fibroblasts adhere poorly and fail to proliferate on pure tenascin-C. This was due to a significant reduction of cyclin-dependent kinase 2 (cdk2) activity, resulting from elevated expression and association of the cdk inhibitors (CKIs) p21Cip1 and p27Kip1. To analyse the effect of tenascin-C on fibronectin-mediated adhesion, cells were plated on a mixed. bronectin/tenascin-C substratum. Compared to fibronectin alone, cell spreading and adhesion signaling were compromised, as determined by delayed phosphorylation kinetics of focal adhesion kinase (FAK). Despite the presence of growth factors, these cells remained arrested in the G1 phase of the cell cycle. In contrast to cells plated on pure tenascin-C, cdk2activity appeared to be inhibited independently of CKIs. Interestingly, overexpression of the transmembrane proteoglycan syndecan-4 restored cell spreading, adhesion signaling and DNA replication on the fibronectin/tenascin-C substratum. A similar rescue was observed using a recombinant peptide that spans the syndecan-4-binding site in fibronectin. This indicates that tenascin-C causes cell cycle arrest and cdk2 inactivation by interfering with fibronectin-syndecan-4 interactions. We therefore propose that syndecan-4 signaling plays a central role in the control of cellular proliferation of anchorage-dependent fibroblasts.	Novartis Forschungsstiftung, Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Orend, G (corresponding author), Univ Basel, Inst Biochem & Genet, Vesalgasse 1, CH-4051 Basel, Switzerland.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195				Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Denhez F, 2002, J BIOL CHEM, V277, P12270, DOI 10.1074/jbc.M110291200; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Garcion E, 2001, DEVELOPMENT, V128, P2485; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOULD VE, 1990, CELL DIFFER DEV, V32, P409, DOI 10.1016/0922-3371(90)90057-4; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hauzenberger D, 1999, EUR J IMMUNOL, V29, P1435, DOI 10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Huang WT, 2001, CANCER RES, V61, P8586; HYNES RO, 1994, CURR OPIN GENET DEV, V4, P569, DOI 10.1016/0959-437X(94)90074-D; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kalembeyi I, 1997, INT J DEV BIOL, V41, P569; Kuzumaki T, 1997, BIOCHEM BIOPH RES CO, V238, P169, DOI 10.1006/bbrc.1997.7267; Landry R, 2001, CELL GROWTH DIFFER, V12, P497; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Mackie EJ, 1999, J CELL SCI, V112, P3847; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Orend G, 2000, EXP CELL RES, V261, P104, DOI 10.1006/excr.2000.5041; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VAN AL, 1997, GENE DEV, V11, P2295; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vollmer G, 1997, CRIT REV ONCOL HEMAT, V25, P187, DOI 10.1016/S1040-8428(97)00004-8; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; YOUNG SL, 1994, DEV BIOL, V161, P615, DOI 10.1006/dbio.1994.1057; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	55	71	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3917	3926		10.1038/sj.onc.1206618	http://dx.doi.org/10.1038/sj.onc.1206618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813465				2022-12-25	WOS:000183612000011
J	Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE				Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE			Protein kinase inhibitor 2-aminopurine overrides multiple genotoxic stress-induced cellular pathways to promote cell survival	ONCOGENE			English	Article						2-aminopurine; p53; DNA damage; protein phosphorylation; cell cycle control; apoptosis	DOUBLE-STRANDED-RNA; DAMAGE-INDUCED PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P53; CHECKPOINT; ATR	2-Aminopurine (2-AP) is an adenine analog shown to cause cells to bypass chemical- and radiation-induced cell cycle arrest through as-yet unidentified mechanisms. 2-AP has also been shown to act as a kinase inhibitor. Tumor suppressor p53 plays an important role in the control of cell cycle and apoptosis in response to genotoxic stress. We were interested in examining the effect of 2-AP on p53 phosphorylation and its possible consequences on checkpoint control in cells subjected to various forms of DNA damage. Here, we show that 2-AP suppresses p53 phosphorylation in response to gamma radiation, adriamycin, or ultraviolet treatment. This is partly explained by the ability of the kinase inhibitor to inhibit ATM or ATR activities in vitro and impair ATM- or ATR-dependent p53 phosphorylation in vivo. However, 2-AP is also capable of inhibiting p53 phosphorylation in cells deficient in ATM, DNA-PK, or ATR suggesting the existence of multiple pathways by which this kinase inhibitor modulates p53 activation. Biologically, the 2AP-mediated inhibition of p53 stabilization enables wildtype p53-containing cells to bypass adriamycin-induced G(2)/M arrest. In the long term, however, 2-AP facilitates cells to resist DNA damage-induced cell death independently, of p53.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ H3A 2T5, Canada; Natl Inst Canc Res, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ H3A 2T5, Canada	McGill University; Lady Davis Institute; McGill University; McGill University; National Cancer Center - Japan; McGill University	Koromilas, AE (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada.	antonis.koromilas@mcgill.ca		Cuddihy, Andrew/0000-0002-9898-0443				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Araki R, 1999, CANCER RES, V59, P3543; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carrier F, 1998, BIOCHEM PHARMACOL, V55, P853, DOI 10.1016/S0006-2952(97)00592-3; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 2000, GENE DEV, V14, P278; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	52	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3721	3733		10.1038/sj.onc.1206490	http://dx.doi.org/10.1038/sj.onc.1206490			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802279				2022-12-25	WOS:000183551000006
J	Jurk, K; Clemetson, KJ; de Groot, PG; Brodde, MF; Steiner, M; Savion, N; Varon, D; Sixma, JJ; Van Aken, H; Kehrel, BE				Jurk, K; Clemetson, KJ; de Groot, PG; Brodde, MF; Steiner, M; Savion, N; Varon, D; Sixma, JJ; Van Aken, H; Kehrel, BE			Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor	FASEB JOURNAL			English	Article						adhesion molecules; extracellular matrix; thrombosis; arteriosclerosis; inflammation	INTEGRIN-ASSOCIATED PROTEIN; MEMBRANE-GLYCOPROTEINS; EXTRACELLULAR-MATRIX; THROMBUS FORMATION; FLOW CONDITIONS; WHOLE-BLOOD; RECEPTOR; BINDS; FIBRONECTIN; SPECIFICITY	Acute thrombotic arterial occlusion is the leading cause of morbidity and mortality in the Western world. Von Willebrand factor is thought to be the only indispensable adhesive substrate to promote thrombus formation in high shear environments. We found that thrombospondin-1, a glycoprotein enriched in arteriosclerotic plaques, might function as an alternative substrate for thrombus formation. Platelets adhered to thrombospondin-1 in a shear dependent manner with an optimum shear as found in stenosed arteries. Adhesion is extremely firm, with no detachment of platelets up to a shear rate of 4000 s(-1). Experiments using platelets from a patient completely lacking von Willebrand factor showed that von Willebrand factor is not involved in platelet binding to thrombospondin-1. Platelet adhesion to thrombospondin-1 is not mediated via beta(3)-integrins or GPIa. CD36 partially mediates the adhesion of pre-activated platelets. We identified GPIb as high shear adhesion-receptor for thrombospondin-1. Soluble GPIb, as well as antibodies against the GPIb, blocked platelet adhesion almost completely. The new discovered thrombospondin-1-GPIb adhesion axis under arterial shear conditions might be important, not only during thrombus formation but also for pathological processes where other cells bind to the endothelium or subendothelium, including arteriosclerosis, inflammation and tumor metastasis, and a promising therapeutic target.	Univ Hosp Munster, Dept Anaesthesiol & Intens Care, D-48149 Munster, Germany; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Univ Med Ctr Utrecht, Dept Haematol, Utrecht, Netherlands; Univ Rostock, Inst Clin Chem, D-2500 Rostock, Germany; Tel Aviv Univ, Sackler Fac Med, Goldschleger Eye Res Inst, IL-69978 Tel Aviv, Israel; Hadassah Hebrew Univ Med Ctr, Dept Hematol, Coagulat Unit, Jerusalem, Israel	University of Munster; University of Bern; Utrecht University; Utrecht University Medical Center; University of Rostock; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	Kehrel, BE (corresponding author), Univ Hosp Munster, Dept Anaesthesiol & Intens Care, Mendelstr 11, D-48149 Munster, Germany.	kehrel@uni-muenster.de	Savion, Naphtali/K-1013-2019; Jurk, Kerstin/AAT-7768-2020	Savion, Naphtali/0000-0001-8899-0624				Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Beacham DA, 1999, J CELL BIOCHEM, V73, P508, DOI 10.1002/(SICI)1097-4644(19990615)73:4<508::AID-JCB9>3.0.CO;2-O; BEUMER S, 1994, BLOOD, V84, P3724, DOI 10.1182/blood.V84.11.3724.bloodjournal84113724; Bonnefoy A, 2001, THROMB HAEMOSTASIS, V85, P552, DOI 10.1055/s-0037-1615620; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; Dardik R, 1999, EXP CELL RES, V248, P407, DOI 10.1006/excr.1999.4415; DETWILER TC, 1987, SEMIN THROMB HEMOST, V13, P276, DOI 10.1055/s-2007-1003502; DiPietro LA, 1996, AM J PATHOL, V148, P1851; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Herrmann M, 1997, J INFECT DIS, V176, P984, DOI 10.1086/516502; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kasirer-Friede A, 2001, THROMB HAEMOSTASIS, V86, P653, DOI 10.1055/s-0037-1616101; Kehrel B, 1996, BLOOD COAGUL FIBRIN, V7, P202, DOI 10.1097/00001721-199603000-00023; KEHREL B, 1991, BIOCHEM BIOPH RES CO, V179, P985, DOI 10.1016/0006-291X(91)91915-Y; KEHREL B, 1993, BLOOD, V82, P3364; KLEIN H, 1996, LEUCOCYTE TYPING, V6, P643; Kronenberg A, 1998, THROMB HAEMOSTASIS, V79, P1021; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1989, BLOOD, V74, P2022; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEVELSTEIN PFEM, 1988, BLOOD, V72, P82; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; Roest M, 2000, BLOOD, V96, P1433, DOI 10.1182/blood.V96.4.1433.h8001433_1433_1437; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Varon D, 1997, THROMB RES, V85, P283, DOI 10.1016/S0049-3848(97)00014-5; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; Wu YP, 1997, ARTERIOSCL THROM VAS, V17, P3202, DOI 10.1161/01.ATV.17.11.3202; Yamamoto K, 1998, BLOOD, V92, P2791, DOI 10.1182/blood.V92.8.2791.420k24_2791_2801; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	43	109	118	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1490	+		10.1096/fj.02-0830fje	http://dx.doi.org/10.1096/fj.02-0830fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824298				2022-12-25	WOS:000183818000025
J	Solito, E; Kamal, A; Russo-Marie, F; Buckingham, JC; Marullo, S; Perretti, M				Solito, E; Kamal, A; Russo-Marie, F; Buckingham, JC; Marullo, S; Perretti, M			A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils	FASEB JOURNAL			English	Article						inflammation; calcium channel; fMLP; chemotaxis; L-selectin	L-SELECTIN; MOLECULAR-STRUCTURE; HUMAN-LEUKOCYTES; MONOCYTIC CELLS; LIPOCORTIN 1; APOPTOSIS; ADHESION; DEXAMETHASONE; EXPRESSION; MEMBRANE	The glucocorticoid-inducible protein annexin (ANXA) 1 is an anti-inflammatory mediator that down-regulates the host response. Endogenously, ANXA1 is released in large amounts from adherent polymorphonuclear neutrophils (PMN) and binds to their cell surface to inhibit their extravasation into inflamed tissues. The present study determined the effects of exogenous ANXA1 on several functions of human PMN in vitro. Addition of 0.1-1 mu human recombinant ANXA1 to the PMN provoked rapid and transient changes in intracellular Ca2+ concentrations that were blocked by the Ca2+ channel inhibitor SKF-96365. Although ANXA1 did not affect oxidant production and only minimally affected PMN chemotactic properties, the ANXA1-promoted Ca2+ influx was associated with two important functional effects: shedding of L-selectin and acceleration of PMN apoptosis. The latter effect was confirmed using three distinct technical procedures, namely, cell cycle, Hoechst staining, and ANXA5 binding assay. ANXA1-induced PMN apoptosis was insensitive to inhibitors of L-selectin shedding, whereas it appeared to be associated with dephosphorylation of the proapoptotic intracellular mediator BAD. In conclusion, exogenous ANXA1 displayed selective actions on human PMN. We propose that the new proapoptotic effect reported here may be part of the spectrum of ANXA1-mediated events involved in the resolution of acute inflammation.	Univ London Imperial Coll Sci Technol & Med, Dept Neuroendocrinol, London W12 0NN, England; Queen Mary SMD, Barts London, William Harvey Res Inst, London EC1M 6BQ, England; Inst Cochin Genet Mol, Dept Cell Biol, F-75014 Paris, France	Imperial College London; University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Solito, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Neuroendocrinol, Hammersmith Campus,Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.	e.solito@ic.ac.uk	Marullo, Stefano/C-6142-2008	Marullo, Stefano/0000-0001-9604-9973; Solito, Egle/0000-0001-5279-0049				Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; Dalpiaz A, 1999, BBA-PROTEIN STRUCT M, V1432, P27, DOI 10.1016/S0167-4838(99)00081-3; Dalpiaz A, 2002, EUR J PHARMACOL, V436, P187, DOI 10.1016/S0014-2999(01)01627-2; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1990, BIOCHEM SOC T, V18, P1237, DOI 10.1042/bst0181237; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KELLER HU, 1976, AGENTS ACTIONS, V6, P326, DOI 10.1007/BF01972250; Kern PM, 2000, INT J RADIAT BIOL, V76, P1265, DOI 10.1080/09553000050134492; Kettritz R, 1997, J AM SOC NEPHROL, V8, P1091; Kubista H, 1999, CURR BIOL, V9, P1403, DOI 10.1016/S0960-9822(00)80085-8; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; MANCUSO F, 1995, J IMMUNOL, V155, P377; Matsuda R, 1997, BIOCHEM BIOPH RES CO, V237, P499, DOI 10.1006/bbrc.1997.7177; Meagher LC, 1996, J IMMUNOL, V156, P4422; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; PEERS SH, 1991, EUR J PHARMACOL, V196, P37, DOI 10.1016/0014-2999(91)90406-G; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; POLLARD H, 1992, SYNEXIN ANNEXIN 7; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSOMARIE F, 1992, ANNEXINS; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; TISSOT M, 1991, J LEUKOCYTE BIOL, V50, P607, DOI 10.1002/jlb.50.6.607; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; Vergnolle N, 1997, AM J PHYSIOL-REG I, V273, pR623, DOI 10.1152/ajpregu.1997.273.2.R623; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Watson RWG, 1997, J IMMUNOL, V158, P945; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; Zouki C, 2000, FASEB J, V14, P572, DOI 10.1096/fasebj.14.3.572	68	154	163	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1544	+		10.1096/fj.02-0941fje	http://dx.doi.org/10.1096/fj.02-0941fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824302				2022-12-25	WOS:000183818000023
J	Bortner, CD; Cidlowski, JA				Bortner, CD; Cidlowski, JA			Uncoupling cell shrinkage from apoptosis reveals that Na+ influx is required for volume loss during programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE ACTIVATION; NEURONAL APOPTOSIS; K+ CHANNELS; POTASSIUM; EFFLUX; MECHANISMS; DEGRADATION; LYMPHOCYTES; THYMOCYTES; INHIBITION	Cell shrinkage, or the loss of cell volume, is a ubiquitous characteristic of programmed cell death that is observed in all examples of apoptosis, independent of the death stimulus. This decrease in cell volume occurs in synchrony with other classical features of apoptosis. The molecular basis for cell shrinkage during apoptosis involves fluxes of intracellular ions including K+, Na+, and Cl-. Here we show for the first time that these ion fluxes, but not cell shrinkage, are necessary for apoptosis. Using sodium-substituted medium during anti-Fas treatment of Jurkat cells, we observed cellular swelling, a property normally associated with necrosis, in contrast to the typical cell shrinkage. Surprisingly, these swollen cells displayed all of the other classical features of apoptosis, including chromatin condensation, externalization of phosphatidylserine, caspase activity, poly(ADP)-ribose polymerase cleavage, and internucleosomal DNA degradation. These swollen cells had a marked decrease in intracellular potassium, and subsequent inhibition of this potassium loss completely blocked apoptosis. Reintroduction of sodium ions in cell cultures reversed this cellular swelling, resulting in a dramatic loss of cell volume and the characteristic apoptotic morphology. Additionally, inhibition of sodium influx using a sodium channel blocker saxitoxin completely prevented the onset of anti-Fas-induced apoptosis in Jurkat cells. These findings suggest that sodium influx can control not only changes in cell size but also the activation of apoptosis, whereas potassium ion loss controls the progression of the cell death process. Therefore cell shrinkage can be separated from other features of apoptosis.	NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090079, Z01ES090079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bilney AJ, 1998, FEBS LETT, V424, P221, DOI 10.1016/S0014-5793(98)00172-0; Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BORTNER CD, 1997, CELL DEATH REPROD PH, P230; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Fernandez-Segura E, 1999, EXP CELL RES, V253, P454, DOI 10.1006/excr.1999.4657; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOFFMANN EK, 1987, CURR TOP MEMBR TRANS, V30, P125; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; Kohler C, 2002, J IMMUNOL METHODS, V265, P97, DOI 10.1016/S0022-1759(02)00073-X; Krick S, 2001, AM J PHYSIOL-CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; Nietsch HH, 2000, J BIOL CHEM, V275, P20556, DOI 10.1074/jbc.M002535200; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Perez GI, 2000, BIOL REPROD, V63, P1358, DOI 10.1095/biolreprod63.5.1358; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Skepper JN, 1999, J PATHOL, V188, P100, DOI 10.1002/(SICI)1096-9896(199905)188:1<100::AID-PATH306>3.0.CO;2-O; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; Widlak P, 2001, MOL CELL BIOCHEM, V218, P125, DOI 10.1023/A:1007231822086; WILLMAN CL, 1989, SEMIN DIAGN PATHOL, V6, P3; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336	39	148	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39176	39184		10.1074/jbc.M303516200	http://dx.doi.org/10.1074/jbc.M303516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12821680	hybrid			2022-12-25	WOS:000185575100131
J	Munoz, NM; Kim, YJ; Meliton, AY; Kim, KP; Han, SK; Boetticher, E; O'Leary, E; Myou, S; Zhu, XD; Bonventre, JV; Leff, AR; Cho, WH				Munoz, NM; Kim, YJ; Meliton, AY; Kim, KP; Han, SK; Boetticher, E; O'Leary, E; Myou, S; Zhu, XD; Bonventre, JV; Leff, AR; Cho, WH			Human group V phospholipase A(2) induces group IVA phospholipase A(2)-independent cysteinyl leukotriene synthesis in human eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; BLOOD EOSINOPHILS; GROUP IIA; 5-LIPOXYGENASE; BINDING; ACTIVATION; BIOSYNTHESIS; EXPRESSION; PROTEIN; KINASES	We previously reported that exogenously added human group V phospholipase A(2) (hVPLA(2)) could elicit leukotriene B-4 biosynthesis in human neutrophils through the activation of group IVA phospholipase A(2) (cPLA(2)) (Kim, Y. J., Kim, K. P., Han, S. K., Munoz, N. M., Zhu, X., Sano, H., Leff, A. R., and Cho, W. (2002) J. Biol. Chem. 277, 36479-36488). In this study, we determined the functional significance and mechanism of the exogenous hVPLA(2)-induced arachidonic acid (AA) release and leukotriene C-4 (LTC4) synthesis in isolated human peripheral blood eosinophils. As low a concentration as 10 nM exogenous hVPLA(2) was able to elicit the significant release of AA and LTC4 from unstimulated eosinophils, which depended on its ability to act on phosphatidylcholine membranes. hVPLA(2) also augmented the release of AA and LTC4 from eosinophils activated with formyl-Met-Leu-Phe + cytochalasin B. A cellular fluorescent PLA(2) assay showed that hVPLA(2) had a lipolytic action first on the outer plasma membrane and then on the perinuclear region. hVPLA(2) also caused the translocation of 5-lipoxygenase from the cytosol to the nuclear membrane and a 2-fold increase in 5-lipoxygenase activity. However, hVPLA(2) induced neither the increase in intracellular calcium concentration nor cPLA(2) phosphorylation; consequently, cPLA(2) activity was not affected by hVPLA(2). Pharmacological inhibition of cPLA(2) and the hVPLA(2)-induced activation of eosinophils derived from the cPLA(2)-deficient mouse corroborated that hVPLA(2) mediates the release of AA and leukotriene in a cPLA(2)-independent manner. As such, this study represents a unique example in which a secretory phospholipase induces the eicosanoid formation in inflammatory cells, completely independent of cPLA(2) activation.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Med, Charlestown, MA 02129 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; Harvard University	Leff, AR (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.			zhu, xiangdong/0000-0002-5627-8082; Kim, Kwang Pyo/0000-0003-0095-3787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046368, P50HL056399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56399, HL-46368] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Blom M, 1998, BLOOD, V91, P3037; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brock TG, 1999, J IMMUNOL, V162, P1669; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Coffey MJ, 2000, J IMMUNOL, V165, P3592, DOI 10.4049/jimmunol.165.7.3592; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Miura K, 1999, J IMMUNOL, V162, P4198; Munoz NM, 2000, HYBRIDOMA, V19, P171, DOI 10.1089/02724570050031220; Munoz NM, 2002, J IMMUNOL METHODS, V262, P41, DOI 10.1016/S0022-1759(01)00573-7; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Sano A, 1999, AM J RESP CRIT CARE, V159, P1903, DOI 10.1164/ajrccm.159.6.9810005; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SUN FF, 1991, J LEUKOCYTE BIOL, V50, P140, DOI 10.1002/jlb.50.2.140; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Zhu XD, 1996, J IMMUNOL METHODS, V199, P119, DOI 10.1016/S0022-1759(96)00166-4; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	42	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38813	38820		10.1074/jbc.M302476200	http://dx.doi.org/10.1074/jbc.M302476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12796497	hybrid			2022-12-25	WOS:000185575100089
J	Campanini, B; Raboni, S; Vaccari, S; Zhang, L; Cook, PF; Hazlett, TL; Mozzarelli, A; Bettati, S				Campanini, B; Raboni, S; Vaccari, S; Zhang, L; Cook, PF; Hazlett, TL; Mozzarelli, A; Bettati, S			Surface-exposed tryptophan residues are essential for O-acetylserine sulfhydrylase structure, function, and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRELATION PHASE FLUOROMETER; SALMONELLA-TYPHIMURIUM LT-2; MULTIPLE SEQUENCE ALIGNMENT; DNA-BINDING DOMAIN; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; CONFORMATIONAL CHANGE; CYSTEINE SYNTHETASE; PROTEIN STABILITY; AMINO-ACIDS	O-Acetylserine sulfhydrylase is a homodimeric enzyme catalyzing the last step of cysteine biosynthesis via a Bi Bi ping-pong mechanism. The subunit is composed of two domains, each containing one tryptophan residue, Trp(50) in the N-terminal domain and Trp(161) in the C-terminal domain. Only Trp(161) is highly conserved in eucaryotes and bacteria. The coenzyme pyridoxal 5'-phosphate is bound in a cleft between the two domains. The enzyme undergoes an open to closed conformational transition upon substrate binding. The effect of single Trp to Tyr mutations on O-acetylserine sulfhydrylase structure, function, and stability was investigated with a variety of spectroscopic techniques. The mutations do not significantly alter the enzyme secondary structure but affect the catalysis, with a predominant influence on the second half reaction. The W50Y mutation strongly affects the unfolding pathway due to the destabilization of the intersubunit interface. The W161Y mutation, occurring in the C-terminal domain, produces a reduction of the accessibility of the active site to acrylamide and stabilizes thermodynamically the N-terminal domain, a result consistent with stronger interdomain interactions.	Univ Parma, Dept Publ Hlth, I-43100 Parma, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Illinois, Fluorescence Dynam Lab, Urbana, IL 61801 USA	University of Parma; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma; University of Oklahoma System; University of Oklahoma - Norman; University of Illinois System; University of Illinois Urbana-Champaign	Bettati, S (corresponding author), Univ Parma, Dept Publ Hlth, I-43100 Parma, Italy.	stefano.bettati@unipr.it	Campanini, Barbara/L-9723-2017; RABONI, Samanta/P-7823-2018; Bettati, Stefano/V-9975-2018; Mozzarelli, Andrea/C-3615-2014	Campanini, Barbara/0000-0003-0359-0627; RABONI, Samanta/0000-0003-3068-3714; Bettati, Stefano/0000-0001-6787-0594; Mozzarelli, Andrea/0000-0003-3762-0062	NCRR NIH HHS [RR03155] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER MA, 1969, J BIOL CHEM, V244, P2418; Benci S, 1999, J PHOTOCH PHOTOBIO B, V48, P17, DOI 10.1016/S1011-1344(99)00003-2; Bettati S, 2002, BBA-PROTEIN STRUCT M, V1596, P47, DOI 10.1016/S0167-4838(01)00316-8; Bettati S, 2000, J BIOL CHEM, V275, P40244, DOI 10.1074/jbc.M007015200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; Eason DE, 1999, BBA-GENE STRUCT EXPR, V1446, P140, DOI 10.1016/S0167-4781(99)00078-0; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Ervin J, 2002, BIOPHYS J, V83, P473, DOI 10.1016/S0006-3495(02)75183-7; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Fulton KF, 2003, BIOCHEMISTRY-US, V42, P2364, DOI 10.1021/bi020564a; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; Greene LH, 2001, PROTEIN SCI, V10, P2301, DOI 10.1110/ps.22901; GREENE RF, 1974, J BIOL CHEM, V249, P5388; HARA S, 1990, Protein Expression and Purification, V1, P70, DOI 10.1016/1046-5928(90)90048-4; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; Honda Y, 1999, BBA-PROTEIN STRUCT M, V1429, P365, DOI 10.1016/S0167-4838(98)00243-X; Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472; Jameson D. M., 1991, BIOPHYSICAL BIOCH AS, P106; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; Kuske CR, 1996, PLANT PHYSIOL, V112, P659, DOI 10.1104/pp.112.2.659; Lakowicz J. R, 1988, TIME RESOLVED LASER, P70; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; Luque I, 2000, PROTEINS, P63; Marie G, 2001, PROTEIN SCI, V10, P99, DOI 10.1110/ps.28201; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; Mino K, 2000, BIOSCI BIOTECH BIOCH, V64, P1628, DOI 10.1271/bbb.64.1628; PACE CN, 1997, PROTEIN STRUCTURE; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; SCHMID FX, 1997, PROTEIN STRUCTURE, V174, P261; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; Segel IH., 1993, ENZYME KINETICS BEHA; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; SPENCER RD, 1969, ANN NY ACAD SCI, V158, P361, DOI 10.1111/j.1749-6632.1969.tb56231.x; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; Subramaniam V, 2001, J BIOL CHEM, V276, P21506, DOI 10.1074/jbc.M102292200; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Tai CH, 2000, ADV ENZYMOL RAMB, V74, P185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchiyama T, 2001, J BIOL CHEM, V276, P41343, DOI 10.1074/jbc.M103610200; Wallace LA, 2000, BBA-PROTEIN STRUCT M, V1478, P325, DOI 10.1016/S0167-4838(00)00023-6; Watanabe H, 2001, BIOCHEM J, V357, P269, DOI 10.1042/0264-6021:3570269; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o; Wrabl JO, 2001, PROTEIN SCI, V10, P1032, DOI 10.1110/ps.01601; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j	55	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37511	37519		10.1074/jbc.M305138200	http://dx.doi.org/10.1074/jbc.M305138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12813039	hybrid			2022-12-25	WOS:000185437200064
J	Kirchhofer, D; Peek, M; Li, W; Stamos, J; Eigenbrot, C; Kadkhodayan, S; Elliott, JM; Corpuz, RT; Lazarus, RA; Moran, P				Kirchhofer, D; Peek, M; Li, W; Stamos, J; Eigenbrot, C; Kadkhodayan, S; Elliott, JM; Corpuz, RT; Lazarus, RA; Moran, P			Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator Inhibitor-1B (HAI-1B), a new splice variant of HAI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET RECEPTOR; SERINE-PROTEASE; FACTOR/SCATTER FACTOR; PROTEOLYTIC CLEAVAGE; PLASMA KALLIKREIN; PLACENTAL BIKUNIN; MOLECULAR-CLONING; SCATTER-FACTOR; CELL-SURFACES; FACTOR XA	Hepatocyte growth factor activator inhibitor-1 (HAI-1) is an integral membrane protein expressed on epithelial cells and contains two extracellular Kunitz domains (N-terminal KD1 and C-terminal KD2) known to inhibit trypsin-like serine proteases. In tumorigenesis and tissue regeneration, HAI-1 regulates the hepatocyte growth factor (HGF)/c-Met pathway by inhibiting the activity of HGF activator (HGFA) and matriptase, two serine proteases that convert pro-HGF into its biologically active form. By screening a placental cDNA library, we discovered a new splice variant of HAI-1 designated HAI-1B that contains an extra 16 amino acids adjacent to the C terminus of KD1. To investigate possible consequences on Kunitz domain function, a soluble form of HAI-1B (sHAI-1B) comprising the entire extracellular domain was produced. First, we found that sHAI-1B displayed remarkable enzyme specificity by potently inhibiting only HGFA (IC50 = 30.5 nM), matriptase (IC50 = 16.5 nM), and trypsin (IC50 = 2.4 nM) among 16 serine proteases examined, including plasminogen activators (urokinase- and tissue-type plasminogen activators), coagulation enzymes thrombin, factors VIIa, Xa, XIa, and XIIa, and activated protein C. Relatively weak inhibition was found for plasmin (IC50 = 399 nM) and plasma kallikrein (IC50 = 686 nM). Second, the functions of the KD1 and KD2 domains in sHAI-1B were investigated using P-1 residue-directed mutagenesis to show that inhibition of HGFA, matriptase, trypsin, and plasmin was due to KD1 and not KD2. Furthermore, analysis by reverse transcription-PCR demonstrated that HAI-1B and HAI-1 were co-expressed in normal tissues and various epithelial-derived cancer cell lines. Both isoforms were up-regulated in eight examined ovarian carcinoma specimens, three of which had higher levels of HAI-1B RNA than of HAI-1 RNA. Therefore, previously demonstrated roles of HAI-1 in various physiological and pathological processes likely involve both HAI-1B and HAI-1.	Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Kirchhofer, D (corresponding author), Genentech Inc, Dept Physiol, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com						Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Delaria KA, 1997, J BIOL CHEM, V272, P12209, DOI 10.1074/jbc.272.18.12209; Denda K, 2002, J BIOL CHEM, V277, P14053, DOI 10.1074/jbc.M112263200; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Itoh M, 2000, EUR J BIOCHEM, V267, P3351, DOI 10.1046/j.1432-1327.2000.01368.x; Kang JY, 2003, CANCER RES, V63, P1101; Kaplan AP, 1997, ADV IMMUNOL, V66, P225, DOI 10.1016/S0065-2776(08)60599-4; Kataoka H, 2000, CANCER RES, V60, P6148; Kataoka H, 2000, J BIOL CHEM, V275, P40453, DOI 10.1074/jbc.M006412200; Kataoka H, 2000, HISTOCHEM CELL BIOL, V114, P469; Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2001, BIOCHEMISTRY-US, V40, P675, DOI 10.1021/bi002013v; Krowarsch D, 1999, J MOL BIOL, V289, P175, DOI 10.1006/jmbi.1999.2757; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; MARS WM, 1993, AM J PATHOL, V143, P949; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; Nagata K, 2001, BIOCHEM BIOPH RES CO, V289, P205, DOI 10.1006/bbrc.2001.5916; NAKA D, 1992, J BIOL CHEM, V267, P20114; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Parr C, 2001, INT J ONCOL, V19, P857; Peek M, 2002, J BIOL CHEM, V277, P47804, DOI 10.1074/jbc.M209778200; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; Simmons LC, 1996, NAT BIOTECHNOL, V14, P629, DOI 10.1038/nbt0596-629; Simmons LC, 2002, J IMMUNOL METHODS, V263, P133, DOI 10.1016/S0022-1759(02)00036-4; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; White G.C., 1994, HEMOSTASIS THROMBOSI, P1134; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	59	86	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36341	36349		10.1074/jbc.M304643200	http://dx.doi.org/10.1074/jbc.M304643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12815039	hybrid			2022-12-25	WOS:000185318300060
J	Tan, CM; Nickols, HH; Limbird, LE				Tan, CM; Nickols, HH; Limbird, LE			Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-COUPLED RECEPTORS; CANINE KIDNEY-CELLS; ALPHA(2A)-ADRENERGIC RECEPTOR; LOCALIZATION; CHAPERONES; MECHANISMS; TERMINUS; SUBTYPES; MUTANTS	To understand the mechanisms of G protein-coupled receptor delivery and steady state localization, we examined the trafficking itineraries of wild type (WT) and mutant V2 vasopressin receptors (V2Rs) in polarized Madin-Darby canine kidney II (MDCK II) cells and in COS M6 cells; the mutant V2Rs represent selected alleles responsible for X-linked nephrogenic diabetes insipidus. The WT V2R is localized on the plasma membrane and mediates arginine vasopressin (AVP)-stimulated cAMP accumulation, whereas the clinically relevant V2R mutants, L292P V2R, DeltaV278 V2R, and R337X V2R, are retained intracellularly, are insensitive to extracellularly added AVP, and are not processed beyond initial immature glycosylation, manifest by their endoglycosidase H sensitivity. Reduced temperature and pharmacological, but not chemical, strategies rescue mutant V2Rs to the cell surface of COS M6 cells; surface rescue of L292P V2R and R337X V2R, but not of DeltaV278 V2R, parallels acquisition of AVP-stimulated cAMP production. Pharmacological rescue of the L292P or R337X V2R by incubation with the membrane-permeant V2R antagonist, SR121463B, leads to a mature glycosylated form of the receptor that achieves localization on the basolateral surface of polarized MDCK II cells indistinguishable from that of the WT V2R. Surprisingly, however, the immature form of the mutant L292P V2R escapes to the apical, but not basolateral, surface of polarized MDCK II cells, even in the absence of SR121463B. These findings are consistent with the interpretation that the receptor conformation that allows appropriate processing through the N-linked glycosylation pathway is also essential for V2R targeting to the appropriate surface of polarized epithelial cells.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Robinson Res Bldg,Rm 464, Nashville, TN 37232 USA.	lee.limbird@mcmail.vanderbilt.edu			NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK43879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK043879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Jaquette J, 1997, ENDOCRINOLOGY, V138, P85, DOI 10.1210/en.138.1.85; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; Leanos-Miranda A, 2002, J CLIN ENDOCR METAB, V87, P4825, DOI 10.1210/jc.2002-020961; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; Saunders C, 1999, PHARMACOL THERAPEUT, V84, P193, DOI 10.1016/S0163-7258(99)00032-7; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1998, FEBS LETT, V441, P170, DOI 10.1016/S0014-5793(98)01519-1; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	26	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35678	35686		10.1074/jbc.M301888200	http://dx.doi.org/10.1074/jbc.M301888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824183	hybrid			2022-12-25	WOS:000185164400113
J	Czerski, LW; Szweda, PA; Szweda, LI				Czerski, LW; Szweda, PA; Szweda, LI			Dissociation of cytochrome c from the inner mitochondrial membrane during cardiac ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; MYOCARDIAL-ISCHEMIA; INTACT MITOCHONDRIA; INTERMEMBRANE SPACE; LIPID-PEROXIDATION; REPERFUSION INJURY; IONIC-STRENGTH; CELL-DEATH; RELEASE; APOPTOSIS	Mitochondria isolated from ischemic cardiac tissue exhibit diminished rates of respiration and ATP synthesis. The present study was undertaken to determine whether cytochrome c release was responsible for ischemia-induced loss in mitochondrial function. Rat hearts were perfused in Langendorff fashion for 60 min (control) or for 30 min followed by 30 min of no flow ischemia. Mitochondria isolated from ischemic hearts in a buffer containing KCl exhibited depressed rates of maximum respiration and a lower cytochrome c content relative to control mitochondria. The addition of cytochrome c restored maximum rates of respiration, indicating that the release of cytochrome c is responsible for observed declines in function. However, mitochondria isolated in a mannitol/sucrose buffer exhibited no ischemia-induced loss in cytochrome c content, indicating that ischemia does not on its own cause the release of cytochrome c. Nevertheless, state 3 respiratory rates remained depressed, and cytochrome c release was enhanced when mitochondria from ischemic relative to perfused tissue were subsequently placed in a high ionic strength buffer, hypotonic solution, or detergent. Thus, events that occur during ischemia favor detachment of cytochrome c from the inner membrane increasing the pool of cytochrome c available for release. These results provide insight into the sequence of events that leads to release of cytochrome c and loss of mitochondrial respiratory activity during cardiac ischemia/reperfusion.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Szweda, LI (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	Lxs54@po.cwru.edu			NATIONAL INSTITUTE ON AGING [R01AG016339] Funding Source: NIH RePORTER; NIA NIH HHS [AG00105-16, AG-16339] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagchi D, 1997, CHEM-BIOL INTERACT, V104, P65, DOI 10.1016/S0009-2797(97)03766-6; Banci L, 1999, J BIOL INORG CHEM, V4, P824, DOI 10.1007/s007750050356; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Cortese JD, 1998, BIOCHEMISTRY-US, V37, P6402, DOI 10.1021/bi9730543; CORTESE JD, 1991, J CELL BIOL, V113, P1331, DOI 10.1083/jcb.113.6.1331; CORTESE JD, 1992, BIOCHIM BIOPHYS ACTA, V1100, P189; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Di Lisa F, 1998, BBA-BIOENERGETICS, V1366, P69, DOI 10.1016/S0005-2728(98)00121-2; Di Lisa F, 1998, MOL CELL BIOCHEM, V184, P379, DOI 10.1023/A:1006810523586; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Ferrari C, 1996, ANNU REV FLUID MECH, V28, P1; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Freude B, 2000, J MOL CELL CARDIOL, V32, P197, DOI 10.1006/jmcc.1999.1066; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; MURFITT RR, 1978, J MOL CELL CARDIOL, V10, P109, DOI 10.1016/0022-2828(78)90036-6; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; REIMER KA, 1992, HEART CARDIOVASCULAR, V2, P1875; SORDAHL LA, 1980, CIRC RES, V47, P814, DOI 10.1161/01.RES.47.6.814; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VASDEV SC, 1980, CAN J BIOCHEM CELL B, V58, P1112, DOI 10.1139/o80-149	37	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34499	34504		10.1074/jbc.M302021200	http://dx.doi.org/10.1074/jbc.M302021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813053	hybrid			2022-12-25	WOS:000185047500110
J	Fuki, IV; Blanchard, N; Jin, WJ; Marchadier, DHL; Millar, JS; Glick, JM; Rader, DJ				Fuki, IV; Blanchard, N; Jin, WJ; Marchadier, DHL; Millar, JS; Glick, JM; Rader, DJ			Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELL; IN-VIVO EVIDENCE; VERY-LOW-DENSITY; HEPATIC LIPASE; SELECTIVE UPTAKE; CHOLESTERYL ESTERS; BETA-VLDL; APO-B; RECEPTOR	Endothelial lipase (EL) is a new member of the triglyceride lipase gene family, which includes lipoprotein lipase (LpL) and hepatic lipase (HL). Enzymatic activity of EL has been studied before. Here we characterized the ability of EL to bridge lipoproteins to the cell surface. Expression of EL in wild-type Chinese hamster ovary (CHO)-K1 but not in heparan sulfate proteoglycan ( HSPG)-deficient CHO-677 cells resulted in 3-4.4-fold increases of I-125-low density lipoprotein (LDL) and I-125-high density lipoprotein 3 binding (HDL3). Inhibition of proteoglycan sulfation by sodium chlorate or incubation of cells with labeled lipoproteins in the presence of heparin ( 100 mug/ml) abolished bridging effects of EL. An enzymatically inactive EL, EL-S149A, was equally effective in facilitating lipoprotein bridging as native EL. Processing of LDL and HDL differed notably after initial binding via EL to the cell surface. More than 90% of the surface-bound I-125-LDL was destined for internalization and degradation, whereas about 70% of the surface-bound I-125-HDL3 was released back into the medium. These differences were significantly attenuated after HDL clustering was promoted using antibody against apolipoprotein A-I. At equal protein concentration of added lipoproteins the ratio of HDL3 to VLDL bridging via EL was 0.092 compared with 0.174 via HL and 0.002 via LpL. In summary, EL mediates binding and uptake of plasma lipoproteins via a process that is independent of its enzymatic activity, requires cellular heparan sulfate proteoglycans, and is regulated by ligand clustering.	Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fuki, IV (corresponding author), Univ Penn, Med Ctr, Dept Med, 649 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	iliaf@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055323, R01HL055323, R01HL055756] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55323, HL55756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; Boren J, 2001, J BIOL CHEM, V276, P26916, DOI 10.1074/jbc.M011090200; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; Choi SY, 1998, J BIOL CHEM, V273, P20456, DOI 10.1074/jbc.273.32.20456; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Cohen JC, 2003, J CLIN INVEST, V111, P318, DOI 10.1172/JCI200317744; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Dugi KA, 2000, ARTERIOSCL THROM VAS, V20, P793, DOI 10.1161/01.ATV.20.3.793; Duriez P, 1999, CLIN CHIM ACTA, V286, P97, DOI 10.1016/S0009-8981(99)00096-0; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FernandezBorja M, 1996, J LIPID RES, V37, P464; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Fuki IV, 2002, ARTERIOSCL THROM VAS, V22, pA55; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; JANSEN H, 1979, FEBS LETT, V98, P299, DOI 10.1016/0014-5793(79)80204-5; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; JI ZS, 1994, J BIOL CHEM, V269, P13429; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; Krapp A, 1996, J LIPID RES, V37, P926; LAPOSATA EA, 1987, J BIOL CHEM, V262, P5333; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; McCoy MG, 2002, J LIPID RES, V43, P921; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; Murthy V, 1996, PHARMACOL THERAPEUT, V70, P101, DOI 10.1016/0163-7258(96)00005-8; Panzenboeck U, 1997, J LIPID RES, V38, P239; Rader DJ, 2000, CURR OPIN LIPIDOL, V11, P141, DOI 10.1097/00041433-200004000-00006; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Rinninger F, 1998, ATHEROSCLEROSIS, V141, P273, DOI 10.1016/S0021-9150(98)00181-6; Rinninger F, 1998, J LIPID RES, V39, P1335; Rinninger F, 2001, J LIPID RES, V42, P1740; ROBINSON DS, 1987, LIPOPROTEIN LIPASE, P1; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Sanan DA, 1997, J LIPID RES, V38, P1002; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; Schorsch F, 1997, FEBS LETT, V414, P507, DOI 10.1016/S0014-5793(97)01061-2; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; Seo T, 1997, J LIPID RES, V38, P765; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; SUN X, 1992, SEMIN THROMB HEMOST, V18, P243, DOI 10.1055/s-2007-1002430; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Weaver AM, 1997, J LIPID RES, V38, P1841; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Windler E, 1996, HEPATOLOGY, V24, P344; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Zambon A, 2000, J LIPID RES, V41, P2094	67	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34331	34338		10.1074/jbc.M302181200	http://dx.doi.org/10.1074/jbc.M302181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810721	hybrid			2022-12-25	WOS:000185047500089
J	Hamdane, M; Sambo, AV; Delobel, P; Begard, S; Violleau, A; Delacourte, A; Bertrand, P; Benavides, J; Buee, L				Hamdane, M; Sambo, AV; Delobel, P; Begard, S; Violleau, A; Delacourte, A; Bertrand, P; Benavides, J; Buee, L			Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; ACTIVATOR P35; CDK5 ACTIVITY; IN-VITRO; PROTEIN; P25; SITES; PIN1; NEURONS	Among tau phosphorylation sites, some phosphoepitopes referred to as abnormal ones are exclusively found on tau aggregated into filaments in Alzheimer's disease. Recent data suggested that molecular mechanisms similar to those encountered during mitosis may play a role in abnormal tau phosphorylation. In particular, TG-3 phosphoepitope is associated with early stages of neurofibrillary tangles (NFTs). In this study, we reported a suitable cell model consisting of SH-SY5Y cells stably transfected with an inducible p25 expression vector. It allows investigation of tau phosphorylation by p25-Cdk5 kinase complex in a neuronal context and avoiding p25-induced cytotoxicity. Immunoblotting analyses showed that p25-Cdk5 strongly phosphorylates tau protein not only at the AT8 epitope but also at the AT180 epitope and at the Alzheimer's mitotic epitope TG-3. Further biochemical analyses showed that abnormal phosphorylated tau accumulated in cytosol as a microtubule-free form, suggesting its impact on tau biological activity. Since tau abnormal phosphorylation occurred in dividing cells, TG-3 immunoreactivity was also investigated in differentiated neuronal ones, and both TG-3-immunoreactive tau and nucleolin, another early marker for NFT, were also generated. These data suggest that p25-Cdk5 is responsible for the mitotic-like phosphoepitopes present in NFT and argue for a critical role of Cdk5 in neurodegenerative mechanisms.	INSERM, U422, IMPRT, F-59045 Lille, France; Aventis Pharma, CNS Res, F-94400 Vitry Sur Seine, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Sanofi France	Buee, L (corresponding author), INSERM, U422, IMPRT, Pl Verdun, F-59045 Lille, France.	buee@lille.inserm.fr	BUEE, Luc/B-3126-2010	BUEE, Luc/0000-0002-6261-4230; Hamdane, Malika/0000-0001-7971-8696				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bian F, 2002, J COMP NEUROL, V446, P257, DOI 10.1002/cne.10186; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; Busser J, 1998, J NEUROSCI, V18, P2801; DAHAVAN R, 2001, MOL CELL BIOL, V2, P749; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delobel P, 2002, FEBS LETT, V516, P151, DOI 10.1016/S0014-5793(02)02525-5; Delobel P, 2002, J NEUROCHEM, V83, P412, DOI 10.1046/j.1471-4159.2002.01143.x; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Hamdane M, 2002, J MOL NEUROSCI, V19, P275, DOI 10.1385/JMN:19:3:275; Haque N, 1999, BRAIN RES, V838, P69, DOI 10.1016/S0006-8993(99)01622-4; Holzer M, 2002, ACTA NEUROPATHOL, V104, P471, DOI 10.1007/s00401-002-0581-1; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lu PJ, 1999, NATURE, V399, P784; Lund ET, 2001, J NEUROCHEM, V76, P1221, DOI 10.1046/j.1471-4159.2001.00130.x; Mailliot C, 2000, ANN NY ACAD SCI, V920, P107; Nagy Z, 1997, ACTA NEUROPATHOL, V94, P6, DOI 10.1007/s004010050665; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 2001, NATURE, V411, P764, DOI 10.1038/35081149; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Pei JJ, 1998, BRAIN RES, V797, P267, DOI 10.1016/S0006-8993(98)00296-0; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; Ranganathan S, 2001, J ALZHEIMERS DIS, V3, P377, DOI 10.3233/JAD-2001-3403; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sahara N, 2002, J NEUROCHEM, V83, P1498, DOI 10.1046/j.1471-4159.2002.01241.x; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Satoh JI, 2001, PARKINSONISM RELAT D, V8, P7, DOI 10.1016/S1353-8020(00)00075-4; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; Takashima A, 2001, NEUROSCI LETT, V306, P37, DOI 10.1016/S0304-3940(01)01864-X; Van den Haute C, 2001, NEUROBIOL DIS, V8, P32, DOI 10.1006/nbdi.2000.0333; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1998, NEUROBIOL AGING, V19, P287, DOI 10.1016/S0197-4580(98)00071-2; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhu XW, 2000, INT J DEV NEUROSCI, V18, P433, DOI 10.1016/S0736-5748(00)00010-1	52	79	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34026	34034		10.1074/jbc.M302872200	http://dx.doi.org/10.1074/jbc.M302872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826674	hybrid			2022-12-25	WOS:000185047500051
J	Hinton, A; Zuiderweg, ERP; Ackerman, SH				Hinton, A; Zuiderweg, ERP; Ackerman, SH			A purified subfragment of yeast Atp11p retains full molecular chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL F-1-ATPASE; PROTEIN; F1-ATPASE; IDENTIFICATION; SUBUNIT	Atp11p is a molecular chaperone of the mitochondrial matrix that participates in the biogenesis pathway to form F-1, the catalytic unit of the ATP synthase. Affinity tag pull-down assays and yeast two-hybrid screens have shown that Atp11p binds to free beta subunits of F-1 (Wang, Z. G., and Ackerman, S. H. ( 2000) J. Biol. Chem. 275, 5767 - 5772). This binding action prevents the beta subunit from associating with itself in non-productive complexes and fosters the formation of a (alphabeta)(3) hexamer. Following the premise that Atp11p action is mediated primarily through a surface ( as opposed to specific amino acids, as in an enzyme active site), solving its three-dimensional structure so that we may learn how the shape of the protein influences its function is a high priority. Recombinant yeast Atp11p has proven refractory for such analysis because of the presence of a disordered region in the protein. In this article, we show that removal of 67 residues from the amino terminus of recombinant Atp11p yields a subfragment of the protein ( called Atp11p(TRNC)) that retains molecular chaperone function as determined in vitro with both a surrogate substrate ( reduced insulin) and the natural substrate (F-1 beta). Moreover, preliminary N-15-H-1 heteronuclear single quantum coherence spectra obtained with Atp11p(TRNC) indicate that the truncated protein is well ordered and amenable to structure determination by nuclear magnetic resonance.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA	Wayne State University; Wayne State University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ackerman, SH (corresponding author), 421 E Canfield Ave, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM065068, R01GM048157, R01GM052421] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM48157, R01GM65068, R01GM52421] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Kochan G, 2003, ARCH VIROL, V148, P723, DOI 10.1007/s00705-002-0949-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PAUL MF, 1994, J BIOL CHEM, V269, P26158; SANGER F, 1949, BIOCHEM J, V44, P126, DOI 10.1042/bj0440126; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; Zhu K, 2002, BIOCHEMISTRY-US, V41, P9516, DOI 10.1021/bi0203280	17	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34110	34113		10.1074/jbc.M305353200	http://dx.doi.org/10.1074/jbc.M305353200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829692	hybrid			2022-12-25	WOS:000185047500062
J	Kato, M; Khan, S; Gonzalez, N; O'Neill, BP; McDonald, KJ; Cooper, BJ; Angel, NZ; Hart, DNJ				Kato, M; Khan, S; Gonzalez, N; O'Neill, BP; McDonald, KJ; Cooper, BJ; Angel, NZ; Hart, DNJ			Hodgkin's lymphoma cell lines express a fusion protein encoded by intergenically spliced mRNA for the multilectin receptor DEC-205 (CD205) and a novel C-type lectin receptor DCL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REED-STERNBERG CELLS; MACROPHAGE MANNOSE RECEPTOR; SECRETORY PHOSPHOLIPASES A(2); DENDRITIC CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; 180-KDA RECEPTOR; SOLUBLE FORM; DISEASE; ANTIGEN	Classic Hodgkin's lymphoma (HL) tissue contains a small population of morphologically distinct malignant cells called Hodgkin and Reed-Sternberg (HRS) cells, associated with the development of HL. Using 3'-rapid amplification of cDNA ends ( RACE) we identified an alternative mRNA for the DEC-205 multilectin receptor in the HRS cell line L428. Sequence analysis revealed that the mRNA encodes a fusion protein between DEC-205 and a novel C-type lectin DCL-1. Although the 7.5-kb DEC-205 and 4.2-kb DCL-1 mRNA were expressed independently in myeloid and B lymphoid cell lines, the DEC-205/DCL-1 fusion mRNA (9.5 kb) predominated in the HRS cell lines ( L428, KM-H2, and HDLM-2). The DEC-205 and DCL-1 genes comprising 35 and 6 exons, respectively, are juxtaposed on chromosome band 2q24 and separated by only 5.4 kb. We determined the DCL-1 transcription initiation site within the intervening sequence by 5'-RACE, confirming that DCL-1 is an independent gene. Two DEC-205/DCL-1 fusion mRNA variants may result from cotranscription of DEC-205 and DCL-1, followed by splicing DEC-205 exon 35 or 34-35 along with DCL-1 exon 1. The resulting reading frames encode the DEC-205 ectodomain plus the DCL-1 ectodomain, the transmembrane, and the cytoplasmic domain. Using DCL-1 cytoplasmic domain-specific polyclonal and DEC-205 monoclonal antibodies for immunoprecipitation/Western blot analysis, we showed that the fusion mRNA is translated into a DEC-205/DCL-1 fusion protein, expressed in the HRS cell lines. These results imply an unusual transcriptional control mechanism in HRS cells, which cotranscribe an mRNA containing DEC-205 and DCL-1 prior to generating the intergenically spliced mRNA to produce a DEC-205/DCL-1 fusion protein.	Mat Med Res Inst, Brisbane, Qld 4101, Australia	Mater Research	Kato, M (corresponding author), Mat Med Res Inst, Aubigny Pl,Raymond Terrace, Brisbane, Qld 4101, Australia.	mkato@mmri.mater.org.au	Hart, Derek NJ/B-9505-2014					ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Communi D, 2001, J BIOL CHEM, V276, P16561, DOI 10.1074/jbc.M009609200; Dekker JW, 2002, IMMUNOGENETICS, V53, P993, DOI 10.1007/s00251-001-0402-z; DELABIE J, 1993, BLOOD, V82, P2845; DIEHL V, 1985, CANCER SURV, V4, P399; ELLIS PA, 1992, CLIN EXP IMMUNOL, V90, P117; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FALINI B, 1995, BLOOD, V85, P1; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; GRUSS HJ, 1994, BLOOD, V84, P2305; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hock BD, 1999, TISSUE ANTIGENS, V53, P320, DOI 10.1034/j.1399-0039.1999.530402.x; HOCK BD, 1994, IMMUNOLOGY, V83, P573; Hock BD, 2001, INT IMMUNOL, V13, P959, DOI 10.1093/intimm/13.7.959; Howard MJ, 2002, J BIOL CHEM, V277, P32320, DOI 10.1074/jbc.M203631200; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KAMESAKI H, 1986, BLOOD, V68, P285; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kato M, 1998, IMMUNOGENETICS, V47, P442, DOI 10.1007/s002510050381; KATO M, 2002, LEUCOCYTE TYPING, V7, P298; Keilholz U, 1999, LEUKEMIA LYMPHOMA, V35, P641, DOI 10.1080/10428199909169633; KRETSCHMER C, 1990, AM J PATHOL, V137, P341; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magrangeas F, 1998, J BIOL CHEM, V273, P16005, DOI 10.1074/jbc.273.26.16005; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; MCKENZIE JL, 1992, IMMUNOLOGY, V77, P345; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; PAIETTA E, 1990, CANCER RES, V50, P2049; SCHAADT M, 1980, INT J CANCER, V26, P723, DOI 10.1002/ijc.2910260605; Schweizer A, 2000, J BIOL CHEM, V275, P29694, DOI 10.1074/jbc.M000571200; Sheikh H, 2000, J CELL SCI, V113, P1021; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Sorg UR, 1997, PATHOLOGY, V29, P294, DOI 10.1080/00313029700169125; STEINMAN RM, 1980, IMMUNOL REV, V53, P127, DOI 10.1111/j.1600-065X.1980.tb01042.x; STRAUCHEN JA, 1989, PATHOL ANNU, V24, P149; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Uehira K, 2001, INT J HEMATOL, V73, P236, DOI 10.1007/BF02981944; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	47	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34035	34041		10.1074/jbc.M303112200	http://dx.doi.org/10.1074/jbc.M303112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824192	hybrid			2022-12-25	WOS:000185047500052
J	Leu, SJ; Liu, Y; Chen, NY; Chen, CC; Lam, SCT; Lau, LF				Leu, SJ; Liu, Y; Chen, NY; Chen, CC; Lam, SCT; Lau, LF			Identification of a novel integrin alpha(6)beta(1) binding site in the angiogenic inducer CCN1 (CYR61)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; HEPARAN-SULFATE PROTEOGLYCANS; VEIN ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; BREAST-CANCER; MATRICELLULAR PROTEINS; SYNTHETIC PEPTIDES; IN-VITRO	The angiogenic inducer CCN1 (cysteine-rich 61, CYR61), a secreted matricellular protein of the CCN family, is a ligand of multiple integrins, including alpha(6)beta(1). Previous studies have shown that CCN1 interaction with integrin alpha(6)beta(1) mediates adhesion of fibroblasts, endothelial cells, and smooth muscle cells, as well as migration of smooth muscle cells. Recently, we have reported that CCN1-induced tubule formation of unactivated endothelial cells is also mediated through integrin alpha(6)beta(1). In this study, we demonstrate that human skin fibroblasts adhere specifically to the T1 sequence (GQKCIVQTTSWSQCSKS) within domain III of CCN1, and this process is blocked by anti-alpha(6) and anti-beta(1) monoclonal antibodies. Alanine substitution mutagenesis of the T1 sequence further defines the sequence TTSWSQC-SKS as the critical determinant for mediating alpha(6)beta(1)-dependent adhesion. Soluble T1 peptide specifically inhibits fibroblast adhesion to CCN1 in a dose-dependent manner. Furthermore, T1 also inhibits cell adhesion to other alpha(6)beta(1) ligands, including CCN2 ( CTGF), CCN3 (NOV), and laminin, but not to ligands of other integrins. In addition, T1 specifically inhibits alpha(6)beta(1)-dependent tubule formation of unactivated endothelial cells in a CCN1-containing collagen gel matrix. To confirm that T1 binds integrin alpha(6)beta(1) directly, we perform affinity chromatography and show that integrin alpha(6)beta(1) is isolated from an octylglucoside extract of fibroblasts on T1- coupled Affi-gel. Taken together, these findings define the T1 sequence in CCN1 as a novel binding motif for integrin alpha(6)beta(1), providing the basis for the development of peptide mimetics to examine the functional role of alpha(6)beta(1) in angiogenesis.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R29HL041793] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046565, R01 CA046565-15, CA80080, CA46565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DeRoock IB, 2001, CANCER RES, V61, P3308; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Miao WM, 2001, BLOOD, V97, P1689, DOI 10.1182/blood.V97.6.1689; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Pennington ME, 1996, MOL DIVERS, V2, P19, DOI 10.1007/BF01718696; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; Wu KJ, 2000, INT J MOL MED, V6, P433; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	48	115	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33801	33808		10.1074/jbc.M305862200	http://dx.doi.org/10.1074/jbc.M305862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826661	hybrid			2022-12-25	WOS:000185047500025
J	Malewicz, M; Zeller, N; Yilmaz, ZB; Weih, F				Malewicz, M; Zeller, N; Yilmaz, ZB; Weih, F			NF kappa B controls the balance between fas and tumor necrosis factor cell death pathways during T cell receptor-induced apoptosis via the expression of its target gene A20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; ALPHA-INDUCED APOPTOSIS; TNF-ALPHA; TRANSCRIPTION FACTORS; IMMUNE-RESPONSE; IN-VIVO; ACTIVATION; LIGAND; RIP; UBIQUITINATION	Activation-induced cell death ( AICD), a term originally coined for the anti-CD3-induced apoptosis of T cell hybridomas and thymocytes, is predominantly driven by death receptors and has been involved in the control of autoreactive T cells in the periphery. In the Do-11.10 T cell hybridoma model of AICD, activation of the T cell receptor (TCR) results in Fas-dependent apoptosis. Here, we show that inhibition of the transcription factor nuclear factor kappaB (NFkappaB) in Do-11.10 cells resulted in increased sensitivity to TCR-mediated apoptosis, correlating with defective induction of the anti-apoptotic NFkappaB target gene A20. Stable expression of the zinc finger protein A20 in NFkappaB-negative Do-11.10 cells rescued the phenotype. TCR activation in NFkappaB-deficient Do-11.10 cells resulted predominantly in tumor necrosis factor (TNF) receptor 2 (TNFR2)-dependent bystander cell death rather than classical Fas-dependent AICD. Strikingly, A20 blocked TNF-mediated apoptosis and simultaneously restored TCR-induced Fas-dependent AICD. In addition, NFkappaB downstream of TNFR was required for up-regulation of Fas expression by endogenous TNF secreted in response to TCR stimulation. Together, these results suggest that NFkappaB can play both pro- and anti-apoptotic roles during AICD. We propose that NFkappaB controls the balance between Fas and TNF cell death pathways during AICD via the expression of the zinc finger protein A20.	Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Weih, F (corresponding author), Forschungszentrum Karlsruhe, Inst Toxicol & Genet, POB 3640, D-76021 Karlsruhe, Germany.							Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Combadiere B, 1998, IMMUNITY, V9, P305, DOI 10.1016/S1074-7613(00)80613-5; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Elzey BD, 2001, J IMMUNOL, V167, P3049, DOI 10.4049/jimmunol.167.6.3049; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Korner H, 1997, EUR J IMMUNOL, V27, P2600, DOI 10.1002/eji.1830271020; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Teh HS, 2000, J IMMUNOL, V165, P4814, DOI 10.4049/jimmunol.165.9.4814; TEWARI M, 1995, J IMMUNOL, V154, P1699; Vallabhapurapu S, 2001, EUR J IMMUNOL, V31, P2612, DOI 10.1002/1521-4141(200109)31:9<2612::AID-IMMU2612>3.0.CO;2-C; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wang RX, 2001, J IMMUNOL, V166, P1983, DOI 10.4049/jimmunol.166.3.1983; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; WEIH F, 1994, ONCOGENE, V9, P3289; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	50	33	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32825	32833		10.1074/jbc.M304000200	http://dx.doi.org/10.1074/jbc.M304000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813034	hybrid			2022-12-25	WOS:000184901800043
J	Ross, MD; Bruggeman, LA; Hanss, B; Sunamoto, M; Marras, D; Klotman, ME; Klotman, PE				Ross, MD; Bruggeman, LA; Hanss, B; Sunamoto, M; Marras, D; Klotman, ME; Klotman, PE			Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; COLLAGEN FIBRILLOGENESIS; SMALL PROTEOGLYCANS; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; TRANSGENIC MICE; DECORIN; BIGLYCAN; LUMICAN	Growing evidence suggests that human immunodeficiency virus (HIV)-1 infection of podocytes plays a central role in the glomerular disease of HIV-associated nephropathy (HIVAN). As an approach to identify host genes involved in the pathogenesis of the sclerotic glomerular lesion in HIVAN, representational difference analysis of cDNA was used to identify differentially expressed genes in HIV-1 transgenic and nontransgenic podocytes. We isolated a novel member of the small leucine-rich repeat (SLR) protein family, podocan, that is expressed at high levels in the HIV-1 transgenic podocytes. In normal embryonic kidney, a 3.2-kb podocan transcript was detected at low levels, and expression increased dramatically within 24 h following birth. Expression of a 2.3-kb transcript became evident after birth and gradually increased to 50% of the total podocan RNA in the mature kidney. Phylogenetically, podocan represents a new class in the SLR protein gene family, an expanding protein family sharing homology with the small leucine-rich repeat proteoglycans. The 3.2-kb transcript encodes a predicted 611-amino acid secretory protein with 20 leucine-rich repeats, a unique N-terminal cysteine-rich cluster pattern and a highly acidic C-terminal domain. In situ hybridization of normal kidney revealed podocan mRNA expression in podocytes and likely vascular endothelial cells within the glomerulus. The immunohistochemical staining pattern of podocan protein in normal kidney glomeruli was consistent with that of the glomerular basement membrane, and staining was markedly increased in sclerotic glomerular lesions in the transgenic HIVAN model. Thus, podocan defines a new class within the SLR protein family and is a previously unrecognized component of the sclerotic glomerular lesion that develops in the course of experimental HIVAN.	Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA; Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Ist Sci Studio & Cura Tumori, Immunol Lab, I-16132 Genoa, Italy	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Case Western Reserve University; MetroHealth System	Ross, MD (corresponding author), Mt Sinai Sch Med, Dept Med, Div Nephrol, Annenberg Bldg,Rm 23-40,Box 1243,1 Gustave L Levy, New York, NY 10029 USA.		klotman, mary e/A-1921-2016		NCI NIH HHS [1 R24 CA095823-01] Funding Source: Medline; NIDDK NIH HHS [1 PO1 DK56492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Bodi I, 1997, KIDNEY INT, V51, P1568, DOI 10.1038/ki.1997.215; BORDER WA, 1990, CELL DIFFER DEV, V32, P425, DOI 10.1016/0922-3371(90)90059-6; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; CANTOR ES, 1991, ARCH INTERN MED, V151, P125, DOI 10.1001/archinte.151.1.125; COHEN AH, 1988, MODERN PATHOL, V1, P87; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; D'Agati V, 1998, SEMIN NEPHROL, V18, P406; DAGATI V, 1989, KIDNEY INT, V35, P1358, DOI 10.1038/ki.1989.135; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; DICKIE P, 1991, VIROLOGY, V185, P109, DOI 10.1016/0042-6822(91)90759-5; Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605; Grover J, 2001, MATRIX BIOL, V20, P555, DOI 10.1016/S0945-053X(01)00165-2; HALE JE, 1995, ANAL BIOCHEM, V231, P46, DOI 10.1006/abio.1995.1501; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Schaefer L, 2000, KIDNEY INT, V58, P1557, DOI 10.1046/j.1523-1755.2000.00317.x; Schaefer L, 2001, FASEB J, V15, P559; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; Shankland SJ, 2000, KIDNEY INT, V58, P674, DOI 10.1046/j.1523-1755.2000.00213.x; SHUKLA RR, 1993, KIDNEY INT, V44, P1022, DOI 10.1038/ki.1993.344; SONI A, 1989, CLIN NEPHROL, V31, P12; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Williams DI, 1998, SEX TRANSM INFECT, V74, P179, DOI 10.1136/sti.74.3.179; Winston JA, 1996, J AM SOC NEPHROL, V7, P1; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamamoto T, 1999, KIDNEY INT, V55, P579, DOI 10.1046/j.1523-1755.1999.00296.x	51	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33248	33255		10.1074/jbc.M301299200	http://dx.doi.org/10.1074/jbc.M301299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796502	hybrid			2022-12-25	WOS:000184901800093
J	Smith, MF; Mitchell, A; Li, GL; Ding, S; Fitzmaurice, AM; Ryan, K; Crowe, S; Goldberg, JB				Smith, MF; Mitchell, A; Li, GL; Ding, S; Fitzmaurice, AM; Ryan, K; Crowe, S; Goldberg, JB			Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-CANCER CELLS; GENE-EXPRESSION; CUTTING EDGE; MACROPHAGES; RECOGNITION; INFECTION; LIPOPOLYSACCHARIDE; ENDOTOXIN; FLAGELLIN; RESPONSES	Infection with Helicobacter pylori, a Gram-negative, microaerophilic, flagellated bacteria that adheres to human gastric mucosa, is strongly associated with gastric ulcers and adenocarcinoma. The mechanisms through which gastric epithelial cells recognize this organism are unclear. In this study we evaluated the interactions between the Toll-like receptors (TLRs) and H. pylori-mediated NF-kappaB activation and the induction of chemokine mRNA expression. By reverse transcriptase-PCR we determined that MKN45 gastric epithelial cells express low but detectable amounts of TLR2, -4, and -5 but no MD-2. To determine which, if any, TLRs may play a role in the response of epithelial cells to H. pylori, HEK293 cells were cotransfected with the NF-kappaB-Luc reporter, CD14 and MD2 expression plasmids, and expression plasmids for TLR2, TLR4, or TLR5. Infection of the cultures with H. pylori (strain 26695) induced NF-kappaB activity in cells transfected with TLR2 and TLR5, but not TLR4. Consistent with the HEK293 experiments, H. pylori-induced NF-kappaB activation was decreased in MKN45 gastric epithelial cells by transfection of dominant-negative versions of TLR2 and TLR5 but not TLR4. Highly purified lipopolysaccharide from H. pylori strain 26695 activated NF-kappaB in HEK293 via TLR2 but not TLR4. Partially purified flagellin from H. pylori was also capable of inducing NF-kappaB activation in HEK cells transfected with TLR5. Additionally, chemokine gene expression was induced by H. pylori in HEK293 cells following stable transfection with TLR2 or TLR5 expression plasmids. These studies demonstrate that gastric epithelial cells recognize and respond to H. pylori infection at least in part via TLR2 and TLR5. Furthermore, the unique lipopolysaccharide of H. pylori is a TLR2, not a TLR4 agonist.	Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Smith, MF (corresponding author), Univ Virginia Hlth Syst, Dept Med, POB 800708, Charlottesville, VA 22908 USA.				NIAID NIH HHS [R01-AI41548, R01-AI34358] Funding Source: Medline; NIDDK NIH HHS [T32 DK07769] Funding Source: Medline; NIGMS NIH HHS [T32 GM08136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041548, R01AI034358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; Backhed F, 2003, J INFECT DIS, V187, P829; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; CROWE SE, 1995, GASTROENTEROLOGY, V108, P65, DOI 10.1016/0016-5085(95)90009-8; Cunningham MD, 1996, INFECT IMMUN, V64, P3601, DOI 10.1128/IAI.64.9.3601-3608.1996; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Eaton KA, 1996, INFECT IMMUN, V64, P2445, DOI 10.1128/IAI.64.7.2445-2448.1996; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawahara Tsukasa, 2001, Journal of Medical Investigation, V48, P190; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; OhtaTada U, 1997, SCAND J GASTROENTERO, V32, P455, DOI 10.3109/00365529709025080; Ottemann KM, 2002, INFECT IMMUN, V70, P1984, DOI 10.1128/IAI.70.4.1984-1990.2002; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; Sakagami T, 1997, INFECT IMMUN, V65, P3310, DOI 10.1128/IAI.65.8.3310-3316.1997; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Vasselon T, 2002, INFECT IMMUN, V70, P1033, DOI 10.1128/IAI.70.3.1033-1041.2002	34	351	368	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32552	32560		10.1074/jbc.M305536200	http://dx.doi.org/10.1074/jbc.M305536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807870	hybrid			2022-12-25	WOS:000184901800011
J	Chami, M; Ferrari, D; Nicotera, P; Paterlini-Brechot, P; Rizzuto, R				Chami, M; Ferrari, D; Nicotera, P; Paterlini-Brechot, P; Rizzuto, R			Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; PLASMA-MEMBRANE; NUCLEAR FACTOR; CELL-DEATH; CALCIUM; GENE; MITOCHONDRIA	The hepatitis B virus X protein (HBx) is a multifunctional protein, acting on different targets ( e. g. transcription factors, cytoplasmic kinases, and mitochondrial proteins) and exerting cellular effects as diverse as stimulation of cell proliferation and apoptosis. In its biological effects, the modulation of cellular Ca2+ signals has been proposed to be involved, but the direct assessment of Ca2+ homeostasis in HBx-transfected cells has not been carried out yet. In this work, we have employed for this purpose aequorin-based recombinant probes specifically targeted to intracellular organelles and microdomains. Using these probes, we observed that overexpression of HBx enhanced agonist-evoked cytosolic Ca2+ signals in HepG2 and HeLa cells, without affecting either the steady state of endoplasmic reticulum Ca2+ concentration or the kinetics of Ca2+ release. Rather, caspase-3-dependent cleavage of the plasma membrane Ca2+ ATPase could be demonstrated, and larger rises were detected in the cytoplasmic rim beneath the plasma membrane. In mitochondria, major morphological ( fragmentation and swelling) and functional ( reduced Ca2+ uptake) alterations were detected in HBx-expressing cells. As to the cellular consequences, we observed that HBx-induced apoptosis was markedly reduced when the alterations in Ca2+ signaling (e.g. by loading a Ca2+ chelator or preventing PMCA cleavage) or the downstream effects ( e. g. by inhibiting mitochondrial permeability transition) were prevented. Overall, these results indicate that HBx perturbs intracellular Ca2+ homeostasis, acting on the extrusion mechanisms, and that this effect plays an important role in the control of HBx-related apoptosis.	Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Necker Fac Inst Med, INSERM Pasteur, U370, F-75015 Paris, France	University of Leicester; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rizzuto, R (corresponding author), Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.		Ferrari, Davide/F-5644-2015; Rizzuto, Rosario/B-6312-2008; Chami, Mounia/S-6471-2019	Ferrari, Davide/0000-0002-5727-9204; Chami, Mounia/0000-0003-1498-7187; Rizzuto, Rosario/0000-0001-7044-5097; Paterlini- Brechot, Patrizia/0000-0001-7981-6325	Telethon [GTF01011] Funding Source: Medline	Telethon(Fondazione Telethon)		Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Carretero M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Guidotti LG, 2002, J VIROL, V76, P2617, DOI 10.1128/JVI.76.6.2617-2621.2002; Gutierrez AA, 1999, J PHYSIOL-LONDON, V517, P95, DOI 10.1111/j.1469-7793.1999.0095z.x; Hajnoczky G, 2001, IUBMB LIFE, V52, P237, DOI 10.1080/15216540152846055; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Mymryk JS, 1996, ONCOGENE, V13, P1581; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; RIZZUTO R, 1987, EUR J BIOCHEM, V162, P239, DOI 10.1111/j.1432-1033.1987.tb10591.x; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; WANG XW, 1995, CANCER RES, V55, P6012; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X	49	93	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31745	31755		10.1074/jbc.M304202200	http://dx.doi.org/10.1074/jbc.M304202200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799372	hybrid			2022-12-25	WOS:000184782100036
J	Mol, CD; Lim, KB; Sridhar, V; Zou, H; Chien, EYT; Sang, BC; Nowakowski, J; Kassel, DB; Cronin, CN; McRee, DE				Mol, CD; Lim, KB; Sridhar, V; Zou, H; Chien, EYT; Sang, BC; Nowakowski, J; Kassel, DB; Cronin, CN; McRee, DE			Structure of a c-Kit product complex reveals the basis for kinase transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; GROWTH-FACTOR RECEPTOR-3; TYROSINE KINASE; THANATOPHORIC DYSPLASIA; SIGNAL-TRANSDUCTION; CDNA CLONING; MUTATIONS; GENE; LIGAND; DIMERIZATION	The c-Kit proto-oncogene is a receptor protein-tyrosine kinase associated with several highly malignant human cancers. Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth. Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors. We report on the phosphorylation state and crystal structure of a c-Kit product complex. The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops. These results provide key insights into the molecular basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.	Syrrx Inc, San Diego, CA 92121 USA		McRee, DE (corresponding author), Syrrx Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.							Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kitamura Y, 2001, MUTAT RES-FUND MOL M, V477, P165, DOI 10.1016/S0027-5107(01)00117-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	30	194	220	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31461	31464		10.1074/jbc.C300186200	http://dx.doi.org/10.1074/jbc.C300186200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12824176	hybrid			2022-12-25	WOS:000184782100002
J	Stearns, ME; Hu, YJ; Wang, M				Stearns, ME; Hu, YJ; Wang, M			IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines	ONCOGENE			English	Article						IL-10; IL-10R; IL-10E1; primary prostate tumor lines; tyrosine phosphorylation; green fluorescent protein tagged IL-10E1; TIMP-1	EPIDERMAL-GROWTH-FACTOR; CYTOKINE RECEPTORS; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; EPITHELIAL-CELLS; INTERLEUKIN-10; ACTIVATION; STAT; BINDING; EXPRESSION	Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22 kDa protein, termed interleukin 10 enhancer I (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL10-E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr(446) and Tyr(496)) located in the cytoplasmic domain of the IL-10R alpha chain were required for receptor function, and for phosphorylation and activation of IL-10E1. Immunoprecipitation studies revealed that 12 amino-acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitate IL-10E1 and blocked figand-dependent IL-10E1 phosphorylation in a cell-free system. In contrast, peptides containing serine substitutions for Tyr(446) and Tyr(496), and tyrosine-phosphorylated peptides containing TNT 2-10 or Tyr(252/259) did not prevent IL-10E1 activation or signaling. To confirm these observations in vivo, fusion protein constructs were made between a modified form of green fluorescent protein or GFP and the intact IL-10E1 protein (IL-10E1-MmGFP) and n-terminal peptides of the IL-10E1 protein (i.e. nt-nls-MmGFP and mutant sequences identified as nt-nls mC61-MmGFP and nt-nis mY57/mY62-MmGFP peptides). Confocal microscopy revealed that IL-10 triggered transport to the nucleus of IL-10E1-MmGFP, nt-nls-MmGFP, and nt-nls mC61-MmGFP by 10-30 min in HPCA-10a (human prostrate cancer cells; derived from Gleason sum 10 tumor tissue) cells. IL-10 failed to induce nuclear translocation of the mY57/mY62-MmGFP peptides with point mutations of the two tyrosine groups. Coinjection of nt-nls-MmGFP with the IL-10R Tyr(446) and Tyr(496) amino-acid residues completely blocked ligand signaling. Coinjection of peptides containing either serine substitutions for Tyr(446) and Tyr(496) or Tyr(230) and Tyr(252/259) failed to block nt-nls-MmGFP signaling. The data demonstrate that IL-10E1 is directly recruited to the ligand-activated IL-10R by binding to specific phosphotyrosine groups which control tyrosine phosphorylation of the LIM domain of the IL-10E1 protein (i.e. Y57/Y62 groups) and IL-10E1 activation.	Drew Univ, Coll Med, Dept Pathol & Lab, Philadelphia, PA 19102 USA		Stearns, ME (corresponding author), Drew Univ, Coll Med, Dept Pathol & Lab, MS 435,15th & Vine Sts, Philadelphia, PA 19102 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bright RK, 1997, CANCER RES, V57, P995; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P744; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LACRAZ S, 1993, CLIN INVESTIGATOR, V90, P382; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; PEEHL DM, 1994, CELL TISSUE RES, V277, P11, DOI 10.1007/BF00303075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 1989, MOL CLONING, pA1; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEARNS M, 1995, ONCOL RES, V7, P173; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang M, 1996, ONCOL RES, V8, P303; Wang M, 2002, CANCER BIOL THER, V1, P556, DOI 10.4161/cbt.1.5.222; Wang M, 1998, ONCOL RES, V10, P219; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3781	3791		10.1038/sj.onc.1206579	http://dx.doi.org/10.1038/sj.onc.1206579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802285				2022-12-25	WOS:000183551000012
J	Murakami, S; Salmon, A; Miller, RA				Murakami, S; Salmon, A; Miller, RA			Multiplex stress resistance in cells from long-lived dwarf mice	FASEB JOURNAL			English	Article						aging; cellular stress resistance; fibroblasts; dwarf mouse	CAENORHABDITIS-ELEGANS; LIFE-SPAN; OXIDATIVE STRESS; EXTENSION; LONGEVITY; DAF-2	Mutations that extend nematode longevity by interference with IGF-I/insulin sensing pathways also lead to resistance to multiple forms of stress. Here, we report that skin-derived fibroblasts from Shell dwarf mice, already known to show increased longevity and delayed aspects of aging, are resistant to multiple forms of cellular stress, including UV light, heat, paraquat, H(2)O(2), and the toxic metal cadmium. The findings suggest that increases in cellular resistance to stress may mediate extended longevity in mammals.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; Univ Michigan, Sch Med, Geriatr Ctr, Ann Arbor, MI USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI USA; Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Miller, RA (corresponding author), 5410 CCGCB,Box 0940,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	millerr@umich.edu	Murakami, Shin/AAQ-3454-2021	Murakami, Shin/0000-0001-8806-0611				Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Brown-Borg HM, 1999, ENDOCRINE, V11, P41, DOI 10.1385/ENDO:11:1:41; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Johnson TE, 1996, J GERONTOL A-BIOL, V51, pB392, DOI 10.1093/gerona/51A.6.B392; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MILLER RA, 2001, HDB BIOL AGING, P369; Murakami S, 1996, GENETICS, V143, P1207; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605	12	166	168	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1565	+		10.1096/fj.02-1092fje	http://dx.doi.org/10.1096/fj.02-1092fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824282	Green Submitted			2022-12-25	WOS:000183818000029
J	Akhtar, M; Watson, JL; Nazli, A; McKay, DM				Akhtar, M; Watson, JL; Nazli, A; McKay, DM			Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF kappa B-independent pathway	FASEB JOURNAL			English	Article						TLR-9; AP-1; signal; permeability; COX-2	ACTIVATED PROTEIN-KINASES; TOLL-LIKE RECEPTOR-9; CPG-DNA; CYCLOOXYGENASE-2 EXPRESSION; CUTTING EDGE; IMMUNE CELLS; MOTIFS; AP-1; INTERLEUKIN-12; INFLAMMATION	Recognition of bacterial products by the innate immune system is dependent on pattern-recognition receptors: toll-like receptor 9 (TLR-9) in the case of bacterial DNA. We hypothesized that bacterial DNA can directly affect enteric epithelial cells. RT-PCR revealed constitutive TLR-9 mRNA expression in three human colonic epithelial cell lines (T84, HT-29, Caco-2) and THP-1 monocytes. Epithelial cells, in six-well culture plates or on filter supports, were exposed to E. coli DNA (1-50 mug/ml), synthetic CpG-rich oligonucleotides, or calf thymus DNA for 6-48 h. Exposure to E. coli DNA resulted in an increase in IL-8 mRNA, and a time- and dose-dependent increase in IL-8 secretion. Also, CpG oligonucleotides induced epithelial IL-8 production, whereas calf thymus DNA did not. Exposure to E. coli DNA resulted in phosphorylation of ERK 1/2 MAPK and inhibitors of ERK activity (PD98059, UO126) significantly reduced the evoked IL-8 production. In contrast, inhibitors of NFkappaB activity (PDTC, SN50) did not block E. coli DNA-induced IL-8 production. Electrophoretic mobility shift assays revealed that E. coli DNA stimulated epithelial AP-1 but not NFkappaB activation. The barrier (i.e., transepithelial resistance) and ion transport parameters of epithelial monolayers (assessed in Ussing chambers) were unaltered following E. coli DNA exposure. Thus model gut epithelia express TLR-9 mRNA and, while maintaining their barrier function, can respond to E. coli DNA by increased IL-8 production.	McMaster Univ, Intestinal Dis Res Programme, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	McKay, DM (corresponding author), McMaster Univ, Intestinal Dis Res Programme, Dept Pathol & Mol Med, HSC-3N5C,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	mckayd@mcmaster.ca	McKay, Derek/HCH-3240-2022	Nazli, Aisha/0000-0001-7410-9963				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akhtar M, 2001, CANCER RES, V61, P2399; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Ballas ZK, 1996, J IMMUNOL, V157, P1840; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Bauer M, 2001, J IMMUNOL, V166, P5000, DOI 10.4049/jimmunol.166.8.5000; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; Deng GM, 1999, NAT MED, V5, P702, DOI 10.1038/9554; Deng GM, 2001, J IMMUNOL, V167, P4616, DOI 10.4049/jimmunol.167.8.4616; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Grandjean-Laquerriere A, 2002, CYTOKINE, V18, P168, DOI 10.1006/cyto.2002.0888; Hacker H, 1999, EMBO J, V18, P6973, DOI 10.1093/emboj/18.24.6973; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; Hayashi R, 2000, EUR RESPIR J, V16, P452, DOI 10.1034/j.1399-3003.2000.016003452.x; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; JORDANA M, 1992, ANN NY ACAD SCI, V664, P180, DOI 10.1111/j.1749-6632.1992.tb39759.x; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Maaser C, 2002, Z GASTROENTEROL, V40, P525, DOI 10.1055/s-2002-32808; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; McKay DM, 1996, AM J PHYSIOL-CELL PH, V270, pC418, DOI 10.1152/ajpcell.1996.270.2.C418; McKay DM, 2001, TRENDS IMMUNOL, V22, P497, DOI 10.1016/S1471-4906(01)02000-2; McKay DM, 1997, J IMMUNOL, V159, P2382; McKay DM, 1999, CAN J GASTROENTEROL, V13, P509, DOI 10.1155/1999/680206; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Miyata M, 2001, ANN RHEUM DIS, V60, P685, DOI 10.1136/ard.60.7.685; PERDUE MH, 1994, AM J PHYSIOL, V267, pG151, DOI 10.1152/ajpgi.1994.267.2.G151; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Utaisincharoen P, 2002, CLIN EXP IMMUNOL, V128, P467, DOI 10.1046/j.1365-2249.2002.01866.x; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wallace JL, 2001, GASTROENTEROL CLIN N, V30, P971, DOI 10.1016/S0889-8553(05)70223-5; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	51	141	144	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1319	+		10.1096/fj.02-0950fje	http://dx.doi.org/10.1096/fj.02-0950fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12832293				2022-12-25	WOS:000183165000037
J	Gonzalez, JM; Jimenez, M; Velez, M; Mingorance, J; Andreu, JM; Vicente, M; Rivas, G				Gonzalez, JM; Jimenez, M; Velez, M; Mingorance, J; Andreu, JM; Vicente, M; Rivas, G			Essential cell division protein FtsZ assembles into one monomer-thick ribbons under conditions resembling the crowded intracellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR SELF-ASSOCIATION; ESCHERICHIA-COLI; RING FORMATION; TUBULIN; GTP; VOLUME; POLYMERIZATION; DYNAMICS; FORCE; ASSAY	Experimental conditions that simulate the crowded bacterial cytoplasmic environment have been used to study the assembly of the essential cell division protein FtsZ from Escherichia coli. In solutions containing a suitable concentration of physiological osmolytes, macromolecular crowding promotes the GTP-dependent assembly of FtsZ into dynamic two-dimensional polymers that disassemble upon GTP depletion. Atomic force microscopy reveals that these FtsZ polymers adopt the shape of ribbons that are one subunit thick. When compared with the FtsZ filaments observed in vitro in the absence of crowding, the ribbons show a lag in the GTPase activity and a decrease in the GTPase rate and in the rate of GTP exchange within the polymer. We propose that, in the crowded bacterial cytoplasm under assembly-promoting conditions, the FtsZ filaments tend to align forming dynamic ribbon polymers. In vivo these ribbons would fit into the Z-ring even in the absence of other interactions. Therefore, the presence of mechanisms to prevent the spontaneous assembly of the Z-ring in non-dividing cells must be invoked.	Univ Autonoma Madrid, Ctr Invest Biol, CSIC, E-28040 Madrid, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, CSIC, E-28040 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, Inst Nicolas Cabrera, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid	Rivas, G (corresponding author), Univ Autonoma Madrid, Ctr Invest Biol, CSIC, Ramiro Maeztu 9, E-28040 Madrid, Spain.	grivas@cib.csic.es	Rivas, German/AAG-7458-2022; Rivas, German/AFL-7528-2022; Velez, Marisela/F-2900-2013; Mingorance, Jesus/B-7562-2009; Jimenez Sarmiento, Mercedes/K-2691-2014	Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Velez, Marisela/0000-0002-9424-510X; Mingorance, Jesus/0000-0001-6173-5711; Jimenez Sarmiento, Mercedes/0000-0003-2006-1903; Andreu, Jose M/0000-0001-8064-6933				Addinall SG, 2002, J MOL BIOL, V318, P219, DOI 10.1016/S0022-2836(02)00024-4; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Caplan MR, 2003, J BIOL CHEM, V278, P13784, DOI 10.1074/jbc.M300860200; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Hall D, 2002, BIOPHYS CHEM, V98, P93, DOI 10.1016/S0301-4622(02)00087-X; Hall D, 2002, BIOPHYS CHEM, V98, P233, DOI 10.1016/S0301-4622(02)00072-8; Herzfeld J, 1996, ACCOUNTS CHEM RES, V29, P31, DOI 10.1021/ar9500224; HERZOG W, 1978, EUR J BIOCHEM, V91, P249, DOI 10.1111/j.1432-1033.1978.tb20959.x; HOENIG M, 1989, J BIOCHEM BIOPH METH, V19, P249, DOI 10.1016/0165-022X(89)90031-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Lindner RA, 1997, BIOPHYS CHEM, V66, P57, DOI 10.1016/S0301-4622(97)00011-2; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 1998, METHOD ENZYMOL, V298, P305, DOI 10.1016/S0076-6879(98)98027-2; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Margolin W, 2003, CURR BIOL, V13, pR16, DOI 10.1016/S0960-9822(02)01381-7; Margolin W, 2001, CURR OPIN MICROBIOL, V4, P647, DOI 10.1016/S1369-5274(01)00264-8; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Moreno-Herrero F, 2002, APPL PHYS LETT, V81, P2620, DOI 10.1063/1.1509856; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; NEURARD J, 1987, ESCHERICHIA COLI SAL, P445; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; POLLARD TD, 1999, GUIDEBOOK CYTOSKELET; PURICH DL, 1982, METHOD ENZYMOL, V85, P416; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Rueda S, 2003, J BACTERIOL, V185, P3344, DOI 10.1128/JB.185.11.3344-3351.2003; Scheffers DJ, 2001, FEBS LETT, V506, P6, DOI 10.1016/S0014-5793(01)02855-1; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; SUZUKI A, 1989, BIOCHEMISTRY-US, V28, P6513, DOI 10.1021/bi00441a052; Vitha S, 2001, J CELL BIOL, V153, P111, DOI 10.1083/jcb.153.1.111; Wenner JR, 1999, BIOPHYS J, V77, P3234, DOI 10.1016/S0006-3495(99)77154-7; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; [No title captured]	53	147	149	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37664	37671		10.1074/jbc.M305230200	http://dx.doi.org/10.1074/jbc.M305230200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12807907	Green Published, hybrid			2022-12-25	WOS:000185437200082
J	Han, JS; Kang, S; Lee, H; Kim, HK; Hwang, DS				Han, JS; Kang, S; Lee, H; Kim, HK; Hwang, DS			Sequential binding of SeqA to paired hemi-methylated GATC sequences mediates formation of higher order complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; DNA-REPLICATION INITIATION; PROTEIN BINDS; DAM METHYLTRANSFERASE; IN-VITRO; ORIGIN; SEQUESTRATION; SEGREGATION; PROMOTER; MODULATION	Preferential binding of the SeqA protein to hemi-methylated GATC sequences functions as a negative regulator for Escherichia coli initiation of chromosomal replication at oriC and is implicated in segregating replicated chromosomes for cell division. We demonstrate that sequential binding of one SeqA tetramer to a set of two hemi-methylated sites mediates formation of higher-order complexes. The absence of cross-binding to separate DNAs suggests that two monomers of a SeqA tetramer bind to two hemi-methylated sites on DNA. The interaction among SeqA proteins bound to at least six adjacent hemi-methylated sites induces aggregation of free proteins to bound proteins. Aggregation might be indicative of SeqA foci, which appear to track replication forks in vivo. Studies of the properties of SeqA binding will contribute to our understanding of the function of SeqA.	Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea	Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea.			Kang, Sukhyun/0000-0002-7567-0231				Bach T, 2003, EMBO J, V22, P315, DOI 10.1093/emboj/cdg020; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; Bahloul A, 1996, MOL MICROBIOL, V22, P275, DOI 10.1046/j.1365-2958.1996.00106.x; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Fossum S, 2003, MOL MICROBIOL, V47, P619, DOI 10.1046/j.1365-2958.2003.t01-1-03329.x; Fujikawa N, 2003, BIOCHEM BIOPH RES CO, V300, P699, DOI 10.1016/S0006-291X(02)02891-7; GEIER GE, 1979, J BIOL CHEM, V254, P1408; Guarne A, 2002, NAT STRUCT BIOL, V9, P839, DOI 10.1038/nsb857; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hiraga S, 2000, GENES CELLS, V5, P327, DOI 10.1046/j.1365-2443.2000.00334.x; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Lee H, 2001, J BIOL CHEM, V276, P34600, DOI 10.1074/jbc.M101339200; Lee YS, 1997, J BIOL CHEM, V272, P83; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; Papavassiliou AG., 1994, DNA-protein interactions, P43, DOI 10.1385/0-89603-256-6:43; Sambrook J., 2002, MOL CLONING LAB MANU; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Skarstad K, 2000, MOL MICROBIOL, V36, P1319, DOI 10.1046/j.1365-2958.2000.01943.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Taghbalout A, 2000, GENES CELLS, V5, P873, DOI 10.1046/j.1365-2443.2000.00380.x; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; Wold S, 1998, EMBO J, V17, P4158, DOI 10.1093/emboj/17.14.4158	32	24	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34983	34989		10.1074/jbc.M304923200	http://dx.doi.org/10.1074/jbc.M304923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824161	hybrid			2022-12-25	WOS:000185164400031
J	Xu, HQ; Deprez, E; Zhang, AH; Tauc, P; Ladjimi, MM; Brochon, JC; Auclair, C; Xi, XG				Xu, HQ; Deprez, E; Zhang, AH; Tauc, P; Ladjimi, MM; Brochon, JC; Auclair, C; Xi, XG			The Escherichia coli RecQ helicase functions as a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; HEPATITIS-C VIRUS; MAXIMUM-ENTROPY METHOD; UNWINDING ACTIVITY; CRYSTAL-STRUCTURES; SYNDROME GENE; PROTEIN; BINDING; MECHANISM; BLOOMS	The RecQ helicases belong to an important family of highly conserved DNA helicases that play a key role in chromosomal maintenance, and their defects have been shown to lead to several disorders and cancer in humans. In this work, the conformational and functional properties of the Escherichia coli RecQ helicase have been determined using a wide array of biochemical and biophysical techniques. The results obtained clearly indicate that E. coli RecQ helicase is monomeric in solution up to a concentration of 20 muM and in a temperature range between 4 and 37 degreesC. Furthermore, these properties are not affected by the presence of ATP, which is strictly required for the unwinding and translocating activity of the protein, or by its nonhydrolyzable analogue 5'-adenylyl-beta,gamma-imidodiphosphate. Consistent with the structural properties, functional analysis shows that both DNA unwinding activity and single-stranded DNA-stimulated ATPase specific activity were independent of RecQ concentration. The monomeric state was further confirmed by the ATPase-deficient mutants of RecQ protein. The rate of unwinding was unchanged when the wild type RecQ helicase was mixed with the ATPase-deficient mutants, indicating that non-protein-protein interactions were involved in the unwinding processes. Taken together, these results indicate that RecQ helicase functions as a monomer and provide new data on the structural and functional properties of RecQ helicase that may help elucidate its mechanism action.	Ecole Normale Super, Lab Biotechnol & Pharmacol Genet Appl, CNRS, UMR 8113, F-94235 Cachan, France; Univ Paris 06, CNRS, UMR 7631, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Xi, XG (corresponding author), Ecole Normale Super, Lab Biotechnol & Pharmacol Genet Appl, CNRS, UMR 8113, 61 Ave President Wilson, F-94235 Cachan, France.		Xi, Xu Guang/AAK-4511-2020					ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; Bailey MF, 1996, J MOL BIOL, V263, P671, DOI 10.1006/jmbi.1996.0607; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Birrell GB, 2003, BIOPHYS J, V84, P3264; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; CARDENAS ML, 1985, ARCH BIOL MED EXP, V18, P273; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; IRION N, 1986, MOL GEN GENET, V205, P298; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; Neet K E, 1980, Methods Enzymol, V64, P139; NEET KE, 1990, BIOCHEMISTRY-US, V29, P770, DOI 10.1021/bi00455a026; Phillips RJ, 1997, MOL GEN GENET, V254, P319, DOI 10.1007/PL00008605; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; RICHARD J, 1985, EUR J BIOCHEM, V152, P557; SCHUCK P, 1994, PROG COLL POL SCI S, V94, P1; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WOLF AV, 1988, CRC HDB CHEM PHYSICS, pD219; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	54	58	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34925	34933		10.1074/jbc.M303581200	http://dx.doi.org/10.1074/jbc.M303581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12805371	hybrid			2022-12-25	WOS:000185164400024
J	Bebenek, K; Garcia-Diaz, M; Blanco, L; Kunkel, TA				Bebenek, K; Garcia-Diaz, M; Blanco, L; Kunkel, TA			The frameshift infidelity of human DNA polymerase lambda - Implications for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; STRAND BREAK REPAIR; MU POL-MU; NUCLEOTIDE INCORPORATION; SOMATIC HYPERMUTATION; DELETION MUTATIONS; ESCHERICHIA-COLI; LIGASE-IV; Y-FAMILY; BETA	DNA polymerase lambda (Pol lambda) is a member of the Pol X family having properties in common with several other mammalian DNA polymerases. To obtain clues to possible functions in vivo, we have determined the fidelity of DNA synthesis by human Pol lambda. The results indicate that the average single-base deletion error rate of Pol lambda is higher than those of other mammalian polymerases. In fact, unlike other DNA polymerases, Pol lambda generates single-base deletions at average rates that substantially exceed base substitution rates. Moreover, the sequence specificity for single-base deletions made by Pol lambda is different from that of other DNA polymerases and reveals that Pol lambda readily uses template-primers with limited base pair homology at the primer terminus. This ability, together with an ability to fill short gaps in DNA at low dNTP concentrations, is consistent with a role for mammalian Pol lambda in non-homologous end-joining. This may include non-homologous end-joining of strand breaks resulting from DNA damage, because Pol lambda has intrinsic 5', 2'-deoxyribose-5-phosphate lyase activity.	NIEHS, Mol Genet Lab, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019; Blanco, Luis/I-1848-2015	Kunkel, Thomas A./0000-0002-9900-1788; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; BOLLUM FJ, 1974, ENZYMES, P10; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CHANG LMS, 1986, CRC CR REV BIOCH MOL, V21, P27, DOI 10.3109/10409238609113608; CRITCHLOW SE, 1998, TRENDS BIOCHEM SCI, V42, P9564; DeRose EF, 2003, BIOCHEMISTRY-US, V42, P9564, DOI 10.1021/bi034298s; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Efrati E, 1997, J BIOL CHEM, V272, P2559; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gilfillan S, 1995, IMMUNOL REV, V148, P201, DOI 10.1111/j.1600-065X.1995.tb00099.x; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Heidenreich E, 2003, EMBO J, V22, P2274, DOI 10.1093/emboj/cdg203; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; Lee JW, 2003, CANCER RES, V63, P22; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Ruiz JF, 2001, PHILOS T R SOC B, V356, P99, DOI 10.1098/rstb.2000.0754; Shimazaki N, 2002, GENES CELLS, V7, P639, DOI 10.1046/j.1365-2443.2002.00547.x; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Tian KG, 2002, DNA REPAIR, V1, P1039, DOI 10.1016/S1568-7864(02)00163-5; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	59	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34685	34690		10.1074/jbc.M305705200	http://dx.doi.org/10.1074/jbc.M305705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829698	hybrid			2022-12-25	WOS:000185047500129
J	Caro, AA; Cederbaum, AI				Caro, AA; Cederbaum, AI			Role of phospholipase A(2) activation and calcium in CYP2E1-dependent toxicity in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; ARACHIDONIC-ACID RELEASE; HUMAN CYTOCHROME P4502E1; SMOOTH-MUSCLE-CELLS; RAT-LIVER; SARCOPLASMIC-RETICULUM; LIPID-PEROXIDATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION	Previous studies suggested a role for calcium in CYP2E1-dependent toxicity. The possible role of phospholipase A(2) (PLA2) activation in this toxicity was investigated. HepG2 cells that overexpress CYP2E1 (E47 cells) exposed to arachidonic acid (AA) +Fe-NTA showed higher toxicity than control HepG2 cells not expressing CYP2E1 (C34 cells). This toxicity was inhibited by the PLA2 inhibitors aristolochic acid, quinacrine, and PTK. PLA2 activity assessed by release of preloaded [H-3] AA after treatment with AA+Fe was higher in the CYP2E1 expressing HepG2 cells. This [ 3H] AA release was inhibited by PLA2 inhibitors, alpha-tocopherol, and by depleting Ca2+ from the cells ( intracellular + extracellular sources), but not by removal of extracellular calcium alone. Toxicity was preceded by an increase in intracellular calcium caused by influx from the extracellular space, and this was prevented by PLA2 inhibitors. PLA2 inhibitors also blocked mitochondrial damage in the CYP2E1-expressing HepG2 cells exposed to AA+Fe. Ca2+ depletion and removal of extracellular calcium inhibited toxicity at early time periods, although a delayed toxicity was evident at later times in Ca2+-free medium. This later toxicity was also inhibited by PLA2 inhibitors. Analogous to PLA2 activity, Ca2+ depletion but not removal of extracellular calcium alone prevented the activation of calpain activity by AA+Fe. These results suggest that release of stored calcium by AA+Fe, induced by lipid peroxidation, can initially activate calpain and PLA2 activity, that PLA2 activation is critical for a subsequent increased influx of extracellular Ca2+, and that the combination of increased PLA2 and calpain activity, increased calcium and oxidative stress cause mitochondrial damage, that ultimately produces the rapid toxicity of AA+Fe in CYP2E1-expressing HepG2 cells.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAAA NIH HHS [AA06610] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R37AA006610] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONVENTRE JV, 1991, ENV HLTH PERSPECT, V84, P155; Briand S I, 1998, Methods Mol Biol, V105, P161; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; Caro AA, 2002, ARCH BIOCHEM BIOPHYS, V408, P162, DOI 10.1016/S0003-9861(02)00544-1; Caro AA, 2002, J BIOL CHEM, V277, P104, DOI 10.1074/jbc.M107864200; Caro AA, 2001, MOL PHARMACOL, V60, P742; CHAKRABORTI S, 1993, BIOCHEM J, V292, P585, DOI 10.1042/bj2920585; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Chen X, 1996, BBA-LIPID LIPID MET, V1299, P23, DOI 10.1016/0005-2760(95)00166-2; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FENG L, 1992, CELL CALCIUM, V13, P79, DOI 10.1016/0143-4160(92)90001-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GOLIGORSKY MS, 1993, ARCH BIOCHEM BIOPHYS, V301, P119, DOI 10.1006/abbi.1993.1123; Guidarelli A, 2000, BRIT J PHARMACOL, V129, P1539, DOI 10.1038/sj.bjp.0703275; Guttmann RP, 2000, METH MOL B, V144, P143; Han C, 2002, AM J PHYSIOL-GASTR L, V282, pG586, DOI 10.1152/ajpgi.00305.2001; HATCH GM, 1993, BIOCHEM J, V293, P143, DOI 10.1042/bj2930143; Kambayashi Y, 1997, J BIOCHEM, V121, P425; Keys SSA, 1997, EXP EYE RES, V64, P313, DOI 10.1006/exer.1996.0204; Kim JS, 1999, HEPATOLOGY, V30, P1232, DOI 10.1002/hep.510300531; LILLY LB, 1995, AM J PHYSIOL-GASTR L, V268, pG1017, DOI 10.1152/ajpgi.1995.268.6.G1017; Madesh M, 1997, ARCH BIOCHEM BIOPHYS, V346, P187, DOI 10.1006/abbi.1997.0288; MALIS CD, 1990, P NATL ACAD SCI USA, V87, P8845, DOI 10.1073/pnas.87.22.8845; Mari R, 2000, J BIOL CHEM, V275, P15563; Martinez J, 2001, ARCH BIOCHEM BIOPHYS, V392, P257, DOI 10.1006/abbi.2001.2439; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Mytilineou C, 2002, PARKINSONISM RELAT D, V8, P385, DOI 10.1016/S1353-8020(02)00018-4; NANJI AA, 1993, ALCOHOL CLIN EXP RES, V17, P598, DOI 10.1111/j.1530-0277.1993.tb00806.x; OKAYASU T, 1985, ARCH BIOCHEM BIOPHYS, V236, P638, DOI 10.1016/0003-9861(85)90668-X; PAPPU AS, 1978, BIOCHEM J, V172, P349, DOI 10.1042/bj1720349; Perez MJ, 2002, FREE RADICAL BIO MED, V33, P111, DOI 10.1016/S0891-5849(02)00865-1; Perret A, 1998, BIOCHEMISTRY-US, V37, P11412, DOI 10.1021/bi980908q; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; RICE KL, 1992, AM J PHYSIOL, V263, pL430, DOI 10.1152/ajplung.1992.263.4.L430; Rodriguez RJ, 2001, FOOD CHEM TOXICOL, V39, P437, DOI 10.1016/S0278-6915(00)00159-9; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; SALAMA G, 1984, J BIOL CHEM, V259, P3363; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shin KJ, 2002, TOXICOL APPL PHARM, V178, P37, DOI 10.1006/taap.2001.9317; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; Stoyanovsky DA, 1999, TOXICOL LETT, V106, P23, DOI 10.1016/S0378-4274(99)00009-0; Stoyanovsky DA, 1998, FREE RADICAL BIO MED, V24, P745, DOI 10.1016/S0891-5849(97)00328-6; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Terao Y, 1997, RES COMMUN MOL PATH, V96, P277; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Weigel G, 1997, THROMB RES, V87, P363, DOI 10.1016/S0049-3848(97)00140-0; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Xie Q, 2002, J BIOL CHEM, V277, P16559, DOI 10.1074/jbc.M109518200; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Yu M, 1998, BIOCHEM PHARMACOL, V55, P193, DOI 10.1016/S0006-2952(97)00418-8; Zager RA, 1996, J AM SOC NEPHROL, V7, P2327; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2	68	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33866	33877		10.1074/jbc.M300408200	http://dx.doi.org/10.1074/jbc.M300408200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813050	hybrid			2022-12-25	WOS:000185047500032
J	Hua, H; Munk, S; Goldberg, H; Fantus, IG; Whiteside, CI				Hua, H; Munk, S; Goldberg, H; Fantus, IG; Whiteside, CI			High glucose-suppressed endothelin-1 Ca2+ signaling via NADPH oxidase and diacylglycerol-sensitive protein kinase C isozymes in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE ANION PRODUCTION; OXIDATIVE STRESS; NAD(P)H OXIDASE; DIABETIC-NEPHROPATHY; ACTIVATION; EXPRESSION; CALCIUM; ALPHA; BETA; INHIBITION	High glucose (HG) is the underlying factor contributing to long term complications of diabetes mellitus. The molecular mechanisms transforming the glomerular mesangial cell phenotype to cause nephropathy including diacylglycerol-sensitive protein kinase C (PKC) are still being defined. Reactive oxygen species (ROS) have been postulated as a unifying mechanism for HG-induced complications. We hypothesized that in HG an interaction between ROS generation, from NADPH oxidase, and PKC suppresses mesangial Ca2+ signaling in response to endothelin-1 (ET-1). In primary rat mesangial cells, growth-arrested (48 h) in 5.6 mM (NG) or 30 mM (HG) glucose, the total cell peak [Ca2+](i) response to ET-1 (50 nM) was 630 +/- 102 nM in NG and was reduced to 159 +/- 15 nM in HG, measured by confocal imaging. Inhibition of PKC with phorbol ester down-regulation in HG normalized the ET-1-stimulated [Ca2+](i) response to 541 +/- 74 nM. Conversely, an inhibitory peptide specific for PKC-zeta did not alter Ca2+ signaling in HG. Furthermore, overexpression of conventional PKC-beta or novel PKC-delta in NG diminished the [Ca2+](i) response to ET-1, reflecting the condition observed in HG. Likewise, catalase or p47(phox) antisense oligonucleotide normalized the [Ca2+](i) response to ET-1 in HG to 521 +/- 58 nM and 514 +/- 48 nM, respectively. Pretreatment with carbonyl cyanide m-chlorophenylhydrazone or rotenone did not restore Ca2+ signaling in HG. Detection of increased intracellular ROS in HG by dichlorofluorescein was inhibited by catalase, diphenyleneiodonium, or p47(phox) antisense oligonucleotide. HG increased p47(phox) mRNA by 1.7 +/- 0.1-fold as measured by reverse transcriptase-PCR. In NG, H2O2 increased membrane-enriched PKC-beta and -delta, suggesting activation of these isozymes. HG-enhanced immunoreactivity of PKC-delta visualized by confocal imaging was attenuated by diphenyleneiodium chloride. Thus, mesangial cell [Ca2+](i) signaling in response to ET-1 in HG is attenuated through an interaction mechanism between NADPH oxidase ROS production and diacylglycerol-sensitive PKC.	Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5S 1A8, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5S 1A8, Canada; Univ Toronto, Mt Sinai Hosp, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Whiteside, CI (corresponding author), Med Sci Bldg,Rm 7302,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	catharine.whiteside@utoronto.ca						Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Bey EA, 2000, J LIPID RES, V41, P489; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Catherwood MA, 2002, KIDNEY INT, V61, P599, DOI 10.1046/j.1523-1755.2002.00168.x; Chen SL, 2000, LAB INVEST, V80, P1311, DOI 10.1038/labinvest.3780139; Dlugosz JA, 1998, AM J PHYSIOL-RENAL, V275, pF423, DOI 10.1152/ajprenal.1998.275.3.F423; Dlugosz JA, 2002, AM J PHYSIOL-RENAL, V282, pF151, DOI 10.1152/ajprenal.0055.2001; Dorsam G, 2000, J PHARMACOL EXP THER, V292, P271; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Fei JW, 2000, ARTERIOSCL THROM VAS, V20, P1244, DOI 10.1161/01.ATV.20.5.1244; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; Grewal JS, 1999, AM J PHYSIOL-RENAL, V276, pF922, DOI 10.1152/ajprenal.1999.276.6.F922; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Ha H, 1999, DIABETES RES CLIN PR, V45, P147, DOI 10.1016/S0168-8227(99)00044-3; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; Hink U, 2001, CIRC RES, V88, pE14; Hu QH, 2002, J BIOL CHEM, V277, P32546, DOI 10.1074/jbc.M201550200; Hua H, 2001, DIABETES, V50, P2376, DOI 10.2337/diabetes.50.10.2376; Huang CK, 2000, J LEUKOCYTE BIOL, V67, P210, DOI 10.1002/jlb.67.2.210; HURST RD, 1995, DIABETES, V44, P759, DOI 10.2337/diabetes.44.7.759; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; Kapor-Drezgic J, 1999, J AM SOC NEPHROL, V10, P1193; Kim YK, 2002, DIABETES, V51, P522, DOI 10.2337/diabetes.51.2.522; Kimura C, 1998, CIRC RES, V82, P677, DOI 10.1161/01.RES.82.6.677; KING GL, 1999, DIABETES S3, V45, P105; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Lounsbury KM, 2000, FREE RADICAL BIO MED, V28, P1362, DOI 10.1016/S0891-5849(00)00222-7; Meier M, 2000, VASC MED, V5, P173, DOI 10.1177/1358836X0000500307; Mene P, 1997, DIABETOLOGIA, V40, P521, DOI 10.1007/s001250050710; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Nutt LK, 2000, J AM SOC NEPHROL, V11, P1225, DOI 10.1681/ASN.V1171225; Onozato ML, 2002, KIDNEY INT, V61, P186, DOI 10.1046/j.1523-1755.2002.00123.x; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Shannon H, 2000, NEW ENGL J MED, V342, P381; Sharma K, 2000, AM J PHYSIOL-RENAL, V278, pF1022, DOI 10.1152/ajprenal.2000.278.6.F1022; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Venugopal SK, 2002, DIABETES, V51, P3049, DOI 10.2337/diabetes.51.10.3049; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Whiteside C, 1998, J AM SOC NEPHROL, V9, P14; Whiteside CI, 2002, AM J PHYSIOL-RENAL, V282, pF975, DOI 10.1152/ajprenal.00014.2002; Yamagishi S, 2001, DIABETES, V50, P1491, DOI 10.2337/diabetes.50.6.1491	54	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33951	33962		10.1074/jbc.M302823200	http://dx.doi.org/10.1074/jbc.M302823200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821678	hybrid			2022-12-25	WOS:000185047500042
J	Li, Y; Zhang, L				Li, Y; Zhang, L			The fourth blade within the beta-propeller is involved specifically in C3bi recognition by integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; MAC-1 CD11B CD18; INTERCELLULAR-ADHESION MOLECULE-1; NEUTROPHIL INHIBITORY FACTOR; LIGAND-BINDING POCKET; AMINO-ACID-SEQUENCES; I-DOMAIN; ALPHA-SUBUNIT; A-DOMAIN; SITE	Interactions between the complement degradation product C3bi and leukocyte integrin alpha(M)beta(2) are critical to phagocytosis of opsonized particles in host defense against foreign pathogens and certain malignant cells. Previous studies have mapped critical residues for C3bi binding to the I-domains of the alpha(M) and the beta(2) subunits. However, the role of the alpha(M) beta-propeller in ligand binding remains less well defined, and the functional residues are still unknown. In the present study, we studied the function of the alpha(M) beta-propeller in specific ligand recognition by alpha(M)beta(2) using a number of different approaches, and we report four major findings. 1) Substitution of five individual segments (Asp(398) - Ala(402), Leu(412)-Leu(419), Tyr(426) - Met(434), Phe(435) - Glu(443), and Ser(444) - Thr(451)) within the W4 blade of the beta-propeller with their homologous counterparts in integrin alpha(2) abrogated C3bi binding, whereas substitution of eight other segments outside this blade had no effect. 2) These five mutants defective in C3bi binding supported strong alpha(M)beta(2)-mediated and cation-dependent cell adhesion to fibrinogen, suggesting that the conformations of these five defective mutants were intact. 3) Polyclonal antibodies recognizing sequences within the W4 blade significantly blocked C3bi binding by wild-type alpha(M)beta(2). 4) A synthetic peptide corresponding to Gln(424) -Gly(440) within W4 interacted directly with C3bi. In conclusion, our data demonstrate that the W4 blade ( residues Asp398 to Thr451) is involved specifically in C3bi but not fibrinogen binding to alpha(M)beta(2). Altogether, our study supports a model in which three separate domains of alpha(M)beta(2) (the alpha(M)I-domain, the alpha(M) beta-propeller, and the beta(2)I-domain) function together and contribute to the formation of the C3bi-binding site.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA	American Red Cross	Zhang, L (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061589, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL054710, R01 HL61589-01, 2P01 HL54710-06, R01 HL061589] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ARNAOUT MA, 1987, METHOD ENZYMOL, V150, P602; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Plow EF, 1997, J CLIN INVEST, V99, P1145, DOI 10.1172/JCI119267; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2002, J BIOL CHEM, V277, P46639, DOI 10.1074/jbc.M207971200; Yalamanchili P, 2000, J BIOL CHEM, V275, P21877, DOI 10.1074/jbc.M908868199; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	38	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34395	34402		10.1074/jbc.M304190200	http://dx.doi.org/10.1074/jbc.M304190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12816955	hybrid			2022-12-25	WOS:000185047500097
J	Sharpe, IA; Thomas, L; Loughnan, M; Motin, L; Palant, E; Croker, DE; Alewood, D; Chen, SH; Graham, RM; Alewood, PF; Adams, DJ; Lewis, RJ				Sharpe, IA; Thomas, L; Loughnan, M; Motin, L; Palant, E; Croker, DE; Alewood, D; Chen, SH; Graham, RM; Alewood, PF; Adams, DJ; Lewis, RJ			Allosteric alpha(1)-adrenoreceptor antagonism by the conopeptide rho-TIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VAS-DEFERENS; PHASE PEPTIDE-SYNTHESIS; AGE-RELATED-CHANGES; MEDIATING CONTRACTIONS; RECEPTOR SUBTYPES; ALPHA-1-ADRENOCEPTOR; NORADRENALINE; IDENTIFICATION; CONOTOXINS; EXPRESSION	A peptide contained in the venom of the predatory marine snail Conus tulipa, rho-TIA, has previously been shown to possess alpha(1)-adrenoreceptor antagonist activity. Here, we further characterize its pharmacological activity as well as its structure-activity relationships. In the isolated rat vas deferens, rho-TIA inhibited alpha(1)-adrenoreceptor-mediated increases in cytosolic Ca2+ concentration that were triggered by norepinephrine, but did not affect presynaptic alpha(2)-adrenoreceptor-mediated responses. In radioligand binding assays using [I-125] HEAT, rho-TIA displayed slightly greater potency at the alpha(1B) than at the alpha(1A) or alpha(1D) subtypes. Moreover, although it did not affect the rate of association for [H-3] prazosin binding to the alpha(1B)-adrenoreceptor, the dissociation rate was increased, indicating non-competitive antagonism by rho-TIA. N- terminally truncated analogs of rho-TIA were less active than the full-length peptide, with a large decline in activity observed upon removal of the fourth residue of rho-TIA (Arg(4)). An alanine walk of rho-TIA confirmed the importance of Arg(4) for activity and revealed a number of other residues clustered around Arg(4) that contribute to the potency of rho-TIA. The unique allosteric antagonism of rho-TIA resulting from its interaction with receptor residues that constitute a binding site that is distinct from that of the classical competitive alpha(1)-adrenoreceptor antagonists may allow the development of inhibitors that are highly subtype selective.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Xenome Ltd, Indooroopilly, Qld 4068, Australia; Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Darlinghurst, NSW 2010, Australia	University of Queensland; University of Queensland; Victor Chang Cardiac Research Institute	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Croker, Daniel/N-7134-2013; Loughnan, Marion/B-4508-2009; Adams, David John/K-3578-2019; Adams, David/J-9125-2014; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Croker, Daniel/0000-0001-9533-4019; Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; chen, songhai/0000-0001-7316-7125; Alewood, Paul/0000-0001-7454-6522				ABOUD R, 1993, BRIT J PHARMACOL, V109, P80, DOI 10.1111/j.1476-5381.1993.tb13534.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burt RP, 1998, BRIT J PHARMACOL, V123, P317, DOI 10.1038/sj.bjp.0701588; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; CHIUWEI YF, 1984, Q J EXP PHYSIOL CMS, V69, P703, DOI 10.1113/expphysiol.1984.sp002862; Costa E, 1975, Adv Biochem Psychopharmacol, P113; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEAVELLAR MCW, 1990, N-S ARCH PHARMACOL, V341, P295; DIAZTOLEDO A, 1988, EUR J PHARMACOL, V156, P315, DOI 10.1016/0014-2999(88)90276-2; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haefely W, 1975, Adv Biochem Psychopharmacol, P131; Honner V, 1999, BRIT J PHARMACOL, V128, P1323, DOI 10.1038/sj.bjp.0702913; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; LANGER SZ, 1982, J CARDIOVASC PHARM, V4, P8; LEEDHAM JA, 1982, BRIT J PHARMACOL, V77, P293, DOI 10.1111/j.1476-5381.1982.tb09298.x; Leppik RA, 2000, MOL PHARMACOL, V57, P436, DOI 10.1124/mol.57.3.436; Liu DL, 2000, J PHYSIOL-LONDON, V526, P287, DOI 10.1111/j.1469-7793.2000.00287.x; MACDONALD A, 1984, BRIT J PHARMACOL, V82, P25, DOI 10.1111/j.1476-5381.1984.tb16438.x; MALLARD NJ, 1992, BRIT J PHARMACOL, V105, P727, DOI 10.1111/j.1476-5381.1992.tb09046.x; Markus RP, 1997, J AUTON PHARMACOL, V17, P147, DOI 10.1046/j.1365-2680.1997.00449.x; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MINNEMAN KP, 1984, MOL PHARMACOL, V25, P56; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; OHMURA T, 1992, BRIT J PHARMACOL, V107, P697, DOI 10.1111/j.1476-5381.1992.tb14509.x; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shapiro RE, 2000, HYPERTENSION, V36, P553, DOI 10.1161/01.HYP.36.4.553; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Shen H, 2000, CAN J PHYSIOL PHARM, V78, P237, DOI 10.1139/cjpp-78-3-237; SNEDDON P, 1984, J PHYSIOL-LONDON, V347, P561, DOI 10.1113/jphysiol.1984.sp015083; TAKAYANAGI I, 1989, CAN J PHYSIOL PHARM, V67, P1398, DOI 10.1139/y89-224; Tammela T, 1997, DRUG AGING, V10, P349, DOI 10.2165/00002512-199710050-00004; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Waugh DJJ, 1999, J PHARMACOL EXP THER, V291, P1164	41	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34451	34457		10.1074/jbc.M305410200	http://dx.doi.org/10.1074/jbc.M305410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824165	Green Published, hybrid			2022-12-25	WOS:000185047500104
J	Knudsen, GM; Nishida, CR; Mooney, SD; de Montellano, PRO				Knudsen, GM; Nishida, CR; Mooney, SD; de Montellano, PRO			Nitric-oxide synthase (NOS) reductase domain models suggest a new control element in endothelial NOS that attenuates calmodulin-dependent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; ELECTRON FLOW-THROUGH; CRYSTAL-STRUCTURE; BINDING DOMAIN; CYTOCHROME-P450 REDUCTASE; CHROMOSOMAL LOCALIZATION; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; SEQUENCE ALIGNMENT; PROTEIN STRUCTURES	Inducible ( iNOS) and constitutive ( eNOS, nNOS) nitric-oxide synthases differ in their Ca2+-calmodulin (CaM) dependence. iNOS binds CaM irreversibly but eNOS and nNOS, which bind CaM reversibly, have inserts in their reductase domains that regulate electron transfer. These include the 43 - 45-amino acid autoinhibitory element ( AI) that attenuates electron transfer in the absence of CaM, and the C-terminal 20-40-amino acid tail that attenuates electron transfer in a CaM-independent manner. We constructed models of the reductase domains of the three NOS isoforms to predict the structural basis for CaM-dependent regulation. We have identified and characterized a loop (CD2A) within the NOS connecting domain that is highly conserved by isoform and that, like the AI element, is within direct interaction distance of the CaM binding region. The eNOS CD2A loop ( eCD2A) has the sequence (834)KGSPG-GPPPG(843), and is truncated to (809)ESGSY(813) (iCD2A) in iNOS. The eCD2A contributes to the Ca2+ dependence of CaM-bound activity to a level similar to that of the AI element. The eCD2A plays an autoinhibitory role in the control of NO, and CaM-dependent and - independent reductase activity, but this autoinhibitory function is masked by the dominant AI element. Finally, the iCD2A is involved in determining the salt dependence of NO activity at a post-flavin reduction level. Electrostatic interactions between the CD2A loop and the CaM-binding region, and CaM itself, provide a structural means for the CD2A to mediate CaM regulation of intra-subunit electron transfer within the active NOS complex.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Stanford Univ, Standford Med Informat, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu		MOONEY, SEAN D/0000-0003-2654-0833	NIAMS NIH HHS [AR47720-01] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; Champier L, 2002, BIOCHEMISTRY-US, V41, P3770, DOI 10.1021/bi016008i; Chang YT, 2000, BIOCHEMISTRY-US, V39, P2484, DOI 10.1021/bi991966u; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DEGTYARENKO KN, 1995, PROTEIN ENG, V8, P737, DOI 10.1093/protein/8.8.737; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; *GEN COMP GROUP, 2001, PROGR MAN WISC PACK; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; HALL AV, 1994, J BIOL CHEM, V269, P33082; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hubbard PA, 2001, J BIOL CHEM, V276, P29163, DOI 10.1074/jbc.M101731200; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nishida CR, 2002, DRUG METAB REV, V34, P479, DOI 10.1081/DMR-120005648; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Perry JM, 1998, CHEM BIOL, V5, P355, DOI 10.1016/S1074-5521(98)90069-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sanchez R, 1997, PROTEINS, P50; Sauder JM, 2000, PROTEINS, V40, P6, DOI 10.1002/(SICI)1097-0134(20000701)40:1<6::AID-PROT30>3.0.CO;2-7; Schrammel A, 1998, BBA-PROTEIN STRUCT M, V1387, P257, DOI 10.1016/S0167-4838(98)00138-1; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; WALSH MA, 1991, EUR J BIOCHEM, V258, P362; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Yuan T, 1998, FEBS LETT, V431, P210, DOI 10.1016/S0014-5793(98)00750-9; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; Zhao Q, 1999, PROTEIN SCI, V8, P298; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t	71	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31814	31824		10.1074/jbc.M303267200	http://dx.doi.org/10.1074/jbc.M303267200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805387	hybrid			2022-12-25	WOS:000184782100044
J	Mizuno, K; Hayashi, T; Bachinger, HP				Mizuno, K; Hayashi, T; Bachinger, HP			Hydroxylation-induced stabilization of the collagen triple helix - Further characterization of peptides with 4(R)-hydroxyproline in the Xaa position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARTHWORM CUTICLE COLLAGEN; SEA HYDROTHERMAL VENTS; THERMAL-STABILITY; MUSSEL BYSSUS; INTERSTITIAL COLLAGENS; CRYSTAL-STRUCTURE; BOUND WATER; HYDROXYPROLINE; SEQUENCE; 4-HYDROXYPROLINE	4(R)-Hydroxyproline in the Yaa position of the -Gly-Xaa-Yaa-repeated sequence of collagen plays a crucial role in the stability of the triple helix. Since the peptide (4(R)-Hyp-Pro-Gly) 10 does not form a triple helix, it was generally believed that polypeptides with a -Gly-4(R)-Hyp-Yaa- repeated sequence do not form a triple helix. Recently, we found that acetyl-(Gly-4(R)-Hyp-Thr)(10)-NH2 forms a triple helix in aqueous solutions. To further study the role of 4(R)-hydroxyproline in the Xaa position, we made a series of acetyl-(Gly-4(R)-Hyp-Yaa)(10)-NH2 peptides where Yaa was alanine, serine, valine, and allo-threonine. We previously hypothesized that the hydroxyl group of threonine might form a hydrogen bond to the hydroxyl group of 4(R)hydroxyproline. In water, only the threonine-and the valine-containing peptides were triple helical. The remaining peptides did not form a triple helix in water. In 1,2- and in 1,3-propanediol at 4degreesC, all the soluble peptides were triple helical. From the transition temperature of the triple helices, it was found that among the examined residues, threonine was the most stable residue in the acetyl-(Gly-4(R)-Hyp-Yaa)(10)-NH2 peptide. The transition temperatures of the valine- and allo-threonine-containing peptides were 10 degrees lower than those of the threonine peptide. Surprisingly, the serine-containing peptide was the least stable. These results indicate that the stability of these peptides depends on the presence of a methyl group as well as the hydroxyl group and that the stereo configuration of the two groups is essential for the stability. In the threonine peptide, we hypothesize that the methyl group shields the interchain hydrogen bond between the glycine and the Xaa residue from water and that the hydroxyl groups of threonine and 4(R)hydroxyproline can form direct or water-mediated hydrogen bonds.	Shriners Hosp Children, Dept Res, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Tokyo, Dept Life Sci, Tokyo 1538902, Japan	Oregon Health & Science University; University of Tokyo	Bachinger, HP (corresponding author), Shriners Hosp Children, Dept Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264				BACHINGER HP, 1990, MATRIX, V10, P331; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Bann JG, 2003, BIOCHEMISTRY-US, V42, P4042, DOI 10.1021/bi027050w; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; Berisio R, 2000, ACTA CRYSTALLOGR D, V56, P55, DOI 10.1107/S0907444999014158; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Berisio R, 2001, BIOPOLYMERS, V56, P8, DOI 10.1002/1097-0282(2000)56:1<8::AID-BIP1037>3.0.CO;2-W; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Burjanadze TV, 1997, CONNECT TISSUE RES, V36, P347, DOI 10.3109/03008209709160233; Coyne KJ, 1997, SCIENCE, V277, P1830, DOI 10.1126/science.277.5333.1830; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Feng YB, 1997, BIOCHEMISTRY-US, V36, P8716, DOI 10.1021/bi962980z; GAILL F, 1991, J MOL BIOL, V221, P209, DOI 10.1016/0022-2836(91)80215-G; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GOLDSTEIN A, 1970, J BIOL CHEM, V245, P5478; Gough CA, 1998, J BIOMOL STRUCT DYN, V15, P1029, DOI 10.1080/07391102.1998.10508998; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; MUIR L, 1970, J BIOL CHEM, V245, P502; Qin XX, 1997, J BIOL CHEM, V272, P32623, DOI 10.1074/jbc.272.51.32623; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; Vitagliano L, 2001, PROTEIN SCI, V10, P2627, DOI 10.1110/ps.ps.26601a; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; Waite JH, 1998, MATRIX BIOL, V17, P93, DOI 10.1016/S0945-053X(98)90023-3	32	73	73	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32373	32379		10.1074/jbc.M304741200	http://dx.doi.org/10.1074/jbc.M304741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12807876	hybrid			2022-12-25	WOS:000184782100116
J	Ngamkitidechakul, C; Warejcka, DJ; Burke, JM; O'Brien, WJ; Twining, SS				Ngamkitidechakul, C; Warejcka, DJ; Burke, JM; O'Brien, WJ; Twining, SS			Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion - Conversion of ovalbumin to a maspin-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSING ACTIVITY; CONFORMATIONAL CHANGE; PROTEASE INHIBITOR; BREAST-CANCER; SERPIN; EXPRESSION; PROTEINS; MAMMARY; BINDING; COMPLEX	Maspin, an ov-serpin, inhibits tumor invasion and induces cell adhesion to extracellular matrix molecules. Here, we use maspin/ovalbumin chimeric proteins and the maspin reactive site loop (RSL) peptide to characterize the role of the RSL in maspin-mediated functions. Replacement of the RSL plus the C-terminal region or the RSL alone of maspin with that of ovalbumin resulted in the loss of the stimulatory effect on adhesion of corneal stromal cells to type I collagen, fibronectin, and laminin and of mammary carcinoma MDA-MB-231 cells to fibronectin. Maspin with ovalbumin as the C-terminal region retained activity, suggesting the maspin C-terminal polypeptide is not required. An R340Q mutant retained full maspin activity; however, an R340A mutant lost activity. This indicates the arginine side chain at the putative P1 site forms a hydrogen bond and not an ionic bond. The RSL peptide ( P10-P5', amino acids 330-345) alone induced cell-matrix adhesion of mammary carcinoma cells and corneal stromal cells and inhibited invasion of the carcinoma cells. Substitution of the RSL of ovalbumin with that of maspin converted inactive ovalbumin into a fully active molecule. Maspin bound specifically to the surface of the mammary carcinoma cells with a k(d) of 367 +/- 67 nM and 32.0 +/- 2.2 x 10(6) binding sites/cell. The maspin RSL peptide inhibited binding, suggesting the RSL is involved in maspin binding to cells. Sufficiency of the maspin RSL for activity suggests the mechanism by which maspin regulates cell-matrix adhesion and tumor cell invasion does not involve the serpin mechanism of protease inhibition.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Twining, SS (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Wongnopavich, Ariyaphong/AAE-2938-2020	Wongnopavich, Ariyaphong/0000-0002-9238-0447	NATIONAL EYE INSTITUTE [P30EY001931, R01EY014168] Funding Source: NIH RePORTER; NEI NIH HHS [EY14168, R01-EY12931, P30-EY-01931] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Askew YS, 2001, J BIOL CHEM, V276, P49320, DOI 10.1074/jbc.M108879200; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Biliran H, 2001, CANCER RES, V61, P8676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Djie MZ, 1997, J BIOL CHEM, V272, P16268, DOI 10.1074/jbc.272.26.16268; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Griffith M, 1999, SCIENCE, V286, P2169, DOI 10.1126/science.286.5447.2169; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hojo T, 2001, CANCER LETT, V171, P103, DOI 10.1016/S0304-3835(01)00569-9; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Maass N, 2001, J PATHOL, V195, P321; Maass N, 2000, ACTA ONCOL, V39, P931; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; Ngamkitidechakul C, 2002, BIOTECHNIQUES, V33, P1296, DOI 10.2144/02336pt02; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Schick C, 1998, P NATL ACAD SCI USA, V95, P13465, DOI 10.1073/pnas.95.23.13465; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEPHENS AW, 2003, J BIOL CHEM, P15849; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Suda SA, 2000, ARCH BIOCHEM BIOPHYS, V384, P31, DOI 10.1006/abbi.2000.2110; WEIMER MP, 1994, GENE, V151, P119; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	38	56	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31796	31806		10.1074/jbc.M302408200	http://dx.doi.org/10.1074/jbc.M302408200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799381	hybrid			2022-12-25	WOS:000184782100042
J	Provost, E; Yamamoto, Y; Lizardi, I; Stern, J; D'Aquila, TG; Gaynor, RB; Rimm, DL				Provost, E; Yamamoto, Y; Lizardi, I; Stern, J; D'Aquila, TG; Gaynor, RB; Rimm, DL			Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; COLORECTAL-CANCER; GROWTH; EXPRESSION; MECHANISMS; CARCINOMAS; FEATURES; PATHWAY; NUCLEUS; AXIN1	beta-Catenin-mediated signaling can be constitutively activated by truncation or mutation of serine and threonine residues in exon 3. Mutations in this region are observed in many human tumors. Examination of the locations of these mutations reveals interesting patterns; specifically, Ser(45) and Thr(41) appear more frequently in malignant tumors, and Ser(37) and Ser(33) are more common in benign entities. To test whether these patterns represent functional differences in beta-catenin signaling mechanisms, we generated mutations of each of these residues. Stable transformation of Madin-Darby canine kidney cells showed a transformed phenotype with each of the four mutations, as assessed by growth in soft agar and collagen. Functional assays including proliferation assays, cell shedding assays, and wounding assays demonstrated two groups. Ser(45) and Thr(41) represent a more transformed phenotype, whereas Ser(37) and Ser(33) behaved similarly to the vector in these assays. Assessment of downstream genes demonstrated increased activation of the beta-catenin target gene cyclin D1 by Ser(45). Finally, we examined the kinase activity of IkappaB kinase-alpha and found that this kinase, unlike glycogen synthase kinase-3beta, appears to preferentially phosphorylate Ser(45) and Thr(41), independent of priming by casein kinase-1. We conclude that these sites may represent an alternative (non-wnt) signaling pathway, which may be inappropriately activated in tumors with mutations of these residues.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Texas, Dept Med, Med Ctr, Dallas, TX 75390 USA	Yale University; University of Texas System; University of Texas Dallas	Rimm, DL (corresponding author), Yale Univ, Sch Med, Dept Pathol, POB 208023,310 Cedar St, New Haven, CT 06520 USA.	david.rimm@yale.edu		Rimm, David/0000-0001-5820-4397	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057604] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0-1 GM 57604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAO Q, 1995, J CELL SCI, V108, P2791; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chung GG, 2001, CLIN CANCER RES, V7, P4013; Dahmen RP, 2001, CANCER RES, V61, P7039; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Goodman RH, 2000, GENE DEV, V14, P1553; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Koesters R, 2001, CARCINOGENESIS, V22, P1885, DOI 10.1093/carcin/22.11.1885; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Marin O, 2002, BIOCHEMISTRY-US, V41, P618, DOI 10.1021/bi0112309; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto H, 2002, CANCER RES, V62, P1641	29	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31781	31789		10.1074/jbc.M304953200	http://dx.doi.org/10.1074/jbc.M304953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799363	hybrid			2022-12-25	WOS:000184782100040
J	Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW				Shin, HJ; Baek, KH; Jeon, AH; Kim, SJ; Jang, KL; Sung, YC; Kim, CM; Lee, CW			Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation	ONCOGENE			English	Article							CYCLIN-A; KINETOCHORE LOCALIZATION; APOPTOSIS; KINASE; BUBR1; MITOSIS	Histone modification through acetylation and deacetylation is a key process in transcription, DNA replication, and chromosome segregation. During mitosis, histones are highly acetylated and chromatin is condensed. Here, we investigate the mechanistic involvement of histone deacetylase (HDAC) activity in the regulation of mitotic checkpoint activation. Inhibition of HDAC activity was found to cause the improper kinetochore localization of the mitotic checkpoint proteins, and to prolong mitotic arrest, and thus to lead to chromosomal instability due to aberrant exit from the mitotic cell cycle arrest. In addition, treatment with HDAC inhibitor attenuated the activations of p38 and ERK kinases, and increased the expression levels of cIAP-1, suggesting that the observed increased adaptation and chromosomal instability induced by inhibiting HDAC activity might be directly connected with the activations of cell survival and/or antiapoptotic signals. Moreover, the treatment of cells with mitotic defects with HDAC inhibitor increased their susceptibility to chromosomal instability. These results support the notion that HDAC activity plays an important role in the regulation of mitotic checkpoint activation, and thus the aberrant control of HDAC activity contributes to chromosomal instability.	Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang, South Korea; Pusan Natl Univ, Dept Microbiol, Pusan 609735, South Korea	National Cancer Center - Korea (NCC); Pohang University of Science & Technology (POSTECH); Pusan National University	Lee, CW (corresponding author), Natl Canc Ctr, Res Inst, Goyang 411764, Gyeonggi Do, South Korea.	cwlee@ncc.re.kr		Lee, Chang-Woo/0000-0002-0943-1646				Amato SF, 1998, CANCER RES, V58, P241; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Lieu CH, 1998, CELL GROWTH DIFFER, V9, P767; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1	26	73	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3853	3858		10.1038/sj.onc.1206502	http://dx.doi.org/10.1038/sj.onc.1206502			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813458				2022-12-25	WOS:000183612000004
J	Alwan, HAJ; van Zoelen, EJJ; van Leeuwen, JEM				Alwan, HAJ; van Zoelen, EJJ; van Leeuwen, JEM			Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; FACTOR-ALPHA; C-CBL; MULTIVESICULAR ENDOSOMES; TYROSINE PHOSPHORYLATION; SIGNALING NETWORK; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; CATHEPSIN-B; COMPLEX	Studies on the differential routing of internalized epidermal growth factor receptors (EGFRs) induced by EGF, TGFalpha, and the superagonist EGF-TGFalpha chimera E4T suggested a correlation between receptor recycling and their mitogenic potency. EGFR sorting to lysosomes depends on its kinase domain and its ubiquitination by Cbl proteins. Proteasomes have also been proposed to regulate EGFR degradation, but the underlying mechanism remains obscure. Here we evaluated EGFR activation, Cbl recruitment, EGFR ubiquitination and degradation in response to EGF, TGFalpha, and E4T. We also determined the fate of activated EGFRs and Cbl proteins by using v-ATPase (bafilomycin A1) and proteasome (lactacystin) inhibitors. Our results demonstrate that E4T and TGFalpha provoke decreased Cbl recruitment, EGFR ubiquitination and EGFR degradation compared with EGF. Furthermore, bafilomycin treatment blocks EGFR but not c-Cbl degradation. In contrast, lactacystin treatment blocks EGF-induced c-Cbl degradation but does not block EGFR degradation, even though lactacystin causes a minor delay in EGFR degradation. Surprisingly, even though bafilomycin completely blocks EGFR degradation, it does not prevent EGFR de-ubiquitination upon prolonged EGF stimulation. Strikingly, when combined with bafilomycin, lactacystin treatment stabilizes the ubiquitinated EGFR and prevents its de-ubiquitination. We conclude that the enhanced EGFR recycling that has been observed in HER-14 cells following TGFalpha or E4T stimulation correlates with decreased EGFR ubiquitination and EGFR degradation, and that proteasomal activity is required for de-ubiquitination of the EGFR prior to its lysosomal degradation.	Catholic Univ Nijmegen, Dept Cell Biol, FNWI, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van Leeuwen, JEM (corresponding author), Catholic Univ Nijmegen, Dept Cell Biol, FNWI, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		van Leeuwen, Jeroen/G-3555-2010; van Zoelen, Everardus J./D-9192-2012					Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; de Melker AA, 2001, J CELL SCI, V114, P2167; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lenferink AEG, 2000, J BIOL CHEM, V275, P26748; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SORKIN A, 1998, FRONT BIOSCI, V3, P729; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	47	144	149	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35781	35790		10.1074/jbc.M301326200	http://dx.doi.org/10.1074/jbc.M301326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829707	Green Published, hybrid			2022-12-25	WOS:000185164400126
J	Denault, JB; Salvesen, GS				Denault, JB; Salvesen, GS			Human caspase-7 activity and regulation by its N-terminal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANZYME-B; CELL-DEATH; INDUCED APOPTOSIS; ACTIVATION; SUBSTRATE; PROTEASE; PRODOMAIN; CLEAVAGE; PROTEINS; FAMILY	Central to the execution phase of apoptosis are the two closely related caspase-3 and -7. They share common substrate specificity and structure, but differ completely in the sequence of their respective N-terminal regions including their N-peptides, a 23-28 residue segment that are removed during zymogen activation. We show that the N-peptide of caspase-7 plays no role in the fundamental activation or properties of the active protease in vitro. However, the N-peptide modifies the properties of caspase-7 in vivo. In ectopic expression experiments, caspase-7 constructs with no N-peptide are far more lethal than constructs that have an uncleavable peptide. Moreover, the N-peptide of caspase-7 must be removed before efficient activation of the zymogen can occur in vivo. These disparate requirements for the N-peptide argue that it serves to physically sequester the caspase-7 zymogen in a cytosolic location that prevents access by upstream activators (caspase-8, -9, and -10). The N-peptide must first be removed, probably by caspase-3, before efficient conversion and activation of the zymogen can occur in vivo.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Denault, Jean-Bernard/AAC-5945-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37878] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bose K, 2001, BIOCHEMISTRY-US, V40, P14236, DOI 10.1021/bi0110387; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kang BH, 2002, BIOCHEM J, V364, P629, DOI 10.1042/BJ20011787; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meergans T, 2000, BIOCHEM J, V349, P135, DOI 10.1042/0264-6021:3490135; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	40	88	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34042	34050		10.1074/jbc.M305110200	http://dx.doi.org/10.1074/jbc.M305110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824163	hybrid			2022-12-25	WOS:000185047500053
J	Johnson, KR; Johnson, KY; Becker, KP; Bielawski, J; Mao, CG; Obeid, LM				Johnson, KR; Johnson, KY; Becker, KP; Bielawski, J; Mao, CG; Obeid, LM			Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SPHINGOSINE KINASE; SPHINGOLIPID METABOLISM; STRESS-RESPONSE; HEAT-STRESS; PHOSPHOHYDROLASE; 1-PHOSPHATE; IDENTIFICATION; DEATH; ACTIVATION	Sphingosine-1-phosphate (S1P) is a highly bioactive lipid that exerts numerous biological effects both intracellularly as a second messenger and extracellularly by binding to its G-protein-coupled receptors of the endothelial differentiation gene family (S1P receptors-(1-5)). Intracellularly, at least two enzymes, sphingosine kinase and S1P phosphatase, regulate the activity of S1P by governing the phosphorylation status of S1P. To study the regulation of S1P levels, we cloned the human isoform of S1P phosphatase 1 (hSPPase1). The hSPPase1 has 78% homology to the mouse SPPase at the amino acid level with 6-8 possible transmembrane domains. Confocal microscopy revealed green fluorescent protein-tagged hSPPase1, expressed in either MCF7 or HEK293 cells, co-localized to endoplasmic reticulum with calreticulin. According to Northern blot analysis, hSPPase1 is expressed in most tissues, with the strongest levels found in the highly vascular tissues of placenta and kidney. Transient overexpression of hSPPase1 exhibited a 2-fold increase in phosphatase activity against S1P and dihydro-S1P, indicating that the expressed protein was functional. Small interfering RNA (siRNA) knockdown of endogenous hSPPase1 drastically reduced hSPPase1 mRNA levels, as confirmed by reverse transcription PCR, and resulted in an overall 25% reduction of in vitro phosphatase activity in the membrane fractions. Sphingolipid mass measurements in hSPPase1 siRNA knockdown cells revealed a 2-fold increase of S1P levels and concomitant decrease in sphingosine. In vivo labeling of hSPPase1 siRNA-treated cells showed accumulation of S1P within cells, as well as significantly increased secretion of S1P into the media, indicating that hSPPase1 regulates secreted S1P. In addition, siRNA-induced knockdown of hSPPase1 endowed resistance to tumor necrosis factor-alpha and the chemotherapeutic agent daunorubicin. Collectively, these data suggest that regulation of hSPPase1 with the resultant changes in cellular and secreted S1P could have important implications to cell proliferation, angiogenesis, and apoptosis.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Citadel, Dept Biol, Charleston, SC 29409 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062287] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR17677] Funding Source: Medline; NHLBI NIH HHS [HL 07260] Funding Source: Medline; NIGMS NIH HHS [GM62287] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DECEUSTER P, 1995, BIOCHEM J, V311, P139, DOI 10.1042/bj3110139; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; English D, 2002, BBA-MOL CELL BIOL L, V1582, P228, DOI 10.1016/S1388-1981(02)00176-2; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kleuser B, 1998, CANCER RES, V58, P1817; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; PETTUS BJ, 2003, IN PRESS FASEB J; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Stukey J, 1997, PROTEIN SCI, V6, P469; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; VANVELDHOVEN PP, 1994, BIOCHEM J, V299, P597, DOI 10.1042/bj2990597; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X	25	125	132	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34541	34547		10.1074/jbc.M301741200	http://dx.doi.org/10.1074/jbc.M301741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815058	hybrid			2022-12-25	WOS:000185047500115
J	Kosswig, N; Rice, S; Daugherty, A; Post, SR				Kosswig, N; Rice, S; Daugherty, A; Post, SR			Class A scavenger receptor-mediated adhesion and internalization require distinct cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM; MACROPHAGE ADHESION; CELL-ADHESION; COLLAGEN; MEMBRANE; PROTEINS; EXPRESSION; DEPOSITION; TRANSPORT	Class A scavenger receptors (SR-A) are transmembrane glycoproteins that mediate both ligand internalization and cell adhesion. Previous studies have identified specific amino acids in the cytoplasmic tail of SR-A that regulate receptor internalization; however, the role of cytoplasmic domains in regulating cell adhesion has not been addressed. To investigate the role of cytoplasmic domains in SR-A-mediated adhesion and to address whether SR-A-mediated adhesion and internalization require distinct cytoplasmic domains, different SR-A constructs were stably expressed in human embryonic kidney (HEK 293) cells. Deleting the entire cytoplasmic tail (SR-A(Delta1-55)) greatly reduced receptor protein abundance. Retaining the six amino acids proximal to the membrane (SR-A(Delta1-49)) restored receptor protein abundance. Although SR-A(Delta1-49) localized to the cell surface, cells expressing this receptor failed to internalize the ligand acetylated low density lipoprotein. Replacing the cytoplasmic tail of SR-A with that of the transferrin receptor (TfR/SR-A) resulted in retention of the chimeric receptor in the endoplasmic reticulum suggesting a specific role for the membrane-proximal amino acids in trafficking SR-A from the endoplasmic reticulum to the Golgi. Like SR-A expressing cells, cells expressing SR-A(Delta1-49) displayed increased spreading and adhesion, demonstrating that the membrane-proximal amino acids were sufficient for SR-A-mediated cell adhesion. Together, our results indicate a critical role for the membrane-proximal amino acids in SR-A trafficking and demonstrate that SR-A-mediated adhesion and internalization require distinct cytoplasmic domains.	Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Post, SR (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, MS305, Lexington, KY 40536 USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775; Post, Steven/0000-0002-4711-1723	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065708, R01HL055487] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65708, HL55487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DahlinHuppe K, 1997, MOL CELL NEUROSCI, V9, P144, DOI 10.1006/mcne.1997.0608; Daugherty A, 2001, J LIPID RES, V42, P1049; Daugherty A, 2000, J LIPID RES, V41, P1568; DAUGHERTY A, 2000, CURR OPIN CARDIOVASC, V2, P223; DOI T, 1993, J BIOL CHEM, V268, P2126; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ElKhoury J, 1996, NATURE, V382, P716; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; Fong LG, 1996, J LIPID RES, V37, P574; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FUKUDA S, 1986, VIRCHOWS ARCH B, V52, P1, DOI 10.1007/BF02889945; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Gorelick FS, 2001, MOL CELL ENDOCRINOL, V177, P13, DOI 10.1016/S0303-7207(01)00438-5; Gowen BB, 2000, MATRIX BIOL, V19, P61, DOI 10.1016/S0945-053X(99)00052-9; Gowen BB, 2001, J LEUKOCYTE BIOL, V69, P575; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Morimoto K, 1999, BIOL PHARM BULL, V22, P1022; PENMAN M, 1991, J BIOL CHEM, V266, P23985; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Post SR, 2002, J LIPID RES, V43, P1829, DOI 10.1194/jlr.M200231-JLR200; Santiago-Garcia J, 2003, J BIOL CHEM, V278, P6942, DOI 10.1074/jbc.M208358200; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; Wilkinson BM, 1997, J MEMBRANE BIOL, V155, P189, DOI 10.1007/s002329900171; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191	26	40	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34219	34225		10.1074/jbc.M303465200	http://dx.doi.org/10.1074/jbc.M303465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819208	hybrid			2022-12-25	WOS:000185047500076
J	Lamble, HJ; Heyer, NI; Bull, SD; Hough, DW; Danson, MJ				Lamble, HJ; Heyer, NI; Bull, SD; Hough, DW; Danson, MJ			Metabolic pathway promiscuity in the Archaeon Sulfolobus solfataricus revealed by studies on glucose dehydrogenase and 2-keto-3-deoxygluconate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTNER-DOUDOROFF PATHWAY; CARBOHYDRATE-METABOLISM; CITRATE SYNTHASE; ACID; ENZYME; ARCHAEBACTERIA; PURIFICATION; DEGRADATION; EFFICIENCY; GLUCONATE	The hyperthermophilic Archaeon Sulfolobus solfataricus metabolizes glucose by a non-phosphorylative variant of the Entner-Doudoroff pathway. In this pathway glucose dehydrogenase and gluconate dehydratase catalyze the oxidation of glucose to gluconate and the subsequent dehydration of gluconate to 2-keto-3-deoxygluconate. 2-Keto-3-deoxygluconate (KDG) aldolase then catalyzes the cleavage of 2-keto-3-deoxygluconate to glyceraldehyde and pyruvate. The gene encoding glucose dehydrogenase has been cloned and expressed in Escherichia coli to give a fully active enzyme, with properties indistinguishable from the enzyme purified from S. solfataricus cells. Kinetic analysis revealed the enzyme to have a high catalytic efficiency for both glucose and galactose. KDG aldolase from S. solfataricus has previously been cloned and expressed in E. coli. In the current work its stereoselectivity was investigated by aldol condensation reactions between D-glyceraldehyde and pyruvate; this revealed the enzyme to have an unexpected lack of facial selectivity, yielding approximately equal quantities of 2-keto-3-deoxygluconate and 2-keto-3-deoxygalactonate. The KDG aldolase-catalyzed cleavage reaction was also investigated, and a comparable catalytic efficiency was observed with both compounds. Our evidence suggests that the same enzymes are responsible for the catabolism of both glucose and galactose in this Archaeon. The physiological and evolutionary implications of this observation are discussed in terms of catalytic and metabolic promiscuity.	Univ Bath, Ctr Extremophile Res, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Bath, Dept Chem, Bath BA2 7AY, Avon, England	University of Bath; University of Bath	Danson, MJ (corresponding author), Univ Bath, Ctr Extremophile Res, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	M.J.Danson@bath.ac.uk						Albers SV, 1999, J BACTERIOL, V181, P4285, DOI 10.1128/JB.181.14.4285-4291.1999; AUGE C, 1993, TETRAHEDRON-ASYMMETR, V4, P1165, DOI 10.1016/S0957-4166(00)80224-4; AUGE C, 1995, TETRAHEDRON-ASYMMETR, V6, P863, DOI 10.1016/0957-4166(95)00090-C; Baer E, 1939, J AM CHEM SOC, V61, P761, DOI 10.1021/ja01873a001; Bonete MJ, 1996, FEBS LETT, V383, P227, DOI 10.1016/0014-5793(96)00235-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown JR, 2003, NAT REV GENET, V4, P121, DOI 10.1038/nrg1000; Buchanan CL, 1999, BIOCHEM J, V343, P563, DOI 10.1042/0264-6021:3430563; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Connaris H, 1998, EXTREMOPHILES, V2, P61, DOI 10.1007/s007920050043; Cusdin FS, 1996, FEBS LETT, V387, P193, DOI 10.1016/0014-5793(96)00497-8; DANSON MJ, 1985, FEBS LETT, V179, P120, DOI 10.1016/0014-5793(85)80204-0; DELEY J, 1957, J BIOL CHEM, V227, P745; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ELSHAFEI AM, 1989, ACTA BIOTECHNOL, V9, P485, DOI 10.1002/abio.370090523; Elshafei AM, 2001, ENZYME MICROB TECH, V29, P76, DOI 10.1016/S0141-0229(01)00346-5; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; ENTNER N, 1952, J BIOL CHEM, V196, P853; Fong S, 2000, CHEM BIOL, V7, P873, DOI 10.1016/S1074-5521(00)00035-1; GIARDINA P, 1986, BIOCHEM J, V239, P517, DOI 10.1042/bj2390517; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; GROGAN DW, 1991, APPL ENVIRON MICROB, V57, P1644, DOI 10.1128/AEM.57.6.1644-1649.1991; Henderson DP, 1998, J ORG CHEM, V63, P906, DOI 10.1021/jo9718814; HIRTH G, 1985, HELV CHIM ACTA, V68, P1863, DOI 10.1002/hlca.19850680708; Johnson CD, 1996, MATH PROBL ENG, V2, P393, DOI 10.1155/S1024123X96000403; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSTERS K, 1968, A VAN LEEUW J MICROB, V34, P393, DOI 10.1007/BF02046462; KUHN R, 1959, LIEBIGS ANN CHEM, V628, P207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NIXON A, 1992, ARCH MICROBIOL, V157, P155, DOI 10.1007/BF00245284; NOBBS TJ, 1994, BIOCHEM J, V300, P491, DOI 10.1042/bj3000491; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; OSHIMA R, 1981, CHEM LETT, P943, DOI 10.1246/cl.1981.943; PLANTIERROYON R, 1991, J CARBOHYD CHEM, V10, P239, DOI 10.1080/07328309108543903; PLANTIERROYON R, 1991, J CARBOHYD CHEM, V10, P787, DOI 10.1080/07328309108543951; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shelton MC, 1996, J AM CHEM SOC, V118, P2117, DOI 10.1021/ja952596+; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; SKORKO R, 1989, J BACTERIOL, V171, P5162, DOI 10.1128/jb.171.9.5162-5164.1989; SMITH LD, 1989, BIOCHEM J, V261, P973, DOI 10.1042/bj2610973; TIPTON KF, 2002, ENZYME ASSAYS PRACTI, P32; TOMLINSO.GA, 1972, CAN J MICROBIOL, V18, P1973, DOI 10.1139/m72-308; TOMLINSON GA, 1974, CAN J MICROBIOL, V20, P1085, DOI 10.1139/m74-170; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	54	117	126	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34066	34072		10.1074/jbc.M305818200	http://dx.doi.org/10.1074/jbc.M305818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824170	hybrid			2022-12-25	WOS:000185047500056
J	Machaca, K				Machaca, K			Ca2+-calmodulin-dependent protein kinase II potentiates store-operated Ca2+ current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; MULTIFUNCTIONAL CAM KINASE; XENOPUS-OOCYTES; T-LYMPHOCYTES; DEPENDENT ENHANCEMENT; CL CURRENTS; MAST-CELLS; DEPLETION; ENTRY; CALMODULIN	A rise in intracellular Ca2+ (Ca-i(2+)) mediates various cellular functions ranging from fertilization to gene expression. A ubiquitous Ca2+ influx pathway that contributes significantly to the generation of Ca-i(2+) signals, especially in non-excitable cells, is store-operated Ca2+ entry (SOCE). Consequently, the modulation of SOCE current affects Ca-i(2+) dynamics and thus the ensuing cellular response. Therefore, it is important to define the mechanisms that regulate SOCE. Here we show that a rise in Ca-i(2+) potentiates SOCE. This potentiation is mediated by Ca2+-calmodulin-dependent protein kinase II ( CaMKII), because inhibition of endogenous CaMKII activity abrogates Ca-i(2+)-mediated SOCE potentiation and expression of constitutively active CaMKII potentiates SOCE current independently of Ca-i(2+). Moreover, we present evidence that CaMKII potentiates SOCE by altering SOCE channel gating. The regulation of SOCE by CaMKII defines a novel modulatory mechanism of SOCE with important physiological consequences.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Machaca, K (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.		Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061829] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-61829, R01 GM061829-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett PQ, 2000, AM J PHYSIOL-CELL PH, V279, pC1694, DOI 10.1152/ajpcell.2000.279.6.C1694; Christian EP, 1996, J MEMBRANE BIOL, V150, P63, DOI 10.1007/s002329900030; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Fomina AF, 1999, J NEUROSCI, V19, P3711; Gailly P, 1996, J PHYSIOL-LONDON, V491, P635, DOI 10.1113/jphysiol.1996.sp021245; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Machaca K, 2002, J CELL BIOL, V156, P75, DOI 10.1083/jcb.200110059; Machaca K, 1999, J GEN PHYSIOL, V113, P249, DOI 10.1085/jgp.113.2.249; Machaca K, 2000, J BIOL CHEM, V275, P38710, DOI 10.1074/jbc.M007887200; Matifat F, 1997, BIOCHEM J, V322, P267, DOI 10.1042/bj3220267; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; Norwood N, 2000, AM J PHYSIOL-LUNG C, V279, pL815, DOI 10.1152/ajplung.2000.279.5.L815; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; QUICK MW, 1994, J BIOL CHEM, V269, P30164; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Stevens N, 2001, J BIOCHEM, V129, P551, DOI 10.1093/oxfordjournals.jbchem.a002890; Vazquez G, 2000, J BIOL CHEM, V275, P16134, DOI 10.1074/jbc.C901008199; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	39	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33730	33737		10.1074/jbc.M305023200	http://dx.doi.org/10.1074/jbc.M305023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821654	Green Accepted, hybrid			2022-12-25	WOS:000185047500017
J	Maiorino, M; Scapin, M; Ursini, F; Biasolo, M; Bosello, V; Flohe, L				Maiorino, M; Scapin, M; Ursini, F; Biasolo, M; Bosello, V; Flohe, L			Distinct promoters determine alternative transcription of gpx-4 into phospholipid-hydroperoxide glutathione peroxidase variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; SELENOPROTEIN PHGPX; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; SPERM MATURATION; OXIDATIVE STRESS; RAT TESTIS; GENE; EXPRESSION; MICE	A nuclear variant of phospholipid-hydroperoxide glutathione peroxidase ( PHGPx, GPx-4) was considered to be derived from alternative pre-mRNA splicing in testis and to regulate sperm maturation. The genomic sequence of rat gpx-4 was established and investigated in respect to expression into the cytosolic, mitochondrial, and nuclear forms of PHGPx. In silico analysis suggested the presence of two distinct promoter regions, the upstream one leading to transcripts translating into cPHGPx or mPHGPx and the downstream one yielding nPHGPx. The promoter activity of both regions was verified by luciferase-based reporter constructs in A7r5 and H9c2 cells. The data reveal that the formation of nPHGPx is due to alternative transcription and not to alternative splicing. Transcripts encoding nPHGPx were most abundant in testis although not restricted to this organ. This observation points to a general role of the nuclear PHGPx variant in regulating cell division.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy; Tech Univ Carolo Wilhelmina Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany	University of Padua; University of Padua; Braunschweig University of Technology	Maiorino, M (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.			bosello travain, valentina/0000-0003-4659-1873				Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; Behne D, 1997, BIOMED ENVIRON SCI, V10, P340; Borchert A, 2003, J BIOL CHEM, V278, P2571, DOI 10.1074/jbc.M209064200; Borchert A, 1999, FEBS LETT, V446, P223, DOI 10.1016/S0014-5793(99)00221-5; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUSFLOHE R, 2002, HDB ANTIOXIDANTS, P633; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; CONRAD M, 2000, 7 INT S SEL COOP LIB; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Esworthy RS, 2001, AM J PHYSIOL-GASTR L, V281, pG848, DOI 10.1152/ajpgi.2001.281.3.G848; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; Fu YX, 1999, FREE RADICAL BIO MED, V27, P605, DOI 10.1016/S0891-5849(99)00104-5; Godeas C, 1997, BIOL REPROD, V57, P1502, DOI 10.1095/biolreprod57.6.1502; Huang HS, 1999, FEBS LETT, V455, P111, DOI 10.1016/S0014-5793(99)00866-2; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; Jaeschke H, 1999, HEPATOLOGY, V29, P443, DOI 10.1002/hep.510290222; Kelner MJ, 1998, BIOCHEM BIOPH RES CO, V249, P53, DOI 10.1006/bbrc.1998.9086; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Maiorino M, 2003, BIOL REPROD, V68, P1134, DOI 10.1095/biolreprod.102.007500; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065; MILLS GC, 1957, J BIOL CHEM, V229, P189; Minotti G, 2001, CANCER RES, V61, P8422; Moreno SG, 2003, BIOL CHEM, V384, P635, DOI 10.1515/BC.2003.070; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; Puglisi R, 2003, BIOL REPROD, V68, P405, DOI 10.1095/biolreprod.102.006544; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; ROVERI A, 1992, J BIOL CHEM, V267, P6142; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; Wallace E, 1987, SELENIUM BIOL MED A, P181; WEITZEL F, 1993, J BIOL CHEM, V268, P6288	42	84	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34286	34290		10.1074/jbc.M305327200	http://dx.doi.org/10.1074/jbc.M305327200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819198	hybrid			2022-12-25	WOS:000185047500084
J	Wilkinson, L; Kolle, G; Wen, DY; Piper, M; Scott, J; Little, M				Wilkinson, L; Kolle, G; Wen, DY; Piper, M; Scott, J; Little, M			CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA EMBRYO; TGF-BETA; CHORDIN; XENOPUS; BMP; EXPRESSION; GENE; RECEPTORS; GRADIENT; DOMAINS	The Crim1 gene is predicted to encode a transmembrane protein containing six von Willebrand-like cysteine-rich repeats (CRRs) similar to those in the BMP-binding antagonist Chordin (Chrd). In this study, we verify that CRIM1 is a glycosylated, Type I transmembrane protein and demonstrate that the extracellular CRR-containing domain can also be secreted, presumably via processing at the membrane. We have previously demonstrated Crim1 expression at sites consistent with an interaction with bone morphogenetic proteins (BMPs). Here we show that CRIM1 can interact with both BMP4 and BMP7 via the CRR-containing portion of the protein and in so doing acts as an antagonist in three ways. CRIM1 binding of BMP4 and -7 occurs when these proteins are co-expressed within the Golgi compartment of the cell and leads to (i) a reduction in the production and processing of preprotein to mature BMP, (ii) tethering of pre-BMP to the cell surface, and (iii) an effective reduction in the secretion of mature BMP. Functional antagonism was verified by examining the effect of coexpression of CRIM1 and BMP4 on metanephric explant culture. The presence of CRIM1 reduced the effective BMP4 concentration of the media, thereby acting as a BMP4 antagonist. Hence, CRIM1 modulates BMP activity by affecting its processing and delivery to the cell surface.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Little, M (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Little, Melissa H/A-6170-2010; Piper, Michael J/B-2805-2010; Wilkinson, Lorine/D-1189-2010	Little, Melissa H/0000-0003-0380-2263; Piper, Michael J/0000-0002-6759-2560; Wilkinson, Lorine/0000-0002-2715-0100				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Coffinier C, 2001, MECH DEVELOP, V100, P119, DOI 10.1016/S0925-4773(00)00507-4; Conley CA, 2000, DEVELOPMENT, V127, P3947; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Dick A, 2000, DEVELOPMENT, V127, P343; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Georgas K, 2000, DEV DYNAM, V219, P582, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1072>3.0.CO;2-I; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Kohl R, 2000, J BIOL CHEM, V275, P15741, DOI 10.1074/jbc.M903271199; Kolle G, 2000, MECH DEVELOP, V90, P181, DOI 10.1016/S0925-4773(99)00248-8; Larrain J, 2000, DEVELOPMENT, V127, P821; Little MH, 2001, AM J PHYSIOL-CELL PH, V281, pC486, DOI 10.1152/ajpcell.2001.281.2.C486; Lovicu FJ, 2000, MECH DEVELOP, V94, P261, DOI 10.1016/S0925-4773(00)00292-6; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Martinez G, 2002, INT J DEV BIOL, V46, P525; Matsui M, 2000, P NATL ACAD SCI USA, V97, P5291, DOI 10.1073/pnas.090020497; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Piper M, 2000, MECH DEVELOP, V94, P213, DOI 10.1016/S0925-4773(00)00313-0; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	27	85	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34181	34188		10.1074/jbc.M301247200	http://dx.doi.org/10.1074/jbc.M301247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12805376	hybrid			2022-12-25	WOS:000185047500072
J	Yamaguchi, K; Beligni, MV; Prieto, S; Haynes, PA; McDonald, WH; Yates, JR; Mayfield, SP				Yamaguchi, K; Beligni, MV; Prieto, S; Haynes, PA; McDonald, WH; Yates, JR; Mayfield, SP			Proteomic characterization of the Chlamydomonas reinhardtii chloroplast ribosome - Identification of proteins unique to the 70 S ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; RNA-BINDING-PROTEIN; 2-DIMENSIONAL GEL-ELECTROPHORESIS; AMINO-ACID-SEQUENCES; MESSENGER-RNA; GENE-EXPRESSION; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; MASS-SPECTROMETRY; POSTTRANSCRIPTIONAL REGULATION; TRANSLATIONAL CONTROL	We have conducted a proteomic analysis of the 70 S ribosome from the Chlamydomonas reinhardtii chloroplast. Twenty-seven orthologs of Escherichia coli large subunit proteins were identified in the 50 S subunit, as well as an ortholog of the spinach plastid-specific ribosomal protein-6. Several of the large subunit proteins of C. reinhardtii have short extension or insertion sequences, but overall the large subunit proteins are very similar to those of spinach chloroplast and E. coli. Two proteins of 38 and 41 kDa, designated RAP38 and RAP41, were identified from the 70 S ribosome that were not found in either of the ribosomal subunits. Phylogenetic analysis identified RAP38 and RAP41 as paralogs of spinach CSP41, a chloroplast RNA-binding protein with endoribonuclease activity. Overall, the chloroplast ribosome of C. reinhardtii is similar to those of spinach chloroplast and E. coli, but the C. reinhardtii ribosome has proteins associated with the 70 S complex that are related to non-ribosomal proteins in other species. In addition, the 30 S subunit contains unusually large orthologs of E. coli S2, S3, and S5 and a novel S1-type protein ( Yamaguchi, K. et al., ( 2002) Plant Cell 14, 2957 2974). These additional proteins and domains likely confer functions used to regulate chloroplast translation in C. reinhardtii.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Syngenta, Torrey Mesa Res Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Syngenta	Mayfield, SP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X; Haynes, Paul/0000-0003-1472-8249; Beligni, Maria Veronica/0000-0003-3418-7160	NIGMS NIH HHS [GM54659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Arnold RJ, 1999, ANAL BIOCHEM, V269, P105, DOI 10.1006/abio.1998.3077; Asamiziu E, 2000, DNA RES, V7, P305, DOI 10.1093/dnares/7.5.305; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; Baker ME, 1998, BIOCHEM BIOPH RES CO, V248, P250, DOI 10.1006/bbrc.1998.8951; Barnes D, 2003, ANTIOXID REDOX SIGN, V5, P89, DOI 10.1089/152308603321223577; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; BOGORAD L, 1975, SCIENCE, V188, P891, DOI 10.1126/science.1138359; BOURQUE DP, 1971, J CELL SCI, V8, P153; BRUGGER M, 1975, EUR J BIOCHEM, V58, P603, DOI 10.1111/j.1432-1033.1975.tb02411.x; Bruick RK, 1999, TRENDS PLANT SCI, V4, P190, DOI 10.1016/S1360-1385(99)01402-8; Bruick RK, 1998, J CELL BIOL, V143, P1145, DOI 10.1083/jcb.143.5.1145; CHUA NH, 1973, J CELL BIOL, V57, P798, DOI 10.1083/jcb.57.3.798; CHUA NH, 1973, BIOCH SOC S, V38, P163; Cohen A, 1998, METHOD ENZYMOL, V297, P192; Dent RM, 2001, TRENDS PLANT SCI, V6, P364, DOI 10.1016/S1360-1385(01)02018-0; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; Gallois JL, 2001, GENE, V274, P179, DOI 10.1016/S0378-1119(01)00613-8; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; HANSON MR, 1974, MOL GEN GENET, V132, P105, DOI 10.1007/BF00272176; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Harris EH, 2001, ANNU REV PLANT PHYS, V52, P363, DOI 10.1146/annurev.arplant.52.1.363; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; INAMINE G, 1985, P NATL ACAD SCI USA, V82, P5690, DOI 10.1073/pnas.82.17.5690; KELLER M, 1991, PLANT MOL BIOL, V17, P73, DOI 10.1007/BF00036807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING W, 1988, PLANTA, V176, P269, DOI 10.1007/BF00392455; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; LIU XQ, 1988, MOL GEN GENET, V214, P588, DOI 10.1007/BF00330499; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MARGULIES MM, 1979, BIOCHIM BIOPHYS ACTA, V563, P171, DOI 10.1016/0005-2787(79)90018-2; Maul JE, 2002, PLANT CELL, V14, P2659, DOI 10.1105/tpc.006155; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; MURZIN A, 1994, STRUCT BIOL, V1, P146; Price CA, 2001, NUCLEIC ACIDS RES, V29, P118, DOI 10.1093/nar/29.1.118; RANDOLPHANDERSON BL, 1989, J MOL EVOL, V29, P68, DOI 10.1007/BF02106183; REINBOTHE S, 1993, EMBO J, V12, P1505, DOI 10.1002/j.1460-2075.1993.tb05794.x; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; SAGER R, 1967, SCIENCE, V157, P709, DOI 10.1126/science.157.3789.709; SAKAMOTO W, 1994, MOL CELL BIOL, V14, P6180, DOI 10.1128/MCB.14.9.6180; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; SCHMIDT RJ, 1983, J CELL BIOL, V96, P1451, DOI 10.1083/jcb.96.5.1451; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Somanchi A, 2001, ADV PHOTOSYNTH, V11, P137; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vian A, 1999, PLANT PHYSIOL, V121, P517, DOI 10.1104/pp.121.2.517; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; WOOL IG, 1995, CELL BIOL, V73, P933; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200; Yamaguchi K, 2003, EUR J BIOCHEM, V270, P190, DOI 10.1046/j.1432-1033.2003.03359.x; Yamaguchi K, 2002, PLANT CELL, V14, P2957, DOI 10.1105/tpc.004341; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; Yang JJ, 1997, J BIOL CHEM, V272, P12874, DOI 10.1074/jbc.272.19.12874; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zerges W, 2000, BIOCHIMIE, V82, P583, DOI 10.1016/S0300-9084(00)00603-9	66	81	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33774	33785		10.1074/jbc.M301934200	http://dx.doi.org/10.1074/jbc.M301934200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826678	hybrid, Green Published			2022-12-25	WOS:000185047500022
J	Kishore, N; Sommers, C; Mathialagan, S; Guzova, J; Yao, M; Hauser, S; Huynh, K; Bonar, S; Mielke, C; Albee, L; Weier, R; Graneto, M; Hanau, C; Perry, T; Tripp, CS				Kishore, N; Sommers, C; Mathialagan, S; Guzova, J; Yao, M; Hauser, S; Huynh, K; Bonar, S; Mielke, C; Albee, L; Weier, R; Graneto, M; Hanau, C; Perry, T; Tripp, CS			A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; NUCLEAR EXPORT SIGNAL; TRANSCRIPTIONAL ACTIVATION; THERAPEUTIC TARGET; BETA SUBUNIT; IN-VIVO; ALPHA; KINASE; PHOSPHORYLATION; UBIQUITINATION	NF-kappaB-induced gene expression contributes significantly to the pathogenesis of inflammatory diseases such as arthritis. IkappaB kinase (IKK) is the converging point for the activation of NF-kappaB by a broad spectrum of inflammatory agonists and is thus a novel target for therapeutic intervention. We describe a small molecule, selective inhibitor of IKK-2, SC-514, which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases. SC-514 inhibits the native IKK complex or recombinant human IKK-1/IKK-2 heterodimer and IKK-2 homodimer similarly. IKK-2 inhibition by SC-514 is selective, reversible, and competitive with ATP. SC-514 inhibits transcription of NF-kappaB-dependent genes in IL-1beta-induced rheumatoid arthritis-derived synovial fibroblasts in a dose-dependent manner. When the mechanism of NF-kappaB activation was evaluated in the presence of this inhibitor, several interesting observations were found. First, SC-514 did not inhibit the phosphorylation and activation of the IKK complex. Second, there was a delay but not a complete blockade in IkappaBalpha phosphorylation and degradation; likewise there was a slightly slowed, decreased import of p65 into the nucleus and a faster export of p65 from the nucleus. Finally, both IkappaBalpha and p65 were comparable substrates for IKK-2, with similar K-m and K-cat values, and SC-514 inhibited the phosphorylation of either substrate similarly. Thus, the effect of SC-514 on cytokine gene expression may be a combination of inhibiting IkappaBalpha phosphorylation/ degradation, affecting NF-kappaB nuclear import/ export as well as the phosphorylation and transactivation of p65.	Pharmacia Corp, Dept Arthrit & Inflammat Pharmacol, St Louis, MO 63167 USA; Pharmacia Corp, Dept Biotechnol, St Louis, MO 63167 USA; Pharmacia Corp, Dept Med Chem, Skokie, IL 60077 USA	Pfizer; Pfizer; Pfizer	Kishore, N (corresponding author), Pfizer, 700 Chesterfield Pkwy W, Chesterfield, MO 63017 USA.							ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Jue DM, 1999, J KOREAN MED SCI, V14, P231, DOI 10.3346/jkms.1999.14.3.231; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	51	257	263	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32861	32871		10.1074/jbc.M211439200	http://dx.doi.org/10.1074/jbc.M211439200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813046	hybrid			2022-12-25	WOS:000184901800047
J	Podolnikova, NP; Yakubenko, VP; Volkov, GL; Plow, EF; Ugarova, TP				Podolnikova, NP; Yakubenko, VP; Volkov, GL; Plow, EF; Ugarova, TP			Identification of a novel binding site for platelet integrins alpha(IIb)beta(3) (GPIIbIIIa) and alpha(5)beta(1) in the gamma C-domain of fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; GLYCOPROTEIN-IIB; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; CLOT RETRACTION; ALPHA-CHAIN; RECEPTOR; ADHESION; MUTATION; SUBUNIT	The interactions of platelets with fibrinogen mediate a variety of responses including adhesion, platelet aggregation, and fibrin clot retraction. Whereas it was assumed that interactions of the platelet integrin alpha(IIb)beta(3) with the AGDV sequence in the gammaC-domain of fibrinogen and/or RGD sites in the Aalpha chains are involved in clot retraction and adhesion, recent data demonstrated that fibrinogen lacking these sites still supported clot retraction. These findings suggested that an unknown site in fibrinogen and/or other integrins participate in clot retraction. Here we have identified a sequence within gammaC that mediates binding of fibrinogen to platelets. Synthetic peptide duplicating the 365 - 383 sequence in gammaC, designated P3, efficiently inhibited clot retraction in a dose-dependent manner. Furthermore, P3 supported platelet adhesion and was an effective inhibitor of platelet adhesion to fibrinogen fragments. Analysis of overlapping peptides spanning P3 and mutant recombinant gammaC-domains demonstrated that the P3 activity is contained primarily within gamma370-383. Integrins alpha(IIb)beta(3) and beta(5)beta(1) were implicated in recognition of P3, since platelet adhesion to the peptide was blocked by function-blocking monoclonal antibodies against these receptors. Direct evidence that alpha(IIb)beta(3) and alpha(5)beta(1) bind P3 was obtained by selective capture of these integrins from platelet lysates using a P3 affinity matrix. Thus, these data suggest that the P3 sequence in the gammaC-domain of fibrinogen defines a previously unknown recognition specificity of alpha(IIb)beta(3) and alpha(5)beta(1) and may function as a binding site for these integrins.	Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; AV Palladin Biochem Inst, UA-01601 Kiev, Ukraine	Cleveland Clinic Foundation; National Academy of Sciences Ukraine; Palladin Institute of Biochemistry of NASU	Ugarova, TP (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,Mail Code NB-50, Cleveland, OH 44195 USA.	ugarovt@ccf.org		Volkov, Georgii/0000-0003-0355-0510	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924, R01HL063199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63199, HL 54924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura S, 1997, J BIOL CHEM, V272, P8824, DOI 10.1074/jbc.272.13.8824; BAJT ML, 1992, J BIOL CHEM, V267, P3789; Basani RB, 2000, BLOOD, V95, P180, DOI 10.1182/blood.V95.1.180.001k16_180_188; BLUMENSTEIN M, 1992, BIOCHEMISTRY-US, V31, P10692, DOI 10.1021/bi00159a008; BOLYARD MG, 1988, GENE, V66, P183, DOI 10.1016/0378-1119(88)90355-1; BRAATEN JV, 1994, BLOOD, V83, P982; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; COHEN I, 1989, BLOOD, V73, P1880; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; Farrell DH, 1997, BIOCHEMISTRY-US, V36, P1123, DOI 10.1021/bi962446r; GARTNER TK, 1988, THROMB RES, V49, P43; GARTNER TK, 1993, THROMB RES, V71, P47; Grimaldi CM, 1998, BLOOD, V91, P1562, DOI 10.1182/blood.V91.5.1562.1562_1562_1571; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Liu QD, 1998, BBA-PROTEIN STRUCT M, V1385, P33, DOI 10.1016/S0167-4838(98)00039-9; Liu QD, 1998, BBA-PROTEIN STRUCT M, V1429, P217, DOI 10.1016/S0167-4838(98)00235-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Loike JD, 1999, J CELL BIOL, V144, P1047, DOI 10.1083/jcb.144.5.1047; MACIEIRACOELHO A, 1990, J CELL PHYSIOL, V142, P610, DOI 10.1002/jcp.1041420322; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MATSUEDA GR, 1988, FIBRINOGEN, V3, P133; Mayo KH, 1996, BIOCHEMISTRY-US, V35, P4434, DOI 10.1021/bi952485n; Moskowitz KA, 1998, THROMB HAEMOSTASIS, V79, P824, DOI 10.1055/s-0037-1615072; Nurden AT, 1999, THROMB HAEMOSTASIS, V82, P468; Osdoit S, 2001, J BIOL CHEM, V276, P6703, DOI 10.1074/jbc.M008945200; PARISE LV, 1993, BIOCHEM J, V289, P445, DOI 10.1042/bj2890445; PEERSCHKE EIB, 1998, THROMBOSIS HEMORRHAG, P229; Rooney MM, 1998, BLOOD, V92, P2374, DOI 10.1182/blood.V92.7.2374.2374_2374_2381; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Smith RA, 2000, THROMB HAEMOSTASIS, V84, P819; Smith RA, 1997, J BIOL CHEM, V272, P22080, DOI 10.1074/jbc.272.35.22080; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; Tozer EC, 1999, BLOOD, V93, P918, DOI 10.1182/blood.V93.3.918.403k26_918_924; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; Ward CM, 2000, BLOOD, V96, P161, DOI 10.1182/blood.V96.1.161.013k50_161_169; Ware S, 1999, PROTEIN SCI, V8, P2663, DOI 10.1110/ps.8.12.2663; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967; ZAMARRON C, 1990, THROMB HAEMOSTASIS, V64, P41; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193; 1998, J BIOL CHEM, V273, P35039	53	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32251	32258		10.1074/jbc.M300410200	http://dx.doi.org/10.1074/jbc.M300410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799374	hybrid			2022-12-25	WOS:000184782100100
J	Tibbetts, AS; Oesterlin, L; Chan, SY; Kramer, G; Hardesty, B; Appling, DR				Tibbetts, AS; Oesterlin, L; Chan, SY; Kramer, G; Hardesty, B; Appling, DR			Mammalian mitochondrial initiation factor 2 supports yeast mitochondrial translation without formylated initiator tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; FUNCTIONAL DOMAINS; FACTOR IF2; PURIFICATION; TRANSFORMYLASE; EXPRESSION; FACTOR-IF2; SEQUENCE; CLONING	Initiation of protein synthesis in mitochondria and chloroplasts is widely believed to require a formylated initiator methionyl-tRNA (fMet-tRNA(f)(Met)) in a process involving initiation factor 2 (IF2). However, yeast strains disrupted at the FMT1 locus, encoding mitochondrial methionyl-tRNA formyltransferase, lack detectable fMet-tRNA(f)(Met) but exhibit normal mitochondrial function as evidenced by normal growth on non-fermentable carbon sources. Here we show that mitochondrial translation products in Saccharomyces cerevisiae were synthesized in the absence of formylated initiator tRNA. ifm1 mutants, lacking the mitochondrial initiation factor 2 ( mIF2), are unable to respire, indicative of defective mitochondrial protein synthesis, but their respiratory defect could be complemented by plasmid-borne copies of either the yeast IFM1 gene or a cDNA encoding bovine mIF2. Moreover, the bovine mIF2 sustained normal respiration in ifm1 fmt1 double mutants. Bovine mIF2 supported the same pattern of mitochondrial translation products as yeast mIF2, and the pattern did not change in cells lacking formylated Met-tRNA(f)(Met). Mutant yeast lacking any mIF2 retained the ability to synthesize low levels of a subset of mitochondrially encoded proteins. The ifm1 null mutant was used to analyze the domain structure of yeast mIF2. Contrary to a previous report, the C terminus of yeast mIF2 is required for its function in vivo, whereas the N-terminal domain could be deleted. Our results indicate that formylation of initiator methionyl-tRNA is not required for mitochondrial protein synthesis. The ability of bovine mIF2 to support mitochondrial translation in the yeast fmt1 mutant suggests that this phenomenon may extend to mammalian mitochondria as well.	Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, 1 Univ Stn A5300, Austin, TX 78712 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061428] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; EPLER JL, 1970, BIOCHEMISTRY-US, V9, P3575, DOI 10.1021/bi00820a011; FELDMAN F, 1974, J BIOL CHEM, V249, P3702; GALPER JB, 1969, BIOCHEM BIOPH RES CO, V34, P205, DOI 10.1016/0006-291X(69)90633-0; Garofalo C, 2003, ARCH BIOCHEM BIOPHYS, V413, P243, DOI 10.1016/S0003-9861(03)00119-X; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; HALBREICH A, 1971, P NATL ACAD SCI USA, V68, P294, DOI 10.1073/pnas.68.2.294; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; LAALAMI S, 1991, BIOCHIMIE, V73, P1557, DOI 10.1016/0300-9084(91)90191-3; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; LIAO HX, 1991, J BIOL CHEM, V266, P20714; Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805; MA JH, 1995, BBA-GENE STRUCT EXPR, V1261, P321, DOI 10.1016/0167-4781(95)00041-E; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; Szkaradkiewicz K, 2000, EUR J BIOCHEM, V267, P4290, DOI 10.1046/j.1432-1327.2000.01480.x; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; Takeuchi N, 1998, J BIOL CHEM, V273, P15085, DOI 10.1074/jbc.273.24.15085; Tan THP, 2002, P NATL ACAD SCI USA, V99, P1152, DOI 10.1073/pnas.022522299; TERPSTRA P, 1979, J BIOL CHEM, V254, P2662; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Vial L, 2003, BIOCHEMISTRY-US, V42, P932, DOI 10.1021/bi026901x; Westermann B, 2001, METHOD CELL BIOL, V65, P429, DOI 10.1016/S0091-679X(01)65025-8; ZIMMERMANN FK, 1969, MOL GEN GENET, V103, P348, DOI 10.1007/BF00383485	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31774	31780		10.1074/jbc.M304962200	http://dx.doi.org/10.1074/jbc.M304962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799364	hybrid			2022-12-25	WOS:000184782100039
J	Sacco, A; Siepi, F; Crescenzi, M				Sacco, A; Siepi, F; Crescenzi, M			HPV E7 expression in skeletal muscle cells distinguishes initiation of the postmitotic state from its maintenance	ONCOGENE			English	Article						cell cycle reactivation; terminal differentiation; papillomavirus; postmitotic state; retinoblastoma protein	PAPILLOMAVIRUS TYPE-16 E7; TERMINALLY DIFFERENTIATED CELLS; A GENE-EXPRESSION; CYCLIN-A; RETINOBLASTOMA PROTEIN; CELLULAR-DIFFERENTIATION; MYOGENIC DIFFERENTIATION; KINASE-ACTIVITY; DNA-SYNTHESIS; S-PHASE	The E7 oncogene is an essential tool used by papillomaviruses to interfere with the cell cycle and cellular differentiation. We investigated the effects of E7 expression on both cellular functions in skeletal muscle cells, a terminally differentiating system. When expressed in myoblasts, E7 impaired differentiation only partially, but allowed continuation of DNA synthesis during and after differentiation. Surprisingly, E7 expression in terminally differentiated myotubes could not reactivate DNA synthesis even though the oncogene bound the retinoblastoma protein, reduced its levels, and increased E2F transcriptional activity. Despite the high cyclin E protein levels induced by E7, the myotubes remained devoid of cyclin E-associated kinase activity. Enforcement of such activity in the presence of E7 brought myotubes into S phase. These results show that E7, unlike other DNA tumor-virus oncogenes, cannot reactivate the cell cycle in postmitotic myotubes. In contrast, E7 allows significant differentiation to occur in the presence of persisting DNA synthesis. These observations distinguish E7 from other functionally related oncogenes and bear significance for the understanding of the natural life cycle of human papillomaviruses. The fact that E7 alone inhibits the initiation but not the maintenance of the postmitotic state indicates that the mechanisms underlying these two functions are at least partially distinct.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Crescenzi, M (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018	Crescenzi, Marco/0000-0003-0156-1494	Telethon [GP0293Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; BIGNAMI M, 1988, ONCOGENE, V2, P509; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Chien WM, 2002, J VIROL, V76, P2964, DOI 10.1128/JVI.76.6.2964-2972.2002; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; ENDO T, 1989, UCLA S MOL CELL BIOL, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; MAIONE R, 1992, ONCOGENE, V7, P85; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pajalunga D, 1999, ONCOGENE, V18, P5054, DOI 10.1038/sj.onc.1202897; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Puri PL, 1998, CANCER RES, V58, P1325; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Tedesco D, 1997, J VIROL, V71, P2217, DOI 10.1128/JVI.71.3.2217-2224.1997; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	43	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4027	4034		10.1038/sj.onc.1206353	http://dx.doi.org/10.1038/sj.onc.1206353			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821937				2022-12-25	WOS:000183707600006
J	Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C				Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C			Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene	ONCOGENE			English	Article						Hepatitis B Virus; insertional mutagenesis; hepatocellular carcinoma; hTERT	HUMAN COLORECTAL CARCINOMAS; CELLS-IN-VITRO; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS; HUMAN GENOME; INTEGRATION; ACTIVATION; RECEPTOR; DNA; PROTEIN	Integration of Hepatitis B Virus (HBV) DNA into liver cell DNA has been well established, but its implication in liver carcinogenesis is still being debated. In particular, insertion of the viral genome into cellular genes has been viewed as a rare event. By using HBV-Alu PCR, we have now isolated, from nine hepatocellular carcinomas, nine HBV-DNA integration sites showing that the viral genome mutates key regulatory cellular genes: neurotropic tyrosin receptor kinase 2 (NTRK2) gene, IL-1R-associated kinase 2 (IRAK2) gene, p42 mitogen-activated protein kinase 1 (p42MAPK1) gene, inositol 1,4,5-triphosphate receptor type 2 (IP3R2) gene, inositol 1,4,5-triphosphate receptor (IP3R) type 1 (IP3R1) gene, alpha 2,3 sialyltransferase (ST3GAL VI or SITA) gene, thyroid hormone uncoupling protein (TRUP) gene, EMX2-like gene, and human telomerase reverse transcriptase (hTERT) gene. This result brings to 15 the total number of genes targeted by HBV in a study of 22 human liver cancers. Overall, we found that both the inositol 1,4,5-triphosphate receptor gene and the telomerase gene were targeted by HBV in two different tumors. Thus, HBV frequently targets cellular genes involved in cell signalling and some of them may be preferential targets of the viral integration.	Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Sch Med, Chiba 2608670, Japan; Hop Necker Enfants Malad, Dept Biostat & Med Informat, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France.	paterlini@necker.fr	Devrim, Gozuacik/C-3330-2008; Chami, Mounia/S-6471-2019	Devrim, Gozuacik/0000-0001-7739-2346; Chami, Mounia/0000-0003-1498-7187; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Fourel G, 1994, PRIMARY LIVER CANC E, P89; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; GRAEF E, 1994, ONCOGENE, V9, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAYNE GS, 1982, NATURE, V21, P209; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schneider F, 2001, CANCER RES, V61, P4605; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shibayama E, 1996, AM J PATHOL, V148, P1807; Sugimoto T, 2001, JPN J CANCER RES, V92, P152, DOI 10.1111/j.1349-7006.2001.tb01077.x; TAHARA H, 1995, CANCER RES, V55, P2734; Tu H, 2001, CANCER RES, V61, P7803; Urashima T, 1997, J HEPATOL, V26, P771, DOI 10.1016/S0168-8278(97)80241-3; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wang YX, 2000, INT J ONCOL, V16, P757; Weber G, 1996, ANTICANCER RES, V16, P3271; YU C, 2002, 93 ANN M AM ASS CANC, V43; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	40	226	235	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3911	3916		10.1038/sj.onc.1206492	http://dx.doi.org/10.1038/sj.onc.1206492			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813464				2022-12-25	WOS:000183612000010
J	Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC				Fleury-Feith, J; Lecomte, C; Renier, A; Matrat, M; Kheuang, L; Abramowski, V; Levy, F; Janin, A; Giovannini, M; Jaurand, MC			Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours	ONCOGENE			English	Article						asbestos; NF2; mesothelioma; hemizygous mice	HUMAN-MALIGNANT MESOTHELIOMA; FACTOR SCATTER FACTOR; NEUROFIBROMATOSIS TYPE-2; SUPPRESSOR GENES; FISCHER-344 RATS; VITREOUS FIBERS; MINERAL FIBERS; INTRAPERITONEAL; GROWTH; TOXICITY	Biallelic NF2 gene inactivation is frequently found in human malignant mesothelioma. In order to assess whether NF2 hemizygosity may enhance susceptibility to asbestos fibres, we investigated the Nf2 status in mesothelioma developed in mice presenting a heterozygous mutation of the Nf2 gene (Nf2(KO3/+)), after intraperitoneal inoculation of crocidolite fibres. Asbestos-exposed Nf2(KO3/+) mice developed tumoural ascites and mesothelioma at a higher frequency than their wild-type (WT) counterparts (P<0.05). Six out of seven mesothelioma cell lines established from neoplastic ascitic fluids of Nf2(KO3/+) mice exhibited loss of the WT Nf2 allele and no neurofibromatosis type 2 protein expression was found in these cells. The res its show the importance of the NF2 gene in mesothelial oncogenesis, the potential association of asbestos exposure and tumour suppressor gene inactivation, and suggest that NF2 gene mutation may be a susceptibility factor to asbestos.	Univ Paris 12, INSERM EMI 99 09, Fac Med, F-94010 Creteil, France; Hop Tenon, Serv Histol Biol Tumorale, F-75020 Paris, France; Ctr Hosp Intercommunal, Serv Pathol Professionelles, F-94010 Creteil, France; Fdn Jean Dasset, INSERM U434, CEPH, F-75010 Paris, France; Univ Paris 07, Pathol Lab, ERM 220 INSERM, Hop St Louis, F-75010 Paris, France; Univ Paris 07, ERM 220 INSERM, Pathol Lab, Hop St Louis, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jaurand, MC (corresponding author), Univ Paris 12, INSERM EMI 99 09, Fac Med, 8 Rue Gen Sarrail, F-94010 Creteil, France.		JAURAND, MARIE-CLAUDE/S-3538-2017	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; Matrat, Mireille/0000-0001-9252-2612; Boulange-Lecomte, Celine/0000-0002-2461-7473				Adachi S, 2001, IND HEALTH, V39, P168, DOI 10.2486/indhealth.39.168; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ASPLUND T, 1994, CANCER RES, V54, P4516; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; CRAIGHEAD JE, 1994, LUNG BIOL HEALTH DIS, V78, P79; Cullen RT, 2000, INHAL TOXICOL, V12, P959; Cullen RT, 2000, J APPL TOXICOL, V20, P49, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<49::AID-JAT627>3.0.CO;2-L; DAVIS JMG, 1991, INT J EXP PATHOL, V72, P263; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Giovannini M, 2000, GENE DEV, V14, P1617; GOODGLICK LA, 1986, CANCER RES, V46, P5558; Grander D, 1998, MED ONCOL, V15, P20, DOI 10.1007/BF02787340; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; HANSTEEN IL, 1993, CANCER GENET CYTOGEN, V70, P94, DOI 10.1016/0165-4608(93)90174-K; Harvey P, 1996, J PATHOL, V180, P389; HESTERBERG TW, 1993, FUND APPL TOXICOL, V20, P464, DOI 10.1006/faat.1993.1057; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kociok N, 1999, CANCER GENET CYTOGEN, V111, P71, DOI 10.1016/S0165-4608(98)00221-0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lechner JF, 1997, ENVIRON HEALTH PERSP, V105, P1061, DOI 10.2307/3433510; Lee YCG, 2002, AM J RESP CRIT CARE, V165, P88, DOI 10.1164/ajrccm.165.1.2104006; MAST RW, 1995, INHAL TOXICOL, V7, P425, DOI 10.3109/08958379509015208; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MOALLI PA, 1987, AM J PATHOL, V128, P426; Murthy SS, 1999, J CELL PHYSIOL, V180, P150, DOI 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0; Pylkkanen L, 2002, ONCOL REP, V9, P955; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; Roller M, 1997, ENVIRON HEALTH PERSP, V105, P1253, DOI 10.2307/3433542; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shibuya M, 1999, CANCER CHEMOTH PHARM, V43, pS72, DOI 10.1007/s002800051102; SMITH DM, 1987, ANN OCCUP HYG, V31, P731, DOI 10.1093/annhyg/31.4B.731; SUZUKI Y, 1984, ENVIRON RES, V35, P277, DOI 10.1016/0013-9351(84)90136-1; Unfried K, 1997, ENVIRON HEALTH PERSP, V105, P1103, DOI 10.2307/3433516; Vaslet CA, 2002, TOXICOL SCI, V68, P331, DOI 10.1093/toxsci/68.2.331; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364; 2001, J O REPUBLIQUE  0608, P9094	41	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3799	3805		10.1038/sj.onc.1206593	http://dx.doi.org/10.1038/sj.onc.1206593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802287				2022-12-25	WOS:000183551000014
J	Bajari, TM; Strasser, V; Nimpf, J; Schneider, WJ				Bajari, TM; Strasser, V; Nimpf, J; Schneider, WJ			A model for modulation of leptin activity by association with clusterin	FASEB JOURNAL			English	Article						apolipoprotein; LDL receptor; obesity; signaling; uptake	DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-J/CLUSTERIN; BINDING DOMAIN; HUMAN BLOOD; GENE; EXPRESSION; PROTEIN; COMPLEMENT; PLASMA; SP-40,40	Transport, biological actions, and clearance of leptin are subject to modulation by plasma components responsible for the formation of the so-called "bound" fraction of serum leptin. Candidates for modulators have been identified previously, but mechanisms for their action, and thus their physiological roles, have remained unclear. Here we have obtained evidence for a role of serum-borne clusterin in leptin biology and have delineated a possible mechanism for its action. We demonstrate complex formation between clusterin and leptin by several approaches and show that the binary complex retains the ability to transduce the leptin signal via binding to the leptin receptor and activation of the Janus kinase/signal transducer and activator of transcription pathway. The interaction of leptin with clusterin does not require additional serum components. Furthermore, and importantly for modulation of the bioactivity of leptin, uptake of leptin present in the complex can be mediated by members of the low density lipoprotein (LDL) receptor family, i.e., apolipoprotein receptor type-2 and the very LDL receptor, which here are shown to efficiently endocytose both free and leptin-associated clusterin. Thus, bioavailability of leptin at a given tissue site may be determined by the levels of clusterin and/or by the relative distribution of certain relatives of the LDL receptor vis-a-vis active leptin receptors.	Inst Med Biochem, Dept Mol Genet, Bioctr, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna	Schneider, WJ (corresponding author), Inst Med Biochem, Dept Mol Genet, Bioctr, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wjs@mol.univie.ac.at		Nimpf, Johannes/0000-0002-9273-3492				Bajari TM, 1998, BIOL CHEM, V379, P1053, DOI 10.1515/bchm.1998.379.8-9.1053; Barth S, 2000, APPL ENVIRON MICROB, V66, P1572, DOI 10.1128/AEM.66.4.1572-1579.2000; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Birkenmeier G, 1998, EUR J ENDOCRINOL, V139, P224, DOI 10.1530/eje.0.1390224; Brabant G, 2000, DIABETOLOGIA, V43, P438, DOI 10.1007/s001250051326; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chapman IM, 1997, CLIN ENDOCRINOL, V46, P175, DOI 10.1046/j.1365-2265.1997.1200936.x; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; CHOIMIURA NH, 1993, CLIN EXP IMMUNOL, V93, P242; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diamond FB, 1997, BIOCHEM BIOPH RES CO, V233, P818, DOI 10.1006/bbrc.1997.6538; Faggioni R, 1998, AM J PHYSIOL-REG I, V274, pR204, DOI 10.1152/ajpregu.1998.274.1.R204; Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407; Forte TM, 1999, J LIPID RES, V40, P1276; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Hatters DM, 2002, EUR J BIOCHEM, V269, P2789, DOI 10.1046/j.1432-1033.2002.02957.x; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Holub M, 1999, INT J OBESITY, V23, P60, DOI 10.1038/sj.ijo.0800759; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Hynes GR, 2001, CURR OPIN LIPIDOL, V12, P321, DOI 10.1097/00041433-200106000-00012; JAMES RW, 1991, ARTERIOSCLER THROMB, V11, P645, DOI 10.1161/01.ATV.11.3.645; JENNE DE, 1991, J BIOL CHEM, V266, P11030; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; KIPRIYANOV SM, 1994, MOL IMMUNOL, V31, P1047, DOI 10.1016/0161-5890(94)90100-7; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; Klimaschewski L, 2001, CELL TISSUE RES, V306, P209, DOI 10.1007/s004410100431; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Mahon MG, 1999, J BIOL CHEM, V274, P4036, DOI 10.1074/jbc.274.7.4036; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Ronacher B, 2000, VIROLOGY, V278, P541, DOI 10.1006/viro.2000.0636; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Silkensen JR, 1998, J LAB CLIN MED, V131, P28, DOI 10.1016/S0022-2143(98)90074-9; SINHA MK, 1996, J CLIN INVEST, V98, P127; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Swertfeger DK, 1996, AM J PATHOL, V148, P1971; TARGAGLIA LA, 1995, CELL, V83, P1263; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	56	39	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1505	+		10.1096/fj.02-1106fje	http://dx.doi.org/10.1096/fj.02-1106fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824284				2022-12-25	WOS:000183818000038
J	Franklin, CC; Rosenfeld-Franklin, ME; White, C; Kavanagh, TJ; Fausto, N				Franklin, CC; Rosenfeld-Franklin, ME; White, C; Kavanagh, TJ; Fausto, N			TGF beta 1-induced suppression of glutathione antioxidant defenses in hepatocytes: caspase-dependent posttranslational and caspase-independent transcriptional regulatory mechanisms	FASEB JOURNAL			English	Article						glutamate cysteine ligase; apoptosis; Bcl-X-L	GROWTH-FACTOR-BETA; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; CYTOCHROME-C RELEASE; FACTOR-BETA(1) INDUCES APOPTOSIS; TRANSFORMING GROWTH-FACTOR-BETA-1; CELL-DEATH; CATALYTIC SUBUNIT; FETAL HEPATOCYTES; ACTIVATION; EXPRESSION	TGFbeta1-induced hepatocyte apoptosis involves the production of reactive oxygen species. An effective cellular defense mechanism against oxidative stress is the tripeptide glutathione (GSH), and the rate-limiting step in GSH biosynthesis is catalyzed by the heterodimeric holoenzyme glutamate cysteine ligase (GCL). Here, we demonstrate the TGFbeta1-induced apoptosis in the TAMH murine hepatocyte cell line is accompanied by both the cleavage and loss of the catalytic subunit of GCL (GCLC) and the down-regulation of GCLC gene expression resulting in a reduction in GCL activity and depletion of intracellular GSH. TGFbeta1-induced apoptosis is also accompanied by a reduction in Bcl-X-L, an effect that may facilitate TGFbeta1-induced apoptosis as Bcl-X-L overexpression inhibits TGFbeta1-induced caspase activation and cell death. Interestingly, Bcl-X-L overexpression prevents TGFbeta1-induced cleavage of GCLC protein but not down-regulation of GCLC mRNA. Furthermore, TGFbeta1-induced down-regulation of GCLC mRNA is prevented by inhibition of histone deacetylase activity, suggesting that this is an active repression of GCLF gene transcription. These findings suggest that the suppression of GSH antioxidant defenses associated with the caspase-dependent cleavage of GCLC protein, caspase-independent suppression of GCLC gene expression, and depletion of intracellular GSH may play a role enhancing TGFbeta1-induced oxidative stress and potentiating apoptotic cell death.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Franklin, CC (corresponding author), Univ Washington, Dept Pathol, Box 357705,1959 NE Pacific St,HSB K-088, Seattle, WA 98195 USA.	cfrankli@u.washington.edu			NATIONAL CANCER INSTITUTE [R29CA075316, R01CA090473, R37CA023226, R01CA023226, R01CA074131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, P42ES004696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NCI NIH HHS [CA75316, CA23226, CA90473, CA74131] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NIDDK NIH HHS [F32-DK09920] Funding Source: Medline; NIEHS NIH HHS [ES07033, ES04696] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arsalane K, 1997, AM J RESP CELL MOL, V17, P599, DOI 10.1165/ajrcmb.17.5.2833; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Bellas RE, 1997, AM J PATHOL, V151, P891; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Christensen JG, 1998, CELL GROWTH DIFFER, V9, P815; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Demasi M, 2001, ARCH BIOCHEM BIOPHYS, V389, P254, DOI 10.1006/abbi.2001.2332; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lu SC, 1998, SEMIN LIVER DIS, V18, P331, DOI 10.1055/s-2007-1007168; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Schrum LW, 2001, AM J PHYSIOL-GASTR L, V280, pG139, DOI 10.1152/ajpgi.2001.280.1.G139; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	56	79	79	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1535	+		10.1096/fj.02-0867fje	http://dx.doi.org/10.1096/fj.02-0867fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824300				2022-12-25	WOS:000183818000021
J	Giannoni, E; Chiarugi, P; Cozzi, G; Magnelli, L; Taddei, ML; Fiaschi, T; Buricchi, F; Raugei, G; Ramponi, G				Giannoni, E; Chiarugi, P; Cozzi, G; Magnelli, L; Taddei, ML; Fiaschi, T; Buricchi, F; Raugei, G; Ramponi, G			Lymphocyte function-associated antigen-1-mediated T cell adhesion is impaired by low molecular weight phosphotyrosine phosphatase-dependent inhibition of FAK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; IMMUNOLOGICAL SYNAPSE; INTERCELLULAR-ADHESION; ACTIN CYTOSKELETON; LEUKOCYTE ADHESION; IMMUNE-SYSTEM; KINASE; ACTIVATION; LFA-1; INTEGRINS	Protein tyrosine phosphorylation is one of the earliest signaling events detected in response to lymphocyte function-associated antigen-1 (LFA-1) engagement during lymphocyte adhesion. In particular, the focal adhesion kinase p125FAK, involved in the modulation and rearrangement of the actin cytoskeleton, seems to be a crucial mediator of LFA-1 signaling. Herein, we investigate the role of a FAK tyrosine phosphatase, namely low molecular weight phosphotyrosine phosphatase (LMW-PTP), in the modulation of LFA-1-mediated T cell adhesion. Overexpression of LMW-PTP in Jurkat cells revealed an impairment of LFA-1-dependent cell-cell adhesion upon T cell receptor (TCR) stimulation. Moreover, in these conditions LMW-PTP causes FAK dephosphorylation, thus preventing the activation of FAK downstream pathways. Our results also demonstrated that, upon antigen stimulation, LMW-PTP-dependent FAK inhibition is associated to a strong reduction of LFA-1 and TCR co-clustering toward a single region of T cell surface, thus causing an impairment of receptor activity by preventing changes in their avidity state. Because co-localization of both LFA-1 and TCR is an essential event during encounters of T cells with antigen-presenting cells and immunological synapse ( IS) formation, we suggest an intriguing role of LMW-PTP in IS establishment and stabilization through the negative control of FAK activity and, in turn, of cell surface receptor redistribution.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Dipartimento Patol & Oncol Sperimentali, I-50134 Florence, Italy	University of Florence; University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Vle Morgagni 50, I-50134 Florence, Italy.	ramponi@scibio.unifi.it	Chiarugi, Paola/CDD-7988-2022; Magnelli, Lucia/J-7077-2018; Giannoni, Elisa/AAE-2092-2020	Magnelli, Lucia/0000-0003-4585-1450; raugei, giovanni/0000-0003-1294-786X; Giannoni, Elisa/0000-0001-7136-1098; Chiarugi, Paola/0000-0001-7655-2969				ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; Bottini N, 2002, J BIOL CHEM, V277, P24220, DOI 10.1074/jbc.M202885200; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; delPozo MA, 1996, IMMUNOL TODAY, V17, P127, DOI 10.1016/0167-5699(96)80604-9; DISOMMA MM, 1995, FEBS LETT, V363, P101, DOI 10.1016/0014-5793(95)00292-H; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KILGORE KS, 1995, J IMMUNOL, V155, P1434; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; Rigacci S, 2002, J BIOL CHEM, V277, P41631, DOI 10.1074/jbc.M201709200; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; Roth SJ, 1995, J IMMUNOL METHODS, V188, P97, DOI 10.1016/0022-1759(95)00208-1; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Tabassam FH, 1999, CELL IMMUNOL, V193, P179, DOI 10.1006/cimm.1999.1472; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	45	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36763	36776		10.1074/jbc.M302686200	http://dx.doi.org/10.1074/jbc.M302686200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12815062	Green Published, hybrid			2022-12-25	WOS:000185318300109
J	Singh, S; Powell, DW; Rane, MJ; Millard, TH; Trent, JO; Pierce, WM; Klein, JB; Machesky, LM; McLeish, KR				Singh, S; Powell, DW; Rane, MJ; Millard, TH; Trent, JO; Pierce, WM; Klein, JB; Machesky, LM; McLeish, KR			Identification of the p16-Arc subunit of the Arp 2/3 complex as a substrate of MAPK-activated protein kinase 2 by proteomic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADES; METHIONYL-LEUCYL-PHENYLALANINE; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN ARP2/3 COMPLEX; HUMAN NEUTROPHILS; TNF-ALPHA; TYROSINE PHOSPHORYLATION; ACTIN POLYMERIZATION; SELECTIVE INHIBITOR; HEAT-SHOCK	The p38 MAPK pathway regulates multiple neutrophil functional responses via activation of the serine-threonine kinase MAPK-activated protein kinase 2 (MAP-KAPK2). To identify substrates of MAPKAPK2 that mediate these responses, a proteomic approach was used in which in vitro phosphorylation of neutrophil lysates by exogenously added active recombinant MAPKAPK2 was followed by protein separation using two-dimensional electrophoresis. Peptide mass fingerprinting of peptides defined by MALDI-MS was then utilized to identify phosphorylated proteins detected by autoradiography. Six candidate substrates were identified, including the p16 subunit of the seven-member Arp2/3 complex ( p16-Arc). In vitro studies confirmed that MAPKAPK2 interacts with and phosphorylates the A isoform, but not the B isoform, of p16-Arc with a stoichiometry of 0.6 to 0.7. MAPKAPK2 also phosphorylated p16-Arc in intact Arp2/3 complexes precipitated from neutrophil lysates. Mutation of serine-77 to alanine on the A isoform prevented phosphorylation by MAPKAPK2. The ability of MAPKAPK2 to phosphorylate one isoform of p16-Arc suggests a possible mechanism by which the p38 MAPK cascade regulates remodeling of the actin cytoskeleton.	Univ Louisville, Dept Med, Kidney Dis Program, Mol Signaling Grp, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol, Louisville, KY 40202 USA; James Graham Brown Canc Ctr, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Louisville; University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Birmingham	McLeish, KR (corresponding author), Univ Louisville, Dept Med, Kidney Dis Program, Mol Signaling Grp, 615 S Preston St, Louisville, KY 40202 USA.	k.mcleish@louisville.edu	Klein, Jon/B-9833-2013; Machesky, Laura/Z-4554-2019; Powell, David W/E-9288-2013; McLeish, Kenneth R./B-9819-2013	Machesky, Laura/0000-0002-7592-9856; McLeish, Kenneth R./0000-0002-7816-3286; trent, John/0000-0002-7346-4231	NHLBI NIH HHS [R01 HL66358-01] Funding Source: Medline; NIDDK NIH HHS [R21 DK629686-01, R21 DK62389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Badger AM, 1998, J IMMUNOL, V161, P467; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coxon PY, 2000, J IMMUNOL, V164, P6530, DOI 10.4049/jimmunol.164.12.6530; COXON PY, 2003, IN PRESS CELL SIGNAL; Detmers PA, 1998, J IMMUNOL, V161, P1921; Escott KJ, 2000, BRIT J PHARMACOL, V131, P173, DOI 10.1038/sj.bjp.0703605; Fijen JW, 2001, CLIN EXP IMMUNOL, V124, P16, DOI 10.1046/j.1365-2249.2001.01485.x; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; HASLETT C, 1985, AM J PATHOL, V119, P101; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Jensen ON, 1999, METH MOL B, V112, P513; Jongstra-Bilen J, 2000, BLOOD, V96, P1827, DOI 10.1182/blood.V96.5.1827.h8001827_1827_1835; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Millard TH, 2003, CELL MOTIL CYTOSKEL, V54, P81, DOI 10.1002/cm.10087; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Patton WF, 2000, ELECTROPHORESIS, V21, P1123, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1123::AID-ELPS1123>3.3.CO;2-5; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Rane MJ, 1997, J IMMUNOL, V159, P5070; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rose DM, 1997, J IMMUNOL, V158, P3433; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trent JO, 2001, METHOD ENZYMOL, V340, P290; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; Zu YL, 1998, J IMMUNOL, V160, P1982	57	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36410	36417		10.1074/jbc.M306428200	http://dx.doi.org/10.1074/jbc.M306428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829704	Green Accepted, hybrid			2022-12-25	WOS:000185318300069
J	Cha, MK; Hong, SK; Oh, YM; Kim, IH				Cha, MK; Hong, SK; Oh, YM; Kim, IH			The protein interaction of Saccharomyces cerevisiae cytoplasmic thiol peroxidase II with SFH2p and its in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT PROTEIN; MAMMALIAN PEROXIREDOXIN; CONSERVED CYSTEINE; PROTECTOR PROTEIN; ESCHERICHIA-COLI; YEAST; GENE; PURIFICATION; THIOREDOXIN; CLONING	Previously, we reported that the yeast cytoplasmic thiol peroxidase type II isoform (cTPx II), a member of the TSA/AhpC family, showed a very low peroxidase activity when compared with other cytoplasmic yeast isoforms, and that cTPx II mutant (cTPx IIDelta) showed a severe growth retardation compared with that of the wild-type cells. To reveal the physiological function of cTPx II in yeast cell growth, we searched for proteins which react with cTPx II. In this study, we identified a novel interaction between cTPx II and CSR1p using the yeast two-hybrid system. CSR1p (SFH2p) has been known to be one member of Sec14 homologous (SFH2) proteins. SFH2p exhibits phosphatidylinositol transfer protein activity. Interestingly, we found that cTPx II selectively bound to SFH2p among the five types of SFH proteins and Sec14p. The interaction required the dimerization of cTPx II. In addition, SFH2p also specifically bound to cTPx II among the yeast thiol peroxidase isoforms. The selective interaction of the dimer form of cTPx II ( the oxidized form) with SFH2p was also confirmed by glutathione S-transferase pull-down and immunoprecipitation assays. The growth retardation, clearly reflected by the length of the lag phase, of cTPx IIDelta was rescued by deleting SFH2p in the cTPx IIDelta strain. The SFH2Delta strain did not show any growth retardation. In addition, the double mutant showed a higher susceptibility to oxidative stress. This finding provides the first in vivo demonstration of the specific interaction of cTPx II with SFH2p in an oxidative stress-sensitive manner and a novel physiological function of the complex of cTPx II and SFH2p.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong Seo Gu, Taejon 302735, South Korea.		Kim, Il-Han/W-1401-2019					Adams A, 1997, METHODS YEAST GENETI; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Cha MK, 1998, J BIOCHEM MOL BIOL, V31, P409; Cha MK, 1996, J BIOCHEM MOL BIOL, V29, P236; Cha MK, 2000, BIOCHEMISTRY-US, V39, P6944, DOI 10.1021/bi000034j; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HJ, 1994, J BIOL CHEM, V269, P27671; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Hong SK, 2002, J BIOL CHEM, V277, P12109, DOI 10.1074/jbc.M111341200; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Jeong W, 2000, J BIOCHEM MOL BIOL, V33, P234; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Li XM, 2000, BBA-MOL CELL BIOL L, V1486, P55, DOI 10.1016/S1388-1981(00)00048-2; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456	33	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34952	34958		10.1074/jbc.M301819200	http://dx.doi.org/10.1074/jbc.M301819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824182	hybrid			2022-12-25	WOS:000185164400027
J	Kemp, DM; Lin, JC; Habener, JF				Kemp, DM; Lin, JC; Habener, JF			Regulation of Pax4 paired homeodomain gene by neuron-restrictive silencer factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-PRODUCING CELLS; PANCREATIC AR42J CELLS; TRANSCRIPTION FACTORS; TARGET GENES; FACTOR NRSF; BETA-CELLS; ACTIVIN-A; IN-VIVO; EXPRESSION; DIFFERENTIATION	An elucidation of the key regulatory factors in pancreas development is critical for understanding the pathogenesis of diabetes mellitus. This study examined whether a specific regulatory mechanism that exists in neuronal development also plays a role in the pancreas. In non-neuronal cells, neuron-restrictive silencer factor (NSRF) actively represses gene transcription via a sequence-specific DNA motif known as the neuron-restrictive silencer element (NRSE). This DNA motif has been identified in many genes that are specific markers for cells of neuronal and neuroendocrine lineage. We identified several genes involved in pancreas development that also harbor NRSE-like motifs, including pdx-1, Beta2/NeuroD, and pax4. The paired homeodomain transcription factor Pax4 is implicated in the differentiation of the insulin-producing beta-cell lineage because disruption of the pax4 gene results in a severe deficiency of beta-cells and the manifestation of diabetes mellitus in mice. The NRSE-like motif identified in the upstream pax4 promoter is highly conserved throughout evolution, forms a DNA-protein complex with NRSF, and confers NRSF-dependent transcriptional repression in the context of a surrogate gene promoter. This cis-activating NRSE element also confers NRSF-dependent modulation in the context of the native pax4 gene promoter. Together with earlier reports, these new findings suggest an important functional role for NRSF in the expression of the pax4 gene and infer a role for NRSF in pancreatic islet development.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Habener, JF (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, 55 Fruit St,WEL 320, Boston, MA 02114 USA.		Szymański, Michał K/H-6951-2018; Szymański, Michał Krzysztof/X-5627-2019	Szymański, Michał K/0000-0002-0548-8995; Szymański, Michał Krzysztof/0000-0002-0548-8995	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abderrahmani A, 2001, MOL CELL BIOL, V21, P7256, DOI 10.1128/MCB.21.21.7256-7267.2001; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Atouf F, 1997, J BIOL CHEM, V272, P1929, DOI 10.1074/jbc.272.3.1929; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Brink C, 2001, MECH DEVELOP, V100, P37, DOI 10.1016/S0925-4773(00)00500-1; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Kemp DM, 2003, REV ENDOCR METAB DIS, V4, P5, DOI 10.1023/A:1021809917576; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318; Roopra A, 2001, Mol Interv, V1, P219; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seth KA, 2001, J BIOL CHEM, V276, P13917, DOI 10.1074/jbc.M007745200; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Ueda Y, 2000, FEBS LETT, V480, P101, DOI 10.1016/S0014-5793(00)01914-1; Xu WZ, 2000, MOL CELL ENDOCRINOL, V170, P79, DOI 10.1016/S0303-7207(00)00329-4; Yoo JY, 2001, BIOCHEM BIOPH RES CO, V283, P928, DOI 10.1006/bbrc.2001.4857; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10	25	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35057	35062		10.1074/jbc.M305891200	http://dx.doi.org/10.1074/jbc.M305891200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829700	hybrid			2022-12-25	WOS:000185164400039
J	Laughery, MD; Todd, ML; Kaplan, JH				Laughery, MD; Todd, ML; Kaplan, JH			Mutational analysis of alpha-beta subunit interactions in the delivery of Na,K-ATPase heterodimers to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; INTRACELLULAR-TRANSPORT; PHOSPHORYLATION DOMAIN; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAIN; DISULFIDE BONDS; ATP-BINDING; H+-ATPASE; GLYCOSYLATION	The beta-subunit of the Na, K-ATPase is required to deliver functional alphabeta-heterodimers to the plasma membrane (PM) of baculovirus-infected insect cells. We have investigated the molecular determinants in the beta-subunit for the assembly and delivery processes. Trafficking of both subunits was analyzed by Western blots of fractionated membranes enriched in endoplasmic reticulum ( ER), Golgi, and PM. Heterodimer assembly was evaluated by co-immunoprecipitation, and enzymatic activity was measured by ATPase assay. Elimination of enzymatic activity by D369A point mutation of the alpha-subunit had no effect on the compartmental distribution of the Na, K-ATPase, demonstrating that enzymatic functioning is not a prerequisite for PM delivery. Replacement of all three N-glycosylation site asparagines with glutamines produced no effect on the delivery to the PM or the activity of the enzyme, but increased susceptibility to degradation was observed. Analysis of beta-subunits in which the disulfide bonds were removed through substitution reveals that the bridges are important for PM targeting but not for assembly of the heterodimer. Assembly is supported by beta-subunits with greatly truncated extracellular domains. The presence of the amino-terminal domain and transmembrane segment is sufficient for assembly and PM delivery. Intermediate length truncated beta-subunits and some disulfide bridge substitution mutants assemble with the alpha-subunit but are not able to exit the ER. We conclude that there are different and separable requirements for the assembly of Na, K-ATPase heterodimer complexes, exit of the dimer from the ER, delivery to the PM, and catalytic activity of the dimer.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Oregon Health & Science University	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL 30315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beggah AT, 1997, J BIOL CHEM, V272, P10318; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; Ivanov A, 2000, BIOCHEMISTRY-US, V39, P9778, DOI 10.1021/bi001004j; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kimura T, 2002, J BIOL CHEM, V277, P20671, DOI 10.1074/jbc.M200523200; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; PEDEMONTE CH, 1990, P NATL ACAD SCI USA, V87, P9789, DOI 10.1073/pnas.87.24.9789; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; RAO R, 1993, J BIOL CHEM, V268, P6708; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; RENAUD KJ, 1991, SODIUM PUMP RECENT D, P25; Schmalzing G, 1997, P NATL ACAD SCI USA, V94, P1136, DOI 10.1073/pnas.94.4.1136; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Zamofing D, 1988, Prog Clin Biol Res, V268B, P163; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	36	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34794	34803		10.1074/jbc.M302899200	http://dx.doi.org/10.1074/jbc.M302899200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826673	hybrid			2022-12-25	WOS:000185164400010
J	Utani, A; Momota, Y; Endo, H; Kasuya, Y; Beck, K; Suzuki, N; Nomizu, M; Shinkai, H				Utani, A; Momota, Y; Endo, H; Kasuya, Y; Beck, K; Suzuki, N; Nomizu, M; Shinkai, H			Laminin alpha 3 LG4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT G-DOMAIN; CHAIN-G-DOMAIN; UP-REGULATION; VII COLLAGEN; I COLLAGEN; HUMAN SKIN; INTEGRIN; SEQUENCES; ADHESION; BINDS	The LG4 module of the laminin alpha3 chain (alpha3 LG4), a component of epithelial-specific laminin-5, has cell attachment activity and binds syndecan (Utani, A., Nomizu, M., Matsuura, H., Kato, K., Kobayashi, T., Takeda, U., Aota, S., Nielsen, P. K., and Shinkai, H. (2001) J. Biol. Chem. 276, 28779-28788). Here, we show that recombinant alpha3 LG4 and a 19-mer synthetic peptide (A3G756) within alpha3 LG4 active for syndecan binding increased the expression of matrix metalloproteinase-1 (MMP-1) in keratinocytes and fibroblasts. This induction was inhibited by heparin and required de novo synthesis of proteins. In keratinocytes, A3G756 up-regulated interleukin (IL)-1beta and MMP-1 expression and an IL-1 receptor antagonist thoroughly inhibited A3G756-mediated induction of MMP-1. A3G756 also activated p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal-related kinase (Erk). Studies with specific inhibitors of MAPKs showed that p38 MAPK activation was necessary for both IL-1beta and MMP-1 induction, but Erk activation was required only for MMP-1 induction. In fibroblasts, IL-1 receptor antagonist did not block A3G756-mediated induction of MMP-1. These results indicated that induction of MMP-1 by alpha3 LG4 is mediated through the IL-1beta autocrine loop in keratinocytes but the mechanism of the induction in fibroblasts is different. Our study suggests that the laminin alpha3 LG4 module may play an important role in tissue remodeling by inducing MMP-1 expression during wound healing.	Chiba Univ, Sch Med, Dept Dermatol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pharmacol & Biochem, Chiba 2608670, Japan; Univ Wales Coll Med, Dept Dent Hlth & Biol Sci, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, S Glam, Wales; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 0600810, Japan	Chiba University; Chiba University; Cardiff University; Hokkaido University	Utani, A (corresponding author), Chiba Univ, Sch Med, Dept Dermatol, Chuo Ku, Inohana 1-8-1, Chiba 2608670, Japan.		Beck, Konrad/AAX-1351-2020	Beck, Konrad/0000-0001-5098-9484; Kasuya, Yoshitoshi/0000-0003-0614-5836				Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Guex N., 2000, CURRENT PROTOCOLS PR, V2, P1; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Kato K, 2002, BIOCHEMISTRY-US, V41, P10747, DOI 10.1021/bi020180k; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Lambert CA, 1998, J BIOL CHEM, V273, P23143, DOI 10.1074/jbc.273.36.23143; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Maruyama M, 2000, BRAIN RES, V887, P350, DOI 10.1016/S0006-8993(00)03063-8; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Rees S, 1996, BIOTECHNIQUES, V20, P102; Ridley SH, 1997, J IMMUNOL, V158, P3165; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814; UTANI A, 1995, J BIOL CHEM, V270, P3292, DOI 10.1074/jbc.270.7.3292; UTANI A, 1994, J BIOL CHEM, V269, P19167; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Wan YS, 2001, INT J MOL MED, V7, P329; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yamamoto T, 2000, J IMMUNOL, V164, P6174, DOI 10.4049/jimmunol.164.12.6174	39	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34483	34490		10.1074/jbc.M304827200	http://dx.doi.org/10.1074/jbc.M304827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826666	hybrid, Green Accepted			2022-12-25	WOS:000185047500108
J	Oliva, MA; Huecas, S; Palacios, JM; Martin-Benito, J; Valpuesta, JM; Andreu, JM				Oliva, MA; Huecas, S; Palacios, JM; Martin-Benito, J; Valpuesta, JM; Andreu, JM			Assembly of archaeal cell division protein FtsZ and a GTPase-inactive mutant into double-stranded filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TUBULIN; RING; POLYMERIZATION; HYDROLYSIS; ACTIVATION; IMAGES	We have studied the assembly and GTPase of purified FtsZ from the hyperthermophilic archaeon Methanococcus jannaschii, a structural homolog of eukaryotic tubulin, employing wild-type FtsZ, FtsZ-His(6) (histidine-tagged FtsZ), and the new mutants FtsZ-W319Y and FtsZ-W319Y-His(6), with light scattering, nucleotide analyses, electron microscopy, and image processing methods. This has revealed novel properties of FtsZ. The GTPase of archaeal FtsZ polymers is suppressed in Na+-containing buffer, generating stabilized structures that require GDP addition for disassembly. FtsZ assembly is polymorphic. Archaeal FtsZ(wt) assembles into associated and isolated filaments made of two parallel protofilaments with a 43 Angstrom longitudinal spacing between monomers, and this structure is also observed in bacterial FtsZ from Escherichia coli. The His(6) extension facilitates the artificial formation of helical tubes and sheets. FtsZ-W319Y-His(6) is an inactivated GTPase whose assembly remains regulated by GTP and Mg2+. It forms two-dimensional crystals made of symmetrical pairs of tubulin-like protofilaments, which associate in an antiparallel array (similarly to the known Ca2+-induced sheets of FtsZ-His(6)). In contrast to the lateral interactions of microtubule protofilaments, we propose that the primary assembly product of FtsZ is the double-stranded filament, one or several of which might form the dynamic Z ring during prokaryotic cell division.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Andreu, JM (corresponding author), CSIC, CIB, Ramiro Maeztu 9, Madrid 28020, Spain.	j.m.andreu@cib.csic.es	Oliva, Marian/H-8867-2015; Huecas, Sonia/P-2542-2019; Valpuesta, Jose M/AAA-6002-2019; Valpuesta, José M/T-1977-2017; Huecas, Sonia/K-1754-2014	Oliva, Marian/0000-0002-2215-4639; Huecas, Sonia/0000-0002-6419-441X; Valpuesta, José M/0000-0001-7468-8053; Huecas, Sonia/0000-0002-6419-441X; Andreu, Jose M/0000-0001-8064-6933; Martin-Benito Romero, Jaime/0000-0002-8541-4709				ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Andreu JM, 2002, J BIOL CHEM, V277, P43262, DOI 10.1074/jbc.M206723200; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Buddelmeijer N, 2002, CURR OPIN MICROBIOL, V5, P553, DOI 10.1016/S1369-5274(02)00374-0; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DAI K, 1994, J BACTERIOL, V176, P130, DOI 10.1128/JB.176.1.130-136.1994; Desai A, 1998, BIOESSAYS, V20, P523, DOI 10.1002/(SICI)1521-1878(199807)20:7<523::AID-BIES1>3.0.CO;2-L; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Feucht A, 2001, MOL MICROBIOL, V40, P115, DOI 10.1046/j.1365-2958.2001.02356.x; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hardt S, 1996, J STRUCT BIOL, V116, P68, DOI 10.1006/jsbi.1996.0012; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2000, BIOL CHEM, V381, P993, DOI 10.1515/BC.2000.122; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Lu C, 2001, BMC Microbiol, V1, P7, DOI 10.1186/1471-2180-1-7; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Margolin W, 2003, CURR BIOL, V13, pR16, DOI 10.1016/S0960-9822(02)01381-7; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; MUKERJEE A, 2001, MOL MICROBIOL, V183, P7190; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; Scheffers DJ, 2001, FEBS LETT, V494, P34, DOI 10.1016/S0014-5793(01)02310-9; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WANG XD, 1993, MOL MICROBIOL, V9, P435, DOI 10.1111/j.1365-2958.1993.tb01705.x; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	46	77	79	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33562	33570		10.1074/jbc.M303798200	http://dx.doi.org/10.1074/jbc.M303798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807911	Green Published, hybrid			2022-12-25	WOS:000184901800129
J	Urbankova, E; Voltchenko, A; Pohl, P; Jezek, P; Pohl, EE				Urbankova, E; Voltchenko, A; Pohl, P; Jezek, P; Pohl, EE			Transport kinetics of uncoupling proteins - Analysis of UCP1 reconstituted in planar lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FATTY-ACID INTERACTION; FLIP-FLOP; PHOSPHOLIPID-BILAYERS; PROTON CONDUCTANCE; H+ TRANSPORT; MEMBRANES; MITOCHONDRIA; LONG; PERMEABILITY	According to alternative hypotheses, mitochondrial uncoupling protein 1 (UCP1) is either a proton channel ("buffering model") or a fatty acid anion carrier ("fatty acid cycling"). Transport across the proton channel along a chain of hydrogen bonds (Grotthus mechanism) may include fatty acid carboxyl groups or occur in the absence of fatty acids. In this work, we demonstrate that planar bilayers reconstituted with UCP1 exhibit an increase in membrane conductivity exclusively in the presence of fatty acids. Hence, we can exclude the hypothesis considering a preexisting H+ channel in UCP1, which does not require fatty acid for function. The augmented conductivity is nearly completely blocked by ATP. Direct application of transmembrane voltage and precise current measurements allowed determination of ATP-sensitive conductances at 0 and 150 mV as 11.5 and 54.3 pS, respectively, by reconstituting nearly 3x10(5) copies of UCP1. The proton conductivity measurements carried out in presence of a pH gradient (0.4 units) allowed estimation of proton turnover numbers per UCP1 molecule. The observed transport rate of 14 s(-1) is compatible both with carrier and channel nature of UCP1.	Humboldt Univ, Med Dept Charite, Neurosci Res Ctr, D-10117 Berlin, Germany; Acad Sci Czech Republic, Inst Physiol, Dept Membrane Transport Biophys, Prague, Czech Republic; Res Inst Mol Pharmacol, Berlin, Germany; Humboldt Univ, Inst Biol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Humboldt University of Berlin	Pohl, EE (corresponding author), Humboldt Univ, Med Dept Charite, Neurosci Res Ctr, Schumannstr 20-21, D-10117 Berlin, Germany.	elena.pohl@charite.de	Pohl, Peter/A-5361-2008; Jezek, Petr/B-9264-2012; Pohl, Elena E./A-4025-2009	Pohl, Peter/0000-0002-1792-2314; Jezek, Petr/0000-0002-2720-9395; Pohl, Elena E./0000-0002-0604-5950				BRAHM J, 1983, J PHYSIOL-LONDON, V339, P339, DOI 10.1113/jphysiol.1983.sp014720; CANNON B, 1985, ESSAYS BIOCHEM, V20, P110; Cannon B, 1979, Methods Enzymol, V55, P65; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; FUKS B, 1994, BIOPHYS J, V66, P1404, DOI 10.1016/S0006-3495(94)80931-2; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; HEATON GM, 1976, BIOCHEM J, V156, P635, DOI 10.1042/bj1560635; Huang SG, 1996, BIOCHEMISTRY-US, V35, P16806, DOI 10.1021/bi960989v; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1999, J BIOENERG BIOMEMBR, V31, P457, DOI 10.1023/A:1005496306893; JEZEK P, 1990, J BIOL CHEM, V265, P19296; JORGENSEN PL, 1974, Q REV BIOPHYS, V7, P239, DOI 10.1017/S0033583500001426; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BIOCHEM SOC T, V29, P806; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; LIN CS, 1980, FEBS LETT, V113, P304, DOI 10.1016/0014-5793(80)80614-4; MACLENNAN DH, 1975, ANNU REV BIOPHYS BIO, V4, P377, DOI 10.1146/annurev.bb.04.060175.002113; Modriansky M, 1997, J BIOL CHEM, V272, P24759, DOI 10.1074/jbc.272.40.24759; Nicholls DG, 2001, BIOCHEM SOC T, V29, P751, DOI 10.1042/bst0290751; Pohl EE, 2000, BIOCHEMISTRY-US, V39, P1834, DOI 10.1021/bi9919549; Pohl P, 2001, P NATL ACAD SCI USA, V98, P9624, DOI 10.1073/pnas.161299398; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b	38	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32497	32500		10.1074/jbc.M303721200	http://dx.doi.org/10.1074/jbc.M303721200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12826670	hybrid			2022-12-25	WOS:000184901800004
J	Eisenhofer, G; Tian, H; Holmes, C; Matsunaga, J; Roffler-Tarlov, S; Hearing, VJ				Eisenhofer, G; Tian, H; Holmes, C; Matsunaga, J; Roffler-Tarlov, S; Hearing, VJ			Tyrosinase: a developmentally specific major determinant of peripheral dopamine	FASEB JOURNAL			English	Article						L-dopa; tyrosine hydroxylase; sympathetic nervous system; melanocyte; melanin	TARGETED DISRUPTION; MONOAMINE-OXIDASE; SUBSTANTIA-NIGRA; CATECHOLAMINES; HYDROXYLASE; BRAIN; GENE; POPULATIONS; EXPRESSION; METABOLISM	L-3,4-dihydroxyphenylalanine, the immediate precursor of dopamine, can be formed by two enzymes: tyrosine hydroxylase (TH) in catecholamine-producing neurons and chromaffin cells and tyrosinase in melanocytes. In this study we examined whether tyrosinase contributes to production of dopamine. Deficiency of TH caused marked reductions in norepinephrine in albino and pigmented 15-day-old mice. In contrast, peripheral levels of dopamine were reduced only in albino TH-deficient mice and were higher in pigmented than in albino mice, regardless of the presence or absence of TH. We next examined age-related changes in dopamine and cutaneous expression of tyrosinase and melanin in albino and pigmented TH wild-type mice. We found that the differences in peripheral dopamine between pigmented and albino mice disappeared with advancing age following changes in expression and function of tyrosinase. In young animals, tyrosinase was present in epidermis but did not produce detectable melanin. With advancing age, tyrosinase was localized only around hair follicles, melanin synthesis became more pronounced, and dopamine synthesis decreased. The data reveal a previously unrecognized TH-independent major pathway of peripheral dopamine synthesis in young, but not adult, mice. The transient nature of this source of dopamine reflects a developmental switch in tyrosinase-dependent production of dopamine to production of melanin.	NINDS, Sect Clin Neurocardiol, NIH, Bethesda, MD 20892 USA; NINDS, Sect Neural Dev, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Cell Biol, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts University; Tufts University; Tufts University	Eisenhofer, G (corresponding author), NINDS, Sect Clin Neurocardiol, NIH, Bldg 10,Room 6N252,10 Ctr Dr,MSC 1620, Bethesda, MD 20892 USA.	ge@box-g.nih.gov	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	NINDS NIH HHS [NS35639] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035639] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amicarelli F, 1999, CELL MOL BIOL, V45, P1093; BATTYANI Z, 1993, PIGM CELL RES, V6, P400; Biswas S, 1999, ARCH DIS CHILD, V80, P565, DOI 10.1136/adc.80.6.565; BRADBURY AJ, 1986, NEUROPHARMACOLOGY, V25, P897, DOI 10.1016/0028-3908(86)90016-X; CICCARONE V, 1989, CANCER RES, V49, P219; Cransac H, 1997, COMP BIOCHEM PHYS A, V116, P341, DOI 10.1016/S0300-9629(96)00231-9; DAVID JC, 1974, ARCH BIOCHEM BIOPHYS, V160, P561, DOI 10.1016/0003-9861(74)90432-9; EISENHOFER G, 1995, AM J PHYSIOL-GASTR L, V268, pG641, DOI 10.1152/ajpgi.1995.268.4.G641; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Eisenhofer G, 1998, Adv Pharmacol, V42, P374; Fenoll LG, 2002, INT J BIOCHEM CELL B, V34, P1594, DOI 10.1016/S1357-2725(02)00076-6; GilLoyzaga P, 1997, BRAIN RES, V746, P265, DOI 10.1016/S0006-8993(96)01258-9; Goldstein D S, 1995, Hypertens Res, V18 Suppl 1, pS93, DOI 10.1291/hypres.18.SupplementI_S93; GREEN E, 1973, MOUSE NEWS LETT, V49, P31; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hofele K, 2001, EXP NEUROL, V168, P116, DOI 10.1006/exnr.2000.7588; Ilia M, 1999, J COMP NEUROL, V405, P394, DOI 10.1002/(SICI)1096-9861(19990315)405:3<394::AID-CNE9>3.0.CO;2-Y; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; KURTZKE JF, 1990, NEUROLOGY, V40, P42, DOI 10.1212/WNL.40.1.42; LAMBERT GW, 1991, LIFE SCI, V49, P1061, DOI 10.1016/0024-3205(91)90593-Z; LeFur N, 1996, GENOMICS, V37, P245; LUPP A, 1993, N-S ARCH PHARMACOL, V347, P141; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Rachel RA, 2002, J NEUROSCI, V22, P4249, DOI 10.1523/JNEUROSCI.22-11-04249.2002; Raper HS, 1926, BIOCHEM J, V20, P735, DOI 10.1042/bj0200735; Richards M, 1996, NEUROEPIDEMIOLOGY, V15, P214, DOI 10.1159/000109910; Riley PA, 1999, CELL MOL BIOL, V45, P951; Rios M, 1999, J NEUROSCI, V19, P3519; ROSATI G, 1980, NEUROLOGY, V30, P250, DOI 10.1212/WNL.30.3.250; ROSS RA, 1985, CANCER RES, V45, P1628; SLACK R, 1992, EXP CELL RES, V202, P17, DOI 10.1016/0014-4827(92)90399-S; Tian H, 2000, J NEUROSCI, V20, P7362; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; Xu YM, 1997, MOL BRAIN RES, V45, P159, DOI 10.1016/S0169-328X(96)00308-7; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	38	63	80	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1248	1255		10.1096/fj.02-0736com	http://dx.doi.org/10.1096/fj.02-0736com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832289				2022-12-25	WOS:000184471600036
J	Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z				Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z			ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis	ONCOGENE			English	Article						ERK; PI3K; STAT; melanoma; apoptosis	PERIPHERAL-BLOOD CELLS; KAPPA-B ACTIVATION; CONSTITUTIVE ACTIVATION; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; MAP KINASE; C-JUN; INHIBITION; INTERFERON	Signal transducers and activators of transcription (STAT) proteins nuclear translocation and transcriptional activity are regulated by diverse protein kinases in response to extracellular stimuli by cytokines, growth factors and stress. Using two melanoma-derived cell lines that exhibit marked differences in basal activities of MAPKs and PI3K-AKT, we studied changes both in STAT activities and in their sensitization to apoptosis. Activating mutations of B-RAF (T1796A) and impaired expression of PTEN are detected in LU1205, but not in FEMX melanoma cells, and are reflected in high basal levels of expression and activities of MAPKs and PI3K-AKT. Treatment with either PD98059 (PD) or LY294002 (LY), the pharmacological inhibitors of MEK-ERK and PI3K, respectively, markedly increased GAS-Luc activity in LU1205, but not in FEMX cells. Tyrosine phosphorylation of STAT3/5 and of JAK2 also increased upon treatment of LU1205 cells with either PD or LY, suggesting that constitutive active MAPK and PI3K signals inhibit tyrosine phosphorylation of JAK/STATs. Treatment of FEMX and LU1205 with PD sensitized the cells to apoptosis, albeit by TNFalpha and TRAIL death cascades, respectively, indicating that additional yet distinct targets are affected by each signaling pathway. Indeed, the combination of LY and PD treatment synergistically increased the apoptosis of LU1205 and FEMX cells. Overall, whereas PI3K and MAPK downregulate JAK-STAT signaling, additional targets are affected by these kinases and sensitizes melanoma to apoptosis via distinct death cascades.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NN Blochin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Krasil'nikov, Mikhail/R-6938-2019; Ivanov, Vladimir N/A-3081-2008	Krasil'nikov, Mikhail/0000-0002-5902-7633; Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brose MS, 2002, CANCER RES, V62, P6997; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chai SK, 1997, J IMMUNOL, V159, P4720; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Edwards E, 2002, CANCER RES, V62, P4671; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Ozes ON, 1999, NATURE, V401, P82; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	49	111	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4092	4101		10.1038/sj.onc.1206598	http://dx.doi.org/10.1038/sj.onc.1206598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821943	Green Published			2022-12-25	WOS:000183707600012
J	Penengo, L; Rubin, C; Yarden, Y; Gaudino, G				Penengo, L; Rubin, C; Yarden, Y; Gaudino, G			c-Cbl is a critical modulator of the Ron tyrosine kinase receptor	ONCOGENE			English	Article						c-Cbl; Grb2; Ron; ubiquitylation	MACROPHAGE-STIMULATING PROTEIN; GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; BINDING DOMAIN; RING FINGER; ACTIVATION; PHOSPHORYLATION; MET; PROTOONCOGENE; REGULATOR	Ron, the receptor tyrosine kinase (RTK) for the macrophage stimulating protein (MSP), activates multiple signaling pathways by recruiting several positive regulators to a multifunctional docking site. Here we show that stimulation by MSP also recruits a negative regulator, the c-Cbl ubiquitin ligase, to the multifunctional docking site as well as to a juxtamembrane tyrosine autophosphorylation site. c-Cbl recruitment to these two sites results in polyubiquitylation of Ron molecules, which are subsequently sorted for endocytosis and degradation. Both the phosphotyrosine binding domain of c-Cbl and its RING domain are essential for downregulation of Ron. Although Ron and c-Cbl are found also in physical complexes that include Grb2, these associations are insufficient for productive ubiquitylation of Ron. Our results shed light on the mechanism of receptor desensitization mediated by c-Cbl and its binding partner Grb2.	Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Weizmann Inst Sci, Dept Biol Sci, IL-76100 Rehovot, Israel	University of Eastern Piedmont Amedeo Avogadro; Weizmann Institute of Science	Gaudino, G (corresponding author), Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy.		YARDEN, YOSEF/K-1467-2012	PENENGO, Lorenza/0000-0001-7888-4473				Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 1998, J IMMUNOL, V161, P4950; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	36	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3669	3679		10.1038/sj.onc.1206585	http://dx.doi.org/10.1038/sj.onc.1206585			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802274				2022-12-25	WOS:000183551000001
J	Harfouche, R; Gratton, JP; Yancopoulos, GD; Noseda, M; Karsan, A; Hussain, SNA				Harfouche, R; Gratton, JP; Yancopoulos, GD; Noseda, M; Karsan, A; Hussain, SNA			Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases	FASEB JOURNAL			English	Article						angiogenesis; caspases; programmed cell death; JNK/SAPK kinases; apopotosis	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; TIE2 RECEPTOR; APOPTOSIS; PATHWAYS; DEATH; AKT; PHOSPHORYLATION	In this study, we identified whether mitogen-activated protein kinases (MAPKs) mediate the effects of angiopoietin-1 (Ang-1) on endothelial cell apoptosis. Exposure of human umbilical vein endothelial cells to Ang-1 (300 ng/ml) evoked within 15-30 min a 15-fold and a 5-fold increase in phosphorylation of ERK1/2 and p38 MAPKs, respectively. Inhibitors of the PI-3 kinase pathway attenuated Ang-1-induced ERK1/2 phosphorylation at a level up-stream from Raf and MEK1/2, but these inhibitors augmented Ang-1-induced p38 phosphorylation. When serum and growth supplements were withdrawn, the percentage of endothelial apoptosis tripled over 24 h compared with control cells. The presence of Ang-1 (300 ng/ml) significantly attenuated endothelial cell apoptosis and inhibited caspase-9, -7, and -3 activation. These antiapoptotic effects were augmented when a p38 inhibitor was combined with Ang-1, whereas inhibition of ERK1/2 eliminated the antiapoptotic properties of Ang-1. We conclude that both anti- (ERK1/2) and pro- (p38) apoptotic members of MAPKs are simultaneously activated by Ang-1 in endothelial cells and that activation of ERK1/2 by Ang-1 is mediated through the PI-3 kinase pathway. The strong antiapoptotic effects of the ERK and the PI-3 kinase pathways mask the proapoptotic function of p38 MAPKs resulting in net attenuation of apoptosis by Ang-1.	Royal Victoria Hosp, Crit Care Div, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Div Resp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; McGill Univ, Inst Rech Clin Montreal, Montreal, PQ, Canada; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 4E6, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Institut de Recherche Clinique de Montreal (IRCM); McGill University; Universite de Montreal; Regeneron; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Hussain, SNA (corresponding author), Royal Victoria Hosp, Crit Care Div, Room L3-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	sabah.hussain@muhc.mcgill.ca	Karsan, Aly/K-2067-2015; Hussain, Sabah/ABC-5315-2021	Gratton, Jean-Philippe/0000-0001-9877-8520				Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Cardier JE, 2002, MICROVASC RES, V63, P10, DOI 10.1006/mvre.2001.2360; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; HUANG LW, 1995, ONCOGENE, V11, P2097; Jan MS, 1999, BIOCHEM BIOPH RES CO, V264, P724, DOI 10.1006/bbrc.1999.1475; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIM I, 2002, FASEB J, V16, pU63; KOLIZEK TI, 1998, CURR BIOL, V8, P529; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou JH, 2001, J IMMUNOL, V167, P4436, DOI 10.4049/jimmunol.167.8.4436	42	90	91	4	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1523	+		10.1096/fj.02-0698fje	http://dx.doi.org/10.1096/fj.02-0698fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824293				2022-12-25	WOS:000183818000026
J	Shibata, R; Misonou, H; Campomanes, CR; Anderson, AE; Schrader, LA; Doliveira, LC; Carroll, KI; Sweatt, JD; Rhodes, KJ; Trimmer, JS				Shibata, R; Misonou, H; Campomanes, CR; Anderson, AE; Schrader, LA; Doliveira, LC; Carroll, KI; Sweatt, JD; Rhodes, KJ; Trimmer, JS			A fundamental role for KChIPs in determining the molecular properties and trafficking of Kv4.2 potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; RAT HIPPOCAMPAL-NEURONS; K+ CHANNEL; BETA-SUBUNITS; DIFFERENTIAL EXPRESSION; SURFACE EXPRESSION; I-TO; PROTEIN; CURRENTS; INACTIVATION	Kv4 potassium channels regulate action potentials in neurons and cardiac myocytes. Co-expression of EF hand-containing Ca2+-binding proteins termed KChIPs with pore-forming Kv4 alpha subunits causes changes in the gating and amplitude of Kv4 currents ( An, W. F., Bowlby, M. R., Betty, M., Cao, J., Ling, H. P., Mendoza, G., Hinson, J. W., Mattsson, K. I., Strassle, B. W., Trimmer, J. S., and Rhodes, K. J. ( 2000) Nature 403, 553 - 556). Here we show that KChIPs profoundly affect the intracellular trafficking and molecular properties of Kv4.2 alpha subunits. Coexpression of KChIPs1-3 causes a dramatic redistribution of Kv4.2, releasing intrinsic endoplasmic reticulum retention and allowing for trafficking to the cell surface. KChIP co-expression also causes fundamental changes in Kv4.2 steady-state expression levels, phosphorylation, detergent solubility, and stability that reconstitute the molecular properties of Kv4.2 in native cells. Interestingly, the KChIP4a isoform, which exhibits unique effects on Kv4 channel gating, does not exert these effects on Kv4.2 and negatively influences the impact of other KChIPs. We provide evidence that these KChIP effects occur through the masking of an N-terminal Kv4.2 hydrophobic domain. These studies point to an essential role for KChIPs in determining both the biophysical and molecular characteristics of Kv4 channels and provide a molecular basis for the dramatic phenotype of KChIP knockout mice.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Wyeth Res, Neurosci Discovery Res, Princeton, NJ 08543 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; Pfizer	Trimmer, JS (corresponding author), Univ Calif Davis, Sch Med, Dept Pharmacol, 1311 Tupper Hall,1 Shields Ave, Davis, CA 95616 USA.	jtrimmer@ucdavis.edu	Schrader, Laura/ABH-4854-2020	Schrader, Laura/0000-0003-3355-1194; Sweatt, J. David/0000-0003-3567-485X; Misono, Hiroaki/0000-0001-5892-1804	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042225, P01NS037444] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42225, NS37444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Amberg GC, 2002, J PHYSIOL-LONDON, V544, P403, DOI 10.1113/jphysiol.2002.025163; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anderson AE, 2000, J BIOL CHEM, V275, P5337, DOI 10.1074/jbc.275.8.5337; Antonucci DE, 2001, NEUROSCIENCE, V108, P69, DOI 10.1016/S0306-4522(01)00476-6; Antzelevitch C, 2001, BASIC RES CARDIOL, V96, P517, DOI 10.1007/s003950170002; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; HILLE B, 2001, IONIC CHANNELS EXCIT, P136; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; Liss B, 2001, EMBO J, V20, P5715, DOI 10.1093/emboj/20.20.5715; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Malin SA, 2001, J NEUROSCI, V21, P8004, DOI 10.1523/JNEUROSCI.21-20-08004.2001; Malin SA, 2000, J NEUROSCI, V20, P5191, DOI 10.1523/JNEUROSCI.20-14-05191.2000; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Nakamura TY, 2003, PEDIATR RES, V53, P554, DOI 10.1203/01.PDR.0000057203.72435.C9; Oudit GY, 2001, J MOL CELL CARDIOL, V33, P851, DOI 10.1006/jmcc.2001.1376; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Patel SP, 2002, J PHYSIOL-LONDON, V545, P5, DOI 10.1113/jphysiol.2002.031856; Rasband MN, 2002, J CELL BIOL, V159, P663, DOI 10.1083/jcb.200206024; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Schrader LA, 2002, J NEUROSCI, V22, P10123; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081, DOI 10.1152/jn.1998.79.2.1081; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SHI GY, 1994, J BIOL CHEM, V269, P23204; Shibata R, 1999, DEV NEUROSCI-BASEL, V21, P87, DOI 10.1159/000017370; Song WJ, 1998, J NEUROSCI, V18, P3124; Spreafico F, 2001, MOL CELL NEUROSCI, V17, P1, DOI 10.1006/mcne.2000.0913; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Tkatch T, 2000, J NEUROSCI, V20, P579, DOI 10.1523/JNEUROSCI.20-02-00579.2000; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Tsaur ML, 1997, FEBS LETT, V400, P215, DOI 10.1016/S0014-5793(96)01388-9; Varga AW, 2000, LEARN MEMORY, V7, P321, DOI 10.1101/lm.35300; WARD GE, 1985, SCIENCE, V227, P768, DOI 10.1126/science.2857502; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	61	215	230	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36445	36454		10.1074/jbc.M306142200	http://dx.doi.org/10.1074/jbc.M306142200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829703	hybrid			2022-12-25	WOS:000185318300073
J	Bai, XH; Cerimele, F; Ushio-Fukai, M; Waqas, M; Campbell, PM; Govindarajan, B; Der, CJ; Battle, T; Frank, DA; Ye, KQ; Murad, E; Dubiel, W; Soff, G; Arbiser, JL				Bai, XH; Cerimele, F; Ushio-Fukai, M; Waqas, M; Campbell, PM; Govindarajan, B; Der, CJ; Battle, T; Frank, DA; Ye, KQ; Murad, E; Dubiel, W; Soff, G; Arbiser, JL			Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; RIE-1 EPITHELIAL-CELLS; INDUCED APOPTOSIS; DIETARY CURCUMIN; MELANOMA-CELLS; MAGNOLIA BARK; COLON-CANCER; ACTIVATION; KINASE; TRAIL	Natural products comprise a major source of small molecular weight angiogenesis inhibitors. We have used the transformed endothelial cell line SVR as an effective screen of natural product extracts to isolate anti-angiogenesis and anti-tumor compounds. Aqueous extracts of Magnolia grandiflora exhibit potent activity in our SVR proliferation assays. We found that the small molecular weight compound honokiol is the active principle of magnolia extract. Honokiol exhibited potent anti-proliferative activity against SVR cells in vitro. In addition, honokiol demonstrated preferential inhibition of primary human endothelial cells compared with fibroblasts and this inhibition was antagonized by antibodies against TNF alpha-related apoptosis-inducing ligand. In vivo, honokiol was highly effective against angiosarcoma in nude mice. Our preclinical data suggests that honokiol is a systemically available and non-toxic inhibitor of angiogenesis and should be further evaluated as a potential chemotherapeutic agent.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Cardiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Humboldt Univ, Dept Surg, Berlin, Germany; Humboldt Univ, Fac Med Charite, Div Mol Biol, Berlin, Germany; Northwestern Univ, Sch Med, Evanston, IL 60208 USA	Emory University; Emory University; Emory University; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Northwestern University	Arbiser, JL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu		Dubiel, Wolfgang/0000-0002-3393-0701; Campbell, Paul/0000-0002-3345-5007; Der, Channing/0000-0002-7751-2747	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044947, P30AR042687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02030, AR44947, AR42687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ai JL, 2001, PHARMACOLOGY, V63, P34, DOI 10.1159/000056110; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arbiser JL, 1999, J AM ACAD DERMATOL, V40, P925, DOI 10.1016/S0190-9622(99)70080-0; Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Daneker GW, 1998, IN VITRO CELL DEV-AN, V34, P370, DOI 10.1007/s11626-998-0018-9; Dinkova-Kostova AT, 1999, CARCINOGENESIS, V20, P911, DOI 10.1093/carcin/20.5.911; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; FUJITA M, 1973, YAKUGAKU ZASSHI, V93, P429, DOI 10.1248/yakushi1947.93.4_429; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1991, CANCER RES, V51, P813; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Kuribara H, 2000, J PHARM PHARMACOL, V52, P1425, DOI 10.1211/0022357001777432; Kuribara H, 1999, J PHARM PHARMACOL, V51, P97; LaMontagne KR, 2000, AM J PATHOL, V157, P1937, DOI 10.1016/S0002-9440(10)64832-8; LaVallee TM, 2003, CANCER RES, V63, P468; Lin WW, 1997, J CHIN INST CHEM ENG, V28, P29; Maruyama Y, 1998, J NAT PROD, V61, P135, DOI 10.1021/np9702446; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Pieri L, 2003, BBA-GEN SUBJECTS, V1621, P76, DOI 10.1016/S0304-4165(03)00048-5; Pollmann C, 2001, CANCER RES, V61, P8416; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; Rao CV, 1995, ANN NY ACAD SCI, V768, P201, DOI 10.1111/j.1749-6632.1995.tb12122.x; Samaha HS, 1997, CANCER RES, V57, P1301; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Thaloor D, 1998, CELL GROWTH DIFFER, V9, P305; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	42	304	333	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35501	35507		10.1074/jbc.M302967200	http://dx.doi.org/10.1074/jbc.M302967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12816951	hybrid, Green Published			2022-12-25	WOS:000185164400092
J	Li, GY; Liu, KF; Baldwin, SA; Wang, DW				Li, GY; Liu, KF; Baldwin, SA; Wang, DW			Equilibrative nucleoside transporters of Arabidopsis thaliana - cDNA cloning, expression pattern, and analysis of transport activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; MOLECULAR-BIOLOGY; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; CELLULAR UPTAKE; PETUNIA POLLEN; NITROBENZYLTHIOINOSINE; PROTEINS; PURINE	Equilibrative nucleoside transporters (ENTs) occur in diverse organisms. In the model plant Arabidopsis thaliana, eight potential ENTs (AtENTs) have been predicted by genome sequencing. We here report the cloning of the cDNAs for AtENTs 2, 3, 4, 6, 7, and 8. Conceptual translation of the cDNAs of AtENTs 2, 3, 4, 6, 7, and 8 yielded polypeptides possessing strong similarities to ENTs characterized previously. Eleven putative transmembrane domains were identified in each of the six AtENTs. In suspension cells, the transcription of AtENTs 1, 3, 4, 6, and 8 was increased by two treatments ( nitrogen deprivation, application of 5-fluorouracil and methotrexate) that inhibited the de novo pathway of nucleotide synthesis, indicating that multiple members of the Arabidopsis ENT family may function in the salvage pathway of nucleotide synthesis. Except for AtENT1, the transcription of the remaining six AtENTs showed varying degrees of organ specificity. However, all seven AtENTs were expressed in the leaf and flower. In plant, insect, and yeast cells, ectopically expressed AtENT3 was targeted to the plasma membrane. AtENT3 expressed in yeast cells transported adenosine and uridine with high affinity. Furthermore, the activities of AtENT3 appear not to require a transmembrane proton gradient because protonophores did not abolish adenosine or uridine transport. In competition experiments, the transport of [H-3] adenosine by AtENT3 was most significantly inhibited by a number of different purine and pyrimidine nucleosides and 2'-deoxynucleosides, although certain nucleobases and nucleotides were also found to have some inhibitory effect. This indicates that AtENT3 may possess broad substrate specificity. Adenosine and uridine transport by AtENT3, although partly sensitive to the vasodilator drugs dilazep and dipyridamole, was resistant to the nucleoside analogue nitrobenzylmercaptopurine ribonucleoside. We conclude that AtENT3 represents the first ei type ENT characterized from higher plants. The potential functions of ENTs in the biology of A. thaliana are discussed.	Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; University of Leeds	Wang, DW (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China.		Li, Guangyong/G-8702-2014	wang, dao wen/0000-0002-6230-8735				Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BARROS LF, 1995, PFLUG ARCH EUR J PHY, V429, P394, DOI 10.1007/BF00374155; BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1983, BIOCHEM BIOPH RES CO, V110, P417, DOI 10.1016/0006-291X(83)91165-8; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BUCHANAN BB, 2000, BIOCH MOL BIOL PLANT, P861; Cabrita MA, 2002, BIOCHEM CELL BIOL, V80, P623, DOI 10.1139/O02-153; CAMPBELL MK, 1999, BIOCHEMISTRY-US, P670; Cass C E, 1999, Pharm Biotechnol, V12, P313; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; Daram P, 1998, PLANTA, V206, P225, DOI 10.1007/s004250050394; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; FOSKET DE, 1998, PLANT PHYSIOL, P621; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Hervas JP, 2002, BIOTECH HISTOCHEM, V77, P145; Hu YX, 2000, PLANT J, V24, P693, DOI 10.1046/j.1365-313x.2000.00915.x; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; HYDE RJ, 2000, DRUG DEVELOP RES, V50, P38; Jennings LL, 2001, NEUROPHARMACOLOGY, V40, P722, DOI 10.1016/S0028-3908(00)00207-0; KAMBOJ RK, 1985, PLANT PHYSIOL, V79, P801, DOI 10.1104/pp.79.3.801; KAMBOJ RK, 1987, PLANT PHYSIOL, V84, P688, DOI 10.1104/pp.84.3.688; KOMBRINK E, 1983, PLANT PHYSIOL, V73, P370, DOI 10.1104/pp.73.2.370; Landfear SM, 2001, BIOCHEM PHARMACOL, V62, P149, DOI 10.1016/S0006-2952(01)00663-3; Li DP, 2002, J BIOL CHEM, V277, P27772, DOI 10.1074/jbc.M204183200; Li J, 2000, PLANT SCI, V157, P23, DOI 10.1016/S0168-9452(00)00261-2; LIN BL, 1991, AM J BOT, V78, P740, DOI 10.2307/2445065; Lopez ME, 2002, PROTOPLASMA, V219, P82, DOI 10.1007/s007090200008; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; MOFFATT B, 1988, PLANT PHYSIOL, V86, P1150, DOI 10.1104/pp.86.4.1150; Mohlmann T, 2001, FEBS LETT, V509, P370, DOI 10.1016/S0014-5793(01)03195-7; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; NAZARIO GM, 1993, PLANT PHYSIOL, V103, P1203, DOI 10.1104/pp.103.4.1203; Nei N., 2000, MOL EVOLUTION PHYLOG; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NOODEN LD, 1993, AUST J PLANT PHYSIOL, V20, P639, DOI 10.1071/PP9930639; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; ROSS CW, 1981, BIOCH PLANTS, V6, P169; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; Sherman Irwin W., 1998, P177; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; Silva NF, 2002, PLANT MOL BIOL, V50, P667, DOI 10.1023/A:1019951120788; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Thomas C, 1999, PLANT PHYSIOL, V119, P543, DOI 10.1104/pp.119.2.543; TORREY JG, 1976, ANNU REV PLANT PHYS, V27, P435, DOI 10.1146/annurev.pp.27.060176.002251; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VAN'TH OF JACK, 1968, J CELL BIOL, V37, P773, DOI 10.1083/jcb.37.3.773; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 2002, BIOCHEM CELL BIOL, V80, P639, DOI 10.1139/O02-148; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Wohlhueter R M, 1978, Methods Cell Biol, V20, P211, DOI 10.1016/S0091-679X(08)62020-8; Young JD, 2001, CURR TOP MEMBR, V50, P329	61	68	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35732	35742		10.1074/jbc.M304768200	http://dx.doi.org/10.1074/jbc.M304768200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12810710	hybrid			2022-12-25	WOS:000185164400120
J	Conner, SR; Scott, G; Aplin, AE				Conner, SR; Scott, G; Aplin, AE			Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN MELANOCYTES; MAP KINASE PATHWAY; RECEPTOR TYROSINE KINASES; FIBROBLAST-GROWTH-FACTOR; SIGNAL-REGULATED KINASE; CYCLIN D1 EXPRESSION; CONSTITUTIVE ACTIVATION; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; IN-VITRO	Normal cells are dependent upon integrin-mediated adhesion to the extracellular matrix for cell proliferation and survival. Integrins regulate these processes partially through control of extracellular signal-regulated kinases 1 and 2 (ERK1/2). A trait of malignant cells is their ability to undergo anchorage-independent growth. Melanomas are tumors arising from normal melanocytes that, if undetected at an early stage, are highly invasive and poorly treatable. Proliferation of melanoma cells and melanocytes is dependent upon ERK1/2 signaling, and mutation of B-Raf, a component of the ERK1/2 pathway, is commonly found in melanomas. We addressed the role of integrin-mediated adhesion in ERK1/2 signaling in human melanoma cells and primary melanocytes. Basal ERK1/2 activity was low, and growth factor activation was adhesion-dependent in normal human melanocytes. By contrast in mutant B-Raf-expressing melanoma cells (SK-MEL-24 and SKMEL-28), the ERK1/2 pathway was constitutively active, and adhesion-dependent regulation of ERK1/2 activity was by-passed. Furthermore, in melanoma cells, ERK1/2 translocated to the nucleus and regulated transcription events in an adhesion-independent manner. Expression of mutant V599E B-Raf in normal melanocytes was sufficient to promote adhesion-independent ERK1/2 signaling. These results indicate that alterations in the adhesion requirement for ERK1/2 signaling in melanocytes are associated with the acquisition of malignant cell behavior.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Univ Rochester, Sch Med, Dept Dermatol, Rochester, NY 14642 USA	Albany Medical College; University of Rochester	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.							ALBELDA SM, 1990, CANCER RES, V50, P6757; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, J CELL SCI, V112, P695; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; CIRIELLI C, 1995, INT J CANCER, V63, P673, DOI 10.1002/ijc.2910630512; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GASPERICAMPANI A, 1993, MELANOMA RES, V3, P363, DOI 10.1097/00008390-199310000-00011; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Tada A, 2002, J INVEST DERMATOL, V118, P316, DOI 10.1046/j.0022-202x.2001.01694.x; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	54	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34548	34554		10.1074/jbc.M305797200	http://dx.doi.org/10.1074/jbc.M305797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821662	hybrid			2022-12-25	WOS:000185047500116
J	Gajic, O; Buist, G; Kojic, M; Topisirovic, L; Kuipers, OP; Kok, J				Gajic, O; Buist, G; Kojic, M; Topisirovic, L; Kuipers, OP; Kok, J			Novel mechanism of bacteriocin secretion and immunity carried out by lactococcal multidrug resistance proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; SEC-DEPENDENT BACTERIOCIN; ENTEROCOCCUS-FAECIUM L50; ANTIMICROBIAL PEPTIDES; PEDIOCOCCUS-ACIDILACTICI; ABC TRANSPORTERS; ENTEROCINS L50A; LACTIS; PLASMID; SEQUENCE	A natural isolate of Lactococcus lactis was shown to produce two narrow spectrum class II bacteriocins, designated LsbA and LsbB. The cognate genes are located on a 5.6-kb plasmid within a gene cluster specifying LmrB, an ATP-binding cassette-type multidrug resistance transporter protein. LsbA is a hydrophobic peptide that is initially synthesized with an N-terminal extension. The housekeeping surface proteinase HtrA was shown to be responsible for the cleavage of precursor peptide to yield the active bacteriocin. LsbB is a relatively hydrophilic protein synthesized without an N-terminal leader sequence or signal peptide. The secretion of both polypeptides was shown to be mediated by LmrB. An L. lactis strain lacking plasmid-encoded LmrB and the chromosomally encoded LmrA is unable to secrete either of the two bacteriocins. Complementation of the strain with an active LmrB protein resulted in restored export of the two polypeptides across the cytoplasmic membrane. When expressed in an L. lactis strain that is sensitive to LsbA and LsbB, LmrB was shown to confer resistance toward both bacteriocins. It does so, most likely, by removing the two polypeptides from the cytoplasmic membrane. This is the first report in which a multidrug transporter protein is shown to be involved in both secretion and immunity of antimicrobial peptides.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Inst Mol Genet & Genet Engn, YU-11000 Belgrade, Serbia	University of Groningen	Kok, J (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	j.kok@biol.rug.nl	Kok, Jan/C-9972-2012; Kojic, Milan/I-4528-2019; Kuipers, Oscar/B-6752-2009	Kojic, Milan/0000-0001-5645-750X; Kuipers, Oscar/0000-0001-5596-7735				BHUNIA AK, 1987, J IND MICROBIOL, V2, P319, DOI 10.1007/BF01569434; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; CHOPIN A, 1984, PLASMID, V11, P260, DOI 10.1016/0147-619X(84)90033-7; Cintas LM, 1997, APPL ENVIRON MICROB, V63, P4321, DOI 10.1128/AEM.63.11.4321-4330.1997; Cintas LM, 2000, J BACTERIOL, V182, P6806, DOI 10.1128/JB.182.23.6806-6814.2000; Cintas LM, 1998, J BACTERIOL, V180, P1988, DOI 10.1128/JB.180.8.1988-1994.1998; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Diep DB, 1996, J BACTERIOL, V178, P4472, DOI 10.1128/jb.178.15.4472-4483.1996; Drouault S, 2000, APPL ENVIRON MICROB, V66, P588, DOI 10.1128/AEM.66.2.588-598.2000; Franke CM, 1996, J BACTERIOL, V178, P1766, DOI 10.1128/jb.178.6.1766-1769.1996; GAJIC O, 1999, ARCH BIOL SCI, V51, P69; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HAANDRIKMAN AJ, 1990, THESIS U GRONINGEN G, P64; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1994, MICROBIOL-SGM, V140, P2383, DOI 10.1099/13500872-140-9-2383; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; Kalmokoff ML, 2001, APPL ENVIRON MICROB, V67, P4041, DOI 10.1128/AEM.67.9.4041-4047.2001; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; Kleerebezem M, 1997, APPL ENVIRON MICROB, V63, P4581, DOI 10.1128/AEM.63.11.4581-4584.1997; KLEIN M, 1994, FEMS MICROBIOL LETT, V124, P393; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LEER RJ, 1995, MICROBIOL-SGM, V141, P1629, DOI 10.1099/13500872-141-7-1629; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; MIERAU I, 1994, J BACTERIOL, V176, P2854, DOI 10.1128/JB.176.10.2854-2861.1994; Nes IF, 1996, ANTON LEEUW INT J G, V70, P113, DOI 10.1007/BF00395929; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Poquet I, 2000, MOL MICROBIOL, V35, P1042, DOI 10.1046/j.1365-2958.2000.01757.x; Putman M, 1999, BIOCHEMISTRY-US, V38, P1002, DOI 10.1021/bi981863w; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUYE DM, 1995, ANAL BIOCHEM, V226, P382; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; VANASSELDONK M, 1993, J BACTERIOL, V175, P1637, DOI 10.1128/JB.175.6.1637-1644.1993; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOROBO RW, 1995, J BACTERIOL, V177, P3143, DOI 10.1128/jb.177.11.3143-3149.1995; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	54	78	80	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34291	34298		10.1074/jbc.M211100200	http://dx.doi.org/10.1074/jbc.M211100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12801935	hybrid, Green Published			2022-12-25	WOS:000185047500085
J	Girouard, M; Diallo, K; Marchand, B; McCormick, S; Gotte, M				Girouard, M; Diallo, K; Marchand, B; McCormick, S; Gotte, M			Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT PRIMER UNBLOCKING; HIGH-LEVEL RESISTANCE; NUCLEOSIDE INHIBITORS; DNA-SYNTHESIS; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; LAMIVUDINE RESISTANCE; COMBINATION THERAPY; ANALOG RESISTANCE; IN-VITRO	Retroviral resistance to AZT and 3TC has been associated with two different mechanisms. The M184V mutation in the reverse transcriptase (RT) of the human immunodeficiency virus, type 1 (HIV-1) diminishes the incorporation of 3TC-monophosphate (3TC-MP), whereas AZT resistance-conferring mutations were shown to facilitate the phosphorolytic excision of incorporated AZT-MP in the presence of ATP. Both mechanisms show a certain degree of incompatibility; however, previous clinical data revealed that mutations E44D and V118I, when present in a background of classical AZT mutations (M41L, D67N, L210W, and T215Y), confer dual resistance to AZT and 3TC. We have purified RT enzymes that contain E44D and V118I either alone or in a background of different combinations of AZT mutations to study the underlying biochemical mechanisms. We found that enzymes containing E44D in a background of these latter mutations increase the efficiency of excision of 3TC-MP. Unexpectedly, V118I-containing enzymes show dramatic reductions in rates of incorporation of AZT-MP and 3TC-MP. The V118I mutant is also associated with diminished rates of ATP-dependent primer unblocking. The additional presence of mutations M41L, D67N, L210W, and T215Y can partially neutralize this deficit, which helps to explain the concurrent presence of these changes in resistant isolates. These biochemical data make clear that mutations E44D and V118I play distinct mechanistic roles in dual resistance to AZT and 3TC. Our findings are consistent with an increasing number of clinical studies suggesting that the V118I cluster constitutes a novel pathway for HIV resistance to multiple nucleotide analogue RT inhibitors.	McGill Univ, Jewish Gen Hosp, McGill Univ AIDS Ctr 226, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Gotte, M (corresponding author), McGill Univ, Jewish Gen Hosp, McGill Univ AIDS Ctr 226, Lady Davis Inst, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada.							Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Chamberlain PP, 2002, J VIROL, V76, P10015, DOI 10.1128/JVI.76.19.10015-10019.2002; Delaugerre C, 2001, ANTIMICROB AGENTS CH, V45, P946, DOI 10.1128/AAC.45.3.946-948.2001; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Gallego O, 2000, J ACQ IMMUN DEF SYND, V25, P95, DOI 10.1097/00126334-200009010-00015; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Gotte M, 2001, J BIOL CHEM, V276, P6711, DOI 10.1074/jbc.M009097200; Gotte M, 2000, DRUG RESIST UPDATE, V3, P30, DOI 10.1054/drup.2000.0126; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Hanna GJ, 2000, J INFECT DIS, V181, P904, DOI 10.1086/315329; Hertogs K, 2000, ANTIMICROB AGENTS CH, V44, P568, DOI 10.1128/AAC.44.3.568-573.2000; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1992, J BIOL CHEM, V267, P15789; Larder BA, 1999, ANTIMICROB AGENTS CH, V43, P1961, DOI 10.1128/AAC.43.8.1961; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Montes B, 2002, J MED VIROL, V66, P299, DOI 10.1002/jmv.2145; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; Romano L, 2002, J INFECT DIS, V185, P898, DOI 10.1086/339706; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Stoeckli TC, 2002, ANTIMICROB AGENTS CH, V46, P4000, DOI 10.1128/AAC.46.12.4000-4003.2002; Van Vaerenbergh K, 2000, ANTIMICROB AGENTS CH, V44, P2109, DOI 10.1128/AAC.44.8.2109-2117.2000; Walter H, 2002, ANTIMICROB AGENTS CH, V46, P89, DOI 10.1128/AAC.46.1.89-94.2002	39	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34403	34410		10.1074/jbc.M303528200	http://dx.doi.org/10.1074/jbc.M303528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819190	hybrid			2022-12-25	WOS:000185047500098
J	Nedea, E; He, XY; Kim, M; Pootoolal, J; Zhong, GQ; Canadien, V; Hughes, T; Buratowski, S; Moore, CL; Greenblatt, J				Nedea, E; He, XY; Kim, M; Pootoolal, J; Zhong, GQ; Canadien, V; Hughes, T; Buratowski, S; Moore, CL; Greenblatt, J			Organization and function of APT, a subcomplex of the yeast cleavage and polyadenylation factor involved in the formation of mRNA and small nucleolar RNA 3 '-ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; POLY(A) POLYMERASE; TRANSCRIPTION TERMINATION; AFFINITY PURIFICATION; SPECIFICITY FACTOR; PROCESSING FACTORS; WD-REPEAT; IN-VIVO	Messenger RNA 3'-end formation is functionally coupled to transcription by RNA polymerase II. By tagging and purifying Ref2, a non-essential protein previously implicated in mRNA cleavage and termination, we isolated a multiprotein complex, holo-CPF, containing the yeast cleavage and polyadenylation factor (CPF) and six additional polypeptides. The latter can form a distinct complex, APT, in which Pti1, Swd2, a type I protein phosphatase (Glc7), Ssu72 (a TFIIB and RNA polymerase II-associated factor), Ref2, and Syc1 are (a) under bar ssociated with the (Pt) under bar a1 subunit of CPF. Systematic tagging and purification of holo-CPF subunits revealed that yeast extracts contain similar amounts of CPF and holo-CPF. By purifying holo-CPF from strains lacking Ref2 or containing truncated subunits, subcomplexes were isolated that revealed additional aspects of the architecture of APT and holo-CPF. Chromatin immunoprecipitation was used to localize Ref2, Ssu72, Pta1, and other APT subunits on small nucleolar RNA ( snoRNA) genes and primarily near the polyadenylation signals of the constitutively expressed PYK1 and PMA1 genes. Use of mutant components of APT revealed that Ssu72 is important for preventing readthrough-dependent expression of downstream genes for both snoRNAs and polyadenylated transcripts. Ref2 and Pta1 similarly affect at least one snoRNA transcript.	Univ Toronto, Banting & Best Dept Med Res, Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Affinium Pharmaceut, Toronto, ON M5J 1V6, Canada	University of Toronto; University of Toronto; Tufts University; Harvard University; Harvard Medical School	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Dept Med Res, 112 Coll St,Rm 210, Toronto, ON M5G 1L6, Canada.	jack.greenblatt@utoronto.ca	NEDEA, EDUARD/D-5476-2009		NIGMS NIH HHS [GM56663, GM41752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Brachmann CB, 1998, YEAST, V14, P115; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Dheur S, 2003, EMBO J, V22, P2831, DOI 10.1093/emboj/cdg253; Dichtl B, 2002, EMBO J, V21, P4125, DOI 10.1093/emboj/cdf390; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; Ganem C, 2003, EMBO J, V22, P1588, DOI 10.1093/emboj/cdg141; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Graber JH, 2002, NUCLEIC ACIDS RES, V30, P1851, DOI 10.1093/nar/30.8.1851; Graber JH, 1999, NUCLEIC ACIDS RES, V27, P888, DOI 10.1093/nar/27.3.888; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Gross S, 2001, P NATL ACAD SCI USA, V98, P6080, DOI 10.1073/pnas.101046598; He XY, 2003, GENE DEV, V17, P1030, DOI 10.1101/gad.1075203; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Helming S, 2001, MOL CELL BIOL, V21, P2026, DOI 10.1128/MCB.21.6.2026-2037.2001; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Magrath C, 1999, GENETICS, V152, P129; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; Mizrahi N, 2000, MOL CELL BIOL, V20, P2794, DOI 10.1128/MCB.20.8.2794-2802.2000; Morlando M, 2002, MOL CELL BIOL, V22, P1379, DOI 10.1128/MCB.22.5.1379-1389.2002; Ohnacker M, 2000, EMBO J, V19, P37, DOI 10.1093/emboj/19.1.37; Pappas DL, 2000, MOL CELL BIOL, V20, P8343, DOI 10.1128/MCB.20.22.8343-8351.2000; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Russnak R, 1996, GENE EXPRESSION, V6, P241; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SIKORSKI RS, 1989, GENETICS, V122, P19; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Steinmetz EJ, 1998, P NATL ACAD SCI USA, V95, P6699, DOI 10.1073/pnas.95.12.6699; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Helden J, 2000, NUCLEIC ACIDS RES, V28, P1000; Vo LTA, 2001, MOL CELL BIOL, V21, P8346, DOI 10.1128/MCB.21.24.8346-8356.2001; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Wu WH, 1999, GENETICS, V153, P643; Zhao J, 1997, J BIOL CHEM, V272, P10831; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	75	141	156	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33000	33010		10.1074/jbc.M304454200	http://dx.doi.org/10.1074/jbc.M304454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819204	hybrid			2022-12-25	WOS:000184901800064
J	Saydam, N; Steiner, F; Georgiev, O; Schaffner, W				Saydam, N; Steiner, F; Georgiev, O; Schaffner, W			Heat and heavy metal stress synergize to mediate transcriptional hyperactivation by metal-responsive transcription factor MTF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; MOLECULAR CHAPERONES; OXIDATIVE STRESS; SHOCK RESPONSE; INDUCED ACTIVATION; INDUCED APOPTOSIS; MAMMALIAN-CELLS; FACTOR-I; PROTEINS; PROMOTER	Mammalian cells react to heavy metal stress by transcribing a number of genes that contain metal-response elements (MREs) in their promoter/enhancer region; this activation is mediated by metal-responsive transcription factor-1 (MTF-1). Well-known target genes of MTF-1 are those encoding metallothioneins, small, cysteine-rich proteins with a high affinity for heavy metals. The response to heat shock, another cell stress, is mediated by heat shock transcription factor 1 (HSF1), which activates a battery of heat shock genes. Little is known about the cross-talk between the different anti-stress systems of the cell. Here we report a synergistic activation of metal-responsive promoters by heavy metal load ( zinc or cadmium) and heat shock. An obvious explanation, cooperativity between MTF-1 and HSF1, seems unlikely: transfected HSF1 boosts the activity of an Hsp70 promoter but hardly affects an MRE-containing promoter upon exposure to metal and heat shock. A clue to the mechanism is given by our finding that heat shock leads to intracellular accumulation of heavy metals. We propose that the known anti-apoptotic effect of heat shock proteins allows for cell survival despite heavy metal accumulation and, consequently, results in a hyperactivation of the metal response pathway.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Schaffner, W (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; Bruwer M, 2001, INFLAMM RES, V50, P289, DOI 10.1007/PL00000246; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; COYLE P, 1995, INFLAMM RES, V44, P475, DOI 10.1007/BF01837913; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; FULLER KJ, 1994, EUR J CANCER, V30A, P1884, DOI 10.1016/0959-8049(94)00362-9; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Giedroc DP, 2001, ANTIOXID REDOX SIGN, V3, P577, DOI 10.1089/15230860152542943; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIDER A, 1989, J LAB CLIN MED, V113, P221; Hasday JD, 2000, CELL STRESS CHAPERON, V5, P471, DOI 10.1379/1466-1268(2000)005<0471:FATHSR>2.0.CO;2; Heid SE, 2000, MOL PHARMACOL, V57, P82; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; Kang KI, 1999, P NATL ACAD SCI USA, V96, P1439, DOI 10.1073/pnas.96.4.1439; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; Lee MJ, 2002, TOXICOLOGY, V174, P109, DOI 10.1016/S0300-483X(02)00045-8; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Liu HD, 1996, GENE DEV, V10, P592; Liu J, 2002, FREE RADICAL BIO MED, V32, P525, DOI 10.1016/S0891-5849(01)00826-7; Liu XD, 1997, METHODS, V11, P289, DOI 10.1006/meth.1996.0423; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nollen EAA, 2002, J CELL SCI, V115, P2809; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Polla BS, 1998, ANN NY ACAD SCI, V851, P75, DOI 10.1111/j.1749-6632.1998.tb08979.x; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Rink L, 2000, J NUTR, V130, p1407S, DOI 10.1093/jn/130.5.1407S; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; Tchounwou PB, 2001, MOL CELL BIOCHEM, V222, P21, DOI 10.1023/A:1017922114201; Vanacore RM, 2000, ANTIOXID REDOX SIGN, V2, P739, DOI 10.1089/ars.2000.2.4-739; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	57	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31879	31883		10.1074/jbc.M302138200	http://dx.doi.org/10.1074/jbc.M302138200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805380	hybrid			2022-12-25	WOS:000184782100053
J	Funke-Kaiser, H; Lemmer, J; Langsdorff, CV; Thomas, A; Kovacevic, SD; Strasdat, M; Behrouzi, T; Zollmann, FS; Paul, M; Orzechowski, HD				Funke-Kaiser, H; Lemmer, J; Langsdorff, CV; Thomas, A; Kovacevic, SD; Strasdat, M; Behrouzi, T; Zollmann, FS; Paul, M; Orzechowski, HD			Endothelin-converting enzyme-1 is a downstream target of the homeobox transcription factor Nkx2-5	FASEB JOURNAL			English	Article						Nkx2-5; ECE-1; heart development; alternative promoters; gene regulation	ISOFORM-SPECIFIC EXPRESSION; HEART-FAILURE; ALTERNATIVE PROMOTERS; GENE-EXPRESSION; B RECEPTOR; SUBCELLULAR LOCALIZATIONS; MOLECULAR-CLONING; UP-REGULATION; ECE-1; CELLS	The homeobox transcription factor Nkx2-5 and the zinc metalloprotease endothelin-converting enzyme-1 (ECE-1) are essential for cardiac development. Here, we demonstrate for the first time a functional link between Nkx2-5 and ECE-1. In transiently transfected rat H9c2 cardiomyoblasts, the alternative promoters specific for ECE-1a, ECE-1b, and ECE-1c are activated by Nkx2-5 coexpression. Lack of a consensus sequence for Nkx2-5 binding within the ECE-1c promoter and mutational analyses of Nkx2-5 consensus sequences identified in the ECE-1a and ECE-1b promoters, respectively, reveal an indirect mechanism of activation that is supported by gel shift assays. Furthermore, we have evidence of an additional direct activation mechanism of the ECE-1b promoter by Nkx2-5. With the use of RNase protection assay, Northern blot, and real-time PCR, the activating effect of Nkx2-5 on mRNA expression of ECE-1 isoforms was confirmed in the chromatin context of H9c2 and endothelial EA. hy926 cells, respectively, by stable Nkx2-5 overexpression. The interaction presented in this work provides a possible explanation for distinct phenotypic aspects of patients carrying mutations in the Nkx2-5 gene and may also be of significance for the pathophysiology of heart failure.	Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Clin Pharmacol, Inst Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Orzechowski, HD (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Clin Pharmacol, Inst Clin Pharmacol & Toxicol, Hindenburgdamm 30, D-12200 Berlin, Germany.	hans-dieter.orzechowski@medizin.fu-berlin.de	Paul, Martin/K-5425-2015; Funke-Kaiser, Heiko/E-2519-2012					Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; Cattaruzza M, 2000, FASEB J, V14, P991, DOI 10.1096/fasebj.14.7.991; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Ergul A, 2000, AM J PHYSIOL-HEART C, V278, pH2050, DOI 10.1152/ajpheart.2000.278.6.H2050; Evans SM, 1999, SEMIN CELL DEV BIOL, V10, P73, DOI 10.1006/scdb.1999.0282; Funke-Kaiser H, 2000, FEBS LETT, V466, P310, DOI 10.1016/S0014-5793(00)01086-3; Giannessi D, 2001, PHARMACOL RES, V43, P111, DOI 10.1006/phrs.2000.0758; Goldmuntz E, 2001, CIRCULATION, V104, P2565, DOI 10.1161/hc4601.098427; Goto K, 2001, BIOL PHARM BULL, V24, P1219, DOI 10.1248/bpb.24.1219; Hasegawa H, 1998, FEBS LETT, V428, P304, DOI 10.1016/S0014-5793(98)00554-7; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hofstra RMW, 1999, AM J HUM GENET, V64, P304, DOI 10.1086/302184; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Muller L, 2003, J BIOL CHEM, V278, P545, DOI 10.1074/jbc.M208949200; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; Parnot C, 1997, HYPERTENSION, V30, P837, DOI 10.1161/01.HYP.30.4.837; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; Schiffrin EL, 2001, AM J HYPERTENS, V14, p83S, DOI 10.1016/S0895-7061(01)02074-X; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Serneri GGN, 2000, CIRC RES, V86, P377, DOI 10.1161/01.RES.86.4.377; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; Takebayashi-Suzuki K, 2000, DEVELOPMENT, V127, P3523; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thompson JT, 1998, AM J PHYSIOL-HEART C, V274, pH1569, DOI 10.1152/ajpheart.1998.274.5.H1569; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Zolk O, 1999, CIRCULATION, V99, P2118, DOI 10.1161/01.CIR.99.16.2118	56	13	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1487	+		10.1096/fj.02-0700fje	http://dx.doi.org/10.1096/fj.02-0700fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824294				2022-12-25	WOS:000183818000028
J	Iwabuchi, K; Basu, BP; Kysela, B; Kurihara, T; Shibata, M; Guan, DY; Cao, YH; Hamada, T; Imamura, K; Jeggo, PA; Date, T; Doherty, AJ				Iwabuchi, K; Basu, BP; Kysela, B; Kurihara, T; Shibata, M; Guan, DY; Cao, YH; Hamada, T; Imamura, K; Jeggo, PA; Date, T; Doherty, AJ			Potential role for 53BP1 in DNA end-joining repair through direct interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE RESPONSE; BRCT DOMAINS; PROTEIN; BINDING; P53; STIMULATION; RAD9; KU; PHOSPHORYLATION; LOCALIZATION	Upon DNA damage, p53-binding protein 1 (53BP1) relocalizes to sites of DNA double-strand breaks and forms discrete nuclear foci, suggesting its role in DNA damage responses. We show that 53BP1 changed its localization from the detergent soluble to insoluble fraction after treatment of cells with x-ray, but not with ultraviolet or hydroxyurea. Either DNase or phosphatase treatment of the insoluble fraction released 53BP1 into the soluble fraction, showing that 53BP1 binds to chromatin in a phosphorylation-dependent manner after X-irradiation of cells. 53BP1 was retained at discrete nuclear foci in X-irradiated cells even after detergent extraction of cells, showing that the chromatin binding of 53BP1 occurs at sites of DNA double-strand breaks. The minimal domain for focus formation was identified by immunofluorescence staining of cells ectopically expressed with 53BP1 deletion mutants. This domain consisted of conserved Tudor and Myb motifs. The Tudor plus Myb domain possessed chromatin binding activity in vivo and bound directly to both double-stranded and single-stranded DNA in vitro. This domain also stimulated end-joining by DNA ligase IV/Xrcc4, but not by T4 DNA ligase in vitro. We conclude that 53BP1 has the potential to participate directly in the repair of DNA double-strand breaks.	Kanazawa Med Univ, Dept Biochem, Uchinada, Ishikawa 9200293, Japan; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RR, E Sussex, England; Kanazawa Med Univ, Med Res Inst, Uchinada, Ishikawa 9200293, Japan; Med & Biol Labs Co Ltd, Nagano 3960002, Japan	Kanazawa Medical University; University of Cambridge; University of Cambridge; University of Sussex; Kanazawa Medical University	Iwabuchi, K (corresponding author), Kanazawa Med Univ, Dept Biochem, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	kuni-kmu@kanazawa-med.ac.jp; AJD42@cam.ac.uk		Doherty, Aidan/0000-0002-6370-1109				Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Derbyshire DJ, 2002, ACTA CRYSTALLOGR D, V58, P1826, DOI 10.1107/S0907444902010910; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Jullien D, 2002, J CELL SCI, V115, P71; Kawahire S, 1997, J BIOCHEM-TOKYO, V121, P881, DOI 10.1093/oxfordjournals.jbchem.a021669; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	44	127	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36487	36495		10.1074/jbc.M304066200	http://dx.doi.org/10.1074/jbc.M304066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12824158	hybrid			2022-12-25	WOS:000185318300077
J	Bornhauser, BC; Olsson, PA; Lindholm, D				Bornhauser, BC; Olsson, PA; Lindholm, D			MSAP is a novel MIR-interacting protein that enhances neurite outgrowth and increases myosin regulatory light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERM-LIKE PROTEIN; CELL-DEATH; PLASMA-MEMBRANE; GENE-EXPRESSION; EZRIN; PROSAPOSIN; ADHESION; NEURONS; ASSOCIATION; ACTIVATION	Dynamic interactions between the actin cytoskeleton and specific proteins are crucial for changes in cell shape and motility. Here we describe a novel protein MSAP (MIR-interacting saposin-like protein) that is a positive regulator of neurite outgrowth. MSAP is expressed in different tissues, including brain, and has an apparent molecular weight of 21 kDa. MSAP interacts with the ezrin-radixin-moesin (ERM)-like myosin regulatory light chain-interacting protein (MIR), and the two proteins are co-localized in cell lines and in primary neurons. Overexpression of MSAP enhances neurite outgrowth in neuroblastoma and PC12 cells, whereas downregulation of MSAP using RNA silencing led to inhibition of neurite formation. The stimulation of neurite outgrowth by MSAP was abrogated by the overexpression of MIR, which induced a decrease in the levels of myosin regulatory light chain (MRLC). This reduction in MRLC by MIR was inhibited by blocking the activity of proteasome and by overexpression of MSAP, suggesting an effect on protein stability. Evidence was obtained that MIR decreases MRLC by inducing its ubiquitination. The results show that the levels of MRLC are controlled by MIR via ubiquitination and that the effect of MIR on MRLC is counteracted in the presence of MSAP. MSAP can stabilize MRLC and thus bring about an increase in neurite outgrowth.	Univ Uppsala, Ctr Biomed, Dept Neurosci & Neurobiol, S-75123 Uppsala, Sweden	Uppsala University	Lindholm, D (corresponding author), Univ Uppsala, Ctr Biomed, Dept Neurosci & Neurobiol, Box 587, S-75123 Uppsala, Sweden.		Bornhauser, Beat/M-4437-2014; Lindholm, Dan/B-3777-2014					Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; Bridgman PC, 2002, CELL MOTIL CYTOSKEL, V52, P91, DOI 10.1002/cm.10038; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Chaudoir BM, 1999, J CELL SCI, V112, P1611; CHEN J, 1994, AM J PHYSIOL, V267, pC784, DOI 10.1152/ajpcell.1994.267.3.C784; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; Goswami SK, 2001, MOL CELL BIOCHEM, V217, P13, DOI 10.1023/A:1007296330181; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huang HK, 2000, J BIOL CHEM, V275, P26661; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kim YS, 2002, DEV BIOL, V249, P367, DOI 10.1006/dbio.2002.0768; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Olsson PA, 1999, J BIOL CHEM, V274, P36288, DOI 10.1074/jbc.274.51.36288; Olsson PA, 2000, BIOCHEM BIOPH RES CO, V279, P879, DOI 10.1006/bbrc.2000.4028; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TAKEUCHI K, 1994, J BIOL CHEM, V269, P1271; Tsuboi K, 1998, DEV BRAIN RES, V110, P249, DOI 10.1016/S0165-3806(98)00109-6; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613; Yokoyama-Kobayashi M, 1999, GENE, V228, P161, DOI 10.1016/S0378-1119(99)00004-9; Yu LY, 2003, MOL CELL NEUROSCI, V22, P308, DOI 10.1016/S1044-7431(02)00038-6	40	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35412	35420		10.1074/jbc.M306271200	http://dx.doi.org/10.1074/jbc.M306271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826659	hybrid			2022-12-25	WOS:000185164400081
J	Padanyi, R; Paszty, K; Penheiter, AR; Filoteo, AG; Penniston, JT; Enyedi, A				Padanyi, R; Paszty, K; Penheiter, AR; Filoteo, AG; Penniston, JT; Enyedi, A			Intramolecular interactions of the regulatory region with the catalytic core in the plasma membrane calcium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CA2+ PUMP; ISOFORM 4B; CA-2+-ATPASE; PHOSPHORYLATION; ACTIVATION; PROTEASE; ATPASE; ENZYME; GENES	The access of three proteases to their sites of cleavage was used as a measure of regulatory interactions in the plasma membrane Ca2+ pump isoform 4b (PMCA4b). When the proteases could not cut at their sites in the C-terminal regulatory region, the interaction was judged to be tight. This was the case in the absence of Ca2+, when chymotrypsin and caspase cut PMCA only very slowly. Ca2+ accelerated the fragmentation, but the digestion remained incomplete. In the presence of Ca2+ plus calmodulin, the digestion became nearly complete in all cases, indicating a more flexible conformation of the carboxyl terminus in the fully activated state. The acceleration of proteolysis by Ca2+ or Ca2+ plus calmodulin occurred equally at the caspase site upstream of the calmodulin-binding domain and the chymotrypsin and calpain sites downstream of that domain. Replacing Trp(1093) (a key residue within the calmodulin-binding domain) with alanine had a much more specific effect, because it exposed only proteolytic sites within the calmodulin-binding domain that had previously been shielded in the native protein. At these sites, both calpain and chymotrypsin cut the Trp1093 3 Ala mutant in the absence of calmodulin. These data indicate that, in the auto-inhibited conformation, the calmodulin-binding/auto-inhibitory sequence and the regions both upstream and downstream are in close contact with the catalytic core. Trp1093 plays an essential role not only in stabilizing the Ca2+-calmodulin/calmodulin-binding domain complex but also in the formation or stability of the inhibitory conformation of that domain when it interacts with the catalytic core of PMCA4b.	Natl Med Ctr, H-1113 Budapest, Hungary; Hungarian Acad Sci, Membrane Res Grp, H-1051 Budapest, Hungary; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Hungarian Academy of Sciences; Mayo Clinic	Enyedi, A (corresponding author), Natl Med Ctr, Dioszegi Utca 64, H-1113 Budapest, Hungary.	enyedi@biomembrane.hu	Pászty, Katalin/X-3785-2019; Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376; Paszty, Katalin/0000-0003-2457-8555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1990, J BIOL CHEM, V265, P3789; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; JAMES P, 1989, J BIOL CHEM, V264, P8289; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Paszty K, 2002, J BIOL CHEM, V277, P36146, DOI 10.1074/jbc.M205457200; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VERMA AK, 1994, J BIOL CHEM, V269, P1687; WANG KKW, 1991, BIOCHEM J, V279, P537, DOI 10.1042/bj2790537; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	26	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35798	35804		10.1074/jbc.M305794200	http://dx.doi.org/10.1074/jbc.M305794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829699	hybrid			2022-12-25	WOS:000185164400128
J	Zhang, WW; Mendez, S; Ghosh, A; Myler, P; Ivens, A; Clos, J; Sacks, DL; Matlashewski, G				Zhang, WW; Mendez, S; Ghosh, A; Myler, P; Ivens, A; Clos, J; Sacks, DL; Matlashewski, G			Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMASTIGOTE-SPECIFIC PROTEIN; STAGE-SPECIFIC GENE; AXENIC AMASTIGOTES; VIRULENCE FACTOR; LIPOPHOSPHOGLYCAN; EXPRESSION; TROPICA	In Old World Leishmania infections, Leishmania donovani is responsible for fatal visceral leishmaniasis, and L. major is responsible for non-fatal cutaneous leishmaniasis in humans. The genetic differences between these species which govern the pathology or site of infection are not known. We have therefore carried out detailed analysis of the A2 loci in L. major and L. donovani because A2 is expressed in L. donovani but not L. major, and A2 is required for survival in visceral organs by L. donovani. We demonstrate that although L. major contains A2 gene regulatory sequences, the multiple repeats that exist in L. donovani A2 protein coding regions are absent in L. major, and the remaining corresponding A2 sequences appear to represent non-expressed pseudogenes. It was possible to restore amastigote-specific A2 expression to L. major, confirming that A2 regulatory sequences remain functional in L. major. Although L. major is a cutaneous parasite in rodents and humans, restoring A2 expression to L. major inhibited its ability to establish a cutaneous infection in susceptible BALB/c or resistant C57BL6 mice, a phenotype typical of L. donovani. There was no detectable cellular immune response against L. major after cutaneous infection with A2-expressing L. major, suggesting that the lack of growth was not attributable to acquired host resistance but to an A2-mediated suppression of parasite survival in skin macrophages. These observations argue that the lack of A2 expression in L. major contributed to its divergence from L. donovani with respect to the pathology of infection.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; Sanger Inst, Cambridge CB10 1SA, England; Bernhard Nocht Inst Trop Med, Leishmaniasis Unit, D-20359 Hamburg, Germany	McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Center for Infectious Disease Research; Wellcome Trust Sanger Institute; Bernhard Nocht Institut fur Tropenmedizin	Matlashewski, G (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	greg.matlashewski@mcgill.ca	Myler, Peter John/AAR-9535-2021	Zhang, Wenwei/0000-0003-1996-876X; Ivens, Al/0000-0002-0112-3876; Myler, Peter/0000-0002-0056-0513				ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; DOYLE PS, 1991, EXP PARASITOL, V73, P326, DOI 10.1016/0014-4894(91)90104-5; Ghedin E, 1998, MOL BIOCHEM PARASIT, V93, P23, DOI 10.1016/S0166-6851(98)00027-9; Ghedin E, 1997, CLIN DIAGN LAB IMMUN, V4, P530, DOI 10.1128/CDLI.4.5.530-535.1997; Gupta N, 2001, TRENDS PARASITOL, V17, P150, DOI 10.1016/S1471-4922(00)01811-0; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; Matlashewski G, 2002, WORLD CL PARASITES, V4, P105; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; Noyes HA, 2000, MEM I OSWALDO CRUZ, V95, P575, DOI 10.1590/S0074-02762000000400021; Pogue GP, 1996, MOL BIOCHEM PARASIT, V81, P27, DOI 10.1016/0166-6851(96)02697-7; SACKS DL, 1995, LANCET, V345, P959, DOI 10.1016/S0140-6736(95)90703-3; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; Stober C, 2002, PHILOS T ROY SOC B, V357, P5, DOI 10.1098/rstb.2001.0985; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZHANG WW, 1995, NUCLEIC ACIDS RES, V23, P4073, DOI 10.1093/nar/23.20.4073; Zhang WW, 2001, MOL MICROBIOL, V39, P935, DOI 10.1046/j.1365-2958.2001.02286.x	25	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35508	35515		10.1074/jbc.M305030200	http://dx.doi.org/10.1074/jbc.M305030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829719	hybrid			2022-12-25	WOS:000185164400093
J	Imoto, S; Sugiyama, K; Muromoto, R; Sato, N; Yamamoto, T; Matsuda, T				Imoto, S; Sugiyama, K; Muromoto, R; Sato, N; Yamamoto, T; Matsuda, T			Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; GENE ACTIVATION; CO-REPRESSOR; CROSS-TALK; SKI ACTS; TGF; INTERACTS; SUMO; COACTIVATORS; SUMOYLATION	Smads proteins play a key role in the intracellular signaling of the transforming growth factor (TGF)-beta family of growth factors, which exhibits a diverse set of cellular responses, including cell proliferation and differentiation. In particular, Smad7 acts as an antagonist of TGF-beta signaling, which could determine the intensity or duration of its signaling cascade. In this study we identified a protein inhibitor of activated STAT ( signal transducers and activators of transcription), PIASy, as a novel interaction partner of Smad7 by yeast two-hybrid screening using the MH2 domain of Smad7 as bait. The association of Smad7 and PIASy was confirmed using co-expressed tagged proteins in 293T cells. Moreover, we found that other Smads including Smad3 also associated with PIASy through its MH2 domain, and PIASy suppressed TGF-beta-mediated activation of Smad3. PIASy also stimulated the sumoylation of Smad3 in vivo. Furthermore, endogenous PIASy expression was induced by TGF-beta in Hep3B cells. These findings provide the first evidence that a PIAS family protein, PIASy, associates with Smads and involves the regulation of TGF-beta signaling using the negative feedback loop.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Matsuda, Tadashi/A-3835-2012; Muromoto, Ryuta/E-4203-2012	Matsuda, Tadashi/0000-0002-3089-3757; Muromoto, Ryuta/0000-0002-7474-493X				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bitzer M, 2000, GENE DEV, V14, P187; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2000, FEBS LETT, V472, P235, DOI 10.1016/S0014-5793(00)01444-7; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2003, J BIOL CHEM, V278, P33571, DOI 10.1074/jbc.M300159200; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Xu GX, 2002, BIOCHEM BIOPH RES CO, V294, P1079, DOI 10.1016/S0006-291X(02)00605-8; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	47	72	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34253	34258		10.1074/jbc.M304961200	http://dx.doi.org/10.1074/jbc.M304961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815042	hybrid, Green Published			2022-12-25	WOS:000185047500080
J	Kubiak, TM; Larsen, MJ; Nulf, SC; Zantello, MR; Burton, KJ; Bowman, JW; Modric, T; Lowery, DE				Kubiak, TM; Larsen, MJ; Nulf, SC; Zantello, MR; Burton, KJ; Bowman, JW; Modric, T; Lowery, DE			Differential activation of "social" and "solitary" variants of the Caenorhabditis elegans G protein-coupled receptor NPR-1 by its cognate ligand AF9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	27th European Peptide Symposium (EPS)	AUG 31-SEP 06, 2002	SORRENTO, ITALY				TRANSMEMBRANE CONDUCTANCE REGULATOR; TEMPERATURE-SENSITIVE EXPRESSION; DROSOPHILA-MELANOGASTER; FUNCTIONAL EXPRESSION; NEUROPEPTIDES; IDENTIFICATION; STIMULATION; BEHAVIOR; MUTANTS; NEURONS	Natural variations of wild Caenorhabditis elegans isolates having either Phe-215 or Val-215 in NPR-1, a putative orphan neuropeptide Y-like G protein-coupled receptor, result in either "social" or "solitary" feeding behaviors ( de Bono, M., and Bargmann, C. I. ( 1998) Cell 94, 679 - 689). We identified a nematode peptide, GLGPR-PLRF-NH2 (AF9), as a ligand activating the cloned NPR-1 receptor heterologously expressed in mammalian cells. Shifting cell culture temperatures from 37 to 28 degreesC, implemented 24 h after transfections, was essential for detectable functional expression of NPR-1. AF9 treatments linked both cloned receptor variants to activation of Gi/Go proteins and cAMP inhibition, thus allowing for classification of NPR-1 as an inhibitory G protein-coupled receptor. The Val-215 receptor isoform displayed higher binding and functional activity than its Phe-215 counterpart. This finding parallels the in vivo observation of a more potent repression of social feeding by the npr-1 gene encoding the Val-215 form of the receptor, resulting in dispersing ( solitary) animals. Since neuropeptide Y shows no sequence homology to AF9 and was functionally inactive at the cloned NPR-1, we propose to rename NPR-1 and refer to it as an AF9 receptor, AF9-R1.	Pharmacia Corp, Anim Hlth Discovery Res, Kalamazoo, MI 49001 USA	Pfizer	Kubiak, TM (corresponding author), Pharmacia Corp, Anim Hlth Discovery Res, Kalamazoo, MI 49001 USA.	teresa.m.kubiak@pfizer.com		Lowery, David/0000-0001-5111-4719				Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BLUML K, 1994, J BIOL CHEM, V269, P402; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chiulli AC, 2000, J BIOMOL SCREEN, V5, P239, DOI 10.1177/108705710000500406; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; COWDEN C, 1995, PEPTIDES, V16, P491, DOI 10.1016/0196-9781(94)00211-N; Davis RE, 2001, PEPTIDES, V22, P7, DOI 10.1016/S0196-9781(00)00351-X; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; de Bono M, 2002, NATURE, V419, P899, DOI 10.1038/nature01169; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; GOTTESMAN MM, 1980, SOMAT CELL GENET, V6, P45, DOI 10.1007/BF01538695; Iversen A, 2002, BIOCHEM BIOPH RES CO, V299, P628, DOI 10.1016/S0006-291X(02)02709-2; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Jaquette J, 1997, ENDOCRINOLOGY, V138, P85, DOI 10.1210/en.138.1.85; Jeyaraj SC, 2001, MOL PHARMACOL, V60, P1195, DOI 10.1124/mol.60.6.1195; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kubiak TM, 2002, BIOCHEM BIOPH RES CO, V291, P313, DOI 10.1006/bbrc.2002.6459; LAJINESS ME, 1993, J PHARMACOL EXP THER, V267, P1573; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; Larsen MJ, 2001, BIOCHEM BIOPH RES CO, V286, P895, DOI 10.1006/bbrc.2001.5476; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Thomas JH, 1998, CELL, V94, P549, DOI 10.1016/S0092-8674(00)81595-0; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162	33	60	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33724	33729		10.1074/jbc.M304861200	http://dx.doi.org/10.1074/jbc.M304861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	716UK	12821653	hybrid			2022-12-25	WOS:000185047500016
J	Ling, YH; Liebes, L; Zou, YY; Perez-Soler, R				Ling, YH; Liebes, L; Zou, YY; Perez-Soler, R			Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; REDOX REGULATION; KAPPA-B; DEATH; BCL-2; MEMBRANE; PHOSPHORYLATION; CASPASES; PATHWAY	Bortezomib, a proteasome inhibitor, shows substantial anti-tumor activity in a variety of tumor cell lines, is in phase I, II, and III clinical trials and has recently been approved for the treatment of patients with multiple myeloma. The sequence of events leading to apoptosis following proteasome inhibition by bortezomib is unclear. Bortezomib effects on components of the mitochondrial apoptotic pathway were examined: generation of reactive oxygen species (ROS), alteration in the mitochondrial membrane potential (Deltapsi(m)), and release of cytochrome c from mitochondria. With human H460 lung cancer cells, bortezomib exposure at 0.1 muM showed induction of apoptotic cell death starting at 24 h, with increasing effects after 48 - 72 h of treatment. After 3 - 6 h, an elevation in ROS generation, an increase in Deltapsi(m), and the release of cytochrome c into the cytosol, were observed in a time-dependent manner. Co-incubation with rotenone and antimycin A, inhibitors of mitochondrial electron transport chain complexes I and III, or with cyclosporine A, an inhibitor of mitochondrial permeability transition pore, resulted in inhibition of bortezomib-induced ROS generation, increase in Deltapsi(m), and cytochrome c release. Tiron, an antioxidant agent, blocked the bortezomib-induced ROS production, Deltapsi(m) increase, and cytochrome c release. Tiron treatment also protected against the bortezomib-induced PARP protein cleavage and cell death. Benzyloxycarbonyl-VAD-fluoromethyl ketone, an inhibitor of pan-caspase, did not alter the bortezomib-induced ROS generation and increase in Deltapsi(m), although it prevented bortezomib-induced poly( ADP-ribose) polymerase cleavage and apoptotic death. In PC-3 prostate carcinoma cells ( with overexpression of Bcl-2), a reduction of bortezomib-induced ROS generation, Deltapsi(m) increase was correlated with cellular resistance to bortezomib and the attenuation of drug-induced apoptosis. The transient transfection of wild type p53 in p53 null H358 cells caused stimulation of the bortezomib-induced apoptosis but failed to enhance ROS generation and Deltapsi(m) increase. Thus ROS generation plays a critical role in the initiation of the bortezomib-induced apoptotic cascade by mediation of the disruption of Deltapsi(m) and the release of cytochrome c from mitochondria.	Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Yeshiva University; Albert Einstein College of Medicine; New York University	Ling, YH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	yling@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U01CA076642, K24CA084119] Funding Source: NIH RePORTER; NCI NIH HHS [CA84119, U01CA76642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; AGHAJANIAN C, 2001, P AM SOC CLIN ONC MA; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bondar VM, 2002, PROSTATE, V51, P42, DOI 10.1002/pros.10070; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Childs AC, 2002, CANCER RES, V62, P4592; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; ERLICHMAN C, 2001, P AM SOC CLIN ONC MA; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; HAMILTON AL, 2001, P AM SOC CLIN ONC MA; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; JURGENSMEIER JM, 1998, P NATL ACAD SCI USA, V94, P3668; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2002, MOL CANCER THER, V1, P841; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Mohanraj P, 1998, J APPL PHYSIOL, V84, P1960, DOI 10.1152/jappl.1998.84.6.1960; Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200; OCONNOR O, 2002, P AM SOC HEM DEC 6 1; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; PAPANDREOU CN, 2001, P AM SOC CLIN ONC MA; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RICHARDSON P, 2002, P AM SOC HEM DEC 6 1; Shchepina LA, 2002, ONCOGENE, V21, P8149, DOI 10.1038/sj.onc.1206053; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Yamada J, 2003, NEUROSCI RES, V45, P1, DOI 10.1016/S0168-0102(02)00196-7; Zou YY, 1998, J NATL CANCER I, V90, P1130, DOI 10.1093/jnci/90.15.1130	57	396	405	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33714	33723		10.1074/jbc.M302559200	http://dx.doi.org/10.1074/jbc.M302559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821677	hybrid			2022-12-25	WOS:000185047500015
J	Qin, CL; Brunn, JC; Cook, RG; Orkiszewski, RS; Malone, JP; Veis, A; Butler, WT				Qin, CL; Brunn, JC; Cook, RG; Orkiszewski, RS; Malone, JP; Veis, A; Butler, WT			Evidence for the proteolytic processing of dentin matrix protein 1 - Identification and characterization of processed fragments and cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEIN; TISSUE DISTRIBUTION; MINERAL INDUCTION; DMP1 GENE; HUMAN PEX; EXPRESSION; SIALOPROTEIN; CLONING; BONE; SEQUENCE	Full-length cDNA coding for dentin matrix protein 1 (DMP1) has been cloned and sequenced, but the corresponding complete protein has not been isolated. In searching for naturally occurring DMP1, we recently discovered that the extracellular matrix of bone contains fragments originating from DMP1. Shortened forms of DMP1, termed 37K and 57K fragments, were treated with alkaline phosphatase and then digested with trypsin. The resultant peptides were purified by a two-dimensional method: size exclusion followed by reversed-phase high performance liquid chromatography. Purified peptides were sequenced by Edman degradation and mass spectrometry, and the sequences compared with the DMP1 sequence predicted from cDNA. Extensive sequencing of tryptic peptides revealed that the 37K fragments originated from the NH2-terminal region, and the 57K fragments were from the COOH-terminal part of DMP1. Phosphate analysis indicated that the 37K fragments contained 12 phosphates, and the 57K fragments had 41. From 37K fragments, two peptides lacked a COOH-terminal lysine or arginine; instead they ended at Phe(173) and Ser(180) and were thus COOH termini of 37K fragments. Two peptides were from the NH2 termini of 57K fragments, starting at Asp(218) and Asp(222). These findings indicated that DMP1 is proteolytically cleaved at four bonds, Phe(173) - Asp(174), Ser(180) - Asp(181), Ser(217) - Asp(218), and Gln(221) - Asp(222), forming eight fragments. The uniformity of cleavages at the NH2-terminal peptide bonds of aspartyl residues suggests that a single proteinase is involved. Based on its reported specificity, we hypothesize that these scissions are catalyzed by PHEX protein. We envision that the proteolytic processing of DMP1 plays a crucial role during osteogenesis and dentinogenesis.	Univ Texas, Houston Hlth Sci Ctr, Dept Basic Sci, Dent Branch,DBB, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA; Northwestern Univ, Feinberg Med Sch, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; Northwestern University; Feinberg School of Medicine	Qin, CL (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Basic Sci, Dent Branch,DBB, 6516 MD Anderson Blvd,Rm 4-133, Houston, TX 77030 USA.	Chunlin.Qin@uth.tmc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR013921, R01AR013921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374, R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092, R37DE001374] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 13921] Funding Source: Medline; NIDCR NIH HHS [DE 05092, DE 01374] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; Boskey A, 2000, CALCIFIED TISSUE INT, V67, P472, DOI 10.1007/s002230001169; BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169-6009(90)90015-8; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Campos M, 2003, BIOCHEM J, V373, P271, DOI 10.1042/BJ20030287; CRINE P, 1997, ENDOPEPTIDASE 24 11, P79; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; FISHER LW, 1983, J BIOL CHEM, V258, P2723; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; Kulkarni GV, 2000, ARCH ORAL BIOL, V45, P475, DOI 10.1016/S0003-9969(00)00010-8; LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Razzouk S, 2002, BONE, V30, P40, DOI 10.1016/S8756-3282(01)00637-8; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ruchon AF, 1998, J HISTOCHEM CYTOCHEM, V46, P459; Ruchon AF, 2000, J BONE MINER RES, V15, P1440, DOI 10.1359/jbmr.2000.15.8.1440; SAFRAN JB, 1998, P 6 INT C CHEM BIOL, P113; Saito T, 1997, BONE, V21, P305, DOI 10.1016/S8756-3282(97)00149-X; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Thotakura SR, 2000, J BIOL CHEM, V275, P10272, DOI 10.1074/jbc.275.14.10272; Toyosawa S, 1999, GENE, V234, P307, DOI 10.1016/S0378-1119(99)00195-X; Toyosawa S, 2000, J MOL EVOL, V50, P31, DOI 10.1007/s002399910004; Toyosawa S, 1999, J MOL EVOL, V48, P160, DOI 10.1007/PL00006454; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VEIS A, 1993, J BONE MINER RES, V8, pS493	45	133	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34700	34708		10.1074/jbc.M305315200	http://dx.doi.org/10.1074/jbc.M305315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813042	hybrid			2022-12-25	WOS:000185047500131
J	Tanaka, Y; Gavrielides, MV; Mitsuuchi, Y; Fujii, T; Kazanietz, MG				Tanaka, Y; Gavrielides, MV; Mitsuuchi, Y; Fujii, T; Kazanietz, MG			Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PHORBOL ESTER RECEPTORS; SIGNAL-TRANSDUCTION; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; PKC-DELTA; ALPHA; GROWTH; INDUCTION; ANCHORAGE	Activation of protein kinase C (PKC) by phorbol esters ordiacylglycerol mimetics induces apoptosis in androgen-dependent prostate cancer cells, an effect that involves both the activation of the classic PKCalpha and the novel PKCdelta isozymes (Fujii, T., Garcia-Bermejo, M. L., Bernabo, J. L., Caamano, J., Ohba, M., Kuroki, T., Li, L., Yuspa, S. H., and Kazanietz, M. G. ( 2000) J. Biol. Chem. 275, 7574 - 7582 and Garcia-Bermejo, M. L., Leskow, F. C., Fujii, T., Wang, Q., Blumberg, P. M., Ohba, M., Kuroki, T., Han, K. C., Lee, J., Marquez, V. E., and Kazanietz, M. G. ( 2002) J. Biol. Chem. 277, 645 - 655). In the present study we explored the signaling events involved in this PKC-mediated effect, using the androgen-dependent LNCaP cell line as a model. Stimulation of PKC by phorbol 12-myristate 13-acetate (PMA) leads to the activation of ERK1/2, p38 MAPK, and JNK in LNCaP cells. Here we present evidence that p38 MAPK, but not JNK, mediates PKC-induced apoptosis. Because LNCaP cells have hyperactivated Akt function due to PTEN inactivation, we examined whether this survival pathway could be affected by PKC activation. Interestingly, activation of PKC leads to a rapid and reversible dephosphorylation of Akt, an effect that was prevented by the pan-PKC inhibitor GF109302X and the cPKC inhibitor Go6976. In addition, the diacylglycerol mimetic agent HK654, which selectively stimulates PKCalpha in LNCaP cells, also induced the dephosphorylation of Akt in LNCaP cells. Inactivation of Akt function by PKC does not involve the inhibition of PI3K, and it is prevented by okadaic acid, suggesting the involvement of a phosphatase 2A in PMA-induced Akt dephosphorylation. Finally, we show that, when an activated form of Akt is delivered into LNCaP cells by either transient transfection or adenoviral infection, the apoptotic effect of PMA is significantly reduced. Our results highlight a complex array of signaling pathways regulated by PKC isozymes in LNCaP prostate cancer cells and suggest that both p38 MAPK and Akt play critical roles as downstream effectors of PKC isozymes in this cellular model.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Dept Pharmacol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Kurume Univ, Dept Surg, Kurume, Fukuoka 830, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan	University of Pennsylvania; Fox Chase Cancer Center; Kurume University; Kurume University	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER; NCI NIH HHS [CA89202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Carson JP, 1999, CANCER RES, V59, P1449; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gioeli D, 1999, CANCER RES, V59, P279; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Ito T, 2000, HYPERTENSION, V35, P673, DOI 10.1161/01.HYP.35.2.673; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kanda Y, 2001, LIFE SCI, V68, P1989, DOI 10.1016/S0024-3205(01)00990-0; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Li LW, 1999, MOL CELL BIOL, V19, P8547; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Malik SN, 2002, CLIN CANCER RES, V8, P1168; McMenamin ME, 1999, CANCER RES, V59, P4291; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907; Murillo H, 2001, CANCER RES, V61, P7408; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Okuda H, 1999, ONCOGENE, V18, P5604, DOI 10.1038/sj.onc.1202946; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Weinstein IB, 1997, ADV EXP MED BIOL, V400, P313; Wu DQ, 2002, CANCER RES, V62, P2423; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yashima R, 2001, J CELL PHYSIOL, V188, P201, DOI 10.1002/jcp.1107; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	51	213	222	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33753	33762		10.1074/jbc.M303313200	http://dx.doi.org/10.1074/jbc.M303313200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824193	hybrid			2022-12-25	WOS:000185047500020
J	Farnaes, L; Ditzel, HJ				Farnaes, L; Ditzel, HJ			Dissecting the cellular functions of annexin XI using recombinant human annexin XI-specific autoantibodies cloned by phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC AUTOIMMUNE-DISEASES; CALCYCLIN S100A6 BINDING; NUCLEAR-LOCALIZATION; MEMBRANE-FUSION; ANTIBODIES; SPINDLE; PROTEIN; DOMAIN; SITE; TRANSLOCATION	Functional studies of cellular proteins are often complicated by the lack of well-defined monoclonal antibodies, the production of which is hampered by the highly conserved nature of these cellular proteins across species. Annexin XI, a member of the Ca2+-dependent, phospholipid-binding protein family, is an example of such a protein and was used in studies to devise a strategy using human autoimmune phage display libraries to generate reagents for biological studies of conserved cellular proteins. An IgG phage display library was generated from bone marrow of an autoimmune patient with high serum antibody titer against annexin XI, which was identified recently as an autoantigen targeted by autoantibodies in several systemic autoimmune diseases. From this phage library, a panel of human monoclonal annexin XI-specific Fabs were isolated and applied to studies of the cellular functions of annexin XI. Confocal microscopy showed a cell cycle-specific redistribution of annexin XI from the cytoplasm to the mitotic spindle. In metaphase, annexin XI was upregulated and costained with alpha-tubulin. The subcellular distribution of annexin XI in COS-7 cells was shown to be Ca2+-dependent, and exhibited a predominantly nuclear pattern at low concentrations and a cytoplasmic pattern at high Ca2+ concentrations. Calcyclin, found previously to bind annexin XI in vitro, in vivo coated the nuclear membrane of cultured cell lines and did not colocalize with annexin XI. Ultrastructural analysis by immunoelectron microscopy revealed that annexin XI associated with specific granules in both neutrophils and eosinophils, suggesting a role in the exocytotic pathway. Our results illuminate the multifunctional nature of human annexin XI, provide the first evidence that annexin XI associates with the mitotic spindles and might play a role in cell division, and clearly illustrate the potential of phage display-derived human autoantibodies in broader analyses of the function of highly conserved cellular proteins.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ditzel, HJ (corresponding author), Scripps Res Inst, Dept Immunol, IMM2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Ditzel, Henrik J./0000-0003-3927-5135	NIAID NIH HHS [AI041590] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041590] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Boussac M, 2000, ELECTROPHORESIS, V21, P665, DOI 10.1002/(SICI)1522-2683(20000201)21:3<665::AID-ELPS665>3.0.CO;2-U; BRINCK U, 1995, J DERMATOL SCI, V10, P181, DOI 10.1016/0923-1811(95)00402-E; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CREUTZ CE, 1978, J BIOL CHEM, V253, P3798; DITZEL HJ, 1995, J IMMUNOL, V154, P893; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; HASLETT C, 1985, AM J PATHOL, V119, P101; Iino S, 2000, FEBS LETT, V479, P46, DOI 10.1016/S0014-5793(00)01877-9; Jorgensen CS, 2000, LUPUS, V9, P515; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; MAMIYA N, 1994, BIOCHEM BIOPH RES CO, V202, P403, DOI 10.1006/bbrc.1994.1942; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; MISAKI Y, 1994, J BIOL CHEM, V269, P4240; MISAKI Y, 1995, J RHEUMATOL, V22, P97; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; Morgan RO, 1998, GENOMICS, V48, P100, DOI 10.1006/geno.1997.5148; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NEPARTSTEK Y, 1993, ANNU REV IMMUNOL, V11, P79; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Sjolin C, 1997, BBA-BIOMEMBRANES, V1326, P149, DOI 10.1016/S0005-2736(97)00018-7; Sjolin C, 1996, BLOOD, V87, P4817, DOI 10.1182/blood.V87.11.4817.bloodjournal87114817; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; Sudo T, 1996, BIOCHEM BIOPH RES CO, V223, P706, DOI 10.1006/bbrc.1996.0967; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; Whitehead CM, 1996, ARTHRITIS RHEUM, V39, P1635, DOI 10.1002/art.1780391005; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669	32	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33120	33126		10.1074/jbc.M210852200	http://dx.doi.org/10.1074/jbc.M210852200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805373	hybrid			2022-12-25	WOS:000184901800077
J	Jiang, Q; Blount, BC; Ames, BN				Jiang, Q; Blount, BC; Ames, BN			5-chlorouracil, a marker of DNA damage from hypochlorous acid during inflammation - A gas chromatography-mass spectrometry assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; HUMAN NEUTROPHILS; MYELOPEROXIDASE; CHLORINATION; 5-CHLOROCYTOSINE; 5-BROMOURACIL; CHLORAMINES; NUCLEOTIDES; PYRIMIDINE; PHAGOCYTES	Hypochlorous acid (HOCl), generated from H2O2 and Cl- by myeloperoxidase in activated neutrophils, causes tissue damage during inflammation. We have developed a simple, sensitive (similar to0.2 fmol on column) and specific GC-MS assay for the detection of 5-chlorouracil (5-ClUra), a signature product of HOCl-mediated damage to nucleobases. In this assay, 5-ClUra is released from isolated DNA by a digestion with nuclease P1, alkaline phosphatase, and thymidine phosphorylase (TP), or from chlorinated nucleosides in biological fluids by TP. The freed 5-ClUra is derivatized with 3, 5-bis-(trifluoromethyl)benzyl bromide, which is detected by negative chemical ionization mass spectrometry. The assay can be used to simultaneously detect other halogenated uracils including bromouracil. Using this assay, we showed that 5-ClUra is generated by the reaction of low micromolar HOCl with ( deoxy) cytidine, ( deoxy) uridine, and DNA. In cell cultures, an increase of 5-ClUra was detected in DNA when cells were treated with sublethal doses of HOCl and allowed to proliferate. The elevation of 5-ClUra was markedly accentuated when physiologically relevant concentrations of ( deoxy) uridine, ( deoxy) cytidine, uracil, or cytosine were present in the medium during HOCl treatment. In the carrageenan-induced inflammation model in rats, chlorinated nucleosides was significantly increased, compared with controls, in the exudate fluid isolated from the inflammation site. Our study provides the direct evidence that chlorinated nucleosides are found in the inflammation site and can be incorporated in DNA during cell/tissue proliferation. These findings may be relevant to the carcinogensis associated with chronic inflammation.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California Berkeley	Ames, BN (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES01896] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BILZER M, 1991, J HEPATOL, V13, P84, DOI 10.1016/0168-8278(91)90868-C; BLOUNT BC, 1994, ANAL BIOCHEM, V219, P195, DOI 10.1006/abio.1994.1257; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Chen HJC, 2002, CHEM RES TOXICOL, V15, P262, DOI 10.1021/tx015578g; Christen S, 1999, MICROBES AND MALIGNANCY, P35; DENNIS WH, 1979, WATER RES, V13, P357, DOI 10.1016/0043-1354(79)90023-X; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; GOULD JP, 1984, WATER RES, V18, P205, DOI 10.1016/0043-1354(84)90070-8; GOULD JP, 1984, WATER RES, V18, P991, DOI 10.1016/0043-1354(84)90250-1; Hale JT, 2002, BIOCHEM PHARMACOL, V64, P1493, DOI 10.1016/S0006-2952(02)01413-2; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jiang Q, 2003, FASEB J, V17, P816, DOI 10.1096/fj.02-0877com; Jiang Q, 1997, CHEM RES TOXICOL, V10, P1080, DOI 10.1021/tx9700984; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; OLIVARES J, 1988, J MOL CELL CARDIOL, V20, P313, DOI 10.1016/S0022-2828(88)80065-8; PAL BC, 1981, MUTAT RES, V91, P395, DOI 10.1016/0165-7992(81)90021-X; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; SEDGWICK AD, 1986, AGENTS ACTIONS, V18, P429, DOI 10.1007/BF01965008; STETSON PL, 1986, J CHROMATOGR, V375, P1, DOI 10.1016/S0378-4347(00)83686-5; WANG L, 1994, NUCLEIC ACIDS RES, V22, P1774, DOI 10.1093/nar/22.9.1774; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 2002, BIOCHEM BIOPH RES CO, V296, P883, DOI 10.1016/S0006-291X(02)02018-1	30	61	62	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32834	32840		10.1074/jbc.M304021200	http://dx.doi.org/10.1074/jbc.M304021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810714	hybrid			2022-12-25	WOS:000184901800044
J	Parfrey, H; Mahadeva, R; Ravenhill, NA; Zhou, AW; Dafforn, TR; Foreman, RC; Lomas, DA				Parfrey, H; Mahadeva, R; Ravenhill, NA; Zhou, AW; Dafforn, TR; Foreman, RC; Lomas, DA			Targeting a surface cavity of alpha(1)-antitrypsin to prevent conformational disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-SHEET POLYMERIZATION; INHIBITORY MECHANISM; UNCLEAVED ALPHA(1)-ANTITRYPSIN; ALPHA-1-ANTITRYPSIN DEFICIENCY; PROTEASE INHIBITOR; HYDROPHOBIC CORE; REACTIVE CENTER; BETA-SHEET; LIVER; CIRRHOSIS	Conformational diseases are caused by a structural rearrangement within a protein that results in aberrant intermolecular linkage and tissue deposition. This is typified by the polymers that form with the Z deficiency variant of alpha(1)-antitrypsin (Glu-342-->Lys). These polymers are retained within hepatocytes to form inclusions that are associated with hepatitis, cirrhosis, and hepatocellular carcinoma. We have assessed a surface hydrophobic cavity in alpha(1)-antitrypsin as a potential target for rational drug design in order to prevent polymer formation and the associated liver disease. The introduction of either Thr-114-->Phe or Gly-117-->Phe on strand 2 of beta-sheet A within this cavity significantly raised the melting temperature and retarded polymer formation. Conversely, Leu-100-->Phe on helix D accelerated polymer formation, but this effect was abrogated by the addition of Thr-114-->Phe. None of these mutations affected the inhibitory activity of alpha(1)-antitrypsin. The importance of these observations was underscored by the finding that the Thr-114-->Phe mutation reduced polymer formation and increased the secretion of Z alpha(1)-antitrypsin from a Xenopus oocyte expression system. Moreover cysteine mutants within the hydrophobic pocket were able to bind a range of fluorophores illustrating the accessibility of the cavity to external agents. These results demonstrate the importance of this cavity as a site for drug design to ameliorate polymerization and prevent the associated conformational disease.	Univ Cambridge, Cambridge Inst Med Res, Dept Med, Resp Med Unit, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Hematol, Cambridge CB2 2XY, England; Univ Southampton, Dept Cell Sci, Southampton SO16 7PX, Hants, England	University of Cambridge; University of Cambridge; University of Southampton	Parfrey, H (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med, Resp Med Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	hp226@cam.ac.uk	Parfrey, Helen/GMW-4265-2022; Dafforn, Tim/A-9072-2015	ZHOU, Aiwu/0000-0002-2555-5091; Dafforn, Tim/0000-0003-2257-6679				BEATTY K, 1980, J BIOL CHEM, V255, P3931; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Devlin GL, 2001, AM J RESP CELL MOL, V24, P727, DOI 10.1165/ajrcmb.24.6.4407; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Janciauskiene S, 2002, J BIOL CHEM, V277, P26540, DOI 10.1074/jbc.M203832200; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KEZDY FJ, 1970, METHOD ENZYMOL, V19, P3; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; Lee C, 2001, PROTEIN SCI, V10, P1446, DOI 10.1110/ps.840101; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; Piitulainen E, 1999, EUR RESPIR J, V13, P247, DOI 10.1183/09031936.99.13224799; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; SVEGER T, 1988, ACTA PAEDIATR SCAND, V77, P847, DOI 10.1111/j.1651-2227.1988.tb10767.x; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	42	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33060	33066		10.1074/jbc.M302646200	http://dx.doi.org/10.1074/jbc.M302646200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807889	hybrid			2022-12-25	WOS:000184901800071
J	Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L				Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L			p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair	ONCOGENE			English	Article						genome stability; homologous recombination; p53; transcriptional transactivation; tumor suppression	BASE EXCISION-REPAIR; DNA-POLYMERASE BETA; MUTANT P53; REPLICATION FIDELITY; GENOMIC INTEGRITY; PROMOTER REGION; MISMATCH REPAIR; RECOMBINATION; PROTEIN; GENE	The tumor suppressor p53 transcriptionally transactivates cellular target genes that are implicated in growth control, apoptosis, and DNA repair. However, several studies involving p53 core domain mutants suggested that regulatory functions in recombinative repair do not require transcriptional transactivation and are separable from growth-regulation and apoptosis. Leu22 and Trp23 within the transactivation domain of human p53 play a critical role in binding basal components of the transcription machinery and, therefore, in the transactivation activity of p53. To further delineate whether p53 target genes are involved in recombination regulation, we ectopically expressed p53(22Q,23S) in p53-negative cell lines, which carry reporter systems for different homology-directed double-strand break (DSB) repair events. Like wild-type p53, p53(22Q,23S) efficiently downregulated homologous recombination on two chromosomally integrated substrates without affecting exchange on a substrate for the compound pathway of gene conversion and nonhomologous end joining. Only upon lowering the p53 protein to DNA substrate ratio by several orders of magnitude, we noticed a weak defect of a p53 transactivation domain mutant in DSB repair assays. In conclusion, molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to this genome stabilizing function.	Univ Ulm, Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Saarland, Dept Virol, D-66421 Homburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg; Saarland University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doetsch PW, 2001, PROG NUCLEIC ACID RE, V68, P29; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Mahdi T, 1998, BIOL CHEM, V90, P15; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schaffner DL, 1996, LAB INVEST, V74, P1005; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SOUSSI T, 1993, NOUV REV FR HEMATOL, V35, P33; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Theis S, 1997, INT J CANCER, V71, P858; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	56	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4111	4117		10.1038/sj.onc.1206632	http://dx.doi.org/10.1038/sj.onc.1206632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821945				2022-12-25	WOS:000183707600014
J	Stalker, TJ; Skvarka, CB; Scalia, R				Stalker, TJ; Skvarka, CB; Scalia, R			A novel role for calpains in the endothelial dysfunction of hyperglycemia	FASEB JOURNAL			English	Article						diabetes mellitus; endothelium; NO; superoxide; cell adhesion	NITRIC-OXIDE SYNTHASE; ADHESION MOLECULE EXPRESSION; C-REACTIVE PROTEIN; FACTOR-KAPPA-B; INHIBITOR-I; ACTIVATION; PROTEOLYSIS; REPERFUSION; HSP90; MICROVASCULATURE	Recent studies have reported that the activity of the calcium-dependent protease calpain is increased in acute inflammatory processes of the cardiovascular system. Because diabetes is associated with vascular inflammation, we hypothesized that increased calpain activity in response to hyperglycemia may play a role in diabetic cardiovascular disease. The effects of calpain inhibition on leukocyte-endothelium interactions induced by hyperglycemia were examined by intravital microscopy. Intraperitoneal administration of the selective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 mumol/L) prevented the up-regulation of leukocyte-endothelium interactions in response to 25 mmol/L D-glucose via a nitric oxide-dependent mechanism. Furthermore, treatment of rats with D-glucose significantly decreased basal endothelial NO release in mesenteric post-capillary venules, a phenomenon prevented by inhibition of calpain activity. Immunoprecipitation studies revealed that glucose induces loss of NO via a calpain-dependent decrease in the association of hsp90 with endothelial nitric oxide synthase. In addition, inhibition of calpain activity decreased endothelial cell surface expression of the pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 during hyperglycemia. These data demonstrate that calpains contribute to important inflammatory events during hyperglycemia and that pharmacological inhibition of calpain activity attenuates leuckocyte-endothelium interactions and preserves eNOS function.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.	Rosario.Scalia@mail.tju.edu		Stalker, Timothy/0000-0002-0017-4268; Scalia, Rosario/0000-0002-1829-943X				Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Booth G, 2002, DIABETES, V51, P1556, DOI 10.2337/diabetes.51.5.1556; Booth G, 2001, AM J PHYSIOL-ENDOC M, V280, pE848, DOI 10.1152/ajpendo.2001.280.6.E848; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hink U, 2001, CIRC RES, V88, pE14; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Ikeda Y, 2002, AM J PHYSIOL-HEART C, V282, pH1421, DOI 10.1152/ajpheart.00626.2001; KOBAYASHI S, 1989, ENDOCRINOL JAPON, V36, P833; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Newcomb JK, 2000, METH MOL B, V144, P219; Panes J, 1996, CIRCULATION, V93, P161, DOI 10.1161/01.CIR.93.1.161; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; Scalia R, 2000, FASEB J, V14, P2357, DOI 10.1096/fj.00-0183com; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Srivastava K, 2002, CLIN CHIM ACTA, V317, P213, DOI 10.1016/S0009-8981(01)00794-X; Stehouwer CDA, 1997, CARDIOVASC RES, V34, P55, DOI 10.1016/S0008-6363(96)00272-6; Su YC, 2000, AM J PHYSIOL-LUNG C, V278, pL1204, DOI 10.1152/ajplung.2000.278.6.L1204; Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEYRICH AS, 1995, J LEUKOCYTE BIOL, V57, P45, DOI 10.1002/jlb.57.1.45; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603	47	67	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1511	+		10.1096/fj.02-1213fje	http://dx.doi.org/10.1096/fj.02-1213fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824289				2022-12-25	WOS:000183818000037
J	Galindo, CL; Sha, J; Ribardo, DA; Fadl, AA; Pillai, L; Chopra, AK				Galindo, CL; Sha, J; Ribardo, DA; Fadl, AA; Pillai, L; Chopra, AK			Identification of Aeromonas hydrophila cytotoxic enterotoxininduced genes in macrophages using microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KINASE ACTIVATION; CELL; EXPRESSION; MECHANISM; RESPONSES; LINE	A cytotoxic enterotoxin (Act) of Aeromonas hydrophila possesses several biological activities, and it induces an inflammatory response in the host. In this study, we used microarrays to gain a global and molecular view of the cellular transcriptional responses to Act and to identify important genes up-regulated by this toxin. Total RNA was isolated at 0, 2, and 12 h from Act-treated macrophages and applied to Affymetrix MGU74 arrays, and the data were processed using a multi-analysis approach to identify genes that might be critical in the inflammatory process evoked by Act. Seventy-six genes were significantly and consistently up-regulated. Many of these genes were immune-related, and several were transcription factors, adhesion molecules, and cytokines. Additionally, we identified several apoptosis-associated genes that were significantly up-regulated in Act-treated macrophages. Act-induced apoptosis of macrophages was confirmed by annexin V staining and DNA laddering. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay were used to verify increased expression of some inflammatory and apoptosis-associated genes identified by the microarray analysis. To further confirm Act-induced increases in gene expression, real-time RT-PCR was also used for selected genes. Taken together, the array data provided for the first time a global view of Act-mediated signal transduction and clearly demonstrated an inflammatory response and apoptosis mediated by this toxin in host cells at the molecular level.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Chopra, AK (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	achopra@utmb.edu			NIAID NIH HHS [AI41611] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041611] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barbour SE, 1998, MOL IMMUNOL, V35, P977, DOI 10.1016/S0161-5890(98)00070-4; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Chopra AK, 1999, MICROBES INFECT, V1, P1129, DOI 10.1016/S1286-4579(99)00202-6; Chopra AK, 2000, INFECT IMMUN, V68, P2808, DOI 10.1128/IAI.68.5.2808-2818.2000; Crescenzi M, 2001, FEBS LETT, V507, P114, DOI 10.1016/S0014-5793(01)02973-8; Ferguson MR, 1997, INFECT IMMUN, V65, P4299, DOI 10.1128/IAI.65.10.4299-4308.1997; Hamilton JA, 1998, INT J BIOCHEM CELL B, V30, P271, DOI 10.1016/S1357-2725(97)00111-8; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Hinz T, 2001, CELL SIGNAL, V13, P345, DOI 10.1016/S0898-6568(01)00141-3; Hiura TS, 1999, J IMMUNOL, V163, P5582; Janda JM, 1998, CLIN INFECT DIS, V27, P332, DOI 10.1086/514652; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; Kubo A, 1998, J BIOL CHEM, V273, P16730, DOI 10.1074/jbc.273.27.16730; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; Merino S, 1999, INFECT IMMUN, V67, P4008, DOI 10.1128/IAI.67.8.4008-4013.1999; Merino S, 1995, INT J FOOD MICROBIOL, V28, P157, DOI 10.1016/0168-1605(95)00054-2; Ortiz BD, 1997, IMMUNOL TODAY, V18, P468, DOI 10.1016/S0167-5699(97)01128-6; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Rao KMK, 2002, J TOXICOL ENV HEAL A, V65, P757, DOI 10.1080/00984100290071027; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Ribardo DA, 2002, MICROB PATHOGENESIS, V32, P149, DOI 10.1006/mpat.2001.0490; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Sha J, 2002, INFECT IMMUN, V70, P1924, DOI 10.1128/IAI.70.4.1924-1935.2002; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Tang GQ, 1999, INFECT IMMUN, V67, P3055, DOI 10.1128/IAI.67.6.3055-3060.1999; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xu XJ, 1998, INFECT IMMUN, V66, P3501, DOI 10.1128/IAI.66.8.3501-3509.1998; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114	38	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40198	40212		10.1074/jbc.M305788200	http://dx.doi.org/10.1074/jbc.M305788200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12824169	hybrid			2022-12-25	WOS:000185713800113
J	Atmane, N; Dairou, J; Paul, A; Dupret, JM; Rodrigues-Lima, F				Atmane, N; Dairou, J; Paul, A; Dupret, JM; Rodrigues-Lima, F			Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) - Reversible inactivation by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFENIC ACID; N-ACETYLTRANSFERASE; OXIDATIVE STRESS; ACTIVE-SITE; FUNCTIONAL-CHARACTERIZATION; CATALYTIC MECHANISM; AMINO-ACIDS; DNA-DAMAGE; IDENTIFICATION; RAT	Oxidative stress is increasingly recognized as a key mechanism in the biotransformation and/or toxicity of many xenobiotics. Human arylamine N-acetyltransferase 1 (NAT1) is a polymorphic ubiquitous phase II xenobiotic metabolizing enzyme that catalyzes the biotransformation of primary aromatic amine or hydrazine drugs and carcinogens. Functional and structural studies have shown that NAT1 catalytic activity is based on a cysteine protease-like catalytic triad, containing a reactive cysteine residue. Reactive protein cysteine residues are highly susceptible to oxidation by hydrogen peroxide (H2O2) generated within the cell. We, therefore, investigated whether human NAT1 activity was regulated by this cellular oxidant. Using purified recombinant NAT1, we show here that NAT1 is rapidly (k(inact) = 420 M-1.min(-1)) inactivated by physiological concentrations of H2O2. Reducing agents, such as reduced glutathione (GSH), reverse the H2O2-dependent inactivation of NAT1. Kinetic analysis and protection experiments with acetyl-CoA, the physiological acetyl-donor substrate of the enzyme, suggested that the H2O2-dependent inactivation reaction targets the active-site cysteine residue. Finally, we show that the reversible inactivation of NAT1 by H2O2 is due to the formation of a stable sulfenic acid group at the active-site cysteine. Our results suggest that, in addition to known genetically controlled interindividual variations in NAT1 activity, oxidative stress and cellular redox status may also regulate NAT1 activity. This may have important consequences with regard to drug biotransformation and cancer risk.	Univ Paris 06, CNRS, UMR 7000, F-75013 Paris, France; Univ Paris 07, UFR Biochim, F-75005 Paris, France; Inst Canc Res, CRUK Ctr Cell & Mol Biol, London SW3 6JB, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rodrigues-Lima, F (corresponding author), Univ Paris 06, CNRS, UMR 7000, F-75013 Paris, France.	rlima@ext.jussieu.fr						ANDRES HH, 1988, J BIOL CHEM, V263, P7521; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; Boelsterli, 2003, MECH TOXICOLOGY MOL; Borutaite V, 2001, FEBS LETT, V500, P114, DOI 10.1016/S0014-5793(01)02593-5; Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; Butcher NJ, 2000, BIOCHEM PHARMACOL, V60, P1829, DOI 10.1016/S0006-2952(00)00501-3; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Culotta VC, 2000, CURR TOP CELL REGUL, V36, P117; Delgoda R, 2003, BBA-GEN SUBJECTS, V1620, P8, DOI 10.1016/S0304-4165(02)00500-7; Delomenie C, 2001, J BACTERIOL, V183, P3417, DOI 10.1128/JB.183.11.3417-3427.2001; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Fretland AJ, 2001, PHARMACOGENETICS, V11, P511, DOI 10.1097/00008571-200108000-00006; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Gergel D, 1997, ARCH BIOCHEM BIOPHYS, V337, P239, DOI 10.1006/abbi.1996.9765; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; Goodfellow GH, 2000, BIOCHEM J, V348, P159, DOI 10.1042/0264-6021:3480159; GRANT DM, 1991, MOL PHARMACOL, V39, P184; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Hampton MB, 2002, FEBS LETT, V517, P229, DOI 10.1016/S0014-5793(02)02629-7; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEIN D, 2002, MUTAT RES, V65, P506; Hein DW, 2000, TOXICOL LETT, V112, P349, DOI 10.1016/S0378-4274(99)00226-X; Hightower LE, 1998, BIOL CHEM, V379, P1213; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; Meisel P, 2002, PHARMACOGENOMICS, V3, P349, DOI 10.1517/14622416.3.3.349; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Mushtaq A, 2002, J BIOL CHEM, V277, P12175, DOI 10.1074/jbc.M104365200; Pagano G, 2002, HUM EXP TOXICOL, V21, P77, DOI 10.1191/0960327102ht214oa; Panayiotidis R, 1999, FREE RADICAL BIO MED, V26, P548, DOI 10.1016/S0891-5849(98)00249-4; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Pompeo F, 2002, PHARMACOGENOMICS, V3, P19, DOI 10.1517/14622416.3.1.19; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Rodrigues-Lima F., 2002, Pharmacogenomics Journal, V2, P152, DOI 10.1038/sj.tpj.6500114; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V293, P783, DOI 10.1016/S0006-291X(02)00299-1; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Sinclair J, 1997, BIOCHEM PHARMACOL, V53, P11, DOI 10.1016/S0006-2952(96)00592-8; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Upton A, 2001, TRENDS PHARMACOL SCI, V22, P140, DOI 10.1016/S0165-6147(00)01639-4; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X	63	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35086	35092		10.1074/jbc.M303813200	http://dx.doi.org/10.1074/jbc.M303813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832400	hybrid			2022-12-25	WOS:000185164400043
J	Binz, SK; Lao, Y; Lowry, DF; Wold, MS				Binz, SK; Lao, Y; Lowry, DF; Wold, MS			The phosphorylation domain of the 32-kDa subunit of replication protein a (RPA) modulates RPA-DNA interactions - Evidence for an intersubunit interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; 70 KDA SUBUNIT; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; 70-KDA SUBUNIT; FUNCTIONAL DOMAINS; DAMAGE CHECKPOINTS; HELA-CELLS	Replication protein A (RPA) is a heterotrimeric (subunits of 70, 32, and 14 kDa) single-stranded DNA-binding protein that is required for DNA replication, recombination, and repair. The 40-residue N-terminal domain of the 32-kDa subunit of RPA (RPA32) becomes phosphorylated during S-phase and after DNA damage. Recently it has been shown that phosphorylation or the addition of negative charges to this N-terminal phosphorylation domain modulates RPA-protein interactions and increases cell sensitivity to DNA damage. We found that addition of multiple negative charges to the N-terminal phosphorylation domain also caused a significant decrease in the ability of a mutant form of RPA to destabilize double-stranded (ds) DNA. Kinetic studies suggested that the addition of negative charges to the N-terminal phosphorylation domain caused defects in both complex formation ( nucleation) and subsequent destabilization of dsDNA by RPA. We conclude that the N-terminal phosphorylation domain modulates RPA interactions with dsDNA. Similar changes in DNA interactions were observed with a mutant form of RPA in which the N-terminal domain of the 70-kDa subunit was deleted. This suggested a functional link between the N-terminal domains of the 70- and 32-kDa subunits of RPA. NMR experiments provided evidence for a direct interaction between the N-terminal domain of the 70- kDa subunit and the negatively charged N-terminal phosphorylation domain of RPA32. These findings suggest that phosphorylation causes a conformational change in the RPA complex that regulates RPA function.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Pacific NW Natl Lab, Richland, WA 99352 USA	University of Iowa; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Wold, MS (corresponding author), Univ Iowa, Coll Med, Dept Biochem, 51 Newton Rd, Iowa City, IA 52242 USA.	marc-wold@uiowa.edu	Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NIGMS NIH HHS [GM4471] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Daughdrill GW, 2001, NUCLEIC ACIDS RES, V29, P3270, DOI 10.1093/nar/29.15.3270; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Iftode C, 1997, MOL CELL BIOL, V17, P3876, DOI 10.1128/MCB.17.7.3876; Iftode C, 1998, NUCLEIC ACIDS RES, V26, P5636, DOI 10.1093/nar/26.24.5636; Ishibashi T, 2001, GENE, V272, P335, DOI 10.1016/S0378-1119(01)00555-8; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KANTAKE N, 2003, J BIOL CHEM; KESHAV KF, 1995, MOL CELL BIOL, V15, P3119; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; Kim HS, 2001, MOL CELL BIOL, V21, P3725, DOI 10.1128/MCB.21.11.3725-3737.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; LAO Y, 2000, THESIS U IOWA; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Loo YM, 2000, NUCLEIC ACIDS RES, V28, P3354, DOI 10.1093/nar/28.17.3354; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Missura M, 2001, EMBO J, V20, P3554, DOI 10.1093/emboj/20.13.3554; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Soustelle C, 2002, GENETICS, V161, P535; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Treuner K, 1999, NUCLEIC ACIDS RES, V27, P1499, DOI 10.1093/nar/27.6.1499; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; Umezu K, 1998, GENETICS, V148, P989; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	59	83	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35584	35591		10.1074/jbc.M305388200	http://dx.doi.org/10.1074/jbc.M305388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12819197	hybrid			2022-12-25	WOS:000185164400102
J	Badugu, R; Shareef, MM; Kellum, R				Badugu, R; Shareef, MM; Kellum, R			Novel Drosophila heterochromatin protein 1 (HP1)/origin recognition complex-associated protein (HOAP) repeat motif in HP1/HOAP interactions and chromocenter associations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; ZINC-FINGER PROTEINS; NONHISTONE CHROMOSOMAL PROTEIN; CHROME SHADOW DOMAIN; HISTONE H3; HP1 PROTEINS; CENTROMERIC HETEROCHROMATIN; MAMMALIAN-CELLS; LYSINE 9; MELANOGASTER	Association of the highly conserved heterochromatin protein, HP1, with the specialized chromatin of centromeres and telomeres requires binding to a specific histone H3 modification of methylation on lysine 9. This modification is catalyzed by the Drosophila Su(var) 3-9 gene product and its homologues. Specific DNA binding activities are also likely to be required for targeting this activity along with HP1 to specific chromosomal regions. The Drosophila HOAP protein is a DNA-binding protein that was identified as a component of a multiprotein complex of HP1 containing Drosophila origin recognition complex (ORC) subunits in the early Drosophila embryo. Here we show direct physical interactions between the HOAP protein and HP1 and specific ORC subunits. Two additional HP1-like proteins (HP1b and HP1c) were recently identified in Drosophila, and the unique chromosomal distribution of each isoform is determined by two independently acting HP1 domains (hinge and chromoshadow domain) (47). We find heterochromatin protein 1/origin recognition complex-associated protein (HOAP) to interact specifically with the originally described predominantly heterochromatic HP1a protein. Both the hinge and chromoshadow domains of HP1a are required for its interaction with HOAP, and a novel peptide repeat located in the carboxyl terminus of the HOAP protein is required for the interaction with the HP1 hinge domain. Peptides that interfere with HP1a/HOAP interactions in co-precipitation experiments also displace HP1 from the heterochromatic chromocenter of polytene chromosomes in larval salivary glands. A mutant for the HOAP protein also suppresses centric heterochromatin-induced silencing, supporting a role for HOAP in centric heterochromatin.	Univ Kentucky, Dept Biol, Lexington, KY 40506 USA	University of Kentucky	Kellum, R (corresponding author), Univ Kentucky, Dept Biol, 101 TH Morgan Bldg, Lexington, KY 40506 USA.		Badugu, RamaKrishna/A-8572-2008		NIGMS NIH HHS [GM59765] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; ALFAGEMIE CR, 1980, CHROMOSOMA, V78, P1; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Cenci G, 2003, NAT CELL BIOL, V5, P82, DOI 10.1038/ncb902; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; EBERL DF, 1993, GENETICS, V134, P277; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1993, MOL GEN GENET, V240, P333, DOI 10.1007/BF00280383; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; HEARN MG, 1991, GENETICS, V128, P785; Heitz E, 1928, JAHRB WISS BOT, V69, P762; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KIT S, 1961, J MOL BIOL, V3, P711, DOI 10.1016/S0022-2836(61)80075-2; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; Lu BY, 2000, GENETICS, V155, P699; Lu BY, 1998, DEVELOPMENT, V125, P2223; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; RAE PMM, 1970, P NATL ACAD SCI USA, V67, P1018, DOI 10.1073/pnas.67.2.1018; RIS H, 1979, STRUCTURE REPLICATIO, P268; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shareef MM, 2001, MOL BIOL CELL, V12, P1671, DOI 10.1091/mbc.12.6.1671; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; SINCLAIR DAR, 1983, MOL GEN GENET, V191, P326, DOI 10.1007/BF00334834; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Smothers JF, 2001, MOL CELL BIOL, V21, P2555, DOI 10.1128/MCB.21.7.2555-2569.2001; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WUSTMANN G, 1989, MOL GEN GENET, V217, P520, DOI 10.1007/BF02464926	51	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34491	34498		10.1074/jbc.M305262200	http://dx.doi.org/10.1074/jbc.M305262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826664	hybrid			2022-12-25	WOS:000185047500109
J	Baker, SA; Freeman, K; Luby-Phelps, K; Pazour, GJ; Besharse, JC				Baker, SA; Freeman, K; Luby-Phelps, K; Pazour, GJ; Besharse, JC			IFT20 links kinesin II with a mammalian intraflagellar transport complex that is conserved in motile flagella and sensory cilia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; LEFT-RIGHT ASYMMETRY; CHLAMYDOMONAS FLAGELLA; CAENORHABDITIS-ELEGANS; MOLECULAR-STRUCTURE; CYTOPLASMIC DYNEIN; MOTOR PROTEIN; GENE TG737; HOMOLOG; SUPERFAMILY	Intraflagellar transport (IFT) is an evolutionarily conserved mechanism thought to be required for the assembly and maintenance of all eukaryotic cilia and flagella. Although IFT proteins are present in cells with sensory cilia, the organization of IFT protein complexes in those cells has not been analyzed. To determine whether the IFT complex is conserved in the sensory cilia of photoreceptors, we investigated protein interactions among four mammalian IFT proteins: IFT88/Polaris, IFT57/ Hippi, IFT52/NGD5, and IFT20. We demonstrate that IFT proteins extracted from bovine photoreceptor outer segments, a modified sensory cilium, co-fractionate at similar to17 S, similar to IFT proteins extracted from mouse testis. Using antibodies to IFT88 and IFT57, we demonstrate that all four IFT proteins co-immunoprecipitate from lysates of mouse testis, kidney, and retina. We also extended our analysis to interactions outside of the IFT complex and demonstrate an ATP-regulated co-immunoprecipitation of heterotrimeric kinesin II with the IFT complex. The internal architecture of the IFT complex was investigated using the yeast two-hybrid system. IFT20 exhibited a strong interaction with IFT57/ Hippi and the kinesin II subunit, KIF3B. Our data indicate that all four mammalian IFT proteins are part of a highly conserved complex in multiple ciliated cell types. Furthermore, IFT20 appears to bridge kinesin II with the IFT complex.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Medical College of Wisconsin; University of Massachusetts System; University of Massachusetts Worcester	Besharse, JC (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.	jbeshars@mcw.edu		Luby-Phelps, Katherine/0000-0002-8378-1409; Pazour, Gregory/0000-0002-6285-8796; Baker, Sheila/0000-0002-0259-0652	NATIONAL EYE INSTITUTE [R01EY003222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060992] Funding Source: NIH RePORTER; NEI NIH HHS [EY03222] Funding Source: Medline; NIGMS NIH HHS [GM60992] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brazelton WJ, 2001, CURR BIOL, V11, P1591, DOI 10.1016/S0960-9822(01)00485-7; Cai YF, 2001, J BIOL CHEM, V276, P41594, DOI 10.1074/jbc.M104514200; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Deane JA, 2001, CURR BIOL, V11, P1586, DOI 10.1016/S0960-9822(01)00484-5; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Haycraft CJ, 2003, EXP CELL RES, V284, P251, DOI 10.1016/S0014-4827(02)00089-7; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HUANG B, 1977, J CELL BIOL, V72, P67, DOI 10.1083/jcb.72.1.67; Iomini C, 2001, J CELL BIOL, V153, P13, DOI 10.1083/jcb.153.1.13; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Marszalek JR, 2000, BBA-MOL CELL RES, V1496, P142, DOI 10.1016/S0167-4889(00)00015-X; Mikami A, 2002, J CELL SCI, V115, P4801, DOI 10.1242/jcs.00168; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Orozco JT, 1999, NATURE, V398, P674, DOI 10.1038/19448; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Pazour GJ, 2002, J CELL BIOL, V157, P103, DOI 10.1083/jcb.200107108; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Piperno G, 1998, J CELL BIOL, V143, P1591, DOI 10.1083/jcb.143.6.1591; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; Qin HM, 2001, CURR BIOL, V11, P457, DOI 10.1016/S0960-9822(01)00122-1; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sambrook J., 2001, MOL CLONING LAB MANU; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Tsai MY, 2000, MOL BIOL CELL, V11, P2161, DOI 10.1091/mbc.11.6.2161; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011	47	110	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34211	34218		10.1074/jbc.M300156200	http://dx.doi.org/10.1074/jbc.M300156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821668	hybrid			2022-12-25	WOS:000185047500075
J	Frenkel, Z; Gregory, W; Kornfeld, S; Lederkremer, GZ				Frenkel, Z; Gregory, W; Kornfeld, S; Lederkremer, GZ			Endoplasmic reticulum-associated degradation of mammalian glycoproteins involves sugar chain trimming to Man(6-5)GlcNAc(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; MANNOSIDASE-LIKE PROTEIN; N-LINKED GLYCANS; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; MISFOLDED GLYCOPROTEINS; ER DEGRADATION; H2 SUBUNIT; PIG-LIVER; YEAST	Endoplasmic reticulum-associated degradation of misfolded or misprocessed glycoproteins in mammalian cells is prevented by inhibitors of class I alpha-mannosidases implicating mannose trimming from the precursor oligosaccharide Glc(3)Man(9)GlcNAc(2) as an essential step in this pathway. However, the extent of mannose removal has not been determined. We show here that glycoproteins subject to endoplasmic reticulum-associated degradation undergo reglucosylation, deglucosylation, and mannose trimming to yield Man(6)GlcNAc(2) and Man(5)GlcNAc(2). These structures lack the mannose residue that is the acceptor of glucose transferred by UDPGlc: glycoprotein glucosyltransferase. This could serve as a mechanism for removal of the glycoproteins from folding attempts catalyzed by cycles of reglucosylation and calnexin/calreticulin binding and result in targeting of these molecules for proteasomal degradation.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Tel Aviv University; Washington University (WUSTL)	Lederkremer, GZ (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.			Lederkremer, Gerardo/0000-0002-9857-7152				Ayalon-Soffer M, 1999, J CELL SCI, V112, P3309; BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; Bieberich E, 1997, EUR J BIOCHEM, V246, P681, DOI 10.1111/j.1432-1033.1997.t01-1-00681.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ermonval M, 2001, GLYCOBIOLOGY, V11, P565, DOI 10.1093/glycob/11.7.565; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Herscovics A, 2002, GLYCOBIOLOGY, V12, p14G; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Igdoura SA, 1999, EUR J CELL BIOL, V78, P441, DOI 10.1016/S0171-9335(99)80071-5; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; LAL A, 1994, J BIOL CHEM, V269, P9872; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; ROTH J, 1990, EUR J CELL BIOL, V53, P131; Shenkman M, 1997, P NATL ACAD SCI USA, V94, P11363, DOI 10.1073/pnas.94.21.11363; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Todorow Z, 2000, P NATL ACAD SCI USA, V97, P13643, DOI 10.1073/pnas.250472397; Tolchinsky S, 1996, J BIOL CHEM, V271, P14496, DOI 10.1074/jbc.271.24.14496; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	37	98	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34119	34124		10.1074/jbc.M305929200	http://dx.doi.org/10.1074/jbc.M305929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829701	hybrid			2022-12-25	WOS:000185047500064
J	Miyazaki, M; Jacobson, MJ; Man, WC; Cohen, P; Asilmaz, E; Friedman, JM; Ntambi, JM				Miyazaki, M; Jacobson, MJ; Man, WC; Cohen, P; Asilmaz, E; Friedman, JM; Ntambi, JM			Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; BINDING PROTEIN-1 EXPRESSION; INDUCED GENE-EXPRESSION; 3T3-L1 PREADIPOCYTES; MOUSE-LIVER; OLEOYL-COA; CHOLESTEROL; DIFFERENTIATION; MECHANISM; BIOSYNTHESIS	Stearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids. Thus far, three isoforms of SCD (SCD1, SCD2, and SCD3) have been identified and characterized. Regulation of the SCD1 isoform has been shown to be an important component of the metabolic actions of leptin in liver, but the effects of leptin on SCD isoforms in other tissues have not been investigated. We found that although the mRNA levels of SCD1 and SCD2 were not affected by leptin deficiency in the hearts of ob/ob mice, the SCD activity and levels of monounsaturated fatty acids were increased, implying the existence of another SCD isoform. This observation has led to the cDNA cloning and characterization of a fourth SCD isoform (SCD4) that is expressed exclusively in the heart. SCD4 encodes a 352-amino acid protein that shares 79% sequence identity with the SCD1, SCD2, and SCD3 isoforms. Liver X receptor alpha (LXRalpha) agonists and a high carbohydrate fat-free diet induced SCD4 expression, but unlike SCD1, SCD4 expression was not repressed by dietary polyunsaturated fatty acids. SCD4 mRNA levels were elevated 5-fold in the hearts of leptin-deficient ob/ob mice relative to wild type controls. Treatment of ob/ob mice with leptin decreased mRNA levels of SCD4, whereas levels of SCD1 and SCD2 were not affected. Furthermore, in the hearts of SCD1-deficient mice, SCD4 mRNA levels were induced 3-fold, whereas the levels of SCD2 were not altered. The current studies identify a novel heart-specific SCD isoform that demonstrates tissue-specific regulation by leptin and dietary factors.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Ntambi, JM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.				NIDDK NIH HHS [R01DK162388, R01DK-41096] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkinson LL, 2002, J BIOL CHEM, V277, P29424, DOI 10.1074/jbc.M203813200; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Garbay B, 1998, J NEUROCHEM, V71, P1719; Gomez FE, 2002, BIOCHEMISTRY-US, V41, P5473, DOI 10.1021/bi012177r; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kim HJ, 2002, J LIPID RES, V43, P1750, DOI 10.1194/jlr.M100433-JLR200; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2002, J LIPID RES, V43, P2146, DOI 10.1194/jlr.M200271-JLR200; Miyazaki M, 2001, J BIOL CHEM, V276, P39455, DOI 10.1074/jbc.M106442200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Mziaut H, 2000, P NATL ACAD SCI USA, V97, P8883, DOI 10.1073/pnas.97.16.8883; Mziaut H, 2002, BBA-MOL CELL BIOL L, V1583, P45, DOI 10.1016/S1388-1981(02)00159-2; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2001, J MOL NEUROSCI, V16, P273, DOI 10.1385/JMN:16:2-3:273; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Soukas A, 2000, GENE DEV, V14, P963; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	31	158	173	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33904	33911		10.1074/jbc.M304724200	http://dx.doi.org/10.1074/jbc.M304724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815040	hybrid			2022-12-25	WOS:000185047500036
J	Bolger, GB; Peden, AH; Steele, MR; MacKenzie, C; McEwan, DG; Wallace, DA; Huston, E; Baillie, GS; Houslay, MD				Bolger, GB; Peden, AH; Steele, MR; MacKenzie, C; McEwan, DG; Wallace, DA; Huston, E; Baillie, GS; Houslay, MD			Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; TETRATRICOPEPTIDE REPEATS; ROLIPRAM INHIBITION; RPDE-6 RNPDE4A5; AH RECEPTOR; BINDING; DOMAIN; PHOSPHORYLATION	The cyclic AMP-specific phosphodiesterase (PDE4) isoform PDE4A5 interacted with the immunophilin XAP2 in a yeast two-hybrid assay. The interaction was confirmed in biochemical pull-down analyses. The interaction was specific, in that PDE4A5 did not interact with the closely related immunophilins AIPL1, FKBP51, or FKBP52. XAP2 also did not interact with other PDE4A isoforms or typical isoforms from the three other PDE4 subfamilies. Functionally, XAP2 reversibly inhibited the enzymatic activity of PDE4A5, increased the sensitivity of PDE4A5 to inhibition by the prototypical PDE4 inhibitor 4-[3-(cyclopentyloxy)4-methoxyphenyl]-2-pyrrolidinone (rolipram) and attenuated the ability of cAMP-dependent protein kinase to phosphorylate PDE4A5 in intact cells. XAP2 maximally inhibited PDE4A5 by similar to60%, with an IC50 of 120 nM, and reduced the IC50 for rolipram from 390 nM to 70-90 nM. Co-expression of XAP2 and PDE4A5 in COS7 cells showed that they could be co-immunoprecipitated and also reduced both the enzymatic activity of PDE4A5 and its IC50 for rolipram. Native XAP2 and PDE4A5 could be co-immunoprecipitated from the brain. The isolated COOH-terminal half of XAP2 (amino acids 170-330), containing its tetratricopeptide repeat domain, but not the isolated NH2-terminal half (amino acids 1-169), containing the immunophilin homology region, similarly reduced PDE4A5 activity and its IC50 for rolipram. Mutation of Arg(271) to alanine, in the XAP2 tetratricopeptide repeat region, attenuated its ability to both interact with PDE4A5 in two-hybrid assays and to inhibit PDE4A5 activity. Either the deletion of a specific portion of the unique amino-terminal region or specific mutations in the regulatory UCR2 domain of PDE4A5 attenuated its ability be inhibited by XAP2. We suggest that XAP2 functionally interacts with PDE4A5 in cells.	Univ Utah, Hlth Sci Ctr, Vet Affairs Med Ctr,Huntsman Canc Inst, Dept Med,Div Oncol, Salt Lake City, UT 84148 USA; Univ Utah, Hlth Sci Ctr, Vet Affairs Med Ctr,Huntsman Canc Inst, Dept Oncol Sci,Div Oncol, Salt Lake City, UT 84148 USA; Univ Glasgow, Inst Biol & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	Huntsman Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; University of Glasgow	Bolger, GB (corresponding author), Univ Alabama Birmingham, Ctr Comprehens Canc, WTI 520,1530 3rd Ave S, Birmingham, AL 35294 USA.	Graeme.Bolger@ccc.uab.edu	McEwan, David/AAY-6264-2020; Houslay, Miles D/A-6825-2011; McEwan, David/A-3754-2015; Houslay, Miles/AAM-5281-2020	McEwan, David/0000-0003-0353-6532; Houslay, Miles/0000-0002-3826-8091	NIGMS NIH HHS [R01-GM58553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; Beard MB, 2002, CELL SIGNAL, V14, P453, DOI 10.1016/S0898-6568(01)00264-9; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOLGER GB, 1994, GENE, V149, P237, DOI 10.1016/0378-1119(94)90155-4; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Bolger GB, 1998, METH MOL B, V88, P101; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARLOW E, 1999, ANTIBODIES LAB MANUA; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Huston E, 2000, J BIOL CHEM, V275, P28063; JIN YJ, 1992, J BIOL CHEM, V267, P10942; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Ma Q, 1997, J BIOL CHEM, V272, P8878; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; McPhee I, 2001, CELL SIGNAL, V13, P911, DOI 10.1016/S0898-6568(01)00217-0; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Rena G, 2001, MOL PHARMACOL, V59, P996, DOI 10.1124/mol.59.5.996; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Shepherd M, 2003, BIOCHEM J, V370, P429, DOI 10.1042/BJ20021082; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1993, J BIOL CHEM, V268, P24270; Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Torphy Theodore J., 2000, Trends in Pharmacological Sciences, V21, P157; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	59	134	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33351	33363		10.1074/jbc.M303269200	http://dx.doi.org/10.1074/jbc.M303269200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810716	hybrid			2022-12-25	WOS:000184901800106
J	Charbonnier, F; Della Gaspera, B; Armand, AS; Lecolle, S; Launay, T; Gallien, CL; Chanoine, C				Charbonnier, F; Della Gaspera, B; Armand, AS; Lecolle, S; Launay, T; Gallien, CL; Chanoine, C			Specific activation of the acetylcholine receptor subunit genes by MyoD family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DEVELOPMENT; XENOPUS-LAEVIS; MOLECULAR DISTINCTION; EPSILON-SUBUNIT; SKELETAL-MUSCLE; UP-REGULATION; EXPRESSION; MYOGENESIS; MRF4; DIFFERENTIATION	Whether the myogenic regulatory factors (MRFs) of the MyoD family can discriminate among the muscle gene targets for the proper and reproducible formation of skeletal muscle is a recurrent question. We have previously shown that, in Xenopus laevis, myogenin specifically transactivated muscle structural genes in vivo. In the present study, we used the Xenopus model to examine the role of XMyoD, XMyf5, and XMRF4 for the transactivation of the ( nicotinic acetylcholine receptor) nAChR genes in vivo. During early Xenopus development, the expression patterns of nAChR subunit genes proved to be correlated with the expression patterns of the MRFs. We show that XMyf5 specifically induced the expression of the delta-subunit gene in cap animal assays and in endoderm cells of Xenopus embryos but was unable to activate the expression of the gamma-subunit gene. In embryos, overexpression of a dominant-negative XMyf5 variant led to the repression of delta- but not gamma-subunit gene expression. Conversely, XMyoD and XMRF4 activated gamma-subunit gene expression but were unable to activate delta-subunit gene expression. Finally, all MRFs induced expression of the alpha-subunit gene. These findings strengthen the concept that one MRF can specifically control a subset of muscle genes that cannot be activated by the other MRFs.	Univ Paris 05, Ctr Univ St Peres, CNRS,UMR 7060, Equipe Biol Dev & Differenciat Neuromusculaire, F-75270 Paris 06, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Chanoine, C (corresponding author), Univ Paris 05, Ctr Univ St Peres, CNRS,UMR 7060, Equipe Biol Dev & Differenciat Neuromusculaire, F-75270 Paris 06, France.			Armand, Anne-Sophie/0000-0002-0291-6421; chanoine, christophe/0000-0001-8155-2357; Charbonnier, Frederic/0000-0003-4341-3246				Arnold HH, 1996, INT J DEV BIOL, V40, P345; BALDWIN TJ, 1988, J CELL BIOL, V106, P469, DOI 10.1083/jcb.106.2.469; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; Charbonnier F, 2002, J BIOL CHEM, V277, P1139, DOI 10.1074/jbc.M107018200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; DALE L, 1987, DEVELOPMENT, V99, P527; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HOPWOOD ND, 1991, DEVELOPMENT, V111, P551; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; JENNINGS CGB, 1992, DEV BIOL, V150, P121, DOI 10.1016/0012-1606(92)90012-6; KULLBERG RW, 1994, RECEPTOR CHANNEL, V2, P23; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MURRAY N, 1995, NEURON, V14, P865, DOI 10.1016/0896-6273(95)90230-9; Nicolas N, 1998, DEV DYNAM, V213, P309, DOI 10.1002/(SICI)1097-0177(199811)213:3<309::AID-AJA7>3.0.CO;2-Z; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; POWNALL ME, 2000, ANNU REV CELL DEV BI, V18, P747; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; Rawls A, 1998, DEVELOPMENT, V125, P2349; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SHIEH BH, 1988, NEUROSCIENCE, V24, P175, DOI 10.1016/0306-4522(88)90321-1; Steinbach OC, 1998, DEV BIOL, V202, P280, DOI 10.1006/dbio.1998.8993; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	33	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33169	33174		10.1074/jbc.M304744200	http://dx.doi.org/10.1074/jbc.M304744200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807909	hybrid			2022-12-25	WOS:000184901800083
J	Dufner-Beattie, J; Wang, FD; Kuo, YM; Gitschier, J; Eide, D; Andrews, GK				Dufner-Beattie, J; Wang, FD; Kuo, YM; Gitschier, J; Eide, D; Andrews, GK			The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE METALLOTHIONEIN-I; METAL-ION TRANSPORT; TERMINAL DI-LEUCINE; DIETARY ZINC; SACCHAROMYCES-CEREVISIAE; MOLECULAR-BIOLOGY; MENKES PROTEIN; EXPRESSION; FAMILY; CELLS	The human ZIP4 gene (SLC39A4) is a candidate for the genetic disorder of zinc metabolism acrodermatitis enteropathica. To understand its role in zinc homeostasis, we examined the function and expression of mouse ZIP4. This gene encodes a well conserved eight-transmembrane protein that can specifically increase the influx of zinc into transfected cells. Expression of this gene is robust in tissues involved in nutrient uptake, such as the intestines and embryonic visceral yolk sac, and is dynamically regulated by zinc. Dietary zinc deficiency causes a marked increase in the accumulation of ZIP4 mRNA in these tissues, whereas injection of zinc or increasing zinc content of the diet rapidly reduces its abundance. Zinc can also regulate the accumulation of ZIP4 protein at the apical surface of enterocytes and visceral endoderm cells. These results provide compelling evidence that ZIP4 is a zinc transporter that plays an important role in zinc homeostasis, a process that is defective in acrodermatitis enteropathica in humans.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of Kansas; University of Kansas Medical Center; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Mail Stop 3030,39th & Rainbow Blvd, Kansas City, KS 66160 USA.		Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK063975] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; ATHERTON DJ, 1979, CLIN SCI, V56, P505, DOI 10.1042/cs0560505; BAUDON JJ, 1978, ARCH FR PEDIATR, V35, P63; BOHANE TD, 1977, GASTROENTEROLOGY, V73, P587; BRAUN OH, 1976, EUR J PEDIATR, V121, P247, DOI 10.1007/BF00443018; CHESTERS JK, 1983, J INHERIT METAB DIS, V6, P34, DOI 10.1007/BF01811321; COOKMILLS JM, 1993, BRIT J NUTR, V69, P835, DOI 10.1079/BJN19930084; Cousins R J, 1989, Adv Exp Med Biol, V249, P3; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DESMONS F, 1979, ANN DERMATOL VENER, V106, P9; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gozdasoglu S, 2000, J TRACE ELEM EXP MED, V13, P317; Grider A, 1998, BIOL TRACE ELEM RES, V61, P1, DOI 10.1007/BF02784035; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; HEMPE JM, 1991, J NUTR, V121, P1389, DOI 10.1093/jn/121.9.1389; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Krebs NF, 2000, J NUTR, V130, p1374S, DOI 10.1093/jn/130.5.1374S; KRIEGER I, 1982, PEDIATRICS, V69, P773; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; LARREGUE M, 1977, ANN DERMATOL VENER, V104, P737; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; LOMBECK I, 1975, Z KINDERHEILKD, V120, P181, DOI 10.1007/BF00439007; LORINCZ AL, 1967, ARCH DERMATOL, V96, P736, DOI 10.1001/archderm.96.6.736; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHLSSON A, 1981, ACTA PAEDIATR SCAND, V70, P269, DOI 10.1111/j.1651-2227.1981.tb05556.x; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; PRASAD AS, 1984, FED PROC, V43, P2829; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; VAZQUEZ F, 1995, BIOL TRACE ELEM RES, V50, P109, DOI 10.1007/BF02789413; Wang K, 2001, AM J HUM GENET, V68, P1055, DOI 10.1086/319514; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	49	207	213	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33474	33481		10.1074/jbc.M305000200	http://dx.doi.org/10.1074/jbc.M305000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12801924	hybrid			2022-12-25	WOS:000184901800121
J	Galiana-Arnoux, D; Lejeune, F; Gesnel, MC; Stevenin, J; Breathnach, R; Del Gatto-Konczak, F				Galiana-Arnoux, D; Lejeune, F; Gesnel, MC; Stevenin, J; Breathnach, R; Del Gatto-Konczak, F			The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR 2; TRACT-BINDING-PROTEIN; RNA-BINDING; INVOLVEMENT; IDENTIFICATION; EXPRESSION; DIVERSITY; SELECTION; ELEMENTS; VARIANT	The CD44 gene alternative exons v8, v9, and v10 are frequently spliced as a block by epithelial cells. By transfecting minigenes containing only one of these alternative exons, we show that splicing of each of them is under cell type-specific control. By using minigenes carrying short block mutations within exons v8 and v9, we detected a candidate exon splicing enhancer in each of these exons. These candidates activated splicing in vitro of a heterologous transcript and are thus true exon splicing enhancers. We analyzed further a v9 exon splicing enhancer covering similar to30 nucleotides. This enhancer can be UV cross-linked to SR proteins of 35 and 20 kDa in HeLa nuclear extract. By using individual recombinant SR proteins for UV cross-linking in S100 extract, these proteins were identified as 9G8, ASF/SF2, and SRp20. S100 complementation studies using recombinant 9G8, ASF/SF2, and SRp20 showed that all three proteins can activate splicing in vitro of a heterologous exon containing the v9 enhancer; the strongest activation was obtained with 9G8. Progressive truncation of the 30-nucleotide enhancer leads to a progressive decrease in splicing activation. We propose that 9G8, ASF/SF2, SRp20, and possibly other non-SR proteins cooperate in vivo to activate v9 exon splicing.	Inst Biol CHR, INSERM, U463, F-44093 Nantes, France; Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Breathnach, R (corresponding author), Inst Biol CHR, INSERM, U463, 9 Quai Moncousu, F-44093 Nantes, France.	breathna@nantes.inserm.fr	Breathnach, Richard/K-7599-2015; Del Gatto-Konczak, Fabienne/L-1506-2015; Lejeune, Fabrice/N-3886-2017; Lejeune, Fabrice/P-9843-2019	Lejeune, Fabrice/0000-0002-5132-3585				Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Ghigna C, 1998, CANCER RES, V58, P5818; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Honig A, 2002, MOL CELL BIOL, V22, P5698, DOI 10.1128/MCB.22.16.5698-5707.2002; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Le Guiner C, 2001, J BIOL CHEM, V276, P43677, DOI 10.1074/jbc.M107381200; Lejeune F, 2001, J BIOL CHEM, V276, P7850, DOI 10.1074/jbc.M009510200; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; PONTA H, 1994, INVAS METAST, V14, P82; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; Yamaguchi A, 2000, ONCOL REP, V7, P541; Yu Q, 1996, J BIOL CHEM, V271, P20603, DOI 10.1074/jbc.271.34.20603	45	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32943	32953		10.1074/jbc.M301090200	http://dx.doi.org/10.1074/jbc.M301090200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12826680	hybrid			2022-12-25	WOS:000184901800057
J	Hisamatsu, T; Suzuki, M; Podolsky, DK				Hisamatsu, T; Suzuki, M; Podolsky, DK			Interferon-gamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INFLAMMATORY-BOWEL-DISEASE; INVASIVE SHIGELLA-FLEXNERI; FAMILY-MEMBER; TNF-ALPHA; ACTIVATION; NOD2; BACTERIAL; TRANSCRIPTION; RECOGNITION	Although intestinal epithelial cells appear to be functionally hyporesponsive to normal intestinal flora, human intestinal epithelial cells can respond to enteroinvasive bacteria and induce an inflammatory response. This initial inflammatory response leads to the recruitment of polymorphonuclear leukocytes to the affected site in vitro and in vivo. CARD4/NOD1 is a potential cytosolic receptor for peptidoglycan in mammalian cells that resembles pathogen-resistant proteins of plants. In this context, CARD4/NOD1 is a candidate for a recognition protein of intracellular bacteria or peptidoglycan in intestinal epithelial cells. In this study, we demonstrate that CARD4/NOD1 is constitutively expressed in intestinal epithelial cell lines and isolated primary intestinal epithelial cells. Interferon-gamma (IFNgamma), which is a potent pro-inflammatory cytokine in intestinal mucosal inflammation, activates CARD4/NOD1 mRNA transcription in a time- and dose-dependent manner and results in augmentation of CARD4/NOD1 protein in SW480 cells. Promoter analysis of CARD4/NOD1 indicates that interferon regulatory factor-1 (IRF-1) binding motif (-791 to -782) is essential for the effect of IFNgamma. Nuclear extracts from SW480 cells treated with IFNgamma show specific binding of oligonucleotides corresponding to this IRF-1-binding motif, which was supershifted by anti-IRF-1 antibody in electrophoretic mobility shift assay. Overexpression of IRF-1 protein activates the CARD4/NOD1 promoter but not the deletion mutant of the IRF-1-binding site in a co-transfection assay of IRF-1 expression plasmid with CARD4/NOD1 promoter. These studies suggest that the Th1 cytokine, IFNgamma, activates CARD4/NOD1 transcription and regulate innate immune mechanisms in the condition of intestinal mucosal inflammation.	Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.				NIDDK NIH HHS [DK53304, DK43351, DK41557] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK041557, R37DK041557, R01DK053304] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Awane M, 1999, J IMMUNOL, V162, P5337; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Elewaut D, 1999, J IMMUNOL, V163, P1457; Ellis JG, 1999, PLANT CELL, V11, P495, DOI 10.1105/tpc.11.3.495; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Schreiber S, 2002, GUT, V51, P379, DOI 10.1136/gut.51.3.379; Schultsz C, 1999, GASTROENTEROLOGY, V117, P1089, DOI 10.1016/S0016-5085(99)70393-8; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614	32	82	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32962	32968		10.1074/jbc.M304355200	http://dx.doi.org/10.1074/jbc.M304355200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813035	hybrid			2022-12-25	WOS:000184901800059
J	Liu, G; Li, DS; Pasumarthy, MK; Kowalczyk, TH; Gedeon, CR; Hyatt, SL; Payne, JM; Miller, TJ; Brunovskis, P; Fink, TL; Muhammad, O; Moen, RC; Hanson, RW; Cooper, MJ				Liu, G; Li, DS; Pasumarthy, MK; Kowalczyk, TH; Gedeon, CR; Hyatt, SL; Payne, JM; Miller, TJ; Brunovskis, P; Fink, TL; Muhammad, O; Moen, RC; Hanson, RW; Cooper, MJ			Nanoparticles of compacted DNA transfect postmitotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-MEDIATED TRANSFECTION; NUCLEAR-LOCALIZATION SIGNAL; GENE-TRANSFER; PLASMID DNA; HUMAN FIBROBLASTS; IN-VITRO; TRANSPORT; EXPRESSION; DELIVERY; HEPATOCYTES	Charge-neutral DNA nanoparticles have been developed in which single molecules of DNA are compacted to their minimal possible size. We speculated that the small size of these DNA nanoparticles may facilitate gene transfer in postmitotic cells, permitting nuclear uptake across the 25-nm nuclear membrane pore. To determine whether DNA nanoparticles can transfect nondividing cells, growth-arrested neuroblastoma and hepatoma cells were transfected with DNA/liposome mixtures encoding luciferase. In both models, growth-arrested cells were robustly transfected by compacted DNA (6,900-360-fold more than naked DNA). To evaluate mechanisms responsible for enhanced transfection, HuH-7 cells were microinjected with naked or compacted plasmids encoding enhanced green fluorescent protein. Cytoplasmic microinjection of DNA nanoparticles generated a similar to10-fold improvement in transgene expression as compared with naked DNA; this enhancement was reversed by the nuclear pore inhibitor, wheat germ agglutinin. To determine the upper size limit for gene transfer, DNA nanoparticles of various sizes were microinjected into the cytoplasm. A marked decrease in transgene expression was observed as the minor ellipsoidal diameter approached 25 nm. In summary, suitably sized DNA nanoparticles productively transfect growth arrested cells by traversing the nuclear membrane pore.	Copernicus Therapeut Inc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Cooper, MJ (corresponding author), Copernicus Therapeut Inc, 11000 Cedar Ave,Suite 145, Cleveland, OH 44106 USA.	mcooper@cgsys.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; Armitage P, 2002, STAT METHODS MED RES, P306; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P550; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P179; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; Chan CK, 2000, GENE THER, V7, P1690, DOI 10.1038/sj.gt.3301275; Chan CK, 1999, HUM GENE THER, V10, P1695, DOI 10.1089/10430349950017699; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; Fasbender A, 1997, GENE THER, V4, P1173, DOI 10.1038/sj.gt.3300524; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; Feldherr CM, 1997, J CELL SCI, V110, P3065; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Hagstrom JE, 1997, J CELL SCI, V110, P2323; Harada A, 1999, SCIENCE, V283, P65, DOI 10.1126/science.283.5398.65; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P148; Jiang CW, 1998, HUM GENE THER, V9, P1531, DOI 10.1089/hum.1998.9.11-1531; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Katayose S, 1998, J PHARM SCI, V87, P160, DOI 10.1021/js970304s; KERSCHMANN R, 2001, MOL THER, V3, pS404; Konstan MW, 2003, MOL THER, V7, pS386; Kowalczyk T, 2001, MOL THER, V3, pS359; KOWALCZYK TH, 2002, MOL THER, V5, pS435; KOWALCZYK TH, 2000, MOL THER, V1, pS120; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Ludtke JJ, 1999, J CELL SCI, V112, P2033; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; MAUL GG, 1977, J CELL BIOL, V73, P748, DOI 10.1083/jcb.73.3.748; MIRZAYANS R, 1992, MUTAT RES, V281, P115, DOI 10.1016/0165-7992(92)90045-J; Mortimer I, 1999, GENE THER, V6, P403, DOI 10.1038/sj.gt.3300837; Nakanishi M, 2001, EUR J PHARM SCI, V13, P17, DOI 10.1016/S0928-0987(00)00203-7; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OUPICKY D, 2001, NONVIRAL VECTOS GENE, P70; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; PLUM GE, 1990, BIOPOLYMERS, V30, P631, DOI 10.1002/bip.360300515; Pollard H, 2001, J GENE MED, V3, P153, DOI 10.1002/jgm.160; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Pouton CW, 1998, ADV DRUG DELIVER REV, V34, P51, DOI 10.1016/S0169-409X(98)00050-7; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; SHAPIRO JT, 1969, BIOCHEMISTRY-US, V8, P3219, DOI 10.1021/bi00836a014; STOCKS SJ, 1986, ANAL BIOCHEM, V154, P232, DOI 10.1016/0003-2697(86)90520-8; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; Tinoco V.A, 2000, NUCL ACIDS STRUCTURE, P335; Tseng WC, 1999, BBA-GENE STRUCT EXPR, V1445, P53, DOI 10.1016/S0167-4781(99)00039-1; Tulman ER, 2000, J VIROL, V74, P7980, DOI 10.1128/JVI.74.17.7980-7988.2000; Wilke M, 1996, GENE THER, V3, P1133; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zauner W, 1999, BBA-GEN SUBJECTS, V1428, P57, DOI 10.1016/S0304-4165(99)00022-7; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang W, 1996, P NATL ACAD SCI USA, V93, P2511, DOI 10.1073/pnas.93.6.2511; Ziady AG, 2002, MOL THER, V5, P413, DOI 10.1006/mthe.2002.0556	62	158	165	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32578	32586		10.1074/jbc.M305776200	http://dx.doi.org/10.1074/jbc.M305776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807905	hybrid			2022-12-25	WOS:000184901800014
J	Ducruet, AP; Lazo, JS				Ducruet, AP; Lazo, JS			Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TYROSINE PHOSPHATASE; CHECKPOINT PATHWAY; ACTIVATES P34CDC2; PROTEIN-KINASE; DNA-DAMAGE; C-MYC; PHOSPHORYLATION; MITOSIS; DEPHOSPHORYLATION	Cdc25A regulates cell cycle progression, has oncogenic and anti-apoptotic activity, and is over-expressed in many human tumors. Phosphorylation by Chk1 and Cds1/Chk2 down-regulates Cdc25A levels in response to genotoxic stresses. Nevertheless, it remains unclear whether Chk1 and Cds1/Chk2 are uniquely responsible for regulating Cdc25A stability during interphase or if other kinase activities contribute. Here we report that treatment of HeLa cells with the cyclin-dependent kinase inhibitor roscovitine caused a concentration- and time-dependent increase in Cdc25A protein levels. Transfection with dominant-negative Cdk mutants demonstrated that only a Cdk2 mutant increased Cdc25A protein levels; Cdk1 and Cdk3 mutants had no effect. The increased Cdc25A protein levels were the result of an increase in the half-life of the protein; no increase in Cdc25A mRNA levels was observed. These results demonstrate Cdk2 kinase activity contributes to the labile nature of Cdc25A during interphase and redefine the nature of the Cdc25A-Cdk2 autoamplification feedback loop.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E-1340, Pittsburgh, PA 15261 USA.				NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Katich SC, 2001, ONCOGENE, V20, P543, DOI 10.1038/sj.onc.1204130; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lyon MA, 2002, NAT REV DRUG DISCOV, V1, P961, DOI 10.1038/nrd963; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qu ZL, 2003, AM J PHYSIOL-CELL PH, V284, pC349, DOI 10.1152/ajpcell.00066.2002; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	39	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31838	31842		10.1074/jbc.M303604200	http://dx.doi.org/10.1074/jbc.M303604200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801928	hybrid			2022-12-25	WOS:000184782100047
J	Weggen, S; Eriksen, JL; Sagi, SA; Pietrzik, CU; Ozols, V; Fauq, A; Golde, TE; Koo, EH				Weggen, S; Eriksen, JL; Sagi, SA; Pietrzik, CU; Ozols, V; Fauq, A; Golde, TE; Koo, EH			Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; ERBB-4 RECEPTOR; INHIBITOR; PRESENILIN-1; A-BETA-42; CLEAVAGE; APP; INFLAMMATION	Chronic use of nonsteroidal anti-inflammatory drugs ( NSAIDs) is associated with a lower risk of developing Alzheimer's disease. Recent evidence indicates that some NSAIDs specifically inhibit secretion of the amyloidogenic Abeta42 peptide in cultured cells and mouse models of Alzheimer's disease. The reduction of Abeta42 peptides is not mediated by inhibition of cyclooxygenases ( COX) but the molecular mechanism underlying this novel activity of NSAIDs has not been further defined. We now demonstrate that NSAIDs efficiently reduce the intracellular pool of Abeta42 in cell-based studies and selectively decrease Abeta42 production in a cell-free assay of gamma-secretase activity. Moreover, we find that presenilin-1 (PS1) mutations, which affect gamma-secretase activity, differentially modulate the cellular Abeta42 response to NSAID treatment. Overexpression of the PS1-M146L mutation enhances the cellular drug response to Abeta42 lowering NSAIDs as compared with cells expressing wildtype PS1. In contrast, expression of the PS1-DeltaExon9 mutation strongly diminishes the Abeta42 response, showing that PS1 mutations can modulate the cellular drug response to NSAID treatment both positively and negatively. Enhancement of the NSAID drug response was also observed with overexpression of the APP V717F mutation but not with Swedish mutant APP, which affects beta-secretase cleavage. In sum, these results strongly suggest that NSAIDs represent a founding group of compounds that lower Abeta42 production by direct modulation of gamma-secretase activity or its substrate.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Mayo Clin, Dept Neurosci & Pharmacol, Jacksonville, FL 32224 USA	University of California System; University of California San Diego; Mayo Clinic	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Eriksen, Jason/A-8054-2008	Eriksen, Jason/0000-0003-1549-4165	NIA NIH HHS [AG 20206] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG020206] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Brooks WS, 2003, BRAIN, V126, P783, DOI 10.1093/brain/awg084; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; De Strooper B, 2001, NATURE, V414, P159, DOI 10.1038/35102656; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; IKEUCHI T, 2002, J BIOL CHEM, V19, P19; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McLendon C, 2000, FASEB J, V14, P2383; Moore CL, 2000, J MED CHEM, V43, P3434, DOI 10.1021/jm000100f; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okochi M, 1997, FEBS LETT, V418, P162, DOI 10.1016/S0014-5793(97)01378-1; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shureiqi I, 2001, CANCER RES, V61, P6307; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tsai JY, 2002, CURR MED CHEM, V9, P1087, DOI 10.2174/0929867023370185; Uljon SN, 2000, METH MOL B, V146, P439, DOI 10.1385/1-59259-045-4:439; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weggen S, 2003, J BIOL CHEM, V278, P30748, DOI 10.1074/jbc.M304824200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 2000, NEUROBIOL DIS, V7, P673, DOI 10.1006/nbdi.2000.0322; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	58	246	269	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31831	31837		10.1074/jbc.M303592200	http://dx.doi.org/10.1074/jbc.M303592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805356	hybrid			2022-12-25	WOS:000184782100046
J	Edwardson, JM; Wang, CT; Gong, B; Wyttenbach, A; Bai, JH; Jackson, MB; Chapman, ER; Morton, AJ				Edwardson, JM; Wang, CT; Gong, B; Wyttenbach, A; Bai, JH; Jackson, MB; Chapman, ER; Morton, AJ			Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; DISEASE GENE HOMOLOG; NEUROTRANSMITTER RELEASE; SNARE COMPLEX; EMBRYONIC LETHALITY; FUSION PORE; MICE; MUTATION; POLYGLUTAMINE; LOCALIZATION	Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. We reported recently that complexin II, a protein involved in neurotransmitter release, is depleted from both the brains of mice carrying the HD mutation and from the striatum of post mortem HD brains. Here we show that this loss of complexin II is recapitulated in PC12 cells expressing the HD mutation and is accompanied by a dramatic decline in Ca2+-triggered exocytosis of neurotransmitter. Overexpression of complexin II (but not complexin I) rescued exocytosis, demonstrating that the decline in neurotransmitter release is a direct consequence of complexin II depletion. Complexin II depletion in the brain may account for some of the abnormalities in neurotransmission associated with HD.	Dept Pharmacol, Cambridge CB2 1PD, England; Univ Wisconsin, Dept Physiol, Madison, WI 53705 USA; Dept Biochem, Cambridge CB2 1QW, England	University of Wisconsin System; University of Wisconsin Madison	Morton, AJ (corresponding author), Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.		Wang, Chih-Tien/GRE-8232-2022	Wang, Chih-Tien/0000-0001-7639-7508; Chapman, Edwin/0000-0001-9787-8140				Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V369, P493; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; FOROUD T, 1995, ANN NEUROL, V37, P657, DOI 10.1002/ana.410370516; Hu KA, 2002, J BIOL CHEM, V277, P41652, DOI 10.1074/jbc.M205044200; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Lawrence AD, 1998, BRAIN, V121, P1329, DOI 10.1093/brain/121.7.1329; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lione LA, 1999, J NEUROSCI, V19, P10428; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Morton AJ, 2001, J NEUROCHEM, V76, P166, DOI 10.1046/j.1471-4159.2001.00059.x; Morton AJ, 2001, BRAIN RES BULL, V56, P111, DOI 10.1016/S0361-9230(01)00611-6; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Smith MA, 2000, NATURE, V403, P544, DOI 10.1038/35000576; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Wilkinson FL, 1999, MOL BRAIN RES, V69, P10, DOI 10.1016/S0169-328X(99)00097-2; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yamada M, 1999, NEUROSCIENCE, V93, P7, DOI 10.1016/S0306-4522(99)00104-9; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	44	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30849	30853		10.1074/jbc.M304615200	http://dx.doi.org/10.1074/jbc.M304615200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12807877	hybrid			2022-12-25	WOS:000184658800055
J	Van der Meer-Van Kraaij, C; Van Lieshout, EMM; Kramer, E; Van der Meer, R; Keijer, J				Van der Meer-Van Kraaij, C; Van Lieshout, EMM; Kramer, E; Van der Meer, R; Keijer, J			Mucosal pentraxin (Mptx), a novel rat gene 10-fold down-regulated in colon by dietary heme	FASEB JOURNAL			English	Article						red meat; microarray; colon cancer	AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; RED MEAT; COLORECTAL-CANCER; EXPRESSION; MICROARRAY; BINDING; RISK; FAT; PCR	Consumption of red meat is associated with increased colon cancer risk. Our previous work indicated that this association might be due to the heme content of red meat. In rat studies, dietary heme increased colonic cytotoxicity and epithelial cell turnover, carcinogenesis biomarkers. Here we apply DNA microarray technology to examine effects of heme on colonic gene expression. A rat colon-specific microarray was constructed and hybridized in duplicate to RNA extracts from colon scrapings of rats fed diets with or without heme (n = 6 - 7). We were able to reproducibly identify changes in colonic mRNA abundance in response to heme. Most striking was a > 10-fold downregulation of a single rat gene, an unprecedented gene-modulating effect of a dietary component. Based on homology, the novel gene encodes a pentraxin, the first identified in colon. Pentraxins are postulated to be involved in dealing with dying cells. Quantitative PCR confirmed the strong heme-induced down-regulation of this gene, which we named mucosal pentraxin (Mptx). Overall, our data support the efficacy of cDNA array expression profiling to investigate effects of specific nutrients in an in vivo system and may provide an approach to establishing markers for diet-induced stress of mammalian colonic mucosa.	WCFS, NL-6700 AE Wageningen, Netherlands; RIKILT, Inst Food Safety, NL-6700 AE Wageningen, Netherlands; NIZO Food Res, NL-6710 BA Ede, Netherlands	Wageningen University & Research; NIZO Food Research	Keijer, J (corresponding author), WCFS, Bornsesteeg 45,POB 230, NL-6700 AE Wageningen, Netherlands.	jaap.keijer@wur.nl	Keijer, Jaap/J-8089-2013	Keijer, Jaap/0000-0002-9720-7491				Bharadwaj D, 2001, J IMMUNOL, V166, P6735, DOI 10.4049/jimmunol.166.11.6735; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Boeuf S, 2001, PHYSIOL GENOMICS, V7, P15, DOI 10.1152/physiolgenomics.00048.2001; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Crescenzi M, 2001, FEBS LETT, V507, P114, DOI 10.1016/S0014-5793(01)02973-8; de Haas CJC, 1999, FEMS IMMUNOL MED MIC, V26, P197, DOI 10.1016/S0928-8244(99)00148-0; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; DuClos TW, 1996, MOL BIOL REP, V23, P253, DOI 10.1007/BF00351177; Eastwood GL, 1995, J CLIN GASTROENTEROL, V21, pS1; Familian A, 2001, J IMMUNOL, V167, P647, DOI 10.4049/jimmunol.167.2.647; Franssen-val Hal NLW, 2002, ANAL BIOCHEM, V308, P5, DOI 10.1016/S0003-2697(02)00203-8; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McGeer EG, 2001, NEUROBIOL AGING, V22, P843, DOI 10.1016/S0197-4580(01)00288-3; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Reeves PG, 1993, AIN 93 PURIFIED DIET; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sesink ALA, 2001, CARCINOGENESIS, V22, P1653, DOI 10.1093/carcin/22.10.1653; Sesink ALA, 1999, CANCER RES, V59, P5704; Sesink ALA, 2000, CARCINOGENESIS, V21, P1909, DOI 10.1093/carcin/21.10.1909; SESINK LA, 2001, THESIS U GRONINGEN N; van Hal NLW, 2000, J BIOTECHNOL, V78, P271, DOI 10.1016/S0168-1656(00)00204-2; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404	26	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1277	1285		10.1096/fj.02-1036com	http://dx.doi.org/10.1096/fj.02-1036com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832292				2022-12-25	WOS:000184471600039
J	Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E				Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E			Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; insulin receptor substrate; proteasome degradation; cell survival; breast cancer	GROWTH-FACTOR-I; HUMAN PANCREATIC-CANCER; HUMAN SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3-OH KINASE; MEDIATED DEGRADATION; DOWN-REGULATION; 26S PROTEASOME; IRS-2 GENE	In breast cancer cells, 17-beta-estradiol (E2) upregulates the expression of insulin receptor substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways. The stimulation of IRS-1 by E2 has been documented on the transcriptional level. Here we studied whether the expression of estrogen receptor (ER)-alpha affects IRS molecules post-transcriptionally. We used ER-alpha-negative MDA-MB-231 breast cancer cells and MDA-MB-231 cells with re-expressed ER-alpha. In MDA-MB-231 cells cultured under serum-free conditions, IRS-1 and IRS-2 were degraded through the 26S proteasome and calpain pathways. Re-expression of ER-alpha in MDA-MB-231 cells correlated with enhanced stability of IRS molecules. This effect coincided with significantly reduced ubiquitination of IRS-1 and IRS-2, but did not involve increased IRS-1 and IRS-2 transcription. The interference of ER-alpha with IRS-1 and IRS-2 turnover could rely on the competition for common degradation pathways, as in MDA-MB-231/ER cells, ER-alpha processing was blocked by proteasome and calpain inhibitors. Notably, a fraction of the cytosolic ER-alpha colocalized and coprecipitated with IRS-1 and IRS-2, indicating a possible common destination for these proteins. The stabilization of IRS-1 in MDA-MB-231/ER cells was paralleled by the upregulation of the IRS-1/Akt/GSK-3 pathway and improved survival in the presence of IGF-I, whereas IRS-2 was not involved in IGF-I signaling.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Fac Pharm, Postgrad Sch Clin Pathol, I-87030 Commenda Di Rende, Italy	Jefferson University; University of Calabria	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.		Garofalo, Cecilia/B-3834-2017; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; Morelli, Catia/0000-0002-9407-0805				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguirre V., 2000, CURRENT OPIN ENDOCRI, V7, P1, DOI [10.1097/00060793-200002000-00001, DOI 10.1097/00060793-200002000-00001]; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Ashok BT, 2001, INT J MOL MED, V8, P385; Bartucci M, 2001, CANCER RES, V61, P6747; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Dupont J, 1999, J ENDOCRINOL, V162, P67, DOI 10.1677/joe.0.1620067; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Guvakova MA, 1997, CANCER RES, V57, P2606; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kornmann M, 1998, CANCER RES, V58, P4250; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Powzaniuk MA, 2001, J IMMUNOL, V167, P242, DOI 10.4049/jimmunol.167.1.242; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Richards RG, 2001, ENDOCRINOLOGY, V142, P3842, DOI 10.1210/en.142.9.3842; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Salerno M, 1999, INT J CANCER, V81, P299; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shiba E, 1996, ANTICANCER RES, V16, P773; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Spector SA, 1999, J SURG RES, V83, P32, DOI 10.1006/jsre.1998.5553; Sun M, 2001, CANCER RES, V61, P5985; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4007	4016		10.1038/sj.onc.1206436	http://dx.doi.org/10.1038/sj.onc.1206436			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821935				2022-12-25	WOS:000183707600004
J	Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S				Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S			Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro	ONCOGENE			English	Article						p75(NTR); stem cells; esophagus; keratinocytes; integrin beta 1; integrin beta 4	NERVE GROWTH-FACTOR; TRANSIT AMPLIFYING CELLS; HUMAN EPITHELIAL-CELLS; EPIDERMAL-CELLS; TELOMERASE ACTIVITY; SURFACE PHENOTYPE; HUMAN-SKIN; INTEGRIN; FOLLICLE; EXPRESSION	We report here that human esophageal keratinocyte stem cells are characterized by the expression of the low-affinity neurotrophin receptor p75(NTR) and differentially expressed cell adhesion molecules, the beta1 and beta4 integrins. The candidate stem cells could be fractionated from keratinocytes as a minor cell subset by means of immunocytochemical cell sorting based on the different levels of expression of these cell surface molecules. Flow cytometric analysis revealed that this minor cell subset retained a relatively slow-cycling phenotype in vitro. These cells expressed low levels of involucrin and cytokeratin 13, indicating that the p75(NTR)-positive cell subset is immature relative to the other predominant subpopulations coexpressing beta1 integrin at higher levels. The p75(NTR)-positive cell subset was crucial for achieving longevity and the greatest output of keratinocytes comprising all distinguishable subpopulations in vitro. This process was associated with self-renewal and self-amplification of the p75(NTR)-positive cell subset. These findings strongly implicate p75(NTR) as a stem cell marker, which will be valuable for prospectively investigating stem cell regulation in association with different biological processes including neoplastic transformation of regenerative epithelia.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Kyoto, Japan	Kanagawa Prefectural Cancer Center; Kyoto University	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 2410815, Japan.	yasumoto@gancen.asahi.yokohama.jp						ALBARWARI SE, 1976, INT J RADIAT BIOL, V30, P201, DOI 10.1080/09553007614550981; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; HALL PA, 1989, DEVELOPMENT, V106, P619; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kaur P, 2000, J INVEST DERMATOL, V114, P413, DOI 10.1046/j.1523-1747.2000.00884.x; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Miller Stanley J., 1997, P331, DOI 10.1016/B978-012563455-7/50012-X; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1988, J CELL SCI, P45; Price J, 2001, CURR OPIN NEUROBIOL, V11, P564, DOI 10.1016/S0959-4388(00)00250-6; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Seery JP, 2002, J CELL SCI, V115, P1783; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Yasumoto S, 1996, ONCOGENE, V13, P433	34	101	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4017	4026		10.1038/sj.onc.1206525	http://dx.doi.org/10.1038/sj.onc.1206525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821936	Green Submitted			2022-12-25	WOS:000183707600005
J	Burgermeister, E; Tencer, L; Liscovitch, M				Burgermeister, E; Tencer, L; Liscovitch, M			Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells	ONCOGENE			English	Article						cancer; caveolin; differentiation; peroxisome proliferator-activated receptor-gamma; transcriptional regulation; multidrug resistance	HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; ANCHORAGE-INDEPENDENT GROWTH; HUMAN PROSTATE-CANCER; D7S522 LOCUS 7Q31.1; MAP KINASE CASCADE; GENE-EXPRESSION; IN-VIVO; PPAR-GAMMA; TERMINAL DIFFERENTIATION	Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear receptor for eicosanoids that promotes differentiation of human epithelial and mesenchymal cells in vitro and in vivo. PPARgamma was proposed as a target for drug-induced differentiation therapy of cancer. Caveolin-1 is a constituent of plasma membrane caveolae in epithelial cells that is often downregulated upon oncogenic transformation. Caveolin-1 has growth-inhibitory activities and its disruption is sufficient to induce transformation in fibroblasts. Herein we have tested the hypothesis that caveolins are transcriptional target genes for PPARgamma. In human HT-29 colon carcinoma cells, thiazolidinedione PPARgamma ligands increased the levels of caveolin-1 and caveolin-2 proteins two to fivefold in a concentration-dependent manner within 24 h. In human MCF-7 breast adenocarcinoma cells, nonthiazolidinedione PPARgamma ligands elevated caveolin-2 protein three to fourfold, while the thiazoli-dinediones were less effective. Caveolin-1 mRNA levels were found to be upregulated by PPARgamma ligands already after 3 h in both the cell lines. Ectopic expression of a dominant-negative PPARgamma construct attenuated ligand-induced upregulation of caveolins in both HT-29 and HEK-293T cells, indicating that ligand action is mediated by PPARgamma. Ligand-treated MCF-7 cells exhibited a differentiated phenotype, as evinced by analysis of cell-specific differentiation markers: protein levels of maspin were elevated and perinuclear lipid droplets accumulated. In contrast, in HT-29 cells, caveolin expression was not correlated with differentiation. Interestingly, PPARgamma partially cofractionated in lipid rafts and could be coimmunoprecipitated from cell lysates with caveolin-1, indicating that PPARgamma and caveolin-1 may coexist in a complex. Our data indicate that PPARgamma participates in the regulation of caveolin gene expression in human carcinoma cells and suggest that caveolin-1 may mediate some of the phenotypic changes induced by this nuclear receptor in cancer cells. These findings may have potentially important functional implications in the context of cancer differentiation therapy and multidrug resistance.	Weizmann Inst Sci, Dept Biochem Regulat, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Biochem Regulat, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Bender FC, 2000, CANCER RES, V60, P5870; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; Fra AM, 2000, GENE, V243, P75, DOI 10.1016/S0378-1119(99)00559-4; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kilgore MW, 1997, MOL CELL ENDOCRINOL, V129, P229, DOI 10.1016/S0303-7207(97)04057-4; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kubota T, 1998, CANCER RES, V58, P3344; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Matveev S, 1999, J LIPID RES, V40, P1647; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Pignatelli M, 2001, J CELL SCI, V114, P4117; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Samid D, 2000, CLIN CANCER RES, V6, P933; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tahir SA, 2001, CANCER RES, V61, P3882; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Wu YF, 2003, J BIOL CHEM, V278, P8637, DOI 10.1074/jbc.M210910200; Yamamoto M, 1999, LIFE SCI, V64, P1349, DOI 10.1016/S0024-3205(99)00070-3; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	66	91	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3888	3900		10.1038/sj.onc.1206625	http://dx.doi.org/10.1038/sj.onc.1206625			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813462				2022-12-25	WOS:000183612000008
J	Nicchia, GP; Frigeri, A; Liuzzi, GM; Svelto, M				Nicchia, GP; Frigeri, A; Liuzzi, GM; Svelto, M			Inhibition of AQP4 expression in astrocytes by RNAi determines alterations in cell morphology, growth, and water transport and induces changes in ischemia related genes	FASEB JOURNAL			English	Article						aquaporin 4; astrocyte primary cultures; GLUT1	FIBRILLARY ACIDIC PROTEIN; CULTURED-MAMMALIAN-CELLS; FOCAL CEREBRAL-ISCHEMIA; HSP70 MESSENGER-RNA; RAT-BRAIN; MEMBRANE DOMAINS; TRANSGENIC MICE; SKELETAL-MUSCLE; RECEPTOR GENE; MULLER CELLS	Recent studies indicate a key role of aquaporin (AQP) 4 in astrocyte swelling and brain edema and suggest that AQP4 inhibition may be a new therapeutic way for reducing cerebral water accumulation. To understand the physiological role of AQP4-mediated astroglial swelling, we used 21-nucleotide small interfering RNA duplexes (siRNA) to specifically suppress AQP4 expression in astrocyte primary cultures. Semiquantitative RT-PCR experiments and Western blot analysis showed that AQP4 silencing determined a progressive and parallel reduction in AQP4 mRNA and protein. AQP4 gene suppression determined the appearance of a new morphological cell phenotype associated with a strong reduction in cell growth. Water transport measurements showed that the rate of shrinkage of AQP4 knockdown astrocytes was one-half of that of controls. Finally, cDNA microarray analysis revealed that the gene expression pattern perturbed by AQP4 gene silencing concerned ischemia-related genes, such as GLUT1 and hexokinase. Taken together, these results indicate that 1) AQP4 seems to be the major factor responsible for the fast water transport of cultured astrocytes; 2) as in skeletal muscle, AQP4 is a protein involved in cell plasticity; 3) AQP4 alteration may be a primary factor in ischemia-induced cerebral edema; and 4) RNA interference could be a new potent tool for studying AQP pathophysiology in those organs and tissues where they are expressed.	Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Bari, Ctr Excellence Comparat Genom, I-70126 Bari, Italy; Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	Liuzzi, Grazia Maria/GVR-7164-2022; frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014	Latronico, Tiziana/0000-0001-6971-5416; Liuzzi, Grazia Maria/0000-0001-5692-9335; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; CAZIN M, 1990, EUR RESPIR J, V3, P1015; Cogoni C, 2001, ANNU REV MICROBIOL, V55, P381, DOI 10.1146/annurev.micro.55.1.381; Crepel V, 1998, J NEUROSCI, V18, P1196; EBADI M, 1995, NEUROCHEM INT, V27, P1, DOI 10.1016/0197-0186(94)00164-P; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; GARCIASEGURA LM, 1994, GLIA, V10, P59, DOI 10.1002/glia.440100108; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; Harborth J, 2001, J CELL SCI, V114, P4557; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hawrylak N, 1998, GLIA, V22, P260, DOI 10.1002/(SICI)1098-1136(199803)22:3<260::AID-GLIA5>3.0.CO;2-9; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUGOWISSEMANN D, 1991, HEPATOLOGY, V13, P297, DOI 10.1016/0270-9139(91)92443-C; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kimelberg H.K., 1986, ASTROCYTES CELL BIOL, P77; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; Lavialle M, 2001, GLIA, V34, P88, DOI 10.1002/glia.1044; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matzke MA, 2001, CURR OPIN GENET DEV, V11, P221, DOI 10.1016/S0959-437X(00)00183-0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Niitsu Y, 1999, MOL BRAIN RES, V74, P26, DOI 10.1016/S0169-328X(99)00245-4; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pekny M, 2001, Prog Brain Res, V132, P23; SAGAR SM, 1995, BRAIN RES BULL, V36, P381, DOI 10.1016/0361-9230(94)00217-O; SALM AK, 1982, BRAIN RES, V236, P471, DOI 10.1016/0006-8993(82)90729-6; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; SIREVAAG AM, 1991, BRAIN RES, V540, P273, DOI 10.1016/0006-8993(91)90517-Y; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wasterlain CG, 1997, EPILEPSIA, V38, P728, DOI 10.1111/j.1528-1157.1997.tb01244.x; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P71, DOI 10.1001/archneur.1968.00480010089007; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; Wells T, 1998, MOL CELL ENDOCRINOL, V136, P103, DOI 10.1016/S0303-7207(97)00219-0; Won CK, 2000, BRAIN RES, V887, P250, DOI 10.1016/S0006-8993(00)02922-X; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	65	122	143	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1508	+		10.1096/fj.02-1183fje	http://dx.doi.org/10.1096/fj.02-1183fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824287				2022-12-25	WOS:000183818000019
J	Nikitenko, LL; Smith, DM; Bicknell, R; Rees, MCP				Nikitenko, LL; Smith, DM; Bicknell, R; Rees, MCP			Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia	FASEB JOURNAL			English	Article						G-protein coupled receptor; CRLR; 5 '-flanking region; promoter; HRE; hypoxia; adrenomedullin; RAMP; microvascular endothelial cells	RECEPTOR-LIKE RECEPTOR; ACTIVITY-MODIFYING PROTEINS; POSSIBLE PROMOTION MECHANISM; RAT ADRENOMEDULLIN RECEPTOR; SMOOTH-MUSCLE CELLS; GENOMIC ORGANIZATION; INDUCIBLE FACTOR-1; UP-REGULATION; CANCER-CELLS; TUMOR-GROWTH	Adrenomedullin is a 52 amino acid peptide that shows a remarkable range of effects on the vasculature that include inter alia, vasodilatation, regulation of permeability, inhibition of endothelial cell apoptosis, and promotion of angiogenesis. Recently the G-protein coupled receptor (GPCR) calcitonin receptor-like receptor (CRLR), and receptor activity modifying proteins (RAMPs) have become recognized as integral components of the adrenomedullin signaling system. However, mechanisms of regulation of CRLR expression are still largely unknown. This is in part due to lack of information on the gene promoter. In this study we have determined the transcriptional start of human CRLR cDNA by 5'-RACE and cloned the proximal 5'-flanking region of the gene by PCR. The 2318 bp genomic fragment contains the basal promoter of human CRLR, including potential TATA-boxes and several GC boxes. Regulatory elements binding known transcription factors, such as Sp-1, Pit-1, glucocorticoid receptor, and hypoxia-inducible factor-1alpha (HIF-1alpha) were also identified. When cloned into reporter gene vectors, the genomic fragment showed significant promoter activity, indicating that the 5'-flanking region isolated by PCR contains the gene promoter of human CRLR. Of significance is that the cloned promoter fragments were activated by hypoxia when transfected in primary microvascular endothelial cells. Site-directed mutagenesis of the consensus hypoxia-response element (HRE) in the 5'-flanking region abolished such a response. We also demonstrated by semi-quantitative RT-PCR that transcription of the gene is activated by hypoxia in microvascular endothelial cells. In contrast, expression of RAMPs 1, 2, and 3 was unaffected by low oxygen tension. We conclude that simultaneous transcriptional up-regulation of CRLR and its ligand adrenomedullin in endothelial cells could lead to a potent survival loop and therefore might play a significant role in vascular responses to hypoxia and ischemia.	Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; AstraZeneca, CVGI, Macclesfield SK10 4TG, Cheshire, England; Canc Res UK, Weatherall Inst Mol Med, Nuffield Dept Obstet & Gynaecol, Macclesfield SK10 4TG, Cheshire, England; Canc Res UK, Weatherall Inst Mol Med, Mol Angiogenesis Lab, Macclesfield SK10 4TG, Cheshire, England	University of Oxford; AstraZeneca; Cancer Research UK; Cancer Research UK	Nikitenko, LL (corresponding author), Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England.	leonid.nikitenko@obs-gyn.ox.ac.uk	Nikitenko, Leonid L/I-3215-2013	Nikitenko, Leonid L/0000-0003-3801-729X; Smith, David/0000-0001-6831-280X; Bicknell, Roy/0000-0002-0941-8919				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Ameri K, 2002, BRIT J CANCER, V87, P1173, DOI 10.1038/sj.bjc.6600576; Anagnou N P, 1985, Prog Clin Biol Res, V191, P163; Brakhage AA, 1998, MICROBIOL MOL BIOL R, V62, P547, DOI 10.1128/MMBR.62.3.547-585.1998; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chakravarty P, 2000, BRIT J PHARMACOL, V130, P189, DOI 10.1038/sj.bjp.0702975; Champion HC, 2000, CIRCULATION, V101, P923, DOI 10.1161/01.CIR.101.8.923; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Conner AC, 2001, TRENDS PHARMACOL SCI, V22, P272, DOI 10.1016/S0165-6147(00)01721-1; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Frayon S, 2000, BIOCHEM BIOPH RES CO, V270, P1063, DOI 10.1006/bbrc.2000.2552; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Hagner S, 2002, CELL TISSUE RES, V310, P41, DOI 10.1007/s00441-002-0616-x; Hanze J, 2002, BIOCHEM BIOPH RES CO, V291, P1160, DOI 10.1006/bbrc.2002.6595; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He B, 2002, J MOL ENDOCRINOL, V29, P193, DOI 10.1677/jme.0.0290193; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kennedy SP, 1998, BIOCHEM BIOPH RES CO, V244, P832, DOI 10.1006/bbrc.1998.8349; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; LYUBCHENKO YL, 1993, BIOCHEMISTRY-US, V32, P4121, DOI 10.1021/bi00066a038; Mandriota SJ, 2000, AM J PATHOL, V156, P2077, DOI 10.1016/S0002-9440(10)65079-1; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Minamino N, 2000, CLIN HEMORHEOL MICRO, V23, P95; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Nakayama M, 1999, PEPTIDES, V20, P769, DOI 10.1016/S0196-9781(99)00061-3; Nakazawa I, 2001, J HUM GENET, V46, P132, DOI 10.1007/s100380170100; Nikitenko LL, 2002, TRENDS PHARMACOL SCI, V23, P101, DOI 10.1016/S0165-6147(00)01983-0; Nikitenko LL, 2001, MOL HUM REPROD, V7, P655, DOI 10.1093/molehr/7.7.655; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ogbourne S, 1998, BIOCHEM J, V331, P1; Ogita T, 2001, J HYPERTENS, V19, P603, DOI 10.1097/00004872-200103001-00013; Oliver KR, 2002, J CEREBR BLOOD F MET, V22, P620, DOI 10.1097/00004647-200205000-00014; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Prestridge D S, 2000, Methods Mol Biol, V130, P265; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rabadan-Diehl C, 2000, J NEUROENDOCRINOL, V12, P437; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Whitworth JA, 2001, CLIN EXP PHARMACOL P, V28, P993, DOI 10.1046/j.1440-1681.2001.03584.x	55	61	64	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1499	+		10.1096/fj.02-0993fje	http://dx.doi.org/10.1096/fj.02-0993fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824306				2022-12-25	WOS:000183818000020
J	Yun, M; Keshvara, L; Park, CG; Zhang, YM; Dickerson, JB; Zheng, J; Rock, CO; Curran, T; Park, HW				Yun, M; Keshvara, L; Park, CG; Zhang, YM; Dickerson, JB; Zheng, J; Rock, CO; Curran, T; Park, HW			Crystal structures of the DAB homology domains of mouse disabled 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; FACTOR-BETA RECEPTORS; ABL TYROSINE KINASE; PTB DOMAIN; ADAPTER PROTEIN; SIGNALING PATHWAY; REELIN; RECOGNITION; PHOSPHORYLATION; SHC	Disabled (Dab) 1 and 2 are mammalian homologues of Drosophila DAB. Dab1 is a key cytoplasmic mediator in Reelin signaling that controls cell positioning in the developing central nervous system, whereas Dab2 is an adapter protein that plays a role in endocytosis. DAB family proteins possess an amino-terminal DAB homology (DH) domain that is similar to the phosphotyrosine binding/phosphotyrosine interaction (PTB/PI) domain. We have solved the structures of the DH domains of Dab2 (Dab2-DH) and Dab1 (Dab1-DH) in three different ligand forms, ligand-free Dab2-DH, the binary complex of Dab2-DH with the Asn-Pro-X-Tyr (NPXY) peptide of amyloid precursor protein (APP), and the ternary complex of Dab1-DH with the APP peptide and inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3, the head group of phosphatidylinositol-4,5-diphosphate (PtdIns-4,5-P-2)). The similarity of these structures suggests that the rigid Dab DH domain maintains two independent pockets for binding of the APP/lipoprotein receptors and phosphoinositides. Mutagenesis confirmed the structural determinants specific for the NPXY sequence and PtdIns-4,5-P-2 binding. NMR spectroscopy confirmed that the DH domain binds to Ins-1,4,5-P-3 independent of the NPXY peptides. These findings suggest that simultaneous interaction of the rigid DH domain with the NPXY sequence and PtdIns-4,5-P-2 plays a role in the attachment of Dab proteins to the APP/lipoprotein receptors and phosphoinositide-rich membranes.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Zheng, Jie/0000-0001-6524-6800	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069916, R01GM061739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036558] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [R01 GM069916, R01 GM061739] Funding Source: Medline; NINDS NIH HHS [R37 NS036558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; AULD DS, 1993, PROTEIN SCI, V2, P2187, DOI 10.1002/pro.5560021218; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Benhayon D, 2003, MOL BRAIN RES, V112, P33, DOI 10.1016/S0169-328X(03)00032-9; BENNETT RL, 1992, DEVELOPMENT, V116, P953; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GODDARD TD, 2002, SPARKY; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Homayouni R, 2001, BIOCHEM BIOPH RES CO, V289, P539, DOI 10.1006/bbrc.2001.5998; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LAMBERT DR, 1998, ADV ANAT EMBRYOL CEL, V150, P1; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1998, DEVELOPMENT, V125, P3719; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TRUB T, 1995, J BIOL CHEM, V270, P18205; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	63	99	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36572	36581		10.1074/jbc.M304384200	http://dx.doi.org/10.1074/jbc.M304384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12826668	hybrid			2022-12-25	WOS:000185318300087
J	Flierman, D; Ye, YH; Dai, M; Chau, V; Rapoport, TA				Flierman, D; Ye, YH; Dai, M; Chau, V; Rapoport, TA			Polyubiquitin serves as a recognition signal, rather than a ratcheting molecule, during retrotranslocation of proteins across the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HEAVY-CHAINS; UBIQUITIN-PROTEASOME PATHWAY; MULTIUBIQUITIN CHAIN; QUALITY-CONTROL; ER MEMBRANE; DNA-REPAIR; DEGRADATION; COMPLEX; CYTOSOL; TRANSLOCATION	Polyubiquitination is required for retrotranslocation of proteins from the endoplasmic reticulum back into the cytosol, where they are degraded by the proteasome. We have tested whether the release of a polypeptide chain into the cytosol is caused by a ratcheting mechanism in which the attachment of polyubiquitin prevents the chain from moving back into the endoplasmic reticulum. Using a permeabilized cell system in which major histocompatibility complex class I heavy chains are retrotranslocated under the influence of the human cytomegalovirus protein US11, we demonstrate that polyubiquitination alone is insufficient to provide the driving force for retrotranslocation. Substrate release into the cytosol requires an additional ATP-dependent step. Release requires a lysine 48 linkage of ubiquitin chains. It does not occur when polyubiquitination of the substrate is carried out with glutathione S-transferase (GST)-ubiquitin, and this correlates with poly-GST-ubiquitin not being recognized by a ubiquitin-binding domain in the Ufd1-Npl4 cofactor of the ATPase p97. These data suggest that polyubiquitin does not serve as a ratcheting molecule. Rather, it may serve as a recognition signal for the p97-Ufd1-Npl4 complex, a component implicated in the movement of substrate into the cytosol.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062194] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	36	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34774	34782		10.1074/jbc.M303360200	http://dx.doi.org/10.1074/jbc.M303360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12813030	Green Published, hybrid			2022-12-25	WOS:000185164400008
J	Hieta, R; Kukkola, L; Permi, P; Pirila, P; Kivirikko, KI; Kilpelainen, I; Myllyharju, J				Hieta, R; Kukkola, L; Permi, P; Pirila, P; Kivirikko, KI; Kilpelainen, I; Myllyharju, J			The peptide-substrate-binding domain of human collagen prolyl 4-hydroxylases - Backbone assignments, secondary structure, and binding of proline-rich peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; HYPOXIA-INDUCIBLE FACTOR; TRIPLE-RESONANCE NMR; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; LARGER PROTEINS; BETA-SUBUNIT; HIF-ALPHA	The collagen prolyl 4-hydroxylases (C-P4Hs) catalyze the formation of 4-hydroxyproline by the hydroxylation of proline residues in -Xaa-Pro-Gly- sequences. The vertebrate enzymes are alpha(2)beta(2) tetramers in which protein-disulfide isomerase serves as the beta subunit. Two isoforms of the catalytic alpha subunit have been identified and shown to form [alpha(I)](2)beta(2) and [alpha(II)](2)beta(2) tetramers, the type I and type II C-P4Hs, respectively. The peptide-substrate-binding domain of type I C-P4H has been shown to be located between residues 138 and 244 in the 517-residue alpha( I) subunit and to be distinct from the catalytic domain that is located in the C-terminal region. We report here that a recombinant human C-P4H alpha(I) polypeptide Phe(144)-Ser(244) forms a folded domain consisting of five alpha helices and one short beta strand. This structure is quite different from those of other proline-rich peptide-binding modules, which consist mainly of beta strands. Binding of the peptide (Pro-Pro-Gly)(2) to this domain caused major chemical shifts in many backbone amide resonances, the residues showing the largest shifts being mainly hydrophobic, including three tyrosines. The K-d values determined by surface plasmon resonance and isothermal titration calorimetry for the binding of several synthetic peptides to the alpha(I) and the corresponding alpha(II) domain were very similar to the K-m and K-i values for these peptides as substrates and inhibitors of the type I and type II C-P4H tetramers. The K-d values of the alpha(I) and alpha(II) domains for (Gly-Pro-4Hyp)(5) were much higher than those for (Pro-Pro-Gly)(5), indicating a marked decrease in the affinity of hydroxylated peptides for the domain. Many characteristic features of the binding of peptides to the type I and type II C-P4H tetramers can thus be explained by the properties of binding to this domain rather than the catalytic domain.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Inst Biotechnol, NMR Lab, Struct Biol & Biophys Programme, FIN-00014 Helsinki, Finland	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.			Hieta, Reija/0000-0001-5724-6253				Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; DEJONG L, 1991, BIOCHIM BIOPHYS ACTA, V1097, P103; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; Goddard T.D., SPARKY 3; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HOPKINSON I, 1994, GENE, V149, P391, DOI 10.1016/0378-1119(94)90188-0; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1969, J BIOL CHEM, V244, P2755; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nodelman IM, 1999, J MOL BIOL, V294, P1271, DOI 10.1006/jmbi.1999.3318; Pekkala M, 2003, ACTA CRYSTALLOGR D, V59, P940, DOI 10.1107/S0907444903005420; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Rost B, 1996, METHOD ENZYMOL, V266, P525; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033	46	39	39	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34966	34974		10.1074/jbc.M303624200	http://dx.doi.org/10.1074/jbc.M303624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824157	hybrid			2022-12-25	WOS:000185164400029
J	Holmes, SF; Erie, DA				Holmes, SF; Erie, DA			Downstream DNA sequence effects on transcription elongation - Allosteric binding of nucleoside triphosphates facilitates translocation via a ratchet motion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RNA; RHO-INDEPENDENT TERMINATORS; 3.3 ANGSTROM RESOLUTION; POLYMERASE-II; BETA-SUBUNIT; STREPTOLYDIGIN RESISTANCE; RIFAMPICIN-RESISTANT; CRYSTAL-STRUCTURE; CHAIN ELONGATION; STRUCTURAL BASIS	The ability of RNA polymerase ( RNAP) to adopt multiple conformations is central to transcriptional regulation. In previous work, we demonstrated that RNAP can exist in an unactivated state that catalyzes synthesis slowly and an activated state that catalyzes synthesis rapidly, with the transition from the unactivated to the activated state being induced by the templated NTP binding to an allosteric site on the RNAP. In this work, we investigate the effects of downstream DNA sequences on the kinetics of single nucleotide incorporation. We demonstrate that changing the identity of the DNA base 1 bp downstream ( + 2) from the site of incorporation ( + 1) can regulate the catalytic activity of RNAP. Combining these data with sequence and structural analyses and molecular modeling, we identify the streptolydigin-binding region ( Escherichia coli beta residues 543 - 546), which lies across from the downstream DNA, as the putative allosteric NTP binding site. We present a structural model in which the NTP binds to the streptolydigin loop and upon pairing with the +1 DNA base in the unactivated state or the +2 DNA base in the activated state facilitates translocation via a ratchet motion. This model provides an alternative mechanism for pausing as well as a structural explanation not only for our kinetic data but also for data from elongation studies on yeast RNAP II.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Mat Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Erie, DA (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	derie@email.unc.edu			NIGMS NIH HHS [GM-54316] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; Aranda A, 1999, MOL CELL BIOL, V19, P1251; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CASSANI G, 1971, NATURE-NEW BIOL, V230, P197, DOI 10.1038/newbio230197a0; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Chan CL, 1997, J MOL BIOL, V268, P37, DOI 10.1006/jmbi.1997.0934; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; Fivaz J, 2000, GENE, V255, P185, DOI 10.1016/S0378-1119(00)00340-1; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Guthold M, 2001, CHEMBIOCHEM, V2, P167; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; JIN DJ, 1991, J BIOL CHEM, V266, P14478; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1984, J BIOL CHEM, V259, P1550; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Landick R, 1999, SCIENCE, V284, P598, DOI 10.1126/science.284.5414.598; LEE DN, 1990, J BIOL CHEM, V265, P15145; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCCLURE WR, 1980, J BIOL CHEM, V255, P1610; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; NEFF NF, 1980, BIOCHEMISTRY-US, V19, P3005, DOI 10.1021/bi00554a027; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SHIMAMOTO N, 1980, BIOCHEMISTRY-US, V19, P842, DOI 10.1021/bi00546a003; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; TOMIZAWA J, 1987, CELL, V51, P623, DOI 10.1016/0092-8674(87)90131-0; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Via A, 2000, J MOL BIOL, V303, P455, DOI 10.1006/jmbi.2000.4151; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	60	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35597	35608		10.1074/jbc.M304496200	http://dx.doi.org/10.1074/jbc.M304496200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12813036	hybrid			2022-12-25	WOS:000185164400104
J	Kurakin, AV; Wu, S; Bredesen, DE				Kurakin, AV; Wu, S; Bredesen, DE			Atypical recognition consensus of CIN85/SETA/Ruk SH3 domains revealed by target-assisted iterative screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTION PROTEIN ZO-2; ADAPTER PROTEIN; DOWN-REGULATION; TIGHT JUNCTION; PEPTIDE RECOGNITION; ACTIN CYTOSKELETON; C-CBL; SRC; CIN85; INTERACTS	Target-assisted iterative screening applied to random peptide libraries unveiled a novel and atypical recognition consensus shared by CIN85/SETA/Ruk SH3 domains, PX(P/A) XXR. Confirmed by mutagenesis and in vitro binding experiments, the novel consensus allowed for the accurate mapping of CIN85 SH3 binding sites within known CIN85 interactors, c-Cbl, BLNK, Cbl-b, AIP1/Alix, SB1, and CD2 proteins, as well as the prediction of CIN85 novel-interacting partners in protein databases. Synaptojanin 1, PAK2, ZO-2, and TAF(II)70, which contain CIN85 SH3 recognition consensus sites, were selectively precipitated from mouse brain lysates by CIN85 SH3 domains in glutathione S-transferase pull-down experiments. A direct interaction of synaptojanin 1 and PAK2 with CIN85 SH3 domains was confirmed by Far Western blotting.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Kurakin, AV (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	akourakine@buckinstitute.org			NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS45093] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BOKOCH GM, 2003, IN PRESS ANN REV BIO; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kurakin A, 2002, J BIOMOL STRUCT DYN, V19, P1015, DOI 10.1080/07391102.2002.10506805; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Robinson JM, 2002, HISTOCHEM CELL BIOL, V118, P117, DOI 10.1007/s00418-002-0040-0; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; Zucconi A, 2000, FEBS LETT, V480, P49, DOI 10.1016/S0014-5793(00)01777-4	42	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34102	34109		10.1074/jbc.M305264200	http://dx.doi.org/10.1074/jbc.M305264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829691	hybrid			2022-12-25	WOS:000185047500061
J	Lamparter, T; Michael, N; Caspani, O; Miyata, T; Shirai, K; Inomata, K				Lamparter, T; Michael, N; Caspani, O; Miyata, T; Shirai, K; Inomata, K			Biliverdin binds covalently to Agrobacterium phytochrome Agp1 via its ring a vinyl side chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRAL PROPERTIES; HISTIDINE KINASES; EFFICIENT METHOD; CHROMOPHORE; BACTERIOPHYTOCHROMES; PHOTORECEPTOR; LIGHT; PHYCOCYANOBILIN; PURIFICATION; TUMEFACIENS	The widely distributed phytochrome photoreceptors carry a bilin chromophore, which is covalently attached to the protein during a lyase reaction. In plant phytochromes, the natural chromophore is coupled by a thioether bond between its ring A ethylidene side chain and a conserved cysteine residue within the so-called GAF domain of the protein. Many bacterial phytochromes carry biliverdin as natural chromophore, which is coupled in a different manner to the protein. In phytochrome Agp1 of Agrobacterium tumefaciens, biliverdin is covalently attached to a cysteine residue close to the N terminus ( position 20). By testing different natural and synthetic biliverdin derivatives, it was found that the ring A vinyl side chain is used for chromophore attachment. Only those bilins that have ring A vinyl side chain were covalently attached, whereas bilins with an ethylidene or ethyl side chain were bound in a noncovalent manner. Phycocyanobilin, which belongs to the latter group, was however covalently attached to a mutant in which a cysteine was introduced into the GAF domain of Agp1 ( position 249). It is proposed that the regions around positions 20 and 249 are in close contact and contribute both to the chromophore pocket. In competition experiments it was found that phycocyanobilin and biliverdin bind with similar strength to the wild type protein. However, in the V249C mutant, phycocyanobilin bound much more strongly than biliverdin. This finding could explain why during phytochrome evolution in cyanobacteria, the chromophore-binding site swapped from the N terminus into the GAF domain.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Dept Chem Sci, Kanazawa, Ishikawa 9201192, Japan; Free Univ Berlin, D-14195 Berlin, Germany	Kanazawa University; Free University of Berlin	Inomata, K (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Dept Chem Sci, Kanazawa, Ishikawa 9201192, Japan.	inomata@cacheibm.s.kanazawa-u.ac.jp	Lamparter, Tilman/E-4421-2013	Lamparter, Tilman/0000-0003-4327-9737; Caspani, Ombretta/0000-0002-9700-3149				Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; BUTLER WL, 1959, P NATL ACAD SCI USA, V45, P1703, DOI 10.1073/pnas.45.12.1703; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hanzawa H, 2002, P NATL ACAD SCI USA, V99, P4725, DOI 10.1073/pnas.062713399; Hanzawa H, 2001, P NATL ACAD SCI USA, V98, P3612, DOI 10.1073/pnas.051629698; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hubschmann T, 2001, EUR J BIOCHEM, V268, P2055, DOI 10.1046/j.1432-1327.2001.02083.x; Jorissen HJMM, 2002, EUR J BIOCHEM, V269, P2662, DOI 10.1046/j.1432-1033.2002.02928.x; Kakiuchi T, 1998, CHEM LETT, P1001, DOI 10.1246/cl.1998.1001; Kakiuchi T, 1999, SYNLETT, P901; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Lamparter T, 2001, EUR J BIOCHEM, V268, P4720, DOI 10.1046/j.1432-1327.2001.02395.x; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Lindner I, 1998, ANGEW CHEM INT EDIT, V37, P1843, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1843::AID-ANIE1843>3.0.CO;2-W; Mancinelli Alberto L., 1994, P211; McDonagh A. F., 1979, PORPHYRINS, VVI; Montgomery BL, 2002, TRENDS PLANT SCI, V7, P357, DOI 10.1016/S1360-1385(02)02304-X; Rudiger W., 1994, PHOTOMORPHOGENESIS P, V2nd, P51; Sawamoto D, 2001, CHEM LETT, P588, DOI 10.1246/cl.2001.588; STAROSTZIK C, 1995, FEBS LETT, V370, P146, DOI 10.1016/0014-5793(95)00820-Y; Takeda S, 2001, CHEM LETT, P590, DOI 10.1246/cl.2001.590; Wu SH, 1997, J BIOL CHEM, V272, P25700, DOI 10.1074/jbc.272.41.25700; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhu YX, 2000, P NATL ACAD SCI USA, V97, P13419, DOI 10.1073/pnas.230433797	32	76	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33786	33792		10.1074/jbc.M305563200	http://dx.doi.org/10.1074/jbc.M305563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824166	hybrid			2022-12-25	WOS:000185047500023
J	Pedron, T; Thibault, C; Sansonetti, PJ				Pedron, T; Thibault, C; Sansonetti, PJ			The invasive phenotype of Shigella flexneri directs a distinct gene expression pattern in the human intestinal epithelial cell line Caco-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; INNATE IMMUNE-RESPONSE; GAMMA-INTERFERON; HEPARIN-BINDING; INFECTION; RECEPTOR; INTERLEUKIN-8; AMPHIREGULIN; DESTRUCTION	Invasion of the human colonic epithelium by Shigella flexneri causes inflammation that disrupts the intestinal barrier. Invaded intestinal epithelial cells are the major source of mediators recruiting the inflammatory infiltrate. To better characterize the global response of intestinal epithelial cells to Shigella invasion, Caco-2 cells were infected by an invasive isolate of S. flexneri 5a, and their transcriptome was analyzed by Affymetrix (Santa Clara, CA) microarrays (12,000 genes) and compared with these elicited by a non-invasive Shigella mutant and tumor necrosis factor (TNF)-alpha. The invasive and non-invasive strains enhanced transcription of a common pattern of 240 genes, among which genes encoding isoforms of cytochrome P-450 were induced. These genes were not induced by TNF-alpha. Conversely, both the invasive strain and TNF-alpha induced a common set of 18 genes, mainly encoding proinflammatory molecules. They also induced specific sets of genes. The transcriptome induced by the invasive strain was characterized by the induction of early genes (i.e. expressed within the first 45 min of invasion) and late genes (i.e. after 60 min of invasion) whose pattern was strongly biased toward stimulation of granulopoiesis, chemoattraction, activation, and adherence of polymorphonuclear leukocytes. When compared with a non-invasive Shigella and TNF-alpha, invasive Shigella induced a narrow transcriptome that seems to program infected epithelial cells to recruit a mucosal polymorphonuclear leukocyte to infiltrate. Dramatic increase in IL-8 gene transcription points to this chemokine as the major molecule orchestrating mucosal inflammation in shigellosis.	Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France; Inst Pasteur, INSERM, U389, F-75724 Paris 15, France; Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sansonetti, PJ (corresponding author), Inst Pasteur, Unite Pathogenie Microbienne Mol, 28 Rue Docteur Roux, F-75724 Paris 15, France.	psanson@pasteur.fr		Thibault-Carpentier, Christelle/0000-0003-1562-1451				Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bahrani FK, 1997, INFECT IMMUN, V65, P4005, DOI 10.1128/IAI.65.10.4005-4010.1997; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Chomarat P, 1997, CARCINOGENESIS, V18, P2179, DOI 10.1093/carcin/18.11.2179; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Cuadras MA, 2002, J VIROL, V76, P4467, DOI 10.1128/JVI.76.9.4467-4482.2002; Cummings CA, 2000, EMERG INFECT DIS, V6, P513, DOI 10.3201/eid0605.000511; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; De Grado M, 2001, INFECT IMMUN, V69, P6217, DOI 10.1128/IAI.69.10.6217-6224.2001; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Eckmann L, 2000, J BIOL CHEM, V275, P14084, DOI 10.1074/jbc.275.19.14084; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Edgeworth JD, 2002, EUR J IMMUNOL, V32, P1464, DOI 10.1002/1521-4141(200205)32:5<1464::AID-IMMU1464>3.0.CO;2-G; Elewaut D, 1999, J IMMUNOL, V163, P1457; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; Francois M, 2000, INFECT IMMUN, V68, P1289, DOI 10.1128/IAI.68.3.1289-1296.2000; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GRANT SM, 1992, DRUGS, V43, P516, DOI 10.2165/00003495-199243040-00008; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HALE TL, 1998, TOPLEY WILSONS MICRO, V3, P479; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hla T, 1997, FEBS LETT, V414, P419, DOI 10.1016/S0014-5793(97)01053-3; Huang GTJ, 1996, J CLIN INVEST, V98, P572, DOI 10.1172/JCI118825; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Hurbin A, 2002, J BIOL CHEM, V277, P49127, DOI 10.1074/jbc.M207584200; Iber H, 1999, DRUG METAB REV, V31, P29, DOI 10.1081/DMR-100101906; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; MandicMulec I, 1997, INFECT IMMUN, V65, P110, DOI 10.1128/IAI.65.1.110-115.1997; Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1; MATHAN MM, 1991, REV INFECT DIS, V13, pS314; Miyazaki Y, 1996, BIOCHEM BIOPH RES CO, V226, P542, DOI 10.1006/bbrc.1996.1391; Morgan ET, 2001, DRUG METAB DISPOS, V29, P207; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; PERDOMO JJ, 1994, J CLIN INVEST, V93, P633, DOI 10.1172/JCI117015; PERDOMO OJJ, 1994, J EXP MED, V180, P1307, DOI 10.1084/jem.180.4.1307; Philpott DJ, 2001, CURR OPIN IMMUNOL, V13, P410; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Renton KW, 2001, PHARMACOL THERAPEUT, V92, P147, DOI 10.1016/S0163-7258(01)00165-6; Resta-Lenert S, 2002, GASTROENTEROLOGY, V122, P1070, DOI 10.1053/gast.2002.32372; Rosenberger CM, 2001, MICROBES INFECT, V3, P1353, DOI 10.1016/S1286-4579(01)01497-6; ROT A, 1991, CYTOKINE, V3, P21, DOI 10.1016/1043-4666(91)90006-Y; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; Sansonetti PJ, 1999, INFECT IMMUN, V67, P1471, DOI 10.1128/IAI.67.3.1471-1480.1999; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; Sophos NA, 2001, CHEM-BIOL INTERACT, V130, P323, DOI 10.1016/S0009-2797(00)00275-1; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C; Way SS, 1998, INFECT IMMUN, V66, P1342, DOI 10.1128/IAI.66.4.1342-1348.1998; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; Wenneras C, 2000, J IMMUNOL, V164, P3214, DOI 10.4049/jimmunol.164.6.3214; Yrlid U, 2000, J EXP MED, V191, P613, DOI 10.1084/jem.191.4.613; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	81	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33878	33886		10.1074/jbc.M303749200	http://dx.doi.org/10.1074/jbc.M303749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813033	hybrid			2022-12-25	WOS:000185047500033
J	Schofield, CM; Jenkins, A; Harrison, NL				Schofield, CM; Jenkins, A; Harrison, NL			A highly conserved aspartic acid residue in the signature disulfide loop of the alpha 1 subunit is a determinant of gating in the glycine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL SUPERFAMILY; AGONIST BINDING-SITE; PROTEIN; HYPEREKPLEXIA; MUTATION; DOMAIN	Ligand-gated ion channels (LGICs) mediate rapid chemical neurotransmission. This gene superfamily includes the nicotinic acetylcholine, GABA(A/C), 5-hydroxytryptamine type 3, and glycine receptors. A signature disulfide loop (Cys loop) in the extracellular domain is a structural motif common to all LGIC member subunits. Here we report that a highly conserved aspartic acid residue within the Cys loop at position 148 (Asp-148) of the glycine receptor alpha1 subunit is critical in the process of receptor activation. Mutation of this acidic residue to the basic amino acid lysine produces a large decrease in the potency of glycine, produces a decrease in the Hill slope, and converts taurine from a full agonist to a partial agonist; these data are consistent with a molecular defect in the receptor gating mechanism. Additional mutation of Asp-148 shows that alterations in the EC50 for agonists are dependent upon the charge of the side chain at this position and not molecular volume, polarity, or hydropathy. This study implicates negative charge at position Asp-148 as a critical component of the process in which agonist binding is coupled to channel gating. This finding adds to an emerging body of evidence supporting the involvement of the Cys loop in the gating mechanism of the LGICs.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Grad Program Neurosci, New York, NY 10021 USA; Emory Univ, Dept Anesthesiol, Atlanta, GA 30322 USA	Cornell University; Cornell University; Cornell University; Emory University	Schofield, CM (corresponding author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, Rm A1040,525 E 68th St, New York, NY 10021 USA.	cms2002@med.cornell.edu	Jenkins, Andrew/E-1180-2011					AMIN J, 1994, MOL PHARMACOL, V45, P317; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Dougherty DA, 2001, NATURE, V411, P252, DOI 10.1038/35077192; Elmslie FV, 1996, J MED GENET, V33, P435, DOI 10.1136/jmg.33.5.435; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEWIS R, 1998, BIOPHOTO INT J, V50, P40; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Moorhouse AJ, 1999, MOL PHARMACOL, V55, P386, DOI 10.1124/mol.55.2.386; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198; ZIMMERMAN JM, 1968, J THEOR BIOL, V21, P170, DOI 10.1016/0022-5193(68)90069-6	22	46	46	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34079	34083		10.1074/jbc.M302416200	http://dx.doi.org/10.1074/jbc.M302416200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826676	hybrid			2022-12-25	WOS:000185047500058
J	Servitja, JM; Marinissen, MJ; Sodhi, A; Bustelo, XR; Gutkind, JS				Servitja, JM; Marinissen, MJ; Sodhi, A; Bustelo, XR; Gutkind, JS			Rac1 function is required for Src-induced transformation - Evidence of a role for Tiam1 and Vav2 in RAC activation by Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTORS; HETEROTRIMERIC G-PROTEINS; RHO-INDEPENDENT PATHWAY; GROWTH-FACTOR RECEPTORS; SWISS 3T3 FIBROBLASTS; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; CYCLIN D1; PROTOONCOGENE PRODUCT	The proto-oncogene c-Src has been implicated in the development and progression of a number of human cancers including those of colon and breast. Accumulating evidence indicates that activated alleles of Src may induce cell transformation through Ras-ERK-dependent and - independent pathways. Here we show that Rac1 activity is strongly elevated in Src-transformed cells and that this small G protein is a critical component of the pathway connecting oncogenic Src with cell transformation. We further show that Vav2 and the ubiquitously expressed Rac1 guanine nucleotide exchange factor Tiam1 are phosphorylated in tyrosine residues in cells transfected with active and oncogenic Src. Moreover, phosphorylation of Tiam1 in cells treated with pervanadate, a potent inhibitor of tyrosine phosphatases, was partially inhibited by the Src inhibitor SU6656. Using truncated mutants of Tiam1, we demonstrate that multiple sites can be tyrosine-phosphorylated by Src. Furthermore, Tiam1 cooperated with Src to induce activation of Rac1 in vivo and the formation of membrane ruffles. Similarly, activation of JNK and the c-jun promoter by Src were also potently increased by Tiam1. Together, these results suggest that Vav2 and Tiam1 may act as downstream effectors of Src, thereby regulating Rac1-dependent pathways that participate in Src-induced cell transformation.	NIDCD, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Gutkind, JS (corresponding author), NIDCD, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/J-1201-2016	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Gutkind, J. Silvio/0000-0002-5150-4482; SERVITJA, JOAN-MARC/0000-0002-1241-8004	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; ROUS P, 1983, JAMA-J AM MED ASSOC, V250, P1445; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; Servitja JM, 2003, NEUROPHARMACOLOGY, V44, P171, DOI 10.1016/S0028-3908(02)00361-1; SPECTOR DH, 1978, P NATL ACAD SCI USA, V75, P4102, DOI 10.1073/pnas.75.9.4102; STEHELIN D, 1978, CELL, V13, P745, DOI 10.1016/0092-8674(78)90224-6; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	50	140	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34339	34346		10.1074/jbc.M302960200	http://dx.doi.org/10.1074/jbc.M302960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810717	hybrid			2022-12-25	WOS:000185047500090
J	Bauer, H; Massey, V; Arscott, LD; Schirmer, RH; Ballou, DP; Williams, CH				Bauer, H; Massey, V; Arscott, LD; Schirmer, RH; Ballou, DP; Williams, CH			The mechanism of high M-r thioredoxin reductase from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI; ACTIVE-SITE; HUMAN PLACENTA; SELENOCYSTEINE; CATALYSIS; DISTINCT; DEHYDROGENASE; SELENOPROTEIN	Drosophila melanogaster thioredoxin reductase-1 (DmTrxR-1) is a key flavoenzyme in dipteran insects, where it substitutes for glutathione reductase. DmTrxR-1 belongs to the family of dimeric, high M-r thioredoxin reductases, which catalyze reduction of thioredoxin by NADPH. Thioredoxin reductase has an N-terminal redox-active disulfide (Cys(57)-Cys(62)) adjacent to the flavin and a redox-active C-terminal cysteine pair (Cys(489')-Cys(490') in the other subunit) that transfer electrons from Cys(57)-Cys(62) to the substrate thioredoxin. Cys(489')-Cys(490') functions similarly to Cys(495)-Sec(496) (Sec=selenocysteine) and Cys(535)-XXXX-Cys(540) in human and parasite Plasmodium falciparum enzymes, but a catalytic redox center formed by adjacent Cys residues, as observed in DmTrxR-1, is unprecedented. Our data show, for the first time in a high M-r TrxR, that DmTrxR-1 oscillates between the 2-electron reduced state, EH2, and the 4-electron state, EH4, in catalysis, after the initial priming reduction of the oxidized enzyme (E-ox) to EH2. The reductive half-reaction consumes 2 eq of NADPH in two observable steps to produce EH4. The first equivalent yields a FADH(-)-NADP(+) charge-transfer complex that reduces the adjacent disulfide to form a thiolate-flavin charge-transfer complex. EH4 reacts with thioredoxin rapidly to produce EH2. In contrast, E-ox formation is slow and incomplete; thus, EH2 of wild-type cannot reduce thioredoxin at catalytically competent rates. Mutants lacking the C-terminal redox center, C489S, C490S, and C489S/C490S, are incapable of reducing thioredoxin and can only be reduced to EH2 forms. Additional data suggest that Cys(57) attacks Cys(490') in the interchange reaction between the N-terminal dithiol and the C-terminal disulfide.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	University of Michigan System; University of Michigan; Ruprecht Karls University Heidelberg	Williams, CH (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine St, Ann Arbor, MI 48109 USA.		dballou@umich.edu, David P/A-1298-2007		NIGMS NIH HHS [GM21444, GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bauer H, 2002, J BIOL CHEM, V277, P17457, DOI 10.1074/jbc.M200636200; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Gilberger TW, 1998, FEBS LETT, V425, P407, DOI 10.1016/S0014-5793(98)00270-1; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Keese MA, 1999, FEBS LETT, V447, P135, DOI 10.1016/S0014-5793(99)00296-3; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Press W.H., 1992, NUMERICAL RECIPES C, P683; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	30	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33020	33028		10.1074/jbc.M303762200	http://dx.doi.org/10.1074/jbc.M303762200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12816954	hybrid			2022-12-25	WOS:000184901800066
J	Wang, Q; Snell, WJ				Wang, Q; Snell, WJ			Flagellar adhesion between mating type plus and mating type minus gametes activates a flagellar protein-tyrosine kinase during fertilization in Chlamydomonas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAFLAGELLAR TRANSPORT; KINESIN-II; DEPENDENT REGULATION; HOMEODOMAIN PROTEIN; SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CELL ADHESION; CYCLIC-AMP; REINHARDTII; PHOSPHORYLATION	When Chlamydomonas gametes of opposite mating type are mixed together, flagellar adhesion through sex-specific adhesion molecules triggers a transient elevation of intracellular cAMP, leading to gamete activation in preparation for cell-cell fusion and zygote formation. Here, we have identified a protein-tyrosine kinase (PTK) activity that is stimulated by flagellar adhesion. We determined that the protein-tyrosine kinase inhibitor genistein inhibited fertilization, and that fertilization was rescued by dibutyryl cAMP, indicating that the genistein-sensitive step was upstream of the increase in cAMP. Incubation with ATP of flagella isolated from non-adhering and adhering gametes followed by SDS-PAGE and immunoblotting with anti-phosphotyrosine antibodies showed that adhesion activated a flagellar PTK that phosphorylated a 105-kDa flagellar protein. Assays using an exogenous protein-tyrosine kinase substrate confirmed that the activated PTK could be detected only in flagella isolated from adhering gametes. Our results indicate that stimulation of the PTK is a very early event during fertilization. Activation of the PTK was blocked when gametes underwent flagellar adhesion in the presence of the protein kinase inhibitor staurosporine, but not in the presence of the cyclic nucleotide-dependent protein kinase inhibitor, H8, which (unlike staurosporine) does not block the increases in cAMP. In addition, incubation of gametes of a single mating type in dibutyryl cAMP failed to activate the PTK. Finally, flagella adhesion between plus and minus fla10-1 gametes, which have a temperature-sensitive lesion in the microtubule motor protein kinesin-II, failed to activate the PTK at elevated temperatures. Our results show that kinesin-II is essential for coupling flagellar adhesion to activation of a flagellar PTK and cAMP generation during fertilization in Chlamydomonas.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Snell, WJ (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025661] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM025661, GM-25661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1986, ANAL BIOCHEM, V159, P58, DOI 10.1016/0003-2697(86)90307-6; BLOODGOOD RA, 1992, EXP CELL RES, V198, P228, DOI 10.1016/0014-4827(92)90375-I; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; GOODENOUGH UW, 1995, ANNU REV PLANT PHYS, V46, P21; GOODENOUGH UW, 1976, GENETICS, V82, P169; HUANG B, 1977, J CELL BIOL, V72, P67, DOI 10.1083/jcb.72.1.67; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Kurvari V, 1996, P NATL ACAD SCI USA, V93, P39, DOI 10.1073/pnas.93.1.39; LUX FG, 1991, GENETICS, V128, P549; Misamore MJ, 2003, MOL BIOL CELL, V14, P2530, DOI 10.1091/mbc.E02-12-0790; Pan JM, 2000, CURR OPIN MICROBIOL, V3, P596, DOI 10.1016/S1369-5274(00)00146-6; Pan JM, 2003, J CELL SCI, V116, P2179, DOI 10.1242/jcs.00438; Pan JM, 2003, TRAFFIC, V4, P452, DOI 10.1034/j.1600-0854.2003.00105.x; Pan JM, 2002, MOL BIOL CELL, V13, P1417, DOI 10.1091/mbc.01-11-0531; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; PIJST HLA, 1984, FEBS LETT, V174, P132, DOI 10.1016/0014-5793(84)81091-1; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; SAITO T, 1993, J CELL BIOL, V122, P137, DOI 10.1083/jcb.122.1.137; SNELL WJ, 1976, J CELL BIOL, V68, P48, DOI 10.1083/jcb.68.1.48; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Wilson NF, 1999, J BIOL CHEM, V274, P34383, DOI 10.1074/jbc.274.48.34383; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; ZHANG YH, 1991, J BIOL CHEM, V266, P22954; ZHANG YH, 1994, J CELL BIOL, V125, P617, DOI 10.1083/jcb.125.3.617; ZHANG YH, 1993, J BIOL CHEM, V268, P1786; Zhang YH, 1996, MOL BIOL CELL, V7, P515, DOI 10.1091/mbc.7.4.515; ZHANG YH, 1995, METHOD CELL BIOL, V47, P459, DOI 10.1016/S0091-679X(08)60845-6; Zhao H, 2001, GENE DEV, V15, P2767, DOI 10.1101/gad.919501	30	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32936	32942		10.1074/jbc.M303261200	http://dx.doi.org/10.1074/jbc.M303261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12821679	hybrid			2022-12-25	WOS:000184901800056
J	Chang, HC; Zhang, SM; Oldham, I; Naeger, L; Hoey, T; Kaplan, MH				Chang, HC; Zhang, SM; Oldham, I; Naeger, L; Hoey, T; Kaplan, MH			STAT4 requires the N-terminal domain for efficient phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; ALPHA-INTERFERON; DNA-BINDING; TH2 CELLS; RECEPTOR; EXPRESSION; RESPONSES; PROTEIN; DIFFERENTIATION; TRANSCRIPTION	STAT4 ((s) under bar ignal (t) under bar ransducer and (a) under bar ctivator of (t) under bar ranscription-(4) under bar) mediates biological effects in response to interleukin-12 (IL-12). STAT4 has multiple domains that have distinct functions in signaling and gene activation. To characterize the role of the STAT4 N-terminal domain in mediating STAT4 biological function, we have generated STAT4-deficient transgenic mice that express human full-length STAT4 or an N-terminal deletion mutant (DeltaN-STAT4) lacking the N-terminal 51 amino acids. Whereas full-length STAT4 rescued IL-12 responsiveness, T lymphocytes expressing the STAT4 N-terminal mutant failed to proliferate in response to IL-12 and had limited Th1 cell development as evidenced by minimal interferon-gamma production. Deletion of the N-terminal domain resulted in failure of STAT4 to be phosphorylated following IL-12 stimulation despite similar phosphorylation of JAK2 and TYK2 in full-length STAT4 and DeltaN-STAT4 transgenic T cells. We demonstrate that the lack of phosphorylation in cultured cells is due to reduced efficiency of phosphorylation of DeltaN-STAT4 by Janus kinases. These data support a new model wherein the N-terminal domain is required to mediate the phosphorylation of STAT4 in addition to the previously documented role in gene transactivation.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Tularik Inc, San Francisco, CA 94080 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Kaplan, MH (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Walther Oncol Ctr, Rm 302,950 W Walnut St, Indianapolis, IN 46202 USA.			Kaplan, Mark/0000-0002-2923-8245	NIAID NIH HHS [AI45515] Funding Source: Medline; NIDDK NIH HHS [T32DK007519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045515, R56AI045515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Broxmeyer HE, 2002, IMMUNITY, V16, P815, DOI 10.1016/S1074-7613(02)00319-9; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Galon J, 1999, J IMMUNOL, V162, P7256; Glimcher LH, 2000, GENE DEV, V14, P1693; Guler ML, 1999, J IMMUNOL, V162, P1339; John S, 1999, MOL CELL BIOL, V19, P1910; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Lawless VA, 2000, J IMMUNOL, V165, P6803, DOI 10.4049/jimmunol.165.12.6803; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; Nguyen VP, 2002, J BIOL CHEM, V277, P9713, DOI 10.1074/jbc.m111161200; Nishikomori R, 2002, J IMMUNOL, V169, P4388, DOI 10.4049/jimmunol.169.8.4388; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shen R, 2002, J IMMUNOL, V169, P714, DOI 10.4049/jimmunol.169.2.714; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yao BB, 1999, ARCH BIOCHEM BIOPHYS, V368, P147, DOI 10.1006/abbi.1999.1302; Zhang SM, 2000, J IMMUNOL, V165, P10, DOI 10.4049/jimmunol.165.1.10; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; Zou J, 1997, J BIOL CHEM, V272, P6073, DOI 10.1074/jbc.272.9.6073	35	17	17	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32471	32477		10.1074/jbc.M302776200	http://dx.doi.org/10.1074/jbc.M302776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805384	hybrid			2022-12-25	WOS:000184782100128
J	Ljutic, B; Carlyle, JR; Zuniga-Pflucke, JC				Ljutic, B; Carlyle, JR; Zuniga-Pflucke, JC			Identification of upstream cis-acting regulatory elements controlling lineage-specific expression of the mouse NK cell activation receptor, NKR-P1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODY; NK1.1 ANTIGEN; T-CELLS; PROGENITOR THYMOCYTES; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROMOTER REGIONS; FETAL THYMUS; GENES	Mouse NKR-P1C (NK1.1) is a homodimeric type II transmembrane protein expressed on natural killer (NK) cells, NKT cells, and on CD117(+) progenitor thymocytes capable of giving rise to cells of the T and NK lineages. Although its physiological ligands remain unknown, NKR-P1C engagement with a monoclonal antibody (mAb) leads to interferon-gamma (IFN-gamma) production and the directed release of cytotoxic granules from NK cells. We have cloned and sequenced a similar to10-kb genomic fragment corresponding to the 5'-flanking region of the C57Bl/6 mouse NKR-P1C gene. A transcriptional initiation site has been mapped in NK cells and an NK1.1(+) T cell line by primer extension and rapid amplification of 5'-cDNA ends (5'-RACE) techniques. Although the 5'-flanking region of NKR-P1C is TATA-less, we have identified an initiator region and a downstream promoter element, which together constitute the principal minimal functional promoter. Computational analysis of the 10-kb 5'-flanking region revealed potential regulatory factor binding sites. DNaseI hypersensitivity assays identified a single hypersensitive site (HS) about a 9-kb upstream of the transcriptional initiation site. This site, termed HS1, was able to act as a transcriptional enhancer element in an NK cell line, while minimally affecting transcription in non-NK cell lines. Moreover, the HS1 element was shown to function as a promoter, with a transcript detected only in fetal NK1.1(+) cells. An additional promoter and two non-coding exons were also characterized. These results identify the minimal upstream cis-acting elements, and point to a complex regulatory mechanism involved in the lineage-specific control of NKR-P1C expression in NK lymphocytes.	Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Immunol, Toronto, ON M4N 3M5, Canada; Univ Calif Berkeley, Dept Mol & Cell Biol, Canc Res Lab, Berkeley, CA 94720 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of California System; University of California Berkeley	Zuniga-Pflucke, JC (corresponding author), Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Immunol, Room A-331,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Carlyle, James R/A-1224-2008; Zuniga-Pflucker, Juan C/H-1295-2012	Carlyle, James/0000-0002-3579-0300; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178				ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BENDELAC A, 1995, CURR OPIN IMMUNOL, V7, P367, DOI 10.1016/0952-7915(95)80112-X; Bezouska K, 1996, NATURE, V380, P559, DOI 10.1038/380559a0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; Carlyle JR, 1999, J IMMUNOL, V162, P5917; Carlyle JR, 1998, J IMMUNOL, V161, P6544; Carlyle JR, 1998, IMMUNOL REV, V165, P63, DOI 10.1111/j.1600-065X.1998.tb01230.x; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; Chuang SS, 1999, BBA-GENE STRUCT EXPR, V1447, P244, DOI 10.1016/S0167-4781(99)00180-3; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GIORDA R, 1992, J IMMUNOL, V149, P1957; HACKETT J, 1986, J IMMUNOL, V136, P3124; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; Kogelberg H, 2001, CURR OPIN STRUC BIOL, V11, P635, DOI 10.1016/S0959-440X(00)00259-1; Kogelberg H, 1999, J BIOL CHEM, V274, P30335; Kogelberg H, 2000, PROTEIN EXPRES PURIF, V20, P10, DOI 10.1006/prep.2000.1257; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUBO S, 1993, GENE, V136, P329; Kung SKP, 1999, J IMMUNOL, V162, P5876; McQueen KL, 2001, IMMUNOGENETICS, V52, P212; Michie AM, 1999, J EXP MED, V190, P1647, DOI 10.1084/jem.190.11.1647; Michie AM, 2000, J IMMUNOL, V164, P1730, DOI 10.4049/jimmunol.164.4.1730; MICHIE AM, 1999, METHODS MOL BIOL PRO, V52; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Plougastel B, 1998, GENOMICS, V49, P193, DOI 10.1006/geno.1997.5197; Plougastel B, 2001, IMMUNOGENETICS, V53, P592, DOI 10.1007/s002510100367; RYAN JC, 1992, J IMMUNOL, V149, P1631; Ryan JC, 1997, IMMUNOL REV, V155, P79, DOI 10.1111/j.1600-065X.1997.tb00941.x; Saleh A, 2002, J IMMUNOL, V168, P5163, DOI 10.4049/jimmunol.168.10.5163; SEAMAN WE, 1987, J IMMUNOL, V138, P4539; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; Wilhelm BT, 2001, IMMUNOGENETICS, V53, P215, DOI 10.1007/s002510100313; Zarrin AA, 1997, J IMMUNOL, V159, P4382	40	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31909	31917		10.1074/jbc.M212869200	http://dx.doi.org/10.1074/jbc.M212869200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12813047	hybrid			2022-12-25	WOS:000184782100058
J	Amir, AL; Barua, M; McKnight, NC; Cheng, ST; Yuan, X; Balk, SP				Amir, AL; Barua, M; McKnight, NC; Cheng, ST; Yuan, X; Balk, SP			A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; ESTROGEN RESPONSE ELEMENT; COLON-CARCINOMA CELLS; MEDIATED TRANSCRIPTION; PROSTATE-CANCER; BINDING DOMAIN; PROTEIN HMG-1; IN-VITRO; ACTIVATION; DNA	T cell factor (Tcf) proteins bind beta-catenin and are downstream effectors of Wnt/beta-catenin signals. A recently demonstrated interaction between beta-catenin and the androgen receptor (AR) ligand binding domain has suggested that AR may be a Tcf-independent Wnt/beta-catenin effector. This study demonstrates that there is a direct interaction between the AR DNA binding domain (DBD) and Tcf4. Tcf4 bound specifically to a glutathione S-transferase-ARDBD fusion protein and could be coimmunoprecipitated with beta-catenin and transfected AR or endogenous AR in prostate cancer cells. Transfected Tcf4 repressed the transcriptional activity of full-length AR and a VP16-ARDBD fusion protein, and this repression was only partially reversed by transfected beta-catenin. AR activation by cyproterone acetate, a partial agonist that did not support beta-catenin binding to the AR, was also repressed by Tcf4, further indicating that repression was not due to beta-catenin sequestration. Tcf4 could recruit beta-catenin to the AR DBD in vitro and to the cyproterone acetate-liganded AR in vivo. Chromatin immunoprecipitation experiments in LNCaP prostate cancer cells showed that endogenous AR was bound to a Tcf4-responsive element in the c-myc promoter. These findings indicate that AR and Tcf4 can interact directly and that this interaction may occur on the promoters or enhancers of particular genes. The direct AR-Tcf4 interaction, in conjunction AR- and Tcf4-beta-catenin binding, provides a mechanism for cooperative and selective gene regulation by AR and the Wnt/beta-catenin-Tcf pathway that may contribute to normal and neoplastic prostate growth.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Amsterdam, Amsterdam, Netherlands; Univ Toronto, Toronto, ON M5S 1Y9, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Amsterdam; University of Toronto	Balk, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Dept Med, Boston, MA 02215 USA.		Barua, Moumita/B-6300-2019	Barua, Moumita/0000-0003-0628-9071; McKnight, Nicole/0000-0003-4269-3960				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Duval A, 2000, CANCER RES, V60, P3872; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Gonzalez MI, 2001, J BIOL CHEM, V276, P6420, DOI 10.1074/jbc.M008689200; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; SCHRODER FH, 1993, CANCER, V72, P3810, DOI 10.1002/1097-0142(19931215)72:12+<3810::AID-CNCR2820721710>3.0.CO;2-O; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632	60	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30828	30834		10.1074/jbc.M301208200	http://dx.doi.org/10.1074/jbc.M301208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12799378	hybrid			2022-12-25	WOS:000184658800052
J	Yamada, K; Kawata, H; Shou, ZF; Mizutani, T; Noguchi, T; Miyamoto, K				Yamada, K; Kawata, H; Shou, ZF; Mizutani, T; Noguchi, T; Miyamoto, K			Insulin induces the expression of the SHARP-2/Stra13/DEC1 gene via a phosphoinositide 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE RESPONSE ELEMENT; PYRUVATE-KINASE; TRANSCRIPTION FACTOR; BINDING PROTEIN-1C; DOWNSTREAM TARGET; TUMOR-SUPPRESSOR; RAT HEPATOCYTES; MESSENGER-RNA; GROWTH ARREST; PROMOTER	Transcription of the rat fatty acid synthase (FAS) gene in the rat liver can be regulated by feeding a high carbohydrate diet. A carbohydrate response element (ChoRE) located on the rat FAS gene promoter has been identified. Using multiple copies of the ChoRE as the bait in a yeast one-hybrid system, a rat liver cDNA library was screened, and the cDNA of ChoRE-binding proteins was cloned. A positive clone that encodes a basic helix-loop-helix protein, enhancer of split- and hairy-related protein-2 (SHARP-2), was obtained. Northern blot analysis revealed that the levels of SHARP-2 mRNA increase when a high carbohydrate diet is fed to normal rats or when insulin is administered to diabetic rats. In primary cultured rat hepatocytes, insulin rapidly induced an accumulation of SHARP-2 mRNA even in the absence of glucose. A time course for the increase in SHARP-2 mRNA levels indicated that it followed by those of FAS and L-type pyruvate kinase mRNAs and that the initial time course of SHARP-2 mRNA was similar to changes in the levels of glucokinase mRNA and phosphoenolpyruvate carboxykinase mRNA. Although wortmannin, LY294002, and actinomycin D blocked the increase in SHARP-2 mRNA levels by insulin, rapamycin, staurosporine, PD98059, okadaic acid, and 8-bromocyclic AMP had no effect. In addition, nuclear run-on assay revealed that transcription of the rat SHARP-2 gene was induced by insulin. Thus, we conclude that insulin induces the transcription of the rat SHARP-2 gene via a phosphoinositide 3-kinase pathway.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Fukui 9101193, Japan; Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	University of Fukui; Japan Science & Technology Agency (JST); Nagoya University	Yamada, K (corresponding author), Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan.	kazuya@fmsrsa.fukui-med.ac.jp						Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEALE EG, 1985, J BIOL CHEM, V260, P748; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Fere P, 2001, BIOCHEM SOC T, V29, P547; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MATSUDA T, 1990, J BIOCHEM, V107, P655, DOI 10.1093/oxfordjournals.jbchem.a123103; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; NOGUCHI T, 1993, FEBS LETT, V328, P145, DOI 10.1016/0014-5793(93)80982-Z; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shou ZF, 2003, GENE, V302, P83, DOI 10.1016/S0378-1119(02)01093-4; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wolf SS, 1996, BIOTECHNIQUES, V20, P568; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yamada K, 1998, BIOTECHNIQUES, V24, P596, DOI 10.2144/98244bm19; Yamada K, 2001, BIOL REPROD, V64, P1315, DOI 10.1095/biolreprod64.5.1315; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoshino M, 2002, BIOL REPROD, V66, P1813, DOI 10.1095/biolreprod66.6.1813; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	46	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30719	30724		10.1074/jbc.M301597200	http://dx.doi.org/10.1074/jbc.M301597200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796501	hybrid			2022-12-25	WOS:000184658800038
J	Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R				Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R			Role of the p38 MAPK pathway in cisplatin-based therapy	ONCOGENE			English	Article						p38 MAPK; cisplatin; phosphorylation resistance; p38 MAPK gamma/ERK6; p38 MAPK delta/SAPK4	ACTIVATED PROTEIN-KINASE; SQUAMOUS-CELL CARCINOMAS; C-ABL ACTIVATION; INDUCED APOPTOSIS; CANCER-CELLS; UV-RADIATION; GENOTOXIC STRESS; TRANS ISOMER; CYCLE ARREST; CROSS-LINKS	p38 MAPK has been implicated in the response to cancer therapy. To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines. Activation of p38 MAPK was measured after exposure to several chemotherapeutic agents, using specific phosphoantibodies. Only cisplatin was able to activate p38 MAPK in all the cell lines tested. Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK. The kinetics of this activation is a key event in the biological role of p38 MAPK in response to cisplatin, as we conclude from the differences observed after treatment with transplatin and cisplatin. The p38 MAPK activation is independent of the origin or genetic alterations of the cell lines and seems to be mediated through both upstream activators MKK6 and MKK3. Although the isoforms alpha/beta are mainly activated, we also demonstrated that other members of the p38 MAPK family were susceptible to activation by cisplatin when they were overexpressed in 293 T. Finally, pretreatment with specific inhibitors (SB 203580 and SKF 86002) induces a resistant phenotype in response to cisplatin. Furthermore, low activation of this SAPK pathway correlates with a resistant phenotype as demonstrated in our experimental model of head and neck cancer. Therefore, we conclude that the p38 MAPK pathway is a specific target for cisplatin-based therapy with clinical implications.	Hosp Univ Puerta de Hierro, Unidad Patol Mol, Madrid 28035, Spain	Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Hosp Univ Puerta de Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Sanchez-Prieto, Ricardo/B-6877-2008; Ramon y Cajal, Santiago/H-4955-2016; Javier, Hernandez Losa/C-1173-2008; Sanchez-Prieto, Ricardo/AAY-4271-2021; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Prieto, Ricardo/AAZ-7221-2021	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; 				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Asselin E, 2001, CANCER RES, V61, P1862; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOUDVILLAIN M, 1995, NUCLEIC ACIDS RES, V23, P2381, DOI 10.1093/nar/23.13.2381; Brognard J, 2001, CANCER RES, V61, P3986; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; CUMMINGS J, 1993, ANN ONCOL, V4, P533, DOI 10.1093/oxfordjournals.annonc.a058584; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Hayakawa J, 2000, CANCER RES, V60, P5988; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P32; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lippert B, 1996, MET IONS BIOL SYST, V33, P105; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NOMURA M, 2001, J BIOL CHEM, V11, P11; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Patel V, 1997, INT J CANCER, V73, P551, DOI 10.1002/(SICI)1097-0215(19971114)73:4<551::AID-IJC16>3.0.CO;2-C; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sodhi A, 2000, CANCER RES, V60, P4873; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	54	145	151	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3998	4006		10.1038/sj.onc.1206608	http://dx.doi.org/10.1038/sj.onc.1206608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821934				2022-12-25	WOS:000183707600003
J	Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C				Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C			Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma	ONCOGENE			English	Article						pancreatic adenocarcinoma; neuroendocrine pancreatic tumor; pancreatitis; methylation; RASSF1; K-ras; p16	TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; CANCER CELL-LINES; EPIGENETIC INACTIVATION; ULCERATIVE-COLITIS; CLINICAL-FEATURES; DNA METHYLATION; BREAST CANCERS; LUNG; ADENOCARCINOMA	Recently, we have characterized the Ras association domain family 1A gene (RASSF1A) at the segment 3p21.3, which is frequently lost in variety of human cancers and epigenetically inactivated in many types of primary tumors, such as lung, breast, kidney, prostate and thyroid carcinomas. Here, we investigated the methylation status of the RASSF1A CpG island promoter in the pathogenesis of pancreatic cancer. RASSF1A hypermethylation was detected in 29 out of 45 (64%) primary adenocarcinomas, in 10 out of 12 (83%) endocrine tumors and in eight out of 18 (44%) pancreatitis samples. In seven out of eight pancreas cancer cell lines, RASSF1A was silenced and was retranscribed after treatment with 5-aza-2'-deoxycytidine. Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancreatitis and in 63% of pancreas cancer cell lines. K-ras mutations were detected in 16 out of 45 (36%) primary adenocarcinomas. Pancreatic adenocarcinomas with K-ras mutation have significantly less RASSF1A methylation and vice versa (P = 0.001, X-2 test). In conclusion, our data indicate that inactivation of the RASSF1A gene is a frequent event in pancreatic cancer and suggest an inverse correlation between RASSF1A silencing and K-ras activation.	Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, D-06097 Halle Saale, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Klin & Poliklin Allgemein Viszeral & Gefasschirur, D-06097 Halle Saale, Germany; Univ Ulm, Dept Internal Med, Div Endocrinol, D-89070 Ulm, Germany	Martin Luther University Halle Wittenberg; City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Ulm University	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, Magdeburger Str 2, D-06097 Halle Saale, Germany.		Schagdarsurengin, Undraga/AAH-4312-2020; Dralle, Henning/ABD-4454-2020; Boehm, Bernhard Otto/F-8750-2015; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Barghom A, 2001, J PATHOL, V194, P451, DOI 10.1002/path.886; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chan AOO, 2003, ONCOGENE, V22, P924, DOI 10.1038/sj.onc.1206123; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Furuya N, 1997, GASTROENTEROLOGY, V113, P593, DOI 10.1053/gast.1997.v113.pm9247481; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gunzburg WH, 2001, TRENDS MOL MED, V7, P30, DOI 10.1016/S1471-4914(00)01865-7; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hruban R H, 1998, J Hepatobiliary Pancreat Surg, V5, P383, DOI 10.1007/s005340050062; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; Issa JPJ, 2001, CANCER RES, V61, P3573; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Kwong J, 2002, CLIN CANCER RES, V8, P131; Laghi L, 2002, ONCOGENE, V21, P4301, DOI 10.1038/sj.onc.1205533; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Moore PS, 2001, AM J PATHOL, V158, P317, DOI 10.1016/S0002-9440(10)63971-5; Muscarella P, 1998, CANCER RES, V58, P237; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Perugini RA, 1998, CRIT REV EUKAR GENE, V8, P377, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.70; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schutte M, 1997, CANCER RES, V57, P3126; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; TADA M, 1991, CANCER, V67, P634, DOI 10.1002/1097-0142(19910201)67:3<634::AID-CNCR2820670318>3.0.CO;2-7; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Yamamoto H, 2001, CANCER RES, V61, P3139; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	51	134	155	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3806	3812		10.1038/sj.onc.1206582	http://dx.doi.org/10.1038/sj.onc.1206582			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802288				2022-12-25	WOS:000183551000015
J	Saito, K; Yajima, T; Nishimura, H; Aiba, K; Ishimitsu, R; Matsuguchi, T; Fushimi, T; Ohshima, Y; Tsukamoto, Y; Yoshikai, Y				Saito, K; Yajima, T; Nishimura, H; Aiba, K; Ishimitsu, R; Matsuguchi, T; Fushimi, T; Ohshima, Y; Tsukamoto, Y; Yoshikai, Y			Soluble branched beta-(1,4)Glucans from Acetobacter species show strong activities to induce interleukin-12 in vitro and inhibit T-helper 2 cellular response with immunoglobulin E production in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETIC-ACID BACTERIA; TOLL-LIKE RECEPTOR-2; MYD88-DEPENDENT SIGNALING PATHWAY; BETA-GLUCAN RECEPTOR; DROSOPHILA TOLL; CUTTING EDGE; PATTERN-RECOGNITION; IMMUNE CELLS; MACROPHAGES; ACTIVATION	An extracellular polysaccharide, AC-1, produced by Acetobacter polysaccharogenes is composed of beta-(1,4) glucan with branches of glucosyl residues. We found that AC-1 showed a strong activity to induce production of interleukin-12 p40 and tumor necrosis factor-alpha by macrophage cell lines in vitro. Cellulase treatment completely abolished the activity of AC-1 to induce tumor necrosis factor-alpha production by macrophages, whereas treatment of AC-1 with polymyxin B or proteinase did not affect the activity. Results of experiments using Toll-like receptor (TLR) 4-deficient mice and TLR4-transfected human cell line indicated that TLR4 is involved in pattern recognition of AC-1. In vivo administration of AC-1 significantly reduced the serum levels of ovalbumin (OVA)-specific IgE and interleukin- 4 production by T cells in response to OVA in mice immunized with OVA. AC-1, a soluble branched beta-(1,4) glucan may be useful in prevention and treatment of allergic disorders with IgE production.	Kyushu Univ, Med Inst Bioregulat, Div Host Def, Res Ctr Prevent Infect Dis,Higashi Ku, Fukuoka 8128582, Japan; Nagoya Univ, Dept Host Def, Sch Med, Nagoya, Aichi 4668550, Japan; Mitsukan Grp Co Ltd, Cent Res Inst, Handa 4758585, Japan	Kyushu University; Nagoya University	Yajima, T (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Host Def, Res Ctr Prevent Infect Dis,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yajimato@bioreg.kyushu-u.ac.jp		Fushimi, Takashi/0000-0002-2872-1198				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; CHIHARA G, 1969, Nature (London), V222, P687; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.0.CO;2-G; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MINAKAMI H, 1984, AGR BIOL CHEM TOKYO, V48, P2405, DOI 10.1080/00021369.1984.10866534; MIZUTANI Y, 1992, J UROLOGY, V148, P1571, DOI 10.1016/S0022-5347(17)36972-0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nagata J, 2001, J AGR FOOD CHEM, V49, P4965, DOI 10.1021/jf0104883; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRETUS HA, 1991, J PHARMACOL EXP THER, V257, P500; RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663; Reichner JS, 2001, IMMUNOLOGY, V104, P198, DOI 10.1046/j.1365-2567.2001.01291.x; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sorenson WG, 1998, ANN AGR ENV MED, V5, P65; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TAYAMA K, 1986, AGR BIOL CHEM TOKYO, V50, P1271, DOI 10.1080/00021369.1986.10867547; TAYAMA K, 1985, AGR BIOL CHEM TOKYO, V49, P959, DOI 10.1080/00021369.1985.10866836; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200	41	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38571	38578		10.1074/jbc.M304948200	http://dx.doi.org/10.1074/jbc.M304948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12799362	hybrid			2022-12-25	WOS:000185575100060
J	Rapacciuolo, A; Suvarna, S; Barki-Harrington, L; Luttrell, LM; Cong, M; Lefkowitz, RJ; Rockman, HA				Rapacciuolo, A; Suvarna, S; Barki-Harrington, L; Luttrell, LM; Cong, M; Lefkowitz, RJ; Rockman, HA			Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BETA-ADRENERGIC-RECEPTORS; SIGNAL-REGULATED KINASE; BETA-2-ADRENERGIC RECEPTOR; CARDIAC MYOCYTES; CYCLIC-AMP; PHOSPHOINOSITIDE 3-KINASE; CHOLESTEROL DEPLETION; CAVEOLAE; DESENSITIZATION	Agonist-induced phosphorylation of beta-adrenergic receptors (betaARs) by G protein-coupled receptor kinases (GRKs) results in their desensitization followed by internalization. Whether protein kinase A (PKA)-mediated phosphorylation of betaARs, particularly the beta(1)AR subtype, can also trigger internalization is currently not known. To test this, we cloned the mouse wild type beta(1)AR (WTbeta(1)AR) and created 3 mutants lacking, respectively: the putative PKA phosphorylation sites (PKA- beta(1)AR), the putative GRK phosphorylation sites (GRK(-)beta(1)AR), and both sets of phosphorylation sites (PKA(-)/ GRK(-)beta(1)AR). Following agonist stimulation, both PKA(-)beta(1)AR and GRK(-)beta(1)AR mutants showed comparable increases in phosphorylation and desensitization. Saturating concentrations of agonist induced only 50% internalization of either mutant compared with wild type, suggesting that both PKA and GRK phosphorylation of the receptor contributed to receptor sequestration in an additive manner. Moreover, in contrast to the WTbeta(1)AR and PKA(-)beta(1)AR, sequestration of the GRK(-)beta(1)AR and PKA-/GRK(-)beta(1)AR was independent of beta-arrestin recruitment. Importantly, clathrin inhibitors abolished agonist-dependent internalization for both the WTbeta(1)AR and PKA(-)beta(1)AR, whereas caveolae inhibitors prevented internalization only of the GRK(-)beta(1)AR mutant. Taken together, these data demonstrate that: 1) PKA- mediated phosphorylation can trigger agonist-induced internalization of the beta(1)AR and 2) the pathway selected for beta(1)AR internalization is primarily determined by the kinase that phosphorylates the receptor, i.e. PKA-mediated phosphorylation directs internalization via a caveolae pathway, whereas GRK-mediated phosphorylation directs it through clathrin-coated pits.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Rockman, HA (corresponding author), Duke Univ, Med Ctr, Dept Med, DUMC 3104, Durham, NC 27710 USA.		Rapacciuolo, Antonio/AAR-8012-2020; Lefkowitz, Robert/AAW-2649-2021	Rapacciuolo, Antonio/0000-0002-4739-7004; Luttrell, Louis/0000-0003-2805-6949				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marx J, 2001, SCIENCE, V294, P1862, DOI 10.1126/science.294.5548.1862; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200	50	122	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35403	35411		10.1074/jbc.M305675200	http://dx.doi.org/10.1074/jbc.M305675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12821660	hybrid			2022-12-25	WOS:000185164400080
J	Verlinden, L; Verstuyf, S; Verboven, C; Eelen, G; De Ranter, C; Gao, LJ; Chen, YJ; Murad, I; Choi, M; Yamamoto, K; Yamada, S; Van Haver, D; Vandewalle, M; De Clercq, PJ; Bouillon, R				Verlinden, L; Verstuyf, S; Verboven, C; Eelen, G; De Ranter, C; Gao, LJ; Chen, YJ; Murad, I; Choi, M; Yamamoto, K; Yamada, S; Van Haver, D; Vandewalle, M; De Clercq, PJ; Bouillon, R			Previtamin D-3 with a trans-fused decalin CD-ring has pronounced genomic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; BIOLOGICAL RESPONSES; 6-S-CIS CONFORMATION; ANALOGS; CALCIFEROL; ELEMENTS; CELLS	Deletion of C19 in the structure of 1alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] does not substantially alter the biological potency but prevents the conversion between the vitamin and the previtamin form. Hence, this modification allows the study of locked previtamin and vitamin forms. The locked 19-nor-1,25(OH)(2)-previtamin D-3 analog (19-nor-previtamin D) had a low biological activity and was a rather weak activator of the genomic signal transduction pathway. 19-Nor-trans-decalin-1,25(OH)(2)-vitamin D-3 (19-nor-TD-vitamin D), characterized by the presence of a trans-fused decalin CD-ring system, was 10-fold more potent than the parent compound and was a potent activator of the genomic signal transduction pathway. Surprisingly, the previtamin, 19-nor-trans- decalin-1,25(OH)(2)-previtamin D-3 (19-nor-TD-previtamin D), was as potent as 1,25(OH)(2)D-3 in inhibiting cell proliferation and inducing cell differentiation and represents the first previtamin structure with pronounced vitamin D-like activity. Furthermore, this compound interacted as efficiently as 1,25( OH) 2D3 with the vitamin D receptor (VDR), retinoid X receptor (RXR), coactivators, and DNA, which illustrated its potent ability to activate the genomic signal transduction pathway. Analysis of the transactivation potency of 12 VDR point mutants after stimulation with 19-nor-TD-previtamin D revealed that this analog used the same contact points within the receptor as did 1,25(OH)(2)D-3. This could be confirmed by modeling analysis of this compound in the ligand binding pocket of VDR. In conclusion, a previtamin D-3 analog is presented with genomic activities equivalent to 1,25(OH)(2)D-3.	Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Analyt Chem & Med Fysicochem, B-3000 Louvain, Belgium; State Univ Ghent, Organ Synth Lab, B-9000 Ghent, Belgium; Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan	KU Leuven; KU Leuven; Ghent University; Tokyo Medical & Dental University (TMDU)	Bouillon, R (corresponding author), Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, Herestr 49, B-3000 Louvain, Belgium.		Verlinden, Lieve/E-6517-2011	Verlinden, Lieve/0000-0002-9621-3662; Yamamoto, Keiko/0000-0001-6642-7961; Verstuyf, Annemieke/0000-0003-3193-2698				BOUILLON R, 1980, J STEROID BIOCHEM, V13, P1029, DOI 10.1016/0022-4731(80)90133-8; BOUILLON R, 1993, J BONE MINER RES, V8, P1009; Chen YJ, 2003, ORG BIOMOL CHEM, V1, P257, DOI 10.1039/b209147j; Choi MW, 2001, BIOORGAN MED CHEM, V9, P1721, DOI 10.1016/S0968-0896(01)00060-8; CURTIN ML, 1991, J AM CHEM SOC, V113, P6958, DOI 10.1021/ja00018a038; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OKAMURA WH, 1995, ANN NY ACAD SCI, V761, P344, DOI 10.1111/j.1749-6632.1995.tb31389.x; OSTREM VK, 1987, P NATL ACAD SCI USA, V84, P2610, DOI 10.1073/pnas.84.9.2610; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; PERLMAN KL, 1990, TETRAHEDRON LETT, V31, P1823, DOI 10.1016/S0040-4039(00)98795-1; PERLMAN KL, 1991, TETRAHEDRON LETT, V32, P7663, DOI 10.1016/0040-4039(91)80559-O; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Tocchini-Valentini G, 2001, P NATL ACAD SCI USA, V98, P5491, DOI 10.1073/pnas.091018698; VELLUZ L, 1955, B SOC CHIM FR, P1341; Verlinden L, 2001, J BONE MINER RES, V16, P625, DOI 10.1359/jbmr.2001.16.4.625; Verstuyf A, 2000, J BONE MINER RES, V15, P237, DOI 10.1359/jbmr.2000.15.2.237; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Yamamoto K, 2000, P NATL ACAD SCI USA, V97, P1467, DOI 10.1073/pnas.020522697	26	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35476	35482		10.1074/jbc.M302045200	http://dx.doi.org/10.1074/jbc.M302045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829710	hybrid			2022-12-25	WOS:000185164400089
J	Zhao, YF; Kacskovics, I; Rabbani, H; Hammarstrom, L				Zhao, YF; Kacskovics, I; Rabbani, H; Hammarstrom, L			Physical mapping of the bovine immunoglobulin heavy chain constant region gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE REGION; IG; DIVERSITY; SEGMENTS; SEQUENCE; ORGANIZATION; ANTIBODIES; CATTLE; MU; JH	Bovine antibodies have recently attracted increasing attention, as they have been shown to exhibit prophylactic and therapeutic properties in selected infectious diseases in humans. In the present study, we have isolated bacterial artificial chromosomes and cosmid clones containing the bovine JH, mu, delta, gamma1, gamma2, gamma3, epsilon, and alpha genes, which allowed us to make a contig of the genes within the bovine IGHC locus. The genes are arranged in a 5'-JH-7 kb-mu-5 kb-delta-33 kb-gamma3-20 kb-gamma1-34 kb-gamma2-20 kb-epsilon- 13 kb-alpha-3' order, spanning similar to150 kb DNA. Examination of the bovine germline JH locus revealed six JH segments, two of which, JH1 and JH2, were shown to be functional although there was a strong preference for expression of the former. Sequence alignment of the bovine 5' Emu enhancer core region with those of other mammals, demonstrated an absence of the muE3 motif and a shortened spacer between the muA and muB sites within the bovine Emu enhancer core region. Furthermore, the essential sequence element for class switching, switch mu, spanning similar to3-kb repetitive sequence and abundant in the switch region motifs CTGGG (187 repeats) and CTGAG (127 repeats), was identified immediately upstream of the mu gene. A further sequence comparison revealed that the bovine IGHC genes display an extensive polymorphism leading to expression of multiple antibody allotypes.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden; Szent Istvan Univ, Fac Vet Sci, Dept Physiol & Biochem, H-1400 Budapest, Hungary; Karolinska Hosp, Canc Ctr Karolinska, Immune & Gene Therapy Lab, SE-17176 Stockholm, Sweden	Karolinska Institutet; Hungarian University of Agriculture & Life Sciences; Karolinska Institutet; Karolinska University Hospital	Hammarstrom, L (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden.	lennart.hammarstrom@biosci.ki.se	Kacskovics, Imre/J-8449-2013	Kacskovics, Imre/0000-0002-0402-3862				BANGS LA, 1991, J IMMUNOL, V146, P1996; BECKER RS, 1989, J IMMUNOL, V142, P1351; Berens SJ, 1997, INT IMMUNOL, V9, P189, DOI 10.1093/intimm/9.1.189; Brown WR, 1997, IMMUNOLOGY, V91, P1, DOI 10.1046/j.1365-2567.1997.00227.x; BRUGGEMANN M, 1986, P NATL ACAD SCI USA, V83, P6075, DOI 10.1073/pnas.83.16.6075; BUTLER JE, 1986, MOL IMMUNOL, V23, P291, DOI 10.1016/0161-5890(86)90056-8; Butler JE, 1996, INT IMMUNOL, V8, P1897, DOI 10.1093/intimm/8.12.1897; CAI L, 1995, GENOMICS, V29, P413, DOI 10.1006/geno.1995.9986; Casswall TH, 2002, SCAND J GASTROENTERO, V37, P1380, DOI 10.1080/003655202762671242; Chowdhary BP, 1996, MAMM GENOME, V7, P297, DOI 10.1007/s003359900086; Clarkson C. A., 1993, Molecular Immunology, V30, P1195, DOI 10.1016/0161-5890(93)90138-2; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; CUISINIER AM, 1993, EUR J IMMUNOL, V23, P110, DOI 10.1002/eji.1830230118; Dufour V, 1997, IMMUNOGENETICS, V46, P283, DOI 10.1007/s002510050274; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; HAMMARSTROM L, 1994, IMMUNOL REV, V139, P43, DOI 10.1111/j.1600-065X.1994.tb00856.x; HAYES HC, 1993, MAMM GENOME, V4, P207, DOI 10.1007/BF00417564; HOFKER MH, 1989, P NATL ACAD SCI USA, V86, P5567, DOI 10.1073/pnas.86.14.5567; KABAT EA, 1991, SEQUENCE PROTEINS IM; Kacskovics I, 1996, MOL IMMUNOL, V33, P189, DOI 10.1016/0161-5890(95)00107-7; KNIGHT KL, 1985, J IMMUNOL, V134, P1245; KNIGHT KL, 1988, J IMMUNOL, V140, P3654; Korhonen H, 2000, BRIT J NUTR, V84, pS135; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Kuroiwa Y, 2002, NAT BIOTECHNOL, V20, P889, DOI 10.1038/nbt727; Lilius EM, 2001, CURR OPIN INFECT DIS, V14, P295, DOI 10.1097/00001432-200106000-00008; MAGOR BG, 1994, J IMMUNOL, V153, P5556; Magor BG, 1999, IMMUNOL TODAY, V20, P13, DOI 10.1016/S0167-5699(98)01380-2; Matsuda F, 1998, J EXP MED, V188, P2151, DOI 10.1084/jem.188.11.2151; Mousavi M, 1997, IMMUNOLOGY, V92, P369, DOI 10.1046/j.1365-2567.1997.00352.x; Mousavi M, 1998, IMMUNOLOGY, V93, P581, DOI 10.1046/j.1365-2567.1998.00444.x; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Rabbani H, 1997, IMMUNOGENETICS, V46, P326, DOI 10.1007/s002510050279; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; Sinclair MC, 1997, J IMMUNOL, V159, P3883; SYMONS DBA, 1989, MOL IMMUNOL, V26, P841, DOI 10.1016/0161-5890(89)90140-5; Tashiro J, 2001, INT IMMUNOL, V13, P495, DOI 10.1093/intimm/13.4.495; TobinJanzen TC, 1996, ANIM BIOTECHNOL, V7, P163, DOI 10.1080/10495399609525857; TOBINJANZEN TC, 1992, IMMUNOGENETICS, V36, P157, DOI 10.1007/BF00661092; TUCKER PW, 1980, SCIENCE, V209, P1353, DOI 10.1126/science.6968091; Wagner B, 2002, IMMUNOGENETICS, V54, P353, DOI 10.1007/s00251-002-0458-4; Weiner C, 1999, CLIN EXP IMMUNOL, V116, P193; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; Zhao YF, 2002, J IMMUNOL, V169, P4408, DOI 10.4049/jimmunol.169.8.4408	46	48	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35024	35032		10.1074/jbc.M301337200	http://dx.doi.org/10.1074/jbc.M301337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829708	hybrid			2022-12-25	WOS:000185164400035
J	Bax, DV; Bernard, SE; Lomas, A; Morgan, A; Humphries, J; Shuttleworth, CA; Humphries, MJ; Kielty, CM				Bax, DV; Bernard, SE; Lomas, A; Morgan, A; Humphries, J; Shuttleworth, CA; Humphries, MJ; Kielty, CM			Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha(5)beta(1) and alpha(v)beta(3) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; COLLAGEN-VI; BINDING; FIBRONECTIN; GROWTH; ORGANIZATION; SEQUENCE; RECEPTOR	Fibrillins are the major glycoprotein components of microfibrils that form a template for tropoelastin during elastic fibrillogenesis. We have examined cell adhesion to assembled purified microfibrils, and its molecular basis. Human dermal fibroblasts exhibited Arg-Gly-Asp and cation-dependent adhesion to microfibrils and recombinant fibrillin-1 protein fragments. Strong integrin alpha(5)beta(1) interactions with fibrillin ligands were identified, but integrin alpha(v)beta(3) also contributed to cell adhesion. Fluorescence-activated cell sorting analysis confirmed the presence of abundant alpha(5)beta(1) and some alpha(v)beta(3) receptors on these cells. Adhesion to microfibrils and to Arg-Gly-Asp-containing fibrillin-1 protein fragments induced signaling events that led to cell spreading, altered cytoskeletal organization, and enhanced extracellular fibrillin-1 deposition. Differences in cell shape when plated on fibrillin or fibronectin implied substrate-specific alpha(5)beta(1)-mediated cellular responses. An Arg-Gly-Asp-independent cell adhesion sequence was also identified within fibrillin-1. Adhesion and spreading of smooth muscle cells on fibrillin ligands was enhanced by antibody-induced beta(1) integrin activation. A375-SM melanoma cells bound Arg-Gly-Asp-containing fibrillin-1 protein fragments mainly through alpha(v)beta(3), whereas HT1080 cells used mainly alpha(5)beta(1). This study has shown that fibrillin microfibrils mediate cell adhesion, that alpha(5)beta(1) and alpha(v)beta(3) are both important but cell-specific fibrillin-1 receptors, and that cellular interactions with fibrillin-1 influence cell behavior.	Univ Manchester, UK Ctr Tissue Engn, Manchester M13 9PT, Lancs, England; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Manchester	Kielty, CM (corresponding author), Univ Manchester, UK Ctr Tissue Engn, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.		Humphries, Jonathan D./AAE-7760-2022	Humphries, Jonathan D./0000-0002-8953-7079; McGovern, Amanda/0000-0001-7727-3283; Humphries, Martin/0000-0002-4331-6967				AOTA S, 1994, J BIOL CHEM, V269, P24756; Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; Ashworth JL, 1999, J CELL SCI, V112, P4163; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37; Cardy CM, 1998, J MOL BIOL, V276, P855, DOI 10.1006/jmbi.1997.1593; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; D'Arrigo C, 1998, CONNECT TISSUE RES, V37, P29, DOI 10.3109/03008209809028898; DAVIS EC, 1993, CELL TISSUE RES, V272, P211, DOI 10.1007/BF00302726; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Humphries MJ, 2002, ARTHRITIS RES THER, V4, pS69, DOI 10.1186/ar563; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; KIELTY CM, 1991, J CELL SCI, V99, P797; KIELTY CM, 1992, J CELL SCI, V103, P445; Kielty CM, 2002, J CELL SCI, V115, P2817; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; MOULD AP, 1990, J BIOL CHEM, V265, P4020; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Quondamatteo F, 2002, MATRIX BIOL, V21, P637, DOI 10.1016/S0945-053X(02)00100-2; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Tselepis VH, 1997, J BIOL CHEM, V272, P21341, DOI 10.1074/jbc.272.34.21341; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	40	147	158	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34605	34616		10.1074/jbc.M303159200	http://dx.doi.org/10.1074/jbc.M303159200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807887	hybrid			2022-12-25	WOS:000185047500122
J	Bland, FA; Lemberg, MK; McMichael, AJ; Martoglio, B; Braud, VM				Bland, FA; Lemberg, MK; McMichael, AJ; Martoglio, B; Braud, VM			Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; SURFACE EXPRESSION; INTRAMEMBRANE PROTEOLYSIS; ANTIGEN PRESENTATION; ASPARTIC PROTEASE; GENERATION; CYTOSOL; RECOGNITION; CD94/NKG2A; INHIBITOR	The nonclassical major histocompatibility complex class I molecule HLA-E acts as a ligand for CD94/NKG2 receptors on the surface of natural killer cells and a subset of T cells. HLA-E presents closely related nonameric peptide epitopes derived from the highly conserved signal sequences of classical major histocompatibility complex class I molecules as well as HLA-G. Their generation requires cleavage of the signal sequence by signal peptidase followed by the intramembrane-cleaving aspartic protease, signal peptide peptidase. In this study, we have assessed the subsequent proteolytic requirements leading to generation of the nonameric HLA-E peptide epitopes. We show that proteasome activity is required for further processing of the peptide generated by signal peptide peptidase. This constitutes the first example of capture of a naturally derived short peptide by the proteasome, producing a class I peptide ligand.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Oxford; Swiss Federal Institutes of Technology Domain; ETH Zurich	Braud, VM (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Lemberg, Marius K/B-8881-2016; braud, veronique M/I-4597-2013	Lemberg, Marius K/0000-0002-0996-1268; braud, veronique M/0000-0001-8213-3947				Bai AL, 1997, J IMMUNOL, V159, P2139; Benham AM, 1998, J IMMUNOL, V161, P83; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; Borrego F, 1998, J EXP MED, V187, P813, DOI 10.1084/jem.187.5.813; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brielmeier M, 1998, NUCLEIC ACIDS RES, V26, P2082, DOI 10.1093/nar/26.9.2082; Brooks AG, 1999, J IMMUNOL, V162, P305; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Garcia P, 2002, EUR J IMMUNOL, V32, P936, DOI 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.3.CO;2-D; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Heinzel AS, 2002, J EXP MED, V196, P1473, DOI 10.1084/jem.20020609; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; Li JF, 2001, J IMMUNOL, V167, P3800, DOI 10.4049/jimmunol.167.7.3800; Luckey CJ, 2001, J IMMUNOL, V167, P1212, DOI 10.4049/jimmunol.167.3.1212; Luckey CJ, 1998, J IMMUNOL, V161, P112; Moretta L, 2003, TRENDS IMMUNOL, V24, P136, DOI 10.1016/S1471-4906(03)00031-0; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2002, MOL IMMUNOL, V39, P203, DOI 10.1016/S0161-5890(02)00102-5; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Tomasec P, 2000, SCIENCE, V287, P1031, DOI 10.1126/science.287.5455.1031; Vales-Gomez M, 1999, EMBO J, V18, P4250, DOI 10.1093/emboj/18.15.4250; Vinitsky A, 1997, J IMMUNOL, V159, P554; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	39	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33747	33752		10.1074/jbc.M305593200	http://dx.doi.org/10.1074/jbc.M305593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821659	hybrid			2022-12-25	WOS:000185047500019
J	Brandt, DT; Goerke, A; Heuer, M; Gimona, M; Leitges, M; Kremmer, E; Lammers, R; Haller, H; Mischak, H				Brandt, DT; Goerke, A; Heuer, M; Gimona, M; Leitges, M; Kremmer, E; Lammers, R; Haller, H; Mischak, H			Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY KINASES; SIGNALING PATHWAYS; PHORBOL ESTER; PHOSPHORYLATION; ISOZYMES; DIFFERENTIATION; TRANSFORMATION; PP60(C-SRC); ASSOCIATION; ADHESION	Previously we have shown that protein kinase C (PKC)-mediated reorganization of the actin cytoskeleton in smooth muscle cells is transmitted by the nonreceptor tyrosine kinase, Src. Several authors have described how 12-O- tetradecanoylphorbol-13-acetate(TPA) stimulation of cells results in an increase of Src activity, but the mechanism of the PKC-mediated Src activation is unknown. Using PKC isozymes purified from Spodoptera frugiperda insect cells, we show here that PKC is not able to activate Src directly. Our data reveal that the PKC-dependent Src activation occurs via the activation of the protein tyrosine phosphatase (PTP) PTPalpha. PTPalpha becomes activated in vivo after TPA stimulation. Further, we show that PKCdelta phosphorylates and activates only PTPalpha in vitro but not any other of the TPA-responsive PKC isozymes that are expressed in A7r5 rat aortic smooth muscle cells. To further substantiate our data, we show that cells lacking PKCdelta have a markedly reduced PTPalpha and Src activity after 12-O-tetradecanoylphorbol-13-acetate stimulation. These data support a model in which the main mechanism of 12-O-tetradecanoylphorbol-13- acetate-induced Src activation is the direct phosphorylation and activation of PTPalpha by PKCdelta, which in turn dephosphorylates and activates Src.	Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria; Max Planck Inst Endocrinol, D-30625 Hannover, Germany; Gesell Biotechnol Forsch mbH, Inst Mol Immunol, D-81377 Munich, Germany; Univ Tubingen, Div Diabet Res, D-72074 Tubingen, Germany; Mosaiques Diagnost, D-30625 Hannover, Germany	Hannover Medical School; Austrian Academy of Sciences; Max Planck Society; Gesellschaft fur Biotechnologische Forschung mbH; Eberhard Karls University of Tubingen	Mischak, H (corresponding author), Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany.		Mischak, Harald/E-8685-2011; Leitges, Michael/AAN-1953-2021	Mischak, Harald/0000-0003-0323-0306				Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Leitges M, 2001, J CLIN INVEST, V108, P1505; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Stetak A, 2001, BIOCHEM BIOPH RES CO, V288, P564, DOI 10.1006/bbrc.2001.5811; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	30	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34073	34078		10.1074/jbc.M211650200	http://dx.doi.org/10.1074/jbc.M211650200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826681	hybrid			2022-12-25	WOS:000185047500057
J	Karasawa, S; Araki, T; Yamamoto-Hino, M; Miyawaki, A				Karasawa, S; Araki, T; Yamamoto-Hino, M; Miyawaki, A			A Green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+	We have cloned a gene which encodes a fluorescent protein from the stony coral, Galaxeidae. This protein absorbs light maximally at 492 nm and emits green light at 505 nm, and as a result, we have designated it "Azami-Green (AG)." Despite sharing a similar spectral profile with enhanced green fluorescent protein (EGFP) ( Clontech), the most popular variant of the Aequorea victoria green fluorescent protein, the identity between these two proteins at the amino acid level is only 5.7%. However, since AG has a high extinction coefficient, fluorescence quantum yield, and acid stability, it produces brighter green fluorescence in cultured cells than EGFP. Similar to other fluorescent proteins isolated from coral animals, AG forms a tight tetrameric complex, resulting in poor labeling of subcellular structures such as the plasma membrane and mitochondria. We have converted tetrameric AG into a monomeric form by the introduction of three amino acid substitutions, which were recently reported to be effective for monomerizing the red fluorescent protein from Discosoma coral ( DsRed, Clontech). The resultant monomeric AG allowed for efficient fluorescent labeling of all of the subcellular structures and proteins tested while retaining nearly all of the brightness of the original tetrameric form. Thus, monomeric AG is a useful monomeric green-emitting fluorescent protein comparable to EGFP.	RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Adv Technol Dev Grp, Wako, Saitama 3510198, Japan; Amalgaam Co Ltd, Itabashi Ku, Tokyo 1730004, Japan; Med & Biol Labs Co Ltd, Naka Ku, Nagoya, Aichi 4600002, Japan	RIKEN	Miyawaki, A (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Adv Technol Dev Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235				Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; SAWANO A, 2000, NUCL ACIDS RES; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Yanushevich YG, 2002, FEBS LETT, V511, P11, DOI 10.1016/S0014-5793(01)03263-X; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	11	138	146	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34167	34171		10.1074/jbc.M304063200	http://dx.doi.org/10.1074/jbc.M304063200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819206	hybrid			2022-12-25	WOS:000185047500070
J	Weinberg, RB; Cook, VR; Beckstead, JA; Martin, DDO; Gallagher, JW; Shelness, GS; Ryan, RO				Weinberg, RB; Cook, VR; Beckstead, JA; Martin, DDO; Gallagher, JW; Shelness, GS; Ryan, RO			Structure and interfacial properties of human apolipoprotein A-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-ACTIVITIES; TRIGLYCERIDES; GENE; IV; LIPOPROTEINS; CHOLESTEROL; ADSORPTION; EXPRESSION; SECRETION; KINETICS	Apolipoprotein A-V (apoA-V), the newest member of the plasma apolipoprotein family, was recently discovered by comparison of the mouse and human genomes. Studies in rodents and population surveys of human apoA-V polymorphisms have noted a strong effect of apoA-V on plasma triglyceride levels. Toward the elucidation of the biologic function of apoA-V, we used spectroscopic and surface chemistry techniques to probe its structure and interfacial activity. Computer-assisted sequence analysis of apoA-V predicts that it is very hydrophobic, contains a significant amount of alpha-helical secondary structure, and probably is composed of discrete structural regions with varying degrees of lipid affinity. Fluorescence spectroscopy of recombinant human apoA-V provided evidence of tertiary folding, and light scattering studies indicated that apoA-V transforms dimyristoylphosphatidylcholine vesicles into discoidal complexes with an efficiency similar to that of apoA-I. Surface chemistry techniques revealed that apoA-V displays high affinity, low elasticity, and slow binding kinetics at hydrophobic interfaces, properties we propose may retard triglyceride-rich particle assembly. Metabolic labeling and immunofluorescence studies of COS-1 cells transfected with human apoA-V demonstrated that apoA-V is poorly secreted, remains associated with the endoplasmic reticulum, and does not traffic to the Golgi. Given that overexpression of the apoA-V gene lowers plasma triglycerides in mice, these data together suggest that apoA-V may function intracellularly to modulate hepatic VLDL synthesis and/or secretion.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Wake Forest University; Wake Forest University; Wake Forest University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Weinberg, RB (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	weinberg@wfubmc.edu	Martin, Dale/L-6351-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030897, R01HL030897, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897, R01 HL030897-23, HL30897, HL49373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Endo K, 2002, HUM GENET, V111, P570, DOI 10.1007/s00439-002-0825-0; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; Hodis HN, 1999, CLIN CARDIOL, V22, pII15; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; KREBS KE, 1984, FEBS LETT, V175, P263, DOI 10.1016/0014-5793(84)80748-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LABOURDENNE S, 1994, CHEM PHYS LIPIDS, V71, P163, DOI 10.1016/0009-3084(94)90068-X; LUO CC, 1986, J MOL BIOL, V187, P325, DOI 10.1016/0022-2836(86)90436-5; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Middelberg APJ, 2000, P NATL ACAD SCI USA, V97, P5054, DOI 10.1073/pnas.080042597; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Ribalta J, 2002, CLIN CHEM, V48, P1597; ROSEN MJ, 1989, SURFACTANTS INTERFAC, P304; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; SEGREST JP, 1992, J LIPID RES, V33, P141; Sellers JA, 2001, J LIPID RES, V42, P1897; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHORE B, 1969, BIOCHEMISTRY-US, V8, P4510, DOI 10.1021/bi00839a043; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARKS JD, 1994, METABOLISM, V43, P681, DOI 10.1016/0026-0495(94)90115-5; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; Weinberg RB, 2002, J BIOL CHEM, V277, P21549, DOI 10.1074/jbc.M202197200; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WEINBERG RB, 1994, J LIPID RES, V35, P2212; Weinberg RB, 1996, METHOD ENZYMOL, V263, P282; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinberg RB, 2000, J LIPID RES, V41, P1419; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; XU YM, 1995, ENERG FUEL, V9, P148, DOI 10.1021/ef00049a022	42	120	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34438	34444		10.1074/jbc.M303784200	http://dx.doi.org/10.1074/jbc.M303784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810715	hybrid			2022-12-25	WOS:000185047500102
J	Makrides, V; Shen, TE; Bhatia, R; Smith, BL; Thimm, J; Lal, R; Feinstein, SC				Makrides, V; Shen, TE; Bhatia, R; Smith, BL; Thimm, J; Lal, R; Feinstein, SC			Microtubule-dependent oligomerization of tau - Implications for physiological tau function and tauopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ATOMIC-FORCE MICROSCOPE; PROTEIN-TAU; DYNAMIC INSTABILITY; NEURODEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; NEURITE OUTGROWTH; FTDP-17 MUTANTS; IN-VITRO; GENE	The accumulation of abnormal tau filaments is a pathological hallmark of many neurodegenerative diseases. In 1998, genetic analyses revealed a direct linkage between structural and regulatory mutations in the tau gene and the neurodegenerative disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). Importantly, the FTDP-17 phenotype is transmitted in a dominant rather than a recessive manner. However, the underlying molecular mechanisms causing disease remain uncertain. The most common molecular mechanism generating dominant phenotypes is the loss of function of a multimeric complex containing both mutant and wild-type subunits. Therefore, we sought to determine whether tau might normally function as a multimer. We co-incubated S-35-radiolabeled tau and biotinylated tau with taxol stabilized microtubules, at very low molar ratios of tau to tubulin. Subsequent covalent cross-linking followed by affinity-precipitation of the biotinylated tau revealed the formation of microtubule-dependent tau oligomers. We next used atomic force microscopy to independently assess this conclusion. Our results are consistent with the hypothesis that tau forms oligomers upon binding to microtubules. In addition to providing insights into normal tau action, our findings lead us to propose that one mechanism by which mutations in tau may cause cell death is through the formation of tau complexes containing mutant tau molecules in association with wild-type tau. These wild-type-mutant tau complexes may possess altered biological and/or biophysical properties that promote onset of the FTDP-17 phenotype, including neuronal cell death by either altering normal tau-mediated regulation of microtubule-dependent cellular functions and/or promoting the formation of pathological tau aggregates.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.		Thimm, Julian/D-1214-2009; makrides, victoria/GSN-6210-2022; Maddux, Bettye/D-1269-2009	Maddux, Bettye/0000-0001-5890-5249	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM056290] Funding Source: Medline; NINDS NIH HHS [NS35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; ALBERTS B, 1989, MOL BIOL CELL, P116; Baumgartner W, 2000, ULTRAMICROSCOPY, V82, P85, DOI 10.1016/S0304-3991(99)00154-0; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chau MF, 1998, BIOCHEMISTRY-US, V37, P17692, DOI 10.1021/bi9812118; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Dawson HN, 2001, J CELL SCI, V114, P1179; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FRITZSCHE W, 1995, SCANNING MICROSCOPY, V9, P729; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Goedert M, 1999, FEBS LETT, V450, P306, DOI 10.1016/S0014-5793(99)00508-6; Goedert M, 1999, NAT MED, V5, P454, DOI 10.1038/7454; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; LAL R, 1994, AM J PHYSIOL, V266, P1; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Liu CWA, 1999, CELL MOTIL CYTOSKEL, V43, P232, DOI 10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; MCEWEN B, 1980, J MOL BIOL, V139, P123, DOI 10.1016/0022-2836(80)90300-9; Muller DJ, 1997, BIOPHYS J, V73, P1633, DOI 10.1016/S0006-3495(97)78195-5; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Takei Y, 2000, J CELL BIOL, V150, P989, DOI 10.1083/jcb.150.5.989; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	47	87	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33298	33304		10.1074/jbc.M305207200	http://dx.doi.org/10.1074/jbc.M305207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805366	hybrid			2022-12-25	WOS:000184901800099
J	Matsuo, N; Yu-Hua, W; Sumiyoshi, H; Sakata-Takatani, K; Nagato, H; Sakai, K; Sakurai, M; Yoshioka, H				Matsuo, N; Yu-Hua, W; Sumiyoshi, H; Sakata-Takatani, K; Nagato, H; Sakai, K; Sakurai, M; Yoshioka, H			The transcription factor CCAAT-binding factor CBF/NF-Y regulates the proximal promoter activity in the human alpha 1(XI) collagen gene (COL11A1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; HUMAN CARTILAGE; DNA-BINDING; COL2A1 GENE; V COLLAGEN; EXPRESSION; IDENTIFICATION; ELEMENTS; TISSUE; XI	We have characterized the proximal promoter region of the human COL11A1 gene. Transient transfection assays indicate that the segment from - 199 to + 1 is necessary for the activation of basal transcription. Electrophoretic mobility shift assays (EMSAs) demonstrated that the ATTGG sequence, within the - 147 to - 121 fragment, is critical to bind nuclear proteins in the proximal COL11A1 promoter. We demonstrated that the CCAAT binding factor (CBF/NF-Y) bound to this region using an interference assay with consensus oligonucleotides and a supershift assay with specific antibodies in an EMSA. In a chromatin immunoprecipitation assay and EMSA using DNA-affinity-purified proteins, CBF/NF-Y proteins directly bound this region in vitro and in vivo. We also showed that four tandem copies of the CBF/NF-Y-binding fragment produced higher transcriptional activity than one or two copies, whereas the absence of a CBF/NF-Y-binding fragment suppressed the COL11A1 promoter activity. Furthermore, overexpression of a dominant-negative CBF-B/NF-YA subunit significantly inhibited promoter activity in both transient and stable cells. These results indicate that the CBF/NF-Y proteins regulate the transcription of COL11A1 by directly binding to the ATTGG sequence in the proximal promoter region.	Oita Med Univ, Dept Anat Biol & Med, Oita 8795593, Japan; Oita Med Univ, Res Lab Ctr, Oita 8795593, Japan	Oita University; Oita University	Yoshioka, H (corresponding author), Oita Med Univ, Dept Anat Biol & Med, Hasama Machi, Oita 8795593, Japan.	hidey@oita-med.ac.jp						BERNARD M, 1988, J BIOL CHEM, V263, P17159; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; Ghayor C, 2000, J BIOL CHEM, V275, P27421; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kinoshita A, 1997, J BIOL CHEM, V272, P31777, DOI 10.1074/jbc.272.50.31777; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Lok CN, 2002, BIOCHEM J, V368, P741, DOI 10.1042/BJ20020791; Lui VCH, 1996, GENOMICS, V32, P401, DOI 10.1006/geno.1996.0135; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matuoka K, 2002, AGEING RES REV, V1, P639, DOI 10.1016/S1568-1637(02)00026-0; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; NAH HD, 1992, J BIOL CHEM, V267, P22581; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLSEN BR, 1999, EXTRACELLULAR MATRIX, P380; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rabe C, 1998, EXTRACELLULAR MATRIX-CELL INTERACTION, P217; RUTESHOUSER EC, 1989, J BIOL CHEM, V264, P13740; RUTESHOUSER EC, 1992, J BIOL CHEM, V267, P14398; SANKAR N, 1998, TRENDS BIOCHEM SCI, V23, P174; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRUTER S, 1992, J BIOL CHEM, V267, P25389; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Vandenberg P, 1996, MATRIX BIOL, V15, P359, DOI 10.1016/S0945-053X(96)90139-0; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; YOSHIOKA H, 1995, J BIOL CHEM, V270, P418, DOI 10.1074/jbc.270.1.418; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YOSHIOKA H, 1995, DEV DYNAM, V204, P41, DOI 10.1002/aja.1002040106; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	55	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32763	32770		10.1074/jbc.M305599200	http://dx.doi.org/10.1074/jbc.M305599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805369	hybrid			2022-12-25	WOS:000184901800035
J	Rotsaert, FAJ; Hallberg, BM; de Vries, S; Moenne-Loccoz, P; Divne, C; Renganathan, V; Gold, MH				Rotsaert, FAJ; Hallberg, BM; de Vries, S; Moenne-Loccoz, P; Divne, C; Renganathan, V; Gold, MH			Biophysical and structural analysis of a novel heme b iron ligation in the flavocytochrome cellobiose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; RESONANCE RAMAN-SPECTRA; ESCHERICHIA-COLI; AXIAL LIGAND; NITROSOMONAS-EUROPAEA; HOMOLOGOUS EXPRESSION; CYTOCHROME C554; DOUBLE MUTANT; PROTEIN; TRANSFORMATION	The fungal extracellular flavocytochrome cellobiose dehydrogenase (CDH) participates in lignocellulose degradation. The enzyme has a cytochrome domain connected to a flavin-binding domain by a peptide linker. The cytochrome domain contains a 6-coordinate low spin b-type heme with unusual iron ligands and coordination geometry. Wild type CDH is only the second example of a b-type heme with Met-His ligation, and it is the first example of a Met-His ligation of heme b where the ligands are arranged in a nearly perpendicular orientation. To investigate the ligation further, Met(65) was replaced with a histidine to create a bis-histidyl ligated iron typical of b-type cytochromes. The variant is expressed as a stable 90-kDa protein that retains the flavin domain catalytic reactivity. However, the ability of the mutant to reduce external one-electron acceptors such as cytochrome c is impaired. Electrochemical measurements demonstrate a decrease in the redox midpoint potential of the heme by 210 mV. In contrast to the wild type enzyme, the ferric state of the protoheme displays a mixed low spin/high spin state at room temperature and low spin character at 90 K, as determined by resonance Raman spectroscopy. The wild type cytochrome does not bind CO, but the ferrous state of the variant forms a CO complex, although the association rate is very low. The crystal structure of the M65H cytochrome domain has been determined at 1.9 Angstrom resolution. The variant structure confirms a bis-histidyl ligation but reveals unusual features. As for the wild type enzyme, the ligands have a nearly perpendicular arrangement. Furthermore, the iron is bound by imidazole N-delta1 and N-epsilon2 nitrogen atoms, rather than the typical N-epsilon2/N-epsilon2 coordination encountered in bis-histidyl ligated heme proteins. To our knowledge, this is the first example of a bis-histidyl N-delta1/N-epsilon2-coordinated protoporphyrin IX iron.	Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Uppsala Univ, Dept Cell & Mol Biol, Ctr Biomed, SE-75124 Uppsala, Sweden; Albanova Univ Ctr, KTH, Dept Biotechnol, SE-10691 Stockholm, Sweden; Delft Univ Technol, Kluyver Dept Biotechnol, NL-2628 BC Delft, Netherlands	Oregon Health & Science University; Uppsala University; Royal Institute of Technology; Delft University of Technology	Gold, MH (corresponding author), Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	mhgold@myexcel.com	Hallberg, B. Martin/C-5361-2009; Milton, Ross D/J-7164-2012; Divne, Christina/E-8646-2010	Hallberg, B. Martin/0000-0002-6781-0345; Divne, Christina/0000-0002-5805-2693; MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617				AKILESWARAN L, 1993, CURR GENET, V23, P351, DOI 10.1007/BF00310898; ALIC M, 1989, APPL ENVIRON MICROB, V55, P406, DOI 10.1128/AEM.55.2.406-411.1989; ALIC M, 1991, CURR GENET, V19, P491, DOI 10.1007/BF00312741; ALIC M, 1990, CURR GENET, V17, P305, DOI 10.1007/BF00314877; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Aubert C, 2001, BIOCHEMISTRY-US, V40, P13690, DOI 10.1021/bi011202q; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Cohen JD, 1997, ARCH BIOCHEM BIOPHYS, V341, P321, DOI 10.1006/abbi.1997.9987; COX MC, 1992, FEBS LETT, V307, P233, DOI 10.1016/0014-5793(92)80774-B; Darrouzet E, 1999, BIOCHEMISTRY-US, V38, P7908, DOI 10.1021/bi990211k; Davis CA, 2002, ARCH BIOCHEM BIOPHYS, V400, P63, DOI 10.1006/abbi.2002.2783; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Dutton P L, 1978, Methods Enzymol, V54, P411; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Gelpke MDS, 1999, APPL ENVIRON MICROB, V65, P1670; Gonzalez G, 2002, BIOCHEMISTRY-US, V41, P8414, DOI 10.1021/bi025845x; Gunner MR, 1997, J BIOL INORG CHEM, V2, P126, DOI 10.1007/s007750050116; Hallberg BM, 2000, STRUCT FOLD DES, V8, P79, DOI 10.1016/S0969-2126(00)00082-4; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; HARBURY HA, 1965, P NATL ACAD SCI USA, V54, P1658, DOI 10.1073/pnas.54.6.1658; HENRIKSSON G, 1991, EUR J BIOCHEM, V196, P101, DOI 10.1111/j.1432-1033.1991.tb15791.x; HENRIKSSON G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P184, DOI 10.1016/0005-2728(93)90171-B; Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6; HIGHAM CW, 1994, FEBS LETT, V351, P128, DOI 10.1016/0014-5793(94)00847-7; Igarashi K, 1999, J BIOL CHEM, V274, P3338, DOI 10.1074/jbc.274.6.3338; Igarashi K, 2002, BIOCHEM J, V365, P521, DOI 10.1042/BJ20011809; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; Iverson TM, 2001, J BIOL INORG CHEM, V6, P390, DOI 10.1007/s007750100213; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 2000, ACTA CRYSTALLOGR D, V56, P249, DOI 10.1107/S0907444999016364; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li B, 1996, APPL ENVIRON MICROB, V62, P1329, DOI 10.1128/AEM.62.4.1329-1335.1996; Li B, 2000, BIOCHEM BIOPH RES CO, V270, P141, DOI 10.1006/bbrc.2000.2381; LLOYD E, 1995, J AM CHEM SOC, V117, P6434, DOI 10.1021/ja00129a003; McPherson A, 1982, PREPARATION ANAL PRO; MILES CS, 1993, BIOCHIM BIOPHYS ACTA, V1202, P82, DOI 10.1016/0167-4838(93)90066-Z; Miller GT, 2000, BIOCHEMISTRY-US, V39, P9010, DOI 10.1021/bi000232a; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OZOLS J, 1964, J BIOL CHEM, V239, P1018; Pettigrew, 1990, CYTOCHROME C EVOLUTI; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; QIN J, 1994, J BIOL CHEM, V269, P1083; RAICES M, 1995, FEBS LETT, V369, P233, DOI 10.1016/0014-5793(95)00758-2; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RAPHAEL AL, 1989, PROTEINS, V6, P338, DOI 10.1002/prot.340060316; REID LS, 1982, J AM CHEM SOC, V104, P7516, DOI 10.1021/ja00390a021; Rotsaert FAJ, 2001, ARCH BIOCHEM BIOPHYS, V390, P206, DOI 10.1006/abbi.2001.2362; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; TAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V268, P292, DOI 10.1016/0005-2744(72)90324-5; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; Zaric SD, 2001, BIOCHEMISTRY-US, V40, P7914, DOI 10.1021/bi010428q	60	18	19	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33224	33231		10.1074/jbc.M302653200	http://dx.doi.org/10.1074/jbc.M302653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796496	hybrid			2022-12-25	WOS:000184901800090
J	Wilson, GM; Lu, JB; Sutphen, K; Sun, Y; Huynh, Y; Brewer, G				Wilson, GM; Lu, JB; Sutphen, K; Sun, Y; Huynh, Y; Brewer, G			Regulation of A+U-rich element-directed mRNA turnover involving reversible phosphorylation of AUF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; BINDING PROTEIN; MASS-SPECTROMETRY; MAMMALIAN-CELLS; HNRNP-D; STABILITY; ALPHA; TRISTETRAPROLIN	Proteins binding A+U-rich elements (AREs) contribute to the rapid cytoplasmic turnover of mRNAs containing these sequences. However, this process is a regulated event and may be accelerated or inhibited by myriad signal transduction systems. For example, monocyte adherence at sites of inflammation or tissue injury is associated with inhibition of ARE-directed mRNA decay, which contributes to rapid increases in cytokine and inflammatory mediator production. Here, we show that acute exposure of THP-1 monocytic leukemia cells to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate mimics several features of monocyte adherence, including rapid induction and stabilization of ARE-containing mRNAs encoding interleukin-1beta and tumor necrosis factor alpha. Additionally, TPA treatment alters the activity of cytoplasmic complexes that bind AREs, including complexes containing the ARE-specific, mRNA-destabilizing factor, AUF1. Analyses of AUF1 from control and TPA-treated cells indicated that post-translational modifications of the major cytoplasmic isoform, p40(AUF1), are altered concomitant with changes in RNA binding activity and stabilization of ARE-containing mRNAs. In particular, p40(AUF1) recovered from polysomes was phosphorylated on Ser(83) and Ser(87) in untreated cells but lost these modifications following TPA treatment. We propose that selected signal transduction pathways may regulate ARE-directed mRNA turnover by reversible phosphorylation of polysome-associated p40(AUF1).	UMDNJ, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Spect, Baltimore, MD 21201 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Wilson, GM (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	gwils001@umaryland.edu; brewerga@umdnj.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1990, METHOD ENZYMOL, V181, P202; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Fuentes-Panana EM, 2000, J VIROL, V74, P8166, DOI 10.1128/JVI.74.17.8166-8175.2000; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEE J, 1987, BLOOD, V69, P1542; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Montero L, 1999, CANCER RES, V59, P5286; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; MYER VE, 1995, RNA, V1, P171; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Qian XH, 1999, ANAL BIOCHEM, V274, P174, DOI 10.1006/abio.1999.4268; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stoecklin G, 2003, MOL CELL BIOL, V23, P3506, DOI 10.1128/MCB.23.10.3506-3515.2003; Tolnay M, 1997, J IMMUNOL, V159, P5492; Tolnay M, 2000, BIOCHEM J, V348, P151, DOI 10.1042/0264-6021:3480151; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Vihinen H, 2000, J BIOL CHEM, V275, P27775; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Wilson GM, 1999, MOL CELL BIOL, V19, P4056; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	68	106	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33029	33038		10.1074/jbc.M305772200	http://dx.doi.org/10.1074/jbc.M305772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819195	hybrid			2022-12-25	WOS:000184901800067
J	Contreras-Zentella, M; Mendoza, G; Membrillo-Hernandez, J; Escamilla, JE				Contreras-Zentella, M; Mendoza, G; Membrillo-Hernandez, J; Escamilla, JE			A novel double heme substitution produces a functional bo(3) variant of the quinol oxidase aa(3) of Bacillus cereus - Purification and partial characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; ACETOBACTER-ACETI; UBIQUINOL OXIDASE; CYOE GENE; SUBTILIS; BO; MUTANT; SITE	A novel bo(3)-type quinol oxidase was highly purified from Bacillus cereus PYM1, a spontaneous mutant unable to synthesize heme A and therefore spectroscopically detectable cytochromes aa(3) and caa(3). The purified enzyme contained 12.4 nmol of heme O and 11.5 nmol of heme B mg(-1) protein. The enzyme was composed of two subunits with an M-r of 51,000 and 30,000, respectively. Both subunits were immunoreactive to antibodies raised against the B cereus aa3 oxidase. Moreover, amino-terminal sequence analysis of the 30-kDa subunit revealed that the first 19 residues were identical to those from the 30-kDa subunit of the B. cereus aa3 oxidase. The purified bo(3) oxidase failed to oxidize ferrrocytochrome c (neither yeast nor horse) but oxidized tetrachlorohydroquinol with an apparent K-m of 498 muM, a V-max of 21 mumol of O-2 min(-1) mg(-1), and a calculated turnover of 55 s(-1). The quinol oxidase activity with tetrachlorohydroquinol was inhibited by potassium cyanide and 2-n-heptyl 4-hydroxyquinoline-N-oxide with an I-50 of 24 and 300 muM, respectively. Our results demonstrate that the bo(3) oxidase of this mutant is not the product of a new operon but instead is a cytochrome aa(3) apoprotein encoded by the qox operon of the aa(3) oxidase of B. cereus wild type promiscuously assembled with hemes B and O replacing heme A, producing a novel bo(3) cytochrome. This is the first reported example of an enzymatically active promiscuous oxidase resulting from the simultaneous substitution of its original hemes in the high and low spin sites.	Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Escamilla, JE (corresponding author), Univ Nacl Autonoma Mexico, Dept Bioquim, Inst Fisiol Celular, Apdo Postal 70-242, Mexico City 04510, DF, Mexico.		Membrillo-Hernández, Jorge/AAN-4996-2021	Membrillo-Hernández, Jorge/0000-0001-7650-8116				ANDREOLI AJ, 1973, J BACTERIOL, V115, P1159, DOI 10.1128/JB.115.3.1159-1166.1973; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; Auer G, 1995, BIOCHEM MOL BIOL INT, V37, P1173; Azarkina N, 1999, J BIOL CHEM, V274, P32810, DOI 10.1074/jbc.274.46.32810; CARTERMINGHETTI K, 1992, BIOCHEMISTRY-US, V31, P6917; Contreras ML, 1999, MICROBIOL-SGM, V145, P1563, DOI 10.1099/13500872-145-7-1563; DelArenal IP, 1997, ARCH MICROBIOL, V167, P24; FROUD SJ, 1984, J GEN MICROBIOL, V130, P2201; GARCIAHORSMAN JA, 1991, MOL MICROBIOL, V5, P197, DOI 10.1111/j.1365-2958.1991.tb01840.x; GARCIAHORSMAN JA, 1991, EUR J BIOCHEM, V199, P761, DOI 10.1111/j.1432-1033.1991.tb16181.x; HEDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; JAMES WS, 1989, FEMS MICROBIOL LETT, V58, P277; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; Markwell M A, 1981, Methods Enzymol, V72, P296; MATSUSHITA K, 1992, J BACTERIOL, V174, P122, DOI 10.1128/jb.174.1.122-129.1992; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; PESCHEK GA, 1995, J BIOL CHEM, V270, P27937, DOI 10.1074/jbc.270.46.27937; POOLE RK, 1994, MICROBIOL-SGM, V140, P1027, DOI 10.1099/13500872-140-5-1027; POOLE RK, 1979, BIOCHEM J, V184, P379, DOI 10.1042/bj1840379; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; QUERESHI MH, 1990, J BIOCH, V107, P408; Riistama S, 2000, BBA-BIOENERGETICS, V1456, P1, DOI 10.1016/S0005-2728(99)00097-3; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sakamoto J, 1997, J BIOCHEM-TOKYO, V122, P764; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P5356, DOI 10.1021/bi9727592; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, J BIOCH, V107, P547; Svensson B, 1996, EUR J BIOCHEM, V238, P287, DOI 10.1111/j.1432-1033.1996.0287q.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Zickermann I, 1997, EUR J BIOCHEM, V246, P618, DOI 10.1111/j.1432-1033.1997.00618.x	32	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31473	31478		10.1074/jbc.M302583200	http://dx.doi.org/10.1074/jbc.M302583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805383	hybrid			2022-12-25	WOS:000184782100005
J	Noviello, C; Vito, P; Lopez, P; Abdallah, M; D'Adamio, L				Noviello, C; Vito, P; Lopez, P; Abdallah, M; D'Adamio, L			Autosomal recessive hypercholesterolemia protein interacts with and regulates the cell surface level of Alzheimer's amyloid beta precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; INTRACELLULAR DOMAIN; MISSENSE MUTATIONS; ADAPTER PROTEIN; LDL RECEPTOR; DISEASE; FE65; PRESENILINS; GENE; APP	The familial Alzheimer's disease gene product amyloid beta protein precursor (AbetaPP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide. Although much is known about the biochemical pathway leading to Abeta formation, because extracellular aggregates of Abeta peptides are considered the cause of Alzheimer's disease, the biological role of AbetaPP processing is only recently being investigated. Cleavage of AbetaPP by gamma-secretase releases, together with Abeta, a COOH-terminal AbetaPP intracellular domain, termed AID. Hoping to gain clues about proteins that regulates AbetaPP processing and function, we used the yeast two-hybrid system to identify proteins that interact with the AID region of AbetaPP. One of the interactors isolated is the autosomal recessive hypercholesterolemia (ARH) adapter protein. This molecular interaction is confirmed in vitro and in vivo by fluorescence resonance energy transfer and in cell lysates. Moreover, we show that reduction of ARH expression by RNA interference results in increased levels of cell membrane AbetaPP. These data assert a physiological role for ARH in AbetaPP internalization, transport, and/or processing.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Naples Federico II, CEINGE Biotecnol Avanzate, I-80131 Naples, Italy; Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Zymed Labs, San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Sannio; Rockefeller University	D'Adamio, L (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lopez, Peter/AAP-7234-2020; vito, pasquale/ABF-5505-2020	Lopez, Peter/0000-0002-8587-7148; D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882; vito, pasquale/0000-0002-5721-7716	Telethon [GFP02006] Funding Source: Medline	Telethon(Fondazione Telethon)		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	38	26	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31843	31847		10.1074/jbc.M304133200	http://dx.doi.org/10.1074/jbc.M304133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805363	hybrid			2022-12-25	WOS:000184782100048
J	Sun, Y; Qi, XY; Grabowski, GA				Sun, Y; Qi, XY; Grabowski, GA			Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEIN-2; SITE-DIRECTED MUTAGENESIS; GAUCHER-DISEASE TYPE-1; METACHROMATIC LEUKODYSTROPHY; SULFATIDE ACTIVATOR; HUMAN PROSAPOSIN; SAP PRECURSOR; DEFICIENCY; PATIENT; MUTATION	Saposins (A, B, C, and D) are small sphingolipid activator proteins that are derived by proteolytic processing of a common precursor, prosaposin. In the lysosomal sphingolipid degradation pathway, acid beta-glucosidase (GCase) requires saposin C for optimal in vitro and in vivo hydrolysis of glucocerebroside. The deficiency of prosaposin/saposins (PS-/-) in humans and mice leads to a decrease of GCase activity in selected tissues. Concordant decreases (>50%) of GCase protein and in vitro activity were detected in extracts of cultured fibroblasts and hepatocytes from PS-/- mice and human prosaposin-deficient fibroblasts. GCase RNA in the PS-/- cells was at wild-type levels. Compared with that in wild-type cells (t(1/2)>24 h), the GCase protein in the PS-/- cells had a faster disappearance rate (t(1/2)similar to1 h in mouse and similar to8 h in human) as determined by metabolic labeling and immunoprecipitation with anti-GCase antibodies. Treatment of PS-/- cells with leupeptin, an inhibitor of cysteine proteases, led to significant increases (similar to2-fold) in GCase protein and in vitro activity. Loading saposin C to human PS-/- fibroblasts resulted in an enhancement of GCase protein and in vitro activity. Saposin D loading had no effect. These data indicate that saposin C is required for GCase resistance to proteolytic degradation in the cell. Thus, diminished in vivo GCase activity would be greater than expected only from the lack of GCase activation by saposin C. These results indicate a new property for saposin C, an anti-proteolytic protective function toward GCase.	Childrens Hosp Res Fdn, Childrens Hosp Med Ctr, Div & Program Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Grabowski, GA (corresponding author), Childrens Hosp Res Fdn, Childrens Hosp Med Ctr, Div & Program Human Genet, 3333 Burnet Ave,Pavil E5-253, Cincinnati, OH 45229 USA.	greg.grabowski@chmcc.org			NINDS NIH HHS [NS34071, NS36681] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036681, R01NS034071] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BERGMANN JE, 1989, AM J HUM GENET, V44, P741; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GATT S, 1985, ENZYME, V33, P109, DOI 10.1159/000469416; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1994, J BIOL CHEM, V269, P2283; GRINDE B, 1980, BIOCHIM BIOPHYS ACTA, V632, P73, DOI 10.1016/0304-4165(80)90250-0; Harzer K, 1997, FEBS LETT, V417, P270, DOI 10.1016/S0014-5793(97)01302-1; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; Hulkova H, 2001, HUM MOL GENET, V10, P927, DOI 10.1093/hmg/10.9.927; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Leonova T, 2000, MOL GENET METAB, V70, P281, DOI 10.1006/mgme.2000.3035; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; Liu YJ, 1997, P NATL ACAD SCI USA, V94, P8138, DOI 10.1073/pnas.94.15.8138; Matsuda J, 2001, HUM MOL GENET, V10, P1191, DOI 10.1093/hmg/10.11.1191; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PATON BC, 1992, BIOCHEM J, V285, P481, DOI 10.1042/bj2850481; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 2001, J BIOL CHEM, V276, P27010, DOI 10.1074/jbc.M101075200; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; RORMAN EG, 1992, GENOMICS, V13, P312, DOI 10.1016/0888-7543(92)90247-P; Sandhoff K, 1998, ANN NY ACAD SCI, V845, P139, DOI 10.1111/j.1749-6632.1998.tb09667.x; SANDHOFF K, 1992, BIOCHEM SOC T, V20, P695, DOI 10.1042/bst0200695; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; STEVENS RL, 1981, AM J HUM GENET, V33, P900; Sun Y, 2003, BIOCHEM J, V370, P557, DOI 10.1042/BJ20021120; Sun Y, 2002, MOL GENET METAB, V76, P271, DOI 10.1016/S1096-7192(02)00114-2; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Vielhaber G, 1996, J BIOL CHEM, V271, P32438, DOI 10.1074/jbc.271.50.32438; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Xu YH, 1996, PEDIATR RES, V39, P313, DOI 10.1203/00006450-199602000-00021; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	46	56	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31918	31923		10.1074/jbc.M302752200	http://dx.doi.org/10.1074/jbc.M302752200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12813057	hybrid			2022-12-25	WOS:000184782100059
J	Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M				Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M			v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3	ONCOGENE			English	Article						cell transformation; v-Jun; Sp1; Sp3; SPARC; primary chick embryo fibroblasts	CHICK-EMBRYO FIBROBLASTS; EXTRACELLULAR-MATRIX PROTEIN; C-JUN; TRANSCRIPTION FACTOR; NEOPLASTIC PROGRESSION; TRANSFORMING ACTIVITY; CELL-TRANSFORMATION; IN-VIVO; EXPRESSION; CANCER	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a downregulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA. Repression of SPARC contributes to the oncogenic process by facilitating tumor development in vivo. A proximal promoter fragment, designated -124/+16, is responsible for high constitutive activity of the SPARC gene and is the target of repression by v-Jun. In this paper, using electrophoretic mobility shift and pull-down assays in vitro, and transient transfections and chromatin immunoprecipitation assays in Sp1/3-deficient Drosophila SL2 cells and in chick embryo fibroblasts, we show that (i) Sp1 and/or Sp3 is required for constitutive activation of SPARC transcription, by binding directly to the GGA-rich -92/-57 fragment; and (ii) v-Jun does not bind -124/+16 directly, but binds to the GGA-rich fragment indirectly, most likely through a physical interaction with Sp1/3. Moreover, a transactivation-proficient v-Jun derivative, designated v-Jun/cebp/glz, which cannot bind Jun DNA motifs anymore and cannot heterodimerize, is still capable of downregulating SPARC efficiently. Taken together, these data strongly suggest that v-Jun downregulates SPARC through the formation of a DNA-Sp1/3-v-Jun, chromatin-associated complex.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Eastern Virginia Medical School; University of Siena	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.	marc.castellazzi@ens-lyon.fr	Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Acloque H, 2001, MECH DEVELOP, V103, P79, DOI 10.1016/S0925-4773(01)00336-7; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Jacob K, 1999, CANCER RES, V59, P4453; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEL L, 1995, ONCOGENE, V10, P495; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422	50	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4047	4061		10.1038/sj.onc.1206713	http://dx.doi.org/10.1038/sj.onc.1206713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821939				2022-12-25	WOS:000183707600008
J	Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C				Alpy, F; Boulay, A; Moog-Lutz, C; Andarawewa, KL; Degot, S; Stoll, I; Rio, MC; Tomasetto, C			Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors	ONCOGENE			English	Article						erbB-2; MLN64; MENTHO; StAR; Sp1	HIGHLY EXPRESSED GENES; PROTEIN STAR; ESOPHAGEAL-CARCINOMA; CHROMOSOMAL DOMAINS; DNA AMPLIFICATION; FACTOR RECEPTOR; IN-VITRO; FAMILY; GENOME; REVEALS	MLN64, is invariably coamplified and coexpressed with erbB-2 in breast cancers. The human MLN64 and ERBB2 genes are positioned at less than 50 kb from each other, on chromosome 17q12. To understand the molecular basis of MLN64 overexpression in cancer, the genomic region containing the MLN64 and ERBB2 genes was isolated and mapped. The two genes, DARPP32 and Telethonin, flanking MLN64 respectively on its centromeric and telomeric sides, although coamplified, are not over-expressed in breast cancer cells, indicating that gene amplification is not sufficient to allow overexpression. The MLN64 minimal promoter was isolated and found to be a housekeeping gene promoter containing four potential Sp1 binding elements. Using Sp1-deficient Drosophila SL2 cells, MLN64 promoter activity was induced in a dose-dependent manner by exogenous Sp1 addition. Furthermore, mutation of each individual Sp1 element resulted in a significant decrease in reporter gene activity, indicating that all the Sp1 binding elements are functional and act together to promote gene expression. Since the ERBB2 promoter is also positively regulated by Sp1, this study indicates that MLN64 and ERBB2 genes share common transcriptional controls together with a physical link on chromosome 17q. We speculate that, in addition to the oncogenic potential of erbB-2 overexpression, the unbalanced action of MLN64 contributes to the poor clinical outcome of breast tumors bearing this amplified region.	Univ Louis Pasteur Strasbourg 1, CNRS INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tomasetto, C (corresponding author), IGBMC, Dept Mol Pathol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, France.		Alpy, Fabien/ABD-5893-2020; MOOG-LUTZ, Christel/F-1975-2011; Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014	Alpy, Fabien/0000-0002-0526-0720; Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848				Alpy F, 2002, J BIOL CHEM, V277, P50780, DOI 10.1074/jbc.M208290200; Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blumenthal T, 2002, NATURE, V417, P851, DOI 10.1038/nature00831; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; CHEN YY, 1994, ONCOGENE, V9, P2269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Foster KW, 2000, CANCER RES, V60, P6488; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hyman E, 2002, CANCER RES, V62, P6240; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kauraniemi P, 2001, CANCER RES, V61, P8235; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Mayerhofer A, 1999, J CLIN ENDOCR METAB, V84, P257, DOI 10.1210/jc.84.1.257; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soury E, 2001, IMMUNOGENETICS, V53, P634, DOI 10.1007/s00251-001-0374-z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462	52	23	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3770	3780		10.1038/sj.onc.1206500	http://dx.doi.org/10.1038/sj.onc.1206500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802284				2022-12-25	WOS:000183551000011
J	Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR				Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR			Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers	ONCOGENE			English	Article						hepatitis B virus; human papillomavirus; telomerase reverse transcriptase; hepatocellular carcinoma; cervical cancer; viral integration	RESTRICTION-SITE PCR; COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; DNA INTEGRATION; CELL-LINES; MYC GENES; ACTIVATION; TYPE-16; SEQUENCE; REGION	Chronic infections with the hepatitis B virus (HBV) and high-risk human papillomaviruses (HPVs) are important risk factors for hepatocellular carcinoma (HCC) and cervical cancer (CC), respectively. HBV and HPV are DNA viruses that almost invariably integrate into the host genome in invasive tumors. The viral integration sites occur throughout the genome, leading to the presumption that there are no preferred sites of integration. A number of viral integrations have been shown to occur within the vicinity of important cancer-related genes. In studies of HBV-induced HCC and HPV-induced CC, we have identified two HBV and three HPV integrations into the human telomerase reverse transcriptase (hTERT) gene. Detailed characterization of the integrations revealed that four integrations occurred within the hTERT promoter and upstream region and the fifth integration occurred in intron 3 of the hTERT gene. None of the integrations altered the hTERT coding sequence and all resulted in juxtaposition of viral enhancers near hTERT, with potential activation of hTERT expression. Our work supports the hypothesis that the sites of oncogenic viral integration are nonrandom and that genes at the sites of viral integration may play important roles in carcinogenesis.	Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Obstet & Gynaecol, Rochester, MN 55905 USA; Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; Univ Barcelona, IMD Hosp Clin, BCLC Grp Liver Unit, Barcelona 08036, Spain; Alaska Native Med Ctr, Anchorage, AK 99508 USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Barcelona; Alaska Native Medical Center; Chinese University of Hong Kong; Prince of Wales Hospital	Roberts, LR (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA.			CHUNG, Tony/0000-0002-6362-8546; Bruix, Jordi/0000-0002-9826-0753; Roberts, Lewis/0000-0001-7885-8574	NATIONAL CANCER INSTITUTE [R01CA048031, K08CA082862] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA82862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DEJEAN A, 1990, MOL BIOL MED, V7, P213; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horikawa I, 1999, CANCER RES, V59, P826; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kozuka T, 2000, JPN J CANCER RES, V91, P271, DOI 10.1111/j.1349-7006.2000.tb00941.x; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Smola-Hess S, 2001, J GEN VIROL, V82, P2335, DOI 10.1099/0022-1317-82-10-2335; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Waris G, 2002, J VIROL, V76, P2721, DOI 10.1128/JVI.76.6.2721-2729.2002; Weber KL, 1998, BIOTECHNIQUES, V25, P415, DOI 10.2144/98253st02; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187	34	145	167	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3813	3820		10.1038/sj.onc.1206528	http://dx.doi.org/10.1038/sj.onc.1206528			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802289				2022-12-25	WOS:000183551000016
J	Hinoi, E; Fujimori, S; Yoneda, Y				Hinoi, E; Fujimori, S; Yoneda, Y			Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts	FASEB JOURNAL			English	Article						glutamate; CBFA1; osteocalcin; alkaline phosphatase; Ca2+ accumulation	IONOTROPIC GLUTAMATE RECEPTORS; NICOTINIC ACETYLCHOLINE-RECEPTOR; CULTURED CALVARIAL OSTEOBLASTS; TRANSCRIPTION FACTOR CBFA1; PIG MYENTERIC PLEXUS; RAT ADRENAL-MEDULLA; BONE-RESORPTION; CLEIDOCRANIAL DYSPLASIA; BINDING-SITE; EXPRESSION	N-Methyl-D-aspartate (NMDA) receptors for the central neurotransmitter L-glutamate (Glu) have been shown to be present in both osteoblasts and osteoclasts. Sustained exposure to the NMDA channel antagonist dizocilpine (MK-801) significantly prevented increases in both alkaline phosphatase activity and Ca2+ accumulation in a concentration-dependent manner in osteoblasts cultured for 7-28 days in vitro (DIV), without significantly affecting cell survivability. Osteocalcin expression was markedly reduced in the presence of MK-801 in osteoblasts cultured for 28 DIV. Both an NMDA domain antagonist and a glycine domain antagonist similarly prevented Ca2+ accumulation in osteoblasts exposed for 28 consecutive DIV. MK-801 was effective in significantly inhibiting Ca2+ accumulation determined at 28 DIV in osteoblast s exposed before 7 DIV but was in effective in cells exposed after 11-21 DIV. Sustained exposure to MK-801 significantly inhibited DNA binding activity and expression of corebinding factor alpha-1 (CBFA1) in osteoblasts exposed after 7 DIV up to 28 DIV, but not in those exposed before 7 DIV. These results suggest that heteromeric NMDA receptor channels may be function ally expressed to regulate mechanisms underlying cellular differentiation rather than proliferation and/or maturation through modulation of expression of CBFA1 in cultured rat calvarial osteoblasts.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	yyoneda@anet.ne.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X				AAS P, 1989, EUR J PHARMACOL, V164, P93, DOI 10.1016/0014-2999(89)90235-5; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; Arias HR, 2001, MOL PHARMACOL, V59, P1051, DOI 10.1124/mol.59.5.1051; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fujimori S, 2002, BIOCHEM BIOPH RES CO, V293, P1445, DOI 10.1016/S0006-291X(02)00405-9; Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00-0594fje; GOVITRAPONG P, 1986, J PINEAL RES, V3, P223, DOI 10.1111/j.1600-079X.1986.tb00745.x; Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hinoi E, 2001, BIOCHEM BIOPH RES CO, V281, P341, DOI 10.1006/bbrc.2001.4355; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Hinoi E, 2002, J NEUROSCI RES, V68, P36, DOI 10.1002/jnr.10202; Hinoi E, 2002, BRAIN RES, V943, P112, DOI 10.1016/S0006-8993(02)02726-9; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V297, P452, DOI 10.1016/S0006-291X(02)02223-4; Hinoi E, 2001, NEUROCHEM INT, V38, P539, DOI 10.1016/S0197-0186(00)00115-7; HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huggett J, 2000, FEBS LETT, V485, P13, DOI 10.1016/S0014-5793(00)02175-X; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Itzstein C, 2001, J CELL BIOCHEM, V82, P134, DOI 10.1002/jcb.1114; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KIYAMA H, 1993, MOL BRAIN RES, V19, P262, DOI 10.1016/0169-328X(93)90039-R; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KRISTENSEN P, 1993, FEBS LETT, V332, P14, DOI 10.1016/0014-5793(93)80472-7; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; LUZZI S, 1988, BRIT J PHARMACOL, V95, P1271, DOI 10.1111/j.1476-5381.1988.tb11764.x; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Miyamoto Y, 2002, J NEUROSCI, V22, P2335, DOI 10.1523/JNEUROSCI.22-06-02335.2002; MORONI F, 1986, NEUROSCI LETT, V68, P57, DOI 10.1016/0304-3940(86)90229-6; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; RAMOA AS, 1990, J PHARMACOL EXP THER, V254, P71; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; Skerry TM, 2001, CURR PHARM DESIGN, V7, P737, DOI 10.2174/1381612013397771; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THURKRAL V, 1997, NEUROSCIENCE, V79, P411; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Villalobos C, 1996, FASEB J, V10, P654, DOI 10.1096/fasebj.10.5.8621065; WANG ZQ, 1995, CANCER RES, V55, P6244; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Yatsushiro S, 2000, J NEUROCHEM, V75, P288, DOI 10.1046/j.1471-4159.2000.0750288.x; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6; Yoneda Y, 2001, PROG NEUROBIOL, V63, P697, DOI 10.1016/S0301-0082(00)00036-8; YONEDA Y, 1986, Neuroscience Research, V3, P430, DOI 10.1016/0168-0102(86)90034-9	54	85	87	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1532	+		10.1096/fj.02-0820fje	http://dx.doi.org/10.1096/fj.02-0820fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824297				2022-12-25	WOS:000183818000015
J	Bai, F; Xi, JH; Wawrousek, EF; Fleming, TP; Andley, UP				Bai, F; Xi, JH; Wawrousek, EF; Fleming, TP; Andley, UP			Hyperproliferation and p53 status of lens epithelial cells derived from alpha B-crystallin knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; HEAT-SHOCK PROTEIN; A-CRYSTALLIN; DNA-DAMAGE; MOLECULAR CHAPERONES; GENOMIC INSTABILITY; MITOTIC SPINDLE; T-ANTIGEN; HA-RAS; V-MOS	alphaB-Crystallin, a major protein of lens fiber cells, is a stress-induced chaperone expressed at low levels in the lens epithelium and numerous other tissues, and its expression is enhanced in certain pathological conditions. However, the function of alphaB in these tissues is not known. Lenses of alphaB-/- mice develop degeneration of specific skeletal muscles but do not develop cataracts. Recent work in our laboratory indicates that primary cultures of alphaB-/- lens epithelial cells demonstrate genomic instability and undergo hyperproliferation at a frequency 4 orders of magnitude greater than that predicted by spontaneous immortalization of rodent cells. We now demonstrate that the hyperproliferative alphaB-/- lens epithelial cells undergo phenotypic changes that include the appearance of the p53 protein as shown by immunoblot analysis. Sequence analysis showed a lack of mutations in the p53 coding region of hyperproliferative alphaB-/- cells. However, the reentry of hyperproliferative alphaB-/- cells into S phase and mitosis after DNA damage by gamma-irradiation were consistent with impaired p53 checkpoint function in these cells. The results demonstrate that expression of functionally impaired p53 is one of the factors that promote immortalization of lens epithelial cells derived from alphaB-/- mice. Fluorescence in situ hybridization using probes prepared from centromere-specific mouse P1 clones of chromosomes 1 and 9 demonstrated that the hyperproliferative alphaB-/- cells were 30% diploid and 70% tetraploid, whereas wild type cells were 83% diploid. Further evidence of genomic instability was obtained when the hyperproliferative alphaB-/- cells were labeled with anti-beta-tubulin antibodies. Examination of the hyperproliferative alphaB-/- mitotic profiles revealed the presence of cells that failed to round up for mitosis, or arrested in cytokinesis, and binucleated cells in which nuclear division had occurred without cell division. These results suggest that the stress protein and molecular chaperone alphaB-crystallin protects cells from acquiring impaired p53 protein and genomic instability.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@vision.wustl.edu	Wawrousek, Eric/A-4547-2008	Andley, Usha/0000-0001-7049-7591	NATIONAL EYE INSTITUTE [ZIAEY000286, Z01EY000286, R01EY005681, P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY05681, EY02687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Brown CR, 1996, J BIOL CHEM, V271, P824, DOI 10.1074/jbc.271.2.824; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cole SL, 2002, J VIROL, V76, P8420, DOI 10.1128/JVI.76.16.8420-8432.2002; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Djabali K, 1999, EXP CELL RES, V253, P649, DOI 10.1006/excr.1999.4679; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gjoerup O, 2001, J VIROL, V75, P9142, DOI 10.1128/JVI.75.19.9142-9155.2001; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; Hopfer U, 1996, AM J PHYSIOL-CELL PH, V270, pC1, DOI 10.1152/ajpcell.1996.270.1.C1; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1991, AM J PATHOL, V139, P1303; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kastan MB, 1997, CURR TOP MICROBIOL, V221, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1989, ONCOGENE, V4, P799; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V91, P7525; Lange BMH, 2000, EMBO J, V19, P1252, DOI 10.1093/emboj/19.6.1252; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Martin ACR, 2002, HUM MUTAT, V19, P149, DOI 10.1002/humu.10032; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rakic JM, 1997, EXP EYE RES, V64, P67, DOI 10.1006/exer.1996.0179; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; Tlsty TD, 1996, CANCER SURV, V28, P217; Tlsty TD, 2002, CANCER CELL, V2, P2, DOI 10.1016/S1535-6108(02)00088-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wigley WC, 1999, J CELL BIOL, V145, P481; Xi JH, 2003, J CELL SCI, V116, P1073, DOI 10.1242/jcs.00325; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070	74	47	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36876	36886		10.1074/jbc.M304010200	http://dx.doi.org/10.1074/jbc.M304010200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12826669	hybrid			2022-12-25	WOS:000185318300121
J	Guerardel, Y; Maes, E; Briken, V; Chirat, F; Leroy, Y; Locht, C; Strecker, G; Kremer, L				Guerardel, Y; Maes, E; Briken, V; Chirat, F; Leroy, Y; Locht, C; Strecker, G; Kremer, L			Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii - Novel structural features and apoptosis-inducing properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYO-INOSITOL ANCHOR; MAGNETIC-RESONANCE-SPECTROSCOPY; T-CELL PROLIFERATION; BOVIS BCG; MANNOSYLATED-LIPOARABINOMANNANS; MULTIACYLATED FORMS; HUMAN MACROPHAGES; NMR-SPECTROSCOPY; MANNOSE RECEPTOR	Although Mycobacterium kansasii has emerged as an important pathogen frequently encountered in immunocompromised patients, little is known about the mechanisms of M. kansasii pathogenicity. Lipoarabinomannan (LAM), a major mycobacterial cell wall lipoglycan, is an important virulence factor for many mycobacteria, as it modulates the host immune response. Therefore, the detailed structures of the of M. kansasii LAM (KanLAM), as well as of its biosynthetic precursor lipomannan (KanLM), were determined in a clinical strain isolated from a human immunodeficiency virus-positive patient. Structural analyses revealed that these lipoglycans possess important differences as compared with those from other mycobacterial species. KanLAM carries a mannooligosaccharide cap but is devoid of the inositol phosphate cap present in Mycobacterium smegmatis. Characterization of the mannan core of KanLM and KanLAM demonstrated the following occurrences: 1) alpha1,2-oligomannopyranosyl side chains, contrasting with the single mannopyranosyl residues substituting the mannan core in all the other structures reported so far; and 2) 5-methylthiopentose residues that were described to substitute the arabinan moiety from Mycobacterium tuberculosis LAM. With respect to the arabinan domain of KanLAM, succinyl groups were found to substitute the C-3 position on 5-arabinofuranosyl residues, reported to be linked to the C-2 of the 3,5-arabinofuranose in Mycobacterium bovis bacillus calmette-guerin LAM. Because M. kansasii has been reported to induce apoptosis, we examined the possibility of the M. kansasii lipoglycans to induce apoptosis of THP-1 cells. Our results indicate that, in contrast to KanLAM, KanLM was a potent apoptosis-inducing factor. This work underlines the diversity of LAM structures among various pathogenic mycobacterial species and also provides evidence of LM being a potential virulence factor in M. kansasii infections by inducing apoptosis.	Inst Pasteur, INSERM, U447, IBL,Lab Mecanismes Mol Pathogenie Microbienne, F-59019 Lille, France; Univ Sci & Technol Lille, CNRS, UMR8576, Lab Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Yeshiva University; Albert Einstein College of Medicine	Kremer, L (corresponding author), Inst Pasteur, INSERM, U447, IBL,Lab Mecanismes Mol Pathogenie Microbienne, 1 Rue Pr Calmette,BP245, F-59019 Lille, France.	laurent.kremer@ibl.fr	Kremer, Laurent/M-4935-2017; Locht, Camille/L-3516-2018	Kremer, Laurent/0000-0002-6604-4458; Briken, Volker/0000-0001-5830-6107; Guerardel, Yann/0000-0003-4967-9512	NIAID NIH HHS [AI 51696-01, N01-AI-75320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320, R21AI051696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcaide F, 1997, J CLIN MICROBIOL, V35, P1959, DOI 10.1128/JCM.35.8.1959-1964.1997; BARNES PF, 1992, J IMMUNOL, V149, P541; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; Campo RE, 1997, CLIN INFECT DIS, V24, P1233, DOI 10.1086/513666; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Delmas C, 1997, GLYCOBIOLOGY, V7, P811, DOI 10.1093/glycob/7.6.811; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guay DRP, 1996, ANN PHARMACOTHER, V30, P819, DOI 10.1177/106002809603000721; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; JOYNSON DHM, 1979, TUBERCLE, V60, P77, DOI 10.1016/0041-3879(79)90039-4; KAPLAN G, 1987, J IMMUNOL, V138, P3028; Keane J, 2000, J IMMUNOL, V164, P2016, DOI 10.4049/jimmunol.164.4.2016; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; KOBAYASHI H, 1994, INFECT IMMUN, V62, P4425, DOI 10.1128/IAI.62.10.4425-4431.1994; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Means TK, 1999, J IMMUNOL, V163, P3920; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; OBRIEN RJ, 1987, AM REV RESPIR DIS, V135, P1007; Pintado V, 1999, EUR J CLIN MICROBIOL, V18, P582, DOI 10.1007/s100960050351; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Riendeau CJ, 2003, INFECT IMMUN, V71, P254, DOI 10.1128/IAI.71.1.254-259.2003; Rojas M, 1997, J IMMUNOL, V159, P1352; Rojas M, 2000, J INFECT DIS, V182, P240, DOI 10.1086/315676; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHARP JK, 1984, CARBOHYD RES, V128, P193, DOI 10.1016/0008-6215(84)85329-X; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; Treumann A, 2002, J MOL BIOL, V316, P89, DOI 10.1006/jmbi.2001.5317; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VENISSE A, 1993, J BIOL CHEM, V268, P12401; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; Vignal C, 2003, J IMMUNOL, V171, P2014, DOI 10.4049/jimmunol.171.4.2014; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; WITZIG RS, 1995, CLIN INFECT DIS, V21, P77, DOI 10.1093/clinids/21.1.77	57	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36637	36651		10.1074/jbc.M305427200	http://dx.doi.org/10.1074/jbc.M305427200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829695	hybrid			2022-12-25	WOS:000185318300095
J	Kelley, WP; Wolters, AM; Sack, JT; Jockusch, RA; Jurchen, JC; Williams, ER; Sweedler, JV; Gilly, WF				Kelley, WP; Wolters, AM; Sack, JT; Jockusch, RA; Jurchen, JC; Williams, ER; Sweedler, JV; Gilly, WF			Characterization of a novel gastropod toxin (6-bromo-2-mercaptotryptamine) that inhibits shaker K channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-CONOTOXIN PVIIA; POTASSIUM CHANNEL; TYRIAN PURPLE; CHARYBDOTOXIN; BLOCK; IDENTIFICATION; INACTIVATION; BROMINATION; TRYPTOPHAN; MECHANISM	A novel potassium channel antagonist has been purified from the defensive mucus secreted by Calliostoma canaliculatum, a marine snail found in the temperate coastal waters of the western Pacific. The toxin is expelled from the hypobranchial gland as part of a defensive response and is contained within a viscous matrix that minimizes dilution and degradation. The active compound was isolated by multistage microbore HPLC separations followed by bioactivity assays. Nuclear magnetic resonance, combined with electrospray ionization Fourier-transform ion cyclotron resonance and electrospray ionization ion trap mass spectrometry indicate that the active component is a heretofore unknown indole-derivative, a disulfide-linked dimer of 6-bromo-2-mercaptotryptamine (BrMT). Exudates from the hypobranchial glands of various marine mollusks have been sources for dye compounds such as 6-6 dibromoindigo, the ancient dye Tyrian purple. BrMT represents the first correlation of a hypobranchial gland exudate with a molecular response. Voltage clamp experiments with a number of K channel subtypes indicate that BrMT inhibits certain voltage-gated K channels of the Kv1 subfamily.	Univ Illinois, Dept Chem, Urbana, IL 61820 USA; Univ Illinois, Beckman Inst, Urbana, IL 61820 USA; Stanford Univ, Dept Biol Sci, Hopkins Marine Stn, Pacific Grove, CA 93950 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Stanford University; University of California System; University of California Berkeley	Sweedler, JV (corresponding author), Univ Illinois, Dept Chem, Urbana, IL 61820 USA.	sweedler@scs.uiuc.edu; lignje@stanford.edu	Williams, Evan/I-3924-2013; Sweedler, Jonathan V/A-9405-2009	Sweedler, Jonathan V/0000-0003-3107-9922	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031609, R01NS017510, R01NS031609] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-17510, NS31609] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Avdonin V, 2001, BIOPHYS J, V81, P97, DOI 10.1016/S0006-3495(01)75683-4; BAKER JT, 1974, ENDEAVOUR, V32, P11; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Brock MW, 2001, J GEN PHYSIOL, V118, P113, DOI 10.1085/jgp.118.1.113; Bryan PJ, 1997, J CHEM ECOL, V23, P645, DOI 10.1023/B:JOEC.0000006401.97339.b9; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; Clark RJH, 1997, J SOC DYERS COLOUR, V113, P316; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; Ellis KC, 2001, BIOCHEMISTRY-US, V40, P5942, DOI 10.1021/bi010173g; England LJ, 1998, SCIENCE, V281, P575, DOI 10.1126/science.281.5376.575; Ferber M, 2003, J BIOL CHEM, V278, P2177, DOI 10.1074/jbc.M205953200; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Gao HF, 1999, TETRAHEDRON, V55, P9717, DOI 10.1016/S0040-4020(99)00553-0; GARCIA AA, 1993, BIOCHIM BIOPHYS ACTA, V1157, P86; Garcia E, 1999, J GEN PHYSIOL, V114, P141, DOI 10.1085/jgp.114.1.141; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1992, J BIOL CHEM, V267, P20971; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Harvey AL, 2001, TOXICON, V39, P15, DOI 10.1016/S0041-0101(00)00162-8; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jockusch RA, 2000, J PHYS CHEM A, V104, P3188, DOI 10.1021/jp993147p; Lanigan MD, 2002, BIOCHEMISTRY-US, V41, P11963, DOI 10.1021/bi026400b; Li-Smerin Y, 2000, J GEN PHYSIOL, V115, P673, DOI 10.1085/jgp.115.6.673; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MORRIS RH, 1980, INTERTIDAL INVERTEBR, P250; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; Peters L, 2002, J NAT PROD, V65, P1633, DOI 10.1021/np0105984; Pretsch E., 1989, TABLES SPECTRAL DATA; Price WD, 1996, ANAL CHEM, V68, P859, DOI 10.1021/ac951038a; RAMASWAMI M, 1990, Molecular and Cellular Neuroscience, V1, P214, DOI 10.1016/1044-7431(90)90004-N; Rosenthal JC, 1996, J GEN PHYSIOL, V108, P207, DOI 10.1085/jgp.108.3.207; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Terlau H, 1999, J GEN PHYSIOL, V114, P125, DOI 10.1085/jgp.114.1.125; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637	45	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34934	34942		10.1074/jbc.M301271200	http://dx.doi.org/10.1074/jbc.M301271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12815055	hybrid			2022-12-25	WOS:000185164400025
J	Spycher, C; Klonis, N; Spielmann, T; Kump, E; Steiger, S; Tilley, L; Beck, HP				Spycher, C; Klonis, N; Spielmann, T; Kump, E; Steiger, S; Tilley, L; Beck, HP			MAHRP-1, a novel Plasmodium falciparum histidine-rich protein, binds ferriprotoporphyrin IX and localizes to the Maurer's clefts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; ERYTHROCYTE-MEMBRANE; INFECTED ERYTHROCYTES; HEME; CYTOADHERENCE; AGGREGATION; CHLOROQUINE; GENE; INHIBITION; SURFACE	Using a stage-specific cDNA library from Plasmodium falciparum we have identified a gene coding for a novel histidine-rich protein (MAHRP-1). The gene is exclusively transcribed during early erythrocyte stages and codes for a small transmembrane protein. The C-terminal region contains a polymorphic stretch of histidine-rich repeats. Fluorescence microscopy studies using polyclonal mouse sera revealed that MAHRP-1 is located at the Maurer's clefts, which represent parasite-induced structures within the cytosol of infected erythrocytes. Biochemical studies showed that recombinant MAHRP-1 binds the toxic hemoglobin degradation product, ferriprotoporphyrin ( FP) with a submicromolar dissociation constant and a stoichiometry determined by the number of DHGH motifs. The bound FP has increased peroxidase-like activity and is 10-fold more susceptible to H2O2-induced degradation compared with unbound FP. These properties of MAHRP-1 suggest it may play a protective role against oxidative stress, and its location at the Maurer's clefts suggests a function in promoting the correct trafficking of exported proteins, such as P. falciparum erythrocyte membrane protein-1.	Swiss Trop Inst, Dept Med Parasitol & Infect Biol, CH-4051 Basel, Switzerland; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia	University of Basel; Swiss Tropical & Public Health Institute; La Trobe University	Beck, HP (corresponding author), Swiss Trop Inst, Dept Med Parasitol & Infect Biol, Socinstr 51, CH-4051 Basel, Switzerland.	Hans-Peter.Beck@unibas.ch	Tilley, Leann/AAU-5281-2020	Spielmann, Tobias/0000-0002-3968-4601; Beck, Hans-Peter/0000-0001-8326-4834; Spycher, Cornelia/0000-0002-7579-9668; Tilley, Leann/0000-0001-9910-0199				Adisa A, 2001, J CELL SCI, V114, P3377; AIKAWA M, 1971, EXP PARASITOL, V30, P284, DOI 10.1016/0014-4894(71)90094-4; Akompong T, 2002, J BIOL CHEM, V277, P28923, DOI 10.1074/jbc.M201968200; Albano F R, 1999, Novartis Found Symp, V226, P157; Blisnick T, 2000, MOL BIOCHEM PARASIT, V111, P107, DOI 10.1016/S0166-6851(00)00301-7; BROWN SB, 1979, BIOCHIM BIOPHYS ACTA, V585, P143, DOI 10.1016/0304-4165(79)90334-9; BROWN SB, 1970, BIOCHEM J, V117, P733, DOI 10.1042/bj1170733; Choi CYH, 1999, BIOCHEMISTRY-US, V38, P16916, DOI 10.1021/bi991665k; CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; CREWTHER PE, 1990, EXP PARASITOL, V70, P193, DOI 10.1016/0014-4894(90)90100-Q; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; GALLAGHER WA, 1973, ANN NY ACAD SCI, V206, P463, DOI 10.1111/j.1749-6632.1973.tb43230.x; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; Giribaldi G, 2001, BRIT J HAEMATOL, V113, P492, DOI 10.1046/j.1365-2141.2001.02707.x; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P149, DOI 10.1016/0166-6851(91)90208-N; HALDAR K, 1991, MOL BIOCHEM PARASIT, V49, P143, DOI 10.1016/0166-6851(91)90137-U; HINTERBERG K, 1994, EXP PARASITOL, V79, P279, DOI 10.1006/expr.1994.1091; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; JOHNSON D, 1994, PARASITOLOGY, V109, P1, DOI 10.1017/S0031182000077696; Kalkanidis M, 2002, BIOCHEM PHARMACOL, V63, P833, DOI 10.1016/S0006-2952(01)00840-1; Kuzelova K, 1997, BBA-GEN SUBJECTS, V1336, P497, DOI 10.1016/S0304-4165(97)00062-7; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LENSTRA R, 1987, BIOCHEM BIOPH RES CO, V146, P368, DOI 10.1016/0006-291X(87)90734-0; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Mashima R, 2002, J BIOL CHEM, V277, P14514, DOI 10.1074/jbc.M109386200; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; SHERMAN IW, 1977, B WORLD HEALTH ORGAN, V55, P265; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Spielmann T, 2003, MOL BIOL CELL, V14, P1529, DOI 10.1091/mbc.E02-04-0240; Spielmann T, 2000, MOL BIOCHEM PARASIT, V111, P453, DOI 10.1016/S0166-6851(00)00333-9; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; Taraschi TF, 2001, INT J PARASITOL, V31, P1381, DOI 10.1016/S0020-7519(01)00256-9; Tilley Leann, 2001, P87; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; TRAYLOR TG, 1995, J AM CHEM SOC, V117, P3468, DOI 10.1021/ja00117a015; van Dooren GG, 2000, PARASITOL TODAY, V16, P421, DOI 10.1016/S0169-4758(00)01792-0; Waller KL, 1999, J BIOL CHEM, V274, P23808, DOI 10.1074/jbc.274.34.23808; Waterkeyn JG, 2000, EMBO J, V19, P2813, DOI 10.1093/emboj/19.12.2813; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Yuan Z, 2002, BIOINFORMATICS, V18, P1109, DOI 10.1093/bioinformatics/18.8.1109; Ziegler J, 2001, CURR MED CHEM, V8, P171, DOI 10.2174/0929867013373840	53	79	79	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35373	35383		10.1074/jbc.M305851200	http://dx.doi.org/10.1074/jbc.M305851200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12815049	hybrid			2022-12-25	WOS:000185164400077
J	Argentaro, A; Sim, H; Kelly, S; Preiss, S; Clayton, A; Jans, DA; Harley, VR				Argentaro, A; Sim, H; Kelly, S; Preiss, S; Clayton, A; Jans, DA; Harley, VR			A SOX9 defect of calmodulin-dependent nuclear import in campomelic dysplasia/autosomal sex reversal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; SRY-RELATED GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; LOCALIZATION SIGNALS; COLLAGEN GENE; PROTEINS; MUTATIONS; DYSPLASIA; TRANSPORT	During mammalian sex determination, SOX9 is translocated into the nuclei of Sertoli cells within the developing XY gonad. The N-terminal nuclear localization signal (NLS) is contained within a SOX consensus calmodulin (CaM) binding region, thereby implicating CaM in nuclear import of SOX9. By fluorescence spectroscopy and glutaraldehyde cross-linking, we show that the SOX9 HMG domain and CaM interact in vitro. The formation of a SOX9.CaM binary complex is calcium-dependent and is accompanied by a conformational change in SOX9. A CaM antagonist, calmidazolium chloride (CDZ), was observed to block CaM recognition of SOX9 in vitro and inhibit both nuclear import and consequent transcriptional activity of SOX9 in treated cells. The significance of the SOX9-CaM interaction was highlighted by analysis of a missense SOX9 mutation, A158T, identified from a XY female with campomelic dysplasia/autosomal sex reversal (CD/SRA). This mutant binds importin beta normally despite defective nuclear import. Fluorescence and quenching studies indicate that in the unbound state, the A158T mutant shows a similar conformation to that of the WT SOX9, but in the presence of CaM, the mutant undergoes unusual conformational changes. Furthermore, SOX9-mediated transcriptional activation by cells expressing the A158T mutant is more sensitive to CDZ than cells expressing WT SOX9. These results suggest first that CaM is involved in the nuclear transport of SOX9 in a process likely to involve direct interaction and second, that CD/SRA can arise, at least in part, from a defect in CaM recognition, ultimately leading to reduced ability of SOX9 to activate transcription of cartilage and testes-forming genes.	Monash Med Ctr, Prince Henrys Inst Med Res, Human Mol Genet Lab, Clayton, Vic 3168, Australia; Univ Melbourne, Dept Anat & Cell Biol, Melbourne, Vic 3010, Australia; Univ Melbourne, Howard Florey Inst, Dept Genet, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, Vic 3168, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Monash University; Prince Henry's Institute of Medical Research; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Monash University; Monash University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Harley, VR (corresponding author), Monash Med Ctr, Prince Henrys Inst Med Res, Human Mol Genet Lab, Level 4 Block E,246 Clayton Rd, Clayton, Vic 3168, Australia.	Vincent.Harley@phimr.monash.edu.au	Harley, Vincent/B-8092-2018	Harley, Vincent/0000-0002-2405-1262; Jans, David/0000-0001-5115-4745				Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 2003, NUCLEIC ACIDS RES, V31, P1541, DOI 10.1093/nar/gkg230; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; ITOH H, 1984, J BIOCHEM-TOKYO, V96, P1721, DOI 10.1093/oxfordjournals.jbchem.a135004; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; McDowall S, 1999, J BIOL CHEM, V274, P24023, DOI 10.1074/jbc.274.34.24023; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; MORIYA M, 1993, CELL TISSUE RES, V271, P441, DOI 10.1007/BF02913726; Moroianu J, 1999, CRIT REV EUKAR GENE, V9, P89, DOI 10.1615/CritRevEukarGeneExpr.v9.i2.10; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; Shen JHC, 2002, MOL ENDOCRINOL, V16, P529, DOI 10.1210/me.16.3.529; SILVER PJ, 1986, BIOCHEM PHARMACOL, V35, P2545, DOI 10.1016/0006-2952(86)90052-3; SMEDLEY M, 1984, EXPERIENTIA, V40, P992, DOI 10.1007/BF01946475; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Trejo R, 1997, MOL REPROD DEV, V48, P127, DOI 10.1002/(SICI)1098-2795(199709)48:1&lt;127::AID-MRD15&gt;3.0.CO;2-Y; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; TUANA BS, 1984, J BIOL CHEM, V259, P6979; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	47	90	95	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33839	33847		10.1074/jbc.M302078200	http://dx.doi.org/10.1074/jbc.M302078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810722	hybrid			2022-12-25	WOS:000185047500029
J	Connolly, KM; Smith, BT; Pilpa, R; Ilangovan, U; Jung, ME; Clubb, RT				Connolly, KM; Smith, BT; Pilpa, R; Ilangovan, U; Jung, ME; Clubb, RT			Sortase from Staphylococcus aureus does not contain a thiolate-imidazolium ion pair in its active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; CYSTEINE PROTEASE INHIBITORS; NUCLEAR-MAGNETIC-RESONANCE; CELL-WALL; SURFACE-PROTEINS; LISTERIA-MONOCYTOGENES; VINYL SULFONES; LPXTG MOTIF; SRTA GENE; IN-VITRO	Many surface proteins are anchored to the cell wall by the action of sortase enzymes, a recently discovered family of cysteine transpeptidases. As the surface proteins of human pathogens are frequently required for virulence, the sortase-mediated anchoring reaction represents a potential target for new anti-infective agents. It has been suggested that the sortase from Staphylococcus aureus (SrtA), may use a similar catalytic strategy as the papain cysteine proteases, holding its Cys(184) side chain in an active configuration through a thiolate-imidazolium ion interaction with residue His(120). To investigate the mechanism of transpeptidation, we have synthesized a peptidyl-vinyl sulfone substrate mimic that irreversibly inhibits SrtA. Through the study of the pH dependence of SrtA inhibition and NMR, we have estimated the pK(a)s of the active site thiol (Cys(184)) and imidazole (His(120)) to be similar to9.4 and 7.0, respectively. These measurements are inconsistent with the existence of a thiolate-imidazolium ion pair and suggest a general base catalysis mechanism during transpeptidation.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy, Inst Genom & Proteom, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Jung, ME (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI/GM52217] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052217] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; BERLINER LJ, 1982, ANAL BIOCHEM, V119, P450, DOI 10.1016/0003-2697(82)90612-1; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Bromme D, 1996, BIOCHEM J, V315, P85; Cossart P, 2000, P NATL ACAD SCI USA, V97, P5013, DOI 10.1073/pnas.97.10.5013; Dawson R.M.C., 1986, DATA BIOCH RES, P131; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; Janulczyk R, 2001, INFECT IMMUN, V69, P4019, DOI 10.1128/IAI.69.6.4019-4026.2001; Jimenez MA, 2003, PROTEIN SCI, V12, P296, DOI 10.1110/ps.0227303; Jonsson IM, 2002, J INFECT DIS, V185, P1417, DOI 10.1086/340503; Khare D, 1997, BIOCHEMISTRY-US, V36, P3580, DOI 10.1021/bi9630927; Krekel F, 2000, BIOCHEMISTRY-US, V39, P12671, DOI 10.1021/bi001310x; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Novick RP, 2000, TRENDS MICROBIOL, V8, P148, DOI 10.1016/S0966-842X(00)01741-8; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; PALMER JT, 1995, CHEM ABSTR 309464A, V123; Pauly TA, 2003, BIOCHEMISTRY-US, V42, P3203, DOI 10.1021/bi027308i; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Pinitglang S, 1997, BIOCHEMISTRY-US, V36, P9968, DOI 10.1021/bi9705974; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; Sarkany Z, 2003, BIOCHEMISTRY-US, V42, P516, DOI 10.1021/bi027004w; Sarkany Z, 2001, BIOCHEMISTRY-US, V40, P10601, DOI 10.1021/bi010550p; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Scott CJ, 2002, BIOCHEM J, V366, P953, DOI 10.1042/BJ20020602; Somoza JR, 2002, J MOL BIOL, V322, P559, DOI 10.1016/S0022-2836(02)00780-5; STORER AC, 1994, METHOD ENZYMOL, V244, P486; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; WHITAKER JR, 1965, J AM CHEM SOC, V87, P2728, DOI 10.1021/ja01090a034; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746	47	66	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34061	34065		10.1074/jbc.M305245200	http://dx.doi.org/10.1074/jbc.M305245200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824164	hybrid			2022-12-25	WOS:000185047500055
J	Olsen, SK; Garbi, M; Zampieri, N; Eliseenkova, AV; Ornitz, DM; Goldfarb, M; Mohammadi, M				Olsen, SK; Garbi, M; Zampieri, N; Eliseenkova, AV; Ornitz, DM; Goldfarb, M; Mohammadi, M			Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR FAMILY; RECEPTOR SPECIFICITY; NERVOUS-SYSTEM; FACTOR (FHF)-4; C-TERMINUS; FACTOR 1B; EXPRESSION; HEPARIN; BINDING	Fibroblast growth factors (FGFs) interact with heparan sulfate glycosaminoglycans and the extracellular domains of FGF cell surface receptors (FGFRs) to trigger receptor activation and biological responses. FGF homologous factors (FHF1-FHF4; also known as FGF11-FGF14) are related to FGFs by substantial sequence homology, yet their only documented interactions are with an intracellular kinase scaffold protein, islet brain-2 (IB2) and with voltage-gated sodium channels. In this report, we show that recombinant FHFs can bind heparin with high affinity like classical FGFs yet fail to activate any of the seven principal FGFRs. Instead, we demonstrate that FHFs bind IB2 directly, furthering the contention that FHFs and FGFs elicit their biological effects by binding to different protein partners. To understand the molecular basis for this differential target binding specificity, we elucidated the crystal structure of FHF1b to 1.7-Angstrom resolution. The FHF1b core domain assumes a beta-trefoil fold consisting of 12 antiparallel beta strands (beta(1) through beta(12)). The FHF1b beta-trefoil core is remarkably similar to that of classical FGFs and exhibits an FGF-characteristic heparin-binding surface as attested to by the number of bound sulfate ions. Using molecular modeling and structure-based mutational analysis, we identified two surface residues, Arg(52) in the beta(4) -beta(5) loop and Val(95) in the beta(9) strand of FHF1b that are required for the interaction of FHF1b with IB2. These two residues are unique to FHFs, and mutations of the corresponding residues of FGF1 to Arg and Val diminish the capacity of FGF1 to activate FGFRs, suggesting that these two FHF residues contribute to the inability of FHFs to activate FGFRs. Hence, FHFs and FGFs bear striking structural similarity but have diverged to direct related surfaces toward interaction with distinct protein targets.	Mt Sinai Sch Med, Brookdale Dept Mol Cellular & Dev Biol, New York, NY 10029 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Icahn School of Medicine at Mount Sinai; New York University; Washington University (WUSTL)	Goldfarb, M (corresponding author), Mt Sinai Sch Med, Brookdale Dept Mol Cellular & Dev Biol, New York, NY 10029 USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Ornitz, David/0000-0003-1592-7629; Olsen, Shaun/0000-0002-1265-7101; Zampieri, Niccolo/0000-0002-2228-9453	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039906] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline; NIDCR NIH HHS [DE13686] Funding Source: Medline; NINDS NIH HHS [R01 NS039906-03, R01 NS039906, NS39906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellosta P, 2001, MOL CELL BIOL, V21, P5946, DOI 10.1128/MCB.21.17.5946-5957.2001; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu CJ, 2003, J BIOL CHEM, V278, P1029, DOI 10.1074/jbc.M207074200; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; Martin G, 2001, BIOESSAYS, V23, P865, DOI 10.1002/bies.1126; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Munoz-Sanjuan I, 1999, DEVELOPMENT, V126, P409; Munoz-Sanjuan I, 2001, DEV DYNAM, V220, P238, DOI 10.1002/1097-0177(20010301)220:3<238::AID-DVDY1104>3.0.CO;2-T; Munoz-Sanjuan I, 2000, MECH DEVELOP, V95, P101, DOI 10.1016/S0925-4773(00)00336-1; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Osslund TD, 1998, PROTEIN SCI, V7, P1681, DOI 10.1002/pro.5560070803; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Plotnikov AN, 2001, J BIOL CHEM, V276, P4322, DOI 10.1074/jbc.M006502200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; van Swieten JC, 2003, AM J HUM GENET, V72, P191, DOI 10.1086/345488; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wang Q, 2002, NEURON, V35, P25, DOI 10.1016/S0896-6273(02)00744-4; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Yamamoto S, 2000, BBA-GENE STRUCT EXPR, V1490, P121, DOI 10.1016/S0167-4781(99)00217-1; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	59	188	217	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34226	34236		10.1074/jbc.M303183200	http://dx.doi.org/10.1074/jbc.M303183200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815063	hybrid			2022-12-25	WOS:000185047500077
J	Dho, SH; Kwon, KS				Dho, SH; Kwon, KS			The ret finger protein induces apoptosis via its RING finger-B box-coiled-coil motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS LIGAND; TRANSFORMING ACTIVITY; CASPASE ACTIVATION; TRIPARTITE MOTIF; TYROSINE KINASE; MAP KINASES; CELL-DEATH; RAR-ALPHA; GENE; PML	The Ret finger protein (RFP) is a member of the tripartite motif family, which is characterized by a conserved RING finger, a B-box, and a coiled- coil domain (together called RBCC). Although RFP is known to become oncogenic when its RBCC moiety is connected to a tyrosine kinase domain by DNA rearrangement, its biological function is not well defined. Here we show that ectopic expression of RFP in human embryonic kidney 293 cells causes extensive apoptosis, as assessed by multiple criteria. RFP expression activates Jun N-terminal kinase and p38 kinase and also increases caspase-3-like activity. However, RFP failed to release cytochrome c and, therefore, to increase caspase-9-like activity. RFP-induced apoptosis could be blocked by the caspase-8 inhibitor crmA and dominant negative ASK1 but not by Bcl-2. These results reveal a novel RFP death pathway that recruits mitogen-activated protein kinase and caspases independently of mitochondrial events. Domain mapping showed that the intact RBCC moiety is necessary for the pro-apoptotic function of RFP. Moreover, expression of the RBCC moiety further potentiated the pro-apoptotic activity and resulted in a 7-fold increase of caspase activation compared with that induced by full-length RFP. This suggests that a large number of tripartite motif family members sharing the RBCC moiety may participate in the control of cell survival.	Korea Res Inst Biosci & Biotechnol, Lab Funct Proteom, Taejon 305333, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kwon, KS (corresponding author), 52 Oun Dong, Taejon 305333, South Korea.			Dho, So Hee/0000-0001-7343-713X				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Avela K, 2000, NAT GENET, V25, P298, DOI 10.1038/77053; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CONSORTIUM TIF, 1997, CELL, V90, P797, DOI DOI 10.1016/S0092-8674(00)80539-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Gibson EM, 2002, J BIOL CHEM, V277, P10573, DOI 10.1074/jbc.M108366200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kapanadze B, 1998, FEBS LETT, V426, P266, DOI 10.1016/S0014-5793(98)00357-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Remboutsika E, 1999, J CELL SCI, V112, P1671; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tong Q, 1997, J BIOL CHEM, V272, P9043; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vanderheyde N, 2001, J IMMUNOL, V167, P3565, DOI 10.4049/jimmunol.167.7.3565; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wei WL, 2002, BRAIN, V125, P2036, DOI 10.1093/brain/awf205; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	52	34	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31902	31908		10.1074/jbc.M304062200	http://dx.doi.org/10.1074/jbc.M304062200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12807881	hybrid			2022-12-25	WOS:000184782100057
J	Hardy, S; El-Assaad, W; Przybytkowski, E; Joly, E; Prentki, M; Langelier, Y				Hardy, S; El-Assaad, W; Przybytkowski, E; Joly, E; Prentki, M; Langelier, Y			Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells - A role for cardiolipin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITATE-INDUCED APOPTOSIS; CARNITINE PALMITOYLTRANSFERASE-I; ACETYL-COA CARBOXYLASE; CYTOCHROME-C RELEASE; PROTEIN-KINASE-B; SERINE PALMITOYLTRANSFERASE; NEONATAL CARDIOMYOCYTES; MITOCHONDRIAL-MEMBRANE; CERAMIDE GENERATION; CASPASE ACTIVATION	Little is known about the biochemical basis of the action of free fatty acids ( FFA) on breast cancer cell proliferation and apoptosis. Here we report that unsaturated FFAs stimulated the proliferation of human MDA-MB-231 breast cancer cells, whereas saturated FFAs inhibited it and caused apoptosis. Saturated FFA palmitate decreased the mitochondrial membrane potential and caused cytochrome c release. Palmitate-induced apoptosis was enhanced by the fat oxidation inhibitor etomoxir, whereas it was reduced by fatty-acyl CoA synthase inhibitor triacsin C. The non-metabolizable analog 2-bromopalmitate was not cytotoxic. This indicates that palmitate must be metabolized to exert its toxic effect but that its action does not involve fat oxidation. Pharmacological studies showed that the action of palmitate is not mediated via ceramides, reactive oxygen species, or changes in phosphatidylinositol 3-kinase activity. Palmitate caused early enhancement of cardiolipin turnover and decreased the levels of this mitochondrial phospholipid, which is necessary for cytochrome c retention. Cosupplementation of oleate, or increasing beta-oxidation with the AMP-activated protein kinase activator, 5-aminoimidazole-4- carboxamide-1-beta-D-ribonucleoside, both restored cardiolipin levels and blocked palmitate-induced apoptosis. Oleate was preferentially metabolized to triglycerides, and oleate cosupplementation channeled palmitate esterification processes to triglycerides. Overexpression of Bcl-2 family members blocked palmitate-induced apoptosis. The results provide evidence that a decrease in cardiolipin levels and altered mitochondrial function are involved in palmitate-induced breast cancer cell death. They also suggest that the antiapoptotic action of oleate on palmitate-induced cell death involves both restoration of cardiolipin levels and redirection of palmitate esterification processes to triglycerides.	Univ Montreal, Ctr Rech, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Langelier, Y (corresponding author), Univ Montreal, Ctr Rech, Ctr Hosp, Hop Notre Dame, Y-5603,1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			El-Assaad, Wissal/0000-0002-4287-2814				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; CHOI SH, 1995, BIOPHYS CHEM, V54, P271, DOI 10.1016/0301-4622(94)00151-9; Choi Y, 2002, BIOCHEM BIOPH RES CO, V294, P785, DOI 10.1016/S0006-291X(02)00554-5; Cifone MG, 1997, P ASSOC AM PHYSICIAN, V109, P146; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; ESKO JD, 1980, J BIOL CHEM, V255, P4474; Fay MP, 1997, CANCER RES, V57, P3979; Furuno T, 2001, BIOCHEM PHARMACOL, V62, P1037, DOI 10.1016/S0006-2952(01)00745-6; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hardy S, 2000, CANCER RES, V60, P6353; Hickson-Bick DLM, 2002, AM J PHYSIOL-HEART C, V282, pH656, DOI 10.1152/ajpheart.00726.2001; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee MM, 2000, ANNU REV NUTR, V20, P221, DOI 10.1146/annurev.nutr.20.1.221; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; McArthur MJ, 1999, J LIPID RES, V40, P1371; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pizer ES, 1996, CANCER RES, V56, P2745; REVOLTELLA RP, 1994, BBA-MOL CELL RES, V1224, P333, DOI 10.1016/0167-4889(94)90265-8; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Rose DP, 1997, AM J CLIN NUTR, V66, P1513; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Soltys CLM, 2002, AM J PHYSIOL-HEART C, V283, pH1056, DOI 10.1152/ajpheart.00275.2002; Sparagna GC, 2000, AM J PHYSIOL-HEART C, V279, pH2124, DOI 10.1152/ajpheart.2000.279.5.H2124; Sparagna GC, 2001, ANTIOXID REDOX SIGN, V3, P71, DOI 10.1089/152308601750100524; Thress K, 1999, J BIOENERG BIOMEMBR, V31, P321, DOI 10.1023/A:1005471701441; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Velasco G, 1998, FEBS LETT, V439, P317, DOI 10.1016/S0014-5793(98)01400-8; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Wright MM, 2002, BIOL RES, V35, P223, DOI 10.4067/S0716-97602002000200014; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	58	215	222	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31861	31870		10.1074/jbc.M300190200	http://dx.doi.org/10.1074/jbc.M300190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805375	hybrid			2022-12-25	WOS:000184782100051
J	Agarwal, AK; Rogers, PD; Baerson, SR; Jacob, MR; Barker, KS; Cleary, JD; Walker, LA; Nagle, DG; Clark, AM				Agarwal, AK; Rogers, PD; Baerson, SR; Jacob, MR; Barker, KS; Cleary, JD; Walker, LA; Nagle, DG; Clark, AM			Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASIVE FUNGAL-INFECTIONS; DNA-DAMAGE RESPONSE; CELL-WALL; GENE-EXPRESSION; STEROL UPTAKE; AMPHOTERICIN-B; DIFFERENTIAL REGULATION; CLINICAL-PHARMACOLOGY; CANDIDA-ALBICANS; STRESS-RESPONSE	Antifungal compounds exert their activity through a variety of mechanisms, some of which are poorly understood. Novel approaches to characterize the mechanism of action of antifungal agents will be of great use in the antifungal drug development process. The aim of the present study was to investigate the changes in the gene expression profile of Saccharomyces cerevisiae following exposure to representatives of the four currently available classes of antifungal agents used in the management of systemic fungal infections. Microarray analysis indicated differential expression of 0.8, 4.1, 3.0, and 2.6% of the genes represented on the Affymetrix S98 yeast gene array in response to ketoconazole, amphotericin B, caspofungin, and 5-fluorocytosine (5-FC), respectively. Quantitative real time reverse transcriptase-PCR was used to confirm the microarray analyses. Genes responsive to ketoconazole, caspofungin, and 5-FC were indicative of the drug-specific effects. Ketoconazole exposure primarily affected genes involved in ergosterol biosynthesis and sterol uptake; caspofungin exposure affected genes involved in cell wall integrity; and 5-FC affected genes involved in DNA and protein synthesis, DNA damage repair, and cell cycle control. In contrast, amphotericin B elicited changes in gene expression reflecting cell stress, membrane reconstruction, transport, phosphate uptake, and cell wall integrity. Genes with the greatest specificity for a particular drug were grouped together as drug-specific genes, whereas genes with a lack of drug specificity were also identified. Taken together, these data shed new light on the mechanisms of action of these classes of antifungal agents and demonstrate the potential utility of gene expression profiling in antifungal drug development.	Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA; Univ Mississippi, Sch Pharm, Dept Pharmacognosy, University, MS 38677 USA; Univ Mississippi, Sch Pharm, Dept Pharmacol, University, MS 38677 USA; Univ Mississippi, Sch Pharm, Pharmaceut Sci Res Inst, University, MS 38677 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharm, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Pediat, Memphis, TN 38163 USA; USDA ARS, Nat Prod Utilizat Res Unit, University, MS 38677 USA; Univ Mississippi, Med Ctr, Dept Clin Pharm, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Practice & Med, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Sch Pharm, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Sch Med, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi; University of Mississippi; University of Mississippi; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; United States Department of Agriculture (USDA); University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Agarwal, AK (corresponding author), Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA.		Agarwal, Ameeta K./H-3935-2019	Nagle, Dale/0000-0001-7883-2673	NIAID NIH HHS [R01 AI27094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramova NE, 2001, GENETICS, V157, P1169; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Barker KS, 2003, J ANTIMICROB CHEMOTH, V51, P1131, DOI 10.1093/jac/dkg217; BARNS SM, 1991, J BACTERIOL, V173, P2250, DOI 10.1128/JB.173.7.2250-2255.1991; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; BOUROT S, 1995, GENE, V165, P97, DOI 10.1016/0378-1119(95)00478-O; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; De Backer MD, 2001, ANTIMICROB AGENTS CH, V45, P1660, DOI 10.1128/AAC.45.6.1660-1670.2001; DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ENGELS WR, 1993, TRENDS BIOCHEM SCI, V18, P448, DOI 10.1016/0968-0004(93)90148-G; GALLIS HA, 1990, REV INFECT DIS, V12, P308; Gasch AP, 2001, MOL BIOL CELL, V12, P2987, DOI 10.1091/mbc.12.10.2987; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Groll AH, 2001, CLIN MICROBIOL INFEC, V7, P8, DOI 10.1111/j.1469-0691.2001.tb00005.x; Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5; Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0; Groll AH, 2001, EXPERT OPIN INV DRUG, V10, P1545, DOI 10.1517/13543784.10.8.1545; Hartsel S, 1996, TRENDS PHARMACOL SCI, V17, P445, DOI 10.1016/S0165-6147(96)01012-7; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; JosephHorne T, 1997, FEMS MICROBIOL LETT, V149, P141, DOI 10.1111/j.1574-6968.1997.tb10321.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; KELLY SL, 1993, BIOCHEM SOC T, V21, P1034, DOI 10.1042/bst0211034; Klepser ME, 1998, ANTIMICROB AGENTS CH, V42, P1207, DOI 10.1128/AAC.42.5.1207; Koerkamp MG, 2002, MOL BIOL CELL, V13, P2783, DOI 10.1091/mbc.E02-02-0075; Kontoyiannis DP, 2002, LANCET, V359, P1135, DOI 10.1016/S0140-6736(02)08162-X; Lee JK, 2001, CLIN CHEM, V47, P1350; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; LEWIS TA, 1985, J BACTERIOL, V163, P199, DOI 10.1128/JB.163.1.199-207.1985; LEWIS TL, 1988, YEAST, V4, P93, DOI 10.1002/yea.320040203; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; LORENZ RT, 1991, LIPIDS, V26, P598, DOI 10.1007/BF02536423; LYMAN CA, 1992, DRUGS, V44, P9, DOI 10.2165/00003495-199244010-00002; MA QF, 1995, ONCOGENE, V10, P487; Mao CG, 2000, METHOD ENZYMOL, V311, P223; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; Mieczkowski PA, 1997, MOL GEN GENET, V253, P655, DOI 10.1007/s004380050369; Morschhauser J, 2002, BBA-MOL BASIS DIS, V1587, P240, DOI 10.1016/S0925-4439(02)00087-X; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Osherov N, 2002, ANTIMICROB AGENTS CH, V46, P2462, DOI 10.1128/AAC.46.8.2462-2469.2002; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; Ponton J, 2000, MED MYCOL, V38, P225, DOI 10.1080/mmy.38.s1.225.236; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; RATTRAY AJ, 1995, GENETICS, V139, P45; Sanglard D, 2002, CURR OPIN MICROBIOL, V5, P379, DOI 10.1016/S1369-5274(02)00344-2; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmidt A, 2002, MOL MICROBIOL, V45, P1433, DOI 10.1046/j.1365-2958.2002.03110.x; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Terashima H, 2000, MOL GEN GENET, V264, P64, DOI 10.1007/s004380000285; The National Committee for Clinical Laboratory Standard, 1997, M27A NCCLS; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Viscoli C, 1999, CLIN INFECT DIS, V28, P1071, DOI 10.1086/514731; Wald A, 1997, J INFECT DIS, V175, P1459, DOI 10.1086/516480; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0; Zhang L, 2002, INT J ANTIMICROB AG, V20, P444, DOI 10.1016/S0924-8579(02)00201-7; Zhang L, 2002, J ANTIMICROB CHEMOTH, V49, P905, DOI 10.1093/jac/dkf001; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	75	111	115	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34998	35015		10.1074/jbc.M306291200	http://dx.doi.org/10.1074/jbc.M306291200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824174	hybrid			2022-12-25	WOS:000185164400033
J	Lafevre-Bernt, MA; Ellerby, LM				Lafevre-Bernt, MA; Ellerby, LM			Kennedy's disease - Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its clevage by caspase-3 and enhances cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCA1 TRANSGENIC MICE; HUNTINGTONS-DISEASE; CLEAVAGE; NEURODEGENERATION; APOPTOSIS; AGGREGATION; ATAXIN-1; PROTEIN; GENE; AKT	X-linked spinal and bulbar muscular atrophy is a degenerative disease affecting motor neurons that is caused by polyglutamine ( polyQ) expansion within the androgen receptor (AR). The polyQ-expanded form of AR is cytotoxic to cells, and proteolytic cleavage enhances cell death. The intracellular signaling pathways activated and/or required for cell death induced by the expanded form of AR (AR112) are unknown. We found that AR regulates mitogen-activated protein kinase ( MAP kinase) pathways and, therefore, hypothesized that these pathway(s) may be required for AR112-induced cell death. The polyQ expansion in AR activates three MAP kinase pathways, causing increasing levels of phosphorylation of p44/42, p38, and SAPK/JNK MAP kinase. Inhibitors of either the JNK or p38 pathways had no effect on AR112-induced cell death, suggesting they are not required for polyQ-induced cell death. Strikingly, the MEK1/2 inhibitor, U0126, which selectively inhibits the p44/42 MAP kinase pathway, reduces AR112-stimulated cell death. The inhibition of the MEK1/2 pathway correlates directly with a change in phosphorylation state of the androgen receptor. Mutation of the MAP kinase consensus phosphorylation site in AR at serine 514 blocked AR-induced cell death and the generation of caspase-3-derived cleavage products. We propose a mechanism by which phosphorylation at serine 514 of AR enhances the ability of caspase-3 to cleave AR and generate cytotoxic polyQ fragments.	Buck Inst Aging Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Ellerby, LM (corresponding author), Buck Inst Aging Res, 8001 Redwood Blvd, Novato, CA 94945 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40251] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel A, 2001, HUM MOL GENET, V10, P107, DOI 10.1093/hmg/10.2.107; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brinkmann AO, 2000, ADV PHARMACOL, V47, P317; BROWN TR, 1988, P NATL ACAD SCI USA, V85, P8151, DOI 10.1073/pnas.85.21.8151; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KYRIAKIS JM, 2000, SCI STKE; LA SA, 1991, NATURE, V352, P77; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lu PJ, 1999, NATURE, V399, P784; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; NUCIFORA FC, 2002, J BIOL CHEM, V2, P2; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; PINSKY L, 1992, CLIN INVEST MED, V15, P456; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sampt ER, 2001, J BIOCHEM BIOPH METH, V48, P219, DOI 10.1016/S0165-022X(01)00136-1; Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Welch WJ, 2001, HUM MOL GENET, V10, P3063, DOI 10.1093/hmg/10.26.3063; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YONG EL, 1994, LANCET, V344, P826, DOI 10.1016/S0140-6736(94)92385-X	44	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34918	34924		10.1074/jbc.M302841200	http://dx.doi.org/10.1074/jbc.M302841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824190	hybrid			2022-12-25	WOS:000185164400023
J	Widberg, CH; Bryant, NJ; Girotti, M; Rea, S; James, DE				Widberg, CH; Bryant, NJ; Girotti, M; Rea, S; James, DE			Tomosyn interacts with the t-SNAREs Syntaxin4 and SNAP23 and plays a role in insulin-stimulated GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GLUCOSE TRANSPORTERS; 3T3-L1 ADIPOCYTES; PROTEIN; COMPLEX; DOCKING; BINDING; FUSION; AQUAPORIN-2; EXOCYTOSIS	The Sec1p-like/Munc18 (SM) protein Munc18a binds to the neuronal t-SNARE Syntaxin1A and inhibits SNARE complex assembly. Tomosyn, a cytosolic Syntaxin1A-binding protein, is thought to regulate the interaction between Syntaxin1A and Munc18a, thus acting as a positive regulator of SNARE assembly. In the present study we have investigated the interaction between b-Tomosyn and the adipocyte SNARE complex involving Syntaxin4/SNAP23/VAMP-2 and the SM protein Munc18c, in vitro, and the potential involvement of Tomosyn in regulating the translocation of GLUT4 containing vesicles, in vivo. Tomosyn formed a high affinity ternary complex with Syntaxin4 and SNAP23 that was competitively inhibited by VAMP-2. Using a yeast two-hybrid assay we demonstrate that the VAMP-2-like domain in Tomosyn facilitates the interaction with Syntaxin4. Overexpression of Tomosyn in 3T3-L1 adipocytes inhibited the translocation of green fluorescent protein-GLUT4 to the plasma membrane. The SM protein Munc18c was shown to interact with the Syntaxin4 monomer, Syntaxin4 containing SNARE complexes, and the Syntaxin4/Tomosyn complex. These data suggest that Tomosyn and Munc18c operate at a similar stage of the Syntaxin4 SNARE assembly cycle, which likely primes Syntaxin4 for entry into the ternary SNARE complex.	Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research	James, DE (corresponding author), Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.	d.james@garvan.org.au	Bryant, Nia/AAS-5637-2021; Rea, Shane/F-4073-2014	James, David/0000-0001-5946-5257; Bryant, Nia Jane/0000-0001-7431-3809				BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Bryant NJ, 2003, J CELL BIOL, V161, P691, DOI 10.1083/jcb.200212078; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; BYRD A, 2000, METH MOL B, V177, P107; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coe JGS, 1999, MOL BIOL CELL, V10, P2407, DOI 10.1091/mbc.10.7.2407; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Grusovin J, 2000, BIOCHEM J, V350, P741, DOI 10.1042/0264-6021:3500741; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Kagami M, 1998, GENETICS, V149, P1717; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MONTANO MM, 2000, METH MOL B, V177, P99; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nichols BJ, 1998, EUR J CELL BIOL, V77, P263, DOI 10.1016/S0171-9335(98)80084-8; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; PENG R, 2002, J CELL BIOL, V6, P6; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Pombo I, 2001, J BIOL CHEM, V276, P42893, DOI 10.1074/jbc.M103527200; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; ROTHMAN JE, 1994, ADV SEC MESS PHOSPH, V29, P81; Scales SJ, 2002, J BIOL CHEM, V277, P28271, DOI 10.1074/jbc.M204929200; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	69	69	76	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35093	35101		10.1074/jbc.M304261200	http://dx.doi.org/10.1074/jbc.M304261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12832401	hybrid			2022-12-25	WOS:000185164400044
J	Yin, L; Li, YQ; Ren, J; Kuwahara, H; Kufe, D				Yin, L; Li, YQ; Ren, J; Kuwahara, H; Kufe, D			Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; REDOX REGULATION; C-ABL; CELLS; DNA; ACTIVATION; GENERATION; CATENIN; DF3; SRC	The DF3/MUC1 transmembrane oncoprotein is aberrantly overexpressed by most human carcinomas. Certain insights are available regarding a role for MUC1 in intracellular signaling; however, no precise function has been ascribed to this molecule. The present results demonstrate that MUC1 expression is up-regulated by oxidative stress and that this response is mediated by activation of MUC1 gene transcription. A role for MUC1 in the oxidative stress response is supported by the demonstration that MUC1 expression is associated with attenuation of endogenous and H2O2-induced intracellular levels of reactive oxygen species (ROS). MUC1-dependent regulation of ROS is mediated at least in part by up-regulation of anti-oxidant enzyme ( superoxide dismutase, catalase, and glutathione peroxidase) expression. In concert with these findings, we show that the apoptotic response to oxidative stress is attenuated by a MUC1-dependent mechanism. These results support a model in which activation of MUC1 by oxidative stress provides a protective function against increased intracellular oxidant levels and ROS-induced apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	Donald_Kufe@DFCI.Harvard.edu			NCI NIH HHS [CA97098, CA98628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA098628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2001, MOL CANCER THER, V1, P43; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	33	131	141	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35458	35464		10.1074/jbc.M301987200	http://dx.doi.org/10.1074/jbc.M301987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826677	hybrid			2022-12-25	WOS:000185164400087
J	Kristof, AS; Marks-Konczalik, J; Billings, E; Moss, J				Kristof, AS; Marks-Konczalik, J; Billings, E; Moss, J			Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C; P70 S6 KINASE; CELL-GROWTH; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; MAXIMAL ACTIVATION; UP-REGULATION; IFN-GAMMA; MTOR	Mammalian target of rapamycin ( mTOR) and phosphatidylinositol 3-kinase (PI3K) regulate cell growth, protein synthesis, and apoptosis in response to nutrients and mitogens. As an important source of nitric oxide during inflammation, human inducible nitric oxide synthase also plays a role in the regulation of cytokine-driven cell proliferation and apoptosis. The role of mTOR and PI3K in the activation of human inducible nitric oxide synthase transcription by cytokines and lipopolysaccharide (LPS) was investigated in lung epithelial adenocarcinoma (A549) cells. LY294002, a dual mTOR and PI3K inhibitor, blocked human inducible nitric oxide synthase (hiNOS) promoter activation and mRNA induction by cytokines and LPS in a PI3K-independent fashion. On gene expression analysis, LY294002 selectively blocked the induction of a subset of 14 LPS/interferon-gamma (IFN-gamma)-induced genes, previously characterized as signal transducer and activator of transcription-1 (STAT1)-dependent. LY294002, but not wortmannin, inhibited LPS/IFN-gamma-dependent STAT1 phosphorylation at Ser-727 and STAT1 activity. Consistent with dual inhibition of mTOR and PI3K by LY294002, dominant-negative mTOR, anti-mTOR small interfering RNA, or rapamycin each inhibited phosphorylation of STAT1 only in the presence of wortmannin. LPS/IFN-gamma led to the formation of a macromolecular complex containing mTOR, STAT1, as well as protein kinase Cdelta, a known STAT1alpha kinase. Thus, LPS and IFN-gamma activate the PI3K and mTOR pathways, which converge to regulate STAT1-dependent transcription of pro-apoptotic and pro-inflammatory genes in a rapamycin-insensitive manner.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Bioinformat Core Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kristof, AS (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, 9000 Rockville Pike,Bldg 10,Rm 5N307, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002541, Z01HL002541] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banan A, 2003, J PHARMACOL EXP THER, V305, P482, DOI 10.1124/jpet.102.047308; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chen CC, 1998, J BIOL CHEM, V273, P19424, DOI 10.1074/jbc.273.31.19424; Chen CC, 1998, J IMMUNOL, V161, P6206; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; GANSTER RW, 2001, P NATL ACAD SCI US; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pacheco-Rodriguez G, 2002, CHEST, V121, p56S, DOI 10.1378/chest.121.3_suppl.56S; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; RHEE SH, 2003, J BIOL CHEM; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Strieter RM, 2002, J CLIN INVEST, V109, P699, DOI 10.1172/JCI200215277; UDDIN S, 2002, J BIOL CHEM; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	47	74	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33637	33644		10.1074/jbc.M301053200	http://dx.doi.org/10.1074/jbc.M301053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807916	hybrid			2022-12-25	WOS:000185047500007
J	Muller-Loennies, S; Lindner, B; Brade, H				Muller-Loennies, S; Lindner, B; Brade, H			Structural analysis of oligosaccharides from lipopolysaccharide (LPS) of Escherichia coli K12 strain W3100 reveals a link between inner and outer core LPS biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI J-5 LIPOPOLYSACCHARIDE; GENUS-SPECIFIC EPITOPE; SALMONELLA-MINNESOTA; CHEMICAL-STRUCTURE; HEXOSE REGION; CELL-SURFACE; LIPID-A; K-12; GENES; POLYSACCHARIDE	Lipopolysaccharide (LPS) from Escherichia coli K12 W3100 is known to contain several glycoforms, and the basic structure has been investigated previously by methylation analyses (Holst, O. ( 1999) in Endotoxin in Health and Disease (Brade, H., Opal, S. M., Vogel, S. N., and Morrison, D., eds) pp. 115 - 154; Marcel Dekker, Inc., New York). In order to reveal dependences of gene activity and LPS structure, we have now determined the composition of de-O-acylated LPS by electrospray ionization-Fourier transform ion cyclotron-mass spectrometry (ESI-FT-MS) and identified 11 different LPS molecules. We have isolated the major glycoforms after de-O- and de-N-acylation and obtained four oligosaccharides that differed in their carbohydrate structure and phosphate substitution. The main oligosaccharide accounted for similar to70% of the total and had a molecular mass of 2516 Da according to ESI-FT-MS. The dodecasaccharide structure ( glycoform I) as determined by NMR was consistent with MS and compositional analysis. One minor oligosaccharide (5%) of the same carbohydrate structure did not contain the 4'-phosphate of the lipid A. Two oligosaccharides contained the same phosphate substitution but differed in their carbohydrate structure, one ( 5%) which contained an additional beta-D-GlcN in 137 linkage on a terminal heptose residue ( glycoform II) which was N-acetylated in LPS. A minor amount of a molecule lacking the terminal L-alpha-D-Hep in the outer core but otherwise identical to the major oligosaccharide ( glycoform III) could only be identified by ESI-FT-MS of the de-O-acylated LPS. The other oligosaccharide (20%) contained an alpha-Kdo-(2-->4)-[alpha-L-Rha-(1-->5)]-alpha-Kdo-( 2-->4)-alpha-Kdo branched tetrasaccharide connected to the lipid A ( glycoform IV). This novel inner core structure was accompanied by a truncation of the outer core in which the terminal disaccharide L-alpha-D-Hep-(1-->6)-alpha-D-Glc was missing. The latter structure was identified for the first time in LPS and revealed that changes in the inner core structure may be accompanied by structural changes in the outer core.	Ctr Med & Biosci, Borstel Res Ctr, D-23845 Borstel, Germany	Forschungszentrum Borstel	Muller-Loennies, S (corresponding author), Ctr Med & Biosci, Borstel Res Ctr, Pk Allee 22, D-23845 Borstel, Germany.		Lindner, Buko/G-9731-2014					AUSTIN EA, 1990, J BACTERIOL, V172, P5312, DOI 10.1128/jb.172.9.5312-5325.1990; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; BRADE L, 1993, INFECT IMMUN, V61, P4514, DOI 10.1128/IAI.61.10.4514-4517.1993; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Frirdich E, 2003, J BACTERIOL, V185, P1659, DOI 10.1128/JB.185.5.1659-1671.2003; HAISHIMA Y, 1992, EUR J BIOCHEM, V203, P127, DOI 10.1111/j.1432-1033.1992.tb19837.x; Heine H, 2003, EUR J BIOCHEM, V270, P440, DOI 10.1046/j.1432-1033.2003.03392.x; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HOLST O, 1990, CARBOHYD RES, V204, P93, DOI 10.1016/0008-6215(90)84024-O; HOLST O, 1990, CARBOHYD RES, V207, P327, DOI 10.1016/0008-6215(90)84060-8; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KLENA JD, 1992, J BACTERIOL, V174, P7297, DOI 10.1128/jb.174.22.7297-7307.1992; KLENA JD, 1992, J BACTERIOL, V174, P4746, DOI 10.1128/JB.174.14.4746-4752.1992; Kramer RA, 2002, EUR J BIOCHEM, V269, P1746, DOI 10.1046/j.1432-1327.2002.02820.x; MAKELA HP, 1984, HDB ENDOTOXIN, P59; MAYER H, 1976, EUR J BIOCHEM, V66, P357, DOI 10.1111/j.1432-1033.1976.tb10525.x; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; Muller-Loennies S, 2002, J ENDOTOXIN RES, V8, P295, DOI 10.1179/096805102125000506; Muller-Loennies S, 1999, EUR J BIOCHEM, V260, P235, DOI 10.1046/j.1432-1327.1999.00134.x; MULLERLOENNIES S, 1994, EUR J BIOCHEM, V224, P751, DOI 10.1111/j.1432-1033.1994.t01-1-00751.x; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PRADEL E, 1992, J BACTERIOL, V174, P4736, DOI 10.1128/JB.174.14.4736-4745.1992; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Redl H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P795; SCHMIDT G, 1973, Journal of General Microbiology, V77, P151; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Suffredini AF, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P817; Vaara M, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P31; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	37	54	60	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34090	34101		10.1074/jbc.M303985200	http://dx.doi.org/10.1074/jbc.M303985200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819207	hybrid			2022-12-25	WOS:000185047500060
J	Popova, JS; Rasenick, MM				Popova, JS; Rasenick, MM			G beta gamma mediates the interplay between tubulin dimers and microtubules in the modulation of G(q) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC CHOLINERGIC RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; NEURO-BLASTOMA CELLS; PHOSPHOLIPASE C-BETA(1); G-PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMERIZATION DYNAMICS; MEMBRANE ASSOCIATION; ADENYLYL-CYCLASE; PLASMA-MEMBRANE	Agonist stimulation causes tubulin association with the plasma membrane and activation of PLCbeta1 through direct interaction with, and transactivation of, Galpha(q). Here we demonstrate that Gbetagamma interaction with tubulin downregulates this signaling pathway. Purified Gbetagamma, alone or with phosphatidylinositol 4,5-bisphosphate (PIP2), inhibited carbachol-evoked membrane recruitment of tubulin and Galpha(q) transactivation by tubulin. Polymerization of microtubules elicited by Gbetagamma overrode tubulin translocation to the membrane in response to carbachol stimulation. Gbetagamma sequestration of tubulin reduced the inhibition of PLCbeta1 observed at high tubulin concentration. Gbeta(1)gamma(2) interacted preferentially with tubulin-GDP, whereas Galpha(q) was transactivated by tubulin-GTP. Prenylation of the gamma(2) polypeptide was required for Gbetagamma/tubulin interaction. Both confocal microscopy and coimmunoprecipitation studies revealed the spatiotemporal pattern of Gbetagamma/ tubulin interaction during carbachol stimulation of neuroblastoma SK-N-SH cells. In resting cells Gbetagamma localized predominantly at the cell membrane, whereas tubulin was found in well defined microtubules in the cytosol. Within 2 min of agonist exposure, a subset of tubulin translocated to the plasma membrane and colocalized with Gbeta. Fifteen min post-carbachol addition, tubulin and Gbeta colocalized in vesicle-like structures in the cytosol. Gbeta/tubulin colocalization increased after pretreatment of cells with the microtubule-depolymerizing agent, colchicine, and was inhibited by taxol. Taxol also inhibited carbachol-induced PIP2 hydrolysis. It is suggested that Gbetagamma/ tubulin interaction mediates internalization of membrane-associated tubulin at the offset of PLCbeta1 signaling. Newly cytosolic Gbetagamma/tubulin complexes might promote microtubule polymerization attenuating further tubulin association with the plasma membrane. Thus G protein-coupled receptors might evoke Galpha and Gbetagamma to orchestrate regulation of phospholipase signaling by tubulin dimers and control of cell shape by microtubules.	Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rasenick, MM (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.				NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN RK, 1982, J NEUROCHEM, V38, P94, DOI 10.1111/j.1471-4159.1982.tb10858.x; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen NF, 2003, J BIOL CHEM, V278, P15285, DOI 10.1074/jbc.M300841200; Ciruela F, 2001, J NEUROCHEM, V76, P750, DOI 10.1046/j.1471-4159.2001.00099.x; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; FISHER SK, 1987, MOL PHARMACOL, V32, P81; FISHER SK, 1988, J NEUROCHEM, V50, P984, DOI 10.1111/j.1471-4159.1988.tb03008.x; FISHER SK, 1988, MOL PHARMACOL, V33, P414; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hamill DR, 1998, J BIOL CHEM, V273, P9285, DOI 10.1074/jbc.273.15.9285; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LI QW, 1994, J BIOL CHEM, V269, P31777; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; PARKER EM, 1991, J BIOL CHEM, V266, P519; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POPOVA JS, 1995, J NEUROCHEM, V64, P130; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; PUSZKIN S, 1989, J NEUROCHEM, V53, P51, DOI 10.1111/j.1471-4159.1989.tb07294.x; RASENICK MM, 1994, METHOD ENZYMOL, V237, P100; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SILVA WI, 1986, J BIOL CHEM, V261, P4788; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Tucker C, 1997, J BIOL CHEM, V272, P9481; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Yan K, 1996, J NEUROCHEM, V66, P1489	61	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34299	34308		10.1074/jbc.M301748200	http://dx.doi.org/10.1074/jbc.M301748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807915	hybrid			2022-12-25	WOS:000185047500086
J	Rodriguez-Hernandez, CJ; Sanchez-Perez, I; Gil-Mascarell, R; Rodriguez-Afonso, A; Torres, A; Perona, R; Murguia, JR				Rodriguez-Hernandez, CJ; Sanchez-Perez, I; Gil-Mascarell, R; Rodriguez-Afonso, A; Torres, A; Perona, R; Murguia, JR			The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR EIF2B; TRANSFER-RNA BINDING; OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; MAP KINASE; OSMOTIC-STRESS; PROTEIN-KINASE; TRYPTOPHAN PERMEASE; GENE-EXPRESSION; TRANSLATIONAL REGULATION	The immunosuppressant Tacrolimus (FK506) has increased the survival rates of organ transplantation. FK506 exerts its immunosuppressive effect by inhibition of the protein phosphatase calcineurin in activated T-cells. Unfortunately, FK506 therapy is associated with undesired non-therapeutic effects involving targets other than calcineurin. To identify these targets we have addressed FK506 cellular toxicity in budding yeast. We show that FK506 increased cell sensitivity upon osmotic challenge independently of calcineurin and the FK506-binding proteins Fpr1p, -2p, -3p, and -4p. FK506 also induced strong amino acid starvation and activation of the general control (GCN) pathway. Tryptophan prototrophy or excess tryptophan overcame FK506 toxicity, showing that tryptophan deprivation mediated this effect. Mutation of the GCN3 and -4 genes partially alleviated FK506 toxicity, suggesting that activation of the GCN pathway by FK506 was also involved in osmotic tolerance. FK506 enhanced osmotic stress-dependent Hog1p kinase phosphorylation that was not accompanied by induction of a Hog1p-dependent reporter. Interestingly, deletion of the GCN2 gene suppressed FK506-dependent Hog1p hyperphosphorylation and restored Hog1p-dependent reporter activity. Conversely, deletion of the HOG1 gene impaired FK506-dependent activation of Gcn2p kinase and translation of a GCN4-LacZ reporter, highlighting functional cross-talk between the Gcn2p and Hog1p protein kinases. Taken together, these data demonstrate that both FK506-induced amino acid starvation and activation of the GCN pathway contribute to cell sensitivity to osmotic stress and reveal a positive regulatory loop between the Hog1p and Gcn2p pathways. Given the conserved nature of Gcn2p and Hog1p pathways, this mechanism of FK506 toxicity could be relevant to the non-therapeutic effects of FK506 therapy.	Hosp Univ Canarias, Res Unit, San Cristobal la Laguna 38320, Spain; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Universidad de la Laguna; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Murguia, JR (corresponding author), Hosp Univ Canarias, Res Unit, Ofra S-N La Cuesta, San Cristobal la Laguna 38320, Spain.	jmurguia@hecit.es	Sánchez-Pérez, Isabel/R-4107-2016; Murguia, Jose R./H-4419-2015	Sánchez-Pérez, Isabel/0000-0002-4829-201X; Murguia, Jose R./0000-0001-9364-4603; Torres, Armando/0000-0003-1121-5173; Rodriguez-Hernandez, Carlos J/0000-0002-5867-3182				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Abe F, 2000, MOL CELL BIOL, V20, P8093, DOI 10.1128/MCB.20.21.8093-8102.2000; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Ashe MP, 2001, EMBO J, V20, P6464, DOI 10.1093/emboj/20.22.6464; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHEN XH, 1994, MOL GEN GENET, V244, P260, DOI 10.1007/BF00285453; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dumont FJ, 2000, CURR MED CHEM, V7, P731, DOI 10.2174/0929867003374723; EBERHARDT I, 1995, CURR GENET, V27, P306, DOI 10.1007/BF00352097; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Garcia-Barrio M, 2002, J BIOL CHEM, V277, P30675, DOI 10.1074/jbc.M203187200; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kultz D, 1998, J EXP BIOL, V201, P3015; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; Mager WH, 2002, FEMS YEAST RES, V2, P251, DOI 10.1016/S1567-1356(02)00116-2; Marbach I, 2001, J BIOL CHEM, V276, P16944, DOI 10.1074/jbc.M100383200; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Matthews DJ, 2001, DRUG DISCOV TODAY, V6, P141, DOI 10.1016/S1359-6446(00)01612-3; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Palmer LK, 2002, GENETICS, V161, P563; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Pinson B, 1998, NUCLEIC ACIDS RES, V26, P3977, DOI 10.1093/nar/26.17.3977; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; PRINZ W, 2003, ANAL BIOCHEM, V315, P289; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 1999, MOL CELL BIOL, V19, P5474; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SINGH A, 1974, GENETICS, V77, P651; SINGH A, 1974, GENETICS, V77, P661; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Uesono Y, 2002, J BIOL CHEM, V277, P13848, DOI 10.1074/jbc.M108848200; van Duijnhoven EM, 2001, J AM SOC NEPHROL, V12, P583, DOI 10.1681/ASN.V123583; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; Vanrenterghem YFC, 1999, CURR OPIN NEPHROL HY, V8, P669, DOI 10.1097/00041552-199911000-00003; Weir MR, 1999, AM J KIDNEY DIS, V34, P1, DOI 10.1016/S0272-6386(99)70101-0; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang WM, 1996, MOL CELL BIOL, V16, P6603	63	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33887	33895		10.1074/jbc.M305220200	http://dx.doi.org/10.1074/jbc.M305220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813040	hybrid			2022-12-25	WOS:000185047500034
J	Saridakis, V; Pai, EF				Saridakis, V; Pai, EF			Mutational, structural, and kinetic studies of the ATP-binding site of Methanobacterium thermoautotrophicum nicotinamide mononucleotide adenylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NMN ADENYLYLTRANSFERASE; TRANSFER RNA-SYNTHETASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-SOLFATARICUS; DIRECTED MUTAGENESIS; BACILLUS-SUBTILIS; NUCLEAR ENZYME; KEY ENZYME	Several residues lining the ATP-binding site of Methanobacterium thermoautotrophicum nicotinamide mononucleotide adenylyltransferase (NMNATase) were mutated in an effort to better characterize their roles in substrate binding and catalysis. Residues selected were Arg-11 and Arg-136, both of which had previously been implicated as substrate binding residues, as well as His-16 and His-19, part of the HXGH active site motif and postulated to be of importance in catalysis. Kinetic studies revealed that both Arg-11 and Arg-136 contributed to the binding of the substrate, ATP. When these amino acids were replaced by lysines, the apparent K-m values of the respective mutants for ATP decreased by factors of 1.3 and 2.9 and by factors of 1.9 and 8.8 when the same residues were changed to alanines. All four Arg mutants displayed unaltered K-m values for NMN. The apparent k(cat) values of the R11K and R136K mutants were the same as those of WT NMNATase but the apparent k(cat) values of the alanine mutants had decreased. Crystal structures of the Arg mutants revealed NAD(+) and SO42- molecules trapped at their active sites. The binding interactions of NAD(+) were unchanged but the binding of SO42- was altered in these mutants compared with wild type. The alanine mutants at positions His-16 and His-19 retained similar to6 and 1.3%, respectively, of WT NMNATase activity indicating that His-19 is a key catalytic group. Surprisingly, this H19A mutant displayed a novel and distinct mode of NAD(+) binding when co-crystallized in the presence of NAD(+) and SO42-.	Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto	Pai, EF (corresponding author), Univ Hlth Network, Ontario Canc Inst, Div Mol & Struct Biol, Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Pai, Emil F/D-2526-2013; Pai, Emil/R-8908-2019	Pai, Emil/0000-0002-1162-7242	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cleland W W, 1979, Methods Enzymol, V63, P103; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; DAHMEN W, 1967, ARCH BIOCHEM BIOPHYS, V120, P440, DOI 10.1016/0003-9861(67)90262-7; Deyrup AT, 1999, J BIOL CHEM, V274, P28929, DOI 10.1074/jbc.274.41.28929; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Haldane JBS, 1930, ENZYMES; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNBERG A, 1948, J BIOL CHEM, V176, P1475; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mehl RA, 2000, J BACTERIOL, V182, P4372, DOI 10.1128/JB.182.15.4372-4374.2000; MERRIT EA, 1991, ACTA CRYSTALLOGR D, V50, P869; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; RAFFAELLI N, 1994, FEBS LETT, V355, P233, DOI 10.1016/0014-5793(94)01195-8; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, MOL CELL BIOCHEM, V193, P99, DOI 10.1023/A:1006968328186; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; Raffaelli N, 2001, METHOD ENZYMOL, V331, P292; Raffaelli N, 2001, METHOD ENZYMOL, V331, P281; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Ullrich TC, 2001, EMBO J, V20, P316, DOI 10.1093/emboj/20.3.316; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Zhang H, 2002, STRUCTURE, V10, P69, DOI 10.1016/S0969-2126(01)00693-1; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200; [No title captured]	43	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34356	34363		10.1074/jbc.M205369200	http://dx.doi.org/10.1074/jbc.M205369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810729	hybrid			2022-12-25	WOS:000185047500092
J	Stefanidakis, M; Bjorklund, M; Ihanus, E; Gahmberg, CG; Koivunen, E				Stefanidakis, M; Bjorklund, M; Ihanus, E; Gahmberg, CG; Koivunen, E			Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta(2) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CATION-BINDING; GELATINASE-B; I DOMAIN; ALPHA(M)BETA(2); MATRIX; LIGAND; RECOGNITION; MAC-1; SITE	The alpha(M)beta(2) integrin of leukocytes can bind a variety of ligands. We screened phage display libraries to isolate peptides that bind to the alpha(M) I domain, the principal ligand binding site of the integrin. Only one peptide motif, (D/E)(D/E)(G/L)W, was obtained with this approach despite the known ligand binding promiscuity of the I domain. Interestingly, such negatively charged sequences are present in many known beta(2) integrin ligands also in the catalytic domain of matrix metalloproteinases (MMPs). We show that purified beta(2) integrins bind to pro-MMP-2 and pro-MMP-9 gelatinases and that that the negatively charged sequence of the MMP catalytic domain is an active beta(2) integrin-binding site. Furthermore, a synthetic DDGW-containing phage display peptide inhibited the ability of beta(2) integrin to bind progelatinases but did not inhibit the binding of cell adhesion-mediating substrates such as intercellular adhesion molecule-1, fibrinogen, or an LLG-containing peptide. Immunoprecipitation and cell surface labeling demonstrated complexes of pro-MMP-9 with both the alpha(M)beta(2) and alpha(L)beta(2) integrins in leukocytes, and pro-MMP-9 colocalized with alpha(M)beta(2) in cell surface protrusions. The DDGW peptide and the gelatinase-specific inhibitor peptide CTTHWGFTLC blocked beta(2) integrin-dependent leukocyte migration in a transwell assay. These results suggest that leukocytes may move in a progelatinase-beta(2) integrin complex-dependent manner.	Univ Helsinki, Dept Biosci, Div Biochem, FIN-0014 Helsinki, Finland	University of Helsinki	Koivunen, E (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikinkaari 5, FIN-0014 Helsinki, Finland.	erkki.koivunen@helsinki.fi	Bjørklund, Geir/B-7319-2014; Björklund, Mikael/D-3362-2009; Bjorklund, Mikael/AAA-2894-2020; Gahmberg, Carl/AAE-1876-2019	Bjørklund, Geir/0000-0003-2632-3935; Björklund, Mikael/0000-0002-2176-681X; Gahmberg, Carl/0000-0001-9892-9296; Koivunen, Erkki/0000-0002-6443-9595				Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Bjorklund M, 2003, COMB CHEM HIGH T SCR, V6, P29; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; COLOMBATTI A, 1991, BLOOD, V77, P2305; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; Galt SW, 2001, CIRC RES, V89, P509, DOI 10.1161/hh1801.096339; Griggs DW, 1998, J BIOL CHEM, V273, P22113, DOI 10.1074/jbc.273.34.22113; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Heiskanen T, 1999, VIROLOGY, V262, P321, DOI 10.1006/viro.1999.9930; Johansson MW, 1997, J CELL SCI, V110, P1133; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Kraft S, 1999, J BIOL CHEM, V274, P1979, DOI 10.1074/jbc.274.4.1979; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; LI R, 1993, J BIOL CHEM, V268, P17513; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER JL, 1982, BLOOD, V60, P790; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Schneider H, 1998, FEBS LETT, V429, P269, DOI 10.1016/S0014-5793(98)00612-7; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Tian L, 1997, J IMMUNOL, V158, P928; Tian L, 2000, EUR J IMMUNOL, V30, P810, DOI 10.1002/1521-4141(200003)30:3<810::AID-IMMU810>3.3.CO;2-O; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WANG C, 1989, LEUKEMIA, V3, P699; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Yakubenko VP, 2002, J BIOL CHEM, V277, P48635, DOI 10.1074/jbc.M208877200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h	55	54	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34674	34684		10.1074/jbc.M302288200	http://dx.doi.org/10.1074/jbc.M302288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824186	hybrid			2022-12-25	WOS:000185047500135
J	Wang, WW; Sineshchekov, OA; Spudich, EN; Spudich, JL				Wang, WW; Sineshchekov, OA; Spudich, EN; Spudich, JL			Spectroscopic and photochemical characterization of a deep ocean proteorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY RHODOPSIN-II; PROTON TRANSPORT; REACTION CYCLE; SCHIFF-BASE; BACTERIORHODOPSIN; PHOTOTAXIS; COUNTERION; PHOTOTROPHY; TRANSDUCER; LIGHT	A second group of proteorhodopsin-encoding genes (blue-absorbing proteorhodopsin, BPR) differing by 20-30% in predicted primary structure from the first-discovered green-absorbing (GPR) group has been detected in picoplankton from Hawaiian deep sea water. Here we compare BPR and GPR absorption spectra, photochemical reactions, and proton transport activity. The photochemical reaction cycle of Hawaiian deep ocean BPR in cells is 10-fold slower than that of GPR with very low accumulation of a deprotonated Schiff base intermediate in cells and exhibits mechanistic differences, some of which are due to its glutamine residue rather than leucine at position 105. In contrast to GPR and other characterized microbial rhodopsins, spectral titrations of BPR indicate that a second titratable group, in addition to the retinylidene Schiff base counterion Asp-97, modulates the absorption spectrum near neutral pH. Mutant analysis confirms that Asp-97 and Glu-108 are proton acceptor and proton donor, respectively, in retinylidene Schiff base proton transfer reactions during the BPR photocycle as previously shown for GPR, but BPR contains an alternative acceptor evident in its D97N mutant, possibly the same as the second titratable group modulating the absorption spectrum. BPR, similar to GPR, carries out outward light-driven proton transport in Escherichia coli vesicles but with a reduced translocation rate attributable to its slower photocycle. In energized E. coli cells at physiological pH, the net effect of BPR photocycling is to generate proton currents dominated by a triggered proton influx, rather than efflux as observed with GPR-containing cells. Reversal of the proton current with the K+-ionophore valinomycin supports that the influx is because of voltage-gated channels in the E. coli cell membrane. These observations demonstrate diversity in photochemistry and mechanism among proteorhodopsins. Calculations of photon fluence rates at different ocean depths show that the difference in photocycle rates between GPR and BPR as well as their different absorption maxima may be explained as an adaptation to the different light intensities available in their respective marine environments. Finally, the results raise the possibility of regulatory (i.e. sensory) rather than energy harvesting functions of some members of the proteorhodopsin family.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Spudich, JL (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, MSB 6-130,6431 Fannin St, Houston, TX 77030 USA.			, weiwu/0000-0001-6922-9207	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM27750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASHOV SP, 1995, BIOCHEMISTRY-US, V34, P8820, DOI 10.1021/bi00027a034; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; Chen XP, 2002, BIOCHEMISTRY-US, V41, P3891, DOI 10.1021/bi015966h; Dioumaev AK, 2003, BIOCHEMISTRY-US, V42, P6582, DOI 10.1021/bi034253r; Dioumaev AK, 2002, BIOCHEMISTRY-US, V41, P5348, DOI 10.1021/bi025563x; Friedrich T, 2002, J MOL BIOL, V321, P821, DOI 10.1016/S0022-2836(02)00696-4; HELGERSON SL, 1985, ARCH BIOCHEM BIOPHYS, V241, P616, DOI 10.1016/0003-9861(85)90588-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JERLOV NG, 1976, MARINE OPTICS, P231; Krebs Richard A, 2002, BMC Physiol, V2, P5, DOI 10.1186/1472-6793-2-5; Lakatos M, 2003, BIOPHYS J, V84, P3252, DOI 10.1016/S0006-3495(03)70049-6; Man DL, 2003, EMBO J, V22, P1725, DOI 10.1093/emboj/cdg183; OLSON KD, 1995, P NATL ACAD SCI USA, V92, P3185, DOI 10.1073/pnas.92.8.3185; OTTOLENGHI M, 1989, J MEMBRANE BIOL, V112, P193, DOI 10.1007/BF01870951; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; Sudo Y, 2001, BIOPHYS J, V80, P916, DOI 10.1016/S0006-3495(01)76070-5; TAKAHASHI T, 1990, BIOCHEMISTRY-US, V29, P8467, DOI 10.1021/bi00488a038; YAN B, 1995, J BIOL CHEM, V270, P29668; Zhu JY, 1997, PHOTOCHEM PHOTOBIOL, V66, P788, DOI 10.1111/j.1751-1097.1997.tb03225.x	26	131	137	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33985	33991		10.1074/jbc.M305716200	http://dx.doi.org/10.1074/jbc.M305716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821661	hybrid			2022-12-25	WOS:000185047500046
J	Komuro, A; Nagai, M; Navin, NE; Sudol, M				Komuro, A; Nagai, M; Navin, NE; Sudol, M			WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; RECEPTOR; LOCALIZATION; ISOFORM; FE65; CLEAVAGE; BINDS	The ErbB-4 receptor protein-tyrosine kinase is proteolytically processed by membrane proteases in response to the ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation resulting in the cytoplasmic fragment translocating to the cell nucleus. The WW domain-containing co-transcriptional activator Yes-associated protein ( YAP) associates physically with the full-length ErbB-4 receptor and functionally with the ErbB-4 cytoplasmic fragment in the nucleus. The YAP . ErbB4 complex is mediated by the first WW domain of YAP and the most carboxyl-terminal PPXY motif of ErbB-4. In human tissues, we documented the expression of YAP1 with a single WW domain and YAP2 with two WW domains. It is known that the COOH-terminal fragment of ErbB4 does not have transcriptional activity by itself; however, we show here that in the presence of YAP its transcriptional activity is revealed. There is a difference in the extent of transactivation activity among YAP isoforms: YAP2 is the stronger activator compared with YAP1. This transactivation is abolished by mutations that abrogate the YAP . ErbB4 complex formation. The unphosphorylatable mutation that increases the nuclear localization of YAP increases transcription activity. The COOH-terminal fragment of ErbB-4 and full-length YAP2 overexpressed in cells partially co-localize to the nucleus. Our data indicate that YAP is a potential signaling partner of the full-length ErbB4 receptor at the membrane and of the COOH-terminal fragment of ErbB-4 that translocates to the nucleus to regulate transcription.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.	Marius.Sudol@mssm.edu			NIAMS NIH HHS [AR45626] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045626] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Heldin CH, 2001, SCIENCE, V294, P2111, DOI 10.1126/science.1067628; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	41	369	383	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33334	33341		10.1074/jbc.M305597200	http://dx.doi.org/10.1074/jbc.M305597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807903	hybrid			2022-12-25	WOS:000184901800104
J	Reed, RC; Berwin, B; Baker, JP; Nicchitta, CV				Reed, RC; Berwin, B; Baker, JP; Nicchitta, CV			GRP94/gp96 elicits ERK activation in murine macrophages - A role for endotoxin contamination in NF-kappa B activation and nitric oxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NUCLEOTIDE-BINDING DOMAIN; GP96 INDUCES MATURATION; HSP90 CHAPERONE GRP94; INNATE IMMUNE-SYSTEM; DENDRITIC CELLS; PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; BACTERIAL LIPOPOLYSACCHARIDE; LIGAND INTERACTIONS	Vaccination of mice with GRP94/gp96, the endoplasmic reticulum Hsp90, elicits a variety of immune responses sufficient for tumor rejection and the suppression of metastatic tumor progression. Macrophages are a prominent GRP94/gp96 target, with GRP94/gp96 reported to activate macrophage NF-kappaB signaling and nitric oxide production, as well as the MAP kinase p38, JNK, and ERK signaling cascades. However, recent studies report that heat shock protein elicited macrophage activation is due, in large part, to contaminating endotoxin. To examine the generality of this finding, we have investigated the role of endotoxin in GRP94/gp96 elicited macrophage activation. We report that GRP94/ gp96 binds endotoxin in a high-affinity, saturable, and specific manner. Low endotoxin calreticulin and GRP94/ gp96 were purified, the latter using a novel method of depyrogenation; this resulted in GRP94/ gp96 and calreticulin preparations with endotoxin levels substantially lower than those of previously reported preparations. Low endotoxin GRP94/ gp96 retained its native conformation, ligand binding activity, and in vitro chaperone function, yet did not activate macrophage NF-kappaB signaling, nitric oxide production or inducible nitric-oxide synthase production. Low endotoxin GRP94/ gp96 and calreticulin did, however, elicit a marked increase in ERK phosphorylation at protein concentrations as low as 2 mug/ml. These results are discussed with respect to current understanding of the contributions of endotoxin and heat shock/chaperone proteins to the stimulation of innate immune responses.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	c.nicchitta@cellbio.duke.edu		Berwin, Brent/0000-0001-9196-3256	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anton LC, 1998, J IMMUNOL, V160, P4859; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Barouch R, 2001, J LEUKOCYTE BIOL, V69, P1019; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Caudill MM, 2001, EXPERT OPIN BIOL TH, V1, P539, DOI 10.1517/14712598.1.3.539; Chen W, 1999, J IMMUNOL, V162, P3212; Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1; DUBOIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P7669, DOI 10.1073/pnas.79.24.7669; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; GIROT P, 1990, J CHROMATOGR, V510, P213, DOI 10.1016/S0021-9673(01)93755-0; Janetzki S, 2000, INT J CANCER, V88, P232, DOI 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KARPLUS TE, 1987, J IMMUNOL METHODS, V105, P211, DOI 10.1016/0022-1759(87)90268-7; Kuppner MC, 2001, EUR J IMMUNOL, V31, P1602, DOI 10.1002/1521-4141(200105)31:5<1602::AID-IMMU1602>3.0.CO;2-W; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MONKS SA, 2003, AM ASS CANC RES ANN, V44, P2854; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; Nair S, 1999, J IMMUNOL, V162, P6426; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; Puig-Kroger A, 2001, BLOOD, V98, P2175, DOI 10.1182/blood.V98.7.2175; Reed RC, 2002, J BIOL CHEM, V277, P25082, DOI 10.1074/jbc.M203195200; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; Strbo N, 2003, IMMUNITY, V18, P381, DOI 10.1016/S1074-7613(03)00056-6; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wright JR, 1999, AM J PHYSIOL-LUNG C, V276, pL650, DOI 10.1152/ajplung.1999.276.4.L650; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamazaki K, 1999, J IMMUNOL, V163, P5178; Yanagawa Y, 2002, J LEUKOCYTE BIOL, V71, P125	55	87	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31853	31860		10.1074/jbc.M305480200	http://dx.doi.org/10.1074/jbc.M305480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805368	hybrid			2022-12-25	WOS:000184782100050
J	Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Feng, XH				Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Feng, XH			SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; TGF-BETA; DEPENDENT DEGRADATION; UBIQUITIN LIGASE; PORE COMPLEX; SUMO; TRANSCRIPTION; SUMOYLATION; ACTIVATORS; P15(INK4B)	Tumor suppressor Smad4/DPC4 is a central intracellular signal transducer for transforming growth factor-beta (TGF-beta) signaling. We recently reported that transcriptional potential of Smad4 was regulated by SUMOylation in transfected HeLa cells (1), but the precise mechanism and function of Smad4 SUMOylation in TGF-beta signaling remain to be elucidated. Here, we describe the regulation of TGF-beta signaling by SUMOylation through the control of Smad4 metabolic stability and subcellular localization. We found that SUMO-1 overexpression strongly increases Smad4 levels, while inhibition of SUMOylation by small interfering RNA (siRNA)-mediated knockdown of the E2 enzyme Ubc9 reduces endogenous Smad4 levels. Concomitantly, SUMO-1 overexpression enhances and Ubc9 knockdown reduces levels of intranuclear Smad4, growth inhibitory response, as well as transcriptional responses to TGF-beta. Comparison of wild type and mutant forms of Smad4 for SUMOylation, ubiquitination, and half-life allows the conclusion that SUMO-1 modification serves to protect Smad4 from ubiquitin-dependent degradation and consequently enhances the growth inhibitory and transcriptional responses of Smad4.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Rm 137D, Houston, TX 77030 USA.				NIGMS NIH HHS [R01GM63773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 2001, J CELL SCI, V114, P4359; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	33	150	161	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31043	31048		10.1074/jbc.C300112200	http://dx.doi.org/10.1074/jbc.C300112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12813045	hybrid			2022-12-25	WOS:000184658800080
J	Park, KJ; Choi, SH; Choi, DH; Park, JM; Yie, SW; Lee, SY; Hwang, SB				Park, KJ; Choi, SH; Choi, DH; Park, JM; Yie, SW; Lee, SY; Hwang, SB			1 Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; NONSTRUCTURAL 5A PROTEIN; FACTOR-ALPHA; INDUCED APOPTOSIS; TNF RECEPTOR-1; CELL-DEATH; HEPATOCELLULAR-CARCINOMA; SIGNAL-TRANSDUCTION; NON-A; TRAF2	The nonstructural 5A (NS5A) protein of hepatitis C virus (HCV) is a phosphoprotein possessing various functions. We have previously reported that the HCV NS5A protein interacts with tumor necrosis factor (TNF) receptor-associated factor (TRAF) domain of TRAF2 (Park, K.-J., Choi, S.-H., Lee, S. Y., Hwang, S. B., and Lai, M. M. C. (2002) J. Biol. Chem. 277, 13122-13128). Both TNF-alpha- and TRAF2-mediated nuclear factor-kappaB (NF-kappaB) activations were inhibited by NS5A-TRAF2 interaction. Because TRAF2 is required for the activation of both NF-kappaB and c-Jun N-terminal kinase (JNK), we investigated HCV NS5A protein for its potential capacity to modulate TRAF2-mediated JNK activity. Using in vitro kinase assay, we have found that NS5A protein synergistically activated both TNF-alpha- and TRAF2-medidated JNK in human embryonic kidney 293T cells. Furthermore, synergism of NS5A-mediated JNK activation was inhibited by dominant-negative form of MEK kinase 1. Our in vivo binding data show that NS5A does not inhibit interaction between TNF receptor-associated death domain and TRAF2 protein, indicating that NS5A and TRAF2 may form a ternary complex with TNF receptor-associated death domain. These results indicate that HCV NS5A protein modulates TNF signaling of the host cells and may play a role in HCV pathogenesis.	Hallym Univ, Ilsong Inst Life Sci, Chunchon 200702, South Korea; Kangweon Natl Univ, Dept Microbiol, Chunchon 200701, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling, Seoul 120750, South Korea	Hallym University; Kangwon National University; Ewha Womans University; Ewha Womans University	Hwang, SB (corresponding author), Hallym Univ, Ilsong Inst Life Sci, 1 Ockcheon Dong, Chunchon 200702, South Korea.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIBISCEGLIE AM, 1994, J CLIN GASTROENTEROL, V19, P222, DOI 10.1097/00004836-199410000-00011; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Park KJ, 2001, VIRUS RES, V74, P89, DOI 10.1016/S0168-1702(00)00251-3; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SHIMOTOHNO K, 1993, SEMIN VIROL, V4, P305, DOI 10.1006/smvy.1993.1027; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	49	53	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30711	30718		10.1074/jbc.M209623200	http://dx.doi.org/10.1074/jbc.M209623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12796506	hybrid			2022-12-25	WOS:000184658800037
J	de Vries, S; Strampraad, MJF; Lu, S; Moenne-Loccoz, P; Schroder, I				de Vries, S; Strampraad, MJF; Lu, S; Moenne-Loccoz, P; Schroder, I			Purification and characterization of the MQH(2): NO oxidoreductase from the hyperthermophilic archaeon Pyrobaculum aerophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; CYTOCHROME-C-OXIDASE; NITRATE REDUCTION; ACTIVE-SITE; BC COMPLEX; RESONANCE; PROTON; RESOLUTION; MECHANISM; PATHWAYS	The membrane-bound NO reductase from the hyperthermophilic denitrifying archaeon Pyrobaculum aerophilum was purified to homogeneity. The enzyme displays MQH(2): NO oxidoreductase (qNOR) activity, consists of a single subunit, and contains heme and nonheme iron in a 2: 1 ratio. The combined results of EPR, resonance Raman, and UV-visible spectroscopy show that one of the hemes is bis-His-coordinated low spin (g(z) = 3.015; g(y) = 2.226; g(x) = 1.45), whereas the other heme adopts a high spin configuration. The enzyme also contains one nonheme iron center, which in the oxidized enzyme is antiferromagnetically coupled to the high spin heme. This binuclear high spin heme/nonheme iron center is EPR-silent and the site of NO reduction. The reduced high spin heme is bound to a neutral histidine and can bind CO to form of a low spin complex. The oxidized high spin heme binds NO, yielding a ferric nitrosyl complex, the intermediate causing the commonly found substrate inhibition in NO reductases (K-i( NO) = 7 muM). The qNOR as present in the membrane is, in contrast to the purified enzyme, quite thermostable, incubation at 100 degreesC for 86 min leading to 50% inhibition. The pure enzyme lacks heme b and instead contains stoichiometric amounts of hemes O-p1 and O-p2, ethenylgeranylgeranyl and hydroxyethylgeranylgeranyl derivatives of heme b, respectively. The archaeal qNOR is the first example of a NO reductase, which contains modified hemes reminiscent of cytochrome bo(3) and aa(3) oxidases. This report is the first describing the purification and structural and spectroscopic properties of a thermostable NO reductase.	Delft Univ Technol, Kluyver Lab Biotechnol, NL-2628 BC Delft, Netherlands; Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	Delft University of Technology; Oregon Health & Science University; University of California System; University of California Los Angeles	de Vries, S (corresponding author), Delft Univ Technol, Kluyver Lab Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	S.deVries@tnw.tudelft.nl		MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NIGMS NIH HHS [GM-18865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Afshar S, 2001, J BACTERIOL, V183, P5491, DOI 10.1128/JB.183.19.5491-5495.2001; Afshar S, 1998, APPL ENVIRON MICROB, V64, P3004; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; Busch A, 2002, APPL ENVIRON MICROB, V68, P668, DOI 10.1128/AEM.68.2.668-672.2002; Castresana J, 1999, J MOL EVOL, V49, P453, DOI 10.1007/PL00006568; Cramm R, 1999, FEBS LETT, V460, P6, DOI 10.1016/S0014-5793(99)01315-0; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; de Vries S, 2002, BIOCHEM SOC T, V30, P662, DOI 10.1042/bst0300662; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; Hendriks J, 1998, J BIOENERG BIOMEMBR, V30, P15, DOI 10.1023/A:1020547225398; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Hendriks J, 2000, BBA-BIOENERGETICS, V1459, P266, DOI 10.1016/S0005-2728(00)00161-4; Hendriks JHM, 2002, BIOCHEMISTRY-US, V41, P2331, DOI 10.1021/bi0121050; Householder TC, 2000, INFECT IMMUN, V68, P5241, DOI 10.1128/IAI.68.9.5241-5246.2000; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Ju TD, 2000, INORG CHIM ACTA, V297, P362, DOI 10.1016/S0020-1693(99)00404-1; KASTRAU DHW, 1994, EUR J BIOCHEM, V222, P293, DOI 10.1111/j.1432-1033.1994.tb18868.x; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; Michel H, 1999, NATURE, V402, P602, DOI 10.1038/45133; Moenne-Loccoz P, 2000, J AM CHEM SOC, V122, P9344, DOI 10.1021/ja0016295; Moenne-Loccoz P, 1998, J AM CHEM SOC, V120, P5147, DOI 10.1021/ja973671e; NEUGEBAUER JM, 1990, METHOD ENZYMOL, V182, P239; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; Pinakoulaki E, 2002, J BIOL CHEM, V277, P23407, DOI 10.1074/jbc.M201913200; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Sakurai T, 1998, BIOCHEM BIOPH RES CO, V251, P248, DOI 10.1006/bbrc.1998.9451; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Suharti, 2001, BIOCHEMISTRY-US, V40, P2632, DOI 10.1021/bi0020067; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; VONWACHENFELDT C, 1994, FEBS LETT, V340, P109, DOI 10.1016/0014-5793(94)80182-7; Vorholt JA, 1997, ARCH MICROBIOL, V167, P19, DOI 10.1007/s002030050411; Wasser IM, 2002, CHEM REV, V102, P1201, DOI 10.1021/cr0006627; WERBER MM, 1978, ARCH BIOCHEM BIOPHYS, V186, P60, DOI 10.1016/0003-9861(78)90463-0; Wikstrom M, 2000, BBA-BIOENERGETICS, V1458, P188, DOI 10.1016/S0005-2728(00)00068-2; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	52	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35861	35868		10.1074/jbc.M300857200	http://dx.doi.org/10.1074/jbc.M300857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12799376	hybrid			2022-12-25	WOS:000185318300002
J	Yang, L; Yan, D; Yan, C; Du, H				Yang, L; Yan, D; Yan, C; Du, H			Peroxisome proliferator-activated receptor gamma and ligands inhibit surfactant protein B gene expression in the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID TRANSCRIPTION FACTOR-1; APOPTOSIS; ENHANCER; ADIPOGENESIS; REGULATOR; DISEASE; REGION; TISSUE; ALPHA; CELLS	Pulmonary nonciliated bronchiolar epithelial cells (Clara cells) and alveolar type II (AT II) epithelial cells are responsible for surfactant synthesis and secretion. These cells are highly lipogenic with a high lipid turnover rate. Although only 10% of surfactant lipids are neutral lipids, they play very important roles in maintaining pulmonary surfactant homeostasis. Many metabolic intermediate products of neutral lipids serve as ligands for various nuclear receptors that bind to target genes to influence gene transcription. In this report, the functional role of the neutral lipid metabolites, 15-deoxy-Delta(12,14)- prostaglandin J(2) and 9-hydroxyoctadecanoic acids, and peroxisome proliferator-activated receptor gamma was evaluated in surfactant protein B gene regulation. These reagents down-regulated surfactant protein B gene expression in respiratory epithelial cells at the transcriptional level in both cell line and whole lung explant systems. The studies support the concept that surfactant protein B homeostasis is influenced by neutral lipid metabolites in the lung.	Childrens Hosp, Med Ctr, Div Human Genet, TCHRF, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Grad Program Mol & Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Du, H (corresponding author), Childrens Hosp, Med Ctr, Div Human Genet, TCHRF, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Hong.Du@cchmc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061803, R01HL067862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054930] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061803, HL61803, R01 HL067862] Funding Source: Medline; NIDDK NIH HHS [DK54930] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V268, pL381; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Du H, 1996, J LIPID RES, V37, P937; Glass CK, 2000, GENE DEV, V14, P121; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schlezinger JJ, 2002, J IMMUNOL, V169, P6831, DOI 10.4049/jimmunol.169.12.6831; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; YAN C, 1990, J BIOL CHEM, V265, P20188; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Yang L, 2003, ENDOCRINOLOGY, V144, P3004, DOI 10.1210/en.2002-0121; Yang L, 2003, AM J PHYSIOL-LUNG C, V284, pL481, DOI 10.1152/ajplung.00280.2002	28	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36841	36847		10.1074/jbc.M304156200	http://dx.doi.org/10.1074/jbc.M304156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12829715	hybrid			2022-12-25	WOS:000185318300117
J	Buchanan, FG; Wang, DZ; Bargiacchi, F; DuBois, RN				Buchanan, FG; Wang, DZ; Bargiacchi, F; DuBois, RN			Prostaglandin E-2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NECROSIS-FACTOR-ALPHA; COLON-CANCER CELLS; LYSOPHOSPHATIDIC ACID; COLORECTAL-CANCER; CARCINOMA CELLS; EGF RECEPTOR; ASPIRIN USE; CYCLOOXYGENASE-2; TRANSACTIVATION	Over the past decade cyclooxygenase-2-derived prostaglandins have been implicated in the development and progression of many types of cancer. Recently our laboratory has shown that treatment with prostaglandin E-2 (PGE(2)) induces increased proliferation, migration, and invasiveness of colorectal carcinoma cells ( Sheng, H., Shao, J., Washington, M. K., and DuBois, R. N. (2001) J. Biol. Chem. 276, 18075 - 18081). The stimulatory effects of PGE2 were dependent upon the activation of the phosphatidylinositol 3-kinase/Akt pathway. However, the exact signaling cascade responsible for phosphatidylinositol 3-kinase/Akt activation by PGE2 remains poorly defined. In the present study, we demonstrate that the PGE(2)-induced migration and invasion occurs via rapid transactivation and phosphorylation of the epidermal growth factor receptor ( EGFR). Within minutes following treatment, PGE2 induces the activation of Akt. This effect was completely abolished by EGFR-specific tyrosine kinase inhibitors providing evidence for the role of the EGFR in this response. The rapid transactivation of the EGFR occurs via an intracellular Src-mediated event but not through the release of an extracellular epidermal growth factor-like ligand. EGFR transactivation was also observed in vivo by the direct comparison of normal and malignant human colorectal samples. These results suggest that in developing colonic carcinomas, the early effects of cyclooxygenase-2- derived PGE2 are in part mediated by the EGFR, and this transactivation is responsible for subsequent downstream effects including the stimulation of cell migration and invasion.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Genentech Inc, San Francisco, CA 94080 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NCI NIH HHS [P01CA-77839, P30CA-68485] Funding Source: Medline; NIDDK NIH HHS [DK 47297, DK 62112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297, R01DK047297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CARPENTER G, 2000, SCI STKE; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daniel TO, 1999, CANCER RES, V59, P4574; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2002, CANCER RES, V62, P6329; Gupta RA, 2003, CANCER RES, V63, P906; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; THUN MJ, 1993, CANCER RES, V53, P1322; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vacca F, 2000, CANCER RES, V60, P5310; Williams CS, 2001, NEOPLASIA, V3, P428, DOI 10.1038/sj.neo.7900177; Williams CS, 1996, AM J PHYSIOL, V270, P393; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Xia MH, 1996, J IMMUNOL, V156, P160	38	392	409	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35451	35457		10.1074/jbc.M302474200	http://dx.doi.org/10.1074/jbc.M302474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824187	hybrid			2022-12-25	WOS:000185164400086
J	Halevi, S; Yassin, L; Eshel, M; Sala, F; Sala, S; Criado, M; Treinin, M				Halevi, S; Yassin, L; Eshel, M; Sala, F; Sala, S; Criado, M; Treinin, M			Conservation within the RIC-3 gene family - Effectors of mammalian nicotinic acetylcholine receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-7 SUBUNIT; IDENTIFICATION; LOCALIZATION; PERSPECTIVE; BINDING	In Caenorhabditis elegans, the ric-3 gene is required for the maturation of multiple nicotinic acetylcholine receptors (nAChRs), whereas other neurotransmittergated channels expressed within the same cells are unaffected by the presence of RIC-3. Here we show that RIC-3 is a member of a conserved gene family with representatives in both vertebrates and invertebrates. All members of this family have two transmembrane domains followed by a coiled-coil domain. Expression of the human ric-3 homolog, hric3, like the C. elegans ric-3, enhances C. elegans DEG-3/DES-2, rat alpha7, and human alpha7 nAChR-dependent whole-cell current amplitudes in Xenopus leavis oocytes, thus demonstrating functional conservation. However, hric3 also reduces human alpha4beta2 and alpha3beta4 nAChR- dependent whole-cell current amplitudes. Thus, hric3 shows differential effects on human nAChRs unlike the observed uniform effect of ric-3 on C. elegans nAChRs. Moreover, hric3 totally abolished currents evoked by 5-HT3 serotonin receptors, whereas it barely modified alpha1 glycine receptor currents. With this caveat, RIC-3 belongs to a conserved family of genes likely to regulate nAChR- mediated transmission throughout evolution. Analysis of transcripts encoded by the hric3 locus shows that it encodes for multiple transcripts, likely to produce multiple hric3 isoforms, and that hric3 is expressed in neurons and muscles, thus enabling its interactions with nAChRs in vivo.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante 03550, Spain	Hebrew University of Jerusalem; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Treinin, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel.		Criado, Manuel/K-5109-2014; Sala, Salvador/L-7104-2014	Criado, Manuel/0000-0002-3953-0346; Sala, Salvador/0000-0002-5607-0097; Sala, Francisco/0000-0002-2080-7683				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Clementi F, 2000, EUR J PHARMACOL, V393, P3, DOI 10.1016/S0014-2999(00)00066-2; Cooper ST, 1997, J NEUROCHEM, V68, P2140; DELTORO ED, 1994, J COMP NEUROL, V349, P325, DOI 10.1002/cne.903490302; GARCIAGUZMAN M, 1994, BIOCHEMISTRY-US, V33, P15198, DOI 10.1021/bi00254a031; Grauso M, 2002, GENETICS, V160, P1519; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Mallya M, 2002, GENOMICS, V80, P113, DOI 10.1006/geno.2002.6794; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; Nelson ME, 1999, J PHYSIOL-LONDON, V516, P657, DOI 10.1111/j.1469-7793.1999.0657u.x; Sharma G, 2002, J NEUROBIOL, V53, P524, DOI 10.1002/neu.10114; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sweileh W, 2000, MOL BRAIN RES, V75, P293, DOI 10.1016/S0169-328X(99)00302-2; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Yassin L, 2001, MOL CELL NEUROSCI, V17, P589, DOI 10.1006/mcne.2000.0944	22	139	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34411	34417		10.1074/jbc.M300170200	http://dx.doi.org/10.1074/jbc.M300170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821669	hybrid			2022-12-25	WOS:000185047500099
J	Marcadier, JL; Pearson, CE				Marcadier, JL; Pearson, CE			Fidelity of primate cell repair of a double-strand break within a (CTG)center dot(CAG) tract - Effect of slipped DNA structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; SPINOCEREBELLAR ATAXIA TYPE-1; CAG TRINUCLEOTIDE REPEAT; MACHADO-JOSEPH-DISEASE; MYOTONIC-DYSTROPHY; PLASMID DNA; SOMATIC MOSAICISM; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RECOMBINATION	At least 15 human diseases are caused by the instability of gene-specific (CTG).(CAG) repeats. The precise mechanism of instability remains unknown, though bacterial and yeast models have suggested a role for aberrant repair of double-strand breaks (DSBs). Using an established primate DSB repair system, we have investigated the fidelity of repair of a DSB within a (CTG).(CAG) repeat tract. DSB repair substrates were generated from plasmids that are stably replicated in their circular form, permitting us to highlight the effects of DSB repair on repeat stability and minimize the contribution of replication. DSBs were introduced into repeat-containing plasmids using a unique BsmI site, such that the entire repeat tract comprised one free end of the linearized plasmid. Substrates containing 17, 47, and 79 repeats, in either their linear duplex form or containing slipped structures (out-of-register inter-strand mispairings at repeat sequences), were transiently transfected into primate cells. Linearized plasmids with repeats were repaired with mildly reduced efficiency, while the presence of slipped structures considerably reduced repair efficiency. The repaired products were characterized for alterations within the repeat tract and flanking sequence. DSB repair induced predominantly repeat deletions. Notably, a polarized/directional deletion effect was observed, in that the repetitive end of the DSB was preferentially removed. This phenomenon was dramatically enhanced when slipped structures were present within the repeat tract, providing the first evidence for error-prone processing of slipped-strand structures. These results suggest the existence of primate nuclease activities that are specific for (CTG).(CAG) repeats and the structures they form.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5A 1X8, Canada; Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Pearson, CE (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5A 1X8, Canada.			Pearson, Christopher/0000-0001-9545-4205				Aoki M, 1996, CLIN GENET, V50, P199; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; BOHENZKY RA, 1988, VIROLOGY, V166, P316, DOI 10.1016/0042-6822(88)90502-8; BRUNNER HG, 1993, NEW ENGL J MED, V328, P476, DOI 10.1056/NEJM199302183280705; Cervantes RB, 2002, CURR OPIN CELL BIOL, V14, P351, DOI 10.1016/S0955-0674(02)00325-3; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; Cleary JD, 2002, NAT GENET, V31, P37, DOI 10.1038/ng870; CLEARY JD, IN PRESS CYTOGENET G; CONLEY EC, 1984, MOL GEN GENET, V194, P211, DOI 10.1007/BF00383519; CONLEY EC, 1986, NUCLEIC ACIDS RES, V14, P8919; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Flores MJ, 2001, EMBO J, V20, P619, DOI 10.1093/emboj/20.3.619; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GANESH A, 1993, MUTAT RES, V299, P251, DOI 10.1016/0165-1218(93)90101-I; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hashida H, 1997, ANN NEUROL, V41, P505, DOI 10.1002/ana.410410414; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Ishii S, 1996, HUM GENET, V98, P138, DOI 10.1007/s004390050176; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; Panigrahi GB, 2002, J BIOL CHEM, V277, P13926, DOI 10.1074/jbc.M109761200; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Pearson CE, 2002, NUCLEIC ACIDS RES, V30, P4534, DOI 10.1093/nar/gkf572; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Pelletier R, 2003, MOL CELL BIOL, V23, P1349, DOI 10.1128/MCB.23.4.1349-1357.2003; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; ROYCHOUDHURY R, 1979, NUCLEIC ACIDS RES, V6, P1323, DOI 10.1093/nar/6.4.1323; RUNGER TM, 1989, EMBO J, V8, P1419, DOI 10.1002/j.1460-2075.1989.tb03523.x; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; Takano H, 1996, AM J HUM GENET, V58, P1212; Tanaka F, 1996, J NEUROL SCI, V135, P43, DOI 10.1016/0022-510X(95)00249-2; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; THORNTON CA, 1994, ANN NEUROL, V35, P104, DOI 10.1002/ana.410350116	46	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33848	33856		10.1074/jbc.M304284200	http://dx.doi.org/10.1074/jbc.M304284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807901	hybrid			2022-12-25	WOS:000185047500030
J	McLaughlin, JP; Xu, M; Mackie, K; Chavkin, C				McLaughlin, JP; Xu, M; Mackie, K; Chavkin, C			Phosphorylation of a carboxyl-terminal serine within the kappa-opioid receptor produces desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC OPIATE TREATMENT; RAT SPINAL-CORD; BETA-ARRESTIN; AGONIST; RESENSITIZATION; MECHANISM; KINASE; CELLS; DYNAMIN; TRAFFICKING	G-protein receptor kinase and beta-arrestin mediated desensitization of the rat kappa-opioid receptor (KOR) was previously shown using Xenopus oocyte expression to require serine 369 within the C terminus of KOR. To define the effects of phosphorylation of this residue in desensitization and internalization processes in mammalian expression systems, wild-type KOR-green fluorescent protein (KOR-GFP) and KOR(S369A)-GFP were stably expressed in AtT-20 and HEK293 cells. Using whole-cell patch clamp recording in transfected AtT-20 cells, agonist activation of either kappa receptor form produced equivalent activation of the intrinsic G-protein-gated inwardly rectifying potassium channel. Incubation for 60 min with the kappa agonist U50,488 ( 100 nM) desensitized the response in cells expressing wild-type KOR-GFP by 86% but had no effect on KOR( S369A)-GFP-expressing cells. Phosphorylation of serine 369 was detected using a phosphospecific antibody (KOR-P) able to distinguish the phosphorylated form of the receptor. The agonist-induced increase in KOR-P labeling was dose-dependent, blocked by co-treatment with the kappa antagonist norbinaltorphimine, and prevented by co-expression of the dominant negative form of the G-protein receptor kinase, GRK2(K220R). In contrast, agonist-induced increase in KOR-P labeling was not evident in KOR( S369A) expressing cells. Prolonged activation resulted in receptor internalization that was also blocked by KOR( S369A) substitution, but interestingly, KOR-P labeling was evident at lower agonist concentrations than required to induce internalization. Following the removal of agonist, receptor dephosphorylation detected by loss of KOR-P labeling was complete within 60 min, could be blocked by okadaic acid, and was not blocked by sucrose inhibition of receptor internalization. These results demonstrate that GRK-mediated phosphorylation of serine 369 mediates rat KOR desensitization and internalization.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Chavkin, Charles/G-2797-2010	Mackie, Ken/0000-0001-8501-6199; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011672, T32DA007278, R37DA011672] Funding Source: NIH RePORTER; NIDA NIH HHS [R37 DA011672, R01 DA11672, T32 DA07278] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ATTALI B, 1989, J NEUROCHEM, V52, P360, DOI 10.1111/j.1471-4159.1989.tb09130.x; ATTALI B, 1990, BRAIN RES, V517, P182, DOI 10.1016/0006-8993(90)91024-B; Befort K, 1996, MOL PHARMACOL, V49, P216; Bennett VJ, 2002, J PHARMACOL EXP THER, V303, P1155, DOI 10.1124/jpet.102.040378; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Coutts AA, 2001, J NEUROSCI, V21, P2425; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; Drake CT, 1996, J COMP NEUROL, V370, P377; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gutstein HB, 2001, GOODMAN GILMANS PHAR, P569; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Jordan BA, 2000, DNA CELL BIOL, V19, P19, DOI 10.1089/104454900314672; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; KONG GH, 1994, J BIOL CHEM, V269, P13084; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LAW PY, 1982, MOL PHARMACOL, V22, P1; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang FQ, 2002, J PHARMACOL EXP THER, V302, P1184, DOI 10.1124/jpet.302.3.1184; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	34	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34631	34640		10.1074/jbc.M304022200	http://dx.doi.org/10.1074/jbc.M304022200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815037	hybrid			2022-12-25	WOS:000185047500124
J	Opal, P; Garcia, JJ; Propst, F; Matilla, A; Orr, HT; Zoghbi, HY				Opal, P; Garcia, JJ; Propst, F; Matilla, A; Orr, HT; Zoghbi, HY			Mapmodulin/leucine-rich acidic nuclear protein binds the light chain of microtubule-associated protein 1B and modulates neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE KINASE 3-BETA; MESSENGER-RNAS; NERVOUS-SYSTEM; CELL-DIFFERENTIATION; NEUROBLASTOMA-CELLS; DEVELOPING BRAIN; GRANZYME-A; RAT-BRAIN; MAP1B; GENE	We had previously described the leucine-rich acidic nuclear protein ( LANP) as a candidate mediator of toxicity in the polyglutamine disease, spinocerebellar ataxia type 1 (SCA1). This was based on the observation that LANP binds ataxin-1, the protein involved in this disease, in a glutamine repeat-dependent manner. Furthermore, LANP is expressed abundantly in purkinje cells, the primary site of ataxin-1 pathology. Here we focused our efforts on understanding the neuronal properties of LANP. In undifferentiated neuronal cells LANP is predominantly a nuclear protein, requiring a bona fide nuclear localization signal to be imported into the nucleus. LANP translocates from the nucleus to the cytoplasm during the process of neuritogenesis, interacts with the light chain of the microtubule-associated protein 1B (MAP1B), and modulates the effects of MAP1B on neurite extension. LANP thus could play a key role in neuronal development and/or neurodegeneration by its interactions with microtubule associated proteins.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Vienna, Inst Biochem & Mol Cell Biol, Vienna Bioctr, A-1030 Vienna, Austria; UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Vienna; Vienna Biocenter (VBC); University of London; University College London; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Opal, P (corresponding author), Northwestern Univ, Feinberg Sch Med, Davee Dept Neurol, Ward Ward 10-332,303 E Chicago Ave, Chicago, IL 60611 USA.	p-opal@northwestern.edu	MATILLA-DUEÑAS, ANTONI/C-7980-2011	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Orr, Harry/0000-0001-6118-741X; Zoghbi, Huda/0000-0002-0700-3349	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027699, K08NS002246] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS27699-13, K08 NS02246-03] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; Carlock L, 1996, MOL BRAIN RES, V42, P202, DOI 10.1016/S0169-328X(96)00115-5; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; De Girolamo LA, 2000, J NEUROCHEM, V75, P133, DOI 10.1046/j.1471-4159.2000.0750133.x; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; Ding JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055; DiTella MC, 1996, J CELL SCI, V109, P467; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Goold RG, 2001, J CELL SCI, V114, P4273; Goold RG, 1999, J CELL SCI, V112, P3373; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; Hummel T, 2000, NEURON, V26, P357, DOI 10.1016/S0896-6273(00)81169-1; Itin C, 1999, MOL BIOL CELL, V10, P2191, DOI 10.1091/mbc.10.7.2191; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 2001, BREAST CANCER RES TR, V68, P65, DOI 10.1023/A:1017919507109; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LEWIS SA, 1986, J CELL BIOL, V102, P2106, DOI 10.1083/jcb.102.6.2106; Lucas FR, 1998, J CELL SCI, V111, P1351; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Matsubae M, 2000, FEBS LETT, V468, P171, DOI 10.1016/S0014-5793(00)01218-7; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mei X, 2000, J NEUROSCI RES, V62, P56, DOI 10.1002/1097-4547(20001001)62:1<56::AID-JNR6>3.0.CO;2-#; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; Mutai H, 2000, BIOCHEM BIOPH RES CO, V274, P427, DOI 10.1006/bbrc.2000.3133; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; RIEDERER B, 1986, J NEUROCYTOL, V15, P763, DOI 10.1007/BF01625193; Roos J, 2000, NEURON, V26, P371, DOI 10.1016/S0896-6273(00)81170-8; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; SWANSON JA, 1992, J CELL SCI, V103, P201; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; TAKEMURA R, 1992, J CELL SCI, V103, P953; Togel M, 1999, FEBS LETT, V451, P15, DOI 10.1016/S0014-5793(99)00523-2; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Uchida Y, 2003, J BIOL CHEM, V278, P366, DOI 10.1074/jbc.M210091200; Ulitzur N, 1997, J BIOL CHEM, V272, P30577, DOI 10.1074/jbc.272.48.30577; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; WICHE G, 1991, INT REV CYTOL, V124, P217; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; ZAUNER W, 1992, EUR J CELL BIOL, V57, P66; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	70	53	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34691	34699		10.1074/jbc.M302785200	http://dx.doi.org/10.1074/jbc.M302785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807913	hybrid			2022-12-25	WOS:000185047500130
J	Tanaka, M; Machida, Y; Nishikawa, Y; Akagi, T; Hashikawa, T; Fujisawa, T; Nukina, N				Tanaka, M; Machida, Y; Nishikawa, Y; Akagi, T; Hashikawa, T; Fujisawa, T; Nukina, N			Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; X-RAY-DIFFRACTION; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; IN-VITRO; FIBRIL FORMATION; FIBRILLOGENESIS; SCATTERING; MODEL; PROTOFIBRILS	We examined the effects of the expansion of glutamine repeats on the early stage of protein fibrillization. Small-angle x-ray scattering (SAXS) and electron microscopic studies revealed that the elongation of polyglutamine from 35 to 50 repeats in protein induced a large assembly of the protein upon incubation at 37 degreesC and that its formation was completed in similar to 3 h. A bead modeling procedure based on SAXS spectra indicated that the largely assembled species of the protein, quasi-aggregate, is composed of 80 to similar to90 monomers and a bowl-like structure with long and short axes of 400 and 190 Angstrom, respectively. Contrary to fibril, the quasi-aggregate did not show a peak at S = 0.21 Angstrom(-1) corresponding to the 4.8-Angstrom spacing of beta-pleated sheets in SAXS spectra, and reacted with a monoclonal antibody specific to expanded polyglutamine. These results imply that beta-sheets of expanded polyglutamines in the quasi-aggregate are not orderly aligned and are partially exposed, in contrast to regularly oriented and buried beta-pleated sheets in fibril. The formation of non-fibrillary quasi-aggregate in the early phase of fibril formation would be one of the major characteristics of the protein containing an expanded polyglutamine.	RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan; RIKEN, Harima Inst SPring 8, Struct Biol Lab, Hyogo 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Saitama 3510198, Japan	RIKEN; RIKEN; RIKEN	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab Struct Neuropathol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Tanaka, Motomasa/N-5064-2015; Nukina, Nobuyuki/GPP-6265-2022; Fujisawa, Tetsuro/AAA-5202-2019	Tanaka, Motomasa/0000-0002-2994-7703; Nishikawa, Yukihiro/0000-0002-0739-8491				AMEYAMA Y, 1995, REV SCI INSTRUM, V66, P2290; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Fujisawa T, 2000, J APPL CRYSTALLOGR, V33, P797, DOI 10.1107/S002188980000131X; Fujisawa T, 2001, FEBS LETT, V498, P67, DOI 10.1016/S0014-5793(01)02498-X; Guinier A., 1955, SMALL ANGLE SCATTERI; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; McGowan DP, 2000, NEUROSCIENCE, V100, P677, DOI 10.1016/S0306-4522(00)00391-2; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Yong W, 2002, P NATL ACAD SCI USA, V99, P150, DOI 10.1073/pnas.012584899; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	34	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34717	34724		10.1074/jbc.M209852200	http://dx.doi.org/10.1074/jbc.M209852200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815051	hybrid			2022-12-25	WOS:000185047500133
J	Yang, RB; Ng, CKD; Wasserman, SM; Komuves, LG; Gerritsen, ME; Topper, JN				Yang, RB; Ng, CKD; Wasserman, SM; Komuves, LG; Gerritsen, ME; Topper, JN			A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-ALLOGRAFT REJECTION; TUMOR-SUPPRESSOR LOCUS; IN-VIVO; DROSOPHILA SPROUTY; GENE-EXPRESSION; CYTOKINE FAMILY; IL-17; FGF; DIFFERENTIATION; ACTIVATION	We have previously utilized a combination of high throughput sequencing and genome-wide microarray profiling analyses to identify novel cell-surface proteins expressed in human umbilical vein endothelial cells. One gene identified by this approach encodes a type I transmembrane receptor that shares sequence homology with the intracellular domain of members of the interleukin-17 (IL-17) receptor family. Real-time quantitative PCR and Northern analyses revealed that this gene is highly expressed in human umbilical vein endothelial cells and in several highly vascularized tissues such as kidney, colon, skeletal muscle, heart, and small intestine. In addition, we also found that it is also highly expressed in the ductal epithelial cells of human salivary glands, seminal vesicles, and the collecting tubules of the kidney by in situ hybridization. This putative receptor, which we have termed human SEF (hSEF), is also expressed in a variety of breast cancer tissues. In co-immunoprecipitation assays, this receptor is capable of forming homomeric complexes and can interact with fibroblast growth factor (FGF) receptor 1. Overexpression of this receptor inhibits FGF induction of an FGF-responsive reporter gene in human 293T cells. This appears to occur as a result of specific inhibition of p42/p44 ERK in the absence of upstream MEK inhibition. This inhibitory effect is dependent upon a functional intracellular domain since deletion mutants missing the IL-17 receptor-like domain lack this inhibitory effect. These findings are consistent with the recent discovery of the zebrafish homologue, Sef ( similar expression to fgf genes), which specifically antagonizes FGF signaling when ectopically expressed in zebrafish or Xenopus laevis embryos. Based on sequence and functional similarities, this novel IL-17 receptor homologue represents a potential human SEF and is likely to play critical roles in endothelial or epithelial functions such as proliferation, migration, and angiogenesis.	Millennium Pharmaceut Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Yang, RB (corresponding author), Millennium Pharmaceut Inc, Dept Cardiovasc Res, 256 E Grand Ave, San Francisco, CA 94080 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714	NHLBI NIH HHS [HL-62823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Antonysamy MA, 1999, TRANSPLANT P, V31, P93, DOI 10.1016/S0041-1345(98)01453-5; Brown RE, 2002, ANN CLIN LAB SCI, V32, P12; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Cines DB, 1998, BLOOD, V91, P3527; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Komuves LG, 2000, J HISTOCHEM CYTOCHEM, V48, P821, DOI 10.1177/002215540004800610; KOVACS G, 1989, INT J CANCER, V43, P422, DOI 10.1002/ijc.2910430313; Kramer S, 1999, DEVELOPMENT, V126, P2515; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Loong CC, 2000, TRANSPL P, V32, P1773, DOI 10.1016/S0041-1345(00)01382-8; Lubberts E, 2000, ARTHRITIS RHEUM-US, V43, P1300, DOI 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Minowada G, 1999, DEVELOPMENT, V126, P4465; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Yang RB, 2002, J BIOL CHEM, V277, P46364, DOI 10.1074/jbc.M207410200; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	48	79	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33232	33238		10.1074/jbc.M305022200	http://dx.doi.org/10.1074/jbc.M305022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807873	hybrid			2022-12-25	WOS:000184901800091
J	Liao, JH; Wolfman, JC; Wolfman, A				Liao, JH; Wolfman, JC; Wolfman, A			K-Ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-N-RAS; IV COLLAGENASE; H-RAS; MATRIX METALLOPROTEINASES; INVASIVE PHENOTYPE; ACTIVATE RAF-1; PROTEIN-KINASE; GELATINASE-A; CELL-CYCLE; IN-VIVO	Fibroblasts constitutively express matrix metalloproteinase 2 (MMP-2), which specifically cleaves type IV collagen, a major structural component of basement membranes. The level of MMP-2 expression was not altered by serum withdrawal, suggesting that MMP-2 expression is regulated by a series of steady-state conditions that impinge on the MMP-2 promoter. Expression of a dominant-negative Ras protein significantly inhibited MMP-2 transcription, thereby suggesting a role for steady-state Ras function in the regulation of MMP-2 expression. Kirsten-Ras (K-Ras) knockout fibroblasts express undetectable basal levels of MMP-2, whereas N-Ras knockout fibroblasts expressed constitutive levels of MMP-2 similar to those observed in wild-type control fibroblasts. Using an MMP-2 promoter-luciferase reporter assay, we demonstrated that the transcription of MMP-2 in K-Ras knockout fibroblasts was partially restored by transient expression of c-K(B)-Ras but not cK( A)-Ras. A phosphoinositide-3 (PI-3) kinase-specific inhibitor (LY294002) decreased the basal level of MMP-2 in wild-type fibroblasts. Blocking PI-3 kinase signaling by overexpression of the regulatory domain of PI-3 kinase (p85) also down-regulated the steady-state MMP-2 levels. Fibroblasts that fail to express AKT1 also expressed decreased amounts of MMP-2 compared with wild-type fibroblasts. These data suggest that steady-state MMP-2 expression is regulated by c-K( B)-Ras through a PI-3 kinase: AKT-dependent signaling pathway. Because the majority of the MMP-2 assays were performed using conditioned media from serum-starved fibroblasts, these data also highlight our previous observations that Ras proteins have functions in the absence of acute mitogenic stimulations. In addition, this is the first demonstration of a specific steady-state function attributable to K(B)-Ras.	Cleveland Clin, Dept Cell Biol, Lerner Coll Med, Cleveland, OH 44195 USA	Case Western Reserve University; Cleveland Clinic Foundation	Wolfman, A (corresponding author), 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062644] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62644] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alhasan SA, 2001, CLIN CANCER RES, V7, P4174; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Charvat S, 1999, CLIN EXP METASTAS, V17, P677, DOI 10.1023/A:1006709403193; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Liabakk NB, 1996, CANCER RES, V56, P190; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; REPONEN P, 1992, J BIOL CHEM, V267, P7856; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vaisanen A, 1996, J PATHOL, V180, P283; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	39	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31871	31878		10.1074/jbc.M301931200	http://dx.doi.org/10.1074/jbc.M301931200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805379	hybrid			2022-12-25	WOS:000184782100052
J	Persson, K; Russell, W; Morgelin, M; Herwald, H				Persson, K; Russell, W; Morgelin, M; Herwald, H			The conversion of fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to the generation of proinflammatory fibrinopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; SALMONELLA-ENTERITIDIS; VIRULENCE DETERMINANT; AGGREGATIVE FIMBRIAE; ELECTRON-MICROSCOPY; INFECTIOUS-DISEASES; HUMAN PLASMA; PROTEIN; FIBRONECTIN; ACTIVATION	The inflammatory response to bacterial infection is the result of a complex interplay between bacterial products and host effector systems, such as the immune and complement systems. Here we show that Escherichia coli bacteria expressing fibrous surface proteins, known as curli, assemble and activate factors of the human coagulation cascade at their surface. As a result of this interaction, fibrinogen is converted to fibrin and fibrinogen-derived peptides, termed fibrinopeptides, are generated. The molecular mechanisms behind the bacteria-induced formation of fibrinopeptides were investigated and shown to be triggered by the activation of the contact system, also known as the kallikrein/kinin system or the intrinsic pathway of coagulation. Samples containing fibrinopeptides generated by the interaction between bacteria and plasma were injected into animals and the inflammatory response was monitored. We found that this treatment provoked an infiltration of white blood cells, and the induction of the proinflammatory cytokine MCP-1 at the inflamed site. Our results therefore demonstrate that activation of the coagulation system at the bacterial surface contributes to the pathophysiology of bacterial infectious diseases.	Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, SE-22184 Lund, Sweden	Lund University	Herwald, H (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, B14,Tornavagen 10, SE-22184 Lund, Sweden.		Herwald, Heiko/AAN-3708-2021	Herwald, Heiko/0000-0002-8111-2842				AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BenNasr A, 1997, BIOCHEM J, V326, P657, DOI 10.1042/bj3260657; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BenNasr A, 1996, MOL MICROBIOL, V20, P927; Bernard GR, 2003, CRIT CARE MED, V31, pS85, DOI 10.1097/00003246-200301001-00012; Bian Z, 2000, J INFECT DIS, V181, P602, DOI 10.1086/315233; Bian Z, 2001, J INFECT DIS, V183, P612, DOI 10.1086/318528; BICK RL, 1992, INT J HEMATOL, V55, P1; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991; Dibb-Fuller MP, 1999, MICROBIOL-SGM, V145, P1023, DOI 10.1099/13500872-145-5-1023; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; EVANS DG, 1977, INFECT IMMUN, V18, P330, DOI 10.1128/IAI.18.2.330-337.1977; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111; GHEBREHIWET B, 1983, J CLIN INVEST, V71, P1450, DOI 10.1172/JCI110898; Gophna U, 2002, FEMS MICROBIOL LETT, V212, P55, DOI 10.1111/j.1574-6968.2002.tb11244.x; Hack C Erik, 2003, Contrib Microbiol, V10, P18; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Klemm P, 2000, INT J MED MICROBIOL, V290, P27; Levi M, 2002, BLOOD REV, V16, P217, DOI 10.1016/S0268-960X(02)00032-2; Mattsson E, 2001, INFECT IMMUN, V69, P3877, DOI 10.1128/IAI.69.6.3877-3882.2001; MOMBELLI G, 1987, THROMB HAEMOSTASIS, V58, P758; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; Olsen A, 1998, INFECT IMMUN, V66, P944; Olsen A, 2002, J BIOL CHEM, V277, P34568, DOI 10.1074/jbc.M206353200; OLSEN A, 1993, MOL MICROBIOL, V7, P523, DOI 10.1111/j.1365-2958.1993.tb01143.x; Persson K, 2000, J EXP MED, V192, P1415, DOI 10.1084/jem.192.10.1415; RICHENBERG HV, 1955, J GEN MICROBIOL, V13, P279; Rocha E, 1998, HAEMATOLOGICA, V83, P1024; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SINGH TM, 1990, AM J SURG, V160, P156, DOI 10.1016/S0002-9610(05)80297-1; SJOBRING U, 1994, MOL MICROBIOL, V14, P443, DOI 10.1111/j.1365-2958.1994.tb02179.x; SKOGEN WF, 1988, BLOOD, V71, P1475; Stathopoulos C, 2000, MICROBES INFECT, V2, P1061, DOI 10.1016/S1286-4579(00)01260-0; Tapper H, 2000, BLOOD, V96, P2329; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Uhlich GA, 2002, INFECT IMMUN, V70, P395, DOI 10.1128/IAI.70.1.395-399.2002	42	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31884	31890		10.1074/jbc.M302522200	http://dx.doi.org/10.1074/jbc.M302522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805381	hybrid			2022-12-25	WOS:000184782100054
J	Ortega-Velazquez, R; Marques, ML; Ruiz-Torres, MP; Gonzalez-Rubio, M; Rodriguez-Puyol, M; Puyol, DR				Ortega-Velazquez, R; Marques, ML; Ruiz-Torres, MP; Gonzalez-Rubio, M; Rodriguez-Puyol, M; Puyol, DR			Arg-Gly-Asp-Ser peptide stimulates transforming growth factor-beta 1 transcription and secretion through integrin activation	FASEB JOURNAL			English	Article						RGD-containing peptides; fibronectin; extracellular matrix components secretion; integrin-linked kinase; tyrosine phosphorylation	GROWTH-FACTOR-BETA; GLYCOGEN-SYNTHASE KINASE; EXTRACELLULAR-MATRIX; LINKED KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; TGF-BETA; APOPTOSIS; RGD; PINCH	Extracellular matrix (ECM) components, through specific peptide motifs such as Arg-Gly-Asp (RGD), interact with integrins and can modify the behavior of cells. Transforming growth factor-beta1 (TGF-beta1) is the main cytokine involved in the synthesis of ECM proteins. We analyzed the effect of a RGD-containing peptide, as Arg-Gly-Asp-Ser (RGDS), on the regulation of TGF-beta1 secretion in cultured human mesangial cells. We found that RGDS increased mRNA expression and secretion of TGF-beta1 by stimulating the TGF-beta1 gene promoter. This effect was dependent on the interaction of RGDS with integrins. We evaluated the signaling pathways implicated in TGF-beta1 production by analyzing the effect of RGDS on kinase-related integrins. RGDS stimulated tyrosine phosphorylation as well as integrin-linked kinase (ILK) activity. However, tyrosine kinase inhibitors did not prevent the RGDS effect. In contrast, the inhibition of ILK by cell transfection with a kinase dead-ILK completely abolished the increased TGF-beta1 secretion and promoter activity in the presence of RGDS. Thus RGDS modulates the secretion of TGF-beta1, probably through increased synthesis by interacting with integrins and activating ILK. This supports a role for ECM components in the regulation of their own secretion.	Univ Alcala de Henares, Dept Physiol, Alcala De Henares, Spain; Univ Alcala de Henares, Dept Med, Alcala De Henares, Spain; Hosp Principe de Asturias, Nephrol Sect, Alcala De Henares, Spain; Inst Reina Sofia Invest Nefrol, Alcala De Henares, Spain	Universidad de Alcala; Universidad de Alcala; Prince of Asturias University Hospital	Puyol, DR (corresponding author), Univ Alcala De Henares, Fac Med, Dept Fisiol, Carretera Barcelona,Km 33-600, Madrid 28880, Spain.	diego.rodriguez@uah.es	Ruiz-Torres, María/I-1985-2017; Puyol, Diego Rodriguez/AAG-9752-2020; Puyol, Manuel Rodriguez/AAG-7049-2020	Ruiz-Torres, María/0000-0003-1640-7326; Puyol, Diego Rodriguez/0000-0002-9125-9311; Puyol, Manuel Rodriguez/0000-0002-5230-6664; Ortega-Velazquez, Rocio/0000-0003-3254-6641; Ortega-Velazquez, Rocio/0000-0002-2804-4908				BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hedin U, 1997, ARTERIOSCL THROM VAS, V17, P1977, DOI 10.1161/01.ATV.17.10.1977; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Iglesias-de la Cruz MC, 2000, EXP NEPHROL, V8, P97; Ilic D, 1997, J CELL SCI, V110, P401; Kagami S, 2000, KIDNEY INT, V58, P1088, DOI 10.1046/j.1523-1755.2000.00266.x; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Li FG, 1999, J CELL SCI, V112, P4589; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Marchand-Brynaert J, 1999, BIOMATERIALS, V20, P1773, DOI 10.1016/S0142-9612(99)00072-1; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; MIGITA K, 1994, J IMMUNOL, V153, P3457; Monno R, 2001, J AM SOC NEPHROL, V12, P891, DOI 10.1681/ASN.V125891; Mooney A, 1999, AM J PATHOL, V155, P599, DOI 10.1016/S0002-9440(10)65155-3; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; Moreno-Manzano V, 2000, BIOCHEM BIOPH RES CO, V277, P293, DOI 10.1006/bbrc.2000.3654; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; STERZEL RB, 1993, KIDNEY INT, V43, pS26; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077	38	36	38	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1529	+		10.1096/fj.02-0785fje	http://dx.doi.org/10.1096/fj.02-0785fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824296				2022-12-25	WOS:000183818000035
J	Biroccio, A; Amodei, S; Antonelli, A; Benassi, B; Zupi, G				Biroccio, A; Amodei, S; Antonelli, A; Benassi, B; Zupi, G			Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; TELOMERASE ACTIVITY; ANTISENSE OLIGODEOXYNUCLEOTIDES; REPLICATIVE SENESCENCE; ONCOGENE EXPRESSION; PROGNOSTIC MARKER; HUMAN FIBROBLASTS; IMMORTAL CELLS; IN-VITRO; P53	Here, we show that inhibition of c-Myc causes a proliferative arrest of M14 melanoma cells through cellular crisis, evident by the increase in size, multiple nuclei, vacuolated cytoplasm, induction of senescence-associated beta-galactosidase activity and massive apoptosis. The c-Myc-induced crisis is associated with decreased human telomerase reverse transcriptase expression, telomerase activity, progressive telomere shortening, glutathione (GSH), depletion and, increased production of reactive oxygen species. Treatment of control cells with L-buthionine sulfoximine decreases GSH to levels of c-Myc low expressing cells, but it does not modify the growth kinetic of the cells. Surprisingly, when GSH is increased in the c-Myc low expressing cells by treatment with N-acetyl-L-cysteine, cells escape crisis. To test the hypothesis that both oxidative stress and telomerase dysfunction are involved in the c-Myc-dependent crisis, we directly inhibited telomerase function and glutathione levels. Inactivation of telomerase, by expression of a catalytically inactive, dominant negative form of reverse transcriptase, reduces cellular lifespan by inducing telomere shortening. Treatment of cells with L-buthionine sulfoximine decreases GSH content and accelerates cell crisis. Analysis of telomere status demonstrated that oxidative stress affects c-Myc-induced crisis by increasing telomere dysfunction. Our results demonstrate that inhibition of c-Myc oncoprotein induces cellular crisis through cooperation between telomerase dysfunction and oxidative stress.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Ctr Ric Sperimentale, I-00158 Rome, Italy; Univ Roma La Sapienza, Cellular Biotechnol & Hematol Dept, I-00185 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome	Biroccio, A (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Ctr Ric Sperimentale, Via Messi Oro 156, I-00158 Rome, Italy.		Biroccio, Annamaria/B-2861-2018	Biroccio, Annamaria/0000-0003-3198-3532				Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Biroccio A, 2002, J BIOL CHEM, V277, P43763, DOI 10.1074/jbc.M207684200; BISHOP JM, 1991, COLD SH Q B, V56, P99; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brantley MA, 2000, AM J PATHOL, V157, P1795, DOI 10.1016/S0002-9440(10)64817-1; Caldini R, 1998, MECH AGEING DEV, V105, P137, DOI 10.1016/S0047-6374(98)00085-2; Chana JS, 2002, BRIT J PLAST SURG, V55, P623, DOI 10.1054/bjps.2002.3964; Chana JS, 2001, ANN PLAS SURG, V47, P172, DOI 10.1097/00000637-200108000-00011; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Citro G, 1998, CANCER RES, V58, P283; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Grover R, 2003, ANN PLAS SURG, V50, P183, DOI 10.1097/01.SAP.0000032308.89737.EA; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KINNULA VL, 1981, ACTA PHYSIOL SCAND, V112, P387, DOI 10.1111/j.1748-1716.1981.tb06834.x; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35693	35701		10.1074/jbc.M304597200	http://dx.doi.org/10.1074/jbc.M304597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12824159	hybrid			2022-12-25	WOS:000185164400115
J	Shingai, T; Ikeda, W; Kakunaga, S; Morimoto, K; Takekuni, K; Itoh, S; Satoh, K; Takeuchi, M; Imai, T; Monden, M; Takai, Y				Shingai, T; Ikeda, W; Kakunaga, S; Morimoto, K; Takekuni, K; Itoh, S; Satoh, K; Takeuchi, M; Imai, T; Monden, M; Takai, Y			Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR TSLC1 GENE; IMMUNOGLOBULIN SUPERFAMILY; LUNG-CANCER; DIFFERENTIAL BEHAVIOR; MOLECULAR-CLONING; ADHERENS JUNCTION; CADHERIN; AFADIN; MEMBER; EXPRESSION	Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules that play roles in organization of a variety of cell-cell junctions in cooperation with or independently of cadherins. Four nectins have been identified. Five nectin-like molecules, which have domain structures similar to those of nectins, have been identified, and we characterized here nectin-like molecule-2 (Necl-2)/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1. Necl-2 showed Ca2+-independent homophilic cell-cell adhesion activity. It furthermore showed Ca2+-independent heterophilic cell-cell adhesion activity with Necl-1/TSLL1/SynCAM3 and nectin-3. Necl-2 was widely expressed in rat tissues examined. Necl-2 localized at the basolateral plasma membrane in epithelial cells of the mouse gall bladder, but not at specialized cell-cell junctions, such as tight junctions, adherens junctions, and desmosomes. Nectins bind afadin, whereas Necl-2 did not bind afadin but bound Pals2, a membrane-associated guanylate kinase family member known to bind Lin-7, implicated in the proper localization of the Let-23 protein in Caenorhabditis elegans, the homologue of mammalian epidermal growth factor receptor. These results indicate the unique localization of Necl-2 and its possible involvement in localization of a transmembrane protein(s) through Pals2.	Osaka Univ, Fac Med, Grad Sch Med, Dept Biochem & Mol Biol, Osaka 5650871, Japan; Osaka Univ, Fac Med, Grad Sch Med, Dept Surg & Clin Oncol, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Biochem & Mol Biol, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Itoh, Shinsuke/0000-0001-9567-8188				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; James P, 1996, GENETICS, V144, P1425; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tran YK, 1999, CANCER RES, V59, P35; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129; YONEMURA S, 1995, J CELL SCI, V108, P127	42	178	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35421	35427		10.1074/jbc.M305387200	http://dx.doi.org/10.1074/jbc.M305387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826663	hybrid			2022-12-25	WOS:000185164400082
J	Ten Hagen, KG; Tran, DT; Gerken, TA; Stein, DS; Zhang, ZY				Ten Hagen, KG; Tran, DT; Gerken, TA; Stein, DS; Zhang, ZY			Functional characterization and expression analysis of members of the UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase family from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; MOLECULAR-CLONING; CDNA CLONING; CAENORHABDITIS-ELEGANS; O-GLYCANS; MUCIN; GENE; GLYCOSYLATION; SEQUENCE; N-ACETYLGALACTOSAMINYLTRANSFERASE-T3	Here we report the cloning and functional characterization of eight members of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase gene family from Drosophila melanogaster (polypeptide GalNAc transferase = pgant1-8). Full-length cDNAs were isolated from a Drosophila embryonic library based on homology to known ppGaNTases. Alignments with characterized mammalian isoforms revealed strong sequence similarities between certain fly and mammalian isoforms, highlighting putative orthologues between the species. In vitro activity assays demonstrated biochemical transferase activity for each gene, with three isoforms requiring glycosylated substrates. Comparison of the activities of Drosophila and mammalian orthologues revealed conservation of substrate preferences against a panel of peptide and glycopeptide substrates. Furthermore, Edman degradation analysis demonstrated that preferred sites of GalNac addition were also conserved between certain fly and mammalian orthologues. Semi-quantitative PCR amplification of Drosophila cDNA revealed expression of most isoforms at each developmental stage, with some isoforms being less abundant at certain stages relative to others. In situ hybridization to Drosophila embryos revealed specific staining of pgant5 and pgant6 in the salivary glands and pgant5 in the developing hindgut. Additionally, pgant5 and pgant6 expression within the egg chamber was restricted to the follicle cells, cells known to be involved in egg formation and subsequent embryonic patterning. The characterization reported here provides additional insight into the use of this model system to dissect the biological role of this enzyme family in vivo during both fly and mammalian development.	NIDDK, Sect Biol Chem, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Texas, Inst Mol & Cellular Biol, Sect Mol Cell & Dev Biol, Austin, TX 78712 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Case Western Reserve University; Case Western Reserve University; University of Texas System; University of Texas Austin	Ten Hagen, KG (corresponding author), NIDDK, Sect Biol Chem, NIH, 9000 Rockville Pike,Bldg 50,Rm 4120, Bethesda, MD 20892 USA.	Kelly.Tenhagen@nih.gov		Zhang, Zhenyu/0000-0001-6655-053X	NATIONAL CANCER INSTITUTE [R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052761] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078834] Funding Source: Medline; NIGMS NIH HHS [GM52761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Andrew DJ, 2000, MECH DEVELOP, V92, P5, DOI 10.1016/S0925-4773(99)00321-4; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gerken TA, 2002, J BIOL CHEM, V277, P7736, DOI 10.1074/jbc.M111690200; Guo JM, 2002, FEBS LETT, V524, P211, DOI 10.1016/S0014-5793(02)03007-7; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hiki Y, 2001, KIDNEY INT, V59, P1077, DOI 10.1046/j.1523-1755.2001.00591.x; King R. C., 1970, OVARIAN DEV DROSOPHI; McManus AM, 1999, BIOCHEMISTRY-US, V38, P705, DOI 10.1021/bi981956d; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Varki A., 1999, ESSENTIALS GLYCOBIOL; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang H, 2003, BIOCHEM BIOPH RES CO, V300, P738, DOI 10.1016/S0006-291X(02)02908-X; Westerman EL, 1999, GLYCOBIOLOGY, V9, P1121; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613; Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200	38	67	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35039	35048		10.1074/jbc.M303836200	http://dx.doi.org/10.1074/jbc.M303836200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829714	hybrid			2022-12-25	WOS:000185164400037
J	Chappell, SA; Mauro, VP				Chappell, SA; Mauro, VP			The internal ribosome entry site (IRES) contained within the RNA-binding motif protein 3 (Rbm3) mRNA is composed of functionally distinct elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; HEPATITIS-C VIRUS; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; SEGMENT; COMPLEMENTARITY; LEADER; 18S; IDENTIFICATION; PICORNAVIRUS	Although the internal ribosome entry sites (IRESes) of viral mRNAs are highly structured and comprise several hundred nucleotides, there is a variety of evidence indicating that very short nucleotide sequences, both naturally occurring and synthetic, can similarly mediate internal initiation of translation. In this study, we performed deletion and mutational analyses of an IRES contained within the 720-nucleotide (nt) 5' leader of the Rbm3 mRNA and demonstrated that this IRES is highly modular, with at least 9 discrete cis-acting sequences. These cis-acting sequences include a 22-nt IRES module, a 10-nt enhancer, and 2 inhibitory sequences. The 22-nt sequence was shown to function as an IRES when tested in isolation, and we demonstrated that it did not enhance translation by functioning as a transcriptional promoter, enhancer, or splice site. The activities of all 4 cis-acting sequences were further confirmed by their mutation in the context of the full IRES. Interestingly, one of the inhibitory cis-acting sequences is contained within an upstream open reading frame (uORF), and its activity seems to be masked by translation of this uORF. Binding studies revealed that all 4 cis-acting sequences could bind specifically to distinct cytoplasmic proteins. In addition, the 22-nt IRES module was shown to bind specifically to 40 S ribosomal subunits. The results demonstrate that different types of cis-acting sequences mediate or modulate translation of the Rbm3 mRNA and suggest that one of the IRES modules contained within the 5' leader facilitates translation initiation by binding directly to 40 S ribosomal subunits.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Mauro, VP (corresponding author), Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA.	vmauro@scripps.edu			NIGMS NIH HHS [GM61725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2001, J BIOL CHEM, V276, P36917, DOI 10.1074/jbc.M106008200; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; Dorokhov YL, 2002, P NATL ACAD SCI USA, V99, P5301, DOI 10.1073/pnas.082107599; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; HOLMBERG L, 1994, NUCLEIC ACIDS RES, V22, P1374, DOI 10.1093/nar/22.8.1374; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jackson RJ, 1995, RNA, V1, P985; JACKSON RJ, 1995, OPERATIONAL DISTINCT, P203; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; Mauro VP, 1997, P NATL ACAD SCI USA, V94, P422, DOI 10.1073/pnas.94.2.422; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Otto GA, 2002, RNA, V8, P913, DOI 10.1017/S1355838202022057; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Tranque P, 1998, P NATL ACAD SCI USA, V95, P12238, DOI 10.1073/pnas.95.21.12238; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Verrier SB, 2000, RNA, V6, P584, DOI 10.1017/S1355838200992239; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Zhou W, 2001, P NATL ACAD SCI USA, V98, P1531, DOI 10.1073/pnas.98.4.1531; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	41	56	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33793	33800		10.1074/jbc.M303495200	http://dx.doi.org/10.1074/jbc.M303495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824175	hybrid			2022-12-25	WOS:000185047500024
J	Ishida, T; Kundu, RK; Yang, E; Hirata, K; Ho, YD; Quertermous, T				Ishida, T; Kundu, RK; Yang, E; Hirata, K; Ho, YD; Quertermous, T			Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-GROWTH; IMMUNOGLOBULIN SUPERFAMILY; HUMAN-MELANOMA; PECAM-1 CD31; VASCULAR-PERMEABILITY; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; CLONING; IDENTIFICATION; MIGRATION	Endothelial cell-selective adhesion molecule ( ESAM) is a member of the immunoglobulin receptor family that mediates homophilic interactions between endothelial cells. To address potential in vivo angiogenic functions of this molecule, mice lacking ESAM ( ESAM -/-) were generated by gene-targeted deletion. ESAM -/- mice did not show overt morphological defects in the vasculature. To evaluate the role of ESAM in pathological angiogenesis, wild type (WT) and ESAM -/- mice were injected with melanoma and Lewis lung carcinoma cells. By 14 days after injection, tumor volumes of B16F10 and LL/2 in ESAM -/- mice were 48 and 37% smaller, respectively, compared with WT mice. Vascular density of the tumors, as determined by CD31 staining, was also decreased in the ESAM null animals. Matrigel plug assays showed less neovascularization in ESAM -/- mice than in WT mice. ESAM -/- endothelial cells exhibited less in vitro tube formation and decreased migration in response to basic fibroblast growth factor when compared with WT cells, and endothelial-like yolk sac cells engineered to overexpress ESAM showed accelerated tube formation in vitro. These in vitro and in vivo studies suggest that ESAM has a redundant functional role in physiological angiogenesis but serves a unique and essential role in pathological angiogenic processes such as tumor growth.	Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA; Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan	Stanford University; Kobe University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, 300 Pasteur Dr,Falk CVRC, Stanford, CA 94305 USA.			Quertermous, Thomas/0000-0002-7645-9067				Anfosso F, 2001, J BIOL CHEM, V276, P1564, DOI 10.1074/jbc.M007065200; Aoka Y, 2002, MICROVASC RES, V64, P148, DOI 10.1006/mvre.2002.2414; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Aurrand-Lions MA, 2000, CURR TOP MICROBIOL, V251, P91; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Bird IN, 1999, J CELL SCI, V112, P1989; Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; DeLisser HM, 1997, AM J PATHOL, V151, P671; Duncan GS, 1999, J IMMUNOL, V162, P3022; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Guan JZ, 1999, BLOOD, V94, P3405, DOI 10.1182/blood.V94.10.3405.422k28_3405_3412; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim CS, 1998, LAB INVEST, V78, P583; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Matsumura T, 1997, J IMMUNOL, V158, P3408; Mills L, 2002, CANCER RES, V62, P5106; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PASSANITI A, 1992, LAB INVEST, V67, P519; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; St Croix B, 2000, SCIENCE, V289, P1197; Telo P, 1998, J BIOL CHEM, V273, P17565, DOI 10.1074/jbc.273.28.17565; Xie SH, 1997, CANCER RES, V57, P2295; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7	47	85	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34598	34604		10.1074/jbc.M304890200	http://dx.doi.org/10.1074/jbc.M304890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819200	hybrid			2022-12-25	WOS:000185047500121
J	Maccarrone, M; Di Rienzo, M; Battista, N; Gasperi, V; Guerrieri, P; Rossi, A; Finazzi-Agro, A				Maccarrone, M; Di Rienzo, M; Battista, N; Gasperi, V; Guerrieri, P; Rossi, A; Finazzi-Agro, A			The endocannabinoid system in human keratinocytes - Evidence that anandamide inhibits epidermal differentiation through CB1 receptordependent inhibition of protein kinase C, activating protein-1, and transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; HUMAN ENDOTHELIAL-CELLS; N-ARACHIDONOYLETHANOLAMINE ANANDAMIDE; CANNABINOID RECEPTORS; ENDOGENOUS CANNABINOIDS; VANILLOID RECEPTORS; NITRIC-OXIDE; BRAIN; 2-ARACHIDONOYLGLYCEROL; ACYLETHANOLAMINES	Anandamide (AEA), a prominent member of the endogenous ligands of cannabinoid receptors (endocannabinoids), is known to affect several functions of brain and peripheral tissues. A potential role for AEA in skin pathophysiology has been proposed, yet its molecular basis remains unknown. Here we report unprecedented evidence that spontaneously immortalized human keratinocytes (HaCaT) and normal human epidermal keratinocytes (NHEK) have the biochemical machinery to bind and metabolize AEA, i.e. a functional type-1 cannabinoid receptor (CB1R), a selective AEA membrane transporter (AMT), an AEA-degrading fatty acid amide hydrolase (FAAH), and an AEA-synthesizing phospholipase D (PLD). We show that, unlike CB1R and PLD, the activity of AMT and the activity and expression of FAAH increase while the endogenous levels of AEA decrease in HaCaT and NHEK cells induced to differentiate in vitro by 12-O-tetradecanoylphorbol 13-acetate (TPA) plus calcium. We also show that exogenous AEA inhibits the formation of cornified envelopes, a hallmark of keratinocyte differentiation, in HaCaT and NHEK cells treated with TPA plus calcium, through a CB1R-dependent reduction of transglutaminase and protein kinase C activity. Moreover, transient expression in HaCaT cells of the chloramphenicol acetyltransferase reporter gene under control of the loricrin promoter, which contained a wild-type or mutated activating protein-1 (AP-1) site, showed that AEA inhibited AP-1 in a CB1R-dependent manner. Taken together, these data demonstrate that human keratinocytes partake in the peripheral endo-cannabinoid system and show a novel signaling mechanism of CB1 receptors, which may have important implications in epidermal differentiation and skin development.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Mondino Tor Vergata St Lucia Ctr Expt Neurobiol, Ist Ricovero & Cura Carattere Sci C Mondino, I-00179 Rome, Italy	University of Teramo; University of Rome Tor Vergata; IRCCS Fondazione Casimiro Mondino	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, Piazza A Moro 45, I-64100 Teramo, Italy.		Gasperi, Valeria/AAN-9210-2021; Battista, Natalia/AAC-2529-2019; gasperi, valeria/AGO-4500-2022	gasperi, valeria/0000-0003-3200-8093; Battista, Natalia/0000-0002-1936-6710				Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Calignano A, 2000, Prog Brain Res, V129, P471; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Candi E, 2001, J BIOL CHEM, V276, P35014, DOI 10.1074/jbc.M010157200; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Day TA, 2001, MOL PHARMACOL, V59, P1369, DOI 10.1124/mol.59.6.1369; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; Deutsch DG, 2001, J BIOL CHEM, V276, P6967, DOI 10.1074/jbc.M003161200; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Ellington HC, 2002, NEUROPHARMACOLOGY, V42, P966, DOI 10.1016/S0028-3908(02)00040-0; Fride E, 2002, PROSTAG LEUKOTR ESS, V66, P221, DOI 10.1054/plef.2001.0360; Garcia DE, 1998, J NEUROSCI, V18, P2834; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Gubellini P, 2002, J NEUROSCI, V22, P6900; Guzman M, 2002, PHARMACOL THERAPEUT, V95, P175, DOI 10.1016/S0163-7258(02)00256-5; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kunos G, 2000, CHEM PHYS LIPIDS, V108, P159, DOI 10.1016/S0009-3084(00)00194-8; Lin SY, 1998, J MED CHEM, V41, P5353, DOI 10.1021/jm970257g; Maccarrone M, 2001, J IMMUNOL, V166, P7183, DOI 10.4049/jimmunol.166.12.7183; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Maccarrone M, 2002, VITAM HORM, V65, P225, DOI 10.1016/S0083-6729(02)65066-6; Maccarrone M, 2002, BLOOD, V100, P4040, DOI 10.1182/blood-2002-05-1444; Maccarrone M, 2001, J NEUROCHEM, V76, P594, DOI 10.1046/j.1471-4159.2001.00092.x; McAllister SD, 2002, PROSTAG LEUKOTR ESS, V66, P161, DOI 10.1054/plef.2001.0344; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Moesgaard B, 2000, J LIPID RES, V41, P985; Nakamura A, 1999, JPN J PHARMACOL, V79, P427, DOI 10.1254/jjp.79.427; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Ross RA, 2001, BRIT J PHARMACOL, V132, P631, DOI 10.1038/sj.bjp.0703850; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Rossi A, 2000, J INVEST DERMATOL, V115, P731, DOI 10.1046/j.1523-1747.2000.00116.x; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Rutberg SE, 1996, ONCOGENE, V13, P167; Savini I, 2002, J INVEST DERMATOL, V118, P372, DOI 10.1046/j.0022-202x.2001.01624.x; STEVEN AC, 1994, J CELL SCI, V107, P693; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Ueda N, 2000, CHEM PHYS LIPIDS, V108, P107, DOI 10.1016/S0009-3084(00)00190-0; Walker JM, 2002, PROSTAG LEUKOTR ESS, V66, P235, DOI 10.1054/plef.2001.0361; Welter JF, 1995, ONCOGENE, V11, P2681; Yamaji K, 2003, THROMB HAEMOSTASIS, V89, P875, DOI 10.1055/s-0037-1613475	55	121	128	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33896	33903		10.1074/jbc.M303994200	http://dx.doi.org/10.1074/jbc.M303994200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815050	hybrid			2022-12-25	WOS:000185047500035
J	Napal, L; Dai, J; Treber, M; Haro, D; Marrero, PF; Woldegiorgis, G				Napal, L; Dai, J; Treber, M; Haro, D; Marrero, PF; Woldegiorgis, G			A single amino acid change (substitution of the conserved Glu-590 with alanine) in the C-terminal domain of rat liver carnitine palmitoyltransferase I increases its malonyl-CoA sensitivity close to that observed with the muscle isoform of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC-ACTIVITY; CPT-I; HEART; IDENTIFICATION; RESIDUES; MUTAGENESIS; AFFINITY; INHIBITION; EXPRESSION; ARGININE	Carnitine palmitoyltransferase I ( CPTI) catalyzes the conversion of long-chain fatty acyl-CoAs to acylcarnitines in the presence of L-carnitine. To determine the role of the highly conserved C-terminal glutamate residue, Glu-590, on catalysis and malonyl-CoA sensitivity, we separately changed the residue to alanine, lysine, glutamine, and aspartate. Substitution of Glu-590 with aspartate, a negatively charged amino acid with only one methyl group less than the glutamate residue in the wild-type enzyme, resulted in complete loss in the activity of the liver isoform of CPTI (L-CPTI). A change of Glu-590 to alanine, glutamine, and lysine caused a significant 9- to 16-fold increase in malonyl-CoA sensitivity but only a partial decrease in catalytic activity. Substitution of Glu-590 with neutral uncharged residues ( alanine and glutamine) and/or a basic positively charged residue ( lysine) significantly increased L-CPTI malonyl-CoA sensitivity to the level observed with the muscle isoform of the enzyme, suggesting the importance of neutral and/or positive charges in the switch of the kinetic properties of L-CPTI to the muscle isoform of CPTI. Since a conservative substitution of Glu-590 to aspartate but not glutamine resulted in complete loss in activity, we suggest that the longer side chain of glutamate is essential for catalysis and malonyl-CoA sensitivity. This is the first demonstration whereby a single residue mutation in the C-terminal region of the liver isoform of CPTI resulted in a change of its kinetic properties close to that observed with the muscle isoform of the enzyme and provides the rationale for the high malonyl-CoA sensitivity of muscle CPTI compared with the liver isoform of the enzyme.	Oregon Hlth & Sci Univ, OGI, Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA; Univ Barcelona, Dept Biochem & Mol Biol, Sch Pharm, E-08028 Barcelona, Spain	Oregon Health & Science University; University of Barcelona	Woldegiorgis, G (corresponding author), Oregon Hlth & Sci Univ, OGI, Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 N W Walker Rd, Beaverton, OR 97006 USA.	gwoldeg@ebs.ogi.edu	Marrero, Pedro F/I-1919-2015; Haro, Diego/I-4623-2015	Haro, Diego/0000-0001-9147-0486	NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams SH, 1998, BIOL REPROD, V59, P1399, DOI 10.1095/biolreprod59.6.1399; Barycki JJ, 2001, J BIOL CHEM, V276, P36718, DOI 10.1074/jbc.M104839200; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bonnefont JP, 1996, AM J HUM GENET, V58, P971; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CORR PB, 1995, HERZ, V20, P156; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Tao Bernard Y., 1994, P69; Treber M, 2003, J BIOL CHEM, V278, P11145, DOI 10.1074/jbc.M210566200; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; Woldegiorgis G, 2000, J NUTR, V130, p310S, DOI 10.1093/jn/130.2.310S; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zheng GL, 2002, J BIOL CHEM, V277, P42219, DOI 10.1074/jbc.M202914200; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314; Zhu HF, 2003, ARCH BIOCHEM BIOPHYS, V413, P67, DOI 10.1016/S0003-9861(03)00081-X	30	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34084	34089		10.1074/jbc.M305826200	http://dx.doi.org/10.1074/jbc.M305826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12826662	hybrid			2022-12-25	WOS:000185047500059
J	Shin, DJ; Osborne, TF				Shin, DJ; Osborne, TF			Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; COENZYME-A REDUCTASE; FATTY-ACID SYNTHASE; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; ALPHA TRANSCRIPTION; NUCLEAR RECEPTORS; LDL RECEPTOR; RAT-LIVER; TRIIODOTHYRONINE	High affinity uptake of serum-derived low density lipoprotein (LDL) cholesterol is accomplished through the LDL receptor in the liver. In mammals, thyroid hormone depletion leads to decreased LDL receptor expression and elevated serum cholesterol. The clinical association in humans has been known since the 1920s; however, a molecular explanation has been lacking. LDL receptor levels are subject to negative feedback regulation by cellular cholesterol through sterol regulatory element-binding protein-2 (SREBP-2). Here we demonstrate that the SREBP-2 gene is regulated by thyroid hormone and that increased SREBP-2 nuclear protein levels in hypothyroid animals results in thyroid hormone-independent activation of LDL receptor gene expression and reversal of the associated hypercholesterolemia. This occurs without effects on other thyroid hormone-regulated genes. Thus, we propose that the decreased LDL receptor and increased serum cholesterol associated with hypothyroidism are secondary to the thyroid hormone effects on SREBP-2. These results suggest that hypercholesterolemia associated with hypothyroidism can be reversed by agents that directly increase SREBP-2. Additionally, these results indicate that mutations or drugs that lower nuclear SREBP-2 would cause hypercholesterolemia.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline; NIAAA NIH HHS [R01 AA026322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABRAMS JJ, 1981, J LIPID RES, V22, P323; Bakker O, 1998, BIOCHEM BIOPH RES CO, V249, P517, DOI 10.1006/bbrc.1998.9174; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DUMAS LH, 2002, THYROID, V12, P287; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; NESS GC, 1995, ARCH BIOCHEM BIOPHYS, V323, P404, DOI 10.1006/abbi.1995.0061; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Osborne TF, 2001, GENE DEV, V15, P1873, DOI 10.1101/gad.916601; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; Takeuchi Y, 2002, ENDOCRINOLOGY, V143, P1346, DOI 10.1210/en.143.4.1346; THOMPSON GR, 1981, P NATL ACAD SCI-BIOL, V78, P2591, DOI 10.1073/pnas.78.4.2591; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Weiss R E, 2000, Rev Endocr Metab Disord, V1, P97, DOI 10.1023/A:1010072605757; Weiss RE, 1997, ENDOCRINOLOGY, V138, P3624, DOI 10.1210/en.138.9.3624; YAMADA T, 1981, J ENDOCRINOL INVEST, V4, P379, DOI 10.1007/BF03348299; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yin LY, 2002, J BIOL CHEM, V277, P19554, DOI 10.1074/jbc.M111771200; Yokoyama C., 1993, CELL, V75, P185; Zhang YQ, 2003, J LIPID RES, V44, P356, DOI 10.1194/jlr.M200283-JLR200	32	177	185	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34114	34118		10.1074/jbc.M305417200	http://dx.doi.org/10.1074/jbc.M305417200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12829694	hybrid			2022-12-25	WOS:000185047500063
J	Khoo, S; Griffen, SC; Xia, Y; Baer, RJ; German, MS; Cobb, MH				Khoo, S; Griffen, SC; Xia, Y; Baer, RJ; German, MS; Cobb, MH			Regulation of insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LOOP-HELIX PROTEINS; MESSENGER-RNA; ISLET CELLS; SIGNAL-TRANSDUCTION; DIABETES-MELLITUS; BINDING PROTEINS; HOMEOBOX FACTOR; RIN-5F CELLS; FACTOR-I	We show that the mitogen-activated protein kinases ERK1/2 are components of the mechanism by which glucose stimulates insulin gene expression. ERK1/2 activity is required for glucose-dependent transcription from both the full-length rat insulin I promoter and the glucose-sensitive isolated E2A3/4 promoter element in intact islets and beta cell lines. Dominant negative ERK2 and MEK inhibitors suppress glucose stimulation of the rat insulin I promoter and the E2A3/4 element. Overexpression of ERK2 is sufficient to stimulate transcription from the E2A3/4 element. The glucose-induced response is dependent upon ERK1/2 phosphorylation of a subset of transcription factors that include Beta2 (also known as NeuroD1) and PDX-1. Phosphorylation increases their functional activity and results in a cumulative transactivation of the promoter. Thus, ERK1/2 act at multiple points to transduce a glucose signal to insulin gene transcription.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344, R01DK055310] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK021344, DK55310] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1995, J CLIN INVEST, V95, P1032, DOI 10.1172/JCI117748; Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496; Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; Dumonteil E, 1996, DIABETES METAB, V22, P164; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Petersen HV, 2002, FEBS LETT, V528, P241, DOI 10.1016/S0014-5793(02)03318-5; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; REDMON JB, 1994, DIABETES, V43, P546, DOI 10.2337/diabetes.43.4.546; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590; Xia ZG, 1996, J NEUROSCI, V16, P5425	63	130	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32969	32977		10.1074/jbc.M301198200	http://dx.doi.org/10.1074/jbc.M301198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810726	hybrid			2022-12-25	WOS:000184901800060
J	Luberto, C; Stonehouse, MJ; Collins, EA; Marchesini, N; El-Bawab, S; Vasil, AI; Vasil, ML; Hannun, YA				Luberto, C; Stonehouse, MJ; Collins, EA; Marchesini, N; El-Bawab, S; Vasil, AI; Vasil, ML; Hannun, YA			Purification, characterization, and identification of a sphingomyelin synthase from Pseudomonas aeruginosa - PlcH is a multifunctional enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC PHOSPHOLIPASE-C; PLASMA-MEMBRANE; RAT-LIVER; NEUTRAL SPHINGOMYELINASE; ALKALINE CERAMIDASE; MOLECULAR-CLONING; GOLGI-APPARATUS; SACCHAROMYCES-CEREVISIAE; CULTURED FIBROBLASTS; MOUSE FIBROBLASTS	Sphingomyelin synthase is the enzyme that synthesizes sphingomyelin (SM) in mammalian cells by transferring a phosphorylcholine moiety from phosphatidylcholine to ceramide. Despite its importance, the gene and/or the protein responsible for this activity has not yet been identified. Here we report the purification, identification, and biochemical characterization of an enzymatic activity that synthesizes SM in Pseudomonas aeruginosa. SM synthase-like activity was found secreted in the culture medium of P. aeruginosa, strains PA01 and PAK, whereas it could not be detected in cultures of Escherichia coli. From the medium of PAK cultures, SM synthase was purified through sequential chromatographic columns. After separation on polyacrylamide-SDS gels and visualization by silver staining, the purified enzyme showed two bands, one of similar to 75 kDa and one of 30- 35 kDa. Interestingly, the highly purified SM synthase preparation also showed neutral sphingomyelinase activity. We therefore investigated whether the protein we purified as SM synthase could actually be the previously identified PlcH, a 78-kDa phospholipase C known to hydrolyze phosphatidylcholine and SM in P. aeruginosa. First, the purified SM synthase preparation contained a 78-kDa protein that reacted with monoclonal antibodies raised against purified PlcH. Second, purified PlcH showed SM synthase activity. Third, using different knockout mutant strains for the PlcH operon, PlcH was found to be necessary for SM synthase activity in P. aeruginosa. Interestingly, SM synthase activity was specific to the Pseudomonas PlcH as other bacterial phospholipases did not display SM synthase activity. Biochemical studies on the Pseudomonas SM synthase confirmed that it is a transferase, similar to the mammalian enzyme, that specifically recognizes the choline head-group and the primary hydroxyl on ceramide. This SM synthase did not have reverse transferase activity. In conclusion, the Pseudomonas PlcH also exerts SM synthase activity; therefore, for the first time, we have identified a structural gene for a SM synthase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Medical University of South Carolina; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Luberto, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, STB Rm 652, Charleston, SC 29425 USA.	luberto@musc.edu			NHLBI NIH HHS [HL43707, HL62608] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062608, R01HL043707] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albi E, 2002, J HEPATOL, V36, P395, DOI 10.1016/S0168-8278(01)00301-4; Albi E, 1999, FEBS LETT, V460, P369, DOI 10.1016/S0014-5793(99)01378-2; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; COLEMAN DC, 1986, MICROB PATHOGENESIS, V1, P549, DOI 10.1016/0882-4010(86)90040-9; CotaGomez A, 1997, INFECT IMMUN, V65, P2904, DOI 10.1128/IAI.65.7.2904-2913.1997; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jaffrezou Jean-Pierre, 2002, Subcell Biochem, V36, P269; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MARGGRAF WD, 1987, BIOCHIM BIOPHYS ACTA, V897, P57, DOI 10.1016/0005-2736(87)90315-4; MARGGRAF WD, 1982, BIOCHIM BIOPHYS ACTA, V710, P314, DOI 10.1016/0005-2760(82)90114-X; MARGGRAF WD, 1981, BIOCHIM BIOPHYS ACTA, V664, P61, DOI 10.1016/0005-2760(81)90028-X; MIROOBRADORS MJ, 1993, CARCINOGENESIS, V14, P941, DOI 10.1093/carcin/14.5.941; Obradors MJM, 1997, BBA-MOL CELL RES, V1359, P1; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; OSTROFF RM, 1990, J BACTERIOL, V172, P5915, DOI 10.1128/jb.172.10.5915-5923.1990; Quest AFG, 1997, ADV EXP MED BIOL, V400, P297; Riboni L, 2001, J BIOL CHEM, V276, P12797, DOI 10.1074/jbc.M011570200; Roelofsen B, 1974, Methods Enzymol, V32, P131; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; Stonehouse MJ, 2002, MOL MICROBIOL, V46, P661, DOI 10.1046/j.1365-2958.2002.03194.x; Sueyoshi N, 2002, J BACTERIOL, V184, P540, DOI 10.1128/JB.184.2.540-546.2002; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANDENHILL A, 1985, BIOCHIM BIOPHYS ACTA, V833, P354, DOI 10.1016/0005-2760(85)90210-3; VASIL ML, 1990, INFECT IMMUN, V58, P4020, DOI 10.1128/IAI.58.12.4020-4029.1990; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; YAMADA A, 1988, EUR J BIOCHEM, V175, P213, DOI 10.1111/j.1432-1033.1988.tb14186.x	46	41	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32733	32743		10.1074/jbc.M300932200	http://dx.doi.org/10.1074/jbc.M300932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799377	hybrid			2022-12-25	WOS:000184901800032
J	Mangin, P; Yuan, YP; Goncalves, I; Eckly, A; Freund, M; Cazenave, JP; Gachet, C; Jackson, SP; Lanza, F				Mangin, P; Yuan, YP; Goncalves, I; Eckly, A; Freund, M; Cazenave, JP; Gachet, C; Jackson, SP; Lanza, F			Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization - Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; IX-V COMPLEX; CYTOPLASMIC DOMAIN; INTEGRIN ALPHA(IIB)BETA(3); ADHESION RECEPTOR; FACTOR BINDING; AGGREGATION; COLLAGEN; ACTIVATION; IB/V/IX	Interaction of the platelet GPIb-V-IX complex with surface immobilized von Willebrand factor (vWf) is required for the capture of circulating platelets and their ensuing activation. In previous work, it was found that GPIb/vWf-mediated platelet adhesion triggers Ca2+ release from intracellular stores, leading to cytoskeletal reorganization and filopodia extension. Despite the potential functional importance of GPIb-induced cytoskeletal changes, the signaling mechanisms regulating this process have remained ill-defined. The studies presented here demonstrate an important role for phospholipase C ( PLC)-dependent phosphoinositide turnover for GPIb-dependent cytoskeletal remodeling. This is supported by the findings that the vWf-GPIb interaction induced a small increase in inositol 1,4,5-triphosphate (IP3) and that treating platelets with the IP3 receptor antagonist APB-2 or the PLC inhibitor U73122 blocked cytosolic Ca2+ flux and platelet shape change. Normal shape change was observed in Galpha(q)(-/-) mouse platelets, excluding a role for PLCbeta isoforms in this process. However, decreased shape change and Ca2+ mobilization were observed in mice lacking PLCgamma2, demonstrating that this isotype played an important, albeit incomplete, role in GPIb signaling. The signaling pathways utilized by GPIb involved one or more members of the Src kinase family as platelet shape change and Ca2+ flux were inhibited by the Src kinase inhibitors PP1 and PP2. Strikingly, shape change and Ca2+ release occurred independently of immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, because these platelet responses were normal in human platelets treated with the anti-FcgammaRIIA blocking monoclonal antibody IV.3 and in mouse platelets deficient in the FcRgamma chain. Taken together, these studies define an important role for PLCgamma2 in GPIb signaling linked to platelet shape change. Moreover, they demonstrate that GPIb-dependent calcium flux and cytoskeletal reorganization involves a signaling pathway distinct from that utilized by ITAM-containing receptors.	Etablissement Francais Sang Alsace, INSERM, U311, F-67065 Strasbourg, France; Monash Univ, Australian Ctr Blood Dis, Dept Med, Clayton, Vic 3127, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Monash University	Lanza, F (corresponding author), Etablissement Francais Sang Alsace, INSERM, U311, 10 Rue Spielmann,BP 36, F-67065 Strasbourg, France.	francois.lanza@efs-alsace.fr	Mangin, Pierre/H-9354-2016; Lanza, Francois/H-9252-2016; Cazenave, Jean-Pierre/AAE-2935-2019; Gachet, Christian/H-9156-2016; Goncalves, Isaac/AAO-8371-2020	Lanza, Francois/0000-0002-5802-4748; Jackson, Shaun/0000-0002-4750-1991; Eckly, Anita/0000-0001-9620-4961				Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; Canobbio I, 2001, J BIOL CHEM, V276, P26022, DOI 10.1074/jbc.M102639200; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; CHOW TW, 1992, BLOOD, V80, P113; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Kanaji T, 2002, BLOOD, V100, P2102, DOI 10.1182/blood-2002-03-0997; Lee SB, 1996, BLOOD, V88, P1684; Mangin P, 2003, FEBS LETT, V542, P53, DOI 10.1016/S0014-5793(03)00337-5; Marshall SJ, 2002, BIOCHEM J, V361, P297, DOI 10.1042/0264-6021:3610297; Mazzucato M, 1996, THROMB HAEMOSTASIS, V75, P655; Milner EP, 1998, J LAB CLIN MED, V131, P49, DOI 10.1016/S0022-2143(98)90077-4; Mistry N, 2000, BLOOD, V96, P3480; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; Moog S, 2001, BLOOD, V98, P1038, DOI 10.1182/blood.V98.4.1038; Munday AD, 2000, BLOOD, V96, P577; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; REDDICK RL, 1982, P NATL ACAD SCI-BIOL, V79, P5076, DOI 10.1073/pnas.79.16.5076; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; SUZUKIINOUE K, 2003, BLOOD           0501, DOI DOI 10.1182/BLOOD-2003-01-0029; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Torti M, 1999, J BIOL CHEM, V274, P13690, DOI 10.1074/jbc.274.19.13690; Ulsemer P, 2001, BIOCHEM J, V358, P295, DOI 10.1042/0264-6021:3580295; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Wu Y, 2003, BLOOD, V101, P3469, DOI 10.1182/blood-2002-03-0806; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241	44	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32880	32891		10.1074/jbc.M302333200	http://dx.doi.org/10.1074/jbc.M302333200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813055	hybrid			2022-12-25	WOS:000184901800049
J	Ryan, CM; Militello, KT; Read, LK				Ryan, CM; Militello, KT; Read, LK			Polyadenylation regulates the stability of Trypanosoma brucei mitochondrial RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MESSENGER-RNA; NADH DEHYDROGENASE; DEVELOPMENTAL REGULATION; PROTEIN COMPLEX; LIFE-CYCLE; SUBUNIT; GENE; DEGRADATION; POLY(A); TRANSCRIPTS	Polyadenylation of RNAs plays a critical role in modulating rates of RNA turnover and ultimately in controlling gene expression in all systems examined to date. In mitochondria, the precise mechanisms by which RNAs are degraded, including the role of polyadenylation, are not well understood. Our previous in organello pulse-chase experiments suggest that poly( A) tails stimulate degradation of mRNAs in the mitochondria of the protozoan parasite Trypanosoma brucei (Militello, K. T., and Read, L. K. ( 2000) Mol. Cell. Biol. 21, 731 - 742). In this report, we developed an in vitro assay to directly examine the effects of specific 3'-sequences on RNA degradation. We found that a salt-extracted mitochondrial membrane fraction preferentially degraded polyadenylated mitochondrially and non-mitochondrially encoded RNAs over their non-adenylated counterparts. A poly( A) tail as short as 5 nucleotides was sufficient to stimulate rapid degradation, although an in vivo tail length of 20 adenosines supported the most rapid decay. A poly( U) extension did not promote rapid RNA degradation, and RNA turnover was slowed by the addition of uridine residues to the poly( A) tail. To stimulate degradation, the poly( A) element must be located at the 3' terminus of the RNA. Finally, we demonstrate that degradation of polyadenylated RNAs occurs in the 3' to 5' direction through the action of a hydrolytic exonuclease. These experiments demonstrate that the poly( A) tail can act as a cis-acting element to facilitate degradation of T. brucei mitochondrial mRNAs.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Read, LK (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	lread@acsu.buffalo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047329, R56AI047329] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47329, AI07614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVADHANI NG, 1979, BIOCHEMISTRY-US, V18, P2673, DOI 10.1021/bi00579a038; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRUN R, 1979, ACTA TROP, V36, P289; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; CORELL RA, 1994, MOL BIOCHEM PARASIT, V64, P65, DOI 10.1016/0166-6851(94)90135-X; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Dziembowski A, 2003, J BIOL CHEM, V278, P1603, DOI 10.1074/jbc.M208287200; Dziembowski A, 1998, MOL GEN GENET, V260, P108, DOI 10.1007/s004380050876; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Gagliardi D, 2001, J BIOL CHEM, V276, P43541, DOI 10.1074/jbc.M106601200; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1987, MOL CELL BIOL, V7, P925, DOI 10.1128/MCB.7.2.925; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Hayman ML, 1999, J BIOL CHEM, V274, P12067, DOI 10.1074/jbc.274.17.12067; JASMER DP, 1985, MOL CELL BIOL, V5, P3041, DOI 10.1128/MCB.5.11.3041; Koslowsky DJ, 1997, MOL BIOCHEM PARASIT, V90, P81, DOI 10.1016/S0166-6851(97)00133-3; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; Kuhn J, 2001, MOL CELL BIOL, V21, P731, DOI 10.1128/MCB.21.3.731-742.2001; Lupold DS, 1999, PLANT CELL, V11, P1565, DOI 10.1105/tpc.11.8.1565; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; Militello KT, 2000, MOL CELL BIOL, V20, P2308, DOI 10.1128/MCB.20.7.2308-2316.2000; Militello KT, 1999, NUCLEIC ACIDS RES, V27, P1377, DOI 10.1093/nar/27.5.1377; READ LK, 1994, MOL BIOCHEM PARASIT, V68, P297, DOI 10.1016/0166-6851(94)90174-0; READ LK, 1992, J BIOL CHEM, V267, P1123; READ LK, 1994, NUCLEIC ACIDS RES, V22, P1489, DOI 10.1093/nar/22.8.1489; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; SOUZA AE, 1993, MOL CELL BIOL, V13, P6832, DOI 10.1128/MCB.13.11.6832; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023	39	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32753	32762		10.1074/jbc.M303552200	http://dx.doi.org/10.1074/jbc.M303552200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12801929	hybrid			2022-12-25	WOS:000184901800034
J	Minakhin, L; Severinov, K				Minakhin, L; Severinov, K			On the role of the Escherichia coli RNA polymerase sigma(70) region 4.2 and alpha-subunit C-terminal domains in promoter complex formation on the extended-10 galP1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 ASIA PROTEIN; THERMAL-ENERGY REQUIREMENT; TRANSCRIPTION INITIATION; DEPENDENT PROMOTERS; BACTERIAL PROMOTERS; RECOGNITION; DNA; PURIFICATION; HOLOENZYME; SEQUENCES	Bacterial promoters of the extended -10 class contain a single consensus element, and the DNA sequence upstream of this element is not critical for promoter activity. Open promoter complexes can be formed on an extended -10 Escherichia coli galP1 promoter at temperatures as low as 6degreesC, when complexes on most promoters are closed. Here, we studied the contribution of upstream contacts to promoter complex formation using galP1 and its derivatives lacking the extended -10 motif and/or containing the -35 promoter consensus element. A panel of E. coli RNA polymerase holoenzymes containing two, one, or no alpha-subunit C-terminal domains (alphaCTD) and either wild-type sigma(70) subunit or sigma(70) lacking region 4.2 was assembled and tested for promoter complex formation. At 37degreesC, alphaCTD and sigma(70) region 4.2 were individually dispensable for promoter complex formation on galP1 derivatives with extended -10 motif. However, no promoter complexes formed when both alphaCTD and sigma(70) region 4.2 were absent. Thus, in the context of an extended -10 promoter, alphaCTD and sigma(70) region 4.2 interactions with upstream DNA can functionally substitute for each other. In contrast, at low temperature, alphaCTD and sigma(70) region 4.2 interactions with upstream DNA were found to be functionally distinct, for sigma(70) region 4.2 but not alphaCTD was required for open promoter complex formation on galP1 derivatives with extended -10 motif. We propose a model involving sigma(70) region 4.2 interaction with the beta flap domain that explains these observations.	Rutgers State Univ, Waksman Inst, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA; Rutgers State Univ, Waksman Inst Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, Dept Biochem & Mol Biol, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [R01 GM59295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; BELYAEVA T, 1993, BIOCHEM J, V296, P851, DOI 10.1042/bj2960851; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; Burns HD, 1996, BIOCHEM J, V317, P305, DOI 10.1042/bj3170305; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Heyduk E, 2001, J BIOL CHEM, V276, P44598, DOI 10.1074/jbc.M107760200; Kamali-Moghaddam M, 2003, J BIOL CHEM, V278, P29701, DOI 10.1074/jbc.M304604200; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303; Minakhin L, 2003, J MOL BIOL, V326, P679, DOI 10.1016/S0022-2836(02)01442-0; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Severinova E, 1998, J MOL BIOL, V279, P9, DOI 10.1006/jmbi.1998.1742; Simeonov MF, 2003, BIOCHEMISTRY-US, V42, P7717, DOI 10.1021/bi0340797; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Urbauer JL, 2002, P NATL ACAD SCI USA, V99, P1831, DOI 10.1073/pnas.032464699; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	29	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	2003	278	32					29710	29718		10.1074/jbc.M304906200	http://dx.doi.org/10.1074/jbc.M304906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	707JF	12801925	hybrid			2022-12-25	WOS:000184507000042
J	Oertle, T; Klinger, M; Stuermer, CAO; Schwab, ME				Oertle, T; Klinger, M; Stuermer, CAO; Schwab, ME			A reticular rhapsody: phylogenic evolution and nomenclature of the RTN/Nogo gene family	FASEB JOURNAL			English	Article						reticulon; intron loss; endoplasmic reticulum	MYELIN-ASSOCIATED GLYCOPROTEIN; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL EXPRESSION; GENOMIC ORGANIZATION; NEURITE OUTGROWTH; NOGO-A; PROTEIN; IDENTIFICATION; RECEPTOR	Reticulon (RTN) genes code for a family of proteins relatively recently described in higher vertebrates. The four known mammalian paralogues (RTN1, - 2, - 3, and - 4/Nogo) have homologous carboxyl termini with two characteristic large hydrophobic regions. Except for RTN4-A/Nogo-A, thought to be an inhibitor for neurite outgrowth, restricting the regenerative capabilities of the mammalian CNS after injury, the functions of other family members are largely unknown. The overall occurrence of RTNs in different phyla and the evolution of the RTN gene family have hitherto not been analyzed. Here we expound data showing that the RTN family has arisen during early eukaryotic evolution potentially concerted to the establishment of the endomembrane system. Over 250 reticulon-like (RTNL) genes were identified in deeply diverging eukaryotes, fungi, plants, and animals. A systematic nomenclature for all identified family members is introduced. The analysis of exon-intron arrangements and of protein homologies allowed us to isolate key steps in the history of these genes. Our data corroborate the hypothesis that present RTNs evolved from an intron-rich reticulon ancestor mainly by the loss of different introns in diverse phyla. We also present evidence that the exceptionally large RTN4-A-specific exon 3, which harbors a potent neurite growth inhibitory region, may have arisen de novo similar to 350 MYA during transition to land vertebrates. These data emphasize on the one hand the universal role of reticulons in the eukaryotic system and on the other hand the acquisition of putative new functions through acquirement of novel amino-terminal exons.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Konstanz	Oertle, T (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	oertle@hifo.unizh.ch	Schwab, Martin E/B-6818-2016					Abi-Rached L, 2002, NAT GENET, V31, P100, DOI 10.1038/ng855; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BEATTIE MS, 1990, J NEUROBIOL, V21, P1108, DOI 10.1002/neu.480210714; Becker T, 1998, J NEUROSCI, V18, P5789; Burchett SA, 2002, J BIOL CHEM, V277, P22156, DOI 10.1074/jbc.M202254200; Canestro C, 2002, J MOL EVOL, V54, P81, DOI 10.1007/s00239-001-0020-2; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; De Souza SJ, 1998, P NATL ACAD SCI USA, V95, P5094, DOI 10.1073/pnas.95.9.5094; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fragaki K, 2001, VACCINE, V19, P1701, DOI 10.1016/S0264-410X(00)00398-4; GAY GD, 1994, PROTEIN ENG, V7, P103; Godoy C, 1996, YEAST, V12, P983, DOI 10.1002/(SICI)1097-0061(199608)12:10<983::AID-YEA2>3.0.CO;2-D; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hamada N, 2002, CELL MOL BIOL, V48, P163; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huber AB, 2002, J NEUROSCI, V22, P3553; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Iwahashi J, 2002, BIOCHEM BIOPH RES CO, V293, P698, DOI 10.1016/S0006-291X(02)00282-6; KAUSHIK R, 2002, ANN DROS RES C, V43, pC186; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Llopart A, 2002, P NATL ACAD SCI USA, V99, P8121, DOI 10.1073/pnas.122570299; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Niederost B, 2002, J NEUROSCI, V22, P10368; Oertle T, 2003, ONCOGENE, V22, P1390, DOI 10.1038/sj.onc.1206278; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; OERTLE T, 2003, IN PRESS J NEUROSCI; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Suffia I, 2000, INFECT IMMUN, V68, P630, DOI 10.1128/IAI.68.2.630-636.2000; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WANNER M, 1995, J NEUROSCI, V15, P7500; Wendland B, 2001, NAT CELL BIOL, V3, pE133, DOI 10.1038/35078592; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOOD MR, 1979, SCIENCE, V206, P344, DOI 10.1126/science.482943; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	55	139	157	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1238	1247		10.1096/fj.02-1166hyp	http://dx.doi.org/10.1096/fj.02-1166hyp			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832288	Green Submitted			2022-12-25	WOS:000184471600035
J	Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I				Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I			VDUP1 upregulated by TGF-beta 1 and 1,25-dihydorxyvitamin D-3 inhibits tumor cell growth by blocking cell-cycle progression	ONCOGENE			English	Article						VDUP1; tumor; TGF-beta 1; cell cycle; PLZF	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; PML-RAR-ALPHA; HISTONE DEACETYLASE; MONOCYTIC DIFFERENTIATION; THIOREDOXIN FUNCTION; HL-60 CELLS; GENE; PLZF; EXPRESSION	Vitamin D-3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-beta1 and 1,25(OH)(2)D-3, its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cell-cycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.	Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Genome Res Ctr, Taejon 305333, South Korea; Chungnam Natl Univ, Coll Med, Dept Pathol, Dept Anat, Taejon 301131, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Choi, I (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea.			Yang, Young/0000-0003-4239-0804				BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bocchia M, 1997, LEUKEMIA RES, V21, P439, DOI 10.1016/S0145-2126(96)00085-9; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kirshenbaum LA, 2001, CIRC RES, V88, P978, DOI 10.1161/hh1001.091865; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ludwig DL, 2001, GENE, V269, P103, DOI 10.1016/S0378-1119(01)00455-3; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Olsson I, 1996, EUR J HAEMATOL, V57, P1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Piek JMJ, 2001, HISTOPATHOLOGY, V38, P481, DOI 10.1046/j.1365-2559.2001.1163c.x; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sainty D, 2000, BLOOD, V96, P1287; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 2000, CANCER RES, V60, P3689; Takahashi Y, 2002, ONCOL REP, V9, P75; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	37	229	241	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4035	4046		10.1038/sj.onc.1206610	http://dx.doi.org/10.1038/sj.onc.1206610			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821938				2022-12-25	WOS:000183707600007
J	Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR				Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR			Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer	ONCOGENE			English	Article						breast cancer; invasion; microarrays; microdissection	LASER CAPTURE MICRODISSECTION; BINDING PROTEIN; INVASION; PROGRESSION; METASTASIS; PATTERNS; ADENOCARCINOMA; GROWTH; ALPHA; CDNA	Comparison of gene expression changes between cancer cells at the periphery and in the centre of breast cancers was performed using a combination of microdissection and microarray analysis. Cancer cells from the two areas were pooled separately from five patients with ductal carcinoma in situ and separately from five patients with frankly invasive cancer. Limited total RNA, 100-200 ng, from this microdissected tissue required use of the Atlas SMART(TM) Probe Amplification Kit to synthesize and amplify cDNA and make P-33-labelled probes. Probes were then hybridized to Atlas Human Cancer 1.2 Arrays containing 1176 known genes. Triplicate analysis revealed that 22 genes changed their expression levels in the periphery relative to the central region: 15 upregulated and seven down-regulated (arbitrary threshold of 1.5-fold or greater). Differences in RNA levels were confirmed by quantitative real-time PCR for two of the genes and by changes in protein levels, detected by immunohistochemistry, for a couple of representative gene products. Thus, changes in gene expression associated with variation in microanatomical location of neoplastic cells can be detected within even small developing tumour masses.	St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, London SE1 7EH, England; St Thomas Hosp, Rayne Inst, Canc Res UK, Cell Adhes & Dis Lab, London SE1 7EH, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK, London, England; Guys Hosp, Clin Oncol Dept, Hedley Atkins Breast Pathol Lab, London, England; St Bartholomews Hosp, Sch Med, Canc Res UK, Translat Oncol Lab,Queen Mary Coll, London, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; University of London; Queen Mary University London	Hart, IR (corresponding author), St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, 4th Floor,Lambeth Wing, London SE1 7EH, England.		Van Trappen, Philippe/ABF-7431-2021	Van Trappen, Philippe/0000-0002-9784-7974; Marshall, John/0000-0002-0494-2295				Assmann V, 2001, J PATHOL, V195, P191, DOI 10.1002/path.941; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DeRisi J, 1996, NAT GENET, V14, P457; Edmonds BT, 1996, J CELL SCI, V109, P2705; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HALL PA, 1994, BRIT J CANCER, V70, P244, DOI 10.1038/bjc.1994.287; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Luzzi V, 2001, AM J PATHOL, V158, P2005, DOI 10.1016/S0002-9440(10)64672-X; Mariani L, 2001, CANCER RES, V61, P4190; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Scheidl SJ, 2002, AM J PATHOL, V160, P801, DOI 10.1016/S0002-9440(10)64903-6; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schutze K, 1998, CELL MOL BIOL, V44, P735; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Van Trappen PO, 2001, LANCET, V357, P15, DOI 10.1016/S0140-6736(00)03566-2; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01	24	58	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3742	3748		10.1038/sj.onc.1206428	http://dx.doi.org/10.1038/sj.onc.1206428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802281				2022-12-25	WOS:000183551000008
J	Suo, ZM; Wu, M; Citron, BA; Palazzo, RE; Festoff, BW				Suo, ZM; Wu, M; Citron, BA; Palazzo, RE; Festoff, BW			Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEASE-ACTIVATED RECEPTOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; APOLIPOPROTEIN-E; NEUROFIBRILLARY TANGLES; CELL-DEATH; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; OXIDATIVE STRESS	Tau hyperphosphorylation, leading to self-aggregation, is widely held to underlie the neurofibrillary degeneration found in Alzheimer's disease (AD) and other tauopathies. However, it is unclear exactly what environmental factors may trigger this pathogenetic tau hyperphosphorylation. From several perspectives, the coagulation serine protease, thrombin, has been implicated in AD and activates several different protein kinase pathways but has not previously been shown how it may contribute to AD pathogenesis. Here we report that nanomolar thrombin induced rapid tau hyperphosphorylation and aggregation in murine hippocampal neurons via protease-activated receptors, which was followed by delayed synaptophysin reduction and apoptotic neuronal death. Mechanistic study revealed that a persistent thrombin signaling via protease-activated receptor 4 and prolonged downstream p44/42 mitogenactivated protein kinase activation are at least in part responsible. These results pathogenetically linked thrombin to subpopulations of AD and other tauopathies associated with cerebrovascular damage. Such knowledge may be instrumental in transforming therapeutic paradigms.	Vet Adm Med Ctr, Neurobiol Res Lab 151, Kansas City, MO 64128 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Univ Kansas, Dept Neurol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Pharmacol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Toxicol & Therapeut, Sch Med, Kansas City, KS 66170 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Festoff, BW (corresponding author), Vet Adm Med Ctr, Neurobiol Res Lab 151, Kansas City, MO 64128 USA.	bfestoff@kumc.edu						AKIYAMA H, 1994, TOHOKU J EXP MED, V174, P295, DOI 10.1620/tjem.174.295; AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Alonso AD, 2001, J BIOL CHEM, V276, P37967; Armstrong RA, 2002, NEUROPATHOLOGY, V22, P133, DOI 10.1046/j.1440-1789.2002.00446.x; BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; BELL MA, 1981, ACTA NEUROPATHOL, V53, P299, DOI 10.1007/BF00690372; Bi XN, 2001, P NATL ACAD SCI USA, V98, P8832, DOI 10.1073/pnas.151253098; Bondareff W, 1998, J NEUROSCI RES, V52, P498, DOI 10.1002/(SICI)1097-4547(19980601)52:5<498::AID-JNR2>3.0.CO;2-7; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; Brewer GJ, 1996, J NEUROCHEM, V67, P119; BREWER GJ, 1995, BRAIN RES, V683, P258, DOI 10.1016/0006-8993(95)00332-K; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; CARNEY DH, 1992, SEMIN THROMB HEMOST, V18, P91, DOI 10.1055/s-2007-1002414; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CHEN J, 1994, J BIOL CHEM, V269, P16041; CHOI BH, 1990, AM J PATHOL, V137, P741; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CROMACK DT, 1992, J SURG RES, V53, P117, DOI 10.1016/0022-4804(92)90022-R; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; Dewachter I, 2001, BIOCHEM SOC SYMP, V67, P203; Donovan FM, 1997, J NEUROSCI, V17, P5316; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Gill JS, 1998, BRAIN RES, V797, P321, DOI 10.1016/S0006-8993(98)00344-8; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GRABHAM P, 1995, J NEUROCHEM, V64, P583; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Hall GF, 2001, AM J PATHOL, V158, P235, DOI 10.1016/S0002-9440(10)63962-4; HAWKINS RL, 1986, BRAIN RES, V398, P63, DOI 10.1016/0006-8993(86)91250-3; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Imahori K, 1997, J BIOCHEM, V121, P179; Imahori K, 1998, NEUROBIOL AGING, V19, pS93, DOI 10.1016/S0197-4580(98)00025-6; Iqbal K, 1998, J NEURAL TRANSM-SUPP, P169; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kim KY, 2002, NEUROREPORT, V13, P849, DOI 10.1097/00001756-200205070-00022; Lau Lit-Fui, 2002, Current Topics in Medicinal Chemistry, V2, P395, DOI 10.2174/1568026024607526; Launer LJ, 2002, AGEING RES REV, V1, P61, DOI 10.1016/S0047-6374(01)00364-5; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maccioni RB, 2001, ARCH MED RES, V32, P367, DOI 10.1016/S0188-4409(01)00316-2; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MEANS ED, 1986, ANN NY ACAD SCI, V485, P314, DOI 10.1111/j.1749-6632.1986.tb34593.x; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Pansari K, 2002, INT J CLIN PRACT, V56, P197; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Pindon A, 1998, EUR J BIOCHEM, V255, P766, DOI 10.1046/j.1432-1327.1998.2550766.x; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Sayas CL, 2002, J NEUROSCI, V22, P6863; Siman R, 1999, NEUROSCIENCE, V92, P1425, DOI 10.1016/S0306-4522(99)00034-2; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; SMIRNOVA IV, 1994, J NEUROL SCI, V127, P207, DOI 10.1016/0022-510X(94)90074-4; Smirnova IV, 1998, J MOL NEUROSCI, V10, P31, DOI 10.1007/BF02737083; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SNIDER RM, 1983, SCIENCE, V221, P566, DOI 10.1126/science.6306770; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; STIERNBERG J, 1993, THROMB HAEMOSTASIS, V70, P158; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Suo ZM, 1998, ALZHEIMERS REP, V1, P381; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Terry RD, 1998, J NEURAL TRANSM-SUPP, P141; Tolar M, 1997, J NEUROSCI, V17, P5678; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Ugolini G, 1997, NEUROREPORT, V8, P3709, DOI 10.1097/00001756-199712010-00010; VAUGHAN PJ, 1994, BRAIN RES, V668, P160, DOI 10.1016/0006-8993(94)90521-5; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	104	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37681	37689		10.1074/jbc.M301406200	http://dx.doi.org/10.1074/jbc.M301406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12821672	hybrid			2022-12-25	WOS:000185437200084
J	Wang, WL; Yeh, SF; Chang, YI; Hsiao, SF; Lian, WN; Lin, CH; Huang, CYF; Lin, WJ				Wang, WL; Yeh, SF; Chang, YI; Hsiao, SF; Lian, WN; Lin, CH; Huang, CYF; Lin, WJ			PICK1, an anchoring protein that specifically targets protein kinase C alpha to mitochondria selectively upon serum stimulation in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAIN; BINDING-PROTEIN; ACTIVE MITOCHONDRIA; PLASMA-MEMBRANE; TIS21 PROTEIN; TRANSLOCATION; PHOSPHORYLATION; ORGANIZATION; CELLS; LOCALIZATION	PICK1 binds to protein kinase Calpha (PKCalpha) through the carboxylate-binding loop in its PDZ (PSD95/Disc-large/ZO-1) domain and the C terminus of PKCalpha. We have previously shown that PICK1 modulates the catalytic activity of PKC selectively toward the antiproliferative gene TIS21. To investigate whether PICK1 plays a role in targeting activated PKCalpha to a particular intracellular compartment in addition to regulating PKC activity, we examine the localization of PICK1 and PKCalpha in response to various stimuli. Double staining with organelle markers and anti-rPICK1 antibodies reveals that PICK1 is associated with mitochondria but not with endoplasmic reticulum or Golgi in NIH 3T3 cells. Deletion of the PDZ domain impairs the mitochondria localization of PICK1, whereas mutations in the carboxylate-binding loop do not have an effect, suggesting that PICK1 can bind PKCalpha and mitochondria simultaneously. Upon serum stimulation, PICK1 translocates and displays a dense ring-like structure around the nucleus, where it still associates with mitochondria. A substantial portion of PKCalpha is concomitantly found in the condense perinuclear region. The C terminal-deleted PKCalpha fails to translocate and remains a diffuse cytoplasmic distribution, indicating that a direct interaction between PICK1 and PKCalpha is required for PKCalpha anchoring to mitochondria. 12-O-Tetradecanoylphorbol-13-acetate stimulation, in contrast, causes translocation of PKCalpha to the plasma membrane, whereas the majority of PICK1 remains in a cytoplasmic punctate pattern. Deletion at the C terminus of PKCalpha has no effect on 12-O-tetradecanoylphorbol-13-acetate-induced translocation. These findings indicate a previously unidentified role for PICK1 in anchoring PKCalpha to mitochondria in a ligand-specific manner.	Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Dept Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Lin, WJ (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.		Huang, Chi-Ying/AFL-7729-2022; Chang, Yuan-I/AAY-1711-2021; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Barnett DK, 1997, MOL REPROD DEV, V48, P227, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;227::AID-MRD10&gt;3.0.CO;2-V; Boudin H, 2001, J BIOL CHEM, V276, P30270, DOI 10.1074/jbc.M102991200; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dev KK, 2000, J NEUROSCI, V20, P7252; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murata T, 2000, J GEN VIROL, V81, P401, DOI 10.1099/0022-1317-81-2-401; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Sun QY, 2001, REPRODUCTION, V122, P155, DOI 10.1530/rep.0.1220155; Takeya R, 2000, BIOCHEM BIOPH RES CO, V267, P149, DOI 10.1006/bbrc.1999.1932; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	37	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37705	37712		10.1074/jbc.M304619200	http://dx.doi.org/10.1074/jbc.M304619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12826667	hybrid			2022-12-25	WOS:000185437200087
J	Koppaka, V; Paul, C; Murray, IVJ; Axelsen, PH				Koppaka, V; Paul, C; Murray, IVJ; Axelsen, PH			Early synergy between A beta 42 and oxidatively damaged membranes in promoting amyloid fibril formation by A beta 40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; BETA-PROTEIN; ALZHEIMERS-DISEASE; INFRARED-SPECTROSCOPY; LIPID-PEROXIDATION; ULTRASTRUCTURAL EVIDENCE; INTENSITY DISTRIBUTION; PRECURSOR PROTEIN; DUTCH TYPE; PEPTIDE	Oxidative lipid membrane damage is known to promote the misfolding of Abeta42 into pathological beta structure. In fully developed senile plaques of Alzheimer's disease, however, it is the shorter and more soluble amyloid beta protein, Abeta40, that predominates. To investigate the role of oxidative membrane damage in the misfolding of Abeta40, we have examined its interaction with supported lipid monolayer membranes using internal reflection infrared spectroscopy. Oxidatively damaged lipids modestly increased Abeta40 accumulation, with adsorption kinetics and a conformation that are distinct from that of Abeta42. In stark contrast, pretreatment of oxidatively damaged monolayer membranes with Abeta42 vigorously promoted Abeta40 accumulation and misfolding. Pretreatment of saturated or undamaged membranes with Abeta42 had no such effect. Parallel studies of lipid bilayer vesicles using a dye binding assay to detect fibril formation and electron microscopy to examine morphology demonstrated that Abeta42 pretreatment of oxidatively damaged membranes promoted the formation of mature Abeta40 amyloid fibrils. We conclude that oxidative membrane damage and Abeta42 act synergistically at an early stage to promote fibril formation by Abeta40. This synergy could be detected within minutes using internal reflection spectroscopy, whereas a dye-binding assay required several days and much higher protein concentrations to demonstrate this synergy.	Univ Penn, Sch Med, Johnson Fdn Mol Biophys, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Fdn Mol Biophys, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Axelsen, PH (corresponding author), Univ Penn, Sch Med, Johnson Fdn Mol Biophys, Dept Pharmacol, Philadelphia, PA 19104 USA.	axe@pharm.med.upenn.edu	Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360	NHLBI NIH HHS [HL68186] Funding Source: Medline; NIA NIH HHS [AG20238] Funding Source: Medline; NIGMS NIH HHS [GM54617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG020238, R01AG020238] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; AXELSEN PH, 1995, APPL SPECTROSC, V49, P526, DOI 10.1366/0003702953964273; Axelsen PH, 1996, PROG BIOPHYS MOL BIO, V66, P227, DOI 10.1016/S0079-6107(97)00007-2; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Brauner JW, 2000, J AM CHEM SOC, V122, P677, DOI 10.1021/ja992522o; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; Choo DW, 1996, MACROMOLECULES, V29, P355, DOI 10.1021/ma950703e; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Dluhy RA, 1998, THIN SOLID FILMS, V327, P308, DOI 10.1016/S0040-6090(98)00651-8; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; GANGANI RA, 2002, BIOCHEMISTRY-US, V41, P15296; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Koppaka V, 2001, LANGMUIR, V17, P6309, DOI 10.1021/la010731s; Kubelka J, 2001, J AM CHEM SOC, V123, P6142, DOI 10.1021/ja010270x; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Lynch T, 2000, EXP GERONTOL, V35, P445, DOI 10.1016/S0531-5565(00)00112-1; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; McLaurin J, 2002, ANN NY ACAD SCI, V977, P376, DOI 10.1111/j.1749-6632.2002.tb04840.x; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Natte R, 1999, ACTA NEUROPATHOL, V98, P577, DOI 10.1007/s004010051121; Nesloney CL, 1996, BIOORGAN MED CHEM, V4, P739, DOI 10.1016/0968-0896(96)00051-X; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SELKOE DJ, 1995, NAT MED, V1, P998, DOI 10.1038/nm1095-998; Silvestro L, 2000, BIOPHYS J, V79, P1465, DOI 10.1016/S0006-3495(00)76398-3; Silvestro L, 1999, BIOCHEMISTRY-US, V38, P113, DOI 10.1021/bi981289o; Silvestro L, 1998, CHEM PHYS LIPIDS, V96, P69, DOI 10.1016/S0009-3084(98)00081-4; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; SUSI H, 1967, J BIOL CHEM, V242, P5460; TAMM LK, 1998, Q REV BIOPHYS, V30, P1; Torp R, 2000, NEUROSCIENCE, V96, P495, DOI 10.1016/S0306-4522(99)00568-0; VOSSEN RCRM, 1993, LIPIDS, V28, P857, DOI 10.1007/BF02536243; Weinstein EA, 2000, J BIOL CHEM, V275, P22925, DOI 10.1074/jbc.M002438200; White AR, 1999, J NEUROSCI, V19, P9170; Wimley WC, 1998, J MOL BIOL, V277, P1091, DOI 10.1006/jmbi.1998.1640; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yamaguchi H, 2000, J NEUROPATH EXP NEUR, V59, P723, DOI 10.1093/jnen/59.8.723; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; ZAMAN Z, 1992, AGE AGEING, V21, P91, DOI 10.1093/ageing/21.2.91	59	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36277	36284		10.1074/jbc.M301334200	http://dx.doi.org/10.1074/jbc.M301334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12821671	hybrid			2022-12-25	WOS:000185318300051
J	Lin, HR; Ting, NSY; Qin, J; Lee, WH				Lin, HR; Ting, NSY; Qin, J; Lee, WH			M phase-specific phosphorylation of BRCA2 by polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; HOMOLOGY-DIRECTED REPAIR; DOUBLE-STRAND BREAKS; CELL-CYCLE; RADIATION HYPERSENSITIVITY; RECOMBINATIONAL REPAIR; CHROMOSOME STABILITY; RETINOBLASTOMA GENE; MITOTIC CHECKPOINT; DNA RECOMBINATION	BRCA2 is a breast tumor susceptibility gene encoding a 390-kDa protein with functions in maintaining genomic stability and cell cycle progression. Evidence has been accumulated to support the concept that BRCA2 has a critical role in homologous recombination of DNA double-stranded breaks by interacting with RAD51. In addition, BRCA2 may have chromatin modifying activity through interaction with a histone acetyltransferase protein, p300/CBP-associated factor (P/ CAF). To explore how the functions of BRCA2 may be regulated, the post-translational modifications of BRCA2 throughout the cell cycle were examined. We found that BRCA2 is hyperphosphorylated specifically in M phase and becomes dephosphorylated as cells exit M phase and enter interphase. This specific phosphorylation of BRCA2 was not observed in cells treated with DNA-damaging agents. Systematic mapping of the potential mitosis specific phosphorylation sites revealed the N-terminal 284 amino acids of BRCA2 (BR-N1) as the major region of phosphorylation and mass spectrometric analysis identified two phosphopeptides that contain "phosphorylation consensus motifs" for Polo-like kinase 1 (Plk1). Phosphorylation of BR-N1 with Plk1 recapitulated the electrophoretic mobility change as seen in BR-N1 isolated from M phase cells. Plk1interacts with BRCA2 in vivo, and mutation of Ser(193), Ser(205/206), and Thr(203/207) to Ala in BR-N1 abolished Plk1 phosphorylation, suggesting that BRCA2 is the substrate of Plk1. Furthermore, both the hyperphosphorylated and hypophosphorylated forms of BRCA2 bind to RAD51, whereas the M phase hyperphosphorylated form of BRCA2 no longer associates with the P/ CAF, suggesting that the dissociation of P/CAF-BRCA2 complex is regulated by phosphorylation. Taken together, these results implicate a potential role of BRCA2 in modulating M phase progression.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Baylor Coll Med, Dept Cell Biol, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	whlee@uci.edu			NCI NIH HHS [CA 94170, CA 81020] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081020, R01CA094170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertwistle D, 1997, CANCER RES, V57, P5485; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Donaldson MM, 2001, J CELL SCI, V114, P2357; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Futamura M, 2000, CANCER RES, V60, P1531; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nordling M, 1998, CANCER RES, V58, P1372; Park M, 2000, CANCER RES, V60, P542; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Vaughn JP, 1996, CANCER RES, V56, P4590; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2001, CURR OPIN CELL BIOL, V13, P338; Wang SC, 2002, CANCER RES, V62, P1311; Weitzer S, 2002, DEV CELL, V2, P381, DOI 10.1016/S1534-5807(02)00155-7; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan Y, 2001, J BIOL CHEM, V276, P48318, DOI 10.1074/jbc.M102557200; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	69	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35979	35987		10.1074/jbc.M210659200	http://dx.doi.org/10.1074/jbc.M210659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12815053	hybrid			2022-12-25	WOS:000185318300015
J	Calzolai, L; Zahn, R				Calzolai, L; Zahn, R			Influence of pH on NMR structure and stability of the human prion protein globular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION; HYDROGEN-EXCHANGE; ACIDIC PH; CONVERSION; PRP; PROGRAM; BRAIN; PRP(121-231); CONFORMATION; INTERMEDIATE	The NMR structure of the globular domain of the human prion protein (hPrP) with residues 121 - 230 at pH 7.0 shows the same global fold as the previously published structure determined at pH 4.5. It contains three alpha-helices, comprising residues 144 - 156, 174 - 194, and 200 - 228, and a short anti-parallel beta-sheet, comprising residues 128 - 131 and 161 - 164. There are slight, strictly localized, conformational changes at neutral pH when compared with acidic solution conditions: helix alpha1 is elongated at the C-terminal end with residues 153 - 156 forming a 3(10)-helix, and the population of helical structure in the C-terminal two turns of helix alpha2 is increased. The protonation of His(155) and His(187) presumably contributes to these structural changes. Thermal unfolding monitored by far UV CD indicates that hPrP-(121-230) is significantly more stable at neutral pH. Measurements of amide proton protection factors map local differences in protein stability within residues 154 - 157 at the C-terminal end of helix alpha1 and residues 161 - 164 of beta-strand 2. These two segments appear to form a separate domain that at acidic pH has a larger tendency to unfold than the overall protein structure. This domain could provide a "starting point" for pH-induced unfolding and thus may be implicated in endosomic PrPC to PrPSc conformational transition resulting in transmissible spongiform encephalopaties.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Calzolai, L (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.							Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; ARMSTRONG KM, 1993, P NATL ACAD SCI USA, V90, P11337, DOI 10.1073/pnas.90.23.11337; ARNOLD JE, 1995, J PATHOL, V176, P403, DOI 10.1002/path.1711760412; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Chishti MA, 1997, NEUROSCI LETT, V234, P11; Cornell WD, 1996, J AM CHEM SOC, V118, P2309, DOI 10.1021/ja955032e; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KIM D, 1994, J MOL BIOL, V240, P385, DOI 10.1006/jmbi.1994.1452; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Morrissey MP, 1999, P NATL ACAD SCI USA, V96, P11293, DOI 10.1073/pnas.96.20.11293; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Riesner D, 2001, CONTRIB MICROBIOL, V7, P7; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Weissmann C, 2002, P NATL ACAD SCI USA, V99, P16378, DOI 10.1073/pnas.172403799; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; WISHART DS, 1995, J BIOMOL NMR, V5, P332, DOI 10.1007/BF00211764; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	50	158	167	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35592	35596		10.1074/jbc.M303005200	http://dx.doi.org/10.1074/jbc.M303005200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12826672	hybrid			2022-12-25	WOS:000185164400103
J	Konishi, A; Berk, BC				Konishi, A; Berk, BC			Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-II; FOCAL ADHESIONS; GENE-EXPRESSION; BINDING; MECHANISM; SRC; MICRODOMAINS; INHIBITION; MIGRATION	We hypothesized that glucose-mediated alterations in vascular smooth muscle cell signal transduction contribute to diabetic complications. We found enhanced AngII activation of Akt and extracellular ERK1/2 in vascular smooth muscle cells incubated with high glucose (27.5 mM) compared with low glucose (5.5 mM). Because AngII-mediated transactivation of the epidermal growth factor receptor (EGFR) is important in Akt and ERK1/2 activation, we studied the effects of glucose on EGFR function. The EGFR in cells cultured for 48 h in low glucose was smaller (145 kDa) than the EGFR in cells cultured with high glucose (170 kDa). The shift from the 170-kDa isoform to the 145-kDa isoform was reversible and dependent upon glucose concentration with EC50 similar to 1 mM. N-Glycosylation was responsible because peptide N-glycosidase F treatment of isolated 170-kDa EGFR yielded a single band at 145 kDa. Cell surface biotinylation showed that the 145-kDa EGFR was present on plasma membrane. AngII and other G-protein-coupled receptor ligands known to transactivate EGFR phosphorylated the 170-kDa EGFR but not the 145-kDa EGFR, whereas EGF, heparin-binding EGF-like growth factor, and transforming growth factor-alpha phosphorylated both receptors. Subcellular fractionation showed that the 145-kDa receptor localized to a different plasma membrane domain than the 170-kDa receptor. These results establish a novel mechanism by which glucose-dependent EGFR N-glycosylation modulates AngII signal transduction and suggest a potential mechanism for pathogenic effects of AngII in diabetic vasculopathy.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115				Ahn JD, 2001, DIABETOLOGIA, V44, P713, DOI 10.1007/s001250051680; Amiri F, 1999, J BIOL CHEM, V274, P32382, DOI 10.1074/jbc.274.45.32382; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Cai B, 1998, J CELL PHYSIOL, V177, P282, DOI 10.1002/(SICI)1097-4652(199811)177:2<282::AID-JCP10>3.0.CO;2-C; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Gerstein HC, 2000, LANCET, V355, P253; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Hwang JB, 1999, J BIOL CHEM, V274, P22813, DOI 10.1074/jbc.274.32.22813; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kalmes A., 2001, ANN NY ACAD SCI, V947, P54; KITZMAN HH, 1993, J BIOL CHEM, V268, P1320; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PRATT RM, 1978, NATURE, V272, P68, DOI 10.1038/272068a0; Renard CB, 2001, DIABETOLOGIA, V44, P1067; Saito S, 2002, BIOCHEM BIOPH RES CO, V294, P1023, DOI 10.1016/S0006-291X(02)00595-8; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Takeda K, 2001, ARTERIOSCL THROM VAS, V21, P868, DOI 10.1161/01.ATV.21.5.868; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Zheng Z, 1997, J CLIN INVEST, V100, P1217, DOI 10.1172/JCI119635	37	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35049	35056		10.1074/jbc.M304913200	http://dx.doi.org/10.1074/jbc.M304913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829718	hybrid			2022-12-25	WOS:000185164400038
J	Kim, SH; Ikeuchi, T; Yu, CJ; Sisodia, SS				Kim, SH; Ikeuchi, T; Yu, CJ; Sisodia, SS			Regulated hyperaccumulation of presenilin-1 and the "gamma-secretase" complex - Evidence for differential intramembranous processing of transmembrane substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE PRODUCTION; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; NICASTRIN COMPLEXES; GOLGI-APPARATUS; APH-1 INTERACTS; IN-VIVO; NOTCH; CLEAVAGE	Intramembranous "gamma-secretase" processing of beta-amyloid precursor protein (APP) and other transmembrane proteins, including Notch, is mediated by a macromolecular complex consisting of presenilins (PSs), nicastrin (NCT), APH-1, and PEN-2. We now demonstrate that in cells coexpressing PS1, APH-1, and NCT, full-length PS1 accumulates to high levels and is fairly stable. Upon expression of PEN-2, the levels of PS1 holoprotein are significantly reduced, commensurate with an elevation in levels of PS1 fragments. These findings suggest that APH-1 and NCT are necessary for stabilization of full-length PS1 and that PEN-2 is critical for the proteolysis of stabilized PS1. In N2a and 293 cell lines that stably overexpress PS1, APH-1, NCT, and PEN-2, PS1 fragment levels are elevated by up to 10-fold over endogenous levels. In these cells, we find a marked accumulation of the APP-CTFgamma (AICD) fragment and a concomitant reduction in levels of both APP-CTFbeta and CTFalpha. Moreover, the production of the gamma-secretase-generated Notch S3/NICD derivative is modestly elevated. However, we failed to observe a corresponding increase in levels of secreted Abeta peptides in the medium of these cells. These results lead us to conclude that, although the PS1, APH-1, NCT, and PEN-2 are essential for gamma-secretase activity, the proteolysis of APP-CTF and Notch S2/NEXT are differentially regulated and require the activity of additional cofactors that promote production of AICD, NICD, and Abeta.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.		Yu, Chunjiang/E-9419-2012		NIA NIH HHS [AG021494] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Blat Y, 2002, BIOCHEM BIOPH RES CO, V299, P569, DOI 10.1016/S0006-291X(02)02705-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Lamb BT, 1999, NAT NEUROSCI, V2, P695, DOI 10.1038/11154; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Siman R, 2003, J NEUROCHEM, V84, P1143, DOI 10.1046/j.1471-4159.2003.01616.x; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; VANNOSTRAND WE, 1989, NATURE, V341, P546; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	63	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33992	34002		10.1074/jbc.M305834200	http://dx.doi.org/10.1074/jbc.M305834200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821663	hybrid			2022-12-25	WOS:000185047500047
J	Mitchell, R; Robertson, DN; Holland, PJ; Collins, D; Lutz, EM; Johnson, MS				Mitchell, R; Robertson, DN; Holland, PJ; Collins, D; Lutz, EM; Johnson, MS			ADP-ribosylation factor-dependent phospholipase D activation by the M-3 muscarinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMA-MEMBRANE; MAMMALIAN-CELLS; BREFELDIN-A; INTRACELLULAR-LOCALIZATION; TYROSINE PHOSPHORYLATION; SUBCELLULAR-DISTRIBUTION; ACETYLCHOLINE-RECEPTOR; COUPLED RECEPTORS; PHOSPHATIDIC-ACID	G protein-coupled receptors can potentially activate phospholipase D ( PLD) by a number of routes. We show here that the native M-3 muscarinic receptor in 1321N1 cells and an epitope-tagged M-3 receptor expressed in COS7 cells substantially utilize an ADP-ribosylation factor (ARF)-dependent route of PLD activation. This pathway is activated at the plasma membrane but appears to be largely independent of G(q/11), phospholipase C, Ca2+, protein kinase C, tyrosine kinases, and phosphatidyl inositol 3-kinase. We report instead that it involves physical association of ARF with the M3 receptor as demonstrated by co-immunoprecipitation and by in vitro interaction with a glutathione S-transferase fusion protein of the receptor's third intracellular loop domain. Experiments with mutant constructs of ARF1/6 and PLD1/2 indicate that the M3 receptor displays a major ARF1-dependent route of PLD1 activation with an additional ARF6-dependent pathway to PLD1 or PLD2. Examples of other G protein-coupled receptors assessed in comparison display alternative pathways of protein kinase C- or ARF6-dependent activation of PLD2.	Univ Edinburgh, MRC, Membrane & Adapter Prot Cooperat Grp, Membrane Biol Interdisciplinary Res Grp,Sch Biome, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Strathclyde, Dept Biosci, Glasgow G1 1XW, Lanark, Scotland	University of Edinburgh; University of Strathclyde	Mitchell, R (corresponding author), Univ Edinburgh, MRC, Membrane & Adapter Prot Cooperat Grp, Membrane Biol Interdisciplinary Res Grp,Sch Biome, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.							Beraud-Dufour S, 2001, METHOD ENZYMOL, V329, P245; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chahdi A, 2002, MOL IMMUNOL, V38, P1269, DOI 10.1016/S0161-5890(02)00074-3; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Donaldson JG, 2001, METHOD ENZYMOL, V329, P247; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; EDWARDS JS, 1995, BIOCHEM J, V308, P473, DOI 10.1042/bj3080473; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Guillemain I, 1997, EUR J BIOCHEM, V249, P812, DOI 10.1111/j.1432-1033.1997.00812.x; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; HUWILER A, 1993, EUR J BIOCHEM, V217, P69, DOI 10.1111/j.1432-1033.1993.tb18219.x; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Ktistakis NT, 1999, BIOCHEM SOC T, V27, P634, DOI 10.1042/bst0270634; Kuai J, 2002, METHOD ENZYMOL, V345, P359; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lee SD, 2000, NEUROSCI LETT, V294, P130, DOI 10.1016/S0304-3940(00)01563-9; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MacKenzie CJ, 2001, ENDOCRINOLOGY, V142, P1209, DOI 10.1210/en.142.3.1209; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; McCulloch DA, 2001, MOL PHARMACOL, V59, P1523, DOI 10.1124/mol.59.6.1523; Meacci E, 1999, J BIOL CHEM, V274, P18605, DOI 10.1074/jbc.274.26.18605; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; NIETO M, 1994, MOL PHARMACOL, V46, P406; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Shome K, 2000, ENDOCRINOLOGY, V141, P2200, DOI 10.1210/en.141.6.2200; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Vasudevan C, 1998, J CELL SCI, V111, P1277; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WALL SJ, 1991, MOL PHARMACOL, V40, P783; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	72	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33818	33830		10.1074/jbc.M305825200	http://dx.doi.org/10.1074/jbc.M305825200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12799371	hybrid			2022-12-25	WOS:000185047500027
J	O'Byrne, J; Hunt, MC; Rai, DK; Saeki, M; Alexson, SEH				O'Byrne, J; Hunt, MC; Rai, DK; Saeki, M; Alexson, SEH			The human bile acid-CoA : amino acid N-acyltransferase functions in the conjugation of fatty acids to glycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; CHOLYL-COA; LIPID-METABOLISM; COENZYME-A; RAT-LIVER; BOVINE LIVER; BLOOD SPOTS; TAURINE; SYNTHETASE; PURIFICATION	Bile acid-CoA: amino acid N-acyltransferase (BACAT) catalyzes the conjugation of bile acids to glycine and taurine for excretion into bile. By use of site-directed mutagenesis and sequence comparisons, we have identified Cys-235, Asp-328, and His-362 as constituting a catalytic triad in human BACAT (hBACAT) and identifying BACAT as a member of the type I acyl-CoA thioesterase gene family. We therefore hypothesized that hBACAT may also hydrolyze fatty acyl-CoAs and/or conjugate fatty acids to glycine. We show here that recombinant hBACAT also can hydrolyze long- and very long- chain saturated acyl-CoAs ( mainly C16:0-C26: 0) and by mass spectrometry verified that hBACAT also conjugates fatty acids to glycine. Tissue expression studies showed strong expression of BACAT in liver, gallbladder, and the proximal and distal intestine. However, BACAT is also expressed in a variety of tissues unrelated to bile acid formation and transport, suggesting important functions also in the regulation of intracellular levels of very long- chain fatty acids. Green fluorescent protein localization experiments in human skin fibroblasts showed that the hBACAT enzyme is mainly cytosolic. Therefore, the cytosolic BACAT enzyme may play important roles in protection against toxicity by accumulation of unconjugated bile acids and non-esterified very long- chain fatty acids.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Lab Med, SE-14186 Stockholm, Sweden	Karolinska Institutet	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, Dept Lab Med, C1-74, SE-14186 Stockholm, Sweden.		K., Dilip/E-9022-2011; O'Byrne, James/AAE-8182-2021	K., Dilip/0000-0002-8073-4981; Hunt, Mary/0000-0001-6415-2992				Barnes S., 1996, Hepatology, V24, p370A; BENNETT MJ, 1994, ANN CLIN BIOCHEM, V31, P72, DOI 10.1177/000456329403100112; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1956, ACTA CHEM SCAND, V10, P56, DOI 10.3891/acta.chem.scand.10-0056; Carlton VEH, 2003, NAT GENET, V34, P91, DOI 10.1038/ng1147; Carter SMB, 1996, J CHROMATOGR B, V677, P29, DOI 10.1016/0378-4347(95)00415-7; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; CZUBA B, 1981, BIOCHIM BIOPHYS ACTA, V665, P612, DOI 10.1016/0005-2760(81)90278-2; CZUBA B, 1982, J BIOL CHEM, V257, P8761; CZUBA B, 1980, J BIOL CHEM, V255, P5296; CZUBA B, 1981, BIOCHEM J, V195, P263, DOI 10.1042/bj1950263; ELLIOTT WH, 1955, BIOCHIM BIOPHYS ACTA, V17, P440, DOI 10.1016/0006-3002(55)90394-2; FALANY CN, 1994, J BIOL CHEM, V269, P19375; Falany CN, 1997, J LIPID RES, V38, P1139; FURUTANI M, 1995, BIOCHEM J, V311, P203, DOI 10.1042/bj3110203; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Huhtinen K, 2002, J BIOL CHEM, V277, P3424, DOI 10.1074/jbc.M109040200; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; JOHNSON MR, 1991, J BIOL CHEM, V266, P10227; KASE BF, 1986, BIOCHIM BIOPHYS ACTA, V877, P37, DOI 10.1016/0005-2760(86)90115-3; KASE BF, 1989, J BIOL CHEM, V264, P9220; KASE BF, 1990, PEDIATR RES, V29, P64; KASE F, 1983, J LIPID RES, V24, P1560; KILLENBERG PG, 1978, J BIOL CHEM, V253, P10005; KWAKYE JB, 1993, J LIPID RES, V34, P95; KWAKYE JB, 1991, COMP BIOCHEM PHYS B, V100, P131, DOI 10.1016/0305-0491(91)90095-U; LAMETSCHWANDTNE.G, 1996, J BIOL CHEM, V273, P33635; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; SCHERSTE.T, 1967, BIOCHIM BIOPHYS ACTA, V141, P155, DOI 10.1016/0304-4165(67)90254-1; Sfakianos MK, 2002, J BIOL CHEM, V277, P47270, DOI 10.1074/jbc.M207463200; Solaas K, 2000, J LIPID RES, V41, P1154; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 2000, J BIOL CHEM, V275, P15605, DOI 10.1074/jbc.C000015200; VESSEY DA, 1978, BIOCHEM J, V174, P621, DOI 10.1042/bj1740621; VESSEY DA, 1990, COMP BIOCHEM PHYS B, V95, P647, DOI 10.1016/0305-0491(90)90299-9; VESSEY DA, 1979, J BIOL CHEM, V254, P2059	43	65	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34237	34244		10.1074/jbc.M300987200	http://dx.doi.org/10.1074/jbc.M300987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810727	hybrid			2022-12-25	WOS:000185047500078
J	Joshi, AK; Zhang, L; Rangan, VS; Smith, S				Joshi, AK; Zhang, L; Rangan, VS; Smith, S			Cloning, expression, and characterization of a human 4 '-phosphopantetheinyl transferase with broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; FATTY-ACID SYNTHASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOPANTETHEINYL TRANSFERASE; PEPTIDE SYNTHETASES; BACILLUS-SUBTILIS; NEUROSPORA-CRASSA; MITOCHONDRIA; YEAST; BIOSYNTHESIS	A single candidate 4'-phosphopantetheine transferase, identified by BLAST searches of the human genome sequence data base, has been cloned, expressed, and characterized. The human enzyme, which is expressed mainly in the cytosolic compartment in a wide range of tissues, is a 329-residue, monomeric protein. The enzyme is capable of transferring the 4'-phosphopantetheine moiety of coenzyme A to a conserved serine residue in both the acyl carrier protein domain of the human cytosolic multifunctional fatty acid synthase and the acyl carrier protein associated independently with human mitochondria. The human 4'-phosphopantetheine transferase is also capable of phosphopantetheinylation of peptidyl carrier and acyl carrier proteins from prokaryotes. The same human protein also has recently been implicated in phosphopantetheinylation of the alpha-aminoadipate semialdehyde dehydrogenase involved in lysine catabolism (Praphanphoj, V., Sacksteder, K. A., Gould, S. J., Thomas, G. H., and Geraghty, M. T. ( 2001) Mol. Genet. Metab. 72, 336 - 342). Thus, in contrast to yeast, which utilizes separate 4'-phosphopantetheine transferases to service each of three different carrier protein substrates, humans appear to utilize a single, broad specificity enzyme for all posttranslational 4'-phosphopantetheinylation reactions.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Ehmann DE, 1999, BIOCHEMISTRY-US, V38, P6171, DOI 10.1021/bi9829940; Fichtlscherer F, 2000, EUR J BIOCHEM, V267, P2666, DOI 10.1046/j.1432-1327.2000.01282.x; Finking R, 2002, J BIOL CHEM, V277, P50293, DOI 10.1074/jbc.M205042200; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Heath R. J., 2002, BIOCH LIPIDS LIPOPRO, P55, DOI DOI 10.1016/S0167-7306(02)36005-8; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Keszenman-Pereyra D, 2003, CURR GENET, V43, P186, DOI 10.1007/s00294-003-0382-7; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; Mofid MR, 2002, J BIOL CHEM, V277, P17023, DOI 10.1074/jbc.M200120200; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Praphanphoj V, 2001, MOL GENET METAB, V72, P336, DOI 10.1006/mgme.2000.3138; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Stuible HP, 1998, J BIOL CHEM, V273, P22334, DOI 10.1074/jbc.273.35.22334; Suo ZC, 2001, P NATL ACAD SCI USA, V98, P99, DOI 10.1073/pnas.021537498; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Weber T, 2001, STRUCTURE, V9, pR3, DOI 10.1016/S0969-2126(00)00560-8; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9	30	67	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33142	33149		10.1074/jbc.M305459200	http://dx.doi.org/10.1074/jbc.M305459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815048	hybrid			2022-12-25	WOS:000184901800080
J	Klunker, D; Haas, B; Hirtreiter, A; Figueiredo, L; Naylor, DJ; Pfeifer, G; Muller, V; Deppenmeier, U; Gottschalk, G; Hartl, FU; Hayer-Hartl, M				Klunker, D; Haas, B; Hirtreiter, A; Figueiredo, L; Naylor, DJ; Pfeifer, G; Muller, V; Deppenmeier, U; Gottschalk, G; Hartl, FU; Hayer-Hartl, M			Coexistence of group I and group II chaperonins in the archaeon Methanosarcina mazei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; CYTOSOLIC CHAPERONIN; THERMOPHILIC ARCHAEBACTERIUM; STRUCTURAL CHARACTERIZATION; THERMOPLASMA-ACIDOPHILUM; SULFOLOBUS-SOLFATARICUS; METHANOPYRUS-KANDLERI; POLYPEPTIDE-BINDING; UNFOLDED PROTEINS	Two distantly related classes of cylindrical chaperonin complexes assist in the folding of newly synthesized and stress-denatured proteins in an ATP-dependent manner. Group I chaperonins are thought to be restricted to the cytosol of bacteria and to mitochondria and chloroplasts, whereas the group II chaperonins are found in the archaeal and eukaryotic cytosol. Here we show that members of the archaeal genus Methanosarcina co-express both the complete group I (GroEL/ GroES) and group II ( thermosome/prefoldin) chaperonin systems in their cytosol. These mesophilic archaea have acquired between 20 and 35% of their genes by lateral gene transfer from bacteria. In Methanosarcina mazei Go1, both chaperonins are similarly abundant and are moderately induced under heat stress. The M. mazei GroEL/ GroES proteins have the structural features of their bacterial counterparts. The thermosome contains three paralogous subunits, alpha, beta, and gamma, which assemble preferentially at a molar ratio of 2: 1: 1. As shown in vitro, the assembly reaction is dependent on ATP/Mg2+ or ADP/Mg2+ and the regulatory role of the beta subunit. The co-existence of both chaperonin systems in the same cellular compartment suggests the Methanosarcina species as useful model systems in studying the differential substrate specificity of the group I and II chaperonins and in elucidating how newly synthesized proteins are sorted from the ribosome to the proper chaperonin for folding.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany; Univ Munich, Dept Biol 1, Microbiol Sect, D-80638 Munich, Germany; Univ Gottingen, Dept Gen Microbiol, Gottingen Genom Lab, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society; University of Munich; University of Gottingen	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hayer-Hartl, Manajit/V-8078-2017; Mueller, Volker/ABE-4305-2021; Hartl, F. Ulrich/Y-8206-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; Mueller, Volker/0000-0001-7955-5508; 				Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; Andra S, 1998, EUR J BIOCHEM, V255, P93, DOI 10.1046/j.1432-1327.1998.2550093.x; Archibald JM, 2002, J MOL BIOL, V316, P1041, DOI 10.1006/jmbi.2002.5409; Archibald JM, 2001, J STRUCT BIOL, V135, P157, DOI 10.1006/jsbi.2001.4353; Archibald JM, 1999, CURR BIOL, V9, P1053, DOI 10.1016/S0960-9822(99)80457-6; Baumer S, 2000, J BIOL CHEM, V275, P17968, DOI 10.1074/jbc.M000650200; Bosch G, 2000, J MOL BIOL, V301, P19, DOI 10.1006/jmbi.2000.3955; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; DEPPENMEIER U, 1989, EUR J BIOCHEM, V186, P317, DOI 10.1111/j.1432-1033.1989.tb15211.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Gribaldo S, 1999, J BACTERIOL, V181, P434, DOI 10.1128/JB.181.2.434-443.1999; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KNAPP S, 1994, J MOL BIOL, V242, P397; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Leroux MR, 2001, ADV APPL MICROBIOL, V50, P219, DOI 10.1016/S0065-2164(01)50007-6; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Macario AJL, 1999, GENETICS, V152, P1277; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; Saibil H, 2000, CURR OPIN STRUC BIOL, V10, P251, DOI 10.1016/S0959-440X(00)00074-9; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANDON S, 1989, J BIOL CHEM, V264, P9859; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yoshida T, 1997, J MOL BIOL, V273, P635, DOI 10.1006/jmbi.1997.1337	82	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33256	33267		10.1074/jbc.M302018200	http://dx.doi.org/10.1074/jbc.M302018200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796498	hybrid			2022-12-25	WOS:000184901800094
J	Knight, RF; Bader, DM; Backstrom, JR				Knight, RF; Bader, DM; Backstrom, JR			Membrane topology of Bves/Pop1A, a cell adhesion molecule that displays dynamic changes in cellular distribution during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPICARDIAL MESOTHELIAL CELLS; SKELETAL-MUSCLE; SMOOTH-MUSCLE; HEART; ORIGIN; MOUSE; BVES	We investigated the membrane topology of Bves/ Pop1A as a foundation to dissect the molecular basis and function of Bves/ Pop1A trafficking during development. Bves contains two asparagine-linked glycosylation sites within the amino terminus and three putative membrane domains. Therefore, glycosylation assays were performed to determine if the amino terminus of Bves is delivered into the endoplasmic reticulum lumen and glycosylated. We establish that Bves from chick heart and transfected cells is glycosylated, implying that the amino terminus of cell surface molecules is extracellular. Three biochemically distinct approaches were utilized to determine the orientation of the carboxyl terminus of Bves. First, glycosylation of Bves at exogenous sites within the carboxyl terminus was only observed in a construct that lacked the third membrane domain, which presumably reversed the orientation of the carboxyl terminus. Second, co-expression of full-length Bves with soluble, carboxyl-terminal Bves constructs that reside in different subcellular compartments revealed that Bves-Bves interactions occur in the cytoplasm. Third, the immunoreactivity of endogenous Bves at the cell surface of epicardial cells was dramatically enhanced with detergent. These results suggest that the membrane topology of cell surface Bves/ Pop1A is composed of an extracellular amino terminus, three transmembrane domains, and a cytoplasmic carboxyl terminus. We therefore hypothesize that the carboxyl terminus regulates the cellular distribution of Bves/ Pop1A during coronary vessel development.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Stahlman Cardiovasc Res Labs, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Backstrom, JR (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 342 PRB, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067105] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andree B, 2000, DEV BIOL, V223, P371, DOI 10.1006/dbio.2000.9751; Andree B, 2002, MOL CELL BIOL, V22, P1504, DOI 10.1128/MCB.22.5.1504-1512.2002; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; EID H, 1994, J CARDIOVASC PHARM, V24, P715, DOI 10.1097/00005344-199424050-00005; EID H, 1992, CIRC RES, V71, P40, DOI 10.1161/01.RES.71.1.40; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; HIRUMA T, 1989, AM J ANAT, V184, P129, DOI 10.1002/aja.1001840204; MANASEK FJ, 1968, J MORPHOL, V125, P329, DOI 10.1002/jmor.1051250306; MANNER J, 1993, ANAT EMBRYOL, V187, P281; Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068; Reese DE, 1999, DEV BIOL, V209, P159, DOI 10.1006/dbio.1999.9246; VIRAGH S, 1981, ANAT REC, V201, P157, DOI 10.1002/ar.1092010117; Wada AM, 2001, DEVELOPMENT, V128, P2085	15	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32872	32879		10.1074/jbc.M301961200	http://dx.doi.org/10.1074/jbc.M301961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815060	hybrid			2022-12-25	WOS:000184901800048
J	Kodama, T; Shimizu, N; Yoshikawa, N; Makino, Y; Ouchida, R; Okamoto, K; Hisada, T; Nakamura, H; Morimoto, C; Tanaka, H				Kodama, T; Shimizu, N; Yoshikawa, N; Makino, Y; Ouchida, R; Okamoto, K; Hisada, T; Nakamura, H; Morimoto, C; Tanaka, H			Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; INDUCIBLE FACTOR-1; DNA-BINDING; HORMONE RECEPTORS; HIF-ALPHA; STRESS; DOMAIN; SPECIFICITY; COACTIVATOR; REPRESSION	Glucocorticoids are secreted from the adrenal glands and act as a peripheral effector of the hypothalamic-pituitary-adrenal axis, playing an essential role in stress response and homeostatic regulation. In target cells, however, it remains unknown how glucocorticoids fine-tune the cellular pathways mediating tissue and systemic adaptation. Recently, considerable evidence indicates that adaptation to hypoxic environments is influenced by glucocorticoids and there is cross-talk between hypoxia-dependent signals and glucocorticoid-mediated regulation of gene expression. We therefore investigated the interaction between these important stress-responsive pathways, focusing on the glucocorticoid receptor (GR) and hypoxia-inducible transcription factor HIF-1. Here we show that, under hypoxic conditions, HIF-1-dependent gene expression is further up-regulated by glucocorticoids via the GR. This up-regulation cannot be substituted by the other steroid receptors and is suggested to result from the interaction between the GR and the transactivation domain of HIF-1alpha. Moreover, our results also indicate that the ligand binding domain of the GR is essential for this interaction, and the critical requirement for GR agonists suggests the importance of the ligand-mediated conformational change of the GR. Because these proteins are shown to colocalize in the distinct compartments of the nucleus, we suggest that these stress-responsive transcription factors have intimate communication in close proximity to each other, thereby enabling the fine-tuning of cellular responses for adaptation.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 088639, Japan	University of Tokyo	Tanaka, H (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 088639, Japan.	hirotnk@ims.u-tokyo.ac.jp						Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berger S, 1998, P NATL ACAD SCI USA, V95, P9424, DOI 10.1073/pnas.95.16.9424; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Caldwell CC, 2001, J IMMUNOL, V167, P6140, DOI 10.4049/jimmunol.167.11.6140; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fuller PJ, 2000, KIDNEY INT, V57, P1256, DOI 10.1046/j.1523-1755.2000.00959.x; Funder J, 2001, CLIN EXP PHARMACOL P, V28, P1002, DOI 10.1046/j.1440-1681.2001.03586.x; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Gardner DS, 2001, ENDOCRINOLOGY, V142, P589, DOI 10.1210/en.142.2.589; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Glass CK, 2000, GENE DEV, V14, P121; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Herman JP, 1999, ENDOCRINOLOGY, V140, P3981, DOI 10.1210/en.140.9.3981; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jelkmann W, 1998, J INTERF CYTOK RES, V18, P555, DOI 10.1089/jir.1998.18.555; JOHNSON TS, 1984, NEW ENGL J MED, V310, P683, DOI 10.1056/NEJM198403153101103; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Laderoute KR, 2002, MOL CELL BIOL, V22, P2515, DOI 10.1128/MCB.22.8.2515-2523.2002; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Larsen JJ, 1997, J PHYSIOL-LONDON, V504, P241, DOI 10.1111/j.1469-7793.1997.241bf.x; LimTio SS, 1997, ENDOCRINOLOGY, V138, P2537, DOI 10.1210/en.138.6.2537; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATHERNE GP, 1990, PEDIATR RES, V28, P348, DOI 10.1203/00006450-199010000-00010; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; MONCLOA F, 1965, J CLIN ENDOCR METAB, V25, P1640, DOI 10.1210/jcem-25-12-1640; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; Nussdorfer GG, 2001, INT REV CYTOL, V206, P249; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rogerson FM, 1999, J BIOL CHEM, V274, P36305, DOI 10.1074/jbc.274.51.36305; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Tanaka H, 1999, VITAM HORM, V57, P153; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; VAUPEL P, 1989, CANCER RES, V49, P6449; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Vincent KA, 2000, CIRCULATION, V102, P2255; Yoshikawa N, 2002, J BIOL CHEM, V277, P5529, DOI 10.1074/jbc.M107946200	58	90	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33384	33391		10.1074/jbc.M302581200	http://dx.doi.org/10.1074/jbc.M302581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12810720	hybrid			2022-12-25	WOS:000184901800110
J	Wilson, GM; Lu, JB; Sutphen, K; Suarez, Y; Sinha, S; Brewer, B; Villanueva-Feliciano, EC; Ysla, RM; Charles, S; Brewer, G				Wilson, GM; Lu, JB; Sutphen, K; Suarez, Y; Sinha, S; Brewer, B; Villanueva-Feliciano, EC; Ysla, RM; Charles, S; Brewer, G			Phosphorylation of p40(AUF1) regulates binding to A+U-rich mRNA-destabilizing elements and protein-induced changes in ribonucleoprotein structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; MAMMALIAN-CELLS; KINASE-A; AUF1; TRISTETRAPROLIN; HUR; STABILITY; DEGRADATION; ASSOCIATION; EXPRESSION	Messenger RNA turnover directed by A+U-rich elements (AREs) involves selected ARE-binding proteins. Whereas several signaling systems may modulate ARE-directed mRNA decay and/or post-translationally modify specific trans-acting factors, it is unclear how these mechanisms are linked. In THP-1 monocytic leukemia cells, phorbol ester-induced stabilization of some mRNAs containing AREs was accompanied by dephosphorylation of Ser(83) and Ser(87) of polysome-associated p40(AUF1). Here, we report that phosphorylation of p40(AUF1) influences its ARE-binding affinity as well as the RNA conformational dynamics and global structure of the p40(AUF1)-ARE ribonucleoprotein complex. Most notably, association of unphosphorylated p40(AUF1) induces a condensed RNA conformation upon ARE substrates. By contrast, phosphorylation of p40(AUF1) at Ser(83) and Ser(87) inhibits this RNA structural transition. These data indicate that selective AUF1 phosphorylation may regulate ARE-directed mRNA turnover by remodeling local RNA structures, thus potentially altering the presentation of RNA and/or protein determinants involved in subsequent trans-factor recruitment.	UMDNJ, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Spect, Baltimore, MD 21201 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Wilson, GM (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Wilson, Gerald/AAF-3874-2019	Suarez, Yvelisse/0000-0002-0456-3260; Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA52443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pioli PA, 2002, J BIOL CHEM, V277, P35738, DOI 10.1074/jbc.M204002200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WILSON GM, 2002, RNA BINDING PROTEINS, P101; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	39	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33039	33048		10.1074/jbc.M305775200	http://dx.doi.org/10.1074/jbc.M305775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12819194	hybrid			2022-12-25	WOS:000184901800068
J	Bais, HP; Vepachedu, R; Lawrence, CB; Stermitz, FR; Vivanco, JM				Bais, HP; Vepachedu, R; Lawrence, CB; Stermitz, FR; Vivanco, JM			Molecular and biochemical characterization of an enzyme responsible for the formation of hypericin in St. John's Wort (Hypericum perforatum L.)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLCOUMARAN BENZYLIC ETHER; PATHOGENESIS-RELATED PROTEINS; CELL-SUSPENSION CULTURES; MAJOR ALLERGEN; BIRCH POLLEN; BET-V-1; CLONING; FAMILY; GENES; REDUCTASES	A major gene termed Hyp-1 encoding for hypericin (HyH) biosynthesis was cloned and characterized from Hypericum perforatum (St. John's wort) cell cultures. H. perforatum leaves are widely used as an herbal remedy in the treatment of mild to moderate depression. Hypericin, a photosensitive and red-colored naphthodianthrone, has been reported as the bioactive compound responsible for reversing the depression symptoms. In this study a novel red-color-based colony screening method for examining a cDNA library (lambda-TriplEX2) derived from H. perforatum cell cultures revealed the gene responsible for hypericin biosynthesis after the administration of emodin, a precursor of hypericin. The selected clones were expressed in Escherichia coli ( BM 25.8 line) and were further screened for biosynthesis of emodin to hypericin, which resulted in an 84.6% conversion. The full-length cDNA sequence of Hyp-1 is 782 nucleotides in length with an open reading frame of 477 nucleotides coding for a protein of 159 amino acids, with a 45.1% homology to Bet.v.1 class allergens. Reverse transcriptase-PCR analysis showed high levels of Hyp-1 transcripts in dark-grown cell cultures compared with the levels in light-grown cell cultures and leaves. Southern blot analysis showed the presence of a single Hyp-1 gene in H. perforatum. Furthermore, Hyp-1 was expressed with a His(6) affinity tag linked to its N terminal region using the expression vector pET-28a, and the recombinant Hyp-1 protein was able to convert HyH from emodin under in vitro conditions. HyH product inhibition was observed with emodin analogues, rhein, rhein methyl ester, and DNA3-55-1. Our results demonstrate a direct and complex conversion of emodin to HyH that is solely catalyzed by Hyp-1, a Bet.v.1 class allergen from H. perforatum.	Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Bioagr Sci & Pest Management, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University; Colorado State University	Vivanco, JM (corresponding author), Colorado State Univ, Dept Hort & Landscape Architecture, 217 Shepardson, Ft Collins, CO 80523 USA.	jvivanco@lamar.colostate.edu	Rechsteiner, Cynthia/C-5894-2011					*AM BOT COUNC, 1998, THER MON MED PLANTS, P256; Bais HP, 2002, IN VITRO CELL DEV-PL, V38, P58, DOI 10.1079/IV2001253; Bray BJ, 2002, LIFE SCI, V70, P1325, DOI 10.1016/S0024-3205(01)01499-0; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Butterweck V, 2002, BRAIN RES, V930, P21, DOI 10.1016/S0006-8993(01)03394-7; Calvo A. P., 1999, Plant Physiology, V120, P933, DOI 10.1104/pp.120.3.933; Cosgrove DJ, 2000, CURR OPIN PLANT BIOL, V3, P73, DOI 10.1016/S1369-5266(99)00039-4; Deltito J, 1998, J AFFECT DISORDERS, V51, P345, DOI 10.1016/S0165-0327(99)00008-7; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Gang DR, 1999, J BIOL CHEM, V274, P7516, DOI 10.1074/jbc.274.11.7516; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; HoffmannSommergruber K, 1997, GENE, V197, P91, DOI 10.1016/S0378-1119(97)00246-1; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Kientsch U, 2001, PHARMACOPSYCHIATRY, V34, pS56, DOI 10.1055/s-2001-15452; LEISTNER AG, 1971, PHOTOCHEM PHOTOBIOL, V27, P347; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; MAZUR Y, 1992, Patent No. 0432496; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Moiseyev GP, 1997, FEBS LETT, V407, P207, DOI 10.1016/S0014-5793(97)00337-2; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Schulz V, 2001, PHYTOMEDICINE, V8, P152; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vivanco JM, 1999, PLANT PHYSIOL, V119, P1447, DOI 10.1104/pp.119.4.1447; Vogel G, 2001, SCIENCE, V291, P35, DOI 10.1126/SCIENCE.291.5501.35; Walker TS, 2002, PHYTOCHEMISTRY, V60, P289, DOI 10.1016/S0031-9422(02)00074-2; WARNER SAJ, 1992, PLANT MOL BIOL, V19, P555, DOI 10.1007/BF00026782	33	106	116	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32413	32422		10.1074/jbc.M301681200	http://dx.doi.org/10.1074/jbc.M301681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799379	hybrid			2022-12-25	WOS:000184782100121
J	Basi, G; Frigon, N; Barbour, R; Doan, T; Gordon, G; McConlogue, L; Sinha, S; Zeller, M				Basi, G; Frigon, N; Barbour, R; Doan, T; Gordon, G; McConlogue, L; Sinha, S; Zeller, M			Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED A-BETA; ALZHEIMERS-DISEASE; RNA INTERFERENCE; MAMMALIAN-CELLS; SECRETASE ACTIVITY; GENE-EXPRESSION; HUMAN BRAIN; BACE2; GENERATION; MICE	The deposition of extracellular beta-amyloid peptide (Abeta) in the brain is a pathologic feature of Alzheimer's disease. The beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), an integral membrane aspartyl protease responsible for cleavage of amyloid precursor protein (APP) at the beta-site, promotes Abeta production. A second integral membrane aspartyl protease related to BACE1, referred to as beta-site amyloid precursor protein cleaving enzyme 2 (BACE2) has also been demonstrated to cleave APP at the beta-cleavage site in transfected cells. The role of endogenous BACE2 in Abeta production remains unresolved. We investigated the role of endogenous BACE2 in Abeta production in cells by selective inactivation of its transcripts using RNA interference. We are able to reduce steady state levels for mRNA for each enzyme by >85%, and protein amounts by 88-94% in cells. Selective inactivation of BACE1 by RNA interference results in decreased beta-cleaved secreted APP and Abeta peptide secretion from cells, as expected. Selective inactivation of BACE2 by RNAi results in increased beta-cleaved secreted APP and Abeta peptide secretion from cells. Simultaneous targeting of both enzymes by RNA interference does not have any net effect on Abeta released from cells. Our observations of changes in APP metabolism and Abeta are consistent with a role of BACE2 in suppressing Abeta production in cells that co-express both enzymes.	Elan Pharmaceut, San Francisco, CA 94080 USA		Basi, G (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, San Francisco, CA 94080 USA.							Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; De Strooper B, 1999, NATURE, V402, P471, DOI 10.1038/44973; Ehehalt R, 2002, BIOCHEM BIOPH RES CO, V293, P30, DOI 10.1016/S0006-291X(02)00169-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; KANDEL ER, 1985, PRINES NEURAL SCI, P17; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Saunders A.J, 1999, SCIENCE, V286, P1255, DOI DOI 10.1126/SCIENCE.286.5443.1255A; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	47	80	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31512	31520		10.1074/jbc.M300169200	http://dx.doi.org/10.1074/jbc.M300169200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801932	hybrid			2022-12-25	WOS:000184782100010
J	Hiratsuka, T; Katoh, T				Hiratsuka, T; Katoh, T			Chemical identification of serine 181 at the ATP-binding site of myosin as a residue esterified selectively by the fluorescent reagent 9-anthroylnitrile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANADATE-DEPENDENT MODIFICATION; NH2-TERMINAL TRYPTIC PEPTIDE; SUBFRAGMENT-1 HEAVY-CHAIN; CONFORMATIONAL-CHANGES; MUSCLE MYOSIN; CROSS-LINKING; MOTOR DOMAIN; ACTIVE-SITE; PHOSPHORYLATION; CLEAVAGE	The esterification reagent 9-anthroylnitrile (ANN) reacts with a serine residue in the NH2-terminal 23-kDa peptide segment of myosin subfragment-1 heavy chain to yield a fluorescent S1 derivative labeled by the anthroyl group (Hiratsuka, T. (1989) J. Biol. Chem. 264, 18188-18194). The labeling was highly selective and accelerated by nucleotides. In the present study, to determine the exact location of the labeled serine residue, the labeled 23-kDa peptide fragment was isolated. The subsequent extensive proteolytic digestion of the peptide fragment yielded two labeled peptides, a pentapeptide and its precursor nonapeptide. Amino acid sequence and composition analyses of both labeled peptides revealed that the anthroyl group is attached to Ser-181 involved in the phosphate binding loop for ATP (Smith, C. A., and Rayment, I. (1996) Biochemistry 35, 5404-5417). We concluded that ANN can esterify Ser-181 selectively out of over 40 serine residues in the subfragment 1 heavy chain. Thus ANN is proved to be a valuable fluorescent tool to identify peptides containing the phosphate binding loop of S1 and to detect the conformational changes around this loop.	Asahikawa Med Coll, Dept Chem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Hiratsuka, T (corresponding author), Asahikawa Med Coll, Dept Chem, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.							BETTACHE N, 1992, BIOCHEMISTRY-US, V31, P389, DOI 10.1021/bi00117a012; BLOTNICK E, 1994, BIOCHEMISTRY-US, V33, P6867, DOI 10.1021/bi00188a016; CREMO CR, 1988, BIOCHEMISTRY-US, V27, P8415, DOI 10.1021/bi00422a018; CREMO CR, 1989, J BIOL CHEM, V264, P6608; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GRAMMER JC, 1988, BIOCHEMISTRY-US, V27, P8408, DOI 10.1021/bi00422a017; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HIRATSUKA T, 1989, J BIOL CHEM, V264, P18188; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Schaffhauser H, 2000, J NEUROSCI, V20, P5663, DOI 10.1523/JNEUROSCI.20-15-05663.2000; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Szarka K, 2001, BIOCHEMISTRY-US, V40, P14806, DOI 10.1021/bi011097k; TONG SW, 1990, J BIOL CHEM, V265, P4893; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044; YUN HY, 1995, J BIOL CHEM, V270, P30075	20	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31891	31894		10.1074/jbc.M303212200	http://dx.doi.org/10.1074/jbc.M303212200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12805386	hybrid			2022-12-25	WOS:000184782100055
J	Kim, JI; Jo, EJ; Lee, HY; Cha, MS; Min, JK; Choi, CH; Lee, YM; Choi, YA; Baek, SH; Ryu, SH; Lee, KS; Kwak, JY; Bae, YS				Kim, JI; Jo, EJ; Lee, HY; Cha, MS; Min, JK; Choi, CH; Lee, YM; Choi, YA; Baek, SH; Ryu, SH; Lee, KS; Kwak, JY; Bae, YS			Sphingosine 1-phosphate in amniotic fluid modulates cyclooxygenase-2 expression in human amnion-derived WISH cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAYS; PHOSPHOLIPASE-C; ACTIVATION; SPHINGOSINE-1-PHOSPHATE; EDG-1; TRANSDUCTION; PARTURITION; INHIBITION; LIGAND	The metabolism of arachidonic acid, in particular the generation of prostaglandins (PGs), has been proposed to play a key role in the regulation of labor. Moreover, several extracellular proteins have been reported to modulate PG synthesis in amnion cells. In this study, we found that lipid components dissolved in the amniotic fluid modulate PG synthesis in WISH human amnion cells and identified one of these components as a sphingosine 1-phosphate (S1P). WISH cells express several S1P receptors including S1P(1), S1P(2), and S1P(3). When WISH cells were stimulated with S1P, PGE(2) synthesis increased in a concentration-dependent manner, showing maximal activity at around 100 nM. S1P treatment also caused the up-regulation of cyclooxygenase-2 (COX-2) mRNA and protein, which was apparent within 3-12 h of stimulation. In terms of the intracellular signaling pathway of S1P-induced WISH cell activation, we found that S1P stimulated two kinds of MAPK, ERK, and p38 kinase. We examined the roles of these two MAPKs in S1P-induced COX-2 expression. S1P-induced COX-2 expression was blocked completely by PD-98059 but not by SB-203580, suggesting that ERK has a critical role in the process. Transfection of S1P(1) or S1P(3) but not of S1P(2) antisense oligonucleotide inhibited S1P-induced COX-2 expression and PGE(2) production in WISH cells, indicating the involvements of S1P(1) and S1P(3) in the processes. This study demonstrates the physiological role of S1P in amniotic fluid and its effect on the modulation of COX-2 expression and PGs synthesis in WISH cells.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Dong A Univ, Coll Med, Med Res Ctr Canc Molec Therapy, Pusan 602714, South Korea; Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea; Dong A Univ, Coll Med, Dept Obstet & Gynecol, Pusan 602714, South Korea; Chungbuk Natl Univ, Coll Pharm, Chonju 361763, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Molec Biol, Taegu 705717, South Korea; Pusan Natl Univ, Coll Med, Dept Obstet & Gynecol, Pusan 602739, South Korea	Pohang University of Science & Technology (POSTECH); Dong A University; Dong A University; Dong A University; Chungbuk National University; Yeungnam University; Pusan National University	Kwak, JY (corresponding author), Dong A Univ, Coll Med, Med Res Ctr Canc Molec Therapy, Pusan 602714, South Korea.		Min, Jung Kee/V-5010-2019	Min, Jung Kee/0000-0002-8006-8560; Ryu, Sung Ho/0000-0003-0913-3048				ALBERT TJ, 1994, PROSTAGLANDINS, V48, P401, DOI 10.1016/0090-6980(94)90006-X; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1999, MOL PHARMACOL, V55, P787; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Gibb W, 1998, ANN MED, V30, P235, DOI 10.3109/07853899809005850; Idzko M, 2002, FASEB J, V16, P625, DOI 10.1096/fj.01-0625fje; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Johnson CA, 1999, J BIOL CHEM, V274, P27689, DOI 10.1074/jbc.274.39.27689; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; MAGGI M, 1994, J ENDOCRINOL INVEST, V17, P757, DOI 10.1007/BF03347772; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Park DW, 2002, MOL PHARMACOL, V61, P614, DOI 10.1124/mol.61.3.614; Perkins DJ, 1997, PROSTAG OTH LIPID M, V54, P727, DOI 10.1016/S0090-6980(97)00144-5; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yatomi Y, 2000, BLOOD, V96, P3431; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4	27	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31731	31736		10.1074/jbc.M300625200	http://dx.doi.org/10.1074/jbc.M300625200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12796504	hybrid			2022-12-25	WOS:000184782100034
J	Shimada, T; Yamada, K; Kataoka, M; Nakaune, S; Koumoto, Y; Kuroyanagi, M; Tabata, S; Kato, T; Shinozaki, K; Seki, M; Kobayashi, M; Kondo, M; Nishimura, M; Hara-Nishimura, I				Shimada, T; Yamada, K; Kataoka, M; Nakaune, S; Koumoto, Y; Kuroyanagi, M; Tabata, S; Kato, T; Shinozaki, K; Seki, M; Kobayashi, M; Kondo, M; Nishimura, M; Hara-Nishimura, I			Vacuolar processing enzymes are essential for proper processing of seed storage proteins in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHISTOSOMA-MANSONI; LYTIC VACUOLES; MATURE FORMS; EXPRESSION; PRECURSORS; FAMILY; ENDOPEPTIDASE; ACTIVATION; PROTEASES; LEGUMAIN	The proprotein precursors of storage proteins are post-translationally processed to produce their respective mature forms within the protein storage vacuoles of maturing seeds. To investigate the processing mechanism in vivo, we isolated Arabidopsis mutants that accumulate detectable amounts of the precursors of the storage proteins, 12 S globulins and 2 S albumins, in their seeds. All six mutants isolated have a defect in the betaVPE gene. VPE ( vacuolar processing enzyme) is a cysteine proteinase with substrate specificity toward an asparagine residue. We further generated various mutants lacking different VPE isoforms: alphaVPE, betaVPE, and/or gammaVPE. More than 90% of VPE activity is abolished in the alphavpe-3 seeds, and no VPE activity is detected in the alphavpe-1/betavpe-3/gammavpe-1 seeds. The triple mutant seeds accumulate no properly processed mature storage proteins. Instead, large amounts of storage protein precursors are found in the seeds of this mutant. In contrast to betavpe-3 seeds, which accumulate both precursors and mature storage proteins, the other single (alphavpe-1 and gammavpe-1) and double (alphavpe-1/gammavpe-1) mutants accumulate no precursors in their seeds at all. Therefore, the vegetative VPEs, alphaVPE and gammaVPE, are not necessary for precursor processing in the presence of betaVPE, but partly compensates for the deficiency in betaVPE in betavpe-3 seeds. In the absence of functional VPEs, a proportion of pro2S albumin molecules are alternatively cleaved by aspartic proteinase. This cleavage by aspartic proteinase is promoted by the initial processing of pro2S albumins by VPE. Our overall results suggest that seed-type betaVPE is most essential for the processing of storage proteins, and that the vegetative-type VPEs and aspartic proteinase complement betaVPE activity in this processing.	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Kazusa DNA Res Inst, Dept Plant Gene Res, Chiba 2920818, Japan; RIKEN, Inst Phys & Chem Res, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kazusa DNA Research Institute; RIKEN	Hara-Nishimura, I (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.		Yamada, Kenji/C-4336-2018; Seki, Motoaki/I-2854-2012; Shinozaki, Kazuo/G-4202-2013; Kobayashi, Masatomo/A-5945-2016	Yamada, Kenji/0000-0003-4872-3729; Seki, Motoaki/0000-0001-8288-0467; Shinozaki, Kazuo/0000-0002-6317-9867; Nishimura, Mikio/0000-0001-7960-9721; Kuroyanagi, Miwa/0000-0003-4362-8415				Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; DHONDT K, 1993, J BIOL CHEM, V268, P20884; Gruis D, 2002, PLANT CELL, V14, P2863, DOI 10.1105/tpc.005009; Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2; Hara-Nishimura I, 1998, J PLANT PHYSIOL, V152, P668, DOI 10.1016/S0176-1617(98)80028-X; Hara-Nishimura I, 1998, HDB PROTEOLYTIC ENZY, P746; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1995, J PLANT PHYSIOL, V145, P632, DOI 10.1016/S0176-1617(11)81275-7; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; HARANISHIMURA I, 2000, VACUOLAR COMPARTMENT, P20; Hiraiwa N, 1997, EUR J BIOCHEM, V246, P133, DOI 10.1111/j.1432-1033.1997.00133.x; HIRAIWA N, 1993, PLANT CELL PHYSIOL, V34, P1197; HOH B, 1995, J CELL SCI, V108, P299; Kinoshita T, 1999, PLANT J, V19, P43, DOI 10.1046/j.1365-313X.1999.00497.x; KINOSHITA T, 1995, PLANT MOL BIOL, V29, P81, DOI 10.1007/BF00019120; Kinoshita T, 1995, PLANT CELL PHYSIOL, V36, P1555; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; Muntz K, 2002, TRENDS PLANT SCI, V7, P340, DOI 10.1016/S1360-1385(02)02298-7; Muntz K, 1998, PLANT MOL BIOL, V38, P77, DOI 10.1023/A:1006020208380; PANG PP, 1988, PLANT MOL BIOL, V11, P805, DOI 10.1007/BF00019521; Robinson DG, 1998, J PLANT PHYSIOL, V152, P659, DOI 10.1016/S0176-1617(98)80027-8; Shimada T, 2002, PLANT CELL PHYSIOL, V43, P1086, DOI 10.1093/pcp/pcf152; SHIMADA T, 1994, PLANT CELL PHYSIOL, V35, P713, DOI 10.1093/oxfordjournals.pcp.a078648; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200	26	152	167	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32292	32299		10.1074/jbc.M305740200	http://dx.doi.org/10.1074/jbc.M305740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799370	hybrid			2022-12-25	WOS:000184782100105
J	Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T				Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T			Molecular processes of chromosome 9p21 deletions in human cancers	ONCOGENE			English	Article						9p21 deletion; p16/CDKN2A; lung cancer; DNA double-strand break; nonhomologous end joining	DOUBLE-STRAND BREAK; FRAGILE REGION; GENE; RECOMBINATION; MECHANISM; SEQUENCE; REPAIR; DAMAGE; P15	Interstitial deletions of the chromosome 9p21 segment encoding the p16/CDKN2A tumor suppressor gene (i.e., 9p21 deletions) are frequently observed in a variety of human cancers. A majority of these deletions in lymphoid leukemia have been indicated to be mediated by illegitimate V(D)J recombination. In the present study, to elucidate the molecular processes of 9p21 deletions in nonlymphocytic malignancies, breakpoints for these deletions were analysed in 21 lung cancer cell lines and 32 nonlymphocytic cancer cell lines of nine other histological types. In all, 32 breakpoints in 21 lung cancer cell lines and 56 breakpoints in 32 nonlung cancer cell lines were mapped in a 450-kb segment encompassing the CDKN2A locus with a 10-kb resolution. The largest number of breakpoints (i.e., seven breakpoints in lung cancer and 12 breakpoints in noulung cancers) was mapped in a 10-kb region containing the CDKN2A gene. More precise mapping of these seven and 12 breakpoints revealed that none of these breakpoints were located within 50-bp intervals to each other in this 10kb region. Cloning and sequencing of breakpoints in 18 representative cell lines (six lung and 12 nonlung cancers) further revealed that there were no significant homologies among breakpoints in these 18 cell lines. In 11 (61%) cell lines, 1-5-bp nucleotides were overlapped at breakpoint junctions. These results indicate that DNA double-strand breaks triggering 9p21 deletions do not occur at specific DNA sequences, although they preferentially occur in or near the CDKN2A locus. It was also indicated that two broken DNA ends are rejoined by nonhomologous end-joining repair, preferentially utilizing microhomologies of DNA ends, in the occurrence of 9p21 deletions.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Surg 1, Maebashi, Gumma 3718511, Japan; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	National Cancer Center - Japan; Gunma University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp	Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.3.CO;2-N; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sherr CJ, 2000, CANCER RES, V60, P3689; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	29	58	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3792	3798		10.1038/sj.onc.1206589	http://dx.doi.org/10.1038/sj.onc.1206589			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802286				2022-12-25	WOS:000183551000013
J	Knox, BE; Salcedo, E; Mathiesz, K; Schaefer, J; Chou, WH; Chadwell, LV; Smith, WC; Britt, SG; Barlow, RB				Knox, BE; Salcedo, E; Mathiesz, K; Schaefer, J; Chou, WH; Chadwell, LV; Smith, WC; Britt, SG; Barlow, RB			Heterologous expression of Limulus rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPHILIN HOMOLOG NINAA; PROTEIN-COUPLED RECEPTOR; VISUAL PIGMENT; BOVINE RHODOPSIN; XENOPUS-OOCYTES; IN-VIVO; INVERTEBRATE PHOTORECEPTORS; RETINAL PHOTORECEPTORS; ROD TRANSDUCIN; OPSIN	Invertebrates such as Drosophila or Limulus assemble their visual pigment into the specialized rhabdomeric membranes of photoreceptors where phototransduction occurs. We have investigated the biosynthesis of rhodopsin from the Limulus lateral eye with three cell culture expression systems: mammalian COS1 cells, insect Sf9 cells, and amphibian Xenopus oocytes. We extracted and affinity-purified epitope-tagged Limulus rhodopsin expressed from a cDNA or cRNA from these systems. We found that all three culture systems could efficiently synthesize the opsin polypeptide in quantities comparable with that found for bovine opsin. However, none of the systems expressed a protein that stably bound 11-cis-retinal. The protein expressed in COS1 and Sf9 cells appeared to be misfolded, improperly localized, and proteolytically degraded. Similarly, Xenopus oocytes injected with Limulus opsin cRNA did not evoke light-sensitive currents after incubation with 11-cis-retinal. However, injecting Xenopus oocytes with mRNA from Limulus lateral eyes yielded light- dependent conductance changes after incubation with 11-cis-retinal. Also, expressing Limulus opsin cDNA in the R1-R6 photoreceptors of transgenic Drosophila yielded a visual pigment that bound retinal, had normal spectral properties, and coupled to the endogenous phototransduction cascade. These results indicate that Limulus opsin may require one or more photoreceptor-specific proteins for correct folding and/or chromophore binding. This may be a general property of invertebrate opsins and may underlie some of the functional differences between invertebrate and vertebrate visual pigments.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Ophthalmol, Ctr Vis Res, Syracuse, NY 13210 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Ophthalmol, Denver, CO 80262 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Health San Antonio	Knox, BE (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	knoxb@upstate.edu; barlowr@upstate.edu	Smith, W. Clay/AAQ-1589-2021; Chou, Wen-Hai/H-1970-2016; Britt, Steven/GVT-1340-2022	Chou, Wen-Hai/0000-0002-7899-1129; Britt, Steven/0000-0001-7656-7984	NEI NIH HHS [R01-EY-10759, EY-12975, EY-00667, EY-11256] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010759, R56EY000667, R01EY011256, R01EY012975, R01EY000667] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 2000, METHOD ENZYMOL, V315, P3; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARLOW RB, 1993, NATURE, V366, P64, DOI 10.1038/366064a0; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; BIRGE RR, 1992, STRUCTURES FUNCTIONS, V221, P283; Blackshaw S, 1997, J NEUROSCI, V17, P8083; Blackshaw S, 1999, J NEUROSCI, V19, P3681; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRITT SG, 1993, NEURON, V11, P29, DOI 10.1016/0896-6273(93)90268-V; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Concepcion F, 2002, VISION RES, V42, P417, DOI 10.1016/S0042-6989(01)00195-X; DeCaluwe GLJ, 1996, BIOCHEM J, V320, P807, DOI 10.1042/bj3200807; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Farrens DL, 2002, J PEPT RES, V60, P336, DOI 10.1034/j.1399-3011.2002.21066.x; FEILER R, 1992, J NEUROSCI, V12, P3862; FEILER R, 1988, NATURE, V333, P737, DOI 10.1038/333737a0; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FRANCESCHINI N, 1979, INVEST OPTHALMOL S, V5; FRANCESCHINI N, 1984, PHOTORECEPTORS, P319; Hamdorf K., 1973, P155; Hamdorf K., 1979, HDB SENSORY PHYSL, V7/6A, P145; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HUBBARD R, 1960, NATURE, V186, P213, DOI 10.1038/186212b0; KAPLAN E, 1980, NATURE, V286, P393, DOI 10.1038/286393a0; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KIRSCHFELD K, 1977, NATURE, V269, P386, DOI 10.1038/269386a0; KIRSCHFELD K, 1986, VISION RES, V26, P1771, DOI 10.1016/0042-6989(86)90127-6; Klaassen CHW, 2000, METHOD ENZYMOL, V315, P12; KNOX BE, 1993, J PHYSIOL-LONDON, V466, P157; Knox BE, 2000, METHOD ENZYMOL, V316, P41; Max M, 1998, J BIOL CHEM, V273, P26820, DOI 10.1074/jbc.273.41.26820; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mole EJ, 1996, BIOL BULL, V191, P264, DOI 10.1086/BBLv191n2p264; Mollaaghababa R, 1996, P NATL ACAD SCI USA, V93, P11482, DOI 10.1073/pnas.93.21.11482; Moutsaki P, 2003, MOL BRAIN RES, V112, P135, DOI 10.1016/S0169-328X(03)00059-7; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NODA K, 1994, J BIOL CHEM, V269, P6743; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SCHWEMER J, 1984, J COMP PHYSIOL, V154, P535, DOI 10.1007/BF00610167; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Seki T, 1998, COMP BIOCHEM PHYS B, V119, P53, DOI 10.1016/S0305-0491(97)00322-2; SHEN DW, 1994, BIOCHEMISTRY-US, V33, P13117, DOI 10.1021/bi00248a022; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; SMITH WC, 1993, P NATL ACAD SCI USA, V90, P6150, DOI 10.1073/pnas.90.13.6150; SMITH WC, 1992, VISUAL NEUROSCI, V8, P329, DOI 10.1017/S095252380000506X; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Starace DM, 1998, EXP EYE RES, V67, P209, DOI 10.1006/exer.1998.0507; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; STAVENGA DG, 1993, VISION RES, V33, P1011, DOI 10.1016/0042-6989(93)90237-Q; Stitham J, 2002, MOL PHARMACOL, V61, P1202, DOI 10.1124/mol.61.5.1202; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; Townson SM, 1998, J NEUROSCI, V18, P2412; Vought BW, 2000, BIOCHEMISTRY-US, V39, P14128, DOI 10.1021/bi001135k; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Weng K, 1997, J BIOL CHEM, V272, P33100, DOI 10.1074/jbc.272.52.33100; [No title captured]	69	25	46	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40493	40502		10.1074/jbc.M304567200	http://dx.doi.org/10.1074/jbc.M304567200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12821651	hybrid			2022-12-25	WOS:000185847200010
J	Der-Sarkissian, A; Jao, CC; Chen, J; Langen, R				Der-Sarkissian, A; Jao, CC; Chen, J; Langen, R			Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE DATA; A-BETA COMPONENT; SOLID-STATE NMR; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; AMYLOID FIBRILS; T4 LYSOZYME; LEWY BODIES; PROTEIN; FILAMENTS	Despite its importance in Parkinson's disease, a detailed understanding of the structure and mechanism of alpha-synuclein fibril formation remains elusive. In this study, we used site-directed spin labeling and electron paramagnetic resonance spectroscopy to study the structural features of monomeric and fibrillar alpha-synuclein. Our results indicate that monomeric alpha-synuclein, in solution, has a highly dynamic structure, in agreement with the notion that alpha-synuclein is a natively unfolded protein. In contrast, fibrillar aggregates of alpha-synuclein exhibit a distinct domain organization. Our data identify a highly ordered and specifically folded central core region of similar to 70 amino acids, whereas the N terminus is structurally more heterogeneous and the C terminus ( similar to 40 amino acids) is completely unfolded. Interestingly, the central core region of alpha-synuclein exhibits several features reminiscent of those observed in the core region of fibrillar Alzheimer's amyloid beta peptide, including an in-register parallel structure. Although the lengths of the respective core regions differ, fibrils from different amyloid proteins nevertheless appear to be able to take up highly similar, and possibly conserved, structures.	Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Arnold & Mabel Beckman Macular Res Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Mary D Allen Lab Vis Res, Doheny Eye Inst, Dept Ophthalmol,Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Neurobiol, Keck Sch Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; Doheny Eye Institute; University of Southern California; University of Southern California	Langen, R (corresponding author), Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, 1501 San Pablo St, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE07211] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kim TD, 2000, BIOCHEMISTRY-US, V39, P14839, DOI 10.1021/bi001441y; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Makin OS, 2002, BIOCHEM SOC T, V30, P521, DOI 10.1042/bst0300521; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; Murray IVJ, 2001, CLIN NEUROSCI RES, V1, P445, DOI 10.1016/S1566-2772(01)00023-8; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2003, BIOCHEMISTRY-US, V42, P3151, DOI 10.1021/bi027378p; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	47	281	285	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37530	37535		10.1074/jbc.M305266200	http://dx.doi.org/10.1074/jbc.M305266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12815044	hybrid			2022-12-25	WOS:000185437200066
J	Pierrat, OA; Maxwell, A				Pierrat, OA; Maxwell, A			The action of the bacterial toxin microcin B17 - Insight into the cleavage-religation reaction of DNA gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE-II; N-TERMINAL FRAGMENT; ALTERED BISHETEROCYCLIC SITES; ESCHERICHIA-COLI; B-PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; QUINOLONE ACTION; NALIDIXIC-ACID; MECHANISM; ENZYME	We have examined the effects of the bacterial toxin microcin B17 (MccB17) on the reactions of Escherichia coli DNA gyrase. MccB17 slows down but does not completely inhibit the DNA supercoiling and relaxation reactions of gyrase. A kinetic analysis of the cleavage-religation equilibrium of gyrase was performed to determine the effect of the toxin on the forward ( cleavage) and reverse (religation) reactions. A simple mechanism of two consecutive reversible reactions with a nicked DNA intermediate was used to simulate the kinetics of cleavage and religation. The action of MccB17 on the kinetics of cleavage and religation was compared with that of the quinolones ciprofloxacin and oxolinic acid. With relaxed DNA as substrate, only a small amount of gyrase cleavage complex is observed with MccB17 in the absence of ATP, whereas the presence of the nucleotide significantly enhances the effect of the toxin on both the cleavage and religation reactions. In contrast, ciprofloxacin, oxolinic acid, and Ca2+ show lesser dependence on ATP to stabilize the cleavage complex. MccB17 enhances the overall rate of DNA cleavage by increasing the forward rate constant (k(2)) of the second equilibrium. In contrast, ciprofloxacin increases the amount of cleaved DNA by a combined effect on the forward and reverse rate constants of both equilibria. Based on these results and on the observations that MccB17 only slowly inhibits the supercoiling and relaxation reactions, we suggest a model of the interaction of MccB17 with gyrase.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Maxwell, A (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.			Maxwell, Anthony/0000-0002-5756-6430	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000201] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Anderson VE, 1998, J BIOL CHEM, V273, P17879, DOI 10.1074/jbc.273.28.17879; ASENSIO C, 1976, BIOCHEM BIOPH RES CO, V69, P7, DOI 10.1016/S0006-291X(76)80264-1; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Bromberg KD, 2003, BIOCHEMISTRY-US, V42, P3393, DOI 10.1021/bi027383t; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Critchlow SE, 1997, J MOL BIOL, V273, P826, DOI 10.1006/jmbi.1997.1357; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Heddle J, 2002, ANTIMICROB AGENTS CH, V46, P1805, DOI 10.1128/AAC.46.6.1805-1815.2002; Heddle JG, 2001, J MOL BIOL, V309, P1219, DOI 10.1006/jmbi.2001.4733; Heddle JG, 2001, J MOL BIOL, V307, P1223, DOI 10.1006/jmbi.2001.4562; HERRERO M, 1986, J GEN MICROBIOL, V132, P393; Hockings SC, 2002, J MOL BIOL, V318, P351, DOI 10.1016/S0022-2836(02)00048-7; Kampranis SC, 1998, J BIOL CHEM, V273, P22615, DOI 10.1074/jbc.273.35.22615; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Kampranis SC, 1998, J BIOL CHEM, V273, P22606, DOI 10.1074/jbc.273.35.22606; Li TK, 1998, ANTIMICROB AGENTS CH, V42, P1022, DOI 10.1128/AAC.42.5.1022; Li YM, 1996, SCIENCE, V274, P1188, DOI 10.1126/science.274.5290.1188; LIU J, 1994, P NATL ACAD SCI USA, V91, P4618, DOI 10.1073/pnas.91.11.4618; LIU LF, 1983, J BIOL CHEM, V258, P5365; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; MAXWELL A, 1999, PROTOCOLS DNA TOPOIS, V1, P135; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; MORENO F, 1995, GENETICS BIOCH ANTIB, P307; Noble CG, 2002, J MOL BIOL, V318, P361, DOI 10.1016/S0022-2836(02)00049-9; Nurse P, 2000, J BIOL CHEM, V275, P4104, DOI 10.1074/jbc.275.6.4104; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Roy RS, 1999, NAT PROD REP, V16, P249, DOI 10.1039/a806930a; Roy RS, 1999, CHEM BIOL, V6, P305, DOI 10.1016/S1074-5521(99)80076-3; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519; Zamble DB, 2001, P NATL ACAD SCI USA, V98, P7712, DOI 10.1073/pnas.141225698; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	44	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35016	35023		10.1074/jbc.M304516200	http://dx.doi.org/10.1074/jbc.M304516200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829716	hybrid			2022-12-25	WOS:000185164400034
J	Bisaillon, M; Bougie, I				Bisaillon, M; Bougie, I			Investigating the role of metal ions in the catalytic mechanism of the yeast RNA triphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING ENZYME; MUTATIONAL ANALYSIS; NUCLEOSIDE TRIPHOSPHATASE; CAP METHYLTRANSFERASE; ACTIVE-SITE; BINDING; COMPONENT; SUBUNIT; 5'-TRIPHOSPHATASE; APPARATUS	The Saccharomyces cerevisiae RNA triphosphatase (Cet1) requires the presence of metal ion cofactors to catalyze its phosphohydrolase activity, the first step in the formation of the 5'-terminal cap structure of mRNAs. We have used endogenous tryptophan fluorescence studies to elucidate both the nature and the role(s) of the metal ions in the Cet1-mediated phosphohydrolase reaction. The association of Mg2+, Mn2+, and Co2+ ions with the enzyme resulted in a decrease in the intensity of the tryptophan emission spectrum. This decrease was then used to determine the apparent dissociation constants for these ions. Subsequent dual ligand titration experiments demonstrated that the metal ions bind to a common site, for which they compete. The kinetics of real-time metal ion binding to the Cet1 protein were also investigated, and the effects on RNA and nucleotide binding were evaluated. To provide additional insight into the relationship between Cet1 structure and metal ion binding, we correlated the effect of ion binding on protein structure using both circular dichroism and guanidium hydrochloride-induced denaturation as structural indicators. Our data indicate that binding of RNA, nucleotides, and metal ion cofactors does not lead to significant structural modifications of the Cet1 architecture. This suggests a model in which Cet1 possesses a preformed active site, and where major domain rearrangements are not required to form an active catalytic site. Finally, denaturation studies demonstrate that the metal ion cofactors can act by stabilizing the ground state binding of the phosphohydrolase substrate.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bisaillon, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave, Sherbrooke, PQ J1H 5N4, Canada.	Martin.Bisaillon@USherbrooke.ca						Bisaillon M, 2001, J BIOL CHEM, V276, P30514, DOI 10.1074/jbc.M104936200; Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Mao XD, 1996, MOL CELL BIOL, V16, P475; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Pace CN, 1995, METHOD ENZYMOL, V259, P538; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206	31	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33963	33971		10.1074/jbc.M303007200	http://dx.doi.org/10.1074/jbc.M303007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12819229	hybrid			2022-12-25	WOS:000185047500043
J	Ge, L; Ly, Y; Hollenberg, M; DeFea, K				Ge, L; Ly, Y; Hollenberg, M; DeFea, K			A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INTEGRIN ACTIVATION; RECEPTOR; KINASE; ENDOCYTOSIS; CELLS; ERK; PHOSPHORYLATION; SUPPRESSION; TRAFFICKING	Cell motility during wound healing and inflammation is often dependent on the ability of the cell to sense a gradient of agonist. The first step in this process is the extension of a pseudopod in the direction of the agonist, and a diverse set of signals mediate pseudopod extension by different receptors. We have reported previously that protease-activated receptor-2 (PAR-2), a proinflammatory receptor that is highly expressed in motile cells such as neutrophils, macrophages, and tumor cells, is one of a growing family of receptors that utilizes a beta-arrestin-dependent mechanism for activation of the 42-44-kDa members of the MAPK family ( extracellular signal-regulated kinases 1 and 2; ERK1/2). beta-Arrestin-bound PAR-2 serves as a scaffold to sequester a pool of activated ERK1/2 in the cytosol; however, a specific role for the sequestered kinase activity has not been established. We now show that PAR-2 activation promotes ERK1/2- and beta-arrestin-dependent reorganization of the actin cytoskeleton, polarized pseudopodia extension, and chemotaxis. Using subcellular fractionation, confocal microscopy, and physical isolation of pseudopodial proteins, we demonstrate that the previously identified PAR-2/beta-arrestin/ERK1/2 scaffolding complex is enriched in the pseudopodia, where it appears to prolong ERK1/2 activation. These studies suggest that the formation of a beta-arrestin/ERK1/2 signaling complex at the leading edge may be involved in localized actin assembly and chemotaxis and provide the first example of a distinct cellular consequence of beta-arrestin-sequestered ERK1/2 activity.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Biochem & Mol Biol Program, Riverside, CA 92521 USA; Univ Calif Riverside, Cellular Mol & Dev Biol Program, Riverside, CA 92521 USA; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med, Calgary, AB T2N 4N1, Canada	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside; University of Calgary; University of Calgary	DeFea, K (corresponding author), Univ Calif Riverside, Div Biomed Sci, B604 Stat Rd, Riverside, CA 92521 USA.	katied@citrus.ucr.edu	Hollenberg, Morley/AFV-6966-2022	DeFea, Kathryn/0000-0001-6056-907X	NIGMS NIH HHS [R01 GM066151-02, R01 GM066151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; BUETTNER HM, 1989, J IMMUNOL METHODS, V123, P25, DOI 10.1016/0022-1759(89)90026-4; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kamath L, 2001, CANCER RES, V61, P5933; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536	36	168	174	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34418	34426		10.1074/jbc.M300573200	http://dx.doi.org/10.1074/jbc.M300573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821670	hybrid			2022-12-25	WOS:000185047500100
J	Lutters, BCH; Derksen, RHWM; Tekelenburg, WL; Lenting, PJ; Arnout, J; de Groot, PG				Lutters, BCH; Derksen, RHWM; Tekelenburg, WL; Lenting, PJ; Arnout, J; de Groot, PG			Dimers of beta(2)-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2 '	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN-BLOOD-PLATELETS; ACTIVATED-PROTEIN-C; AMINO-ACID-SEQUENCE; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; ANTICOAGULANT ACTIVITY; 5TH DOMAIN; HUMAN BETA-2-GLYCOPROTEIN-I; PROTHROMBINASE ACTIVITY	Patients with prolonged clotting times caused by lupus anticoagulant (LAC) are at risk for thrombosis. This paradoxal association is not understood. LAC is frequently caused by anti-beta(2)-glycoprotein I (beta(2)GPI) antibodies. Antibody-induced dimerization of beta(2)GPI increases the affinity of beta(2)GPI for phospholipids, explaining the observed prolonged clotting times. We constructed dimers of beta(2)GPI that mimic effects of beta(2)GPI-anti-beta(2)GPI antibody complexes, and we studied their effects on platelet adhesion and thrombus formation in a flow system. Dimeric beta(2)GPI increased platelet adhesion to collagen by 150% and increased the number of large aggregates. We also observed increased platelet adhesion to collagen when whole blood was spiked with patient-derived polyclonal anti-beta(2)GPI or some, but not all, monoclonal anti-beta(2)GPI antibodies with LAC activity. These effects could be abrogated by inhibition of thromboxane synthesis. A LAC-positive monoclonal anti-beta(2)GPI antibody, which did not affect platelet adhesion, prevented the induced increase in platelet adhesion by beta(2)GPI dimers. Furthermore, increased platelet adhesion disappeared after preincubation with receptor-associated protein, a universal inhibitor of interaction of ligands with members of the low density lipoprotein receptor family. Using co-immunoprecipitation, it was shown that dimeric beta(2)GPI can interact with apolipoprotein E receptor 2 (apoER2'), a member of the low density lipoprotein receptor family present on platelets. These results demonstrate that dimeric beta(2)GPI induces increased platelet adhesion and thrombus formation, which depends on activation via apoER2'.	Univ Med Ctr Utrecht, Dept Haematol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3508 GA Utrecht, Netherlands; Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; KU Leuven	de Groot, PG (corresponding author), Univ Med Ctr Utrecht, Thrombosis & Haemostasis Lab, Dept Haematol G03 647, POB 85-500, NL-3508 GA Utrecht, Netherlands.		Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				Arnout J, 1998, THROMB HAEMOSTASIS, V79, P79; ARVIEUX J, 1993, THROMB HAEMOSTASIS, V70, P336; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; BENDIXEN E, 1992, BIOCHEMISTRY-US, V31, P3611, DOI 10.1021/bi00129a009; BEVERS EM, 1985, ADV EXP MED BIOL, V192, P359; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; CARRERAS LO, 1981, LANCET, V1, P244; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; DAHLBACK B, 1983, BLOOD, V62, P218; DEGROOT PG, 1993, BAILLIERE CLIN HAEM, V6, P691, DOI 10.1016/S0950-3536(05)80194-5; Forastiero R, 1998, THROMB HAEMOSTASIS, V79, P42, DOI 10.1055/s-0037-1614216; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; Hasunuma Y, 1997, CLIN EXP IMMUNOL, V107, P569, DOI 10.1046/j.1365-2249.1997.d01-948.x; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Horbach DA, 1998, THROMB HAEMOSTASIS, V80, P791; Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Ieko M, 1998, SEMIN THROMB HEMOST, V24, P211, DOI 10.1055/s-2007-995844; Jankowski M, 2003, BLOOD, V101, P157, DOI 10.1182/blood-2002-05-1310; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; KEELING DM, 1993, J CLIN PATHOL, V46, P908, DOI 10.1136/jcp.46.10.908; KRISTENSEN T, 1991, FEBS LETT, V289, P183, DOI 10.1016/0014-5793(91)81065-G; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; Lutters BCH, 2001, J BIOL CHEM, V276, P3060, DOI 10.1074/jbc.M008224200; MARTINUZZO ME, 1993, THROMB HAEMOSTASIS, V70, P667; MATSUDA J, 1995, AM J HEMATOL, V49, P89, DOI 10.1002/ajh.2830490116; Mehdi H, 2000, EUR J BIOCHEM, V267, P1770, DOI 10.1046/j.1432-1327.2000.01174.x; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Mori T, 1996, THROMB HAEMOSTASIS, V75, P49; NIMPF J, 1985, THROMB HAEMOSTASIS, V54, P397; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OOSTING JD, 1992, THROMB HAEMOSTASIS, V67, P499; OSTFELD I, 1992, J CLIN IMMUNOL, V12, P415, DOI 10.1007/BF00918853; Robbins DL, 1998, J RHEUMATOL, V25, P51; ROUBEY RAS, 1994, BLOOD, V84, P2854; ROUBEY RAS, 1992, J CLIN INVEST, V90, P1100, DOI 10.1172/JCI115926; SCHORER AE, 1989, BRIT J HAEMATOL, V71, P399; SCHOUSBOE I, 1995, THROMB HAEMOSTASIS, V73, P798; SCHOUSBOE I, 1980, THROMB RES, V19, P225, DOI 10.1016/0049-3848(80)90421-1; SCHOUSBOE I, 1985, BLOOD, V66, P1086; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Sheng YH, 1996, J IMMUNOL, V157, P3744; SHI W, 1993, THROMB HAEMOSTASIS, V70, P342; SIXMA JJ, 1994, ANN NY ACAD SCI, V714, P190, DOI 10.1111/j.1749-6632.1994.tb12044.x; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; VANHEERDE WL, 1994, ARTERIOSCLER THROMB, V14, P824, DOI 10.1161/01.ATV.14.5.824; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; WATSON KV, 1991, AM J MED, V90, P47, DOI 10.1016/0002-9343(91)90505-R; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	56	159	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33831	33838		10.1074/jbc.M212655200	http://dx.doi.org/10.1074/jbc.M212655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807892	hybrid			2022-12-25	WOS:000185047500028
J	McCullar, JS; Larsen, SA; Millimaki, RA; Filtz, TM				McCullar, JS; Larsen, SA; Millimaki, RA; Filtz, TM			Calmodulin is a phospholipase C-beta interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; G-ALPHA-Q; GAMMA-SUBUNITS; KINASE-II; MESSENGER-RNAS; RECEPTOR; BINDING; ACTIVATION; C-BETA(1); CA2+/CALMODULIN	Phospholipase C-beta(3) (PLCbeta(3)) is an important effector enzyme in G protein-coupled signaling pathways. Activation of PLCbeta(3) by Galpha and Gbetagamma subunits has been fairly well characterized, but little is known about other protein interactions that may also regulate PLCbeta(3) function. A yeast two-hybrid screen of a mouse brain cDNA library with the amino terminus of PLCbeta(3) has yielded potential PLCbeta(3) interacting proteins including calmodulin (CaM). Physical interaction between CaM and PLCbeta(3) is supported by a positive secondary screen in yeast and the identification of a CaM binding site in the amino terminus of PLCbeta(3). Co-precipitation of in vitro translated and transcribed amino- and carboxyl-terminal PLCbeta(3) revealed CaM binding at a putative amino-terminal binding site. Direct physical interaction of PLCbeta(3) and PLCbeta(1) isoforms with CaM is supported by pull-down of both isoenzymes with CaM-Sepharose beads from 1321N1 cell lysates. CaM inhibitors reduced M1-muscarinic receptor stimulation of inositol phospholipid hydrolysis in 1321N1 astrocytoma cells consistent with a physiologic role for CaM in modulation of PLCbeta activity. There was no effect of CaM kinase II inhibitors, KN-93 and KN-62, on M1-muscarinic receptor stimulation of inositol phosphate hydrolysis, consistent with a direct interaction between PLCbeta isoforms and CaM.	Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Filtz, TM (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA.	theresa.filtz@orst.edu		Filtz, Theresa/0000-0002-5348-1114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61244, R01 GM061244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; EVANS T, 1985, BIOCHEM J, V232, P751, DOI 10.1042/bj2320751; FERREIRA PA, 1994, J BIOL CHEM, V269, P3129; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; Fischer R, 1998, FEBS LETT, V425, P175, DOI 10.1016/S0014-5793(98)00225-7; Gnegy M E, 1995, Prog Drug Res, V45, P33; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; Labelle EF, 1996, J CELL PHYSIOL, V169, P358, DOI 10.1002/(SICI)1097-4652(199611)169:2<358::AID-JCP15>3.0.CO;2-5; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE SB, 1993, J BIOL CHEM, V268, P25952; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; Matsubara M, 1997, J BIOL CHEM, V272, P23050, DOI 10.1074/jbc.272.37.23050; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIN DS, 1993, FEBS LETT, V331, P38, DOI 10.1016/0014-5793(93)80293-4; NAIRN AC, 1992, CIBA F SYMP, V164, P145; PARK DG, 1993, J BIOL CHEM, V268, P3710; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; RYU SH, 1987, J BIOL CHEM, V262, P12511; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Yue CP, 2001, MOL CELL ENDOCRINOL, V175, P149, DOI 10.1016/S0303-7207(01)00383-5	50	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33708	33713		10.1074/jbc.M301940200	http://dx.doi.org/10.1074/jbc.M301940200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821674	hybrid			2022-12-25	WOS:000185047500014
J	Westfall, MV; Borton, AR				Westfall, MV; Borton, AR			Role of troponin I phosphorylation in protein kinase C-mediated enhanced contractile performance of rat myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT CARDIAC MYOCYTES; HUMAN HEART-FAILURE; ISOFORM EXPRESSION; GENE-TRANSFER; DIFFERENTIAL REGULATION; ARACHIDONIC-ACID; VENTRICULAR MYOCYTES; MYOFILAMENT TENSION; CHIMERA ANALYSIS; ENDOTHELIN	Our goal was to define the role of phosphorylated cardiac troponin-I in the adult myocyte contractile performance response to activated protein kinase C. In agreement with earlier work, endothelin enhanced both adult rat myocyte contractile performance and cardiac troponin-I phosphorylation. Protein kinase C participated in both responses. The role of cardiac troponin-I phosphorylation in the contractile function response to protein kinase C was further investigated using gene transfer into myocytes of troponin-I isoforms/mutants lacking one or more phosphorylation sites previously identified in purified cardiac troponin-I. Sarcomeric replacement with slow skeletal troponin-I-abrogated protein kinase C-mediated troponin-I phosphorylation. In functional studies, endothelin slowed relaxation in myocytes expressing slow skeletal troponin-I, while the relaxation rate increased in myocytes expressing cardiac troponin-I. Based on these results, acceleration of myocyte relaxation during protein kinase C activation largely depended on cardiac troponin-I phosphorylation. Experiments with troponin-I isoform chimeras provided evidence that phosphorylation sites in the amino portion of cardiac troponin I-mediated the protein kinase C acceleration of relaxation. The cardiac troponin-I Thr-144 phosphorylation site identified in earlier biochemical studies was not significantly phosphorylated during the acute contractile response. Thus, aminoterminal protein kinase C-dependent phosphorylation sites in cardiac troponin-I are likely responsible for the accelerated relaxation observed in adult myocytes.	Univ Michigan, Dept Surg, Cardiac Surg Sect, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Westfall, MV (corresponding author), Univ Michigan, Dept Surg, Cardiac Surg Sect, 1150 W Med Ctr Dr,B560 MSRB2, Ann Arbor, MI 48109 USA.	wfall@umich.edu		Westfall, Margaret/0000-0001-9491-0125				Asano K, 2002, J MOL CELL CARDIOL, V34, P833, DOI 10.1006/jmcc.2002.2022; Bartel S, 1996, MOL CELL BIOCHEM, V157, P171; Baudet S, 2001, CARDIOVASC RES, V50, P486, DOI 10.1016/S0008-6363(01)00225-5; Bodor GS, 1997, CIRCULATION, V96, P1495, DOI 10.1161/01.CIR.96.5.1495; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; Boixel C, 2001, AM J PHYSIOL-HEART C, V281, pH764, DOI 10.1152/ajpheart.2001.281.2.H764; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Braun MU, 2002, CARDIOVASC RES, V56, P52, DOI 10.1016/S0008-6363(02)00511-4; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; Cingolani HE, 1998, CIRC RES, V83, P775, DOI 10.1161/01.RES.83.8.775; CLEMENT O, 1992, BIOCHEM J, V285, P311, DOI 10.1042/bj2850311; Cook SA, 1999, J MOL CELL CARDIOL, V31, P1429, DOI 10.1006/jmcc.1999.0979; Coutu P, 2002, BIOPHYS J, V82, P2565, DOI 10.1016/S0006-3495(02)75599-9; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAMRON DS, 1995, CIRC RES, V76, P1011, DOI 10.1161/01.RES.76.6.1011; Erdbrugger W, 1997, BRIT J PHARMACOL, V120, P177, DOI 10.1038/sj.bjp.0700877; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Giles TD, 1998, AM J PHYSIOL-HEART C, V274, pH295, DOI 10.1152/ajpheart.1998.274.1.H295; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; Goldberg AT, 2000, ANN THORAC SURG, V69, P711, DOI 10.1016/S0003-4975(99)01515-5; GWATHMEY JK, 1990, CIRC RES, V67, P744, DOI 10.1161/01.RES.67.3.744; HAJJAR RJ, 1992, BASIC RES CARDIOL, V87, P143; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; Helmes M, 2003, J GEN PHYSIOL, V121, P97, DOI 10.1085/jgp.20028652; Huang XP, 1997, J CELL SCI, V110, P1625; Iwanaga Y, 1998, CIRCULATION, V98, P2065, DOI 10.1161/01.CIR.98.19.2065; Jiang TR, 1996, CIRC RES, V78, P724, DOI 10.1161/01.RES.78.4.724; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Lester JW, 1996, AM J PHYSIOL-HEART C, V271, pH1778, DOI 10.1152/ajpheart.1996.271.5.H1778; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; Lo CF, 1998, CIRC RES, V83, P995, DOI 10.1161/01.RES.83.10.995; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; MCCLELLAN G, 1995, AM J PHYSIOL-HEART C, V268, pH1621, DOI 10.1152/ajpheart.1995.268.4.H1621; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Montgomery DE, 2002, AM J PHYSIOL-HEART C, V282, pH2397, DOI 10.1152/ajpheart.00714.2001; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Noland TA, 1996, BIOCHEMISTRY-US, V35, P14923, DOI 10.1021/bi9616357; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; PEARSON RB, 1991, METHOD ENZYMOL A, V200, P62; Peters SLM, 2002, N-S ARCH PHARMACOL, V366, P189, DOI 10.1007/s00210-002-0573-7; Pi YQ, 2002, CIRC RES, V90, P649, DOI 10.1161/01.RES.0000014080.82861.5F; Pi YQ, 1997, CIRC RES, V81, P92, DOI 10.1161/01.RES.81.1.92; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Schreiber KL, 2001, AM J PHYSIOL-HEART C, V281, pH2062, DOI 10.1152/ajpheart.2001.281.5.H2062; STEINBERG SF, 1995, J MOL CELL CARDIOL, V27, P141, DOI 10.1016/S0022-2828(08)80014-4; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TAKANASHI M, 1991, AM J PHYSIOL, V261, pH611, DOI 10.1152/ajpheart.1991.261.3.H611; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Thomas PB, 1996, AM J PHYSIOL-HEART C, V271, pH2629, DOI 10.1152/ajpheart.1996.271.6.H2629; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Wahr PA, 1999, P NATL ACAD SCI USA, V96, P11982, DOI 10.1073/pnas.96.21.11982; WANG JX, 1991, CIRC RES, V69, P582, DOI 10.1161/01.RES.69.3.582; Ward DG, 2001, EUR J BIOCHEM, V268, P179, DOI 10.1046/j.1432-1327.2001.01871.x; Westfall MV, 1996, DEV DYNAM, V206, P24, DOI 10.1002/(SICI)1097-0177(199605)206:1<24::AID-AJA3>3.0.CO;2-2; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 1999, J BIOL CHEM, V274, P22508, DOI 10.1074/jbc.274.32.22508; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2001, AM J PHYSIOL-CELL PH, V280, pC324, DOI 10.1152/ajpcell.2001.280.2.C324; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; Zakhary DR, 2000, CIRCULATION, V101, P1459, DOI 10.1161/01.CIR.101.12.1459	65	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33694	33700		10.1074/jbc.M305404200	http://dx.doi.org/10.1074/jbc.M305404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815045	hybrid			2022-12-25	WOS:000185047500012
J	Li, JH; Fici, GJ; Mao, CA; Myers, RL; Shuang, R; Donoho, GP; Pauley, AM; Himes, CS; Qin, WN; Kola, I; Merchant, KM; Nye, JS				Li, JH; Fici, GJ; Mao, CA; Myers, RL; Shuang, R; Donoho, GP; Pauley, AM; Himes, CS; Qin, WN; Kola, I; Merchant, KM; Nye, JS			Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-PEPTIDE PRODUCTION; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; A-BETA; PRESENILIN; CLEAVAGE; NOTCH; EXPRESSION; DEFICIENCY	Nicastrin is a component of the gamma-secretase complex that has been shown to adhere to presenilin-1 (PS1), Notch, and APP. Here we demonstrate that Nicastrin-deficient mice showed a phenotype that is indistinguishable from PS1/PS2 double knock-out mice, whereas heterozygotes were healthy and viable. Fibroblasts derived from Nicastrin-deficient embryos were unable to generate amyloid beta-peptide and failed to release the intracellular domain of APP- or Notch1-Gal4-VP16 fusion proteins. Additionally, C- and N-terminal fragments of PS1 and the C- terminal fragments of PS2 were not detectable in Nicastrin-null fibroblasts, whereas full-length PS1 accumulated in null fibroblasts, indicating that Nicastrin is required for the endoproteolytic processing of presenilins. Interestingly, cells derived from Nicastrin heterozygotes produced relatively higher levels of amyloid beta-peptide whether the source was endogenous mouse or transfected human APP. These data demonstrate that Nicastrin is essential for the gamma-secretase cleavage of APP and Notch in mammalian cells and that Nicastrin has both positive and negative functions in the regulation of gamma-secretase activity.	Pfizer Inc, Discovery Res, Kalamazoo, MI 49001 USA	Pfizer	Li, JH (corresponding author), Pfizer Inc, Discovery Res, 301 Henrietta St,209-517, Kalamazoo, MI 49001 USA.	jinhe.li@pfizer.com	Nye, Jeffrey/G-6520-2012; Kola, Ismail/C-5254-2013	Nye, Jeffrey/0000-0002-6056-281X; Mao, Chai-An/0000-0002-9700-6964				Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Berechid BE, 2002, J BIOL CHEM, V277, P8154, DOI 10.1074/jbc.M108238200; Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li T, 2003, J NEUROSCI, V23, P3272; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Potempska A, 1999, AMYLOID, V6, P14, DOI 10.3109/13506129908993283; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wattler S, 1999, BIOTECHNIQUES, V26, P1150, DOI 10.2144/99266rr02; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	38	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33445	33449		10.1074/jbc.M301288200	http://dx.doi.org/10.1074/jbc.M301288200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815056	hybrid			2022-12-25	WOS:000184901800117
J	Li, Z; Yan, JL; Matheny, CJ; Corpora, T; Bravo, J; Warren, AJ; Bushweller, JH; Speck, NA				Li, Z; Yan, JL; Matheny, CJ; Corpora, T; Bravo, J; Warren, AJ; Bushweller, JH; Speck, NA			Energetic contribution of residues in the Runx1 Runt domain to DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILIAL PLATELET DISORDER; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; P53 CANCER MUTATIONS; CBF-BETA SUBUNIT; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; AML1 GENE	Core-binding factors (CBFs) are a small family of heterodimeric transcription factors that play critical roles in hematopoiesis and in the development of bone, stomach epithelium, and proprioceptive neurons. Mutations in CBF genes are found in leukemias, bone disorders, and gastric cancer. CBFs consist of a DNA-binding CBFalpha subunit and a non-DNA-binding CBFbeta subunit. DNA binding and heterodimerization with CBFbeta are mediated by the Runt domain in CBFalpha. Here we report an alanine-scanning mutagenesis study of the Runt domain that targeted amino acids identified by structural studies to reside at the DNA or CBFbeta interface, as well as amino acids mutated in human disease. We determined the energy contributed by each of the DNA-contacting residues in the Runt domain to DNA binding both in the absence and presence of CBFbeta. We propose mechanisms by which mutations in the Runt domain found in hematopoietic and bone disorders affect its affinity for DNA.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22906 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Dartmouth College; University of Virginia; University of Virginia; MRC Laboratory Molecular Biology	Speck, NA (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	nancy.speck@dartmouth.edu	Bravo, Jeronimo/K-9103-2014	Bravo, Jeronimo/0000-0001-6695-2846; Bushweller, John/0000-0002-5386-1758	NATIONAL CANCER INSTITUTE [R01CA089419, R01CA058343, R01CA075611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045120, R29AI039536, R01AI039536, R01AI139536] Funding Source: NIH RePORTER; NCI NIH HHS [CA89419, CA75611, CA058343] Funding Source: Medline; NIAID NIH HHS [AI45120, AI01481, AI39536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; Bartfeld D, 2002, STRUCTURE, V10, P1395, DOI 10.1016/S0969-2126(02)00853-5; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Giannotti A, 2000, HUM MUTAT, V16, DOI 10.1002/1098-1004(200009)16:3<277::AID-HUMU24>3.0.CO;2-Y; GLOB TR, 1995, P NATL ACAD SCI USA, V92, P4917; Golling G, 1996, MOL CELL BIOL, V16, P932; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lewis AF, 1999, J VIROL, V73, P5535, DOI 10.1128/JVI.73.7.5535-5547.1999; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Panda M, 2000, J PROTEIN CHEM, V19, P399, DOI 10.1023/A:1026491615076; Perez-Alvarado GC, 2000, FEBS LETT, V470, P125, DOI 10.1016/S0014-5793(00)01296-5; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Quack I, 1999, AM J HUM GENET, V65, P1268, DOI 10.1086/302622; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Rubnitz J E, 1998, Curr Opin Hematol, V5, P264; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P384, DOI 10.1038/87531; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tang YY, 2000, J BIOL CHEM, V275, P39579, DOI 10.1074/jbc.M007350200; Tang YY, 2000, FEBS LETT, V470, P167, DOI 10.1016/S0014-5793(00)01312-0; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zhang L, 2003, J BIOL CHEM, V278, P33097, DOI 10.1074/jbc.M303972200; Zhang YW, 2000, GENE, V244, P21, DOI 10.1016/S0378-1119(99)00558-2; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	73	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33088	33096		10.1074/jbc.M303973200	http://dx.doi.org/10.1074/jbc.M303973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807882	hybrid			2022-12-25	WOS:000184901800074
J	Qiu, HW; Edmunds, T; Baker-Malcolm, J; Karey, KP; Estes, S; Schwarz, C; Hughes, H; Van Patten, SM				Qiu, HW; Edmunds, T; Baker-Malcolm, J; Karey, KP; Estes, S; Schwarz, C; Hughes, H; Van Patten, SM			Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL SPHINGOMYELINASE; NEUTRAL SPHINGOMYELINASE; NUCLEOTIDE-SEQUENCE; ALPHA-GLUCOSIDASE; S100B PROTEIN; CATHEPSIN-D; APOPTOSIS; PURIFICATION; GENE; EXPRESSION	One form of Niemann-Pick disease is caused by a deficiency in the enzymatic activity of acid sphingomyelinase. During efforts to develop an enzyme replacement therapy based on a recombinant form of human acid sphingomyelinase (rhASM), purified preparations of the recombinant enzyme were found to have substantially increased specific activity if cell harvest media were stored for several weeks at -20degreesC prior to purification. This increase in activity was found to correlate with the loss of the single free thiol on rhASM, suggesting the involvement of a cysteine residue. It was demonstrated that a variety of chemical modifications of the free cysteine on rhASM all result in substantial activation of the enzyme, and the modified cysteine responsible for this activation was shown to be the C-terminal residue (Cys(629)). Activation was also achieved by copper-promoted dimerization of rhASM ( via cysteine) and by C-terminal truncation using carboxypeptidase Y. The role of the C-terminal cysteine in activation was confirmed by creating mutant forms of rhASM in which this residue was either deleted or replaced by a serine, with both forms having substantially higher specific activity than wild-type rhASM. These results indicate that purified rhASM can be activated in vitro by loss of the free thiol on the C-terminal cysteine via chemical modification, dimerization, or deletion of this amino acid residue. This method of activation is similar to the cysteine switch mechanism described previously for matrix metalloproteinases and could represent a means of posttranslational regulation of ASM activity in vivo.	Genzyme Corp, Cell & Prot Therapeut R&D Dept, Framingham, MA 01701 USA	Sanofi-Aventis; Genzyme Corporation	Qiu, HW (corresponding author), Genzyme Corp, Cell & Prot Therapeut R&D Dept, 1 Mt Rd, Framingham, MA 01701 USA.	huawei.qiu@genzyme.com						Alliegro MC, 2000, ANAL BIOCHEM, V282, P102, DOI 10.1006/abio.2000.4557; Amalfitano A, 2001, GENET MED, V3, P132, DOI 10.1097/00125817-200103000-00008; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; Bartelsen O, 1998, J BIOTECHNOL, V63, P29, DOI 10.1016/S0168-1656(98)00070-4; Beutler E, 1997, BAILLIERE CLIN HAEM, V10, P751, DOI 10.1016/S0950-3536(97)80038-8; Bezombes C, 2001, FASEB J, V15, P297; CALLAHAN JW, 1978, CAN J BIOCHEM CELL B, V56, P885, DOI 10.1139/o78-137; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; Lansmann S, 2003, EUR J BIOCHEM, V270, P1076, DOI 10.1046/j.1432-1033.2003.03435.x; Lee ISM, 2000, ARCH BIOCHEM BIOPHYS, V374, P137, DOI 10.1006/abbi.1999.1595; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LLOYD JB, 1996, SUBCELLULAR BIOCH, V27; Pentchev P., 1995, METABOLIC MOL BASES, P2625; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUCHMAN EH, 1995, METABOLIC MOL BASIS, V2, P2601; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VOET D, 1990, BIOCHEMISTRY-US, P446; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; YAMAMOTO K, 1977, ANAL BIOCHEM, V79, P83, DOI 10.1016/0003-2697(77)90381-5; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	42	109	121	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32744	32752		10.1074/jbc.M303022200	http://dx.doi.org/10.1074/jbc.M303022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12801930	hybrid			2022-12-25	WOS:000184901800033
J	Waller, KL; Muhle, RA; Ursos, LM; Horrocks, P; Verdier-Pinard, D; Sidhu, ABS; Fujioka, H; Roepe, PD; Fidock, DA				Waller, KL; Muhle, RA; Ursos, LM; Horrocks, P; Verdier-Pinard, D; Sidhu, ABS; Fujioka, H; Roepe, PD; Fidock, DA			Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEIN PFCRT; DIGESTIVE VACUOLAR PH; MALARIA PARASITE; FERRIPROTOPORPHYRIN-IX; MULTIDRUG-RESISTANCE; ERYTHROCYTIC STAGES; DRUG-RESISTANCE; PFMDR1 GENE; MUTATIONS; AMPLIFICATION	Plasmodium falciparum malaria is increasingly difficult to treat and control due to the emergence of parasite resistance to the major antimalarials, notably chloroquine. Recent work has shown that the chloroquine resistance phenotype can be conferred by multiple amino acid mutations in the parasite digestive vacuole transmembrane protein PfCRT. Here, we have addressed whether chloroquine resistance can also be affected by changes in expression levels of this protein. Transient transfection reporter assays revealed that truncation of the pfcrt 3'-untranslated region just prior to putative polyadenylation sites resulted in a 10-fold decrease in luciferase expression levels. Using allelic exchange on a chloroquine-resistant line (7G8 from Brazil), this truncated 3'-untranslated region was inserted downstream of the pfcrt coding sequence, in the place of the endogenous 3'-untranslated region. The resulting pfcrt-modified "knockdown" clones displayed a marked decrease in pfcrt transcription and an estimated 30-40% decrease in PfCRT protein expression levels. [H-3] hypoxanthine incorporation assays demonstrated up to a 40% decrease in chloroquine with or without verapamil IC50 levels of pfcrt knockdown clones, relative to the 7G8 parent. Single-cell photometric analyses were consistent with an altered intracellular pH in the knockdown clones, providing further evidence for a relationship between PfCRT, pH regulation, and chloroquine resistance. Genetic truncation of 3'-untranslated regions provides a useful approach for assessing the impact of candidate genes on drug resistance or other quantifiable phenotypes in P. falciparum.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Georgetown Univ, Dept Chem, Washington, DC 20057 USA; Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20057 USA; Georgetown Univ, Program Tumor Biol, Washington, DC 20057 USA; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Yeshiva University; Albert Einstein College of Medicine; Georgetown University; Georgetown University; Georgetown University; University of Oxford; Case Western Reserve University	Fidock, DA (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.	dfidock@aecom.yu.edu	Horrocks, Paul/C-2615-2009	Horrocks, Paul/0000-0003-3981-0732; Waller, Karena/0000-0001-8786-4407; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [R37 AI050234, R01 AI45957, R01 AI50234] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050234, R01AI045957, R37AI050234] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; Babiker HA, 2001, J INFECT DIS, V183, P1535, DOI 10.1086/320195; Banerjee R, 2001, INFEC DIS S, P43; BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; Basco LK, 2002, AM J TROP MED HYG, V67, P388, DOI 10.4269/ajtmh.2002.67.388; Basco LK, 2001, J INFECT DIS, V183, P1828, DOI 10.1086/320726; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P1; Bray PG, 1998, PHARMACOL THERAPEUT, V77, P1, DOI 10.1016/S0163-7258(97)00083-1; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P301, DOI 10.1016/S0166-6851(01)00403-0; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Chen N, 2001, J INFECT DIS, V183, P1543, DOI 10.1086/320206; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREMER G, 1995, EXP PARASITOL, V81, P1, DOI 10.1006/expr.1995.1086; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P727, DOI 10.1016/S0006-2952(97)00510-8; Durand R, 2001, MOL BIOCHEM PARASIT, V114, P95, DOI 10.1016/S0166-6851(01)00247-X; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; Fidock DA, 2000, MOL BIOCHEM PARASIT, V110, P1, DOI 10.1016/S0166-6851(00)00249-8; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Goodyer ID, 1997, EXP PARASITOL, V86, P158, DOI 10.1006/expr.1997.4156; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leed A, 2002, BIOCHEMISTRY-US, V41, P10245, DOI 10.1021/bi020195i; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7; Mehlotra RK, 2001, P NATL ACAD SCI USA, V98, P12689, DOI 10.1073/pnas.221440898; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Patankar S, 2001, MOL BIOL CELL, V12, P3114, DOI 10.1091/mbc.12.10.3114; PEEL SA, 1994, AM J TROP MED HYG, V51, P648, DOI 10.4269/ajtmh.1994.51.648; Peel SA, 2001, DRUG RESIST UPDATE, V4, P66, DOI 10.1054/drup.2001.0183; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Rosenthal Philip J., 1998, P145; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; Spiller DG, 2002, TRENDS PARASITOL, V18, P441, DOI 10.1016/S1471-4922(02)02365-6; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578, DOI 10.4269/ajtmh.2002.67.578; Thathy V, 2002, EMBO J, V21, P1586, DOI 10.1093/emboj/21.7.1586; Tilley L, 2001, INFEC DIS S, P87; Trape JF, 2002, TRENDS PARASITOL, V18, P224, DOI 10.1016/S1471-4922(02)02249-3; Ursos LMB, 2002, MED RES REV, V22, P465, DOI 10.1002/med.10016; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; WALLER KL, 2003, IN PRESS GENOMES MOL; Warhurst DC, 2002, LANCET, V360, P1527, DOI 10.1016/S0140-6736(02)11577-7; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; Wissing F, 2002, J BIOL CHEM, V277, P37747, DOI 10.1074/jbc.M204845200; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Zhang HB, 2002, J BIOL CHEM, V277, P49767, DOI 10.1074/jbc.M204005200; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	66	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33593	33601		10.1074/jbc.M302215200	http://dx.doi.org/10.1074/jbc.M302215200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813054	hybrid			2022-12-25	WOS:000184901800132
J	Robert, K; Chasse, JF; Santiard-Baron, D; Vayssettes, C; Chabli, A; Aupetit, J; Maeda, N; Kamoun, P; London, J; Janel, N				Robert, K; Chasse, JF; Santiard-Baron, D; Vayssettes, C; Chabli, A; Aupetit, J; Maeda, N; Kamoun, P; London, J; Janel, N			Altered gene expression in liver from a murine model of hyperhomocysteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; ENDOPLASMIC-RETICULUM STRESS; HOMOCYSTEINE METABOLISM; S-ADENOSYLHOMOCYSTEINE; DENSITY-LIPOPROTEIN; PLASMA HOMOCYSTEINE; ENDOTHELIAL DYSFUNCTION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; CELL-GROWTH	Cystathionine beta-synthase (CBS) deficiency causes severe hyperhomocysteinemia and other signs of homocystinuria syndrome, in particular a premature atherosclerosis with multiple thrombosis. However, the molecular mechanisms by which homocysteine could interfere with normal cell function are poorly understood in a whole organ like the liver, which is central to the catabolism of homocysteine. We used a combination of differential display and cDNA arrays to analyze differential gene expression in association with elevated hepatic homocysteine levels in CBS-deficient mice, a murine model of hyperhomocysteinemia. Expression of several genes was found to be reproducibly abnormal in the livers of heterozygous and homozygous CBS-deficient mice. We report altered expression of genes encoding ribosomal protein S3a and methylthioadenosine phosphorylase, suggesting such cellular growth and proliferation perturbations may occur in homozygous CBS-deficient mice liver. Many up- or down-regulated genes encoded cytochromes P450, evidence of perturbations of the redox potential in heterozygous and homozygous CBS-deficient mice liver. The expression of various genes involved in severe oxidative processes was also abnormal in homozygous CBS-deficient mice liver. Among them, the expression of heme oxygenase 1 gene was increased, concomitant with overexpression of heme oxygenase 1 at the protein level. Commensurate with the difference in hepatic mRNA paraoxonase 1 abundance, the mean hepatic activity of paraoxonase 1, an enzyme that protects low density lipoprotein from oxidation, was 3-fold lower in homozygous CBS-deficient mice. Heterozygous CBS-deficient mice, when fed a hyperhomocysteinemic diet, have also reduced PON1 activity, which demonstrates the effect of hyperhomocysteinemia in the paraoxonase 1 activity.	Univ Paris 07, EA 3508, F-75231 Paris, France; Fac Med Necker Enfants Malad, INSERM, U490, F-75743 Paris 15, France; Aventis, Cent Nervous Syst Dept, F-94403 Vitry Sur Seine, France; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France; University of North Carolina; University of North Carolina Chapel Hill	Janel, N (corresponding author), Univ Paris 07, EA 3508, Case 7104,2 Pl Jussieu, F-75231 Paris, France.	janel@paris7.jussieu.fr		Janel, Nathalie/0000-0002-4746-8941				Althausen S, 2000, MOL BRAIN RES, V84, P32, DOI 10.1016/S0169-328X(00)00208-4; APPLEGATE LA, 1991, CANCER RES, V51, P974; Austin RC, 1998, J BIOL CHEM, V273, P30808, DOI 10.1074/jbc.273.46.30808; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Bellamy MF, 1998, CIRCULATION, V98, P1848, DOI 10.1161/01.CIR.98.18.1848; Cattaneo M, 1999, THROMB HAEMOSTASIS, V81, P165; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; CHABLI A, 2002, ANN BIOL CLIN, V60, P220; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Choumenkovitch SF, 2002, J NUTR, V132, P2157, DOI 10.1093/jn/132.8.2157; Cravo ML, 1996, AM J CLIN NUTR, V63, P220, DOI 10.1093/ajcn/63.2.220; Dayal S, 2001, CIRC RES, V88, P1203, DOI 10.1161/hh1101.092180; Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200; Denis CV, 2003, THROMB HAEMOSTASIS, V90, P362, DOI 10.1055/s-0037-1613490; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; Ferretti G, 2003, METABOLISM, V52, P146, DOI 10.1053/meta.2003.50033; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Kho CJ, 1996, CELL GROWTH DIFFER, V7, P1157; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; KRAUS JP, 1998, EUR J PEDIATR, V157, P50; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lentz SR, 2000, AM J PHYSIOL-HEART C, V279, pH970, DOI 10.1152/ajpheart.2000.279.3.H970; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Naora H, 1998, LEUKEMIA, V12, P532, DOI 10.1038/sj.leu.2400979; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; SESHADRI T, 1993, J BIOL CHEM, V268, P18474; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; SHIPCHANDLER MT, 1995, CLIN CHEM, V41, P991; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tawakol A, 1997, CIRCULATION, V95, P1119; Torres L, 1999, BBA-MOL BASIS DIS, V1455, P12, DOI 10.1016/S0925-4439(99)00049-6; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1993, CLIN CHEM, V39, P1764; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; WEISS N, 2002, ARTERIOSCLER THROMB, V22, P4; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X	56	52	54	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31504	31511		10.1074/jbc.M213036200	http://dx.doi.org/10.1074/jbc.M213036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799373	Green Published, hybrid			2022-12-25	WOS:000184782100009
J	Wang, W; Ungermannova, D; Chen, L; Liu, XD				Wang, W; Ungermannova, D; Chen, L; Liu, XD			A negatively charged amino acid in Skp2 is required for Skp2-Cks1 interaction and ubiquitination of p27(Kip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS SUC1/CKS PROTEIN; CDK INHIBITOR P27; CELL-CYCLE; CRYSTAL-STRUCTURE; F-BOX; MUTATIONAL ANALYSIS; LIGASE COMPLEX; KINASE COMPLEX; S-PHASE; CKS1	Proteolysis of cyclin-dependent kinase inhibitor p27 occurs predominately in the late G(1) phase of the cell cycle through a ubiquitin-mediated protein degradation pathway. Ubiquitination of p27 requires the SCFSkp2 ubiquitin ligase and Skp2 F-box binding protein Cks1. The mechanisms by which Skp2 recognizes Cks1 to ubiquitylate p27 remain obscure. Here we show that Asp-331 in the carboxyl terminus of Skp2 is required for its association with Cks1 and ubiquitination of p27. Mutation of Asp-331 to Ala disrupts the interaction between Skp2 and Cks1. Although Asp-331 mutation negates the ability of the Skp1-Cullin-F-box protein (SCF) complex to ubiquitylate p27, such a mutation has no effect on Skp2 self-ubiquitination. A conservative change from Asp to Glu at position 331 of Skp2 does not affect Skp2-Cks1 interaction. Our results revealed a unique requirement for a negatively charged residue in the carboxyl-terminal region of Skp2 in recognition of Cks1 and ubiquitination of p27.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199; LIU, XUEDONG/0000-0001-7209-4964	NCI NIH HHS [R01 CA107098, CA95527-01] Funding Source: Medline; NIAID NIH HHS [R21 AI049905] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107098, R01CA095527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bartek J, 2001, NAT CELL BIOL, V3, pE95, DOI 10.1038/35070160; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	34	26	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32390	32396		10.1074/jbc.M305241200	http://dx.doi.org/10.1074/jbc.M305241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12813041	hybrid			2022-12-25	WOS:000184782100118
J	Zhang, JJ; Zhang, YL; Inouye, M				Zhang, JJ; Zhang, YL; Inouye, M			Characterization of the interactions within the mazEF addiction module of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; STABLE MAINTENANCE; PLASMID R100; CRYSTAL-STRUCTURE; DNA GYRASE; SYSTEM; PHD; CCDB; P1; TOXIN	In bacteria, programmed cell death is mediated through the unique genetic system called "addiction module," which consists of a pair of genes encoding a stable toxin and an unstable antitoxin. The mazEF system is known as an addiction module located on the Escherichia coli chromosome. MazF is a stable toxin, and MazE is a labile antitoxin interacting with MazF to form a complex. MazE and the MazE-MazF complex can bind to the mazEF promoter region to regulate the mazEF expression. Here we show that the binding of purified (His)(6)MazE to the mazEF promoter DNA was enhanced by MazF. The site-directed mutations at the conserved amino acid residues in MazE N-terminal region (K7A, R8A, S12A, and R16A) disrupted the DNA binding ability of both (His)(6)MazE and the MazE-MazF(His)(6) complex, suggesting that MazE binds to the mazEF promoter DNA through the N-terminal domain. The ratio of MazE to MazF(His)(6) in the MazE-MazF(His)(6) complex is about 1:2. Because both MazE and MazF(His)(6) exist as dimers by themselves, the MazE-MazF(His)(6) complex (76.9 kDa) is predicted to consist of one MazE dimer and two MazF(His)(6) dimers. The interaction between MazE and MazF was also characterized with the yeast two-hybrid system. It was found that the region from residues 38 to 75 of MazE was required for its binding to MazF. Site-directed mutagenesis at this region revealed that Leu(55) and Leu(58) play an important role in the MazE-MazF complex formation but not in MazE binding to the mazEF promoter DNA. The present results demonstrate that MazE is composed of two domains, the N-terminal DNA-binding domain and the C-terminal domain interacting with MazF.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.			Zhang, Junjie/0000-0001-8809-1485				Afif H, 2001, MOL MICROBIOL, V41, P73, DOI 10.1046/j.1365-2958.2001.02492.x; Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Bahassi EM, 1999, J BIOL CHEM, V274, P10936, DOI 10.1074/jbc.274.16.10936; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; Hazan R, 2001, J BACTERIOL, V183, P2046, DOI 10.1128/JB.183.6.2046-2050.2001; James P, 1996, GENETICS, V144, P1425; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Magnuson R, 1998, J BACTERIOL, V180, P6342; Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Sat B, 2003, J BACTERIOL, V185, P1803, DOI 10.1128/JB.185.6.1803-1807.2003; Sat B, 2001, J BACTERIOL, V183, P2041, DOI 10.1128/JB.183.6.2041-2045.2001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TSUCHIMOTO S, 1989, MOL GEN GENET, V215, P463, DOI 10.1007/BF00427044; TSUCHIMOTO S, 1992, J BACTERIOL, V174, P4205, DOI 10.1128/JB.174.13.4205-4211.1992; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; TSUCHIMOTO S, 1988, J BACTERIOL, V170, P1461, DOI 10.1128/jb.170.4.1461-1466.1988; Van Melderen L, 2002, INT J MED MICROBIOL, V291, P537; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; Wagner R, 2002, J MOL MICROB BIOTECH, V4, P331	32	86	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32300	32306		10.1074/jbc.M304767200	http://dx.doi.org/10.1074/jbc.M304767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12810711	hybrid			2022-12-25	WOS:000184782100106
J	Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK				Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK			Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma	ONCOGENE			English	Article						chromosome 17; Barrett's oesophageal adenocarcinoma; transcript map; tumour suppressor gene; gene prediction programmes	CANDIDATE TUMOR-SUPPRESSOR; TARGET SITES; GENE; EXPRESSION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-17; DISCOVERY	Allelic imbalance (AI) studies on chromosome 17 (C17) in Barrett's oesophageal adenocarcinoma (BOA) tumours strongly suggest that a minimally deleted region on C17p harbours a BOA-associated gene with tumour suppressor function. This deleted region, designated minimal region III (MRIII), lies between the two microsatellite markers D17S1852 and D17S954. Computational sequence analysis techniques, BLAST and NIX, were used to assemble a physical map of MRIII, consisting of three overlapping bacterial artificial chromosome (BAC) clones, 297N7, 963H4 and 795F17, from the RPCI-11 library. The 270 kb genomic sequence of MRIII was analysed using the computational gene prediction methods NIX and TAP to identify putative BOA genes. A transcript map of MRIII has been generated and contains 25 candidate BOA genes, four of which are the named genes MYH3, SCO1, x006 and MAGOH-LIKE. The other candidates consist of seven genes predicted by TAP with associated ESTs identified by NIX, two genes predicted by TAP alone and 12 genes/ESTs (or pairs of ESTs) identified by NIX alone. No disease-specific mutations were identified in x006 or MAGOH-LIKE, although expression analysis of these genes suggests that they may show alternative splicing or be altered epigenetically or in regulatory regions in oesophageal cancer.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England; Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Pathol, Liverpool, Merseyside, England; Royal Liverpool Univ Hosp, Dept Med, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Field, JK (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England.	J.K.Field@liv.ac.uk	Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Bruening W, 1999, CANCER RES, V59, P4973; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Dunn JR, 2000, CLIN CANCER RES, V6, P4033; GISH W, 1996, WU BLASTN2; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Holscher AH, 1997, BRIT J SURG, V84, P1470, DOI 10.1111/j.1365-2168.1997.02800.x; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Marchese A, 1999, GENOMICS, V56, P12, DOI 10.1006/geno.1998.5655; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Phillips NJ, 1996, CANCER RES, V56, P606; RANKIN SC, 2000, OESOPHAGEAL CANC STA; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Russell SEH, 2000, CANCER RES, V60, P4729; Schultz DC, 1996, CANCER RES, V56, P1997; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; Zhao XF, 1998, GENOMICS, V47, P319, DOI 10.1006/geno.1997.5126	25	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4134	4142		10.1038/sj.onc.1206466	http://dx.doi.org/10.1038/sj.onc.1206466			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821948				2022-12-25	WOS:000183707600017
J	Jing, Y; Xia, LJ; Lu, M; Waxman, S				Jing, Y; Xia, LJ; Lu, M; Waxman, S			The cleavage product Delta PML-RAR alpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML-RAR alpha; all-trans retinoic acid	RESISTANT NB4 CELLS; PML/RAR-ALPHA; HISTONE DEACETYLASE; IN-VITRO; PROTEASOME PATHWAY; ARSENIC TRIOXIDE; NUCLEAR-BODIES; FUSION PROTEIN; CHIMERIC GENE; NEW-YORK	PML-RARalpha protein, the leukemogenic product of t(15,17) in acute promyelocytic leukemia, is cleaved into a truncated form termed DeltaPML-RARalpha during all-trans retinoic acid (ATRA)-induced differentiation of NB4 cells. DeltaPML-RARalpha is not formed in ATRA differentiation resistant NB4 subclones. As2O3 inhibits DeltaPML-RARalpha formation and differentiation-induction when given in combination with ATRA. Treatment with hexamethylene bisacetamide (HMBA) combined with ATRA enhances ATRA-induced differentiation in ATRA-insensitive NB4-CI and arsenic-resistant NB4/As cells, and is associated with stabilization of PML-RARalpha protein and increased DeltaPML-RARalpha formation. Unlike forced expression of PML-RARalpha, forced DPML-RARalpha expression based on an estimated deletion of the N-terminal PML portion does not repress RARE-tk-luc reporter activity mediated by endogenous retinoic acid receptors. The cleavage of PML-RARalpha is blocked by RARalpha antagonist Ro-41-5253 and cycloheximide and therefore requires a RARalpha transactivation-dependent pathway. Proteasome inhibitor MG-132 and caspase inhibitor Z-VAD-FMK do not block ATRA-induced PML-RARalpha cleavage and differentiation. These data suggest that (a) ATRA treatment induces PML-RARalpha cleavage by induction of unknown enzymes independent of proteasome- and caspase-mediated pathways; (b) DeltaPML-RARalpha might function differently from both PML-RARalpha and RARalpha; (c) failure to cleave PML-RARalpha and form DeltaPML-RARalpha after ATRA treatment may contribute to ATRA resistance in APL cells.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, Y (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA93533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castaigne Sylvie, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P515; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DEGOS L, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93135-C; DELVA L, 1993, BLOOD, V82, P2175; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jing YK, 2002, BLOOD, V100, P1008, DOI 10.1182/blood.V100.3.1008; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LANOTTE M, 1991, BLOOD, V77, P1080; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Nervi C, 1998, BLOOD, V92, P2244; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Takayama N, 2001, EXP HEMATOL, V29, P864, DOI 10.1016/S0301-472X(01)00651-8; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, pS33; Yoshida H, 1996, CANCER RES, V56, P2945; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4083	4091		10.1038/sj.onc.1206568	http://dx.doi.org/10.1038/sj.onc.1206568			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821942				2022-12-25	WOS:000183707600011
J	Hanada, T; Takeuchi, A; Sondarva, G; Chishti, AH				Hanada, T; Takeuchi, A; Sondarva, G; Chishti, AH			Protein 4.1-mediated membrane targeting of human discs large in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; HUMAN HOMOLOG; TIGHT JUNCTION; GLYCOPHORIN-C; T-LYMPHOCYTES; MAGUK FAMILY; DROSOPHILA; DOMAIN; IDENTIFICATION; KINASE	Human discs large ( hDlg) protein binds to protein 4.1R via a motif encoded by an alternatively spliced exon located between the SH3 and the C-terminal guanylate kinase-like domains. To evaluate the functional significance of protein 4.1R binding for subcellular localization of hDlg in vivo, we expressed full-length recombinant constructs of two naturally occurring isoforms of hDlg termed hDlg-I-2 and hDlg-I-3. The hDlg-I-3 but not the hDlg-I-2 isoform binds to the FERM (Four.1-Ezrin- Radixin-Moesin) domain of protein 4.1R in vitro. Upon transient transfection into subconfluent Madine-Darby canine kidney (MDCK) epithelial cells, the hDlg-I-3 fused with the green fluorescent protein accumulated predominantly at the plasma membrane of cell-cell contact sites, whereas the hDlg-I-2 fusion protein distributed in the cytoplasm. In contrast, in stably transfected confluent MDCK cells, both hDlg-I-2 and - I-3 isoforms localized efficiently to the lateral membrane, consistent with the previous notion that the N-terminal domain of hDlg mediates its membrane targeting in polarized epithelial cells. We introduced a double mutation (I38A/I40A) into the N-terminal domain of hDlg, which disrupted its interaction with DLG2, a key event in the membrane targeting of hDlg. Interestingly, the hDlg-I-2 isoform harboring the I38A/I40A mutation mislocalized from the membrane into cytoplasm. Importantly, the hDlg-I-3 isoform with the same mutation localized efficiently to the membrane of confluent MDCK cells. Together, our results demonstrate that in addition to the N-terminal targeting domain, the alternatively spliced I-3 insertion plays a critical role in recruiting hDlg to the lateral membrane in epithelial cells via its interaction with protein 4.1R.	Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med, Boston, MA 02135 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Anat, Boston, MA 02135 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Cellular Biol, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Chishti, AH (corresponding author), Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med, CBR 404,736 Cambridge St, Boston, MA 02135 USA.				NATIONAL CANCER INSTITUTE [R01CA094414] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060755] Funding Source: NIH RePORTER; NCI NIH HHS [CA94414] Funding Source: Medline; NHLBI NIH HHS [HL 60755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Asaba N, 2003, J BIOL CHEM, V278, P8395, DOI 10.1074/jbc.M210362200; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Karnak D, 2002, J BIOL CHEM, V277, P46730, DOI 10.1074/jbc.M208781200; Kohu K, 2002, GENES CELLS, V7, P707, DOI 10.1046/j.1365-2443.2002.00555.x; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Mendoza C, 2003, J NEUROSCI, V23, P2093; Mori K, 1998, J HUM GENET, V43, P123, DOI 10.1007/s100380050052; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Wu HJ, 1998, J CELL SCI, V111, P2365	45	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34445	34450		10.1074/jbc.M305209200	http://dx.doi.org/10.1074/jbc.M305209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807908	hybrid			2022-12-25	WOS:000185047500103
J	Michaelevski, I; Chikvashvili, D; Tsuk, S; Singer-Lahat, D; Kang, YH; Linial, M; Gaisano, HY; Fili, O; Lotan, I				Michaelevski, I; Chikvashvili, D; Tsuk, S; Singer-Lahat, D; Kang, YH; Linial, M; Gaisano, HY; Fili, O; Lotan, I			Direct interaction of target SNAREs with the Kv2.1 channel - Modal regulation of channel activation and inactivation gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNEL; SYNAPTOSOME-ASSOCIATED PROTEIN; G-BETA-GAMMA; SYNTAXIN 1A; CALCIUM-CHANNELS; MOLECULAR DETERMINANTS; POTASSIUM CHANNELS; INSULIN-SECRETION; XENOPUS-OOCYTES; 4-HELIX BUNDLE	Previously we suggested that interaction between voltage-gated K+ channels and protein components of the exocytotic machinery regulated transmitter release. This study concerns the interaction between the Kv2.1 channel, the prevalent delayed rectifier K+ channel in neuroendocrine and endocrine cells, and syntaxin 1A and SNAP-25. We recently showed in islet beta-cells that the Kv2.1 K+ current is modulated by syntaxin 1A and SNAP-25. Here we demonstrate, using co-immunoprecipitation and immunocytochemistry analyses, the existence of a physical interaction in neuroendocrine cells between Kv2.1 and syntaxin 1A. Furthermore, using concomitant co-immunoprecipitation from plasma membranes and two-electrode voltage clamp analyses in Xenopus oocytes combined with in vitro binding analysis, we characterized the effects of these interactions on the Kv2.1 channel gating pertaining to the assembly/ disassembly of the syntaxin 1A/SNAP-25 ( target (t)-SNARE) complex. Syntaxin 1A alone binds strongly to Kv2.1 and shifts both activation and inactivation to hyperpolarized potentials. SNAP-25 alone binds weakly to Kv2.1 and probably has no effect by itself. Expression of SNAP-25 together with syntaxin 1A results in the formation of t-SNARE complexes, with consequent elimination of the effects of syntaxin 1A alone on both activation and inactivation. Moreover, inactivation is shifted to the opposite direction, toward depolarized potentials, and its extent and rate are attenuated. Based on these results we suggest that exocytosis in neuroendocrine cells is tuned by the dynamic coupling of the Kv2.1 channel gating to the assembly status of the t-SNARE complex.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; University of Toronto; University of Toronto	Lotan, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.		Linial, Michal/B-9143-2011; Michaelevski, Izhak/G-8940-2018	Michaelevski, Izhak/0000-0002-0783-1443; Linial, Michal/0000-0002-9357-4526				BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; DASCAL N, 1992, J PHYSIOL-LONDON, V450, P469, DOI 10.1113/jphysiol.1992.sp019137; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Ji JZ, 2002, J BIOL CHEM, V277, P20195, DOI 10.1074/jbc.M201034200; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kits KS, 2000, BRAIN RES REV, V33, P78, DOI 10.1016/S0165-0173(00)00023-0; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; Linial M, 1996, BBA-REV BIOMEMBRANES, V1286, P117, DOI 10.1016/0304-4157(96)00007-X; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Michaelevski L, 2002, J BIOL CHEM, V277, P34909, DOI 10.1074/jbc.M203943200; PETERS KW, 2001, PFLUEGERS ARCH S1, V443, P65; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRIMMER JS, 1993, FEBS LETT, V324, P205, DOI 10.1016/0014-5793(93)81394-F; Turton K, 2002, TRENDS BIOCHEM SCI, V27, P552, DOI 10.1016/S0968-0004(02)02177-1; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200; Zhou Q, 2000, J NEUROSCI RES, V61, P321, DOI 10.1002/1097-4547(20000801)61:3<321::AID-JNR10>3.0.CO;2-L	35	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34320	34330		10.1074/jbc.M304943200	http://dx.doi.org/10.1074/jbc.M304943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12807875	hybrid			2022-12-25	WOS:000185047500088
J	Schroder, NWJ; Schombel, U; Heine, H; Gobel, UB; Zahringer, U; Schumann, RR				Schroder, NWJ; Schombel, U; Heine, H; Gobel, UB; Zahringer, U; Schumann, RR			Acylated cholesteryl galactoside as a novel immunogenic motif in Borrelia burgdorferi sensu stricto	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TOLL-LIKE RECEPTOR-2; SURFACE PROTEIN-A; NF-KAPPA-B; LYME-DISEASE; STAPHYLOCOCCUS-AUREUS; LIPOPOLYSACCHARIDE; SERODIAGNOSIS; LIPOPROTEINS; VACCINATION	Borrelia burgdorferi sensu lato is the causing agent of Lyme disease, an infectious disease frequently occurring in the United States, Europe, and Northern Asia. Currently, diagnosis of and vaccination strategies against this pathogen are exclusively based on proteinaceous structures. Here we report on a novel class of immunogenic glycolipids purified from B. burgdorferi sensu stricto B31. Employing a butanol/water extraction procedure with subsequent Bligh/Dyer extraction of the organic phase, thin layer chromatography analysis revealed the presence of three distinct glycolipids, which were chemically analyzed employing combined gas-liquid chromatography/ mass spectroscopy, matrix-assisted laser desorption/ionization mass spectrometry, and NMR. We identified acylated cholesteryl galactoside (ACG) next to cholesteryl galactoside and alpha- monogalactosyldiacylglycerol. After extensive purification, the glycolipids investigated failed to cause proinflammatory responses in human cells transfected with human toll-like receptor (TLR)-2 or -4. However, we observed a marked recognition of ACG by sera derived from patients suffering from Lyme disease. These data indicate that newly described ACG is involved in developing host immunity during Lyme disease and thus may be useful for diagnosis and vaccination.	Humboldt Univ, Fak Med, Univ Klinikum Charite, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; Leibniz Ctr Med & Biosci, Div Immunochem, D-23845 Borstel, Germany; Leibniz Ctr Med & Biosci, Jr Res Grp Innate Immun, Res Ctr Borstel, D-23845 Borstel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel	Schumann, RR (corresponding author), Humboldt Univ, Fak Med, Univ Klinikum Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.		Heine, Holger/H-4552-2012	Heine, Holger/0000-0001-8128-5068				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BOCK K, 1982, ANNU REP NMR SPECTRO, V13, P1; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DITTMER JC, 1964, J LIPID RES, V5, P126; Exner M, 2001, EXPERT OPIN BIOL TH, V1, P783, DOI 10.1517/14712598.1.5.783; FROST DJ, 1975, CHEM PHYS LIPIDS, V15, P53, DOI 10.1016/0009-3084(75)90032-8; HAQUE M, 1995, J BACTERIOL, V177, P5334, DOI 10.1128/jb.177.18.5334-5337.1995; Hauser U, 1997, J CLIN MICROBIOL, V35, P1433, DOI 10.1128/JCM.35.6.1433-1444.1997; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hossain H, 2001, BIOCHIMIE, V83, P683, DOI 10.1016/S0300-9084(01)01296-2; JOHNSON RC, 1977, ANNU REV MICROBIOL, V31, P89, DOI 10.1146/annurev.mi.31.100177.000513; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; MARCONI RT, 1993, INFECT IMMUN, V61, P2611, DOI 10.1128/IAI.61.6.2611-2617.1993; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; PURCELL JM, 1966, ANAL CHEM, V38, P588, DOI 10.1021/ac60236a016; Reed KD, 2002, J CLIN MICROBIOL, V40, P319, DOI 10.1128/JCM.40.2.319-324.2002; Robertson J, 2000, J CLIN MICROBIOL, V38, P2097; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Schumann RR, 1998, GLIA, V22, P295, DOI 10.1002/(SICI)1098-1136(199803)22:3<295::AID-GLIA8>3.0.CO;2-4; Shapiro ED, 2000, CLIN INFECT DIS, V31, P533, DOI 10.1086/313982; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; Weber K, 2001, EUR J CLIN MICROBIOL, V20, P6, DOI 10.1007/s100960000412; WILL G, 1995, MED MICROBIOL IMMUN, V184, P73, DOI 10.1007/BF00221390; Wilske B, 1996, INFECTION, V24, P208, DOI 10.1007/BF01713341; WILSKE B, 1993, MED MICROBIOL IMMUN, V182, P255, DOI 10.1007/BF00579624; Wilson WK, 1996, J LIPID RES, V37, P1529	36	34	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33645	33653		10.1074/jbc.M305799200	http://dx.doi.org/10.1074/jbc.M305799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12810705	hybrid			2022-12-25	WOS:000185047500008
J	Stieber, J; Thomer, A; Much, B; Schneider, A; Biel, M; Hofmann, F				Stieber, J; Thomer, A; Much, B; Schneider, A; Biel, M; Hofmann, F			Molecular basis for the different activation kinetics of the pacemaker channels HCN2 and HCN4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP MODULATION; HEART; IDENTIFICATION; TERMINUS; NEURONS; FAMILY; MICE	The pacemaker channels HCN2 and HCN4 have been identified in cardiac sino-atrial node cells. These channels differ considerably in several kinetic properties including the activation time constant (tau(act)), which is fast for HCN2 (144 ms at -140 mV) and slow for HCN4 ( 461 ms at -140 mV). Here, by analyzing HCN2/4 chimeras and mutants we identified single amino acid residues in transmembrane segments 1 and 2 and the connecting loop between S1 and S2 that are major determinants of this difference. Replacement of leucine 272 in S1 of HCN4 by the corresponding phenylalanine present in HCN2 decreased tau(act) of HCN4 to 149 ms. Conversely, activation of the fast channel HCN2 was decreased 3-fold upon the corresponding mutation of F221L in the S1 segment. Mutation of N291T and T293A in the linker between S1 and S2 of HCN4 shifted tau(act) to 275 ms. While residues 272, 291, and 293 of HCN4 affected the activation speed at basal conditions they had no obvious influence on the cAMP-dependent acceleration of activation kinetics. In contrast, mutation of I308M in S2 of HCN4 abolished the cAMP-dependent decrease in tau(act). Surprisingly, this mutation also prevented the acceleration of channel activation observed after deletion of the C-terminal cAMP binding site. Taken together our results indicate that the speed of activation of the HCN4 channel is determined by structural elements present in the S1, S1-S2 linker, and the S2 segment.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Munich, Zentrum Pharmaforsch, Dept Pharm, D-81377 Munich, Germany	Technical University of Munich; University of Munich	Stieber, J (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	stieber@ipt.med.tu-muenchen.de	Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Accili EA, 2002, NEWS PHYSIOL SCI, V17, P32, DOI 10.1152/physiologyonline.2002.17.1.32; Brauer AU, 2001, FASEB J, V15, P2689, DOI 10.1096/fj.01-0235com; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Doan TN, 1999, J PHYSIOL-LONDON, V514, P125, DOI 10.1111/j.1469-7793.1999.125af.x; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Ishii TM, 2001, J PHYSIOL-LONDON, V537, P93, DOI 10.1111/j.1469-7793.2001.0093k.x; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Moroni A, 2001, J BIOL CHEM, V276, P29233, DOI 10.1074/jbc.M100830200; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Qu JH, 2002, PFLUG ARCH EUR J PHY, V444, P597, DOI 10.1007/s00424-002-0860-7; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Shi WM, 1999, CIRC RES, V85, pE1; Thoby-Brisson M, 2000, J NEUROSCI, V20, P2994; Timofeev I, 2002, P NATL ACAD SCI USA, V99, P9533, DOI 10.1073/pnas.132259899; Viscomi C, 2001, J BIOL CHEM, V276, P29930, DOI 10.1074/jbc.M103971200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2002, NEURON, V36, P451, DOI 10.1016/S0896-6273(02)00968-6; Wang J, 2001, J GEN PHYSIOL, V118, P237, DOI 10.1085/jgp.118.3.237	25	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33672	33680		10.1074/jbc.M305318200	http://dx.doi.org/10.1074/jbc.M305318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12813043	hybrid			2022-12-25	WOS:000185047500010
J	Wang, CX; Barry, JK; Min, Z; Tordsen, G; Rao, AG; Olsen, OA				Wang, CX; Barry, JK; Min, Z; Tordsen, G; Rao, AG; Olsen, OA			The calpain domain of the maize DEK1 protein contains the conserved catalytic triad and functions as a cysteine proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOSPERM DEVELOPMENT; CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; CELL-LAYERS; MU-CALPAIN; ACTIVATION; ALEURONE; CALCIUM; IDENTIFICATION	Development of the aleurone layer of maize grains requires the activity of the Defective kernel 1 ( Dek1) gene, encoding a predicted 240-kDa membrane-anchored protein with a C terminus similar to animal calpain domain II&III. Three-dimensional modeling shows that DEK1 domain II contains a conserved calpain catalytic triad and that domain II&III has a predicted structure similar to m-calpain. Recombinant DEK1 domain II&III exhibits activity in the caseinolytic assay in the absence of calcium, although the activity is enhanced by calcium. This is in sharp contrast to animal calpains, which require Ca2+ to be active. Bacterially expressed DEK1 domain II does not display caseinolytic activity, suggesting an important role for DEK1 domain III. Mutation of the catalytic Cys residue to Ser leads to a loss of caseinolytic activity of DEK1 domain II&III. Two features of DEK1 calpain may contribute to maintaining the active site triad in an "active" configuration in the absence of Ca2+, both of which are predicted to keep m-calpain domains IIa and IIb apart. First, DEK1 lacks key charged residues in the basic loop of domain II, and secondly, the absence of an acidic loop in domain III, both of which are predicted to be neutralized upon Ca2+ binding. The Dek1 transcript is present in all cell types in developing maize endosperm, suggesting that the activity of the DEK1 calpain is regulated at the post-transcription level. The role of DEK1 in aleurone signaling is discussed.	Pioneer HiBred Int Inc, Johnston, IA 50131 USA	DuPont	Olsen, OA (corresponding author), Pioneer HiBred Int Inc, Johnston, IA 50131 USA.	odd-arne.olsen@pioneer.com						Amano S, 1997, J BIOCHEM, V122, P865; Aragon B, 2002, MOL CELL BIOCHEM, V231, P97, DOI 10.1023/A:1014460730664; ARTHUR JSC, 1995, FEBS LETT, V368, P397, DOI 10.1016/0014-5793(95)00691-2; Becraft PW, 2002, ANNU REV CELL DEV BI, V18, P163, DOI 10.1146/annurev.cellbio.18.012502.083431; Becraft PW, 2000, DEVELOPMENT, V127, P4039; Becraft PW, 2002, DEVELOPMENT, V129, P5217; Becraft PW, 1996, SCIENCE, V273, P1406, DOI 10.1126/science.273.5280.1406; Becraft PW, 2001, PLANT PHYSIOL, V127, P486, DOI 10.1104/pp.010299; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bordone L, 2002, J BIOL CHEM, V277, P26673, DOI 10.1074/jbc.M112037200; BROWN RC, 1994, PLANT CELL, V6, P1241, DOI 10.1105/tpc.6.9.1241; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; Dutt P, 2002, BIOCHEM J, V367, P263, DOI 10.1042/BJ20020485; Futai E, 2001, BBA-GENE STRUCT EXPR, V1517, P316, DOI 10.1016/S0167-4781(00)00256-6; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; GUROFF G, 1964, J BIOL CHEM, V239, P149; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Jackson DP., 1992, MOL PLANT PATHOLOGY, P163; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Laval M, 2002, BBA-GEN SUBJECTS, V1570, P121, DOI 10.1016/S0304-4165(02)00184-8; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Olsen OA, 1998, TRENDS PLANT SCI, V3, P168, DOI 10.1016/S1360-1385(98)01224-2; Olsen OA, 2001, ANNU REV PLANT PHYS, V52, P233, DOI 10.1146/annurev.arplant.52.1.233; Ritchie S, 1998, P NATL ACAD SCI USA, V95, P2697, DOI 10.1073/pnas.95.5.2697; SATO K, 1995, EUR J BIOCHEM, V230, P25, DOI 10.1111/j.1432-1033.1995.0025i.x; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Sazontova T.G., 1999, PATHOPHYSIOLOGY, V6, P91; Schad E, 2002, BIOCHEM J, V362, P383, DOI 10.1042/0264-6021:3620383; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; Shen B, 2003, P NATL ACAD SCI USA, V100, P6552, DOI 10.1073/pnas.0732023100; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Tanaka H, 2002, PLANT CELL PHYSIOL, V43, P419, DOI 10.1093/pcp/pcf052; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701	45	55	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34467	34474		10.1074/jbc.M300745200	http://dx.doi.org/10.1074/jbc.M300745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12824178	hybrid			2022-12-25	WOS:000185047500106
J	Fiermonte, G; Dolce, V; David, L; Santorelli, FM; Dionisi-Vici, C; Palmieri, F; Walker, JE				Fiermonte, G; Dolce, V; David, L; Santorelli, FM; Dionisi-Vici, C; Palmieri, F; Walker, JE			The mitochondrial ornithine transporter - Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ORNITHINE/CITRULLINE CARRIER; BOVINE MITOCHONDRIA; MESSENGER-RNA; AMINOTRANSFERASE; IDENTIFICATION; GENE; TRANSLOCATION; TRANSAMINASE; PURIFICATION	Two isoforms of the human ornithine carrier, ORC1 and ORC2, have been identified by overexpression of the proteins in bacteria and by study of the transport properties of the purified proteins reconstituted into liposomes. Both transport L-isomers of ornithine, lysine, arginine, and citrulline by exchange and by unidirectional mechanisms, and they are inactivated by the same inhibitors. ORC2 has a broader specificity than ORC1, and L- and D-histidine, L-homoarginine, and D-isomers of ornithine, lysine, and ornithine are all substrates. Both proteins are expressed in a wide range of human tissues, but ORC1 is the predominant form. The highest levels of expression of both isoforms are in the liver. Five mutant forms of ORC1 associated with the human disease hyperornithinemia-hyperammonemia- homocitrullinuria were also made. The mutations abolish the transport properties of the protein. In patients with hyperornithinemia-hyperammonemia-homocitrullinuria, isoform ORC2 is unmodified, and its presence compensates partially for defective ORC1.	Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; Univ Calabria, Dept Pharmacobiol, I-87100 Cosenza, Italy; Osped Bambino Gesu, Div Metab Dis, I-00165 Rome, Italy; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	Universita degli Studi di Bari Aldo Moro; University of Calabria; IRCCS Bambino Gesu; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Walker, JE (corresponding author), Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.		Dionisi-Vici, Carlo/K-2045-2018; Fiermonte, Giuseppe/D-3680-2018; Santorelli, Filippo M/ABE-5124-2020	Dionisi-Vici, Carlo/0000-0002-0007-3379; Fiermonte, Giuseppe/0000-0002-6764-9395; Santorelli, Filippo M/0000-0002-1359-9062; Walker, John/0000-0001-7929-2162; Dolce, Vincenza/0000-0003-2966-4866				BRADFORD NM, 1980, FEBS LETT, V113, P294, DOI 10.1016/0014-5793(80)80612-0; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Camacho JA, 1999, NAT GENET, V22, P151, DOI 10.1038/9658; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; HERZFELD A, 1968, J BIOL CHEM, V243, P3327; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; INDIVERI C, 1994, BBA-BIOENERGETICS, V1188, P293, DOI 10.1016/0005-2728(94)90048-5; Indiveri C, 1999, BIOCHEM J, V341, P705, DOI 10.1042/0264-6021:3410705; INDIVERI C, 1992, EUR J BIOCHEM, V207, P449, DOI 10.1111/j.1432-1033.1992.tb17070.x; Indiveri C, 1997, BIOCHEM J, V327, P349, DOI 10.1042/bj3270349; Indiveri C, 2001, BBA-BIOENERGETICS, V1503, P303, DOI 10.1016/S0005-2728(00)00208-5; Ip M M, 1974, Biochim Biophys Acta, V354, P29, DOI 10.1016/0304-4165(74)90049-X; KREBS HA, 1976, GLUCONEOGENESIS ITS, P269; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; MEIJER AJ, 1975, J BIOL CHEM, V250, P7728; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; PERAINO C, 1965, J BIOL CHEM, V240, P3039; Salvi S, 2001, Hum Mutat, V18, P460, DOI 10.1002/humu.1221; Salvi S, 2001, NEUROLOGY, V57, P911, DOI 10.1212/WNL.57.5.911; VOLPE P, 1969, J BIOL CHEM, V244, P719; WINDMUELLER HG, 1978, J BIOL CHEM, V253, P69; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301	27	102	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32778	32783		10.1074/jbc.M302317200	http://dx.doi.org/10.1074/jbc.M302317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807890	hybrid			2022-12-25	WOS:000184901800037
J	Nicolas, FJ; Hill, CS				Nicolas, FJ; Hill, CS			Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest	ONCOGENE			English	Article						TGF-beta; Smad; signal duration; pancreatic tumor cells; cell cycle arrest	PLASMINOGEN-ACTIVATOR INHIBITOR; TRANSCRIPTIONAL ACTIVATION; ACTIVIN RECEPTOR; CDK INHIBITORS; CYCLE ARREST; CANCER CELLS; C-MYC; REPRESSION; EXPRESSION; GENE	We have investigated the mechanism whereby tumor cells become resistant to the antiproliferative effects of transforming growth factor (TGF)-beta, while maintaining other responses that can lead to increased malignancy and invasiveness. TGF-beta signaling results in nuclear accumulation of active Smad complexes which regulate transcription of target genes. Here we show that in two pancreatic carcinoma cell lines, PT45 and Panc-1, that are resistant to TGF-beta-induced growth arrest, the TGF-beta-Smad signaling pathway is attenuated compared with epithelial cells that are sensitive to the antiproliferative effects of TGF-beta (HaCaT and Colo-357). In PT45 and Panc-1 cells, active Smad complexes remain nuclear for only 1-2 It compared with more than 6 h in HaCaT and Colo-357 cells. The attenuated pathway in PT45 and Panc-1 cells correlates with low levels of TGF-beta type I receptor and results in an altered expression profile of TGF-beta-inducible genes required for cell cycle arrest. Most significantly, expression of the CDK inhibitor, p21(Cip1/WAF1), which is required for TGF-beta-induced growth arrest in these cells, is not maintained. Moreover, we show that artificially attenuating the TGF-beta-Smad signaling pathway in HaCaT cells is sufficient to prevent TGF-beta-induced growth arrest. Our results demonstrate that the duration of TGF-beta-Smad signaling is a critical determinant of the specificity of the TGF-beta response.	Canc Res UK, London Res Inst, Lab Dev Signalling, London WC2A 3PX, England	Cancer Research UK	Hill, CS (corresponding author), Canc Res UK, London Res Inst, Lab Dev Signalling, 44 Lincolns Inn Fields, London WC2A 3PX, England.	caroline.hill@cancer.org.uk	Nicolás, Francisco José/H-9422-2019	Nicolás, Francisco José/0000-0002-3969-1430; Hill, Caroline/0000-0002-8632-0480				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; Faure S, 2000, DEVELOPMENT, V127, P2917; Fink SP, 2001, CANCER RES, V61, P256; Florenes VA, 1996, ONCOGENE, V13, P2447; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Goggins M, 1998, CANCER RES, V58, P5329; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Hay ED, 1995, ACTA ANAT, V154, P8; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Iavarone A, 1997, NATURE, V387, P417; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jonson T, 2001, INT J ONCOL, V19, P71; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P6791, DOI 10.1073/pnas.96.12.6791; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wells RG, 1997, J BIOL CHEM, V272, P11444; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wong C, 1999, MOL CELL BIOL, V19, P1821	67	114	126	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3698	3711		10.1038/sj.onc.1206420	http://dx.doi.org/10.1038/sj.onc.1206420			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802277				2022-12-25	WOS:000183551000004
J	Bartoli, M; Platt, DH; Lemtalsi, T; Gu, XL; Brooks, SE; Marrero, MB; Caldwell, RB				Bartoli, M; Platt, DH; Lemtalsi, T; Gu, XL; Brooks, SE; Marrero, MB; Caldwell, RB			VEGF differentially activates STAT3 in microvascular endothelial cells	FASEB JOURNAL			English	Article						VEGFR2; angiogenesis	GROWTH-FACTOR; SIGNAL TRANSDUCER; EXPRESSION; ANGIOGENESIS; PROLIFERATION; INDUCTION; HYPOXIA	Increased VEGF expression is found in several pathologies characterized by abnormal angiogenesis. Previous studies have shown that the transcription factor STAT3 mediates VEGF gene transcription and its activation. In this study, Western analysis and confocal immunocytochemistry were used to examine STAT3 activation in retinal microvascular endothelial cells (BREC). We found that VEGF rapidly induces STAT3 tyrosine phosphorylation and nuclear translocation. Immunoprecipitation studies also showed that VEGF forms a complex with VEGFR2 only in BREC and not in aortic macrovascular endothelial cells (BAEC). In addition, quantitative real-time RT-PCR analysis of VEGF-induced VEGF expression showed a significant increase in specific mRNA formation only in BREC and not in BAEC, and this effect was significantly reduced by antisense-mediated reduction of STAT3 expression. Furthermore, studies conducted in human dermal microvascular endothelial cells (HDMEC) showed that, in this endothelial cell type, VEGF autocrine expression is also accompanied by STAT3 activation as in BREC. In this study we showed that VEGF can differentially induce STAT3 activation in micro-versus macro-vascular endothelial cells and that this effect is linked to VEGFR2/STAT3 complex formation, which correlates with VEGF autocrine ability to stimulate its own gene expression.	Med Coll Georgia, Vasc Biol Ctr, Dept Pathol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bartoli, M (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Dept Pathol, CB3209,1459 Laney Walker Blvd, Augusta, GA 30912 USA.	mbartoli@mail.mcg.edu		Caldwell, Ruth/0000-0003-0168-0354				Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Castilla MA, 1999, CIRC RES, V85, P1132; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Hess DC, 2000, STROKE, V31, P1179, DOI 10.1161/01.STR.31.5.1179; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakamura M, 2002, PATHOL INT, V52, P331, DOI 10.1046/j.1440-1827.2002.01367.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4	32	139	145	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1562	+		10.1096/fj.02-1084fje	http://dx.doi.org/10.1096/fj.02-1084fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824281				2022-12-25	WOS:000183818000016
J	Woods, CC; Banks, KE; Gruener, R; DeLuca, D				Woods, CC; Banks, KE; Gruener, R; DeLuca, D			Loss of T cell precursors after spaceflight and exposure to vector-averaged gravity	FASEB JOURNAL			English	Article						fetal thymus organ culture; microgravity; clinostat	POSITIVE NONLYMPHOID CELLS; THYMUS ORGAN-CULTURES; PRE-TCR; IMMUNOLOGICAL SYNAPSE; MURINE THYMOCYTES; BONE-MARROW; FETAL; DIFFERENTIATION; ACTIVATION; CLINOROTATION	Using fetal thymus organ culture (FTOC), we examined the effects of spaceflight and vector-averaged gravity on T cell development. Under both conditions, the development of T cells was significantly attenuated. Exposure to spaceflight for 16 days resulted in a loss of precursors for CD4(+), CD8(+), and CD4(+) CD8(+) T cells in a rat/mouse xenogeneic co-culture. A significant decrease in the same precursor cells, as well as a decrease in CD4(-)CD8(-) T cell precursors, was also observed in a murine C57BL/6 FTOC after rotation in a clinostat to produce a vector-averaged microgravity-like environment. The block in T cell development appeared to occur between the pre-T cell and CD4(+)CD8(+) T cell stage. These data indicate that gravity plays a decisive role in the development of T cells.	Univ Arizona, Dept Microbiol & Immunol, Tucson, AZ 85724 USA; Univ Arizona, Dept Physiol, Tucson, AZ USA	University of Arizona; University of Arizona	DeLuca, D (corresponding author), Univ Arizona, Dept Microbiol & Immunol, 1501 N Campbell,POB 245049, Tucson, AZ 85724 USA.	deluca@u.arizona.edu						Basson MA, 2000, IMMUNOL TODAY, V21, P509, DOI 10.1016/S0167-5699(00)01711-4; Carleton M, 2002, J IMMUNOL, V168, P1649, DOI 10.4049/jimmunol.168.4.1649; Congdon CC, 1996, J APPL PHYSIOL, V81, P172, DOI 10.1152/jappl.1996.81.1.172; Cooper D, 2001, IN VITRO CELL DEV-AN, V37, P63; DELUCA D, 1995, J IMMUNOL METHODS, V178, P13, DOI 10.1016/0022-1759(94)00236-P; DELUCA D, 1986, J IMMUNOL, V136, P430; DELUCA D, 1986, J IMMUNOL, V137, P1435; DEUGNIER MA, 1990, EUR J IMMUNOL, V20, P2075, DOI 10.1002/eji.1830200928; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FUCHS BB, 1993, J LEUKOCYTE BIOL, V54, P245, DOI 10.1002/jlb.54.3.245; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GROVE DS, 1995, EXP CELL RES, V219, P102, DOI 10.1006/excr.1995.1210; Gruener R, 1994, Biol Sci Space, V8, P79; Hailman E, 2002, IMMUNITY, V16, P839, DOI 10.1016/S1074-7613(02)00326-6; Haks MC, 1999, SEMIN IMMUNOL, V11, P23, DOI 10.1006/smim.1998.0153; Hashemi BB, 1999, FASEB J, V13, P2071, DOI 10.1096/fasebj.13.14.2071; Horneck G, 1999, MUTAT RES-FUND MOL M, V430, P221, DOI 10.1016/S0027-5107(99)00133-5; Klaus DM, 1998, ADV SPACE RES, V21, P1315, DOI 10.1016/S0273-1177(97)00404-3; Kobayashi K, 2000, BIOCHEM BIOPH RES CO, V279, P258, DOI 10.1006/bbrc.2000.3945; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Kuo YP, 2002, J NEUROIMMUNOL, V130, P140, DOI 10.1016/S0165-5728(02)00220-5; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Malissen B, 1996, CURR OPIN IMMUNOL, V8, P383, DOI 10.1016/S0952-7915(96)80129-4; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; MATSUMOTO K, 1991, IMMUNOLOGY, V72, P20; Middlebrook AJ, 2002, J IMMUNOL, V169, P2915, DOI 10.4049/jimmunol.169.6.2915; Nickerson CA, 2000, INFECT IMMUN, V68, P3147, DOI 10.1128/IAI.68.6.3147-3152.2000; Petrie HT, 2000, J IMMUNOL, V165, P3094, DOI 10.4049/jimmunol.165.6.3094; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sarkar D, 2000, J BONE MINER RES, V15, P489, DOI 10.1359/jbmr.2000.15.3.489; Shao H, 1999, J IMMUNOL, V163, P603; Strollo F, 1999, ADV SPACE B, V7, P99, DOI 10.1016/S1569-2574(08)60008-8; SUSHKOV FV, 1983, KOSM BIOL AVIAK MED+, V17, P56; Tabourn B, 1999, IN VITRO CELL DEV-AN, V35, P4; Taylor G R, 1997, Adv Space Biol Med, V6, P1, DOI 10.1016/S1569-2574(08)60076-3; TAYLOR GR, 1993, J LEUKOCYTE BIOL, V54, P179, DOI 10.1002/jlb.54.3.179; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; Wilkinson B, 2001, CELL IMMUNOL, V211, P86, DOI 10.1006/cimm.2001.1827; YEOMAN H, 1993, P NATL ACAD SCI USA, V90, P10778, DOI 10.1073/pnas.90.22.10778; Zipris D, 2001, CELL MOL BIOL, V47, P65	42	26	32	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1526	+		10.1096/fj.02-0749fje	http://dx.doi.org/10.1096/fj.02-0749fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824295				2022-12-25	WOS:000183818000042
J	Marques, ETA; Chikhlikar, P; de Arruda, LB; Leao, IC; Lu, Y; Wong, J; Chen, JS; Byrne, B; August, JT				Marques, ETA; Chikhlikar, P; de Arruda, LB; Leao, IC; Lu, Y; Wong, J; Chen, JS; Byrne, B; August, JT			HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; T-LYMPHOCYTE RESPONSES; VIRUS TYPE-1 GAG; ANTIGEN PRESENTATION; DENDRITIC CELLS; LONGITUDINAL ANALYSIS; CD4(+); INDUCTION; COMPLEX; IMMUNIZATION	Several genetic vaccines encoding antigen chimeras containing the lysosome-associated membrane protein ( LAMP) translocon, transmembrane, and cytoplasmic domain sequences have elicited strong mouse antigen-specific immune responses. The increased immune response is attributed to trafficking of the antigen chimera to the major histocompatibility class II (MHC II) compartment where LAMP is colocalized with MHC II. In this report, we describe a new form of an HIV-1 p55gag DNA vaccine, with the gag sequence incorporated into the complete LAMP cDNA sequence. Gag encoded with the translocon, transmembrane and cytoplasmic lysosomal membrane targeting sequences of LAMP, without the luminal domain, was poorly expressed, did not traffic to lysosomes or MHC II compartments of transfected cells, and elicited a limited immune response from DNA immunized mice. In contrast, addition of the LAMP luminal domain sequence to the construct resulted in a high level of expression of the LAMP/ Gag protein chimera in transfected cells that was further increased by including the inverted terminal repeat sequences of the adeno-associated virus to the plasmid vector. This LAMP/ Gag chimera with the complete LAMP protein colocalized with endogenous MHC II of transfected cells and elicited strong cellular and humoral immune responses of immunized mice as compared with the response to DNA-encoding native Gag, with a 10-fold increase in CD4(+) responses, a 4- to 5-fold increase in CD8(+) T-cell responses, and antibody titers of > 100,000. These results reveal novel roles of the LAMP luminal domain as a determinant of Gag protein expression, lysosomal trafficking, and possibly of the immune response to Gag.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St,Biophys Rm 309, Baltimore, MD 21205 USA.	taugust@jhmi.edu	Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana B/N-9086-2013; Arruda, Luciana/B-5806-2014	Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI041908, R21AI044317] Funding Source: NIH RePORTER; NIAID NIH HHS [R21-AI44317, R37-AI41908] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarraberes FA, 2001, J CELL SCI, V114, P2491; Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169; Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110; ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998; Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113; Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001; Drake JR, 1999, J IMMUNOL, V162, P1150; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; DUBEY C, 1995, J IMMUNOL, V155, P45; Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; HUGHES EN, 1981, J BIOL CHEM, V256, P664; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Ji HX, 1999, HUM GENE THER, V10, P2727, DOI 10.1089/10430349950016474; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lem L, 1999, J IMMUNOL, V162, P523; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Lin KY, 1996, CANCER RES, V56, P21; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4; Maecker HT, 1998, J IMMUNOL, V161, P6532; MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4; McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005; MORENO J, 1991, J IMMUNOL, V147, P3306; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; Norris PJ, 2001, J VIROL, V75, P9771, DOI 10.1128/JVI.75.20.9771-9779.2001; Obermuller S, 2002, J CELL SCI, V115, P185; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pontesilli O, 1998, J INFECT DIS, V178, P1008, DOI 10.1086/515659; Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075; Prasad DVR, 2002, J IMMUNOL, V169, P1801, DOI 10.4049/jimmunol.169.4.1801; Qiu JT, 2000, J VIROL, V74, P5997, DOI 10.1128/JVI.74.13.5997-6005.2000; Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999; Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x; Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROWELL JF, 1995, J IMMUNOL, V155, P1818; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671; Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997; Su Z, 2002, CANCER RES, V62, P5041; Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671; zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000	79	71	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37926	37936		10.1074/jbc.M303336200	http://dx.doi.org/10.1074/jbc.M303336200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12824194	hybrid			2022-12-25	WOS:000185437200115
J	deFelice, M; Silberschmidt, D; DiLauro, R; Xu, Y; Wert, SE; Weaver, TE; Bachurski, CJ; Clark, JC; Whitsett, JA				deFelice, M; Silberschmidt, D; DiLauro, R; Xu, Y; Wert, SE; Weaver, TE; Bachurski, CJ; Clark, JC; Whitsett, JA			TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-B; HEPATOCYTE NUCLEAR FACTOR-3; DEVELOPING MOUSE LUNG; DNA-BINDING; A GENE; EPITHELIAL-CELLS; PROMOTER; DIFFERENTIATION; ORGANOGENESIS	Thyroid transcription factor-1 (TTF-1) is a 43-kDa, phosphorylated member of the Nkx2 family of homeodomain-containing proteins expressed selectively in lung, thyroid, and the central nervous system. To assess the role of TTF-1 and its phosphorylation during lung morphogenesis, mice bearing a mutant allele, in which seven serine phosphorylation sites were mutated, Titf1(PM/PM), were generated by homologous recombination. Although heterozygous Titf1(PM/+) mice were unaffected, homozygous Titf1(PM/PM) mice died immediately following birth. In contrast to Titf1 null mutant mice, which lack peripheral lung tissues, bronchiolar and peripheral acinar components of the lung were present in the Titf1(PM/PM) mice. Although lobulation and early branching morphogenesis were maintained in the mutant mice, abnormalities in acinar tubules and pulmonary hypoplasia indicated defects in lung morphogenesis later in development. Although TTF-1(PM) protein was readily detected within the nuclei of pulmonary epithelial cells at sites and abundance consistent with that of endogenous TTF-1, expression of a number of known TTF-1 target genes, including surfactant proteins and secretoglobulin 1A, was variably decreased in the mutant mice. Vascular endothelial growth factor mRNA was decreased in association with decreased formation of peripheral pulmonary blood vessels. Genes mediating surfactant homeostasis, vasculogenesis, host defense, fluid homeostasis, and inflammation were highly represented among those regulated by TTF-1. Thus, in contrast to the null Titf1 mutation, the Titf1(PM/PM) mutant substantially restored lung morphogenesis. Direct and indirect transcriptional targets of TTF-1 were identified that are likely to play important roles in lung formation and function.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Cincinnati Children's Hospital Medical Center; Stazione Zoologica Anton Dohrn di Napoli	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; , Yan/0000-0003-2025-027X; Bachurski, Cindy/0000-0002-3118-0636	NHLBI NIH HHS [HL38859, HL56387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038859, R01HL038859, P50HL056387, P01HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bruno MD, 1999, J BIOL CHEM, V274, P27523, DOI 10.1074/jbc.274.39.27523; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Feliciello A, 2000, CELL GROWTH DIFFER, V11, P649; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Krane CM, 2001, P NATL ACAD SCI USA, V98, P14114, DOI 10.1073/pnas.231273398; Kumar AS, 2000, BBA-GENE STRUCT EXPR, V1492, P45, DOI 10.1016/S0167-4781(00)00058-0; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Mansouri A, 2000, DEVELOPMENT, V127, P2251; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; MELTON KR, 2003, IN PRESS AM J PHYSL; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Mori K, 2001, ARCH HISTOL CYTOL, V64, P319, DOI 10.1679/aohc.64.319; MUCENSKI ML, 2003, J BIOL CHEM; Notterman DA, 2001, CANCER RES, V61, P3124; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Tichelaar JW, 1999, J HISTOCHEM CYTOCHEM, V47, P823, DOI 10.1177/002215549904700612; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WHITSETT JA, 1981, AM J PHYSIOL, V240, pE351, DOI 10.1152/ajpendo.1981.240.4.E351; Xu Y, 2003, J BIOL CHEM, V278, P7674, DOI 10.1074/jbc.M210277200; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	34	111	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35574	35583		10.1074/jbc.M304885200	http://dx.doi.org/10.1074/jbc.M304885200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829717	hybrid			2022-12-25	WOS:000185164400101
J	Estevez, AM; Lehner, B; Sanderson, CM; Ruppert, T; Clayton, C				Estevez, AM; Lehner, B; Sanderson, CM; Ruppert, T; Clayton, C			The roles of intersubunit interactions in exosome stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TRYPANOSOMA-BRUCEI; MESSENGER-RNA; BINDING-PROTEINS; YEAST EXOSOME; RIBOSOMAL-RNA; COMPLEX; DEGRADATION; PROTEASOME; PURIFICATION	In eukaryotes, at least 10 proteins associate in a 3'-5' exonuclease complex, the exosome, which is involved in the processing of many RNA species. A recent model for the exosome placed six RNase PH-related components in a hexameric ring core structure, with three S1 domain proteins associated with the ring surface. So far, however, this model lacks experimental support. Using a combination of RNA interference, complex affinity purification, and yeast two-hybrid approaches, we show here that the RNase PH homologues are important for maintenance of complex integrity. In contrast, the S1 domain proteins are not required for complex stability, although they are required for exosome function. Our results are partially consistent with the proposed model of the exosome, but indicate a different arrangement of the RNase PH proteins.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; United Kingdom Med Res Council Human Genome Mappi, Cambridge CB10 1SB, England	Ruprecht Karls University Heidelberg	Estevez, AM (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, C Ventanilla 11, Granada 18001, Spain.		Lehner, Ben/L-3413-2014; Clayton, Christine/K-7700-2019; Estevez, Antonio M/K-7835-2014; Lehner, Ben/ABH-6562-2020	Lehner, Ben/0000-0002-8817-1124; Estevez, Antonio M/0000-0002-8272-5405; Lehner, Ben/0000-0002-8817-1124; Clayton, Christine/0000-0002-6384-0731; Ruppert, Thomas/0000-0001-9152-2266				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Chekanova JA, 2000, J BIOL CHEM, V275, P33158, DOI 10.1074/jbc.M005493200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Guerra-Giraidez C, 2002, J CELL SCI, V115, P2651; Irmer H, 2001, NUCLEIC ACIDS RES, V29, P4707, DOI 10.1093/nar/29.22.4707; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; James P, 1996, GENETICS, V144, P1425; Marshak DR, 1996, STRATEGIES PROTEIN P; Milone J, 2002, NUCLEIC ACIDS RES, V30, P4040, DOI 10.1093/nar/gkf521; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mutomba MC, 1997, MOL BIOCHEM PARASIT, V90, P491, DOI 10.1016/S0166-6851(97)00197-7; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Oliveira CC, 2002, NUCLEIC ACIDS RES, V30, P4186, DOI 10.1093/nar/gkf545; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Quijada L, 2002, NUCLEIC ACIDS RES, V30, P4414, DOI 10.1093/nar/gkf577; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Raijmakers R, 2002, J MOL BIOL, V315, P809, DOI 10.1006/jmbi.2001.5265; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Zhang J, 1998, MOL BIOCHEM PARASIT, V92, P79, DOI 10.1016/S0166-6851(97)00228-4	37	75	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34943	34951		10.1074/jbc.M305333200	http://dx.doi.org/10.1074/jbc.M305333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12821657	hybrid			2022-12-25	WOS:000185164400026
J	Havlickova, M; Blahos, J; Brabet, I; Liu, JF; Hruskova, B; Prezeau, L; Pin, JP				Havlickova, M; Blahos, J; Brabet, I; Liu, JF; Hruskova, B; Prezeau, L; Pin, JP			The second intracellular loop of metabotropic glutamate receptors recognizes C termini of G-protein alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-ACTIVATED RHODOPSIN; COVALENT CROSS-LINKING; COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; AMINO-ACIDS; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; CONTACT SITES	Heptahelical receptor coupling selectivity to G-proteins is controlled by a large contact area that involves several portions of the receptor and each subunit of the G-protein. In the G-protein alpha subunit, the C-terminal 5 residues, the N terminus, and the alphaN-beta1 and alpha4-alpha5 loops play important roles. On the receptor side, both the second and third (i2 and i3) intracellular loops as well as the C-terminal tail probably contact these different regions of the G-protein. It is now accepted that the C terminus of the alpha subunit binds in a cavity formed by the i2 and i3 loops. Among the various G-protein-coupled receptors (GPCRs), class III receptors that include metabotropic glutamate (mGlu) receptors greatly differ from the rhodopsin-like GPCRs, but the contact zone between these receptors and the G-protein is less understood. The C terminus of the alpha subunit has been shown to play a pivotal role in the selective recognition of class III GPCRs. Indeed, the mGlu2 and mGlu4 and -8 receptors can discriminate between alpha subunits that differ at the level of their C-terminal end only (such as G(qo) and G(qz)). Here, we examine the role of the i2 loop of mGluRs in the selective recognition of this region of the alpha subunit. To that aim, we analyzed the coupling properties of mGlu2 and mGlu4 or -8 receptors and chimeras containing the i2 loop of the converse receptor to G-protein alpha subunits that only differ by their C termini (G(qo), G(qz), and their point mutants). Our data demonstrate that the central portion of the i2 loop is responsible for the selective recognition of the C-terminal end of the alpha subunit, especially the residue on position -4. These data are consistent with the proposal that the C-terminal end of the G-protein alpha subunit interacts with residues in a cavity formed by the i2 and i3 loops in class III GPCRs, as reported for class I GPCRs.	CNRS, Dept Mol Pharmacol, Lab Funct Genom, UPR2580, F-34094 Montpellier 5, France; Acad Sci Czech Republ, Inst Expt Med, Dept Mol Pharmacol, Prague 14220 4, Czech Republic	Centre National de la Recherche Scientifique (CNRS); Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences	Pin, JP (corresponding author), CNRS, Dept Mol Pharmacol, Lab Funct Genom, UPR2580, 141 Rue Cardonille, F-34094 Montpellier 5, France.		Blahos, Jaroslav/G-4397-2014; Kralikova, Michaela/H-2588-2014; Pin, Jean-Philippe/Y-6668-2019; Liu, Jianfeng/E-2786-2012; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; Blahos J, 2001, J BIOL CHEM, V276, P3262, DOI 10.1074/jbc.M004880200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Fourgeaud L, 2003, J BIOL CHEM, V278, P12222, DOI 10.1074/jbc.M205663200; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Kammermeier PJ, 2003, MOL PHARMACOL, V63, P183, DOI 10.1124/mol.63.1.183; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Perroy J, 2000, J NEUROSCI, V20, P7896; Perroy J, 2001, J BIOL CHEM, V276, P45800, DOI 10.1074/jbc.M106876200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Yamashita T, 2001, J BIOCHEM-TOKYO, V130, P149, DOI 10.1093/oxfordjournals.jbchem.a002954; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	52	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35063	35070		10.1074/jbc.M306555200	http://dx.doi.org/10.1074/jbc.M306555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12829705	hybrid			2022-12-25	WOS:000185164400040
J	Lee, MH; Kim, YJ; Kim, HJ; Park, HD; Kang, AR; Kyung, HM; Sung, JH; Wozney, JM; Kim, HJ; Ryoo, HM				Lee, MH; Kim, YJ; Kim, HJ; Park, HD; Kang, AR; Kyung, HM; Sung, JH; Wozney, JM; Kim, HJ; Ryoo, HM			BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; BONE MORPHOGENETIC PROTEIN-2; INHIBITS MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; C2C12 MYOBLASTS; FACTOR BETA-1; SMAD PROTEINS; I RECEPTORS; CBFA1; CELLS	Intramuscular injection of BMP-2 induces ectopic bone formation in vivo. Similarly, BMP-2 treatment blocks myogenic differentiation and induces osteoblastic transdifferentiation of premyoblastic C2C12 cells. Previous reports suggested that BMP-2-stimulated Runx2 expression could play a pivotal role in transdifferentiation. However, increased Runx2 expression by TGF-beta1 did not support osteoblast differentiation in vitro. These results indicate that the induction of Runx2 is not sufficient to explain the BMP-induced transdifferentiation. We found that Dlx5 is specifically expressed in osteogenic cells, and is specifically induced by BMP-2 or -4 signaling but not by other osteotrophic signals or other TGF-beta superfamily members. Cycloheximide treatment indicated that Dlx5 was immediately induced by BMP signaling, while Runx2 required de novo protein synthesis. In addition, blocking or overexpressing each transcription factor indicated that Dlx5 is an indispensable mediator of BMP-2-induced Runx2 expression but is not involved in TGF-beta1-induced Runx2 expression. Moreover, TGF-beta1 opposed BMP-2-induced osteogenic transdifferentiation through Dlx5 suppression by de novo induction of AP-1. Taken together, these results indicate that Dlx5 is an indispensable regulator of BMP-2-induced osteoblast differentiation as well as the counteraction point of the opposing TGF-beta1 action.	Kyungpook Natl Univ, Dept Biochem, Sch Dent, Taegu 700422, South Korea; Kyungpook Natl Univ, Dept Orthodont, Sch Dent, Taegu 700422, South Korea; Genet Inst Inc, Cambridge, MA 02140 USA; Kyungpook Natl Univ, Sch Dent, Dept Pediat Dent, Taegu 700422, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Ryoo, HM (corresponding author), Kyungpook Natl Univ, Dept Biochem, Sch Dent, 101 Dong In Dong, Taegu 700422, South Korea.		Ryoo, Hyun-Mo/D-5839-2012	Ryoo, Hyun-Mo/0000-0001-6769-8341; Lee, Mi-Hye/0000-0002-5484-3383				Acampora D, 1999, DEVELOPMENT, V126, P3795; Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto-Iwamoto M, 2000, J BONE MINER RES, V15, P1659, DOI 10.1359/jbmr.2000.15.9.1659; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; LI L, 1990, J BIOL CHEM, V265, P1556; Luo T, 2001, INT J DEV BIOL, V45, P681; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537; Wong C, 1999, MOL CELL BIOL, V19, P1821; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; ZHAO GQ, 1994, DEV BIOL, V164, P37, DOI 10.1006/dbio.1994.1178; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	39	340	357	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34387	34394		10.1074/jbc.M211386200	http://dx.doi.org/10.1074/jbc.M211386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12815054	hybrid			2022-12-25	WOS:000185047500096
J	Nguyen, MT; Beck, J; Lue, HQ; Funfzig, H; Kleemann, R; Koolwijk, P; Kapurniotu, A; Bernhagen, J				Nguyen, MT; Beck, J; Lue, HQ; Funfzig, H; Kleemann, R; Koolwijk, P; Kapurniotu, A; Bernhagen, J			A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OLIGOMERIZATION STATE; INSULIN DISULFIDES; OXIDATIVE STRESS; REGULATORY ROLE; GROWTH-FACTOR; IN-VITRO; PROTEIN; CYTOKINE; THIOREDOXIN	Macrophage migration inhibitory factor (MIF) is a cytokine that participates in the host inflammatory response. A Cys-Xaa-Xaa-Cys (CXXC)-based thiol-protein oxidoreductase activity of MIF is associated with certain biological functions. Peptides spanning the CXXC region of thiol-protein oxidoreductases retain some biochemical properties of the full-length protein. We report on the characterization of CXXC-spanning MIF-(50-65) and its serine variant, C57S/C60S-MIF-(50-65). Following disulfide-mediated cyclization, MIF-(50-65) adapted a beta-turn conformation comparable with that of beta-turn-containing cyclo-57,60-[Asp(57), Dap(60)] MIF-(50-65). MIF( 50 - 65) had a redox potential E'(0) of - 0.258 V and formed mixed disulfides with glutathione and cysteine. MIF( 50 - 65) but not C57S/C60S-MIF-( 50 - 65) had oxidoreductase activity in vitro. Intriguingly, MIF-( 50 - 65) exhibited MIF- like cellular activities. The peptide but not its variant had glucocorticoid overriding and proliferation-enhancing activity and stimulated ERK1/2 phosphorylation. MIF-( 50 - 65) and its variant bound to the MIF-binding protein JAB1 and enhanced cellular levels of p27(Kip1). As the peptide and its variant were endocytosed at similar efficiency, sequence 50 - 65 appears sufficient for the JAB1-related effects of MIF, whereas other activities require CXXC. Cyclo-57,60-[ Asp57, Dap60] MIF-( 50 65) activated ERK1/2, indicating that CXXC-dependent disulfide and beta-turn formation is associated with an activity-inducing conformation. We conclude that CXXC and sequence 50 - 65 are critical for the activities of MIF. MIF-( 50 - 65) is a surprisingly short sequence with MIF-like functions that could be an excellent molecular template for MIF therapeutics.	Univ Hosp RWTH Aachen, Inst Biochem, Div Biochem & Mol Cell Biol, D-52074 Aachen, Germany; Univ Hosp RWTH Aachen, Inst Biochem, Lab Bioorgan & Med Chem, D-52074 Aachen, Germany; Univ Stuttgart, Inst Interfacial Engn, Biochem Lab, D-70569 Stuttgart, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany; Toegepast Natuurwetenschappelijk Onderzoek Preven, Gaubius Lab, NL-2301 Leiden, Netherlands	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University of Stuttgart; Eberhard Karls University of Tubingen	Kapurniotu, A (corresponding author), Univ Hosp RWTH Aachen, Inst Biochem, Div Biochem & Mol Cell Biol, Pauwelsstr 30, D-52074 Aachen, Germany.	akapurniotu@ukaachen.de; jbernhagen@ukaachen.de	Nguyen, Minh Tho/N-9582-2019	Nguyen, Minh Tho/0000-0002-3803-0569				Arkin MR, 2003, P NATL ACAD SCI USA, V100, P1603, DOI 10.1073/pnas.252756299; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; Cabrele C, 2002, CHEM BIOL, V9, P731, DOI 10.1016/S1074-5521(02)00152-7; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; Fingerle-Rowson G, 2003, AM J PATHOL, V162, P47, DOI 10.1016/S0002-9440(10)63797-2; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; Kleemann R, 1998, FEBS LETT, V430, P191, DOI 10.1016/S0014-5793(98)00654-1; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kleemann R, 2000, EUR J BIOCHEM, V267, P7183, DOI 10.1046/j.1432-1327.2000.01823.x; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Martin L, 2000, CURR PROTEIN PEPT SC, V1, P403, DOI 10.2174/1389203003381306; McInnes C, 1998, J BIOL CHEM, V273, P27357, DOI 10.1074/jbc.273.42.27357; Mikulowska A, 1997, J IMMUNOL, V158, P5514; MILLIS KK, 1993, J ORG CHEM, V58, P4144, DOI 10.1021/jo00067a060; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Pekkari K, 2000, J BIOL CHEM, V275, P37474, DOI 10.1074/jbc.M001012200; Potolicchio I, 2003, J BIOL CHEM, V278, P30889, DOI 10.1074/jbc.M302854200; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; SIEDLER F, 1994, BIOPOLYMERS, V34, P1563, DOI 10.1002/bip.360341114; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; Soulimane T, 2000, PROTEIN SCI, V9, P2068, DOI 10.1110/ps.9.11.2068; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; VANHINSBERGH VWM, 1994, BLOOD, V84, P2984; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Watarai H, 2000, P NATL ACAD SCI USA, V97, P13251, DOI 10.1073/pnas.230445397; Weston R.E., 1972, CHEM KINETICS; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZHANG RM, 1989, J BIOL CHEM, V264, P18472	72	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33654	33671		10.1074/jbc.M301735200	http://dx.doi.org/10.1074/jbc.M301735200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12796500	Green Published, hybrid			2022-12-25	WOS:000185047500009
J	Turko, IV; Li, L; Aulak, KS; Stuehr, DJ; Chang, JY; Murad, F				Turko, IV; Li, L; Aulak, KS; Stuehr, DJ; Chang, JY; Murad, F			Protein tyrosine nitration in the mitochondria from diabetic mouse heart - Implications to dysfunctional mitochondria in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REDUCTASE-ACTIVITY; MASS-SPECTROMETRY; COMPLEX-I; PEROXYNITRITE; MYELOPEROXIDASE; LOCALIZATION; ASSOCIATION; PEROXIDASE; DISEASE	Oxidative stress has been implicated in dysfunctional mitochondria in diabetes. Tyrosine nitration of mitochondrial proteins was observed under conditions of oxidative stress. We hypothesize that nitration of mitochondrial proteins is a common mechanism by which oxidative stress causes dysfunctional mitochondria. The putative mechanism of nitration in a diabetic model of oxidative stress and functional changes of nitrated proteins were studied in this work. As a source of mitochondria, alloxan-susceptible and alloxan-resistant mice were used. These inbred strains are distinguished by the differential ability to detoxify free radicals. A proteomic approach revealed significant similarity between patterns of tyrosine-nitrated proteins generated in the heart mitochondria under different in vitro and in vivo conditions of oxidative stress. This observation points to a common nitrating species, which may derive from different nitrating pathways in vivo and may be responsible for the majority of nitrotyrosine formed. Functional studies show that protein nitration has an adverse effect on protein function and that protection against nitration protects functional properties of proteins. Because proteins that undergo nitration are involved in major mitochondrial functions, such as energy production, antioxidant defense, and apoptosis, we concluded that tyrosine nitration of mitochondrial proteins may lead to dysfunctional mitochondria in diabetes.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Inst Mol Med, Houston, TX 77030 USA; Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	University of Texas System; University of Texas System; Cleveland Clinic Foundation	Murad, F (corresponding author), Univ Texas, Houston Med Sch, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.	Ferid.Murad@uth.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061731] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Gehanne S, 2002, RAPID COMMUN MASS SP, V16, P1692, DOI 10.1002/rcm.773; Goss SPA, 1999, FREE RADICAL RES, V31, P597, DOI 10.1080/10715769900301171; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Lopez MF, 2002, CIRC RES, V90, P380, DOI 10.1161/hh0402.105757; MacMillan-Crow LA, 2001, FREE RADICAL BIO MED, V31, P1603, DOI 10.1016/S0891-5849(01)00750-X; Mathews CE, 1999, DIABETES, V48, P2189, DOI 10.2337/diabetes.48.11.2189; Mathews CE, 1999, FREE RADICAL BIO MED, V27, P449, DOI 10.1016/S0891-5849(99)00084-2; MOKHTAR N, 1993, DIABETES, V42, P682, DOI 10.2337/diabetes.42.5.682; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Pearce LL, 2001, NITRIC OXIDE-BIOL CH, V5, P128, DOI 10.1006/niox.2001.0338; Petersson AS, 2001, J MASS SPECTROM, V36, P616, DOI 10.1002/jms.161; Pierce G N, 1985, Can J Cardiol, V1, P48; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Sechi S, 2002, RAPID COMMUN MASS SP, V16, P1416, DOI 10.1002/rcm.734; Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800; TANAKA Y, 1992, CARDIOVASC RES, V26, P409, DOI 10.1093/cvr/26.4.409; Tomita M, 1996, JPN CIRC J, V60, P673, DOI 10.1253/jcj.60.673; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Turko IV, 2001, AM J PHYSIOL-HEART C, V281, pH2289, DOI 10.1152/ajpheart.2001.281.6.H2289; Valdez LB, 2000, FREE RADICAL BIO MED, V29, P349, DOI 10.1016/S0891-5849(00)00301-4; WILLIAMS.DH, 1971, BIOCHEM J, V121, P41, DOI 10.1042/bj1210041; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1; Zhang H, 2003, J BIOL CHEM, V278, P8969, DOI 10.1074/jbc.M211561200	30	184	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33972	33977		10.1074/jbc.M303734200	http://dx.doi.org/10.1074/jbc.M303734200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821649	hybrid			2022-12-25	WOS:000185047500044
J	Yamamoto, K; Hamada, H; Shinkai, H; Kohno, Y; Koseki, H; Aoe, T				Yamamoto, K; Hamada, H; Shinkai, H; Kohno, Y; Koseki, H; Aoe, T			The KDEL receptor modulates the endoplasmic reticulum stress response through mitogen-activated protein kinase signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; ER STRESS; MESSENGER-RNA; GOLGI-COMPLEX; CELL-DEATH; APOPTOSIS; YEAST; ATF6; RETENTION; RETRIEVAL	The accumulation of misfolded proteins in the endoplasmic reticulum (ER) evokes the ER stress response. The resultant outcomes are cytoprotective but also proapoptotic. ER chaperones and misfolded proteins exit to the secretory pathway and are retrieved to the ER, during which process the KDEL receptor plays a significant role. Using an expression of a mutant KDEL receptor that lacks the ability for ligand recognition, we show that the impairment of retrieval by the KDEL receptor led to a mis-sorting of the immunoglobulin-binding protein BiP, an ER chaperone that has a retrieval signal from the early secretory pathway, which induced intense ER stress response and an increase in susceptibility to ER stress in HeLa cells. Furthermore, we show that the ER stress response accompanied the activation of p38 mitogen-activated protein (MAP) kinases and c-Jun amino-terminal kinases (JNKs) and that the expression of the mutant KDEL receptor suppressed the activation of p38 and JNK1 but not JNK2. The effect of the expression of the mutant KDEL receptor was consistent with the effect of a specific inhibitor for p38 MAP kinases, because the inhibitor sensitized HeLa cells to ER stress. We also found that activation of the KDEL receptor by the ligand induced the phosphorylation of p38 MAP kinases. These results indicate that the KDEL receptor participates in the ER stress response not only by its retrieval ability but also by modulating MAP kinase signaling, which may affect the outcomes of the mammalian ER stress response.	Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dermatol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Pediat, Chuo Ku, Chiba 2608670, Japan	Chiba University; Chiba University; Chiba University	Aoe, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Embryol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	taoe@faculty.chiba-u.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854				Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; BEH CT, 1995, P NATL ACAD SCI USA, V92, P9820, DOI 10.1073/pnas.92.21.9820; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fayadat L, 2003, MOL BIOL CELL, V14, P1268, DOI 10.1091/mbc.E02-06-0363; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Llewellyn DH, 1997, BIOCHEM BIOPH RES CO, V240, P36, DOI 10.1006/bbrc.1997.7607; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	52	71	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34525	34532		10.1074/jbc.M304188200	http://dx.doi.org/10.1074/jbc.M304188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12821650	hybrid			2022-12-25	WOS:000185047500113
J	Arastu-Kapur, S; Ford, E; Ullman, B; Carter, NS				Arastu-Kapur, S; Ford, E; Ullman, B; Carter, NS			Functional analysis of an inosine-guanosine transporter from Leishmania donovani - The role of conserved residues, aspartate 389 and arginine 393	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAHELICAL SALT BRIDGE; NUCLEOSIDE TRANSPORTER; SUBSTRATE SELECTIVITY; DEFICIENT MUTANT; ESCHERICHIA-COLI; MEMBRANE-PROTEIN; CELLULAR UPTAKE; GENE; NITROBENZYLTHIOINOSINE; EXPRESSION	Equilibrative nucleoside transporters encompass two conserved, charged residues that occur within predicted transmembrane domain 8. To assess the role of these "signature" residues in transporter function, the Asp(389) and Arg(393) residues within the LdNT2 nucleoside transporter from Leishmania donovani were mutated and the resultant phenotypes evaluated after transfection into Deltaldnt2 parasites. Whereas an R393K mutant retained transporter activity similar to that of wild type LdNT2, the R393L, D389E, and D389N mutations resulted in dramatic losses of transport capability. Tagging the wild type and mutant ldnt2 proteins with green fluorescent protein demonstrated that the D389N and D389E mutants targeted properly to the parasite cell surface and flagellum, whereas the expression of R393L at the cell surface was profoundly compromised. To test whether Asp(389) and Arg(393) interact, a series of mutants was generated, D389R/R393R, D389D/R393D, and D389R/ R393D, within the green fluorescent protein-tagged LdNT2 construct. Although all of these ldnt2 mutants were transport-deficient, D389R/ R393D localized properly to the plasma membrane, while neither D389R/ R393R nor D389D/R393D could be detected. Moreover, a transport-incompetent D389N/R393N double ldnt2 mutant also localized to the parasite membrane, whereas a D389L/R393L ldnt2 mutant did not, suggesting that an interaction between residues 389 and 393 may be involved in LdNT2 membrane targeting. These studies establish genetically that Asp(389) is critical for optimal transporter function and that a positively charged or polar residue at Arg(393) is essential for proper expression of LdNT2 at the plasma membrane.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Carter, NS (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	cartern@ohsu.edu			NIAID NIH HHS [R01 AI23682, R01 AI44138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R01AI023682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; CARTER NS, 2003, MOL MED PARASITOLOGY, P197; DREW ME, 1995, MOL CELL BIOL, V15, P5508; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Franco PJ, 1999, J BACTERIOL, V181, P6377, DOI 10.1128/JB.181.20.6377-6386.1999; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Rager N, 2001, J BIOL CHEM, V276, P41095, DOI 10.1074/jbc.M107037200; ROBINSON N, 1984, J BIOL CHEM, V259, P7637; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; SILVA NLD, 1989, MOL BIOCHEM PARASIT, V37, P129, DOI 10.1016/0166-6851(89)90109-6; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387	34	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33327	33333		10.1074/jbc.M305141200	http://dx.doi.org/10.1074/jbc.M305141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807872	hybrid			2022-12-25	WOS:000184901800103
J	Bartnikas, TB; Gitlin, JD				Bartnikas, TB; Gitlin, JD			Mechanisms of biosynthesis of mammalian copper/zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN-SUPEROXIDE DISMUTASE; PHYSIOLOGICAL-ROLE; CRYSTAL-STRUCTURE; CHAPERONE; METALLOCHAPERONE; ACTIVATION; SOD1; CCS; LYMPHOBLASTS	Copper/zinc superoxide dismutase (SOD1) is an abundant intracellular enzyme with an essential role in antioxidant defense. The activity of SOD1 is dependent upon the presence of a bound copper ion incorporated by the copper chaperone for superoxide dismutase, CCS. To elucidate the cell biological mechanisms of this process, SOD1 synthesis and turnover were examined following Cu-64 metabolic labeling of fibroblasts derived from CCS+/+ and CCS-/- embryos. The data indicate that copper is rapidly incorporated into both newly synthesized SOD1 and preformed SOD1 apoprotein, that each process is dependent upon CCS and that once incorporated, copper is unavailable for cellular exchange. The abundance of apoSOD1 is inversely proportional to the intracellular copper content and immunoblot and gel filtration analysis indicate that this apoprotein exists as a homodimer that is distinguishable from SOD1. Despite these distinct differences, the abundance and half-life of SOD1 is equivalent in CCS+/+ and CCS-/- fibroblasts, indicating that neither CCS nor copper incorporation has any essential role in the stability or turnover of SOD1 in vivo. Taken together, these data provide a cell biological model of SOD1 biosynthesis that is consistent with the concept of limited intracellular copper availability and indicate that the metallochaperone CCS is a critical determinant of SOD1 activity in mammalian cells. These kinetic and biochemical findings also provide an important framework for understanding the role of mutant SOD1 in the pathogenesis of familial amyotrophic lateral sclerosis.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.				NIDDK NIH HHS [DK 44464] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DISILVESTRO RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P298, DOI 10.1016/0003-9861(89)90442-6; FIELD LS, 2003, IN PRESS J BIOL CHEM, V278; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Petrovic N, 1996, J BIOL CHEM, V271, P28335, DOI 10.1074/jbc.271.45.28335; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; Torres AS, 2001, J BIOL CHEM, V276, P38410, DOI 10.1074/jbc.M104790200; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197	35	53	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33602	33608		10.1074/jbc.M305435200	http://dx.doi.org/10.1074/jbc.M305435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12815046	hybrid			2022-12-25	WOS:000184901800133
J	Meredith, TC; Woodard, RW				Meredith, TC; Woodard, RW			Escherichia coli YrbH is a D-Arabinose 5-phosphate isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SALMONELLA-TYPHIMURIUM; LIPOPOLYSACCHARIDE BIOSYNTHESIS; TRIOSEPHOSPHATE ISOMERASE; NEISSERIA-MENINGITIDIS; 8-PHOSPHATE SYNTHASE; LETHAL MUTANT; ZINC ENZYMES; ACTIVE-SITE; GENETICS	A gene encoding for arabinose 5-phosphate isomerase (API), which catalyzes the interconversion of D-ribulose 5-phosphate (Ru5P) and D-arabinose 5-phosphate (A5P), has been identified from the genome of Escherichia coli K-12. API is the first enzyme in the biosynthesis of 3-deoxy-D-manno- octulosonate (KDO), a sugar moiety located in the lipopolysaccharide layer of most Gram-negative bacteria. The API gene yrbH is located next to the recently identified specific KDO 8-P phosphatase gene, yrbI. The 328-amino acid open reading frame yrbH was cloned, overexpressed, and characterized. The purified recombinant enzyme is a tetramer and is sensitive to inhibition by zinc cations. API has optimal activity at pH 8.4 and catalytic residues with estimated pK(a) values of 6.55 +/- 0.04 and 10.34 +/- 0.07. The enzyme is specific for A5P and Ru5P, with apparent K-m values of 0.61 +/- 0.06 mM for A5P and 0.35 +/- 0.08 mM for Ru5P. The apparent k(cat) in the A5P to Ru5P direction is 157 +/- 4 s(-1), and in the Ru5P to A5P direction it is 255 +/- 16 s(-1). The value of K-eq (Ru5P/A5P) is 0.50 +/- 0.06. Homology searches of the E. coli genome suggest yrbH may be one of multiple genes that encode proteins with API activity.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.		Meredith, Timothy/X-2713-2019	Meredith, Timothy/0000-0002-1901-6841; Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; Bateman A, 1999, TRENDS BIOCHEM SCI, V24, P94, DOI 10.1016/S0968-0004(99)01357-2; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BIGHAM EC, 1984, J MED CHEM, V27, P717, DOI 10.1021/jm00372a003; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; DISCHE Z, 1951, J BIOL CHEM, V192, P583; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Hull S., 1997, P145; Jeffery CJ, 2001, BIOCHEMISTRY-US, V40, P1560, DOI 10.1021/bi0018483; KROPINSKI AMB, 1978, ANTIMICROB AGENTS CH, V13, P494, DOI 10.1128/AAC.13.3.494; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAY PH, 1983, ACS SYM SER, V231, P141; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROANTREE RJ, 1977, J GEN MICROBIOL, V103, P223, DOI 10.1099/00221287-103-2-223; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Sprenger GA, 1995, ARCH MICROBIOL, V164, P324, DOI 10.1007/BF02529978; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2272, DOI 10.1073/pnas.82.8.2272; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799; WELLS TNC, 1993, BIOCHEMISTRY-US, V32, P1294, DOI 10.1021/bi00056a014; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Wu J, 2003, J BIOL CHEM, V278, P18117, DOI 10.1074/jbc.M301983200; Yamada M, 1990, DNA Seq, V1, P141, DOI 10.3109/10425179009016042	40	55	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32771	32777		10.1074/jbc.M303661200	http://dx.doi.org/10.1074/jbc.M303661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12805358	hybrid			2022-12-25	WOS:000184901800036
J	Morgan, JR; Prasad, K; Jin, SP; Augustine, GJ; Lafer, EM				Morgan, JR; Prasad, K; Jin, SP; Augustine, GJ; Lafer, EM			Eps15 homology domain-NPF motif interactions regulate clathrin coat assembly during synaptic vesicle recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; PROTEIN INTERACTIONS; ENDOCYTIC PROTEINS; NERVE-TERMINALS; ADAPTER AP-2; EH DOMAIN; BINDING; AP180; PITS; LOCALIZATION	Although genetic and biochemical studies suggest a role for Eps15 homology domain containing proteins in clathrin-mediated endocytosis, the specific functions of these proteins have been elusive. Eps15 is found at the growing edges of clathrin-coated pits, leading to the hypothesis that it participates in the formation of coated vesicles. We have evaluated this hypothesis by examining the effect of Eps15 on clathrin assembly. We found that although Eps15 has no intrinsic ability to assemble clathrin, it potently stimulates the ability of the clathrin adaptor protein, AP180, to assemble clathrin at physiological pH. We have also defined the binding sites for Eps15 on squid AP180. These sites contain an NPF motif, and peptides derived from these binding sites inhibit the ability of Eps15 to stimulate clathrin assembly in vitro. Furthermore, when injected into squid giant presynaptic nerve terminals, these peptides inhibit the formation of clathrin-coated pits and coated vesicles during synaptic vesicle endocytosis. This is consistent with the hypothesis that Eps15 regulates clathrin coat assembly in vivo, and indicates that interactions between Eps15 homology domains and NPF motifs are involved in clathrin-coated vesicle formation during synaptic vesicle recycling.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Duke Univ, Sch Med, Dept Neurobiol, Durham, NC 27710 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	University of Texas System; University of Texas Health San Antonio; Duke University; Marine Biological Laboratory - Woods Hole	Lafer, EM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Lafer@UTHSCSA.edu	Augustine, George James/J-9228-2013	Lafer, Eileen/0000-0002-0493-6522	NCI NIH HHS [P30 CA054174] Funding Source: Medline; NCRR NIH HHS [S10 RR015883, 1S10RR15883] Funding Source: Medline; NINDS NIH HHS [NS21624, R01 NS029051, R01 NS29051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624, R01NS029051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Mayer BJ, 1999, CURR BIOL, V9, pR70, DOI 10.1016/S0960-9822(99)80014-1; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan JR, 1999, J NEUROSCI, V19, P10201; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Salcini AE, 2001, NAT CELL BIOL, V3, P755, DOI 10.1038/35087075; SANCHEZ ME, 1990, J EXP BIOL, V152, P369; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	39	50	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33583	33592		10.1074/jbc.M304346200	http://dx.doi.org/10.1074/jbc.M304346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12807910	hybrid			2022-12-25	WOS:000184901800131
J	Viapiano, MS; Matthews, RT; Hockfield, S				Viapiano, MS; Matthews, RT; Hockfield, S			A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED HYALURONAN-BINDING; CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; IN-VIVO; PROTEIN INTERACTIONS; PERINEURONAL NETS; NEURITE OUTGROWTH; NERVOUS-SYSTEM; CELL-ADHESION; BREVICAN	BEHAB (brain-enriched hyaluronan-binding protein)/ brevican is the most abundant chondroitin sulfate proteoglycan in the extracellular matrix of the adult rat brain. BEHAB/brevican expression is up-regulated coincident with glial cell proliferation and/or motility, including during early central nervous system development and in invasive glioma. An understanding of the molecular interactions that mediate BEHAB/brevican function is still in its infancy because of the existence of several BEHAB/brevican isoforms, each of which may mediate different functions. Here, we describe a novel BEHAB/brevican isoform, B/b(130), and demonstrate that it is neither the glycosylphosphatidylinositol-linked splice variant of BEHAB/brevican nor a cleavage product of the full-length protein (B/b(150)). B/b(130) is an underglycosylated isoform of BEHAB/brevican, lacking glycosaminoglycan chains as well as most of the sugars that invest B/b(150). B/b(130) localizes exclusively to the particulate fraction of rat brain and associates with the cell membrane by a previously undescribed calcium-independent mechanism. In addition, B/b(130) is the major isoform of BEHAB/brevican that is up-regulated in a rat model of invasive glioma and may therefore contribute to the invasive ability of glioma cells. Further understanding of BEHAB/brevican isoforms will advance our knowledge of the function of this ECM component and may help identify new potential therapeutic targets for primary brain tumors.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA	Yale University	Matthews, RT (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St,SHM C405, New Haven, CT 06510 USA.		Viapiano, Mariano/B-8095-2009; Viapiano, Mariano/AAE-5787-2019	Viapiano, Mariano/0000-0002-8756-388X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035228] Funding Source: NIH RePORTER; NINDS NIH HHS [1R01NS35228, R01 NS035228] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Borland G, 1998, IMMUNOLOGY, V93, P139; Burchell JM, 2001, J MAMMARY GLAND BIOL, V6, P355, DOI 10.1023/A:1011331809881; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Dwek MV, 2001, PROTEOMICS, V1, P756; Gross N, 2001, MED PEDIATR ONCOL, V36, P139; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; JAWORSKI DM, 1995, J NEUROSCI, V15, P1352; Jaworski DM, 1996, CANCER RES, V56, P2293; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; KRUSE CA, 1994, J NEURO-ONCOL, V22, P191, DOI 10.1007/BF01052919; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; Martin PT, 2002, GLYCOBIOLOGY, V12, p1R, DOI 10.1093/glycob/12.1.1R; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Matthews RT, 2002, J NEUROSCI, V22, P7536; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Miura R, 2001, J NEUROCHEM, V76, P413, DOI 10.1046/j.1471-4159.2001.00042.x; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Nutt CL, 2001, NEUROSCIENTIST, V7, P113, DOI 10.1177/107385840100700206; Nutt CL, 2001, CANCER RES, V61, P7056; Rodriguez de Lores A., 1967, J NEUROCHEM, V14, P215; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; Seidenbecher CI, 2002, J NEUROCHEM, V83, P738, DOI 10.1046/j.1471-4159.2002.01183.x; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Zhang H, 1998, J NEUROSCI, V18, P2370	41	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33239	33247		10.1074/jbc.M303480200	http://dx.doi.org/10.1074/jbc.M303480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12799382	hybrid			2022-12-25	WOS:000184901800092
J	Yamada, T; Zhu, DC; Zhang, K; Saxon, A				Yamada, T; Zhu, DC; Zhang, K; Saxon, A			Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc gamma-Fc epsilon chimeric protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; JANUS KINASE; MAP KINASE; INTERFERON-GAMMA; IN-VIVO; IGE; ACTIVATION; TRANSCRIPTION; INVOLVEMENT; ANTIBODIES	Immunoglobulin E (IgE) is important in mediating human allergic diseases. We tested the hypothesis that a human Ig Fcgamma-Fcepsilon bifunctional chimeric protein, GE2, would inhibit IgE class switch recombination (CSR) by co-aggregating B-cell CD32 and CD23. Indeed, GE2 directly inhibited epsilon germ-line transcription, subsequent CSR to epsilon and IgE protein production. This CSR inhibition was dependent on CD23 binding and the phosphorylation of extracellular signal-related kinase (ERK), and it was mediated via suppression of interleukin-4-induced STAT6 phosphorylation. Treatment with PD98059, a specific inhibitor of mitogen-activated protein kinase kinase 1 (MAPKK1 (MEK1)) and MEK2 reversed the ability of GE2 to decrease CSR and STAT6 phosphorylation. GE2 stimulation induced ERK phosphorylation, whereas it did not alter the phosphorylation of c-Jun N-terminal kinase or p38 MAPK. The ability of GE2 to block human isotype switching to epsilon, in addition to its already demonstrated ability to inhibit mast cell and basophil function, suggests that it will provide an important novel benefit in the treatment of IgE-mediated diseases.	Fukui Med Univ, Dept Otorhinolaryngol, Fukui 9101193, Japan; Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA 90095 USA	University of Fukui; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yamada, T (corresponding author), Fukui Med Univ, Dept Otorhinolaryngol, Fukui 9101193, Japan.				NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI-28697, AI-15251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697, R21AI015251, R01AI015251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENGHAO X, 1995, J CLIN INVEST, V96, P907, DOI 10.1172/JCI118138; Fernandez N, 2002, EUR J IMMUNOL, V32, P383, DOI 10.1002/1521-4141(200202)32:2<383::AID-IMMU383>3.0.CO;2-9; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; KOLB JP, 1990, J IMMUNOL, V145, P429; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Linehan LA, 1998, J IMMUNOL, V161, P302; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; STEVNEZERNORDGR.J, 1986, EMBO J, V5, P95; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yabuuchi S, 2002, INT IMMUNOPHARMACOL, V2, P453, DOI 10.1016/S1567-5769(01)00187-4; Yamada T, 2002, J BIOL CHEM, V277, P28830, DOI 10.1074/jbc.M201781200; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0; Zhang K, 2002, J ALLERGY CLIN IMMUN, V110, P421, DOI 10.1067/mai.2002.126382; Zhang K, 2002, EUR J IMMUNOL, V32, P424, DOI 10.1002/1521-4141(200202)32:2<424::AID-IMMU424>3.0.CO;2-P; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	31	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32818	32824		10.1074/jbc.M304590200	http://dx.doi.org/10.1074/jbc.M304590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12801927	hybrid			2022-12-25	WOS:000184901800042
J	Young, MT; Tanner, MJA				Young, MT; Tanner, MJA			Distinct regions of human glycophorin A enhance human red cell anion exchanger (Band 3; AE1) transport function and surface trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; HUMAN ERYTHROCYTE BAND-3; RENAL TUBULAR-ACIDOSIS; MEMBRANE-PROTEIN; XENOPUS-OOCYTES; BLOOD-CELLS; DIMERIZATION; MUTATIONS; HETEROGENEITY; GLYCOSYLATION	Human red cell glycophorin A (GPA) enhances the expression of band 3 anion transport activity at the cell surface of Xenopus oocytes. This effect of GPA could occur in two ways, enhancement of band 3 anion transport function or enhancement of band 3 trafficking to the cell surface. We have examined the GPA effect using GPA mutants. We compared the sequences of GPA and its homolog glycophorin B (GPB; which does not facilitate band 3 cell-surface activity or trafficking) to identify candidate regions of GPA for study. We constructed several GPA or GPB mutants, including naturally occurring GPA/GPB hybrid molecules and insertion, deletion, and substitution mutants. We analyzed the effects of the mutant proteins on band 3-specific chloride transport and surface presentation using co-expression in Xenopus oocytes. We find that the C-terminal cytoplasmic tail of GPA enhances trafficking of band 3 to the cell surface, whereas the extracellular residues 68-70 increase the specific anion transport activity of band 3. In addition, examination of the oligomerization of GPA mutants showed that single amino acid substitutions N-terminal to the transmembrane domain greatly reduce SDS-stable GPA dimer formation, implying that regions outside the transmembrane domain of GPA are important for GPA dimer formation.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Young, MT (corresponding author), Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	mty24@totalise.co.uk	Young, Mark T/E-8928-2010	Young, Mark T/0000-0002-9615-9002				ANSTEE DJ, 1990, VOX SANG, V58, P1, DOI 10.1111/j.1423-0410.1990.tb02049.x; Brosig B, 1998, PROTEIN SCI, V7, P1052; Bruce LJ, 2000, BIOCHEM J, V350, P41, DOI 10.1042/0264-6021:3500041; BRUCE LJ, 1994, BLOOD, V84, P916; BRUCE LJ, 1995, BLOOD, V85, P541; CARTRON J-P, 1992, Transfusion Medicine Reviews, V6, P63, DOI 10.1016/S0887-7963(92)70158-8; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DAHR W, 1987, BLUT, V55, P19, DOI 10.1007/BF00319637; DAHR W, 1976, BLUT, V32, P171, DOI 10.1007/BF00995910; DAHR W, 1986, RECENT ADV BLOOD GRO, P23; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GROVES JD, 1992, J BIOL CHEM, V267, P22163; Hassoun H, 1998, BLOOD, V91, P2146, DOI 10.1182/blood.V91.6.2146.2146_2146_2151; Kanki T, 2003, J BIOL CHEM, V278, P5564, DOI 10.1074/jbc.M211662200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mingarro I, 1997, J MOL BIOL, V272, P633, DOI 10.1006/jmbi.1997.1276; Padgett KA, 1996, GENE, V168, P31, DOI 10.1016/0378-1119(95)00731-8; PADGETT KA, 1996, STRATEGIES, V9, P14; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Reid M, 1997, BLOOD GROUP ANTIGEN; REITHMEIER RAF, 1993, SOC GEN PHY, V48, P161; RING SM, 1994, VOX SANG, V67, P226, DOI 10.1111/j.1423-0410.1994.tb01665.x; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STECK TL, 1978, J SUPRAMOL STR CELL, V8, P311, DOI 10.1002/jss.400080309; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; TELEN MJ, 1990, BLOOD, V76, P842; WANG DN, 1994, FEBS LETT, V346, P26, DOI 10.1016/0014-5793(94)00468-4; Wang L, 1997, J BIOL CHEM, V272, P10631; Young MT, 2000, BIOCHEM J, V350, P53, DOI 10.1042/0264-6021:3500053	40	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32954	32961		10.1074/jbc.M302527200	http://dx.doi.org/10.1074/jbc.M302527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12813056	Green Accepted, hybrid			2022-12-25	WOS:000184901800058
J	Zhang, F; Phiel, CJ; Spece, L; Gurvich, N; Klein, PS				Zhang, F; Phiel, CJ; Spece, L; Gurvich, N; Klein, PS			Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium - Evidence for autoregulation of GSK-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; DEPENDENT PROTEIN PHOSPHATASE; REDUCES TAU-PHOSPHORYLATION; RABBIT SKELETAL-MUSCLE; P70 S6 KINASE; BETA-CATENIN; ALZHEIMERS-DISEASE; XENOPUS EMBRYOS; PHOSPHOPROTEIN PHOSPHATASE; SUBSTRATE-SPECIFICITY	Glycogen synthase kinase-3 (GSK-3) is a critical, negative regulator of diverse signaling pathways. Lithium is a direct inhibitor of GSK-3 and has been widely used to test the putative role of GSK-3 in multiple settings. However, lithium also inhibits other targets, including inositol monophosphatase and structurally related phosphomonoesterases, and thus additional approaches are needed to attribute a given biological effect of lithium to a specific target. For example, lithium is known to increase the inhibitory N-terminal phosphorylation of GSK-3, but the target of lithium responsible for this indirect regulation has not been identified. We have characterized a short peptide derived from the GSK-3 interaction domain of Axin that potently inhibits GSK-3 activity in vitro and in mammalian cells and robustly activates Wnt-dependent transcription, mimicking lithium action. We show here, using the GSK-3 interaction domain peptide, as well as small molecule inhibitors of GSK-3, that lithium induces GSK-3 N-terminal phosphorylation through direct inhibition of GSK-3 itself. Reduction of GSK-3 protein levels, either by RNA interference or by disruption of the mouse GSK-3beta gene, causes increased N-terminal phosphorylation of GSK-3, confirming that GSK-3 regulates its own phosphorylation status. Finally, evidence is presented that N-terminal phosphorylation of GSK-3 can be regulated by the GSK-3-dependent protein phosphatase-1.inhibitor-2 complex.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Klein, PS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.							ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CADE JFJ, 1949, MED J AUSTRALIA, V2, P349, DOI 10.5694/j.1326-5377.1949.tb36912.x; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Mesquita DD, 2001, FEBS LETT, V502, P84, DOI 10.1016/S0014-5793(01)02669-2; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOSTMANN WRG, 1995, FEBS LETT, V375, P231, DOI 10.1016/0014-5793(95)01201-O; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hall AC, 2002, MOL CELL NEUROSCI, V20, P257, DOI 10.1006/mcne.2002.1117; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8; Lucas FR, 1998, J CELL SCI, V111, P1351; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; Manji HK, 1999, BIOL PSYCHIAT, V46, P1328, DOI 10.1016/S0006-3223(99)00235-8; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; PARK IK, 1994, J BIOL CHEM, V269, P28919; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; RAY WJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P434, DOI 10.1016/0005-2744(78)90076-1; Rogers C, 1989, Aust Nurses J, V19, P29; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Salinas PC, 1999, BIOCHEM SOC SYMP, V65, P101; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smith DG, 2001, BIOORG MED CHEM LETT, V11, P635, DOI 10.1016/S0960-894X(00)00721-6; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stoothof WH, 2002, J NEUROCHEM, V83, P904, DOI 10.1046/j.1471-4159.2002.01197.x; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takahashi M, 1999, J NEUROCHEM, V73, P2073; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG QM, 1994, J BIOL CHEM, V269, P14566; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Williams RSB, 2000, TRENDS PHARMACOL SCI, V21, P61, DOI 10.1016/S0165-6147(99)01428-5; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	92	364	385	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					33067	33077		10.1074/jbc.M212635200	http://dx.doi.org/10.1074/jbc.M212635200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12796505	hybrid			2022-12-25	WOS:000184901800072
J	Kasus-Jacobi, A; Ou, JF; Bashmakov, YK; Shelton, JM; Richardson, JA; Goldstein, JL; Brown, MS				Kasus-Jacobi, A; Ou, JF; Bashmakov, YK; Shelton, JM; Richardson, JA; Goldstein, JL; Brown, MS			Characterization of mouse short-chain aldehyde reductase (SCALD), an enzyme regulated by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; DEHYDROGENASE/REDUCTASE FAMILY; LIPID-SYNTHESIS; CULTURED-CELLS; ADIPOSE-TISSUE; MICE; CHOLESTEROL; EXPRESSION; LIVER; SREBP	Sterol regulatory element-binding proteins (SREBPs) enhance transcription of genes encoding all of the proteins required for the cellular synthesis and uptake of cholesterol and unsaturated fatty acids. Here, we use suppression subtractive hybridization to identify a previously unrecognized SREBP-enhanced gene in mice. The gene encodes a membrane-bound enzyme that we designate SCALD, for short-chain aldehyde reductase. We expressed SCALD in bacteria, purified it extensively, and studied its catalytic properties in detergent solution. The enzyme specifically uses NADPH to reduce a variety of short-chain aldehydes, including nonanal and 4-hydroxy-2-nonenal. The enzyme also reduces retinal-dehydes, showing equal activity for all-trans-retinal and 9-cis-retinal. Northern blot analysis indicates that SCALD is expressed most abundantly in mouse liver and testis. In the liver of mice, SCALD is suppressed by fasting and induced by refeeding, consistent with regulation by SREBPs. In testis, SCALD expression is restricted to pachytene spermatocytes, as revealed by visualization of mRNA and protein. SCALD is also expressed in four layers of the retina, including the outer segment of rods and cones, as revealed by immunohistochemistry. SCALD appears to be the mouse ortholog of the human protein that has been designated variously as prostate short-chain dehydrogenase/reductase 1, retinal reductase 1, and retinol dehydrogenase 11. In view of its ability to reduce short-chain aldehydes in addition to retinals, we propose that SCALD may be induced by SREBP in liver and other tissues to prevent toxicity from fatty aldehydes that are generated from oxidation of unsaturated fatty acids that are synthesized as a result of SREBP activity.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.		KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; Bashmakov, Yuriy/0000-0002-2265-3817	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Borvak J, 1998, INT IMMUNOL, V10, P1289, DOI 10.1093/intimm/10.9.1289; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cianga P, 1999, EUR J IMMUNOL, V29, P2515, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2515::AID-IMMU2515&gt;3.0.CO;2-D; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lin BY, 2001, CANCER RES, V61, P1611; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; Moore S, 2002, GENE, V293, P149, DOI 10.1016/S0378-1119(02)00718-7; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sheehan D.C., 1980, THEORY PRACTICE HIST; Shelton JM, 2000, J LIPID RES, V41, P532; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; VALERA V, 1987, BIOCHEM BIOPH RES CO, V148, P515, DOI 10.1016/0006-291X(87)91141-7; Wang H, 2002, MOL CELL BIOL, V22, P8478, DOI 10.1128/MCB.22.24.8478-8490.2002; Woods A, 1994, LAB HISTOPATHOLOGY C; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910	41	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					32380	32389		10.1074/jbc.M304969200	http://dx.doi.org/10.1074/jbc.M304969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12807874	hybrid			2022-12-25	WOS:000184782100117
J	Oshiro, J; Han, GS; Iwanyshyn, WM; Conover, K; Carman, GM				Oshiro, J; Han, GS; Iwanyshyn, WM; Conover, K; Carman, GM			Regulation of the yeast DPP1-encoded diacylglycerol pyrophosphate phosphatase by transcription factor Gis1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PHOSPHOLIPID BIOSYNTHESIS; STATIONARY-PHASE; SHUTTLE VECTORS; SEQUENCE MOTIF; GENE; ZINC; ACID; PHOSPHATIDYLSERINE	The Saccharomyces cerevisiae DPP1-encoded diacylglycerol pyrophosphate phosphatase catalyzes the dephosphorylation of diacylglycerol pyrophosphate to form phosphatidate and P-i. The enzyme also dephosphorylates phosphatidate to form diacylglycerol and P-i. Because diacylglycerol pyrophosphate, phosphatidate, and diacylglycerol have roles as lipid signal molecules in higher eukaryotic cells, it is important to understand how diacylglycerol pyrophosphate phosphatase is regulated. Analysis of DPP1 expression using P-DPP1-lacZ reporter genes with a series of deletions from the 5' end of the promoter indicated sequences responsible for enzyme expression. Three binding sites (URSPDS) for transcription factor Gis1p were identified in the DPP1 promoter (consensus sequence of 5'-T(A/T)AGGGAT-3'). A gis1Delta mutant exhibited elevated levels of DPP1 expression and diacylglycerol pyrophosphate phosphatase activity. Direct interaction between Gis1p and DPP1 promoter elements was demonstrated by electrophoretic mobility shift assays. Mutations in the three URSPDS elements within the DPP1 promoter abolished Gis1p-DNA interactions in vitro and abolished the regulation of DPP1 in vivo. These data indicated that Gis1p was a repressor of DPP1 expression. Phospholipid composition analysis of the gis1Delta mutant showed that Gis1p played a role in regulating the cellular level of diacylglycerol pyrophosphate, as well as the levels of the major phospholipids phosphatidylethanolamine and phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.		Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023	NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Balboa MA, 1999, J BIOL CHEM, V274, P522, DOI 10.1074/jbc.274.1.522; Balciunas D, 1999, MOL GEN GENET, V262, P589; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; den Hartog M, 2001, PLANT J, V25, P55, DOI 10.1046/j.1365-313x.2001.00931.x; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Faulkner A, 1999, J BIOL CHEM, V274, P14831, DOI 10.1074/jbc.274.21.14831; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Pedruzzi I, 2000, EMBO J, V19, P2569, DOI 10.1093/emboj/19.11.2569; ROSEN MD, 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; Stukey J, 1997, PROTEIN SCI, V6, P469; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Toke DA, 1999, BIOCHEMISTRY-US, V38, P14606, DOI 10.1021/bi991472x; van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713	48	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31495	31503		10.1074/jbc.M305452200	http://dx.doi.org/10.1074/jbc.M305452200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12799368	hybrid			2022-12-25	WOS:000184782100008
J	Roda, RH; Balakrishnan, M; Hanson, MN; Wohr, BM; Le Grice, SFJ; Roques, BP; Gorelick, RJ; Bambara, RA				Roda, RH; Balakrishnan, M; Hanson, MN; Wohr, BM; Le Grice, SFJ; Roques, BP; Gorelick, RJ; Bambara, RA			Role of the reverse transcriptase, nucleocapsid protein, and template structure in the two-step transfer mechanism in retroviral recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; DNA STRAND TRANSFER; SINGLE REPLICATION CYCLE; RNA ANNEALING ACTIVITIES; PRIMER BINDING-SITE; IN-VIVO; GENETIC-RECOMBINATION; INTERNAL REGIONS; COPY-CHOICE; HOMOLOGOUS RECOMBINATION	Template switching during reverse transcription promotes recombination in retroviruses. Efficient switches have been measured in vitro on hairpin-containing RNA templates by a two-step mechanism. Pausing of the reverse transcriptase (RT) at the hairpin base allowed enhanced cleavage of the initial donor RNA template, exposing regions of the cDNA and allowing the acceptor to base pair with the cDNA. This defines the first or docking step. The primer continued synthesis on the donor, transferring or locking in a second step. Here we determine the enzyme-dependent factors that influence template switching by comparing the RTs from human immunodeficiency virus, type 1 (HIV-1), and equine infectious anemia virus (EIAV). HIV-1 RT promoted transfers with higher efficiency than EIAV RT. We found that both RTs paused strongly at the base of the hairpin. While stalled, HIV-1 RT made closely spaced cuts, whereas EIAV RT made only a single cut. Docking occurred efficiently at the multiply cut but not at the singly cut site. HIV-1 nucleocapsid (NC) protein stimulated strand transfers. It improved RNase H activity of both RTs. It allowed the EIAV RT to make a distribution of cuts, greatly stimulating docking at the base of the hairpin. Most likely, it also promoted strand exchange, allowing transfers to be initiated from sites throughout the hairpin. Minor pause sites beyond the base of the hairpin correlated with the locking sites. The strand exchange properties of NC likely promote this step. We present a model that explains the roles of RNase H specificity, template structure, and properties of NC in the two-step transfer reaction.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; NCI Frederick, HIV Drug Resistance Program, Frederick, MD 21702 USA; NCI Frederick, AIDS Vaccine Program, Sci Applicat Int Corp, Frederick, MD 21702 USA; Dept Pharmacochem Mol & Struct, INSERM, U266, CNRS,UMR 8600, F-75270 Paris 06, France	University of Rochester; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [Z01BC010493, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020911, T32GM007356, R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400, T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [T32-GM07356, GM49573, F31 GM20911-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Anderson JA, 1998, J VIROL, V72, P1186, DOI 10.1128/JVI.72.2.1186-1194.1998; Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; BLAIR DG, 1977, VIROLOGY, V77, P534, DOI 10.1016/0042-6822(77)90479-2; Brincat JL, 2002, J VIROL, V76, P88, DOI 10.1128/JVI.76.1.88-95.2002; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COFFIN JM, 1997, RETROVIRUSES, P88; COLICELLI J, 1987, VIROLOGY, V160, P518, DOI 10.1016/0042-6822(87)90030-4; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Davis WR, 2000, BIOCHEMISTRY-US, V39, P14279, DOI 10.1021/bi0015764; Davis WR, 1998, BIOCHEMISTRY-US, V37, P14213, DOI 10.1021/bi9814890; Delviks KA, 1999, J VIROL, V73, P7923, DOI 10.1128/JVI.73.10.7923-7932.1999; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DeStefano JJ, 1997, ARCH VIROL, V142, P1797, DOI 10.1007/s007050050198; DEVICO A, 1991, VIROLOGY, V185, P387, DOI 10.1016/0042-6822(91)90786-B; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1993, REVERSE TRANSCRIPTAS, P49; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; Gunthard HF, 1999, VIROLOGY, V259, P154, DOI 10.1006/viro.1999.9774; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Halvas EK, 2000, J VIROL, V74, P10349, DOI 10.1128/JVI.74.22.10349-10358.2000; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; HU WS, 1992, J VIROL, V66, P4457, DOI 10.1128/JVI.66.7.4457-4463.1992; Hu WS, 1997, J VIROL, V71, P6028, DOI 10.1128/JVI.71.8.6028-6036.1997; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; KAWAI S, 1972, VIROLOGY, V49, P37, DOI 10.1016/S0042-6822(72)80005-9; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Lee R, 1998, BIOCHEMISTRY-US, V37, P900, DOI 10.1021/bi972197m; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1991, J VIROL, V65, P7004, DOI 10.1128/JVI.65.12.7004-7007.1991; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Mikkelsen JG, 1996, J VIROL, V70, P1439, DOI 10.1128/JVI.70.3.1439-1447.1996; MONTELARO R, 1992, VIRUSES, V4, P257; Moumen A, 2003, J BIOL CHEM, V278, P15973, DOI 10.1074/jbc.M212306200; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; MURPHY JE, 1994, VIROLOGY, V204, P458, DOI 10.1006/viro.1994.1554; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; Peeters M, 2000, AIDS, V14, pS129; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2000, J VIROL, V74, P9629, DOI 10.1128/JVI.74.20.9629-9636.2000; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Raja A, 1999, BIOCHEMISTRY-US, V38, P5178, DOI 10.1021/bi9828019; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; RUBINEK T, 1994, EUR J BIOCHEM, V219, P977, DOI 10.1111/j.1432-1033.1994.tb18580.x; SCHWARTZBERG P, 1985, J VIROL, V53, P719, DOI 10.1128/JVI.53.3.719-726.1985; SHAHARABANY M, 1993, BIOCHEM BIOPH RES CO, V196, P914, DOI 10.1006/bbrc.1993.2336; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; VOGT PK, 1971, VIROLOGY, V46, P947, DOI 10.1016/0042-6822(71)90093-6; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; YOU JC, 1994, J BIOL CHEM, V269, P31491; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000	96	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31536	31546		10.1074/jbc.M304608200	http://dx.doi.org/10.1074/jbc.M304608200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12801926	hybrid			2022-12-25	WOS:000184782100013
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Transcriptional regulation of the promoter of the rat frizzled related protein gene by CREB	ONCOGENE			English	Article						rat frizzled related protein (rFrp); transcriptional regulation; CREB	BETA-CATENIN; MOLECULAR-CLONING; SPEMANN ORGANIZER; COLON-CARCINOMA; BREAST-TUMORS; CYCLIN D1; C-MYC; BINDING; EXPRESSION; APOPTOSIS	Frizzled related proteins (Frps) are secreted proteins structurally similar to frizzled receptors; they bind Wnt via the cysteine-rich domain and antagonize the Wnt signaling pathway. In this study, we have investigated the mechanisms regulating the transcriptional regulation of rat Frp (rFrp) promoter. From previous findings, we know that the transcriptional activation domain of rFrp resides in the region -202 to -144 relative to the transcription start site, and that it is essential for efficient promoter activity. The study presented here was designed to identify trans-acting factors that bind to this critical domain of the rFrp promoter and to elucidate the pathway involved in the regulation of rFrp expression. Electrophoretic mobility shift assay (EMSA) demonstrated that specific DNA protein binding activities fall into two adjacent core sequences with (CTTTGGGGG) at -197 to -189 and (AGATGATGTAA) at -151 to -141 of the rFrp promoter. Reporter assay showed that these core sequences are both required for the activation of rFrp promoter. Mutation within either one or both core sequence drastically reduced the promoter activity. Southwestern blotting showed that the estimated molecular mass of the distinct binding protein to the (AGATGATGTAA) domain is about 43 kDa. Further EMSA suggested CREB as the trans-acting factor in the DNA-protein complex, which was out competed by CREB consensus oligonucleotides and supershifted by anti-CREB antibody. Overexpression of PKA and CREB also transactivated rFrp promoter, and dominant-negative CREB inhibited the promoter activity in transient reporter assays. More importantly, CREB, phosphorylated CREB and the adaptor protein CBP were found binding to the endogenous rFrp promoter using chromatin immunoprecipitation assay. Collectively, our results demonstrate the induction of rFrp promoter activity by PKA and CREB in vitro, and the binding of CREB and CBP to the rFrp promoter core motif in vivo.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.		; Yam, Judy Wai Ping/C-4454-2009	Hsiao, W.L.Wendy/0000-0002-9113-8819; Yam, Judy Wai Ping/0000-0002-5637-121X				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Bui TD, 1997, GENE, V189, P25, DOI 10.1016/S0378-1119(96)00808-6; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Dennis S, 1999, J CELL SCI, V112, P3815; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321; Katoh M, 2001, BIOCHEM BIOPH RES CO, V282, P116, DOI 10.1006/bbrc.2001.4551; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LeGros L, 2001, J BIOL CHEM, V276, P24918, DOI 10.1074/jbc.M102816200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Preiherr J, 2000, ANTICANCER RES, V20, P2255; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008-6363(99)00376-4; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xu LF, 2000, GENE DEV, V14, P585; Yam JWP, 2001, BIOCHEM BIOPH RES CO, V286, P94, DOI 10.1006/bbrc.2001.5349; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	50	4	4	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3901	3910		10.1038/sj.onc.1206489	http://dx.doi.org/10.1038/sj.onc.1206489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813463				2022-12-25	WOS:000183612000009
J	Rajesh, D; Stenzel, RA; Howard, SP				Rajesh, D; Stenzel, RA; Howard, SP			Perillyl alcohol as a radio-/chemosensitizer in malignant glioma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOBLASTOMA CELL-LINES; FAS-LIGAND; INDUCED APOPTOSIS; IONIZING-RADIATION; CD95 LIGAND; SIGNALING PATHWAY; G0/G1 ARREST; TUMOR-CELLS; DNA-DAMAGE; ACTIVATION	The prognosis for patients with malignant glioma has not significantly changed in two decades, despite advances in surgery, radiation, and chemotherapy, emphasizing the growing need for novel approaches to glioma therapy. Perillyl alcohol (POH) is a naturally occurring monoterpene that has been shown to possess chemotherapeutic as well as chemopreventive activity in animal tumor models and is currently in Phase I and Phase II clinical trials. In the present study, we have demonstrated that POH is an effective radiosensitizer at clinically relevant doses of radiation using established glioma cell lines. POH caused a transient arrest in the G(2)/M phase of the cell cycle and induced apoptosis in glioma cells. POH treatment sensitized glioma cells to Fas-mediated apoptosis, which was further augmented in the presence of ionizing radiation and abrogated in the presence of antagonistic antibody. POH-induced radiosensitization was partially inhibited in glioma cells expressing dominant negative Fas-associated death domain and completely inhibited in glioma cells overexpressing the cytokine response modifier A. In addition, POH treatment resulted in a dose-dependent sensitization to cisplatin and doxorubicin induced cytotoxicity in glioma cells, highlighting its usefulness as a potent radio/chemosensitizer in the treatment of malignant glioma.	Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Madison, WI 53792 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Howard, SP (corresponding author), CSC, K4-354,600 Highland Ave, Madison, WI 53792 USA.	howard@mail.humonc.wisc.edu		Roux, Jeremie/0000-0001-5712-8660	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051829] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P50HL60288] Funding Source: Medline; NIDDK NIH HHS [DK51829] Funding Source: Medline; NIGMS NIH HHS [GM33551] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albasanz JL, 1997, EUR J PHARMACOL, V326, P85, DOI 10.1016/S0014-2999(97)00154-4; Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Ariazi EA, 1999, CANCER RES, V59, P1917; Bailey HH, 2002, GYNECOL ONCOL, V85, P464, DOI 10.1006/gyno.2002.6647; BALTUCH GH, 1993, NEUROSURGERY, V33, P495; Belanger J T, 1998, Altern Med Rev, V3, P448; Chamberlain MC, 2001, J CLIN ONCOL, V19, P3997, DOI 10.1200/JCO.2001.19.19.3997; Chmura SJ, 1997, CANCER RES, V57, P1270; Clark SS, 2002, LEUKEMIA, V16, P213, DOI 10.1038/sj.leu.2402369; CROWELL PL, 1992, CARCINOGENESIS, V13, P1261, DOI 10.1093/carcin/13.7.1261; Crowell PL, 1996, ADV EXP MED BIOL, V401, P131; Darzynkiewicz Z, 1998, Adv Biochem Eng Biotechnol, V62, P33, DOI 10.1007/BFb0102305; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; Ezennia EI, 1997, J CHROMATOGR B, V688, P354, DOI 10.1016/S0378-4347(96)00322-2; Feldman D., 1996, SYNTHETIC POLYM, DOI [DOI 10.1002/(SICI)1097-4644(1996)25+<1::AID-JCB1>3.0.CO;2-4, 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G, DOI 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G]; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 1998, KLIN PADIATR, V210, P148, DOI 10.1055/s-2008-1043870; Gorczyca W, 1998, METH MOL B, V91, P217; Goto K, 2002, ORAL ONCOL, V38, P16, DOI 10.1016/S1368-8375(00)00134-2; GOULD MN, 1994, CANCER RES, V54, P3540; GOULD MN, 1995, J CELL BIOCHEM, P139; Gould MN, 1997, ENVIRON HEALTH PERSP, V105, P977, DOI 10.2307/3433313; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; HAAG JD, 1994, CANCER CHEMOTH PHARM, V34, P477, DOI 10.1007/BF00685658; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hudes GR, 2000, CLIN CANCER RES, V6, P3071; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Krammer P H, 1999, Adv Immunol, V71, P163; Maecker HL, 2000, CANCER RES, V60, P4638; MARIN LA, 1991, INT J RADIAT ONCOL, V21, P397, DOI 10.1016/0360-3016(91)90788-6; Mehta M, 2001, Int J Radiat Oncol Biol Phys, V51, P11; Mehta M P, 2000, Curr Oncol Rep, V2, P438, DOI 10.1007/s11912-000-0064-2; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reddy BS, 1997, CANCER RES, V57, P420; Reimer T, 2000, CANCER RES, V60, P822; Ren ZB, 1998, CARCINOGENESIS, V19, P827, DOI 10.1093/carcin/19.5.827; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Ripple GH, 1998, CLIN CANCER RES, V4, P1159; Ripple GH, 2000, CLIN CANCER RES, V6, P390; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Roth W, 1998, J NEUROIMMUNOL, V87, P121, DOI 10.1016/S0165-5728(98)00079-4; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; Sahin MB, 1999, LEUKEMIA, V13, P1581, DOI 10.1038/sj.leu.2401536; Satomi Y, 1999, CARCINOGENESIS, V20, P1957, DOI 10.1093/carcin/20.10.1957; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Sheard MA, 2001, INT J CANCER, V96, P213, DOI 10.1002/ijc.1020; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Shinohara H, 2000, CANCER RES, V60, P1766; Shinoura N, 2000, CANCER GENE THER, V7, P224, DOI 10.1038/sj.cgt.7700110; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Solary E, 1998, B CANCER, V85, P685; Stayrook KR, 1997, CARCINOGENESIS, V18, P1655, DOI 10.1093/carcin/18.8.1655; Stayrook KR, 1998, ANTICANCER RES, V18, P823; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Su S, 1997, BIOTECHNIQUES, V22, P1107, DOI 10.2144/97226st02; Tachibana O, 1996, ACTA NEUROPATHOL, V92, P431, DOI 10.1007/s004010050542; Tao LH, 1998, J CHROMATOGR A, V793, P71, DOI 10.1016/S0021-9673(97)00867-4; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Unlu S, 2000, J CARDIOVASC PHARM, V35, P341, DOI 10.1097/00005344-200002000-00025; Wang JL, 1997, ANTICANCER RES, V17, P4615; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; Yount GL, 1998, CANCER RES, V58, P3819; Yount GL, 1999, CANCER RES, V59, P1362; Yount GL, 2001, ONCOGENE, V20, P2826, DOI 10.1038/sj.onc.1204393; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	83	102	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35968	35978		10.1074/jbc.M303280200	http://dx.doi.org/10.1074/jbc.M303280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12837761	hybrid			2022-12-25	WOS:000185318300014
